| Entries |
| Document | Title | Date |
|---|
| 20080199854 | Methods and compositions for identifying RNA-binding proteins - The present invention includes compositions, methods and kits for the identification of a polypeptide that binds to a predetermined RNA sequence. The invention comprises, in part, a photoreactive moiety to aid in identification of such a polypeptide. | 08-21-2008 |
| 20080199855 | Identification And Characterization Of A Subset of Glioblastomas Sensitive To Treatment With Imatinib - The present invention relates to methods for in vitro diagnosing a cell proliferative disease in a mammal, for predicting the behaviour of a mammal having a cell proliferative disease in response to a medical treatment using at least one PDGF receptor antagonist, and for selecting a mammal having a cell proliferative disease and predicted to be responsive to a medical treatment using at least one PDGF receptor antagonist, by using given genetic markers. | 08-21-2008 |
| 20080199856 | Probe for Diagnosis of Marfan Syndrome and a Method for Screening Using the Probe - The purpose of this invention is to provide a probe for diagnosis of Marfan syndrome, which enables early diagnosis of Marfan syndrome, and to provide a method for screening using said probe. The invention is a probe for a Marfan Syndrome characterized by using a nucleic acid comprising following (a) or (b);
| 08-21-2008 |
| 20080199857 | METHOD OF INCREASING SPECIFICITY OF NUCLEIC ACID HYBRIDIZATION USING ZWITTERIONIC COMPOUND - A method of increasing the specificity of nucleic acid hybridization, comprising hybridizing nucleic acid in a solution containing a zwitterionic compound selected from the group consisting of 3-(cyclohexylamino)-1-propanesulfonic acid (CAPS), 3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonate (CHAPS), 3-(cyclohexylamino)-2-hydroxy-1-propane sulfonate (CAPSO), and 2-(cyclohexylamino)ethane sulfonate (CHES) is provided. The method allows a reduction in the yield of non-specific amplification products in multiplex PCRs while maintaining the yield of target amplification products. | 08-21-2008 |
| 20080199858 | Method for Detecting Estrogen-Like Chemicals by Plant | 08-21-2008 |
| 20080199859 | Identification Marker Responsive to Interferon Therapy for Renal Cell Cancer - The present invention provides an identification marker responsive to IFN therapy for renal cell cancer and a means of detecting the same. Namely, a method which comprises preparing a genomic DNA of a human gene or a complementary strand thereof from a specimen of a patient with renal cell cancer, analyzing the DNA sequence of the genomic DNA or the complementary strand thereof to determine the gene polymorphism of the human gene, and evaluating the tumor-suppression effect of IFN therapy on renal cell cancer by using the polymorphism as an indicator. | 08-21-2008 |
| 20080199860 | VARIANTS OF THE ALPHA 1 SUBUNIT OF HUMAN AMPK - Variants of the α subunit of AMPK, nucleic acids encoding such variants, and methods for their use are provided. | 08-21-2008 |
| 20080199861 | Real-time microarray apparatus and methods related thereto - Embodiments of the invention relate to a real-time microarray apparatus comprising an upper substrate, a lower substrate, a buffer positioned between the upper and lower substrate, a microarray positioned on either the upper substrate or the lower substrate, a heater positioned near the microarray, a pump positioned near the buffer and microarray and an imaging sensor positioned near the microarray. | 08-21-2008 |
| 20080199862 | Active biochip for nucleic acid analysis - Embodiments of the invention relate to an active biochip for nucleic acid analysis. The biochip comprises an inlet for introducing a nucleic acid sample, fluid channels, valves in contact with the fluid channels and pumps in contact with the fluid channels and adapted to generate a carrier gas or move a buffer through a portion of the fluid channels. The biochip also includes one or more hydroxyapatite columns for separating a portion of the nucleic acid sample, buffer reservoirs in contact with the fluid channels and positioned near the pumps, air exits, a waste reservoir and a nucleic acid analysis region. | 08-21-2008 |
| 20080199863 | PROBES AND METHODS FOR DETECTION OF PATHOGENS AND ANTIBIOTIC RESISTANCE - Described are probes and methods for detecting pathogens and antibiotic resistance of a specimen. The method comprises contacting the specimen with a growth medium; and lysing the specimen to release nucleic acid molecules from the specimen. The lysate of the specimen is contacted with a capture probe immobilized on a substrate, wherein the capture probe comprises an oligonucleotide that specifically hybridizes with a first target nucleic acid sequence region of ribosomal RNA. The lysate is in contact with a detector probe that comprises a detectably labeled oligonucleotide that specifically hybridizes with a second target nucleic acid sequence region of ribosomal RNA. The presence or absence of labeled oligonucleotide complexed with the substrate is determined. Detection of labeled oligonucleotide complexed with the substrate is indicative of the presence of pathogen. Performing the method in the presence and absence of an antibiotic permits detection of antibiotic resistance. | 08-21-2008 |
| 20080199864 | METHODS FOR CELL SCREENING OF COMPOUNDS CAPABLE OF MODULATING THE ACTIVITY OF UBIQUITIN-LIGASE SCF COMPLEXES AND THEIR USES - The invention concerns methods for cell screening of agents capable of modulating the activity of SCF.sup.Met30 complexes comprising the following steps: (i) contacting the product to be tested with a modified yeast strain, including (a) a hybrid sequence comprising a sequence coding for a Met4 protein, in its wild or mutated form, fused in phase with at least a sequence coding for an appropriate marker, said hybrid sequence being expressed under the control of a promoter, active in the yeast and optionally (b) a reporter transcriptional system, consisting of a reporter gene placed under the control of an appropriate operating sequence or an appropriate yeast promoter, (ii) adding methionine and (iii) determining the level of expression and stability of the expressed protein from the hybrid sequence, and their uses. The invention also concerns plasmids and yeast strains capable of being used in said methods. | 08-21-2008 |
| 20080199865 | Methods for Detecting and Treating the Early Onset of Aging-Related Conditions - Certain aspects of the invention relate to methods for determining a subject's susceptibility to the early onset or progression of aging-related conditions. In certain aspects the invention relates to accessing the genotype of a subject with respect to an allele of IL-1 pattern 1, pattern 2 and/or pattern 3. In other aspects, the invention relates to methods for selecting a therapeutic regimen, identifying age-related biomarkers, monitoring the progress of age-related conditions and identifying therapeutics for delaying or diminishing the onset of aging-related conditions. | 08-21-2008 |
| 20080199866 | SNP DETECTION AND OTHER METHODS FOR CHARACTERIZING AND TREATING BIPOLAR DISORDER AND OTHER AILMENTS - The present application relates to the use of SNPs and differential exon expression to characterize, diagnose or treat bipolar disorder and other mental illnesses, such as major depressive disorder and schizophrenia. | 08-21-2008 |
| 20080199867 | MULTIPLE MODE MULTIPLEX REACTION QUENCHING METHOD - Methods for balancing multiplexed PCR reactions are provided which exploit differences in primer and amplicon Tms. The methods may be controlled by a computer process. Also provided are articles of manufacture useful in such methods and compositions containing primers and probes useful in such methods. | 08-21-2008 |
| 20080199868 | Massive parallel method for decoding DNA and RNA - This invention provides methods for attaching a nucleic acid to a solid surface and for sequencing nucleic acid by detecting the identity of each nucleotide analogue after the nucleotide analogue is incorporated into a growing strand of DNA in a polymerase reaction. The invention also provides nucleotide analogues which comprise unique labels attached to the nucleotide analogue through a cleavable linker, and a cleavable chemical group to cap the —OH group at the 3′-position of the deoxyribose. | 08-21-2008 |
| 20080199869 | Novel mycobacterium tuberculosis protein composition - proteins and protein compositions that are components of a desaturase complex are provided. The | 08-21-2008 |
| 20080199870 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF PROTEIN SYNTHESIS - Compositions and methods for identifying inhibitors of RNA-target molecule interactions are provided as well as identifying inhibitors that block the role of tRNA in protein synthesis. The methods involve forming a mixture comprising a tRNA fragment molecule containing a modified nucleotide, a target molecule capable of binding to the tRNA fragment, and a test compound. The mixture is incubated under conditions that allow binding of the tRNA and the target molecule in the absence of the test compound. Assays can then be performed that detect whether or not the test compound inhibits the binding of the tRNA molecule and the target molecule. High throughput assays are also provided. | 08-21-2008 |
| 20080199871 | Systems and methods of analyzing nucleic acid polymers and related components - Systems and methods of identifying, sequencing and/or detecting nucleic acid polymers, as well as related components (e.g., substrates, software and the like) are disclosed. | 08-21-2008 |
| 20080199872 | Method and Kit for Analyzing a Target Nucleic Acid Sequence - This invention discloses methods for determining the presence of a target nucleic acid sequence using oligonucleotides that cooperate in a nucleic acid processing reaction to produce a detectable signal. In some embodiments, the methods also facilitate quantification of a target nucleic acid sequence. The present invention further discloses kits that can be used to conduct the methods of the present invention. | 08-21-2008 |
| 20080199873 | Companion diagnostic assays for cancer therapy - Methods for identifying cancer patients eligible to receive Bcl-2 family inhibitor therapy and for monitoring patient response to Bcl-2 family inhibitor therapy comprise assessment of the expression levels of the biomarker combinations set out in TABLES 1, 2, 3, 4, 5 or 6 in a patient tissue sample. The methods of the invention allow more effective identification of patients to receive Bcl-2 family inhibitor therapy and of determination of patient response to the therapy. | 08-21-2008 |
| 20080199874 | CONTROLLABLE STRAND SCISSION OF MINI CIRCLE DNA - The invention provides methods and compositions for the controlled termination of polymerase mediated primer extension reactions. The methods and compositions of the invention are broadly useful, and in a preferred aspect can be used in identifying sequence elements of template nucleic acids. Control of termination not only provides temporal control over termination, but, when used in conjunction with optically confined reaction regions, also spatially controls such termination. | 08-21-2008 |
| 20080199875 | UNSYMMETRICAL CYANINE DIMER COMPOUNDS AND THEIR APPLICATION - Embodiments of the present invention provide methods and nucleic acid reporter molecules for the detection of nucleic acid in a sample. The nucleic acid reporter molecule comprises two unsymmetrical cyanine monomer moieties, which may be the same or different, that are covalently attached by a linker comprising at least one aromatic, heteroaromatic, cyclic or heterocyclic moiety comprising 3-20 non-hydrogen atoms selected from the group consisting of O, N, S, P and C. The linker may be rigid, relatively flexible or some degree thereof. The unsymmetrical cyanine monomer moieties comprise a substituted or unsubstituted benzazolium moiety and a substituted or unsubstituted pyridinium or quinolinium moiety that is connected by a methine bridge that is monomethine, trimethine or pentamethine. The linkers form the cyanine dimer compounds by attaching to the pyridinium or quinolinium moiety of the monomer moieties. The present nucleic acid reporter molecules find utility in forming a nucleic acid-reporter molecule complex and detecting the nucleic acid. In particular, present nucleic acid reporter molecules with a rigid linker and monomer moieties with a monomethine bridge find utility in detecting RNA in the presence of DNA. | 08-21-2008 |
| 20080199876 | Method of Detection of Alterations in MSH5 - We have now discovered that mammals have a DNA gene analogous to that existing in bacteria. MSH5 defects or alterations in this mismatch repair pathway in a mammal, such as a human can be diagnostic of a predisposition to cancer, and prognostic for a particular cancer. We have discovered and sequenced MSH5 in this in a number of mammals, including humans. This gene can be used in assays, to express gene product, for drug screens, and therapeutically. | 08-21-2008 |
| 20080199877 | OLIGONUCLEOTIDE PROBES FOR DETECTING ENTEROBACTERIACEAE AND QUINOLONE-RESISTANT ENTEROBACTERIACEAE - Oligonucleotide probes for detecting Enterobacteriaceae species. Unique gyrA coding regions permit the development of probes specific for eight different species: | 08-21-2008 |
| 20080199878 | DETECTION, IDENTIFICATION AND DIFFERENTIATION OF EUBACTERIAL TAXA USING A HYBRIDIZATION ASSAY - The present invention relates to a method for the specific detection and/or identification of | 08-21-2008 |
| 20080206743 | Rapid and Specific Detection of Enterobacter Sakazakii - The present invention provides a method for specifically detecting pathogenic | 08-28-2008 |
| 20080206744 | Functional Genomics and Gene Trapping in Haploid or Hypodiploid Cells - The present invention provides methods and compositions for performing functional genomics and gene trapping using haploid cells, including haploid or hypodiploid vertebrate cells. The present invention further provides methods for identifying genes involved in cellular signaling pathways. | 08-28-2008 |
| 20080206745 | Nucleic acid extraction solution and use thereof - Disclosed are methods and compositions for extracting nucleic acids from a biological sample. In particular, disclosed is a nucleic acid extraction solution together with methods using such a solution for extracting nucleic acid sequences from biological samples containing cells, cellular debris or both. The nucleic acid extraction solution contains a molecule having the formula R | 08-28-2008 |
| 20080206746 | Plasmid DNA isolation - Apparatus, reagents, and methods for isolating plasmid DNA from bacteria by alkaline lysis using a solid or immobilized P | 08-28-2008 |
| 20080206747 | Methods, Kits and Compositions Pertaining to Combination Oligomers and Libraries for Their Preparation - This invention pertains to the field of combination oligomers, including the block synthesis of combination oligomers in the absence of a template, as well as related methods, kits, libraries and other compositions. | 08-28-2008 |
| 20080206748 | Methods for genetic analysis of DNA to detect sequence variances - Methods for determining genotypes and haplotypes of genes are described. Also described are single nucleotide polymorphisms and haplotypes in the ApoE gene and methods of using that information. | 08-28-2008 |
| 20080206749 | Methods and kits for diagnosis, prognosis or monitoring of Epstein-Barr virus (EBV)-associated cancer - Disclosed is a non-invasive method for diagnosis, prognosis or monitoring of Epstein-Barr virus (EBV)-associated cancer by detecting and/or quantifying EBV associated nucleic acid fragments in a urine sample from an individual. Kits for diagnosis, prognosis or monitoring of cancer are also disclosed. | 08-28-2008 |
| 20080206750 | Novel fetal genes - Novel fetal genes (fls353 and fls485) have been successfully isolated from human fetal liver-derived cDNAs. These genes were specifically expressed in tissues including fetal tissues which are thought to contain a large number of undifferentiated cells and actively differentiating/proliferating cells. High levels of expression of these genes were observed also in a variety of cancer cells. The proteins and genes encoding the proteins can be used as the tool for developing drugs for the treatment of tumors. | 08-28-2008 |
| 20080206751 | Method For Carrying Out A Multi-Step Reaction, Breakable Container For Storing Reagents And Method For Transferring Solid Reagent Using An Electrostatically Charged Wand - The application relates to a method of performing a multi-step reaction vessel ( | 08-28-2008 |
| 20080206752 | Method For the Photochemical Attachment of Biomolecules to a Substrate - Methods and devices for attaching biomolecules to a solid substrate surface for example to the inner surface of a capillary. In particular, the invention relates to compounds and methods for creating patterned arrays of biomolecules inside fused silica capillaries so that a plurality of bioassays can be conducted simultaneously. | 08-28-2008 |
| 20080206753 | Methods for Cancer Prognosis - A method for assessing prognosis in a subject having a breast tumor comprises determining the level of expression of at least one Notch receptor gene, Notch ligand gene or Notch signaling target gene. A method of treating a subject suffering from a breast tumor associated with increased Notch signaling comprises administering to the subject an effective amount of an inhibitor of Notch signaling. | 08-28-2008 |
| 20080206754 | Method for producing monoclonal antibodies - An improved method for the production of monoclonal antibodies is disclosed. | 08-28-2008 |
| 20080206755 | Method for genetic detection using interspersed genetic elements - The way to design a “filled” site (which contains an interspersed element) primer set to target a particular locus is to design one of the two primers such that it encompasses that unique information (e.g., interspersed element+flanking genomic sequence+direct repeat). The way to design an “empty” site primer is to design one of the two primers such that the entire direct repeat sequence in addition to flanking genomic sequence is included on both sides. To improve efficiency, the “empty” site primer designed around the direct repeat should not be too long. This primer design of the present invention allows for the ability to test any type of interspersed genetic element containing characteristic direct repeat sequences (direct repeats). This gives the option of many new polymorphic marker sites because Alu elements are not the only interspersed genetic elements having direct repeats flanking their core sequence. | 08-28-2008 |
| 20080206756 | Biomarker panel for colorectal cancer - A panel of biomarkers has been identified for analysis of colorectal cancer. The panel, originally identified using a mouse colon cancer model, has been used to assess changes in human tissue from surgical and biopsy samples against a normal human control panel of biomarkers. The panel may be used for providing a cost effective, rapid, noninvasive procedure for risk assessment, early diagnosis, establishing prognosis, monitoring patient treatment, detecting relapse, and for the discovery of therapeutic intervention of colorectal cancer. | 08-28-2008 |
| 20080206757 | METHODS AND COMPOSITIONS FOR DETECTING RARE CELLS FROM A BIOLOGICAL SAMPLE - The present invention provides methods and compositions for isolating and detecting rare cells from a biological sample containing other types of cells. In particular, the present invention includes a debulking step that uses a microfabricated filters for filtering fluid samples and the enriched rare cells can be used in a downstream process such as identifies, characterizes or even grown in culture or used in other ways. The invention also include a method of determining the aggressiveness of the tumor or of the number or proportion of cancer cells in the enriched sample by detecting the presence or amount of telomerase activity or telomerase nucleic acid or telomerase expression after enrichment of rare cells. This invention further provides an efficient and rapid method to specifically remove red blood cells as well as white blood cells from a biological sample containing at least one of each of red blood cells and white blood cells, resulting in the enrichment of rare target cells including circulating tumor cells (CTC), stromal cells, mesenchymal cells, endothelial cells, fetal cells, stem cells, non-hematopoietic cells etc from a blood sample. The method is based upon combination of immuno-microparticles (antibody coated microparticles) and density-based separation. The final enriched target cells can be subjected to a variety of analysis and manipulations, such as flowcytometry, PCR, immunofluorescence, immunocytochemistry, image analysis, enzymatic assays, gene expression profiling analysis, efficacy tests of therapeutics, culturing of enriched rare cells, and therapeutic use of enriched rare cells. In addition, depleted plasma protein and white blood cells can be optionally recovered, and subjected to other analysis such as inflammation studies, gene expression profiling, etc. | 08-28-2008 |
| 20080206758 | POLYNUCLEIC ACID-ATTACHED PARTICLES AND THEIR USE IN GENOMIC ANALYSIS - Disclosed are methods for preparing particle-linked polynucleotides, and using the particle linked polynucleotides in genomic analysis. The particles as disclosed are characterized as having a size variance of less than 2%. | 08-28-2008 |
| 20080206759 | Gene regulatory networks and methods of interdiction for controlling the differentiation state of a cell - The invention provides a method of modulating a regulatory state of a cell. The method consists of: (a) identifying a point of interdiction within a cis regulatory network specifying a genetic regulatory architecture of a cell, and (b) introducing into a progenitor cell two or more network elements within said network to induce a predetermined series of cis regulatory network interactions resulting in a specified regulatory state of said progenitor cell. Also provided is a method of modulating a regulatory state of a cell. The method consists of: (a) identifying a point of interdiction within a cis regulatory network specifying a genetic regulatory architecture of a cellular state, and (b) introducing into a progenitor cell two or more network elements within said network to induce a predetermined series of cis regulatory network interactions resulting in a specified regulatory state of said progenitor cell. A cell having a specified regulatory state consisting of a modified genetic regulatory architecture is further provided. Methods of diagnosing and methods of treating an individual suffering from a cellular defect also are provided. The invention additionally provides a method of identifying a compound having differentiation or cell fate inducing activity. | 08-28-2008 |
| 20080206760 | Method for detecting DNA methylation using labelled S-adenosylmethionine analogs - The invention relates to a method for detecting the methylation status in DNA samples. According to the invention, a DNA methyl transferase and a labeled S-adenosylmethionine derivative allow a detectable label to be covalently bonded to the DNA, in accordance with the respective methylation status of the DNA sample. | 08-28-2008 |
| 20080206761 | Ex Vivo Gene Expression in Whole Blood as a Model of Assessment of Individual Variation to Dietary Supplements - A method is disclosed for individually tailoring the administration of dietary components such as supplements. In the method, whole blood of a mammal is exposed to a dietary component. The level of a marker mRNA linked to a disease state is measured in leukocytes after exposure to the dietary component, and in some cases after further stimulation of the exposed blood cells. By comparing the mRNA level after exposure with the value found in unexposed blood cells, it is possible to determine what the effect of the dietary component will be in the mammal. By screening blood of the mammal against a number of possible dietary components, it is possible to develop an optimized set of dietary components tailored to the specific mammal to treat or prevent a disease state. | 08-28-2008 |
| 20080206762 | Method for the Diagnosis of Alzeimer's Disease - The invention relates to a method for the diagnosis and/or prognosis of Alzheimer's disease, consisting in determining the expression level of a gene encoding a lysosomal marker. | 08-28-2008 |
| 20080206763 | METHODS FOR ISOLATING AND CHARACTERIZING ENDOGENOUS mRNA-PROTEIN (mRNP) COMPLEXES - Cellular mRNA-protein (mRNP) complexes are partitioned in vivo by contacting a biological sample with at least one ligand that specifically binds at least one component of a mRNP complex. Suitable biological samples comprise at least one mRNA-protein (mRNP) complex and include cell cultures, cell extracts, and whole tissue, including tumor tissue. Ligands include antibodies that specifically bind RNA-binding or RNA-associated proteins present in the mRNP complex. The mRNP complex is separated by binding the ligand with a binding molecule specific for the ligand, where the binding molecule is attached to a solid support. The mRNP complex is collected by removing the mRNP complex from the solid support. After collecting the mRNP complex, the mRNA bound within the complex may be characterized and identified. Subsets of the total mRNA population of a cell may accordingly be characterized, and a gene expression profile of the cell obtained. | 08-28-2008 |
| 20080206764 | Flowcell system for single molecule detection - The present invention provides compounds, methods and systems for sequencing nucleic acid using single molecule detection. Using labeled NPs that exhibit charge-switching behavior, single-molecule DNA sequencing in a microchannel sorting system is realized. In operation, sequencing products are detected enabling real-time sequencing as successive detectable moieties flow through a detection channel. By electrically sorting charged molecules, the cleaved product molecules are detected in isolation without interference from unincorporated NPs and without illuminating the polymerase-DNA complex. | 08-28-2008 |
| 20080206765 | MN Gene and Protein - Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular contacts. The MN protein binding site is a therapeutic target that can be blocked by organic or inorganic molecules, preferably organic molecules, more preferably proteins/polypeptides that specifically bind to that site. Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Vectors are provided that encode the variable domains of MN-specific antibodies and a flexible linker polypeptide separating those domains. Further vectors are disclosed that encode a cytotoxic protein/polypeptide operatively linked to the MN gene promoter or a MN gene promoter fragment comprising the HIF-1 consensus binding sequence, and which vectors preferably further encode a cytokine. The MN gene promoter is characterized, and the binding site for a repressor of MN transcription is disclosed. Further, the hypoxia inducibility of the MN gene and the uses of such inducibility are disclosed. | 08-28-2008 |
| 20080206766 | Compositions and Methods for Detecting And Treating Prostate Disorders - The present invention relates to compositions and methods for the detecting, treating, and empirically investigating cellular proliferation disorders and cellular motility disorders. In particular, the present invention provides compositions and methods for using CXCL chemokines (e.g., CXCL1, CXCL5, CXCL6, CXCL12), CXCL receptors (e.g., CXCR1, CXCR2, CXCR4, CXCR7), and/or pathway related compounds (e.g., NF-kappaB, ERK ½, ELK-1) in the diagnosis, treatment, and empirical investigation of prostate disorders (e.g., prostate cancer, benign prostatic hypertrophy, prostatitis). | 08-28-2008 |
| 20080206767 | System and method for tracking and controlling infections - The present invention is a system and method for performing real-time infection control over a computer network. The method comprises obtaining a sample of a microorganism at a health care facility, sequencing a first region of a nucleic acid from the microorganism sample, comparing the first sequenced region with historical sequence data stored in a database, determining a measure of phylogenetic relatedness between the microorganism sample and historical samples stored in the database, and providing infection control information based on the phylogenetic relatedness determination to the health care facility, thereby allowing the health care facility to use the infection control information to control or prevent the spread of an infection. | 08-28-2008 |
| 20080206768 | Predicting a response to olanzapine - The invention relates generally to the relative effect of specific genetic polymorphisms in predicting the clinical outcome of olanzapine therapy in patients suffering from a psychiatric disease such as schizophrenia. | 08-28-2008 |
| 20080206769 | Molecular prognostic signature for predicting breast cancer distant metastasis, and uses thereof - The present invention is based on the discovery of a unique 14-gene molecular prognostic signature that is useful for predicting breast cancer metastasis. In particular, the present invention relates to methods and reagents for detecting and profiling the expression levels of these genes, and methods of using the expression level information in predicting risk of breast cancer metastasis. | 08-28-2008 |
| 20080206770 | SCREENING METHODS USED TO IDENTIFY COMPOUNDS THAT MODULATE SKIN STROMAL CELLS (FIBROBLASTS) ABILITY TO MODIFY FUNCTION OF EXTRACELLULAR MATRIX - The cellular response to cosmetic products has been characterized on the molecular level through the use of gene and protein expression technologies. Nucleic acid and protein molecules, the expression of which are induced or repressed in response to exposure to cosmetics, are identified according to a temporal pattern of altered expression post exposure. Methods are disclosed that utilized these cosmetics-regulated molecules as markers for effectiveness of cosmetics. Other screening methods of the invention are designed for the identification of compounds that modulate the response of a cell to exposure to cosmetics. The invention also provides compositions useful for drug screening or pharmaceutical purposes. | 08-28-2008 |
| 20080206771 | Method For Recovering Nucleic Acid From A Mixed Cell Suspension, Without Centrifugation - A method for selectively recovering nucleic acid from a first cell type in a sample containing cells of at least a first cell type and a second cell type, and a cell suspension medium comprising extracellular impurities, is provided. The method entails combining the sample with particles responsive to a magnetic field in a vessel, the magnetic particles having the ability to sequester the cells from the cell suspension medium upon application of a magnetic field; exposing the vessel to a magnetic field for a time sufficient to cause sequestration of the cells by the particles; removing the impurities-containing cell suspension medium from the vessel while retaining the cells; lysing selectively cells of the first cell type; and isolating the nucleic acid from the lysed cells. Methods for recovering nucleic acid from the second cell type are also provided. | 08-28-2008 |
| 20080206772 | SAMPLE TREATMENT SOLUTION AND REAGENT KIT FOR PREPARING SAMPLE FOR DETECTING DNA METHYLATION - The present invention provides a sample treatment solution for preparing a sample for DNA methylation which can achieve stable detection results in detection of DNA methylation and be easily pretreated, comprising an aqueous solution containing a protease. | 08-28-2008 |
| 20080206773 | DNA Fingerprinting Using Allelic Specific Oligonucleotide Reversed DOT BLOT (ASO-RDB) Flow Through Hybridization Process and Device - The present invention disclosed the use of single nucleotide polymorphism (SNP) as the detection assay for human identification. Using the reversed dot-blot format and the flow through hybridization process, the process can be more efficient, less expensive and with similar or better power of exclusion in definitive identification. The present method can be applied to any other organisms. | 08-28-2008 |
| 20080206774 | AUTOMATED CANCER DIAGNOSTIC METHODS USING FISH - In various embodiments methods for automated screening for gene amplification in biological tissue samples using an automated fluorescence microscope to analyze fluorescence in situ hybridized samples are provided. Various additional embodiments provide methods of high throughput screening for gene amplification. | 08-28-2008 |
| 20080206775 | Method of Amplifying Nucleic Acids, Reagent Kit for Amplifying Nucleic Acids, Method of Detecting Single Nucleotide Polymorphism, and Reagent Kit for Detecting Single Nucleotide Polymorphism - An object of the present invention is to provide a nucleic acid amplification method for amplifying a desired nucleic acid while suppressing amplification of byproducts in a PCR reaction, a reagent kit used for nucleic acid amplification, a method of detecting single nucleotide polymorphism to detect single nucleotide polymorphism by utilizing that amplification of byproducts is suppressed in a PCR reaction, and a reagent kit used for detecting single nucleotide polymorphism. The method of amplifying nucleic acids by PCR is characterized by admixing in a reaction solution, a homologous recombinant protein which contains at least one of a RecA protein derived from | 08-28-2008 |
| 20080206776 | Use of Both Rd9 and Is6110 as Nucleic Acid Targets for the Diagnosis of Tuberculosis, and Provision of Multiplex-Compliant Is6110 and Rd9 Targets - The present invention relates to the use of both RD9 and IS6110 as nucleic acid targets, for the specific and sensitive detection of a mycobacterium of the | 08-28-2008 |
| 20080206777 | Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors - The present invention provides protein and gene expression profiles indicative of whether a patient afflicted with non-small cell lung cancer is likely to be responsive to treatment with a therapeutic compound that is a EGFR-TK inhibitor. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and protein expression profiles, and assays for identifying the presence of a gene or protein expression profile in a patient sample. | 08-28-2008 |
| 20080206778 | Feline Hemoplasma Isolate - A newly identified hemoplasma agent, Candidatus | 08-28-2008 |
| 20080206779 | Methods and Kits for Multiplex Hybridization Assays - The invention provides a method for genotyping interfering polymorphic loci in a target polynucleotide, such as a strand of genomic DNA, in a multiplex hybridization-based assay. The invention also provides nucleic acid standards for validating the performance of such hybridization-based assays. In one aspect, the method of the invention is carried out by providing for each interfering polymorphic locus one or more probes so that at least one probe is capable of forming a perfectly match duplex at the locus regardless of the characteristic sequence of an adjacent polymorphism. | 08-28-2008 |
| 20080213754 | Method of Amplifying Atp and Use Thereof - The ATP amplification method of the present invention is a method for amplifying and detecting a very trace amount of exogenous ATP by allowing a fusion protein (PPK-ADK) of a polyphosphate kinase and an adenylate kinase, the fusion protein not containing ADP, to act on a mixture of ATP, AMP, and a polyphosphate compound. The present invention also provides an ultrasensitive ATP amplification method by which ATP at a single cell level can be amplified and detected, and an ultrasensitive microbial assay based on this ATP amplification method. | 09-04-2008 |
| 20080213755 | Method and Device for Detection of Nucleic Acid Sequences | 09-04-2008 |
| 20080213756 | Real-Time Pcr Point Mutation Assays For Detecting Hiv - 1 Resistance to Antiviral Drugs - Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein. | 09-04-2008 |
| 20080213757 | Methods of Distinguishing Types of Spinal Neurons Using Corl1 Gene as an Indicator - As a result of screening for genes that are selectively expressed in fetal mouse brain region by subtraction method, the present inventors obtained a cDNA fragment encoding Corl1. The expression of Corl1 was examined by RT-PCR, in situ hybridization, and immunostaining using polyclonal antibodies. The results demonstrated that Corl1 was especially expressed at a high level of selectively in the central nervous system during embryonic stages. The expression patterns of Corl1 determined using various markers in embryonic spinal cord were compared to identify types of neurons expressing Corl1. The results revealed that Corl1 was specifically expressed in spinal cord interneurons dI4, dI5, dILA, and dILB. Accordingly, the present invention provides for discrimination between dI4 and dI6, neurons which previously could only be discriminated based on developmental location, using the expression of Corl1 as an indicator. | 09-04-2008 |
| 20080213758 | Method For Estimating End Use Qualities of Wheat at Growth Stage - The invention provides a means for estimating the end use qualities of wheat flour that will be obtained in the future from the harvested wheat at an early stage before maturation of the wheat seeds. The invention relates to a method for estimating the end use qualities of a matured wheat seed, comprising measuring the expression level of at least 1 gene selected from genes, each of which is defined by any one of the nucleotide sequences of SEQ ID NOS: 1 to 121 in immature wheat. | 09-04-2008 |
| 20080213759 | Novel Angiogenesis Inhibitor - Because AK022567 has angiogenesis inhibitory activity, it is useful as an angiogenesis inhibitor. Furthermore, 4 splicing variants obtained from the same gene are also useful as an angiogenesis inhibitor. These 5 polypeptides, polynucleotides encoding the polypeptides and antibodies against the polypeptides are useful for screening of a candidate compound as an angiogenesis inhibitor or promoter. A compound obtained from the screening is useful as a medicine and can be used for a preventive or therapeutic agent for an angiogenesis related disease. | 09-04-2008 |
| 20080213760 | COMPOSITIONS AND METHODS FOR PROTEIN ISOLATION - The invention provides for polynucleotides and vectors comprising at least two tag sequences. The invention also provides for polynucleotides and vectors comprising a streptavidin binding peptide sequence and a calmodulin binding peptide sequence. The invention also provides for polynucleotides and vectors wherein a gene of interest is fused in frame to at least two tag sequences, for example, a streptavidin binding peptide sequence and a calmodulin binding peptide sequence. The invention also provides for the chimeric proteins encoded by these polynucleotides. The invention also provides for methods of using the polynucleotides of the invention for detecting and/isolating protein complexes or identifying a binding partner for a protein of interest. | 09-04-2008 |
| 20080213761 | Agonists of Bitter Taste Receptors and Uses Thereof - The present invention relates to agonists of the hTAS2R1, hTAS2R3, hTAS2R7 and hTAS2R40 bitter taste receptors, respectively, and their role in bitter taste transduction. The invention also relates to assays for screening molecules that modulate, e.g. suppress or block hTAS2R1, hTAS2R3, hTAS2R7 or hTAS2R40 bitter taste transduction or bitter taste response. | 09-04-2008 |
| 20080213762 | Method of Gene Sequence Examination - The present invention provides a method for detecting quantitatively a specific nucleic acid sequence and for detecting gene polymorphism or mutation by homogenous system simply, promptly, accurately, and inexpensively, and an oligonucleotide probe used therefor. The nucleic acid having a specific sequence is quantitatively detected and gene polymorphism or mutation is detected in such a way that a probe DNA containing one or two labeling materials is hybridized to the target nucleic acid, and decomposed from the 5′- or the 3′-terminal by exonuclease action to release one of the labeling materials, the signal emitted by which is then detected. | 09-04-2008 |
| 20080213763 | Human Protooncogene and Protein Encoded by Same, and Expression Vector Containing Same - Disclosed are a novel protooncogene and a protein encoded by same. The protooncogene of the present invention is a novel gene, and may be effectively used for diagnosing the cancers, including leukemia, uterine cancer, lymphoma, colon cancer, lung cancer, skin cancer, etc., as well as producing transformed animals, etc. | 09-04-2008 |
| 20080213764 | Human Protooncogene and Protein Encoded Therein - Disclosed are a novel protooncogene and a protein encoded therein. The protooncogene of the present invention, which is a novel gene that takes part in human carcinogenesis and simultaneously has an ability to induce cancer metastasis, may be effectively used for diagnosing the cancers, including lung cancer, leukemia, uterine cancer, lymphoma, colon cancer, skin cancer, etc., as well as producing transformed animals, etc. | 09-04-2008 |
| 20080213765 | Human Autism Susceptibility Genes Encoding a Neurotransmitter Transporter and Uses Thereof - The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the SLC6A1 or SLC6A11 gene on chromosome 3 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the SLC6A1 or SLC6A11 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of Asperger syndrome, pervasive developmental disorder, childhood disintegrative disorder, mental retardation, anxiety, depression, attention deficit hyperactivity disorders, speech delay, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological diseases including schizophrenia. | 09-04-2008 |
| 20080213766 | METHOD AND DEVICE FOR DETECTING THE PRESENCE OF A SINGLE TARGET NUCLEIC ACID IN SAMPLES - A method comprising for each individual sample of a plurality of samples, loading at least one sample portion of the individual sample into at least one respective sample chamber of a plurality of sample chambers, subjecting the sample portions to at least a first amplification step; and then determining whether sample portions contain at least one molecule of the target nucleic acid. For each sample portion, if the sample portion contains at least a single molecule of the target nucleic acid, the sample portion would attain a detectable concentration of the target nucleic acid after a single round of amplification. | 09-04-2008 |
| 20080213767 | Detection Of Nucleic Acids By Target-Catalyzed Product Formation - A method is disclosed for modifying an oligonucleotide, which method has application to the detection of a polynucleotide analyte. An oligonucleotide is reversibly hybridized with a polynucleotide, for example, a polynucleotide analyte, in the presence of a 5′-nuclease under isothermal conditions. The polynucleotide analyte serves as a recognition element to enable a 5′-nuclease to cleave the oligonucleotide to provide (i) a first fragment that is substantially non-hybridizable to the polynucleotide analyte and (ii) a second fragment that lies 3′ of the first fragment (in the intact oligonucleotide) and is substantially hybridizable to the polynucleotide analyte. At least a 100-fold molar excess of the first fragment and/or the second fragment are obtained relative to the molar amount of the polynucleotide analyte. The presence of the first fragment and/or the second fragment is detected, the presence thereof indicating the presence of the polynucleotide analyte. The method has particular application to the detection of a polynucleotide analyte such as DNA. Kits for conducting methods in accordance with the present invention are also disclosed. | 09-04-2008 |
| 20080213768 | Identification and use of biomarkers for non-invasive and early detection of liver injury - The present invention provides methods for identifying and evaluating suites of biochemical and/or gene entities useful as biomarkers for early prediction of disease and/or toxicity, disease staging, target identification/validation, and monitoring of drug efficacy/toxicity. The present invention further provides suites of small molecule entities as biomarkers for non-invasive and early prediction of hepatic injury. | 09-04-2008 |
| 20080213769 | Automated Method for Detecting Cancers and High Grade Hyperplasias - Automated methods for detecting cancer and related hyperplasias in biological samples. | 09-04-2008 |
| 20080213770 | Method of Determining The Nucleotide Sequence of Oligonucleotides and DNA Molecules - The present invention relates to a novel method for analyzing nucleic acid sequences based on real-time detection of DNA polymerase-catalyzed incorporation of each of the four nucleotide bases, supplied individually and serially in a microfluidic system, to a reaction cell containing a template system comprising a DNA fragment of unknown sequence and an oligonucleotide primer. Incorporation of a nucleotide base into the template system can be detected by any of a variety of methods including but not limited to fluorescence and chemiluminescence detection. Alternatively, microcalorimetic detection of the heat generated by the incorporation of a nucleotide into the extending template system using thermopile, thermistor and refractive index measurements can be used to detect extension reactions. | 09-04-2008 |
| 20080213771 | Methods and Compositions for Large-Scale Analysis of Nucleic Acids Using DNA Deletions - The present invention is related generally to analysis of polynucleotides, particularly polynucleotides derived from genomic DNA. The invention provides methods, compositions and systems for such analysis. Encompassed by the invention are constructs that include pairs of target sequences which are separated by a known distance in the polynucleotide from which they are derived. | 09-04-2008 |
| 20080213772 | USE OF MICROPHTHALMIA FOR DIAGNOSIS, PROGNOSIS AND/OR TREATMENT OF MELANOMA - Microphthalmia (Mi) while present in melanocytes, a cells and osteoclast, is not normally present in other cells. We have found that Mi is present in the nucleus of melanoma cells. Melanoma can be diagnosed by contacting a malignant cell with a probe for Mi. If the probe identities Mi in the nucleus of the cell, the cell is a melanoma. | 09-04-2008 |
| 20080213773 | Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing - A method for identifying an RNA form of a bacteria, comprising reverse transcribing RNA material; conducting PCR using primers for a first highly conserved genetic sequence generic of the bacteria; conducting nested PCR using primers for a second highly conserved genetic sequence within the first genetic sequence of the bacteria; and identifying the bacteria based on unconserved amplified sequences linked to the conserved sequences. | 09-04-2008 |
| 20080213774 | Mutations in Kit Confer Imatinib Resistance in Gastrointestinal Stromal Tumors - The present invention relates to methods and compositions concerning resistance to a drug for cancer comprising aberrant KIT signal, such as aberrant KIT sequence or expression. In a specific embodiment, the cancer is also initially responsive to imatinib therapy, such as in gastrointestinal stromal tumors (GISTs). In particular embodiments, a mutation in a KIT polynucleotide confers resistance to imatinib treatment, and in specific embodiments the exemplary mutation is at 1982T→C. Thus, the invention provides a means to adjust for or circumvent the resistance to imatinib drug treatment. | 09-04-2008 |
| 20080213775 | METHODS AND MATERIALS FOR IDENTIFYING POLYMORPHIC VARIANTS, DIAGNOSING SUSCEPTIBILITIES, AND TREATING DISEASE - The invention is directed to materials and methods associated with polymorphic variants in two enzymes involved in folate-dependent and one-carbon metabolic pathways: MTHFD1 (5,10-methylenetetrahydrofolate dehydrogenase, 5,10-methenyltetrahydrofolate cyclohydrolase, 10-formyltetrahydrofolate synthetase) and methylenetetrahydrofolate dehydrogenase (NADP+dependent) 1-like (MTHFD1L). Diagnostic and therapeutic methods are provided involving the correlation of polymorphic variants in MTBFD1, MTHFD1, and other genes with relative susceptibility for various pregnancy-related and other complications. | 09-04-2008 |
| 20080213776 | METHOD FOR TREATING AUTOIMMUNE DISEASES AND SCREENING METHOD FOR PREVENTIVE OR THERAPEUTIC AGENT FOR THE SAME - The present invention is directed to a method for treating autoimmune diseases comprising administering RBAp48 production suppressor or inhibitor; a screening method for a preventive or therapeutic agent for autoimmune diseases comprising determining RBAp48 production suppressing effect or inhibitory effect of a sample; a diagnosis agent or a diagnosing kit for autoimmune diseases containing a reagent for measuring RBAp48 level in gland tissue; and a diagnosis method for autoimmune diseases comprising measuring RBAp48 level in gland tissue. | 09-04-2008 |
| 20080213777 | Tumor suppressor pathway in C. elegans - The invention provides novel lin-8, lin-56, and lin-61 genes and polypeptides involved in cell fate determination and in cell proliferation. In addition, the invention includes mutants of these three genes, as well as methods for utilizing these genes, and their encoded polypeptides, in diagnosing and treating abnormal cell proliferation. | 09-04-2008 |
| 20080213778 | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses - The invention provides isolated TANGO 239, TANGO 219, TANGO 232, TANGO 281, A236 (INTERCEPT 236), TANGO 300, TANGO 353, TANGO 393, TANGO 402, TANGO 351 and TANGO 509 nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 09-04-2008 |
| 20080213779 | Nalp7-Based Diagnosis of Female Reproductive Conditions - Methods, reagents and kits are described for the diagnosis of a female reproductive condition, based on the detection of an alteration in a NALP7-encoding nucleic acid or a NALP7 polypeptide, relative to a corresponding wild-type NALP7-encoding nucleic acid or NALP7 polypeptide. | 09-04-2008 |
| 20080213780 | MULTI-COLOR TIME RESOLVED FLUOROPHORES BASED ON MACROCYCLIC LANTHANIDE COMPLEXES - The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands. | 09-04-2008 |
| 20080213781 | Methods of detecting methylation patterns within a CpG island - A method of increasing sensitivity of a DNA methylation assay by determining complementation within a CpG island of the methylated DNA. | 09-04-2008 |
| 20080213782 | SOCS-1 Gene Methylation in Cancer - Methods are provided for identifying a cell exhibiting unregulated growth associated with methylation-silenced transcription of a suppressor of cytokine signaling (SOCS)/cytokine-inducible SH2 protein (CIS) family member (SOCS/CIS) gene such as the SOCS-1 gene. In addition, methods of treating a cancer patient, wherein cancer cells in the patient exhibit methylation-silenced transcription of SOCS/CIS gene such as a SOCS-1 gene, are provided, as are reagents for practicing such methods. | 09-04-2008 |
| 20080213783 | SITE-SPECIFIC ENZYMATIC DEPOSITION OF METAL IN SITU - The present invention provides compositions, kits, assembles of articles and methodology for carrying out processes that permit biological enzymes to act directly on metals and metal particles. In particular, the invention relates to use of enzymes to selectively deposit metal to the vicinity of a target molecule. The invention also relates to linking of metals to enzyme substrates, control of enzymatic metal deposition and applications of enzymatic metal deposition to sensitively and selectively detect target molecules such as biomarkers in various biological samples, such as chromogenic immunohistochemical (IHC) detection in situ by using bright field light microscope. | 09-04-2008 |
| 20080213784 | SCREENING METHODS AND SEQUENCES RELATING THERETO - A screening method for identifying an individual having a pre-disposition towards having a cancer is disclosed, which screening method comprises the steps of:
| 09-04-2008 |
| 20080213785 | Method of predicting a benefit of antioxidant therapy for prevention or treatment of vasclar disease in hyperglycemic individuals - This invention relates to methods and compositions of determining the benefit of therapy using antioxidant for the treatment of cardiovascular events in individuals with diabetes mellitus based on their haptoglobin phenotype and the treatment of the cardiovascular events using antioxidants based on the haptoglobin phenotype. | 09-04-2008 |
| 20080213786 | Treatment of rheumatoid arthritis with galectin-3 antagonists - The invention encompasses a novel method of treating an inflammatory disease, such as rheumatoid arthritis, and novel methods of identifying and screening for drugs useful in the treatment of inflammatory diseases, such as rheumatoid arthritis, and their clinical symptoms. The inventors have made the discovery that the activity of galectin-3, a β-galactoside-binding lectin known to have an effect on some cancers, has a significant impact on the pathophysiology of rheumatoid arthritis. The symptoms of an inflammatory disease, such as rheumatoid arthritis, may be alleviated by administering a compound that inhibits the activity of galectin-3. | 09-04-2008 |
| 20080213787 | Methods and Compositions for Kir Genotyping - The present invention provides methods for single nucleotide polymorphism (SNP)-based killer cell immunoglobulin-like receptor (KIR) gene cluster genotyping using the matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometer. In general, the methods involve amplifying a plurality of target sequences of a plurality of KIR genes, and detecting the presence or absence of a plurality of single SNPs of the plurality of KIR genes by MALDI-TOF mass spectrometry. The invention also features compositions, including arrays of capture primers and optionally extension primers on a substrate surface, and kits, for use in the methods of the invention. | 09-04-2008 |
| 20080213788 | GENE CODING FOR SCYTALONE DEHYDRATASE EXHIBITING RESISTANCE TO AGRICULTURAL FUNGICIDAL AGENT - The present invention provides a gene that can be used extensively in studies relating to resistant rice blast fungi. | 09-04-2008 |
| 20080213789 | Assay for detecting methylation status by methylation specific primer extension (MSPE) - The present invention relates to detecting the relative methylation levels at one or more CpG sites on a nucleic acid molecule, by using the methylation specific primer extension reaction (MSPE). MSPE uses an agent to modify unmethylated cytosine at a CpG site to uracil and subsequently amplify the chemically treated nucleic acids. The MSPE primers distinguishing between unmethylated and methylated CpG sites are provided to conduct MSPE. Relative methylation levels at one or more CpG sites are performed by detecting the signal intensity of labels incorporated into the MSPE reaction products. | 09-04-2008 |
| 20080213790 | METHOD FOR SYNTHESIZING POLYNUCLEOTIDES - The present invention realized isothermal and rapid polynucleotide synthesis by using as templates polynucleotides having a structure capable of forming loops, and combining a plurality of primers capable of providing a starting point for complementary strand synthesis to such loops. If the LAMP method is applied, all reactions can be carried out isothermally and rapidly since the template polynucleotides themselves can also be synthesized by an isothermal reaction. | 09-04-2008 |
| 20080213791 | Materials and methods for assaying for methylation of CpG islands associated with genes in the evaluation of cancer - Provided are methods, reagents, and kits for evaluating cancer, such as prostate cancer, in a subject. Disclosed methods of evaluating cancer include methods of diagnosing cancer, methods of prognosticating cancer and methods of assessing the efficacy of cancer treatment. The methods include assaying a biological sample for methylation of a CpG island associated with specified genes. Provided reagents and kits include primers suitable for amplifying at least a portion of a target CpG islands associated with specified genes. | 09-04-2008 |
| 20080213792 | Homogeneous Multiplex Screening Kits - Kits for highly multiplexed homogeneous in vitro screening assays for numerous possible nucleic acid targets, any of which might be present in a sample, that utilize fluorescent hybridization probes that are combinatorially coded from a panel of fluorophores by subdividing each probe into portions and differently labeling each portion such that, when portions are combined, each probe has a unique code. The kits may include reagents and primers for target amplification and real-time detection. | 09-04-2008 |
| 20080220413 | Clean-Up Beads - The present invention provides a material for separating an analyte from an undesired constituent, which material comprises a solid phase and a coating, wherein the solid phase is capable of binding the undesired constituent, and wherein the coating covers the exposed surface of the solid phase to an extent that any binding of the solid phase to the analyte is impeded. A method for preparing the material, and uses of the material for separating an analyte from an undesired constituent are also provided. | 09-11-2008 |
| 20080220414 | Method, Chip, Device and Integrated System for Detection Biological Particles - The present invention relates to a method, a chip, a device, and a system for detection of biological particles. The method of the invention typically comprises collecting the biological particles from a gaseous sample, contacting the biological particles with a first liquid reagent, extracting biological material from the collected biological particles, and analysing the biological material for the presence of a target nucleic acid sequence. | 09-11-2008 |
| 20080220415 | Detection Method of Dna Amplification Using Probe Labeled With Intercalating Dye - The present invention relates to a detection method of nucleic acid amplification using probe labeled with intercalating dye. More particularly, the present invention is directed to a real-time detection method of nucleic acid amplification, comprising the steps of i) producing an aqueous buffer which contains a nucleic acid, a pair of primers for amplification of said nucleic acid, a fluorescent probe wherein a fluorescent dye of which intensity of fluorescence is varied when the dye is intercalated into a double-stranded nucleic acid, is connected with an oligonucleotide of which base sequence is complementary with at least a part of said nucleic acid, four (4) kinds of nucleotides and DNA polymerase; ii) denaturing said doublestranded nucleic acid into single strands by heating the aqueous buffer prepared in step i) up to 931 C to 96 C; iii) annealing said pair of primers with said single strand by cooling the solution obtained in step ii) up to 50 C. to 571 C; iv) replicating said single-stranded nucleic acid by heating the solution obtained from step iii) up to 701 C to 74° C.; v) denaturing said replicated nucleic add into single strands by heating the solution obtained in step iv) up to 931 C to 961 C; vi) annealing said fluorescent probe with said single-stranded nucleic acid by cooling the solution obtained in step v up to 501 C to 57 C; vii) measuring an intensity of the fluorescence emitted from the solution obtained in step vi); and viii) repeating more than one steps iv) through vii). | 09-11-2008 |
| 20080220417 | Novel Alanine Transaminase Enzymes and Methods of Use - Novel alanine transaminase (ALT) polypeptides and the use thereof as a diagnostic marker to predict and monitor tissue damage and/or tissue malfunction. The ALT polypeptides are murine and/or | 09-11-2008 |
| 20080220419 | Method of Isolating P450 Gene - The present invention provides a method for preparing a hybrid gene. The method includes a step of amplifying a P450 gene fragment contained in a sample using primers designed on the basis of regions of a plurality of P450 in which amino acid sequences are highly conserved and a step of preparing the hybrid gene using the amplified fragments and a known P450 gene. The method includes no culturing step or a step of normalizing extracted DNAs and is useful in isolating a P450 gene from various microbial resources. | 09-11-2008 |
| 20080220420 | Method of Detecting Gene Polymorphism, Method of Diagnosing, Apparatus Therefor, and Test Reagent Kit - The object of the invention is to carry out typing for multiple SNP sites automatically from the stage of sample preparation. A mixture of sample ( | 09-11-2008 |
| 20080220421 | ISOTHERMAL SCREENING FOR NUCLEIC ACIDS ASSOCIATED WITH DISEASES AND CONDITIONS OF THE GI TRACT - The presently described technology relates generally to the art of molecular diagnostics and more particularly to point-of-care diagnostic methods and materials. The diagnostic methods and materials of the presently described technology are suitable for a variety of uses including but not limited to the bedside or field diagnosis of infectious or noninfectious diseases. | 09-11-2008 |
| 20080220422 | RARE CELL ANALYSIS USING SAMPLE SPLITTING AND DNA TAGS - The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, e.g. aneuploidy. The present invention involves labeling regions of genomic DNA in each cell in said mixed sample with different labels wherein each label is specific to each cell and quantifying the labeled regions of genomic DNA from each cell in the mixed sample. More particularly the invention involves quantifying labeled DNA polymorphisms from each cell in the mixed sample. | 09-11-2008 |
| 20080220423 | Oligonucleotide probes useful for detection and analysis of microRNA precursors - The invention relates to ribonucleic acids and oligonucleotide probes useful for detection and analysis of microRNA precursors and their targets. The invention furthermore relates to oligonucleotide probes for detection and analysis of other non-coding RNAs, mRNAs, mRNA splice variants, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease, such as cancer. | 09-11-2008 |
| 20080220424 | Method for Predicting Responsiveness to Drugs - The present invention provides a novel method to determine the likelihood of effectiveness of a treatment in an individual affected with or at risk for developing cancer. The method involves detecting the presence or absence of Met amplification in an individual. The presence of Met amplification indicates that a Met targeting treatment is likely to be effective. Preferably, the Met targeting treatment is PHA-665752 or PF-02341066. In addition, the present methods allow for the detection of cancer in an individual, wherein the presence of Met amplification indicates that cancer is present and further that it will be treatable, namely with a Met targeting treatment. | 09-11-2008 |
| 20080220425 | Methods and Compositions for Detecting Target Sequences - The present invention relates to compositions and methods for the detection and characterization of nucleic acid sequences and variations in nucleic acid sequences. The present invention relates to methods for amplifying a synthetic DNA from a target nucleic acid, forming a nucleic acid cleavage structure on the synthetic DNA, and detecting cleavage of the nucleic acid cleavage structure as an indicator of the preset of the target nucleic acid. | 09-11-2008 |
| 20080220426 | MN Gene and Protein - Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular contacts. The MN protein binding site is a therapeutic target that can be blocked by organic or inorganic molecules, preferably organic molecules, more preferably proteins/polypeptides that specifically bind to that site. Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Vectors are provided that encode the variable domains of MN-specific antibodies and a flexible linker polypeptide separating those domains. Further vectors are disclosed that encode a cytotoxic protein/polypeptide operatively linked to the MN gene promoter or a MN gene promoter fragment comprising the HIF-1 consensus binding sequence, and which vectors preferably further encode a cytokine. The MN gene promoter is characterized, and the binding site for a repressor of MN transcription is disclosed. Further, the hypoxia inducibility of the MN gene and the uses of such inducibility are disclosed. | 09-11-2008 |
| 20080220427 | TEST FOR DETERMINING BLOOD TYPE IN THE CAT - The present invention provides compositions and methods for detecting mutations associated with blood type determination in the cat. | 09-11-2008 |
| 20080220428 | COMPOSITIONS AND METHODS FOR DETECTING METHICILLIN-RESISTANT S. AUREUS - The present invention relates to methods of detecting the presence or absence of methicillin-resistant | 09-11-2008 |
| 20080220429 | Single nucleotide polymorphisms and the identification of lactose intolerance - The present invention relates generally to methods, kits, genotyping and/or nucleic acid molecules associated with the identification of a predisposition for lactase persistence, lactase non-persistence, lactose tolerance and/or lactose intolerance. The methods of the present invention comprise in general determining the presence or absence of at least one variant allele having one or more single nucleotide polymorphisms within a gene associated with the expression of lactase-phlorizin hydrolase. The single nucleotide polymorphism is selected from the group consisting essentially of C-14010, G-13915 and G-13907, as measured from the start of the LCT gene. | 09-11-2008 |
| 20080220430 | Methods for assessing risk for cardiac dysrythmia in a human subject - The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing Andersen's Syndrome. A tissue sample from a patient is obtained and the DNA or proteins of the sample isolated. From the DNA and protein isolates the sequence of the KCNJ2 gene or the Kir2.1 polypeptide can be obtained. The KCNJ2 gene or the Kir2.1 can be screened for alteration as compared to the wile-type sequence. An alteration in a copy of the KCNJ2 gene or a Kir2.1 polypeptide indicates that the patient has a high risk for developing a cardiac dysrhythmia and can be diagnosed with Andersen's Syndrome. The invention also related to isolated nucleic acid molecules with one or more alterations as compared to the wild-type sequence. | 09-11-2008 |
| 20080220431 | Cell fusion method - The invention provides methods for fusing a first cell with a second cell to form a hybrid cell. The methods involve incubating a first parental cell producing a first partner of a fusogenic binding partner pair on its surface with a second parental cell producing a second partner of the fusogenic binding partner pair on its surface. In certain embodiments, the parental cells are incubated with a known fusogen such as polyethylene glycol and the fusogenic binding partner pair increases the rate of cell fusion. In many embodiments, the first cell is an antibody producing cell, the second cell is an immortal cell, and the hybrid cell is a hybridoma cell that produces a monoclonal antibody. Also provided by the invention are methods for producing hybridoma cells, and methods for screening those cells for production of a monoclonal antibody of interest. The invention further provides systems and kits for carrying out the subject methods. The subject methods, systems, and kits find use in a variety of different industrial, medical and research applications. | 09-11-2008 |
| 20080220432 | Optimized host cells for protein production - The present invention relates to methods for isolating cells that express increased levels of an RNA or protein of interest, wherein the cells exhibit altered growth profiles, such as cells with increased or decreased rates of proliferation, increased or decreased rates of apoptosis, or cells with a biphasic growth profile. | 09-11-2008 |
| 20080220433 | DETECTING METHYLATED MAMMALIAN NUCLEIC ACID IN STOOL - This document includes methods and materials for enriching and detecting cancer markers. For example, this document includes methods and materials for enriching methylated mammalian nucleic acid from stool samples. | 09-11-2008 |
| 20080220434 | Detection Of Molecule Proximity - The present invention provides methods, compositions and kits for identifying molecules such as proteins or nucleic acids that are found in proximity to each other in vitro or in vivo. For example, the present invention provides for the modification of one or more molecules that are complexed with, or in proximity to, a target biomolecule, wherein the modification of the one or more complexed or proximal molecules is detected. | 09-11-2008 |
| 20080220435 | METHOD FOR DETECTING TARGET SUBSTANCE UTILIZING PROBE DESORPTION - It is an object of the present invention to provide a method for detecting a target substance in a specimen with the use of fine particles, whereby the target substance can be readily detected with the exclusive use of a single type of probe and the detection limit is improved. The present invention provides a method for detecting a target substance in a specimen which comprises the steps of: allowing a complex of a fine particle and a probe to come into contact with a specimen; and detecting changes in physical properties of the fine particle that are caused by desorption of the probe from the fine particle due to interaction between the target substance in the specimen and the probe. | 09-11-2008 |
| 20080220436 | METHODS AND COMPOSITIONS FOR RAPID LIGHT-ACTIVATED ISOLATION AND DETECTION OF ANALYTES - The present invention relates to novel methods for isolating a target molecule from a sample suspected of containing the target molecule. The methods of the present invention utilize solid substrates as a means for capturing, separating, and releasing target molecules, such as chemical or biological compounds. The present invention is specifically directed to novel approaches for capturing, separating and releasing such target molecules. | 09-11-2008 |
| 20080220437 | Substrate Material for Handling and Analysing Samples - The invention relates to a substrate material for analyzing one or more fluid samples for the presence, amount or identity of one or more analytes in the samples, whereby the substrate material is adapted in that way that a flow of the sample or parts thereof in and/or with the substrate material is influenced and/or caused by phase transitions, preferably temperature-inducible phase transitions, in selected areas of the substrate material. | 09-11-2008 |
| 20080220438 | Telomerase Promoter Sequences for Screening Telomerase Modulators - Telomerase reverse transcriptase is part of the telomerase complex responsible for maintaining telomere length and increasing the replicative capacity of progenitor cells. Telomerase activity is turned off in mature differentiated cells, but is turned back on again in hyperplastic diseases, including many cancers. This disclosure provides regulatory elements that promote transcription in cells that express telomerase reverse transcriptase (TERT). The disclosure also provides systems using TERT promoter sequences for identifying compounds that can be used to modulate telomerase expression | 09-11-2008 |
| 20080220439 | Microorganism detecting kit, microorganism counting apparatus, and microorganism counting process - A microorganism detecting kit according to the present invention includes a self-adhesive layer | 09-11-2008 |
| 20080227085 | Methods and Systems for the Identification of Rna Regulatory Sequences and Compounds that Modulate their Function - The present invention is directed to a non-cell based method for identifying RNA regulatory sequences involved in translational control. The method includes: combining a translational extract; an RNA test sequence; and a reporter mRNA under suitable conditions for translation of the reporter mRNA. The method also includes measuring the effect of the test sequence on the translation of the reporter mRNA, wherein a test sequence that modifies the translation of the reporter mRNA includes an RNA regulatory element. The invention also provides methods and systems for identifying test compounds that modulate the regulatory activity of an RNA regulatory sequence. In the method, an RNA regulatory sequence, which regulates translation of a reporter mRNA, is combined with a translation extract; the reporter mRNA; and at least one test compound. The method further includes measuring the effect of the test compound on the ability of the RNA regulatory sequence to regulate the translation of the reporter mRNA. | 09-18-2008 |
| 20080227086 | Test System and Method for the Detection of Analytes - The invention relates to analytical test systems and analytical methods, in which molecular switches are used for the qualitative and quantitative determination of analytes in a sample, which have a broad application by means of a selection of the molecular switch suitable for the analyte. The molecular switch comprises a probe, preferably a nucleic acid or a nucleic acid derivative, coupled to a catalytic component, preferably an enzyme. The analyte induces a conformation change in the probe, which alters the accessibility for a substrate in the probe to catalytic components and the change in substrate turnover, corresponding to the change in catalytic activity, is measured. | 09-18-2008 |
| 20080227087 | Sequences for detection and identification of methicillin-resistant Staphylococcus aureus (MRSA) of MREJ types xi to xx - Described herein are novel SCCmec right extremity junction (MREJ) sequences for the detection and/or identification of methicillin-resistant | 09-18-2008 |
| 20080227088 | Approaches to Identify Less Harmful Tobacco and Tobacco Products - Aspects of the invention concern methods for detecting, identifying and evaluating tobacco and tobacco products to determine the potential that these compositions have to contribute to a tobacco-related disease. It is based, at least in part; on the discovery that exposure of pulmonary cells to smoke or smoke condensate obtained from tobacco or tobacco products induces double stranded breaks in cellular DNA, which were efficiently detected using assays that measure the presence, absence, or amount of phosphorylation of the histone, H2AX. | 09-18-2008 |
| 20080227089 | Method of Diagnosing and/or Predicting the Development of an Allergic Disorder - The present invention relates to methods for diagnosing an allergic disorder, predicting the development of an allergic disorder in an animal, monitoring the progress of therapy targeted at an allergic disorder, classification of the allergic disorder into one or more clinical/immunological phenotypes, and/or determining the potentional responsiveness of individual animals suffering from or at risk of an allergic disorder to particular forms of therapy. In particular, the present invention relates to a method of diagnosing and/or predicting the development of an allergic disorder in an animal, comprising the step of analysing a biological sample from the animal to determine the level of activation of one or more allergy-associated genes, in which the level of activation is diagnostic of the allergic disorder or predicative of the relative risk for the development of an allergic disorder in the animal. | 09-18-2008 |
| 20080227090 | METHODS, APPARATUS, AND COMPUTER PROGRAMS FOR VERIFYING THE INTEGRITY OF A PROBE - The present invention provides methods, apparatuses and computer programs for verifying the integrity of a probe by comparing the fluorescence value of a probe to a threshold value. The invention also provides for methods, apparatuses and computer programs for normalizing the fluorescence value of a probe and detecting a target nucleic acid in a sample. | 09-18-2008 |
| 20080227091 | QTL controlling Sclerotinia stem ROT resistance in soybean - Markers associated with | 09-18-2008 |
| 20080227092 | Solid-Phase Oligosaccharide Tagging: a Technique for Manipulation of Immobilized Carbohydrates - The invention relates to methods of manipulating immobilised carbohydrates by derivatisation. Depending on the nature of the derivatisation, the carbohydrate may thereby be more easily detected and/or identified or handled. In particular, the invention relates to methods of preparing a reactive sugar comprising the steps of: i) providing a sample comprising a reducing sugar; ii) providing a solid support covalently attached to a linker comprising a capture group comprising an —NH2 group, wherein said linker optionally is attached to said solid support via a spacer; iii) reacting said reducing sugar with said —NH2 group, thereby obtaining an immobilised sugar; iv) reacting free —NH2 groups with a capping agent, wherein the capping agent comprises a reactive group capable of reacting with an —NH2 group; and v) reducing C═N bonds with a reducing agent, thereby obtaining an reactive sugar of the structure SugarCH | 09-18-2008 |
| 20080227093 | PHENYLTHIOCARBAMIDE (PTC) TASTE RECEPTOR - The invention provides isolated nucleic and amino acid sequences of a taste cell receptor that serves as a sensor for the bitter taste of phenylthiocarbamide (PTC), antibodies to such PTC taste receptor, methods of detecting such nucleic and amino acid sequences, and methods of screening for modulators of such PTC taste receptor. | 09-18-2008 |
| 20080227094 | METHOD OF JUDGING LYMPH NODE METASTASIS OF STOMACH CANCER - Methods of judging the lymph node metastasis of stomach cancer, apparatuses for judging the lymph node metastasis of stomach cancer and kits used therefor are disclosed. | 09-18-2008 |
| 20080227095 | Systems and methods of analyzing nucleic acid polymers and related components - Systems and methods of identifying, sequencing and/or detecting nucleic acid polymers, as well as related components (e.g., substrates, software and the like) are disclosed. | 09-18-2008 |
| 20080227096 | Assay for response to proteasome inhibitors - The invention relates to a method for predicting a response to a proteasome inhibitor in the prophylaxis or treatment of a cancer in an individual. The method comprises providing a sample of cancer cells of the cancer from the individual, and evaluating the level of at least one molecule in the cancer cells associated with the unfolded protein response of the cancer cells, to provide test data indicative of the level of activity of the unfolded protein response. The test data is used to predict the response of the cancer cells to the proteasome inhibitor. The evaluation of the level of the molecule can be utilized for determination of treatment for the cancer. | 09-18-2008 |
| 20080227097 | FLUORESCENT PROTEIN AND CHROMOPROTEIN - It is an object of the present invention to provide a novel chromoprotein and a novel fluorescent protein. The present invention provides chromoproteins derived from | 09-18-2008 |
| 20080227098 | METHOD FOR DIAGNOSING CANCER OF THE PROSTATE - Methods for diagnosis and prognosis of prostate cancer are provided. The methods involve the detection of the level of expression of Claudin-1 in tissue or cell samples. Claudin-1 is underexpressed or non-expressed in the majority of prostate cancers. | 09-18-2008 |
| 20080227099 | COMPOSITIONS AND METHODS FOR INCREASING CHOLESTEROL EFFLUX AND RAISING HDL USING ATP BINDING CASSETTE TRANSPORTER PROTEIN ABC1 - The present invention relates to novel ABC1 polypeptides and nucleic acid molecules encoding the same. The invention also relates to recombinant vectors, host cells, and compositions comprising ABC1 polynucleotides, as well as to methods for producing ABC1 polypeptides. The invention also relates to antibodies that bind specifically to ABC1 polypeptides. In addition, the invention relates to methods for increasing cholesterol efflux as well as to methods for increasing ABC1 expression and activity. The present invention further relates to methods for identifying compounds that modulate the expression of ABC1 and methods for detecting the comparative level of ABC1 polypeptides and polynucleotides in a mammalian subject. The present invention also provides kits and compositions suitable for screening compounds to determine the ABC1 expression modulating activity of the compound, as well as kits and compositions suitable to determine whether a compound modulates ABC1-dependent cholesterol efflux. | 09-18-2008 |
| 20080227100 | METHOD FOR ESTIMATING hERG INHIBITION OF DRUG CANDIDATES USING MULTIVARIATE PROPERTY AND PHARMACOPHORE SAR - The present invention provides a computational model and methods of use thereof for predicting whether a compound is likely to inhibit K | 09-18-2008 |
| 20080227101 | METHODS FOR TESTING MILK - The disclosure is related generally to methods for testing mammary fluid (including milk) to establish or confirm the identity of the donor of the mammary fluid. Such methods are useful in the milk-bank business to improve safety. | 09-18-2008 |
| 20080227102 | Methods for Identification of Merle Gene - Animals with mutations in SILV present with the merle coat color pattern phenotype. Methods for the identification of animals that harbor a mutation in the SILV gene are described. Mutations in the SILV gene can be identified from any biological sample such as a cell or tissue that contains genomic DNA. A microsatellite marker identified using linkage disequilibrium mapping that segregates with merle is also described. | 09-18-2008 |
| 20080227103 | Method for identification of polynucleotides capable of cleaving target mRNA sequences - Provided are methods for identifying a polynucleotide that can reduce the level of a target mRNA. The method can be performed by providing cells that express an RNA polynucleotide that contains a target mRNA sequence, an internal ribosome entry sequence (IRES) and a sequence encoding a secreted reporter protein; introducing to the cells a test polynucleotide, and measuring activity of the secreted reporter protein. A reduction in secreted reporter protein activity relative to a control cell into which the test polynucleotide has not been introduced is indicative that the test polynucleotide is capable of reducing the level of the target mRNA in the cells. The method is adaptable for high throughput screening methods and is suited for identifying polynucleotides that can catalyze cleavage of target mRNA and/or act on target mRNA through and antisense or RNAi mechanism. | 09-18-2008 |
| 20080227104 | Primer, primer set, and nucleic acid amplification method and mutation detection method using the same - The present invention provides a primer that effectively can detect, for example, the double helix structure of a nucleic acid. The primer is a labeled nucleic acid containing at least one structure represented by the following formula (16), | 09-18-2008 |
| 20080227105 | Method for diagnosing diseases - An improved method for diagnosing autoimmune or genetic diseases is provided in this disclosure. In particular, a method to diagnose diseases affecting the tissues of organs selected from the group of spleen, brain, heart, kidney, thyroid, eye, skin, intestine, liver, pancreas, adrenal gland, prostate and lungs or from the tissues selected from the group of muscles and bones or other tissues. More specifically, the present invention provides an improved method for diagnosing diseases affecting neuromuscular junctions. | 09-18-2008 |
| 20080227106 | Compositions and methods for the diagnosis and treatment of tumor - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 09-18-2008 |
| 20080227107 | COMPOSITIONS AND METHODS FOR LABELING OF NUCLEIC ACID MOLECULES - The present invention is generally related to compositions, kits and methods for labeling nucleic acid molecules using reverse transcriptases, preferably multi-subunit reverse transcriptases such as ASLV reverse transcriptases. Specifically, the invention relates to methods, kits and compositions for fluorescently labeling nucleic acid molecules during nucleic acid synthesis. The labeled nucleic acid molecules produced in accordance with the invention are particularly suited as labeled probes for nucleic acid detection and diagnostics. | 09-18-2008 |
| 20080227108 | MOLECULAR IDENTIFICATION OF ASPERGILLUS SPECIES - Novel techniques for the detection of | 09-18-2008 |
| 20080227109 | Risk assessment for adverse drug reactions - The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB 1 and HLA-A region of the specific HLA-B haplotype can also be used for the test. | 09-18-2008 |
| 20080233563 | Enhanced Detection of Rna Using a Panel of Truncated Gene-Specific Primers for Reverse Transcription - The present invention provides truncated gene-specific primers in panels that can be used during the reverse transcription step of RT-PCR to increase signal detection of cancer gene markers in a tissue sample. Also provided are forward and reverse primers for RT-PCR. Methods of using the primers are also provided. | 09-25-2008 |
| 20080233565 | PKHDL1, a homolog of the autosomal recessive kidney disease gene - Nucleic acids encoding fibrocystin-L polypeptides and fibrocystin-L polypeptides are provided. Antibodies against the polypeptides, vectors and host cells containing the nucleic acids, methods for using the nucleic acids and polypeptides, and compositions and articles of manufacture also are provided. | 09-25-2008 |
| 20080233566 | Methods and materials for detecting mutations in quasispecies having length polymorphisms - The present invention is directed to a method for detecting the presence or absence of a mutation of interest in the nucleic acid of a pathogen, wherein the mutation of interest is located adjacent to a length polymorphism defining multiple quasispecies of the pathogen. | 09-25-2008 |
| 20080233567 | Companion diagnostic assays for cancer therapy - A method for classifying cancer patients as eligible to receive cancer therapy with a small molecule inhibitor of Bcl-2 comprising determination of the presence or absence in a patient tissue sample of chromosomal copy number status at the chromosomal locus 13q14 comprising the microRNA's miR15 | 09-25-2008 |
| 20080233568 | Detection of Extracellular Tumor-Associated Nucleic Acid in Blood Plasma or Serum Using Nucleic Acid Amplification Assays - This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such as oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease. The invention thereby provides methods for early identification of colorectal, pancreatic, lung, breast, bladder, ovarian, lymphoma and all other malignancies carrying tumor-related mutations of DNA and methods for monitoring cancer and other neoplastic disorders in humans and other animals. | 09-25-2008 |
| 20080233569 | Detection of Extracellular Tumor-Associated Nucleic Acid in Blood Plasma or Serum Using Nucleic Acid Amplification Assays - This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such as oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease. The invention thereby provides methods for early identification of colorectal, pancreatic, lung, breast, bladder, ovarian, lymphoma and all other malignancies carrying tumor-related mutations of DNA and methods for monitoring cancer and other neoplastic disorders in humans and other animals. | 09-25-2008 |
| 20080233570 | METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA - The present invention provides compositions, kits and methods for rapid identification and quantification of sepsis-causing bacteria by molecular mass and base composition analysis. | 09-25-2008 |
| 20080233571 | Method for identifying compounds which affect synaptogenesis - A method is provided for identifying a compound which affects the formation of AMPA receptors into aggregates. A method is also provided for identifying a compound which affects the formation of synaptic connections. A method is provided for identifying a compound that modulates immediate early gene expression. A method is further provided for increasing the number of excretory synapses of a neuron, including introducing into the neuron a polynucleotide sequence encoding a Narp operatively linked to a promoter, or a Narp polypeptide, thereby increasing the number of excretory synapses of the neuron. A method is provided for treating a subject with a disorder associated with a decrease in a function or expression of Narp, including administering to the subject a therapeutically effective amount of a compound that augments Narp function or expression. A method is provided for treating a subject with a disorder associated with an increase in a function or expression of Narp, including administering to the subject a therapeutically effective of a compound that inhibits Narp function or expression. A method is provided for treating a patient having or at risk of having a disorder associated with decreased Narp expression. The method includes introducing into a cell of a patient having a disorder associated with decreased Narp expression or function a polynucleotide sequence encoding a Narp polypeptide operatively linked to a promoter. A method is provided for treating a subject having a deficiency in a neuron's immediate early gene responsiveness to a stimulus. The method includes administering a nucleic acid encoding a Narp polypeptide to said subject, wherein the administration results in amelioration of the deficiency. | 09-25-2008 |
| 20080233572 | METHODS AND COMPOSITIONS FOR THE DETECTION AND QUANTIFICATION OF E.COLI AND ENTEROCOCCUS - The present invention is drawn to methods and compositions for the rapid assessment of fecal indicator bacteria in a sample. Provided herein are novel primer and probe compositions for use in detecting the presence of these organisms in a sample, particularly using quantitative PCR methods. Provided herein are novel oligonucleotide primers and probes, including the primers set forth in SEQ ID NO:1-4, the novel oligonucleotide probe sequences set forth in SEQ ID NO:5-8, and methods for using these primers and probes for the detection and/or quantification of fecal indicator bacteria, particularly | 09-25-2008 |
| 20080233573 | Gene expression profiling for identification, monitoring and treatment of transplant rejection - The present invention provides methods of characterizing organ transplant rejection or inflammatory conditions associated with organ transplant rejection using gene expression profiling. | 09-25-2008 |
| 20080233574 | Map-Based Genome Mining Method for Identifying Regulatory Loci Controlling the Level of Gene Transcripts and Products - The invention pertains to a method for identifying one or more regions within a genome of an organism of interest that mediate the expression of one or more genes of interest. The method comprises identifying a first and a second organism of interest, the first organism of interest is characterized by exhibiting a measurable response to an environmental stimulus, or otherwise, exhibiting a phenotype associated with differential gene expression associated with a process of interest. The second organism of interest is characterized by lacking or not exhibit as strong a response to the stimulus as that observed within the first organism of interest, or it exhibits a different phenotype compared with that of the first organism of interest, wherein the different phenotype is associated with the process of interest, or it exhibits a phenotype of interest that segregates when compared with the first organism of interest, or a combination thereof. The first and second organisms of interest are crossed to produce a population of segregated progeny and RNA is extracted from each of the segregated progeny. The level of gene expression for one or more genes of interest that are associated with the response to an environmental stimulus, or process of interest is quantified. A linkage map of the segregated progeny using one or more markers is prepared, and the relationship between said one or more markers on the linkage map and the gene expression of the one or more genes of interest is determined and one or more quantitative trait loci (QTL) identified. This method also pertains to identifying one or more QTLs associated with one or more genes of interest in segregated progeny that are subjected a desired environmental stimulus. Furthermore, this method may be used for the identification of one or more QTL corresponding to a transcription factor or any factor controlling the expression of one or more genes of interest, and the one or more genes located at the one or more QTL may be isolated and characterized. | 09-25-2008 |
| 20080233575 | Methods for increasing accuracy of nucleic scid sequencing - The invention provides methods for improving the fidelity of a sequencing-by-synthesis reaction by resequencing at least a portion of a nucleic acid template. | 09-25-2008 |
| 20080233576 | METHOD FOR FEATURE SELECTION IN A SUPPORT VECTOR MACHINE USING FEATURE RANKING - In a pre-processing step prior to training a learning machine, pre-processing includes reducing the quantity of features to be processed using feature selection methods selected from the group consisting of recursive feature elimination (RFE), minimizing the number of non-zero parameters of the system (l | 09-25-2008 |
| 20080233577 | METHOD FOR PRODUCING LIGANDS, LIGANDS AND TEST KIT - The invention relates to a method for producing ligands, in particular aptamers. With this method, a target substance is offered to a set of candidate ligands, and the unbonded ligands are separated out by a cross-flow filtration process. The retentate, which contains ligand-target substance complexes, then undergoes further continuous cross-flow filtration while chemical and/or physical parameters are being varied. After each variation of a parameter, those candidate ligands whose bond with the target substance was dissolved by the parameter variation are collected in separate fractions and separately multiplied. | 09-25-2008 |
| 20080233578 | METHOD FOR DETECTING MUTATION OF NUCLEIC ACID USING SINGLE-STRANDED DNA-BINDING PROTEIN - A method for judging the presence or absence of a mutation in a nucleic acid sequence, the method includes utilizing a single-stranded DNA-binding protein; the aforementioned method for judging the presence or absence of a mutation in a nucleic acid sequence, wherein the aforementioned presence or absence of a mutation in a nucleic acid sequence is judged by a product formed by a nucleic acid amplification reaction utilizing the single-stranded DNA-binding protein; and a kit for judging the presence or absence of the aforementioned mutation in a nucleic acid sequence. | 09-25-2008 |
| 20080233579 | PRIMER SET FOR DETECTING OVEREXPRESSION OF KATP CHANNEL AND KIT COMPRISING SAID PRIMER SET - The present invention relates to a primer set for confirming an increase of mRNA in an ATP-sensitive potassium channel (K | 09-25-2008 |
| 20080233580 | Transgenic animal model - The present invention is related to a transgenic, non-human animal, particularly a transgenic rodent, but especially a transgenic mouse model which allows for the simultaneous, tissue-specific and temporally-controlled regulation of transgene expression and can be used as a tool to investigate the consecutive steps involved in initiation and progression of certain diseases such as cancer, but particularly lung cancer. | 09-25-2008 |
| 20080233581 | HISTONE DEACETYLASE AND METHODS OF USE THEREOF - The present invention provides nucleic acid molecules that encode histone deacetylase, as well as recombinant vectors and host cells that include the subject nucleic acid molecules. Also provided are histone deacetylase polypeptide compositions. The histone deacteylase nucleic acid molecules are useful in a variety of diagnostic and therapeutic applications, which are also provided. | 09-25-2008 |
| 20080233582 | SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH SUSCEPTIBILITY TO CARDIOVASCULAR DISEASE - The present invention provides SNPs, polymorphic variants, and haplotypes associated with cardiovascular disease. The invention also provides methods for detecting the SNPs, polymorphic variants, and haplotypes. The invention also provides methods for determining an individual's genotype with respect to one or more polymorphisms and/or haplotypes associated with cardiovascular disease. The invention further provides methods of determining whether an individual has or is susceptible to development or occurrence of a cardiovascular disease or event. The methods are useful for providing diagnostic and/or prognostic information, selecting therapeutic regimens, etc. The invention further provides reagents and kits for practicing the methods. | 09-25-2008 |
| 20080233583 | BIOMARKERS FOR PREECLAMPSIA - The present invention provides methods for predicting the development of and diagnosing preeclampsia, providing a prognosis, and predicting recurrence of the disease using molecular markers that are overexpressed or underexpressed in preeclampia. Also provided are methods to identify compounds that are useful for the treatment or prevention of preeclampsia. | 09-25-2008 |
| 20080233584 | RNAi MODULATION OF MLL-AF4 AND USES THEREOF - The invention relates to compositions and methods for modulating the expression of the MLL-AF4 fusion gene, and more particularly to the downregulation of MLL-AF4 by chemically modified oligonucleotides. | 09-25-2008 |
| 20080233585 | USE OF DIFFERENTIALLY EXPRESSED NUCLEIC ACID SEQUENCES AS BIOMARKERS FOR CANCER - The present invention relates to novel marker sequences that are differentially expressed in cancer cells or tissue of a subject with cancerous conditions. The present invention also relates to assays for diagnosis, prognosis, staging, monitoring, therapeutic treatment, and marker sequence related agents including probes, primers, antibodies, and therapeutic compositions. | 09-25-2008 |
| 20080233586 | METHODS FOR PREPARING AND PREFORMING ANALYSIS - The invention relates to methods for preparing and performing quantitative PCR analyses, a new sealing device and a new use. According to the invention, a sample vessel containing the samples to be analyzed is sealed by placing a planar sealing device on the vessel to cover the samples and applying pressure on the sealing device in order to deform the sealing device so as to form a light-refracting geometry individually for the samples to be analyzed. The invention offers a convenient way of sealing the vessel and forming analysis-improving optical lenses over the samples simultaneously. | 09-25-2008 |
| 20080233587 | METHOD FOR DIRECT AMPLIFICATION FROM CRUDE NUCLEIC ACID SAMPLES - The present teachings relate to improved methods, kits, and reaction mixtures for amplifying nucleic acids. In some embodiments a novel direct buffer formulation is provided which allows for the direct amplification of the nucleic acids in a crude sample with minimal sample purification. | 09-25-2008 |
| 20080233588 | Analytical Method and Kit - Analytical methods using RNA-containing probes for the detection or analysis of nucleic acid sequences is described. These probes are contacted with a sample suspected of containing the nucleic acid sequence and if they form duplexes, they are hydrolysed. This may be done, for example during an amplification reaction. AMP generated as a result of the hydrolysis is converted to ATP. The ATP may then be detected using bioluminescent reagents. Inclusion of modified adenosine in at least one probe means that the signal arising from one probe will give rise to a different and distinguishable bioluminescent signal thus enabling the use of for example an internal control in bioluminescently-reported nucleic acid tests. | 09-25-2008 |
| 20080233589 | Complementation Systems Utilizing Complexes of Heteroproteins - The present invention provides heterologous complementation systems and methods of using the systems to detect molecular interactions. In particular, the heterologous complementation systems comprise polypeptide fragments derived from heterologous polypeptides. If a molecular interaction occurs, then the heterologous polypeptide fragments are able to associate and produce a detectable signal. | 09-25-2008 |
| 20080233590 | Device For the Analysis of Liquid Samples - The present invention relates to devices for the analysis of liquid samples, comprising a rotational-symmetric rotor ( | 09-25-2008 |
| 20080233591 | METHOD AND TEST KIT FOR QUANTITATIVE DETERMINATION OF POLYNUCLEOTIDES IN A MIXTURE - The invention relates to a method and test kit for quantitative determination of the amounts or relative proportions of polynucleotides in a mixture. The invention enables assessment of dynamic variations in a mixed population of organisms using affinity aided solution hybridization. The test kit comprises organized pools of polynucleotide probes having approximately the same number of nucleotides, which are distinguishable using resolution enabling tags providing the probes with different sizes. The resolution enabling tags may simultaneously act as tracer, affinity or primer tags. The probes are allowed to hybridize with affinity tagged analyte polynucleotides. The result is hybrids, recoverable on separation aiding tools provided with counterparts of the affinity tag. After the quantitative release of the probes, the individual probes can be amplified and recorded. The method and test kit are useful for determining hygienic and epidemiologic situations and evaluating the effect of antibiotic treatment and sanitary measures. | 09-25-2008 |
| 20080233592 | Assay Method for Group Transfer Reactions - The present invention relates to methods for detecting, quantifying and high throughput screening of donor-products and the catalytic activities generating the donor-products in group-transfer reactions catalyzed by adenosine triphosphatase (ATPase) or guanine triphosphatase (GTPase). The invention further provides immunoassays, antibodies and kits that may be used to practice the methods of the invention. | 09-25-2008 |
| 20080233593 | Pseudo-Tissue for Quality Control and Quality Control Method Using Same - A pseudo-tissue for quality control is described, which includes a nucleic acid component selected from the group consisting of a nucleic acid and a cell including a nucleic acid, and a gel for holding nucleic acid component. | 09-25-2008 |
| 20080241822 | GENOME-WIDE LOCATION AND FUNCTION OF DNA BINDING PROTEINS - The present invention relates to a method of identifying a region (one or more) of a genome of a cell to which a protein of interest binds. In the methods described herein, DNA binding protein of a cell is linked (e.g., covalently crosslinked) to genomic DNA of a cell. The genomic DNA to which the DNA binding protein is linked is removed and combined or contacted with DNA comprising a sequence complementary to genomic DNA of the cell under conditions in which hybridization between the identified genomic DNA and the sequence complementary to genomic DNA occurs. Region(s) of hybridization are region(s) of the genome of the cell to which the protein of binds. A method of identifying a set of genes where cell cycle regulator binding correlates with gene expression and of identifying genomic targets of cell cycle transcription activators in living cells is also encompassed. | 10-02-2008 |
| 20080241823 | Method for Hla Typing - A method for the identification of DNA sequence elements in complex and highly variable sequences is described. The method consists of identifying a short sequence element of several DNA bases (2-6 bases) at a given position in the genome simultaneously on all parental alleles. The method allows differentiating mini-haplotypes on different alleles in one analysis. The method consists of carrying out an enzymatic primer extension reaction with a combination of extension primers (pool of primers) and analysing the products by mass spectrometry. The pool of primers is assembled in such a way that the primer extension product allows unambiguous identification of both the primer of the pool that was extended and the base that was added. The method is of great utility for DNA sequences harbouring many SNPs close to each other with many possible haplotypes. Such sequences are known in the Major Histocompatibility Complex (MHC). This method is particularly well suited for DNA-based HLA typing and in combination with a suitable selection of sites tested, it is superior in ease of operation to conventional HLA typing methods. We have identified sets of these assays for HLA-A, HLA-B, and HLA-DRB 1 that allow unambiguous four-digit HLA of each of these genes with between 11 and 28 queried markers. | 10-02-2008 |
| 20080241824 | Mutation Associated With Lacunar Strokes - The present invention relates to a method of identifying a subject predisposed to lacunar stroke. The method includes the step of identifying in the subject the presence of a thymine to cytosine mutation at position -107 in both alleles of the paraoxonase 1 locus. | 10-02-2008 |
| 20080241825 | Materials and Methods for Treatment of Cancer - Glypican 5 is shown for the first time to have a role in proliferation of cancer cells, including tumours which do not show chromosomal amplification at 13q31. The use of glypican 5 (GPC5) antagonists and binding agents for the treatment of cancer, particularly rhabdomyosarcoma and breast cancer, is disclosed. | 10-02-2008 |
| 20080241826 | Probe And Primer For Tubercle Bacillus Detection, And Method Of Detecting Human Tubercle Bacillus Therewith - An object of the present invention is to provide a novel primer and prove for detecting tubercle | 10-02-2008 |
| 20080241827 | Methods For Detecting A Mutant Nucleic Acid - The invention relates to methods for detection of genomic variation. The invention may be used to analyze nucleic acid sequences to detect low frequency mutations in a sample and/or screen for the presence of a disease. | 10-02-2008 |
| 20080241828 | DETECTION OF DNA METHYLATION USING RAMAN SPECTROSCOPY - Epigenetic events such as DNA methylation play important roles in the regulation of gene expression. DNA methylation patterns have been found to differ between healthy and diseased tissue, such as healthy and cancerous tissue, thereby allowing DNA methylation to serve as a biomarker for disease states. Embodiments of the invention provide methods for detecting methylation patterns in DNA polymers. Methylation patterns are detected, in part, through the use of surface enhanced Raman spectroscopy (SERS). SERS provides a sensitive structure-based technique for chemical analysis. | 10-02-2008 |
| 20080241829 | Methods And Kits For Producing Labeled Target Nucleic Acid For Use In Array Based Hybridization Applications - Methods for producing labeled probe nucleic acids from genomic nucleic acid template are provided. In some embodiments of the subject methods, a plurality of sequence-specific primers are employed to enzymatically generate a set of labeled target nucleic acids corresponding to coding regions of genes from a genomic template via a primer extension protocol. The subject methods find use in a variety of different applications, and can be used, for example, in the preparation of labeled probe nucleic acids for use in array based comparative genomic hybridization applications. Also provided are kits for use in practicing the subject methods. | 10-02-2008 |
| 20080241830 | Digital amplification - The identification of pre-defined mutations expected to be present in a minor fraction of a cell population is important for a variety of basic research and clinical applications. The exponential, analog nature of the polymerase chain reaction is transformed into a linear, digital signal suitable for this purpose. Single molecules can be isolated by dilution and individually amplified; each product is then separately analyzed for the presence of pre-defined mutations. The process provides a reliable and quantitative measure of the proportion of variant sequences within a DNA sample. | 10-02-2008 |
| 20080241831 | Methods for detecting small RNA species - The invention provides a method of detecting small target nucleotide sequences, in particular, small RNA species that are present in a sample. The method generally comprises a poly-A polymerization step or a ligation step to add a universal sequence to the 3′-end of all RNA molecules, followed by a universal primer-mediated cDNA synthesis, solid-phase selection, assay oligo annealing, extension and PCR amplification/labeling. The method of the invention can be practiced to amplify and label a small amount of miRNA or other ncRNA. The resulting amplification product can be read out on a universal array or an array with miRNA-specific or ncRNA-specific probes. The invention has multiple embodiments, including methods, compositions, and kits. In general, the nucleic acids, compositions, and kits comprise materials that are useful in carrying out the methods of the invention or are produced by the methods, and that can be used to detect small target nucleic acid sequences present in samples, in particular, small RNA species. | 10-02-2008 |
| 20080241832 | METHOD OF DETECTING AND QUANTIFYING HEPATITIS C VIRUS - Methods, reagents, and kits for detecting hepatitis C virus (HCV) in biological samples. | 10-02-2008 |
| 20080241833 | SYSTEM AND METHOD FOR NUCLEIC ACID SEQUENCING BY POLYMERASE SYNTHESIS - This invention relates to improved methods for sequencing and genotyping nucleic acid in a single molecule configuration. The method involves single molecule detection of fluorescent labeled PPi moieties released from NTPs as a polymerase extension product is created. | 10-02-2008 |
| 20080241834 | Method for improving neoadjuvant chemotherapy - Disclosed is a method and composition for optimizing the efficiency of breast cancer neoadjuvant chemotherapy, depending on the particular constitutional genotype characteristics of the gene BRCA1 in each patient. Generally, the invention concerns a new method to improve neoadjuvant therapy depending on a particular constitutional genotype. Subject of invention allow to synthesize DNA and identification of germline BRCA1 genetic abnormalities which are correlated with a significantly decreased clinical response to neoadjuvant chemotherapy based on taxane-derived cytostatics in breast cancer patients. | 10-02-2008 |
| 20080241835 | DIFFERENTIALLY EXPRESSED GENES INVOLVED IN ANGIOGENESIS, THE POLYPEPTIDES ENCODED THEREBY, AND METHODS OF USING THE SAME - The present invention is directed to nucleic acid sequences and the polypeptides encoded thereby that are differentially expressed in angiogenesis. Also provided are methods for stimulating or inhibiting angiogenesis in mammals, including humans. Pharmaceutical compositions based on polypeptides, agonists, or antagonists thereto are also provided. Additionally, the invention also provides methods for diagnosing and treating angiogenic disorders including, but not limited to, wound healing and cancer. | 10-02-2008 |
| 20080241836 | PROCESS FOR SELF-ASSEMBLY OF STRUCTURES IN A LIQUID - A process and apparatus for self-assembling a number of elements and determining their sequence is provided. In the field of DNA analysis, an iterative process is disclosed wherein an apparatus with a set of reaction chambers in which a species of recognition element nucleotides are differentially added and subjected to a polymerization reaction allows recognition of which species is next in sequence on a template strand by the effect that synthesis has on a detecting template as measured by a detector in a detection area. Stepwise addition of the identified species then determines if an element repeat exists. The process is repeated until the entire structure is complete and the sequence identified. | 10-02-2008 |
| 20080241837 | Automated Method for Determining the Presence of a Target Nucleic Acid in a Sample - An automated analyzer for performing multiple diagnostic assays simultaneously includes multiple stations, or modules, in which discrete aspects of the assay are performed on fluid samples contained in reaction receptacles. The analyzer includes stations for automatically preparing a specimen sample, incubating the sample at prescribed temperatures for prescribed periods, performing an analyte isolation procedure, and ascertaining the presence of a target analyte. An automated receptacle transporting system moves the reaction receptacles from one station to the next. The analyzer further includes devices for carrying a plurality of specimen tubes and disposable pipette tips in a machine-accessible manner, a device for agitating containers of target capture reagents comprising suspensions of solid support material and for presenting the containers for machine access thereto, and a device for holding containers of reagents in a temperature controlled environment and presenting the containers for machine access thereto. A method for performing an automated diagnostic assay includes an automated process for isolating and amplifying a target analyte. The process is performed by automatically moving each of a plurality of reaction receptacles containing a solid support material and a fluid sample between stations for incubating the contents of the reaction receptacle and for separating the target analyte bound to the solid support from the fluid sample. An amplification reagent is added to the separated analyte after the analyte separation step and before a final incubation step. | 10-02-2008 |
| 20080241838 | METHODS AND SYSTEMS FOR DETECTING NUCLEIC ACIDS - Methods and kits for detecting a target nucleic acid in a sample are described. In some embodiments, the sample to be analyzed includes a primer which hybridizes to at least a portion of the target nucleic acid, a probe having a first region which hybridizes to at least a portion of the target nucleic acid and a second region having a detectable label, a polymerase which extends the hybridized primer and an enzyme comprising nuclease activity that can cleave the hybridized hybridization probe to thereby release a labeled probe fragment. In some embodiments, the sample can then be contacted with a solid support comprising surface bound capture probes which can hybridize to the labeled probe fragment(s). These capture probes more readily bind to the probe fragment(s) than to the intact hybridization probe. The label can then be detected on the support surface. In this manner, improved discrimination between the probe fragments and the intact hybridization probes can be achieved. | 10-02-2008 |
| 20080241839 | Method for correlating differential brain images and genotypes; genes that correlate with differential brain images - Methods of assigning quantitative phenotype measurement summary statistics to differential brain image information associated with neuropsychiatric disorders are provided. Summary statistics are correlated to genotype information to identify loci that correlate with differential brain image phenotypes. Methods of identifying modulators of genes at the loci are provided, as well as modulators identified by the methods. Systems for correlating polymorphisms and differential brain image phenotypes, for identifying modulators and for making correlations between differential brain activation phenotypes and genotypes are also provided | 10-02-2008 |
| 20080241840 | Methods of detection using immuno-Q-Amp technology - The present invention describes, in certain embodiments, a composition for detecting a tau protein comprising a modified detector molecule having two ends, a first end capable of binding the tau protein and a second end comprising a single-stranded DNA template, wherein the template is capable of being replicated by an RNA polymerase. | 10-02-2008 |
| 20080241841 | Method and apparatus for sample preparation - A method of the present invention comprises fractionating a sample solution containing analyte DNA molecules into small droplets, wherein the number M of the droplets is greater than the total number N of the DNA molecules, subjecting an emulsion containing the droplets to, for example, PCR amplification, and detecting the presence or absence (amount) of an amplicon obtained in each droplet by fluorescent detection using an intercalator or the like. | 10-02-2008 |
| 20080241842 | Gene Methylation as a Biomarker in Sputum - The present invention provides for a method to monitor the health of a subject. The method includes obtaining a test sample from the patient. A first probe specific for a CpG promoter region of a biomarker selected from p16, MGMT, PAX-α, PAX5-β, RASSF1A, HLHP, GATA4, GATA5, SFRP1, LAMC2, IGFBP3, H-cadherin, BETA 3, HLHP, and DAPK is provided to the sample. The probe contacts the test sample. The DNA of interest from the test sample is isolated. A second stage probe specific for a second CpG promoter region of a biomarker selected from p16, MGMT, PAX-α, PAX5-β, RASSF1A, HLHP, GATA4, GATA5, SFRP1, LAMC2, IGFBP3, H-cadherin, BETA 3, HLHP, and DAPK is provided to the sample to form a second stage PCR product. The DNA is analyzed for hypermethylation of the promoter region for at least one of p16, MGMT, PAX-α, PAX5-β, RASSF1A, HLHP, GATA4, GATA5, SFRP1, LAMC2, IGFBP3, H-cadherin, BETA 3, HLHP, and DAPK. Hypermethylation of the promoter region of at least one of p16, MGMT, PAX-α, PAX5-β, RASSF1A, HLHP, GATA4, GATA5, SFRP1, LAMC2, IGFBP3, H-cadherin, BETA 3, HLHP, and DAPK is an indication that the subject is at increased risk of developing cancer for example, non small cell lung cancer. | 10-02-2008 |
| 20080241843 | Single-cell analysis systems, methods of counting molecules in a single-cell, cylindrical fluorescence detection systems - Embodiments of the present disclosure provide for single-cell analysis systems, methods of detecting target components in a single cell, cylindrical fluorescence detection systems, and the like. | 10-02-2008 |
| 20080241844 | Devices and Methods for the Performance of Miniaturized In Vitro Assays - This invention relates to methods and apparatus for performing microanalytic and microsynthetic analyses and procedures. The invention specifically provides devices and methods for performing miniaturized in vitro assays on biological samples, such as the polymerase chain reaction and Sanger sequencing reactions. Methods specific for the apparatus of the invention for performing PCR are provided. | 10-02-2008 |
| 20080241845 | Method of Extracting Chromatin Fractions From Intact Cells - Methods are provided for isolation of chromatin fractions of nucleoproteins containing histone H1, H2A, H2B, H3 and H4 proteins and/or histone H1, H2A, H2B, H3 and/or H4 proteins, from intact cells. The methods preserve original patterns of covalent modifications of the histone proteins. | 10-02-2008 |
| 20080241846 | Genetic polymorphisms associated with coronary events and drung response, methods of detection and uses thereof - The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection. | 10-02-2008 |
| 20080241847 | METHOD AND APPARATUS FOR IN VIVO SURVEILLANCE OF CIRCULATING BIOLOGICAL COMPONENTS - The invention relates generally to in vivo collection of circulating molecules, tumor cells and other biological markers using a collecting probe. The probe is configured for placement within a living organism for an extended period of time to provide sufficient yield of biological marker for analysis. | 10-02-2008 |
| 20080241848 | METHODS FOR PRENATAL DIAGNOSIS OF ANEUPLOIDY - Methods are disclosed for the automated prenatal genetic diagnosis of aneuploidy using an automated fluorescence microscope, conducted on samples of maternal blood that have been hybridized with FISH probes. | 10-02-2008 |
| 20080241849 | Methods and compositions for diagnosing epithelial cell cancer - Provided is a method for detecting metastases of epithelial cancers, comprising detecting in non-primary tissue overexpression of a nucleic acid of KS1/4, or detecting in non-primary tissue overexpression of a combination of nucleic acids of KS1/4 and PIP, of nucleic acids of KS1/4 and mam, of nucleic acids of PIP and mam, of nucleic acids of KS1/4, PIP and mam, or of nucleic acids of KS1/4 and lunx, the overexpression of a nucleic acid of KS1/4, or the overexpression of a combination of nucleic acids of KS1/4 and PIP, of nucleic acids of KS1/4 and mam, of nucleic acids of PIP and mam, of nucleic acids of KS1/4, PIP and mam, or of nucleic acids of KS1/4 and lunx in non-primary tissue being correlated with metastases of epithelial cancers. | 10-02-2008 |
| 20080248462 | Diagnostics and Therapeutics for Diseases Associated with Arginyl Aminopeptidase (Aminopeptidase B)-Like 1 (Rnpepl1) - The invention provides a human RNPEPL1 which is associated with the cardiovascular diseases, endocrinological diseases, metabolic diseases, cancer, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, neurological diseases, urological diseases and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, endocrinological diseases, metabolic diseases, cancer, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, neurological diseases, urological diseases and reproduction disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of RNPEPL1 as well as pharmaceutical compositions comprising such compounds. | 10-09-2008 |
| 20080248463 | Split Enzyme Linked Immunosorbent and Nucleic Acid Assays - A method for detecting the presence of an analyte in a solution. The analyte includes at least two mutually exclusive recognition sites that are capable of binding to corresponding recognition molecules. Biosensors are provided that include the recognition molecules, which are attached to the inactive portions of a split enzyme. The recognition sites are located such that the inactive enzyme portions combine to form a detectable biologically active enzyme when the recognition molecules bind to recognition sites. | 10-09-2008 |
| 20080248464 | Method of DNA Shuffling with Polynucleotides Produced by Blocking or Interrupting a Synthesis or Amplification Process - Disclosed is a process of performing “sexual” PCR which includes generating random polynucleotides by interrupting or blocking a synthesis or amplification process to show or halt synthesis or amplification of at least one polynucleotide, optionally amplifying the polynucleotides, and reannealing the polynucleotides to produce random mutant polynucleotides. Also provided are vector and expression vehicles including such mutant polynucleotides, polypeptides expressed by the mutant polynucleotides and a method for producing random mutant polypeptides. | 10-09-2008 |
| 20080248465 | Polymorphisms in the Fcgr2b Promoter and Uses Thereof - The invention relates to the FCGR2B gene and its promoter. In particular, the invention relates to FCGR2B promoters with specific nucleotides at polymorphic sites. Characterization of the nucleotides at polymorphic sites is useful for characterizing the gene and the protein and is useful for determining predisposition or susceptibility to certain diseases and infections in a subject or a population of subjects. Such characterization of the gene or protein is also useful for determining immunoresponsiveness or responsiveness to therapeutic agents in a subject or population of subjects. Thus, disclosed herein are a variety of related nucleic acids, methods and tools. | 10-09-2008 |
| 20080248466 | Method Of Detecting Mutations In The Gene Encoding Cytochrome P450-2C19 - The present invention describes a method for the simultaneous identification of two or more mutations located in the gene encoding Cytochrome P450-2C19. Multiplex detection is accomplished using multiplexed tagged allele specific primer extension (ASPE) and hybridization of such extended primers to a probe, preferably an addressable anti-tagged support. | 10-09-2008 |
| 20080248467 | System for pulling out regulatory elements using yeast - Disclosed are methods for identifying molecular interactions between DNA sequences and proteins in vivo. The methods of the invention employ known or suspected DNA-binding proteins and genomic DNA in a plasmid library. Interacting molecules direct the expression of a reporter gene, the expression of which is then assayed. Also disclosed are genetic constructs useful in practicing the methods of the invention. | 10-09-2008 |
| 20080248468 | Method for Improved Selection of Rnai Transfectants - The present invention is directed to a method for inactivation of expression of a gene in a eucaryotic cell comprising (i) transfection of a eucaryotic cell with DNA comprising an expression cassette for expression of a cell surface protein and an expression cassette for expression of a RNAi compound, said compound being capable of inactivating expression of said gene, wherein said expression cassette for expression of a cell surface protein and said expression cassette for expression of a RNAi compound are located on the same vector DNA, and (ii) enrichment and/or selection of cells which express said cell surface protein. | 10-09-2008 |
| 20080248469 | Methods for Identifying Nucleotides of Interest in Target Polynucleotides - In some embodiments, the present teachings provide a method of identifying a nucleotide of interest in a target polynucleotide. In some embodiments, the method can comprise forming an amplification strand, wherein the amplification strand comprises a hairpinning end region; hybridizing the hairpinning end region of the amplification strand with a hairpinning region of a target polynucleotide, to form a self-complementary amplification product. After performing an extension reaction, wherein the hairpinning end region of the amplification strand is extended, an extended reaction product is formed. Detection of the extended reaction product can result in the identification of a nucleotide of interest in the target polynucleotide. Additional methods, as well as kits, are also provided. | 10-09-2008 |
| 20080248470 | GENETIC SCREENING FOR PREDICTING ANTIDEPRESSANT DRUG RESPONSE BASED ON THE MONOAMINE TRANSPORTER GENE POLYMORPHISM COMBINATION - The present invention discloses is a method of selecting a drug based on personal genetic information when prescribing an antidepressant for a depressed patient. According to the invention, either a noradrenaline reuptake inhibitor (NRI) antidepressant or a selective serotonin reuptake inhibitor (SSRI) antidepressant can be selected based on the combination of monoamine transporter gene polymorphisms, that is, NET G1287A polymorphism in a norepinephrine transporter (NET) gene, serotonin transporter gene (5-HTT) promoter polymorphism and 5-HTT gene intron 2 polymorphism. Also, based on the norepinephrine transporter gene NET G1287A polymorphism alone, the noradrenaline reuptake inhibitor (NRI) antidepressant can be selected. | 10-09-2008 |
| 20080248471 | Methods for disease detection - The present invention provides methods for detecting disease by analysis of a patient sample to determine the integrity of nucleic acids in the sample. | 10-09-2008 |
| 20080248472 | Method and Kit for Determination of Thymidine Kinase Activity and Use Thereof - A method and assay kit for determination of thymidine kinase (TK) activity in a biological sample, such as blood, serum, plasma, Cerebral Spinal Fluid (CSF), pleural fluid, ascites, tissues, cells and extracts thereof, is described. The method comprises contacting, in a buffer, a Basic Reaction Mixture comprising: solid surface-attached primer and/or template, a modified deoxy nucleoside, such as BromodeoxyUridine, IododeoxyUridine, Fluorodeoxy-Uridine or VinyldexoyThymidine as a kinase enzyme substrate, a phosphate donor, a nucleotide polymerizing enzyme, and a kinase enzyme source devoid of TK activity, such as a yeast extract, with the biological sample. After incubation the amount of modified deoxy nucleoside that has been incorporated into the solid surface-attached primer and/or template, is determined and the TK activity present in the biological sample is directly proportional to the amount of incorporated modified deoxy nucleoside. The method and assay kit are useful in the diagnosing, prognosis monitoring of disease progression and treatment effects of cell-proliferation disorders or diseases, such as cancer, and in the screening of compounds, e.g. new drug candidates, affecting enzymatic pathways, which may obstruct the formation of thymidine phosphates or interfere with nucleic acid synthesis. | 10-09-2008 |
| 20080248473 | Method and Kit for the Detection of Bacterial Species by Means of Dna Analysis - The present invention relates to the detection and identification of different bacterial species, all of which cause zoonosis, based on DNA analysis. More specifically, the invention provides the primers, probes, genes and genic regions required to apply a method for the simultaneous detection of bacteria and bacterial groups belonging to the genera | 10-09-2008 |
| 20080248474 | AMPLIFICATION METHODS - Methods are provided for amplification and monitoring of oligonucleotide amplification in which a primer has an overlap with one or more bases of a detection probe. | 10-09-2008 |
| 20080248475 | Methods and Compositions for Modulating Gluconeogenesis Using PGC-1 - The invention provides novel methods and compositions for modulating gluconeogenesis through modulation of PGC-1 activity or expression. Also provided are methods for identifying compounds that modulate gluconeogenesis through modulation of PGC-1 activity or expression, as well as methods for identifying compounds that modulate the interaction of PGC-1 with PGC-1 target molecules. Further provided are methods for treating disorders characterized by aberrant gluconeogenesis. | 10-09-2008 |
| 20080248476 | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof - The present invention is based on the discovery of genetic polymorphisms that are associated with myocardial infarction. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 10-09-2008 |
| 20080248477 | Novel ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor - Novel ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST proteins, the invention further provides isolated ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST fusion proteins, antigenic peptides and anti-ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST antibodies. The invention also provides ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 10-09-2008 |
| 20080248478 | MOLECULAR HISTOLOGICAL ANALYSIS OF MULTICELLULAR SAMPLES - The present invention provides modified digital images of a multicellular sample using molecular profiles of cells from said multicellular sample for a molecular histological analysis. | 10-09-2008 |
| 20080248479 | Methods for Isolating and Characterizing Endogenous mRNA-Protein (mRNP) Complexes - Cellular mRNA-protein (mRNP) complexes are partitioned in vivo by contacting a biological sample with at least one ligand that specifically binds at least one component of a mRNP complex. Suitable biological samples comprise at least one mRNA-protein (mRNP) complex and include cell cultures, cell extracts, and whole tissue, including tumor tissue. Ligands include antibodies that specifically bind RNA-binding or RNA-associated proteins present in the mRNP complex. The mRNP complex is separated by binding the ligand with a binding molecule specific for the ligand, where the binding molecule is attached to a solid support. The mRNP complex is collected by removing the mRNP complex from the solid support. After collecting the mRNP complex, the mRNA bound within the complex may be characterized and identified. Subsets of the total mRNA population of a cell may accordingly be characterized, and a gene expression profile of the cell obtained. | 10-09-2008 |
| 20080248480 | Novel nucleotide mixture for improved nucleic acid amplification performance - The present invention relates to modification of amplification buffer used in amplification reactions. The modifications result in a significant improvement in results of amplification. In particular, the present invention provides methods and buffers for performing an amplification reaction utilizing a buffer comprising nucleotide triphosphates comprising treating the buffer to substitute a portion of the nucleotide triphosphates with nucleotide diphosphates. | 10-09-2008 |
| 20080248481 | METHODS OF EVALUATING CELLS AND CELL CULTURES - Methods of evaluating the composition of a cell culture (e.g., to distinguish chondrocytes from fibroblasts) and methods for evaluating the phenotype of an individual cell (e.g., as a chondrocyte) are disclosed. The methods may be used, for example, for assessing chondrocyte cultures used for treatment of cartilage defects. In some embodiments, the invention involves identifying cell culture composition or the identity of a cell based on expression level of a fibroblast marker. In other embodiments, the invention involves comparing expression levels of at least one chondrocyte marker and at least one fibroblast marker in a cell culture sample or in an individual cell. In illustrative embodiments, the chondrocyte marker is hyaluronan and proteoglycan link protein 1 (HAPLN1), and the fibroblast marker is microfibrillar associated protein 5 (MFAP5). | 10-09-2008 |
| 20080248482 | BIOMARKERS FOR TOXIC ALGAE - The present invention is directed toward biomarkers that identify characteristics of algae. The invention is further directed toward biomarkers that serve to identify algae species and strains of algae species as well as detect the presence of algal toxins. Additional embodiments feature methods utilizing algal biomarkers and polypeptides that can serve as biomarkers. | 10-09-2008 |
| 20080248483 | METHODS OF IDENTIFYING THERAPEUTIC COMPOUNDS IN A GENETICALLY DEFINED SETTING - The invention provides a method of identifying therapeutic compounds in a genetically defined setting. The method consists of contacting a cell indicative of a pathological condition from a diseased individual and a cell from a genetically related normal individual with a plurality of candidate therapeutic compounds under suitable assay conditions, and identifying a compound that preferentially alters a predetermined property of the cell from the diseased individual. | 10-09-2008 |
| 20080248484 | METHOD FOR THE EARLY DETECTION OF PANCREATIC CANCER AND OTHER GASTROINTESTINAL DISEASE CONDITIONS - The present invention uses peripheral blood monocyte-lymphocyte for the early diagnosis of pancreatic cancer, as well as other conditions of the pancreas and other organs. The peripheral blood lymphocytes recognize the new neoplasm in the pancreas, as well as disease processes in other organ systems. The evaluation of this specific recognition of the disease process by the peripheral blood monocyte-lymphocyte through gene microarray expression patterns constitute a successful method for the early detection of pancreatic cancer and other organ disease processes. This document describes the process used in this method of early diagnosis. | 10-09-2008 |
| 20080254445 | Prognosis in Cancer Patients Vaccinated with a Cancer Antigen Peptide-Associated Agent - The correlation of clinical benefits and immune responses to peptides in cancer patients who were vaccinated with CTL-directed peptides is shown. The invention relates to a process for determining prognosis in a cancer patient vaccinated with a cancer antigen peptide-associated agent, which comprises measuring a level of an antibody specific to the cancer antigen peptide, and assessing whether the level is significantly increased as compared to the level at pre-vaccination. | 10-16-2008 |
| 20080254446 | Method of Detecting Target Molecule by Using Aptamer - An aptamer-probe complex for detecting the presence of a target molecule is disclosed. The complex of the present invention contains an aptamer moiety which is able to bind to an indicator protein and change the properties of the indicator protein, and a probe moiety which is able to bind to a target molecule, wherein the aptamer moiety and the probe moiety are combined in such a manner that the binding mode between the aptamer moiety and the indicator protein changes when the probe moiety binds to the target molecule. A target molecule can be detected with combination of an aptamer which binds to a certain protein, and a probe which binds to the target molecule, utilizing the properties of that protein as an indicator. | 10-16-2008 |
| 20080254447 | Method and Nucleic Acids for the Improved Treatment of Breast Cell Proliferative Disorders - The present invention relates to modified and genomic sequences, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genomic DNA, as well as to a method for predicting the disease free survival and/or response of a subject with a cell proliferative disorder of the breast tissues, to endocrine treatment. | 10-16-2008 |
| 20080254448 | Analysis Chip With Reference Range, Kits and Methods of Analysis - Analysis chip of at least one analyte, said chip comprising at least one analysis spot for recognition and immobilization specific to the analyte; and a reference range (G) comprising several reference spots each arranged on said chip in a defined manner and independently of one another, each reference spot of this range comprising, immobilized on its surface and in a defined proportion P that is different and known for each spot relative to the other reference spots of said range: a probe reference molecule (PRM) permitting recognition and hybridization specifically to a defined target reference molecule (TRM), and/or an inert oligonucleotide molecule (IM) incapable of recognition and hybridization with said PRM, these molecules both being unable to immobilize said analyte or analytes. The method of the invention comprises the use of said chip with its reference range for analysis of said, at least one, analyte. | 10-16-2008 |
| 20080254449 | Polynucleotides For the Detection of Escherichia Coli 0157 - Polynucleotide primers and probes for the amplification and detection of | 10-16-2008 |
| 20080254450 | Human Obesity Susceptibility Genes Encoding Peptide Hormones and Uses Thereof - The present invention discloses the identification of human obesity susceptibility genes, which can be used for the diagnosis and prevention of obesity and related disorders. The invention more specifically discloses that the PPY and PYY gene on chromosome 17 and certain alleles thereof are related to susceptibility to obesity. The present invention relates to particular mutations in the PPY and PYY gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to or protection from, detection, prevention and/or treatment of coronary heart disease and metabolic disorders, including hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X or multiple metabolic disorder, coronary artery disease, diabetes and dyslipidemia. | 10-16-2008 |
| 20080254451 | Compositions and Methods for Treating Schizophrenia and Related Disorders - The present invention relates, generally, to methods and compositions for detecting or treating mental disorders, such as schizophrenia. The present invention more particularly discloses the identification of human genes which can be used for the diagnosis, prevention and treatment of schizophrenia and related disorders, as well as for the screening of therapeutically active drugs. The invention further discloses specific polymorphisms or alleles of the CNTFR gene that are related to schizophrenia, as well as diagnostic tools and kits based on these markers. The invention can be used in the diagnosis of or predisposition to, detection, prevention and/or treatment of schizophrenia and related disorders. | 10-16-2008 |
| 20080254452 | Pkp3 Oncogene as a Prognostic Indicator for Lung Cancer - The present invention provides the method of predicting an non-small cell lung cancer (NSCLC) prognosis. | 10-16-2008 |
| 20080254453 | Analysis of methylation using selective adaptor ligation - Methods of analyzing DNA to identify regions of the genome that are methylated in a genomic sample are disclosed. In one aspect genomic DNA is fragmented using a restriction enzyme with a degenerate recognition site, methylated restriction fragments are separated from unmethylated fragments by affinity purification. The complexity of the methylated fragments is reduced by amplification of a subset of the fragments using adaptors that ligate to a subset of the fragments. The amplified product is fragmented, labeled and hybridized to an array of probes. The hybridization pattern is analyzed to determine methylation status of cytosines. | 10-16-2008 |
| 20080254454 | GENETIC MARKERS FOR ASSESSING RISK OF PREMATURE BIRTH RESULTING FROM PRETERM PREMATURE RUPTURE OF MEMBRANES - A method to identify women who are at risk for preterm delivery due to premature rupture of membranes (PPROM) is provided. The method entails detecting the presence of SERPINH1 gene variants that express low levels of the gene product, heat shock protein Hsp47. The occurrence of a T (rather than C) at a single nucleotide polymorphism (SNP) site at position −656 of the SERPINH1 gene promoter, together with the absence of a 12 base pair deletion at positions −694 to −683 of the promoter, result in an increased risk of PPROM. The method enables medical professionals to identify those at risk, and to provide suitable therapeutic intervention. | 10-16-2008 |
| 20080254455 | DETECTING PROSTATE CANCER - Methods and kits for detecting prostate cancer in urine samples include detecting the methylation status of various genes. | 10-16-2008 |
| 20080254456 | GENE MARKER FOR HUMAN HEPATOCELLULAR CARCINOMA DIAGNOSIS - The present invention relates to a gene marker for diagnosis of human hepatocellular carcinoma (HCC), which is selected from the group consisting of IGF2, VEGF, MET, SUMO2, CDK4, MMP9, PLK1, AFP, Rb1, CYP3A4, LAP3, RIZ, DLC1, ITIH1, FetB, ALDOB, SULT2A1, ASS, HP, SERIND1, EI24, HGD, RODH, F2, SORD, and KNG. The HCC is diagnosed effectively and efficiently based on detecting the expression levels of the present gene marker from the liver tissue sample of an individual to be diagnosed. | 10-16-2008 |
| 20080254457 | Methods for Evaluating Drug-Resistance Gene Expression in the Cancer Patient - The methods of the invention detect in a qualitative or quantitative fashion drug-resistance RNA and DNA in blood plasma, serum, and other bodily fluids. The methods of the invention thereby enable the assessment of drug resistance in a neoplasm without the requirement of a tissue biopsy. The inventive methods are useful for the evaluation, monitoring, and selecting of drug treatment regimens, and for determining a predisposition for or prognosis of chemoresistant neoplastic disease. | 10-16-2008 |
| 20080254458 | Method of pre-treating in pleural effusion for detection of Mycobacterium tuberculosis - The present invention provides a method for preparing nucleic acid from a sample for detecting | 10-16-2008 |
| 20080254459 | Methods and Biomarkers for Detecting Nanoparticle Exposure - Methods for gene expression profiling for exposure to nanoscale particulates or nanomaterials is provided together with identified biomarkers for nanomaterial exposure. A toxicogenomic exposure profile for nanomaterial contact is provided in accordance with a systems biology approach by iteratively sampling a test system several times after contact with nanomaterials of various chemical types. | 10-16-2008 |
| 20080254460 | Method of Fetal Cell Enrichment - The present invention provides a method of enriching fetal cells in a maternal blood sample wherein cells which are CD34+ and capable of adhering to a solid support are selected, an analysable sample of fetal cells obtainable by the methods of the invention and a kit for use in the methods of the invention. There is also provided a method of fetal gender determination and a method of diagnosing a fetal genetic abnormality. | 10-16-2008 |
| 20080254461 | METHODS FOR ISOLATING AND CHARACTERIZING ENDOGENOUS mRNA-PROTEIN (mRNP) COMPLEXES - Cellular mRNA-protein (mRNP) complexes are partitioned in vivo by contacting a biological sample with at least one ligand that specifically binds at least one component of a mRNP complex. Suitable biological samples comprise at least one mRNA-protein (mRNP) complex and include cell cultures, cell extracts, and whole tissue, including tumor tissue. Ligands include antibodies that specifically bind RNA-binding or RNA-associated proteins present in the mRNP complex. The mRNP complex is separated by binding the ligand with a binding molecule specific for the ligand, where the binding molecule is attached to a solid support. The mRNP complex is collected by removing the mRNP complex from the solid support. After collecting the mRNP complex, the mRNA bound within the complex may be characterized and identified. Subsets of the total mRNA population of a cell may accordingly be characterized, and a gene expression profile of the cell obtained. | 10-16-2008 |
| 20080254462 | ALTERED ZDHHC8 EXPRESSION AS A MARKER OF INCREASED RISK OF SCHIZOPHRENIA - The present invention relates to the role of mutations that perturb expression of ZDHHC8 in increased susceptibility to schizophrenia. It is based, at least in part, on the discovery of a mechanism by which a high risk allele disrupts expression of functional ZDHHC 8, and on the discovery that two proteins involved in synaptic pathways associated with schizophrenia interact with ZDHHC8, at least one of which is a substrate for that enzyme. | 10-16-2008 |
| 20080254463 | DETECTION METHOD FOR DIFFERENTIATING BETWEEN CHICKEN-DERIVED INGREDIENTS AND EGG-DERIVED INGREDIENTS IN PRODUCTS - The present invention relates to a detection method to differentiate between egg-derived ingredients and chicken-derived ingredients (chicken parts/tissues, excluding eggs) in foods or other products and primer pairs and probes used for specifically detecting chicken in foods or products. | 10-16-2008 |
| 20080254464 | Identification of genetic markers of biological age and metabolism - A method of measuring the biological age of a multicellular organism is disclosed. In one embodiment this method comprises the steps of obtaining a sample of nucleic acid isolated from the organism's organ, tissue or cell and determining the expression pattern of a panel of sequences within the nucleic acid that have been predetermined by either increase or decrease in response to biological aging of the organ, tissue or cell. A method of obtaining biomarkers of aging is also disclosed. This method comprises the step of comparing a gene expression profile of a young multicellular organism subject's organ, tissue or cells; a gene expression profile from a chronologically aged subject's organ, tissue or cell; and a gene expression profile from a chronologically aged but biologically younger subject's organ, tissue or cell and identifying gene expression alterations that are observed when comparing the young subjects and the chronologically aged subjects and are not observed or reduced in magnitude when comparing the young subjects and the chronologically aged but biologically younger subjects. | 10-16-2008 |
| 20080254465 | Assays for measuring nucleic acid binding proteins and enzyme activities - Processes for measuring DNA or RNA binding proteins, specific nucleic acids, as well as enzyme activities using labeled nucleic acids of labeled protein/peptide molecules are provided. | 10-16-2008 |
| 20080254466 | Heregulin-like Factor - The present invention relates to a novel HLF protein which is a member of the heregulin family. In particular, isolated nucleic acid molecules are provided encoding the human HLF protein. HLF polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of HLF activity. Also provided are diagnostic methods for detecting disorders of the regulation of cell growth and therapeutic methods for treating disorders of the regulation of cell growth. | 10-16-2008 |
| 20080254467 | Automated High-Throughput Flow-Through Real-Time Diagnostic System - An automated real-time flow-through system capable of processing multiple samples in an asynchronous, simultaneous, and parallel fashion for nucleic acid extraction and purification, followed by assay assembly, genetic amplification, multiplex detection, analysis, and decontamination. The system is able to hold and access an unlimited number of fluorescent reagents that may be used to screen samples for the presence of specific sequences. The apparatus works by associating extracted and purified sample with a series of reagent plugs that have been formed in a flow channel and delivered to a flow-through real-time amplification detector that has a multiplicity of optical windows, to which the sample-reagent plugs are placed in an operative position. The diagnostic apparatus includes sample multi-position valves, a master sample multi-position valve, a master reagent multi-position valve, reagent multi-position valves, and an optical amplification/detection system. | 10-16-2008 |
| 20080254468 | Micro-Fluidic Temperature Driven Valve - Subject of the present invention is a micro-fluidic device for the use in an apparatus for analyzing a liquid sample by nucleic acid amplification, an apparatus for analyzing a liquid sample by nucleic acid amplification, a method for analyzing a liquid sample and a method for amplifying nucleic acids in a liquid. | 10-16-2008 |
| 20080254469 | Method for Regenerating Hydrophilic and Osteophilic Surface of an Implant - Described herein are methods for testing an aged surface on an implant, methods for regenerating a hydrophilic and osteophilic surface on the implant and kits therefor. | 10-16-2008 |
| 20080254470 | Methods and Nucleic Acids For the Analysis of Gene Expression Associated With the Prognosis of Cell Proliferative Disorders - The present application provides methods and nucleic acids for providing a prognosis of cell proliferative disorders, most preferably cancer but not breast cancer. | 10-16-2008 |
| 20080254471 | Apparatus and Method for Microbial and Forensic Sampling and Manipulation - The present invention provides a sterile collection package and methods for sample procurement and manipulation including microbial and forensic testing. The collection package comprises a tissue or sample collection container with a sealable opening, at least one drain container, and at least one tubing set that connects the tissue or sample collection container and the drain container, the tubing set further optionally comprising a sampling hub for withdrawing sample fluid for microbial and forensic testing. Samples, such as donated tissues, diseased tissues and article and tissues for forensic analysis are mixed with a sampling solution in the collection container and aliquots of the sampling solution are withdrawn through the sampling hub for microbial and/or forensic testing. | 10-16-2008 |
| 20080254472 | METHOD FOR DETECTING NUCLEIC ACID IN SAMPLE, METHOD FOR DESIGNING PROBES, SYSTEM FOR DESIGNING PROBES THEREFOR - Accurate detection of a target microorganism from a sample, which may contain a plurality of microorganisms, is intended. This can be realized by eliminating a possibility of cross-hybridization of a microorganism with other probes, which can accelerate the designing speed, detecting microorganisms one-by-one in the designed order, and absorbing all the existing microorganisms. | 10-16-2008 |
| 20080254473 | PREDICTING POST-TREATMENT SURVIVAL IN CANCER PATIENTS WITH MICRORNAS - This invention provides a method for predicting the post-treatment survival prospect of a cancer patient based on the expression level(s) of microRNAs hsa-miR137, hsa-miR372, hsa-miR182*, hsa-miR221, and hsa-let-7a in that cancer patient. | 10-16-2008 |
| 20080254474 | DNA METHYLATION ANALYSIS BY DIGITAL BISULFITE GENOMIC SEQUENCING AND DIGITAL METHYLIGHT - Provided are novel sensitive methylation assays referred to herein as Digital MethyLight, comprising stochastically distributing and compartmentalizing bisulfite-treated genomic DNA over multiple PCR reaction wells for detection of individually methylated DNA molecules in a large background of unmethylated DNA. Digital Bisulfite Genomic DNA Sequencing methods are also provided for high-resolution DNA methylation information without subcloning. Background signal and PCR contaminants are diluted, while the ratio of primer to methylated template DNA is kept high. Preferably, biological fluid (e.g., urine, blood-based (e.g., plasma and/or serum)) samples are analyzed for cancer diagnosis, prognosis and surveillance. Multiplexed PCR formats may be implemented to enhance when using small DNA amounts. Compositions and methods for diagnosis and/or prognosis of breast cancer, comprising the use of FOXE1, CLDN5 and/or RUNX3 gene markers are also provided (SEQ ID NOS: 17, 16 and 18, respectively for respective CpG island sequences), and in preferred embodiments plasma or serum samples are used. | 10-16-2008 |
| 20080254475 | NEMATODES AS MODEL ORGANISMS FOR THE INVESTIGATION OF NEURODEGENERATIVE DISEASES, IN PARTICULAR PARKINSONS DISEASE, USES AND METHODS FOR THE DISCOVERY OF SUBSTANCES AND GENES WHICH CAN USED IN THE TREATMENT OF THE ABOVE DISEASE STATES AND IDENTIFICATION OF A NEMATODE GENE - The invention relates to nematodes as model organisms for the investigation of neurodegenerative diseases, in particular, Parkinsons disease, uses and methods for the discovery of substances and genes which can be used in the treatment of the above disease states and identification of a nematode gene, From | 10-16-2008 |
| 20080254476 | IL-1 GENE CLUSTER AND ASSOCIATED INFLAMMATORY POLYMORPHISMS AND HAPLOTYPES - The invention provides methods and compositions relating to identification and use of genetic information from the IL-1 gene cluster—including the structure and organization of novel IL-1-like genes found within the IL-1 locus as well as polymorphisms and associated haplotypes within these genes. The invention thereby expands the repertoire of useful genetic information available from the IL-1 locus—which contains the previously-identified IL-1α, IL-1β and IL-1RN genes, for predicting IL-1 associated phenotypes (e.g. increased or decreased risks of inflammatory disease) and for treating IL-1 haplotype associated inflammatory phenotypes. | 10-16-2008 |
| 20080254477 | IL-1 GENE CLUSTER AND ASSOCIATED INFLAMMATORY POLYMORPHISMS AND HAPLOTYPES - The invention provides methods and compositions relating to identification and use of genetic information from the IL-1 gene cluster—including the structure and organization of novel IL-1-like genes found within the IL-1 locus as well as polymorphisms and associated haplotypes within these genes. The invention thereby expands the repertoire of useful genetic information available from the IL-1 locus—which contains the previously-identified IL-1α, IL-1β and IL-1RN genes, for predicting IL-1 associated phenotypes (e.g. increased or decreased risks of inflammatory disease) and for treating IL-1 haplotype associated inflammatory phenotypes. | 10-16-2008 |
| 20080254478 | IL-GENE CLUSTER AND ASSOCIATED INFLAMMATORY POLYMORPHISMS AND HAPLOTYPES - The invention provides methods and compositions relating to identification and use of genetic information from the IL-1 gene cluster—including the structure and organization of novel IL-1-like genes found within the IL-1 locus as well as polymorphisms and associated haplotypes within these genes. The invention thereby expands the repertoire of useful genetic information available from the IL-1 locus—which contains the previously-identified IL-1α, IL-1β and IL-1RN genes, for predicting IL-1 associated phenotypes (e.g. increased or decreased risks of inflammatory disease) and for treating IL-1 haplotype associated inflammatory phenotypes. | 10-16-2008 |
| 20080261204 | Polynucleotide Ligation Reactions - The method of the invention is useful in quantifying the absolute or relative number of unique molecules present in a sample after carrying out an analysis procedure on the sample, and comprises the steps of: (i) attaching a unique molecular tag to substantially all of the molecules in the sample; (ii) carrying out the analysis procedure using the molecules of the sample; and (iii) on the basis of the molecular tags determining the absolute or relative number of unique molecules present in the original sample which underwent the analysis procedure. | 10-23-2008 |
| 20080261205 | Method for the Simultaneous Determination of Blood Group and Platelet Antigen Genotypes - RBC and platelet (Plt) alloimmunization requires antigen-matched blood to avoid adverse transfusion reactions. Some blood collection facilities use unregulated Abs to reduce the cost of mass screening, and later confirm the phenotype with government approved reagents. Alternatively, RBC and Plt antigens can be screened by virtue of their associated single nucleotide polymorphisms (SNPs). We developed a multiplex PCR-oligonucleotide extension assay using the GenomeLab SNPStream platform to genotype blood for a plurality of blood group antigen-associated SNPs, including but not limited to: RhD (2), RhC/c, RhE/e, S/s, K/k, Kp | 10-23-2008 |
| 20080261206 | Oligonucleotide for Detection of a Microorganism, Diagnostic Kits and Methods for Detection of Microorganisms Using the Oligonucleotide - The present invention relates to a method so called Bacterial Digitalcode System (BaDis) that identifies microorganism by using bacterial-specific, genus-specific and species-specific oligonucleotides from a variety of samples or specimens for detection and differential diagnosis of microorganism. Particularly, the present invention relates to bacterial-specific, genus-specific and species-specific oligonucleotides designed by the target nucleotide sequences of 23S rDNA or ITS gene, polymerase chain reaction (hereinafter, referred to as “PCR”) kits using the oligonucleotides as a primer, the microarray containing the oligonucleotides as a probe, and methods for detecting microorganism by using the oligonucleotides. Therefore, the present invention can be applied to detect the presence of microorganism and diagnose differentially all microorganism such as pathogenic bacteria of infectious diseases, bacteria inducing food poisoning, bacteria contaminating biomedical products and environmental pollutants. | 10-23-2008 |
| 20080261207 | Method of Measuring Cancer Susceptibility - An individual's susceptibility to cancer is assessed based on the individual's cellular response to mutagenic agents such as radiation. The level of a growth-suppressing marker is measured before and after the individual's cells are exposed to the mutagenic agent. The individual's susceptibility to cancer as a result of the mutagenic agent is correlated with the degree to which the growth-suppressing marker is induced by exposure to the agent. A method is also disclosed for assessing cancer prophylaxis effects of compounds, such as vitamins or food extracts, in individuals. Cells from an individual are incubated with at least one compound in vitro, or the compound is directly administered to the individual, after which some of the incubated cells, as well as non-incubated cells, are exposed to a mutagenic agent such as ionizing radiation. The level of the growth-suppressing marker in the cells incubated with the compound and exposed to the mutagenic agent is then compared with the level in the non-incubated cells exposed to the agent. The cancer prophylaxis effects of the compound are correlated with a higher level of the marker in the incubated cells. | 10-23-2008 |
| 20080261208 | 2'-Nitrobenzyl-Modified Ribonucleotides - This disclosure provides novel reversibly terminated ribonucleotides which can be used as a reagent for DNA sequencing reactions. Methods of sequencing nucleic acids using the disclosed nucleotides are also provided. | 10-23-2008 |
| 20080261209 | Electrophoretic Separation Method for Analyzing Gene Expression - The following invention relates to an improved method of quantitative or qualitative analysis of gene expression of a biological material. | 10-23-2008 |
| 20080261210 | Assay Method - The invention provides a cassette-based automated assay for homocysteine. | 10-23-2008 |
| 20080261211 | Variants in complement regulatory genes predict age-related macular degeneration - Methods for identifying a subject at risk for developing AMD are disclosed, as are kits which can be used to practice the methods. The methods include identifying specific protective or risk polymorphisms or genotypes from the subject's genetic material, including polymorphisms in the BF, C2 and/or CFH genes. Microarrays and kits for use in these methods are also provided. | 10-23-2008 |
| 20080261212 | Method of Diagnosis/Prognosis of Human Chronic Lymphocytic Leukemia Comprising the Profiling of Lpl/Adam Genes - The present invention provides methods of diagnosis and prognosis of human chronic lymphocytic leukemia (CLL) in a patient in need thereof and methods to determine IgVH mutational status. The methods of the present invention involve measuring the expression profile of two known genes: LPL and ADAM29; and comparing the ratio of their expression to diagnose the presence of CLL or to prognose the likelihood of developing CLL or the symptoms consistent with CLL. | 10-23-2008 |
| 20080261213 | Assay - The invention relates to a method for screening for pre-eclampsia in a mammal, such as a human, by determining the amount and quality of foetal 2,3 bisphosphoglycerate mutase (2,3 BPGM) present. Reagents and kits for carrying out the method are also provided. | 10-23-2008 |
| 20080261214 | DNA polymorphisms in sterol-regulator-element binding proteins - The invention relates to DNA polymorphisms in sterol regulator element binding proteins (SREBP) that are characteristic of a higher risk of genetic diseases in humans such as hyperchlolesterolemia. The corresponding polymorphisms, especially the polymorphisms on SREBP-1 and SREBP-2 are frequently observed in Alzheimer patients (SREBP-2). They are also characterized by a specific behavior in the therapy of HIV patients with proteas inhibitors and appear to have an influence on the mortality. | 10-23-2008 |
| 20080261215 | Method for Evaluating the Allergen Sensitivity of an Individual - The present invention discloses a method for evaluating the allergen sensitivity of an individual and/or the clinical efficacy of an allergen immunotherapy comprising the steps: providing at least two samples selected from the group consisting of blood or fractions thereof, connective tissue, nasal, bronchial, skin or gut biopsy material from an individual subjected or intended to be subjected to an immunotherapy with at least one pure allergen or derivative thereof, wherein the samples contain cells capable of releasing mediators in response to said allergen, contacting said sample with said allergen or derivative thereof, and determining the amounts of mediators released from said sample and evaluating the allergen sensitivity of the individual prior to therapy and/or the clinical efficacy of the immunotherapy by comparing said amounts. | 10-23-2008 |
| 20080261216 | HERV Group II Viruses In Lymphoma And Cancer - The present invention relates to compositions and methods for cancer diagnosis and therapy, including but not limited to, cancer markers. In particular, the present invention relates to HERV-K(HML-2) target titers as diagnostic markers, and HERV-K(HML-2) therapeutic targets for HIV-related cancers, and other cancers. | 10-23-2008 |
| 20080261217 | Methylation Profile of Cancer - The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides methods of identifying methylation patterns in genes associated with specific cancers. | 10-23-2008 |
| 20080261218 | Detection of Biomarkers for Neuropsychiatric Disorders - Systems and methods provide a comprehensive high-throughput approach toward the sequential identification, prioritization, verification, and validation of etiologic factors in neuropsychiatric disorders, some of which can also be utilized as biomarkers for these illnesses. The systems and methods determine patterns of gene expression in various tissues from various samples under various experimental and non-experimental conditions, and uses the differences and similarities between the gene expression profiles observed under these conditions to delineate distinct gene expression profiles of risk and treatment of neuropsychiatric disorders. | 10-23-2008 |
| 20080261219 | Polynucleotide Primers - A polynucleotide primer comprising at least the final six nucleotides of one of the following primer sequences, or a sequence complementary thereto: SEQ. ID NOS. 1 to 18, 21 to 45 or 74 to 77. | 10-23-2008 |
| 20080261220 | Nucleic Acid Detection Assays - The present invention relates to novel methods of producing oligonucleotides. In particular, the present invention provides an efficient, safe, and automated process for the production of large quantities of oligonucleotides. | 10-23-2008 |
| 20080261221 | AUTOMATED VNTR GENOTYPING METHOD - The invention provides an automated VNTR genotyping method using multiple variable-number tandem repeats (VNTRs) loci based on mycobacterial interspersed repetitive units (MIRU) undergoing multiplex PGR and high throughput MEGABACE® capillary electrophoresis system. The method uses fluorescent dyes of 6-carboxytetramethylrhodamine(TAMRA), 6-carboxy fluorescein (FAM) and 6-carboxy-2′, 4, 4′, 5′, 7, 7′-hexachlorofluorescein (HEX) labeling PGR primers. The method results in an efficient VNTR genotyping with low cost, less labor-requirement and less reaction time. The method is applicable in organism analyses by VNTR genotyping, such as microorganisms, parasites, animals or plants. | 10-23-2008 |
| 20080261222 | Rapid and comprehensive identification of prokaryotic organisms - An improved method for rapid identification of microorganisms is disclosed, along with sequences of PCR primers optimized for this purpose. The primers are designed based on information analysis of sequences from a large number of organism to amplify certain segments of genomic DNA whose sequences are unique among different organisms. The PCR products are compared with a DNA sequence database to obtain the identity of the microorganisms. This approach provides an accurate and fast identification and taxonomic assignment of microbial species. | 10-23-2008 |
| 20080261223 | ARL-1 Specific Antibodies - This invention provides antibodies immunologically specific for human ARL-1 (also referred to AKR1B10), a species of the aldo-keto reductase superfamily of proteins. The invention also provides methods of making and methods of using said antibodies. | 10-23-2008 |
| 20080261224 | PGC-1Beta, A Novel PGC-1 Homologue and Uses Therefor - The invention provides isolated nucleic acid molecules, designated PGC-1β nucleic acid molecules, which encode novel PGC-1 related coactivator molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1β nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1β gene has been introduced or disrupted. The invention still further provides isolated PGC-1β proteins, fusion proteins, antigenic peptides and anti-PGC-1β antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 10-23-2008 |
| 20080261225 | METHOD AND KIT FOR DETECTING A TARGET PROTEIN USING A DNA APTAMER - A method and a kit for detecting a target protein in a sample with a signal amplification strategy are provided. The signal amplification strategy is established for the aptamer-based molecular recognition of a target protein with concomitant release of single-stranded DNA (G-DNA), which binds complementarily to a single-stranded RNA comprising a fluorophore and a quencher (“F-RNA-Q”). The fluorescence-quenched RNA is then degraded by RNase H to result in a fluorescence signal, and the undamaged G-DNA is recycled to yield fluorescence amplification. | 10-23-2008 |
| 20080261226 | Biomarkers of neurodegenerative disease - The present invention provides biomarkers and diagnostic methods employing such biomarkers based on the discovery of genes that have a two-fold or greater difference in gene expression in the spinal cord of a pre-symptomatic mouse model of amyotrophic lateral sclerosis. Such biomarkers and diagnostic methods are useful for early detection of neural cell injury and death in acute and degenerative disease. | 10-23-2008 |
| 20080261227 | Kinetic Pcr Assay for Quantification of Gene Amplification on Chromosome 17 - Provided is a kinetic PCR (“kPCR”) assay for determining gene copy number of a target gene located on chromosome 17. The kPCR assay uses the MMP-28 gene located at the 17q11.2-17q12 loci as a control and thus, is capable of detecting gene copy number of any gene on chromosome 17 in both singleplex and multiplex format without the need for a standard curve. The kPCR assay is useful for determining the gene copy number of the HER2/neu gene located at loci 17q12-17q21.32, which is a requirement for determining if a breast cancer patient is a candidate for anti-HER2/neu gene therapy. | 10-23-2008 |
| 20080261228 | PCA3 Messenger RNA Species in Benign and Malignant Prostate Tissues - This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer. | 10-23-2008 |
| 20080261229 | SIMULTANEOUS RAPID DETECTION OF MICROBES - The invention includes a method of simultaneously detecting the presence or absence of more than one microbe class (e.g., bacteria, yeast, and mold) in a sample. The method can include the step of applying a sample suspected of containing more than one microbe class to a growth medium, optionally fragmenting the sample, associating the sample with a labeling agent, and simultaneously detecting the presence or absence of each microbe class by detection of the labeling agent. | 10-23-2008 |
| 20080261230 | FERMENTIVE PRODUCTION OF ISOBUTANOL USING HIGHLY ACTIVE KETOL-ACID REDUCTOISOMERASE ENZYMES - Methods for the fermentative production of isobutanol is provided by the fermentative growth of a recombinant microorganism expressing a highly active ketol-acid reductoisomerase enzyme in addition to other enzymes required for conversion of glucose to isobutanol. | 10-23-2008 |
| 20080261231 | DIABETES GENE - The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect human diabetes mellitus predisposing gene, specifically the angiotensinogen (AGT) gene, some mutant alleles of which cause susceptibility to insulin-dependent diabetes mellitus (IDDM). More specifically, the invention relates to germline mutations in the AGT gene and their use in the diagnosis of predisposition to diabetes. The invention also relates to the prophylaxis and/or therapy of diabetes associated with a mutation in the AGT gene. The invention further relates to the screening of drugs for diabetes therapy. Finally, the invention relates to the screening of the AGT gene for mutations, which are useful for diagnosing the predisposition to diabetes. | 10-23-2008 |
| 20080268428 | Chromosome 5 Genetic Variants Related to Dyslexia - An isolated polynucleotide or genetic material from human Chromosome 5 that indicates the presence of dyslexia or a predisposition to develop dyslexia in the individual from whom which the sample was obtained. A method of diagnosing dyslexia or a predisposition to develop dyslexia. | 10-30-2008 |
| 20080268429 | Rna - Containing Microvesicles and Methods Therefor - Contemplated compositions and methods are directed to the use of microvesicles from an optionally recombinant donor cell to impart a desirable effect to a recipient cell. In certain preferred aspects, RNA of the microvesicles is employed to achieve the desirable effect. For example, microvesicles are used in vitro to increase the number of passages of a cell growing in a medium, reduce serum and/or growth factor requirements of a cell growing in a medium, and/or delay differentiation of a cell growing in a medium. Further preferred aspects include use of the microvesicles as therapeutic agents in which RNA, a membrane protein, and/or a cytosolic protein encapsulated in or coupled to the microvesicle provide a therapeutic effect. Additionally, diagnostic methods are contemplated in which RNA of a microvesicle isolated from a mammal is associated with a condition of the mammal. | 10-30-2008 |
| 20080268430 | Methods and Kits Pertaining to the Detection, Identification and Quantification of Bacteria and Yeast in Wine, Beer and Juices - The invention concerns new analytical methods for detecting and identifying qualitatively and quantitatively germ contaminations, e.g. bacterial and yeast contaminations usings specific DNA sequences, indicating living and dead germs within 12 hours time or less. The DNA is amplified and as quantified. The invention also embraces kits. | 10-30-2008 |
| 20080268431 | Information Code System Using Dna Sequences - The present invention provides a molecular level of DNA information code which uses a base pair sequence as an information code unit. Also, the present invention provides a molecular code system which includes designing and coding DNA which is an information code unit; stabilizing the DNA information code by encapsulating it with an inorganic capsule and coating the DNA-inorganic capsule to a medium; taking and extracting the coated DNA information code which is present in a trace amount, collecting the DNA information code using a polypyrrole-maghemite nanohybrid; and amplifying the collected DNA information code using a polymerase chain reaction and reading the amplified DNA information code. According to the present invention, the DNA information code having high security is prepared by assigning a security unit to a DNA which has an excellent accumulating capacity, and then the DNA information code is stabilized so as to be coated to a medium. Only the DNA information code may be extracted, collected, and read, if necessary. Thus, a unified molecular code system can be established. | 10-30-2008 |
| 20080268432 | Method for detection of staphylococcus epidermidis - A method for detecting the bacteria | 10-30-2008 |
| 20080268433 | Use of Mitochondrial Point Mutations as Sensitive Clonal Markers - The present invention relates to a method of detecting an aberrant population of cells in a subject and, more particularly, to a method of qualitatively and/or quantitatively detecting a clonal population of aberrant cells in a subject by ‘screening for mitochondrial DNA mutations. The method of the present invention is useful in a range of applications including, but not limited to, diagnosing a condition characterised by the presence of a clonal population of aberrant cells (such as a neoplastic condition), monitoring the progression of such a condition, predicting the likelihood of a subject's relapse from a remissive state to a disease state or for assessing the effectiveness of existing therapeutic drugs and/or new therapeutic agents. In a related aspect, the present invention also provides a method of characterising clonal populations of aberrant cells by determining the nature and range of mitochondrial DNA mutations expressed by a specific population of aberrant cells. | 10-30-2008 |
| 20080268434 | Temperature Control of Reaction Vessel, System with Reaction Vessel, Software Product for System and Use of System - The invention relates to a method for rapid thermal control of a reaction volume ( | 10-30-2008 |
| 20080268435 | Brca1 Markers - A method of predicting the presence of a non-functional BRCA1 gene in a biological sample, comprises the step of assaying the sample for expression of at least one specific member of the S100 family of genes. The invention also describes a kit for predicting the presence of non-functional BRCA1, comprising means for assaying a sample for expression of at least one specific member of the S100 gene family. A method of detecting a genetic predisposition to cancer is also described, comprising the step of assaying a biological sample for expression of a specific member of the S100 family of genes. Also described is a method of determining a suitable chemotherapeutic agent for an individual. | 10-30-2008 |
| 20080268436 | Schizophrenia, Schizoaffective Disorder and Bipolar Disorder Susceptibility Gene Mutation and Applications to Their Diagnosis and Treatment - The present invention provides the identification of a number of SNPs that are associated schizophrenia, schizoaffective disorder, bipolar disorder and related mental disorders which were found to be strongly linked to individuals with the disease. The invention provides SNP locations on human chromosome 6, as well as methods of making PCR primers and assays for detecting the SNPs in tested individuals. | 10-30-2008 |
| 20080268437 | Method of Targeted and Comprehensive Sequencing Using High-Density Oligonucleotide Array - A method for targeted and comprehensive sequencing using high-density oligonucleotide array, comprising the steps of hybridizing nucleic acid from an investigative species with high-density oligonucleotide arrays of a related species, identifying the oligonucleotide probes that generate high hybridization signals, using the probes sequences to make PCR primers, amplifying heterologous genes by PCR with the gene specific PCR primers and an anchoring primer, and sequencing the PCR products. | 10-30-2008 |
| 20080268438 | MODEL SYSTEM FOR IDENTIFYING ANTI-CANCER AGENTS - A model system for screening and identification of compounds that interfere with Gli2 dependent tumorigenesis and provide potential use as anticancer agents is provided. In particular, the invention includes a Gli2 protein having an S662A point mutation that interferes with binding by the ubiquitin-ligase β-TrCP. The mutation inhibits Gli2 degradation by the ubiquitin pathway. Gli2 stability and half-life are increased in the host cell resulting in an increase in Gli2-dependent transcription and concomitant neoplasia and tumorigenesis. Expression of the Gli2 mutant allows for the high throughput screening of compounds that interfere with the tumorigenesis thereby identifying anticancer agents. | 10-30-2008 |
| 20080268439 | ASSAY SYSTEMS AND METHODS FOR DETECTING MOLECULES THAT INTERACT WITH SK2 CHANNELS - The invention provides methods including steps of: providing cells capable of expressing SK2; contacting the cells with a test molecule; obtaining information indicative of cellular SK2 expression to obtain an SK2 Expression Value; comparing the SK2 Expression Value with a control SK2 Expression Value; and identifying a test molecule that causes the cells to display an SK2 Expression Value that is different from the control SK2 Expression Value. Also provided are methods including steps of: providing a sample comprising an SK2 channel; contacting the sample with a test molecule; obtaining information indicative of SK2 channel activity in the sample to obtain an SK2 Channel Activity Value; comparing the SK2 Channel Activity Value with a control Channel Activity Value; and identifying a test molecule that causes the SK2 Channel Activity Value to be different from the control Channel Activity Value. Methods of identifying a molecule useful for treating neuropathic pain are also described. | 10-30-2008 |
| 20080268440 | BIOMOLECULE IMMOBILIZATION ON SURFACE VIA HYDROPHOBIC INTERACTIONS - A method, apparatus, or system for generating a pattern of polynucleotides on a substrate. The method includes providing a substrate having a hydrophobic surface. The method further includes conjugating a polystyrene moiety to a polynucleotide and applying a polystyrene-polynucleotide conjugate to create a plurality of reaction spots on the hydrophobic surface of the substrate. An apparatus includes a substrate with at least one polystyrene-polynucleotide conjugate on a surface of the substrate. A system can analyze a polystyrene-polynucleotide conjugate and the system may perform PCR. | 10-30-2008 |
| 20080268441 | DETECTABLE LABELED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF - The invention relates to detectable labels useful for detection of nucleotide sequences. Specifically, the invention relates to labeled-imidazole-PEG compounds, such as nucleosides, nucleotides, and nucleic acids incorporating such compounds, and methods utilizing such compounds. The invention further relates to kits comprising labeled imidazole-PEG compounds. | 10-30-2008 |
| 20080268442 | METHOD AND SYSTEM FOR PREPARING A BLOOD SAMPLE FOR A DISEASE ASSOCIATION GENE TRANSCRIPT TEST - System and method for preparing a blood sample for a disease association gene transcript test. Disease considerations for this unique test include a custom set of genetic sequences associated in peer-reviewed literature with various known diseases such as Addison's disease, anemia, asthma, atherosclerosis, autism, breast cancer, estrogen metabolism, Grave's disease, hormone replacement therapy, major histocompatibility complex (MHC) genes, longevity, lupus, multiple sclerosis, obesity, osteoarthritis, prostate cancer, and type 2 diabetes. The base dataset may be developed through clinical samples obtained by third-parties. Online access of real-time phenotype/genotype associative testing for physicians and patients may be promoted through a testing service. | 10-30-2008 |
| 20080268443 | BROAD-BASED DISEASE ASSOCIATION FROM A GENE TRANSCRIPT TEST - Broad-based disease association gene transcript test and data structure. Disease considerations for this unique test include a custom set of genetic sequences associated in peer-reviewed literature with various known diseases such as Addison's disease, anemia, asthma, atherosclerosis, autism, breast cancer, estrogen metabolism, Grave's disease, hormone replacement therapy, major histocompatibility complex (MHC) genes, longevity, lupus, multiple sclerosis, obesity, osteoarthritis, prostate cancer, and type 2 diabetes. The base dataset may be developed through clinical samples obtained by third-parties. Online access of real-time phenotype/genotype associative testing for physicians and patients may be promoted through an analysis of a customized microarray testing service. | 10-30-2008 |
| 20080268444 | Detection method of SNPs - A method for detecting a mismatch between a target nucleic acid as a measuring object and a control nucleic acid, the method comprising: (a) effecting formation of a double-stranded nucleic acid through hybridization of the control nucleic acid and the target nucleic acid; (b) allowing a mismatch binding protein to contact with the double-stranded nucleic acid and thereby to bind to a mismatched site; (c) allowing an intercalating agent which specifically recognizes the double-stranded nucleic acid and is intercalated therein, to contact with the double-stranded nucleic acid; (d) detecting the intercalating agent intercalated into the double-stranded nucleic acid; and (e) judging the presence or absence of a mismatch between the control nucleic acid and the target nucleic acid, by comparing amounts of the intercalating agent intercalated into the double-stranded nucleic acid in the absence and presence of the mismatch binding protein. | 10-30-2008 |
| 20080268445 | Ant2 Conditional Knockout Mouse and Methods - Described are methods for inactivating adenine nucleotide transporter proteins in specific tissues of a transgenic nonhuman animal using a conditional knockin/knockout technology such as the Cre-LoxP, Flip-FLP recombinase, or Tet-on/off technologies. Specifically, the Ant2 gene is functionally inactivated in a mouse in liver, with or without the concurrent inactivation of the Ant1 gene. The result is an animal in which the Ant2 gene and accompanying ANT 2 protein is absent in one or more tissues, either in the presence or absence of the Ant1 gene and accompanying protein. The resulting animals, cells, mitochondria, and subcelluar fractions such as the mitochondrial permeability transition pore can then be used to identify agents that affect animal and/or subcellular function via a direct or indirect interaction with the ANT2 protein and/or its Ant2 gene. | 10-30-2008 |
| 20080268446 | Flexible Culture Medium Bag Containing Nutrient Concentrate - Disclosed is a culture medium container such as a bag comprising a main compartment and a locus of containment that contains a nutrient concentrate until it is released at the time of use. The locus of containment may comprise separated compartments defined by frangible seals or seals comprising a water-reactive material. Sachets comprising frangible seals or a water-reactive material are also suitable for the locus of containment. Matrices and coatings comprising water-reactive material are also suitable. Capsules that can be pulverized and/or dissolved may also be used. | 10-30-2008 |
| 20080268447 | Sequential Cloning System - This invention discloses a cloning system and more particularly a system for sequentially cloning a plurality of heterologous nucleic acid sequences to assemble a chimeric construct of interest. The cloning system employs a marker sequence, which confers an identifiable characteristic on host cells in which it is contained, to chaperone individual insert nucleic acid sequences into recipient constructs that do not comprise the marker sequence but comprise other nucleic acid sequences for inclusion in the chimeric construct. Recombinant constructs into which one or more insert nucleic acid sequences have been introduced with the chaperone marker sequence are isolated by introducing recombinant constructs into host cells and identifying hosts cells with the identifiable characteristic. | 10-30-2008 |
| 20080268448 | Multiplex compositions and methods for quantification of human nuclear DNA and human male DNA and detection of PCR inhibitors - The invention relates to a method for simultaneous quantification of human nuclear DNA and human male DNA in a biological sample while also detecting the presence of PCR inhibitors in a single reaction. The multiplex quantification method also provides a ratio of human nuclear and male DNA present in a biological sample. Such sample characterization is useful for achieving efficient and accurate results in downstream molecular techniques such as genotyping. | 10-30-2008 |
| 20080268449 | UTILITY OF B-RAF DNA MUTATION IN DIAGNOSIS AND TREATMENT OF CANCER - The present invention discloses a method of detecting a wild-type or mutant B-RAF gene in a body fluid sample from a subject. Also disclosed are methods of using B-RAF as a biomarker for detecting cancer, predicting the outcome of cancer, and monitoring the treatment of cancer or the status of cancer. Furthermore, the invention discloses methods and compositions for detecting a mutant gene with a peptide nucleic acid clamp capable of hybridizing to a wild-type gene and a locked nucleic acid probe capable of hybridizing to a mutant of the gene. | 10-30-2008 |
| 20080268450 | AMPLIFICATION ASSAY FOR ANALYTE DETECTION - The present invention provides a method for detecting an analyte of interest via a bio-barcode assay. The present invention provides a calorimetric bio-barcode method that is capable of detecting minute concentrations of an analyte by relying on porous particles, which enable loading of a large number of barcode DNA per particle, and a metal particle-based colorimetric barcode detection method. | 10-30-2008 |
| 20080268451 | MEASUREMENT OF AN INSOLUBLE ANALYTE IN A SAMPLE - The present invention relates to compositions, apparatus and methods useful for concurrently performing singular, multiple, high throughput, biological or chemical assays, using nuclease protection molecules which specifically bind to a target of interest. The nuclease protection molecules are capable of detecting targets in complex biological samples, including, preserved, fixed, dried, and/or cross-linked specimen. The reagents and methods of the instant invention provide an effective means for analyzing a target of interest from a complex biological sample without solubilizing or disrupting the sample. Utilization of such methods in clinical and/or diagnostic applications is also described. | 10-30-2008 |
| 20080268452 | COMPOSITIONS, KITS AND RELATED METHODS FOR THE DETECTION AND/OR MONITORING OF PSEUDOMONAS AERUGINOSA - The present invention provides compositions, methods and kits for the species-specific detection of | 10-30-2008 |
| 20080268453 | Types of lymphoma and method for prognosis thereof - A method for determining the prognosis of a CD5+DLBCL patient and a CD5-DLBCL patient is provided. It is determined that, in the chromosomal DNA from a patient with lymphoma, (1) the prognosis of the CD5+DLBCL patient with amplification of 13 | 10-30-2008 |
| 20080268454 | Compositions, methods and systems for inferring bovine breed or trait - Methods, compositions, and systems are provided for managing bovine subjects in order to maximize their individual potential performance and edible meat value, and to maximize profits obtained in marketing the bovine subjects. The methods and systems draw an inference of a trait of a bovine subject by determining the nucleotide occurrence of at least one bovine SNP that is identified herein as being associated with the trait. The inference is used in methods of the present invention to establish the economic value of a bovine subject, to improve profits related to selling beef from a bovine subject; to manage bovine subjects, to sort bovine subjects; to improve the genetics of a bovine population by selecting and breeding of bovine subjects, to clone a bovine subject with a specific trait, to track meat or another commercial product of a bovine subject; and to diagnose a health condition of a bovine subject. Methods are also disclosed for identifying additional SNPs associated with a trait, by using the associated SNPs identified herein. | 10-30-2008 |
| 20080268455 | DETECTION OF NUCEIC ACIDS BY MULTIPLE SEQUENTIAL INVASIVE CLEAVAGES - The present invention relates to means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences. The present invention also relates to methods for forming a nucleic acid cleavage structure on a target sequence and cleaving the nucleic acid cleavage structure in a site-specific manner. The structure-specific nuclease activity of a variety of enzymes is used to cleave the target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof. The present invention further relates to methods and devices for the separation of nucleic acid molecules based on charge. The present invention also provides methods for the detection of non-target cleavage products via the formation of a complete and activated protein binding region. The invention further provides sensitive and specific methods for the detection of human cytomegalovirus nucleic acid in a sample. | 10-30-2008 |
| 20080268456 | METHOD FOR DETECTING AND QUANTITATING MULTIPLE-SUBCELLULAR COMPONENTS - A method for detecting and quantitating multiple and unique fluorescent signals from a cell sample is provided. The method combines immunohistochemistry and a fluorescent-labeled in situ hybridization techniques. The method is useful for identifying specific subcellular components of cells such as chromosomes and proteins. | 10-30-2008 |
| 20080268457 | siRNA targeting forkhead box P3 (FOXP3) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for FOXP3. | 10-30-2008 |
| 20080268458 | Method of Preparing Nucleic Acids for Detection - A method is provided for preparing a test sample for detecting a predetermined target nucleic acid. The method includes the steps of providing a test probe comprising an oligonucleotide attached to a nanoparticle and providing a hybridization unit containing the test sample and the test probe, wherein said hybridization unit further includes a target sample substrate and a distribution manifold coupled to a first side of the substrate. The method further includes the steps of clamping a processing fluids manifold to the distribution manifold of the hybridization unit, denaturing the test sample and preparing the test sample for detecting the predetermined target nucleic acid by pumping a plurality of processing fluids between the processing fluids source manifold and distribution manifold to hybridize the test probe and predetermined target nucleic acid to the target sample substrate, to wash the hybridized sample and to amplify a detectable parameter of the hybridized sample. | 10-30-2008 |
| 20080274452 | Process For Large Scale Production Of Plasmid Dna By E.Coli Fermentation - The present invention relates generally to a method for increasing the yield of plasmid DNA production. The method includes the steps of selecting a highly productive clonal subtype of a strain of | 11-06-2008 |
| 20080274453 | Diagnostics and therapeutics for macular degeneration - The invention relates to diagnostics and therapeutics and animal models for macular degeneration, specifically as they relate to the association described herein between macular degeneration and arterial wall disruptive disorders. In one embodiment, the invention provides kits and methods for diagnosing macular degeneration comprising identifying a marker for an arterial wall disruptive disorder, including an aneurysm. In one embodiment, the invention provides therapeutics for treating macular degeneration comprising delivering to a subject an agent useful for treating an arterial wall disruptive disorder, including an aneurysm. | 11-06-2008 |
| 20080274454 | Reversible and Chemically Programmable Micelle Assembly With Dna Block-Copolymer Amphiphiles - The present invention is directed to amphiphilic block copolymers. More particularly the present invention is directed to amphiphilic block copolymers comprising a polynucleotide block and a hydrophobic polymer block, to micelles formed from the block copolymers, and to methods of using the micelles. | 11-06-2008 |
| 20080274455 | Use Of Genes As Molecular Markers In Diagnosis Of Schizophrenia And Diagnostic Kit For The Same - Drug-naive and drug-free schizophrenic PBL were screened to identify additional markers that are differentially expressed compared to healthy individuals using microarray and quantitative real-time PCR (QRT-PCR) techniques. Genes for dopamine D | 11-06-2008 |
| 20080274456 | Methods and Compositions for Modifying Gene Regulation and Dna Damage in Ageing - The invention relates to gene regulation in ageing, and age-related cognitive decline. The invention, in particular relates to methods for screening a subject for a propensity to develop diseases associated with oxidative stress, and for age-related conditions, by examining the up-regulation and/or down-regulation of at least one gene associated within the central nervous system. | 11-06-2008 |
| 20080274457 | METHODS FOR DIFFERENTIATING MALIGNANT FROM BENIGN THYROID TISSUE - Methods of identifying malignant thyroid tissue comprising testing a thyroid tissue sample for the expression of at least two genes chosen from CCND2, PCSK2, and PLAB. Kits for use in the disclosed methods are also provided. | 11-06-2008 |
| 20080274458 | NUCLEIC ACID QUANTITATION METHODS - The invention relates to a method of determining the amount of a target nucleic acid sequence in a sample, the method comprising: obtaining multiple distinguishable amplicons of the target nucleic acid sequence, each comprising a distinguishing tag and a target portion; amplifying the amplicons in a single reaction volume; and detecting nucleic acids amplified from the amplicons. Detection of the distinguishable amplicons can be varied in each of the steps of the method, which expands the dynamic range of the nucleic acid quantification methods and improves the reliability and accuracy of the methods. | 11-06-2008 |
| 20080274459 | METHOD FOR COLLECTING AND STORING BIOLOGICAL MATERIALS - A method for collecting and storing biological material includes the steps of obtaining a patient identity of a patient and a biological material from a patient. A DNA identity analysis is performed to establish a DNA identity for the patient. The DNA identity is associated with the patient identity and the biological material. The biological material is stored in a preserving environment, and the patient identity and the DNA identity are stored in a database. A request for the biological material is received from a requestor purporting to have the patient identity. A DNA sample from said requestor is obtained. A DNA identity analysis is performed on the DNA sample from the requestor to obtain a DNA identity of the requestor. The DNA identity of the requestor is then compared to the stored DNA identity of the patient, and if the DNA identities match, the biological material is provided to the requestor. | 11-06-2008 |
| 20080274460 | Common allele on chromosome 9 associated with coronary heart disease - Disclosed are methods and compositions for determining whether a person carries an allele associated with increased risk for coronary atherosclerosis by determining whether the person has had RA-CHR9 allel, such as by determining whether the person has an RA-CHR9 allele-associated single nucleotide polymorphism (SNP). | 11-06-2008 |
| 20080274461 | Perinucleolar Compartment Markers for Cancer - The present invention relates to compositions and methods for cancer diagnostics, prognostics and predictions, including but not limited to, cancer markers. In particular, the present invention provides perinucleolar compartments and their resident molecules as cancer markers. | 11-06-2008 |
| 20080274462 | Universal bases for nucleic acid analyses, methods for using universal bases, and kits comprising universal bases - Compounds, methods and kits for making and analyzing primer extension products incorporating one or more universal bases are described, including methods and kits for nucleic acid sequencing and microsatellite analysis. | 11-06-2008 |
| 20080274463 | Method for quantifying biomolecules conjugated to a nanoparticle - Disclosed embodiments concern quantifying a biomolecule conjugated to a nanoparticle. Quantifying typically comprises determining the number of biomolecules per nanoparticle. Any suitable biomolecule can be used, including but not limited to, amino acids, peptides, proteins, haptens, nucleic acids, oligonucleotides, DNA, RNA, and combinations thereof. A single type of biomolecule may be conjugated to the nanoparticle, more than one biomolecule of a particular class may be conjugated to the nanoparticle, or two or more classes of biomolecules may be conjugated to the nanoparticle. Certain disclosed embodiments comprise enzymatically or chemically digesting a biomolecule conjugated to the nanoparticle, or displacing a biomolecule using ligand-exchange chemistry. Where biomolecule concentrations are determined, any technique suitable for determining biomolecule concentration can be used, such as spectrophotometric techniques, including measuring tryptophan fluorescence and using a standard fluorescence intensity versus biomolecule concentration curve. | 11-06-2008 |
| 20080274464 | Gene Detecting Method - Disclosed is a gene detecting method for determining mutation of a specific base or presence/absence of a specific base in a target gene. There are provided a the target gene sample and a control gene sample having a base sequence which is wild-type or standard-type with respect to the target gene. The method comprises steps of (i) independently subjecting the target gene sample and the control gene sample to a PCR reaction for amplification, using primers having an RNA polymerase promoter sequence at the 5′-end thereof, (ii) independently subjecting the double-stranded DNAs produced by said PCR reaction from the target gene sample and from the control gene sample, to an in vitro transcription reaction to form a single-stranded RNA, (iii) independently hybridizing the single-stranded RNAs with a fluorescence-labeled probe composed of a single-stranded DNA having a base sequence complementary to at least part of the base sequence of the control gene and being combined with a fluorescent dye, to form an RNA/DNA hybrid, and then (iv) comparing the fluorescence intensity of the RNA/DNA hybrid derived from the target gene sample with that of the RNA/DNA hybrid derived from the control gene sample. | 11-06-2008 |
| 20080274465 | Method for Breast Cancer Diagnosis/Prognosis - The present invention relates to a method for breast cancer diagnosis/prognosis comprising the following steps:
| 11-06-2008 |
| 20080274466 | Enrichment Through Heteroduplexed Molecules - The present invention relates to the enrichment of specific target sequences Enrichment can be achieved through the formation of a heteroduplex that includes the specific target sequence and then the specific cleavage of the heteroduplex. A binding moiety is then added to the cleaved heteroduplex, allowing for the subsequent manipulation of the specific target sequence in the heteroduplex. | 11-06-2008 |
| 20080274467 | Novel Therapeutic Targets in Cancer - The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel therapeutic targets against cancer. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer. | 11-06-2008 |
| 20080274468 | NOVEL MEANS FOR THE DIAGNOSIS AND THERAPY OF CTCL - The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL. | 11-06-2008 |
| 20080274469 | C-Kit Oncogene Mutations in Melanoma - The present invention provides methods of detecting c-KIT-dependent-melanoma for diagnostic and prognostic purposes. The invention further provides methods of treating such melanoma by inhibiting c-KIT. | 11-06-2008 |
| 20080274470 | NON-INVASIVE DETECTION OF ENDOMETRIAL CANCER - The present invention provides a non-invasive method of obtaining a sample of endometrial cells for use in the diagnosis of endometrial cancer, as well as methods and kits for diagnosing, determining the prognosis of, and monitoring endometrial cancer. | 11-06-2008 |
| 20080274471 | Methods for detecting an increased risk for coronary heart disease - The invention relates generally to an allele on human chromosome 9 associated with increased risk for coronary heart disease and the use or detection of such an allele in determining whether a human has an increased risk for coronary heart disease. In one aspect, the invention relates to methods for detecting a predisposition or propensity or susceptibility for coronary heart disease in a human, comprising detecting the presence of an allele on human chromosome 9 that is associated with an increased risk for coronary heart disease in a human. Disclosed are methods and compositions for determining whether a person carries an allele associated with increased risk for coronary atherosclerosis by determining whether the person has an RA-CHR9 allele, such as by determining whether the person has an RA-CHR9 allele-associated single nucleotide polymorphism (SNP). The invention also relates to kits for detecting the presence of an allele on chromosome 9 associated with an increased risk for coronary heart disease. | 11-06-2008 |
| 20080274472 | Novel kinases and uses thereof - Novel kinase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase proteins, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided. | 11-06-2008 |
| 20080280286 | Compositions and Methods for Gene Expression - The invention provides nucleotide sequences that mediate one or more functions of IKKα, kits and methods for using these sequences to identify therapeutic compounds that alter IKKα related pathology. | 11-13-2008 |
| 20080280287 | Oligonucleotides For the Detection of Hepatitis B Virus - The invention relates to specific oligonucleotide primers and probes for rapid and sensitive detection of hepatitis B virus by amplification of the HBV nucleic acid, and to methods using the same. It is also concerned with kits useful to perform these detection tests. | 11-13-2008 |
| 20080280288 | Assay Method to Predict Sensitivity of Cancer Cell to Anticancer Drug - If a cancer cell sampled from a cancer patient by biopsy or the like can be examined with respect to its expressed molecules to evaluate sensitivity of the cancer cell to the present compound, the present compound can be selectively administered only to the cancer patient who is expected to benefit from antitumor activity of the present compound, thereby to enhance the therapeutic effect and reduce unnecessary adverse effects. Specifically, the characteristics of a cancer cell with respect to “low level expression of pRB”, “positive expression of p16” and “high level expression of cyclin E” are demonstrated to be useful as markers for sensitivity of the cancer cell to the present compound. Therefore, these characteristics of a cancer cell can be examined to evaluate previously sensitivity of the cancer cell to the present compound. | 11-13-2008 |
| 20080280289 | Primers, Methods and Kits for Detecting Killer-Cell Immunoglobulin-Like Receptor Alleles - Embodiments of the present invention describe primer pairs, methods and kits for identifying and/or detecting killer-cell immunoglobulin-like receptor (KIR) alleles. The present primer sets include one or more primer pairs that can produce amplicons specific for an individual KIR allele and that are less than 1000 bp in size. Additionally, the primer sets can target intra-exon and/or extracellular domains of KIR alleles for amplification. | 11-13-2008 |
| 20080280290 | Method and Device for the Collection and Isolation of Nucleic Acid - A device for collecting and preserving nucleic acids in a sample, the device comprising: a) a support; b) one or more than one sample zone in the support for loading the sample onto the device; and c) a composition comprising i) one or more than one absorbent, and ii) one or more than one stabilizer; where the one or more than one sample zone on the support comprises a recess or space within the support extending from the top surface toward, but not through, the bottom surface, or comprises a space within the support and the composition is retained within the sample zone. A method for collecting and preserving nucleic acids in a sample, the method comprising a) providing a device for collecting and preserving nucleic acids in a sample according to the present invention; b) providing a sample potentially comprising one or more than one nucleic acid; and c) applying part or all of the sample to one or more than one of the sample zones on the device. A method of detecting and quantifying nucleic acids in a sample, the method comprising a) collecting and preserving nucleic acids in the sample according to a method of the present invention; b) removing the absorbent with sample from the sample zones of the device; and c) detecting, or detecting and quantifying the nucleic acids. | 11-13-2008 |
| 20080280291 | Compositions and methods utilizing DNA polymerases - The invention features a novel isolated Family B DNA polymerase, a | 11-13-2008 |
| 20080280292 | Late-PCR - A non-symmetric polymerise chain reaction (PCR) amplification method employing a limiting primer in low concentration whose concentration-adjusted melting point at least equals, and preferably exceeds, that of the excess primer, the latter in turn not being more than 25° C. below the melting temperature of the amplicon. Assays employing such amplification and labeled hybridization probes, including assays that include a detection step following primer extension or a low-temperature probe, or both. Kits for performing such assays and primer or primer-and-probe sets for performing the foregoing amplifications and assays. | 11-13-2008 |
| 20080280293 | Method of Examining Inflammatory Disease and Method of Screening Remedy for Imflammatory Disease - A gene polymorphism on a Toll-like receptor gene is analyzed and an inflammatory disease is examined based on the results of the analysis. A remedy for an inflammatory disease is screened by selecting a substance capable of altering the interaction between Toll-like receptor and galectin-2. | 11-13-2008 |
| 20080280294 | Inherited Mitochondrial Dna Mutations in Cancer - A method is provided for identifying a subject likely to have, or at risk of developing a disease condition correlated with increased reactive oxygen species (ROS), including cancer, by identifying in the subject a missense mutation in a nucleic acid of Complex III, IV and/or V of the OXPHOS system. This invention also provides a method of identifying a likelihood of having a heritable predisposition to cancer by detecting a homoplasmic missense mutation in non-tumor tissue of an OXPHOS system gene. This invention also provides a method for detecting likelihood of having cancer, predisposition to cancer, and likelihood of passing a predisposition to cancer to progeny involving identifying in non-tumor tissue of the subject a missense mutation in a complex III, IV and/or V gene of the mitochondrial OXPHOS system. The mutation may be a nuclear or mitochondrial mutation. The invention has been exemplified with respect to prostate cancer. When the mutation is homoplasmic in non-tumor tissue this is an indication it is an inherited and inheritable trait, and that the subject is likely to pass on the mutation to her progeny in the case of mutations in mitochondrial DNA or his or her progeny in the case of mutations in nuclear DNA. Both homoplasmic and heteroplasmic mutations in non-tumor tissue can indicate the presence of cancer. | 11-13-2008 |
| 20080280295 | Use of Panel of Pairs of Primers Complementary to Reporter Genes of Cell Differentiation - The present invention to a panel comprising at least two pairs of primers that are complementary to at least two different reporter genes, the expression of which are i) either up- or down-regulated upon cell differentiation, and ii) display a similar expression profile in at least two different cell lines of the same kind of cells. The cells may be blastocyst-derived stem (BS) cells or human blastocyst-derived stem (hBS) cells. Furthermore, the present invention relates to the use of a calculated expression index for quantifying and evaluating the expression of the reporter genes, which for example can be used for assessing the state of differentiation of a cell population, such as, e.g. a hBS cell population. | 11-13-2008 |
| 20080280296 | METHOD FOR DETECTION OF FOOT-AND-MOUTH DISEASE VIRUS WITH CHROMATOGRAPHIC STRIP TEST - The present invention discloses a method for detection of foot-and-mouth disease virus with chromatographic strip test. Firstly, the nucleic acid sequence of FMDV NSPs is set up, the nucleic acid sequence is amplified by the reverse transcriptase polymerase chain reaction (RT-PCR) method, the recombinant vector is constructed and performed through a prokaryotic system to transform and express the recombinant protein, and the purified recombinant protein is mass produced. Design principles of the method are based on immunoassay and chromatographic analysis. The advantages are easy and simple to handle, no need of elaborate equipment, only one drop of body fluid is required to quickly complete the qualitative test in 10-20 minutes, and operating with a portable POCT (Point of care testing) instrument to complete the quantitative detection within 40-50 minutes. | 11-13-2008 |
| 20080280297 | Compositions and Methods for Differential Diagnosis of Chronic Lymphocytic Leukemia - The invention provides compositions and methods for determining a prognosis of a B cell chronic lymphocytic leukemia (CLL) in a subject based on the level of expression of at least one marker gene. Marker genes provided by the invention are SEPTlO, KIAA0799, Hs.23133, and ADAM29. The marker genes can be used to differentially diagnose CLL in a subject based on relative gene expression levels in the subject compared to reference gene expression levels established from a clinically characterized population of patients. The invention also provides diagnostic reagents and compositions and kits based on the marker genes. | 11-13-2008 |
| 20080280298 | SATB1: A DETERMINANT OF MORPHOGENESIS AND TUMOR METASTASIS - It is proposed that cancer cells express SATB1, and that SATB1 acts as a determinant for the acquisition of metastatic activity by controlling expression of a specific set of genes that promote metastatic activity. In order for cancer cells to gain the ability to metastasize, SATB1 re-organizes or re-packages genomic sequences in a specific manner to allow a switch in the pattern of gene expression. SATB1 expression was found restricted mainly to aggressive cancer cells where it may regulate the genetic and epigenetic changes that program the steps involved in the metastatic process. The present invention describes reagents and tools to detect the SATB1 protein for use in diagnosis and prognosis of aggressive cancers and therapeutics to inhibit SATB1 protein to deplete its expression in metastatic and aggressive cancers. | 11-13-2008 |
| 20080280299 | Method for Specific Detection of Legionella Pneumophila - A method for specific detection of the presence of | 11-13-2008 |
| 20080280300 | Method - There is described a method for identifying a potential modulator of a cell signalling pathway, comprising the steps of: (a) providing a cell of a first cell type, wherein said first cell type may be differentiated to a second cell type via a progenitor cell by sequentially exposing said first cell type to two or more reaction conditions; (b) adding to or replacing at least one of said two or more reaction conditions to which the progenitor cell has been exposed with exposure to one or more different reaction conditions comprising said potential modulator; -and (c) monitoring the differentiation of the first cell type to determine formation of the second cell type. | 11-13-2008 |
| 20080280301 | Lrp4/Corin DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL MARKERS - In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such. | 11-13-2008 |
| 20080280302 | MULTIGENE DIAGNOSTIC ASSAY FOR MALIGNANT THYROID NEOPLASM - The present invention provides methods for diagnosing, providing a prognosis, and staging thyroid cancer, using panels of molecular markers that are differentially expressed in thyroid cancer. Also provided are methods to identify compounds that are useful for the treatment or prevention of thyroid cancer. | 11-13-2008 |
| 20080280303 | G-PROTEIN COUPLED RECEPTORS HIGH-THROUGHPUT FUNCTIONAL ASSAY - Disclosed herein are methods for enabling or improving functional assays of G-protein coupled receptors through the use of co-expression of helper genes. In some cases, chimeras linking the regulatory domain of the rap1B protein to the effector region of the ras oncogene are used in conduction with existing functional assays for cellular proliferation. Furthermore, overexpression of other genes can further augment the enabling properties of ras/rap chimeras. | 11-13-2008 |
| 20080280304 | METHOD FOR DETECTING TARGET PLANT GENUS - A method for detecting species in a target plant genus comprises the steps of conducting PCR using at least one member selected from the group consisting of primers (A) and (B), which can hybridize under stringent conditions to a nucleic acid molecule having a common nucleotide sequence for all species in the target plant genus in 45S rRNA precursor gene sequence thereof, wherein 3′ end of primer (A) can complementarily bind to a base in ITS-1 sequence of the target plant genus when the primer hybridizes to the nucleic acid molecule while 3′ end of primer (B) can complementarily bind to a base in ITS-2 sequence of the target plant genus when the primer hybridizes to the nucleic acid molecule, and identifying the presence of the resulting amplification product from PCR containing at least a part of ITS-1 or ITS-2 sequence of the target plant genus | 11-13-2008 |
| 20080286760 | Means and Methods for the Determination of Camp In Vitro and In Vivo - The present invention relates to a chimeric peptide, comprising a cAMP binding moiety having only one cAMP binding site and at least two detectable labels, whereby the first of said two detectable labels is located at the carboxy terminus and the second of said two detectable labels is located at the amino terminus of said cAMP binding moiety. Said chimeric peptide of the invention is particularly useful in/for direct determination of cAMP concentrations) in vitro and/or in vivo. Furthermore, nucleic acid molecules encoding said chimeric proteins are described as well as vectors and host cells comprising the same. The present invention also provides methods for producing the chimeric protein of the invention and methods for identification and screening of molecules or compounds which are capable of modifying cAMP binding to the chimeric peptide of the invention or the biological and/or pharmacological function of adenylyl cyclases or phosphodiesterases. In addition, a method for cAMP determination in a sample and a method for the detection of cAMP in the living cell or tissue is described. Finally, a kit comprising the compounds of the present invention is disclosed. | 11-20-2008 |
| 20080286761 | Methods and Nucleic Acids for the Analysis of Gene Expression Associated with the Development of Prostate Cell Proliferative Disorders - The following application provides methods and nucleic acids for the detection of and/or differentiation between prostate cell proliferative disorders. This is achieved by the analysis of the expression status of a panel of genes, or subsets thereof. | 11-20-2008 |
| 20080286762 | Gene Detection Field-Effect Device And Method Of Analyzing Gene Polymorphism Therewith - A gene detection field-effect device provided with an insulation film ( | 11-20-2008 |
| 20080286763 | Method For The Identification Of Sepsis - The invention relates to a method for the in vitro discrimination between systemic inflammatory non-infectious conditions and systemic inflammatory infectious conditions. The method comprises the following steps: a) sample RNA is isolated from a biological sample; b) the sample RNA and/or at least one DNA which represents a gene activity that is specific for distinguishing between SIRS and sepsis and/or a specific gene or gene fragment, is marked with a detectable marker; c) the sample RNA is brought in contact with the DNA in hybridization conditions; d) control RNA is brought in contact with at least one DNA in hybridization conditions, the DNA representing a gene or gene fragment that is specific for distinguishing between SIRS and sepsis; e) the marking signals of the hybridized sample RNA and control RNA are quantitatively recorded; and f) the quantitative data of the marking signals is compared in order to make a statement as to whether genes or gene fragments that are specific for distinguishing between SIRS and sepsis are expressed more prominently or less prominently in the sample than in the control RNA. | 11-20-2008 |
| 20080286765 | Human Obesity Susceptibility Gene Encoding a Taste Receptor and Uses Thereof - The present invention discloses the identification of a human obesity susceptibility gene, which can be used for the diagnosis, prevention and treatment of obesity and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the TAS1R1 gene on chromosome 1 and certain alleles thereof are related to susceptibility to obesity and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the TAS1R1 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of coronary heart disease and metabolic disorders, including hypoalphalipoproteinemia, familial combined hyperlipidemia, insulin resistant syndrome X or multiple metabolic disorder, coronary artery disease, diabetes and dyslipidemia. | 11-20-2008 |
| 20080286766 | Comparing Method for Expression Amount of the Same Gene from Different Sources by Base Sequence Measurement - The present invention relates to an analysis method used to quantitatively compare the expression levels of the same gene from different sources. The method of the present invention can be used to quantitatively compare the gene expression level difference of the same gene of tissues or cells from different sources, making use of the quantitative characteristics of bioluminescent assay and the principle of adding different deoxyribonucleic acids (dNTP) one by one. The concrete steps are: reverse transcript the messenger ribonucleic acids (mRNA) from different sources into cDNA, and label a segment of source specific sequence in cDNA from each source; mix the labeled cDNA of different sources into one tube and use it as the substrate of polymerase chain reaction (PCR); PCR amplification is performed using the same common primer and a gene-specific primer; Detect the base sequence by bioluminescent assay, wherein the base type represents the different gene source, and the signal intensity of each base represents the gene expression level from each source. This method has a significant meaning for the screening of disease-related genes, clinical early diagnosis and the preparation of specific medicine for the treatment of disease. | 11-20-2008 |
| 20080286767 | Method of Analyzing Dna Sequence Using Field-Effect Device, and Base Sequence Analyzer - Since conventional DNA sequence analyzing technologies are based on the fundamental principle of fluorescent detection, expensive, complex optical systems and laser sources have been necessary. | 11-20-2008 |
| 20080286768 | Sequencing a Polymer Molecule - A method for sequencing a target polymer molecule comprises the steps of: (i) treating the target polymer with an agent that degrades sequentially at least one end of the target polymer; (ii) converting at least a portion of the degraded end of different degraded polymers into a readable signal sequence, and labeling each of said degraded polymers with a tag that represents the relative order of degradation; (iii) determining the sequence of the readable signal sequence; and (iv) determining the sequence of the target polymer using the sequence data obtained in step (iii) and the identification of each associated tag. | 11-20-2008 |
| 20080286769 | Method of Quantitative and/or Comparative Measurement of Mrna Expression Levels in Small Biological Samples - The present invention provides a method for quantitative and/or comparative assessment of the relative amounts of mRNA transcripts present in a cell or tissue sample. In the method reverse transcription of the mRNA contained in the sample is first carried out using sequence-modifying primers for one or several genes in the same reaction to obtain a pool of sequence-modified cDNA molecules. After completion of the reverse transcription redundant sequence-modifying primers are removed or inactivated. This step is followed by a step of co-amplifying the sequence-modified cDNA templates with a reference DNA template in individual gene-specific amplification reactions. By quantitatively measuring the amounts and determining the relative levels of the amplification products derived from sequence-modified cDNA and reference DNA templates, a gene-specific cDNA over DNA ratio is obtained in each of the individual amplification reactions. Finally, by combining the ratios obtained, a sample-specific profile can be generated, which reflects the relative amounts of mRNA transcripts originally present in the sample. | 11-20-2008 |
| 20080286770 | DNA Molecules Encoding L-Glutamate-Gated Chloride Channels From Rhipicephalus Sanguineus - The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode | 11-20-2008 |
| 20080286771 | Method of Predicting the Responsiveness of a Tumour to Erbb Receptor Drugs - The invention relates to a method of selecting a mammal having or suspected of having a tumour for treatment with an erbB receptor drug which comprises testing a biological sample from the mammal for expression of anyone of the genes listed in Table 1 or 2 as defined herein whereby to predict an increased likelihood of response to the erbB receptor drug. Preferred genes include anyone of NES, GSPT2, ETR101, TAZ, CHST7, DNAJC3, NPAS2, PIN1, TCEA2, VAMP4, DAPK1, DAPK2, MLLT3, TNNC1, KIAA0931, ACOX2, EMP1, SLC20A1, SPRY2 or PGM1. | 11-20-2008 |
| 20080286772 | Method for Direct Amplification from Crude Nucleic Acid Samples - The present teachings relate to improved methods, kits, and reaction mixtures for amplifying nucleic acids. In some embodiments a novel direct buffer formulation is provided which allows for the direct amplification of the nucleic acids in a crude sample with minimal sample purification. | 11-20-2008 |
| 20080286773 | Method for Typing an Individual Using Short Tandem Repeat (Str) Loci of the Genomic Dna - The present invention relates to a novel STR typing strategy, which allows the simultaneous amplification and subsequent analysis of several (e.g. eleven) polymorphic systems with amplicon sizes of less than 270 bp. Thereby, after a PCR amplification the multiplex reaction is divided into two sets of STR multiplexes and analyzed separately. This multiplex system was particularly developed and tested for use in forensic investigations, where only limited amounts of DNA or only highly degraded DNA is available, for example, when the DNA is isolated from the roots of telogen hair. | 11-20-2008 |
| 20080286774 | Real-time individualized therapy evaluation - A method of individually optimizing drug therapy to a patient that includes the steps of administering a dose of a radiolabeled drug or fluorescent tags or drugs with inherent fluorescent properties to the patient in connection with chemotherapy, collecting a sample from the patient, analyzing the sample producing an analysis, and using the analysis for developing a model for the patient. | 11-20-2008 |
| 20080286775 | METHODS OF NONSPECIFIC TARGET CAPTURE OF NUCLEIC ACIDS - Methods for capturing a target nucleic acid from a sample by using a capture probe that binds nonspecifically to the target nucleic acid and binds specifically to an immobilized probe via a specific binding pair that has one member on the capture probe and one member on the immobilized probe are disclosed. Compositions that include a capture probe that binds nonspecifically to a target nucleic acid and specifically to an immobilized probe via binding of members of a specific binding pair in a solution phase of a reaction mixture are disclosed. | 11-20-2008 |
| 20080286776 | Methods and Compositions for Assessment of Pulmonary Function and Disorders - The present invention provides methods for the assessment of risk of developing lung cancer in smokers and non-smokers using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's risk of developing lung cancer, and the suitability of a subject for an intervention in respect of lung cancer. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided. | 11-20-2008 |
| 20080286777 | Method of Determining the Diversity of T Lymphocytes in a Biological Sample - The invention relates to the field comprising the diagnosis of possible immune system disorders and the analysis of immune responses. In particular, the invention relates to a method of determining the diversity of T lymphocytes in a biological sample, based on the molecular analysis of the structure of the junctions resulting from the recombination rearrangement V(D)J of element δRec-1 with an AJ gene. More specifically, the invention relates to a method of analyzing the combinatorial diversity and/or the junctional diversity of the excision circles (TREC) resulting from the rearrangement of δRec-1, in order to determine the heterogeneity of a given population of T lymphocytes. | 11-20-2008 |
| 20080286778 | Method for Investigating Cytosine Methylations in Dna - The invention relates to a method for sensitively and specifically detecting cytosine methylations. For this purpose, DNA is first analysed by reacting with the aid of a methylation specific restriction enzyme. In such a way, the background DNA is removed from a reaction preparation. At a next step, a specific conversion of a non-methylated cytosine is carried out, while a methylated cytosine remains unchanged. The converted DNA can be analysed according to different methods, in particular by means of real time PCR method. | 11-20-2008 |
| 20080286779 | Host Cells Containing Multiple Integrating Vectors - The present invention relates to the production of proteins in host cells, and more particularly to host cells containing multiple integrated copies of an integrating vector. Suitable integrating vectors for use in the present invention include retrovirus vectors, lentivirus vectors, transposon vectors, and adeno-associated virus vectors. Methods are provided in which the host cells are prepared by using the integrating vectors at a high multiplicity of infection. The host cells are useful for producing pharmaceutical proteins, variants of proteins for use in screening assays, and for direct use in high throughput screening. | 11-20-2008 |
| 20080286780 | Novel compositions and methods for the identification, assessment, prevention and therapy of human cancers - The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent. | 11-20-2008 |
| 20080286781 | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer - The invention relates to nucleic acid molecules and proteins associated with cervical cancer including pre-malignant conditions such as dysplasia. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human cervical cancers are also provided. | 11-20-2008 |
| 20080286782 | ANALYSIS OF DNA SAMPLES - The invention provides an improved method for obtaining information about DNA analysis of samples of uncertain origin by establishing the likelihood that they arose in certain manners compared with other possible manners. In this way all of the analysis information is taken into account and likelihood ratios are provided to express the results. The invention is particularly useful in analysing small DNA samples or DNA samples where the contribution from one or more sources is small. | 11-20-2008 |
| 20080286783 | NOVEL METHOD OF DETECTING GENETIC POLYMORPHISM - The present invention provides a novel polymorphism detecting method suitable for the detection and identification of copy number variation. | 11-20-2008 |
| 20080286784 | Method for Detection of DNA Methyltransferase RNA in Plasma and Serum - The methods of the invention detect in a qualitative or quantitative fashion DNA methyltransferase RNA in blood plasma, serum, and other bodily fluids. The inventive methods are useful for aiding detection, diagnosis, monitoring, treatment, or evaluation of neoplastic disease, and for identifying individuals who have a predisposition to disease or who might benefit from further evaluation, monitoring or therapy. | 11-20-2008 |
| 20080286785 | Method to predict or monitor the response of a patient to an erbb receptor drug - The invention provides a method of detecting ErbB receptor mutations comprising the steps of providing a bio-fluid sample from a patient; extracting DNA from said sample; and screening said DNA for the presence of one or more mutations that alter tyrosine kinase activity in the receptor. | 11-20-2008 |
| 20080286786 | Methods of preparing nucleic acid for detection - Methods of preparing nucleic acid from polysaccharide-containing samples for detection by providing one or more glycosidases to the sample to degrade polysaccharides are provided. The nucleic acids can further be extracted from the sample. The method is particularly useful for detecting nucleic acid in samples with high starch content. | 11-20-2008 |
| 20080286787 | High Throughput Method of DNA Methylation Haplotyping - Particular aspects provide novel, high-throughput methods to quantify DNA methylation (e.g., at a single-base resolution) in an allele-specific manner. The methods comprise use of an allele-specific sequence polymorphism (e.g., allele-specific single nucleotide polymorphism; SNP) in sufficient proximity to a CpG methylation site to provide for distinguishing the methylation levels between two alleles. In particular aspects, after bisulfite modification, the genomic DNA region is PCR-amplified, and the product subjected to allele-specific pyrosequencing, and the percentage of methylation determined based on the percentage of cytosine to thymidine conversion. In further embodiments, MethyLight™ is used after bisulfite treatment. The inventive methodology has, for example, substantial utility for affording quantitative analyses in the regulation of analyses of X-inactivation, the allele-specific expression of genes (e.g., in the immune system) and junk DNA, etc., and in classifying an individual as to whether they have loss of imprinting (LOI). | 11-20-2008 |
| 20080286788 | NUCLEIC ACID LIGANDS TO COMPLEX TARGETS AND USES THEREOF - The present invention relates to a method for isolating a pool of nucleic acid ligands capable of binding to one or more target molecules in a complex mixture. | 11-20-2008 |
| 20080286789 | GENOMIC POLYMORPHISM FOR PREDICTING THERAPEUTIC RESPONSE - The present invention relates to the use of genomic polymorphism to provide individualized therapeutic regimens to treat patients suffering from diseases such as cancer. The invention discloses methods for determining the efficacy or choice of chemotherapeutic drugs and regimens for use in treating a diseased patient by associating genomic polymorphism with the effectiveness of the drugs or regimens, or by associating genomic polymorphism with the intratumoral expression of a gene whereby the gene expression affects effectiveness of the drugs or regimens. In particular, the present invention provides novel methods for screening therapeutic regimens, which comprise determining a patient's genotype at a tandemly repeated 28 base pair region in the thymidilate synthase (TS) gene's 5′ untranslated region (UTR). Patients homozygous for a triple repeat will be least successfully treated with a thymidylate synthase directed drug, while those heterozygous for a triple and a double repeat will be more successfully treated, and those homozygous for a double repeat will be even more successfully treated. Those patients homozygous for the double repeat will likely suffer the least side effects from thymidylate synthase directed drugs such as 5-FU. | 11-20-2008 |
| 20080286790 | Method for Diagnosing Overactive Bladder - Techniques for diagnosing overactive bladder (OAB) in a patient are provided. For example, a technique for diagnosing overactive bladder in a patient includes the step of obtaining peripheral blood mononuclear cells (PBMC) from the patient to provide a reporter function in the patient. | 11-20-2008 |
| 20080286791 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof. | 11-20-2008 |
| 20080286792 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 3 and mutated sequences thereof. | 11-20-2008 |
| 20080286793 | METHOD OF ANALYSIS OF PRIMARY STRUCTURAL CHANGE OF NUCLEIC ACID - The object of the present invention is to offer a method for analyzing primary structure change of nucleic acid which has quantifiability, which has a high degree of sensitivity and reproducibility, and which can be conducted rapidly and at low cost. The method of analysis of primary structural change of nucleic acid of the present invention includes a process for obtaining a reference nucleic acid having a standard sequence and a target sequence, each sequence being bound by a first ligand that differs depending on type of the sequence to which it binds, and being bound by a second ligand; a process for specifically binding first ligands to receptors supported on a carrier, thereby immobilizing standard sequences and target sequences on the carrier; a process for specifically binding labeled receptors to the second ligands in said nucleic acids which have been immobilized; a process for detecting labels to detect standard sequences and target sequences; a process for obtaining the ratio of standard sequences in the reference nucleic acid and subject nucleic acid, calculating a coefficient which corrects detection values of target sequences, and conducting correction; and a process for confirming an increase/decrease in the quantity of target sequences in the subject nucleic acid relative to target sequences in the reference nucleic acid. | 11-20-2008 |
| 20080286794 | METHODS AND PRIMERS FOR DIAGNOSING IDIOPATHIC CONGENITAL CENTRAL HYPOVENTILATION SYNDROME - The present invention provides assays and kits for diagnosing idiopathic congenital central hypoventilation syndrome. The present assays and kits focus on the second polyalanine repeat of the PHOX2b gene or gene product, which is normally 20 residues in length. A polyalanine repeat 25 to 33 residues in length is strongly correlated with idiopathic congenital central hypoventilation syndrome. | 11-20-2008 |
| 20080286795 | Method of nucleic acid amplification - A nucleic acid molecule can be annealed to an appropriate immobilized primer. The primer can then be extended and the molecule and the primer can be separated from one another. The extended primer can then be annealed to another immobilized primer and the other primer can be extended. Both extended primers can then be separated from one another and can be used to provided further extended primers. The process can be repeated to provide amplified, immobilized nucleic acid molecules. These can be used for many different purposes, including sequencing, screening, diagnosis, in situ nucleic acid synthesis, monitoring gene expression, nucleic acid fingerprinting, etc. | 11-20-2008 |
| 20080286796 | Genetic polymorphisms associated with neurodegenerative diseases, methods of detection and uses thereof - The present invention is based on the discovery of genetic polymorphisms that are associated with neurodegenerative disease, particularly Alzheimer's disease and Parkinson's disease. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 11-20-2008 |
| 20080286797 | Accurate identification of organisms based on individual information content - An improved method for specific identification of any organisms by DNA hybridization or amplification is disclosed. Oligonucleotides are designed based on information analysis of sequences from a large number of related species. Oligonucleotide sequences that have the maximal specificity to certain nucleic acids from a particular species (or set of species) or type strain are selected for hybridization or amplification using DNA from the target organism. The presence or absence of a PCR or hybridization product may be used to identify the target organism. The resulting PCR products may also be compared with a DNA sequence database to obtain the identity of the organisms. The methods may prove useful in areas where rapid and accurate identification of an organism is desirable, such as in a hospital where identification of infectious agents may be critical, in the ethanol or beer industry where certain bacteria may be detrimental to the manufacturing process, or in the porcine industry where identification of different type strains of the porcine reproductive and respiratory syndrome virus (PRRV) is important for disease prevention. | 11-20-2008 |
| 20080286798 | CONTROLS FOR PRIMERS IN MULTIPLEX AMPLIFICATION REACTIONS - The present invention provides methods and compositions for confirming the integrity of primers and other components of amplification reactions, including multiplex amplification reactions. | 11-20-2008 |
| 20080286799 | METHODS OF AND KITS AND COMPOSITIONS FOR DIAGNOSING COLORECTAL TUMORS... - In vitro methods of determining whether or not an individual has metastasized colorectal cancer cells are disclosed. In vitro methods of determining whether or not tumor cells are colorectal in origin are disclosed. In vitro kits for practicing the methods of the invention and to reagents and compositions useful to practice the methods, for example as components in such in vitro kits of the invention are provided. Methods of and kits and compositions for analyzing tissue samples from the colon tissue to evaluate the extent of metastasis of colorectal tumor cells are disclosed. | 11-20-2008 |
| 20080286800 | Method and system for biopsy and analysis of a body tissue - Methods and systems for performing biopsies and diagnosing tumors and suspect masses within the body. A biopsy sample is frozen while still in the body of a patient, then removed from the patient, stored frozen, and subject to IHC, microarray or other analysis to determine the amount, type or presence of signaling substances within the tumor or suspect mass. | 11-20-2008 |
| 20080286801 | Method for the analysis of differential expression in colorectal cancer - A method for the analysis of differential expression in colorectal cancer based on the variation in the expression levels of genes encoding for proteins forming part of the condensin complex or associated proteins that occurs in patients with the disease and that can be used as markers for the diagnosis of the cancers, as well as for the prevention and treatment thereof. | 11-20-2008 |
| 20080293043 | Method of Detecting Metastisizing Cancer Cells Originating in Stomach Cancer - Metastatic cancer cells originating from gastric cancer are detected by a method comprising the step of collecting a biological sample from a subject, the step of detecting the presence of at least either aldehyde dehydrogenase or dopa decarboxylase in the biological sample of the subject, and the step of determining that the possibility of containing metastatic cancer cells originating from the gastric cancer in the sample is high when at least either aldehyde dehydrogenase or dopa decarboxylase is present. By the use of these as markers for metastatic cancer cells originating from gastric cancer, the presence or absence of peritoneal metastasis in a gastric cancer patient can be detected rapidly and reliably, and data important for deciding whether intraperitoneal cancer chemotherapy should be applied is provided. | 11-27-2008 |
| 20080293044 | Melks as Modifiers of the Rac Pathway and Methods of Use - Human MELK genes are identified as modulators of the RAC pathway, and thus are therapeutic targets for disorders associated with defective RAC function. Methods for identifying modulators of RAC, comprising screening for agents that modulate the activity of MELK are provided. | 11-27-2008 |
| 20080293045 | Recombinase Polymerase Amplification - This disclosure describes related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods have the advantage of not requiring thermocycling or thermophilic enzymes, thus offering easy and affordable implementation and portability relative to other amplification methods. Further disclosed are conditions to enable real-time monitoring of RPA reactions, methods to regulate RPA reactions using light and otherwise, methods to determine the nature of amplified species without a need for gel electrophoresis, methods to improve and optimize signal to noise ratios in RPA reactions, methods to optimize oligonucleotide primer function, methods to control carryover contamination, and methods to employ sequence-specific third ‘specificity’ probes. Further described are novel properties and approaches for use of probes monitored by light in dynamic recombination environments. | 11-27-2008 |
| 20080293046 | RNA detection assays - The present invention provides novel cleavage agents and polymerases for the cleavage and modification of nucleic acid. The cleavage agents and polymerases find use, for example, for the detection and characterization of nucleic acid sequences and variations in nucleic acid sequences. In some embodiments, the 5′ nuclease activity of a variety of enzymes is used to cleave a target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof. | 11-27-2008 |
| 20080293047 | Method for the Diagnosis of Aspirin Intolerance - The present invention relates to a method for the diagnosis of aspirin intolerance based on a biological sample from a patient, characterized in that it comprises the following steps:
| 11-27-2008 |
| 20080293048 | METHODS AND KITS BASED ON UGT1A7 PROMOTER POLYMORPHISM - The present invention relates to methods for predicting the efficacy, safety and toxicity of substances, e.g. of drugs and prodrugs. Furthermore, the present invention relates to a method for the stratification of mammalians for the treatment of a disease. Moreover, the present invention provides for kits and its use for determining the efficacy, safety and toxicity of substances, in particular of drugs and prodrugs. The present invention allows for the selection of therapeutic regimens utilizing host genetic information, including gene sequence variances. The methods for identification of the specific DNA sequence variations according to the present invention include both in vitro and in vivo approaches. | 11-27-2008 |
| 20080293049 | Methods, Kids and Polynucleotides for Simultaneously Diagnosing Viruses - The present invention provides a simultaneous method for diagnosing HBV, HCV and HIV of a suspected patient. The present invention further provides different primer sets and specific probes for HBV, HCV and HIV. The present invention also provides a kit for simultaneous diagnosing of HBV, HCV and HIV. | 11-27-2008 |
| 20080293050 | Gene analysis for determination of a treatment characteristic - An apparatus, device, methods, computer program product, and systems are described that determine at least one amino acid sequence alteration of an amino acid sequence of a disease associated polypeptide, relative to an amino acid sequence of a corresponding non-disease associated polypeptide, identify a sub-sequence in the amino acid sequence of the disease associated polypeptide in which the amino acid sequence alteration occurs, relate the sub-sequence in the amino acid sequence of the disease associated polypeptide to a corresponding sub-sequence of the amino acid sequence of the corresponding non-disease associated polypeptide, and determine a treatment characteristic, based on the relating. | 11-27-2008 |
| 20080293051 | PROXIMITY LIGATION ASSAY - The present invention relates to compositions and methods for sensitive, rapid and convenient assays to detect and/or quantify one or more target using ribonucleic acid as probes, wherein the method includes binding a first and a second ribonucleic acid probe, each of which binds specifically to the target, wherein the first and second probes each comprise a ribonucleic acid tail; ligating the first and second ribonucleic acids tails thereby producing a ligated ribonucleic acid template; and performing amplification of the ribonucleic acid template across the first and second ribonucleic acids. | 11-27-2008 |
| 20080293052 | SYSTEM AND METHOD FOR AUTHENTICATING SPORTS IDENTIFICATION GOODS - A method for authenticating and verifying garment to be genuine is described. The method for authenticating a garment comprises applying a particular nucleic acid material/marker associated with a particular sequence of nucleic acid bases to a dye or paint and applying the marker to the garment. The method also comprises collecting a sample from the garment and verifying the garment is genuine by detecting the particular nucleic acid material on or within the garment. | 11-27-2008 |
| 20080293053 | shRNA Materials and Methods of Using Same for Inhibition of DKK-1 - Methods and compositions for the treatment of soft tissue cancer are described. More specifically, the invention demonstrates that inhibiting or otherwise decreasing the activity of DKK-1 using shRNA or siRNA molecules will be effective at reducing the cancer phenotype of prostate cancer cells. | 11-27-2008 |
| 20080293054 | Hmgcr isoforms in Prediction of Efficacy and Identification of Cholesterol-Modulating Compounds - The present invention provides methods for assessing a subject's responsiveness to a HMGCR inhibitor therapy, and selection of a HMGCR inhibitor therapy based upon such methods. The invention further provides methods for identifying agents that modulate HMGCR activity, e.g., through modulating HMGCR mRNA splicing, while avoiding elevation of the statin-resistant isoform of HMGCR. | 11-27-2008 |
| 20080293055 | K-ras mutations and anti-EGFr antibody therapy - The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors. | 11-27-2008 |
| 20080293056 | METHOD FOR PREPARING CANCER STEM CELLS - The present invention provides a method for preparing cancer stem cells including the step of subjecting normal cells to Ras activation and p53 deficiency; the cancer stem cells prepared by the preparation method; a method for screening a cancer stem cell-targeting substance and a method for screening an anti-cancer substance using the cancer stem cells; a method for treating a cancer comprising administering to a patient the substances obtainable by the screening methods; and a diagnostic method for cancers including the step of detecting proteins specifically expressed in the cancer stem cells or mRNAs of the protein. | 11-27-2008 |
| 20080293057 | DETECTION OF UNSPECIFIED GENETICALLY MODIFIED ORGANISM (GMO) ON MICRO-ARRAYS - The present invention is related to a method, kit and computer program for detecting the presence in a sample of an unspecified Genetically Modified Organism (GMO). | 11-27-2008 |
| 20080293058 | Association of GSTM1 with autism and assays and methods based thereon - The present invention provides novel markers and assays for autism based on the association of GSTM1 with autism. The invention relates to the use and application of as a susceptibility marker for autism. GSTM1 may be combined with other markers in methods and assays for diagnosis, prenatal diagnosis, and assessment of autism. The invention further relates to a likelihood ratio test. In addition, the present invention discloses a novel method for identifying individuals who are genetically susceptible to have offspring with autism wherein the genotype of GSTM1, alone or in combination with other genetic markers, is determined. | 11-27-2008 |
| 20080293059 | Method of Identifying Induced Variability in in Vitro Cultures - The subject of the present invention is a method of identifying variability induced in in vitro cultures. The subject of the present invention may be used in the production of genetically stable lines, eg. of doubled haploids (determination of their genetic-apigenetic variability level), as well as facilitating a broadly understood, selection process of plant material in in vitro culture, previously unused in practice, for cultivation purposes, as well as the possibility of designing molecular tool for the identification of epigenetic characteristics for culturing purposes. | 11-27-2008 |
| 20080293060 | Methods and Compositions for Identification of Hydrocarbon Response, Transport and Biosynthesis Genes - Disclosed is a method using an alkane response element (ARE) from, e.g., | 11-27-2008 |
| 20080293061 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof. | 11-27-2008 |
| 20080293062 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof. | 11-27-2008 |
| 20080293063 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof. | 11-27-2008 |
| 20080293064 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof. | 11-27-2008 |
| 20080293065 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof. | 11-27-2008 |
| 20080293066 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 3 and mutated sequences thereof. | 11-27-2008 |
| 20080293067 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof. | 11-27-2008 |
| 20080293068 | METHODS FOR ENGINEERING POLYPEPTIDE VARIANTS VIA SOMATIC HYPERMUTATION AND POLYPEPTIDE MADE THEREBY - Methods using somatic hypermutation (SHM) for producing polypeptide and nucleic acid variants, and nucleic acids encoding such polypeptide variants are disclosed. Such variants may have desired properties. Also disclosed are novel polypeptides, such as improved fluorescent proteins, produced by the novel methods, and nucleic acids, vectors, and host cells comprising such vectors. | 11-27-2008 |
| 20080293069 | RAPID PROGNOSTIC ASSAY FOR MALIGNANCIES TREATED WITH EPIDERMAL GROWTH FACTOR RECEPTOR - A molecular assay for determining the sensitivity or resistance of malignancies to chemotherapy prior to initiation of chemotherapy and which also allows for monitoring the therapeutic effects of the chemotherapy during treatment. The molecular assay measures tumor response to therapy with EGFR modulators and utilizes tumor mRNA as a starting material and a quantitative measurement of c-fos expression as an analytical endpoint. | 11-27-2008 |
| 20080293070 | Markers for Memory T Cells and Uses Thereof - Methods, uses, products and kits are described relating to monitoring, assessing and modulating immune function and more particularly memory T cell function. Methods of identifying agents for such modulation are also described, as well as uses of such agents for modulating immune function. | 11-27-2008 |
| 20080293071 | Sequencing and Genotyping Using Reversibly Terminating Nucleotides - The invention provides a method of determining the nucleotide sequence of a target nucleic acid using a reversibly terminating nucleotide that is modified at the 2′ position. | 11-27-2008 |
| 20080293072 | METHOD FOR ENUMERATION OF MAMMALIAN MICRONUCLEATED ERYTHROCYTE POPULATIONS, WHILE DISTINGUISHING PLATELETS AND/OR PLATELET-ASSOCIATED AGGREGATES - A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains DNA (micronuclei) in erythrocyte populations. Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample. In particular, the use of the second antibody prevents interference by platelet-associated aggregates in the scoring procedures. | 11-27-2008 |
| 20080299546 | Canine Cd20 Gene - It is intended to clarify the CD20 amino acid sequence and its gene sequence which are essentially required in constructing an anti-CD20 antibody useful in treating animal malignant lymphoma. It is also intended to provide a method of diagnosing canine malignant lymphoma by using the gene sequence. Using monocytes in canine blood as a sample, mRNA is obtained and the full base sequence of canine CD20 gene (SEQ ID NO:2) is determined. Based on this sequence, its amino acid sequence (SEQ ID NO:1) is determined. Comparing the homologies with human and mouse CD20 genes and amino acid sequences, it is identified as canine CD20 gene. Moreover, a primer specific to the canine gene is constructed and the expression of the CD20 gene in a sample is examined, thereby giving a method of diagnosing canine B lymphocyte-origin malignant lymphoma. | 12-04-2008 |
| 20080299547 | NOVEL STRA6 POLYPEPTIDES - The present invention is directed to novel polypeptides having sequence similarity to Stra6, a murine retinoic acid responsive protein, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. | 12-04-2008 |
| 20080299548 | Gene Expressed Specifically in Es Cells and utilization of the Same - The present invention relates to an ES cell detection marker containing a polynucleotide derived from any one of ECAT15-1 gene, ECAT15-2 gene, ECAT16 gene, Rnf17 gene and LOC380905(TDRD4) gene. | 12-04-2008 |
| 20080299549 | Methods and compositions for the detection of a nucleic acid by a cleavage reaction - The invention provides methods, compositions and kits for generating a signal indicative of the presence of a target nucleic acid sequence in a sample comprising forming a cleavage structure by incubating a sample comprising a target nucleic acid sequence with upstream and downstream oligonucleotides, and cleaving the cleavage structure with a nuclease to generate a signal. The presence of a detectable signal is indicative of the presence of a target nucleic acid sequence and a non-invasive cleavage structure. | 12-04-2008 |
| 20080299550 | Methods and Kits For the Prediction of Therapeutic Success and Recurrence Free Survival In Cancer Therapy - The invention provides novel compositions, methods and uses, for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia and breast cancer. The invention further relates to genes that are differentially expressed in breast tissue of breast cancer patients versus those of normal “healthy” tissue. Differentially expressed genes for the identification of patients which are likely to respond to chemotherapy are also provided. | 12-04-2008 |
| 20080299551 | METHYLATION OF ESTROGEN RECEPTOR ALPHA AND USES THEREOF - Methods for diagnosis, prognosis, and treatment of cancer based on the methylation status of the ER-α gene promoter are disclosed. Methylation of the ER-α gene promoter is indicative of cancer and unfavorable prognosis. The cancer can be treated with a demethylation agent. | 12-04-2008 |
| 20080299552 | Method For Determining The Function Of Nucleic Acid Sequences And Expression Products Coded Thereby - The invention relates to a method for the investigation and determination of the function of nucleic acid sequences and nucleic acid expression products by the introduction of RNA into host cells. | 12-04-2008 |
| 20080299553 | Oligonucleotide Probes for the Genomic Typifying of Erythrocyte Systems, Methods and Relative Diagnostic Kits - The invention relates to oligonucleotide probes for the genomic typifying of erythrocyte systems, relative methods and diagnostic kits. | 12-04-2008 |
| 20080299554 | Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof - The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 12-04-2008 |
| 20080299555 | Multicolor chromogenic detection of biomarkers - The present invention provides compositions, kits, assembles of articles and methodology for detecting multiple target molecules in a sample, such as in a tissue sample. In particular, site-specific deposition of elemental metal is used in conjunction with other means of detection, such as other chromogenic, radioactive, chemiluminescent and fluorescent labeling, to simultaneously detect multiple targets, such a gene, a protein, and a chromosome, in a biological sample. More particularly the multiple targets may be labeled with the specifically deposited metal and other chromogenic labels to allow chromogenic immunohistochemical (IHC) detection in situ by using bright field light microscope. | 12-04-2008 |
| 20080299557 | Sample Lysis and Coating of Reaction Surface - The present invention provides copolymers that facilitate nucleic acid analysis, compositions that comprise such copolymers, and methods for making or using such copolymers. | 12-04-2008 |
| 20080299558 | METHOD FOR DETECTING NUCLEIC ACID - The present invention provides a method for detecting a nucleic acid by specific binding between ligand and receptor, in particular, a method of detecting a SNP by the specific binding between a ligand and receptor. The present invention also provides a method for detecting a nucleic acid that is simpler, requiring only a single measurement operation, and shorter in measurement period. The present invention also provides a highly sensitive and highly accurate method for detecting a nucleic acid by using a specific binding reaction between a ligand and receptor in a reaction at the interface of a liquid and solid. The present invention also detects a nucleic acid by using a coagulation reaction of dispersible particles. | 12-04-2008 |
| 20080299559 | METHODS FOR AUTHENTICATING ARTICLES WITH OPTICAL REPORTERS - This invention pertains to methods for authenticating an article comprising tagging the article with light emitting optical reporter particles, and more specifically tagging the articles with up-converting phosphor particles (UCP), linked to nucleic acids of detectable sequence. | 12-04-2008 |
| 20080299560 | Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof - The invention relates to new nucleophosmin protein (NPM) mutants, corresponding gene sequences and relative uses thereof for diagnosis, monitoring of minimal residual disease; prognostic evaluation and therapy of the acute myeloid leukaemia (AML) | 12-04-2008 |
| 20080299561 | Novel therapeutic targets in cancer - The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel therapeutic targets against cancer. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer. | 12-04-2008 |
| 20080299562 | NUCLEIC ACID-BASED TESTS FOR RHD TYPING, GENDER DETERMINATION AND NUCLEIC ACID QUANTIFICATION - The invention in part provides nucleic acid-based assays, which are particularly useful for non-invasive prenatal testing. The invention in part provides compositions and methods for RhD typing, detecting the presence of fetal nucleic in a sample, determining the relative amount of fetal nucleic acid in a sample and determining the sex of a fetus, wherein each of the assays may be performed alone or in combination. | 12-04-2008 |
| 20080299563 | HUMAN MAP2 GENE PROMOTER - The human MAP2 gene promoter as well as various fragments thereof are disclosed. Nucleic acids and host cells that contain the promoter sequences are also disclosed. Further disclosed are various methods involving the use of these sequences. | 12-04-2008 |
| 20080299564 | Control of Preservation By Biomarkers - The invention lies in the field of microbiology, more particularly in the field of (food) preservation and testing of viability of microbiological spores. It is shown that measurement of the integrity of both rRNA and mRNA in spores is an accurate indicator of viability. Nucleotide assays then form a significant improvement over the state of the art assays for viability. | 12-04-2008 |
| 20080299565 | Probe for Nucleic Acid Sequencing and Methods of Use - A nanoprobe for sequencing of nucleic acid molecules is provided, as well as methods for using the nanoprobe. In particular examples, the probe includes a polymerizing agent and one or more molecular linkers that carry a chemical moiety capable of reversibly binding to the template strand of a nucleic acid molecule, without being detached from the linker, by specifically binding with a complementary nucleotide in the target nucleic acid molecule. The reversible binding of the chemical moiety on the linker with a complementary nucleotide in the target nucleic acid molecule is indicated by emission of a characteristic signal that indicates pairing of the chemical moiety on the linker with its complementary nucleotide. An example of such a chemical moiety is a nonhydrolyzable nucleotide analog. In particular examples, the polymerizing agent and the chemical moiety are associated with a tag, such as a donor fluorophore and acceptor fluorophore characteristic of the particular type of chemical moiety. | 12-04-2008 |
| 20080299566 | Methylation of Gene Promoters as a Predictor of Effectiveness of Therapy - The present invention provides methods for identifying, diagnosing, evaluating or monitoring a disease state in a subject comprising identifying the methylation status of a panel of genes in the subject. The present invention also relates to identifying, diagnosing, evaluating or monitoring the responsiveness of a subject to a therapeutic regimen, with the methods comprising determining the methylation status of a panel of genes in the subject. | 12-04-2008 |
| 20080299567 | PRIMER AND PROBE SEQUENCES FOR DETECTING CHLAMYDIA TRACHOMATIS - The present invention relates to primers and probes that can be used in various assays to detect a new strain of | 12-04-2008 |
| 20080299568 | MATERIALS AND METHODS FOR DETECTION OF HEPATITIS C VIRUS - Disclosed are methods and compositions for detecting hepatitis C virus (HCV) in a sample. Typically, the methods include amplifying nucleic acids and detecting signals, such as signals emitted from fluorophores. The signals may be correlated to the presence and/or quantity of the hepatitis C viral genome in the sample. In some embodiments, primers are provided that specifically hybridize to the 3′ non-coding (NC) region of the HCV genome. | 12-04-2008 |
| 20080299569 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof. | 12-04-2008 |
| 20080299570 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 3 and mutated sequences thereof. | 12-04-2008 |
| 20080299571 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof. | 12-04-2008 |
| 20080299572 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 3 and mutated sequences thereof. | 12-04-2008 |
| 20080299573 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof. | 12-04-2008 |
| 20080299574 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof. | 12-04-2008 |
| 20080299575 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof. | 12-04-2008 |
| 20080299576 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof. | 12-04-2008 |
| 20080299577 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof. | 12-04-2008 |
| 20080299578 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 3 and mutated sequences thereof. | 12-04-2008 |
| 20080299579 | NOVEL CANCER MARKER AND USE THEREOF - This invention provides a method for cancer diagnosis comprising measuring an endogenous antisense RNA whose relative expression to a sense RNA changes cancer-specifically in RNA-containing samples collected from a mammal. Also provided are endogenous antisense RNAs useful as cancer markers, and cancer diagnostic reagents containing the same. | 12-04-2008 |
| 20080299580 | Targeted integration into the PPP1R12C locus - Disclosed herein are methods and compositions for targeted integration of an exogenous sequence into the human PPP1R12C locus, for example, for expression of a polypeptide of interest. | 12-04-2008 |
| 20080299581 | Screening for expressible transfectants in a eukaryotic system - The present invention relates to the field of molecular cloning and to the field of expression cloning in higher, eukaryotic cells. In particular, the present invention relates to a method for fast and reliable identification of vectors and vector DNA which will be capable of providing a desired expression product if a eukaryotic host cell is transfected with the vector DNA. | 12-04-2008 |
| 20080299582 | Culture System for Rapid Expansion of Human Embryonic Stem Cells - This disclosure provides an improved system for culturing human pluripotent stem cells. Traditionally, pluripotent stem cells are cultured on a layer of feeder cells (such as mouse embryonic fibroblasts) to prevent them from differentiating. In the system described here, the role of feeder cells is replaced by components added to the culture environment that support rapid proliferation without differentiation. Effective features are a suitable support structure for the cells, and an effective medium that can be added fresh to the culture without being preconditioned by another cell type. Culturing human embryonic stem cells in fresh medium according to this invention causes the cells to expand surprisingly rapidly, while retaining the ability to differentiate into cells representing all three embryonic germ layers. This new culture system allows for bulk proliferation of pPS cells for commercial production of important products for use in drug screening and human therapy. | 12-04-2008 |
| 20080299583 | METHOD AND SYSTEM FOR ANALYZING REACTIONS USING AN INFORMATION SYSTEM - A method and system for determining the quantity of an analyte initially present in a chemical and or biological reaction as well as a computer implemented method and system to automate portions of the analysis comprising mathematical or graphical analysis of an amplification reaction. | 12-04-2008 |
| 20080305470 | Nucleic Acid Sequencing - A method for determining a target nucleic acid sequence, wherein the target nucleic acid sequence is comprised in a preparation comprising a non-target nucleic acid sequence, the target nucleic acid sequence and the non-target nucleic acid sequence each having a first region of common sequence upstream of a first region of dissimilar sequence upstream of a second region of dissimilar sequence, the method comprising:
| 12-11-2008 |
| 20080305471 | Optoelectronic device and method of fabricating the same - A modified isolated polypeptide comprising an amino acid sequence encoding a photocatalytic unit of a photosynthetic organism being capable of covalent attachment to a solid surface and having a photocatalytic activity when attached thereto is disclosed. | 12-11-2008 |
| 20080305472 | Method of detecting influenza bacillus, primer set for detection of influenza bacillus and kit for detection of influenza bacillus - The present invention provides a method of detecting | 12-11-2008 |
| 20080305473 | Propagation of primary cells - The present invention provides a method of propagating cells of interest obtained from a biological specimen by enriching the cells under conditions that maintain sufficient cell viability; and propagating the cells under conditions effective to allow cell viability, proliferation and integrity. | 12-11-2008 |
| 20080305474 | Method and Apparatus for Using SLC2A10 Genetic Polymorphisms for Determining Peripheral Vascular Disease in Patients with Type-2 Diabetes - Recent data indicate that a loss-of-function mutation of the SLC2A10 gene causes arterial tortuosity syndrome (ATS) via upregulation of the TGF-β pathway in the arterial wall, a mechanism possibly causing vascular changes associated with diabetes. It is determined that SLC2A10 (Solute carrier family 2, facilitated glucose transporter, member 10) genetic polymorphism is associated with peripheral vascular disease (PVD) in patients with type 2 diabetes. | 12-11-2008 |
| 20080305475 | MICROBIAL COMMUNITY ANALYSIS - The present invention provides a method which can enhance the precision of identification of bacterial species using a T-RFLP method and achieve, by itself, the identification of bacteria constituting a bacterial flora and the tracing of distribution changes thereof. The present invention provides a method for analyzing a bacterial community including: amplifying DNAs extracted from a bacterial community by PCR using 16S rRNA genes as templates and fluorescently labeled primers; cleaving the amplification products with a restriction enzyme to thereby obtain sample PCR fragments; electrophoresing the sample PCR fragments together with size standard PCR fragments; and comparing the mobilities thereof to thereby determine the sizes of the sample PCR fragments, wherein PCR fragments amplified by using, as a template, a 16S rRNA gene derived from a bacterium contained in the bacterial community to be analyzed are used as the size standards. | 12-11-2008 |
| 20080305476 | Immunoassay Methods - The invention relates to a method of detecting a disease state or disease susceptibility in a mammalian subject which comprises detecting an antibody in a test sample comprising a bodily fluid from said mammalian subject wherein said antibody is a biological marker of a disease state or disease susceptibility, the method comprising: (a) contacting said test sample with a plurality of different amounts of an antigen specific for said antibody, (b) detecting the amount of specific binding between said antibody and said antigen, (c) plotting or calculating a curve of the amount of said specific binding versus the amount of antigen for each amount of antigen used in step (a) and (d) determining the presence or absence of said disease state or disease susceptibility based upon the amount of specific binding between said antibody and said antigen at each different antigen concentration used. | 12-11-2008 |
| 20080305477 | Novel Iminecalixarene Derivatives and Aminocalixarene Derivatives, Method of Preparation Thereof, and Self-Assembled Monolayer Prepared by the Method, Fixing Method of Oligo-Dna By Using the Self-Assembled Monolayer, and Oligo-Dna Chip Prepared By the Method - The present invention relates to novel iminecalixarene derivatives, method of preparation thereof, and self-assembled monolayer prepared by the method, fixing method of oligo-DNA by using the self-assembled monolayer, and oligo-DNA chip prepared by the method. Also, the present invention relates to novel aminocalixarene derivatives, method of preparation thereof, and self-assembled monolayer prepared by the method, fixing method of oligo-DNA wherein the oligo-DNA is voluntarily fixed by molecular recognition on said self-assembled monolayer in a liquid phase, and oligo-DNA chip prepared by the method. | 12-11-2008 |
| 20080305478 | Processes Using Dual Specificity Oligonucleotide and Dual Specificity Oligonucleotide - The present invention relates to various processes by a template-dependent extension reaction using a dual specificity oligonucleotide and a dual specificity oligonucleotide composed of three different Tm portions therefor. Demonstrated in the present invention are the features of the dual specificity oligonucleotide, which are high hybridization specificity and mismatch tolerance. | 12-11-2008 |
| 20080305479 | DETECTION AND QUANTIFICATION OF BIOMOLECULES USING MASS SPECTROMETRY - The present invention is directed in part to a method for detecting a target nucleic acid using detector oligonucleotides detectable by mass spectrometry. This method uses the 5′ to 3′ nuclease activity of a nucleic acid polymerase to cleave annealed oligonucleotide probes from hybridized duplexes and release labels for detection by mass spectrometry. This process is easily incorporated into a PCR amplification assay. The method also includes embodiments directed to quantitative analysis of target nucleic acids. | 12-11-2008 |
| 20080305480 | NOVEL TUMOR MARKER - The present invention concerns a gene product largely homologous to the epithelial growth factor receptor (EGFR). It further refers to mRNA coding for such epithelial growth factor receptor. The present invention provides such an epithelial growth factor receptor which is characterized in that either exons 12 to 14 or exons 12 to 15 are deleted. These novel variants of the epithelial growth factor receptor can be used for a diagnosis, stratification, therapy guidance of a tumor or therapy guidance of tumor surgery. | 12-11-2008 |
| 20080305481 | SYSTEMS AND METHODS FOR MULTIPLEX ANALYSIS OF PCR IN REAL TIME - The present invention provides methods and systems for real-time measurements of PCR with multiplexing capability. Certain embodiments relate to methods and systems that use fluorescently encoded superparamagnetic microspheres for the immobilization of amplification products during the PCR process, and an imaging chamber of a measurement device that is also capable of controllable thermal cycling for assisting the PCR process. | 12-11-2008 |
| 20080305482 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID AMPLIFICATION - Compositions that are used in nucleic acid amplification in vitro are disclosed, which include a target specific universal (TSU) promoter primer or promoter provider oligonucleotide that includes a target specific (TS) sequence that hybridizes specifically to a target sequence that is amplified and a universal (U) sequence that is introduced into the sequence that is amplified, by using a primer for the universal sequence. Methods of nucleic acid amplification in vitro are disclosed that use one or more TSU oligonucleotides to attached a U sequence to a target nucleic acid in a target capture step and then use a primer for a U sequence in subsequent amplification steps performed in substantially isothermal conditions to make amplification products that contain a U sequence that indicates the presence of the target nucleic acid in a sample. | 12-11-2008 |
| 20080305483 | BIALLELIC MARKERS DERIVED FROM GENOMIC REGIONS CARRYING GENES INVOLVED IN ARACHIDONIC ACID METABOLISM - The invention provides polynucleotides including biallelic markers derived from genes involved in arachidonic acid metabolism and from genomic regions flanking those genes. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype. | 12-11-2008 |
| 20080305484 | Genetic methods for speciating Campylobacter - Species-specific identification of | 12-11-2008 |
| 20080305485 | GENETIC MARKER FOR INCREASED RISK FOR OBESITY-RELATED DISORDERS - The present invention relates to methods of determining an increased risk of a subject to acquire a trait of an obesity disorder or an obesity disorder, with the method comprising determining the genetic sequence of at least one taste receptor gene in the subject and reviewing the test genetic sequence(s) for the presence of at least one risk allele associated with at least one taste receptor. The presence of at least one difference in the test genetic sequence(s) and the presence of a risk allele associated with the taste receptor(s) may indicate an increased risk of the subject acquiring a trait of an obesity disorder or an obesity disorder. | 12-11-2008 |
| 20080305486 | SIGNAL AMPLIFICATION USING CIRCULAR HAIRPIN PROBES - The present invention provides methods for detecting a target nucleic acid using a circular dual-hairpin probe that is formed upon the presence of the target nucleic acid. The detection methods find use in detecting the presence of antibody-antigen complexes and for detecting the binding of a ligand to its binding partner. Kits and reaction mixtures for performing the present methods are also provided. | 12-11-2008 |
| 20080305487 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 3 and mutated sequences thereof. | 12-11-2008 |
| 20080305488 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 3 and mutated sequences thereof. | 12-11-2008 |
| 20080305489 | NEAR-INFRARED DYES AS SURFACE ENHANCED RAMAN SCATTERING REPORTERS - Nanoparticles comprising surface-enhanced Raman scattering (SERS) reporter molecules of the formula A-Y and methods of their use are disclosed, wherein A is selected from the group consisting of: | 12-11-2008 |
| 20080305490 | AMPLIFICATION OF HUMAN MDM2 GENE IN HUMAN TUMORS - A human gene has been discovered which is genetically altered in human tumor cells. The genetic alteration is gene amplification and leads to a corresponding increase in gene products. Detecting that the gene, designated hMDM2, has become amplified or detecting increased expression of gene products is diagnostic of tumorigenesis. Human MD2 protein binds to human p53 and allows the cell to escape from p53-regulated growth. | 12-11-2008 |
| 20080305491 | MCM6 AND MCM7 MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE IN THE DETECTION OF CERVICAL DISEASE - Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM6 or MCM7. Monoclonal antibodies having the binding characteristics of an MCM6 or MCM7 antibody of the invention are further provided. Hybridoma cell lines that produce an MCM6 or MCM7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in practicing methods for diagnosing high-grade cervical disease comprising detecting overexpression of MCM6, MCM7, or both MCM6 and MCM7 in a cervical sample from a patient. Kits for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MCM6 or an MCM7 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention. | 12-11-2008 |
| 20080305492 | DETECTION OF GLEEVEC RESISTANCE - The present invention relates to isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides. | 12-11-2008 |
| 20080311562 | Nucleic Acid Sequencing - A method for determining a target nucleic acid sequence, wherein the target nucleic acid sequence is comprised in a preparation comprising a non-target nucleic acid sequence, the target nucleic acid sequence and the non-target nucleic acid sequence each having a first region of common sequence upstream of a first region of dissimilar sequence upstream of a second region of dissimilar sequence, the method comprising: | 12-18-2008 |
| 20080311563 | Methods for selecting medications - Methods for selecting a medication for a patient are described that include determining the patient's genotype for a panel of genes and selecting the medication based on the genotype. Articles of manufacture also are provided that include nucleic acid molecules for detecting alleles of genes encoding drug metabolizing enzymes and genes encoding products involved in neurotransmission. | 12-18-2008 |
| 20080311564 | Sequences and Methods for Detection of Cytomegalovirus - Amplification primers and methods for specific amplification and detection of a CMV target are disclosed. The primer-target binding sequences are useful for amplification and detection of the CMV target in a variety of amplification and detection reactions. | 12-18-2008 |
| 20080311565 | Methods and Kits for Detecting Germ Cell Genomic Instability - Disclosed are methods for detecting microsatellite instability in the germ line of males, methods of assessing risk for developing testicular cancer, methods of evaluating the microsatellite stability of putative cancer or precancerous cells or a tumor, methods for evaluating germ cells for exposure to mutagens, and kits for use in the methods of the invention. | 12-18-2008 |
| 20080311566 | Method for Quantification of Methylated Dna - The present invention relates to a method for the quantification of methylated cytosines in DNA. In the first step of the invention unmethylated cytosines in the DNA to be analysed are chemically converted into uracil while 5-methylcytosines remain unchanged. In a second step the converted DNA is amplified methylation specifically in a real time PCR using a methylation specific probe. Finally the amount of uniformly methylated DNA is calculated by combining criteria derived from the shape of the real time curve and from the signal intensity. The method is preferably used for diagnosis and/or prognosis of adverse events for individuals, for distinguishing cell types and tissues, or for investigating cell differentiation. | 12-18-2008 |
| 20080311567 | Tumor Markers for Use in the Diagnosis of Colorectal Carcinomas and/or Metastases Originating Therefrom - The invention relates to a method (i) for detecting a carcinoma, especially an adenocarcinoma, preferably a gastrointestinal carcinoma and more preferably a colorectal carcinoma, (ii) for predicting metastases, preferably liver metastases, depending on a primary colon carcinoma and/or (iii) for predicting the response of metastases to a 5-fluorouracil-containing chemotherapy. The inventive method comprises determining a gene expression profile of 120 marker genes or a selection thereof. | 12-18-2008 |
| 20080311568 | Compositions and Methods for Nucleic Acid Analysis of Sequences with Insertions or Deletions - Contemplated methods and kits include a plurality of single stranded oligonucleotides that comprise a discriminating sequence that is encompassed on one end by a label and on the other end by a unique tag sequence. In one preferred aspect, the discriminating sequence is an RNA repeat unit, forms a heteroduplex with a complementary DNA repeat unit of the target nucleic acid, and the discriminating agent is RNaseH. Using such systems, the number of repeat units can be simply identified by hydrolysis of the discriminating sequence where such sequence is adjacent to a predetermined number of DNA repeat units in the single stranded oligonucleotide. | 12-18-2008 |
| 20080311569 | METHOD FOR QUANTITATIVE MEASUREMENT OF GENE EXPRESSION FOR INDENTIFYING INDIVIDUALS AT RISK FOR BRONCHOGENIC CARCINOMA - A method measure expression of multiple target genes in a progenitor cell for bronchogenic carcinoma comprising the use of reverse transcription-polymerase chain reaction (RT-PCR) to allow simultaneous expression measurement of the multiple target genes is disclosed. | 12-18-2008 |
| 20080311570 | CANCER SCREENING METHOD - A method for screening cancer comprises the following steps: (1) providing a test specimen; (2) detecting the methylation state of the CpG sequence in at least one target gene within the genomic DNA of the test specimen, wherein the target genes is consisted of SOX1, PAX1, LMX1A, NKX6-1, WT1 and ONECUT1; and (3) determining whether there is cancer or cancerous pathological change in the specimen based on the presence or absence of the methylation state in the target gene; wherein method for detecting methylation state is methylation-specific PCR (MSP), quantitative methylation-specific PCR (QMSP), bisulfite sequencing (BS), microarrays, mass spectrometer, denaturing high-performance liquid chromatography (DHPLC), and pyrosequencing. | 12-18-2008 |
| 20080311571 | Nucleic Acid Fragments for Detecting Nucleic Acid and Method for Detecting Nucleic Acid - A nucleic acid fragment set according to the present invention comprises a plural number of nucleic acid fragments capable of individually hybridizing with a plural number of target sequences, in which each nucleic acid fragment has a region ligatable with each other and the affinity between such ligatable regions is adjusted to a higher level than the affinity between the target sequence and the nucleic acid fragment. The nucleic acid fragment according to the present invention is for use in a nucleic acid fragment kit. The nucleic acid fragment of the present invention can be used as a probe for detecting nucleic acid or a competitor for detecting nucleic acid. According to the present invention, human leukocyte antigen (HLA) genes, T-cell receptor genes, red blood cell group determining genes, and Rh antigen genes, and the like can be detected at a high accuracy level. | 12-18-2008 |
| 20080311572 | Methods and Compositions For Correlating Ccl3l1/Ccr5 Genotypes With Disorders - The present invention provides compositions and methods for identifying persons at an increased risk of infection by, transmission of, or accelerated progression of a disease caused by an HIV-1 virus. Diagnostic and therapeutic kits are also provided. | 12-18-2008 |
| 20080311573 | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer - The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided. | 12-18-2008 |
| 20080311574 | Novel Missense Mutations and Single Nucleotide Polymorphisms in the Rabphillin-3A-Like Gene and Uses Thereof - The invention relates to methods and compositions of matter for determining or predicting aggressiveness of a subject's tumor, for determining a subject's predisposition to cancer, for diagnosing cancer in a subject, and for selecting a therapy for a subject with cancer. Also provided are methods and compositions of matter for determining a Rabphillin-3A-Like gene genotype in a subject and for characterizing a Rabphillin-3A-Like gene in a subject. | 12-18-2008 |
| 20080311575 | Modulation of Muci-Dependent Anti-Estrogen Resistance - The present invention provides methods for identification and use of compounds that modulate the association of MUC1 with estrogen receptors and thereby antagonize MUC1-related resistance to anti-estrogen treatment. | 12-18-2008 |
| 20080311576 | Replication competent hepatitis C virus and methods of use - The present invention provides a replication competent hepatitis C virus that includes a heterologous polynucleotide. The invention also includes methods for modifying a hepatitis C virus polynucleotide, selecting a replication competent hepatitis C virus polynucleotide, detecting a replication competent hepatitis C virus polynucleotide, and identifying a compound that inhibits replication of a hepatitis C virus polynucleotide. | 12-18-2008 |
| 20080311577 | Method for the Identification of Sulfo-Oxidizing Bacteria and for the Monitoring of Elemental Sulfur in the Environment - A method is described for the identification of sulfooxidizing bacteria comprising the extraction of the DNA from environmental samples and the subsequent identification of at least one fragment of the Thio 16S gene or SoxB gene present in these bacteria. The method can be used for determining the level of elemental sulfur in samples of soil. | 12-18-2008 |
| 20080311578 | System for screening eukaryotic membrane proteins - The present invention provides methods and compositions for expressing eukaryotic membrane proteins. | 12-18-2008 |
| 20080311579 | Hybridisation beacon and method of rapid sequence detection and discrimination - A method for detecting specific DNA sequences and discriminating single nucleotide polymorphisms (SNPs) using fluorescently labelled oligonucleotide probes is disclosed. Oligonucleotide probes are labelled with reporter molecules preferentially attached to an internal nucleotide residue. The fluorescence emission of oligonucleotide probes varies significantly when in single-stranded and double-stranded states despite the absence of quencher moieties, allowing reliable detection of complementary DNA targets. The melting temperature of probe/target duplexes permits discrimination of targets that differ by as little as a single nucleotide residue, such that polymorphic targets may be discriminated by fluorescence quantitation and Tm. The hybridisation probes of this invention have been demonstrated to accurately identify homozygous and heterozygous samples using a single fluorescent oligonucleotide and direct investigation of saliva with hybridisation probes permits ultra-rapid genotypic analysis within 35-40 minutes. Target detection and SNP discrimination assays have been achieved in homogeneous, heterogeneous, ‘real-time’ and solid-phase formats. | 12-18-2008 |
| 20080311580 | Novel genes encoding proteins involved in proanthocyanidin synthesis - This inventions provides an isolated protein or polypeptide having activity in the synthesis of proanthocyanidin (PA) polymer from epicatechin or catechin in plants, and which is not naturally regulated by the TT2 or TT8 regulators, or a fragment comprising at least about 10 contiguous amino acids derived from said protein or polypeptide, particularly TDS1, TDS2, TDS3, TDS4, TDS5, or TDS6 protein, or fragment thereof. | 12-18-2008 |
| 20080311581 | FUNCTIONAL POLYMORPHISMS OF THE INTERLEUKIN-1 LOCUS AFFECTING TRANSCRIPTION AND SUSCEPTIBILITY TO INFLAMMATORY AND INFECTIOUS DISEASES - The invention provides methods and reagents for detecting a polymorphism associated with in an upstream region of the interleukin-1β (IL-B) gene (IL-1B (−3737)) that affects transcription of the gene and susceptibility to inflammatory and infectious diseases such as diffuse coronary artery disease. | 12-18-2008 |
| 20080311582 | Methods Using Pores - The invention relates to a method of identifying an individual nucleotide, comprising (a) contacting the nucleotide with a transmembrane protein pore so that the nucleotide interacts with the pore and (b) measuring the current passing through the pore during the interaction and thereby determining the identity of the nucleotide. The invention also relates to a method of sequencing nucleic acid sequences and kits related thereto. | 12-18-2008 |
| 20080311583 | CHROMOSOME MANIPULATION METHOD - A universal method for chromosome modification (deletion of a desired DNA region) which does not require any special enzymes or sequences is provided. Further, a method for determining whether the DNA region to be deleted contains a gene essential for growth of the cell under certain culture conditions is provided by utilizing the chromosome modification method. | 12-18-2008 |
| 20080311584 | Methods for Detection of Mutations in Myostatin Variants - Methods for detecting allelic variants of the myostatin (growth and differentiation factor-8) gene are provided. Specifically provided are methods of identifying subjects having or having a predisposition for increased muscle mass as compared to subjects having wild-type myostatin. Increased muscle mass is particularly desirable for identification of animals used to produce food products, including bovine, porcine, ovine, avian and piscine species. | 12-18-2008 |
| 20080311585 | System and method for multiplex liquid handling - The present invention generally relates to microfabricated devices for carrying out and controlling chemical reactions and analysis. In particular, the present invention provides systems, methods, devices and computer software products related to multiplex liquid handling systems utilizing lab cards related to biological assays. | 12-18-2008 |
| 20080311586 | METHOD FOR MEASURING IN VIVO HEMATOTOXICITY WITH AN EMPHASIS ON RADIATION EXPOSURE ASSESSMENT - The present invention relates a method for assessing in vivo hematotoxicity. The method utilizes differential staining of nucleated and non-nucleated blood cells, and also differential labeling of cells with functional versus dysfunctional mitochondrial membrane potential. Quantitative analyses can be conducted on stained whole blood specimens, and is based on blood cells' fluorescent emission and light scatter properties following exposure to an excitatory light source. The ratio of certain cell populations can be readily measured. Furthermore, it is also possible to express cell population values in terms of number per unit volume. This invention can be used to evaluate the hematotoxicity of drugs, chemicals, radiation, and other exogenous agents, or the effects that a suspected protective agent may have on induced hematotoxicity. Furthermore, the matrix of measurements provided by this invention is useful in estimating radiation dose, i.e., retrospectively. Kits for practicing the invention are also disclosed. | 12-18-2008 |
| 20080311587 | Use of Genetic Information to Detect a Predisposition for Bone Density Conditions - The invention relates to kits and methods for assessing susceptibility of a human to an undesirable bone density condition, such as osteopenia and osteoporosis, and advising appropriate interventions. The methods involve contemporaneously assessing occurrence in the human's genome of a plurality of polymorphisms (e.g., single nucleotide polymorphisms) that occur in one or more genes associated with bone density regulation and that are associated with a disorder in humans. Preferred assessment and scoring methods are disclosed, as are kits for performing the methods. | 12-18-2008 |
| 20080318209 | Cjd Prion Testing - The present invention provides an assay method for detecting infectious prion protein in a sample from a mammalian subject, said method comprising: obtaining a prion protein containing sample from said subject; contacting said sample with an agent which serves to digest non-infectious prion protein and to partially digest infected prion protein to yield a prion protein polypeptide residue; contacting the digested sample with an antibody capable of binding to a poly peptide having the amino acid sequence Vc (Gly-Gly-Gly-Trp)-Gly-Gln-Gly-Gly-R | 12-25-2008 |
| 20080318210 | BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF - The present invention relates to a first group of novel viral and human associated oligonucleotides, here identified as Genomic Address Messenger or GAM oligonucleotide, and a second group of novel operon-like viral and human polynucleotides, here identified as Genomic Record or GR polynucleotide. GAM oligonucleotides selectively inhibit translation of known ‘target’ genes, many of which are known to be involved in various viral diseases. Nucleic acid molecules are provided respectively encoding 15484 GAM precursors oligonucleotides, and 699 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof. | 12-25-2008 |
| 20080318212 | Orphan Receptor Tyrosine Kinase as a Target in Breast Cancer - Methods and materials relating to the orphan receptor tyrosine kinase (ROR1) are described. ROR1 exhibits restricted tissue expression in normal adult tissue and is overexpressed in certain breast cancer subtypes. ROR1 provides a diagnostic and/or therapeutic target for breast cancers. | 12-25-2008 |
| 20080318213 | Mass Spectrometer - A mass spectrometer and a method of spectrometry are disclosed wherein liquid chromatography mass spectral data are probabilistically clustered on the basis of mass to charge ratio and retention time. | 12-25-2008 |
| 20080318214 | Genome Analysis Method - This invention makes it possible to perform analysis for estimating the characteristics of a population using sample data. By obtaining sample data, embedding genetic (statistical) knowledge in a first and second state variable that have duality, and having the first and second state variables converge to the original value, the characteristics of the population of the sample data are estimated, and the estimated results of the characteristics of the population are output. By doing so, it is possible to perform analysis for estimating characteristics of a population using sample data. | 12-25-2008 |
| 20080318215 | APPARATUS, METHODS AND PRODUCTS FOR DETECTING GENETIC MUTATION - Methods for detecting genetic mutation allowing detection of very low frequency mutation. Methods comprise treating RNA:DNA heteroduplexes of interest with ribonuclease treatment coupled with DNA polymerase treatment. RNA:DNA heteroduplexes of interest are preferentially targeted for digestion by ribonuclease and subsequent sequence extension by DNA polymerase. Methods may be carried out partially or entirely manually, automatically, and combinations thereof. Methods may be performed wholly or partially in solution, on solid phase media, in large scale, adapted for high throughput analysis, and any combinations thereof. Apparatus and products for detecting genetic mutation. | 12-25-2008 |
| 20080318216 | Methods For Determining Presence of Cancer by Analyzing the Expression of Cdk9 and/or Cyclin T1 in Lymphoid Tissue - A method for determining presence of lymphoma in a patient is disclosed. A sample of bone marrow, thymus, spleen, lymph nodes, lymph and/or lymphocytes taken from the patient t is assayed to determine expression of CDK9 and CYCLIN T1. The presence of CDK9 and/or CYCLIN T1 is indicative of a lymphoma other than a mantle cell lymphoma or marginal zone lymphoma in the patient. | 12-25-2008 |
| 20080318217 | Identification of Gene Associated with Reading Disability and Uses Therefor - The present invention relates to identification of a human gene, DCDC2 (MIM: 605755), associated with susceptibility for developing reading disability (RD), which is useful in identifying or aiding in identifying individuals at risk for developing RD, as well as for diagnosing or aiding in the diagnosis of RD. | 12-25-2008 |
| 20080318218 | Compositions and Methods for Inferring an Adverse Effect in Response to a Drug Treatment - Methods are provided for inferring whether a subject to be treated with a drug such as a statin or an ACE inhibitor is likely to suffer an adverse effect due to the treatment. Also provided are compositions for practicing the methods. | 12-25-2008 |
| 20080318219 | METHODS AND COMPOSITIONS FOR PREDICTING DRUG RESPONSES - The present invention relates to methods and compositions for predicting drug responses. In particular, the present invention provides methods and compositions for determining individualized Warfarin dosages based on genotype of DNA polymorphisms and haplotypes derived from them in the VKORC1 gene. | 12-25-2008 |
| 20080318220 | METHOD FOR THE DIAGNOSIS AND/OR PROGNOSIS OF ALZHEIMER'S DISEASE - The present invention relates to a method for the diagnosis and/or prognosis of Alzheimer's disease by means of determining the ZMIZ1 gene expression level in a biological sample and comparing said level with a reference value, in which the alteration of said level is indicative of Alzheimer's disease. | 12-25-2008 |
| 20080318221 | METHOD FOR THE DIAGNOSIS AND/OR PROGNOSIS OF ALZHEIMER'S DISEASE - The present invention relates to a method for the diagnosis and/or prognosis of Alzheimer's disease by means of determining the DARC gene expression level in a biological sample and comparing said level with a reference value, in which the disturbance of said level is indicative of Alzheimer's disease. | 12-25-2008 |
| 20080318222 | Cell Based Methods And Systems For The Identification Of Rna Regulatory Sequences And Compounds That Modulate Their Functions - The present invention is directed to an in vivo method for screening for and/or identifying RNA regulatory sequences involved in translational control. The method includes: culturing cells including: (i) a translational system; (ii) a reporter mRNA; and (iii) an RNA test sequence under suitable conditions for translation of the reporter mRNA, wherein the RNA test sequence is not attached to the reporter mRNA. The method also includes measuring the effect of the test sequence on the translation of the reporter mRNA, wherein a test sequence that modifies the translation of the reporter mRNA includes an RNA regulatory element. The invention also provides methods and systems for screening for and/or identifying test compounds that modulate the regulatory activity of an RNA regulatory sequence. This method includes culturing cells including (i) a translation system; (ii) a reporter mRNA; and (iii) an RNA regulatory sequence in the presence of at least one test compound, wherein the RNA regulatory sequence is not attached to the reporter mRNA. The ability of the test compound to affect the interaction between the RNA regulatory sequence and at least one component of the translation system is sought to be determined. The method further includes monitoring for the effect of the test compound on the this interaction, wherein a compound that modifies this interaction is a drug candidate. | 12-25-2008 |
| 20080318223 | LARGE DELETIONS IN HUMAN BRCA1 GENE AND USE THEREOF - Large deletions have been identified in the BRCA1 gene in patients. The large deletions predispose the patients to breast cancer and ovarian cancer. Thus, methods for detecting the genetic variants are provided which can be used in detecting a predisposition to cancer. | 12-25-2008 |
| 20080318224 | LARGE DELETIONS IN HUMAN BRCA1 GENE AND USE THEREOF - Large deletions have been identified in the BRCA1 gene in patients. The large deletions predispose the patients to breast cancer and ovarian cancer. Thus, methods for detecting the genetic variants are provided which can be used in detecting a predisposition to cancer. | 12-25-2008 |
| 20080318225 | COMPOSITIONS AND METHODS FOR DETECTING CANCER - The present invention provides methods and compositions involving detecting the presence of and/or assessing the risk of cancer in a subject. These methods include methods of detecting and diagnosing cancer in an individual; methods of identifying individuals at risk of developing a cancer; and methods of staging a cancer. The methods generally involve detecting a palladin gene nucleotide sequence alteration that has been found to be associated with cancer and/or detecting a level of a palladin mRNA and/or protein in a biological sample. The present invention further provides nucleic acid probes, nucleic acid primers, and antibodies, as well as kits comprising one or more of the same, for use in a subject method. | 12-25-2008 |
| 20080318226 | Signal Amplification Method - Provided are a signal amplification method of improving signal sensitivity, qualifying properties and handling property in detection of a target gene by using a PALSAR method, a method of detecting a target gene by using the method, and an oligonucleotide probe to be used in the method. A signal amplification method in detection of a target gene using a polymer formed by the use of a plurality of kinds of oligonucleotide probes having complementary base sequence regions capable of hybridizing with each other, including labeling at least one of the plurality of kinds of oligonucleotide probes with acridinium ester for detection. | 12-25-2008 |
| 20080318227 | Intermediates and enzymes of the non-mevalonate isoprenoid pathway - The invention provides a protein in a form that is functional for the enzymatic conversion of 2C-methyl-D-erythritol 2,4-cyclodiphosphate to 1-hydroxy-2-methyl-2-butenyl 4-diphosphate notably in its (E)-form of the non-mevalonate biosynthetic pathway to isoprenoids. The invention also provides a protein in a form that is functional for the enzymatic conversion of 1-hydroxy-2-methyl-2-butenyl 4-diphosphate, notably in its (E)-form, to isopentenyl diphosphate and/or dimethylallyl diphosphate. Further, screening methods for inhibitors of these proteins are provided. Further, 1-hydroxy-2-methyl-2-butenyl 4-diphosphate is provided and chemical and enzymatic methods of its preparation. | 12-25-2008 |
| 20080318228 | Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents - Biomarkers that are useful for identifying a mammal that will respond therapeutically or is responding therapeutically to a method of treating cancer that comprises administering a microtubule-stabilizing agent. In one aspect, the cancer is breast cancer, and the microtubule-stabilizing agent is an epothilone or analog or derivative thereof, or ixabepilone. | 12-25-2008 |
| 20080318229 | Method for Diagnosing Neuro-Degenerative Disease - A method for the diagnosis of Alzheimer's Disease (AD) or Parkinson's Disease (PD), comprises measuring the level of expression of one or more AD markers (Table 1) or PD markers (Table 2) in a sample of platelets isolated from a person suspected of having AD or PD, and determining whether the levels of expression are altered compared to a control. | 12-25-2008 |
| 20080318230 | GENE EXPRESSION MARKERS FOR RESPONSE TO EGFR INHIBITOR DRUGS - The present invention concerns prognostic markers associated with cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed samples of cancer tissue, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor. | 12-25-2008 |
| 20080318231 | 14-3-3 ZETA OVER-EXPRESSION AS A POOR PROGNOSIS FACTOR, AND A THERAPEUTIC TARGET IN MULTIPLE CANCER TYPE - Methods of determining prognosis in a subject with a hyperproliferative disease, including determining expression and/or function of 14-3-3 zeta in the subject, are disclosed. Also disclosed are methods of making a pharmaceutical agent that modulates apoptosis, including the steps of obtaining one or more candidate, testing the one or more candidate substances to determine their ability to modulate the expression and/or function of 14-3-3 zeta, selecting a candidate substance determined to modulate the expression and/or function of 14-3-3 zeta, and making a pharmaceutical composition that includes the selected candidate substance. In addition, methods of treating a subject with a hyperproliferative disease, including making a pharmaceutical agent by the methods set forth herein, and administering the pharmaceutical agent to a subject, are disclosed. The hyperproliferative disease can be cancer, such as breast cancer. | 12-25-2008 |
| 20080318232 | Nucleic Acid Biosensor with Photoelectrochemical Amplification - The present invention relates to electrode systems, methods, apparatus and chips for ultrasensitive detection and quantification of nucleic acids using photoelectrochemical amplification. Upon hybridization of a target nucleic acid to a nucleic acid capture probe, a photoreporter comprising a threading bis-intercalator selectively binds to double-stranded nucleic acid. The stability and reversibility of the photoreporter binding activity provides for ultrasensitive detection of nucleic acid hybridization events. | 12-25-2008 |
| 20080318233 | Source tagging and normalization of DNA for parallel DNA sequencing, and direct measurement of mutation rates using the same - This invention allows efficient tagging and normalization of DNA molecules prior to pooling and characterization using parallel DNA sequencing (e.g., commercially available 454 sequencers). The invention provides novel ways to process independent DNA samples (sources) so that similar numbers of molecules from each source are represented in the pool (i.e., the pool is normalized for representation among the sources). These approaches would save researchers time and energy relative to approaches currently available. In other embodiments, the invention provides novel ways to process large numbers of independently derived DNA samples that can be uniquely tagged in ways that allow the source of the DNA (e.g., an individual) to be tracked. The invention also provides novel ways for processing DNA to consistently obtain various portions of the genome to compare DNA sequences and directly measure mutations using state of the art massively parallel DNA sequencing (e.g., commercially available 454 sequencers and others. The invention is useful for the production of diagnostic assays for individuals prior to reproduction (e.g., cancer survivors who wish to procreate) and also for diagnostics of cancer (thus affecting the choice of treatment for cancer). | 12-25-2008 |
| 20080318234 | Compositions and methods for diagnosing and treating cancer - The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles associated with solid tumor stem cells, as well as novel stem cell cancer gene signatures useful for the diagnosis, characterization, prognosis and treatment of solid tumor stem cells. | 12-25-2008 |
| 20080318235 | Chromosomal Analysis By Molecular Karyotyping - The invention provides a method of karyotyping (for example for the detection of trisomy) a target cell to detect chromosomal imbalance therein, the method comprising: (a) interrogating closely adjacent biallelic SNPs across the chromosome of the target cell (b) comparing the result at (a) with the SNP haplotype of paternal and maternal chromosomes to assemble a notional haplotype of target cell chromosomes of paternal origin and of maternal origin (c) assessing the notional SNP haplotype of target cell chromosomes of paternal origin and of maternal origin to detect aneuploidy of the chromosome in the target cell. Also provided are related computer-implemented embodiments and systems. | 12-25-2008 |
| 20080318236 | Cell Free Screening Assay and Methods of Use - Methods are disclosed for identifying agents for the treatment of cancer and/or Fanconi anemia using | 12-25-2008 |
| 20080318237 | METHODS OF DIAGNOSING ENDOMETRIOSIS - The present invention provides biomarkers for the diagnosis and prognosis of endometriosis. Generally, the methods of this invention find use in diagnosing or for providing a prognosis for endometriosis by detecting the expression levels of biomarkers, which are differentially expressed (up- or down-regulated) in endometrial cells from a patient with endometriosis. Similarly, these markers can be used to diagnose reduced fertility in a patient with endometriosis or to provide a prognosis for a fertility trial in a patient suffering from endometriosis. The present invention also provides methods of identifying a compound for treating or preventing endometriosis. Finally, the present invention provides kits for the diagnosis or prognosis of endometriosis. | 12-25-2008 |
| 20080318238 | METHOD OF DETECTING GENE MUTATION - DNA amplification and hybridization are successively carried out in a reaction system containing primers for the DNA amplification and hybridization probes, followed by detecting the hybrid in the reaction solution by affinity chromatography, wherein at least one of the primers to be used in the DNA amplification is labeled with a first labeling agent so that the amplified DNA will be labeled with the first labeling agent, a hybridization probe is labeled with a second labeling agent and contained in a reaction solution for effecting the DNA amplification, the base sequence of the hybridization probe is designed not to inhibit the DNA amplification, and a hybrid is detected by affinity chromatography with the use of the first and second labeling agents. | 12-25-2008 |
| 20080318239 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 12-25-2008 |
| 20080318240 | METHODS FOR UTILIZING ESR COPY NUMBER CHANGES IN BREAST CANCER TREATMENTS AND PROGNOSES - The present invention relates to methods for estimation of efficacy of therapeutic treatment of cancer patients, in particular breast cancer patients. The estimation is based on determining of the status of aberration of the estrogen receptor alpha gene (ESR1) in situ, and, optionally, the status of aberration of a gene related to ESR1. In particular, the invention relates to determining the presence or absence and, if present, the type of aberration, e.g. amplification, duplication, polyploidization, deletion or translocation of the ESR1 gene in the tumor cells of the patient. The invention further relates to a kit-in-parts comprising probes for the determining the status of aberration of ESR1 and ESR1-related genes in situ. | 12-25-2008 |
| 20080318241 | Methods and Systems for Detecting Antiangiogenesis - The present invention provides methods and systems for the detection of tumor vessel response to antiangiogenic therapies. The present invention also provides compositions and methods for therapeutic and research applications. In particular, the present invention provides systems and methods that employ CD26, HIF-1, and HIF-1 pathway components as biomarkers for monitoring antiangiogenic therapies and as therapeutic targets. | 12-25-2008 |
| 20080318242 | METHODS AND DEVICES FOR EARLY DETECTION OF CANCER CELLS AND TYPES THROUGH MICROMECHANICAL INTERACTIONS - Methods and devices for detecting a cancer cell and cancer cell types in a sample of a subject are provided. | 12-25-2008 |
| 20080318243 | DNA measuring system and method - The present invention provides a DNA sequencer using a FET sensor, capable of long-base decoding. Target DNAs are immobilized on the surfaces of spherical fine particles, the fine particles are disposed in the vicinity of metal electrodes each of which is connected electrically to a corresponding one of conductive wirings of the FET sensor and partly has a spherical surface capable of contacting with the fine particles, and the FET sensor detects a change in interfacial potential incident to an extension reaction of DNA molecules containing a hybridization of the target DNA and probe DNA. | 12-25-2008 |
| 20080318244 | Large-scale parallel nucleic acid analysis method - It is intended to provide a technique for amplifying, individually and in parallel, nucleic acids contained in a mixture of plural kinds of nucleic acid samples. The present invention provides a nucleic acid analysis method comprising amplification means, whereby amplification reaction is performed in a reaction solution comprising a homogeneous solvent and comprising at least plural template nucleic acids and solid phase carriers comprising one or more kinds of amplification probes immobilized on the surface, to prevent amplified products attributed to two or more template nucleic acids from being replicated in one solid phase carrier. According to the present invention, plural kinds of analyte nucleic acid samples in a mixed state can be amplified individually and in parallel. This method achieves one solid phase carrier-one nucleic acid. Therefore, a higher density of solid phase carriers with obtained amplified products is easily achieved, leading to improved throughput of amplified product analysis. Reactions in all the amplification reaction steps are performed under homogeneous solvent conditions. Therefore, the method of the present invention is performed by convenient procedures and as such, is suitable to automation. | 12-25-2008 |
| 20090004645 | Methods for Identifying Genes that Mediate a Response of a Living Cell to an Agent - In one aspect, the present invention provides methods for determining whether a gene mediates the response of a living cell to an agent. In another aspect, the present invention provides methods to identify a mammalian subject responsive to a KSP inhibitor. | 01-01-2009 |
| 20090004646 | Method for Quantifying Methylated Dna - The inventive method makes it possible to quantify methylated DNA by combining the restricted digestion and real-time PCR. For this purpose, the inventive method consists in isolating the examined DNA from a biological sample, in reacting the isolated AND with a methylation specific restriction enzyme, in amplifying by means of a real-time PCR, wherein the amplified products are formed only when the DNA is precut-off and, afterwards, in calculated the methylated and unmethylated DNA proportion in the initial sample with the aid of a reference measurement. Said method is particularly suitable for diagnosis and prognosis cancer and other diseases associated with a methylation state modification and for predicting the drug effects. | 01-01-2009 |
| 20090004647 | Method of Judging Grade of Malignancy of Carcinoma Cell - Means for easily determining the grade of malignancy of cancer cells. The amount of ATBF1 in the whole cell structure of test cancer cells separated from a living organism is detected, and on the basis of detection results, the grade of malignancy of test cancer cells is judged. Alternatively, the amount of ATBF1 in the nuclei of test cancer cells separated from a living organism is detected, and on the basis of detection results, the grade of malignancy of test cancer cells is judged. Still alternatively, the amount of ATBF1 in the cytoplasms of test cancer cells separated from a living organism is detected, and on the basis of detection results, the grade of malignancy of test cancer cells is judged. In a preferred from, at least one of (1) the amount of intranuclear presence and/or intracytoplasmic presence a region corresponding to exon 10 of an ATBF1 gene, (2) the amount of intranuclear presence and/or intracytoplasmic presence a region corresponding to exon 11 of an ATBF1 gene, and (3) the amount of intranuclear presence and/or intracytoplasmic presence a region corresponding to exon 3 of an ATBF1 gene is detected as the amount of ATBF1. | 01-01-2009 |
| 20090004648 | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer - Novel markers for ovarian cancer that are both sensitive and accurate. These markers are overexpressed and/or differentially expressed in ovarian cancer specifically, as opposed to normal ovarian tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis, in ovarian cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between ovarian cancer and non-cancerous states. | 01-01-2009 |
| 20090004649 | EVERNINOMICIN BIOSYNTHETIC GENES - This invention is directed to nucleic acids which encode the proteins that direct the synthesis of the orthosomycin everninomicin and to use of the nucleic acids and proteins to produce compounds exhibiting antibiotic activity based on the everninomycin structure. The DNA sequence for the gene clusters responsible for encoding everninomicin biosynthetic genes, which provide the machinery for producing everninomicin, are provided. Thus, this invention provides the nucleic acid sequences needed to synthesize novel everninomicin-related compounds based on everninomicin, arising from modifications of the DNA sequence designed to change glycosyl and modified orsellinic acid groups contained in everninomicin. A | 01-01-2009 |
| 20090004650 | Methods for detecting a Cyclophilin B SNP associated with Herda - This invention provides compositions and methods for identification of carriers of Hereditary Equine Regional Dermal Asthenia (HERDA) in equine species. In particular, this invention identifies a single nucleotide polymorphorism (SNP) in cyclophlin B that can be used to identify carriers of HERDA and individuals affected by HERDA. | 01-01-2009 |
| 20090004651 | Screening methods for compounds that modulate the activity of G-protein coupled receptors - The present invention relates to a screening system for modulators of GPCRs. Further it relates to recombinant vector systems for the heterologous expression of heterodimeric g-protein coupled receptors (GPCRs) in eucaryotic host cells. Preferably the functional expression of engineered GPCRs for the perception of sweet and L-amino acid taste or more preferably the use of said receptors for the identification of functional ligands is also encompassed. | 01-01-2009 |
| 20090004652 | Methods for identifying and using SNP panels - Described are methods for identifying single nucleotide polymorphism (SNPs) that are useful for analyzing genetic samples, and for using said SNPs to determine genetic identity of samples. | 01-01-2009 |
| 20090004653 | Sulfonated [8,9]benzophenoxazine dyes and the use of their labelled conjugates - Fluorescent, sulfonated 3,7-diamino-[8,9]benzophenoxazine dyes are provided that are especially useful for labelling biopolymers and other substrates. The dye-labelled conjugates can be used in a variety of contexts, including cell surface assays employing intact, live cells and in nucleic acid detection methods. The new dyes are water soluble and can be conjugated to a variety of substrates, such as polynucleotides, nucleosides, nucleotides, peptides, proteins, antibodies, carbohydrates, ligands, particles and surfaces. | 01-01-2009 |
| 20090004654 | METHOD FOR THE DETECTION OF BACTERIAL SPECIES OF THE GENERA ANAPLASMA/EHRLICHIA AND BARTONELLA - The present invention relates to a method for the detection and identification of bacterial species belonging to the genera | 01-01-2009 |
| 20090004655 | RNA BIOASSAY - The present invention relates to methods for evaluating the cell damaging potential of an agent by determining the ability of the agent to increase messenger RNA release in cells. | 01-01-2009 |
| 20090004656 | THERMOSTABLE POLYMERASES HAVING ALTERED FIDELITY AND METHODS OF IDENTIFYING AND USING SAME - The present invention provides a method for identifying a thermostable polymerase having altered fidelity. The method consists of generating a random population of polymerase mutants by mutating at least one amino acid residue of a thermostable polymerase and screening the population for one or more active polymerase mutants by genetic selection. For example, the invention provides a method for identifying a thermostable polymerase having altered fidelity by mutating at least one amino acid residue in an active site O-helix of a thermostable polymerase. The invention also provides thermostable polymerases and nucleic acids encoding thermostable polymerases having altered fidelity, for example, high fidelity polymerases and low fidelity polymerases. The invention additionally provides a method for identifying one or more mutations in a gene by amplifying the gene with a high fidelity polymerase. The invention further provides a method for accurately copying repetitive nucleotide sequences using a high fidelity polymerase mutant. The invention also provides a method for diagnosing a genetic disease using a high fidelity polymerase mutant. The invention further provides a method for randomly mutagenizing a gene by amplifying the gene using a low fidelity polymerase mutant. | 01-01-2009 |
| 20090004657 | 7B2 Knockout transgenic animals as models of endocrine disease - In general, the invention features methods and uses for transposon-mediated gene targeting which greatly enhance the insertion and detection of desired genes in genomic exons by homologous recombination. The invention also features transgenic non-human mammals, and eukaryotic cells, wherein a gene encoding 7B2 protein is modified, as well as nucleic acid vectors capable of undergoing homologous recombination with an endogenous 7B2 gene in a cell. The invention also features transgenic non-human mammals as models of endocrine disorders, as well as methods for diagnosing and treating patients with endocrine disorders. | 01-01-2009 |
| 20090004658 | INTEGRIN ALPHA 7 MUTATIONS IN PROSTATE CANCER, LIVER CANCER, GLIOBLASTOMA MULTIFORME, AND LEIOMYOSARCOMA - Methods are provided for determining the presence of a cancer in a biological sample, such as a tissue biopsy. The methods comprise determining if integrin alpha 7 expression is decreased in the biopsy which is indicative of the presence of a cancer or likelihood of relapse of a cancer. This can be accomplished by determining if levels of integrin alpha 7 mRNA or protein are decreased as compared to a control. This also can be accomplished by determining if a mutation in the integrin alpha 7 gene is present in the biopsy. | 01-01-2009 |
| 20090004659 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof. | 01-01-2009 |
| 20090004660 | METHOD FOR DETECTING NEUROBLASTOMA AND ITS MALIGNANCY AND METHOD FOR SUPPRESSING THE SAME - An object of the present invention is to provide a method for detecting cancer and a cell growth inhibitor through identification of genes exhibiting characteristic behavior in the cases of cancer such as neuroblastoma. The present invention provides a method for detecting cancer, which comprises detecting canceration including malignancy of a specimen through detection of inactivation of a gene in the q22 region of chromosome 14 in the specimen. | 01-01-2009 |
| 20090004661 | METHOD OF GROWING MESENCHYMAL STEM CELLS FROM BONE MARROW - The present invention provides a method for culturing mesenchymal stem cells using cord blood serum, for therapeutic purposes in regenerative medicine; and in particular the present invention provides for the use of these cells in the treatment of PD, and the present invention has provided proliferation and neuronal differentiation of the MSCs in a xenofree culture system for clinical applications in a simple two step protocol, and the in vivo functional efficacy was tested in Parkinson's animal model. | 01-01-2009 |
| 20090004662 | METHOD AND COMPOSITIONS FOR NUCLEIC ACID AMPLIFICATION - The present teachings provide methods, compositions, and kits for nucleic acid amplification. In some embodiments of the present teachings, amplification reactions are performed with at least one high stability primer. In some embodiments, the present teachings provide a method comprising a high stability primer for amplification of a nucleic acid sequence in a sample comprising a target nucleic acid sequence and a PCR inhibitor. | 01-01-2009 |
| 20090004663 | Real-Time Assays Of Neuro-Humoral Factors To Assess Cardiovascular Stress - The present invention relates to rapid assays for neuro-humoral factors modulated in response to cardiovascular stress and integration of data obtained from such assays to provide profiles of response to cardiovascular stress that can guide therapy. | 01-01-2009 |
| 20090004664 | HCV NS3 replicon shuttle vectors - The present invention provides for novel HCV NS3 replicon shuttle vectors useful for cloning in HCV polynucleotide sequences from samples of HCV-infected patients and testing the resulting replicons for drug susceptibility. | 01-01-2009 |
| 20090004665 | METHODS AND COMPOSITIONS FOR ISOLATING NUCLEIC ACID SEQUENCE VARIANTS - The invention is drawn to isolating sequence variants of a genetic locus of interest using a modified iterative primer extension method. The nucleic acids analyzed are generally single stranded and have a reference sequence which is used as a basis for performing iterative single nucleotide extension reactions from a hybridized polymerization primer. The iterative polymerization reactions are configured such that polymerization of the strand will continue if the sequence of the nucleic acid being analyzed matches the reference sequence, whereas polymerization will be terminated if the nucleic acid being analyzed does not match the reference sequence. Nucleic acid strands that have mutations can be isolated using a variety of methods and sequenced to determine the precise identity of the mutation/polymorphism. By performing the method on both strands of the nucleic acid being analyzed, virtually all possible mutations can be identified. | 01-01-2009 |
| 20090004666 | METHOD OF DETECTING NUCLEOTIDE SEQUENCE WITH AN INTRAMOLECULAR PROBE - A nucleotide sequence-detecting method, including preparing a first intramolecular detecting sequence having a sequence complementary to a first sequence located at a 3′-side of the detecting site contained in the nucleotide sample and a second intramolecular detecting sequence having a sequence complementary to a second sequence located at a 5′-side of the detecting site, preparing a detecting chain containing a sequence of the detecting chain by connecting the first intramolecular detecting sequence to the 3′ terminal of the nucleotide sample and the second intramolecular detecting sequence to the 5′ terminal, allowing intramolecular hybridization at two positions of the detecting chain, connecting the 3′ terminal of the first intramolecular detecting sequence to the 5′ terminal of the second intramolecular detecting sequence, obtaining a cyclic structure, detecting the desired sequence in the nucleotide sample from the cyclic structure. | 01-01-2009 |
| 20090004667 | METHOD FOR GENERATING APTAMERS WITH IMPROVED OFF-RATES - The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element. | 01-01-2009 |
| 20090004668 | Pre-miRNA loop-modulated target regulation - By employing essential nucleotides from both the stem and loop of precursor-miRNA, greater specificity is achieved as to the mRNAs that are repressed. It is found that besides the seed sequence of the stem of the pre-miRNA, nucleotides in the loop affect the activity and specificity of the cursor- and the processing and binding to target mRNA. By using both sequences in the natural pre-miRNA or modified mimetics, one can screen for cellular miRNA expression, modulate cell properties with greater specificity and investigate cellular activity as to phenotype and response to external stimuli in the presence and absence of target protein expression. | 01-01-2009 |
| 20090004669 | Methods of diagnosing pre-eclampsia or eclampsia - Disclosed herein are methods for diagnosing pre-eclampsia and eclampsia. Also disclosed herein are methods for treating pre-eclampsia and eclampsia using compounds that increase VEGF or PlGF levels or compounds that decrease sFlt-1 levels. Compounds that inhibit the binding of VEGF or PlGF to sFlt1- are also disclosed herein for the treatment of pre-eclampsia or eclampsia. | 01-01-2009 |
| 20090011405 | Modulating Screening Thresholds for N-Hybrid Screening - The present invention provides improved N-hybrid assays. In particular, the present invention provides an improved reverse N-hybrid assay comprising modulating the amount of a substrate of a reporter gene and/or the amount of a reporter gene thereby enhancing cell death in the absence of a peptide inhibitor of a DNA-protein or protein-protein interaction and/or enhancing cell survival in the presence of a peptide inhibitor of a DNA-protein or protein-protein interaction. Furthermore, the present invention provides an improved forward N-hybrid assay comprising modulating the amount of a reporter gene thereby enhancing cell death in the absence of a heterologous peptide or protein capable of binding to the DNA or protein in a cell and enhancing cell survival in the presence of a heterologous peptide or protein capable of binding to the DNA or protein in a cell. | 01-08-2009 |
| 20090011406 | Method of Judging Fatigue - A method of judging fatigue, which comprises judging fatigue by using, as an index, a value obtained by quantitatively analyzing an adenine nucleotide in a sample to be measured. | 01-08-2009 |
| 20090011407 | Polymorphic Cd24 Genotypes that are Predictive of Multiple Sclerosis Risk and Progression - An image data correction apparatus has a motion information acquisition section, a correction section, and a composition section. The motion information acquisition section acquires motion information indicating spatial distribution of the magnitude of motion, in actual space, of a to-be-imaged portion of a subject. Based on the motion information, the correction section performs correction, which is different from correction in a second region, in a first region of image data collected by a scan by magnetic resonance imaging. The composition section composes individual image data of the first region and the second region that are corrected by the correction section. | 01-08-2009 |
| 20090011408 | Methods for detection of a target nucleic acid by forming a cleavage structure using a reverse transcriptase - The invention relates to and methods for generating a signal indicative of the presence of a target nucleic acid in a sample. The compositions and methods include a reverse transcriptase, a nuclease, an upstream primer and downstream probe. | 01-08-2009 |
| 20090011409 | Antibodies Against Cells of Fetal Origin - This invention relates to antibodies that specific bind to fetal CD36+ cells in preference to binding to maternal CD36+ cells and methods for using these antibodies to detect and separate fetal cells from adult biological fluids including maternal peripheral blood. | 01-08-2009 |
| 20090011410 | METHOD FOR TAILORING ADMINISTRATION OF DRUGS BY QUANTITATION OF MRNA - The present invention discloses a method for tailoring drug protocols to individual patients based on the levels of marker mRNA measured in leukocytes after stimulation of whole blood of the patient with candidate drugs. A method of measuring a patient's responsiveness to a drug is disclosed that includes exposing whole blood of the patient to the drug for 7 hours or less; after the exposure, measuring the amount of an mRNA associated with an effect of the drug in blood cells; and identifying responsiveness to the drug based on the results of the measurement, wherein a change in the amount of the mRNA indicates the patient's responsiveness to the drug. The amount of mRNA measured in the blood cells may be compared with the level of mRNA present in the cells before exposure or with the level of mRNA present in cells exposed for the same amount of time to a control vehicle. Marker mRNAs useful in the present invention include mRNAs encoding the gene product of the p21, BAX, PUMA, NOXA, and IL-2 genes. The method may be employed for patients with, among other conditions, cancer or diseases or conditions requiring immunosuppression. | 01-08-2009 |
| 20090011411 | Method for Detecting and Quantifying Endogenous Wheat Dna Sequence - It is an object of the present invention to provide partial sequences of endogenous wheat DNA (genome) which are single copies and which allow wheat to be specifically detected without cross-reacting with other plants in PCR, and to provide primers for amplifying these partial sequences, along with a good method for detecting and quantifying endogenous DNA using these primers. The present invention provides, in a method for detecting or quantifying an endogenous wheat DNA sequence in a test sample by means of a polymerase chain reaction, a method comprising a step of using a nucleic acid in the test sample or a nucleic acid extracted from the test sample as a template to amplify the nucleic acid of a region comprising at least 80% or more of a nucleotide sequence represented by one of SEQ ID NO:1 through SEQ ID NO:7 using a primer pair capable of amplifying that region, and a step of detecting or quantifying the amplified nucleic acid. | 01-08-2009 |
| 20090011412 | HIP1 cancer markers - The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, HIP | 01-08-2009 |
| 20090011413 | Method for screening colon cancer cells and gene set used for examination of colon cancer - Colon cancer cells in a sample are screened by analyzing the amount of expression of at least 2 or more genes or products thereof selected from the group of genes listed in Tables 1 and 30. As compared to conventional method, patients having colon cancer can be detected with higher accuracy. Colon cancer cells in stool are also screened by analyzing expression of genes selected from the group of genes listed in Table 37. | 01-08-2009 |
| 20090011414 | HUMAN AUTISM SUSCEPTIBILITY GENE ENCODING A KINASE AND USES THEREOF - The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the MARK1 gene on chromosome 1 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the MARKI gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of Asperger syndrome, pervasive developmental disorder, mental retardation, anxiety, depression, attention deficit hyperactivity disorders, speech delay, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological diseases including schizophrenia. | 01-08-2009 |
| 20090011415 | REGULATION OF NEURONAL EXPRESSION OF APOLIPOPROTEIN E - The present invention provides nucleic acids comprising a nucleotide sequence encoding an apolipoprotein E (apoE) splice variant, e.g., an unprocessed apoE, that retains intron 3; and vectors and host cells comprising same. The present invention further provides screening methods to identify agents that inhibit cleavage of intron-3 from the apoE splice variant. The present invention further provides methods of treating apoE-related neurological disorders, involving administering an agent that inhibits removal of intron-3 from a precursor apoE mRNA. | 01-08-2009 |
| 20090011416 | Random array DNA analysis by hybridization - The invention relates to methods and devices for analyzing single molecules, i.e. nucleic acids. Such single molecules may be derived from natural samples, such as cells, tissues, soil, air and water without separating or enriching individual components. In certain aspects of the invention, the methods and devices are useful in performing nucleic acid sequence analysis by probe hybridization. | 01-08-2009 |
| 20090011417 | Testing Device - The invention provides, in different aspects, a system, sample preparation device, sample processing cartridge, kit, methods of use, business methods, and computer program product. | 01-08-2009 |
| 20090011418 | FUNCTIONAL TOLL-LIKE RECEPTORS (TLR) ON MELANOCYTES AND MELANOMA CELLS AND USES THEREOF - The invention relates to a method of detecting Toll-like receptor (TLR) gene expression or protein activity in a melanocyte or melanoma cell. Also disclosed are a method of modulating TLR gene expression or protein activity in a melanocyte or melanoma cell by contacting the cell with a TLR modulating agent and a method of inhibiting melanoma cell migration (e.g., spreading) by contacting the cell with a TLR inhibitor. | 01-08-2009 |
| 20090011419 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof. | 01-08-2009 |
| 20090011420 | SPARSELY CROSS-LINKED NANOGELS: A NOVEL POLYMER STRUCTURE FOR MICROCHANNEL DNA SEQUENCING - The present invention is generally directed to novel polymeric materials for use in the electrophoretic separation of nucleic acids. In particular, the novel polymer materials are sparsely crosslinked nanogels, dissolved in an aqueous buffer to form solutions with moderate to high viscosity. The present invention further provides methods for generating such novel polymers, and related methods of their use. | 01-08-2009 |
| 20090011421 | SUSCEPTIBILITY TO BONE DAMAGE - In one aspect, the present invention provides methods for determining susceptibility to bone damage in a subject. In some embodiments, the methods comprise screening for polymorphisms in the MTHFR and collagen Iα1 genes that are associated with susceptibility to bone damage. In some embodiments, the methods comprise screening for elevated levels of homocysteine in a subject, wherein elevated levels of homocysteine are associated with an increased risk of bone damage. The methods of the invention may be used in predicting the response of a patient to treatment. Also provided are methods for prevention or reducing the risk of bone damage in a subject. | 01-08-2009 |
| 20090011422 | METHODS FOR CLONING SMALL RNA SPECIES - This invention pertains to methods for cloning microRNA (miRNA) and other small ribonucleic acid (RNA) species from relevant cell sources. | 01-08-2009 |
| 20090011423 | GENES FOR PROGNOSIS OF CANCER - To provide a novel method for determining the risk of lymph node metastasis of breast cancer uses as an index the difference in the expression levels of marker genes between metastatic breast cancer tissue (or cell) and non-metastatic breast cancer tissue (or cell). The method involves ( | 01-08-2009 |
| 20090011424 | Cancer-suppressing agents - It is an object of the present invention to provide a cancer-suppressing agent comprising a novel cancer-suppressing gene based on the discovery of such cancer-suppressing gene. The present invention provides a cancer-suppressing agent which comprises NR1I2 gene or a homologous gene thereof; and a cancer-suppressing agent which comprises NR1I2 protein or a homologous protein thereof. | 01-08-2009 |
| 20090017450 | Primer for detection of human papillomavirus - Disclosed are primers specific to the genome of HPV genotypes 11, 16, 18 and 31. Also disclosed are a kit for detecting the HPV genome comprising the primers and a method of detecting the HPV genome using the primers. | 01-15-2009 |
| 20090017451 | Generation of Recombinant Genes in Saccharomyces Cerevisiae - The present invention relates to methods for generating and detecting recombinant DNA sequences in | 01-15-2009 |
| 20090017452 | METHODS AND COMPOSITIONS RELATING TO THE PHARMACOGENETICS OF DIFFERENT GENE VARIANTS - The present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2, UGT1A1, and/or SLCO1B1 gene and correlating these polymorphisms with activity levels of their gene products and making evaluations regarding the effect on their substrates, particularly those substrates that are drugs. In addition, there are methods and compositions of evaluating the risk of an individual for developing toxicity or adverse event(s) to an ABCC2, UGT1A1, and/or SLCO1B1 substrate. In some embodiments, the invention concerns methods and compositions for determining the presence or absence of ABCC2 3972C>T variant and predicting or anticipating the level of activity of ABCC2 and determining dosages of an ABCC2 drug substrate, such as irinotecan, in a patient. Such methods and compositions can be used to evaluate whether irinotecan-based therapy, or therapy involving other ABCC2 substrates, may pose toxicity problems if given to a particular patient or predicting their efficacy. Alterations in suggested therapy may ensue based on genotyping results. | 01-15-2009 |
| 20090017453 | NICKING AND EXTENSION AMPLIFICATION REACTION FOR THE EXPONENTIAL AMPLIFICATION OF NUCLEIC ACIDS - The invention is in general directed to the rapid exponential amplification of short DNA or RNA sequences at a constant temperature. | 01-15-2009 |
| 20090017454 | BIOSENSORS, METHOD FOR OBTAINING THE SAME AND USES THEREOF - The invention relates to biosensors, methods for obtaining them and their use for detecting, assaying or locating, in direct immunofluorescence, a ligand such as an antigen or hapten, in a heterogeneous population. The biosensor includes (i) at least one fragment of a receptor which is protein in nature, capable of binding to a ligand via an active site, where at least one amino acid residues of the fragment located in the proximity of the active site is naturally present in the form of a cystein (Cys) residue, or is substituted with a Cys residue, and (ii) a fluorophore coupled to the Cys residue. | 01-15-2009 |
| 20090017455 | Methods and systems for detecting and/or sorting targets - Provided herein are methods and systems for detecting and/or sorting targets in a sample based on the combined use of polynucleotide-encoded-protein and substrate polynucleotides. The polynucleotide-encoded protein is comprised of a protein that specifically binds to a predetermined target and of an encoding polynucleotide that specifically binds to a substrate polynucleotide, wherein the substrate polynucleotide is attached to a substrate. | 01-15-2009 |
| 20090017456 | DETECTION, IDENTIFICATION AND DIFFERENTIATION OF EUBACTERIAL TAXA USING A HYBRIDIZATION ASSAY - The present invention relates to a method for the specific detection and/or identification of | 01-15-2009 |
| 20090017457 | IDENTIFICATION OF MODULATORS OF SERINE PROTEASE INHIBITOR KAZAL AND THEIR USE AS ANTI-CANCER AND ANTI-VIRAL AGENTS - This invention describes a relevant etiology of cancer and a novel anti-cancer therapeutic strategy, based on the discovery that a protein named serine protease inhibitor (SPIK/SPINK/PSTI) was up-regulated by hepatitis B and C virus infections consequently suppressing the cell apoptosis. Accordingly, this invention provides an inhibitor of SPIK and/or a technology of suppression of over-expression of SPIK in cells. The inhibitors include: 1) chemical compounds, which can inhibit SPIK transcripts, protein activity, and gene expression, 2) SPIK siRNA (RNAi gene silence or dsRNA of SPIK, 3) DNA anti-sense and anti-SPIK antibody. Further, this invention provides a method of using the inhibitor as an anti-cancer agent to re-instate cancer cell apoptosis (e.g., serine protease dependent cell apoptosis). | 01-15-2009 |
| 20090017458 | DISEASE DIAGNOSIS APPARATUS AND METHOD USING PHOTOCURRENT OF AMORPHOUS SILICON - Provided is a disease diagnosis apparatus and method for detecting a specific disease. The disease diagnosis chip, includes: a light sensing layer; a probe molecule fixed on the light sensing layer; and an electrode connected to the light sensing layer to detect an electric signal corresponding to photoelectric charges of the light sensing layer. | 01-15-2009 |
| 20090017459 | MEASURING ANALYTES USING COMPETITIVE INTERFERENCE AND RECUPERATION OF ENZYME ACTIVITY - The present teaching generally discloses a method of measuring the concentration of an analyte in a solution. The method includes selecting a binding compound; selecting an analog to an analyte and conjugating the analog to a polynucleotide substrate to construct a reagent for measuring the amount of the analyte in an assay solution using a desired polynucleotide reaction that comprises a polymerization reaction, a cleavage reaction, or a recombination reaction. The binding of the reagent to the binding compound in the assay solution competes with the binding of the analyte to the binding compound in the assay solution. The method also includes selecting a desired enzyme for catalyzing the desired polynucleotide reaction. Reagents and kits are also provided. | 01-15-2009 |
| 20090017460 | DIFFERENTIAL EXPRESSION PROFILING ANALYSIS OF CELL CULTURE PHENOTYPES AND USES THEREOF - The present invention provides, among other things, systems and methods for identifying genes and proteins that regulate and/or are indicative of cell phenotypes based on expression profiling analysis. The present invention further provides methods of manipulating identified genes and proteins to engineer improved cell lines. | 01-15-2009 |
| 20090017461 | Diagnosis of Gynecological Neoplasms by Detecting the Levels of Oviduct-Specific Glycoprotein - The present invention provides a method for detecting cancer in a patient. A sample from the patient is provided, and the level of oviduct-specific glycoprotein (OGP) in the sample is determined and compared to a control sample. Increased levels of OGP in the sample as compared to the control indicates that the patient has cancer. In one aspect, the cancer is a gynecological cancer, such as ovarian cancer. Kits for conducting the methods of the invention are also provided. | 01-15-2009 |
| 20090017462 | Recombinase polymerase amplification - This disclosure describe three related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of recombinase and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods have the advantage of not requiring thermocycling or thermophilic enzymes. Further, the improved processivity of the disclosed methods may allow amplification of DNA up to hundreds of megabases in length. | 01-15-2009 |
| 20090017463 | METHODS FOR PREDICTING PROSTATE CANCER RECURRENCE - The present invention relates to the identification of four cytokine biomarkers in prostatic tissue that exhibit differential expression following prostatectomy that, in combination at least one other factor, are able to reliably predict the development of biochemical recurrence following surgery. This marker combination improves the risk stratification of patients after primary local treatment for localized prostate cancer. | 01-15-2009 |
| 20090017464 | METHODS FOR DRUG DISCOVERY, DISEASE TREATMENT, AND DIAGNOSIS USING METABOLOMICS - The small molecule profiles of cells are compared to identify small molecules which are modulated in altered states. Cellular small molecule libraries, methods of identifying tissue sources, methods for treating genetic and non-genetic diseases, and methods for predicting the efficacy of drugs are also discussed. | 01-15-2009 |
| 20090017465 | Compound Screening Using Cardiomyocytes - This invention provides populations human cells of the cardiomyocyte lineage. The cells are obtained by causing cultures of pluripotent stem cells to differentiate in vitro, and then harvesting cells with certain phenotypic features. Differentiated cells bear cell surface and morphologic markers characteristic of cardiomyocytes, and a proportion of them undergo spontaneous periodic contraction. Highly enriched populations of cardiomyocytes and their replicating precursors can be obtained, suitable for use in a variety of applications, such as drug screening and therapy for cardiac disease. | 01-15-2009 |
| 20090023134 | Neoplasia diagnostic compositions and methods of use - The invention generally features compositions and methods for the diagnosis and monitoring of a neoplasia (e.g., a prostatic neoplasia) in a subject, as well as methods of treatment selection. | 01-22-2009 |
| 20090023135 | DETECTION OF ENHANCED MULTIPLEX SIGNALS BY SURFACE ENHANCED RAMAN SPECTROSCOPY - Various methods of using Raman-active or SERS-active probe constructs to detect analytes in biological samples, such as the nucleic acid and/or protein-containing analytes in a body fluid are provided. | 01-22-2009 |
| 20090023136 | HSD3B1 sequence variants - Isolated HSD3B1 nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described, as are HSD3B1 allozymes. Methods for determining whether a subject contains an HSD3B1 sequence variant also are provided. | 01-22-2009 |
| 20090023137 | ESR1 and Cervical Cancer - The present invention provides methods and kits for detecting susceptibility to, or the incidence of, cervical cancer in a sample comprising determining the methylation status of the ESR1 gene, optionally as part of a panel of genes. Also provided are methods and kits which involve determining the expression levels of genes including the ESR1 gene in order to diagnose cervical cancer. | 01-22-2009 |
| 20090023138 | ORAL CANCER MARKERS AND THEIR DETECTION - Methods of detecting progression from precancer to cancer are provided utilizing toluidine blue staining as well as detecting allelic variation at microsatellite loci. An allelic variation in one or more locus is indicative of a progression from precancer to cancer. | 01-22-2009 |
| 20090023139 | Method For Site-Specifically Introducing Non-Natural Amino Acid Into Protien Using Mitochondrial Protein and Method For Effectively Preparing Trna - This invention is intended to provide a protein synthesis system used for producing a tryptophan analogue-containing non-natural-amino-acid-containing protein that satisfies the following conditions: (i) tRNA that transfers a non-natural amino acid is not recognized by an endogenous aminoacyl tRNA synthetase (aaRS); (ii) it is recognized selectively by aaRS exclusive for a non-natural amino acid; and (iii) endogenous tRNA is not recognized by aaRS exclusive for a non-natural amino acid. In the eukaryotic organism-derived cell-free protein synthesis system, a yeast mitochondrial tryptophanyl tRNA synthetase is used in combination with mitochondrial tRNA | 01-22-2009 |
| 20090023140 | CROSSLINKING AGENT, CROSSLINKING METHOD, METHOD OF CONTROLLING GENE EXPRESSION, AND METHOD OF EXAMINING GENE FUNCTION - The present invention provides a crosslinking agent which have photodegradable protective groups at two ends to crosslink double-stranded nucleic acid, a nucleic acid and a protein or a polypeptide, or proteins or polypeptides, in particular, double-stranded RNA; a method for crosslinking a double-stranded RNA or the like using the same; a method for regulating gene expression, which can control the expression of a target gene at an arbitrary timing and location; and a method for examining a gene function. | 01-22-2009 |
| 20090023141 | METHOD FOR DETECTING BACTERIA OF THE GENUS MYCOBACTERIUM (ACID-FAST BACTERIA) AND KIT FOR THE SAME - An object of the present invention is to provide an oligonucleotide for rapidly and conveniently detecting bacteria of the genus | 01-22-2009 |
| 20090023142 | Methods for Detecting Minimum Residual Disease - The present invention features methods and compositions for identifying markers of minimum residual disease (MRD), as well as markers of metastatic cells. The present invention further provides methods for detecting MRD and metastatic cell in a subject. | 01-22-2009 |
| 20090023143 | Predicting agent for metastasis - By disclosing part of metastasis mechanisms in cancer cells, the metastatic potential of cancer cells will be determinable. Anti-galectin-9 Ab against galectin-9 is contained as an effective component with or without others, thereby enabling the evaluation or detection of galectin-9 expression levels in cancer cells wherein the metastatic potential of the cancer cells can be assessed or detected. | 01-22-2009 |
| 20090023144 | METHOD AND ITS KIT FOR QUANTITATIVELY DETECTING SPECIFIC ANALYTE WITH SINGLE CAPTURING AGENT - The invention provides a method and its kit for quantitatively detecting a specific analyte with a single capturing agent. The quantitative detection of a specific analyte with a single capturing agent comprises: firstly combining the tested analyte with a solid phase capturing agent, then labeling analyte which has been trapped by the capturing agent with a report molecule; secondly eluting the labeled analyte from the complex, recombining the tested analyte with a new solid phase capturing agent, and ascertaining the content of analyte by detecting the report molecule's label signal. The kit of the invention comprises a capturing device, a detecting device, a report molecule for labeling and an analysis substance eluate. The advantages of the invention are the need of one single capturing agent, the capability of detecting for many analytes which can't be tested at present, wide application, high sensibility and low noise. The invention can be applied to diagnosis, medical expertise, new medicine development, application of protein micro array and chip, and fundamental research. | 01-22-2009 |
| 20090023145 | Methods of diagnosing or prognosing Alzheimer's disease - A method for diagnosing or prognosing Alzheimer's disease in a subject, or determining whether a subject is at increased risk of developing Alzheimer's disease, comprising:
| 01-22-2009 |
| 20090023146 | DEVICE FOR PROCESSING AN ANALYTE AND A METHOD OF PROCESSING AND/OR DETECTING AN ANALYTE USING SAID DEVICE - The present invention relates to a device for processing an analyte and to a method of processing and/or detecting an analyte using said device. | 01-22-2009 |
| 20090023147 | DIAGNOSTICS AND THERAPEUTICS FOR OSTEOPOROSIS - Diagnostics and therapeutics for osteoporosis, which are bases upon the identification of a subjects IL-1 haplotype and genotype pattern are described. | 01-22-2009 |
| 20090023148 | Sensors for biomolecular detection and cell classification - A sensor device is provided for detecting an analyte in a sample in which an analyte is bound to a detection reagent to form a bound complex. The device comprises (a) a sample ( | 01-22-2009 |
| 20090023149 | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy - The present invention features methods, kits, and devices for predicting the sensitivity of a patient to a compound or medical treatment. The invention also features methods for identifying gene biomarkers whose expression correlates to treatment sensitivity or resistance within a patient population or subpopulation. | 01-22-2009 |
| 20090023150 | DNA Diagnostics Based on Mass Spectrometry - Fast and highly accurate mass spectrometry-based processes for detecting a particular nucleic acid sequence in a biological sample are provided. Depending on the sequence to be detected, the processes can be used, for example, to diagnose a genetic disease or chromosomal abnormality; a predisposition to a disease or condition, infection by a pathogenic organism, or for determining identity or heredity. | 01-22-2009 |
| 20090023151 | Method For The Labeling And Detection Of Small Polynucleotides - Methods and kits for use in isolating, labeling or detecting a small polynucleotide of interest from a sample. The method entails hybridizing the small polynucleotide to a capture probe, lengthening the small polynucleotide by primer extension and/or ligation, and degrading the capture probe to provide a single stranded extension product. The kits include the capture probe and additional reagents for the extension, ligation and/or degradation reactions. | 01-22-2009 |
| 20090023152 | Transcription factor MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substances - The present invention relates to a transcription factor of MHC class II genes and its derivatives, inhibitors down-regulating the expression of MHC class II molecules, process to identify these inhibitors and medical uses of these inhibitors. | 01-22-2009 |
| 20090023153 | Targeted modification of chromatin structure - Methods and compositions for targeted modification of chromatin structure, within a region of interest in cellular chromatin, are provided. Such methods and compositions are useful for facilitating processes such as, for example, transcription and recombination, that require access of exogenous molecules to chromosomal DNA sequences. | 01-22-2009 |
| 20090023154 | RELATING TO MARKING - The invention provides a marking system, markers and methods of use of such marking systems and markers which enable unique marking of articles and subsequent detection of that marking. In particular the invention provides a marking system, the marking system comprising a plurality of different DNA fragment types, each of the plurality of different DNA fragment types comprising a plurality of different length DNA fragments and a method in which a sample of the DNA fragment type is taken, amplified and analysed to determine the identity of the marker for an article. | 01-22-2009 |
| 20090029353 | MOLECULAR DETECTOR - Described herein are embodiments of a method and device comprising an electronic charge detector capable of detecting the presence of small quantities of electric charge generated through a universal signal generation process that is configured to detect any biological agents and biomolecular targets of interest. Electric charge results from signal molecules binding to affinity molecules that are attached to a detection surface. Electronic circuits are configured to detect the induced electric charges on the detection surface. Additional electronic devices then process useful quantitative data regarding specific biomolecular interaction events. | 01-29-2009 |
| 20090029354 | Method on clinical applications in head neck cancer by using DSG3 molecule for predicting malignant degree of cancer, serving as a molecular target and using RNA jamming sequence on inhibition-specific of DSG3 expression - The present invention provide a method for analyzing the DSG3 overexpression in tumor tissues with clinical features of cancer cells to validate that DSG3 overexpression is relates to size, depth and migration of tumor. Therefore, DSG3 overexpression is capable for using in clinical applications, determining malignant degree of tumor, serving as molecular target in Head Neck Cancer (HNC). Moreover, a jamming sequence, RNA, is designed to act on DSG3 mRNA and is effective inhibition-specific DSG3 expression, and then inhibits cell growth, invasion and migration in HNC. | 01-29-2009 |
| 20090029355 | Abnormalities of Phosphatase 2A (PP2A) for Diagnosis and Treatment of Alzheimer's Disease - This invention relates to methods of diagnosing Alzheimer's disease and methods of screening for compounds for the treatment or prevention of Alzheimer's disease. The methods are based upon newly discovered differences in protein phosphatase 2A (PP2A) function and related molecular events in Alzheimer's disease cells compared to control cells. In one embodiment, differences in basal PP2A gene expression in Alzheimer's cells are compared to controls. In another embodiment differences in PP2A protein and enzyme activity are compared in test and control cells. In another embodiment differences in response to substances that inhibit PP2A function are compared. Still another embodiment detects differences in the subcellular distribution of phosphorylated Erk1/2, a substrate of PP2A, in normal and Alzheimer's disease cells. The detection of Alzheimer's disease-specific differences in PP2A function and related events in peripheral tissues provides the basis for highly practical and efficient tests and diagnostic test kits for the early diagnosis of Alzheimer's disease, as well as providing a biochemical basis for identifying therapeutic targets for drug development. | 01-29-2009 |
| 20090029356 | Corynebacterium glutamicum genes encoding novel proteins - Isolated nucleic acid molecules, designated MCP nucleic acid molecules, which encode novel MCP proteins from | 01-29-2009 |
| 20090029357 | Method for diagnosing cancer using cancer-associated deletion gene marker - It is an object of the present invention to provide a novel method for diagnosing cancer by discovering a cancer-associated gene which could not be detected by a conventional technique, and detecting deletion, mutation, or an abnormal expression level of such cancer-associated gene. The present invention provides a method for diagnosing cancer which comprises a step of detecting deletion of the GMDS, ANKRD15, TEK, or EBI2 gene in a test sample by using DNA containing all or part of said gene. | 01-29-2009 |
| 20090029358 | Methods and Compositions for the Diagnosis and Treatment of Schizophrenia - Compositions and methods relating to the diagnosis and treatment of neuropsychiatric disorders, such as schizophrenia, schizoaffective disorders, and bipolar disorders are disclosed. Also provided are methods for screening therapeutic agents having efficacy for the treatment of such disorders. | 01-29-2009 |
| 20090029359 | DIAGNOSTIC METHODS FOR EARLY CANCER DETECTION - The present disclosure is directed to compositions and methods for detecting signs of telomere dysfunction as diagnostic indicators of metastatic disease. More particularly, diagnostic reagents and procedures are provided for analyzing samples to detect elevated expression of TRK2 protein or detect the presence of telomere fusions as an early diagnostic test for cancerous or pre-cancerous cells. In one embodiment the methods of the present disclosure are used to diagnose the existence of, or assess the risk of, breast cancer in an individual. | 01-29-2009 |
| 20090029360 | Nucleic Acid Amplification and Detection of Mycobacterium Species - Oligonucleotides used to prime in vitro nucleic acid amplification of 16S rRNA sequences or DNA encoding 16S rRNA sequences for many species within the genus | 01-29-2009 |
| 20090029361 | GROWTH DIFFERENTIATION FACTOR-7 - The present invention provides methods of using polynucleotides that hybridize specifically with a polynucleotide encoding GDF-7 to identify GDF-7 in a sample. | 01-29-2009 |
| 20090029362 | GENE COPY NUMBER PROFILING - The invention relates to copy number profile analysis. Specifically, copy number profile analysis is used to determine whether two or more separate tumors in a single individual are derived from a common source. | 01-29-2009 |
| 20090029363 | METHOD OF SELECTION BY TWO-DIMENSIONAL SEPARATION, OF NUCLEIC ACIDS THAT BIND TO A TARGET WITH HIGH AFFINITY - The invention relates to a method of selection, by two-dimensional separation, of nucleic acids that bind to a target molecule with high affinity from a mixture of nucleic acids, including the following steps: a) subjecting the mixture of nucleic acids to a physico-chemical separation step, thereby obtaining a set of mixed fractions containing the nucleic acids, a run parameter window being associated with every mixed fraction containing the nucleic acids, b) contacting a mixed fraction containing the nucleic acids with the target molecule, thereby obtaining a binding mixture containing nucleic acid/target molecule complexes, c) subjecting the binding mixture from step b) to the same physico-chemical separation step as in step a), thereby selecting nucleic acid/target molecule complexes whose run parameters are outside of the run parameter window. | 01-29-2009 |
| 20090029364 | Specific multiplex analysis of nucleic acids - A method of detecting the presence or absence of variant nucleotides within target nucleic acid sequences, said method comprising the use of at least one pair of target-specific amplification primers capable of hybridizing to target nucleic acid sequences, and the use of at least one set of diagnostic primers, each set consisting of at least two types of diagnostic primers capable of hybridizing to corresponding target nucleic acid sequences 3′-relative to said amplification primers, such that each set of diagnostic primers is semi-nested relative to the corresponding pair of amplification primers. Additionally, the use of said method for genotyping, for diagnostic screening, for assaying the cytosine methylation status and for quantification of nucleic acids is disclosed. | 01-29-2009 |
| 20090029365 | NOVEL GENES, COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF COLON CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with colon cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human colon cancers are provided. | 01-29-2009 |
| 20090029366 | METHODS OF IDENTIFYING MODULATORS OF HYPERPOLARIZATION-ACTIVATED CYCLIC NUCLEOTIDE-GATED (HCN) CHANNELS - Methods, including high-throughput methods, for identifying modulators of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. | 01-29-2009 |
| 20090029367 | POLYMORPHISMS IN PON1 ARE ASSOCIATED WITH ELEVATED ALANINE AMINOTRANSFERASE LEVELS AFTER XIMELAGATRAN OR TACRINE ADMINISTRATION - This invention relates to a method for administering a pharmaceutically useful anticoagulant drug to certain suitable patients and a method for identifying those patients suitable for receiving the drug. In particular, the invention surrounds the identification of an association between certain SNPs in the PON1 gene and susceptibility to increased levels of alanine aminotransferase (ALAT) following ximelagatran or tacrine administration. Thus, this invention relates to methods for predicting susceptibility to elevated ALAT following ximelagatran or tacrine administration and to methods for administering a pharmaceutically useful anticoagulant drug to certain suitable patients. | 01-29-2009 |
| 20090029368 | Method for determining the cell culture history of a cell unit labelled with more than one type of tag - The present invention relates in one aspect to a method for determining the cell culture history of a cell unit labelled with more than one type of tag comprising the steps of: (a) measuring one or more parameters of each tag that is used to label the cell unit; (b) identifying each tag in the cell unit; and (c) correlating the identity of each tag to the identity of the cell unit and/or the specific cell culture conditions to which the cell unit has been exposed. | 01-29-2009 |
| 20090029369 | GENETIC SELECTION SYSTEM TO IDENTIFY PROTEASES, PROTEASE SUBSTRATES AND PROTEASE INHIBITORS - The present invention concerns a tester protein for identifying and/or monitoring protease activity in a cellular assay suitable for high throughput screenings by growth selection, wherein the tester polypeptide is a non-regulatory protein carrying a protease cleavage sequence. Upon co-expression of the protease recognizing said cleavage sequence the tester protein is inactivated, which influences the growth and/or survival of the host cells under the chosen conditions. However, in the presence of protease inhibitor the growth phenotype is reversed. The system can be used to identify proteases, protease inhibitors, and protease cleavage sites. | 01-29-2009 |
| 20090029370 | REAL TIME NUCLEIC ACID DETECTION IN VIVO USING PROTEIN COMPLEMENTATION - The present invention relates to a method to detect nucleic acid molecules, such as RNA molecules in vivo using real time protein complementation methods. The invention further relates to methods for detecting nucleic acids, for example RNA in real-time in living cells with a high sensitivity, using a novel split biomolecular conjugate of the invention. | 01-29-2009 |
| 20090029371 | METHOD FOR DETERMINING VASOREACTIVITY - The present invention is generally directed to methods and materials for determining the genotype of a patient to predict the patient's vasoreactivity. More particularly, the present invention is directed to a method of determining the vasoreactivity of a subject, comprising: obtaining from a subject a sample comprising a nucleic acid sequence of the BMPR2 gene or amino acid sequence of the BMPR2 gene; determining the presence or absence of a non-synonymous mutation in the BMPR2 nucleic acid or amino acid sequence, and correlating the presence of a non-synonymous mutation with non-vasoreactivity or the absence of a non-synonymous mutation with vasoreactivity. | 01-29-2009 |
| 20090029372 | ADAM12 AS A BIOMARKER FOR BLADDER CANCER - The present inventors have shown that the gene and protein expression profiles of ADAM8, ADAM10 and ADAM12 in different grades and stages of bladder cancer. | 01-29-2009 |
| 20090029373 | METHOD FOR THE QUANTITATIVE DETECTION OF NUCLEIC ACIDS - Provided herein is a method for the quantitative detection of HHV-6 subtypes A and/or B based on the use of a calibrator, suitable primers and probes, and a nucleic acid polymerase with 5′-3′ nuclease activity. | 01-29-2009 |
| 20090029374 | SYSTEM AND METHOD FOR IDENTIFYING NETWORKS OF TERNARY RELATIONSHIPS IN COMPLEX DATA SYSTEMS - A system and method for identifying high order associations between variables in complex systems that is particularly useful where there is no correlation or weak correlation between variables due to the influence of a third variable, a ternary relationship. The ternary relationship describes how the variation in the pattern of association between a pair of variables, including its sign and strength, is mediated by a third variable. In one embodiment applied to gene expression data, the activity of pairs of correlated genes due to the activity of one or more third genes is shown. | 01-29-2009 |
| 20090029375 | GENETIC MODELS FOR STRATIFICATION OF CANCER RISK - The present invention provides new methods for the assessment of cancer risk in the general population. These methods utilize particular alleles of in multiple selected genes to identify individuals with increased or decreased risk of breast cancer. In addition, personal history measures such as age and family history are used to further refine the analysis. Using such methods, it is possible to reallocate healthcare costs in cancer screening to patient subpopulations at increased cancer risk. It also permits identification of candidates for cancer prophylactic treatment. | 01-29-2009 |
| 20090029376 | High Fidelity Restriction Endonucleases - Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions include restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor. | 01-29-2009 |
| 20090029377 | DIAGNOSING FETAL CHROMOSOMAL ANEUPLOIDY USING MASSIVELY PARALLEL GENOMIC SEQUENCING - Embodiments of this invention provide methods, systems, and apparatus for determining whether a fetal chromosomal aneuploidy exists from a biological sample obtained from a pregnant female. Nucleic acid molecules of the biological sample are sequenced, such that a fraction of the genome is sequenced. Respective amounts of a clinically-relevant chromosome and of background chromosomes are determined from results of the sequencing. A parameter derived from these amounts (e.g. a ratio) is compared to one or more cutoff values, thereby determining a classification of whether a fetal chromosomal aneuploidy exists. | 01-29-2009 |
| 20090029378 | High sensitivity multiparameter method for rare event analysis in a biological sample - A sample of blood containing CTCs, or other cells of interest, is stained with fluorescent markers for image analysis and scanned to identify the presence and location within the cartridge of target cells or subcellular elements. A sample containing desired target cells or subcellular elements is then further processed, in part by photobleaching the sample, so that those same targets may be re-analyzed with additional biomarkers conjugated to the same or different fluorochromes using the same imaging criteria that were used for the initial analysis. The present invention has applications with targets such as circulating epithelial, cells, circulating tumor cells, circulating endothelial cells, leukocytes, lymphocyte subsets, cells containing an organelle or receptor of interest, cellular debris, disrupted cells and their debris, or any other formed element that might be captured and imaged. The invention provides a means to further interrogate individual targets of interest, especially when coupled with genetic analysis such as FISH. | 01-29-2009 |
| 20090029379 | GENETIC MARKERS FOR PROGNOSIS OF ANTIFOLATE TREATMENT EFFICACY - Methods and kits for predicting the efficacy of antifolate (e.g., methotrexate) treatment of rheumatoid arthritis by detecting polymorphisms, particularly single nucleotide polymorphisms, in adenosine pathway genes. | 01-29-2009 |
| 20090029380 | HUMAN MutY - A human mutY polypeptide and DNA (RNA) encoding such polypeptide and a procedure for producing such polypeptide by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for preventing and/or treating diseases associated with a mutation in this gene. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed. | 01-29-2009 |
| 20090029381 | METHODS AND COMPOSITIONS FOR ANALYZING AHASL GENES - The invention relates to methods and compositions for analyzing plant acetohydroxy acid synthase large subunit (AHASL) genes. In particular, the invention relates to methods for the detection of wild-type AHASL alleles and mutant AHASL alleles that encode imidazolinone-tolerant AHASL proteins. The methods involve the use of PCR amplification and novel compositions comprising allele-specific and gene-specific primers to detect the presence of mutant and/or wild-type alleles present at the individual AHASL genes of a plant. Specifically, the methods and compositions are useful for analyzing the three AHASL genes of | 01-29-2009 |
| 20090029382 | CHARACTERIZATION OF A MEMBRANE ESTROGEN RECEPTOR - The present invention discloses the identification of a novel membrane associated estrogen receptor, termed mER. The membrane associated receptor is involved in rapid signal transduction. Amino acid sequences, nucleic acid sequences, vectors, and host cells are also discussed. Additionally, methods of detecting agonists and antagonists for the receptor are disclosed herein. | 01-29-2009 |
| 20090029383 | Polynucleotide Sequencing Method - The subject invention pertains to a method for determining the sequence of a polynucleotide comprising the steps of (i) contacting a polynucleotide processive enzyme immobilised in a fixed position, with a target polynucleotide under conditions sufficient to induce enzyme activity; (ii) detecting an effect consequent on the interaction of the enzyme and polynucleotide, wherein the effect is detected by measurement of a non-linear optical signal or a linear signal coupled to a non-linear signal. | 01-29-2009 |
| 20090029384 | TECHNIQUES FOR RECORDING SIGNALS - The present invention provides techniques of recording signals. In one aspect of the invention, a method of recording a signal comprises the following steps. One or more errors are selectively introduced during synthesis of a polymer in response to the signal. The one or more occurrences of the one or more errors in the synthesized polymer are recorded. The synthesis of the polymer may comprise a polymer synthetase that can selectively introduce the one or more errors in response to the signal. A method for analyzing signals is also provided. | 01-29-2009 |
| 20090029385 | Molecular redundant sequencing - Methods, systems and compositions where a target nucleic acid includes a registration sequence disposed therein for identification of the number or relative position of determined sequence from the template sequence. Particularly preferred aspects include a registration sequence in a circular template nucleic acid sequence which is, in turn, used in sequence by incorporation processes that rely upon template dependent, polymerase mediated primer extension in the identification of the sequence of the template. | 01-29-2009 |
| 20090029386 | KIT FOR ENUMERATING MAMMALIAN CELL MICRONUCLEI WITH AN EMPHASIS ON DIFFERENTIALLY STAINING MICRONUCLEI AND THE CHROMATIN OF DEAD AND DYING CELLS - The present invention relates a method for the enumeration of mammalian cell micronuclei, while distinguishing micronuclei from the chromatin of dead and dying cells. The method utilizes differential staining of chromatin from dead and dying cells, to distinguish the chromatin from micronuclei and nuclei that can be detected based upon fluorescent emission and light scatter following exposure to an excitatory light source. Counting of micronuclei events relative to the number of nuclei can be used to assess the DNA-damaging potential of a chemical agent, the DNA-damaging potential of a physical agent, the effects of an agent which can modify endogenously-induced DNA damage, and the effects of an agent which can modify exogenously-induced DNA damage. Kits for practicing the invention are also disclosed. | 01-29-2009 |
| 20090035751 | Single Molecule Detection Using Molecular Motors - The present invention provides methods and compositions for highly sensitive nucleic acid detection, down to the single nucleic acid molecule level. In one aspect, the present invention provides methods for detecting a target nucleic acid comprising: (a) providing first and second target-specific nucleic acids, wherein the first and second target-specific nucleic acids each comprise sequences complementary to the target nucleic acid; wherein the first target specific nucleic acid is bound to a first affinity tag and the second target-specific nucleic acid is bound to a second affinity tag, wherein the first affinity tag is capable of binding to a molecular motor, and wherein the second affinity tag is capable of binding to a detection probe; (b) contacting the first and second target-specific nucleic acids to a sample under conditions whereby the first and second target-specific nucleic acids will hybridize to the target nucleic acid if the target nucleic acid is present in the sample, wherein upon hybridization to the target nucleic acid the first and second target-specific nucleic acids are directly adjacent to each other; (c) ligating the first and second target-specific nucleic acids together; (d) binding the molecular motor t˜ the first affinity tag and the detection probe to the second affinity tag; (e) inducing movement of the molecular motor; and (f) detecting movement of the molecular motor through the detection probe, wherein the movement of the molecular motor serves to detect the target nucleic acid in the sample. | 02-05-2009 |
| 20090035752 | Polynucleotide Participating In Rheumatoid Arthritis And Utilization Of The Same - Analysis is made on the DNA methylation of the region (including a promoter region) upstream from the translation initiation point of a rheumatoid arthritis-associated gene DR3 in human genome. As a result, it is found out that an allele-specific methylation occurs in a CpG sequence located about −380 to −180 bp upstream from translation initiation point (ATG) of the gene DR3. It is further found out that the CpG sequences downstream therefrom of the genes DR3 originating in healthy subjects are all in the unmethylated state, while methylated and unmethylated sequences are both observed in the genes DR3 originating in RA patients. | 02-05-2009 |
| 20090035753 | Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same - The present invention relates to novel druggable regions discovered in dengue virus envelope glycoprotein, or dengue virus E protein, which is a class II viral E protein. The present invention further relates to methods of using the druggable regions to screen potential candidate therapeutics for diseases caused by viruses having class II E proteins, e.g. viral fusion inhibitors. | 02-05-2009 |
| 20090035754 | Methods and compositions for detecting steroids - The present invention provides for methods and systems for detecting steroids. Examples of such steroids include estrogen, progesterone, androgen, testosterone, and derivatives and analogs thereof. Systems useful for carrying out the method include tripartite constructs including a DNA-binding domain, a ligand binding domain, and an activation domain. The present invention provides numerous improvements over previous diagnostic systems for detection of steroids, such advantages include that the method allows for detection of steroid analogs and derivatives, whose structures may not yet be known, the method is generally applicable to a wide variety of organisms, and numerous ligand binding domains may be used in conjunction with the present system. | 02-05-2009 |
| 20090035755 | Yeast Strain And Screening Method For Identifying Inhibitors Of The Expression Of The Hexose Transporter Genes By A Positive Phenotype - The present invention provides screening procedures for identifying inhibitors of components of regulatory networks by a positive phenotype and modified yeast cell lines suitable for said screening. The screening procedures are especially suited to screen for substances that re-sensitize resistant pathogenic microorganisms or tumor cells by suspending the expression of resistance-relevant genes. The invention further provides methods for constructing said cell lines and their use in screening systems. | 02-05-2009 |
| 20090035756 | Methods for arbitrary peptide synthesis - Methods, apparatus, systems, computer programs and computing devices related to biologically assembling and/or synthesizing peptides and/or proteins are disclosed. | 02-05-2009 |
| 20090035757 | SUBSTRACTIVE SINGLE LABEL COMPARATIVE HYBRIDIZATION - Provided are methods of determining differences between nucleic acids in a test sample and a reference sample. In certain embodiments the methods are used for detecting and mapping chromosomal or genetic abnormalities associated with various diseases or with predisposition to various diseases, or to detecting the phenomena of large scale copy number variants. In particular, provided are advanced methods of performing array-based comparative hybridization that allow reproducibility between samples and enhanced sensitivity by using the same detectable label for both test sample and reference sample nucleic acids. Invention methods are useful for the detection or diagnosis of particular disease conditions such as cancer, and detecting predisposition to cancer based on detection of chromosomal or genetic abnormalities and gene expression level. Invention methods are also useful for the detection or diagnosis of hereditary genetic disorders or predisposition thereto, especially in prenatal samples. Moreover, invention methods are also useful for the detection or diagnosis of de novo genetic aberrations associated with post-natal developmental abnormalities. | 02-05-2009 |
| 20090035758 | Method of Measurement of Micronucleated Erythrocyte Populations - A method of measuring micronucleated erythrocyte populations is disclosed. The method includes contacting a sample containing erythrocyte populations with a fluorescently labeled antibody specific to immature erythrocytes among erythrocyte populations; adding an aqueous permeation reagent to the sample and incubating the formed permeation sample mixture for an incubation time sufficient to allow the permeation reagent to render cellular membrane of the erythrocyte populations permeable to RNase and dye; adding a RNase reagent to degrade RNA and to inhibit further reaction of permeation reagent; adding a fluorescent nucleic acid dye reagent to stain DNA representing micronuclei in the erythrocyte populations; performing light scatter and fluorescence measurements of the final sample mixture on a flow cytometer; differentiating micronucleated erythrocyte populations from other cell types; and reporting the micronucleated erythrocyte populations of the sample. The method avoids ultracold fixation, centrifugation, and washing cells in sample preparation. | 02-05-2009 |
| 20090035759 | METHOD AND DEVICE FOR DETECTING THE PRESENCE OF A SINGLE TARGET NUCLEIC ACID IN A SAMPLE - A method comprises loading a sample portion into a sample chamber which comprises means for minimizing diffusion of the sample portion, subjecting the sample portion to an amplification step, and determining whether the sample portion contains at least one molecule of a target nucleic acid. If the sample portion contains a single molecule of the target nucleic acid, the sample portion would attain a detectable concentration of the target nucleic acid after a single round of amplification. Also, a microfluidic device comprising a sample portion and a sample chamber comprising means for minimizing diffusion of the sample portion. Also, a microfluidic device comprising a sample chamber and an amplification targeting reagent positioned in the first sample chamber. | 02-05-2009 |
| 20090035760 | CalDAG-GEF1 Gene Mutations Associated with Thrombopathy - The present invention relates to methods and compositions for detecting mutations associated with thrombopathy. In particular, the invention relates to methods and composition for detecting mutations in the CalDAG-GEF1 gene that are associated with thrombopathy. | 02-05-2009 |
| 20090035761 | Method for isolation of DNA, RNA and proteins from formalin-fixed paraffin-embedded tissue specimens - Methods are disclosed for rapid, reliable and simple isolation of RNA from formalin-fixed paraffin-embedded tissue samples. RNA purified in this manner can be used to monitor gene expression levels. The tissue sample can be a tumor or other pathological tissue. | 02-05-2009 |
| 20090035762 | Allele-specific copy number measurement using single nucleotide polymorphism and DNA arrays - Methods and systems for allelic detection and allele-specific copy number are provided herein. The described methods use identification of single nucleotide polymorphism using restriction enzymes and CGH analyses. Microarrays comprising probes designed by the described methods are provided. Also included are methods for identifying SNP sites and copy number in samples obtained from patient populations. | 02-05-2009 |
| 20090035763 | Methods for Detecting Progression of Low Grade Cervical Dysplasia and for Detecting Adenocarcinomas - The invention provides methods for identifying conditions of low grade cervical dysplasia and assessing the progressive potential of individual lesions to develop into high grade cervical dysplasia and cervical squamous cell cancer as well as cervical adenocarcinoma. | 02-05-2009 |
| 20090035764 | Methods and systems for evaluating CGH candidate probe nucleic acid sequences - Methods of evaluating candidate CGH probe nucleic acid sequences are provided. Aspects of the methods include providing a candidate CGH probe nucleic acid sequence for a target sequence of a copy number variation (CNV) of a genome. A proximity score is then determined for the candidate CGH probe nucleic acid sequence and employed to evaluate the sequence. Aspects of the invention further include computer programming and systems that include the same which are configured to evaluate candidate CGH probe nucleic acid sequences using a proximity score. | 02-05-2009 |
| 20090035765 | Polynucleotides and methods for making plants resistant to fungal pathogens - This invention relates to polynucleotide sequences encoding a gene that can confer resistance to the plant pathogen | 02-05-2009 |
| 20090035766 | Methods for Analyzing High Dimension Data for Classifying, Diagnosing, Prognosticating, and/or Predicting Diseases and Other Biological States - A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition. | 02-05-2009 |
| 20090035767 | PRIMER FOR BACTERIUM GENOME AMPLIFICATION REACTION - A primer or a primer set can efficiently amplify the gene sequence of 16S rRNA of a target bacterium out of selected sixty two bacterium species. At least one of the primers having a base sequence selected from sequences No. 1 through No. 6 is employed as bacterium genome amplification reaction primer: | 02-05-2009 |
| 20090035768 | Method of Determining Predisposition to Scoliosis and Uses Thereof - The present invention relates to novel genetic markers associated with scoliosis, risk of developing scoliosis and risk of scoliosis curve progression, and methods and materials for determining whether a human subject has scoliosis, is at risk of developing scoliosis or is at risk of scoliosis curve progression. | 02-05-2009 |
| 20090035769 | Genetic Markers Associated with Scoliosis and Uses Thereof - The present invention relates to novel genetic markers associated with scoliosis, risk of developing scoliosis and risk of scoliosis curve progression, and methods and materials for determining whether a human subject has scoliosis, is at risk of developing scoliosis or is at risk of scoliosis curve progression. | 02-05-2009 |
| 20090035770 | Inline-injection microdevice and microfabricated integrated DNA analysis system using same - Methods and microfluidic circuitry for inline injection of nucleic acids for capillary electrophoresis analysis are provided. According to various embodiments, microfabricated structures including affinity-based capture matrixes inline with separation channels are provided. The affinity-based capture matrixes provide inline sample plug formation and injection into a capillary electrophoresis channel. Also provided are methods and apparatuses for a microbead-based inline injection system for DNA sequencing. | 02-05-2009 |
| 20090035771 | Hepatocellular carcinoma-related genes and polypeptides, and method for detecting hepatocellular carcinomas - Genes up-regulated in hepatocellular carcinomas and polypeptides encoded by these genes are provided. Vectors, transformants and methods for producing the recombinant polypeptides are also provided. Probes and primers of these genes and antibodies against the polypeptides are also provided. The probes, primers and antibodies can be used as reagents for detecting hepatocellular carcinomas. Methods for detecting hepatocellular carcinomas using such detection reagents are further provided. Antisense nucleotide sequences of these genes are also provided and can be used to inhibit growth of hepatocellular carcinomas. | 02-05-2009 |
| 20090035772 | Genetic Markers Associated With Scoliosis And Uses Thereof - The present invention relates to novel genetic markers associated with scoliosis, risk of developing scoliosis and risk of scoliosis curve progression, and methods and materials for determining whether a human subject has scoliosis, is at risk of developing scoliosis or is at risk of scoliosis curve progression. | 02-05-2009 |
| 20090035773 | NUCLEIC ACID SEQUENCES FOR DETECTING GENETIC MARKERS FOR CANCER IN A BIOLOGICAL SAMPLE - Nucleic acid sequences for detecting the presence of nucleic acids, particularly mRNA, encoding human prostate-associated genetic markers encoding prostate-specific antigen (PSA), prostate specific membrane antigen (PSMA) or human kallikrein 2 (hK2) are disclosed. Preferred combinations of nucleic acid sequences amplifying and detecting the prostate-associated genetic markers RNA, used in methods that include amplification of the target sequences and detection of the amplified sequences are disclosed. Methods of detecting the presence of prostate-associated genetic marker nucleic acids, particularly mRNA, in a biological sample of non-prostate origin are disclosed. | 02-05-2009 |
| 20090035774 | METHOD FOR CHARACTERIZING PRIMARY TUMORS - The invention relates to a method for the detection and characterisation of primary tumours and separate areas of primary tumours, respectively. Clusters of tumour cells, extracted from sample material, are isolated and concentrated, followed by an analysis of genetic changes in these isolated cell clusters. | 02-05-2009 |
| 20090035775 | PCR-BASED DETECTION METHOD FOR CHLAMYDIA TREACHOMATIS - A process for designing of PCR-based detection method for | 02-05-2009 |
| 20090035776 | Method and Kit for Hla-B Genotyping Based on Real-Time Pcr - Method and kit based on real-time PCR with specific primers and probes that allow to achieve a high degree of subtyping of the complete HLA-B locus. The main advantages are the greater speed (65 minutes, including the interpretation); the ease of automation, since only eighteen tubes are necessary to obtain a good level of resolution (typing of 300 groups); reduction of the total cost per test thanks to the ease of automation and the simplicity; a surprisingly high degree of allele definition is achieved; and the risk of sample contamination is reduced because the amplified products always remain in the tubes and no post-PCR steps are necessary. | 02-05-2009 |
| 20090035777 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION - Nucleic acid sequencing methods and related products are disclosed. Methods for sequencing a target nucleic acid comprise providing a daughter strand produced by a template-directed synthesis, the daughter strand comprising a plurality of subunits coupled in a sequence corresponding to a contiguous nucleotide sequence of all or a portion of the target nucleic acid, wherein the individual subunits comprise a tether, at least one probe or nucleobase residue, and at least one selectively cleavable bond. The selectively cleavable bond(s) is/are cleaved to yield an Xpandomer of a length longer than the plurality of the subunits of the daughter strand, the Xpandomer comprising the tethers and reporter elements for parsing genetic information in a sequence corresponding to the contiguous nucleotide sequence of all or a portion of the target nucleic acid. Reporter elements of the Xpandomer are then detected. Corresponding products, including Xpandomers and oligomeric and monomeric substrate constructs are also disclosed. | 02-05-2009 |
| 20090035778 | METHODS AND COMPOSITIONS FOR CORRELATING GENETIC MARKERS WITH MULTIPLE SCLEROSIS - The present invention provides, in certain aspects, a method of identifying a subject as having an increased risk of developing multiple sclerosis, comprising detecting in the subject the presence of a nucleotide variant in the interleukin 7 receptor alpha chain gene, whereby the presence of said variant identifies the subject as having an increased risk of developing multiple sclerosis. | 02-05-2009 |
| 20090035779 | SYSTEMS AND METHODS FOR DETERMINING CROSS-TALK COEFFICIENTS IN PCR AND OTHER DATA SETS - Systems and methods for determining cross-talk coefficients in curves, such as sigmoid-type or growth curves, and PCR curves and nucleic acid melting curves in particular, as well as for applying the cross-talk coefficients to produce cross-talk corrected data sets using a linear subtractive model. Cross-talk signal coefficients are determined using cross-talk data acquired across the entire signal acquisition range. Analyzing across all of the signal curve data provides for a more robust cross-talk correction across the entire data acquisition range. A linear subtractive model is used to correct data sets having cross-talk components. | 02-05-2009 |
| 20090035780 | DETECTION OF METHICILLIN-RESISTANT AND METHICILLIN-SENSITIVE STAPHYLOCOCCUS AUREUS IN BIOLOGICAL SAMPLES - Disclosed are methods of identifying a methicillin-resistant | 02-05-2009 |
| 20090035781 | METHODS AND COMPOSITIONS FOR IDENTIFYING A SUBJECT WITH AN INCREASED RISK OF GRAM NEGATIVE BACTERIAL INFECTION - The present invention provides method of identifying a subject as having an increased risk of developing a Gram negative bacterial infection and/or as having an increased risk of mortality, comprising genotyping the subject for the presence of particular alleles of the lipopolysaccharide binding protein gene, wherein the presence of said allele(s) identifies the subject as having an increased risk of developing a Gram negative bacterial infection and/or of having an increased risk of mortality. | 02-05-2009 |
| 20090035782 | BREEDING PLANTS - A process for breeding plants which comprises growing plants of a species in an array of containers charged with growing medium of uniform characteristics in an environment of controlled climatic conditions with controlled supply of nutrients and feed water and changing the positions of the containers within the environment as required to ensure at least substantially uniform exposure of all plants in the containers to conditions in the environment. A process for the breeding of open pollinating plants in a greenhouse environment is also provided. A process for breeding plants which comprises identifying trait leads. | 02-05-2009 |
| 20090042183 | Use of pcr-based techniques to analyze compositions of botanicals - Methods for use in identifying the individual biological components present in a botanical mixture are provided. Using a combination of genomic-locus specific PCR, single strand conformation polymorphism, and sequence analysis, the biologic components of a botanical composition are identified without prior knowledge as to which components may be present. | 02-12-2009 |
| 20090042184 | Method Of Diagnosing Cancer And Reagents Therefor - The present invention provides methods for diagnosis and monitoring the efficacy of treatment of a cancer. More particularly, the methods of the invention comprise detecting an enhanced degree of chromatin modification within Chromosome 2 of the human genome from about map position 2q14.1 to about map position 2q14.3 in a sample derived from a subject. The methods include detecting an enhanced level of methylation, or detecting an enhanced level of modification of a histone positioned within the chromatin within the region of about 2q14.1 to 2q14.3 of Chromosome 2. The methods also include detecting a modulated level of expression of a gene within the region of about 2q14.1 to 2q14.3 of Chromosome 2. The gene may be selected from the group consisting of DEAD box polypeptide 18 (DDX18), translin (TSN), v-ral simian leukaemia viral oncogene homolog B (RALB), secretin recepto (SCTR), engrailed homolog 1 (EN1), macrophage receptor with collagenous structure (MARCO), protein tyrosine phosphatase non-receptor type 4 (PTPN4), insulin induced gene 2 (INSIG2), inhibin beta B (INHBB), GLI-Kruppel family member 2 (GLI2), FLJ10996, STEAP3, diazepam binding inhibitor (DBI), MGC10993, erythrocyte membrane protein band 4.1 like 5 (EPB41L5), FLJ14816, transcription factor CP2-like 1 (TFCP2L1). | 02-12-2009 |
| 20090042185 | Novel polymorphism in bovine prion protein gene sequence - A specific, non-synonymous SNP in the Prnp gene encoding the bovine prion protein affects the susceptibility of bovine animals to bovine spongiform encephalopathy (BSE). Depending on the number of octapeptide repeat units present in the Prnp gene, the position of the SNP is either nucleotide 631 of exon 3 (codon 211) when the Prnp gene comprises six octapeptide repeat region sequences, nucleotide 607 of exon 3 (codon 203) when the Prnp gene comprises five octapeptide repeat region sequences, or nucleotide 655 of exon 3 (codon 219) when the Prnp gene comprises seven octapeptide repeat region sequences. Alleles of the bovine Prnp wherein the SNP at these positions is lysine (K) at the corresponding amino acids (i.e., 211, 203 or 219) in the bovine prion protein are all indicative of increased susceptibility to BSE in comparison to alleles which encode glutamic acid (E) at the same position. This SNP may be used as a marker for selecting bovines susceptible to BSE for disposal and/or removal from breeding, the human food and animal feed supplies. | 02-12-2009 |
| 20090042186 | MAPPING NEW SITES FOR ANTIBIOTIC ACTION IN THE RIBOSOME - The present invention provides a method of mapping and identifying new sites for antibiotic action in the ribosome of a microorganism. The method comprises: (a) providing a random mutant library of the rRNA genes of the microorganism prepared by randomly mutating the rRNA genes of the microorganism; (b) enriching the library in clones with deleterious rRNA mutants by negative selection; (c) screening for clones with deleterious rRNA mutations; (d) mapping the deleterious rRNA mutations in the clones obtained from step (c) to identify sites in the rRNA which are important functional sites in the ribosome; and (e) selecting functional sites identified in the rRNA in step (d) which are not targeted by a known antibiotic as new sites for antibiotic action for the microorganism. The rRNA gene can be the 16S rRNA of the small subunit or the 23S rRNA or the 5S rRNA of the large subunit of the ribosome of the microorganism. | 02-12-2009 |
| 20090042187 | COMPOSITIONS AND METHODS FOR PREDICTING OUTCOME OF TREATMENT - This invention is directed to compositions and their uses for detection of markers. Such markers may be useful in the understanding of the underlying molecular event leading to a condition or a disease in a subject. These markers may also be useful for characterization of neoplastic cells and cancer cells and their response to certain therapeutical regimes. Therefore the invention as disclosed may contribute to the improvement of the stratification of patients for the best possible treatment. | 02-12-2009 |
| 20090042188 | Agent for Differentiating Hematopoietic Stem Cell Into Natural Killer Cell Comprising Vdup1 Protein or Gene Encoding the Same, and a Method of Differentiating Hematopoietic Stem Cell Into Natural Killer Cell Using Thereof - The present invention is related to an agent for differentiating hematopoietic stem cell into natural killer cell comprising VDUP1 protein or gene encoding the same, and a method of differentiating hematopoietic stem cell into natural killer cell using thereof. The present invention reveals for the first time that the VDUP1 gene is a critical factor for the regulation of differentiation of natural killer cell by generating a mouse deficient in VDUP1 gene, which confirms that VDUP1 gene is required for NK maturation. Thus, through the regulation of VDUP1 gene, the modulation of NK cells that have ability to kill cancer cells is possible and can be utilized for cell therapeutics. | 02-12-2009 |
| 20090042189 | Increased sensitivity of nucleic acid-based detection of organisms by fractionation of target genomes - A method of analyzing a sample for detection of presence or absence of an organism of interest in the sample comprising (a) obtaining a sample; (b) subjecting the sample to a disruption treatment sufficient to fractionate any nucleic acid sequences present in the sample; and (c) detecting for presence or absence of an organism of interest in the sample. The detecting step (c) may comprise performing primer-directed amplification (preferably polymerase chain reaction) on the sample to produce an amplification result and analyzing the amplification result for an amplification product, wherein presence or absence of the amplification product is indicative of the presence or absence of the organism of interest in the sample. | 02-12-2009 |
| 20090042190 | Method of detecting gene - A method of detecting a gene including immobilizing a primer for DNA elongation onto an insoluble carrier having on the surface thereof a polymer substance containing a first unit having a phosphorylcholine group and a second unit having a carboxylic acid-derived group having an electron-attractive substituent bound to a carbonyl group; annealing the template DNA fragments or RNA fragments with the primer for DNA elongation, so as to elongate the DNA primer while incorporating therein an enzyme, thereby allowing coloration of a chromogenic reagent by its enzymatic action; and judging whether the DNA fragments or RNA fragments of the gene presents or not, based on the degree of coloration. | 02-12-2009 |
| 20090042191 | SYSTEM AND METHOD FOR SECURE DOCUMENT PRINTING AND DETECTION - A method for authenticating and verifying an item to be genuine is described. The method for authenticating the item comprises applying a particular nucleic acid material associated with a particular sequence of nucleic acid bases to ink within an ink cartridge or a toner compound within a toner housing. The method also comprises collecting a sample of either the ink or toner compound and verifying the ink or toner is genuine by detecting the particular nucleic acid material. | 02-12-2009 |
| 20090042192 | UNIVERSAL AMPLIFICATION OF FRAGMENTED RNA - The invention relates to methods of using fragmented RNA, such as RNA obtained from archived fixed paraffin-embedded tissue material (FPET RNA) or other clinically biopsied tissue specimens for universal gene expression profiling. | 02-12-2009 |
| 20090042193 | Assays for measuring nucleic acid binding proteins and enzyme activities - Processes for measuring DNA or RNA binding proteins, specific nucleic acids, as well as enzyme activities using labeled nucleic acids of labeled protein/peptide molecules are provided. | 02-12-2009 |
| 20090042194 | Predicting a response to risperidone - The invention relates generally to the relative effect of specific genetic polymorphisms in predicting the clinical outcome of risperidone therapy in patients suffering from a psychiatric disease such as schizophrenia. | 02-12-2009 |
| 20090042196 | METHODS FOR IDENTIFYING MULTIPLE DNA ALTERATION MARKERS IN A LARGE BACKGROUND OF WILD-TYPE DNA - Methods for simultaneously surveying the status of a large number of DNA mutation markers are described. In addition, methods for simultaneously determining the methylation status at multiple sites of a collection of genes, in a single assay, are described. | 02-12-2009 |
| 20090042197 | METHOD FOR DETECTING AND AMPLIFYING NUCLEIC ACID - Problem to be Solved There is provided a method for detecting and/or amplifying a nucleic acid contained in a biological sample such as blood or cells conveniently, rapidly, and effectively. | 02-12-2009 |
| 20090042198 | METHOD FOR MEASURING CONCENTRATION OF NUCLEIC ACIDS - A method for measuring a concentration of nucleic acids is described. The method includes providing bioprobe molecules that include single-stranded nucleic acids, wherein the bioprobe molecules are conjugated with magnetic beads in a solution. A sample of single-stranded target nucleic acids is added to solution, where the single-stranded target nucleic acids hybridize with the single-stranded nucleic acids of the bioprobe molecules. A reduction of the ac (alternating current) magnetic susceptibility of the solution prior and after the addition of the sample to the solution is determined. | 02-12-2009 |
| 20090042199 | Methods and Materials Relating to CD84-like Polypeptides and Polynucleotides - The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human secreted CD84-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human spleen (Hyseq clone identification numbers 2938352 (SEQ ID NO: 1)). Other aspects of the invention include vectors containing processes for producing novel human secreted CD84-like polypeptides, and antibodies specific for such polypeptides. | 02-12-2009 |
| 20090042200 | CELLOMICS SYSTEM - In labeling a cell, and separating and collecting the cell according to a degree of the labeling using a cell separator, effects on the cell is minimized and the use of the collected cell is facilitated, thereby, when labeling a cell, the cell is labeled in the state where interaction of each cell is retained. In the labeling, a specific labeling material present on a surface of a target cell is taken in the cell via a transporter, and the cell is dispersed one by one to separate the same with a cell separator. Immediately after the separation, the cell is put in a solution not containing the specific labeling substance to remove the specific labeling substance taken in the cell. This series of steps is continuously conducted with a cell separation chip. | 02-12-2009 |
| 20090042201 | Biomarkers for multiple sclerosis and methods of use thereof - Disclosed are biomarkers, the expression of which is differentially regulated in subjects with multiple sclerosis (MS) as compared to subjects that do not have MS. Also described are methods of identification of such biomarkers, and methods of using such biomarkers as targets for the development and identification of therapeutic compounds and strategies for the treatment of MS, as well as methods and kits for the diagnosis of MS. | 02-12-2009 |
| 20090042202 | PROSTATE-SPECIFIC POLYPEPTIDE PAMP AND ENCODING NUCLEIC ACID MOLECULES - The present invention relates to novel prostate specific nucleic acid molecules and polypeptides and related methods for diagnosing or predicting susceptibility to a prostate neoplastic condition. | 02-12-2009 |
| 20090042203 | Mass Spectrometric Methods for Detecting Mutations in a Target Nucleic Acid - Fast and highly accurate mass spectrometry-based processes for detecting particular nucleic acid molecules and mutations in the molecules are provided. | 02-12-2009 |
| 20090042204 | ACNE LESION BIOMARKERS AND MODULATORS THEREOF - The present invention relates to acne lesions biomarkers/genes expression products pattern and particularly inflammatory acne lesions biomarkers and their uses, modulators thereof and the use of modulators for acne treatment or associated disorders. Invention also concerns in vitro diagnostic methods. | 02-12-2009 |
| 20090042205 | FLUORESCENCE DETECTION OF DNA BREAKS USING MOLECULAR OSCILLATORS - A method to detect DNA breaks includes providing a mixture of fluorescence energy transfer molecular oscillators and a DNA sample. The FET oscillator is a synthetic oligonucleotide that has a topoisomerase recognition sequence, a fluorescence donor and a fluorescence acceptor. The synthetic oligonucleotide is bound to a type I topoisomerase capable of binding to the topoisomerase recognition sequence. The mixture is irradiated at a wavelength of the fluorescence donor, and the emission is measured. Another variant of the disclosure is a probe for detecting DNA breaks utilizing a synthetic oligonucleotide comprising a topoisomerase recognition sequence, a fluorescence donor, and a nonradiative fluorescence quencher. Yet another variant of the disclosure is a probe for detecting DNA breaks utilizing a synthetic oligonucleotide comprising a topoisomerase recognition sequence, a fluorescence donor, and a fluorescence acceptor. The mixture is irradiated at a wavelength of the fluorescence donor; and the emission is measured. A method to detect DNA breaks may use these probes in a manner similar to that of the FET oscillator. The FET oscillators and probes are capable of being prepared in a kit formulation. | 02-12-2009 |
| 20090042206 | Multiplexed Analyses of Test Samples - The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. The described methods, devices, kits, and reagents facilitate the detection and quantification of a non-nucleic acid target (e.g., a protein target) in a test sample by detecting and quantifying a nucleic acid (i.e., an aptamer). The methods described create a nucleic acid surrogate for a non-nucleic acid target, thus allowing the wide variety of nucleic acid technologies, including amplification, to be applied to a broader range of desired targets, especially protein targets. The disclosure further describes aptamer constructs that facilitate the use of aptamers in a variety of analytical detection applications. | 02-12-2009 |
| 20090042207 | INTRACELLULAR EXPRESSION AND DELIVERY OF siRNAs IN MAMMALIAN CELLS - The present invention relates to compositions and methods for intracellular expression and delivery of siRNAs in mammalian cells. The siRNA is transcribed intracellularly as a double stranded RNA of about 18 to about 25 base pairs long from an expression cassette. Intracellular expression of siRNA is effective at reducing or eliminating expression of the targeted genes, and is applicable to reverse genetic analysis of genes and to genetic therapy, as for example to inhibiting expression of pathogenic genes and oncogenes. | 02-12-2009 |
| 20090047666 | Methods and nucleic acids for the analysis of colon proliferative disorders - The invention provides methods, nucleic acids and kits for detecting colon cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of and differentiation between said class of disorders, thereby enabling the improved diagnosis and treatment of patients. | 02-19-2009 |
| 20090047667 | Salivary transcriptome diagnostics - The present invention concerns probes and methods useful in diagnosing, identifying and monitoring the progression of disease states through measurements of gene products in saliva. | 02-19-2009 |
| 20090047668 | Novel method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same - A method for achieving site specific integration of a desired DNA at a target site in a mammalian cell via homologous recombination is described. This method provides for the reproducible selection of cell lines wherein a desired DNA is integrated at a predetermined transcriptionally active site previously marked with a marker plasmid. The method is particularly suitable for the production of mammalian cell lines which secrete mammalian proteins at high levels, in particular immunoglobulins. Novel vectors and vector combinations for use in the subject cloning method are also provided. | 02-19-2009 |
| 20090047669 | DNA recombination junction detection - The present invention provides methods, compositions and kits for detecting the presence or absence of an integrated insertion polynucleotide. | 02-19-2009 |
| 20090047670 | HYBRIDIZATION-BASED BIOSENSOR CONTAINING HAIRPIN PROBES AND USE THEREOF - A sensor chip that includes: a fluorescence quenching surface; a nucleic acid probe that contains first and second ends with the first end bound to the fluorescence quenching surface, and is characterized by being able to self-anneal into a hairpin conformation; and a first fluorophore bound to the second end of the first nucleic acid molecule. When the first nucleic acid molecule is in the hairpin conformation, the fluorescence quenching surface substantially quenches fluorescent emissions by the first fluorophore; and when the first nucleic acid molecule is in a non-hairpin conformation, fluorescent emissions by the fluorophore are substantially free of quenching by the fluorescence quenching surface. Various nucleic acid probes, methods of making the sensor chip, biological sensor devices that contain the sensor chip, and their methods of use are also disclosed. | 02-19-2009 |
| 20090047671 | SPECIFIC AND UNIVERSAL PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY COMMON BACTERIAL PATHOGENS AND ANTIBIOTIC RESISTANCE GENES FROM CLINICAL SPECIMENS FOR ROUTINE DIAGNOSIS IN MICROBIOLOGY LABORATORIES - The present invention relates to DNA-based methods for universal bacterial detection, for specific detection of the common bacterial pathogens | 02-19-2009 |
| 20090047672 | Telomerase RNA Subunit and Methods of Use Thereof - The present invention provides a novel telomere associated RNA (hTERC-2) that mediates the DNA repair function of telomerase. | 02-19-2009 |
| 20090047673 | Miniaturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids - The invention provides miniaturized lateral flow chromatographic and lateral flow chromatographic microarray devices (LFM). The miniaturization of lateral flow nucleic acid detection achieved by the present invention offers reduced reagent use, femtomole sensitivity, excellent linear dynamic range, and rapid detection. Moreover, the small feature sizes of capture oligonucleotides renders the potential information capacity of the platform comparable to more traditional spotted fluorescence microarrays as well as improving sensitivity. The LFM devices exemplified herein enable analytes to be detected within 10 seconds from the time of sample introduction to the LFM device. Sample volumes may be as low as about 10 microliters, significantly reducing assay costs and ameliorating reagent storage logistics. Additionally, the miniaturization of lateral flow opens the door to highly multiplexed assays, allowing many proteins or nucleic acids to be detected in a single assay. | 02-19-2009 |
| 20090047674 | METHOD FOR NUCLEIC ACID ISOLATION AND AMPLIFICATION - The present invention provides methods and compositions for sequence-specific isolation of polynucleotide molecules from nucleic acid populations and subsequent amplification of isolated polynucleotide molecules or fragments thereof. | 02-19-2009 |
| 20090047675 | Compositions and methods for indentifying transforming and tumor suppressor genes - Provided herein are nucleic acids, proteins, vectors, cells, kits, devices and methods useful for identifying regulatable proteins that are able to complement components of cellular signaling pathways. Also provided are compositions and methods using these complementing genes directly as markers for cancer diagnosis or prognosis and as targets for anti-neoplastic therapeutics. Further provided are methods for using changes caused by expression of the complementing genes to indirectly identify associated genes to be used as markers for cancer diagnosis or prognosis and as targets for anti-neoplastic therapeutics. | 02-19-2009 |
| 20090047676 | System and method for obtaining and maintaining high-resistance seals in patch clamp recordings - The invention provides a system, system components, and a method for rapidly obtaining and stably maintaining a cell in optimal contact with the cell-contacting surface of a sensor in a cell-based biosensor. In one aspect, the system maximizes the seal between a whole cell and the cell-contact surface of a patch clamp micropipette, maximizing the efficiency of a whole cell patch clamp recording. | 02-19-2009 |
| 20090047677 | METHODS FOR GENERATING A DISTRIBUTION OF OPTIMAL SOLUTIONS TO NONDETERMINISTIC POLYNOMIAL OPTIMIZATION PROBLEMS - The present invention overcomes problems in prior art DNA-based computing methods for solving non-deterministic polynomial optimization problems, by providing methods that derive the most probable answers in a statistically significant manner that makes the methods scalable with increases in the number of data inputs, and thus makes the methods practical. | 02-19-2009 |
| 20090047678 | ACCELERATED CASCADE AMPLIFICATION (ACA) OF NUCLEIC ACIDS COMPRISING STRAND AND SEQUENCE SPECIFIC DNA NICKING - Particular aspects provide nucleic acid amplification and detection methods comprising: providing a reaction mixture containing a target nucleic acid with an amplifiable target sequence, forward and reverse external nick-directing primers (ND-primers), at least one internal ND-primer, a strand-displacing DNA polymerase, a nick-directing endonuclease for strand-specific cleavage of ND-primer-extension products, and deoxynucleoside 5′-triphosphates; and incubating the reaction mixture with reagents, and under conditions suitable to provide for amplification of the amplifiable target sequence, wherein the amplification comprises primer extension, by least one internal ND-primer, of an external ND-primer extension product comprising the amplifiable target sequence or a portion thereof but lacking the respective external ND-primer sequence or a portion thereof. Preferably, amplification comprises using a plurality of internal ND-primers, extension of one internal ND-primer extension product by a different internal ND-primer, and amplification is isothermal and synergistic with respect to the number of primers employed. Amplification and detection kits are provided. | 02-19-2009 |
| 20090047679 | METHOD AND SYSTEM FOR ANALYZING REACTIONS USING AN INFORMATION SYSTEM - A method and system for determining the quantity of an analyte initially present in a chemical and or biological reaction as well as a computer implemented method and system to automate portions of the analysis comprising mathematical or graphical analysis of an amplification reaction. | 02-19-2009 |
| 20090047680 | METHODS AND COMPOSITIONS FOR HIGH-THROUGHPUT BISULPHITE DNA-SEQUENCING AND UTILITIES - The invention relates to novel methods and compositions to produce DNA templates suitable for chemical modifications and high-throughput DNA-sequencing. A method of the invention relates to a DNA adaptor design where constituent deoxycytosines are substituted with 5-methyl-deoxycytosines rendering the resulting adaptor resistant to bisulphite mediated deamination. When said adaptor is ligated onto double stranded DNA template, subsequent DNA denaturation and bisulphite treatment deaminates template DNA deoxycytosine differentially to deoxyuraeil whilst the 5-methyl-deoxycytosines of the ligated adaptor resist chemical conversion resulting in the adaptor sequence remaining unaltered. Both strands of bisulphite treated DNA can thus be amplified with a single primer set that hybridizes to the unaltered adaptor sequence. The invention also relates to methods to produce control template of a defined methylation composition to optimize conditions for the bisulphite reaction. In a preferred embodiment, the present invention can be used to produce templates suitable for genome-wide bisulphite-DNA sequencing using conventional, Solexa™, SOLiD™ or 454™-type DNA sequencing platforms to study DNA methylation. | 02-19-2009 |
| 20090047681 | ENTROPIC TRAPPING AND SIEVING OF MOLECULES - Nanofluidic entropic traps, comprising alternating thin and thick regions, sieve small molecules such as DNA or protein polymers and other molecules. The thick region is comparable or substantially larger than the molecule to be separated, while the thin region is substantially smaller than the size of the molecules to be separated. Due to the molecular size dependence of the entropic trapping effect, separation of molecules may be achieved. In addition, entropic traps are used to collect, trap and control many molecules in the nanofluidic channel. A fabrication method is disclosed to provide an efficient way to make nanofluidic constrictions in any fluidic devices. | 02-19-2009 |
| 20090047682 | Method of detecting and predicting bronchodilatory response to beta agonist - Present invention relates to a method for predicting an individual's bronchodilatory response to a β agonist. Present invention particularly relates to the detection of specific allelic variants of the β2AR gene and their use as pharmacogenetic markers towards response to β agonist. | 02-19-2009 |
| 20090047683 | CYANINE DYE COMPOUNDS - Cyanine dye compounds having a negatively charged substituent that are nucleic acid stains, particularly for fluorescent staining of DNA, including compounds having the formula | 02-19-2009 |
| 20090047684 | Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan - The present invention includes gene and protein expression profiles indicative of whether a cancer patient is likely to respond to treatment with irinotecan. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and/or protein expression profiles and assays for identifying the presence of a gene and/or protein expression profile in a patient sample. | 02-19-2009 |
| 20090053693 | Identification of polymorphisms in the epcr gene associated with thrombotic risk - The invention relates to an in vitro method for determining the risk of developing thrombosis in a subject, which method involves identifying a particular haplotype EPCR gene. | 02-26-2009 |
| 20090053694 | Photochemically Amplified Bioassay - In the present invention, a reagent capable of immunospecific reaction with the analyte of interest is conjugated to a photocatalytic microparticle. After the immunospecific binding has occurred, the assay amplification is performed by exposing photocatalytic particles to actinic UV light in presence of an oxidizable compound. Photocatalytic particles are catalyzing multiple occurrences of oxidation of oxidizable compound under UV light irradiation resulting in detectable changes such as color change. This provides for amplification of each single act of immunospecific binding and is followed by colormetric detection. Thus a high sensitivity quantitative or qualitative immunoassay can be realized. | 02-26-2009 |
| 20090053695 | Gene Marker and Use Thereof | 02-26-2009 |
| 20090053696 | Biomarker For Heart Failure - The present invention relates, in general, to heart failure, and, in particular, to a method of evaluating heart failure patients by monitoring β-adrenergic receptor kinase (βARK1) levels in lymphocytes from such patients. | 02-26-2009 |
| 20090053697 | Pharmacological Applications of Mitochondrial DNA Assays - The invention provides assays to determine the relative amount of mitochondrial DNA in a subject, such as a subject undergoing drug treatment. The subject may for example be a human patient undergoing treatment for an HIV infection with a nucleic acid precursor such as a nucleoside or nucleotide analogue. The assays of the invention may include PCR assays, such semi-quantitative or quantitative PCR involving the co-amplification of a mitochondrial sequence and a reference sequence, such as a genomic sequence. Information from such assays may be evaluated to provide a ratio of mithchondrial DNA to nuclear DNA in the cells of the subject. | 02-26-2009 |
| 20090053698 | METHOD FOR OBTAINING SUBTRACTION POLYNUCLEOTIDE - The present invention provides a method for obtaining or amplifying a polynucleotide (a tester-specific polynucleotide), in which an amount existing in a sample (tester) is larger than the amount existing in another sample (driver), easily and within a short time as well as with high efficiency, a polynucleotide obtained (amplified) by such method, a method for identifying gene mutation in the tester, and a kit to be used in such methods. | 02-26-2009 |
| 20090053699 | Method for Preparing Polynucleotides for Analysis - A method for analysing a target polynucleotide having distinct units of nucleic acid sequence comprising: (i) forming a first polynucleotide which is a concatemer having multiple repeating target polynucleotide sequences; (ii) forming on the first polynucleotide a second polynucleotide hybridised to a portion of one or more of the target polynucleotides, such that the portion hybridised, or the portion not hybridised, corresponds to a sequence unit on the target, and determining the sequence unit on the target. | 02-26-2009 |
| 20090053700 | Optical sorting method - The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalising genetic elements into microcapsules; (b) expressing the genetic elements to produce their respective gene products within the microcapsules; (c) sorting the genetic elements which produce the gene product having the desired activity using a change in the optical properties of the genetic elements. The invention enables the in vitro evolution of nucleic acids and proteins by repeated mutagenesis and iterative applications of the method of the invention. | 02-26-2009 |
| 20090053701 | Detectable nucleic acid tag - Provided herein are nucleic acid tags that are linked to, or capable of linking to, a protein of interest. In particular, the nucleic acid tags are oligonucleotides comprising a reporter function and a protein tagging function. Also provided herein, are nucleic acid tag compositions, kits and methods of use thereof. | 02-26-2009 |
| 20090053702 | SPECIFIC AND UNIVERSAL PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY COMMON BACTERIAL PATHOGENS AND ANTIBIOTIC RESISTANCE GENES FROM CLINICAL SPECIMENS FOR ROUTINE DIAGNOSIS IN MICROBIOLOGY LABORATORIES - The present invention relates to DNA-based methods for universal bacterial detection, for specific detection of the common bacterial pathogens | 02-26-2009 |
| 20090053703 | SPECIFIC AND UNIVERSAL PROBES AND AMPLIFICATION PRIMERS TO RAPIDLY DETECT AND IDENTIFY COMMON BACTERIAL PATHOGENS AND ANTIBIOTIC RESISTANCE GENES FROM CLINICAL SPECIMENS FOR ROUTINE DIAGNOSIS IN MICROBIOLOGY LABORATORIES - The present invention relates to DNA-based methods for universal bacterial detection, for specific detection of the common bacterial pathogens | 02-26-2009 |
| 20090053704 | STABILIZATION OF NUCLEIC ACIDS ON SOLID SUPPORTS - The present invention provides methods, compositions, and kits for the storage and stabilization of biological molecules. The methods comprise applying Tris(2-carboxyethyl)phosphine (TCEP) to at least one biological molecule bound to a solid substrate and storing in an organic solvent. Preferably, the biological molecules are nucleic acids. Compositions and kits for performing the process according to the invention are also provided. | 02-26-2009 |
| 20090053705 | METHODS FOR INCREASING ACCURACY OF NUCLEIC ACID SEQUENCING - The invention provides methods for improving the accuracy of a sequencing-by-synthesis reaction by sequencing at least a portion of a template and at least a portion of template complementary sequence. | 02-26-2009 |
| 20090053706 | DNA METHYLATION MARKERS ASSOCIATED WITH THE CPG ISLAND METHYLATOR PHENOTYPE (CIMP) IN HUMAN COLORECTAL CANCER - Particular aspects confirm the existence of a CpG island methylator phenotype (CIMP) in colorectal cancer, and provide novel validated DNA methylation markers associated with CIMP. Additional aspects provide novel methods and compositions for: determining CIMP status in colorectal cancers, determining the relationship between CIMP status and other molecular features of the cancers (e.g., BRAF mutation, KRAS mutation and MSI status); determining the relationship between CIMP status and other variables (e.g., age, sex, tumor location, family history, race, country of origin, tumor characteristics (including, tumor type, tumor grade, invasive margin characteristics, lymphocyte infiltration characteristics, direct spread, lymph node spread, venous spread and type of residual adjacent polyp, if present)); and determining, between subgroups defined by CIMP status and BRAF mutations, effects of selected risk factors (e.g., body mass index, smoking history, alcohol intake, dietary folate intake, folate metabolic enzyme polymorphisms and history of hormonal use). | 02-26-2009 |
| 20090053707 | Methods for lightening skin and hair - Methods are described wherein the skin of a vertebrate, or the skin or hair of a mammal can be lightened by administration of an agent, e.g., protein, peptide, active fusion protein, active fragment, or molecular mimic, that binds to BMP-4 transmembrane receptors on melanocytes and decreases the level of melanin synthesis. Also described are methods to identify molecules that mimic the function of BMP-4 in causing a decrease in melanin in melanocytes. | 02-26-2009 |
| 20090053708 | Method and/or Apparatus of Oligonucleotide Design and/or Nucleic Acid Detection - It is provided a method of designing at least one oligonucleotide for nucleic acid detection comprising the following steps in any order: (I) identifying and/or selecting region(s) of at least one target nucleic acid to be amplified, the region(s) having an efficiency of amplification (AE) higher than the average AE; and (II) designing at least one oligonucleotide capable of hybridizing to the selected region(s). It is also provided a method of detecting at least one target nucleic acid comprising the steps of: (i) providing at least one biological sample; (ii) amplifying nucleic acid(s) comprised in the biological sample; (iii) providing at least one oligonucleotide capable of hybridizing to at least one target nucleic acid, if present in the biological sample; and (iv) contacting the oligonucleotide(s) with the amplified nucleic acids and detecting the oligonucleotide(s) hybridized to the target nucleic acid(s). In particular, the method is for detecting the presence of at least one pathogen, for example a virus, in at least one human biological sample. The probes may be placed on a support, for example a microarray. | 02-26-2009 |
| 20090053709 | ENHANCED SENSITIVITY OF A CANTILEVER SENSOR VIA SPECIFIC BINDINGS - Detection of miniscule amounts of an analyte is accomplished via multiple bindings of specific materials on a sensor configured to sense mass. The sensor is prepared by immobilizing an antibody to a surface of the sensor, wherein the antibody is known to bind to the analyte. The prepared sensor is exposed to the analyte. The analyte binds to the antibody. The sensor then is exposed to additional antibody, which binds to the analyte. The sensor then can be sequentially exposed to additional antibodies that are known to bind to previously bound antibodies. Each additional binding further increases the effective mass of accumulated material on the sensor. The total effective mass is greater than the mass of the accumulated analyte, thus providing means for detecting extremely minute amounts of analyte. Applications include detection of pathogens and DNA. | 02-26-2009 |
| 20090053710 | FUNCTIONAL MOLECULE, FUNCTIONAL MOLECULE SYNTHESIZING AMIDITE AND TARGET SUBSTANCE ANALYSIS METHOD - To provide a functional molecule including a modified nucleotide unit having a substituent introduced to a base thereof, wherein the substituent is removably introduced to the base; a functional molecule synthesizing amidite that has a substituent removably introduced to its base and that is used for the manufacture of the functional molecule; and a target substance analysis method including: preparing a random pool of functional molecules using a functional molecule synthesizing amidite; screening a functional molecule having affinity for a target substance from the random pool; amplifying the functional molecules having affinity for the target substance, wherein the method further comprises, prior to the amplification step, removing a substituent from the functional molecule having affinity for the target substance. | 02-26-2009 |
| 20090053711 | PSEUDO-TISSUE FOR ACCURACY CONTROL, METHOD FOR CONTROLLING ACCURACY BY USING THE SAME, AND METHOD FOR MANUFACTURING THE SAME - The present invention provides a pseudo-tissue for accuracy control comprising a nucleic acid or cells, a holding body for holding the nucleic acid or cells, and a protecting body for covering at least a part of the surface of the holding body so as to protect the holding body. A method for controlling accuracy by using the pseudo-tissue, and a method for manufacturing the pseudo-tissue are also disclosed. | 02-26-2009 |
| 20090053712 | Methods of using LEDGF/p75 - The invention provides methods for diagnosing tumors in mammals using a reagent that bind to LEDGF/p75 or to a nucleic acid encoding LEDGF/p75. For example, the tumor may be located in the CNS, the prostate, the skin, the bone marrow, or the gut of the mammal. Also provided are methods for diagnosing brain tumors such as medulloblastomas, meningiomas, astrocytomas, glioblastomas multiforme, and ependymomas by examining LEDGF/p75 or a nucleic acid encoding LEDGF/p75 localization. The invention also involves methods for diagnosing cancers involving cancerous epithelial cells such as colon cancer. The instant invention also provides methods for isolating stem cells from a heterogeneous population of cells, as well as methods for identifying neuroepithelial stem cells, newly differentiated neurons, and astrocytes in a subject. Also provided are methods for inducing the differentiation of neuroepithelial stem cells into astrocytes or neurons and methods for screening candidate compounds that regulate the differentiation of neuroepithelial stem cells. | 02-26-2009 |
| 20090053713 | Isolated nucleic acids and polypeptides associated with glucose homeostasis disorders and method of detecting the same - An isolated and substantially pure nucleic acid sequence located between D20S119 and D20S178 on human chromosome 20q13, the nucleic acid sequence including: a nucleic acid sequence coding for a glucose transporting protein and having the sequence shown in SEQ ID NO: 1; or a nucleic acid sequence having at least 70% sequence identity with the nucleic acid sequence shown in SEQ ID NO: 1. The disclosed nucleic acid sequences map to a locus associated with human Type II diabetes mellitus and, therefore, therapeutic and diagnostic screening methods, which accommodate naturally and artificially occurring polymorphisms, are also disclosed. | 02-26-2009 |
| 20090053714 | Gins gene expression as marker for actively cycling cells and cell cycle phase - The invention relates to a method of detecting an actively cycling cell in a sample, said method comprising determining the state of GINS gene expression within said cell, wherein detection of GINS gene expression in said cell indicates that said cell is actively cycling. Furthermore, the invention relates to methods for detecting an actively cycling cell in a subject, said method comprising assaying a sample from said subject for evidence of GINS gene expression, in particular when the sample is a body fluid such as urine. Preferable the GINS gene is PSFI or SLD | 02-26-2009 |
| 20090053715 | Methods of screening nucleic acids for single nucleotide variations - Disclosed are methods and compositions for detecting variation in nucleic acids. The disclosed method compares the sequence of a nucleic acid of interest with the sequence of a reference nucleic acid to sensitively identify variations between the sequence of a nucleic acid of interest and the sequence of a reference nucleic acid. The disclosed method generally involves excision and replacement of selected nucleotides in nucleic acid strands hybridized to other strands. In the method, if the excised nucleotide was mismatched with the nucleotide in the other, hybridized strand, then the replacement nucleotide will not be mismatched. If the excised nucleotide was not mismatched with the nucleotide in the other, hybridized strand, then the excised nucleotide is not replaced. This difference allows detection of variation in the nucleic acid of interest. In some forms of the method, by replacing excised nucleotides with nuclease-resistant nucleotides, strands in which excised nucleotides are replaced will be resistant to nuclease digestion while strands in which excised nucleotides are not replaced will be sensitive to nuclease digestion. By exposing the hybridizing nucleic acids to nuclease following replacement of excised nucleotides, the strands in which excised nucleotides are not replaced can be destroyed by the nuclease while strands in which excised nucleotides are replaced can be preserved. The remaining strands can then be detected and whether the strand survived nuclease digestion can be noted. Strands that survive nuclease digestion are indicative of the presence of variation in the nucleic acid of interest. | 02-26-2009 |
| 20090053716 | METHOD OF DETECTING HUMAN CYTOCHROME P450 (CYP) 2D6 GENE MUTATION - A defect or multi-existence of a CYP2D6 gene is detected with a primer includes a complementary sequence to a sequence which is common between the CYP2D6 gene and a CYP2D8 gene but different from a CYP2D7 gene and which contains one or more of bases at the 86-, 90- and 93-positions in Exon | 02-26-2009 |
| 20090053718 | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs - The invention relates to ribonucleic acids and oligonucleotide probes useful for detection and analysis of microRNAs and their target mRNAs, as well as small interfering RNAs (siRNAs). The invention furthermore relates to oligonucleotide probes for detection and analysis of other non-coding RNAs, mRNAs, mRNA splice variants, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g. alterations associated with human disease, such as cancer. | 02-26-2009 |
| 20090053719 | ANALYSIS OF NUCLEIC ACIDS BY DIGITAL PCR - The present invention provides a method for analyzing nucleic acids for their lengths and relative abundance in a sample, based on digital amplification of individual template molecules. This invention has many applications, including those in noninvasive prenatal diagnosis, transplantation monitoring, and the detection and monitoring of cancers and virus-associated diseases. | 02-26-2009 |
| 20090053720 | SUPPRESSION OF AMPLIFICATION USING AN OLIGONUCLEOTIDE AND A POLYMERASE SIGNIFICANTLY LACKING 5'-3' NUCLEASE ACTIVITY - Methods and compositions for amplification of a target sequence by suppressing amplification of related sequences are provided. | 02-26-2009 |
| 20090053721 | VOLTAGE-GATED ION CHANNEL MUTANTS FOR USE IN IDENTIFYING ION CHANNEL MODULATING COMPOUNDS - The present invention provides novel methods and compositions for identifying ion channel modulating compounds, including atrial-selective antiarrhythmic agents and ion channel modulating compounds that preferentially modulate K | 02-26-2009 |
| 20090053723 | Peripherin and Neurofilament Light Protein Splice Variants in Amyotrophic Lateral Sclerosis (ALS) - Nucleotide sequences encoding novel splice variants of peripherin and neurofilament light protein, proteins encoded by the novel splice variants and antibodies thereto are disclosed. In addition, methods are described for detecting ALS in a subject suspected of having ALS, comprising detecting the presence or absence of the novel splice variants or resulting proteins or a change in the amount of the novel splice variants or resulting proteins; wherein the presence or change in the amount of the nucleotide sequence is indicative of ALS. | 02-26-2009 |
| 20090053724 | System and method for adaptive reagent control in nucleic acid sequencing - An embodiment of a method for adaptive reagent control is described that comprising a) introducing a first concentration of an enzyme reagent into a reaction environment with a reaction substrate, where the enzyme reagent and reaction substrate are constituent parts of a sequencing process; b) measuring a level of activity of the first concentration of the enzyme reagent in the reaction environment, where the level of activity comprises a measurable product of a reaction between the enzyme reagent and the reaction substrate; c) identifying an optimal concentration using the measured level of activity of the first concentration; and d) performing the sequencing process in the reaction environment using the optimal concentration of the enzyme reagent, where the sequencing process comprises an iterative series of sequencing reactions. | 02-26-2009 |
| 20090053725 | Using DNA aptamers and quantum dots for the detection of proteins or other targets - The solutions provided here use DNA aptamers and quantum dots for the detection of bacteria, viruses, proteins or other targets. An example of a method described here comprises: providing a complex of DNA complementary strands, one strand being an aptamer, having one strand covalently linked to a quantum dot, and having the other strand linked to a quencher; and contacting said complex of DNA complementary strands with a microorganism or components thereof, under conditions that permit binding of said aptamer with said microorganism or components thereof. In some examples described here, the methods and systems are extremely simple to use and appear to have several advantages over the traditional ELISA. Since no blocking steps are required and the number of washing steps is reduced, the time required to conduct the test is greatly reduced. In some examples described here, a quantum dot aptamer complex comprises one strand of a duplex DNA molecule linked to the quantum dot by an amide bond. It does not matter if the aptamer or the complimentary strand is attached. However, the strand that is not attached contains a non-radiative quencher. Upon addition of the aptamers' target, the amount of light emitted by the quantum dots increases. In some examples described here, the methods and systems can also be used in reverse, with the aptamers' target immobilized on a microtiter plate. This permits an assay like a competitive immuno-assay. | 02-26-2009 |
| 20090053726 | SYSTEMS AND METHODS FOR REAL-TIME PCR - In one aspect, the present invention provides a systems and methods for the real-time amplification and analysis of a sample of DNA. | 02-26-2009 |
| 20090053727 | Risk Assessment For Adverse Drug Reactions - The present invention provides a method of predicting the risk of a patient for developing adverse drug reactions, particularly SJS or TEN. It was discovered that an HLA-B allele, HLA-B* 1502, is associated with SJS/TEN that is induced by a variety of drugs. The correlation with HLA-B* 1502 is most significant for carbamazepine-induced SJS/TEN, wherein all the patients tested have the HLA-B* 1502 allele. In addition, another HLA-B allele, HLA-B*5801, is particularly associated with SJS/TEN induced by allopurinol. Milder cutaneous reactions, such as maculopapular rash, erythema multiforme (EM), urticaria, and fixed drug eruption, are particularly associated with a third allele, HLA-B *4601. For any of the alleles, genetic markers (e.g., HLA markers, microsatellite, or single nucleotide polymorphism markers) located between DRB1 and HLA-A region of the specific HLA-B haplotype can also be used for the test. | 02-26-2009 |
| 20090053728 | Analytical Method and Kit - Analytical methods using RNA probes for the detection or analysis of nucleic acid sequences is described. These probes are contacted with a sample suspected of containing the nucleic acid sequence and if they form duplexes, they are hydrolysed. This may be done, for example during an amplification reaction. AMP generated as a result of the hydrolysis is converted to ATP. The ATP may then be detected using bioluminescent reagents. | 02-26-2009 |
| 20090053729 | METHOD FOR DETECTION OF MUTANT GENE - Disclosed is a method for detecting mutation(s) in nucleotide sequence, which comprises performing a nucleic acid amplification reaction by using an oligonucleotide or a salt thereof as a primer and a nucleic acid in a sample as a template and detecting a reaction product, wherein the oligonucleotide is so modified at the nucleotide at the second position from the 3′-terminus as to inhibit the nucleic acid synthesis. Also disclosed is a kit for the method. According to the present invention, since it is possible to completely eliminate any false positive result in the determination and correspond to various mutation patterns by a single run of PCR1 reaction, it becomes possible to design a drug-resistance determination system, which can detect possible plural genetic mutations by a single run of multiplex PCR. | 02-26-2009 |
| 20090061421 | CRYSTAL STRUCTURE OF CMY-10, A BETA-LACTAMASE CAUSING ANTIBIOTIC RESISTANCE WITH EXTENDED-SUBSTRATE SPECTRUM - The present invention related to a method for crystallizing a CMY-10 being a β-lactamase with extended-substrate spectrum, a crystal of CMY-10, and a crystal structure of CMY-10. With utilization of three-dimensional structure of CMY-10 protein provided by the present invention, it is possible to develop novel antibiotics or inhibitors that can prevent an emergence of resistance bacteria appeared by plasmidic class C β-lactamases having extended-substrate specificity. | 03-05-2009 |
| 20090061422 | Diagnostic markers of breast cancer treatment and progression and methods of use thereof - To maximize both the life expectancy and quality of life of patients with operable breast cancer, it is important to predict adjuvant treatment outcome and likelihood of progression before treatment. The instant invention details the usage of a machine-learning based method to develop a cross-validated model to predict the outcome of adjuvant treatment, particularly chemotherapy treatment outcome, and likelihood of progression before treatment. The model includes standard clinicopathological features, as well as molecular markers collected using standard immunohistochemistry and fluorescence in situ hybridization. The model significantly outperformed the St. Gallen Consensus guidelines and the Nottingham Prognostic Index and has the potential to provide a clinically useful and cost-effective prognostic for breast cancer patients. | 03-05-2009 |
| 20090061423 | PHARMACOGENOMIC MARKERS FOR PROGNOSIS OF SOLID TUMORS - The present invention provides methods, systems and equipment for prognosis or evaluation of treatment of solid tumors. Gene markers that are prognostic of solid tumors can be identified according to the present invention. Each gene marker has altered expression patterns in PBMCs of solid tumor patients following initiation of an anti-cancer treatment, and the magnitudes of these alterations are correlated with clinical outcomes of these patients. In one embodiment, a Cox proportional hazards model is used to determine the correlations between clinical outcomes of RCC patients and gene expression changes in PBMCs of these patients during the course of a CCI-779 treatment. Non-limiting examples of genes identified by the Cox model are depicted in Tables 4A3 4B, 5 A and 5B. These genes can be used as surrogate markers for prognosis of RCC. They can also be used as pharmacogenomic indicators for the efficacy of CCI-779 or other anti-cancer drugs. | 03-05-2009 |
| 20090061424 | UNIVERSAL LIGATION ARRAY FOR ANALYZING GENE EXPRESSION OR GENOMIC VARIATIONS - The present invention provides an array system comprising a plurality of immobilized oligonucleotides comprising artificial sequences and a plurality of complementary ligation templates, as well as methods and kits for using the array system to analyze populations of nucleic acids. In particular, target nucleic acids are ligated to the immobilized oligonucleotides on the array in the presence of the complementary ligation templates. | 03-05-2009 |
| 20090061425 | Methods and kits for selectively amplifying, detecting or quantifying target DNA with specific end sequences - Disclosed herein are methods and kits for selectively amplifying, detecting or quantifying a DNA fragment with a specific end sequence, especially generated following restriction enzyme digestion. This method can be used, for example, to detect a hypomethylated DNA fragment. This methods and kits are especially useful in detecting or quantifying a hypomethylated fetal DNA fragment in a maternal plasma sample containing a corresponding hypermethylated maternal DNA fragment. | 03-05-2009 |
| 20090061426 | Binary signaling assay using a split-polymerase - The present invention provides methods, kits and compositions for the detection of an analyte. In the methods of the invention, a complex is formed between two or more analyte specific probes (ASP) and an analyte. The analyte specific probes each have a portion of a polymerase which interact to form a functional polymerase complex upon binding of the ASP to the analyte. The functional polymerase complex then generates a detectable signal which is indicative of the presence and/or amount of the analyte in the sample. | 03-05-2009 |
| 20090061427 | Gene Encoding Protein Responsible for Flocculation Property of Yeast and Use Thereof - The present invention relates to a gene encoding a protein responsible for flocculation property of yeast and use thereof in particular, a brewery yeast with appropriate flocculation property for producing desired alcoholic beverages, alcoholic beverages produced with said yeast, and a method for producing said beverages. More particularly, the present invention relates to a yeast to which suitable flocculation property for brewing desired alcoholic beverages was imparted by controlling expression level of HSP150 gene encoding a protein responsible for flocculation property of brewery yeast, especially non-ScHSP150 gene specific to a lager brewing yeast, to alcoholic beverages produced with said yeast and to a method for producing said beverages. | 03-05-2009 |
| 20090061428 | Thermal Reaction Device and Method for Using the Same - An M times.N matrix microfluidic device for performing a matrix of reactions, the device having a plurality of reaction cells in communication with one of either a sample inlet or a reagent inlet through a via formed within an elastomeric block of the device. Methods provided include a method for forming vias in parallel in an elastomeric layer of an elastomeric block of a microfluidic device, the method comprising using patterned photoresist masks and etching reagents to etch away regions or portions of an elastomeric layer of the elastomeric block. | 03-05-2009 |
| 20090061429 | Reactive surfaces, substrates and methods of producing and using same - Reactive surfaces, substrates and methods of producing and using such substrates and surfaces are provided. The substrates and surfaces provide low density reactive groups preferably on an otherwise non-reactive surface for use in different applications including single molecule analyses. | 03-05-2009 |
| 20090061430 | Reactive surfaces, substrates and methods of producing and using same - Reactive surfaces, substrates and methods of producing and using such substrates and surfaces are provided. The substrates and surfaces provide low density reactive groups preferably on an otherwise non-reactive surface for use in different applications including single molecule analyses. | 03-05-2009 |
| 20090061431 | Method of prognosing and diagnosing hereditary spastic paraplegia, mutant nucleic acid molecules and polypeptides - A method for diagnosing the presence of hereditary spastic paraplegia (HSP) or predicting the risk of developing HSP in a human subject, comprising detecting the presence or absence of a defect in a gene encoding a polypeptide comprising the sequence of FIG. | 03-05-2009 |
| 20090061432 | CSPCNA ISOFORM MODIFICATIONS AND USES THEREOF - Methods and compositions to detect the presence of csPCNA isoform by identifying one or more posttranslational modifications are disclosed. Methods to identify csPCNA isoform through posttranslational modifications including methylesterification levels are disclosed. | 03-05-2009 |
| 20090061433 | NUCLEOTIDE PRIMER SET AND NUCLEOTIDE PROBE FOR DETECTING GENOTYPE OF SERUM AMYLOID A1(SAA1) - Provided is a LAMP-amplification nucleotide primer set for detection of the genotype of single nucleotide polymorphisms C-13T, C2995T and T3010C of the SAA1 gene. Also provided is a nucleotide probe for detection of the amplification product amplified with the primer set according to the present invention. Further provided is a method of detecting the genotype of the single nucleotide polymorphisms C-13T, C2995T and T3010C of the SAA1 gene by using the primer set according to the present invention. | 03-05-2009 |
| 20090061434 | PRIMER COMPOSITION AND A KIT USEFUL FOR THE IDENTIFICATION OF PHYLLANTHUS - The present invention relates to an oligonucleotide primer set useful for the identification of | 03-05-2009 |
| 20090061435 | Methods and compositions for rapid amplification, capture and detection of nucleic acids and proteins - A method for detecting the presence of a nucleic acid template ( | 03-05-2009 |
| 20090061436 | PEPTIDE SEQUENCE THAT PROMOTES TUMOR INVASION - An isolated sequence SGSSEEKQNAVSSEET (OPNcPEP) SEQ ID NO: 8, and uses thereof. The peptide enhanced soft agar clone formation but did not support the growth of cells in plastic dishes, consistent with supporting anchorage-independence rather than growth. This sequence represented and is unique for a domain around the splice junction of OPN variant -c (OPN-c). OPN-c was expressed in a variety of tumor cell lines, but not in normal tissues (e.g., non-cancerous tissue) or in benign tumors. OPN-c antibody may be administered to a patient with a cancer associated with OPN-c expression to prevent the formation and growth of metastases. OPN-c may be used as a diagnostic to determine whether a patient has a malignant, rather than a benign, growth. OPN-c may be used to detect or identify agents that inhibit or mimic OPN-c expression or activity. | 03-05-2009 |
| 20090061437 | Nucleotide Analogs - The invention provides for nucleotide analogs and methods of using the same, e.g., for sequencing nucleic acids. | 03-05-2009 |
| 20090061438 | DETECTION OF MICROSATELLITE INSTABILITY AND ITS USE IN DIAGNOSIS OF TUMORS - Methods and kits are disclosed for use in the analysis of microsatellite instability in genomic DNA. Methods and kits are also disclosed which can be used to detect microsatellite instability DNA present in biological materials, such as tumors. The methods and kits of the present invention can be used to detect or diagnose diseases associated with microsatellite instability, such as certain types of cancer. | 03-05-2009 |
| 20090061439 | Methods and Compositions for Sequencing A Nucleic Acid - The invention provides nucleotide analogs and methods of using them in sequencing reactions. | 03-05-2009 |
| 20090061440 | METHOD FOR AMPLIFYING PLURAL NUCLEIC ACID SEQUENCES FOR DISCRIMINATION - The invention provides a method with fewer distribution of the amount of amplification among plural tags when the plural tags are used for multiplex detection using the tag. | 03-05-2009 |
| 20090061441 | EPIGENETIC SILENCING OF CYCLOOXYGENASE-2 AFFECTS CLINICAL OUTCOME IN GASTRIC CANCER - The present invention discloses methods of using the methylation status of the COX-2 gene promoter region as a biomarker for a gastric cancer patient to determine a prognosis and a treatment regimen, and to monitor the progress of a treatment regimen. | 03-05-2009 |
| 20090061442 | Screening assay to identify non-ATP-competitors targeting protein kinase A - Methods for screening compounds for their activity as a protein kinase A modulators are provided. The methods are based on fluorescence polarization of peptide probes to identify drug candidates that act by activating or inhibiting the catalytic function of PKA. In certain embodiments, the methods are adapted for high throughput screening. | 03-05-2009 |
| 20090061443 | Diagnostic and Therapeutic Targets for Leukemia - The present invention relates to methods of identifying candidate compounds for the treatment of leukemia and diagnostic methods based on histone methylation and HoxA5 promoter activity. | 03-05-2009 |
| 20090061444 | PHYTOCHROME-BASED FLUOROPHORES - Genetically-engineered fluorophore molecules with increased fluorescence are provided. These fluorophores are derived from the domains of phytochromes, and in particular bacterial phytochromes. Methods for generating these fluorophores and various applications of these fluorophores are also provided. | 03-05-2009 |
| 20090061445 | FLUX BALANCE ANALYSIS WITH MOLECULAR CROWDING - Methods are provided herein for: calculating cell growth rates in various environments and genetic backgrounds; calculating the order of substrate utilization from a defined growth medium; calculating metabolic flux reorganization in various environments and at various growth rates; and calculating the maximum metabolic rate and optimal metabolite concentrations and enzyme activities by applying a computational optimization method to a kinetic model of a metabolic pathway. The optimization methods use intracellular molecular crowding parameters and/or well as kinetic rates to assist in modeling metabolic activity. | 03-05-2009 |
| 20090061446 | METHOD FOR QUICKLY IDENTIFYING PATHOGENIC BACTERIA RESPONSIBLE FOR INFECTION - A system rapidly detects and identifies pathogenic bacteria responsible for infection (particularly septicemia), and selects an appropriate antimicrobial drug. A method according to the present invention for detecting and identifying pathogenic bacteria includes performing gene amplification such as real-time PCR, and analyzing the combination of the melting temperatures (Tm values) determined by gene amplification product melting curve analysis or the difference between the Tm values. Specifically, real-time PCR is performed using 4 to 16 primer sets including 1 to 7 primer sets for the 16S ribosomal RNA of bacteria, 1 to 6 primer sets for the 18S ribosomal RNA of fungi, and one primer set respectively for the spa gene and the mecA gene specific to MRSA, and the combination of the Tm values of the amplification product or the combination of the differences between the Tm values is compared with a database to identify pathogenic bacteria responsible for septicemia. Pathogenic bacteria responsible for infection (particularly septicemia) can be rapidly detected and identified using the method according to the invention so that a rapid septicemia diagnosis method and evidence-based medicine in septicemia treatment are implemented. | 03-05-2009 |
| 20090061447 | HIGH SPEED PARALLEL MOLECULAR NUCLEIC ACID SEQUENCING - A method and device is disclosed for high speed, automated sequencing of nucleic acid molecules. A nucleic acid molecule to be sequenced is exposed to a polymerase in the presence of nucleotides which are to be incorporated into a complementary nucleic acid strand. The polymerase carries a donor fluorophore, and each type of nucleotide (e.g. A, T/U, C and G) carries a distinguishable acceptor fluorophore characteristic of the particular type of nucleotide. As the polymerase incorporates individual nucleic acid molecules into a complementary strand, a laser continuously irradiates the donor fluorophore, at a wavelength that causes it to emit an emission signal (but the laser wavelength does not stimulate the acceptor fluorophore). In particular embodiments, no laser is needed if the donor fluorophore is a luminescent molecule or is stimulated by one. The emission signal from the polymerase is capable of stimulating any of the donor fluorophores (but not acceptor fluorophores), so that as a nucleotide is added by the polymerase, the acceptor fluorophore emits a signal associated with the type of nucleotide added to the complementary strand. The series of emission signals from the acceptor fluorophores is detected, and correlated with a sequence of nucleotides that correspond to the sequence of emission signals. | 03-05-2009 |
| 20090061448 | METHOD FOR IDENTIFYING OCULOSKELETAL DYSPLASIA IN DOGS - Provided are methods for identifying dogs as likely to be genetically normal, carriers of, or affected with Oculo-skeletal dysplasia (OSD) by determining the presence or absence of a drd2 COL9A2 mutation and/or a drd1 COL9A3 mutation. Also provided is a method for selective breeding of dogs and kits useful for carrying out the methods of the invention. | 03-05-2009 |
| 20090061449 | SYSTEMS AND METHODS FOR PROCESSING HYBRID SEED - The present disclosure provides for systems and method for producing hybrid seed. In various embodiments, the disclosure provides a system for the high-throughput, nondestructive sampling of seeds. In another embodiment, a high-throughput, nondestructive method for producing hybrid seeds comprises removing a sample from a plurality of seeds in the population while preserving the germination viability of the seed and analyzing the sample for the presence or absence of one or more genetic markers indicative of a male-sterile gene. | 03-05-2009 |
| 20090061450 | SYSTEM AND METHOD FOR DIAGNOSIS OF INFECTIOUS DISEASES - A biosafe apparatus is disclosed for assay and diagnosis of respiratory pathogens comprising a nasal sampling device, a single entry, disposable microfluidic cartridge for target nucleic acid amplification, and an instrument with on-board assay control platform and target detection means. | 03-05-2009 |
| 20090061451 | BIOSENSORS AND RELATED METHODS - Provided herein are biosensors that comprise a biological signal source linked to a substrate by a peptide nucleic acid spacer and methods of use of the biosensor. In one embodiment, the biosensor is used to detect prostate-specific antigen. | 03-05-2009 |
| 20090061452 | Polymorphisms in the human genes for OCT 1 and their use in diagnostic and therapeutic applications - The present invention relates to a polymorphic OCT1 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit. | 03-05-2009 |
| 20090061453 | Methods and compositions for detecting colon cancers - This application describes methods and compositions for detecting and treating HLTF-associated neoplasia. Differential methylation of the HLTF nucleotide sequences has been observed in HLTF-associated neoplasia such as colon neoplasia. | 03-05-2009 |
| 20090061454 | DIAGNOSTIC AND PROGNOSTIC METHODS FOR LUNG DISORDERS USING GENE EXPRESSION PROFILES FROM NOSE EPITHELIAL CELLS - The present invention provides methods for diagnosis and prognosis of lung cancer using expression analysis of one or more groups of genes, and a combination of expression analysis from a nasal epithelial cell sample. The methods of the invention provide far less invasive method with a superior detection accuracy for lung cancer when compared to any other currently available method for lung cancer diagnostic or prognosis. The invention also provides methods of diagnosis and prognosis of other lung diseases, such as lung cancer. | 03-05-2009 |
| 20090068641 | Highly conserved genes and their use to generate probes and primers for detection of microorganisms - Four highly conserved genes, encoding translation elongation factor Tu, translation elongation factor G, the catalytic subunit of proton-translocating ATPase and the RecA recombinase, are used to generate species-specific, genus-specific, family-specific, group-specific and universal nucleic acid probes and amplification primers to rapidly detect and identify algal, archaeal, bacterial, fungal and parasitical pathogens from clinical specimens for diagnosis. The detection of associated antimicrobial agents resistance and toxin genes are also under the scope of the present invention. | 03-12-2009 |
| 20090068642 | Composition and pharmacology of novel alpha6-containing nicotinic acetylcholine receptors - Nicotinic acetylcholine receptors (nAChRs) comprising the α6 receptor subunit; nucleic acids, including vectors, comprising subunit incoding sequences; cells expressing the nAChRs of the invention; and methods of screening compounds are provided. | 03-12-2009 |
| 20090068643 | Dual Function Primers for Amplifying DNA and Methods of Use - The present invention provides novel nucleotide compositions that enable the detection of DNA synthesis products and methods for use thereof. In one embodiment, the method can be used in PCR and allows the progress of the reaction to be monitored as it occurs. In one embodiment, the invention employs at least one fluorescence-quenched oligonucleotide that can prime DNA extension reactions. In a second embodiment, the invention employs at least one fluorescence-quenched oligonucleotide that can function as a template for DNA extension reactions. In both embodiments, the oligonucleotide also functions as a probe for detecting the progress of successive extension reaction cycles. Signal detection is dependent upon DNA synthesis and can occur with or without probe cleavage. | 03-12-2009 |
| 20090068644 | METHOD FOR PRODUCING HIGHLY SENSITIVE ENDONUCLEASES, NOVEL PREPARATIONS OF ENDONUCLEASES AND USES THEREOF - The present invention pertains to methods for producing recombinant endonucleases having a high sensitivity, as well as to endonucleases preparations obtained by said methods, and uses thereof, especially for the detection of mismatches. | 03-12-2009 |
| 20090068645 | Labeling and Sequencing of Nucleic Acids - The invention provides for methods of end labelling a ds DNA molecule with a bar-code as well as adaptor mediated methodology for creating single stranded overhanging ends, lengthening single stranded overhanging ends, controlled size reduction of labelled ds DNA molecules, and adaptor mediated sequencing. Also disclosed are methods for parallel sequencing of multiple ds DNA molecules in a mixture by visual means. | 03-12-2009 |
| 20090068646 | METHODS AND KITS FOR DETECTING MUTATIONS - Disclosed are methods and kits for detecting mutations in DNA by comparing the size of an amplified microsatellite locus to the expected size. The methods and kits may used in various applications, including monitoring exposure of a cell or organism to a mutagen, evaluating the mutagenicity of an agent, and evaluating a putative precancerous or cancerous cell or tumor cell for microsatellite instability. | 03-12-2009 |
| 20090068647 | Dna sequences for the detection of and differentiation amongst pathogenic e.coli - Oligonucleotide sequences and methods for specifically detecting and differentiating amongst pathogenic | 03-12-2009 |
| 20090068648 | Method and system for determining a quality metric for comparative genomic hybridization experimental results - Various embodiments of the present invention determine various quality metrics that reflect the quality of two or more identically-executed or similar array-based comparative-genomic-hybridization (“aCGH”) experiments. In certain embodiments of the present invention, a pairwise quality metric is generated for each possible pair of aCGH experimental results within a set of aCGH experimental results. The pairwise quality metrics may be summed and optionally normalized to produce an overall quality metric for the set of aCGH experimental results. Various pairwise quality metrics can be used in different embodiments of the present invention, including pairwise quality metrics based on measures of aberration overlap. | 03-12-2009 |
| 20090068649 | Methods of DNA Methylation Detection - The present invention provides for methods of DNA methylation detection. The present invention provides for methods of generating and detecting specific electronic signals that report the methylation status of targeted DNA molecules in biological samples. | 03-12-2009 |
| 20090068650 | Metabolic Primers for the Detection of (Per) Chlorate-Reducing Bacteria and Methods of Use Thereof - The present invention is directed to metabolic primers for the detection of (per)chlorate-reducing bacteria and methods and compositions for use of the same in environmental bioremediation. | 03-12-2009 |
| 20090068651 | Method for the detection of the antibiotic resistance spectrum of mycobacterium species - Method for the detection of the antibiotic resistance spectrum of | 03-12-2009 |
| 20090068652 | Method for identifying the sequence of one or more variant nucleotides in a nucleic acid molecule - The invention relates to methods for identifying the sequence of one or more variant nucleotides in a nucleic acid molecule. The method involves cleaving a double-stranded nucleic acid molecule containing a mismatch with a mismatch-specific endonuclease which cleaves on the 3′ side of the mismatch, and preserving the integrity of the variant nucleotide by ligating a double-stranded linker with a 3′-overhang to said variant nucleotide. Because the variant nucleotide is immediately adjacent to the linker, PCR and/or sequence-by-synthesis analysis can be readily carried out. | 03-12-2009 |
| 20090068653 | BIOCHEMICAL AND GENETIC ANALYSIS FOR PREDICTION OF BREAST CANCER RISK - The present invention provides new methods for the assessment of cancer risk in the general population. These methods utilize particular alleles of three selected genes, here associated with specific biochemical activities, to identify individuals with increased or decreased risk of breast cancer. Using such methods, it is possible to reallocate healthcare costs in cancer screening to patient subpopulations at increased cancer risk and to identify candidates for cancer prophylactic treatment. | 03-12-2009 |
| 20090068654 | ASSAY FOR IDENTIFYING COMPOUNDS WHICH AFFECT STABILITY OF MRNA - The present invention relates to an assay for the identification of biologically active compounds, in particular to a reporter gene assay for the identification of compounds, which have an effect on mRNA stability. More particularly, the present invention relates to a reporter gene expression system and cell lines comprising said expression system. The invention further relates to compounds which destabilise mRNA. | 03-12-2009 |
| 20090068655 | COMPOSITION AND METHOD FOR NUCLEIC ACID SEQUENCING - The present invention provides compositions and methods for detecting incorporation of a labeled nucleotide triphosphate onto the growing end of a primer nucleic acid molecule. The method is used, for example, to genotype and sequence a nucleic acid. In a preferred embodiment, the method described herein detects individual NTP molecules. | 03-12-2009 |
| 20090068656 | Methods of diagnosing osteoarthritis - A method of diagnosing osteoarthritis in a mammal is provided comprising the steps of obtaining a biological sample from the mammal; and quantifying in the sample the expression of at least one chondrocyte-specific gene or gene product, wherein a differential in expression of said gene or gene product in comparison with expression of said gene or gene product in a non-osteoarthritic mammal is indicative of osteoarthritis. | 03-12-2009 |
| 20090068657 | METHOD OF PREDICTING THE CLINICAL RESPONSE TO CISPLATIN OR CARBOPLATIN CHEMOTHERAPEUTIC TREATMENT - Method for predicting the survival of a patient suffering from NSCLC to a cisplatin or carboplatin based chemotherapy treatment which comprises the step of determining the methylation state of a nucleic acid encoding 14-3-3 sigma in a biological sample from the patient, wherein the presence of methylation is indicative of longer survival of said patient as a response to said chemotherapy treatment. The methylation status of the 14-3-3 sigma gene can be easily determined in a serum sample. | 03-12-2009 |
| 20090068658 | Soybean mutant strain and soybean oil therefrom - A soybean oil of a decreased content of polyunsaturated fatty acids is produced by hybridizing, selecting and raising a soybean mutant KK21 characterized by a gene having a sequence of base given by the sequence No. 1 of the sequence listing, a soybean mutant M23 characterized by deletion of a gene having a sequence of base given by the sequence No. 2 of the sequence listing, a soybean mutant M24 characterized by a gene having a sequence of base given by the sequence No. 3 of the sequence listing, a soybean mutant M5 characterized by a gene having a sequence of base given by the sequence No. 4 of the sequence listing, a soybean mutant J18 characterized by deletion of a gene having a sequence of base given by the sequence No. 5 of the sequence listing, and one or two kinds or more of these soybean mutants. | 03-12-2009 |
| 20090068659 | Method for identifying the sequence of one or more variant nucleotides in a nucleic acid molecule - The invention relates to methods for identifying the sequence of one or more variant nucleotides in nucleic acid molecules. The method involves cleaving a double-stranded nucleic acid molecule containing a mismatch with a mismatch-specific endonuclease which cleaves on the 3′ side of the mismatch, and preserving the integrity of the variant nucleotide by ligating a Double-Stranded Linker with a degenerate 3′-overhang to said variant nucleotide. Because the variant nucleotide is immediately adjacent to the linker, PCR and/or sequence-by-synthesis analysis can be readily carried out. | 03-12-2009 |
| 20090068660 | USE OF METHYLATED OR UNMETHYLATED LINE-1 DNA AS A CANCER MARKER - The invention relates to a method of detecting LINE-1 (long interspersed nucleotide elements-1) DNA either methylated or unmethylated at the promoter region in a tissue or body fluid sample from a subject. Also disclosed are methods of using LINE-1 DNA as a biomarker for diagnosing, predicting, and monitoring cancer progression and treatment. | 03-12-2009 |
| 20090068661 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof. | 03-12-2009 |
| 20090068662 | METHOD AND TEST KIT FOR THE SEPARATION, PURIFICATION AND RECYCLING OF LONG- AND SHORT-CHAIN NUCLEIC ACIDS - Long- and/or short-chain nucleic acids are separated, purified and recovered by binding the nucleic acid to a solid phase using a binding buffer, to obtain a bonded nucleic acid, and eluting of the bonded nucleic acid from the solid phase, wherein the binding buffer comprises at least one citric acid salt and at least one alcohol. | 03-12-2009 |
| 20090068663 | SCREENING METHODS AND SEQUENCES RELATING THERETO - A screening method for identifying an individual having a pre-disposition towards having a cancer is disclosed, which screening method comprises the steps of:
| 03-12-2009 |
| 20090068664 | AMPLIFICATION METHODS AND COMPOSITIONS - The present invention provides methods and routines for developing and optimizing nucleic acid detection assays for use in basic research, clinical research, and for the development of clinical detection assays. In particular, the present invention provides methods for designing oligonucleotide primers to be used in multiplex amplification reactions. The present invention also provides methods to optimize multiplex amplification reactions. | 03-12-2009 |
| 20090068665 | METHODS AND KITS FOR IDENTIFYING TARGET NUCLEOTIDES IN MIXED POPULATIONS - Ligation-based methods and kits are disclosed for identifying at least two target nucleotides in a mixed population sample that is a sample that contains or potentially contains target nucleic acid sequences from more than one source. Typically, two ligation reaction compositions are formed ligation products generated, and the ligation products or their surrogates are analyzed to identify target nucleotides in the mixed population sample. In certain embodiments, the target nucleic acid sequences, the ligation products, or both are amplified. In certain embodiments, multiplex amplification and/or ligation reactions are performed. | 03-12-2009 |
| 20090068666 | Systems and Methods for Determining an Amount of Starting Reagent using the Polymerase Chain Reaction - Systems and methods for calculating an initial amount of target nucleic acid N | 03-12-2009 |
| 20090068667 | METHODS AND ASSAYS FOR SCREENING STEM CELLS - The present invention provides methods and assays for screening cells, such as stem cells, for chromosomal aberrations. In particular, the present invention provides a rapid, sensitive assay platform for detecting high and low levels of chromosomal aberrations present in a cell population. This includes, but is not limited to, detection of extra chromosomes (trisomies) as well as insertions of small segments that are undetectable using standard cytogenetic studies, wherein the abnormal cells comprise a low percentage of the total cell population. | 03-12-2009 |
| 20090068668 | Waveguide-Based Optical Scanning Systems - A scanning sensor system, methods of use and kits for detecting a biologically active analyte are provided. The scanning sensor system includes a light source, a detector, a substrate comprising a plurality of waveguides and a plurality of optical sensing sites in optical communication with one or more waveguide of the substrate, and at least one adapter configured to couple with the substrate and provide optical communication between the light source, the waveguides of the substrate, and the detector. | 03-12-2009 |
| 20090068669 | SLC9A3R1 DIRECTED DIAGNOSTICS FOR NEOPLASTIC DISEASE - Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of SLC9A3R1 in the test cell sample or fluid sample as compared to the level of expression of SLC9A3R1 in a control cell sample or fluid sample isolated from a normal subject. | 03-12-2009 |
| 20090068670 | STRATIFIN DIRECTED DIAGNOSTICS FOR NEOPLASTIC DISEASE - Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of stratifin in the test cell sample or fluid sample as compared to the level of expression of stratifin in a control cell sample or fluid sample isolated from a normal subject. | 03-12-2009 |
| 20090068671 | Binding method and apparatus for sorting objects - The present invention relates to a method and apparatus of sorting objects including, providing a sample having wanted objects and unwanted objects; coating a surface of a sample holder with an antibody; placing an eluted sample on the sample holder; binding an antigen in the wanted objects with the antibody on the surface of the sample holder to sort the objects into wanted objects and unwanted objects; separating the wanted objects; and performing PCR-based STR analysis on the wanted objects. In one embodiment, holographic optical trapping is used to further sort the wanted objects. In other embodiments, the wanted objects are sperm and the antibody is a human sperm specific antibody, and the PCR is single cell PCR-based STR analysis. In still other embodiments, the binding is direct or indirect, ligands are used to bind to object-specific organomolecules, and protein A or protein G are used to bind the antibody. | 03-12-2009 |
| 20090068672 | DETECTION SYSTEM - The use of a red nucleic acid stain, in particular red fluorescent SYTO® dye in various methods used for the detection or characterisation of nucleic acids is described. In particular, the red nucleic acid stains have been found to be particularly compatible with the polymerase chain reaction (PCR), and therefore form the basis of enhanced detection methods. | 03-12-2009 |
| 20090068673 | UTILIZATION OF COMPATIBLE SOLUTES TO IMPROVE THE PERFORMANCE OF THE TECHNIQUES USING IMMOBILIZED BIOLOGIC MATERIALS - This invention is based upon the application of compatible solutes to immobilized biological materials or to immobilize in order to improve the technical performance using the same, namely nucleic acid and proteins or biosensors micronets. The above mentioned compatible solutes are selected from a group that includes Mannosylglycerate (MG) and its 3 derivatives manno-sylglyceramide (MGA), -mannosylglycerol (MGOH), and mannosyl-lactate (MGLac), 1,1-di-glycerol phosphate (DGP), ectoin, hydroxyectoin, and or derivatives or combinations thereof. The improved performance of the above mentioned techniques might be due to: a better state of preservation of the material to be immobilized, increasing the life expectancy of the material, and/or decreasing the storage and/or transport requirements, a more efficient and uniform deposition of the material on the support, more efficiency and/or specificity of hybridation of the marked material, all this originating an increase of the signal-to-noise ratio. | 03-12-2009 |
| 20090068674 | Method and device for preparing a sample of biological origin in order to determine at least one constituent contained therein - The invention relates to a method of preparing an original sample ( | 03-12-2009 |
| 20090068675 | Methods for improved diagnosis of dysplasias - The present invention relates to a method for improved diagnosis of dysplasias based on simultaneous detection of INK4a gene products and at least one marker for cell proliferation. Particularly the present invention provides a method for discriminating dysplastic cells over-expressing INK4a gene products from cells over-expressing INK4a gene products without being dysplastic by detection of a marker suitable for characterising the proliferation properties of the respective cell. The characterisation of the proliferation properties may comprise the detection of a marker or a set of markers characteristic for active cell proliferation and/or a marker or a set of markers characteristic for retarded or ceased cell proliferation. The method presented herein thus enables for a specific diagnosis of dysplasias in histological and cytological specimens. | 03-12-2009 |
| 20090075251 | Method for analysis of cytosine methylation - A method for the analysis of cytosine methylations in DNA is described. Here, the DNA to be investigated is first chemically or enzymatically converted. Then a promoter is introduced into the DNA. After this, the DNA is converted to RNA. The methylation pattern of the DNA can be concluded in different ways by means of an analysis of the RNA. The RNA is preferably fragmented chemically or enzymatically prior to the analysis, whereby the fragmenting results depend on the methylation pattern of the DNA. The method according to the invention is particularly suitable for the diagnosis and prognosis of cancer disorders and other diseases associated with a modification of the methylation pattern. | 03-19-2009 |
| 20090075252 | Methods for increasing accuracy of nucleic acid sequencing - The invention provides methods for improving the fidelity of a sequencing-by-synthesis reaction by resequencing at least a portion of a nucleic acid template. | 03-19-2009 |
| 20090075253 | BIOREACTIVE AGENTS - This invention relates to agents and conjugates that can be used to detect and isolate target components from complex mixtures such as nucleic acids from biological samples, cells from bodily fluids, and nascent proteins from translation reactions. Agents comprise a detectable moiety bound to a photoreactive moiety. Conjugates comprise agents coupled to substrates by covalent bounds which can be selectively cleaved with the administration of electromagnetic radiation. Targets substances labeled with detectable molecules can be easily identified and separated from a heterologous mixture of substances. Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered. Using photocleavable molecular precursors as the conjugates, label can be incorporated into macromolecules, the nascent macromolecules isolated and the label completely removed. The invention also relates to targets isolated with these conjugates which may be useful as pharmaceutical agents or compositions that can be administered to humans and other mammals. Useful compositions include biological agents such as nucleic acids, proteins, lipids and cytokines. Conjugates can also be used to monitor the pathway and half-life of pharmaceutical composition in vivo and for diagnostic, therapeutic and prophylactic purposes. The invention also relates to kits comprised of agents and conjugates that can be used for the detection of diseases, disorders and nearly any individual substance in a complex background of substances. | 03-19-2009 |
| 20090075254 | PHYSIOGENOMIC METHOD FOR PREDICTING DIABETES AND METABOLIC SYNDROMES INDUCED BY PSYCHOTROPIC DRUGS - The invention is generally directed to a physiogenomic method for predicting diabetes and metabolic syndromes induced by psychotropic drugs. In one embodiment, the invention relates to the use of genetic variants of marker genes to predict the likelihood that an individual will experience undesirable metabolic side effects as a result of the use of a drug including, but not limited to, psychotropic drugs. The invention also relates to methods predicting the likelihood of diabetes and metabolic syndromes induced by the use of drugs with undesirable metabolic side effects. | 03-19-2009 |
| 20090075255 | Androgen regulated nucleic acid molecules and encoded proteins - The present invention provides novel androgen regulated nucleic acid molecules. Related polypeptides and diagnostic methods also are provided. | 03-19-2009 |
| 20090075256 | Nucleic Acid Accessible Hybridization Site Identification Using Mass Spectrometry - The present invention relates to methods and compositions for analyzing nucleic acids, and in particular, methods and compositions for detection and characterization of nucleic acid sequences and sequence changes using mass spectrometry. The present invention also provides methods and compositions for identifying oligonucleotides with desired hybridization properties to nucleic acid targets containing secondary structure using mass spectrometry. | 03-19-2009 |
| 20090075257 | NOVEL NUCLEIC ACID SEQUENCES AND METHODS OF USE THEREOF FOR DIAGNOSIS - Novel splice variant nucleic acid and amino acid sequences are provided. The novel splice variants and their nucleic acid sequences may be used for diagnosis of variant-detectable diseases particularly cancerous diseases. | 03-19-2009 |
| 20090075258 | Methods of Normalization in microRNA Detection Assays - This application describes methods of quantifying a target miRNA in a biological sample by measuring the amounts of a target miRNA and at least one reference oncomir in a reaction volume, and normalizing the amount of target miRNA to the amount of one or more reference oncomirs. | 03-19-2009 |
| 20090075259 | Analyte detection via antibody-associated enzyme assay - The present invention provides methods, kits, and compositions for the detection of an analyte. The invention is particularly suited for the detection and quantification of an analyte in a sample. In the methods of the invention a complex is formed between an analyte specific binding agent and an analyte. The analyte specific agents are coupled to an enzyme possessing an activity that produces a PCR template indicative of the presence of the analyte. Amplification and detection of the PCR template yields a sensitive and quantitative measurement of analyte concentration. | 03-19-2009 |
| 20090075260 | Methods and Nucleic Acids For Analysis of Cellular Proliferative Disorders - Aspects of the invention provide methods, nucleic acids and kits for detecting, or for detecting and distinguishing between or among liver cell proliferative disorders or for detecting, or for detecting and distinguishing between or among colorectal cell proliferative disorders. Particular aspects disclose and provide genomic sequences the methylation patterns of which have substantial utility for the improved detection of and differentiation between said class of disorders, thereby enabling the improved diagnosis and treatment of patients. | 03-19-2009 |
| 20090075261 | SYSTEM AND METHOD FOR AUTHENTICATING TABLETS - A method for authenticating and verifying a pharmaceutical item to be genuine is described. The method for authenticating a tablet comprises applying a particular nucleic acid material associated with a particular sequence of nucleic acid bases to a tablet or capsule. The method also comprises collecting a sample of the tablet and verifying the tablet is genuine by detecting the particular nucleic acid material. | 03-19-2009 |
| 20090075262 | Gene Methylation In Endometrial Cancer Diagnosis - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with endometrial cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of endometrial cancer. | 03-19-2009 |
| 20090075263 | GENE METHYLATION IN OVARIAN CANCER DIAGNOSIS - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with ovarian cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of ovarian cancer. | 03-19-2009 |
| 20090075264 | GENE METHYLATION IN LIVER CANCER DIAGNOSIS - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with liver cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of liver cancer. | 03-19-2009 |
| 20090075265 | GENE METHYLATION IN THYROID CANCER DIAGNOSIS - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with thyroid cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of thyroid cancer. | 03-19-2009 |
| 20090075266 | MULTIPLE ANALYTE DIAGNOSTIC READOUT - The invention provides methods for assessing clinical status through the creation of a diagnostic readout based upon the analysis of multiple biomarkers. According to the invention, an algorithm is provided that allows the use of multiple biomarker thresholds from a patient sample to be used in order to increase the sensitivity and specificity of a diagnostic procedure. | 03-19-2009 |
| 20090075267 | K-ras and B-raf mutations and anti-EGFr antibody therapy - The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to B-raf mutations, to polynucleotides encoding mutant B-raf polypeptides, to vectors containing those polynucleotides, and to methods of identifying B-raf mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors. | 03-19-2009 |
| 20090075268 | Antigenic Targets Of Autoimmune Sensorineural Hearing Loss (AISNHL) And Development Of Tests For Diagnosis And Management Of AISNHL - This invention relates generally to antigens reactive with autoantibodies associated with autoimmune sensorineural hearing loss (AISNHL), and in particular relates to a novel antigen, Inner Ear Supporting Cell Antigen (IESCA) reactive with autoantibodies associated with autoimmune sensorineural hearing loss (AISNHL), and to methods for the detecting therapeutic outcomes in treatment of AISNHL patients, and to methods of detecting genetic lesions in genes encoding for such antigens. | 03-19-2009 |
| 20090075269 | SYSTEM AND METHOD FOR HIGH RESOLUTION ANALYSIS OF NUCLEIC ACIDS TO DETECT SEQUENCE VARIATIONS - Provided herein are methods for assaying a biological sample for microorganisms having drug resistant and/or drug sensitive phenotypes, wherein the methods are capable of detecting resistant and sensitive phenotypes associated with known and/or unknown mutations. In some aspects, methods are provided for detecting drug resistant | 03-19-2009 |
| 20090075270 | Products and Methods Relating to the Use of the Endoribonuclease Kid/PemK - The invention relates to a method for engineering a nucleic acid for expression in the presence of Kid/PemK endoribonuclease comprising (i) screening the nucleotide sequence of the nucleic acid for the sequence UUACU or TTACT (ii) mutating said sequence such that there are no longer any occurrences of UUACU or TTACT. The invention also relates to a method of making a ribonucleic acid resistant to Kid/PemK endoribonuclease, said method comprising (a) providing a nucleic acid; (b) screening the nucleic acid for the nucleotide sequence UUACU or TTACT; (c) mutating said sequence such that there are no longer any occurrences of UUACU or TTACT; wherein when the nucleic acid of (a) is a deoxyribonucleic acid, said method further comprises (d) transcribing said deoxyribonucleic acid to produce ribonucleic acid. The invention also relates to vectors and uses of purified or recombinant Kid/PemK endoribonucleases. | 03-19-2009 |
| 20090075271 | Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke - The present invention relates, in general, to perioperative bleeding and, in particular, to methods of identifying individuals at risk of perioperative bleeding. | 03-19-2009 |
| 20090075272 | Method to Identify CD40-Sensitive Cells Using Gene Expression - Gene expression patterns were analyzed in CD40-sensitive and CD40-resistant diffuse large-cell B-lymphoma (DLCBL) cell lines to identify signaling pathways which are involved in CD40-mediated apoptosis. CD40-resistant lines expressed pre-B cell markers including RAG and VPREB, whereas CD40-sensitive cells resembled mature B-cells and expressed higher levels of transcripts encoding several members of the CD40 signaling pathway including LCK and VAV. In addition, CD40 sensitive DLCBL cell lines also displayed constitutive activation of ERK and failed to undergo apoptosis when ERK phosphorylation was inhibited. In contrast, CD40 resistant lines showed no constitutive activation of ERK and no increase in ERK activity in response to CD40 stimulation. The invention includes methods to differentiate between CD40-sensitive and CD-40 resistant cells based on these differences in gene expression. | 03-19-2009 |
| 20090075273 | Planar Waveguide Detection Chips and Chambers for Performing Multiple PCR Assays - Provided are planar waveguide (“PWG”) detection chips that are used to perform multiplex PCR and kinetic PCR assays with a single fluorescent dye. The PWG detection chips are housed in PWG detection chambers that house at least one PWG chip. The PWG detection chambers may be in a single chamber or a dual chamber configuration. Also provided are methods for analyzing amplification products using the PWG detection chambers of the present invention. | 03-19-2009 |
| 20090075274 | MULTIPLEXED QUANTITATIVE DETECTION OF PATHOGENS - The invention allows for the quantitative detection of a plurality of pathogens in a single sample. The method includes the amplification of a sample with a plurality of pathogen-specific primer pairs to generate amplicons of distinct sizes from each of the pathogen specific primer pairs. The method further includes the use of a plurality of competitor polynucleotide targets that correspond to each of the pathogen-specific primer pairs. The competitor polynucleotides are added to the reaction mixture at a known concentration to allow for the quantitation of the amount of pathogen in the sample. The method can be used for monitoring pathogen infection in an individual, preferably an immunocompromised individual. | 03-19-2009 |
| 20090075275 | NUCLEIC ACID PROBE-IMMOBILIZED SUBSTRATE AND METHOD OF DETECTING THE PRESENCE OF TARGET NUCLEIC ACID BY USING THE SAME - The invention provides a nucleic acid probe-immobilized substrate comprising a substrate and a nucleic acid probe containing a nucleotide sequence complementary to a target sequence and immobilized via a spacer onto the substrate, wherein upon hybridization, with the nucleic acid probe, of a target nucleic acid partially containing the target sequence, the spacer satisfies the relationship: | 03-19-2009 |
| 20090075276 | High throughput mutation screening methods and kits using a universalized approach - differential sequence fill-in (dsf)-enabled sequential adapter ligation and amplification - This disclosure teaches high throughput mutation screening methods allowing simultaneous analysis of multiple genetic regions of interest and sensitive detection of very low frequency mutation(s) by the use of a universalized approach. Methods comprise treating RNA:DNA heteroduplexes of interest with a ribonuclease, sequence extension by an RNA-primed DNA polymerase, ligation with a blocking adapter, and differential sequence fill-in followed by single-strand-specific nuclease digestion to permit full-length sequence extension and subsequent ligation with a tagged reporter adapter solely in mutants filled in with a complementary deoxyribonucleotide triphosphate. By forming tagged mutant-dual adapter hybrids or mutant-triple adapter hybrids, the detection and/or quantification of mutants may be directed to the commonly shared tag(s) or flanking adapter sequences for signal detection/enhancement or sequence amplification in all different mutants regardless of the source or the number of mutations involved, thereby avoiding the tremendous effort of multiple target-specific sequence amplifications. Methods may be performed wholly or partially in solution, on solid phase media, in large scale, adapted for automated or semi-automated analysis, and any combinations thereof. | 03-19-2009 |
| 20090075277 | Method for detecting ovarian cancer and method for suppressing the same - ABSTRACT An object of the present invention is to provide a method for detecting cancer through identification of genes exhibiting characteristic behavior in the cases of cancer such as ovarian cancer, and a cell growth inhibitor. The present invention provides a method for detecting cancer, which comprises detecting canceration including malignancy of a specimen through detection of at least one alteration of a gene existing in a chromosomal region 2q14. 2, 3p24. 1, 3q26. 2, 3q29, 4q34. 2, 6q23, 9p21. 3, 11q13. 3, 13q22.1, 13q33. 1, 13q33. 3, 15q12, 15q15. 1, 17p12, 17p13. 1, 17p13. 3, 18q21. 1, 18q21. 2, 18q21. 31, 18q21. 32, 18q21. 33, 18q23, 20q13. 13, 20q13. 2, 20q13. 31, 20q13. 33, Xp11. 23, Xp13.1, Xp13. 3, Xp26. 2, Xp26. 3, or Xq28 in the specimen. | 03-19-2009 |
| 20090075278 | Compositions and methods for the diagnosis and treatment of tumor - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 03-19-2009 |
| 20090075279 | Compositions and methods for the diagnosis and treatment of tumor - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 03-19-2009 |
| 20090075280 | EUBACTERIAL tmRNA SEQUENCES AND USES THEREOF - The present invention is directed to eubacterial tmDNA sequences and the corresponding tmRNA sequences. The present invention is further directed to alignments of eubacterial tmDNA sequences and the use of the sequences and sequence alignments for the development of antibacterial drugs. The present invention is also directed to the use of the sequences for the development of diagnostic assays. | 03-19-2009 |
| 20090075281 | MTBE GENES - The present invention provides methods and compositions for modulating MTBE degradation. The invention also provides methods for identifying compounds that modulate MTBE expression. | 03-19-2009 |
| 20090075282 | ARTIFICIAL TISSUE CONSTRUCTS COMPRISING ALVEOLAR CELLS AND METHODS FOR USING THE SAME - The present invention comprises artificial tissue constructs that serve as in vitro models of mammalian lung tissue. The artificial tissue constructs of the present invention comprise functionally equivalent in vitro tissue scaffolds that enable immunophysiological function of the lung. The constructs can serve as novel platforms for the study of lung diseases (e.g., interstitial lung diseases, fibrosis, influenza, RSV) as well as smoke- and smoking-related diseases. The artificial tissue constructs of the present invention comprise the two components of alveolar tissue, epithelial and endothelial cell layers. | 03-19-2009 |
| 20090075283 | Vectors and Methods for Cloning Gene Clusters or Portions Thereof - The present invention relates to a shuttle BAC vector for facilitating the cloning, transfer and heterologous expression of streptomycete secondary metabolite biosynthetic gene clusters. The invention also relates to a plasmid rescue method using this vector for enhancing the process of cloning biosynthetic gene clusters for secondary metabolites from streptomycetes without sophisticated generation and screening of cosmids or BAC libraries. The cloned DNA can then be used for sequencing or heterologous expression of putative secondary metabolic gene clusters. | 03-19-2009 |
| 20090075284 | METABOLOMIC PROFILING OF PROSTATE CANCER - The present invention relates to cancer markers. In particular, the present invention provides metabolites that are differentially present in prostate cancer. | 03-19-2009 |
| 20090075285 | PRIMER KIT - The aim of the present invention is to provide a primer kit capable of efficiently amplifying only a required target nucleotide sequence without shortage or excess in the case of amplifying a wide range of target nucleotide sequences. The present invention is directed to a primer kit having a plurality of types of primers for amplifying nucleic acids having a plurality of types of target nucleotide sequences, wherein all of the types of primers are primers capable of amplifying each nucleic acid having a target nucleotide sequence under the same reaction conditions, and a single type of primer or primers corresponding to a single target nucleotide sequence is/are housed in at least one container; and a primer kit having a plurality of types of primers for amplifying nucleic acids having a plurality of types of target nucleotide sequences, wherein all of the types of primers are primers capable of amplifying each nucleic acid having a target nucleotide sequence under the same reaction conditions, and primers corresponding to a single target nucleotide sequence are housed in the same container. | 03-19-2009 |
| 20090075286 | Detection of Polyketide Synthetase Gene Expression in Karenia Brevis - The present invention concerns an assay for the detection of polyketide synthetase (PKS) mRNA from the red tide dinoflagellate | 03-19-2009 |
| 20090075287 | METHODS FOR IDENTIFYING NOVEL PESTICIDAL GENE HOMOLOGUES - Methods and compositions for identifying novel pesticidal gene homologues are provided. Specifically, the methods of the invention comprise systematically designing oligonucleotide primers that are specific for a pesticidal gene of interest and performing successive rounds of PCR amplification of nucleic acid material from a microorganism, particularly a | 03-19-2009 |
| 20090075288 | METHOD FOR DE NOVO DETECTION OF SEQUENCES IN NUCLEIC ACIDS: TARGET SEQUENCING BY FRAGMENTATION - The present invention provides a method for determining nucleic acid sequences of a template nucleic acid that requires no prior knowledge of the nucleic acid sequence present in the template nucleic acid. The method is based on combining information about the mass of a fragment, the mass of any one nucleotide and the combinations thereof, and the sequence specificity of a nucleotide cutter, either enzymatic or chemical cutter, to determine a sequence of a nucleic acid fragment. This method allows for de novo detection of sequences in a target nucleic acid without requiring any prior sequence information. This method is called Partial Sequencing by Fragmentation (PSBF) and it works by fragmenting a target into oligo- or polynucleotides whose masses or lengths are uniquely associated with known sequences. The identities of these sequences are determined solely by the specific fragmentation method used, and are always independent of the target. PSBF can be implemented using electrophoresis, mass spectrometry or any other method that can be used to distinguish the size of the cut nucleic acid sequence fragments. | 03-19-2009 |
| 20090075289 | Collection Assembly for Obtaining Oral Samples From an Animal - The present invention provides a collection assembly for obtaining a sample from within the mouth of an animal. The collection assembly comprises a collection wand, having a scoop-shaped collecting end, and, optionally, an oral speculum. Also provided are methods of using the collection assembly to obtain an oral sample from the mouth of an animal without causing significant discomfort to the animal. | 03-19-2009 |
| 20090081642 | Novel apoptosis gene EI24, compositions, and methods of use - Disclosed is the isolation and characterization of EI24, a novel gene whose 2.4 kb mRNA is induced following etoposide treatment. Induction of EI24 mRNA by etoposide required expression of wild-type p53. Overexpression of functional p53 was sufficient to induce expression of the EI24 mRNA. The EI24 mRNA was also induced in a p53-dependent manner by ionizing irradiation of primary murine thymocytes. The invention is thus directed to an isolated EI24 protein, nucleotide sequences coding for and regulating expression of the protein, antibodies directed against the protein, and recombinant vectors and host cells containing the genetic sequences coding for and regulating the expression of the protein sequence. The invention is also directed to genomic DNA, cDNA, and RNA encoding the EI24 protein sequence and to corresponding antisense RNA sequences. Antibodies can be used to detect EI24 in biological specimens, including, for example, human tissue samples. The present invention is further directed to methods of treating degenerative disorders characterized in inappropriate cell proliferation or inappropriate cell death. The present invention is further directed to methods for diagnosing degenerative disorders characterized in inappropriate cell proliferation or inappropriate cell death, as well as methods for monitoring the progress of such degenerative disorders. | 03-26-2009 |
| 20090081643 | METHODS FOR EVALUATING RIBONUCLEOTIDE SEQUENCES - Methods for identifying ribonucleotide sequences, in vitro, using the ribosome-mediated translation, are provided. | 03-26-2009 |
| 20090081644 | LIGATION AMPLIFICATION - Provided herein are methods and agents for ligation-based exponential ribonucleic acid amplification followed by detection using a nucleic acid polymerization reaction employing terminal-phosphate-labeled nucleotides including three or more phosphates as substrates for nucleic acid polymerase. | 03-26-2009 |
| 20090081645 | METHOD OF ASSUMING DRUG SENSITIVITY TO CDK4 INHIBITOR - It is intended to provide a gene for assuming drug sensitivity, which is to be used for assuming the drug sensitivity to a CDK4 inhibitor based on the expression amount in a test tissue or a test cell, selected from the group consisting of p16 gene, p18 gene and p27 gene. It is also intended to provide a method of assuming the drug sensitivity to a CDK4 inhibitor by using the expression amount of the above gene in a test tissue or a test cell as an indication. | 03-26-2009 |
| 20090081646 | Universal primers and their use for detecting and identifying plant materials in complex mixtures - The invention relates to polynucleotides and primers flanking a variable region of the intron of the chloroplast gene trnL of plant materials for detecting and identifying plant species. The invention also relates to methods for detecting and identifying plant species in complex or degraded mixtures. | 03-26-2009 |
| 20090081647 | Detection of a genetic predisposition to cancers and non-cancerous pathologies in mammals - Methods are provided for the detection of susceptibility to cancer and non-cancerous pathologies in a mammal. Diagnostic kits are also provided. | 03-26-2009 |
| 20090081648 | Detection and analysis of influenza virus - An assay comprising more than one primer pair and more than one detection probe, a low copy number synthetic amplicon corresponding to each of the primer pairs. The assay can detect and distinguish between various sub-types and strains of an influenza virus using any suitable nucleic acid amplification technique. Related kits and methods are also described. | 03-26-2009 |
| 20090081649 | Diagnostic method for detecting cancer by measuring amount of cytokine like il -6 - The present invention relates to a diagnostic method for predicting the possible recurrence of tumours in cancer patients. The method comprises culturing blood cells from a patient suffering from cancer in the presence of a cytokine stimulating factor, where after the amount of induced cytokine thereby produced is determined giving an indication of the risk of recurrence of the cancer. | 03-26-2009 |
| 20090081650 | Method for Identifying Nucleotide Sequences, Use of the Method and Test Kit - A method is disclosed for identifying nucleotide sequences while using non-labeled free oligonucleotides, labeled free and hybridizable oligonucleotides and non-labeled and immobilized oligonucleotides. | 03-26-2009 |
| 20090081651 | METHODS FOR ISOLATING AND CHARACTERIZING ENDOGENOUS mRNA-PROTEIN (mRNP) COMPLEXES - Cellular mRNA-protein (mRNP) complexes are partitioned in vivo by contacting a biological sample with at least one ligand that specifically binds at least one component of a mRNP complex. Suitable biological samples comprise at least one mRNA-protein (mRNP) complex and include cell cultures, cell extracts, and whole tissue, including tumor tissue. Ligands include antibodies that specifically bind RNA-binding or RNA-associated proteins present in the mRNP complex. The mRNP complex is separated by binding the ligand with a binding molecule specific for the ligand, where the binding molecule is attached to a solid support. The mRNP complex is collected by removing the mRNP complex from the solid support. After collecting the mRNP complex, the mRNA bound within the complex may be characterized and identified. Subsets of the total mRNA population of a cell may accordingly be characterized, and a gene expression profile of the cell obtained. | 03-26-2009 |
| 20090081652 | Constitutively Translocating Cell Line - The present invention relates to agonist-independent methods of screening for compounds that alter GPCR desensitization. Included in the present invention are cell lines containing GRKs, in which GPCRs are desensitized in the absence of agonist; the GRKs may be modified. The present invention relates to methods to determine if a GPCR is expressed at the plasma membrane, and if the GPCR has an affinity for arrestin. Modified GPCRs which have increased arrestin affinity are included in the present invention. These modified GPCRs are useful in methods to screen for compounds that alter desensitization, including both the agonist-independent methods and agonist-dependent methods described herein. | 03-26-2009 |
| 20090081653 | Insulin-responsive DNA binding proteins-1 and methods to regulate insulin-responsive genes - The present invention relates to the novel protein Insulin-Responsive DNA Binding Protein-1 (IRDBP-1) and nucleotide sequences that encode it. IRDBP-1 binds to nucleic acid regions of genes that respond when cells are exposed to insulin. IRDBP-1 regulates genes important in mediating the insulin response in mammals and in regulating conditions such as diabetes, obesity, insulin-resistant syndrome and cell proliferative disorders. The present invention provides nucleic acids useful as probes for detecting nucleic acids encoding regions of the IRDBP-1 protein. Within the scope of the present invention are recombinant cells, tissues and animals containing non-naturally occurring recombinant nucleic acid molecules encoding IRDBP-1, including expression vectors, antibodies specific for IRDBP-1, assays for IRDBP-1 polypeptide, and methods relating to all of the foregoing, the development of therapeutic and diagnostic agents that mimic, facilitate or inhibit the action of IRDBP-1, and/or are based on relationships to the structure and action of IRDBP-1. | 03-26-2009 |
| 20090081654 | TRANSFECTION KINETICS AND STRUCTURAL PROMOTERS - The invention features methods of analyzing the kinetics properties of transfection reactions. Also featured are methods for creating structural promoters which are effectively unregulated by enhancers and repressors. The structural promoters are significantly more active than the native promoter sequences upon which they are based. | 03-26-2009 |
| 20090081655 | Multiplex Real-time Quantitative PCR - Disclosed are compositions and methods for analyzing multiple nucleic acids using PCR. | 03-26-2009 |
| 20090081656 | METHOD FOR DETECTING A BACTERIAL PATHOGEN - A method is provided for detecting a bacterial pathogen in a sample. One step of the method includes obtaining a sample and then subjecting the sample to nested PCR. The nested PCR is conducted in the presence of at least two outer oligonucleotide primers complementary to a target nucleotide sequence of the bacterial pathogen so that a first amplified product is produced. The target nucleotide sequence includes at least a portion of a 16S-23S ribosomal RNA sequence. The first amplified product is subjected to the nested PCR in the presence of at least two inner oligonucleotide primers complementary to the nucleotide sequence of the first amplified product so that a second amplified product is obtained. Detection of the second amplified product indicates the presence of the bacterial pathogen in the sample. | 03-26-2009 |
| 20090081657 | Genetic Identification And Validation Of Echinacea Species - A method for identification and validation of | 03-26-2009 |
| 20090081658 | GENEMAP OF THE HUMAN GENES ASSOCIATED WITH CROHN'S DISEASE - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs. | 03-26-2009 |
| 20090081659 | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways - The invention discloses 364 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above. | 03-26-2009 |
| 20090081660 | Compositions and methods for the diagnosis and treatment of tumor - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 03-26-2009 |
| 20090081661 | Alkyl amines improve detection of components of formaldehyde-fixed biological samples - Alkyl amines act to release formaldehyde cross-linking that occurs in biological samples. Thus, contacting alkyl amines to formaldehyde fixed samples is a useful way to render biological components of the samples, including nucleic acids or proteins, more accessible to detection and characterization. | 03-26-2009 |
| 20090081662 | Homogeneous Luminescence Bioassay - This invention relates to a homogenous bioassay for use in measurement of biological activity, its modulation or analyte concentration of a sample, said bioassay comprising a first group comprising an acceptor, which acceptor is a short lifetime fluorescent compound capable of energy transfer, and a second group comprising a quencher, which quencher is capable of energy transfer from an acceptor. The increase or decrease, respectively, of fluorescence of said acceptor due to the decrease or increase, respectively, of energy transfer from said acceptor to said quencher resulting from lengthening or shortening, respectively, of the distance between said acceptor and quencher is measured. Characteristic for the invention is that the bioassay comprises a further third group comprising a donor for energy transfer to said acceptor, which donor is an up-conversion fluorescent compound, a long-lifetime fluorescent compound or an electrogenerated luminescent compound; and said first group comprises a tag, said third group comprises a binder, and said binder has a high affinity for binding to said tag. The fluorescence of said acceptor is brought about by exciting the donor resulting in energy being transferred from the donor to the acceptor. | 03-26-2009 |
| 20090081663 | METHODS, COMPOSITIONS AND KITS FOR DETECTION AND ANALYSIS OF ANTIBIOTIC-RESISTANT BACTERIA - The present invention relates generally to detection of antibiotic-resistant bacteria in a sample. In particular, the invention provides methods, compositions and kits for detecting and analyzing methicillin-resistant | 03-26-2009 |
| 20090081664 | METHOD FOR DETECTING REACTION PRODUCT OF NUCLEIC ACID SYNTHESIS - A method for detecting the occurrence of nucleic acid syntheses using an enzyme through the use of a generated insoluble substance as an indicator. | 03-26-2009 |
| 20090081665 | METHOD OF DIAGNOSIS/PROGNOSIS OF HUMAN CHRONIC LYMPHOCYTIC LEUKEMIA COMPRISING THE PROFILING OF LPL/ADAM GENES - The present invention provides methods of diagnosis and prognosis of human chronic lymphocytic leukemia (CLL) in a subject a patient in need thereof. The methods of the present invention involve measuring the expression profile of two known genes: LPL and ADAM29; and comparing the ratio of their expression to diagnose the presence of CLL or to prognose the likelihood of developing CLL or the symptoms consistent with CLL. | 03-26-2009 |
| 20090081666 | PROBE SET, PROBE CARRIER, AND METHOD FOR DETERMINING AND IDENTIFYING FUNGUS - It is intended to provide a method for identifying a causative fungus of skin disease. The method includes: simultaneously performing amplification treatments under the same conditions using primers common to plural fungal species; then simultaneously performing hybridization procedures under the same conditions using probes respectively specific to fungi; and determining the presence or absence of each fungus from the hybridization intensity of each probe. | 03-26-2009 |
| 20090081667 | Viral Variants With Altered Susceptibility To Nucleoside Analogs And Uses Thereof - The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus. | 03-26-2009 |
| 20090081668 | Glycosyltransferase, nucleic acid encoding the glycosyltransferase and method of testing canceration using the nucleic acid - A tumor marker nucleic acid of the present invention is concerned with a nucleic acid hybridizing under stringent conditions to a nucleotide sequence described in SEQ ID NO: 1 or a complementary nucleotide sequence thereof. A method of testing canceration of the present invention is a method comprising diagnosing a biological sample as being cancerous when the transcription level of the nucleic acid in the biological sample significantly exceeds that in a normal biological sample as a control. The present invention also relates to a β1,3-N-acetyl-D-glucosaminyltransferase protein having an activity of transferring N-acetyl-D-glucosamine from a donor substrate to an acceptor substrate through β1,3-linkage. | 03-26-2009 |
| 20090081669 | Fluorescent Assays Using Orthogonal tRNA - Aminoacyl Synthetase Pairs - An unnatural amino acid comprising a fluorescent moiety is site-specifically incorporated into a protein through the use of an O-tRNA/O-RS pair which is orthogonal to the tRNAs and aminoacyl synthetases of a translation system, thereby allowing the protein to be analyzed. | 03-26-2009 |
| 20090081670 | NICKING AND EXTENSION AMPLIFICATION REACTION FOR THE EXPONENTIAL AMPLIFICATION OF NUCLEIC ACIDS - The invention is in general directed to the rapid exponential amplification of short DNA or RNA sequences at a constant temperature. | 03-26-2009 |
| 20090081671 | METHOD AND APPARATUS FOR JUDGING THE PRESENCE OR ABSENCE OF CANCER CELL - The invention provides a method for judging whether cancer cells are present or not in a sample, comprising a obtaining step of obtaining values related to an expression level of a caner marker gene and a housekeeping gene; a first comparing step of comparing the value related to the expression level of the cancer marker gene with a first threshold value; a normalizing step of normalizing the value related to the expression level of the cancer marker gene based on the value related to the expression level of the housekeeping gene; a second comparing step of comparing the normalized value with a second threshold value; and a judging step of judging whether cancer cells are present or not in the sample based on comparison results obtained in the first and second comparing steps, as well as an apparatus for judging whether cancer cells are present or not. | 03-26-2009 |
| 20090081672 | GENES FROM THE 20Q13 AMPLICON AND THEIR USES - The present invention relates to cDNA sequences from a region of amplification on chromosome 20 associated with disease. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases. The sequences can also be used for treatment of diseases. | 03-26-2009 |
| 20090081673 | PLATENSIMYCIN BIOSYNTHETIC GENE CLUSTER OF STREPTOMYCES PLATENSIS - The present invention relates to the cloning and sequence of a biosynthetic gene cluster from | 03-26-2009 |
| 20090081674 | Methods for Analysis of PDEF and Survivin as Interconnected Cancer Biomarkers and Targets for Personalized Medicine - Provided are methods for determining whether an individual is a candidate to receive treatment with a DNA methylation inhibitor. The method can be performed a biological sample of cancerous tissue of the individual. Determining that PDEF expression is absent or low and survivin expression is present identifies the individual as a candidate to receive a treatment with a DNA methylation inhibitor. The method also includes communicating the result of identifying an individual as a candidate for receiving a DNA methylation inhibitor to a health care provider | 03-26-2009 |
| 20090081675 | METHODS, COMPOUNDS AND SYSTEMS FOR DETECTING A MICROORGANISM IN A SAMPLE - Methods to identify a set of probe polynucleotides suitable for detecting a set of targets and in particular methods for identification of primers suitable for detection of target microorganisms related polynucleotides, set of polynucleotides and compositions, and related methods and systems for detection and/or identification of microorganisms in a sample. | 03-26-2009 |
| 20090081676 | METHODS OF USING FET LABELED OLIGONUCLEOTIDES THAT INCLUDE A 3'-5' EXONUCLEASE RESISTANT QUENCHER DOMAIN AND COMPOSITIONS FOR PRACTICING THE SAME - Methods and compositions are provided for detecting a primer extension product in a reaction mixture. In the subject methods, a primer extension reaction is conducted in the presence of a polymerase having 3′→5′ exonuclease activity and at least one FET labeled oligonucleotide probe that includes a 3′→5′ exonuclease resistant quencher domain. Also provided are systems and kits for practicing the subject methods. The subject invention finds use in a variety of different applications, and are particularly suited for use in high fidelity PCR based reactions, including SNP detection applications, allelic variation detection applications, and the like. | 03-26-2009 |
| 20090081677 | METHOD FOR GENDER IDENTIFICATION OF EAGLES WITH PROBE-BASED REAL-TIME PCR AND THE SEQUENCES USED FOR GENDER IDENTIFICATION OF EAGLES - A method for gender identification of eagles includes: providing a DNA of an eagle; performing a probe-based real-time PCR using the DNA as a template, a universal primer pair P2/P8 as a primer pair and a first probe and a second probe as probes, wherein the 5′ ends of the first probe and the second probe are labeled with a first fluorescent dye and a second fluorescent dye, respectively, and the first probe is a sequence with about 15-38 nucleotides in length of SEQ ID No. 1 and the second probe is a sequence with about 15-44 nucleotides in length of SEQ ID No. 2; and analyzing a result of the PCR, wherein if the result is positive for both the first and the second fluorescent dye, the eagle is a female, and if the result is positive for only the first fluorescent dye, the eagle is a male. | 03-26-2009 |
| 20090081678 | NUCLEIC ACID ISOLATION IN PRESERVED WHOLE BLOOD - A method for isolating nucleic acids is disclosed, wherein a sample having nucleic acid containing starting material is fixed, lysed, and treated to remove unwanted contaminants. The initial fixing of the sample aids in maintaining the structure and integrity of the isolated DNA and reduces the incidence of end product contaminants and DNA shearing. | 03-26-2009 |
| 20090081679 | Compositions and methods for in vivo SELEX - The invention describes methods for the in vivo selection of oligonucleotides, preferably aptamers, that persist in biological compartments. In one embodiment, the biological compartment comprises at least one tissue which, in a preferred embodiment, is the blood within the circulatory system of a living mammal. The invention also contemplates oligonucleotides, preferably aptamers, selected through in vivo SELEX that may be linked to therapeutic or diagnostic compositions including other oligonucleotides. | 03-26-2009 |
| 20090081680 | Mutant firefly luciferase - This invention relates to: the development of a mutant firefly luciferase in order to use dATP as a DNA polymerase substrate upon pyrosequencing, such luciferase being subjected to substrate specificity modification in a manner such that the dATP-induced activity alone is decreased while the ATP-induced activity is maintained; and a mutant firefly luciferase for which the proportion of activity induced by dATP to activity induced by ATP (dATP/ATP) is lower than that for the wild-type firefly luciferase, in which an amino acid identified based on homology analysis as corresponding with the 421 | 03-26-2009 |
| 20090081681 | Method For Genetic Selection Of High-Plasmid Producing E. Coli Clones - The present invention relates to methods of selecting for highly productive clones of | 03-26-2009 |
| 20090081682 | HIGH-THROUGHPUT METHODS FOR IDENTIFYING GENE FUNCTION USING LENTIVIRAL VECTORS - The present invention relates to methods and compositions for the efficient identification of one or more functionalities of a product encoded by a nucleic acid sequence of interest. The methods utilize the abilities to over and/or under express the product in a cell, as well as the combination of these results, to permit the identification of at least one of the product's cellular or in vivo functionality. | 03-26-2009 |
| 20090081683 | Kits and Methods for Assessing the Coenzyme Q Reducing Status of a Patient, Including a Patient Ingesting a Statin - The disclosure relates to kits and methods for assessing whether an individual is likely to benefit from nutritional supplementation with coenzyme Q and, more particularly, a reduced form of coenzyme Q. The methods involve assessing occurrence of a polymorphism in the gene encoding NQO1 in the individual. Individuals homozygous for the polymorphism will receive optimal benefits from supplementation with the reduced form of coenzyme Q. The disclosure further relates to methods for predicting and assigning a coenzyme Q redox status phenotype based on assessment of an individual's genome for a polymorphism in the gene encoding NQO1. | 03-26-2009 |
| 20090081684 | DETECTION OF NEGATIVELY CHARGED POLYMERS USING WATER-SOLUBLE, CATIONIC, POLYTHIOPHENE DERIVATIVES - Novel methods allowing for the simple optical and electrochemical detection of double-stranded oligonucleotides are disclosed. The methods are rapid, selective and versatile. Advantageously, they do not require any chemical reaction on the probes or on the analytes since they are based on different electrostatic interactions between cationic poly(3-alkoxy-4-methylthiophene) derivatives and single-stranded or double-stranded (hybridized) oligonucleotides. | 03-26-2009 |
| 20090081685 | METHODS AND COMPOSITIONS FOR THE DETECTION OF OVARIAN DISEASE - Methods and compositions for identifying ovarian cancer in a patient sample are provided. The methods of the invention comprise detecting overexpression of at least one biomarker in a body sample, wherein the biomarker is selectively overexpressed in ovarian cancer. In preferred embodiments, the body sample is a serum sample. The biomarkers of the invention include any genes or proteins that are selectively overexpressed in ovarian cancer, including, for example, acute phase reactants, lipoproteins, proteins involved in the regulation of the complement system, regulators of apoptosis, proteins that bind hemoglobin, heme, or iron, cytostructural proteins, enzymes that detoxify metabolic byproducts, growth factors, and hormone transporters. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided. | 03-26-2009 |
| 20090081686 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING - Provided are novel nucleotides, nucleoside, and their derivatives described herein, that can be used in DNA sequencing technology and other types of DNA analysis. In one embodiment, the nucleotide or nucleoside with an unprotected 3′-OH group is derivatized at the nucleobase to include a fluorescent dye attached via a linker to a photocleavable terminating group. The photocleavable-fluorescent group is designed to terminate DNA synthesis as well as be cleaved so that DNA oligomers can be sequenced efficiently in a parallel format. The design of such rapidly cleavable fluorescent groups on nucleotides and nucleosides can enhance the speed and accuracy of sequencing of large oligomers of DNA in parallel, to allow rapid whole genome sequencing, and the identification of polymorphisms and other valuable genetic information, as well as allowing further manipulation and analysis of nucleic acid molecules in their native state following cleavage of the fluorescent group. | 03-26-2009 |
| 20090081687 | Nucleic Acid Molecules and Other Molecules Associated with Plants - Expressed Sequence Tags (ESTs) isolated from soybean are disclosed. The ESTs provide a unique molecular tool for the targeting and isolation of novel genes for plant protection and improvement. The disclosed ESTs have utility in the development of new strategies for understanding critical plant developmental and metabolic pathways. The disclosed ESTs have particular utility in isolating genes and promoters, identifying and mapping the genes involved in developmental and metabolic pathways, and determining gene function. Sequence homology analyses using the ESTs provided in the present invention, will result in more efficient gene screening for desirable agronomic traits. An expanding database of these select pieces of the plant genomics puzzle will quickly expand the knowledge necessary for subsequent functional validation, a key limitation in current plant biotechnology efforts. | 03-26-2009 |
| 20090081688 | Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations - Methods of detecting multiple nucleic acid targets in single cells through indirect capture of labels to the nucleic acids are provided. Methods of assaying the relative levels of nucleic acid targets through normalization to levels of reference nucleic acids are also provided. Methods of detecting individual cells, particularly rare cells from large heterogeneous cell populations, through detection of nucleic acids are described. Related compositions, systems, and kits are also provided. | 03-26-2009 |
| 20090081689 | Reagents and methods to enrich rare cells from body fluids - The present invention relates to compositions and methods for separating cells. The present invention utilizes a combination of techniques to deplete non-nucleated and nucleated cells in a biological sample. The use of this invention assists in reducing the complexity of a biological sample such as peripheral blood, and help in the diagnosis and prognosis of many conditions. The invention includes solutions and methods to selectively deplete red and white blood cells from a blood sample. The preferred sample is blood, effusion, or aspirate samples containing one or more cell types that can be enriched from such a sample. The present invention provides methods for identifying target cells, nucleic acids or chromosome quantification. | 03-26-2009 |
| 20090081690 | Site-specific labeling of proteins for NMR studies - Methods of producing and/or analyzing spectroscopically labeled proteins, e.g., proteins site-specifically labeled with NMR active isotopes, spin-labels, chelators for paramagnetic metals, and the like, are provided. The labeled proteins are produced in translation systems including orthogonal aminoacyl tRNA synthetase/tRNA pairs. Methods for assigning NMR resonances, e.g., methods using isotopically labeled proteins, are also provided. | 03-26-2009 |
| 20090087834 | Method for characterising polynucleotides - The method of the invention is used to identify specific characteristics of a target polynucleotide in a sample, and comprises the steps of: i) attaching to one end of each target polynucleotide in the sample a polynucleotide signal sequence that is specific for the characteristic under study; ii) contacting the target polynucleotides with a molecule that interacts with the target polynucleotide if the characteristic is present; iii) attaching a polynucleotide adapter sequence to those targets polynucleotides that interact with the molecule of step (ii), the adapter being attached at the end of the target polynucleotide opposite that at which the signal sequence is attached; iv) carrying out a polynucleotide amplification reaction on those target polynucleotides that comprise both the adapter and signal sequence, optionally repeating steps (i) to (iv) for other characteristics; and (v) identifying which signal sequences are present on the amplified products, and in which order, to thereby determine the characteristics of each target polynucleotide. | 04-02-2009 |
| 20090087835 | Method of Identifying Hairpin DNA Probes by Partial Fold Analysis - Method of identifying molecular beacons in which a secondary structure prediction algorithm is employed to identify oligonucleotide sequences within a target gene having the requisite hairpin structure. Isolated oligonucleotides, molecular beacons prepared from those oligonucleotides, and their use are also disclosed. | 04-02-2009 |
| 20090087836 | IL-B30 ANTIBODIES - Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided. | 04-02-2009 |
| 20090087837 | Method Of Detecting Streptococcus Pneumoniae, Primer Set For The Detection And Kit For The Detection - A method of detecting | 04-02-2009 |
| 20090087838 | ANALYTE DETECTION USING AUTOCATALYTIC CHAIN REACTIONS - Compositions and methods for detecting the presence of analytes employing autocatalytic chain reactions (ACR) having super linear kinetics for amplification of signal are disclosed. | 04-02-2009 |
| 20090087839 | LONG DISTANCE POLYMERASE CHAIN REACTION-BASED ASSAY FOR DETECTING CHROMOSOMAL REARRANGEMENTS - Methods are presented for determining the presence of an inversion in the factor VIII gene which cause hemophilia A. The methods encompass long distance, multiplex PCR (including overlapping PCR). The use of deaza-dGTP, high levels of DNA polymerases and high levels of DMSO aid in successfully performing the PCR. The use of a novel technique called subcycling PCR can also be applied as part of the methods. The technique allows for the determination of whether a person is homozygous or hemizygous for the inversion and has hemophilia A or whether a person is heterozygous for the inversion and is a carrier. The technique of long distance, multiplex PCR including use of deaza-dGTP, high levels of DNA polymerases and high levels of DMSO are applicable to the determination of the presence of other gross chromosomal aberrations such as deletions/inversions, translocations and inversions. The use of subcycling PCR can achieve efficient and more even amplification than normal two or three temperature PCR and is applicable to long distance, multiplex PCR. | 04-02-2009 |
| 20090087840 | Combined extension and ligation for nucleic acid assembly - Certain aspects of the present invention provide methods for assembling nucleic acid molecules. Some embodiments involve analyzing nucleic acid sequences and determining appropriate assembly strategies based on the presence or absence of sequence features that are known or predicted to interfere with extension-based and/or ligation-based assembly techniques. Aspects of the invention also provide kits, compositions, devices, and systems for assembling synthetic nucleic acids using polymerase-based techniques, ligase-based techniques, or combinations thereof. | 04-02-2009 |
| 20090087841 | METHODS AND COMPOSITIONS FOR DETERMINING RESISTANCE OF HIV-1 TO PROTEASE INHIBITORS - This invention relates to methods for determining resistance of HIV-I viruses to protease inhibitors (PIs) based on the viral genotypes. The methods generally comprise detecting, in a gene encoding protease of the HIV-I, the presence of a mutation in at least one of codon 22, 69, 74, or 83 alone or in combination with one or more mutations at certain other codons, or, in a gene encoding gag of the HIV-I, the present of a mutation in at least one of codon 418 or 482 alone or in combination with one or more mutations at certain other codons. Combinations of mutations associated with resistance to PIs are also disclosed. | 04-02-2009 |
| 20090087842 | Presynaptic protein cast - The present invention enabled the detection and quantification of CAST, which is localized to synapses and tightly bound to the cytomatrix, and of the mRNA encoding the CAST. Furthermore, it was revealed that CAST functions as a protein scaffold for localizing RIM1 to synapses, contributing as a molecular basis for active zone formation. | 04-02-2009 |
| 20090087843 | MOLECULAR MARKERS - The present invention relates to genetic sequences exhibiting differential expression patterns in cancer tissue relative to normal tissue. The identification of such sequences permits their use as molecular markers for cancer, as early indicators of cancer progression and/or as predictive markers for a propensity or likelihood of a cancer to develop. The present invention relates particularly to genetic sequences exhibiting expression patterns up-regulated in cervical cells or associated with pre-, early- or late-onset cervical cancer relative to normal cervical cells, such sequences serving as biomarkers. The biomarkers of the present invention provide targets for the development of therapeutic protocols for the treatment or prophylaxis of cervical or related cancer. Such therapeutic protocols are directed to inhibiting expression of the marker or inhibiting the expression product of the marker. The invention is further directed to a method for identifying molecular markers which are useful indicators of cervical cancer and/or its progression. | 04-02-2009 |
| 20090087844 | METHODS AND COMPOSITIONS FOR CORRELATING GENETIC MARKERS WITH CARDIOVASCULAR DISEASE - The present invention provides methods of identifying a subject having an increased or decreased risk of developing cardiovascular disease, comprising:
| 04-02-2009 |
| 20090087845 | Genetic Markers Of True Low Birth Weight - The present application provides for a method of diagnosing TLBW via measurement of expression of various TLBW-related genes. The present application also provides kits for the diagnosis of TLBW in a subject. The present application also provides a method for determining the basis for appropriate therapy for a subject suffering from TLBW. | 04-02-2009 |
| 20090087846 | Method for Detecting Large Mutations and Duplications Using Control Amplification Comparisons to Paralogous Genes - Methods for querying biological samples to detect genetic mutations, particularly insertions and deletions, by co-amplification of a gene of interest in conjunction with a paralogous gene. When the gene of interest and the corresponding paralogous gene are selected from the CYP450 family, the resulting ratios may predict how a particular patient metabolizes certain prescription drugs. | 04-02-2009 |
| 20090087847 | DETERMINING A NUCLEIC ACID SEQUENCE IMBALANCE - Methods, systems, and apparatus are provided for determining whether a nucleic acid sequence imbalance exists within a biological sample. One or more cutoff values for determining an imbalance of, for example, the ratio of the two sequences (or sets of sequences) are chosen. The cutoff value may be determined based at least in part on the percentage of fetal DNA in a sample, such as maternal plasma, containing a background of maternal nucleic acid sequences. The cutoff value may also be determined based on an average concentration of a sequence per reaction. In one aspect, the cutoff value is determined from a proportion of informative wells that are estimated to contain a particular nucleic acid sequence, where the proportion is determined based on the above-mentioned percentage and/or average concentration. The cutoff value may be determined using many different types of methods, such as sequential probability ratio testing (SPRT). | 04-02-2009 |
| 20090087848 | DETERMINING SEGMENTAL ANEUSOMY IN LARGE TARGET ARRAYS USING A COMPUTER SYSTEM - A method and/or system for making determinations regarding samples from biologic sources including statistical methods for making meaning grouping of observed data and/or for pre-selecting endpoints. | 04-02-2009 |
| 20090087849 | NUCLEIC ACID-BASED METHODS AND COMPOSITIONS FOR THE DETECTION OF OVARIAN CANCER - Methods and compositions for identifying ovarian cancer in a patient sample are provided. The methods of the invention comprise detecting overexpression or underexpression of at least one nucleic acid biomarker in a body sample, wherein the biomarker is selectively overexpressed or underexpressed in ovarian cancer. The body sample may be, for example, an ovarian tissue sample. The biomarkers of the invention include any nucleic acid molecule that is selectively overexpressed in ovarian cancer, including, for example, MMP-7, PAEP, CA125, HE4, PLAUR, MUC-1, SLPI, SSP1, MSLN, SPON1, interleukin-7, folate receptor 1, claudin 3, inhibin A, inhibin BB, inhibin BA, and PAI-1. Overexpression or underexpression of a biomarker of interest is detected at the nucleic acid level using such methods as real-time PCR and various nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided. | 04-02-2009 |
| 20090087850 | NUCLEIC ACID SEQUENCING METHODS AND SYSTEMS - Sequencing methods that use an exonuclease that comprises template dependent nucleobase binding activity are provided. Related compositions and sequencing systems are also provided. | 04-02-2009 |
| 20090087851 | Lineage-Restricted Neuronal Precursors - A self-renewing restricted stem cell population has been identified in developing (embryonic day 13.5) spinal cords that can differentiate into multiple neuronal phenotypes, but cannot differentiate into glial phenotypes. This neuronal-restricted precursor (NRP) expresses highly polysialated or embryonic neural cell adhesion molecule (E-NCAM) and is morphologically distinct from neuroepithelial stem cells (NEP cells) and spinal glial progenitors derived from embryonic day 10.5 spinal cord. NRP cells self renew over multiple passages in the presence of fibroblast growth factor (FGF) and neurotrophin 3 (NT-3) and express a characteristic subset of neuronal epitopes. When cultured in the presence of RA and the absence of FGF, NRP cells differentiate into GABAergic, glutaminergic, and cholinergic immunoreactive neurons. NRP cells can also be generated from multipotent NEP cells cultured from embryonic day 10.5 neural tubes. Clonal analysis shows that E-NCAM immunoreactive NRP cells arise from an NEP progenitor cell that generates other restricted CNS precursors. The NEP-derived E-NCAM immunoreactive cells undergo self renewal in defined medium and differentiate into multiple neuronal phenotypes in mass and clonal culture. Thus, a direct lineal relationship exists between multipotential NEP cells and more restricted neuronal precursor cells present in vivo at embryonic day 13.5 in the spinal cord. Methods for treating neurological diseases are also disclosed. | 04-02-2009 |
| 20090087852 | MAMMALIAN SELENOPROTEIN DIFFERENTIALLY EXPRESSED IN TUMOR CELLS - A 15 kDa selenium-containing protein (“selenoprotein”) is disclosed. The protein is shown to be differentially expressed in cancer cells, such as prostate cancer cells. There is a correlation between the presence of a polymorphism at nucleotide positions 811 and 1125 of the 15 kDa selenoprotein gene, and the presence of cancer. This polymorphism is more prevalent in the African American population. The determination of an individual's genotype may be used as an indicator of the need for dietary selenium supplementation to inhibit tumor development. Compositions including the isolated protein, specific binding agents that recognize the protein, as well as underlying nucleic acid sequences are presented, as are methods of using such compositions. | 04-02-2009 |
| 20090087853 | HERBICIDE TOLERANT COTTON PLANTS AND METHODS FOR PRODUCING AND IDENTIFYING SAME - The invention pertains to transgenic cotton plants, plant material and seeds, characterized by harboring a specific transformation event, particularly by the presence of a gene encoding a protein that confers herbicide tolerance, at a specific location in the cotton genome. The cotton plants of the invention combine the herbicide tolerant phenotype with optimal agronomic performance. | 04-02-2009 |
| 20090087854 | METHODS FOR GENETIC ANALYSIS - Methods of treating an individual exhibiting a medical condition are disclosed. The methods involve determining a score of an individual based on the individual's genotypic information, comparing the score to at least one threshold value, wherein the result of the comparison is indicative of a beneficial response to a treatment, and providing a suitable treatment to the individual. | 04-02-2009 |
| 20090087855 | MARKERS OF ALTERATIONS IN THE Y CHROMOSOME AND USES THEREFOR - Novel sequence tagged sites (STSs), probes and primers useful, e.g., for detecting the presence or absence of an STS in a sample, and methods of using these STSs, probes and primers, e.g., in methods of detecting alterations in the Y chromosome are disclosed. These compositions are also useful in methods of diagnosing or aiding in the diagnosis and/or cause of reduced sperm count and in methods of predicting or aiding in the prediction of the likelihood of success of infertility treatments. | 04-02-2009 |
| 20090087856 | METHOD FOR ADMINISTERING ANTICOAGULATION THERAPY - The present invention provides a method for use in treating a patient with an anticoagulant to optimize drug therapy and/or to prevent an adverse drug response. More particularly, the present invention relates to a method and system for use in treating a patient with Coumadin® or a substance containing warfarin. Methods of the present invention utilize variables that include the patient's CYP4F2 genotype. | 04-02-2009 |
| 20090087857 | Molecular Beacons for DNA-Photography - The present invention refers to a detection method for analytes using the principle of black-and-white photography and to reagent kits for performing the method, furthermore applied this new technology to detect a biologically relevant sequence in the nanomolar range (femtomoles) in an application circumventing the necessity of a PCR. There are still numerous ways to optimize this methodology that is suitable for a large variety of applications in the genomic diagnostics and proteomics areas. | 04-02-2009 |
| 20090087858 | Two-color Real-time/End-point Quantitation of MicroRNAs (miRNAs) - The present invention is directed to methods, reagents, kits, and compositions for detecting target polynucleotide sequences, especially small target polynucleotides such as miRNAs, between two samples. A pair of linker probes can be employed in two different reactions to query a particular species of target polynucleotide. A pair of detector probes, a single forward primer specific for the target polynucleotide, and a reverse primer can be employed in an amplification reaction to query the difference in expression level of the target polynucleotide between the two samples. In some embodiments a plurality of small miRNAs are queried with a plurality of linker probes. The plurality of queried miRNAs can then be decoded in a plurality of amplification reactions. | 04-02-2009 |
| 20090092966 | COLLOIDAL METAL AGGREGATES AND METHODS OF USE - Metal colloidal aggregates substrates useful for metal enhanced fluorescence applications, are disclosed. Method of making and using these colloidal aggregates for enhancing the fluorescent signal in biological assays are also described. | 04-09-2009 |
| 20090092967 | METHOD FOR GENERATING TARGET NUCLEIC ACID SEQUENCES - The present invention provides methods of generating target nucleic acids for amplification using nicking enzymes and methods for amplifying the generated target nucleic acids. | 04-09-2009 |
| 20090092968 | SCREENING METHOD FOR MYCOBACTERIA IN METAL REMOVAL FLUID SYSTEMS - One embodiment of the invention includes a method for testing a fluid for contamination by a mycobacterial organism. A plurality of individual standardized samples may be acquired from a plurality of predetermined sampling points and pooled into a pooled sample. The pooled sample may be analyzed using a polymerase chain reaction technique and the results compared against a pool concern level which is calculated from an individual concern level that governs each individual standardized sample. | 04-09-2009 |
| 20090092969 | DETECTION OF ATYPICAL PNEUMONIA - Disclosed herein are methods and compositions for detecting one or more pathogens that cause atypical pneumonia. Detectable pathogens include | 04-09-2009 |
| 20090092970 | COMPOSITION AND METHOD FOR NUCLEIC ACID SEQUENCING - The present invention provides compositions and methods for detecting incorporation of a labeled nucleotide triphosphate onto the growing end of a primer nucleic acid molecule. The method is used, for example, to genotype and sequence a nucleic acid. In a preferred embodiment, the method described herein detects individual NTP molecules. | 04-09-2009 |
| 20090092971 | Method for Detecting p53 Dysfunction, Method for Molecular Diagnosis of Cancer and Method for Evaluating Compound Effective in Treating Cancer - The present invention relates to methods for detecting a dysfunctional cancer suppressing gene, particularly p53. In other aspects, the invention provides methods for diagnosing cell proliferative disorders such as cancer by measuring expression of a predetermined target gene. Methods of evaluating the efficacy of a test compound to treat a cell proliferative disorder are also included. Such methods generally rely on the expression levels of a predetermined or targeted gene. | 04-09-2009 |
| 20090092972 | Method of evaluating drug sensitivity by analyzing girk channel genes - A method of evaluating drug sensitivity or disease vulnerability, includes linking a gene polymorphism in a GIRK channel gene or a haplotype comprising the gene polymorphism to individual drug sensitivity or individual disease vulnerability. | 04-09-2009 |
| 20090092973 | Grading of Breast Cancer - Methods and compositions for the identification of breast cancer grade signatures are provided. The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of molecular criteria for identification of cells as being in one or more particular stages and/or grades of breast cancer. | 04-09-2009 |
| 20090092974 | Micrornas differentially expressed in leukemia and uses thereof - The present invention concerns methods and compositions for identifying a miRNA profile for acute myeloid leukemia (AML), and using the profile in assessing the condition of a patient. | 04-09-2009 |
| 20090092975 | SELECTABLE MARKER - A nucleic acid sequence encoding a decarboxylation enzyme E.G. PAD1 is used as a selectable marker in a recombinant organism. A weak acid is used as the selecting agent. | 04-09-2009 |
| 20090092976 | Hypermethylation of GATA-4 and GATA-5 Transcription Factor Genes in Cancer - Methods are provided for identifying the presence of cancer cells in a sample by detecting hypermethylation of the promoter region of a GATA-4 transcription factor gene, a GATA-5 transcription factor gene, or both. Methods for ameliorating a cancer by effecting expression of a hypermethylation silenced GATA-4 and/or GATA-5 transcription also are provided. | 04-09-2009 |
| 20090092977 | MASS SPECTROMETRIC METHODS FOR DETECTING MUTATIONS IN A TARGET NUCLEIC ACID - Fast and highly accurate mass spectrometry-based processes for detecting particular nucleic acid molecules and mutations in the molecules are provided. | 04-09-2009 |
| 20090092978 | ASSOCIATION OF UQCRC1SNPs WITH FAT DEPOSITION AND FATTY ACID COMPOSITION - The present invention relates to the identification of single nucleotide polymorphisms (SNPs) in a ubiquinol-cytochrome c reductase core protein I (UQCRC1) gene and its associations association with fat deposition and fatty acid composition. The invention further encompasses methods and systems, including network-based processes, to manage the SNP data, haplotype data and other data relating to specific animals and herds of animals, veterinarian care, diagnostic and quality control data and management of livestock which, based on genotyping, have predictable meat quality traits, husbandry conditions, animal welfare, food safety information, audit of existing processes and data from field locations. | 04-09-2009 |
| 20090092979 | METHODS FOR ISOLATING LONG FRAGMENT RNA FROM FIXED SAMPLES - The present invention relates to methods for the extraction of long fragment RNA from fixed tissue specimens. In particular, the present invention relates to methods for the extraction of RNA from formalin-fixed paraffin-embedded tissue specimens for use in biologic applications, including assays based on oligonucleotide hybridization. | 04-09-2009 |
| 20090092980 | miRNA PROCESSING INHIBITOR EFFICACY ASSAYS AND SUBSTANCES - The invention relates to assays for assessing miRNA maturation effector (preferably: inhibitor) efficacy, and to substances useful for influencing, particularly for inhibiting, maturation of miRNA. According to the invention there is provided assay of miRNA processing inhibitor efficacy, comprising the steps of: a) providing a target miRNA precursor, b) providing a potential inhibitor of one or more processing steps of the target miRNA precursor, c) bringing together of the target miRNA precursor and the potential inhibitor under miRNA maturation conditions, and d) determining inhibition efficiency. The assay of the present invention allows for a very fast and easy assessment of the efficacy of a potential inhibitor in inhibiting processing of a miRNA precursor into miRNA. | 04-09-2009 |
| 20090092981 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS - The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, tetrahydropyran nucleoside analogs are provided, having one or more chiral substituents, that are useful for enhancing properties of oligomeric compounds including nuclease resistance and binding affinity. In some embodiments, the oligomeric compounds provided herein hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA. | 04-09-2009 |
| 20090092982 | METHODS AND COMPOSITIONS FOR INCREASING BIOLOGICAL MOLECULE STABILITY - The present invention relates to methods and compositions for enhancing folding and stability of biological molecules. In particular, the present invention relates to methods and compositions for identifying biological molecules with enhanced stability. The present invention further relates to host cells that confer enhanced stability to biological molecules expressed therein. | 04-09-2009 |
| 20090092983 | IDENTIFICATION OF AN ERBB2 GENE EXPRESSION SIGNATURE IN BREAST CANCERS - A method for analyzing differential gene expression associated with breast tumor is based on the analysis of the over-expression or under-expression of polynucleotide sequences in a biological sample. The analysis includes the detection of the over-expression of at least one polynucleotide sequence(s), subsequence(s) or complement(s) thereof selected from predefined polynucleotide sequence sets. | 04-09-2009 |
| 20090092984 | Determining a predisposition to cancer - The present invention relates to methods and kits for determining a predisposition and surveillance protocols for developing cancer of various sites due to specific mutation in at least one allele of CHEK2 gene and/or at least one allele of NOD2 gene and/or at least one allele of CDKN2A gene. | 04-09-2009 |
| 20090092985 | Screening tools for discovery of novel anabolic agents - The disclosure provides nucleic acids including the polynucleotide sequence of the human MAFbx core promoter involved in muscle specific expression. Also provided are reporters operably linked to a polynucleotide sequence including MAFbx transcription regulatory sequences, and constructs including polynucleotides that encode reporters and other polynucleotide sequences operably linked to the MAFbx core transcription regulatory sequence. Systems for identifying agents that inhibit muscle loss and/or increase muscle mass or tone are also provided. | 04-09-2009 |
| 20090092986 | Fluorescent Nucleobase Conjugates Having Anionic Linkers - Provided are nucleotide-dye conjugates and related compounds in which a dye is linked to a nucleobase directly or indirectly by an anionic linker. The anionic character of the linker is provided by one or more anionic moieties which are present in the linker, such as phosphate, phosphonate, sulfonate, and carboxylate groups. When the dye is a provided as a donor/acceptor dye pair, the anionic linker can be located between the donor and the acceptor, or between the nucleobase and either the donor or acceptor, or both. In one embodiment, conjugates of the invention provide enhanced electrophoretic mobility characteristics to sequencing fragments, e.g., for dideoxy sequencing using labeled terminators. | 04-09-2009 |
| 20090092987 | Polymorphic Nucleic Acids Associated With Colorectal Cancer And Uses Thereof - The present invention provides compositions and methods for research, diagnostic, drug screening, and therapeutic applications related to colorectal cancer and related conditions. In particular, the present invention provides genetic variations in or associated with one or more of the STK38L, GPR45, TGFBRAP1, PADI3, IBRDC1, and/or GRK5 genes as being associated with such conditions. | 04-09-2009 |
| 20090092988 | Modulating Gene Expression with agRNA and Gapmers Targeting Antisense Transcripts - Gene expression is selectively modulated in the genome of a mammalian cell determined to be in need thereof by determining the presence of an encoded antisense transcript overlapping a promoter of the target gene; contacting the transcript with an agRNA or gapmer complementary to a portion of the transcript upstream relative to the transcription start site of the gene; and detecting a resultant modulation of expression of the target gene. | 04-09-2009 |
| 20090092989 | MICROFLUIDIC PLATFORMS FOR MULTI-TARGET DETECTION - Disclosed are example methods and devices for detecting one or more targets. An example method includes placing a sample including a first target with in a microfluidic device and hybridizing a plurality of copies of the first target with a plurality of nanostructures. The example method includes applying an electric current to the plurality of nanostructures and using an electric field created by the electric current to move the plurality of nanostructures. In addition, the plurality of nanostructures are sorted and evaluated to determine at least one of a presence, an absence, or a quantity of the first target. | 04-09-2009 |
| 20090092990 | PRIMERS AND METHODS FOR THE DETECTION AND DISCRIMINATION OF NUCLEIC ACIDS - The present invention provides novel primers and methods for the detection of specific nucleic acid sequences. The primers and methods of the invention are useful in a wide variety of molecular biology applications and are particularly useful in allele specific PCR. | 04-09-2009 |
| 20090092991 | Assays, methods and systems for predicting follicular lymphoma outcome - Assays, kits, methods and systems for predicting outcome in patients with follicular lymphoma based upon measurement of one or more phenomenologically competitive or synergistic gene pairs or a set of classifier genes are provided. | 04-09-2009 |
| 20090092992 | Novel human dickkopf-related protein and nucleic molecules and uses therefor - Novel Dkk and Dkk-related polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Dkk and Dkk-related proteins, the invention further provides isolated fusion proteins, antigenic peptides and antibodies. The invention also provides Dkk and Dkk-related nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Dkk and Dkk-related gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 04-09-2009 |
| 20090092993 | Cellular arrays and methods of detecting and using genetic disorder markers - A method is disclosed for rapid molecular profiling of tissue or other cellular specimens by placing a donor specimen in an assigned location in a recipient array, providing copies of the array, and performing a different biological analysis of each copy. The results of the different biological analyses are compared to determine if there are correlations between the results of the different biological analyses at each assigned location. In some embodiments, the specimens may be tissue specimens from different tumors, which are subjected to multiple parallel molecular (including genetic and immunological) analyses. The results of the parallel analyses are then used to detect common molecular characteristics of the genetic disorder type, which can subsequently be used in the diagnosis or treatment of the disease. The biological characteristics of the tissue can be correlated with clinical or other information, to detect characteristics associated with the tissue, such as susceptibility or resistance to particular types of drug treatment. Other examples of suitable tissues which can be placed in the matrix include tissue from transgenic or model organisms, or cellular suspensions (such as cytological preparations or specimens of liquid malignancies or cell lines). | 04-09-2009 |
| 20090092994 | Reagents, methods and kits for classification of fungi and direction of anti-fungal therapy - Provided herein are methods, kits and compositions to classify fungi. Methods are provided for classification of fungi according to established phenotypes, for example, antimicrobial susceptibility profiles. More specifically, the invention provides methods for the use of PNA probes in diagnostic applications, which will aid in the direction of appropriate therapy against fungi. | 04-09-2009 |
| 20090092995 | Method for Identifying Within a Mammal a DNA encoding a Physiologically Active Polypeptide - The present inventors found that a physiological effect of a particular DNA can be detected independently within mice into which a pool of various DNAs in various quantities has been introduced. This finding suggests that it is possible to identify a DNA having a particular physiological effect by successively fractionating a pool of various DNAs in various quantities using the particular physiological effect seen within a mammal as an index. Such a method of screening will have the advantage of saving much time and effort as required in conventional screenings such as those utilizing transgenic and knockout mice. Furthermore, the method of screening has the additional advantage of enabling the identification of a DNA having a physiological activity, for example, even when the cells producing a physiologically active substance cannot be maintained in vitro or in immunodeficient animals, or when the cells change their characteristics during passage and stop producing the physiologically active substance. | 04-09-2009 |
| 20090098533 | Methods and kits for investigating cancer - The invention provides novel compositions, methods and uses, for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia and breast cancer. The invention further relates to genes that are differentially expressed in breast tissue of breast cancer patients versus those of normal “healthy” tissue. Differentially expressed genes for the identification of patients which are likely to respond to chemotherapy are also provided. | 04-16-2009 |
| 20090098534 | Full Karyotype Single Cell Chromosome Analysis - A full set of 24 chromosome-specific probes to analyze single cells or cell organelles to test for abnormalities is described. When used in an assay based on sequential hybridization, the full set is comprised of three subsets of chromosome-specific probes with each set comprised of 8 different probes. Also described are assays using a set of probes to analyze single cells and cellular organelles to accurately determine the number and type of targeted human chromosomes in various types of cells and cell organelles, such as tumor cells, interphase cells and first polar bodies biopsied from non-inseminated oocytes. Methods of selection or generation of suitable probes and hybridization protocols are described, as are preferred probes for frill set of 24 chromosome-specific probes to target all 24 human chromosomes are described in the Tables. | 04-16-2009 |
| 20090098535 | UPREGULATION OF RACK-1 IN MELANOMA AND ITS USE AS A MARKER - The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocytic cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocytic cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocytic cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein. | 04-16-2009 |
| 20090098536 | Method for subgroup analysis in subjects having or being suspected of having inflammatory disease, use of anti-p38MAPK antibodies, kits and their use - The present invention relates to a method of determining whether a subject having or suspected of having inflammatory disease may potentially benefit from treatment with a p38 mitogen-activated protein kinase (p38MAPK) inhibitor, which method comprises
| 04-16-2009 |
| 20090098537 | Biomarker for Sensitivity to mTOR Inhibitor Therapy in Kidney Cancer - The invention disclosed herein provides methods for the examination and/or quantification of biochemical pathways that are disregukted in pathologies such as cancer and to reagents and kits adapted for performing such methods. For example a correlation between VHL loss and mTOR inhibitor sensitivity in human kidney cancer cells is disclosed, indicating that VHL loss confers autonomous and angiogenic competitive advantages to such cells. | 04-16-2009 |
| 20090098538 | Prognostic and diagnostic method for disease therapy - The present invention provides novel methods and kits for diagnosing the presence of cancer within a patient, and for determining whether a subject who has cancer is susceptible to different types of treatment regimens. The cancers to be tested include, but are not limited to, prostate, breast, lung, gastric, ovarian, bladder, lymphoma, mesothelioma, medullablastoma, glioma, and AML. Identification of therapy-resistant patients early in their treatment regimen can lead to a change in therapy in order to achieve a more successful outcome. One embodiment of the present invention is directed to a method for diagnosing cancer or predicting cancer-therapy outcome by detecting the expression levels of multiple markers in the same cell at the same time, and scoring their expression as being above a certain threshold, wherein the markers are from a particular pathway related to cancer, with the score being indicative or a cancer diagnosis or a prognosis for cancer-therapy failure. This method can be used to diagnose cancer or predict cancer-therapy outcomes for a variety of cancers. The markers can come from any pathway involved in the regulation of cancer, including specifically the PcG pathway and the “stemness” pathway. The markers can be mRNA, microRNA, DNA, or protein. | 04-16-2009 |
| 20090098539 | Methods and Kits for Detecting an Enzyme Capable of Modifying a Nucleic Acid - An improved method of detecting an enzyme in a sample, which enzyme is capable of adding or removing a chemical moiety to or from a nucleic acid molecule, thereby conferring the nucleic acid molecule with the ability to be extended to generate a novel detectable nucleic acid molecule, comprises the steps of allowing the sample to be tested for the presence of the enzyme to interact with the nucleic acid molecule; and testing for interaction of the enzyme with the nucleic acid molecule by detecting the novel nucleic acid molecule generated only in the presence of the enzyme. The preferred enzyme is a phosphatase. The methods have a number of applications, for example in enhancing the sensitivity of immunoassays, for detecting pathogen associated phosphatase, for diagnosing certain conditions and for detecting specific contaminants in a sample. | 04-16-2009 |
| 20090098540 | RECIRCULATING MICROFLUIDIC DEVICE AND METHODS OF USE - The present invention relates to a microfluidic test device for detecting or quantifying an analyte in a test sample. The device includes a non-absorbent substrate having at least one microchannel imbedded in the substrate, a non-specific capture device, and one or more stationary mixing structures extending into the at least one microchannel. The present invention also relates to relates to various methods of using the microfluidic test device to detect or quantify an analyte in a test sample. The present invention also relates to a microfluidic device that includes a non-absorbent substrate having at least one microchannel imbedded in the substrate and one or more stationary mixing structures extending into the at least one microchannel. | 04-16-2009 |
| 20090098541 | Devices and processes for analysing individual cells - A device for individually analysing cells of interest, comprising (a) a channel for receiving the contents of a cell of interest, wherein the channel has an input end and an output end, and (b) a cell trapping site in proximity to the input end of the channel, wherein (i) the input end of the channel is adapted such that an intact cell of interest cannot enter the channel; and (ii) the channel contains one or more analytical components for analysing the contents of the cell of interest. In use, a cell is applied to the device, where it is trapped by the cell trapping means. The cell cannot enter the channel intact, but its contents can be released in situ to enter the channel's input end. The contents can then move down the channel, towards the output end, and they encounter the immobilised reagents, thereby permitting analysis of the cell contents. | 04-16-2009 |
| 20090098542 | Gene Methylation in Colon Cancer Diagnosis - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with colon cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of colon cancer. | 04-16-2009 |
| 20090098543 | GENE METHYLATION IN LUNG CANCER DIAGNOSIS - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with lung cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of lung cancer. | 04-16-2009 |
| 20090098544 | MARKER MOLECULES ASSOCIATED WITH LUNG TUMORS - The present invention relates to nucleic acids and polypeptides associated with lung cancer. The invention is more specifically related to a nucleic acids and the polypeptides transcribed thereof, the expression of which is significantly altered in association with lung cancer. The invention relates to a series of differentially spliced transcripts of the gene disclosed herein, that are associated with tumors of the respiratory tract. Furthermore the present invention provides a method for early diagnosis, prognosis and monitoring of the disease course and for therapy and vaccination of cell proliferative disorders such as e.g. lung tumors. | 04-16-2009 |
| 20090098545 | IN VITRO ASSAY FOR IDENTIFICATION OF ALLERGENIC PROTEINS - The present invention relates to a process for in vitro evaluation, of a potentially allergenic or tissue irritating sub-stance whereby test cells are cultivated in the presence of the substance, and the presence of up regulated genes chosen from G1P2, OASL, IFIT1, TRIM22, IFI44L, MXI, RSAD2, IFIT3, IFITM1, IFIT2, SPR, GNB2, XK, IFITM3, C 33.28 HERV-H protein mRNA, IFITM3, XK, GPR15, MT1G, MT1B; MT1A, ADFP, JL8, MT1E, MT1F, MT1H, SLC30A1, SERPINB2, CD83, TncRNA or expression products from them are measured. The invention also regards use of the expression products from one or more of the genes for in vitro analysis of allergy or tissue irritation. It also relates to a probe comprising at least three nucleic acids, preferably 3-40, especially 5-15 chosen from RNA complementary to the RNA corresponding to any of the genes and the use thereof for in vitro analysis of allergy or tissue irritation. Further it regards a reagent kit comprising one or more probes that recognize products produced during the expression of any the genes. | 04-16-2009 |
| 20090098546 | Methods of Screening for LTRPC7 Modulators - The present invention relates to the identification and isolation of a novel family of ATP regulated calcium transmembrane channel polypeptides designated herein as “LTRPC7” (Long Transient Receptor Potential Channel). Channels comprising these polypeptides close in response to concentrations of cytoplasmic ATP in the millimolar range, are subject to inhibition by high intracellular levels of calcium and/or magnesium, and do not respond to depletion or reduction in intracellular calcium stores. The invention further relates to the methods of utilizing LTRPC7 for binding, and the methods for modulating LTRPC7 activity and for measuring LTRPC2 permeability. The invention further relates to the methods of modulating expression of LTRPC7. | 04-16-2009 |
| 20090098547 | Methods for Identifying DNA Copy Number Changes Using Hidden Markov Model Based Estimations - Methods for estimating genomic copy number and loss of heterozygosity using Hidden Markov Model based estimation are disclosed. | 04-16-2009 |
| 20090098548 | MODULATORS OF ENZYMATIC NUCLEIC ACID ELEMENTS MOBILIZATION - The present invention discloses a nucleic acid cleavage assay for members of the transposase/integrase superfamily. A method of using the assay to screen for modulators of the nucleic acid cleavage activity is also disclosed. The present invention further provides a method for screening for modulators of binding of a transposase/integrase to its corresponding recognition sequence. In addition, the present invention provides a method of identifying a modulator for a particular transposase/integrase such as HIV integrase based on modulators of other members of the transposase/integrase superfamily. Also disclosed are Tn5 transposase inhibitors and HIV integration inhibitors. | 04-16-2009 |
| 20090098549 | SELEX AND PHOTOSELEX - The present disclosure describes improved SELEX methods for generating nucleic acid ligands that are capable of binding to target molecules and improved photoSELEX methods for generating photoreactive nucleic acid ligands that are capable of both binding and covalently crosslinking to target molecules. The disclosure further describes nucleic acid libraries having expanded physical and chemical properties and their use in SELEX and photoSELEX; methods for increasing the crosslinking efficiencies of photoaptamers; methods for producing photoaptamers having selective modifications that enhance functionality and minimize non-specific photoreactions; and methods for generating truncated nucleic acid ligands from nucleic acid ligands of longer length. The disclosure further describes aptamers and photoaptamers obtained by using any of the foregoing. | 04-16-2009 |
| 20090098550 | MRI CONTRAST AGENTS AND HIGH-THROUGHPUT SCREENING BY MRI - The present invention provides an MRI contrast agent, comprising: MRI contrast agent particles, and oligonucleotides, attached to the particles. | 04-16-2009 |
| 20090098551 | METHODS AND PRODUCTS RELATED TO GENOTYPING AND DNA ANALYSIS - The invention encompasses methods and products related to genotyping. The method of genotyping of the invention is based on the use of single nucleotide polymorphisms (SNPs) to perform high throughput genome scans. The high throughput method can be performed by hybridizing SNP allele-specific oligonucleotides and a reduced complexity genome (RCG). The invention also relates to methods of preparing the SNP specific oligonucleotides and RCGs, methods of fingerprinting, determining allele frequency for a SNP, characterizing tumors, generating a genomic classification code for a genome, identifying previously unknown SNPs, and related compositions and kits. | 04-16-2009 |
| 20090098552 | METHODS AND COMPOSITIONS FOR ANALYZING AHASL GENES - The invention relates to methods and compositions for analyzing plant acetohydroxy acid synthase large subunit (AHASL) genes. In particular, the invention relates to methods for the detection of wild-type AHASL alleles and mutant AHASL alleles that encode imidazolinone-tolerant AHASL proteins. The methods involve the use of PCR amplification and novel compositions comprising allele-specific and gene-specific primers to detect the presence of mutant and/or wild-type alleles present at the individual AHASL genes of a plant. Specifically, the methods and compositions are useful for analyzing the three AHASL genes of | 04-16-2009 |
| 20090098553 | Urine gene expression ratios for detection of cancer - This invention relates to methods for determining the presence of cancer in a subject based on the analysis of the expression levels of an under-expressed tumour marker (TM) and at least one other TM. Specifically, this invention relates to the determination of a cancer, particularly bladder cancer, by performing ratio, regression or classification analysis of the expression levels of at least one under-expressed TM, particularly an under-expressed bladder TM (BTM), and at least one over-expressed TM, particularly an over-expressed BTM. In various aspects, the invention telates to kits and devices for carrying out these methods. | 04-16-2009 |
| 20090098554 | Method and composition for cancer diagnosis and treatment - Methods and compositions for inhibiting the onset of cancer, and cancer diagnosis and treatment are provided. The treatment method comprises inhibiting the level or function of transcriptional positive factor 4 (PC4). Also provided are methods of screening for cancer inhibition agents based on inhibition of PC4 expression or function. | 04-16-2009 |
| 20090098555 | METHODS AND APPLICATIONS FOR STITCHED DNA BARCODES - Methods of identifying the genotypes of a plurality of single cells, wherein each cell includes a plurality of DNA barcodes, each associated with a genetic mutation or marker, are provided. In particular, methods including linking a plurality of DNA barcodes together to create a stitched barcode, amplifying the stitched barcode and sequencing the stitched barcode are provided. Also provided are methods of determining the presence of at least one genetic mutation in a population of cells. | 04-16-2009 |
| 20090098556 | Genetic Test For PSE-Susceptible Turkeys - This invention relates to methods and compounds for the improvement of turkey meat and turkey populations, but not limited to, a genetic screen to select for turkeys that produce a better quality of meat characterized by a higher postmortem pH and better water holding capacity. | 04-16-2009 |
| 20090098557 | IDENTIFICATION OF GENETIC MARKERS ASSOCIATED WITH PARKINSON DISEASE - The present invention provides methods and compositions for screening a subject for Parkinson disease, for increased risk of developing Parkinson disease and/or for an earlier or later age of developing Parkinson disease, comprising detecting the presence of a genetic marker associated with Parkinson disease. | 04-16-2009 |
| 20090098558 | DETECTION, IDENTIFICATION AND DIFFERENTIATION OF PROTEUS SPECIES USING THE SPACER REGION - The present invention relates to new nucleic acid sequences derived from the ITS region, between the 16S and 23S ribosomal ribionucleic acid (rRNA) or rRNA genes, to be used for the specific detection and/or identification of | 04-16-2009 |
| 20090098559 | FORENSIC SWAB AND KIT - The present invention relates to a high sensitivity crime scene swab device for maximal recovery of trace forensic DNA evidence left at a crime scene for DNA PCR analysis. More particularly, DNA recovery is obtained from fingerprints lifted from surfaces at the crime scene. The invention also relates to a high sensitivity method for DNA analysis of trace DNA obtained by generating small tandem repeat (STR) profiles using a polymerase chain reaction protocol. | 04-16-2009 |
| 20090098560 | PURIFICATION METHOD AND KITS - A method for separating nucleic acid from a liquid sample, said method comprising the steps of causing a liquid sample containing or suspected of containing said nucleic acid to flow along a bibulous membrane, for example of a conventional lateral flow device, so that nucleic acid is distributed along the length of the membrane. The nucleic acid may be detected on the membrane. | 04-16-2009 |
| 20090098561 | Higher-order cellular information processing devices - The invention provides various signal processing devices for integrating two or more biological signals (e.g., the presence, absence or concentration of specific ligands, etc.) to generate a status output, or a response that modulates one or more biological activities based on the status of the biological signals. The various described signal processing/integration mechanisms may be combined with one another to provide the device with more flexibility in integrating high-order cellular information. The signal processing devices of the invention have many uses in various biological systems, including gene expression control or ligand-concentration sensing. | 04-16-2009 |
| 20090098562 | Methods for identifying stem cells based on nuclear morphotypes - Methods for identifying stem cells and other cells specific to embryogenesis and carcinogenesis, classifying tissue samples, diagnosing precancerous and cancerous or atherosclerotic lesions, testing the value of anticancer agents, discovering macromolecules specifically expressed in particular cell types, using stem cells in restorative tissue therapy as well as methods for preparing tissue samples so heteromorphic nuclear morphotypes remain intact are disclosed. | 04-16-2009 |
| 20090098563 | Diagnosis of (a risk of) disease and monitoring of therapy - Provided are methods for typing a sample of an individual suffering from, or at risk of suffering from, a disease and a method for monitoring treatment of an individual suffering from a disease comprising determining whether a sample from the individual comprises an expression product of AC133 in an amount that is indicative for the disease or for the treatment thereof. That amount may be quantified and compared with a reference value. In one aspect, the amount is compared with an amount of the expression product present in a sample that was obtained from the individual before treatment. Use of a nucleic acid molecule comprising at least part of a sequence of AC133, or an analogue thereof, for monitoring a treatment of an individual suffering from a disease is also provided, as well as a diagnostic kit comprising such nucleic acid molecule. | 04-16-2009 |
| 20090098564 | Biomarkers for diagnosing schizophrenia and bipolar disorder - The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in blood and useful in diagnosing schizophrenia and/or bipolar disorder as well as monitoring therapeutic efficacy of treatment for schizophrenia or bipolar disorder. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention can be used to diagnose schizophrenia and/or bipolar disorder. Measurement of the expression level of products of biomarkers of the invention using polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are compositions and kits containing said polynucleotides and proteins. Further encompassed by the invention is the use of the polynucleotides and proteins to monitor the efficacy of therapeutic regimens. The invention also provides for the identification of methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets of schizophrenia and/or bipolar disorder and a method of screening the genes of said biomarkers for additional markers of disease. | 04-16-2009 |
| 20090098565 | MeCP2E1 gene - The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders. | 04-16-2009 |
| 20090098566 | METHOD OF SYNTHESIZING NUCLEIC ACID - The present invention relates to an oligonucleotide having a novel structure and a method of synthesizing nucleic acid by using the same as a primer. This oligonucleotide is provided at the 5′-side of the primer with a nucleotide sequence substantially the same as a region synthesized with this primer as the origin of synthesis. The present invention realizes synthesis of nucleic acid based on an isothermal reaction with a simple constitution of reagents. Further, the present invention provides a method of synthesizing highly specific nucleic acid on the basis of this method of synthesizing nucleic acid. | 04-16-2009 |
| 20090098567 | COLLECTION DEVICE - A cap which can form an essentially leak-proof seal with an open-ended vessel capable of receiving and holding fluid specimens or other materials for analysis. To minimize potentially contaminating contact between a fluid sample present in the vessel and humans or the environment, the present invention features a cap having a frangible seal which is penetrable by a plastic pipette tip or other fluid transfer device. The cap further includes a filter for limiting dissemination of an aerosol or bubbles once the frangible seal has been pierced. The filter is positioned between the frangible seal and a retaining structure. The retaining structure is positioned on the cap above the filter and may be used to contain the filter within the cap. The material of the retaining structure may be penetrable by a fluid transfer device. | 04-16-2009 |
| 20090104598 | Dopamine D2 receptor gene variants - The present invention provides a method of predicting antipsychotic response to drug therapy comprising testing a sample obtained from a subject for the presence of a polymorphism in the dopamine D2 receptor gene DRD2, wherein the presence of the rs1079598T allele, the rs1125394A allele or both is predictive of the subject being susceptible to drug therapy. | 04-23-2009 |
| 20090104599 | GENETIC VARIANT OF THE ANNEXIN A5 GENE - The present invention relates to a nucleic acid molecule comprising an annexin A5 (ANXA5) gene regulation element which comprises at least one point mutation, whereby said at least one point mutation (substitution) is selected from the group consisting of (i) a point mutation G to A at a position which corresponds to nucleotide 186 of SEQ ID NO: 2; (ii) a point mutation A to C at a position which corresponds to nucleotide 203 of SEQ ID NO: 2; (iii) a point mutation T to C at a position which corresponds to nucleotide 229 of SEQ ID NO: 2; and (iv) a point mutation G to A at a position which corresponds to nucleotide 276 of SEQ ID NO: 2. Furthermore, the present invention provides for a vector comprising the nucleic acid molecule the invention and a host transformed with the vector. The invention also relates to specific uses, in particular diagnostic uses of the nucleic acid molecules described herein. Moreover, the invention relates to a method for haplotyping an ANXA5 gene regulation element in an individual comprising the steps of: (a) isolating a nucleic acid from a sample that has been removed from the individual; (b) determining the presence of the nucleotides present at positions 186, 203, 229 and 276 of the individual's copy of the ANXA5 gene regulation element, wherein the position numbers are determined by comparison to SEQ ID NO: 2; (c) assigning the individuals a particular haplotype by comparison of the nucleotides present at said positions to the nucleotides recited in the haplotypes as defined herein. | 04-23-2009 |
| 20090104600 | Mutation within the connexin 26 gene responsible for prelingual non-syndromic deafness and method of detection - A purified polynucleotide having a chain of nucleotides corresponding to a mutated sequence, which in a wild form encodes a polypeptide implicated in hereditary sensory defect, wherein said mutated purified polynucleotide presents a mutation responsible for prelingual non-syndromic deafness selected from the group consisting of a specific deletion of at least one nucleotide. | 04-23-2009 |
| 20090104601 | GENETIC DIAGNOSIS USING MULTIPLE SEQUENCE VARIANT ANALYSIS - The present invention is in the field of nucleic acid-based genetic analysis. More particularly, it discloses novel insights into the overall structure of genetic variation in all living species. The structure can be revealed with the use of any data set of genetic variants from a particular locus. The invention is useful to define the subset of variations that are most suited as genetic markers to search for correlations with certain phenotypic traits. Additionally, the insights are useful for the development of algorithms and computer programs that convert genotype data into the constituent haplotypes that are laborious and costly to derive in an experimental way. The invention is useful in areas such as (i) genome-wide association studies, (ii) clinical in vitro diagnosis, (iii) plant and animal breeding, (iv) the identification of micro-organisms. | 04-23-2009 |
| 20090104602 | Diagnosis of Tuberculosis - The invention provides a method of diagnosing tuberculosis (TB) in a test subject, said method comprising: (i) providing expression data of two or more markers in a subject, wherein at least two of said markers are selected from transthyretin, neopterin, C-reactive protein (CRP), serum amyloid A (SAA), serum albumin, apoliopoprotein-A1 (Apo-A1), apolipoprotein-A2 (Apo-A2), hemoglobin beta, haptoglobin protein, DEP domain protein, leucine-rich alpha-2-glycoprotein (A2GL) and hypothetical protein DFKZp667I032; and (ii) comparing said expression data to expression data of said marker from a group of control subjects, wherein said control subjects comprise patients suffering from inflammatory conditions other than TB, thereby determining whether or not said test subject has TB. | 04-23-2009 |
| 20090104603 | Tissue Carbohydrate Compositions and Analysis Thereof - The present invention reveals novel methods for producing novel carbohydrate compositions, glycomes, from animal tissues. The tissue substrate materials can be total tissue samples and fractionated tissue parts, or artificial models of tissues such as cultivated cell lines. The invention is further directed to the compositions and compositions produced by the methods according to the invention. The invention further represent methods for analysis of the glycomes, especially mass spectrometric methods. | 04-23-2009 |
| 20090104605 | DIAGNOSIS OF SEPSIS - Methods and apparatus for predicting the development of sepsis in a subject at risk for developing sepsis are provided. Features in a biomarker profile of the subject are evaluated. The subject is likely to develop sepsis if these features satisfy a particular value set. Methods and apparatus for predicting the development of a stage of sepsis in a subject at risk for developing a stage of sepsis are provided. A plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to have the stage of sepsis if these feature values satisfy a particular value set. Methods and apparatus for diagnosing sepsis in a subject are provided. A plurality of features in a biomarker profile of the subject is evaluated. The subject is likely to develop sepsis when the plurality of features satisfies a particular value set. | 04-23-2009 |
| 20090104606 | LATE GESTATION LUNG GENES, FRAGMENTS AND USES THEREOF - The present invention provides a family of genes related to late gestation lung genes and fragments thereof. Embodiments of the present invention provide compositions and methods for the therapeutic treatment of disorders in the lung or other tissues. More particularly the invention provides methods for the treatment of abnormalities in alveolarization, and abnormalities in branching morphogenesis. In other embodiments of the invention the use of the LGL1 gene or related products or fragments thereof in research and diagnostics is provided. | 04-23-2009 |
| 20090104607 | EUBACTERIAL tmRNA SEQUENCES AND USES THEREOF - The present invention is directed to eubacterial tmDNA sequences and the corresponding tmRNA sequences. The present invention is further directed to alignments of eubacterial tmDNA sequences and the use of the sequences and sequence alignments for the development of antibacterial drugs. The present invention is also directed to the use of the sequences for the development of diagnostic assays. | 04-23-2009 |
| 20090104608 | EUBACTERIAL tmRNA SEQUENCES AND USES THEREOF - The present invention is directed to eubacterial tmDNA sequences and the corresponding tmRNA sequences. The present invention is further directed to alignments of eubacterial tmDNA sequences and the use of the sequences and sequence alignments for the development of antibacterial drugs. The present invention is also directed to the use of the sequences for the development of diagnostic assays. | 04-23-2009 |
| 20090104609 | METHOD FOR DISCRIMINATION OF METAPLASIAS FROM NEOPLASTIC OR PRENEOPLASTIC LESIONS - The present invention relates to a method for discrimination of p16 | 04-23-2009 |
| 20090104611 | METHODS OF WHOLE GENOME ANALYSIS - Methods are provided for ascertaining the sequence of a genomic DNA sample by nicking the DNA sample with a restriction nicking enzyme, followed by nick translation with labeled nucleotides, such that the labeled nucleotides can be quantified and compared to a known, reference genome. | 04-23-2009 |
| 20090104612 | DETECTION OF BLOOD GROUP GENES - Disclosed herein are nucleic acid molecules which permit the accurate and direct determination of blood groups based on the presence of certain genes. A method of determining blood groups is also provided. | 04-23-2009 |
| 20090104613 | METHODS AND COMPOSITIONS RELATING TO MULTIPLEXED GENOMIC GAIN AND LOSS ASSAYS - Compositions and methods are provided for detecting genomic DNA gain and loss. Embodiments of inventive assays include using a substrate-attached composite nucleic acid probe which specifically hybridizes to two or more genomic loci in a genomic region of a reference genome. The genomic region is characterized by a first terminus and a second terminus and has an intermediate region disposed between the first terminus and second terminus of at least 400 kilobases. The composite nucleic acid probe includes nucleic acid sequences which specifically hybridize to substantially an entire first genomic locus including the first terminus and to substantially an entire second genomic locus including the second terminus. Methods and compositions are provided which include assessment of two or more genomic DNA references. | 04-23-2009 |
| 20090104614 | QUANTITATIVE MOLECULAR PROBES - In accordance with this invention, a molecular probe for detection of a nucleic acid target containing a preselected target sequence is constructed and has at least two sources of a signal: a conventional reporter source and a reference source in a form of a luminescent material, e.g., a fluorophore, quantum dot, fluorescent nanoparticle, or other fluorescent reference dye/nanoparticle/microparticle conjugated to the molecular probe. | 04-23-2009 |
| 20090104615 | PHENOTYPE PREDICTION - Detection of epigenetic alteration, especially methylation, of a gene or a combination of genes, preferably in a perinatal tissue sample such as umbilical cord, for predicting diverse phenotypic characteristics such as propensity for obesity, altered body composition, impaired cognition, low bone mineral content, neuro-behavioural problems and altered cardiovascular structure and function occurring in an individual. | 04-23-2009 |
| 20090104616 | PRIMER SET FOR AMPLIFYING SULT1A1 GENE, REAGENT FOR AMPLIFYING SULT1A1 GENE CONTAINING THE SAME, AND THE USES THEREOF - A primer set for amplifying a region including sites to be detected of SULT1A1*2 and SULT1A1*3 in the SULT1A1 gene by a gene amplification method is provided, wherein the primer set can amplify the region specifically. A pair of primer set is used including a forward primer consisting of the base sequence of SEQ ID NO: 7 as well as a reverse primer consisting of the base sequence of SEQ ID NO: 18. The use of this primer set makes it possible to specifically and efficiently amplify, a region including both sites where two types of polymorphisms (SULT1A1*2 and SULT1A1*3) of the SULT1A1 gene are generated. | 04-23-2009 |
| 20090104617 | Diagnostic and Prognostic Tests - The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from tissue samples, such as cancer tissue samples. The invention also provides sets of genes that are expressed differentially in malignant pleural mesothelioma. These sets of genes can be used to discriminate between normal and malignant tissues, and between classes of malignant tissues. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumor progression/regression also are provided. | 04-23-2009 |
| 20090104618 | Psoriasin Expression By Breast Epithelial Cells - The invention features methods of diagnosing high grade ductal carcinoma in situ (DCIS) These methods involve measuring: (1) the level of HID-5 in a body fluid (e.g., blood or urine) of a subject suspected of having, or at risk of having, high grade DCIS; or (2) the level of HID-5 gene expression in breast tissue from a subject suspected of having, or at risk of having, high grade DCIS. The invention also embodies a method of inhibiting expression of HID-5 protein in DCIS cells and methods of treating a subject suspected of having, or at risk of having, high grade DCIS. | 04-23-2009 |
| 20090104619 | Human G-Protein Coupled Receptors - Two human G-Protein coupled receptor polypeptides and DNA (RNA) encoding each of such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides. Also disclosed are diagnostic methods for detecting a mutation in the nucleic acid sequence of each of the G-protein coupled receptors. | 04-23-2009 |
| 20090104620 | Simplified Method of Determining Predisposition to Scoliosis - The present invention relates to novel genetic markers associated with scoliosis, risk of developing scoliosis and risk of scoliosis curve progression, and simplified methods and materials for determining whether a human subject has scoliosis, is at risk of developing scoliosis or is at risk of scoliosis curve progression. | 04-23-2009 |
| 20090104621 | METHOD FOR DETECTING A TARGET NUCLEIC ACID SEQUENCE - A method of detecting a target nucleic acid sequence comprising providing a stem-and-loop structured nucleic acid for measurement wherein the nucleic acid comprises complementary sequence portions located at both terminals and a target sequence portion therebetween as well as a double-stranded portion formed by hybridization of the complementary sequence portions located at both terminals and a remaining looped single-stranded portion, providing a probe nucleic acid having a sequence complementary to the target sequence portion wherein one end of the probe nucleic acid being immobilized to a solid substrate surface, reacting the nucleic acid for measurement with the probe nucleic acid to specifically hybridize the target sequence portion of the nucleic acid for measurement to the probe nucleic acid, and detecting presence or absence of the nucleic acid for measurement hybridized to the probe nucleic acid. | 04-23-2009 |
| 20090111093 | Methods and compositions for pre-symptomatic or post-symptomatic diagnosis of alzheimer's disease and other neurodegenerative disorders - Methods, compositions and apparatus (e.g., test kits, test systems, reagents, related computer software, calculators, etc.) for pre-symptomatic or post-symptomatic diagnosis of Alzheimer's Disease or other disorders associated with the formation of β-amyloid deposits (e.g., plaques) and/or β-amyloid fibrils. Also, methods, compositions and apparatus assessing the efficacy of treatments for such disorders. Sample cells, tissue or body fluid are obtained from a human or animal subject and analyzed to determine whether or to what extent certain mitochondrial DNA control region (mtDNA CR). Significantly elevated numbers of these mtDNA CR mutations may indicate that the subject suffers from, or is at increased risk for development of, Alzheimer's Disease or other disorders associated with the formation of β-amyloid deposits (e.g., plaques) and/or β-amyloid fibrils. A significant decrease in the numbers of these mtDNA CR mutations during treatment for the disorder may indicate that the treatment is effective. | 04-30-2009 |
| 20090111094 | Methods for preparing hybrid substrates comprising DNA and antibodies and uses thereof - The invention provides substrates that have antibodies and aptamers bound thereto. The invention also provides methods of detecting target analytes in a sample comprising detecting binding of a target analyte to capture probes on a substrate, wherein some of the capture probes comprise antibodies and other capture probes comprise aptamers, and all of the capture probes are bound to the substrate. In addition, the invention provides substrates that have capture probes and capture oligonucleotides bound thereto, wherein the capture oligonucleotides can hybridize to DNA barcodes. The invention also provides methods of detecting target analytes in a sample comprising contacting the sample with a substrate that has capture probes and capture oligonucleotides bound thereto. | 04-30-2009 |
| 20090111095 | NOVEL DIAGNOSTIC KIT FOR MALIGNANT MELANOMA - The object of the present invention is to find out another tumor marker which is useful for early diagnosis of melanoma, and provide a diagnostic kit and diagnostic method for malignant melanoma using such marker. The present invention provides a diagnostic kit for malignant melanoma, which comprises an antibody against SPARC and an antibody against GPC3. | 04-30-2009 |
| 20090111096 | Method of exhaustive analysis of transcriptionally-active domain (non-methylated domain) on genome - The purpose of the present invention is to provide a method to simultaneously detect a number of the non-methylated regions in the genome of two or more types of cells, and to exhaustively compare and analyze them. | 04-30-2009 |
| 20090111097 | Comparative Analysis of Extracellular RNA Species - The invention provides methods for detecting tumor-associated RNA in plasma, serum, and other bodily fluids. In particular, the invention provides methods for detecting translocated gene RNA, including fusion gene RNA, in plasma or serum or other bodily fluids. | 04-30-2009 |
| 20090111098 | REPORTER GENE ASSAY - The invention provides a more highly accurate assay for measuring the transcriptional activity of a test substance. Disclosed is a reporter gene assay, comprising the steps of contacting a cell having a vector wherein a reporter gene containing a gene encoding an epitope tag is ligated downstream to a recognition sequence of a transcription factor and a nucleotide sequence necessary for transcriptional initiation, with a test substance and detection antibodies; detecting a phenomenon caused by the two kinds of detection antibodies coming close to each other; and correlating the detected phenomenon with the effect of the test substance on transcriptional regulatory mechanism. | 04-30-2009 |
| 20090111099 | Promoter Detection and Analysis - The present disclosure discloses an array-based method for promoter detection and analysis. Promoter sequence candidates are analyzed simultaneously in one reaction vial utilizing a vector comprising a TAG sequence wherein transcriptional products are tagged as they are synthesized, in such a way that one specific transcript is labeled with only one type of tag, and one tag labels only one type of transcript. The transcriptional output is analyzed on conventional arrays. | 04-30-2009 |
| 20090111100 | MINOR GROOVE BINDER - ENERGY TRANSFER OLIGONUCLEOTIDES AND METHODS FOR THEIR USE - The incorporation of a minor groove binder spaced close to one member of a matched FRET set in a minor groove binder-oligonucleotide conjugate significantly reduces background fluorescence of a FRET probe or pair of probes and, consequently, increases the S/B ratios. Fluorescent-labeled probes are useful in carrying out hybridization, multiplex nucleic acid detection, and other procedures. | 04-30-2009 |
| 20090111101 | Automated Cancer Diagnostic Methods Using FISH - In various embodiments methods for automated screening for gene amplification in biological tissue samples using an automated fluorescence microscope to analyze fluorescence in situ hybridized samples are provided. Various additional embodiments provide methods of high throughput screening for gene amplification. | 04-30-2009 |
| 20090111102 | METHODS FOR DETECTING INFLAMMATORY BOWEL DISEASE - The present invention provides for a method of detecting the presence of inflammatory bowel disease in gastrointestinal tissues or cells of a mammal by detecting increased expression of LY6 genes in the tissues or cells of the mammal relative to a control. | 04-30-2009 |
| 20090111103 | METHOD FOR MEASURING THE NUMBER OF ORAL LACTOBACILLUS, AND A PCR PRIMERS-PROBE SET USED FOR THE SAME - There is provided a real-time PCR assay capable of measuring the number of | 04-30-2009 |
| 20090111104 | Method for Monitoring Hydrolytic Activity - The present invention relates to methods of measuring the activity of a hydrolytic agent comprising contacting a biomolecule with a hydrolytic agent in the presence of a fluorescent dye under conditions that allow digestion of the biomolecule by the hydrolytic agent. The fluorescence of the dye is monitored over time and a change in fluorescence signifies digestion of the biomolecule by the hydrolytic agent. The biomolecule is preferably a protein, peptide or proteome but can also be a carbohydrate, oligonucleotide or lipid. Further methods relate to determining an end point for digestion of a biomolecule by a hydrolytic agent, and methods of monitoring digestion of a biomolecule by a hydrolytic agent. The monitoring can be performed on the reaction mixture in real time or via sampling. The invention also relates to kits for carrying out the method. | 04-30-2009 |
| 20090111105 | ANDROGEN-DEPENDENT 1-F-AROMATASE REPORTER GENE - The present invention relates to an androgen-dependent 1-f-aromatase reporter gene and a method for the production of the 1-f-aromatase-reporter gene and use thereof in a method for identifying ligands of the androgen receptor. | 04-30-2009 |
| 20090111106 | Vector System - The present invention provides a vector system comprising a mutated post-transcriptional regulatory element. In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell. | 04-30-2009 |
| 20090111107 | TUMOR SUPPRESSOR GENE P33ING2 - The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins. | 04-30-2009 |
| 20090111108 | Method of Detecting Genetic Mutations - The present invention relates, in general, to drug resistance, and, in particular, to a method of detecting drug resistance populations, including minor drug resistance viral populations. | 04-30-2009 |
| 20090111109 | Genes relating to gastric cancer metastasis - The disclosure provides polynucleotides and polypeptides associated with gastric cancer cells, particularly those having a tendency to metastasize. Also provided are methods and kits for detecting, diagnosing, and/or monitoring metastatic gastric cancer cells. | 04-30-2009 |
| 20090111110 | Method of diagnosing adolescent idiopathic scoliosis and related syndromes causing spinal deformities and method for screening for a compound useful in the treatment of any of these diseases - A method for diagnosing an increased risk for a disease characterized by a dysfunctional melatonin-signaling pathway in an animal comprising detecting the presence or absence of at least one impairment in melatonin-signaling pathway in at least one of the animal's cells, wherein the presence of at least one impairment in melatonin-signaling pathway indicates that the animal possesses an increased risk of developing said disease. and a method of screening for a compound useful in the treatment of a disease characterized by a dysfunctional melatonin-signaling pathway, said method comprising the steps of contacting a candidate compound with at least one cell expressing at least one melatonin-signaling pathway impairment, wherein the candidate compound is selected if said melatonin-signaling pathway impairment is reduced in the presence of the candidate compound as compared to that in the absence thereof. | 04-30-2009 |
| 20090111111 | Detection of Group B Streptococcus - The invention provides methods to detect group B | 04-30-2009 |
| 20090111112 | Nucleic Acid Marker Ladder for Estimating Mass - The invention relates to a nucleic acid marker ladder which is a restriction endonuclease digest, wherein a nucleic acid restriction endonuclease digest is a collection of nucleic acid fragments resulting from complete digestion of one or more nucleic acids by one or more restriction endonucleases; the restriction endonuclease digest contains at least 3 fragments; and the size of the fragments in base pairs is a multiple of an integer, wherein the integer is 10 or more. | 04-30-2009 |
| 20090111113 | SOLID SUPPORT HAVING ELECTROSTATIC LAYER AND USE THEREOF - It is intended to provide a solid support capable of immobilizing nucleic acid molecules in a high proportion, and with a high bond strength to nucleic acid molecules. The solid support comprises a substrate and, provided thereon, an electrostatic layer for electrostatically attracting nucleic acid molecules and functional groups capable of covalently binding to nucleic acid molecules. | 04-30-2009 |
| 20090111114 | RNA EXTRACTION METHOD, RNA EXTRACTION REAGENT, AND METHOD FOR ANALYZING BIOLOGICAL MATERIALS - A method to extract RNA with high purity from biological materials containing RNA in a safe, rapid, and simple procedure and a method to analyze it are provided. The procedure includes the steps of mixing a biological material containing RNA with a predetermined concentration of a chaotropic agent and a predetermined concentration of an organic solvent, allowing the mixed solution to contact a nucleic acid-binding solid phase, washing the nucleic-acid binding solid-phase to which RNA is bound, and eluting RNA from the nucleic-acid binding solid-phase having the bound RNA. Furthermore, the obtained RNA is analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) or the like. | 04-30-2009 |
| 20090111115 | SEQUENCE ANALYSIS USING DECORATED NUCLEIC ACIDS - The present invention provides a sequence interrogation chemistry that combines the accuracy and haplotype integrity of long-read sequencing with improved methods of preparing genomic nucleic acids and analyzing sequence information generated from those nucleic acids. The present invention encompasses compositions comprising decorated nucleic acids stretched on substrates. The present invention further encompasses methods of making stretched decorated nucleic acids and methods of using decorated nucleic acids to obtain sequence information. | 04-30-2009 |
| 20090111116 | Method for monitoring the efficacy of a mycobacterium avium subspecies paratuberculosis therapy - The present invention relates to | 04-30-2009 |
| 20090111117 | DEVICE AND METHOD FOR DETECTING COMPLEX FORMATION - The present invention provides devices and methods for measuring electrically detectable bulk properties of liquid samples. Representative electrically detectable bulk properties measurable by the devices and methods of the invention include resistivity (conductivity) and dielectric constant (permittivity). The electrically detectable bulk properties are determined by comparing the experimental electrical output of the devices with mathematically simulated models of the experimental devices. | 04-30-2009 |
| 20090111118 | METHOD FOR A RAPID ANTIBODY-BASED ANALYSIS OF PLATELET POPULATIONS - A method for identifying a platelet population, preferably a population of immature, reticulated platelets, in a biological sample involves incubating the biological sample for less than minutes with at least one labeled, ligand (e.g., monoclonal antibody) that binds to an epitope or antigen on platelets and with a nucleic acid dye. In one embodiment, the dye is Acridine Orange and the label on the ligand is PE-Cy7. The sample is then analyzed and one or more platelet populations is rapidly identified or quantified by passing the incubated sample through a sensing region of a flow cytometer. In one embodiment, this method occurs without a washing or physical cell separation step. The incubated sample is irradiated with a laser light source, and fluorescence of the labeled ligand and the nucleic acid dye are measured along with at least one additional parameter, e.g., light scatter, direct current, axial light loss, opacity, radio frequency, and fluorescence. These parameters are used to identify qualitatively or quantitatively the platelet populations in the sample. This rapid analytic method is particularly valuable in clinical situations where either low platelet counts or interfering conditions lead to inaccuracies of the platelet measurement. This method is suitable for performance in an automated hematology analyzer. | 04-30-2009 |
| 20090111119 | Rapid in vivo identification of biologically active nucleases - Disclosed herein are methods and compositions for rapidly identifying and ranking nucleases for specific cleavage of a target sequence. | 04-30-2009 |
| 20090111120 | METHYLATION OF GENES AS A PREDICTOR OF POLYP FORMATION AND RECURRENCE - The present invention provides methods for identifying or assessing probabilities for developing an abnormal condition in subject and for the recurrence of the abnormal condition in the subject after receiving treatment. The method comprises determining the methylation status of at least one gene in the subject and comparing this methylation status to normal methylation status. Differences between the methylation status of the one or more genes is indicative of the subject developing an abnormal condition or for the recurrence of the abnormal conditions after receiving treatment. | 04-30-2009 |
| 20090117538 | Methods for Obtaining Gene Tags - The present invention provides methods for providing as tags the nucleotide sequences at the 5′ end of mRNA. The method of the present invention comprises the step of synthesizing cDNA using, as a template, mRNA whose CAP structure is linked with a IIs linker having a type IIs endonuclease recognition sequence. Tags including the nucleotide sequence from the 5′ end of mRNA are generated by reacting the type IIs endonuclease to cDNA. Tags can be generated from all mRNA, independently of their nucleotide sequences. Methods for identifying transcriptional start sites and primers for full-length cDNA synthesis are provided based on the nucleotide sequence information of tags of the present invention. | 05-07-2009 |
| 20090117539 | DNA sequences for gene suppression - The present invention provides methods of improving DNA sequences for gene suppression mediated by double-stranded RNA, and constructs and transgenic organisms containing such improved DNA sequences. | 05-07-2009 |
| 20090117540 | Methods for detection of a target nucleic acid by forming a cleavage structure using an RNA polymerase - The invention relates to compositions and methods for generating a signal indicative of the presence of a target nucleic acid in a sample, where the compositions and methods include an RNA polymerase, a FEN nuclease, and a probe. | 05-07-2009 |
| 20090117541 | METHODS OF DETECTING TPMT MUTATIONS - Methods and compositions are described for use in the rapid and simultaneous screening of one or more samples for one or more mutations in the TPMT gene. The methods and compositions of the present invention can be used to rapidly determine if a mutation of the TPMT gene is present in the genome of a subject. Identifying which mutations are present in an individual allows the clinician to design an appropriate therapy using drugs metabolized by TPMT for that individual. | 05-07-2009 |
| 20090117542 | UNIQUE SHORT TANDEM REPEATS AND METHODS OF THEIR USE - Methods for DNA fingerprinting identification of human DNA samples, comprising: a) exposing a DNA sample of an individual to at least one primer specific for a Y chromosome polymorphism at a predetermined loci, said loci being chosen from OSU9, OSU14, OSU22, OSU35, OSU51, OSU57, OSU67, OSU70, OSU73, OSU77, with the proviso that if OSU70 is selected then at least one other OSU locus is also selected; b) amplifying DNA of the DNA sample using the at least one primer specific for a Y chromosome polymorphism; and c) identifying the size of an amplified product. Primers for the methods are also provided. | 05-07-2009 |
| 20090117543 | METHODS AND COMPOSITIONS FOR INDUCING SIRTUINS - Provided herein are compositions comprising agents that increase the level of expression of a sirtuin gene. Also provided are methods for purifying and isolating a factor from serum that stimulates the expression of a sirtuin gene. Diagnostic methods for determining whether a subject is calorically restricted or resistant to stress are also provided. | 05-07-2009 |
| 20090117544 | METHOD OF DESIGNING PRIMERS FOR USE IN METHOD OF DETECTING TARGET NUCLEIC ACID AND ASSAY KIT - A method of designing primers for use in a method of detecting an amplification product by hybridizing it with a probe, the amplification product is amplified from a target nucleic acid with the primers, including placing F3, F2 and F1 regions in this order from a 5′ terminal side and Bc, B2 | 05-07-2009 |
| 20090117545 | Glycine riboswitches, methods for their use, and compositions for use with glycine riboswitches Cross-Reference to Related Applications - It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitches” (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies. In addition, the architecture of riboswitches allows actual pieces of the natural switches to be used to construct new non-immunogenic genetic control elements, for example the aptamer (molecular recognition) domain can be swapped with other non-natural aptamers (or otherwise modified) such that the new recognition domain causes genetic modulation with user-defined effector compounds. The changed switches become part of a therapy regimen-turning on, or off, or regulating protein synthesis. Newly constructed genetic regulation networks can be applied in such areas as living biosensors, metabolic engineering of organisms, and in advanced forms of gene therapy treatments. | 05-07-2009 |
| 20090117546 | Disease detection by digital protein truncation assays - Genetic diseases can be diagnosed by detection of mutations in causative genes. Protein truncation assays can be used to detect gene products of truncation-type mutations. However, the sensitivity of the assays is often insufficient to detect mutations present in a sample of DNA at a low frequency. Sensitivity can be increased by dividing samples so that the signal generated by a mutant allele comprises a larger fraction of the total alleles than prior to dividing. Thus a previously undetectable signal generated by the mutant allele can become detectable in the assay. Such increased sensitivity permits detection at early stages and in samples having high levels of other alleles. | 05-07-2009 |
| 20090117547 | NOVEL HAPLOTYPE OF HUMAN T2R RECEPTOR hT2R50 AND ITS USE IN ASSAYS FOR IDENTIFYING HUMAN BITTER TASTE MODULATORS - The present invention relates to the discovery of a novel haplotype of the human taste receptor hT2R50 in the T2R taste receptor family that responds to particular bitter ligands, i.e., 2-acetylpyrazine and ethylpyrazine. The present invention also relates to the use of this novel haplotype in assays for identifying ligands that modulate the activation of the hT2R50 taste receptor. These compounds potentially may be used as additives in foods, beverages and medicinals for modifying (blocking) hT2R50-associated bitter taste. | 05-07-2009 |
| 20090117548 | ANALYSIS OF HIV-1 CORECEPTOR USE IN THE CLINICAL CARE OF HIV-1 INFECTED PATIENTS - A change in viral tropism occurs in many HIV positive individuals over time and can be indicated by a change in coreceptor usage from CCR5 to CXCR4. The change in coreceptor usage to CXCR4 has been shown to correlate with increased disease progression. In patients undergoing HAART, the predominant populations of virus can be shifted back to CCR5-mediated entry after the CXCR4-specific strains have emerged. The present invention relates to a diagnostic method to monitor coreceptor use in the treatment of human immunodeficiency virus (HIV) infection. The present invention further relates to a diagnostic method applied to HIV-positive individuals undergoing HAART to monitor the suppression of CXCR4 specific strains. The diagnostic methods can be used to assist in selecting antiretroviral therapy and to improve predictions of disease prognosis over time. | 05-07-2009 |
| 20090117549 | Aptamer-based methods for identifying cellular biomarkers - In this invention, a biomarker discovery method has been developed using specific biotin-labeled oligonucleotide ligands and magnetic streptavidin beads. In one embodiment, the oligonucleotide ligands are firstly generated by whole-cell based SELEX technique. Such ligands can recognize target cells with high affinity and specificity and can distinguish cells that are closely related to target cells even in patient samples. The targets of these oligonucleotide ligands are significant biomarkers for certain cells. These important biomarkers can be captured by forming complexes with biotin-labeled oligonucleotide ligands and collecting the complexes using magnetic streptavidin beads, whereupon the captured biomarkers are analyzed to identify the biomarkers. Analysis of biomarkers include HPLC-Mass Spectroscopy analysis, polyacrylamide gel electrophoresis, flow cytometry, and the like. The identified biomarkers can be used for pathological diagnosis and therapeutic applications. Using the disclosed methods, highly specific biomarkers of any kinds of cells, in particular cancer cells, can easily be identified without prior knowledge of the existence of such biomarkers. | 05-07-2009 |
| 20090117550 | Assessing brain aneurysms - This document provides methods and materials related to assessing brain conditions within mammals. For example, methods and materials that can be used to determine whether or not a mammal (e.g., a human) with a brain aneurysm is likely to experience brain aneurysm rupture are provided. | 05-07-2009 |
| 20090117551 | METHOD FOR SIMULTANEOUS ANALYSIS OF MULTIPLE BIOLOGICAL REACTIONS OR CHANGES IN IN VIVO CONDITIONS - It is an object of the preset invention to provide an activity measurement molecule necessary for measuring biological reactions or changes in in vivo conditions, and a method for measuring activity using the above activity measurement molecule. It is intended to provide an activity measurement molecule used for simultaneously analyzing multiple biological reactions and/or changes in in vivo conditions, which is characterized in that one or more fluorescent molecule-labeled and/or -unlabeled biomolecules used as targets of the biological reactions or changes in in vivo conditions bind onto a quantum dot, and a method for simultaneously analyzing multiple biological reactions and/or changes in in vivo conditions using the above activity measurement molecule. | 05-07-2009 |
| 20090117552 | Method for Detection and Quantification of Target Nucleic Acids in a Sample - The present invention relates to methods for multiplex detection and quantification of target nucleic acid sequences in a sample comprising the steps of: (i) providing a solid support having immobilized thereon an array of detector oligonucleotides, wherein said array of detector oligonucleotides is designed by random selection of non-eukaryotic genomic sequences followed by random selection of oligonucleotide sequences and subsequent conversion of these oligonucleotide sequences such that these are composed of only three types of nucleotides; (ii) providing a sample having added thereto a fixed amount of control nucleic acid of known sequence; (iii) contacting said sample with at least two probes that hybridise to adjacent sites of a target sequence under conditions favouring hybridisation between the sample nucleic acids and the said at least two probes, wherein, a) a first probe is composed of a 5′ end sequence part for hybridisation to a PCR primer and a 3′ end sequence part for hybridisation to the target nucleic acid; and b) a second probe is composed of a 5′ end sequence part for hybridisation to the target nucleic acid, and a 3′ end sequence part for hybridisation with a PCR primer, and c) an intermediate sequence is present in between said 5′ and 3′ end sequence parts of said first or second probe; and d) said second probe is characterized by having 5′ phosphate group allowing ligation with a 3′ hydroxyl group at the said first probe forming a ligation-mediated probe; (iv) ligation of the said hybridised first and second probes to form ligation-mediated probes; (v) contacting a set of detectable labelled PCR primers with the ligation-mediated probes allowing amplification thereof; (vi) detection and quantification of sample nucleic acids via hybridisation of the said intermediate parts within the amplified ligation-mediated probes onto the array of detector oligonucleotides provided in The present invention also relates to the use of said methods as well as microarrays and kits for performing said methods. | 05-07-2009 |
| 20090117553 | NUCLEIC ACID MELTING ANALYSIS WITH SATURATION DYES - Methods are provided for nucleic acid analysis wherein a target nucleic acid is mixed with a dsDNA binding dye to form a mixture. Optionally, an unlabeled probe is included in the mixture. A melting curve is generated for the target nucleic acid by measuring fluorescence from the dsDNA binding dye as the mixture is heated. Dyes for use in nucleic acid analysis and methods for making dyes are also provided. | 05-07-2009 |
| 20090117554 | POLYNUCLEOTIDE AND PROTEIN INVOLVED IN SYNAPTOGENESIS, VARIANTS THEREOF, AND THEIR THERAPEUTIC AND DIAGNOSTIC USES - The invention relates to a method and a kit for diagnosing autism linked to a mutation in a protein belonging to the family of human neuroligins. | 05-07-2009 |
| 20090117555 | Microfluidic Flow Lysometer Device, System and Method - The invention provides a device, system and method that enables a microfluidic flow lysometer cell analyzer. Using a population of suspended living cells. cell surface molecule detection reagents, and cell cytoplasm (or nuclear) molecule detection reagents, this microfluidic cell analyzer can rapidly analyze a population of cells by running them on a one-at-a-time basis through small capillary channels. The cell's morphology or surface markers are analyzed, then the cells are lysed, and the molecules present in the cell's cytoplasm or nuclear material are analyzed. Cell morphology is then analyzed as the cell surface molecules are correlated with the molecules present in the same cell's cytoplasm or nucleic acids, and this correlated cell population data is then presented to a user for interpretation. The invention also addresses issues such as device fouling, correction for experimental artifacts (incomplete cell lyis, variable cell debris volume effects), and inadequate data collection that hampered earlier efforts in this area. | 05-07-2009 |
| 20090117556 | Association of Single Nucleotide Polymorphisms in the CBFA2T1 and DECR1 Genes with Performance and Carcass Merit of Beef Cattle - Aspects of the present invention also provide novel compositions and methods based on novel CBFA2T1 and/or DECR1 single nucleotide polymorphisms selected from the group consisting of CBFA2T1 SNP1, CBFA2T1 SNP2, CBFA2T1 SNP3, CBFA2T1 SNP4, DECR1 SNP5, DECR1 SNP6, DECR1 SNP7, DECR1 SNP8, DECR1 SNP9, DECR1 SNP10, DECR1 SNP11, DECR1 SNP12 and DECR1 SNP13, which may provide novel markers for carcass quality, growth and/or feed efficiency. Additional aspects provide for novel methods which may comprise marker-assisted selection or marker-assisted management to improve carcass quality, growth and/or feed efficiency in cattle. | 05-07-2009 |
| 20090117557 | Rapid Detection of Microorganisms - Tools and methods for detecting the presence bacteria, yeast and mold in a sample obtained from a food sample are provided. The methods employ a polymerase chain reaction and primer and probe sets that are based on the 16S rRNA and squalene-hopene cyclase genes of | 05-07-2009 |
| 20090117558 | Method for improved specificity in probe based assays - Disclosed are compositions and methods for analyzing a target sequence in a sample. Generally, the method includes use of at least one pair of probes (Probe A and Probe B). In one embodiment, Probe A hybridizes to wanted and unwanted nucleic acid in the sample and bears a fluorophore and Probe B hybridizes to unwanted nucleic acid in the sample and bears a quencher. Fluorescence signal from Probe A hybridizing to unwanted nucleic acid is quenched by any relatively close hybridization of Probe B hereby increasing the specificity for the presence, amount or absence of the wanted target sequence. In preferred embodiments, the method is referred to as Fluorescence In-Situ Hybridization (FISH). The invention has many useful applications including rapidly detecting a microbial target sequence in a clinical sample. | 05-07-2009 |
| 20090117559 | Methods for Determining Probability of an Adverse or Favorable Reaction to a Niacin Receptor Agonist - The present invention relates generally to a GPR109A niacin receptor. The present invention relates more particularly to assessing a GPR109A polymorphism in an individual, wherein the GPR109A polymorphism is indicative of the subject's risk for an adverse reaction to the administration of a GPR109A receptor agonist, wherein the adverse reaction is associated with stimulation of MAP kinase activity by the GPR109A receptor agonist. More specifically, the present invention relates to assessing a GPR109A polymorphism in an individual and determining the level of risk for the subject for experiencing an adverse reaction, wherein the subject's GPR109A zygosity is predictive of the risk for a cutaneous flushing response that can be experienced following administration of a GPR109A receptor agonist. | 05-07-2009 |
| 20090117560 | Method of Forming Self Assembly Substance on Microsphere and Method of Detecting Target Analyte - It is intended to provide a method, in which the sensitivity in detecting a target analyte on a microsphere can be elevated and plural items can be detected at the same time. The presence of at least one target analyte in a sample is detected by bonding a microsphere having a fluorescent substance on the surface and the target analyte to a self assembly substance formed by using two oligonucleotide probes having complementary base sequence regions which are hybridizable with each other via the target analyte, thus forming a self assembly substance-bonded particle, and then analyzing the self assembly substance-bonded particle. | 05-07-2009 |
| 20090117561 | DIFFERENTIAL EXPRESSION GENE PROFILES AND APPLICATIONS IN MOLECULAR STAGING OF HUMAN GASTRIC CANCER - The invention provides methods for detecting differential gene expression in intestinal gastric tissue in a mammal by comparing the expression of specific genes in an intestinal gastric tissue suspected of being cancerous with that of the corresponding adjacent intestinal gastric tissue or a normal gastric mucosa tissue. The methods can be used in diagnosing or monitoring the progression of intestinal gastric cancer and determining the levels of differentiation of intestinal gastric cancer Systems and kits for methods of the invention are also provided. | 05-07-2009 |
| 20090117562 | Method and kit for diagnosing Autism using gene expression profiling - This invention relates to DNA microarray technology, and more specifically to methods and kits for identifying autism and autism spectrum disorders in humans. | 05-07-2009 |
| 20090117563 | Identification of TRPML3 (MCOLN3) as a Salty Taste Receptor and Use in Assays for Identifying Taste (Salty) Modulators and/or Therapeutics that Modulate Sodium Transport, Absorption or Excretion and/or Aldosterone and/or Vasopressin Production or Release - This invention relates to the elucidation that TRPML3 is involved in salty taste perception in primates including humans and likely other mammals (given the significance of sodium and other ions to physiological functions and conditions this phenotype is likely strongly conserved in different animals). The invention also relates to the discovery that the TRPML3 gene also modulates one or more of sodium metabolism, sodium excretion, blood pressure, fluid retention, cardiac function and urinary functions such as urine production and excretion. The invention also relates to transgenic animals that have been engineered to express or knock out TRPML3 expression and assays using TRPML3 expressing animals, cells and isolated ion channel polypeptides for identifying compounds that modulate TRPML3-associated functions including salty taste, sodium metabolism, sodium excretion, blood pressure, fluid retention, cardiac function and urinary functions such as urine production and excretion. | 05-07-2009 |
| 20090117564 | ESTROGEN RECEPTOR GENES AND UTILIZATION THEREOF - An estrogen receptor gene and utilization of the estrogen receptor gene. The estrogen receptor gene contains a nucleotide sequence coding for any of the following amino acid sequences: (a) the amino acid sequence of SEQ ID NO:1, (b) the amino acid sequence of SEQ ID NO:4, (c) the amino acid sequence of SEQ ID NO:23, (d) an amino acid sequence exhibiting 95% or more amino acid identity to the amino acid sequence of SEQ ID NO:1, (e) an amino acid sequence exhibiting 95% or more amino acid identity to the amino acid sequence of SEQ ID NO:4, and (f) an amino acid sequence exhibiting 85% or more amino acid identity to the amino acid sequence of SEQ ID NO:23. | 05-07-2009 |
| 20090117565 | Compositions and methods for diagnosis and treating mood disorders - The present invention provides methods for diagnosing mental disorders such as mood disorders, including bipolar disorder I and II and major depression; The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders. | 05-07-2009 |
| 20090117566 | Compositions and methods for the diagnosis and treatment of tumor - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 05-07-2009 |
| 20090117567 | EUBACTERIAL tmRNA SEQUENCES AND USES THEREOF - The present invention is directed to eubacterial tmDNA sequences and the corresponding tmRNA sequences. The present invention is further directed to alignments of eubacterial tmDNA sequences and the use of the sequences and sequence alignments for the development of antibacterial drugs. The present invention is also directed to the use of the sequences for the development of diagnostic assays. | 05-07-2009 |
| 20090117568 | EUBACTERIAL tmRNA SEQUENCES AND USES THEREOF - The present invention is directed to eubacterial tmDNA sequences and the corresponding tmRNA sequences. The present invention is further directed to alignments of eubacterial tmDNA sequences and the use of the sequences and sequence alignments for the development of antibacterial drugs. The present invention is also directed to the use of the sequences for the development of diagnostic assays. | 05-07-2009 |
| 20090117569 | EUBACTERIAL tmRNA SEQUENCES AND USES THEREOF - The present invention is directed to eubacterial tmDNA sequences and the corresponding tmRNA sequences. The present invention is further directed to alignments of eubacterial tmDNA sequences and the use of the sequences and sequence alignments for the development of antibacterial drugs. The present invention is also directed to the use of the sequences for the development of diagnostic assays. | 05-07-2009 |
| 20090117570 | EUBACTERIAL tmRNA SEQUENCES AND USES THEREOF - The present invention is directed to eubacterial tmDNA sequences and the corresponding tmRNA sequences. The present invention is further directed to alignments of eubacterial tmDNA sequences and the use of the sequences and sequence alignments for the development of antibacterial drugs. The present invention is also directed to the use of the sequences for the development of diagnostic assays. | 05-07-2009 |
| 20090117571 | IMPEDANCE SPECTROSCOPY OF BIOMOLECULES USING FUNCTIONALIZED NANOPARTICLES - A biosensor system includes a functionalized interdigitated electrode, functionalized nanoparticles, a current/voltage signal generator, and a circuit analyzer. The interdigitated electrode can be functionalized by coating an exposed surface with first biomolecular probes. The nanoparticles are functionalized by coating an outer surface with second biomolecular probes. A signal generator provides a signal (e.g., an alternating current or voltage) having a selected range of frequencies. A circuit analyzer analyzes electrical parameters of the circuit as the signal is applied. Sensitivity is increased by the presence of functionalized nanoparticles in the system. An analytic method includes measuring changes in electrical parameters of the circuit over the range of frequencies. Using these measurements, the biosensor system can determine whether a target biomolecule is bound. The biosensor system can also identify a biomolecule by comparing the detected signal or “electro-fingerprint” with a reference set of signals over the frequency range. | 05-07-2009 |
| 20090117572 | Cell-Based Fluorescence Resonance Energy Transfer (FRET) Assays For Clostridial Toxins - The present invention provides a method of determining clostridial toxin activity by (a) contacting with a sample a cell containing a clostridial toxin substrate that includes a donor fluorophore; an acceptor having an absorbance spectrum overlapping the emission spectrum of the donor fluorophore; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the donor fluorophore and the acceptor, where resonance energy transfer is exhibited between the donor fluorophore and the acceptor under the appropriate conditions; (b) exciting the donor fluorophore; and (c) determining resonance energy transfer of the contacted cell relative to a control cell, where a difference in resonance energy transfer of the contacted cell as compared to the control cell is indicative of clostridial toxin activity. | 05-07-2009 |
| 20090117573 | Locus specific amplification using array probes - Methods are provided for multiplexed amplification of selected targets and analysis of the amplified targets. In preferred aspects the amplification and analysis take place on the same solid support and preferably in a localized area such as a bead or a feature of an array. In preferred aspects the analysis is a determination of sequence at one or more locations in the amplified target. The methods may be used for genotyping, sequencing and analysis of copy number. | 05-07-2009 |
| 20090117574 | SELF-ACTUATING SIGNAL PRODUCING DETECTION DEVICES AND METHODS - An assay system is provided of great sensitivity and portability where the presence of a specific target in a sample, as well as its concentration (qualification and quantification) is detected by reason of a potential or voltage in a closed circuit, built up a redox reaction. The reaction is produced by binding a capture moiety to an enzymatic redox reaction partner, allowing the capture moiety to bind to any target in the sample, and washing any such bound target. The bound target, if not immobilized, may be immobilized through use of a second capture moiety. Substrate for the enzyme is then added. The action of the enzyme upon the substrate frees electrons, creating a potential across an anode and cathode which may be separated by a membrane. | 05-07-2009 |
| 20090117575 | Detection Probe Acting by Molecular Recognition - The present invention relates to a detection probe acting by molecular recognition of a target sequence, comprising successively in the 5′-3′ direction:
| 05-07-2009 |
| 20090117576 | METHODS FOR ANALYZING NUCLEIC ACID - The present invention relates to methods and compositions for analyzing nucleic acids. In particular, the present invention provides methods and compositions for the detection and characterization of nucleic acid sequences and sequence changes. The methods of the present invention permit the detection and/or identification of genetic polymorphism such as those associated with human disease and permit the identification of pathogens (e.g., viral and bacterial strain identification). | 05-07-2009 |
| 20090117577 | METHODS TO IDENTIFY COMPOUNDS USEFUL FOR TUMOR SENSITIZATION TO DNA DAMAGE - Cdc25A is herein identified as a substrate for β-TrCP1- or β-TrCP2-mediated ubiquitination and subsequent degradation via the ubiquitin-proteasome pathway. In particular, it has been found that interfering with β-TrCP expression or function, or increasing β-TrCP degradation, leads to accumulation of Cdc25A in a cell. Since degradation of Cdc25A is a key feature of the response to DNA damage, leading to a stall in the cell cycle during which the cell can repair the damage, Cdc25A accumulation can abolish this response, thereby sensitizing the cell to DNA damage. Described herein are assays for identifying β-TrCP inhibitors, and method of using such inhibitors for modulating Cdc25A degradation, sensitization of tumor cells, and as adjuvants in cancer therapy based on DNA damaging agents. | 05-07-2009 |
| 20090117578 | Method for identifying type I diabetes mellitus in humans - A method and system for classifying subject populations utilizing predictive and diagnostic biomarkers for type I diabetes mellitus. The method including determining the levels of a variety of markers within the serum or plasma of a target organism and correlating this level to general populations as a screen for predisposition or progressive monitoring of disease presence or predisposition. | 05-07-2009 |
| 20090117579 | Relating To The Handling Of DNA - A variety of methods are provided which use a silicon or silicon dioxide channel to extract DNA from a sample and then release it at a later point. The extraction channels are simple to manufacture and reliable in use. Prior art problems with entrainment of gas, liquid and solid material within channels are addressed. The techniques provide a convenient way of controlling the amount or concentration of DNA in the eluant. | 05-07-2009 |
| 20090123911 | ISOLATED STAPHYLOCOCCUS DNAX SUBUNIT AND USE THEREOF - The duplex DNA of chromosomes is replicated in a multicomponent process. A helicase unwinds the DNA, a replicase synthesizes new DNA, and primase repeatedly synthesizes new primed starts on the lagging strand. The present invention is directed to the genes from Gram positive bacterium encoding these proteins, and their characterization. | 05-14-2009 |
| 20090123912 | Methods for quantitating small RNA molecules - In one aspect, the present invention provides methods for amplifying a microRNA molecule to produce DNA molecules. The methods each include the steps of: (a) using primer extension to make a DNA molecule that is complementary to a target microRNA molecule; and (b) using a universal forward primer and a reverse primer to amplify the DNA molecule to produce amplified DNA molecules. In some embodiments of the method, at least one of the forward primer and the reverse primer comprise at least one locked nucleic acid molecule. | 05-14-2009 |
| 20090123913 | Detection of nucleic acid differences using endonuclease cleavage/ligase resealing reactions and capillary electrophoresis or microarrays - The present invention is directed to various methods for detecting DNA sequence differences, including single nucleotide mutations or polymorphisms, one or more nucleotide insertions, and one or more nucleotide deletions. Labeled heteroduplex PCR fragments containing base mismatches are prepared. Endonuclease cleaves the heteroduplex PCR fragments both at the position containing the variation (one or more mismatched bases) and, to a lesser extent, at non-variant (perfectly matched) positions. Ligation of the cleavage products with a DNA ligase corrects non-variant cleavages and thus substantially reduces background. This is then followed by a detection step in which the reaction products are detected, and the position of the sequence variations are determined. | 05-14-2009 |
| 20090123914 | Genomic Assay - A method of detecting a nucleic acid sequence in a genomic sample, includes: providing the genomic sample containing a target nucleic acid sequence of a duplex nucleic acid; providing, a probe containing a probe nucleic acid sequence; providing a hybridization mixture containing the genomic sample, the probe, a hybridization promoting agent and labels; incubating the hybridization mixture; irradiating the incubated mixture with radiation effective to stimulate at least some of the labels to emit energy; and detecting from a fluorescent signal whether the probe perfectly matches the target nucleic acid sequence, wherein the detecting is completed within sixty minutes of the hybridization mixture providing, and the method is conducted without denaturing and without PCR amplifying the duplex nucleic acid. A kit for practicing the method includes the probe, the hybridization promoting agent, and labels. | 05-14-2009 |
| 20090123915 | HIGH THROUGHPUT METHODS COMPRISING ANALYSIS OF REPETITIVE ELEMENT DNA METHYLATION - Preferred aspects provide novel high-throughput, sensitive methods (e.g., real-time PCR-based (MethyLight™) reactions) for detection and/or measurement of global genomic 5-methylcytosine content, based on measurement of DNA methylation of Alu, LINE-1 repetitive sequences, and the chromosome 1 centromeric satellite alpha and juxtacentromeric satellite 2 repeat sequences. Additional aspects provide sensitive methods for determining the amount of a DNA (e.g., in formalin-fixed, paraffin-embedded tissues). Combined (mean) use of Alu and Sat2 repeat methylation measurements provides for a surprisingly close correlation with global genomic 5-methylcytosine content measurements obtained by HPLC. Methylation of Alu repeats was determined to be closely associated with HPLC-based global methylation levels, as was methylation of satellite 2 and LINE-1 global genomic 5-methylcytosine content. The assays provide surrogate markers for global genomic 5-methylcytosine content analyses, and have substantial utility for high-throughput and population-based studies (e.g., genetic and dietary influences on global DNA methylation, folate deficiency, MTHFR gene polymorphisms, etc). | 05-14-2009 |
| 20090123916 | Nucleic Acid Fragments and Specific Detection Method By Molecular Identification of Different Bacteria Species of the Genus Acinetobacter - The present invention relates to complete rpoB genes, rpoB gene fragments SEQ. ID. no 9 to 32 and fragments of hypervariable sequences of said rpoB genes SEQ. ID. no 33 to 56 and 77 to 100, and to nucleic acid fragments of non-coding hypervariable sequences flanking the rpoB gene of sequences SEQ. ID. no 121 to 144 and 165 to 188, and also to oligonucleotides of species-specific sequences taken from said fragments of hypervariable sequences and to consensus oligonucleotides between the different species of | 05-14-2009 |
| 20090123917 | METHODS FOR QUANTIFYING MICRORNA PRECURSORS - Provided herein is a sensitive, high throughput, real-time PCR assay to monitor the expression of miRNA precursors. Gene specific primers and reverse transcriptase were used to convert the primary precursors and pre-miRNAs to cDNA. The expression of 23 miRNA precursors in six human cancer cell lines was assayed using the PCR assay. The miRNA precursors accumulated to different levels when compared to each other or when a single precursor is compared in the various cell lines. The precursor expression profile of three miRNAs determined by the PCR assay was identical to the mature miRNA expression profile determined by Northern blotting. We propose that the PCR assay may be scaled up to include all of the 150+ known human miRNA genes and can easily be adaptable to other organisms such as plants, | 05-14-2009 |
| 20090123918 | Human Protooncogene TRG and Protein Encoded Therein - Disclosed are a protooncogene and a protein encoded by the same. The protooncogene of the present invention, known to be involved in human carcinogenesis, may be effectively used for diagnosing various cancers including uterine cancer, leukemia, lymphoma, colon cancer, lung cancer, skin cancer, etc. | 05-14-2009 |
| 20090123919 | Diagnosing Pathological Conditions Using Interallelic Epigenetic Variations - The present invention is of interallelic epigenetic alterations in cells of cancer-stricken individuals which can be used for diagnosing cancer or cancer risk. In addition, the present invention is of interallelic epigenetic pattern alterations and/or interallelic replication pattern alterations in cells of a conceptus having imbalanced chromosome(s) or in maternal cells of the pregnant female carrying the conceptus, which can be used for prenatal diagnosis of chromosomal imbalances in the conceptus. Moreover, the present invention is of interallelic epigenetic pattern alterations and/or interallelic replication pattern alterations in cells of individuals having a chromosomal imbalance mosaicism which can be used for diagnosing chromosomal imbalance mosaicism, either prenatally or after birth. | 05-14-2009 |
| 20090123920 | JAK2 MUTATIONS - The invention disclosed herein is based on the identification of novel mutations in the JAK2 gene and JAK2 protein. The invention provides methods and compositions useful for diagnosing neoplastic diseases including, for example, myeloproliferative diseases. The invention also provides methods and compositions useful for determining a prognosis of an individual diagnosed as having a neoplastic disease. | 05-14-2009 |
| 20090123921 | IMMUNOGLOBULIN LIBRARIES - Methods and compositions for the screening and isolation of ligand-binding polypeptides, such as antibodies. In some aspects, methods of the invention enable the isolation of intact soluble antibodies comprising a constant domain. Screening methods that employ genetic packages such as bacteria and bacteriophages enable high through-put identification of ligand binding molecules. | 05-14-2009 |
| 20090123922 | Bead Bound Combinatorial Oligonucleoside Phosphorothioate And Phosphorodithioate Aptamer Libraries - The present invention includes composition and methods for making and using a combinatorial library having two or more beads, wherein attached to each bead is a unique nucleic acid aptamer that have disposed thereon a unique sequence. The library aptamers may be attached covalently to the one or more beads, which may be polystyrene beads. The aptamers may include phosphorothioate, phosphorodithioate and/or methylphosphonate linkages and may be single or double stranded DNA, RNA or even PNAs. | 05-14-2009 |
| 20090123923 | Method for obtaining information regarding quantity of DNA after non-methylated cytosine converting treatment in analysis of DNA methylation - The present invention provides an easy and accurate method for obtaining information regarding a quantity of DNA included in a sample used for analyzing a methylation of a target DNA, comprising steps of: treating a biological sample containing DNA including the target DNA with a non-methylated cytosine converting agent for converting non-methylated cytosine of the DNA into another base; and obtaining information regarding a quantity of DNA included in the sample treated in the treating step by using an oligonucleotide complementary to a cytosine-free region of the target DNA. | 05-14-2009 |
| 20090123924 | Method for Breast Cancer Diagnosis - The invention relates to a method for the in vitro diagnosis of breast cancer in a patient who may be suffering from a breast cancer, characterized in that it comprises the following steps:
| 05-14-2009 |
| 20090123925 | CANCER THERAPY PROGNOSIS AND TARGET - The present invention relates to a gene and/or protein expression based method of predicting response to platinum based chemotherapy for lung cancer patients, as well as a method of predicting prognosis of survival based on protein expression and type of lung cancer. The invention also provides novel targets for screening candidate anti-cancer agents. | 05-14-2009 |
| 20090123926 | Method for the diagnosis of genetic diseases by molecular combing and diagnostic kit - The invention concerns a method for detecting or locating one or several genes of one or several specific A DNA sequence or one or several molecules reacting with DNA on a B DNA characterised in that it consists in: (a) fixing and combing a certain amount of said B DNA on a combing surface; (b) reacting the product of the B combing with one or several probes, linked with the gene(s) or specific A DNA sequences, or with the molecules capable of reacting with DNA; (c) extracting information corresponding to at least one of the following categories: (1) the position of the probes. (2) the distance between the probes, (3) the size of the probes (the total sum of sizes for quantifying the number of hybridised probes) for determining therefrom the presence, the location and/or the amount of genes or specific A DNA sequences. This method can be used in particular for the diagnosis of genetic diseases. | 05-14-2009 |
| 20090123927 | ISOLATION OF PRECURSOR CELLS AND THEIR USE FOR TISSUE REPAIR - Cartilage-derived morphogenetic protein CDMP-1 or a transforming growth factor β having at least 80% homology with CDMP-1, or a factor co-expressed and/or co-detectable therewith, is used as a marker of skeletal precursor cells from any part of a mammalian body. | 05-14-2009 |
| 20090123928 | Genomic Landscapes of Human Breast and Colorectal Cancers - Human cancer is caused by the accumulation of mutations in oncogenes and tumor suppressor genes. To catalogue the genetic changes that occur during tumorigenesis, we isolated DNA from 11 breast and 11 colorectal tumors and determined the sequences of the genes in the Reference Sequence database in these samples. Based on analysis of exons representing 20,857 transcripts from 18,191 genes, we conclude that the genomic landscapes of breast and colorectal cancers are composed of a handful of commonly mutated gene “mountains” and a much larger number of gene “hills” that are mutated at low frequency. We describe statistical and bioinformatic tools that may help identify mutations with a role in tumorigenesis. These results have implications for understanding the nature and heterogeneity of human cancers and for using personal genomics for tumor diagnosis and therapy. | 05-14-2009 |
| 20090123929 | Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases - The present invention relates to compositions and methods for diagnosing, monitoring and/or treating an autoimmune or chronic inflammatory disease. In particular, the present invention provides methods for diagnosing, monitoring and treating an autoimmune disease (e.g., rheumatoid arthritis) or chronic inflammatory disease (e.g., systemic lupus erythematosus) based on detecting or altering (e.g., altering expression or methylation status of) autoimmune or chronic inflammatory disease proteins (e.g., CD70 and CD40L). The present invention also provides kits for detecting methylation status of autoimmune or chronic inflammatory disease proteins (e.g., CD70 and CD40L) and for diagnosing, monitoring and/or treating autoimmune or chronic inflammatory diseases. | 05-14-2009 |
| 20090123930 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS - Disclosed herein are methods and compositions useful for identifying therapies likely to confer optimal clinical benefit for patients with cancer. | 05-14-2009 |
| 20090123931 | IDENTIFICATION OF TISSUE FOR DEBRIDEMENT - Provided are methods of determining whether a cell in a tissue site is viable or nonviable. Also provided are methods of debriding tissue from a tissue site. Further provided are kits comprising a compound that distinguishes between viable and nonviable cells and instructions for using the compound on a tissue site. Additionally, the use of a compound that distinguishes between viable and nonviable cells is provided, where the use is to determine whether a cell in a tissue site is viable or nonviable. Also provided is a use of a compound that distinguishes between viable and nonviable cells, where the use is for the manufacture of the above-described kit. | 05-14-2009 |
| 20090123932 | QUANTITATIVE TEST TO DETECT DISEASE PROGRESSION MARKERS OF EPITHELIAL OVARIAN CANCER PATIENTS - The present invention concerns a method of prognosing the risk of early ovarian cancer relapse in a subject having ovarian cancer comprising: a) detecting the level of at least one marker selected from the group consisting of BTF4, GCS and HLA-DRbeta1; and b) comparing the level of the above at least one marker with that of a corresponding control sample, wherein the detection of a lower level of the at least one marker compared to that in the control sample is indicative that the subject is at risk of early cancer relapse. Also provided is a method of stratifying a subject suffering from ovarian cancer based on the expression levels of the disclosed markers and kits for practicing the methods of the present invention. | 05-14-2009 |
| 20090123933 | MICRORNA BIOMARKERS IN LUPUS - The present invention provides methods of screening a subject for systemic lupus erythematosus (SLE), comprising detecting an increase in an amount of one or more markers associated with SLE in a biological sample from the subject, wherein the one or more markers is selected from the group consisting of miR-16-1, miR-16-2, miR-223, let7a-1, let7a-2. let7a-3, let 7c, let7g, and any combination thereof, whereby detection of the increase in the amount of the one or more markers identifies the subject as having SLE. The invention further provides methods of screening a subject for SLE comprising detecting a decrease in miR-95 in a biological sample from the subject, whereby detection of the decrease in the amount of miR-95 identifies the subject as having SLE. | 05-14-2009 |
| 20090123934 | Inhibition of polo kinase by matrimony maintains G2 arrest in the meiotic cell cycle - Matrimony (Mtrm) acts as a negative regulator of Polo kinase (Polo) during the later stages of G2 arrest. Indeed, both the repression of Polo expression until stage 11 and the inactivation of newly synthesized Polo by Mtrm until stage 13 play critical roles in maintaining and properly terminating G2 arrest. Our data suggest a model in which the eventual activation of Cdc25 by an excess of Polo at stage 13 triggers NEB and entry into prometaphase. In view of the foregoing, methods for modulating oocyte maturation are provided. More particularly, methods are provided for in vitro maturation of an oocyte. Further provided are methods for identifying functional orthologs of a | 05-14-2009 |
| 20090123935 | Measurement of a population of nucleic acids, in particular by real time PCR - The invention relates to a method for measuring the amount of nucleic acids of a target sequence in a sample of interest. The method comprises several steps, and in particular subjecting the sample of interest to an amplification treatment, in the presence of at least one nucleic acids label specific for said target sequence; measuring a physical quantity representative of the evolution of the label; calculating a parameter F | 05-14-2009 |
| 20090130656 | NEISSERIA GONORRHOEAE DETECTION - A method for determining whether a human individual is or has been infected with | 05-21-2009 |
| 20090130657 | AMPLIFICATION BLOCKER COMPRISING INTERCALATING NUCLEIC ACIDS (INA) CONTAINING INTERCALATING PSEUDONUCLEOTIDES (IPN) - An amplification blocker comprising an intercalating nucleic acid (INA) containing two or more internal intercalating pseudonucleotides (IPNs) capable of blocking or reducing nucleic acid amplification. Use of the amplification blocker to block or reduce nucleic acid amplification. | 05-21-2009 |
| 20090130658 | Arrangement for integrated and automated dna or protein analysis in a single-use cartridge, method for producing such a cartridge and operating method for dna or protein analysis using such a cartridge - A cartridge (card) having a system of microchannels and/or microcavities is used for automated DNA or protein analysis. In at least one embodiment, the microchannels or microcavities include geometrical structures for receiving dry reagents. For the purpose of industrial production, the cartridge is produced from a flat card support, e.g., by injection moulding. The reagents are spotted into the open channels, dried and then the channels are sealed by way of a film. A finished cartridge can thus be provided with a test sample and the fully automated measuring sequence can be initiated by inserting said cartridge into a read-out device. | 05-21-2009 |
| 20090130659 | KITS AND METHODS FOR DETECTING METHYLATED DNA - The present invention relates to an in vitro method for detecting methylated DNA comprising (a) coating a container with a polypeptide capable of binding methylated DNA; (b) contacting said polypeptide with a sample comprising methylated and/or unmethylated DNA; and (c) detecting the binding of said polypeptide to methylated DNA. In a preferred embodiment, said method further comprises step (d) analyzing the detected methylated DNA by sequencing. Another aspect of the present invention is a kit for detecting methylated DNA according to the methods of the invention comprising (a) a polypeptide capable of binding methylated DNA; (b) a container which can be coated with said polypeptide; (c) means for coating said container; and (d) means for detecting methylated DNA. | 05-21-2009 |
| 20090130660 | Single Nucelotide Polymorphism (SNP) - Association of Type 2 diabetes with single nucleotide polymorphisms and haplotypes are disclosed. Also disclosed are diagnostic applications in identifying those who have Type 2 diabetes or are at risk of developing Type 2 diabetes, and discovery of therapeutic agents and methods of treatment. | 05-21-2009 |
| 20090130661 | Method for Detecting IL-16 Activity and Modulation of IL-16 Activity Based on Phosphorylated Stat-6 Proxy Levels - Methods for detecting IL-16 biological activity, detecting modulation of IL-16 biological activity, and diagnosing the presence of, or susceptibility to, an IL-16-related disorder in a subject involve measuring and comparing the levels of a phosphorylated STAT-6 proxy produced by eukaryotic cells expressing CD4 or CD9, peripheral blood mononuclear cells, HuT-78 cells, or THP-1 cells. | 05-21-2009 |
| 20090130662 | Method for Diagnosis of Prostate Cancer - The present invention provides a method for detecting and/or quantifying PCA-1 in a body fluid sample from a subject as a prostate cancer marker. The present invention also provides a method for detecting and/or quantifying an anti-PCA-1 autoantibody in a body fluid sample from a subject as a prostate cancer marker. The present invention allows diagnosis of prostate cancer to be performed more simply, more rapidly and at lower cost. | 05-21-2009 |
| 20090130663 | Hybridization Detection Method Using an Intercalator - To provide a novel and useful technique capable of achieving an improve S/N ratio in a hybridization detection technique using an intercalator. A method is provided wherein a hybridization is detected by measuring a fluorescence intensity from an intercalator I binding to a probe nucleic acid P and a complementary strand site of a target nucleic acid T. In the invention, a single-stranded target nucleic acid Ts, a single-stranded probe nucleic acid Ps forming no complementary strand and surplus nucleic acid moieties T | 05-21-2009 |
| 20090130664 | Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance in pseudomonas aeruginosa - The “instant evolution” system was initially developed in | 05-21-2009 |
| 20090130665 | POLYMER COMPOSITIONS AND USES THEREOF - Block copolymers labelled with molecular recognition units and comprising a hydrophobic block and a luminescent block are presented. A method of detecting biomolecules using such block copolymers is also presented. More specifically, the block copolymers of the present invention have the following Formula (I): wherein “A” is a hydrophobic block; “B” is a luminescent block; “C” is a hydrophilic block; “D” is a molecular recognition unit; “n” and “m” are integers ranging from 1 to 75; “x” is either 0 or an integer ranging from 1 to 75; and “Y” is either 0 or 1. | 05-21-2009 |
| 20090130666 | Cytometric system including nucleic acid sequence amplification, and method - The invention relates to a cytometric system that can include a first station capable of selectively sorting a nucleic acid sequence-containing biological material from a biological sample, and a second station where nucleic acid of the sorted nucleic acid sequence-containing biological material, can undergo a nucleic acid amplification reaction. The system can include a conduit system adapted to facilitate transfer of a sorted biological material or processed biological material from one region or station, to another. All of the stations can be controlled by a central control system. Methods of sorting a biological material from a biological sample, and methods of amplifying nucleic acid of a sorted nucleic acid sequence-containing material, are also provided. | 05-21-2009 |
| 20090130667 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 81 to 83 and complementary or modified sequences thereof or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 05-21-2009 |
| 20090130668 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 78 to 80 and complementary or modified sequences thereof or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 05-21-2009 |
| 20090130669 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 92 to 93 and complementary or modified sequences thereof or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 05-21-2009 |
| 20090130670 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequence of SEQ ID NO. 94 and complementary or modified sequences thereof or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 05-21-2009 |
| 20090130671 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 73 to 75 and complementary or modified sequences thereof or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 05-21-2009 |
| 20090130672 | METHODS FOR IDENTIFYING NOVEL PESTICIDAL GENE HOMOLOGUES - Methods and compositions for identifying novel pesticidal gene homologues are provided. Specifically, the methods of the invention comprise systematically designing oligonucleotide primers that are specific for a pesticidal gene of interest and performing successive rounds of PCR amplification of nucleic acid material from a microorganism, particularly a | 05-21-2009 |
| 20090130673 | Methods for detecting and differentiating mycobacterium genus and mycobacterium avium complex in a sample or culture - The present invention relates to compositions and methods for detecting | 05-21-2009 |
| 20090130674 | Circular DNA molecule having a conditional origin of replication, process for their preparation and their use in gene therapy - A prokaryotic recombinant host cell comprising a heterologous replication initiation protein that activates a conditional origin of replication and an extrachromosomal DNA molecule comprising a heterologous therapeutic gene and a conditional origin of replication whose functionality in the prokaryotic recombinant host cell requires a replication initiating protein which is foreign to the host cell is described. The host cell may comprise a pir gene having at least one mutation, which may occur in the pir gene copy number control region, the pir gene leucine zipper-like motif, or the pir gene DNA binding region. | 05-21-2009 |
| 20090130675 | Genes Involved in the Biosynthesis of Thiocoraline and Heterologous Production of Same - The invention relates to genes involved in the biosynthesis of thiocoraline and to the heterologous production of same. According to the invention, the cluster of genes responsible for the biosynthesis of thiocoraline was identified and cloned. Said cluster of genes can be used in the heterologous production of thiocoraline which has an antitumor and antibacterial activity. | 05-21-2009 |
| 20090130676 | Interaction trap systems for detecting protein interactions - Disclosed herein is a method of determining whether a first protein is capable of physically interacting with a second protein, involving: (a) providing a host cell which contains (i) a reporter gene operably linked to a protein binding site; (ii) a first fusion gene which expresses a first fusion protein, the first fusion protein including the first protein covalently bonded to a binding moiety which is capable of specifically binding to the protein binding site; and (iii) a second fusion gene which expresses a second fusion protein, the second fusion protein including the second protein covalently bonded to a gene activating moiety and being conformationally-constrained; and (b) measuring expression of the reporter gene as a measure of an interaction between the first and the second proteins. Also disclosed are methods for assaying protein interactions, and identifying antagonists and agonists of protein interactions. Proteins isolated by these methods are also discussed. Finally, populations of eukaryotic cells are disclosed, each cell having a recombinant DNA molecule encoding a conformationally-constrained intracellular peptide. | 05-21-2009 |
| 20090130677 | METHOD FOR ISOTHERMAL AMPLIFICATION OF NUCLEIC ACIDS AND METHOD FOR DETECTING NUCLEIC ACIDS USING SIMULTANEOUS ISOTHERMAL AMPLIFICATION OF NUCLEIC ACIDS AND SIGNAL PROBE - The present invention relates to a method for isothermal amplification of nucleic acids and a method for detecting nucleic acids, which comprises characterized in simultaneous isothermal amplification of nucleic acids and a signal probe to a method for isothermal amplification of target nucleic acids using an external primer set and RNA/DNA hybrid primer set, and a method for detecting amplification products by amplifying nucleic acids and a signal probe simultaneously using an external primer set, RNA-DNA hybrid primer set and DNA-RNA-DNA hybrid probe. The method according to the present invention is convenient compared with the conventional method, it is possible to amplify the target nucleic acids rapidly and exactly without a risk of contamination, and it can simultaneously amplify a signal probe, so that it can be applied to various genome project, such as detection and identification of a pathogen, detection of gene modification causing predetermined phenotype, detection of hereditary diseases or determination of sensibility to diseases, estimation of gene expression and apply to genome project, thus being useful for molecular biological studies and disease diagnosis. | 05-21-2009 |
| 20090130678 | Methods and Kits for Breast Cancer Prognosis - The present invention relates to the field of prognosis of a proliferative disease in a patient. More specifically, the present invention relates to methods for the identification of the likely outcome of breast cancer in a breast cancer patient. The invention also relates to methods for the identification of the likely outcome of breast cancer in a patient on the basis of the ERBB2 status of the patient and expression levels of immune genes in tumour tissue of said patient. | 05-21-2009 |
| 20090130679 | Automated system and method for processing genetic material - The invention discloses an automated system and method for processing genetic material. Additionally, the automated system and method of the invention can extract a target genetic material from a sample; amplifying a target nucleic acid sequence from the genetic material; detecting the target nucleic acid by an optical detection module to qualify and/or quantify the target nucleic acid immediately. | 05-21-2009 |
| 20090130680 | SOLID SUPPORT - The present invention provides a solid support for performing steps of isolation of cell or extraction and purification of nucleic acid, safely, easily, efficiently, and with high yield in the genetic test for investigating the presence of pathogenic bacterial infection. A solid support for binding with cell as an embodiment of the above-described solid support, comprises a polypeptide having capability of binding with mycolic acid-containing glycolipid which is immobilized on the surface of a carrier. In addition, a solid support for binding with nucleic acid as another embodiment of the above-described solid support, comprises a polypeptide having capability of binding with nucleic acid which is immobilized on the surface of a carrier. | 05-21-2009 |
| 20090130681 | 21132, a Human G-protein coupled receptor family member and uses therefor - The invention provides isolated nucleic acids molecules, designated 21132 nucleic acid molecules, which encode novel GPCR family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21132 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21132 gene has been introduced or disrupted. The invention still further provides isolated 21132 proteins, fusion proteins, antigenic peptides and anti-21132 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided. | 05-21-2009 |
| 20090130682 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 05-21-2009 |
| 20090130683 | PREDICTING AND DIAGNOSING PATIENTS WITH AUTOIMMUNE DISEASE - The present invention provides methods for the prediction and diagnosis of autoimmune diseases, including Systemic Lupus Erythematosus, using single nucleotide polymorphism in TNFAIP3 (A20). | 05-21-2009 |
| 20090130684 | METHODS OF DETECTING AND TREATMENT OF CANCERS USING SCUTELLARIA BARBATA EXTRACT - An extract of | 05-21-2009 |
| 20090130685 | Plants With Altered Root Architecture, Related Constructs and Methods Involving Genes Encoding Leucine Rich Repeat Kinase (LLRK) Polypeptides and Homologs Thereof - Isolated polynucleotides and polypeptides and recombinant DNA constructs particularly useful for altering root structure of plants, compositions (such as plants or seeds) comprising these recombinant DNA constructs, and methods utilizing these recombinant DNA constructs. The recombinant DNA construct comprises a polynucleotide operably linked to a promoter functional in a plant, wherein said polynucleotide encodes a polypeptide useful for altering plant root architecture. | 05-21-2009 |
| 20090130686 | Method for the Microscopic Localization of a Selected, Intracellular DNA Segment with a Known Nucleotide Sequence - The method for the microscopic localization in situ of a selected intracellular native genome segment with a known nucleotide sequence is characterized by the nature and the sequence of the following measures: (1.) The target DNA is analyzed, via genome databases, for partial sequences which constitute a unique pattern within the genome. (2.) Single-stranded probe sequences are provided which are identical to these partial sequences or complementary thereto, and which are suitable for hybridizing with the single strands of these subsequences via a Watson-Crick binding. (3.) The probe sequences are coupled with marker molecules, where all units of probe sequence and marker molecule(s) have the same binding behavior or the same melting point as the single strand of the target DNA complementary thereto. (4.) The probe sequences are introduced into the cell and combined with the target DNA so that they hybridize to the corresponding partial sequences, of the target DNA, which are temporarily present as two single strands. (5.) The marker signals emitted are detected, and (6.) the locus of the target DNA on the genome is identified on the basis of the presence and/or intensity and/or the simultaneous occurrence of different marker signals. | 05-21-2009 |
| 20090130687 | FORMULATIONS AND METHOD ISOLATING NUCLEIC ACIDS FROM ARBITRARY COMPLEX STARTING MATERIALS AND SUBSEQUENT COMPLEX GENETIC MATERIALS - The object of the invention is formulations and methods without chaotropic components for the isolation of nucleic acids with binding to a solid phase, in particular of DNA, from arbitrary complex starting materials containing a lysis/binding buffer system manifesting at least one anti-chaotropic salt component, the concentration of the anti-chaotropic salt components being between 0.001 mM and 0.1 M, preferably 0.1 mM, and further a solid phase and washing and elution buffers which are known per se. | 05-21-2009 |
| 20090130688 | Method for Accessing Microbial Diversity - A method of interfering with quorum sensing regulation of genes to promote cell growth is disclosed. The method of is aimed at accessing microbial biodiversity. The method involves obtaining an environmental sample comprising at least one novel (uncultivated in the laboratory) microorganism, contacting the environmental sample with an effective amount of an agent or combination of agents which interferes with the quorum sensing regulation of genes, growing the treated sample in a culture medium containing the quorum sensing signal disrupting agent or agents, and analyzing the colonies of microorganisms grown to demonstrate genetic novelty. | 05-21-2009 |
| 20090136918 | QUANTIFICATION OF MICROSPHERE SUSPENSION HYBRIDIZATION AND USES THEREOF - A novel suspension hybridization assay was used to determine nucleic acid copy number by flow cytometry. The assay was validated with low copy (lc) products ranging in length from 100 to 2304 bp conjugated to spectrally-distinct polystyrene microspheres. In the example provided herein, these conjugated microspheres were used as multiplex hybridization probes to detect homologous sequences in genomic DNA extracted from cytogenetic cell pellets and labeled with biotin-dUTP. Hybridization was detected with phycoerythrin-labeled streptavidin and analyzed by flow cytometry. Copy number differences were distinguishable by comparing the mean fluorescence intensities of test probes with a diploid reference probe in genomic DNA of patient samples and abnormal cell lines. The assay is capable of distinguishing a single allele and three alleles at a test locus from a biallelic reference sequence, regardless of chromosomal context. The assay is an improvement on previous methods which require prior amplification of locus-specific target DNA because, lc probes provide adequate specificity and sensitivity for accurate copy number determination of homologous targets. Because of its high sensitivity and accuracy, the assay is useful for determination of nucleic acid copy number for a variety of applications, including determination of genomic copy number in humans, animal models of disease and in solution, measurement of transcript levels, forensic DNA analysis, and quality control analysis in agriculture. | 05-28-2009 |
| 20090136919 | METHOD TO RAPIDLY QUANTIFY MYCOBACTERIA IN INDUSTRIAL FLUIDS - The invention is a method for detecting and quantifying environmental mycobacteria in industrial fluids comprising extracting bacterial DNA from a sample of an industrial fluid; amplifying the extracted DNA; hybridizing an aliquot of the DNA to two or more amplification primers; and detecting the amplification product. | 05-28-2009 |
| 20090136920 | Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1) - The invention provides a human SGK1 which is associated with cardiovascular diseases, cancer, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, cancer, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, hematological diseases, respiratory diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of SGK1 as well as pharmaceutical compositions comprising such compounds. | 05-28-2009 |
| 20090136921 | Association of Breast Cancer DNA Methylation Profiles with Hormone Receptor Status and Response to Tamoxifen - Particular embodiments provide novel and clinically useful DNA methylation predictors of hormone receptor status, and predictors of response to endocrine (e.g., hormonal) and non-endocrine breast cancer therapy. The ESR1 gene, encoding the estrogen receptor (ER) alpha proved to be the preferred predictor of progesterone receptor (PR) status, while methylation of the PGR gene, encoding PR, was the preferred predictor of ER status. ESR1 methylation outperformed hormone receptor status as a predictor of clinical response in patients treated with antiestroges (e.g., tamoxifen), while promoter methylation of the CYP1B1 gene, encoding a tamoxifen and estradiol metabolizing cytochrome P450, predicted response differentially in tamoxifen-treated and non-treated patients. High levels of promoter methylation of the ARHI gene, encoding a RAS-related small G-protein, were shown to be preferred predictors of better survival in patients who had not received tamoxifen therapy. | 05-28-2009 |
| 20090136922 | Method for carrying out an electrochemical measurement on a liquid measuring sample in a measuring chamber that can be accessed by lines, and corresponding arrangement - Especially in order to carry out the so-called enzyme-coupled DNA hybridisation test in a closed cartridge including a microfluid system, using stored dry reagents, the reagents must be dissolved in the microfluid system and transported into the measuring chamber directly before the measurement. During the dissolution of the reagents in water, air cushions that cannot reach the measuring chamber must absolutely be prevented from forming upstream of the reagent liquid. According to an embodiment of the invention, the liquid measuring sample and the liquid reagents are transported in such a way that the air cushion is directed into the waste line and the measuring sample and the reagents are then introduced into the measuring chamber without any air bubbles. In this way, measuring errors can be avoided. | 05-28-2009 |
| 20090136923 | PRIMER COMPOSITION FOR DETECTING MYCOBACTERIUM SP. AND THE DETECTION METHOD - Disclosed are a primer composition including two pairs of primers targeting one gene (mpb64) concerning Mycobacterium sp., and a pair of primers targeting a human-derived gene (HLA-DR); and a method for detecting Mycobacterium sp. using a multiplex one-tube nested PCR method in which their primers are used to amplify two genes in one tube at the same time. The method of the present invention may provide a useful guide post capable of clinically diagnosing Mycobacterium sp. in a specimen in a more specific, rapid and convenient manner. | 05-28-2009 |
| 20090136924 | RAPID GENERATION OF LONG SYNTHETIC CENTROMERIC TANDEM REPEATS FOR MAMMALIAN ARTIFICIAL CHROMOSOME FORMATION - Methods are described for construction of long synthetic arrays of DNA repeats, such as alphoid repeats or other repeat sequences. The methods include concatamerization of DNA into short repeats (for instance using rolling circle amplification or directional in vitro ligation), followed by assembling the short repeats into long arrays by homologous recombination during transformation into microbe cells. These methods can be described generally as Recombinational Amplification of Repeats (RAR). The long arrays are engineered centromere-like regions that allow one to construct mammalian artificial chromosomes with a predefined centromeric region structure. Artificial chromosomes, including human artificial chromosomes with a regulated centromere, and methods of their use are also provided | 05-28-2009 |
| 20090136925 | IDENTIFICATION OF TERPENOID-BIOSYNTHESIS RELATED REGULATORY PROTEIN-REGULATORY REGION ASSOCIATIONS - Materials and methods for identifying terpenoid regulatory region-regulatory protein associations are disclosed. Materials and methods for modulating expression of a sequence interest are also disclosed. | 05-28-2009 |
| 20090136926 | Device and method for standardizing nucleic acid concentrations - The present invention relates to a device and a method for normalising nucleic acid concentrations, preferably for normalising nucleic acid concentrations in enzymatic nucleic acid amplification and modification methods. | 05-28-2009 |
| 20090136927 | RANDOM HOMOZYGOUS GENE PERTURBATION TO ENHANCE ANTIBODY PRODUCTION - The invention reflects enhanced antibody expression of an antibody of interest by cell lines transformed by random homozygous gene perturbation methods to either increase or decrease the expression pattern of a gene of the cell line other than the antibody of interest. The transformed cell line exhibits specific productivity rates, SPR, for the RHGP transformed cell liens of 1.5 or more, as compared with the antibody expressing cell line parents prior to transformation by RHGP. A knock out or anti-sense construct may be devised to reduce expression of the target gene, a promoter may be inserter to enhance expression of the target gene. The antibodies expressed by the transformed cell lines exhibit the binding properties of their parent cell lines prior to transformation with RHGP, and increase Total Volumetric Production of said antibody by said cells in a given volume. | 05-28-2009 |
| 20090136928 | Compositions and Methods for the Diagnosis and Treatment of Tumor - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 05-28-2009 |
| 20090136929 | NOVEL IN VITRO METHOD OF QUANTIFYING DEMINERALIZED BONE OSTEOINDUCTIVITY - The present invention provides an in vitro method for determining the osteoinductive potential of a biomaterial. In particular, the method measures the expression of osterix by osteoblast progenitor cells incubated with the biomaterial. In various embodiments, the biomaterial is demineralized bone (DMB) and the progenitor cells are incubated with DMB or proteins extracted from DMB. | 05-28-2009 |
| 20090136930 | METHOD FOR THE IDENTIFICATION OF MICROORGANISMS BY MEANS OF IN SITU HYBRIDIZATION AND FLOW CYTOMETRY - The invention relates to a combined method for specifically identifying microorganisms by means of in situ hybridization and flow cytometry. The inventive method is particularly characterized by an improved specificity and a shorter duration of the process as opposed to methods known in prior art. | 05-28-2009 |
| 20090136931 | Novel fluorescent labeling compound - A rare-earth fluorescent complex which forms a fluorescent complex with two or more rare-earth metals such as europium and terbium and can effectively be excited at a wavelength of 340 nm or longer; a fluorescent labeling agent comprising the rare-earth fluorescent complex; a method of fluorescent labeling in which the rare-earth fluorescent complex is used as a labeling agent; and a method of fluorometric analysis in which the fluorescent labeling agent is used. The rare-earth fluorescent complex is characterized by having a cyclic ligand comprising a 4-biphenyl-2,2′:6′,2″-terpyridine skeleton and a 2,6-bis(3′-aminomethyl-1′-pyrazolyl)pyrazine skeleton bonded thereto. | 05-28-2009 |
| 20090136932 | FIBERS WITH ISOLATED BIOMOLECULES AND USES THEREOF - The present invention relates to compositions, methods, and uses for isolated biomolecule-containing fibers. The invention also relates to isolated, elongated biopolymers such as nucleic acids, polypeptides, lipids, and carbohydrates within fibers. The invention relates to methods of detecting and analyzing biomolecules in fibers using light, electrons, and neutrons. The invention further relates to methods of determining the sequence, structure, and properties of isolated, elongated biopolymers fixed within fibers. | 05-28-2009 |
| 20090136933 | Method for Determination of Amount of Double-Stranded DNA and Kit for the Determination - A method and kit for electrochemically simply determining with excellent precision the amount of double-stranded DNA does not require an expensive measurement electrode, such as an immobilized enzyme electrode or any high level electrode production technique which can retain uniform surface area accuracy. A method and kit are provided for electrochemically determining the amount of double-stranded DNA in a sample solution based on a residual amount of a substance capable of binding to the double-stranded DNA which is added to the solution in excess amount, in which a buffering substance is added to a sample solution, the buffering substance being capable of allowing an oxidation wave potential of the potential-current curve for the substance capable of binding to the double-stranded-DNA determined in a solution containing the buffering substance to change depending on the concentration of the free substance capable of binding to the double-stranded DNA in the solution. | 05-28-2009 |
| 20090136934 | TARGETING AND TRACING OF ANTIGENS IN LIVING CELLS - The present invention relates to a method of detecting the presence, amount or subcellular location of an antigenic structure of interest in a cell, comprising the steps of: (a) (i) expressing a fusion protein directed to the antigenic structure of interest in said cell or (ii) introducing a fusion protein directed to the antigenic structure of interest and coupled to a (poly) peptide capable of transducing into said cell; wherein said fusion protein comprises a first (poly) peptide sequence comprising the variable region of a heavy chain antibody of Camelidae and a second (poly) peptide sequence derivable from a fluorescent or chromophoric protein. | 05-28-2009 |
| 20090136935 | Dye Compounds - The present disclosure provides compounds that may be used as chromogens, fluorochromes, or as both. Said compounds may further be used as substrate for at least one enzyme, wherein said enzyme is capable of processing an aromatic amine group (—NH | 05-28-2009 |
| 20090136936 | IMMUNOGLOBULIN FC LIBRARIES - Methods and composition for the screening and isolation of aglycosylated antibody Fc domain polypeptides. For example, in certain aspects methods for identifying aglycosylated Fc domains that bind to Fc receptors or preferentially bind to particular Fc receptors are described. Furthermore, the invention provides aglycosylated Fc domains that bind to Fc receptors with high affinity. Enhanced methods and media for prokaryotic based interaction screening are also provided. | 05-28-2009 |
| 20090136937 | METHODS AND SYSTEMS FOR MONITORING PRODUCTION OF A TARGET PROTEIN IN A NANOLIPOPROTEIN PARTICLE - Provided herein are methods and systems for the monitoring production of a target protein in of a nanolipoprotein particle (NLP) that also includes a scaffold protein and a membrane forming lipid. The target protein is capable of assuming an active form and an inactive form. Monitoring is performed by an indicator protein that is capable of assuming an active form and an inactive form, the active form associated with a detectable activity of the indicator protein, the detectable activity further associated with the active form of the target protein. | 05-28-2009 |
| 20090136938 | METHODS FOR SEQUENCE-DIRECTED MOLECULAR BREEDING - The present invention provides breeding methods and compositions to enhance the germplasm of a plant by the use of direct nucleic acid sequence information. The methods describe the identification and accumulation of preferred nucleic acid sequences in the germplasm of a breeding population of plants. | 05-28-2009 |
| 20090136939 | Methods for diagnosis and therapy for pancreatic cancer and composition useful therein - Polynucleotide and polypeptide UKW are specific for pancreatic tumors. Diagnosis of UKW is therefore valuable for diagnosis of pancreatic tumors. Antibodies against UKW are, besides their value in diagnosis, useful as therapeutic agents for the treatment of pancreatic tumors. | 05-28-2009 |
| 20090136940 | PHOSPHORAMIDITE NUCLEOSIDE ANALOGS - Described are phosphoramidite nucleoside analog monomers, precursors thereof, and oligonucleotides including one or more of the monomers. The monomers can be used during automated synthesis of oligonucleotide derivatives, and allow for incorporation of one or several reporter groups, organic molecules, bio-molecules, small molecules or other chemical groups at the internucleoside phosphotriesters. Oligonucleotides including the monomers have a number of uses in therapeutic, diagnostic, and research applications. | 05-28-2009 |
| 20090136941 | METHODS, KITS AND COMPOSITIONS PERTAINING TO LINEAR BEACONS - This invention is directed to methods for determining amplified nucleic acid using Linear Beacons | 05-28-2009 |
| 20090136942 | Analysis of Extracellular RNA - The invention provides methods for detecting tumor-associated RNA in plasma, serum, and other bodily fluids. In particular, the invention provides methods for detecting translocated gene RNA, including fusion gene RNA, in plasma or serum or other bodily fluids. | 05-28-2009 |
| 20090136943 | METHOD OF DETECTING CANCER USING DELTA-CATENIN - The present invention provides a method for detecting or screening for the presence of cancer in a subject. The method comprises obtaining, providing or collecting a tissue or fluid sample (such as a urine sample) from said subject, and then determining the presence or absence of delta-catenin in said sample, or increased levels of delta-catenin in said sample as compared to a normal or control subject. The presence of delta-catenin in said sample, or increased levels of delta-catenin in said sample, indicating said subject is afflicted with or at least at risk of developing cancer. | 05-28-2009 |
| 20090136944 | Aberrantly Methylated Genes as Markers of Breast Malignancy - The invention is directed to a method of diagnosing a cell proliferative disorder of breast tissue by determining the methylation status of nucleic acids obtained from a subject. Aberrant methylation of several genes including TWIST, HOXA5, NES-1, retinoic acid receptor beta (RARβ), estrogen receptor (ER), cyclin D2, WT-1, 14.3.3 sigma, HIN-1, RASSF1A, and combinations of such genes serve as markers of breast malignancy. | 05-28-2009 |
| 20090136945 | COMPOSITIONS AND METHODS FOR ASSESSING DISORDERS - The present invention relates to compositions and methods for disorder (e.g., hyperproliferative disorders, inflammatory disorders) research, diagnosis, and treatment, including but not limited to, bio-markers specific for a particular disorder (e.g., cancer, systemic lupus erythematosus). In particular, the present invention relates to peripheral blood mononuclear cells (PBMCs) as bio-markers specific for particular disorders. | 05-28-2009 |
| 20090136946 | Automated Enumeration and Characterization of Circulating Melanoma Cells in Blood - The CellTracks® System provides a system to enumerate circulating melanoma cells in blood. The system immunomagnetically concentrates epithelial cells, fluorescently labels the cells and identifies and quantifies circulating melanoma cells. The absolute number of circulating melanoma cells detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy. Diagnosis and monitoring of melanoma has been limited by the inability to monitor circulating melanoma cells. The present invention provides a method to enumerate circulating melanoma cells in blood samples. Accordingly, this technology provides a means and device for monitoring disease progression in patients with melanoma. | 05-28-2009 |
| 20090136947 | METHOD FOR CONDUCTING AN ASSAY FOR NEUTRALIZING ANTIBODIES - A method for conducting a neutralization assay for the determination of the titer of antibodies in a sample is provided which is an improvement over existing neutralization assays because the sensitivity of the reporter gene assay to determine neutralization is increased by the use of a “one time use” cell line transformed with a reporter gene construct. The titer is determined for antibodies specific for a predetermined target molecule that activates the signal transduction activity of a cell surface protein or a pattern recognition receptor or are specific for an antagonist for the predetermined target molecule. | 05-28-2009 |
| 20090136948 | NANOCONFINEMENT- BASED DEVICES AND METHODS OF USE THEREOF - The present invention provides a device/kit and methods of use thereof in rapid detection of target molecule binding to a cognate binding partner. The methods, inter-alia, make use of a device comprising channels or reservoirs, which are linked to nanochannels, whereby upon application of the cognate binding partner to the nanochannel comprising the target molecule under flow, a detectable change in conductance, capacitance or fluorescence or surface potential occurs. | 05-28-2009 |
| 20090136949 | PROCESS FOR PREDICTING THE PROGNOSIS OF SQUAMOUS CELL LUNG CANCER - Disclosed in this specification is a method for predicting the prognosis of squamous cell lung cancer by observing regulatory changes in select miRNA sequences. These sequences may include hsa-mir-146b, hsa-mir-191, hsa-mir-206, hsa-mir-299-3p, hsa-mir-155, hsa-mir-15a, hsa-mir-122a, hsa-mir-513, hsa-mir-184, hsa-mir-511, hsa-mir-100, hsa-mir-10a, hsa-mir-453, hsa-mir-379, hsa-mir-202, hsa-mir-21, hsa-mir-126, hsa-mir-494, hsa-mir-432, hsa-mir-370, and combinations of these sequences. | 05-28-2009 |
| 20090136950 | IMMUNOGLOBULIN DISPLAY VECTORS - Disclosed are mammalian expression vectors for expressing simultaneous expression of immunoglobulins as both a secreted and cell surface bound form. | 05-28-2009 |
| 20090136951 | QUANTIFICATION OF NUCLEIC ACID MOLECULES USING MULTIPLEX PCR - Described are novel quantification methods and systems that permit, within the context of multiplex PCR, the quantification of all targets within a single reaction tube. The methods employ quantitation algorithms applied to the amplification profiles of internal calibration controls or standards utilizing a plurality of nucleic acid templates that are amplified within the same reaction tube as the nucleic acid target(s) interrogated. | 05-28-2009 |
| 20090136952 | MANGANESE SUPEROXIDE DISMUTASE VAL16ALA POLYMORPHISM PREDICTS RESISTANCE TO CHEMOTHERAPEUTIC DRUG CANCER THERAPY - The present invention provides, for the first time, the finding that the manganese superoxide dismutase Val16Ala polymorphism is significantly associated with prognosis for cancer patients treated with chemotherapeutic drug therapy. The alanine allele is a novel biomarker that predicts poor response and poor outcome to chemotherapeutic drug cancer therapy. Conversely, the valine allele predicts a good response and a good outcome to chemotherapeutic drug cancer therapy. Therefore, a genotype assay can be used to determine which alleles a subject is carrying, and subsequently this information can be used to determine if chemotherapeutic drug therapy is appropriate, and to customize therapy according to the patient's MnSOD genotype. | 05-28-2009 |
| 20090136953 | MOLECULAR DIAGNOSTIC METHOD FOR DETERMINING THE RESISTANCE OF A MICROORGANISM TO AN ANTIBIOTIC | 05-28-2009 |
| 20090136954 | GENETIC MARKERS FOR SCD OR SCA THERAPY SELECTION - Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”), or Sudden Cardiac Arrest (“SCA”) risk, are described. Novel genetic markers useful in assessing the risk of SCD, or SCA, and kits containing the same are provided herein. Methods of distinguishing patients having an increased susceptibility to SCD, or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods of assessing the need for an Implantable Cardio Defibrillators (“ICD”) in a patient are taught. | 05-28-2009 |
| 20090136955 | Protocols for making hepatocytes from embryonic stem cells - This disclosure provides a newly developed strategy and particular options for differentiating pluripotent stem cells into cells of the hepatocyte lineage. Many of the protocols are based on a strategy in which the cells are first differentiated into early germ layer cells, then into hepatocyte precursors, and then into mature cells. The cells obtained have morphological features and phenotypic markers characteristic of human adult hepatocytes. They also show evidence of cytochrome p450 enzyme activity, validating their utility for commercial applications such as drug screening, or use in the manufacture of medicaments and medical devices for clinical therapy. | 05-28-2009 |
| 20090136956 | Use of Dual-Tags for the Evaluation of Genomic Variable Repeat Regions - The methods and compositions of the present invention allow for the evaluation of a nucleotide expansion, contraction or deletion. In one embodiment, the present invention provides a method for detecting a nucleotide expansion, contraction or deletion comprising amplifying a target nucleic acid sequence with a primer pair, each primer comprising a target specific sequence and a differentiating tag sequence, labeling the target nucleic acid sequence to produce a dual-tagged amplification product; digesting the dual-tagged amplification product to produce an expansion region fragment and an internal control fragment; hybridizing the fragments to separate capture complexes; detecting the signals produced by the labels on the immobilized fragments and comparing the intensity of the signals to detect the nucleotide expansion, contraction or deletion region. | 05-28-2009 |
| 20090136957 | Methods and compositions for regulating cell cycle progression via the miR-106B family - In one aspect, a method is provided of inhibiting proliferation of a mammalian cell comprising introducing into said cell an effective amount of at least one microRNA-specific inhibitor of at least one miR-106b family member. In another aspect a method is provided for accelerating proliferation of a mammalian cell comprising introducing into said cell an effective amount of at least one miR-106b family member. | 05-28-2009 |
| 20090136958 | Capture, recapture, and trapping of molecules with a nanopore - In a molecular analysis system, there is provided a structure including a nanopore and first and second fluidic reservoirs. The two reservoirs are fluidically connected via the nanopore. A detector is connected to detect molecular species translocation of the nanopore, from one of the two fluidic reservoirs to the other of the two fluidic reservoirs. A controller is connected to generate a control signal to produce conditions at the nanopore to induce the molecular species to re-translocate the nanopore at least once after translocating the nanopore. This enables a method for molecular analysis in which a molecular species is translocated a plurality of times through a nanopore in a structure between two fluidic reservoirs separated by the structure. | 05-28-2009 |
| 20090136959 | Novel genes encoding proteins having prognostic, diagnostic preventive, therapeutic, and other uses - The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. | 05-28-2009 |
| 20090136960 | METHODS AND COMPOSITIONS FOR THE IDENTIFICATION OF CANCER MARKERS - The present invention relates to methods and compositions for the identification of cancer markers. In particular, the present invention provides methods and compositions for the identification of glycosylated proteins and protein glycosylation patterns. The present invention further provides cancer markers identified using the described methods. | 05-28-2009 |
| 20090136961 | Novel compositions and methods for identification, assessment, prevention, and therapy of ovarian cancer - The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer. | 05-28-2009 |
| 20090136962 | DIAGNOSTIC MARKERS FOR CANCER - The present invention provides compositions and methods useful for diagnosing cancer and for monitoring the progression and treatment of cancer, as well as targets for treating cancer. The invention provides sperm and testis associated antigens, such as the protein CABYR, as biomarkers and as targets for chemotherapy. | 05-28-2009 |
| 20090136963 | METHODS OF CONCENTRATING AN ANALYTE - A receptacle having a plurality of interconnected chambers arranged to permit multiple process steps or processes to be performed independently or simultaneously. The receptacles are manufactured to separate liquid from dried reagents and to maintain the stability of the dried reagents. An immiscible liquid, such as an oil, is included to control loading of process materials, facilitate mixing and reconstitution of dried reagents, limit evaporation, control heating of reaction materials, concentrate solid support materials to prevent clogging of fluid connections, provide minimum volumes for fluid transfers, and to prevent process materials from sticking to chamber surfaces. The receptacles can be adapted for use in systems having a processing instrument that includes an actuator system for selectively moving fluid substances between chambers and a detector. The actuator system can be arranged to concentrate an analyte present in a sample. The detector can be used to detect an optical signal emitted by the contents of the receptacle. | 05-28-2009 |
| 20090142749 | Assessment of disease risk by quantitative determination of epimutation in normal tissues - An assay for assessing the risk of disease in an individual, wherein said assay comprises the steps of isolating a population of cells from normal tissue of said individual, and quantitatively determining the frequency of epimutation of a particular gene in said population of cells, wherein the epimutation of said gene is associated with said disease and said gene is other than one that is subject to normal parent of origin-specific expression. Preferably, the epimutation is DNA methylation of a tumour suppressor gene such as hMLH1, hMSH2, APC 1A, APC 1B and p16. | 06-04-2009 |
| 20090142750 | Method of detecting and identifying gram-negative obligative anaerobic bacterium - There is provided a method of detecting potentially beer-spoiling obligatory anaerobic gram-negative bacteria, and a method of simultaneously detecting and distinguishing different beer-spoilage microorganisms including such bacteria. | 06-04-2009 |
| 20090142751 | ANALYZING POLYNUCLEOTIDE SEQUENCES - An apparatus is provided for analysing a polynucleotide. The apparatus includes: a support having an impermeable surface; porous material attached to the impermeable surface; and an array of oligonucleotides with predetermined sequences attached to the porous material. The array includes at least two defined cells, the sequence of the oligonucleotides of a first cell being different from the sequence of the oligonucleotides of a second cell, and the oligonucleotides being shorter than the polynucleotide. | 06-04-2009 |
| 20090142752 | Snap-Back Primers And Detectable Hairpin Structures - The present invention provides methods, compositions, and kits comprising snap-back primers used for forming 3′ hairpin structures, 5′ hairpin structures, and double hairpin structures. The hairpin structures may be used for detecting target sequences (e.g., such as small RNA target sequence), for detecting polymorphisms in target sequences (e.g., such as polymorphisms located near the 5′ or 3′ ends of the target sequence), or other nucleic acid characterization methods. In certain embodiments, the hairpin structures form invasive cleavage structures (e.g., in combination with a probe or upstream oligonucleotide) which may be cleaved by structure-specific enzymes in order to detect the presence or absence of a particular nucleotide or nucleotide sequence. | 06-04-2009 |
| 20090142753 | Compositions and methods for detecting compounds to treat a neurological disorder - The present invention generally provides compositions and methods that can be used to detect compounds that modulate the activity of at least one of the DJ-1, Parkin and Pink-1 genes. | 06-04-2009 |
| 20090142754 | RNA Detection Assays - The present invention provides novel cleavage agents and polymerases for the cleavage and modification of nucleic acid. The cleavage agents and polymerases find use, for example, for the detection and characterization of nucleic acid sequences and variations in nucleic acid sequences. In some embodiments, the 5′ nuclease activity of a variety of enzymes is used to cleave a target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof. | 06-04-2009 |
| 20090142755 | ASSAY FOR DETECTING GENETIC ABNORMALITIES IN GENOMIC NUCLEIC ACIDS - The present invention provides methods of detecting unamplifed genomic nucleic acid anchored to a solid support. The methods are useful for the detecting genetic abnormalities associated with various diseases, diagnosis, and prognosis. | 06-04-2009 |
| 20090142756 | PREDICTION OF BARE METAL STENT RESTENOSIS - Methods for predicting whether or not a patient is likely to experience restenosis after the placement of a bare metal stent are provided. The methods involve detecting and analyzing gene expression patterns of the cellular components of whole blood, where activation of selected genes has been found to be indicative of a high probability of restenosis. The method thus allows the identification, prior to placement of a stent, of patients who are i) likely to experience restenosis, and thus should receive a stent that includes anti-restenosis agents; or ii) unlikely to experience restenosis, and thus should receive a stent without anti-stenosis agents. | 06-04-2009 |
| 20090142757 | STRIP AND METHOD FOR DETECTING NUCLEOTIDE AMPLIFICATION PRODUCTS OF MYCOBACTERIUM TUBERCULOSIS AND NON-TUBERCULOUS MYCOBACTERIUM - The present invention provides a test strip and a method for rapid identifying the presence of the amplified DNA product of | 06-04-2009 |
| 20090142758 | STRATEGIES FOR SEQUENCING COMPLEX GENOMES USING HIGH THROUGHPUT SEQUENCING TECHNOLOGIES - A method for determining a genome sequence comprising the steps of digesting the genome with at least one first restriction endonuclease, ligating at least one adaptor to the restriction fragments of the first subset, selectively amplifying the first set of adaptor-ligated restriction fragments using a first primer combination wherein at least a first primer contains a first selected sequence at the 3′ end of the primer sequence, comprising 1-10 selective nucleotides, repeating these steps with at least a second primer combinations wherein the primer contains a different second selected sequence, fragmenting each of the subsets of amplified adaptor-ligated restriction fragments to generate sequencing libraries, determine the nucleotide sequence of the fragments, aligning the sequence of the fragments in each of the libraries to generate contigs, repeating these steps for one second and/or further restriction endonucleases, aligning the contigs obtained for each of the second and/or further restriction endonucleases to provide for a sequence of the genome. | 06-04-2009 |
| 20090142759 | qPCR array with IN SITU primer synthesis - Application of in situ oligonucleotide synthesis, using a maskless photolithographic oligonucleotide synthesis apparatus or by other means, for direct fabrication of polymerase chain reaction (PCR) primers in situ in PCR reaction wells. The synthesized oligonucleotides contain an enzymatically degradable linker sequence and a specific primer sequence. The method may be used for manufacturing of quantitative PCR (qPCR) arrays containing a plurality of independent qPCR assays while eliminating the need for presynthesized primer libraries. | 06-04-2009 |
| 20090142760 | Nucleic Acid Sequences Associated with Cell States - The present invention is directed to nucleic acid sequences whose expression is associated with different cell states, including nucleic acid sequences whose expression is induced at least 100-fold, or alternatively upregulated, in cells exhibiting asymmetric self-renewal relative to other cells. The invention is also directed to nucleic acid sequences whose expression is induced at least 100-fold, or alternatively upregulated, in cells exhibiting symmetric self-renewal relative to other cells. | 06-04-2009 |
| 20090142761 | METHODS AND KITS FOR METHYLATION DETECTION - Ligation-based methods and kits are disclosed for determining the degree of methylation of one or more target nucleotides. In certain embodiments, the methylation status of one or more target nucleotides is determined by generating misligation products. In certain embodiments, at least one target nucleotide is amplified prior to the ligation reaction. In certain embodiments, at least one ligation product, at least one ligation product surrogate, at least one misligation product, at least one misligation product surrogate, or combinations thereof are amplified. In certain embodiments, one or more ligation probes comprise at least one nucleotide analog, at least one Modification, at least one mismatched nucleotide, or combinations thereof. | 06-04-2009 |
| 20090142762 | Method of Screening for Binding Interaction Using Sets of Microparticles and Unique Probes - The present invention relates to methods for screening for binding interactions using multiple sets of microparticles, wherein said set has the same identifiable characteristic and wherein one of more sets comprise subsets of microparticles and said subset presents at least one unique probe that acts as a binding partner for a target molecule in a biological sample. In particular, the invention provides for methods of detecting tissue-typing antigens in donor tissue or recipient tissue using these multiple sets of microparticles. | 06-04-2009 |
| 20090142763 | NESTED PCR-BASED METHOD FOR SPECIFIC GENOTYPING OF THE FC GAMMA RECEPTOR IIIA GENE - The application describes a novel method for detection of a single nucleotide polymorphism, e.g., the 158 F/V polymorphism, in the FcγRIIIa gene using nested PCR to amplify large gene amplicons to aid in, e.g., genotyping applications. Thus, based on the results obtained in FcγRIIIa genotyping analysis, the present invention provides specific, efficient, reproducible, and accurate detection of such polymorphisms in genomic DNA. | 06-04-2009 |
| 20090142764 | Methods and Kits for Multiplex Amplification of Short Tandem Repeat Loci - Methods and materials are disclosed for use in simultaneously amplifying at least 11 specific STR loci of genomic DNA in a single multiplex reaction, as are methods and materials for use in the analysis of the products of such reactions. Included in the present invention are materials and methods for the simultaneous amplification of 16 specific loci in a single multiplex reaction, comprising the 10 AmpFISTR® SGMplus® STR loci, the Amelogenin locus, and 5 new STR loci, including methods and materials for the analysis of these loci. | 06-04-2009 |
| 20090142765 | METHOD AND APPARATUS FOR RAPIDLY COUNTING AND IDENTIFYING BIOLOGICAL PARTICLES IN A FLOW STREAM - A method for increasing the throughput, or the precision, or both the precision and the throughput, of a flow cytometer, or of a hematology analyzer employing a flow cytometer, and for further reducing the complexity of such a cytometer or analyzer, by utilizing the technique of laser rastering in combination with a lysis-free single-dilution method. Laser rastering involves sweeping a laser beam across a flowing sample stream in a hematology analyzer. A lysis-free single-dilution method involves performing all the flow cytometer measurements on a sample using a single aliquot, a single lysis-free reagent solution, a single dilution, and a single pass of said dilution through the measurement apparatus. An apparatus suitable for carrying out the method of this invention comprises an optical module comprising a source of light, a scanning device, a lens or system of lenses, a flowcell, detectors, and filters; and an electronic module comprising preamplifiers, analog signal conditioning elements, analog-to-digital converters, field-programmable gate arrays, digital signal processing elements, and data storage elements. | 06-04-2009 |
| 20090142766 | METHODS FOR MEASURING THE METABOLISM OF CNS DERIVED BIOMOLECULES IN VIVO - The present invention provides methods for measuring the metabolism of a central nervous system derived biomolecule implicated in a neurological and neurodegenerative disease or disorder. In particular, the method comprises measuring the in vivo metabolism of the biomolecule in the central nervous system of a subject. Also provided is a method for determining whether a therapeutic agent affects the in vivo metabolism of a central nervous system derived biomolecule. | 06-04-2009 |
| 20090142767 | Method for nucleic acid quantitation - It is intended to provide a novel convenient approach for DNA quantitative analysis that overcomes the disadvantages of conventional formulations. A standard DNA sample is prepared by introducing a single-base substitution into target DNA, and a predetermined amount thereof is mixed with a target DNA sample. The target and standard DNAs are amplified using the same primers designed to amplify a region comprising the single-base substitution site. To a hybridization product of a probe capable of binding to a site immediately before the single-base substitution site, ddATP, ddGTP, ddCTP, and ddTTP are sequentially added one by one to perform a complementary strand synthesis reaction. Luciferase reaction-induced luminescence derived from the formed pyrophosphoric acid is detected. The target DNA is quantitated from the amount of the detected luminescence and the amount of the added standard DNA sample. | 06-04-2009 |
| 20090142768 | PERFORIN-2 PROTEINS - Perforin-2 (P2) molecule is a pore forming protein. The 5′ untranslated region of the perforin-2 protein controls translational activity. Compositions include the perforin protein and the 5′ untranslated region. Methods of use include high-throughput screening assays for identification of therapeutic compounds in treatment of diseases. | 06-04-2009 |
| 20090142769 | Methods for determining anti-TNF therapeutic response - The present invention relates to methods for identifying patients that will respond to treatment with anti-TNF-therapy, i.e., anti-TNF responder patients. In particular, the present invention relates to determining response to an inhibitor of tumor necrosis factor (TNF) in a patient with a chronic inflammatory disease by determining the activity of type I interferon in the patient. The invention further relates to quantification of type I interferon as a measure of predicting responsiveness to anti-TNF therapy in patients with a chronic inflammatory disease such as rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, juvenile chronic arthritis, lupus, Crohn's disease, as well as for cardiovascular disease. | 06-04-2009 |
| 20090142770 | Hair Follicle Pharmacodynamic Assay for Telomerase Activity - The invention is directed to methods for determining the efficacy of treatment with telomerase modulators in mammals by the analysis of the level of telomerase reverse transcriptase activity in mammalian hair follicle cells. | 06-04-2009 |
| 20090142771 | Methods and Instruments for Processing a Sample in a Multi-Chambered Receptacle - A receptacle having a plurality of interconnected chambers arranged to permit multiple process steps or processes to be performed independently or simultaneously. The receptacles are manufactured to separate liquid from dried reagents and to maintain the stability of the dried reagents. An immiscible liquid, such as an oil, is included to control loading of process materials, facilitate mixing and reconstitution of dried reagents, limit evaporation, control heating of reaction materials, concentrate solid support materials to prevent clogging of fluid connections, provide minimum volumes for fluid transfers, and to prevent process materials from sticking to chamber surfaces. The receptacles can be adapted for use in systems having a processing instrument that includes an actuator system for selectively moving fluid substances between chambers and a detector. The actuator system can be arranged to concentrate an analyte present in a sample. The detector can be used to detect an optical signal emitted by the contents of the receptacle. | 06-04-2009 |
| 20090148833 | DEVICES FOR GENERATING DETECTABLE POLYMERS - This document provides systems, devices, and methods involved in generating detectable polymers. For example, diagnostic systems, diagnostic devices, primer systems, and collections of primer systems are provided. | 06-11-2009 |
| 20090148834 | Methods of use of alpha-methylacyl-CoA racemase in hormone refractory and metastatic prostate cancers - Methods for identifying patients having or at risk of developing prostate cancer (including hormone refractory or androgen independent prostate cancer) and patients having or at risk of developing a cancer arising from metastasis if a prostate cancer to another tissue, e.g., liver and lymph node, by measuring the expression or activity of alpha-methylacyl-CoA racemase are described. The invention also provides: methods of screening for compounds that can be used to treat prostate cancer (including hormone refractory or androgen independent prostate cancer) or metastases of prostate cancer by screening for compounds that modulate the expression or activity of the alpha-methylacyl-CoA racemase polypeptides or nucleic acids; a process for modulating (i.e., reducing) alpha-methylacyl-CoA racemase polypeptide or nucleic acid expression or activity, e.g., using the screened compounds; and methods for selecting patients for therapy with a compound that reduces the activity or expression of alpha-methylacyl-CoA racemase as well as methods for determining whether such a therapy should be continued in a patient. | 06-11-2009 |
| 20090148835 | METHOD FOR IDENTIFYING THE ORIGIN OF A COMPOUND BIOLOGICAL PRODUCT - The present invention relates to an identification method. In particular, a method for identifying the origin of a compound biological product, including the batch of origin, but also in some cases the actual biological sources of a compound biological product. | 06-11-2009 |
| 20090148836 | Method for Rapid Detection and Identification of Bioagents - Method for detecting and identifying unknown bioagents, including bacteria, viruses and the like, by a combination of nucleic acid amplification and molecular weight determination using primers which hybridize to conserved sequence regions of nucleic acids derived from a bioagent and which bracket variable sequence regions that uniquely identify the bioagent. The result is a “base composition signature” (BCS) which is then matched against a database of base composition signatures, by which the bioagent is identified. | 06-11-2009 |
| 20090148837 | Method for Rapid Detection and Identification of Bioagents - Method for detecting and identifying unknown bioagents, including bacteria, viruses and the like, by a combination of nucleic acid amplification and molecular weight determination using primers which hybridize to conserved sequence regions of nucleic acids derived from a bioagent and which bracket variable sequence regions that uniquely identify the bioagent. The result is a “base composition signature” (BCS) which is then matched against a database of base composition signatures, by which the bioagent is identified. | 06-11-2009 |
| 20090148838 | Methods for analysis of gene expression - This invention provides methods, compositions and kits for gene expression analysis and gene expression profiling. The methods of the invention are highly sensitive; have a wide dynamic range; are rapid and inexpensive; have a high throughput; and allow the simultaneous differential analysis of a defined set of genes. The methods, compositions and kits of the invention also provide tools for gene expression data collection and relational data analysis. | 06-11-2009 |
| 20090148839 | METHOD FOR EVALUATING CELL POPULATIONS - The invention describes specific sialylated structures present on human stem cells and cell populations derived thereof. The invention is especially directed to methods to control the status of stem cells by observing changes in sialylation of the cells; and control of potential contaminations of biological materials; and reagents and methods used in connection with the cells in order to avoid alterations of the cell glycosylation by contaminating materials. The invention is further directed to novel stem cells, the glycosylation of which has been specifically altered. | 06-11-2009 |
| 20090148840 | Method for detecting colon cancer markers - A method of detecting a tumor marker for the diagnosis of large bowel cancer and adenomatous polyposis coli comprising the steps of a) collecting and freezing feces, b) homogenizing the frozen feces in the presence of an RNAase inhibitor and preparing a suspension, c) extracting RNA from the obtained sample from which RNA is extracted, d) obtaining cDNA by reverse transcribing the extracted RNA, e) amplifying the obtained cDNA, and f) detecting the amplified cDNA, characterized in that the tumor marker is one or more tumor markers selected from the group consisting of COX-2, SNAIL and MMP-7 (with the proviso that a case where only COX-2 or MMP-7 is selected is excluded). | 06-11-2009 |
| 20090148841 | MULTIPLEXED GENOMIC GAIN AND LOSS ASSAYS - Encoded bead multiplex assays for chromosomal gains and losses are provided that provide the benefits of complex, large template DNA sources, such as BAC DNA, as the probe material without bead networking or other assay performance problems. Reagents for assaying DNA are described herein which include a plurality of encoded particles having attached amplicons amplified from a template DNA sequence. Each individual attached amplicon includes a nucleic acid sequence identical to a random portion of the template DNA sequence, wherein the amplicons together represent substantially the entire template DNA and wherein the nucleic acid sequence identical to a random portion of the template DNA sequence of each individual amplicon is shorter than the entire template DNA. | 06-11-2009 |
| 20090148842 | Preparation of templates for methylation analysis - The invention relates to a method of preparing and using a library of template polynucleotides suitable for use as templates in solid-phase nucleic acid amplification and sequencing reactions to determine the methylation status of the cytosine bases in the library. In particular, the invention relates to a method of preparing and analysing a library of template polynucleotides suitable for methylation analysis. | 06-11-2009 |
| 20090148843 | Means and Methods for the Prediction of Joint Destruction - The present invention relates to a method of diagnosing and/or predicting joint destruction, early joint destruction and/or accelerated joint destruction in particular, in rheumatoid arthritis, comprising determining in a sample obtained from an individual the presence of at least one nucleic acid sequence encoding an IL-4 receptor (IL-4R) which contains a mutation in position 465 of the nucleotide sequence of the wild-type IL4R as shown in SEQ ID NO: 1, whereby at said position the nucleotide A is replaced or a nucleic acid sequence encoding an IL-4 receptor (IL-4R), said IL-4R comprising at position 75 as shown in SEQ ID NO: 2 a valine instead of an isoleucine. Furthermore, the invention provides for a method of diagnosing and/or predicting early joint destruction and/or accelerated joint destruction comprising determining in a sample obtained from an individual the presence of an encoded IL-4 receptor (IL-4R) which comprises at the homologous position 75 of IL-4 receptor as depicted in SEQ ID NO: 2 a mutation, said mutation comprising the exchange from an isoleucine to a valine. In addition, the present invention relates to a use of specific probes and/or primers for the preparation of a diagnostic composition for diagnosing and/or predicting early joint destruction and/or accelerated joint destruction in particular in rheumatoid arthritis. | 06-11-2009 |
| 20090148844 | DNA MARKER FOR MEAT TENDERNESS IN CATTLE - A method for assessing the tenderness of meat from an animal, comprising the step of testing the animal for a genetic marker in the calpain3 (CAPN3) gene associated with Warner-Bratzler peak force variation or for a genetic marker located other than in CAPN3 which shows allelic association therewith. | 06-11-2009 |
| 20090148845 | ENZYME MEASUREMENT ASSAY USING A MODIFIED SUBSTRATE COMPRISING A SUBSTRATE ATTACHED TO A MACROMOLECULE VIA A SPACER - The invention provides novel reagents and methodologies for detecting free versus bound compounds. It is particularly useful to detect thrombin when it is not bound to A2M in the presence of thrombin bound to A2M by using a modified substrate that is sterically hindered from reacting with the bound thrombin. | 06-11-2009 |
| 20090148846 | Modified Oligonucleotides and Applications Thereof - Disclosed, among other things, are primers containing certain modified nucleobases in the 3′ terminal region of the primers that provide reduced formation of primer-dimers during amplification reactions, and various methods of use thereof. | 06-11-2009 |
| 20090148847 | RAPID MAGNETIC FLOW ASSAYS - Disclosed is an improvement in methods for nucleic acid and immunological bioassays. The methods comprise a step for “sweeping” paramagnetic bead: target molecule complexes so as to capture them with an affinity capture agent on a test pad by moving a magnetic force field from outside to inside the test pad area so as to bring into contact the paramagnetic complexes with the capture agent, while sweeping any unbound paramagnetic material off the test pad by moving the magnetic field from inside to outside the test pad area. Surprisingly, the paramagnetic complexes are rapidly affinity-extracted from the moving magnetic field. | 06-11-2009 |
| 20090148848 | PITX2 Polynucleotide, Polypeptide and Methods of Use Therefor - A novel T-type calcium channel (CACNA1G) is provided, as are polynucleotides encoding the same. CACNA1G has been implicated in cellular proliferative disorders. More specifically, it has been observed that the methylation state of specific regions within CpG islands associated with the CACNA1G gene correlates with a number of cancerous phenotypes involving a variety of tissue and cell types. Also provided are methods for detecting cellular proliferative disorders by determining the methylation state of genes or regulatory regions associated therewith, including CACNA | 06-11-2009 |
| 20090148849 | ONE-STEP TARGET DETECTION ASSAY - The present invention provides nucleic acid amplification, detection, and genotyping techniques. In one embodiment, the present invention provides a method for amplifying and detecting a target nucleic acid sequence by providing a first primer pair comprising: a first primer comprising a target specific sequence, a tag sequence 5′ of the target specific sequence, and a blocker between the target specific sequence and the tag sequence, and a second primer comprising a target specific sequence; providing a reporter attached to either the second primer or to a dNTP; providing a capture complex comprising an anti-tag sequence attached to a solid support; combining the first primer pair, the capture complex, the reporter, and a sample comprising a target nucleic acid sequence under conditions suitable for amplification of the target nucleic acid sequence and hybridization of the amplified target nucleic acid sequence to the capture complex; and detecting the amplified target nucleic acid sequence. | 06-11-2009 |
| 20090148850 | Methods for identifying modulators of P2RY14 - Methods for identifying modulators of P2RY14 are described. The methods are particularly useful for identifying agents that are useful for treating metabolic syndrome. | 06-11-2009 |
| 20090148851 | Methods, kits, and compositions for detecting enzyme activity - The inventive subject matter relates to methods, kits, and compositions for detecting enzyme activity in a biological sample. In particular, the inventive subject matter relates to methods, kits, and compositions for detecting von Willebrand factor degrading enzyme activity in a biological sample. | 06-11-2009 |
| 20090148852 | Sensitive method for detecting low levels of ATP - Methods are provided for sensitive detection of adenosine triphosphate (ATP) in samples using the luciferin-luciferase reaction. Aspects include using a pH composition that maximizes a signal to noise ratio. The maximum signal to noise ratio can be particularly useful with recombinant luciferase including recombinant Coleoptera luciferase. | 06-11-2009 |
| 20090148853 | BIOMARKERS FOR PREDICTING THE SENSITIVITY OF CELLS TO IMMUNOMODULATORY COMPOUNDS DURING TREATMENT OF NON-HODGKIN'S LYMPHOMA - Provided herein are the biomarkers for monitoring the treatment by immunomodulatory compounds. The use of biomarkers such as SPARC, p21, and cyclin D1 mRNA or protein levels as biomarkers to predict whether an immunomodulatory compound is likely to be successful in treating certain types of cancer, such as NHL, is also provided. Further, the expression of these genes or proteins can be used to monitor progress of treatment effectiveness and patient compliance in cancer patients that are receiving treatment with immunomodulatory compounds. | 06-11-2009 |
| 20090148854 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 184P1E2 USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene (designated 184P1E2) and its encoded protein, and variants thereof, are described wherein 184P1E2 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 184P1E2 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 184P1E2 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 184P1E2 can be used in active or passive immunization. | 06-11-2009 |
| 20090148855 | NUCLEIC ACID ENCODING OR TARGETING SODIUM CHANNEL SCN3A ALPHA SUBUNITS - The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognose or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders. | 06-11-2009 |
| 20090155775 | CLONED DNA POLYMERASES FROM THERMOTOGA AND MUTANTS THEREOF - The invention relates to a substantially pure thermostable DNA polymerase from | 06-18-2009 |
| 20090155776 | Fetal methylation markers - This application describes the discovery that, in a pregnant woman, certain genes (such as RASSF1A, APC, CASP8, RARB, SCGB3A1, DAB2IP, PTPN6, THY1, TMEFF2, and PYCARD) originated from a fetus are highly methylated, whereas the same genes of maternal origin are unmethylated. This discovery allows the easy detection of one or more of these methylated fetal genes in a biological sample from a pregnant woman, serving as a universal indicator of the presence of fetal DNA in the sample. These fetal methylation markers are particularly useful as positive controls for a non-invasive analytical process during which the quality and quantity of fetal DNA are monitored. These newly identified fetal markers can also be measured directly for diagnosis of certain pregnancy-related conditions. | 06-18-2009 |
| 20090155777 | Methods for performing direct enzymatic reactions involving nucleic acid molecules - Methods for performing a direct enzymatic reaction involving a nucleic acid molecule include performing the enzymatic reaction directly using a biological specimen in a reaction mixture containing a zwitterionic buffer and/or a non-reducing carbohydrate to prevent the biological specimen from inhibiting the enzymatic reaction, in which a nucleic acid molecule present in the biological specimen is not purified before the enzymatic reaction, and obtaining a product from the enzymatic reaction. | 06-18-2009 |
| 20090155778 | Mental Disorder-Related Gene and Use of the Same - Disclosed is useful means for the therapy or diagnosis of a mental disorder. A method for screening for a compound which is effective for a mental disorder, comprising the steps of (1) providing a cell capable of expressing a gene (target gene) selected from the group consisting of a gene having the nucleotide sequence depicted in SEQ ID NO:1, a gene having the nucleotide sequence depicted in SEQ ID NO:2, a gene having the nucleotide sequence depicted in SEQ ID NO:3 and genes homologous to these genes; (2) exposing the cell to a compound to be tested; (3) determining the amount of a product of the target gene expressed in the cell after the exposure to the compound; and (4) determining the change in amount of the product of the target gene under the influence of exposure to the compound. | 06-18-2009 |
| 20090155779 | APTAMERS THAT BIND TO PRION PROTEIN - Compositions are provided in the form of nucleotide aptamerss that are capapble of binding PrP, and in some embodiments, differentially binding PrP isoforms. Also provided are methods for identifying PrP in a sample, and in some embodiments, either selectively removing PrP or PrP isoforms from a sample, or inactivating them within a sample. | 06-18-2009 |
| 20090155780 | Methods for determining genetic haplotypes and DNA mapping - Improved methods of genetic haplotyping and DNA sequencing and mapping, including methods for making amplified ssDNA, methods for allele determination, and a DNA barcoding strategy based on direct imaging of individual DNA molecules and localization of multiple sequence motifs or polymorphic sites on a single DNA molecule. | 06-18-2009 |
| 20090155781 | High throughput genome sequencing on DNA arrays - The present invention is directed to methods and compositions for acquiring nucleotide sequence information of target sequences using adaptors interspersed in target polynucleotides. The sequence information can be new, e.g. sequencing unknown nucleic acids, re-sequencing, or genotyping. The invention preferably includes methods for inserting a plurality of adaptors at spaced locations within a target polynucleotide or a fragment of a polynucleotide. Such adaptors may serve as platforms for interrogating adjacent sequences using various sequencing chemistries, such as those that identify nucleotides by primer extension, probe ligation, and the like. Encompassed in the invention are methods and compositions for the insertion of known adaptor sequences into target sequences, such that there is an interruption of contiguous target sequence with the adaptors. By sequencing both “upstream” and “downstream” of the adaptors, identification of entire target sequences may be accomplished. | 06-18-2009 |
| 20090155782 | Homoeologous Region Determining Method by Homo Junction Fingerprint Method, Homoeologous Region Determining Device, and Gene Screening Method - To provide a method for efficiently searching for a recessive disease gene without needing any pedigree analysis. In a homoeologous region determining method, the following steps are conducted. It is determined whether or not the base constituting a polymorphic marker of a sample DNA of diploid or higher polyploidy is a homojunction. Homojunction region information representing the region of the sample DNA where polymorphic markers determined as continuous homojunctions acquired. If the continuous probability and/or continuous distance of the polymorphic markers contained in the homojunction region information satisfy a predetermined determination condition, the homojunction region is determined as a homoeologous region. A homoeologous region determining device and a gene screening method for identifying a disease susceptibility gene from the determined homoeologous region are also provided. | 06-18-2009 |
| 20090155783 | Method of preparing a biological specimen slide - A method of preparing a slide of a biological specimen, including the steps of (a) providing a slide containing a biological specimen and a cover slip, (b) placing a liquid non-evaporating sealing compound such as mineral oil at spaced locations around an area on the slide and (c) placing the cover slip over the specimen area whereby the specimen and reagent is between the slide and the cover slip and the sealing compound spreads to define a closed boundary around the specimen in the space between the slide and the cover slip. Testing of the biological specimen may then be performed automatically. | 06-18-2009 |
| 20090155784 | ASSESSMENT OF ASTHMA AND ALLERGEN-DEPENDENT GENE EXPRESSION - The present invention provides methods for the assessment, diagnosis, or prognosis of asthma including methods for providing an assessment, diagnosis, or prognosis comprising the step of exposing a sample derived from a patient to an allergen in vitro. The present invention also provides methods for selecting, as well as evaluating the effectiveness of, asthma treatments. The markers of the present invention can be used in methods to identify or evaluate agents capable of modulating marker expression levels in subjects with asthma | 06-18-2009 |
| 20090155785 | REAL-TIME COLORIMETRIC SCREENING INHIBITORS OF ENDONUCLEASE WITH GOLD NANOPARTICLE SUBSTRATE - The invention provides methods for screening a compound for its effect on endonuclease activity. The methods comprise providing a compound to be screened utilizing a gold nanoparticle aggregate as the substrate for the endonuclease. The gold nanoparticle aggregate is formed by the hybridization of oligonucleotides attached to the nanoparticles, with or without the presence of a third linker oligonucleotide. The hybridized oligonucleotide duplex serves as a substrate for the endonuclease. A detectable change is brought about in the presence of the endonuclease activity. A decrease in the detectable change reflects the reduced levels of endonuclease activities as a result of the effects of endonuclease inhibitors. The present invention also provides kits for screening an endonuclease inhibitor. | 06-18-2009 |
| 20090155786 | COMPOSITIONS AND METHODS FOR DETECTING MARKERS OF CANCER - Disclosed herein are compositions and methods for detecting one or more markers indicative of cancer. In one instance the marker is one or more methylated genes, such as SFRPs. In another instance the marker is an altered protein, such as p53. | 06-18-2009 |
| 20090155787 | Mutations in the BCR-ABL tyrosine kinase associated with resistance to STI-571 - The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS. | 06-18-2009 |
| 20090155788 | GENE EXPRESSION MARKERS FOR INFLAMMATORY BOWEL DISEASE - The present invention provides for a method of detecting the presence of inflammatory bowel disease in gastrointestinal tissues or cells of a mammal by detecting decreased expression of Indian Hedgehog (Ihh) and/or increased expression of Defensin A5 (DefA5) and/or Defensin A6 (DefA6) in the tissues or cells of the mammal relative to a control. | 06-18-2009 |
| 20090155789 | GENES FROM THE 20Q13 AMPLICON AND THEIR USES - The present invention relates to cDNA sequences from a region of amplification on chromosome 20 associated with disease. The sequences can be used in hybridization methods for the identification of chromosomal abnormalities associated with various diseases. The sequences can also be used for treatment of diseases. | 06-18-2009 |
| 20090155790 | CRAB-PII DIRECTED DIAGNOSTICS FOR NEOPLASTIC DISEASE - Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of CRAB-PII in the test cell sample or fluid sample as compared to the level of expression of CRAB-PII in a control cell sample or fluid sample isolated from a normal subject. | 06-18-2009 |
| 20090155791 | Method for detecting methylation status by using methylation-independent primers - A reliable and highly sensitive method is provided for detecting methylation status of CpG-containing nucleic acids by nucleic acid amplification and melting curve analysis of amplification products. The methods and compositions employs a novel design of primers. CpG-containing methylation-independent oligonucleotide primers, wherein both unmethylated and methylated alleles of a CpG-containing nucleic acid can be detected by use of only one set of primers after the CpG-containing nucleic acid has been subjected to cytosine to thymine conversion of unmethylated Cytosine. The method is useful for detection of methylation status in for example cancer genes and other disease related genes, wherein methylation influences gene expression. | 06-18-2009 |
| 20090155792 | PREDICTORS OF LONG-TERM MORTALITY FOLLOWING CORONARY ARTERY BYPASS GRAFT SURGERY - The present invention relates, in general, to perioperative depression and, in particular, to methods of identifying individuals at risk of perioperative depression. | 06-18-2009 |
| 20090155793 | APPARATUS FOR HIGH THROUGHPUT SEQUENCING OF NUCLEIC ACIDS - A scalable reaction and detection system for automated high throughput sequencing of nucleic acids involving a combination of chemical processes and observation processes independent of the chemistry processes. Discrete functional units may be configured in a manner that allows the system to interchangeably utilize different sequencing reaction components in conjunction with discrete apparatus components for optical image collection and/or analysis. | 06-18-2009 |
| 20090155794 | CLONING MULTIPLE CONTROL SEQUENCES INTO CHROMOSOMES OR INTO ARTIFICIAL CENTROMERES - Artificially synthesizing 29 homozygous cystic fibrosis core panel controls demonstrates placing multiple homozygous mutant sequences on the same single control DNA sequence to streamline quality control by minimizing extra control assays, time, and costly formatted test materials and testing all controls during every test. Any rare or unavailable reported DNA sequence can be PCR amplified using primer pairs synthesized with the designated mutation or variant sequence with paired adjacent upstream and downstream primers to amplify target sequences in total genomic DNA. | 06-18-2009 |
| 20090155795 | BASELESS NUCLEOTIDE ANALOGUES AND USES THEREOF - A method of detecting a target nucleic acid. | 06-18-2009 |
| 20090155796 | MARKER FOR CANCER PROGNOSIS AND METHODS RELATED THERETO - The present invention is related to the novel discovery that HIF- | 06-18-2009 |
| 20090155797 | Methods For Generating Enhanced Antibody-Producing Cell Lines With Improved Growth Characteristics - The use of mismatch repair (MMR) defective antibody producer cells offers a method to generate subclone variants with elevated protein production such as antibodies. Using MMR defective cells and animals, new cell lines and animal varieties with novel and useful properties such as enhanced protein production can be generated more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within host cells to alter endogenous genes that can yield increased titer levels of protein production. By employing this method, two genes were discovered whose suppressed expression is associated with enhanced antibody production. Suppressed expression of these genes by a variety of methods leads to increased antibody production for manufacturing as well as strategies for modulating antibody production in immunological disorders. Moreover, the suppression of these two genes in host cells can be useful for generating universal high titer protein production lines. | 06-18-2009 |
| 20090155798 | TLE3 AS A MARKER FOR CHEMOTHERAPY - Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer. | 06-18-2009 |
| 20090155799 | METHODS FOR DIAGNOSING PANCREATIC CANCER USING REG4 PROTEIN - REG4, a new member of REG family was identified as a biomarker of pancreatic adenocarcinoma. The present invention provides sandwich ELISA to detect serum REG4 in patients with resectable pancreatic cancers i.e. PDACs. The present invention also provides a method for diagnosing a pancreatic cancer using REG4 as a serological marker. | 06-18-2009 |
| 20090155800 | BIOSENSOR HAVING NANO WIRE AND MANUFACTURING METHOD THEREOF - There is provided a biosensor capable of increasing a detecting sensitivity of a target substance by using a nano wire having excellent electrical characteristics and by immobilizing a receptor of the target substance to be detected on a substrate which is disposed between a nano wire and another nano wire and a method for manufacturing the same. A biosensor according to the present invention can be manufactured with an arrangement in which the nano wire is selectively arranged on a solid substrate in a matrix and, therefore, many materials can be detected at the same time. Particularly, since the degradation of electrical characteristics of the nano wire can be prevented in the present invention, a target substance is very sensitively detected through a small amount thereof. | 06-18-2009 |
| 20090155801 | METHOD OF SEQUENCING DNA - The present invention provides a method of identifying a base at a target position in a sample nucleic acid sequence, said method comprising: subjecting a primer hybridised to said sample nucleic acid immediately adjacent to the target position, to a polymerase primer extension reaction in the presence of a nucleotide, whereby the nucleotide will only become incorporated if it is complementary to the base in the target position, and determining whether or not said nucleotide is incorporated by detecting whether PPi is released, the identity of the target base being determined from the identity of any nucleotide incorporated, wherein, where said nucleotide comprises an adenine base, an α-thio triphosphate analogue of said nucleotide is used, ant the Rp isomer of said analogue and/or the degradation products of said analogue are eliminated from the polymerase reaction step. | 06-18-2009 |
| 20090155802 | Mutant DNA Polymerases with Improved Pyrophasphorolysis Activated Polymerization (PAP) Ability - Disclosed are mutant DNA polymerases having improved extension rates relative to a corresponding, unmodified polymerase. The mutant polymerases are useful in a variety of disclosed primer extension methods. Also disclosed are related compositions, including recombinant nucleic acids, vectors, and host cells, which are useful, e.g., for production of the mutant DNA polymerases. | 06-18-2009 |
| 20090155803 | METHODS FOR TISSUE ANALYSIS - This invention relates to methods of analyzing a tissue sample from a subject. In particular the invention combines morphological staining and/or immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) within the same section of a tissue sample. The analysis can be automated or manual. The invention also relates to kits for use in the above methods. | 06-18-2009 |
| 20090155804 | DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTS - The increased efficacy and reduced unwanted side effects of drugs can be insured by treating only responsive patients. In an embodiment of the invention, signaling pathways that a particular drug interferes with, are derive together with predictive biomarkers and dynamic biomarker that can read the activity of these pathways before and after drug treatment in order to select a responder patient population. In an alternative embodiment of the invention, certain core pathways that the drug does not interfere with and that are known to be causally involved in a particular disease(s) can be identified, and derive the biomarkers for those to be able to exclude these patients that suffer from a disease in which those drug non effected pathways are involved from being treated with the specific drug in question. | 06-18-2009 |
| 20090155805 | COPY NUMBER ALTERATIONS THAT PREDICT METASTATIC CAPABILITY OF HUMAN BREAST CANCER - Disclosed in this specification is a method of defining chromosome regions of prognostic value by summarizing the significance of all SNPs (single nucleotide polymorphism) in a predetermined section of a chromosome to define chromosome regions of prognostic value. Based on the SNPs in specified genes, a more accurate prognosis for breast cancer may be provided. | 06-18-2009 |
| 20090155806 | Genomic Sequence of the 5-Lipoxygenase-Activating Protein (FLAP), Polymorphic Markers Thereof and Methods for Detection of Asthma - The invention concerns the genomic sequence of the FLAP gene. The invention also concerns biallelic markers of a FLAP gene and the association established between these markers and diseases involving the leukotriene pathway such as asthma. The invention provides means to determine the predisposition of individuals to diseases involving the leukotriene pathway as well as means for the diagnosis of such diseases and for the prognosis/detection of an eventual treatment response to agents acting on the leukotriene pathway. | 06-18-2009 |
| 20090155807 | C-MET MUTATIONS IN LUNG CANCER - The invention provides methods and compositions useful for detecting mutations in c-met in lung cancer cells. | 06-18-2009 |
| 20090155808 | Automated system for isolating, amplifying and detecting a target nucleic acid sequence - A system and method for preparing and testing of targeted nucleic acids is presented. The system integrates a pipetter, extractor, assay reader, and other components, including a selectively compliant articulated robot arm (SCARA). This synergistic integration of previously separate diagnostic tools creates a system and method whereby a minimum of human intervention is required. The resulting system provides a substantially more accurate and precise method of isolating, amplifying and detecting targeted nucleic acids for diagnosing diseases. | 06-18-2009 |
| 20090155809 | SUBTRACTIVE SINGLE LABEL COMPARATIVE HYBRIDIZATION - Provided are methods of determining differences between nucleic acids in a test sample and a reference sample. In certain embodiments the methods are used for detecting and mapping chromosomal or genetic abnormalities associated with various diseases or with predisposition to various diseases, or to detecting the phenomena of large scale copy number variants. In particular, provided are advanced methods of performing array-based comparative hybridization that allow reproducibility between samples and enhanced sensitivity by using the same detectable label for both test sample and reference sample nucleic acids. Invention methods are useful for the detection or diagnosis of particular disease conditions such as cancer, and detecting predisposition to cancer based on detection of chromosomal or genetic abnormalities and gene expression level. Invention methods are also useful for the detection or diagnosis of hereditary genetic disorders or predisposition thereto, especially in prenatal samples. Moreover, invention methods are also useful for the detection or diagnosis of de novo genetic aberrations associated with post-natal developmental abnormalities. | 06-18-2009 |
| 20090162835 | Novel methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries - Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens. | 06-25-2009 |
| 20090162836 | Prognostic and Diagnostic Markers for Cell Proliferative Disorders of The Breast Tissues - The present invention relates to prognostic and diagnostic markers for cell proliferative disorders of the breast tissues. The present invention therefore provides methods and nucleic acids for the analysis of biological samples for features associated with the development of breast cell proliferative disorders. Furthermore, the invention provides for prognosis of treatment effects relating to drug therapy, in particular hormonal/antihormonal therapy, chemotherapy and/or adjuvant therapy. | 06-25-2009 |
| 20090162837 | Inactivated FCV vaccines - The present invention relates to improved inactivated feline calicivirus (FCV) vaccines. The invention also provides a process for producing stabilized inactivated FCV, and the use of such stabilized inactivated FCV, in the production of FCV immunogenic compositions. The invention further provides methods of inducing an immune response in an animal of the Felidae family, preferably a cat, using the immunogenic compositions according to the invention. | 06-25-2009 |
| 20090162838 | FLUORESCENCE RESONANCE ENERGY TRANSFER ENZYME SUBSTRATES - Disclosed are compounds of formula (I) wherein D | 06-25-2009 |
| 20090162839 | DIAGNOSIS AND PROGNOSIS OF CANCER BASED ON TELOMERE LENGTH AS MEASURED ON CYTOLOGICAL SPECIMENS - The present invention concerns a quantitative in situ assessment of mean telomere length, particularly in relation to nuclear area, for the diagnosis and/or prognosis of cancer. In particular aspects, the methods and compositions regard diagnosis and/or prognosis of bladder cancer, urothelial cancer, lung cancer, and lymphoma. | 06-25-2009 |
| 20090162840 | Methods and compositions for use in analyte detection using proximity probes - Methods and compositions for detecting an analyte in a sample are provided. In practicing the subject methods, a sample is combined with at least a pair of proximity probes that each include an analyte binding domain and a nucleic acid domain. The resultant mixture is then contacted with a pair of asymmetric nucleic acid connectors. Proximity dependent connector mediated interaction between the nucleic acid domains of the proximity probes is then detected to determine the presence of the analyte in the sample. Also provided are kits and systems for practicing the subject methods. | 06-25-2009 |
| 20090162841 | Method of selecting a desired protein from a library - Described is an improved method of selecting a member of a specific binding pair (sbp) having a desired specify, preferably an antibody, from a library expressing said member of a sbp, preferably a phage-display antibody library. | 06-25-2009 |
| 20090162842 | Circulating mRNA as diagnostic markers - Methods and kits are provided for diagnosing, monitoring, or predicting the conditions of pre-eclampsia, fetal chromosomal aneuploidy, and pre-term labor in a pregnant woman, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more mRNA species encoding human chorionic gonadotropin β subunit (hCG-β), human placental lactogen (hPL), human corticotropin releasing hormone (hCRH), KiSS-1 metastasis-suppressor (KISS1), tissue factor pathway inhibitor 2 (TPFI2), placenta-specific 1 (PLAC1), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and comparing the amount of the mRNA species with a standard control. | 06-25-2009 |
| 20090162843 | IDENTIFICATION OF HPV16 LINEAGE GROUP - A method for identification of an HPV16 lineage group in a sample, comprising contacting such nucleic acid simultaneously with three probes, each probe being capable of specific hybridization across positions 143 and 145 of a HPV 16 genome. | 06-25-2009 |
| 20090162844 | Identification and characterization of racemases, definition of protein signatures, and a test for detecting D-amino acid and for screening molecules capable of inhibiting the activity of racemase, especially proline racemase - This invention provides identification and characterization of racemases and definition of protein signatures of these racemases. This invention also provides identification of nucleic acid molecules encoding a peptide consisting of a motif characteristic of the protein signatures, and to the peptides consisting of these motifs. Antibodies specific for the peptides and to immune complexes of these antibodies with the peptides are also provided. Further, the invention relates to methods and kits for detecting racemases using the nucleic acid molecules of the invention, as well as the peptides consisting of the motifs and antibodies to these peptides. | 06-25-2009 |
| 20090162845 | Affinity tag nucleic acid and protein compositions, and processes for using same - The present invention concerns compositions and processes that use affinity tags for isolating, and detecting or quantifying analytes, including nucleic acids, proteins and polypeptides. Compositions include nucleic acid compositions and protein compositions with affinity binding pairs, including metal binding peptides and immobilized metals, or peptide affinity groups. | 06-25-2009 |
| 20090162846 | SENP1 as a marker for cancer - The present invention provides methods of detecting cancer cells by detecting the quantity of SENP1 and/or telomerase in a sample. | 06-25-2009 |
| 20090162847 | RAPID DETECTION OF THE "HIGH-VIRULENT" ST-17 CLONE OF GROUP B STREPTOCOCCUS - The present invention relates to polynucleotides enabling the rapid, simple and specific detection of Group B | 06-25-2009 |
| 20090162848 | Noxin, a novel stress-induced gene involved in cell cycle and apoptosis - The invention provides for novel noxin polypeptides and nucleic acids from humans, rats, and mice and to related compositions and uses. The invention also provides for the creation of non-human, transgenic mammals which have, incorporated in their genome, DNA that includes a sequence of a mammalian noxin gene that does not produce noxin polypeptides, i.e. a noxin knockout mouse. | 06-25-2009 |
| 20090162849 | IDENTIFICATION OF A JAK2 MUTATION IN POLYCYTHEMIA VERA - The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group. | 06-25-2009 |
| 20090162850 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 125P5C8 USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene (designated 125P5C8) and its encoded protein, and variants thereof, are described wherein 125P5C8 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 125P5C8 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 125P5C8 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 125P5C8 can be used in active or passive immunization. | 06-25-2009 |
| 20090162851 | DETECTION OF NUCLEIC ACIDS BY TYPE SPECIFIC HYBRID CAPTURE METHOD - Target-specific hybrid capture (TSHC) provides a nucleic acid detection method that is not only rapid and sensitive, but is also highly specific and capable of discriminating highly homologous nucleic acid target sequences. The method produces DNA-RNA hybrids which can be detected by a variety of methods. | 06-25-2009 |
| 20090162852 | BAALC EXPRESSION AS A DIAGNOSTIC MARKER FOR ACUTE LEUKEMIA - Overexpression of the gene, BAALC, in biological samples from a patient is prognostic for tumor aggressiveness and unfavorable patient outcome. The present invention provides polynucleotide primers and probes for assaying for overexpression of BAALC transcripts. Kits containing the primers and probes are also provided. Also provided are antibodies for assaying for overexpression of BAALC proteins as well as peptide immunogens for producing the anti-BAALC antibodies. The present invention also provides methods for characterizing acute myelogenous leukemia, chronic myelogenous leukemia and prostate cancer in a patient, base on detection of BAALC overexpression. | 06-25-2009 |
| 20090162853 | METHODS AND DEVICES FOR CELLULAR ANALYSIS - Embodiments of the present invention are directed to improved methods and devices for analyzing a cell, aggregated cells, or a solid tumor. Such methods and devices are, for example, useful in the field of pathology and can provide improved cell processing and analytical results. | 06-25-2009 |
| 20090162854 | METHODS AND KITS FOR DIAGNOSIS OF SCHIZOPHRENIA - The present invention provides methods and kits for the diagnosis of schizophrenia, which employ mitochondrial complex I as a peripheral biological marker for schizophrenia. In an embodiment of the invention, the present invention provides a method for diagnosing schizophrenia in a subject by determining the level of m-RNA or protein mitochondrial complex I subunits and its activity by determining the cellular basal respiration through complex I enzyme. | 06-25-2009 |
| 20090162855 | Identification of Genetic Variants Associated with Increased Severity of Pulmonary Disease - A method of determining a genetic component contributing to the severity of a pulmonary disease in a patient comprises determining the presence or absence of one or more single nucleotide polymorphisms (SNPs) in the Endothelin Receptor A (EDNRA) gene or the Interleukin-8 (IL-8) gene of the patient. The SNPs are rs5335 or rs1801708 for EDNRA, or rs4O73 for IL-8. The pulmonary disease may be cystic fibrosis or lymphangioleimyomatosis. Determining the presence or absence of one or more of SNPs rs5335 or rs1801708 in the EDNRA gene or rs4073 in the IL-8 gene of the patient may also be used in a method of treating a patient having a pulmonary disease. A kit may comprise one or more probes for determining the presence or absence of one or more of SNPs rs5335 and rs1801708 in the EDNRA gene or the SNP rs4073 in the IL-8 gene. | 06-25-2009 |
| 20090162856 | RNA DETECTION METHOD - It is an object of the present invention to provide a method for rapid, convenient, and highly sensitive detection of trace RNA wherein a risk of contamination is low. The present invention provides a method for amplification of nucleic acid which comprises the steps of: (i) allowing a reverse transcriptase to act on RNA so as to produce a nucleic acid fragment; and (ii) performing substantially isothermal incubation of a reaction solution containing at least one type of deoxynucleotide triphosphate, at least one type of DNA polymerase having strand displacement activity, a divalent cation, a surfactant accounting for at least 0.01% of the solution, at least two types of oligonucleotide primers, and the nucleic acid fragment as a template obtained in the step (i) so as to perform a polymerase reaction that is initiated from the 3′ ends of the primers and thus amplify the nucleic acid fragment. | 06-25-2009 |
| 20090162857 | Pharmaceutical Compositions and Methods for Delivering Nucleic Acids Into Cells - The present invention relates to methods of delivering nucleic acids into cells using a nucleic acid binding molecule containing a multimeric or spacer-incorporated protein transduction domain (PTD). The invention also relates to novel compositions that contain a nucleic acid complexed or conjugated with a nucleic acid binding molecule. The nucleic acid binding molecule may contain a multimeric or spacer-incorporated PTD, and may further contain a nucleic acid binding region. The nucleic acid complexes or conjugations of the present invention may be employed to inhibit expression of a target gene, and/or determine the function of a target gene. | 06-25-2009 |
| 20090162858 | Orthogonal chemical inducer of dimerization - A method for identifying a molecule as being able to bind a protein target in a cell, comprising (a) covalently bonding the molecule to trimethoprim (TMP) to form a screening molecule, (b) introducing the screening molecule into the cell which (A) expresses (i) a first fusion protein comprising a binding domain capable of binding TMP, and (ii) a second fusion protein comprising the protein target, and (B) comprises a reporter gene, wherein one of the fusion proteins comprises a DNA-binding domain and the other fusion protein comprises a transcription activation domain and wherein expression of the reporter gene is conditioned on the proximity of the DNA-binding domain to the transcription activation domain; and (c) determining whether the screening molecule binds to the first fusion protein and to the second fusion protein by determining whether the cell expresses the reporter gene, wherein expression of the reporter gene indicates that the molecule binds the protein target and wherein lack of expression of the reporter gene indicates that the molecule does not bind the protein target. | 06-25-2009 |
| 20090162859 | Compositions, methods and systems for inferring canine breeds for genetic traits and verifying parentage of canine animals - Methods and systems are provided for managing companion animal subjects in order to maximize their individual health and potential performance and to maximize profits obtained in breeding and marketing the companion animal subjects. The methods and systems draw an inference of a phenotype for a genetic trait of a companion animal subject by determining the nucleotide occurrence of at least one companion animal SNP that is determined to be associated with the phenotype. The methods and systems described can be utilized to identify individual animals, determine or verify parentage of a single dog from any breed if the putative parent(s) are also available for testing, and are associated with, and predictive of, canine breeds. The inference is used in some aspects to diagnose a health condition or predisposition of a companion animal subject. | 06-25-2009 |
| 20090162860 | Method of nucleic acid sequence detection and nucleic acid sequence detection substrate - According to an aspect of the present invention, a pair of oligonucleotide strands are anchored onto the surface of a substrate by immobilizing one of the ends thereof onto the substrate. Each of the immobilized oligonucleotide strands is bound to a target nucleic acid sequence (single-stranded) having complementary sequences thereto to form a cross-linked structure on the substrate, thereby forming a finely reticulated space. Ligands are captured by this reticulated space through physical adsorption and caused to color with active substances reactive to the ligands. As a result of this, the present invention is capable of highly sensitively detecting even an exceedingly small concentration of a particular target nucleic acid sequence to be detected, at low cost and for a short time. | 06-25-2009 |
| 20090162861 | METHOD FOR SUPPRESSING A FRET SIGNAL, FRET SIGNAL SUPPRESSOR AGENTS AND USE IN A METHOD FOR MULTIPLEXING BIOLOGICAL EVENTS - The invention relates to a method for suppressing the FRET emitted by a reaction medium containing a pair of fluorescent FRET partner conjugates specific for a biological event, characterized in that a FRET signal killer which does not disturb said biological event is introduced into this medium. | 06-25-2009 |
| 20090162862 | DEVICE AND METHOD FOR THE AUTOMATED AND REPRODUCIBLE PRODUCTION OF CELL OR TISSUE SAMPLES THAT ARE TO BE ANALYZED AND ARE ARRANGED ON OBJECT SUPPORTS - An automatically operating apparatus designed as a table-top apparatus for the reproducible production of cell or tissue samples to be examined and arranged on specimen slides comprises, located its center, a rotatably supported, advance device having arranged on its periphery a plurality of modular processing stations at a distance from the advance device. Receiving devices provided in the peripheral region of the advance device are disposed to receive specimen slides on which automatically segmented cell and tissue segments can be positioned in a reproducible and correctly aligned manner. The cell and tissue segments are durably fixed in position on the specimen slides with the use of a curable adhesive, and the specimen slides, after being delivered, are subjected to further treatment processes in a further treatment device. | 06-25-2009 |
| 20090162863 | Nucleic acid detection probe - It is intended to provide a nucleic acid detection probe that is designed with a high degree of flexibility. The present invention provides a nucleic acid detection probe used in nucleic acid detection, wherein the amount of a particular target gene present in a sample is examined by simultaneously hybridizing, to the target nucleic acid, a first probe labeled at one end with a fluorophore and a second probe labeled with a quencher at an end different from the labeled end of the first probe and observing quenching attributed to the interaction between the fluorophore and the quencher. | 06-25-2009 |
| 20090162864 | BIOLOGICAL SUBSTANCE DETECTION CARTRIDGE,BIOLOGICAL SUBSTANCE DETECTION APPARATUS, AND BIOLOGICAL SUBSTANCE DETECTION METHOD - A biological substance detection cartridge, including: a reaction vessel for reacting a probe with a specific biological substance included in a sample solution, the reaction vessel having a region for fixing the probe for detecting the biological substance; a porous membrane facing the inside of the reaction vessel; a gas-liquid separation membrane superposed with the porous membrane; and a air discharge component which is provided on the opposite side of the gas-liquid separation membrane from the side contacting the porous membrane, and with which the interior can be kept at negative pressure during the reaction between the biological substance and the probe. | 06-25-2009 |
| 20090162865 | BREAST CANCER RELATED PROTEIN, GENE ENCODING THE SAME, AND METHOD OF DIAGNOSING BREAST CANCER USING THE PROTEIN AND GENE - An isolated protein having an amino acid sequence of SEQ ID No. 4 and having an activity inducing apoptosis, and a gene encoding the same are provided. Also, a microarray having a substrate on which the gene or fragment thereof is immobilized is provided. Also, a method of diagnosing breast cancer using an antibody specifically binding to the protein and a method of diagnosing breast cancer by determining whether the gene is expressed in a cell or not, are provided. | 06-25-2009 |
| 20090162866 | COMPOSITIONS AND METHODS FOR OBTAINING NUCLEIC ACIDS FROM SPUTUM - The present invention relates to compositions and methods for preserving and extracting nucleic acids from saliva. The compositions include a chelating agent, a denaturing agent, buffers to maintain the pH of the composition within ranges desirable for DNA and/or RNA. The compositions may also include a reducing agent and/or antimicrobial agent. The invention extends to methods of using the compositions of the invention to preserve and isolate nucleic acids from saliva as well as to containers for the compositions of the invention. | 06-25-2009 |
| 20090162867 | MUTATIONAL PROFILES IN HIV-1 REVERSE TRANSCRIPTASE CORRELATED WITH PHENOTYPIC DRUG RESISTANCE - The invention provides novel mutations, mutation combinations or mutational profiles of HIV-1 reverse transcriptase and/or protease genes correlated with phenotypic resistance to HIV drugs. More particularly, the present invention relates to the use of genotypic characterization of a target population of HIV and the subsequent correlation of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design, clinical management and diagnostic analysis. | 06-25-2009 |
| 20090170073 | FLUORESCENT PROTEIN AND CHROMOPROTEIN - It is an object of the present invention to provide a novel fluorescent protein and a novel chromoprotein. The present invention provides a novel fluorescent protein derived from | 07-02-2009 |
| 20090170074 | SYSTEM AND METHOD FOR NUCLEIC ACID SEQUENCING BY POLYMERASE SYNTHESIS - This invention relates to improved methods for sequencing and genotyping nucleic acid in a single molecule configuration. The method involves single molecule detection of fluorescent labeled PPi moieties released from NTPs as a polymerase extension product is created. | 07-02-2009 |
| 20090170075 | Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer - The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and/or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene. | 07-02-2009 |
| 20090170076 | Polynucleotides for the detection of escherichia coli 0157:h7 and escherichia coli 0157:nm verotoxin producers - Polynucleotide primers and probes for the specific detection of | 07-02-2009 |
| 20090170077 | Method for detecting recombinant event - Methods relating to isolating and amplifying chimeric nucleic acid molecules are provided. The methods of the invention are useful for detecting chromosome translocation events associated with diseases or conditions, such as cancer. | 07-02-2009 |
| 20090170078 | METHOD OF QUANTITATIVELY ANALYSING MICROORGANISM TARGETING RRNA - An object of the present invention is to provide a method of quantitating or detecting a microorganism, capable of detecting a live microorganism at high sensitivity and more precisely. A method of quantitating a microorganism of interest, using as an index the amount of rRNA of the microorganism of interest is provided. | 07-02-2009 |
| 20090170079 | Regulation of RUNX1 for Treatment of Pain - Methods are provides for identifying candidate agents for use in inhibiting expression of certain receptors and ion channels in nociceptors. Also provided are methods for identifying candidates agents for use in inhibiting neurophathic and other types of pain. | 07-02-2009 |
| 20090170080 | IDENTIFICATION OF BETA-PAPILLOMAVIRUS DNA BY TYPE-SPECIFIC REVERSE HYBRIDIZATION - The present invention relates human papilloma virus (HPV), more specific cutaneous, beta-PV. A method is disclosed for typing of any beta-PV nucleic acid with at least one probe capable of specific hybridization within the A region of beta-PV, said region being indicated in FIG. | 07-02-2009 |
| 20090170081 | GENE METHYLATION IN BLADDER CANCER DIAGNOSIS - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with bladder cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of bladder cancer. | 07-02-2009 |
| 20090170082 | GENE METHYLATION IN RENAL CANCER DIAGNOSIS - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with renal cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of renal cancer. | 07-02-2009 |
| 20090170083 | GENE METHYLATION IN DIAGNOSIS OF MELANOMA - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with melanoma. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of melanoma. | 07-02-2009 |
| 20090170084 | GENE METHYLATION IN BREAST CANCER - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with breast cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of breast cancer. | 07-02-2009 |
| 20090170085 | Gene Methylation in Head and Neck Cancer Diagnosis - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with head and neck cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of head and neck cancer. | 07-02-2009 |
| 20090170086 | Gene Methylation In Esophageal Cancer Diagnosis - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with esophageal cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of esophageal cancer. | 07-02-2009 |
| 20090170087 | Gene Methylation in Cervical Cancer Diagnosis - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with cervical cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of cervical cancer. | 07-02-2009 |
| 20090170088 | GENE METHYLATION IN CANCER DIAGNOSIS - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of cancer. | 07-02-2009 |
| 20090170089 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING TISSUES OR CELL TYPES USING EPIGENETIC MARKERS - The present invention provides, inter alia, a method for generating a genome-wide epigenomic map, comprising a correlation between methylation variable CpG positions (MVP) and genomic DNA sample types. MVP are those CpG positions that show a variable quantitative level of methylation between sample types. Particular genomic regions of interest (ROI) provide preferred marker sequences that comprise multiple, and preferably proximate MVP, and that have novel utility for distinguishing sample types. The epigenic maps have broad utility, for example, in identifying sample types, or for distinguishing between and among sample types. In a preferred embodiment the epigenomic map is based on methylation variable regions (MVP) within the major histocompatibility complex (MHC), and has utility, for example, in identifying the cell or tissue source of a genomic DNA sample, or for distinguishing one or more particular cell or tissue types among other cell or tissue types. Analysis of epigenetic characteristics of one, or of a set of nucleic acid sequences, in the context of an inventive epigenomic map, allows for the determination of an origin of the nucleic acids. | 07-02-2009 |
| 20090170090 | Method for Enhancing Enzymatic DNA Polymerase Reactions - The invention relates to a method of enhancing a DNA polymerase reaction by including in a reaction mixture containing a DNA polymerase a protein of DNA ligase. | 07-02-2009 |
| 20090170091 | Method For Predicting Biological Systems Responses - The inventive method employs a “systems biology” approach to predicting biological responses resulting from exposure to the test substance. In one embodiment, the invention provides an automated method for predicting the biological systems effects of a test substance. In another embodiment, the invention provides a method for constructing a knowledgebase (or database) of response profiles for reference substances with known biological systems effects. In another embodiment, the invention provides a set of protocols and software tools used to carry out the profiling. Another embodiment of the invention is a panel of reagents and protocols required for generating response profiles, either to create an knowledgebase, or to use with an existing knowledgebase and informatics software to profile substance physiological effects. Another embodiment of the invention is a database of physiological profiles. | 07-02-2009 |
| 20090170092 | INTEGRATED MICROFLUIDIC ANALYSIS SYSTEMS - The present invention provides an integrated microfluidic analysis system. The system contains at least a first (pre-reaction treatment) domain for treating a sample prior to subjecting the sample to a chemical reaction. The following domains are optionally added to the first domain: a second (reaction) domain for reacting the chemical of interest in the sample; and a third (post-reaction separation) domain for separating products and reactants coming out of the reaction domain. The integrated microfluidic analysis system of the present invention is most applicable to PCR analysis. | 07-02-2009 |
| 20090170093 | SELECTION MARKER SYSTEM AND METHOD FOR SCREENING A CHOLINE TOLERANT PLANT CELL - The present invention relates to a selection marker system for distinguishing genetically modified plant cells from wild-type plant cells comprising (a) a nucleic acid sequence coding for choline oxidase, choline monooxygenase and/or choline dehydrogenase for genetically modifying at least a part of a plant and; (b) at least a part of a wild-type plant of the same plant species, wherein the part of the plant which is genetically modified by the nucleic acid sequence coding for choline oxidase, choline monooxygenase and/or choline dehydrogenase is capable of surviving in a medium containing choline at a concentration which is toxic to the wild-type plant. Furthermore, the invention relates to a method for screening and/or identifying a choline tolerant plant cell and the use of a nucleic sequence coding for a choline oxidase, choline monooxygenase and/or choline dehydrogenase as a selection marker for choline tolerance. | 07-02-2009 |
| 20090170094 | FLUORESCENT LABELING SUBSTANCE COMPRISING NANOPARTICLES OR NANORODS - A fluorescent labeling substance that is capable of realizing highly appropriate labeling through enhancing of the luminous efficiency of semiconductor nanoparticles or nanorods. The fluorescent labeling substance can be provided by disposing on a surface of shell of nanorods or nanoparticles having a modification group capable of adsorption with a biosubstance, such as protein, nucleic acid or antibody, a region devoid of the above modification group. | 07-02-2009 |
| 20090170095 | Mnk KINASE HOMOLOGOUS PROTEINS INVOLVED IN THE REGULATION OF ENERGY HOMEOSTASIS AND ORGANELLE METABOLISM - The present invention discloses Mnk homologous proteins regulating the energy homeostasis, the metabolism of triglycerides, and/or is contributing to membrane stability and/or function of organelles, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders related to body-weight regulation and thermogenesis, for example, but not limited to, metabolic diseases such as obesity, as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, and sleep apnea, and disorders related to ROS defence, such as diabetes mellitus, neurodegenerative disorders, and cancer, e.g. cancers of the reproductive organs, and others. | 07-02-2009 |
| 20090170096 | NUCLEIC ACID AMPLIFICATION METHOD - An object to be achieved by the present invention is to provide a nucleic acid amplification method by which a nucleic acid can be amplified substantially isothermally using oligonucleotide primers and DNA polymerase capable of strand displacement. The present invention provides a nucleic acid amplification method which comprises performing substantially isothermal incubation of a reaction solution containing at least one type of deoxynucleotide triphosphate, at least one type of DNA polymerase having strand displacement activity, a divalent cation, at least 0.01% or more surfactant, at least two types of oligonucleotide primer, and the nucleic acid fragment as a template so as to perform a polymerase reaction that initiates from the 3′ end of the primer and thus amplifying the nucleic acid fragment. | 07-02-2009 |
| 20090170097 | GENE EXPRESSION IN BIOLOGICAL CONDITIONS - The present invention relates to a method of predicting the prognosis of a biological condition in animal tissue, wherein the expression of genes is examined and correlated to standards. The invention further relates to the treatment of the biological condition and an assay for predicting the prognosis. In particular, the invention concerns gene expression in epithelial tissue, such as urinary bladder under both normal and abnormal conditions. | 07-02-2009 |
| 20090170098 | ANTIBODIES TO CELL-CYCLE REGULATORY PROTEIN P16, AND USES RELATED THERETO - The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. The present invention comprises antibodies directed to such CCR-proteins. The present invention is directed to a kit for detecting the level of cyclin-dependent kinase inhibitor p16 gene expression comprising antibodies directed to a p16 protein. | 07-02-2009 |
| 20090170099 | Use of Regulatory Sequences for Specific, Transient Expression in Neuronal Determined Cells - The present invention relates to the use of regulatory sequences for mediating specific, early transient expression in proliferative neuronal determined cells. Furthermore, the uses of recombinant nucleic acid molecules comprising said defined regulatory sequences for mediating specific, early transient expression in proliferative neuronal determined cells as well as for the generation of non-human transgenic organisms and/or host cells are disclosed. In addition, the invention provides for transgenic non-human animals and/or host cells comprising said regulatory sequences and/or recombinant nucleic acid molecules. The invention also describes methods for the preparation of such vectors, host cells and transgenic non-human animals as well as methods for the detection and/or isolation of neuronal determined cells. Additionally, methods for screening of compounds capable of regulating neuronal determined cell activity, neurogenesis, stimulating proliferation of neuronally committed precursor cells and/or neuronal differentiation are provided and the invention also relates to methods for the detection and analysis of neuronal differentiation, neuronal migration and/or neuronal determination processes. Finally, the invention relates to diagnostic and pharmaceutical compositions comprising the regulatory sequences, recombinant nucleic acid molecules, host-cells or isolated neuronal determined cells described herein. | 07-02-2009 |
| 20090170100 | Biomarkers and detection methods for gastric diseases - The present invention provides a biomarker for detecting gastric diseases, especially gastric cancer selected from: a nucleic acid sequence of GroES, complementary strand, or derivatives thereof or an amino acid sequence of GroES, derivatives, fragments or variants thereof or antibodies against said amino acid sequences or combinations thereof, yet provides a kit for detecting gastric cancer by use of above-mentioned biomarkers and a detection method. | 07-02-2009 |
| 20090170101 | IDENTIFICATION OF THYMICALLY DERIVED CD4 T CELLS BY PROTEIN TYROSINE KINASE 7 EXPRESSION - The invention provides methods of identifying naïve T cells by expression of PTK7. | 07-02-2009 |
| 20090170102 | METHODS FOR DETECTING DNA ORIGINATING FROM DIFFERENT INDIVIDUALS - In a first aspect, the present invention features methods for differentiating DNA species originating from different individuals in a biological sample. These methods may be used to differentiate or detect fetal DNA in a maternal sample or to differentiate DNA of an organ donor from DNA of an organ recipient. In preferred embodiments, the DNA species are differentiated by observing epigenetic differences in the DNA species such as differences in DNA methylation. In a second aspect, the present invention features methods of detecting genetic abnormalities in a fetus by detecting fetal DNA in a biological sample obtained from a mother. In a third aspect, the present invention features methods for differentiating DNA species originating from an organ donor from those of an organ recipient. In a fourth aspect, the present invention features kits for differentiating DNA species originating from different individuals in a biological sample. | 07-02-2009 |
| 20090170103 | OLIGONUCLEOTIDE SEQUENCES AND DNA CHIP FOR IDENTIFYING FILAMENTOUS MICROORGANISMS AND THE IDENTIFICATION METHOD THEREOF - A DNA chip for identifying filamentous microorganisms, including a substrate and a plurality of probes, wherein the probe includes SEQ ID No.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, complementary sequences thereof, derivatives thereof or combinations thereof. The derivative is 5′ and/or 3′ end of the sequence SEQ ID No. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 with at least one thymidine residue added or is 5′ and/or 3′ end of the sequence SEQ ID No. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16 with one or two nucleotides added or deleted. | 07-02-2009 |
| 20090170104 | COMPOSITIONS AND METHODS FOR DETECTING GROUP A STREPTOCOCCI - Compositions, methods and kits for detecting Group A streptococci. Particularly described are oligonucleotides that are useful as amplification primers and hybridization probes for detecting very low levels of Group A streptococci nucleic acids. | 07-02-2009 |
| 20090170105 | Diagnostics for Aging-Related Dermatologic Disorders - The present invention provides methods for the early prediction of aging-related dermatologic conditions of including skin changes associated with intrinsic aging or skin damages caused by extrinsic aging such as photoaging. The present invention also provides kits for the early determination of the propensity to develop such disorder and conditions. The method consists of detecting the presence of one or more alleles of an IL-1 haplotype or pattern, specifically the IL-1RN (+2018) and the IL-1B (−511) loci. The presence of allele 2 at the IL-1RN (+2018) and the IL-1B (−511) loci indicates decreased risk for a early onset of aging related dermatologic conditions. | 07-02-2009 |
| 20090170106 | ANALYSIS OF DNA - The invention provides improved techniques for investigating DNA samples, which offers improved sensitivity and specifity. | 07-02-2009 |
| 20090170107 | DETECTION ASSAY FOR MEAT AND BONE MEAL IN FEED - The invention concerns methods, kits and nucleic acids involved in detecting animal tissues, for example processed animal proteins (PAPs) or meat and bone meal (MBM), especially in feeds. In one method, a nucleic acid such as DNA is extracted from a sample using a process involving incubating the sample in an incubation buffer, autoclaving the incubated sample, and then mixing the sample with a metal-chelating agent. DNA extracted in this way may then be subjected to amplification using PCR or real-PCR, for example using primer and probe sequences as set forth in SEQ ID NOs 1-21. | 07-02-2009 |
| 20090170108 | Screening method, a composition comprising substances chosen in the method thereof, and a binding substance - (Problems) The main object of the present invention is to provide a screening method for selecting a substance affecting a bond between thioredoxin and MIF. | 07-02-2009 |
| 20090170109 | CORN EVENT TC1507 AND METHODS FOR DETECTION THEREOF - The invention provides DNA compositions that relate to transgenic insect resistant maize plants. Also provided are assays for detecting the presence of the maize TC1507 event based on the DNA sequence of the recombinant construct inserted into the maize genome and the DNA sequences flanking the insertion site. Kits and conditions useful in conducting the assays are provided. | 07-02-2009 |
| 20090170110 | COMPOSITIONS AND METHODS TO DETECT CANDIDA ALBICANS NUCLEIC ACID - Compositions are disclosed as nucleic acid sequences that may be used as amplification oligomers, including primers, capture probes for sample preparation, and detection probes specific for | 07-02-2009 |
| 20090170111 | GENETIC POLYMORPHISMS ASSOCIATED WITH STROKE, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with vascular diseases, particularly stroke. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 07-02-2009 |
| 20090170112 | Loci Associated Charcoal Rot Drought Complex Tolerance in Soybean - The invention relates to methods and compositions for identifying soybean plants that are tolerant, have improved tolerance or are susceptible to Charcoal Rot Drought Complex. The methods use molecular genetic markers to identify, select and/or construct tolerant plants or identify and counter-select susceptible plants. Soybean plants that display tolerance or improved tolerance to Charcoal Rot Drought Complex that are generated by the methods of the invention are also a feature of the invention. | 07-02-2009 |
| 20090170113 | Non-Invasive Fetal Genetic Screening by Digital Analysis - The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital PCR is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents. | 07-02-2009 |
| 20090170114 | Non-Invasive Fetal Genetic Screening by Digital Analysis - The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital PCR is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents. | 07-02-2009 |
| 20090176205 | Mutant proteins in the dna-binding domain of a telomeric protein, trf2, and telomeric dna mutants, and use of the complex structure of the trf2 dna-binding domain and telomeric dna - A TRF2 DNA-binding domain mutant protein comprising:
| 07-09-2009 |
| 20090176206 | Toll-like receptor 2 (tlr-2) haplotypes predict outcome of patients - The invention provides methods and kits for obtaining a prognosis for a subject having or at risk of developing an inflammatory condition and or a gram positive infection. The method generally includes determining a toll-like receptor 2 (TLR-2) risk genotype of a subject for one or more SNPs, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the subject to recover from the inflammatory condition and identifying subjects based on their prognosis. | 07-09-2009 |
| 20090176207 | Methods for Determining Risk of Developing Regular Smoking Behavior - The present invention relates in general to human genetic polymorphisms and their association with human health and to methods and materials for analyzing allelic variations, and to the use of genetic polymorphisms in the diagnosis and treatment of smoking behavior and nicotine dependence. Provided herein are methods for determining risk in a subject of developing regular smoking behavior. Also provided are primers, probes, microarrays, and kits related thereto. | 07-09-2009 |
| 20090176208 | Methods for detecting, identifying and reporting the presence of animal pathological agents - A business method for use in detecting the presence of one or more pathological agents in a biological sample taken from an animal, using known diagnostic methods including antibodies and PCR, marketing test kits for obtaining and transporting biological samples from animals to a processing center, and reporting the results of diagnosis of biological samples from one or more animals. | 07-09-2009 |
| 20090176209 | Selection - The present invention to a nucleotide sequence encoding one or more Arc DNA binding domains, one or more Arc DNA binding sites and at least one polypeptide domain. | 07-09-2009 |
| 20090176210 | MICROBIAL REDUCTIVE DEHALOGENATION OF VINYL CHLORIDE - Compositions and methods are provided that relate to the bioremediation of chlorinated ethenes, particularly the bioremediation of vinyl chloride by | 07-09-2009 |
| 20090176211 | FLUORESCENT PROTEIN - It is an object of the present invention to provide a fluorescent protein, which allows an acceptor for fluorescence resonance energy transfer (FRET) to appear in a stimulating light-dependent manner, thereby enabling the marking of any given cell organelle, cells, or tissues, with multiple colors. The present invention provides a fluorescent protein which consists of a fused protein of a donor fluorescent protein and an acceptor fluorescent protein, wherein before irradiation with stimulating light, the donor protein is able to emit fluorescence as a result of irradiation of the donor protein with excitation light; and after irradiation with stimulating light, intramolecular FRET occurs between the donor fluorescent protein and the acceptor fluorescent protein as a result of irradiation of the donor protein with excitation light, and the acceptor protein is able to emit fluorescence, and wherein the fluorescence of the donor protein and the fluorescence of the acceptor protein have wavelengths that are different from each other. | 07-09-2009 |
| 20090176212 | Method for Fixing a Supercoiled DNA and the Use for Analyzing the DNA Repair - A method for fixing a supercoiled DNA consists in deposing a supercoiled DNA sample on the surface of a porous polymer film, in fixing said supercoiled DNA therein by a passive diffusion, in obtaining a support by the inventive method and in using said support for analysing the DNA distribution. | 07-09-2009 |
| 20090176213 | STABILIZATION OF SOLID SUPPORT ASSAY REAGENTS - Reagents are disclosed for use in assays for analytes. The reagents are dry assay reagents that may be readily reconstituted for use in the assays. The dry assay reagents comprise a solid support and one or more molecules of a receptor immobilized on the solid support. The receptor comprises one or more binding sites for a ligand. A portion of a total number of the binding sites is bound to a conjugate comprising the ligand linked to a specific binding pair member and a portion of the total number of the binding sites is free. In use in an assay, a combination is provided in an aqueous medium comprising the sample and reagents for detecting the analyte wherein at least one of the reagents comprises the dry assay reagent mentioned above. The combination is incubated under conditions for binding of the analyte to one or more of the reagents. The presence and/or amount of binding of the analyte to one or more of the reagents is detected where the presence and/or amount of the binding is related to the presence and/or amount of the analyte in the sample. | 07-09-2009 |
| 20090176214 | Recombinant antigens for the detection of Coxiella burnetii - The invention relates to a method for the detection of prior exposure to | 07-09-2009 |
| 20090176215 | GENE METHYLATION IN PROSTATE CANCER DIAGNOSIS - The present invention provides DNA biomarker sequences that are differentially methylated in samples from normal individuals and individuals with prostate cancer. The invention further provides methods of identifying differentially methylated DNA biomarker sequences and their use the detection and diagnosis of prostate cancer. | 07-09-2009 |
| 20090176216 | Alleles and polymorphisms predictive of responsiveness to biologic therapy in psoriasis - The invention provides methods for predicting responsiveness to a biologic agent in a subject suffering from psoriasis. The methods involve assaying for the presence or absence of an allele or polymorphism in the subject that is predictive of responsiveness to biologic therapy, such as an HLA-Cw6 allele, a TNFα 238 polymorphism or a TNFα 308 polymorphism. The methods can further comprise selecting a treatment regimen with a biologic agent in a psoriasis subject based upon presence or absence of the allele or polymorphism in the subject. The methods can further comprise administering a biologic agent to the subject according to the selected treatment regimen. Kits that include means for assaying an allele or polymorphism that is predictive of responsiveness to biologic therapy for psoriasis are also provided. Methods of preparing and using databases, and computer program products therefore, for selecting a psoriasis subject for treatment with a biologic agent are also provided. | 07-09-2009 |
| 20090176217 | NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS OF USE THEREOF FOR DIAGNOSIS - Novel splice variants, amino acid sequences and nucleotide sequences thereof, and methods of using same. | 07-09-2009 |
| 20090176218 | Method for the Diagnosis and Prognosis of Cancer - Disclosed are methods for prognostic evaluation, and diagnosis of cancers. The methods of the present invention allow for the diagnosis and prognosis of cancers by analyzing the levels of expression of an enzyme that is involved in the biosynthetic pathway of spermine within tissue samples containing cancerous tissues. In particular, the amount of enzyme mRNA detected in tissue sample correlates with disease status such that enzyme levels can be used to predict the presence of, as well as the metastatic potential of cancer. Thus, measuring the level of spermine pathway enzymes in biological samples provides a quick, easy, and safe screen that can be used to both diagnose and prognose cancer in a patient thus leading to more effective treatments and cures. | 07-09-2009 |
| 20090176219 | DNA BINDING SITE OF A TRANSCRIPTIONAL ACTIVATOR USEFUL IN GENE EXPRESSION - We have discovered DNA binding sites which are specifically recognized by PrtT, a transcriptional activator for protease genes. The DNA binding site can be defined structurally by a consensus nucleotide sequence and functionally by PrtT's ability to regulate transcriptional activation through that sequence. Both PrtT and its cognate DNA binding site (i.e., the nucleotide sequence in each promoter that is recognized by PrtT) can be used in a gene expression system. Possession of only a PrtT transcriptional activator is insufficient, its cognate DNA binding site is necessary for recognition by PrtT (i.e., binding to the site and activating transcription under appropriate conditions). A functional site, such as one obtained from a wild-type fungal gene, will confer PrtT-dependent transcriptional activation on 3′-downstream sequences. A mutation of a wild-type promoter that results in a non-functional site will abolish PrtT-dependent transcriptional activation of 3′-downstream sequences. A mutation of a wild-type promoter that results in a more functional site will enhance PrtT-dependent transcriptional activation of 3′-downstream sequences. | 07-09-2009 |
| 20090176220 | ANTIBODY CHARACTERIZATION TEST - The present invention relates to a method for measuring the ability of an antibody preparation to activate an Fc receptor, wherein this method comprises the following steps: a) aggregating said antibodies with one another, b) bringing cells expressing an Fc receptor into contact with said aggregated antibodies, and c) measuring the reaction of the cells resulting from the activation of the Fc receptor of said cells by the Fc region of said antibodies. | 07-09-2009 |
| 20090176221 | METHOD OF DETECTING AN ANALYTE IN A SAMPLE USING SEMICONDUCTOR NANOCRYSTALS AS DETECTABLE LABEL - The use of semiconductor nanocrystals as detectable labels in various chemical and biological applications is disclosed. The methods find use for detecting a single analyte, as well as multiple analytes by using more than one semiconductor nanocrystal as a detectable label, each of which emits at a distinct wavelength. | 07-09-2009 |
| 20090176222 | Gene for Identifying Individuals with Familial Dysautonomia - This invention relates to methods and compositions useful for detecting mutations which cause Familial Dysautonomia. Familial dysautonomia (FD; Riley-Day syndrome), an Ashkenazi Jewish disorder, is the best known and most frequent of a group of congenital sensory neuropathies and is characterized by widespread sensory and variable autonomic dysfunction. Previously, we mapped the FD gene, DYS, to a 0.5 cM region of chromosome 9q31 and showed that the ethnic bias is due to a founder effect, with >99.5% of disease alleles sharing a common ancestral haplotype. To investigate the molecular basis of FD, we sequenced the minimal candidate region and cloned and characterized its 5 genes. One of these, IKBKAP, harbors two mutations that can cause FD. The major haplotype mutation is located in the donor splice site of intron 20. This mutation can result in skipping of exon 20 in the mRNA from FD patients, although they continue to express varying levels of wild-type message in a tissue-specific manner. RNA isolated from patient lymphoblasts is primarily wild-type, whereas only the deleted message is seen in RNA isolated from brain. The mutation associated with the minor haplotype in four patients is a missense (R696P) mutation in exon 19 that is predicted to disrupt a potential phosphorylation site. Our findings indicate that almost all cases of FD are caused by an unusual splice defect that displays tissue-specific expression; and they also provide the basis for rapid carrier screening in the Ashkenazi Jewish population. | 07-09-2009 |
| 20090176223 | Compositions, Kits, and Methods for the Diagnosis, Prognosis, and Monitoring of Immune Disorders Using Galectin-1 - The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma, anaplastic large cell lymphoma, or MLL | 07-09-2009 |
| 20090176224 | Udder Health Characteristics - The invention relates to a method for determining udder health characteristics in bovine subjects, wherein udder health characteristics comprise sub-clinical and clinical mastitis. In particular, the method of the invention involves identification of genetic markers and/or Quantitative Trait Locus (QTL) for the determination of udder health characteristics in a bovine subject. The determination of udder health characteristics involves resolution of the specific microsatellite status. Furthermore, the invention relates to a diagnostic kit for detection of genetic marker(s) associated with udder health. The method and kit of the present invention can be applied for selection of bovine subjects for breeding purposes. Thus, the invention provides a method of genetically selecting bovine subjects with udder health characteristics that will yield cows less prone to mastitis. | 07-09-2009 |
| 20090176225 | DIAGNOSTIC TEST FOR COLLIE EYE ANOMALY - The invention relates to a method for identifying dogs which are genetically normal, heterozygous for, or homozygous for the mutation primarily responsible for Collie eye anomaly (CEA). The method comprises the steps of obtaining a biological sample from a dog and testing DNA in the biological sample for the presence or absence of a 7.8 kilobase deletion within chromosome 37 in which the CEA mutation is located. No deletion is indicative of a normal dog. A deletion on one allele of chromosome 37 is indicative of a dog that is heterozygous for the CEA mutation. A deletion in both alleles of chromosome 37 are indicative of a dog that is homozygous for the CEA mutation. Also provided is a kit for identifying a dog as normal, heterozygous for, or homozygous for the CEA mutation. | 07-09-2009 |
| 20090176226 | METHOD FOR DIAGNOSING AUTISM SPECTRUM DISORDER - The present invention provides methods of diagnosing and/or predicting autism spectrum disorder comprising determining the presence of microdeletions and microduplications on chromosomes 15 and 16. | 07-09-2009 |
| 20090176227 | Method for Producing Polyploid Plants of Orchids - A method for producing polyploid plants of orchids includes the steps of: providing a protocorm or protocom-like body (PLB) of an orchid, the protocorm or PLB having an upper portion with a growing point and a lower portion without any growing point; cutting the protocorm or PLB approximately at a point of half height to separate the upper portion; subculturing the lower portion of the protocorm or PLB in an inducing medium, and putting a cut surface of the lower portion of the protocorm or PLB to face upward so that one or more next-generation PLBs grow from the cut surface of the lower portion. The method characterized in using no antimicrotubule agent can simplify the entire process of orchid polyploidy breeding, and can be used in mass-production of the stable polyploid plants. | 07-09-2009 |
| 20090176228 | LUNG CANCER MARKERS, AND USES THEREOF - Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods. | 07-09-2009 |
| 20090176229 | Methods and compositions for the identification of insect repellent compounds - Methods for identifying a candidate compound with an ability to modulate cation transport through a transient receptor potential (TRP) channel in a cell are disclosed. The methods can include (a) providing a cell expressing a recombinant nucleic acid sequence encoding an transient receptor potential (TRP) channel gene product or a functional fragment or derivative thereof; (b) contacting the cell with the candidate compound; (c) comparing cation transport in the cell in the absence of the candidate compound with cation transport in the cell in the presence of the candidate compound; and (d) identifying a candidate compound through the comparing step that modulates cation transport in the cell through the transient receptor potential (TRP) channel. Also disclosed are nucleic acid and amino acid sequences for insect TRP channel gene products, antibodies that bind to the disclosed TRP channels, and recombinant host cells the include the disclosed biosequences. | 07-09-2009 |
| 20090176230 | Microfluidic device and methods of using same - A variety of elastomeric-based microfluidic devices and methods for using and manufacturing such devices are provided. Certain of the devices have arrays of reaction sites to facilitate high throughput analyses. Some devices also include reaction sites located at the end of blind channels at which reagents have been previously deposited during manufacture. The reagents become suspended once sample is introduced into the reaction site. The devices can be utilized with a variety of heating devices and thus can be used in a variety of analyses requiring temperature control, including thermocycling applications such as nucleic acid amplification reactions, genotyping and gene expression analyses. | 07-09-2009 |
| 20090176231 | PROBE FOR DETECTING ABL GENE MUTATION AND USES THEREOF - Detection probes are provided that are capable of detecting a sequence to be detected containing a mutation even when a sequence not to be detected containing no mutation coexists with the sequence to be detected containing a mutation, which are different only in a single base from each other. At least one oligonucleotide selected from the group consisting of SEQ ID NOs: 2˜16 is used as a probe. Even in a sample containing an abl gene in which a mutation has occurred and an abl gene in which no mutation has occurred, the use of such probes in, for example, Tm analysis allows the mutation to be detected. | 07-09-2009 |
| 20090176232 | ASSESSMENT OF REACTION KINETICS COMPATIBILITY BETWEEN POLYMERASE CHAIN REACTIONS - A method compares amplification reaction kinetics between two or more quantitative polymerase chain reactions (PCR). These methods enable quality control and/or quality assessment for quantification of nucleic acids by PCR. The method estimates plurality of parameters from each reaction and compares them simultaneously between reactions. | 07-09-2009 |
| 20090176233 | Screening assays for polymerase enhancement - Methods of screening for and selecting for improved polymerases suitable for single molecule sequencing are provided. | 07-09-2009 |
| 20090176234 | Efficient base determination in sequencing reactions - The present invention is directed to compositions and methods for nucleic acid identification and detection. Compositions and methods of the present invention include extracting and fragmenting target nucleic acids from a sample, using the fragmented target nucleic acids to produce target nucleic acid templates and subjecting those target nucleic acid templates to amplification methods to form nucleic acid nanoballs. The invention also includes methods of detecting and identifying sequences using various sequencing applications, including sequencing by ligation methods. | 07-09-2009 |
| 20090176235 | GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with myocardial infarction. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 07-09-2009 |
| 20090176236 | Compositions and Methods for Detecting Certain Flaviviruses, Including Members of the Japanese Encephalitis Virus Serogroup - The present invention provides rapid and accurate methods, primers, probes and kits for identifying the presence of a certain flaviviruses in a sample. Flaviviruses that can be detected include members of the Japanese encephalitis virus serogroup, Dengue virus, St. Louis encephalitis virus, Montana myotis leukoencephalitis virus, Modoc virus, and Yellow Fever virus. The primers and probes of the invention can hybridize to regions in the 3′ untranslated region of the viral genomes to be detected. | 07-09-2009 |
| 20090176237 | USE OF MICRO-RNA AS A BIOMARKER OF IMMUNOMODULATORY DRUG ACTIVITY - Methods of determining the activity of an immunomodulatory compound by measuring the presence of an miRNA in a sample are disclosed. Additionally disclosed are methods of assessing the patient compliance in patients treated with an immunomodulatory compound. | 07-09-2009 |
| 20090176238 | Cynomolgus Toll-Like Receptor 3 - Isolated polynucleotides encoding Cynomolgus monkey Toll-Like Receptor 3 (cynoTLR3), polypeptides obtainable from expression of these polynucleotides, recombinant cells, methods and uses of these are disclosed. | 07-09-2009 |
| 20090176239 | SINGLE-MOLECULE-FORMAT REAL-TIME BIOLUMINESCENCE IMAGING PROBE - The present invention provides an “in vivo and in vitro real-time bioluminescence imaging means,” which can transmit a detection signal promptly in response to an external signal, while taking advantage of a single-molecule-format luminescent probe as a bioluminescent means. | 07-09-2009 |
| 20090176240 | MN/CA IX and Cancer Prognosis - Herein disclosed are methods that are prognostic for neoplastic/preneoplastic disease in a subject vertebrate, wherein said disease is associated with a tissue that normally expresses MN, but which MN expression is lost or diminished upon carcinogenesis. Exemplary of the types of preneoplastic/neoplastic diseases subject to the prognostic methods of this invention are those of gastric mucosa, gallbladder, biliary ducts, and ductal cells of duodenal glands. An exemplary prognostic method comprises comparing the level of MN gene expression product in a tissue sample from the affected subject, with the average MN gene expression product level found in analogous preneoplastic/neoplastic tissue samples; an above average MN gene expression product level indicates poorer prognosis for the subject. MN gene expression products useful in the prognostic methods include MN protein, MN polypeptide, and/or MN nucleic acids. | 07-09-2009 |
| 20090176241 | COMPOSITIONS AND METHODS FOR DETECTING GROUP B STREPTOCOCCI - Compositions, methods and kits for detecting Group B streptococci. Particularly described are oligonucleotides that are useful as amplification primers and hybridization probes for detecting very low levels of Group B streptococci nucleic acids. | 07-09-2009 |
| 20090176242 | COMPOSITIONS AND METHODS FOR LABELING OF NUCLEIC ACID MOLECULES - The present invention is generally related to compositions, kits and methods for labeling nucleic acid molecules using reverse transcriptases, preferably multi-subunit reverse transcriptases such as ASLV reverse transcriptases. Specifically, the invention relates to methods, kits and compositions for fluorescently labeling nucleic acid molecules during nucleic acid synthesis. The labeled nucleic acid molecules produced in accordance with the invention are particularly suited as labeled probes for nucleic acid detection and diagnostics. | 07-09-2009 |
| 20090181366 | INTERNAL POSITIVE CONTROL FOR NUCLEIC ACID ASSAYS - Compositions and methods for detecting a non-specific nucleic acid amplification inhibitor in a reaction are disclosed. An internal positive control (IPC) may be included in samples to be tested for target nucleic acids as a means to monitor non-specific inhibition of nucleic acid amplification and provide confidence in negative results obtained in target-specific assays. Provided herein are an IPC polynucleotide, IPC control primers, and IPC probes. Also provided are methods of using an IPC polynucleotide, primers, and probes to detect a non-specific nucleic acid amplification inhibitor. | 07-16-2009 |
| 20090181367 | Diagnosis of sepsis using mitochondrial nucleic acid assays - The invention provides assays to detect sepsis disease states in a subject by determining the relative amount of mitochondrial nucleic acid in the subject. The assays of the invention may include PCR assays, such semi-quantitative or quantitative PCR involving the co-amplification of a mitochondrial sequence and a reference sequence, such as a genomic sequence. Information from such assays may be evaluated to provide a ratio of mitochondrial nucleic acid to nuclear nucleic add in the cells of the subject. | 07-16-2009 |
| 20090181368 | METHOD OF DETECTING MYCOPLASMA - An object of the present invention is to provide a primer capable of detecting a mycoplasma | 07-16-2009 |
| 20090181369 | Methods for the Treatment of Disease - The present invention is directed to methods to determine the likelihood of therapeutic effectiveness of a farnesyl transferase inhibitor (FTI). The method comprises determining whether the gene encoding the farnesyl transferase beta subunit (FNTB) of said patient comprises at least one nucleic acid variance that causes an alteration in an amino acid residue. The change in the amino acid residue is associated with resistance to a FTI. The absence of at least one variance indicates that the FTI is likely to be effective. | 07-16-2009 |
| 20090181370 | Method for Sequencing a Polynucleotide Template - The invention relates to methods for pairwise sequencing of a double-stranded polynucleotide template, which permit the sequential determination of nucleotide sequences in two distinct and separate regions on complementary strands of the double-stranded polynucleotide template. The two regions for sequence determination may or may not be complementary to each other. | 07-16-2009 |
| 20090181371 | METHODS AND COMPOSITIONS RELATED TO A BRAF MUTATION AND MICROSATELLITE STABILITY - Disclosed are methods and compositions related to a BRAF mutation and microsatellite stability. | 07-16-2009 |
| 20090181372 | Method and compositions for monitoring DNA binding molecules in living cells - The present invention provides a method of screening for a compound that binds to a selected nucleic acid comprising contacting compound fluorescently labeled by a fluorescent protein with a cell having a plurality of copies of the nucleic acid in an array such that the nucleic acid can be directly detected when bound by fluorescently labeled compound; and directly detecting the location of fluorescence within the cell, fluorescence aggregated at the site of the nucleic acid array indicating a compound that binds to the selected nucleic acid. In particular compounds such a transcription factors can be screened. Reagents for such method are provided including a mammalian cell having a plurality of steroid receptor response elements in an array such that the response element can be directly detected when bound by fluorescently labeled steroid receptor and a chimeric protein comprising a fluorescent protein fused to a steroid receptor. | 07-16-2009 |
| 20090181383 | Cancer Risk Biomarker - The present disclosure relates to methods and compositions for identifying biomarkers that indicate a biological state, in particular cancer or predisposition to cancer. Also provided are methods and compositions for identifying a greater risk for a cancer-related condition in an subject. | 07-16-2009 |
| 20090181384 | Prognosis prediction for colorectal cancer - This invention relates to prognostic signatures, and compositions and methods for determining the prognosis of cancer in a patient, particularly for colorectal cancer. Specifically, this invention relates to the use of genetic markers for the prediction of the prognosis of cancer, such as colorectal cancer, based on signatures of genetic markers. In various aspects, the invention relates to a method of predicting the likelihood of long-term survival of a cancer patient, a method of determining a treatment regime for a cancer patient, a method of preparing a treatment modality for a cancer patient, among other methods as well as kits and devices for carrying out these methods. | 07-16-2009 |
| 20090181385 | Reagents, methods, and libraries for bead-based sequencing - The present invention provides methods for determining a nucleic acid sequence by performing successive cycles of duplex extension along a single stranded template. The cycles comprise steps of extension, ligation, and, preferably, cleavage. In certain embodiments the methods make use of extension probes containing phosphorothiolate linkages and employ agents appropriate to cleave such linkages. The invention provides methods of determining information about a sequence using at least two distinguishably labeled probe families. In certain embodiments the methods acquire less than 2 bits of information from each of a plurality of nucleotides in the template in each cycle. In certain embodiments the sequencing reactions are performed on templates attached to immobilized beads. The invention further provides sets of labeled probes containing phosphorothiolate linkages. In addition, the invention includes performing multiple sequencing reactions on a single template by removing initializing oligonucleotides and extended strands and performing subsequent reactions using different initializing oligonucleotides. | 07-16-2009 |
| 20090181386 | Calving Characteristics - The invention relates to a method for determining calving characteristics in bovine subjects, wherein calving characteristics comprise stillbirth, calving difficulty and calf size at birth, which are all economically important factors. In particular, the method of the invention involves identification of genetic markers and/or Quantitative Trait Locus (QTL) for the determination of calving characteristics in a bovine subject. The determination of calving characteristics involves resolution of the specific microsatellite status. Furthermore, the invention relates to a diagnostic kit for detection of genetic marker(s) associated with calving characteristics. The method and kit of the present invention can be applied for selection of bovine subjects for breeding purposes. Thus, the invention provides a method of genetically selecting bovine subjects with calving characteristics that will yield cows less prone to stillbirth, calving difficulties and undesired calf size at birth. | 07-16-2009 |
| 20090181387 | Method for Analysing Nucleic Acids - Method of analyzing nucleic acids comprising the steps of nucleic acid fractionation, adaptor binding and nucleic acid amplification, and an in vitro transcription step. The invention has application in the field of genomic analysis of organisms by the use of DNA microarrays. | 07-16-2009 |
| 20090181388 | Enclosed unit for rapid detection of a target nucleic acid amplification product - The invention relates to a method for rapid detection of a target nucleic acid amplification product while preventing cross-contamination between target nucleic acid amplification products and avoiding false positives, comprising the steps of: a) leaving the reaction tube unopened after the amplification reaction is finished, so as to prevent the target nucleic acid amplification product from leaking out and resulting in contamination; b) placing the unopened reaction tube inside an enclosed unit, making the target nucleic acid amplification product be transferred to a test strip from the reaction tube in a physically enclosed environment; c) performing detection in a visual read-out manner, and determining the result; d) discarding the enclosed unit in a safety place as a whole without opening it after the detection. The invention also relates to a totally enclosed unit for detecting a target nucleic acid amplification product, and still relates to applications of the totally enclosed rapid detection unit in detection of infectious pathogens, food industry, agriculture, livestock husbandry, customs quarantine control, and determination of DNA. | 07-16-2009 |
| 20090181389 | QUANTITATIVE MEASUREMENT OF NUCLEIC ACID VIA LIGATION-BASED LINEAR AMPLIFICATION - Methods, compositions and kits are provided for sensitive and quantitative detection of nucleic acid, especially for the determination of the presence and/or amount of a target nucleic acid with mutations or single nucleotide polymorphism (SNP). In particular, assays are provided for amplifying a target nucleic acid via ligation of designed oligonucleotide probes and linear amplification by using an RNA polymerase, such as T7 polymerase. The assays can be used for diagnosis, prognosis or monitoring of diseases or disorders, for pharmacogenomic studies of patient stratification and drug responses, for discovery of therapeutic targets, or for forensic analysis. | 07-16-2009 |
| 20090181390 | HIGH THROUGHPUT DETECTION OF MICRORNAS AND USE FOR DISEASE DIAGNOSIS - Methods, compositions and kits are provided for high throughput detection of micro RNAs (miRNA), especially for sensitive and specific detection of miRNA that are in low abundance and closely related to each other. In particular, an assembly of designed oligonucleotide probes with unique tag sequences is used to achieve these purposes via high throughput microarrays, optionally in conjunction with branched-DNA based array detection. The assays can be used for diagnosis, prognosis or monitoring of diseases or disorders such as cancer, for pharmacogenomic studies of patient stratification and drug responses, for discovery of therapeutic targets, or for forensic analysis. | 07-16-2009 |
| 20090181391 | METHODS FOR ANALYSIS OF DNA METHYLATION PERCENTAGE - Methods are disclosed for determining the methylation state of DNA samples using melt analysis including high resolution melt analysis. Methods are also provided for determining methyltransferase activity using melt analysis including high resolution melt analysis. Additionally, kits of parts are provided. | 07-16-2009 |
| 20090181392 | Transgenic Zebrafish Models for Neurodegenerative Diseases - The present invention relates to zebrafish models for neurodegenerative disorders that allow screening of compounds for their ability to protect and/or regenerate neurons in vivo in a whole vertebrate organism. The present invention also provides methods of identifying gene targets for neuroprotective compounds, compounds that regenerate neurons and compounds that promote neurogenesis. | 07-16-2009 |
| 20090181393 | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy - The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting. | 07-16-2009 |
| 20090181394 | Diagnostic methods and kits for hepatocellular carcinoma using comparative genomic hybridization - The invention provides diagnostic methods for determining the prognosis of hepatocellular carcinoma (HCC) comprising the steps of (a) observing recurrently altered genomic region on a chromosome; (b) measuring variation of one or more of RAR expression variations selected from the RAR variation group consists of gains of RAR-G1 to RAR-G14 and losses of RAR-L1 to RAR-L18 as defined in table 1, a diagnostic kit, and genes for useful in diagnosis or prognosis of liver cancer. | 07-16-2009 |
| 20090181395 | DETECTION OF ANTIBIOTIC-RESISTANT MICROORGANISMS - Method of detecting methicillin-resistant | 07-16-2009 |
| 20090181396 | METHODS AND SYSTEMS FOR ANALYSIS OF FLUORESCENT REACTIONS WITH MODULATED EXCITATION - Methods, systems and their components for monitoring fluorescent signals and particularly transient fluorescent signals from reaction mixtures of interest, which methods and systems employ modulated excitation light sources to reduce impacts of excessive illumination on the reaction components or the data obtained therefrom. | 07-16-2009 |
| 20090181397 | PREDICTIVE AND DIAGNOSTIC METHODS FOR CANCER - The present disclosure encompasses methods of diagnosing the presence of a cancer, and particularly a cancer of prostate or breast tissue, in a human subject, predicting the outcome or severity of the disease and methods of reversing the prostate cell transformation based on the presence or absence in the human subject of a dinucleotide (TT) deletion in the gene encoding the U50 snoRNA. Provided, therefore, are methods of identifying a genetic marker of a human subject indicating a cancerous tissue in the human subject, embodiments of the methods comprising: determining from an isolated nucleic acid sample the genotype of the human subject with respect to a locus encoding a snoRNA U50, where a mutation within the nucleotide sequence encoding a snoRNA U50, when compared with a wild-type nucleotide sequence encoding a snoRNA U50, identifies in the human subject a genetic marker associated with a cancer in the human subject. The cancer may be, but is not necessarily limited to, a prostate cancer or a breast cancer. | 07-16-2009 |
| 20090181398 | Nanoparticle conjugates - Conjugate compositions are disclosed that include a specific-binding moiety covalently coupled to a nanoparticle through a heterobifunctional polyalkyleneglycol linker. In one embodiment, a conjugates is provided that includes a specific-binding moiety and a fluorescent nanoparticle coupled by a heterobifunctional PEG linker. Fluorescent conjugates according to the disclosure can provide exceptionally intense and stable signals for immunohistochemical and in situ hybridization assays on tissue sections and cytology samples, and enable multiplexing of such assays. | 07-16-2009 |
| 20090181399 | INSECT RESISTANT COTON PLANTS AND METHODS OF DETECTING THE SAME - The present application relates to an insect resistant transgenic cotton event designated COT202. The application also relates to polynucleotides which are characteristic of the COT202 event, plants comprising said polynucleotides, and methods of detecting the COT202 event. | 07-16-2009 |
| 20090181400 | Method of Detection of Prostate Cancer - The present invention provides methods and kits useful for detecting neplasia by measuring the methylation level of biomarkers, especially the promoter region of GSTP1 for the detection of prostate adenocarcinoma. | 07-16-2009 |
| 20090181401 | Detection format for hot start real time polymerase chain reaction - The present invention is directed to a method and a composition for amplifying and detecting a target nucleic comprising subjecting said target nucleic acid to a real time PCR amplification reaction in the presence of a thermostable DNA polymerase, a thermostable double strand dependent 3′-5′ exonuclease having a temperature optimum above 37° C., a pair of amplification primers, deoxynucleoside triphosphates, a detecting oligonucleotide carrying a first label and a second label, said first label being capable of acting as a fluorescent reporter entity when excited with light of an appropriate wavelength, said second label being capable of acting as a fluorescence quenching entity of said fluorescent reporter entity, characterized in that one label is bound to the 3′ end of said detecting oligonucleotide, and further characterized in that the other label is bound either internally or at the 5′ end of said detecting oligonucleotide, and monitoring fluorescence of said fluorescent reporter entity at least after a plurality of amplification cycles. | 07-16-2009 |
| 20090186339 | Human transcriptomes - Global gene expression patterns have been characterized in normal and cancerous human cells using serial analysis of gene expression (SAGE). Cancer cell-specific, cell-type specific, and ubiquitously expressed genes have been identified. This information can be used to provide combinations of cell type- and cancer-specific gene probes, as well as methods of using these probes to identify particular cell types, screen for useful drugs, reduce cancer-specific gene expression, standardize gene expression, and restore function to a diseased cell or tissue. | 07-23-2009 |
| 20090186340 | Gene Analysis - This invention relates to a series of PCR primers that will allow the simultaneous amplification of regions of the clinically significant ABO and RHD genes. | 07-23-2009 |
| 20090186341 | Receptacle for the Separation of Tumor Cells - The invention describes a container ( | 07-23-2009 |
| 20090186342 | Methods of producing competitive aptamer fret reagents and assays - Methods are described for the production and use of fluorescence resonance energy transfer (FRET)-based competitive displacement aptamer assay formats. The assay schemes involve FRET in which the analyte (target) is quencher (Q)-labeled and previously bound by a fluorophore (F)-labeled aptamer such that when unlabeled analyte is added to the system and excited by specific wavelengths of light, the fluorescence intensity of the system changes in proportion to the amount of unlabeled analyte added. Alternatively, the aptamer can be Q-labeled and previously bound to an F-labeled analyte so that when unlabeled analyte enters the system, the fluorescence intensity also changes in proportion to the amount of unlabeled analyte. The F or Q is covalently linked to nucleotide triphosphates (NTPs), which are incorporated into the aptamer by various nucleic acid polymerases, such as Taq or Deep Vent Exo | 07-23-2009 |
| 20090186343 | METHODS FOR PREPARING MODIFIED BIOMOLECULES, MODIFIED BIOMOLECULES AND METHODS FOR USING SAME - A novel and efficient single pot synthetic schemes are disclosed for preparing modified nucleotides, nucleotide analogs, nucleotide polyphosphates, and nucleotide polyphosphate analogs. The novel method is used to prepare nucleotides, nucleotide analogs, nucleotide polyphosphates, and nucleotide polyphosphate analogs having non-persistent or persistent and non-persistent modifications. Novel biomolecular reactions are also disclosed using the novel modified biomolecules disclosed herein. | 07-23-2009 |
| 20090186344 | DEVICES AND METHODS FOR DETECTING AND QUANTITATING NUCLEIC ACIDS USING SIZE SEPARATION OF AMPLICONS - Devices and methods are described for detecting and quantifying nucleic acids using a sealed system that minimizes contamination. In particular, provided herein are devices for and methods using nucleic acid amplification that permit multiple sampling of an amplification reaction mixture and quantitation and identification of amplicons during the course of an amplification reaction. Methods involving the transfer of samples from an amplification reaction mixture into a separation network, separation of nucleic acids based on size, and identification and quantitation of nucleic acids are disclosed. | 07-23-2009 |
| 20090186345 | Instrument and method for nucleic acid isolation - According to the present invention, purified nucleic acids are isolated without the complete removal of components of a washing reagent. Also, nucleic acids are isolated in an elution reagent by allowing a washing reagent comprising at least one component constituting a reaction solution that can be applied to a reaction involving nucleic acids to come into contact with a nucleic-acid-adsorbing solid phase so as to wash the solid phase, separating the washing reagent from the solid phase in a manner such that a certain amount of the washing reagent is allowed to remain in the solid phase, and allowing an elution reagent to come into contact with the nucleic-acid-adsorbing solid phase. | 07-23-2009 |
| 20090186346 | Method for Detecting the Presence or Absence of a Target Cell in a Sample - The present invention relates to a method for detecting the presence or absence of a target cell in a sample, said method comprising (a) binding cells in said sample to a particulate and mixable solid support; (b) eluting the cells from the solid support without the use of competitor molecules to disrupt the interaction between the cell and the solid support; (c) after lysis of said cells, detecting the presence or absence of nucleic acid characteristic of said target cell, wherein said solid support does not have antibodies or antibody fragments immobilised thereon. Kits for carrying out the method of the invention are also provided. | 07-23-2009 |
| 20090186347 | Markers for metabolic syndrome - Correlations between polymorphisms and metabolic syndrome, insulin resistance, obesity, high blood pressure, dyslipidemia, diabetes and/or myocardial infarction are provided. Methods of diagnosing and treating metabolic syndrome, insulin resistance, obesity, high blood pressure, dyslipidemia, diabetes and/or myocardial infarction are provided. Systems and kits for diagnosis and treatment of metabolic syndrome, insulin resistance, obesity, high blood pressure, dyslipidemia, diabetes and/or myocardial infarction are provided. | 07-23-2009 |
| 20090186348 | MICRORNAS DIFFERENTIALLY EXPRESSED IN CERVICAL CANCER AND USES THEREOF - The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as cervical disease, and using the profile in assessing the condition of a patient. | 07-23-2009 |
| 20090186349 | DETECTION OF NUCLEIC ACID REACTIONS ON BEAD ARRAYS - The present invention is directed to methods and compositions for the use of microsphere arrays to detect and quantify a number of nucleic acid reactions. The invention finds use in genotyping, i.e. the determination of the sequence of nucleic acids, particularly alterations such as nucleotide substitutions (mismatches) and single nucleotide polymorphisms (SNPs). Similarly, the invention finds use in the detection and quantification of a nucleic acid target using a variety of amplification techniques, including both signal amplification and target amplification. The methods and compositions of the invention can be used in nucleic acid sequencing reactions as well. All applications can include the use of adapter sequences to allow for universal arrays. | 07-23-2009 |
| 20090186350 | Muitiforms suspension microgranular bioreactor and methods of use - A Multiform Suspension Microgranular Bioreactor (MSMB) is used to detect nucleic acids or peptides/proteins in molecular and biological samples. Polymer-based microgranules, coupled with biomass molecule probes, are constructed with different features. The biomass molecule probes include cDNA probes, oligonucleic acid probes, peptide or protein probes. These microgranules are differentiated according to their features including shape, size, color, fluorescence intensity, magnetic property, gravity, chemical luminal intensity, radioactivity, and other labels. The above microgranules are suspended in a sample solution and are used collectively as a microarray-like bioreactor device. Such MSMB-based microarrays are particularly useful in complicated biological detection assays with flow cytometry. | 07-23-2009 |
| 20090186351 | NUCLEOTIDE ANALOGS - The invention provides for nucleotide analogs and methods of using the same, e.g., for sequencing nucleic acids. | 07-23-2009 |
| 20090186352 | DNA Conformation - Method of detection or diagnosis of abnormal gene expression in an individual comprising determining in a sample from the individual the presence or absence of a chromosome structure in which two separate regions of the gene have been brought into close proximity, to thereby detect or diagnose whether the individual has abnormal gene expression. | 07-23-2009 |
| 20090186353 | CANCER-RELATED NUCLEIC ACIDS - Described herein are polynucleotides associated with specific types of cancers. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids. Methods and compositions are described that can be used for diagnosis, prognosis, and treatment of various cancers. | 07-23-2009 |
| 20090186354 | METHODS AND TOOLS FOR THE SCREENING OF FACTORS AFFECTING PROTEIN MISFOLDING - The present invention relates in general to the fields of chemical, pharmaceutical and genetic screening and to diseases associated with protein misfolding. In particular, it discloses engineered cells and a system based thereon that can be used to screen for substances that affect protein misfolding. The engineered cells of the invention comprise one or more reporter genes under transcriptional control of a promoter that is responsive to protein misfolding. | 07-23-2009 |
| 20090186355 | Method for determination and quantification of radiation or genotoxin exposure - The present invention discloses methods for detecting exposure of a living subject to genotoxic agents, testing sensitivity to a genotoxic agent, and determining DNA damage caused by exposure to an agent, comprising detecting the presence of FANCD2-containing foci from a sample collected from said subject. The presence of concentrated foci is indicative of DNA damage, and the degree of foci formation is correlated with degree of exposure. Diagnostic reagents contain a ligand that binds to human FANCD2 associated with a detectable label. Kits for detecting DNA damage in a biological sample contain such diagnostic reagents and signal detection components. The invention further discloses methods for identifying agents which modulate the ability of FANCD2-containing foci to form. Among other things, such agents are potentially useful chemosensitizing agents or may confer protection against damage caused by genotoxic agents. | 07-23-2009 |
| 20090186356 | DEVICE AND SUBSTANCE FOR THE IMMOBILIZATION OF MESENCHYMAL STEM CELLS (MSCs) - The invention relates to a device comprising at least one surface which comes into contact with biological tissue and/or liquid, which is at least partially coated with a substance which mediates the binding of mesenchymal stem cells (MSCs), a method for the binding and/or isolation of MSCs from biological tissue and/or liquid, a nucleic acid molecule which selectively and highly specifically binds to MSCs, the use of the nucleic acid molecule for the binding and/or isolation of MSCs from biological tissue and/or liquid, as well as a method for the production of a device mentioned at the outset. | 07-23-2009 |
| 20090186357 | Integrated PCR Reactor for Cell Lysis, Nucleic Acid Isolation and Purification, and Nucleic Acid Amplication Related Applications - Disclosed are integrated devices capable of performing a polymerase chain reaction within a single vessel. Also disclosed are related methods of sample analysis. | 07-23-2009 |
| 20090186358 | Pathway Analysis of Cell Culture Phenotypes and Uses Thereof - The present invention provides methods for systematically identifying genes, proteins and/or related pathways that regulate or indicative of cell phenotypes. The present invention further provides methods for manipulating the identified genes, proteins and/or pathways to engineer improved cell lines and/or to evaluate or select cell lines with desirable phenotypes. | 07-23-2009 |
| 20090186359 | DETECTING PROSTATE CANCER - An assay for detecting prostate cancer includes reagents for detecting the methylation of GSTP1 and HIC-1 genes. | 07-23-2009 |
| 20090186360 | Detection of GSTP1 hypermethylation in prostate cancer - An assay for detecting prostate cancer includes reagents for detecting multiple methylation markers from within one gene such as GSTP1. | 07-23-2009 |
| 20090186361 | METHODS OF PREDICTING THE PHARMACEUTICAL TOXICITY OF TAXANES - The present disclosure relates to methods of identifying a recipient subject who has an elevated risk of an adverse or toxic reaction to a taxane. The predictive methods of the present disclosure allow for the recipient subject most at risk of adversely reacting to the taxane, to be administered alternative treatments or to have the dosage modified to reduce or eliminate toxic reactions. It has been discovered that recipient subjects bearing certain SNPs of the cytochrome CYP2C8 and TUBB genes have an elevated risk of toxicity from a taxane. The methods of the present disclosure encompass methods of calculating a Toxicity Index for a recipient subject based on clinical data from the recipient subject as it relates to the administration and reaction to treatment with taxane. This Toxicity Index value is then correlated to the presence of polymorphisms at a site in each of the gene loci CYP2C8 and TUBB, or a combination of both sites. | 07-23-2009 |
| 20090186362 | FUNGAL DELTA-12 DESATURASE AND DELTA-15 DESATURASE MOTIFS - The present invention relates to fungal Δ12 desaturases (responsible for conversion of oleic acid to linoleic acid (18:2, LA)) and Δ15 fatty acid desaturases (responsible for conversion of LA to α-linolenic acid (18:3, ALA)). Amino acid motifs diagnostic of Δ12 desaturases and Δ15 desaturases are also provided. Methods of altering enzyme specificity towards Δ12 desaturation or towards Δ15 desaturation and/or increasing production of specific ω-3 and ω-6 fatty acids by over-expression of the fungal desaturases are also described. | 07-23-2009 |
| 20090186363 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 07-23-2009 |
| 20090191541 | Nucleic Acid Molecules and Other Molecules Associated with Plants - The present invention is in the field of plant genetics. More specifically the invention relates to nucleic acid molecules and nucleic acid molecules that contain markers, in particular, single nucleotide polymorphism (SNP) and repetitive element markers. In addition, the present invention provides nucleic acid molecules having regulatory elements or encoding proteins or fragments thereof. The invention also relates to proteins and fragments of proteins so encoded and antibodies capable of binding the proteins. The invention also relates to methods of using the nucleic acid molecules, markers, repetitive elements and fragments of repetitive elements, regulatory elements, proteins and fragments of proteins. | 07-30-2009 |
| 20090191542 | Multi-variant cell indication technique - The invention provides methods for identifying and isolating cells that express high levels of protein. A method is described for identifying a cell or cell line expressing a desired protein comprising determining in a cell or cell line that has been transfected with a vector comprising a nucleotide sequence encoding the desired protein the intracellular expression levels of elements of the vector and also determining expression of the desired protein on the surface of the cell or cell line, in certain cases in a single assay. | 07-30-2009 |
| 20090191543 | IDENTIFICATION OF RAC1B AS A MARKER AND MEDIATOR OF METALLOPROTEINASE-INDUCED MALIGNANCY - The present invention provides compositions and methods for detecting MMP-induced malignancies by detecting Rac1b expression. The invention further provides compositions and in vitro and in vivo methods for inhibiting MMP-induced malignant transformation by modulating Rac1b expression and/or function. | 07-30-2009 |
| 20090191544 | Correlating chemical and spatial data within pathology samples - A tissue sample to be analyzed is tested. Multiple different samples of multiple areas of said tissue sample, each of said multiple areas is a smaller area than an entire tissue sample to be analyzed. After analysis, the tissue sample is processed in a way that facilitates viewing tumor information on the sample, for example, by fixing or staining. An area is identified on the stained sample, and at least one of the samples that corresponds to an identified area is tested. This small area is tested using a technique that homogenizes the sample before testing. | 07-30-2009 |
| 20090191545 | Selection of High-Producing Cell Lines - The invention describes a method for screening antibody producing cell lines for selection of high expressing clones. | 07-30-2009 |
| 20090191546 | ENGINEERED TOEHOLD REACTIONS AND NETWORKS - A catalytic system and method of catalyzing reactions that uses a novel toehold exchange mechanism that allows a specified input to catalyze the release of a specified output, which in turn can serve as a catalyst for other reactions is provided. This toehold exchange catalyst system, which can be driven forward by the configurational entropy of the released molecule, provides an amplifying circuit element that is simple, fast, modular, composable, and robust. Using this toehold exchange catalyst system it has been possible to construct and characterize several circuits that amplify nucleic acid signals, including a feed-forward cascade with quadratic kinetics and a positive feedback circuit with exponential growth kinetics. | 07-30-2009 |
| 20090191547 | Exon grouping analysis - This invention pertains to the identification of specific disease-causing DNA sequences in a subject. The methods of the present invention can be used to identify genetic alterations, to determine the molecular basis for genetic diseases, and to provide carrier and prenatal diagnosis for genetic counseling. | 07-30-2009 |
| 20090191548 | METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH TISSUE CLASSIFICATION - The present application provides methods and nucleic acids the classification of a biological sample. This is achieved by the analysis of the expression status of at least one of the genes selected from Table 1 as disclosed. | 07-30-2009 |
| 20090191549 | SINGLE NUCLEOTIDE POLYMORPHISMS (SNP) AND THEIR ASSOCIATION WITH TICK RESISTANCE IN BOVINE ANIMALS - A method for assessing tick resistance in a bovine animal, comprising the steps of:
| 07-30-2009 |
| 20090191550 | Diagnosis of whipple's disease - The invention relates to a method for in vitro seriological diagnosis of Whipple's disease, whereby the bacteria responsible for the disease are isolated and established in a culture and brought into contact with the serum or biological fluid of an infected patient. The invention also relates to useful oligonucleotides with a probe and a primer for amplifying, sequencing and detecting the gene rpoB of the bacteria, | 07-30-2009 |
| 20090191551 | Use of Secretor, Lewis and Sialyl Antigen Levels in Clinical Samples as Predictors of Risk for Disease - An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the H-1, H-2, Lewis | 07-30-2009 |
| 20090191552 | Novel Human Acidic Mammalian Chitinase and Use Thereof - Described herein is a variant human acidic mammalian chitinase (AMCase) enzyme having improved stability and an isolated nucleic acid sequence which encodes the variant. The invention also provides to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing recombinant variant AMCase polypeptide and its use in screening assays to identify modulators. | 07-30-2009 |
| 20090191553 | Chase Ligation Sequencing - In various embodiments, the present teachings provide sequencing methods which facilitate enhancing the efficiency of ligation and/or increasing sequencing reads. Various embodiments of the methods enable sequencing through template regions for which complementary labeled extension probes are unavailable or insufficient. In various embodiments, one or more rounds of ligation with unlabeled extension probes can be used in addition to a round of ligation with labeled extension probe. In various embodiments, for example, such methods can facilitate extension on template polynucleotides that do not bind labeled extension probe in the first round of ligation. | 07-30-2009 |
| 20090191554 | MODIFIED GLASS FIBER WITH MONOLAYER OF AMINOCALIXARENE DERIVATIVES AND IMINECALIXARENE DERIVATIVES - Techniques for a surface-modified glass fiber with monolayer of aminocalixarene derivatives and iminecalixrene derivatives are provided. | 07-30-2009 |
| 20090191555 | HCV NS3-NS4 Protease Resistance Mutants - The present invention is directed to mutants of HCV NS3/4A protease. More particularly, the present invention identifies mutant of HCV NS3/4A protease that are resistant to drug treatment. | 07-30-2009 |
| 20090191556 | Method - The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described. | 07-30-2009 |
| 20090191557 | MN/CA IX/CA9 and renal cancer prognosis - Herein disclosed are methods that are prognostic for renal cell carcinoma, particularly renal clear cell carcinoma, afflicting a vertebrate. An exemplary prognostic method comprises detecting the presence of, and quantitating the level and/or extent of a MN/CA9 gene expression product in a sample from the affected subject, wherein if 50% or fewer cells are found to express the MN/CA9 gene, then the subject is considered to have a poorer prognosis. MN/CA9 gene expression products useful in the prognostic methods include MN protein, MN polypeptide and/or MN nucleic acids. The methods are useful as an aid in the selection of treatment for a patient with renal cell carcinoma, alone or in combination with conventional tumor stage and/or grade information. The methods of the invention can be used, for example, to identify those patients requiring more aggressive therapy regimens, or those patients most likely to respond to adjuvant immunotherapies, particularly MN/CA IX/CA9-targeted therapies. | 07-30-2009 |
| 20090191558 | DETECTION, IDENTIFICATION AND DIFFERENTIATION OF SERRATIA SPECIES USING THE SPACER REGION - The present invention relates to new nucleic acid sequences derived from the ITS (Internal Transcribed Spacer) region, between the 16S and 23S rRNA genes, to be used for the specific detection and/or identification of | 07-30-2009 |
| 20090191559 | HER2 DIAGNOSTIC METHODS - In certain aspects, the present invention provides methods for determining whether a Her-2 positive cancer is likely to respond to treatment with a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a slow disease progression. In other aspects, the present invention is drawn to methods for determining whether a subject with a Her-2 positive cancer is unlikely to respond to treatment with at least one chemotherapeutic agent in addition to a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a fast disease progression. | 07-30-2009 |
| 20090191560 | MUTANT DNA POLYMERASES AND USES THEROF - The present invention relates to mutant DNA polymerases which incorporate dideoxynucleotides with about the same efficiency as deoxynucleotides. The present invention also related to mutant DNA polymerases which also have substantially reduced 5′-to-3′ exonuclease activity or 3′-to-5′ exonuclease activity. The invention also relates to DNA molecules coding for the mutant DNA polymerases, and hosts containing the DNA molecules. | 07-30-2009 |
| 20090191561 | METHODS AND OLIGONUCLEOTIDES FOR DETECTION OF MASTITIS CAUSING BACTERIA - The present invention relates to the field of polymerase chain reaction (PCR) based diagnostic assays. More specifically, the present invention provides a PCR-method for detecting mastitis causing bacteria, particularly | 07-30-2009 |
| 20090191562 | METHOD FOR ASSAYING REG IV mRNA - In an RNA amplification process comprising steps of using a first primer and a second primer, at least one of which has a promoter sequence at the 5′ end, and reverse transcriptase, to produce double-stranded DNA containing the promoter sequence, using the double-stranded DNA as template to produce an RNA transcript with RNA polymerase, and using the RNA transcript in turn as template for DNA synthesis with the reverse transcriptase to produce the double-stranded DNA, the amount of amplified RNA product is measured with an intercalating fluorescent dye-labeled nucleic acid probe. | 07-30-2009 |
| 20090191563 | UNIFORM FRAGMENTATION OF DNA USING BINDING PROTEINS - The invention provides a method for preparing and analysing a population of fragmented polynucleotide sequences having a substantially uniform size. The method can include steps of (a) binding at least some protection molecule to at least one polynucleotide sequence; (b) cleaving the at least one polynucleotide sequence to generate a plurality of polynucleotide fragment sequences of substantially uniform size; (c) amplifying the polynucleotide fragments; and (d) determining a sequence characteristic of a plurality of the polynucleotide fragments. | 07-30-2009 |
| 20090191564 | DIAGNOSTICS AND THERAPEUTICS FOR CARDIOVASCULAR DISORDERS - The methods of the present invention relate to the diagnosis of cardiovascular disorders. In one aspect, the specification discloses methods for determining a subject's predisposition to increased risk for myocardial infarction. | 07-30-2009 |
| 20090191565 | SHORT CYCLE METHODS FOR SEQUENCING POLYNUCLEOTIDES - The invention provides methods for sequencing a polynucleotide comprising stopping an extension cycle in a sequence by synthesis reaction before the reaction has run to near or fill completion. | 07-30-2009 |
| 20090191566 | Kits for Isolating Nucleic Acids Using Multifunctional Group-Coated Solid Phase Carriers - The present invention is directed to a method of isolating a target species (e.g., target nucleic acid species) from a mixture. In the methods of the present invention, the mixture is combined with solid phase carriers having a surface comprising multiple functional groups one of which reversibly and selectively binds the target species. In a particular embodiment, the mixture is combined with solid phase carriers having a first functional group which reversibly binds nucleic acids and a second functional group which selectively and reversibly binds the target nucleic acid species, thereby producing a first combination. The first combination is maintained under conditions appropriate for binding of the nucleic acids to the first functional group and binding of the target nucleic acid species to the second functional group. The solid phase carriers are separated from the first combination, and combined with an agent (e.g., buffer) that selectively removes (e.g., elutes) either the nucleic acid from the first functional group or the target nucleic acid species from the second functional group of the solid phase carriers, thereby isolating a target nucleic acid species from a mixture comprising a plurality of nucleic acid species. | 07-30-2009 |
| 20090191567 | SEMICONDUCTOR NANOCRYSTAL PROBES FOR BIOLOGICAL APPLICATIONS AND PROCESS FOR MAKING AND USING SUCH PROBES - A semiconductor nanocrystal compound and probe are described. The compound is capable of linking to one or more affinity molecules. The compound comprises (1) one or more semiconductor nanocrystals capable of, in response to exposure to a first energy, providing a second energy, and (2) one or more linking agents, having a first portion linked to the one or more semiconductor nanocrystals and a second portion capable of linking to one or more affinity molecules. One or more semiconductor nanocrystal compounds are linked to one or more affinity molecules to form a semiconductor nanocrystal probe capable of bonding with one or more detectable substances in a material being analyzed, and capable of, in response to exposure to a first energy, providing a second energy. Also described are processes for respectively: making the semiconductor nanocrystal compound; making the semiconductor nanocrystal probe; and treating materials with the probe. | 07-30-2009 |
| 20090191568 | METHODS AND COMPOSITIONS FOR PREDICTING COMPLIANCE WITH AN ANTIDEPRESSANT TREATMENT REGIMEN - Methods and compositions are provided for predicting whether a subject will comply with an antidepressant treatment regimen. In practicing the subject methods, a subject's serotonin transporter gene-linked polymorphic region (5HTTLPR) is genotyped. Based on the identified genotype, a particular antidepressant treatment regimen suitable for the patient is determined. Also provided are kits for practicing the subject methods. | 07-30-2009 |
| 20090191569 | Mammalian Cytokines; Related Reagents - Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided. | 07-30-2009 |
| 20090197246 | Haplotypes and polymorphisms linked to human thiopurine s-methyltransferase deficiencies - Haplotypes and polymorphisms of thiopurine S-methyltransferase (TPMT) are described that are linked to TPMT deficiencies which can cause potentially fatal toxicity when patients are treated with thiopurines like mercaptopurine, azathioprine, or thioguanine. The mutant alleles as well as PCR fragments, kits and methods for assaying the TPMT genotype of individual patients are disclosed. Furthermore, algorithms are disclosed that combine the genotypes of a set of single nucleotide polymorphisms to haplotypes that give a distinct information about the TPMT phenotype. | 08-06-2009 |
| 20090197247 | Composition for increasing microorganism wall permeability and method for detecting said microorganisms on a membrane - The present invention relates to a composition for permeabilizing microorganism walls, comprising the combination of polyethyleneimine (PEI) with at least one alcohol, and also to a method using said composition for counting and detecting in a targeted manner the microorganisms on a membrane. The invention also relates to a kit and to probes that are suitable for carrying out said method. | 08-06-2009 |
| 20090197248 | VITRO EVOLUTION IN MICROFLUIDIC SYSTEMS - The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalising genetic elements into microcapsules; and (b) sorting the genetic elements which express the gene product having the desired activity; wherein at least one step is under microfluidic control. The invention enables the in vitro evolution of nucleic acids and proteins by repeated mutagenesis and iterative applications of the method of the invention. | 08-06-2009 |
| 20090197249 | COMPOSITIONS AND METHODS FOR DIAGNOSING COLON DISORDERS - The present invention relates to methods and compositions for diagnosing, monitoring, prognosticating, analyzing, etc., polymicrobial diseases. The present invention also relates to the microbial community present in the digestive tract and lumen in normal subjects, and subjects with digestive tract diseases, especially diseases of the colon, such as inflammatory bowel disease, including ulcerative colitis, Crohn's syndrome, and pouchitis. The present invention especially relates to compositions and methods for diagnosing and prognosticating the mentioned diseases and conditions, e.g., to determine the presence of the disease in a subject, to determine a therapeutic regimen, to determine a therapeutic regimen, to determine the onset of active disease, to determine the predisposition to the disease, etc. | 08-06-2009 |
| 20090197250 | METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE PROGNOSIS OF PROSTATE CELL PROLIFERATIVE DISORDERS - Particular aspects provide novel methods and compositions (e.g., nucleic acids, kits, etc.) having substantial utility for providing a prognosis of prostate cell proliferative disorders. In particular aspects, this is achieved by the analysis of the expression status of a panel of genes, or subsets thereof. | 08-06-2009 |
| 20090197251 | Process for marking products with nucleic acids for proving the identity and origin of the products - The invention relates generally to product identification and, more particularly, to processes for marking products with nucleic acids to establish the identity and origin of the products, to track them and to determine their quantity in the event of blending or dilution with other products. The invention also relates to the use of nucleic acids which code characters and character sequences for marking products and to products containing nucleic acids which code characters and character sequences. | 08-06-2009 |
| 20090197252 | Detection of Mutations - The present invention relates to a polypeptide which is flavin-containing monooxygenase 3 (FMO3), wherein said FMO3 is a polypeptide comprising at least a sequence having at least 85% identity with the polypeptide sequence SEQ ID NO: 15, in particular to a polypeptide which is a functionally altered mutant of flavin-containing mono oxygenase 3 (FMO3) leading to a buildup of trimethylamine in an animal. Further, the invention relates to nucleic acid sequences encoding said polypeptide, and to the complements of such nucleic acid sequences. Such nucleic acid sequences and fragments thereof may be useful e.g. as primers. The invention further relates to various methods for determining the presence in e.g. a nucleic acid sample of a nucleic acid sequence encoding a mutated FMO3 polypeptide. | 08-06-2009 |
| 20090197253 | HIGH FREQUENCY OF NEUREXIN 1BETA SIGNAL PEPTIDE STRUCTURAL VARIANTS IN PATIENTS WITH AUTISM - The three β-neurexins have similar roles in synaptogenesis and interact with the neuroligins. Mutations located within the gene encoding neurexin 1 have been identified as molecular markers associated with autism and autism-related disorders. The estimated attributable risk is 2%. The invention provides methods of diagnosing or predicting susceptibility to developing autism in an individual by determining the presence or absence of one or more genetic variant of a neurexin 1 gene in an individual. | 08-06-2009 |
| 20090197254 | VARIANT SCORPION PRIMERS FOR NUCLEIC ACID AMPLIFICATION AND DETECTION - Disclosed herein are methods of detecting target nucleic acids. In particular, methods for avoiding loss of the fluorescent label form an amplicon that is generated using a Scorpion primer and a polymerase with 5′ exonuclease activity. The methods use a Scorpion primer which comprises a fluorophore, a quencher, and in 5′ to 3′ order, a probe region, a linker region and a primer region, wherein the quencher is located at or near the 5′ end, and, wherein the primer is complementary to the target nucleic acid and the probe region hybridizes to a complementary sequence in an extension product of the primer. The methods provide for detection of target nucleic acids in simplex or multiplex formats. | 08-06-2009 |
| 20090197255 | Determining a predisposition to cancer - The present invention relates to methods and kits for determining a predisposition for developing cancer, e.g., prostate and/or breast cancer, due to a germline mutation of a NBS1 gene. The present invention also relates to surveillance protocols for developing cancer, e.g., prostate and/or breast cancer, due to germline mutation of a NBS1 gene. | 08-06-2009 |
| 20090197256 | Use of a fibroblast growth factor-binding protein for the treatment and diagnosis of diabetic wound healing problems - The present invention relates to the use of fibroblast growth factor-binding protein (FGF-BP) polypeptides, and functional variants of these polypeptides, respectively, or of nucleic acids encoding these polypeptides or variants, or of functional variants of these nucleic acids, and/or of a cell which is expressing an FGF-BP polypeptide or functional variants thereof, for treating, diagnosing and/or preventing wound healing disturbances which are characterized by a reduced quantity of FGF-BP, in particular diabetes-associated wounds, and also to the use of at least one FGF-BP polypeptide as depicted in SEQ ID No. 1 and SEQ ID No. 3 and/or of at least one FGF-BP-encoding nucleic acid as depicted in SEQ ID No. 2 and SEQ ID No. 4 and/or of antibodies or antibody fragments which are directed against an FGF-BP polypeptide which can be used in accordance with the invention, or functional variants thereof, and/or of a cell which is expressing an FGF-BP polypeptide or functional variants thereof, for identifying pharmacologically active substances which increase the activity of expression of FGF-BP. | 08-06-2009 |
| 20090197257 | PAIRED-END READS IN SEQUENCING BY SYNTHESIS - The disclosure provides methods of generating paired reads in sequencing-by-synthesis process, particularly, in systems with relatively short read lengths (e.g., 15-35 bases), such as for example, in single molecule sequencing by synthesis. Several implementations of the methods are provided. Of particular advantage are the methods that permit re-sequencing of the template, which yields lower error rates. The invention further provides methods of using paired reads, for example, for positioning them over repeats or for assembly into large sequences, including whole genome assembly. | 08-06-2009 |
| 20090197258 | PRIMARY RAT HEPATOCYTE TOXICITY MODELING - The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes. | 08-06-2009 |
| 20090197259 | Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer - A first embodiment is a breast cancer prognosticator comprising a detection mechanism consisting a 15-gene signature. In addition there are embodiments comprised of 23-gene signatures and 28-gene signatures. The 28-gene signature may also be used for the prognosis of ovarian cancer. A second embodiment is a method to determine metastatic potential, relapse potential, or both in breast cancer patients comprising collecting a sample from an individual, removing marker-derived polynucleotide from said sample, using a detection mechanism to search for positive matches of said polynucleotides and either the 15, 23, or 28-gene signatures, and developing a quantitative expression profile. Utilizing risk analysis the individual can be placed into one of two or more groups predicting risk and/or clincopathogic variables. Another embodiment is a method to determine relapse free potential in breast cancer patients comprising collecting a sample from an individual, removing marker-derived polynucleotide from said sample, using a detection mechanism to search for positive matches of said polynucleotides and a 24-gene signature, and developing a quantitative expression profile. | 08-06-2009 |
| 20090197260 | METHOD FOR PREDICTING THE VIABILITY AND VITALITY OF BACTERIA USABLE IN STRESSING ENVIRONMENT - A method for predicting viability, vitality and stability of bacteria, which are usable in stressing environments, produced in the form of bacterial preparations and packed in a frozen or lyophilised form, includes pre-suspending the bacterial preparations in non-stressing aqueous nutrient medium, carrying out a molecular measurement of at least one type of marker gene whose stress state is representative for each considered bacterium species, measuring intracellular pH and in comparing the measured values with reference and/or reference standard values. The use of the inventive method for controlling quality of stress adaptation of bacterial preparations and for selecting such preparations is also disclosed. The invention in particular relates to malolactic and probiotic ferments. | 08-06-2009 |
| 20090197261 | APTAMER- AND NUCLEIC ACID ENZYME-BASED SYSTEMS FOR SIMULTANEOUS DETECTION OF MULTIPLE ANALYTES - The present invention provides aptamer- and nucleic acid enzyme-based systems for simultaneously determining the presence and optionally the concentration of multiple analytes in a sample. Methods of utilizing the system and kits that include the sensor components are also provided. The system includes a first reactive polynucleotide that reacts to a first analyte; a second reactive polynucleotide that reacts to a second analyte; a third polynucleotide; a fourth polynucleotide; a first particle, coupled to the third polynucleotide; a second particle, coupled to the fourth polynucleotide; and at least one quencher, for quenching emissions of the first and second quantum dots, coupled to the first and second reactive polynucleotides. The first particle includes a quantum dot having a first emission wavelength. The second particle includes a second quantum dot having a second emission wavelength different from the first emission wavelength. The third polynucleotide and the fourth polynucleotide are different. | 08-06-2009 |
| 20090197262 | BORDETELLA DETECTION ASSAY - Disclosed herein are methods and compositions for detecting | 08-06-2009 |
| 20090197263 | Compare-MS: Method Rapid, Sensitive and Accurate Detection of DNA Methylation - The present invention provides methods and kits useful for enriching, identifying and quantifying methylated DNA3 particularly hypermethylated CpG islands by digesting a sample with a methylation-sensitive restriction endonuclease and capturing methylated restriction fragments with a methyl-binding capture reagent. The methods of the invention may be used in the detection of cancer, particularly detection of prostate cancer. | 08-06-2009 |
| 20090197264 | METHOD FOR PREDICTION OF SENSITIVITY TO 5-FLUOROURACIL-TYPE ANTICANCER AGENT - A factor affecting sensitivities to anticancer agents is analyzed and the validity of the factor is demonstrated. | 08-06-2009 |
| 20090197265 | EPIGENETIC ANALYSES - A method of carrying out epigenetic analysis on an analyte biological sample, the method comprising carrying out chromatin immunoprecipitation on an analyte biological sample, characterised in that the method comprises a step of contacting the analyte biological sample with carrier chromatin. The method of the invention wherein the analyte biological sample comprises less than one million cells. The method of the invention wherein the analyte biological sample comprises less than about 6 μg of DNA and/or less than about 12 μg of chromatin. | 08-06-2009 |
| 20090197266 | METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACOGENETICS - The present invention provides methods for optimizing clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. The methods of the present invention may further comprise determining the level of at least one long-chain methotrexate polyglutamate (MTXPG) in a sample obtained from the individual. The present invention also provides methods for generating a pharmacogenetic index for predicting clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. In addition, the present invention provides methods for optimizing therapeutic efficacy of chemotherapy in an individual by calculating the level of at least one long-chain MTXPG in a sample obtained from the individual. | 08-06-2009 |
| 20090197267 | METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACOGENETICS - The present invention provides methods for optimizing clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. The methods of the present invention may further comprise determining the level of at least one long-chain methotrexate polyglutamate (MTXPG) in a sample obtained from the individual. The present invention also provides methods for generating a pharmacogenetic index for predicting clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. In addition, the present invention provides methods for optimizing therapeutic efficacy of chemotherapy in an individual by calculating the level of at least one long-chain MTXPG in a sample obtained from the individual. | 08-06-2009 |
| 20090197268 | METHODS FOR OPTIMIZING CLINICAL RESPONSIVENESS TO METHOTREXATE THERAPY USING METABOLITE PROFILING AND PHARMACOGENETICS - The present invention provides methods for optimizing clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. The methods of the present invention may further comprise determining the level of at least one long-chain methotrexate polyglutamate (MTXPG) in a sample obtained from the individual. The present invention also provides methods for generating a pharmacogenetic index for predicting clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. In addition, the present invention provides methods for optimizing therapeutic efficacy of chemotherapy in an individual by calculating the level of at least one long-chain MTXPG in a sample obtained from the individual. | 08-06-2009 |
| 20090197269 | Translocation and mutant CSF1R Kinase in human leukemia - In accordance with the invention, a novel gene translocation, (3p21, 5q33), in human myelogenous leukemia (AML) that results in a fusion protein combining part of RNA Binding Protein-6 (RBM6) with Macrophage Colony Stimulating Factor-1 Receptor (CSF1R) kinase has now been identified. The RBM6-CSF1R fusion protein and truncated CSF1R kinase itself, which both retain CSF1R tyrosine kinase activity, were confirmed to drive the proliferation and survival of acute megakaryoblastic leukemia (AML-M7). The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant CSF1R kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein and truncated kinase enables new methods for determining the presence of these mutant CSF1R kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention. | 08-06-2009 |
| 20090197270 | DIAGNOSTIC ASSAY FOR SPONGIFORM ENCEPHALOPATHIES - The invention provides a method of diagnosis of a spongiform encephalopathy in a diagnostic sample of a valid body tissue taken from a subject, which comprises detecting an increased proteolytic activity in the diagnostic sample, compared with a sample from a control subject. | 08-06-2009 |
| 20090197271 | FUNCTIONAL NUCLEIC ACID LIGANDS TO FLUORESCENT PROTEINS - The present invention relates to a nucleic acid aptamer having a first domain that binds to a fluorescent protein. The nucleic acid aptamer forms a molecular complex whereby the aptamer binds a fluorescent protein at the first domain. A constructed DNA molecule, expression systems, and host cells containing the molecular complex are also disclosed. The invention also relates to a system containing a first DNA molecule encoding the nucleic acid aptamer of the present invention and a second DNA molecule encoding a fluorescent protein capable of being bound by the first domain. Methods of detecting a molecular target and determining location of a molecular target using the nucleic acid aptamer of the invention are also disclosed. | 08-06-2009 |
| 20090197272 | VITRO METHOD OF DETECTING AND/OR DIAGNOSING CANCER USING UV LIGHT BASED DNA IMAGE CYTOMETRY - The invention relates to a method of determining in vitro the amount of nuclear DNA within a human or animal cell using UV absorption measurement with UV light. The invention also relates to a method for detecting in vitro cancerous cells in a biological sample relying on the aforementioned principles. The invention also relates to an in vitro method of diagnosing or predicting the likely occurrence of cancer in a human or animal subject. | 08-06-2009 |
| 20090197273 | NOVEL N-ACETYLGALACTOSAMINE TRANSFERASES AND NUCLEIC ACIDS ENCODING THE SAME - An enzyme which transfers N-acetylgalactosamine to N-acetylglucosamine via a β1-4 linkage was isolated and the structure of its gene was explained. This led to the production of said enzyme or the like by genetic engineering techniques, the production of oligosaccharides using said enzyme, and the diagnosis of diseases on the basis of said gene or the like. | 08-06-2009 |
| 20090197274 | BIOLOGICAL SAMPLE REACTION CHIP AND BIOLOGICAL SAMPLE REACTION METHOD - A biological sample reaction chip, including: a plurality of reaction containers; a reaction liquid introduction channel having a reaction liquid supply opening at a first end and an evacuation opening at a second end; and a reaction liquid quantifying channel, a third end of which is connected to one of the reaction containers, and a fourth end of which is connected to the reaction liquid introduction channel, wherein an interior of each of the reaction containers is coated with a reagent that is necessary for a reaction. | 08-06-2009 |
| 20090197275 | Controls For Detecting Methicillin Resistant Staphylococcus Aureus (MRSA) - The invention relates to the quality control of | 08-06-2009 |
| 20090197276 | METHODS AND COMPOSITIONS FOR PREDICTING COMPLIANCE WITH AN ANTIDEPRESSANT TREATMENT REGIMEN - Methods and compositions are provided for predicting whether a subject will comply with an antidepressant treatment regimen. In practicing the subject methods, a subject's serotonin transporter gene-linked polymorphic region ( | 08-06-2009 |
| 20090197277 | High Density Plate Filler - A filling apparatus for filling a microplate. The microplate having a plurality of wells each sized to receive an assay. The filling apparatus can comprise an assay input layer having a first surface and an opposing second surface. The assay input layer can comprise an assay input port extending from the first surface to the second surface and at least one pressure nodule extending from the second surface. An output layer can comprise a plurality of staging capillaries each having an inlet and an outlet. A intermediate layer can be disposed between the assay input layer and the output layer. The intermediate layer can be flexible and comprise a plurality of microfluidic channels and a flow aperture being in fluid communication with the assay input port and the plurality of microfluidic channels. The assay input layer can be moveable relative to the intermediate layer such that the at least one pressure nodule engages the intermediate layer to apply a clamping force on at least a portion of one of the plurality of microfluidic channels to reduce flow of the assay therethrough. | 08-06-2009 |
| 20090202986 | METHODS OF OPTIMIZING ANTIBODY VARIABLE REGION BINDING AFFINITY - The present invention provides optimized heteromeric variable region binding fragments and antibodies comprising optimized heteromeric variable region binding fragments. Preferably, the optimized heteromeric variable region binding fragments exhibit optimized activity compared to donor heteromeric variable regions and have unvaried human frameworks. The present invention also provides methods of making the optimized heteromeric variable region binding fragments. | 08-13-2009 |
| 20090202987 | Canis sphingosine 1-phosphate receptor isoform 2 | 08-13-2009 |
| 20090202988 | Trap vectors and gene trapping using the same - A trap vector containing a loxP sequence composed of inverted repeat sequence | 08-13-2009 |
| 20090202989 | EGFR AND KRAS MUTATIONS - The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and KRAS and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein and/or mutated KRAS gene or protein in a tumor sample. | 08-13-2009 |
| 20090202990 | METHODS FOR THE SELECTION OF APTAMERS - The present invention generally relates to methods for selecting aptamers. More specifically, the invention provides methods for the selection of at least one aptamer for use in combination with another epitope binding agent such as another aptamer, an antibody, or a double stranded nucleic acid. The invention also encompasses methods for simultaneously selecting at least two aptamers that each recognize distinct epitopes on a target molecule. | 08-13-2009 |
| 20090202991 | NOVEL DIAGNOSTIC MARKERS, ESPECIALLY FOR IN VIVO IMAGING AND ASSAYS AND METHODS OF USE THEREOF - Novel splice variants as diagnostic markers, preferably membrane-bound. The novel variants according to the present invention may optionally be used for diagnosis of Marker-detectable disease as described herein, optionally through immunohistochemistry. | 08-13-2009 |
| 20090202992 | POLYNUCLEOTIDE AND PROTEIN INVOLVED IN SYNAPTOGENESIS, VARIANTS THEREOF, AND THEIR THERAPEUTIC AND DIAGNOSTIC USES - The invention relates to a kit for diagnosing autism linked to a mutation in a protein belonging to the family of human neuroligins. | 08-13-2009 |
| 20090202993 | Use of DNA polymerases - Use of a DNA polymerase enzyme as a single stranded RNA exoribonuclease. | 08-13-2009 |
| 20090202994 | Human single nucleotide polymorphisms in ion channels and other proteins - The invention provides polynucleotide fragments corresponding to the genomic and/or coding regions of these genes which comprise at least one polymorphic site per fragment. Allele-specific primers and probes that hybridize to these regions, and/or that comprise at least one polymorphic site are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, paternity testing, medicine, and genetic analysis. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders, particularly cardiovascular diseases related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention. | 08-13-2009 |
| 20090202995 | MOLECULAR CARDIOTOXICOLOGY MODELING - The present invention includes methods of predicting cardiotoxicity of test agents and methods of generating cardiotoxicity prediction models using algorithms for analyzing quantitative gene expression information. The invention also includes microarrays, computer systems comprising the toxicity prediction models, as well as methods of using the computer systems by remote users for determining the toxicity of test agents. | 08-13-2009 |
| 20090202996 | Genetic polymorphisms for identifying individuals at risk for drug-induced vestibular dysfunction - In this application is described the identification of genetic variants that contribute to susceptibility to drug-induced vestibular dysfunction, more particularly, GM-induced vestibular dysfunction. Methods, compositions and kits for determining whether an individual has susceptibility for drug-induced vestibular dysfunction are disclosed. | 08-13-2009 |
| 20090202997 | Cell-Free In Vitro Transcription and Translation of Membrane Proteins into Tethered Planar Lipid Layers - The present invention relates to synthetic membranes having membrane proteins incorporated therein and, in particular, to the cell-free in vitro transcription and translation of membrane proteins into tethered planar lipid layers. In particular, the present invention provides a new method for the preparation of such membranes. The membranes, e.g., can be used for investigation of membrane receptor/ligand interactions. | 08-13-2009 |
| 20090202998 | METHOD FOR THE EXTRACTION OF BIOMOLECULES FROM FIXED TISSUES - The present invention relates to a method for treating a fixed biological sample, comprising the steps of the method: i) provision of a fixed biological sample, ii) contacting the fixed biological sample with an aqueous solution comprising at least one nucleophilic reagent, and iii) heating the biological sample contacted with the aqueous solution. The invention also relates to the biological sample obtainable by this method, to the use of a nucleophilic reagent for the treatment of a fixed biological sample, to a kit for isolating a biomolecule from a fixed biological sample, to the use of this kit, and to a method for the treatment of a disease. | 08-13-2009 |
| 20090202999 | METHOD FOR DNA BREAKPOINT ANALYSIS - The present invention relates to a method for identifying a DNA breakpoint and agents for use therein. More particularly, the present invention provides a method for identifying a gene translocation breakpoint based on the application of a novel multiplex DNA amplification technique. The method of the present invention facilitates not only the identification of the breakpoint position but, further, enables the isolation of the DNA segment across which the breakpoint occurs. This provides a valuable opportunity to conduct further analysis of the breakpoint region, such as to sequence across this region. The method of the present invention is useful in a range of applications including, but not limited to, providing a routine means to characterise the gene breakpoint associated with disease onset in a patient and thereby enable the design of patient specific probes and primers for ongoing monitoring of the subject disease condition. In addition to monitoring the progression of a condition characterised by the existence of the breakpoint, there is also enabled assessment of the effectiveness of existing therapeutic drugs and/or new therapeutic drugs and, to the extent that the condition is a neoplasm, prediction of the likelihood of a subject's relapse from a remissive state. | 08-13-2009 |
| 20090203000 | DETECTION OF NUCLEIC ACIDS USING A CANTILEVER SENSOR - Detection of miniscule amounts of nucleic acid is accomplished via binding of target nucleic acid to probe material, composed of nucleic acid, which is bound to a sensor configured to sense mass. The sensor is prepared by immobilizing a probe material to a surface of the sensor, wherein the probe material is known to bind to the target nucleic acid. The prepared sensor is exposed to the target nucleic acid. The target nucleic acid binds to the probe material. The mass accumulated on the sensor reflects the amount of target nucleic acid bound to the probe material. | 08-13-2009 |
| 20090203001 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING MACULAR DEGENERATION - The present invention relates generally to biomarkers for macular degeneration. In particular, the present invention provides a plurality of biomarkers (e.g., polymorphisms and/or haplotypes) for monitoring and diagnosing macular degeneration. The compositions and methods of the present invention find use in diagnostic, therapeutic, research, and drug screening applications. | 08-13-2009 |
| 20090203002 | MESENCHYMAL STEM CELLS AS A VEHICLE FOR ION CHANNEL TRANSFER IN SYNCYTIAL STRUCTURES - The present invention provides a method of selectively amplifying fetal DNA sequences from a mixed, fetal-maternal source. This method utilizes differential methylation to allow for the selective amplification of trophoblast/fetal specific sequences from DNA mixtures that contain a high proportion of non-trophoblast/fetal DNA. The invention also provides methods of using the amplified fetal DNA sequences for aneuploidy detection. | 08-13-2009 |
| 20090203003 | INHIBITION OF METALLO-BETA-LACTAMASE - A method to identify a high affinity nucleic acid ligand to inhibit the activity of a lactamase enzyme. The method comprises several steps that initially involve preparing a candidate mixture of nucleic acids. The candidate mixture of nucleic acids is then allowed to make contact with the lactamase enzyme under controlled conditions of temperature, ionic strength and pH; the combination forms a candidate-enzyme mixture. The target nucleic acids are partitioned from the remainder of the candidate mixture. The target nucleic acids that have been partitioned are amplified to yield a pool of nucleic acids enriched with target nucleic acid sequences. The enriched pool of target nucleic acids have a relatively higher affinity and specificity for binding to the lactamase, whereby nucleic acid ligand of the lactamase are identified. Nucleic acid ligands that inhibit an activity of lactamase. The lactamase includes class B, metallo-β-lactamase. | 08-13-2009 |
| 20090203004 | NON-THIOPURINE METHYLTRANSFERASE RELATED EFFECTS IN 6-MERCAPTOPURINE THERAPY - The present invention provides methods for predicting tolerance associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. In particular, the present invention provides methods for predicting a patient's risk of an adverse drug reaction (or tolerance) to a 6-mercaptopurine drug by genotyping a patient at a polymorphic site in at least one gene selected from the group consisting of a xanthine dehydrogenase (XDH) gene, molybdenum cofactor sulfurase (MOCOS) gene, and aldehyde oxidase (AOX) gene. The present invention further provides methods for optimizing therapeutic efficacy in a patient receiving a 6-mercaptopurine drug by determining whether the patient should be given an alternative drug based on the presence or absence of a polymorphism in at least one of the XDH, MOCOS, and AOX genes. | 08-13-2009 |
| 20090203005 | NOVEL METHOD OF DESIGNING DNA PROBE CHIP FOR ROOM TEMPERATURE HYBRIDIZATION AND THE DNA PROBE CHIP - The present invention relates to a method of designing DNA probe chip for room-temperature hybridization in order to solve the solvent evaporation problem occurring when carrying out said hybridization at a high temperature of 40° C.˜50° C. or higher, wherein the method is designed to allow genotyping through hybridizing at a room temperature of 20° C.˜30° C. The method of designing DNA probe chip comprises designing DNA probe to start at −10˜+5 position that is between −10 position which is overlapped 10 sequences with primer and +5 position which is 5 sequences far from the 3′-terminal of primer, based on 0 position which is 3′-terminal of primer. | 08-13-2009 |
| 20090203006 | BIOLOGICAL MARKERS OF CHRONIC WOUND TISSUE AND METHODS OF USING FOR CRITERIA IN SURGICAL DEBRIDEMENT - The present invention relates to methods for identifying tissue sites in a chronic wound that are suitable for debridement and whether debridement procedure has been successful using particular biological markers of the cells within the tissue sites of the chronic wounds. | 08-13-2009 |
| 20090203007 | METHOD FOR OBTAINING AND INITIATING AMPLIFICATION OF A TARGET NUCLEIC ACID SEQUENCE - The present invention relates to oligonucleotides useful for determining the presence of | 08-13-2009 |
| 20090203008 | Rapid method to determine inhibitor sensitivity of NS3/4A protease sequences cloned from clinical samples - A method for measuring HCV NS3/4A activity from a HCV NS3/4A sequence, comprising obtaining and cloning the sequence into a mammalian expression vector, transiently transfecting a mammalian cell with the vector, which includes a reporter construct encoding a HCV NS3/4A cleavage site fused to a detectable label, measuring signal production from the label resulting from cleavage at the cleavage site, and measuring effects on signal production by addition of a test compound. | 08-13-2009 |
| 20090203009 | Novel method for high-throughput integrated chemical and biochemical reactions - The present invention relates to methods for monitoring in a high through-put fashion a multitude of molecular reaction processes, using a substrate, said substrate comprising a plurality of micro-channels, wherein each micro-channel has inlet and outlet open ends on opposing sides of said substrate, and wherein said micro-channels comprise at least one first reaction component, comprising the steps of: (a) contacting said micro-channels of said solid substrate with a sample, said contacting being via said inlet open ends, wherein said sample comprises an analyte, under conditions that allow said analyte to be specifically retained within said micro-channels by said first reaction component; (b) optionally removing excess of sample via said outlet open ends; (c) contacting the retained analyte with at least one second reaction component, said second reaction component being different from said first reaction component as defined in step (a), under conditions that allow a molecular reaction to take place, said reaction producing a signal; (d) detecting said signal and reading-out reaction results; (e) removing second reaction components via said outlet open ends; (f) repeating steps (c) to (e) at least once, wherein said at least one second reaction component as defined in (c) may be changed in composition; and, final detecting and reading-out of reaction results. The present invention also relates to the uses thereof as well as to microarrays and kits for performing said methods of the invention. | 08-13-2009 |
| 20090203010 | MSMB-gene based diagnosis, staging and prognosis of prostate cancer - This invention relates generally to a method of diagnosis for distinguishing between a benign prostate hyperplasia and a prostate cancer and between a hormone-sensitive and a hormone-refractory prostate cancer condition and specifically to identification of a hypermethylated (on CpG and non-CpG dinucleotides) CpG island in the beta-microseminoprotein (MSMB) regulatory regions surrounding the transcriptional start site of the MSMB gene as a diagnostic indicator of prostate cancer (PrCa) and for distinguishing androgen-refractory from androgen-sensitive prostate cancer. | 08-13-2009 |
| 20090203011 | METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS - Particular aspects provide methods, nucleic acids and kits for detecting cell proliferative disorders. Preferred aspects provide genomic sequences, the methylation patterns of which have substantial utility for the improved detection of said disorders, providing for improved diagnosis and treatment of same in patients. | 08-13-2009 |
| 20090203012 | Metabolic Syndrome Genetics - A gene (and polymorphisms within it) was associated with multiple components of the metabolic syndrome. Methods of screening subjects to identify risk of metabolic syndrome and related conditions are described, as are methods of screening compounds to identify those that act on the gene product as a target for the treatment of these conditions. | 08-13-2009 |
| 20090203013 | Detection of Methicillin-Resistant Staphylococcus aureus - The present invention provides improved tests for the detection of methicillin-resistant | 08-13-2009 |
| 20090203014 | METHOD FOR DIAGNOSING AUTISM SPECTRUM DISORDER - The present invention provides methods of diagnosing and/or predicting autism spectrum disorder comprising determining the presence of microdeletions and microduplications on chromosomes 15 and 16. | 08-13-2009 |
| 20090203015 | MULTIPLEX ASSAYS FOR HORMONAL AND GROWTH FACTOR RECEPTORS, AND USES THEREOF - The present invention provides compositions and methods for simultaneously detecting mRNA expression levels of hormonal receptors, particularly both estrogen receptor (ER) and progesterone receptor (PR), optionally in combination with growth factor receptors, particularly epidermal growth factor receptor ERBB2 (Her-2), and further optionally in combination with control genes, such as the housekeeping genes NUP214 and/or PPIG. Exemplary embodiments of the invention are useful for determining hormonal receptor and/or growth factor receptor status, particular both ER and PR status and optionally also ERBB2 status, such as for assessing or treating breast cancer. | 08-13-2009 |
| 20090203016 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 85P1B3 USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene (designated 85P1B3) and its encoded protein are described. While 85P1B3 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 85P1B3 provides a diagnostic and/or therapeutic target for cancers. The 85P1B3 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response. | 08-13-2009 |
| 20090203017 | Use of Nucleic Acid Probes to Detect Nucleotide Sequences of Interest in a Sample - The invention relates to methods for the determination and detection of nucleic acids sequences in a sample. The nucleic acid may be RNA or DNA or both. The invention also relates to methods for the determination of the presence and species of various microorganisms in a sample. We have also identified a set of oligonucleotide nucleic acid sequences within the rRNAs of Gram-negative organisms that facilitates both the broad identification of Gram-negative organisms as a class when used as a pool, or in combination, for example in a hybridization assay. This set of oligonucleotides may detect sequences that are indicative of the presence of organisms of the broad class of Gram-negative organisms while exhibiting little or no false identification of Gram-positive organisms, and fungi, or other microorganisms. The assay includes concurrent incubation with at least one nucleotide sequence of interest, at least one nucleic acid probe, a fluorosurfactant, and a nuclease. The assay may further be employed to detect the presence of bacteria, fungi, or other microorganisms by use of additional specific probes, or to detect and/or identify target nucleic acid sequences in a sample. Further, the invention also relates to methods of reducing non-specific binding and facilitating complex formation in a binding assay. The binding assay may be, but is not limited to, a nucleic acid hybridization assay or an immunoassay. The invention also relates to methods of detection that employ at least one target of interest, which may be a nucleotide sequence, at least one probe, which may be a nucleic acid probe and a nuclease. | 08-13-2009 |
| 20090203018 | NUCLEIC ACID DETECTION ASSAYS EMPLOYING BLOCKER OLIGONUCLEOTIDES - The present invention provides methods, compositions, and kits for detecting the presence or absence of target sequences in a sample, where the sample also contains interfering sequences that are similar or identical to the target sequences. In particular, the present invention provides blocker oligonucleotides that at least partially inhibit the formation of invasive cleavage structures with the interfering sequences but do not substantially inhibit the formation of invasive cleavage structures with the target sequences. | 08-13-2009 |
| 20090203019 | Methods of Monitoring Metabolic Pathways - The present invention provides methods and compositions for monitoring cofactors and metabolites of a metabolic pathway of interest. The subject compositions and methods are particularly suited for monitoring the mevalonate pathway in a variety of cells. The invention also provides fermentation methods for the production of isoprenoids. | 08-13-2009 |
| 20090203020 | BOVINE POLYMORPHISMS AND METHODS OF PREDICTING BOVINE TRAITS - Methods of predicting the phenotype of a trait in a bovine subject are provided. The methods include obtaining information about polynucleotide sequences specifically regarding the identity of the nucleotides present at one or more identified single nucleotide polymorphisms and using this information to make predictions regarding the trait in the subject. Also provided are kits for and methods of determining the nucleotide present in a bovine subject at a position in which a single nucleotide polymorphism is correlated with a trait. | 08-13-2009 |
| 20090203021 | Detection of Clostridium difficile - The invention provides methods to detect | 08-13-2009 |
| 20090203022 | ANALYSIS - A method of analysing a sample includes providing a first part of the sample and a second part of the sample. A first analysis is conducted on the first part of the sample and the results of the first analysis are considered. A second analysis is conducted on the second part of the sample, the second analysis being conducted according to a procedure using a value for each of one or more characteristics of the procedure. The consideration of the results of the first analysis is used to determine whether the value for one or more of the characteristics of the procedure is changed to a different value. The second analysis is started before the results of the first analysis are obtained. | 08-13-2009 |
| 20090203023 | Concentrating Microorganisms in Aqueous Solution Prior to Selective Staining and Detection - Apparatus and methods for detecting a small number of target microorganisms found in a large volume of aqueous solution by diverting small volumes containing fluorescent microorganisms, including target microorganisms, into a smaller specimen of solution, followed by selectively staining the specimen to tag the target microorganisms and detecting the tagged target microorganisms. | 08-13-2009 |
| 20090203024 | SECRETED PROTEIN CALLED 36P6D5 CHARACTERISTIC OF TUMORS - Described is a gene and its encoded secreted tumor antigen, termed 36P6D5, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express 36P6D5, particularly including cancers of the bladder, kidney, prostate, breast, colon, ovary, and pancreas. | 08-13-2009 |
| 20090203025 | BRANCHED AND MULTI-CHAIN NUCLEIC ACID SWITCHES FOR SENSING AND SCREENING - Embodiments of the invention relate to a branched or multichain nucleic acid switch adapted to switch from a first conformation to a second conformation upon ligand binding. The switch includes a probe strand, P, which includes the ligand binding domain; a switching framework which includes a cover strand (C), and a tether that holds P and C together and a signaling apparatus. Some embodiments include a toggle strand (T) where now the tether holds P, C, T, and the signaling apparatus together. As the switch changes between the first and second conformations; the signaling apparatus reports the state of the switch. The signaling entity is typically a lumiphore and a quencher located along the switching framework. Nucleic acid switches have applications in real time assays for diverse agents including infectious agents, environmental toxins, and terrorist agents, as well as screening methods for such agents. Further applications are found for nanoelectronics, nanofabrication and nanomachines. | 08-13-2009 |
| 20090203026 | Methods and compositions for targeting secretory lysosomes - This invention relates to methods and compositions for targeting proteins to secretory lysosomes. The invention further provides methods of use in drug screening assays, and methods of purifying secretory lysosomes. | 08-13-2009 |
| 20090203027 | Assays for Detecting T2R76 Taste Modulatory Compounds - Isolated nucleic acids encoding T2R76 polypeptides, recombinantly expressed T2R76 polypeptides, heterologous expression systems for recombinant expression of T2R76 polypeptides, assay methods employing the same, and methods for altering taste perception via administration of a T2R76 modulator. These T22R76 polypeptides can be expressed alone or co-expressed with another T2R polypeptide, preferably a different human T2R polypeptide. | 08-13-2009 |
| 20090203028 | NOVEL APTAMERS THAT BIND TO LISTERIA SURFACE PROTEINS - Aptamers bind to | 08-13-2009 |
| 20090203029 | Nucleic Acid Analysis Using Non-templated Nucleotide Addition - One embodiment of the invention is a method of producing an oligonucleotide extended by a single nucleotide base. An oligonucleotide and an extension terminating nucleotide are mixed with an enzyme having terminal transferase activity. The reaction produces an oligonucleotide extended by a single base. The extended oligonucleotide may be used as a size standard for single base extension reactions. Another embodiment of the invention is a method of producing a mixture of oligonucleotides extended by different single bases. An oligonucleotide, a first extension terminating nucleotide, and a second extension terminating nucleotide are mixed with an enzyme having terminal transferase activity. The first and second extension terminating nucleotides comprise different nucleotide bases and are labeled with different labels. The identity of the different extension terminating nucleotides (and hence the extended oligonucleotides) may be ascertained by reference to the specific label incorporated. | 08-13-2009 |
| 20090203030 | Methods for Detecting and Quantifying Specific Probiotic Microorganisms in Animal Feed - Methods and compositions are disclosed for confirming and quantifying the presence of a specific probiotic microorganism in a sample of animal feed. Hybridization and polymerase chain reaction (PCR) techniques are applied to identify the presence of the specific probiotic microorganism in cultures grown in most probable number and serial dilution methods, after calibration of the techniques using blank and control samples. | 08-13-2009 |
| 20090203031 | Methods for Detecting and Quantifying Specific Microorganisms - Methods and compositions are disclosed for confirming and quantifying the presence of a specific kind of microorganism in a sample of material. Hybridization and polymerase chain reaction (PCR) techniques are applied to identify the presence of the specific microorganism in cultures grown in most probable number and serial dilution methods, after calibration of the techniques using blank and control samples. For example, samples of animal feed can be cultured and analyzed to determine the quantity of specific probiotic microorganisms present in the feed. | 08-13-2009 |
| 20090203032 | SPECIES-SPECIFIC PRIMER SETS AND IDENTIFICATION OF SPECIES-SPECIFIC DNA SEQUENCES USING GENOME FRAGMENT ENRICHMENT - Targeted sequencing of genetic regions that differ between two DNA preparations uses genomic fragment enrichment. This method can be used to study genetic variation among closely related species and microbial communities, particularly for identifying sources of fecal pollution. | 08-13-2009 |
| 20090203033 | TEST AND MODEL FOR ALZHEIMER'S DISEASE - The invention provides an isolated nucleic acid characteristic of human amyloid precursor protein 770 including the nucleotides encoding codon 670 and 671, wherein the nucleic acid encodes an amino acid other than lysine at codon 670 and/or an amino acid other than methionine at codon 671. Also provided is a method of diagnosing or predicting a predisposition to Alzheimer's disease, comprising detecting in a sample from a subject the presence of a mutation at a nucleotide position corresponding to codons 670 and/or 671 of amyloid precursor protein or fragment thereof, the presence of the mutation indicating the presence of or a predisposition to Alzheimer's disease. | 08-13-2009 |
| 20090208927 | Methods of detecting sequence-specific DNA binding proteins - Compositions and methods are provided for detecting and measuring DNA-binding proteins. The compositions and methods permit the simultaneous or near-simultaneous detection of multiple DNA-binding proteins in a multiplex or array format, and can be used to generate profiles of DNA binding activity by proteins, specifically, transcription factors. Multiple protein-DNA binding events in a single sample may be detected and quantitated in a high-throughput, format. | 08-20-2009 |
| 20090208928 | Method and device for the in vitro detection of polycystic ovarian syndrome (pcos) and pathologies involving cardiovascular risk - The invention relates to a method and device for the in vitro detection of polycystic ovary syndrome (PCOS) and pathologies involving cardiovascular risk. An in vitro assay method and assay device (kit) for the diagnosis of the presence or the predisposition to suffer from PCOS and/or cardiovascular risk factors including: general obesity, abdominal obesity, hypertension, glucose intolerance, diabetes, hyperinsulinemia, general hypercholesterolemia, hypercholesterolemia with high LDL-cholesterol levels, low HDL-cholesterol levels and hypertriglyceridemia, as well as the grouping of some of these cardiovascular risk factors known as metabolic syndrome. The method and the kit are characterized in that they are based on the detection of at least one genotype or haplotype of a polymorphism in the CAPN5 gene selected from: Nt g.86 A>G, Nt g.344 G>A, Nt c.1320 C>T and Nt c.1469 G>A or combinations thereof. | 08-20-2009 |
| 20090208929 | Method Of In-Vitro Detection And Quantification Of HIV DNA By Quantitative PCR - Process for the detection and quantification in-vitro of HIV DNA by quantitative PCR. The invention consists of developing pairs of oligonucleotides capable of hybridizing with fragments of the gag gene sequence present in the genome of the HIV virus. These oligonucleotides permit amplification of the viral DNA by quantitative PCR. Even in the case of samples with low viral load, the invention permits detection of the HIV DNA virus by juxtaposition either of a conventional PCR with a quantitative PCR, or with a double nested quantitative PCR, using different pairs of primers in each amplification. The invention, compared with the known methods, allows determining qualitatively and quantitatively, in-vitro, the presence of HIV DNA in samples, in a rapid, reproducible manner and with high sensitivity. | 08-20-2009 |
| 20090208930 | Dna decontamination method - The invention is related to a method for amplifying a methylated target nucleic acid in a sample while avoiding amplification of a non-methylated target nucleic acid by inactivating it. This is accomplished by a restriction enzyme digest after bisulfite treatment of the target nucleic acid. The invention is further related to the use of a restriction enzyme to avoid amplification of a non-methylated target nucleic acid while amplifying a methylated target nucleic acid in a sample and kits for performing the methods according to the invention. | 08-20-2009 |
| 20090208931 | Gene Expression Level Normalization Method, Program and System - It is an object to improve the reliability and accuracy of normalization of gene expression levels, which have been measured separately, by providing a method for the acquisition of an index of high reliability and high accuracy as an index for performing the normalization such that the gene expression levels can be compared and verified. Provided is a method for normalizing a gene expression level, which has been measured for an analysis of a gene expression, by using plural gene expression levels measured for an acquisition of an index. The method includes acquiring a correlation among the plural gene expression levels measured for the acquisition of the index, and using the thus-acquired correlation as an index for normalizing the gene expression level measured for the analysis of the gene expression. The correlation function can be obtained by using, as function values, correlations among plural gene expression levels under at least two sets of experimental conditions (numerals | 08-20-2009 |
| 20090208932 | Methods Of Detecting An Analyte In A Sample - The invention relates to methods for detecting an analyte in a sample. The methods rely on the activity of polymerases upon polynucleotide substrates which are linked to a molecule, for example an antibody, which binds the analyte. Activity of the polymerases can be detected by the incorporation of suitably labelled nucleotides, and/or the incorporation of hapten conjugated nucleotides capable of binding a suitably labelled ligand of the hapten. | 08-20-2009 |
| 20090208933 | Method For Diagnosis And/Or Prognosis Of A Septic Syndrome - The present invention relates to a method for the diagnosis/prognosis of a septic syndrome based on a biological sample from a patient, characterized in that it comprises the following steps:
| 08-20-2009 |
| 20090208934 | PECAM-1 GENOTYPE - The invention relates to methods of identifying inter-patient differences in genotype of PECAM- | 08-20-2009 |
| 20090208935 | Reagents and methods for identifying and modulating expression of tumor senescence genes - This invention identifies tumor senescence genes induced by treatment with cytotoxic agents. The invention provides reagents and methods for identifying compounds that induce expression of these cellular genes and produce cellular senescence, particularly senescence in tumor cells. The invention also provides reagents that are recombinant mammalian cells containing recombinant expression constructs that express a reporter gene under the transcriptional control of a promoter for a gene the expression of which is modulated in senescent cells, and methods for using such cells to identify compounds that modulate expression of these cellular genes. | 08-20-2009 |
| 20090208936 | IDENTIFICATION OF MOLECULAR INTERACTIONS AND THERAPEUTIC USES THEREOF - We report the real-time monitoring of protein-protein interactions without labeling either of the two interacting proteins, posing minimum effects on the binding properties of the proteins. In particular, the methods provide protein/aptamer complexes to probe the interactions in a competitive assay where the binding of an aptamer to its target protein is altered by a second protein that interacts with the target protein. Two signal transduction strategies, fluorescence resonance energy transfer (FRET) and fluorescence anisotropy, are described. | 08-20-2009 |
| 20090208937 | Recurrent gene fusions in prostate cancer - Recurrent gene fusions in prostate cancer of androgen regulated genes or housekeeping genes and ETS family member genes are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided. | 08-20-2009 |
| 20090208938 | Use of the MCM8 Gene for the Preparation of a Pharmaceutical Composition - The use of the human or animal MCM8 gene coding for a DNA helicase, or parts of the gene, or transcripts thereof, or antisense nucleic acids able to hybridize with part of the transcripts, or silencing RNA derived from parts of the transcripts and able to repress the MCM8 gene, or proteins or peptidic fragments translated from the transcripts, or antibodies directed against the proteins or peptidic fragments for the preparation of a pharmaceutical composition for the treatment of a human or animal pathology linked to a dysfunction of the expression of the MCM8 gene, or of human or animal cancers. | 08-20-2009 |
| 20090208939 | Identification of Molecular Diagnostic Markers for Endometriosis in Blood Lymphocytes - The invention comprises a method of identifying or predicting the predisposition to endometriosis in a female subject comprising determining the level of gene expression of at least one differentially-expressed gene or protein or peptide of peripheral blood leukocytes in a sample of peripheral blood leukocytes or peripheral blood in a subject to provide a first value, determining the level of gene expression of the at least one differentially-expressed gene or protein or peptide of said leukocytes in a control or reference standard to provide a second value, and comparing whether there is a difference between the first value and second value. | 08-20-2009 |
| 20090208940 | METHOD FOR DETECTING C. ALBICANS - A HWP1 gene sequence or fragment or variants thereof as a target region in a nucleic acid based assay for | 08-20-2009 |
| 20090208941 | Method for investigating cytosine methylations in dna - A method for sensitive and specific detection of cytosine methylation is described wherein the DNA to be analyzed is subjected to initial enrichment. More specifically, said enrichment can be effected in a methylation-specific, sequence-specific or origin-specific fashion. Thereafter, the enriched DNA is converted in a methylation-specific fashion. The converted DNA can be analyzed using various methods, particularly real-time PCR methods. | 08-20-2009 |
| 20090208942 | Method and Apparatus for Correlating Levels of Biomarker Products with Disease - In one aspect the invention is a method of testing for one or more colorectal pathologies or one or more subtypes of colorectal pathology (in one embodiment colorectal cancer) in a test individual by providing data corresponding to a level of products of selected biomarkers and applying the data to a formula to provide an indication of whether the test individual has one or more colorectal pathologies or one or more subtypes of colorectal pathology. In some aspects the method is computer based and a computer applies the data to the formula. In other aspects a computer system is configured with instructions that cause the processor to provide a user with the indication of whether the test individual has colorectal pathology. Also encompassed are kits for measuring data corresponding to the products of selected biomarkers which in some embodiments include a computer readable medium. Also encompassed are kits and methods of monitoring therapeutic efficacy of treatments for one or more colorectal pathologies. | 08-20-2009 |
| 20090208943 | Method for the High Throughput Screening of Transposon Tagging Populations and Massive Parallel Sequence Identification of Insertion Sites - Method for the identification of a gene in a transposon population, comprising isolating genomic DNA, optionally pooling the DNA, restrict the DNA in the pools using an enzyme, ligate adaptors, amplifying the adaptor-ligated fragments with primers, one of which is a primer complementary to a border of a transposon sequence, high throughput sequencing of the fragments, aligning the fragments with known sequences in a database and thereby identifying gene candidates. | 08-20-2009 |
| 20090208944 | ASSESSING OUTCOMES FOR BREAST CANCER PATIENTS TREATED WITH TAMOXIFEN - This document provides methods and materials related to assessing the likely outcome for mammals (e.g., humans) with cancer (e.g., breast cancer). For example, methods and materials that involve assessing a breast cancer patient's cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) genotype to determine the likelihood of the beast cancer patient to experience breast cancer relapse or death are provided. Methods and materials that involve assessing the likelihood that a breast cancer patient being treated with tamoxifen will experience side effects such as hot flashes also are provided. | 08-20-2009 |
| 20090208945 | Method for the Prediction of Adverse Drug Responses to Stains - The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy. Still further the invention provides polymorphic sequences and other genes. The present invention further relates to isolated polynucleotides encoding a SADR gene polypeptide useful in methods to identify therapeutic agents and useful for preparation of a medicament to treat statin induced adverse drug reactions (SADR), the polynucleotide is selected from the group comprising: SEQ ID 1-35 with allelic variation as indicated in the sequences section contained in a functional surrounding like full length cDNA for SADR gene polypeptide and with or without the SADR gene promoter sequence. | 08-20-2009 |
| 20090208946 | Rationale, Methods, and Assays for Identifying Human and Non-Human Primate Taste Specific Genes and Use Thereof in Taste Modulator and Therapeutic Screening Assays - This invention relates to novel rationale and methods for identifying human and primate taste-specific genes, including genes involved in salty taste perception, especially human salty taste perception, but also genes involved in sweet, bitter, umami, and sour taste perception, and genes involved in other taste cell or taste receptor related activities such as digestive function and digestive related diseases, taste cell turnover, immunoregulation of the oral and digestive tract, and metabolic regulation such as in diabetes and obesity, the genes identified using these methods, and assays for identifying taste modulators (enhancers or blockers) and potential therapeutics using these genes. These compounds have potential application in modulating (enhancing or blocking) taste perception, especially salty taste perception and as potential therapeutics. In addition, this invention relates to novel methods for identifying taste-specific genes that can be used as markers for different taste cell types, including sweet, bitter, umami, sour, salty, and other taste cells in mammals as well as assays that measure the activity of the sweet, bitter, umami, or sour receptor in the presence of these genes to identify modulators of sweet, bitter, umami, and sour taste and to identify therapeutics especially for treating digestive or metabolic disorders, taste loss, and oral infections. Particularly, the genes identified herein and antibodies or oligos thereto can be used as markers to identify and/or purify specific taste cells e.g., from taste cell suspensions by use of FACS or magnetic bead cell selection or other known cell purification and isolation procedures. | 08-20-2009 |
| 20090208947 | PRIMERS, METHODS AND KITS FOR AMPLIFYING OR DETECTING HUMAN LEUKOCYTE ANTIGEN ALLELES - The present invention describes primers, methods and kits for amplifying and identifying HLA alleles. Using these primers, all HLA alleles at a single locus can be amplified using either a multiplex or non-multiplex PCR approach. Within sets of the primers, control primer pairs may be used to produce control amplicons of a predetermined size from an HLA allele only if a particular HLA locus is present in the sample. The present invention further describes primers for sequencing HLA alleles following amplification. Methods and kits for using the primers are also disclosed. | 08-20-2009 |
| 20090208948 | DETECTION OF TOXIGENIC STRAINS OF CLOSTRIDIUM DIFFICILE - Primers and probes for detection of toxin-producing (toxigenic) strains of | 08-20-2009 |
| 20090208949 | PHOSPHATIDYLINOSITOL PHOSPHATE KINASE TYPE I GAMMA SPLICE VARIANTS AS BIOMARKERS AND DRUG TARGETS FOR EPITHELIAL CANCERS - The present invention relates generally to the field of phosphatidylinositol based signaling pathways, and more specifically to the use of novel members of these pathways for disease prognosis and treatment. In some aspects, the present invention relates to the use of novel splice variants of type I phosphatidylinositol phosphate kinase γ, named PIPKIγ 700 and PIPKIγ 707, to determine breast cancer and breast cancer prognosis. | 08-20-2009 |
| 20090208950 | METHODS OF IDENTIFYING AN ORGANISM FROM A HETEROGENEOUS SAMPLE - This disclosure features methods of identifying at least one organism from a heterogeneous sample. The methods include: (a) obtaining a nucleic acid from at least one organism in a heterogeneous sample; (b) imaging said nucleic acid; (c) obtaining a restriction map of said nucleic acid; and (d) correlating the restriction map of said nucleic acid with a restriction map database, thereby identifying at least one organism in the heterogeneous sample. | 08-20-2009 |
| 20090208951 | DETECTION OF T-DNA - The present invention relates to a method for the detection of transgenic DNA (tDNA) in a living being and to a kit for performing such a method. | 08-20-2009 |
| 20090208952 | UTILITY OF RET MUTANT IN DIAGNOSIS AND TREATMENT OF MELANOMA - The invention relates to a method of detecting a RET mutant in a melanoma cell. Also disclosed is a method of modulating the activity of a RET mutant in a melanoma cell with an agent that interferes with the activity of the RET mutant. | 08-20-2009 |
| 20090208953 | NEUROFIBROMIN PATHWAY MODULATORS - The present invention encompasses methods for treating neurofibromatosis and methods for screening for modulators of the neurofibromin pathway. | 08-20-2009 |
| 20090208954 | PRIMER SET FOR AMPLIFICATION OF UGT1A1 GENE, REAGENT FOR AMPLIFICATION OF UGT1A1 GENE CONTAINING THE SAME, AND THE USES THEREOF - Primer sets for amplifying target regions containing sites to be detected in the UGT1A1 gene by a gene amplification method are provided, wherein the primer sets can amplify the regions specifically. Three pairs of primer sets are used including forward primers consisting of the base sequences of SEQ ID NOs: 4 or 81, 21, and 42 as well as reverse primers consisting of the base sequences of SEQ ID NOs: 13 or 91, 29 and 48, respectively. The use of these primer sets makes it possible to amplify three target regions including parts where three types of polymorphisms (UGT1A1*6, UGT1A1*27, and UGT1A1*28) of the UGT1A1 gene are generated, respectively, in the same reaction solution at the same time. | 08-20-2009 |
| 20090208955 | METHODS FOR IDENTIFYING SEQUENCE MOTIFS, AND APPLICATIONS THEREOF - The present invention relates to methods and algorithms that can be used to identify sequence motifs that are either under- or over-represented in a given nucleotide sequence as compared to the frequency of those sequences that would be expected to occur by chance, or that are either under- or over-represented as compared to the frequency of those sequences that occur in other nucleotide sequences, and to methods of scoring sequences based on the occurrence of these sequence motifs. Such sequence motifs may be biologically significant, for example they may constitute transcription factor binding sites, mRNA stability/instability signals, epigenetic signals, and the like. The methods of the invention can also be used, inter alia, to classify sequences or organisms in terms of their phylogenetic relationships, or to identify the likely host of a pathogenic organism. The methods of the present invention can also be used to optimize expression of proteins. | 08-20-2009 |
| 20090208956 | PRIMER SET FOR AMPLIFYING CYP2C9 GENE, REAGENT FOR AMPLIFYING CYP2C9 GENE CONTAINING THE SAME, AND THE USES THEREOF - A primer set for amplifying a region including a site to be detected of CT2C9*3 in the C-YT2C9 gene by a gene amplification method is provided, wherein the primer set can amplify the region specifically. A pair of primer set is used including a forward primer consisting of the base sequence of SEQ ID NO: 4 as well as a reverse primer consisting of the base sequence of SEQ ID NO: 17. The use of this primer set makes it possible to specifically and efficiently amplify a target region including the site where a polymorphism, CYP2C9*3, of the CYP2C9 gene is generated. | 08-20-2009 |
| 20090208957 | Alternate labeling strategies for single molecule sequencing - Systems and methods of enhancing fluorescent labeling strategies as well as systems and methods of using non-fluorescent and/or non-optic labeling strategies, e.g., as with single molecule sequencing using ZMWs, are described. | 08-20-2009 |
| 20090208958 | METHODS AND KITS FOR DETECTING SINGLE NUCLEOTIDE POLYMORPHISMS OF CHROMOSOME IMPLICATED IN PREMATURE CANITIES - Methods and kits for diagnosing a predisposition to premature canities in an individual are disclosed. A method for diagnosing a predisposition to premature canities in an individual comprises detecting at least one SNP marker of the human chromosome 9, selected from the group consisting of rs306534, rs3739902, rs575916, and rs365297. A kit for diagnosing a predisposition to premature canities comprises a means for detecting in a sample of human genetic material, the allele of a SNP marker of the human chromosome 9 selected from the markers rs306534, rs3739902, rs575916 and rs365297; and a positive or negative control. | 08-20-2009 |
| 20090208959 | FLUORESCENCE-LABELED OLIGONUCLEOTIDE TO DETECT NUCLEIC ACID AND METHOD FOR ACQUIRING INFORMATION ABOUT DOUBLE-STRAND FORMATION BY USING FLUORESCENCE-LABELED OLIGONUCLEOTIDE TO DETECT NUCLEIC ACID - A fluorescence-labeled oligonucleotide to detect nucleic acid has a base sequence complementary to the nucleic acid chain to be detected and changes in fluorescence characteristics upon double-strand formation with the nucleic acid chain to be detected. The label is an intercalating fluorescent dye and a non-intercalating fluorescent dye. The intercalating fluorescent dye acquires excited energy upon absorption of light and gives it to the non-intercalating fluorescent dye, and the non-intercalating fluorescent dye receives the excited energy to emit light. | 08-20-2009 |
| 20090208960 | METHODS FOR IDENTIFYNG CELLULAR MODULATORS OF DISAGGREGATION ACTIVITY OR AGGREGATION ACTIVITY IN AN ANIMAL - Methods for identifying a cellular modulator of a biological disaggregation activity or a biological aggregation activity of an animal are provided. Methods for identifying a compound which modulates biological disaggregation activity or a biological aggregation activity in a biological sample are provided. | 08-20-2009 |
| 20090208961 | COMPOSITIONS AND METHODS FOR USE IN ANALYTICAL REACTIONS - Compositions, methods, substrates and systems for use in analysis of single molecule reactions and particularly single molecule nucleic acid sequence analysis. Compositions that include non-reactive, distinguishable or undetectable competitive substrates for the reaction system of interest are provided, as well as their use in systems and substrates for such applications, such compounds typically preferably polyphosphate chains or analogous structures. | 08-20-2009 |
| 20090208962 | MARKERS FOR BREAST CANCER - Correlations between polymorphisms and breast cancer are provided. Methods of diagnosing, prognosing, and treating breast cancer are provided. Systems and kits for diagnosis, prognosis and treatment of breast cancer are provided. Methods of identifying breast cancer modulators are also described. | 08-20-2009 |
| 20090208963 | Gene Involved in V(D)J recombination and/or DNA repair - The invention relates to a new gene and protein involved in V(D)J recombination and repair. The invention also relates to methods of diagnosis and therapy using these genes and protein. The invention also relates to transgenic animals over- and under-expressing said gene. | 08-20-2009 |
| 20090208964 | Soybean Polymorphisms and Methods of Genotyping - Polymorphic soybean DNA loci are useful for genotyping between at least two varieties of soybean. Sequences of the loci are useful for designing primers and probe oligonucleotides for detecting polymorphisms in soybean DNA. Polymorphisms are useful for genotyping applications in soybean. The polymorphic markers are useful to establish marker/trait associations, e.g. in linkage disequilibrium mapping and association studies, positional cloning and transgenic applications, marker-aided breeding and marker-assisted selection, and identity by descent studies. The polymorphic markers are also useful in mapping libraries of DNA clones, e.g. for soybean QTLs and genes linked to polymorphisms. | 08-20-2009 |
| 20090208965 | AUTOMATED METHOD FOR DETECTING CANCERS AND HIGH GRADE HYPERPLASIAS - Automated methods for detecting cancer and related hyperplasias in biological samples. | 08-20-2009 |
| 20090208966 | METHOD FOR REMOVING A FLUID SUBSTANCE FROM A CLOSED SYSTEM - A cap which can form an essentially leak-proof seal with an open-ended vessel capable of receiving and holding fluid specimens or other materials for analysis. To minimize potentially contaminating contact between a fluid sample present in the vessel and humans or the environment, the present invention features a cap having a frangible seal which is penetrable by a plastic pipette tip or other fluid transfer device. The cap further includes a filter for limiting dissemination of an aerosol or bubbles once the frangible seal has been pierced. The filter is positioned between the frangible seal and a retaining structure. The retaining structure is positioned on the cap above the filter and may be used to contain the filter within the cap. The material of the retaining structure may be penetrable by a fluid transfer device. | 08-20-2009 |
| 20090208967 | Genetic Polymorphisms As Predictive Diagnostics For Adverse Drug Reactions (ADR) And Drug Efficacy - The invention provides diagnostic methods and kits including oligo and/or polynucleotides or derivatives, including as well antibodies determining whether a human subject is at risk of getting adverse drug reaction after statin therapy or whether the human subject is a high or low responder or a good a or bad metabolizer of statins. The invention provides further diagnostic methods and kits including antibodies determining whether a human subject is at risk for a cardiovascular disease. Still further the invention provides polymorphic sequences and other genes. | 08-20-2009 |
| 20090208968 | COMPOSITIONS AND METHODS FOR DETECTION OF HEPATITIS A VIRUS NUCLEIC ACID - Nucleic acid oligomeric sequences and in vitro nucleic acid amplification and detection methods for detecting the presence of HAV RNA sequences in samples are disclosed. Kits comprising nucleic acid oligomers for amplifying and detecting HAV nucleic acid sequences are disclosed. | 08-20-2009 |
| 20090208969 | Polynucleotides and Polypeptides Encoding Receptors - Receptor polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing receptor polypeptides and polynucleotides in the design of protocols for the treatment of diseases and diagnostic assays for such conditions. | 08-20-2009 |
| 20090215031 | Mutants of mycobacteria and process thereof - The present invention provides mutant | 08-27-2009 |
| 20090215032 | ANALYTE DETECTION USING BARCODED POLYMERS - The invention relates to methods and systems for identifying, quantitating and/or analyzing analytes from samples. The analytes may be organic or inorganic in nature and include but are not limited to pathogens such as viruses. | 08-27-2009 |
| 20090215033 | Prediction of Clinical Outcome Using Gene Expression Profiling and Artificial Neural Networks for Patients with Neuroblastoma - A method of predicting the outcome of a patient with neuroblastoma that includes obtaining experimental data on gene selections. The gene selection functions to predict the outcome of a patient with neuroblastoma when the expression of that gene selection is compared to the identical selection from a non-neuroblastoma cell or a different type of neuroblastoma cell. The invention also includes a method of targeting at least one product of a gene that includes administration of a therapeutic agent. The invention also includes the use of a gene selection for predicting the outcome of patient with neuroblastoma. | 08-27-2009 |
| 20090215034 | Method for selectively detecting subsets of nucleic acid molecules - Method for selectively detecting nucleic acid molecules comprising structural aberrations that are capable of being convented into nicks comprising generating linear nucleic acids from a selected nucleic acid substrate population; denaturing and re-annealing the linear nucleic acids to form nucleic acid duplexes; masking the nucleic acid duplex termini and internal structural aberrations with a masking component; modifying the masked nucleic acids by introducing nicks therein using at least an enzyme possessing endonuclease activity: labelling the modified nucleic acids with labelled nucleotides via nucleic acid nick translation with at least an enzyme displaying a nucleic acid polymerase activity; and selecting and identifying the labelled nucleic acid. | 08-27-2009 |
| 20090215035 | METHOD OF ASSESSING CANCEROUS CONDITIONS AND REAGENT FOR DETECTING GENE PRODUCT TO BE USED IN THE METHOD - It is intended to provide a method of assessing cancerous conditions, which is useful in diagnosing cancer in a therapy or a preventive therapy for cancer diseases or a maintenance therapy therefor, and a reagent for detecting a gene product to be used in the above method. The cancerous conditions of a human-origin specimen is assessed by using, as an indication, the content of a gene product, which shows an increase or a decrease in the expression thereof due to an unusual alternative splicing, from gene products obtained from human PTCH1 gene contained in the human-origin specimen. To measure the content, use is preferably made of, concerning at least one base sequence selected from the group consisting of (a) the base sequences represented by SEQ ID NOS:1 to 4 and (b) base sequences derived from any of the base sequences represented by SEQ ID NOS:1 to 4 by deletion, substitution and/or insertion of one to several bases and having an activity of being hybridized with a chain complementary to the corresponding base sequence selected from the base sequences represented by SEQ ID NOS:1 to 4 under stringent conditions, a probe sequence-specifically binding to the complementary chain of the above-described base sequence or a chemical modification thereof. | 08-27-2009 |
| 20090215036 | Genetic Alterations Useful For The Response Prediction of Malignant Neoplasia to Taxane-Based Medical Treatments - The invention provides novel compositions, methods and uses, for the diagnosis, prognosis, prediction, prevention and aid in treatment of malignant neoplasia such as breast cancer, ovarian cancer, gastric cancer, colon cancer, esophageal cancer, mesenchymal cancer, bladder cancer or non-small cell lung cancer. Genes that are chromosomally amplified in breast tissue of breast cancer patients are disclosed. Further disclosed are chromosomally amplified genes and non-amplified genes that correlate to Taxane resistance, Taxane benefit or adverse Taxane reaction, which can be used as an aid to make therapy dicisions. | 08-27-2009 |
| 20090215037 | Dynamically expressed genes with reduced redundancy - This invention relates to the identification and use of a subset of transcribed genes, wherein the expression of genes in the subset are able to classify cells among a plurality of classes. Methods for the identification or selection of such subsets are provided, along with computer implemented means for the application of the methods. The invention further provides physical embodiments based on the gene sequences of the subsets as well as methods for the use of the identified sets of gene sequences to classify a cell or tissue sample. | 08-27-2009 |
| 20090215038 | Prediction of Metastasis - The present invention relates to the prediction of metastasis by determining RKIP expression levels, and to products and kits adapted for such methods. In some embodiments, the present invention relates to methods of assigning a treatment or monitoring regime to a cancer patient according to the level of RKIP expression. | 08-27-2009 |
| 20090215039 | INVESTIGATIONS - A method of investigation a sample is provided, the sample being a mixture of DNA arising from more than one source. The method includes analysing the sample to obtain a genotype for the DNA present in the sample and assigning a prior probability distribution to the genotype. The likelihood function is considered and a posterior probability distribution for the genotype is established. In this way a probabilistic assessment of the genotype of the major or minor contributor to the sample can be obtained. This is beneficial over prior methods which use a deterministic method, and so involve the use of rule based methods. | 08-27-2009 |
| 20090215040 | HUMAN AUTISM SUSCEPTIBILITY GENE ENCODING A TRANSMEMBRANE PROTEIN AND USES THEREOF - The present invention discloses the identification of a human autism susceptibility gene, which can be used for the diagnosis, prevention and treatment of autism and related disorders, as well as for the screening of therapeutically active drugs. The invention more specifically discloses that the ATP2B2 gene on chromosome 3 and certain alleles thereof are related to susceptibility to autism and represent novel targets for therapeutic intervention. The present invention relates to particular mutations in the ATP2B2 gene and expression products, as well as to diagnostic tools and kits based on these mutations. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of Asperger syndrome, pervasive developmental disorder, childhood disintegrative disorder, mental retardation, anxiety, depression, attention deficit hyperactivity disorders, speech delay or language impairment, epilepsy, metabolic disorder, immune disorder, bipolar disease and other psychiatric and neurological diseases including schizophrenia. | 08-27-2009 |
| 20090215041 | MULTIPLE SNP FOR DIAGNOSING COLORECTAL CANCER, MICROARRAY AND KIT COMPRISING THE SAME, AND METHOD OF DIAGNOSING COLORECTAL CANCER USING THE SAME - Provided is a multiple single nucleotide polymorphism (SNP) for colorectal cancer diagnosis, a microarray and a kit including a polynucleotide having the SNP, and a method of diagnosing colorectal cancer using the SNP. Early diagnosis of incidence or possibility of colorectal cancer can be effectively performed by using the method. | 08-27-2009 |
| 20090215042 | NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS OF USE THEREOF FOR DIAGNOSIS - Novel splice variants, amino acid sequences and nucleotide sequences thereof, and methods of using same. | 08-27-2009 |
| 20090215043 | Polymorphic GHSR Nucleic Acids And Uses Thereof - The present invention relates to methods and compositions for predicting the risk of obesity. In particular, the present invention provides methods and compositions for determining a subject's risk of obesity based on the presence of polymorphisms in the growth hormone secretagogue receptor (GHSR). | 08-27-2009 |
| 20090215044 | Receptor in Dendritic Cells - GPBAR1 for use as a target for selective inhibition of Th1 mediated immune responses. | 08-27-2009 |
| 20090215045 | Methods and Compositions for Vitamin K Epoxide Reductase - The present invention provides a method of identifying a human subject having increased or decreased sensitivity to warfarin, comprising detecting in the subject the presence of a single nucleotide polymorphism in the VKOR gene, wherein the single nucleotide polymorphism is correlated with increased or decreased sensitivity to warfarin, thereby identifying the subject having increased or decreased sensitivity to warfarin. | 08-27-2009 |
| 20090215046 | Novel nucleotide and amino acid sequences, and assays methods of use thereof for diagnosis of colon cancer - Novel markers for colon cancer that are both sensitive and accurate. These markers are overexpressed in colon cancer specifically, as opposed to normal colon tissue. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of colon cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between colon cancer and non-cancerous states. | 08-27-2009 |
| 20090215047 | Methods of Detecting Viability-Associated Molecules - A method of detecting a molecule associated with viability of one or more cells or organisms in a sample comprises the initial step of contacting the sample with an enzyme, which enzyme is capable of adding or removing a chemical moiety to or from a nucleic acid molecule in the presence of the molecule associated with viability of the of the one or more cells or organisms. This thereby generates a novel detectable nucleic acid molecule. The next step involves detecting the presence of the molecule associated with viability of the one or more cells or organisms by detecting the novel nucleic acid molecule generated only in the presence of the molecule associated with viability of the one or more cells or organisms. A most preferred molecule associated with viability is ATP, although NAD may also be detected. A preferred enzyme for use in the methods is ligase. The method has numerous applications, in particular in monitoring viability of cells, toxicology testing and determining whether there is contamination in a sample or on a surface. Kits are also provided for carrying out the methods. | 08-27-2009 |
| 20090215048 | METHOD OF IN-SILICO IMPROVEMENT OF ORGANISMS USING THE FLUX SUM OF METABOLITES - The present invention relates to an in silico method for improving an organism on the basis of the flux sum (φ) of metabolites, and more particularly to a method for screening key metabolites that increase the production yield of a useful substance, the method comprising defining the metabolite utilization of an organism for producing a useful substance as flux sum and perturbing the flux sum, as well as a method for improving an organism producing a useful substance, the method comprising deleting and/or amplifying genes associated with the aforementioned screened key metabolites. According to the present invention, the correlation between specific metabolites and useful substance production can be exactly predicted, so that it is possible to develop an organism having increased useful substance production by introducing and/or amplifying and/or deleting genes expressing enzymes associated with the specific metabolites. In addition, it is also possible to increase the production of a useful substance by adding specific metabolites during culture. | 08-27-2009 |
| 20090215049 | NOVEL LITAF BINDING SITE PEPTIDES AND METHODS OF USING THE SAME - The invention provides molecules containing nucleic acid sequences for fragments of LPS-induced TNF-α factor (LITAF) and vectors containing these sequences. Also provided are molecules that contain the peptide sequence SQTWREPGAAGSPFHL, or homologs thereof. Such molecules may be useful in the treatment of diseases that relate to the expression of TNF-α, where treatment involves the modulation of this expression. The invention also provides methods for identifying compounds that inhibit or enhance the transcription of TNF-α. | 08-27-2009 |
| 20090215050 | SYSTEMS AND METHODS FOR POINT-OF-CARE AMPLIFICATION AND DETECTION OF POLYNUCLEOTIDES - Compositions and methods for amplifying and detecting solution-state polynucleotide targets in a single device are described. In one aspect, a method for a coupled isothermal amplification and detection process utilizes a coated solid support, including a solid substrate, a cationic layer, and a plurality of target-specific probes attached to the coated solid support. Polynucleotide targets in the sample are amplified by an isothermal amplification process involving in situ hybridization onto the coated solid support. The entire process can be carried out with a high degree of specificity under low salt conditions in less than one hour. Further aspects of the present invention include methods for coupled hybridization/detection of polynucleotide targets, coated silicon biosensors optimized for use with the coupled detection systems to provide visual detection of polynucleotide targets under visible light conditions, and kits for practicing the above described methods. | 08-27-2009 |
| 20090215051 | Novel Assay - The invention relates to a translational recoding reporter construct comprising: a first fluorescent protein coding sequence; a second fluorescent protein coding sequence encoding a fluorescent protein different from the first fluorescent protein; and a linker sequence interposed between the first and second fluorescent protein coding sequence; wherein the a first fluorescent protein coding sequence and the second fluorescent protein coding sequence are out-of-frame with respect to each other but are co-expressed as a single fusion polypetpdie upon recoding. The invention also relates to methods of use of the construct in screening modulators of recoding. | 08-27-2009 |
| 20090215052 | Composition for permeabilizing the walls of microorganisms comprising the combination of ethylenediaminetetraacetic acid (EDTA) and polyethyleneimine (PEI) - The present invention relates to a composition for permeabilizing the walls of microorganisms, comprising the combination of polyethyleneimine (PEI) and ethylenediaminetetraacetic acid (EDTA), and to a method using said composition for counting and detecting, in a targeted manner, the microorganisms on a membrane. The invention also relates to a kit comprising probes suitable for implementing said method. | 08-27-2009 |
| 20090215053 | Vitro Method for the Prognosis of Progression of a Cancer and of the Outcome in a Patient and Means for Performing Said Method - The present invention relates to the prognosis of the outcome of a cancer in a patient, which prognosis is based on the quantification of one or several biological markers that are indicative of the presence of, or alternatively the level of, the adaptive immune response of said patient against said cancer. | 08-27-2009 |
| 20090215054 | PROGNOSIS INDICATORS FOR SOLID HUMAN TUMORS - The present teachings provide methods for predicting the clinical outcome of the treatment of human solid tumors. In some embodiments, the method includes measuring in the cells of a tumor the expression level of a set of genes whose change is related to chromosomal instability; taking a statistical measure of the expression level of the set of measured genes; and if the statistical measure of the expression level of the set of measured genes is elevated, determining that the prognosis is poor. Another aspect of the present teachings is the sets of genes, which are useful in predicting the outcome of treatment of solid tumors. | 08-27-2009 |
| 20090215055 | Genetic Brain Tumor Markers - The invention relates to method of genetic analysis for the prediction of treatment sensitivity and survival prognosis of patients with brain tumors, especially oligodendroglial tumors. The invention provides a method for producing a classification scheme for oligodendroglial tumors comprising the steps of a) providing a plurality of reference samples, said reference samples comprising cell samples from a plurality of reference subjects suffering from oligodendroglial tumors; b) providing reference profiles by establishing a gene expression profile for each of said reference samples individually; c) clustering said individual reference profiles according to similarity; and d) assigning an oligodendroglial tumor class to each cluster. | 08-27-2009 |
| 20090215056 | Assay for Methylation in the GST-PI Gene - A diagnostic or prognostic assay is disclosed for a disease of condition characterized by abnormal methylation of cytosine at side or sites within the glutathione-S-transferase (GST) Pi gene and/or its regulatory flanking sequences (e.g., prostate cancer and liver cancer). The assay comprises: (i) isolating DNA from said subject, and (ii) determining (e.g., by selective PCR amplification) the presence of abnormal methylation of cytosine at a site or sites within the GST-Pi gene and/or its regulatory flanking sequences. | 08-27-2009 |
| 20090215057 | Analysis molecule and method for the analysis of a nucleotide position in a nucleic acid - The invention relates to an analysis molecule for the analysis of one or more nucleotide positions in a nucleic acid. The positions are in a first state or an alternative second state. The invention further relates to methods that include the use of the analysis molecule. The invention further relates to kits that include the analysis molecule. | 08-27-2009 |
| 20090215058 | METHODS FOR SCREENING, PREDICTING AND MONITORING PROSTATE CANCER - Biomarkers are identified by analyzing gene expression data using support vector machines (SVM) to rank genes according to their ability to separate prostate cancer from normal tissue. Expression products of identified genes are detected in patient samples, including prostate tissue, serum, semen and urine, to screen, predict and monitor prostate cancer. | 08-27-2009 |
| 20090215059 | Molecular Diagnosis of Bacteremia - A highly specific assay can be used for the detection of bacteremia in the clinical setting. The ubiquitous background endogenous DNA present in all PCR reagents is eliminated using a restriction endonuclease digestion. Universal primers for eubacteria are used for detection, and specific primers or probes for bacterial species can be used for identification of species. | 08-27-2009 |
| 20090215060 | HIGH THROUGHPUT METHODS FOR SAMPLING SEEDS - A high-throughput method is provided for analyzing individual seeds in a population of seeds. The method generally includes removing a tissue sample from at least one or more seeds in the population of seeds while preserving germination viability of the at least one or more seeds from which the tissue sample is taken, depositing the tissue sample into an individual compartment of a sample tray, contacting the tissue sample with an extraction buffer to remove DNA from the sample, and analyzing the extracted DNA for the presence or absence of a transgene of interest. The extraction buffer may be present in the individual compartment of the sample tray before the tissue sample is deposited into the individual compartment. | 08-27-2009 |
| 20090215061 | METHODS AND COMPOSITIONS FOR VITAMIN K EPOXIDE REDUCTASE - The present invention provides a method of identifying a human subject having increased or decreased sensitivity to warfarin, comprising detecting in the subject the presence of a single nucleotide polymorphism in the VKOR gene, wherein the single nucleotide polymorphism is correlated with increased or decreased sensitivity to warfarin, thereby identifying the subject having increased or decreased sensitivity to warfarin. | 08-27-2009 |
| 20090215062 | COMPOSITION AND METHOD FOR SEQUENCING NUCLEIC ACID - A composition for sequencing DNA is provided and comprises a nuclease and a nuclease-resistant sequencing primer. A method of preparing DNA for sequencing and a method of sequencing DNA are also provided. The method of sequencing DNA can comprise contacting amplification reaction products with the composition under conditions in which excess amplification primer is degraded by the nuclease and the nuclease-resistant sequencing primer is essentially non-degraded. | 08-27-2009 |
| 20090215063 | Phosphospecific PAK antibodies and diagnostic kits - The present invention relates to the use of phosphorylated p21-activated protein kinases (PAK), especially PAK4, as biomarkers of tumorogenesis. The present invention contemplates the use of phosphospecific antibodies for detecting phosphorylated PAK from mammalian biopsies, as well as screening assays for identifying compounds that modulate PAK activity. Also contemplated is a method for determining a subset of a given population that is amenable to treatment with a compound that modulates PAK activity. | 08-27-2009 |
| 20090215064 | QUANTITATIVE ASSESSMENT OF INDIVIDUAL CANCER SUSCEPTIBILITY BY MEASURING DNA DAMAGE-INDUCED MRNA IN WHOLE BLOOD - Heparinized human whole blood from patients with invasive breast cancer, with (multiple primary) and without (single primary) a second primary cancer, and from unaffected controls was stimulated with 0.1-10 Gy of radiation and incubated at 37° C. for 2 hours. P21 and PUMA mRNA were then quantified. The results suggest that cancer susceptibility represented by the multiple primary cases was significantly related to over-reaction of p21 mRNA, and not PUMA. | 08-27-2009 |
| 20090215065 | ATLASTIN - The present invention relates to methods and compositions of a novel gene and the peptide encoded by the gene. Mutations in the gene, named atlastin, are factors in the disease Hereditary Spastic Paraplegia and related disorders. The present invention will be used for the in the research, diagnosis and treatment of these disabling diseases. | 08-27-2009 |
| 20090215066 | METHOD AND ASSAY FOR EARLY DIAGNOSIS OF PROSTATE CANCER - A method and assay are described for determining prostate cancer and the general stage of progression of such cancer by quantifying levels of promoter methylation of gal-3, optionally in combination with the quantification of the level of GSTP1 promoter methylation, where the method and assay are non-invasive to a subject and can detect any of Stages I-IV prostate cancer. | 08-27-2009 |
| 20090215067 | NOVEL LIPIDS FOR TRANSFECTION OF NUCLEIC ACIDS - Cationic lipid compositions are provided that are useful for efficient delivery of macromolecules, such as nucleic acids, into a wide variety of eukaryotic cell types. Methods for using the compositions also are provided. | 08-27-2009 |
| 20090215068 | THERMOSTABLE PROTEINASES FROM THERMOPHILIC BACTERIA - The present invention relates to the preparation of a method for the preparation of nucleic acid samples, including the steps of adding at least one non-specific thermophilic enzyme to a sample containing nucleic acid for testing, and incubating said sample for a preferred period at 65-80° C. as required to effect one or more of lysis of cells, digestion of proteins, digestion of cell-wall enzymes, via activity of said thermophilic enzyme, wherein said thermophilic enzyme is substantially stable and active at 65-80° C. but which is readily autolysed and/or denatured when said sample is incubated at or above 90° C. | 08-27-2009 |
| 20090220947 | Biomarkers for toxic algae - The present invention is directed toward biomarkers that identify characteristics of algae. The invention is further directed toward biomarkers that serve to identify algae species and strains of algae species as well as detect the presence of algal toxins. Additional embodiments feature methods utilizing algal biomarkers and polypeptides that can serve as biomarkers. | 09-03-2009 |
| 20090220948 | Methods and Device for Transmitting, Enclosing and Analysing Fluid Samples - A microfluidic device for analysing a fluid sample comprises at least one sample transmission channel; at least one multi-functional channel; and at least one reactor module which provides a fluid connection between the sample transmission channel and the multi-functional channel. Each reactor module comprises at least one reaction chamber, having at least one inlet in fluid communication with the sample transmission channel(s); and at least one fluid isolation chamber, which is in fluid communication with the outlet(s) of the reaction chamber(s). The fluid isolation chamber serves to isolate the fluid sample from the multi-functional channel(s). | 09-03-2009 |
| 20090220949 | Mutations Associated with the Long QT Syndrome and Diagnostic Use Thereof - The present invention is based on the identification of new mutations in KCNQ1 (also termed KvLQTI), KCNH2 (also termed HERG), SCN5A, KCNE1 (also termed minK), KCNE2 (also termed MiRP) genes that encode ionic channels involved in cardiac electrical activity and are potentially responsible for the Long QT Syndrome. According to a main aspect, the invention relates to nucleic acids, oligonucleotides and polynucleotides and mRNA, containing sequences of KCNQ1, KCNH2 SCN5A, KCNE1, KCNE2 genes and cDNAs in a mutated form and to respective variant proteins thereof. A preferred embodiment of the present invention is represented by a diagnostic method based on the identification of a group of about 70 non-private mutations in the KCNQ1, KCNH2 and SCN5A genes, detected at high frequency. The method, which is able to identify about 40% of the probands, is non exclusively based on identification of mutations that are described and characterized in this invention where said identification has both prognostic and diagnostic value for the Long QT Syndrome. | 09-03-2009 |
| 20090220950 | SIMULTANEOUS QUANTIFICATION OF NUCLEIC ACIDS IN DISEASED CELLS - Processes and methods for the simultaneous quantification of nucleic acids in diseased cells that are based on real-time PCR are provided. The real-time PCR protocol is an excellent tool for reliable quantification of in vitro drug screening and evaluation protocols to determine the efficacy of potential anti-viral agents. Quantification using these simultaneous PCR cycle threshold (Ct) detection techniques during one-step real-time RT-PCR (Applied Biosystems, CA) eliminates the variability resulting from quantification of end-point RT-PCR products. In addition, the mitochondrial toxicity assay is an added tool to assess potential side-effects for these chemotherapeutic agents. | 09-03-2009 |
| 20090220951 | Methods and compositions for classifying bacillus bacteria - A method of classifying a | 09-03-2009 |
| 20090220952 | Compositions And Methods For Analyzing Protein Interactions - The present invention relates to compositions and methods for analyzing and modulating (e.g., enhancing or inhibiting) protein-protein interactions. In particular, compositions and methods of the present invention find use in identifying, reconstituting and characterizing protein-protein interactions, identifying binding subunits, and drug screening. The methods and compositions of the invention may also be used to identify agents that may agonize or antagonize a protein-protein interaction (e.g., using test compounds). | 09-03-2009 |
| 20090220953 | IDENTIFICATION OF ANCESTRAL HAPLOTYPES AND USES THEREOF - The present invention relates to the identification of haplospecific geometric elements (HGEs) in a multigene cluster comprising genes encoding complement control proteins. The present invention also relates to methods of performing genomic matching techniques (GMT) which enables the identification of HGEs of a duplicated region within a haplotype block. HGEs identified using the methods of the invention can also be analysed to determine if they are markers for a trait of interest such as a disease trait. Furthermore, the present invention relates to methods of determining an individual's susceptibility or predisposition to age-related macular degeneration, recurrent spontaneous abortion, Sjögren's Syndrome and/or psoriasis vulgaris by analysing the genotype of the individual within a multigene cluster comprising genes encoding complement control proteins. | 09-03-2009 |
| 20090220954 | METHODS OF DIAGNOSING CARDIOVASCULAR DISEASE - Methods are disclosed for diagnosing increased risk of cardiovascular disease in a subject. | 09-03-2009 |
| 20090220955 | METHODS AND COMPOSITION TO GENERATE UNIQUE SEQUENCE DNA PROBES LABELING OF DNA PROBES AND THE USE OF THESE PROBES - The invention relates generally to the field of identification of DNA sequences, genes or chromosomes. Methods and composition to obtain Unique Sequence DNA probes are provided. Composition comprises of any double stranded DNA containing Unique Sequences from which the repetitive sequences are eliminated according to the method described in this invention. The invention also relates to the preservation of cells that have been identified after immunuomagnetic selection and fluorescent labeling in order to further interrogate the cells of interest. Furthermore the invention relates to genetic analysis of cells that have been identified after immunomagnetic selection and fluorescent labeling. | 09-03-2009 |
| 20090220956 | Prediction of Local Recurrence of Breast Cancer - The invention relates to the field of medicine, in particular to cancer, more specifically breast cancer, most specifically to a method to predict the local recurrence of breast cancer after breast conserving therapy. It has been demonstrated that a classification on basis of the similarity of the gene expression profile to the gene expression profile of (serum) activated fibroblasts is able to distinguish significantly in risk of local recurrence in breast cancer patients. | 09-03-2009 |
| 20090220957 | MEMBRANE ASSAY METHOD - The present invention provides an assay method for a cell-containing body sample, said method comprising treating said sample under conditions whereby to cause cell lysis, preferably by means of a detergent; and subjecting the thus-generated lysed sample to conditions causing the cleavage of nucleic acid molecules. The invention additionally provides the use of nucleic acid cleavage conditions in enhancing a membrane assay, a device for carrying out such an assay, and a kit for use in the assay. | 09-03-2009 |
| 20090220958 | METHOD FOR DIAGNOSING HEPATIC DISEASES AND SCREENING METHOD OF MOLECULES FOR TREATMENT OF HEPATIC DISEASE - The invention relates to a method for diagnosticating hepatic diseases consisting in measuring an apolipoprotein A4 expression in hepatic cells or tissues and in the circulation (blood, plasma, serum. A method for screening molecules for treating said diseases by bringing into contact said compounds with a mammal and for measuring the apolipoprotein A4 expression in said hepatic origin cells or in the circulation of said mammal is also disclosed. | 09-03-2009 |
| 20090220959 | MARKERS OF DEFINITIVE ENDODERM - Disclosed herein are reagent-cell complexes comprising one or more definitive endoderm cells. Also described herein are compositions for detecting definitive endoderm. Method of enriching, isolating and/or purifying definitive endoderm cells are also disclosed. | 09-03-2009 |
| 20090220960 | LUCIFERASE GENE OPTIMIZED FOR USE IN IMAGING OF INTRACELLULAR LUMINESCENCE - The present invention provides a gene construct encoding pH insensitive luciferase for visualizing intracellular information, wherein an intracellular expression activity is higher compared with a gene construct of luciferase derived from a firefly. | 09-03-2009 |
| 20090220961 | Fluorescent Primer System For Detection Of Nucleic Acids (Q Priming) - The present invention is directed to a self-quenching primer comprising; a fluorophore that can be quenched by guanine; an oligonucleotide sequence that forms a hairpin; an oligonucleotide that is a target specific sequence and; use in amplification reactions, particularly in polymerase chain reactions, during which the fluorophore is released thereby emitting fluorescence. | 09-03-2009 |
| 20090220962 | MICROGININ PRODUCING PROTEINS AND NUCLEIC ACIDS ENCODING A MICROGININ GENE CLUSTER AS WELL AS METHODS FOR CREATING NOVEL MICROGININS - The invention provides for nucleic acid molecules enabling the synthesis of microginin and microginin analogues. The invention also provides for methods for identifying microginins as well creating microginins which may not be found in nature. | 09-03-2009 |
| 20090220963 | KIT SUITABLE FOR SCREENING AND ESTABLISMENT OF OPTIMAL AMPLIFICATION CONDITION IN PCR CONSTRUCTED WITH DRIED-FORMULATED PCR REAGENT AND METHOD FOR PRODUCING THE SAME - The present invention relates to a kit for screening and establishing optimal amplification condition for individual PCR using a dried-formulated PCR reagent which is composed of different combinations of various components affecting PCR result, to provide a method for screening and establishment of optimal amplification in PCR constructed with a dried-formulated PCR reagent. According to the present invention, researchers can perform PCR under the optimal amplification conditions appropriate for individual PCR even with a PCR-related product constructed from a dried-formulated PCR reagent, suggesting that a unique target gene can be efficiently amplified by PCR constructed with a dried-formulated PCR reagent under the more appropriate conditions. | 09-03-2009 |
| 20090220964 | METHODS FOR DIAGNOSING AND TREATING CANCERS VIA MANIPULATIONS OF A...PATHWAY - Methods for diagnosing, treating, and screening for cancer based on manipulations of a newly discovered pVHL dependent, non-degradative ubiquitylation pathway of Rpb1. In particular, methods comprising the use of biomarkers implicating the pathway, and promoters of either or both of P1465 hydroxylation and CTD Ser-5 phosphorylation of Rpb1. Specifically, the methods may be used to inhibit tumor growth, including, in particular, carcinomas such as renal clear cell carcinoma. | 09-03-2009 |
| 20090220965 | METHODS FOR PROGNOSING THE RECURRENCE OF GASTROINTESTINAL AND OTHER CANCERS USING THE SHC PROTEINS - The invention relates to methods for prognosing the recurrence of gastrointestinal and other cancers using tyrosine phosphorylated Shc (PY-Shc) and/or p66-Shc. | 09-03-2009 |
| 20090220966 | THERMOCYCLER AND SAMPLE PORT - The invention relates to continuous flow systems, in particular thermocyclers for the automated and continuous cycling of fluid between a plurality of temperature zones in the amplification of nucleic acids. The invention also relates to an improved sample port for introducing a volume of a liquid sample into a continuous flow system. | 09-03-2009 |
| 20090220967 | Systemic Carnitine Deficiency Gene and Uses Thereof - The gene responsible for systemic carnitine deficiency was found to be the OCTN2 gene involved in the transportation of organic cations. This invention enables tests for this disease by detecting whether or not the OCTN2 gene has a mutation. Furthermore, systemic carnitine deficiency can be treated using the normal OCTN2 gene and its protein. | 09-03-2009 |
| 20090220968 | Methods and Apparatus for Near Field Irradiation - Irradiation methods and apparatus configured to deliver power, via electromagnetic fields at a variety of frequencies and power levels, in a localized fashion to a target area. In one example, an electromagnetic field generator is disposed on a substrate and configured to deliver power via electromagnetic energy to a thin region proximate to (above) a surface of the substrate, wherein electromagnetic field intensity decreases significantly beyond the thin region. Such methods and apparatus are particularly useful in a wide variety of processes involving chemical and/or physical interactions in connection with a sample of interest located in the thin region. In different aspects, irradiator apparatus may be configured as disposable devices, and/or used in combination with one or more microfluidic or sensing components, for a variety of medical/laboratory/diagnostic methods and instrumentation implementations. | 09-03-2009 |
| 20090220969 | Identifying and quantifying small RNAs - One-step RT-PCR methods, compositions and kits for the detection and quantification of small RNAs in a sample are disclosed. The one-step RT-PCR approach involves polyadenylation of a small RNA followed by reverse transcription with a first primer containing a poly(T) sequence and at least two 3′ nucleotides complementary to the 3′ terminal end nucleotides of the small RNA, to produce a cDNA. This may be followed by PCR amplification using the same first primer as the revere primer and a second, forward primer in which a portion of its sequence is complementary to the 3′ terminal end of the cDNA. This may be then followed by detection and/or quantification of the amplified product. | 09-03-2009 |
| 20090220970 | MOLECULAR TOXICOLOGY MODELING - The present invention is based on the elucidation of the global changes in gene expression and the identification of toxicity markers in tissues or cells exposed to a known toxin. The genes may be used as toxicity markers in drug screening and toxicity assays. The invention includes a database of genes characterized by toxin-induced differential expression that is designed for use with microarrays and other solid-phase probes. | 09-03-2009 |
| 20090220971 | Treatment Response in Generalized Social Phobia - This invention generally pertains to the field of psychiatry. In particular, this invention relates to, inter alia, the discovery that a subject's serotonin transporter gene promoter polymorphism genotype can be used to determine the subject's response to certain drug therapies. | 09-03-2009 |
| 20090220972 | Probe, Probe Set, Probe-Immobilized Carrier, and Genetic Testing Method - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 49 to 51 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 09-03-2009 |
| 20090220973 | OBESITY AND BODY FAT DISTRIBUTION - Described are methods for predicting and diagnosing genetically-based obesity and body fat distribution, and for identifying compounds for the treatment and prevention of obesity. | 09-03-2009 |
| 20090220974 | METHODS AND APPARATUS FOR THE SELECTION AND/OR PROCESSING OF PARTICLES, IN PARTICULAR FOR THE SELECTIVE AND/OR OPTIMISED LYSIS OF CELLS - Methods and apparatus for the selection or processing of particles sensitive to the application of an external stimulus, in which is produced, by applying the external stimulus, the rupture/lysis of at least one selected particle or the fusion of first and second selected particles, by means of the organisation of the particles using a first field of force by selectively energising electrodes of an array of selectable electrodes having dimensions comparable to or smaller than those of the particles, applying to the electrodes a first configuration of stresses; and by applying to the electrodes a second configuration of stresses, so as to create a second field of force, located substantially close to at least one selected particle to be lysated or to a pair of first and second particles to be fused and such as to produce the application of a stimulus suited to produce their lysis or fusion. | 09-03-2009 |
| 20090220975 | USE OF PROTEIN SATB2 AS A MARKER FOR COLORECTAL CANCER - The invention provides new methods, means and uses in connection with detection, characterization and prognosis of colo-rectal cancer, via the identification of the SATB2 protein as a marker for this cancer type. | 09-03-2009 |
| 20090220976 | Test Method for MALT Lymphomas and Kit Therefor - An object of the present invention is to provide a test method for MALT lymphomas for providing genetic diagnosis data which can be used for the diagnosis of MALT lymphomas, identification of disease type, and prediction of progression of pathological conditions and onset thereof and a kit for implementing the method. At least two types of tumor-suppressor genes or cancer-related genes are selected, in particular, at least two types of genes are selected from a gene group consisting of 11 genes in a sample, and the expression levels or the gene expression regulation status of the selected genes are investigated. Early detection and diagnosis with high sensitivity and accuracy can be conducted by quantitatively determining the genetic product and preparing the expression profiles of the gene group on the basis of the results, or by detecting methylation frequencies to analyze the expression regulation. | 09-03-2009 |
| 20090220977 | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses - The invention provides isolated nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 09-03-2009 |
| 20090220978 | METHODS FOR DETECTION AND QUANTIFICATION OF ANALYTES IN COMPLEX MIXTURES - The invention provides a diverse population of uniquely labeled probes, containing about thirty or more target specific nucleic acid probes each attached to a unique label bound to a nucleic acid. Also provided is a method of producing a population of uniquely labeled nucleic acid probes. The method consists of (a) synthesizing a population of target specific nucleic acid probes each having a different specifier; (b) synthesizing a corresponding population of anti-genedigits each having a unique label, the population having a diversity sufficient to uniquely hybridize to genedigits within the specifiers, and (c) hybridizing the populations of target nucleic acid probes to the anti-genedigits, to produce a population in which each of the target specific probes is uniquely labeled. Also provided is a method of detecting a nucleic acid analyte. The method consists of (a) contacting a mixture of nucleic acid analytes under conditions sufficient for hybridization with a plurality of target specific nucleic acid probes each having a different specifier; (b) contacting the mixture under conditions sufficient for hybridization with a corresponding plurality of anti-genedigits each having a unique label, the plurality of anti-genedigits having a diversity sufficient to uniquely hybridize to genedigits within the specifiers, and (c) uniquely detecting a hybridized complex between one or more analytes in the mixture, a target specific probe, and an anti-genedigit. | 09-03-2009 |
| 20090220979 | Methods and Apparatus for Magnetic Separation of Cells - Described here is an automated robotic device that isolates circulating tumor cells (CTCs) or other biological structures with extremely high purity. The device uses powerful magnetic rods covered in removable plastic sleeves. These rods sweep through blood samples, capturing, e.g., cancer cells labeled with antibodies linked to magnetically responsive particles such as superparamagnetic beads. Upon completion of the capturing protocol, the magnetic rods undergo several rounds of washing, thereby removing all contaminating blood cells. The captured target cells are released into a final capture solution by removing the magnetic rods from the sleeves. Additionally, cells captured by this device show no reduced viability when cultured after capture. Cells are captured in a state suitable for genetic analysis. Also disclosed are methods for single cell analysis. Being robotic allows the device to be operated with high throughput. | 09-03-2009 |
| 20090220980 | USE OF METHYLATION STATUS OF MINT LOCI AND TUMOR-RELATED GENES AS A MARKER FOR MELANOMA AND BREAST CANCER - The invention relates to a method of detecting melanoma or breast cancer using DNA methylation in MINT17, MINT31, or the promoter region of WIF1, TFPI2, RASSF1A, SOCS1, GATA4, or RARβ2 as a biomarker. Also disclosed are methods of using the biomarker for determining the cancer status and predicting the outcome of the cancer. | 09-03-2009 |
| 20090220981 | COMPOSITIONS AND METHODS FOR DETERMINING THE PRESENCE OF CHLAMYDOPHILA PNEUMONIAE IN A TEST SAMPLE - Oligonucleotides for use in determining the presence of | 09-03-2009 |
| 20090220982 | COMPOSITIONS AND METHODS FOR DETERMINING NEPHROTOXICITY - The present invention provides novel in vitro assays for determining the nephrotoxicity of a compound. These assays correlate well with in vivo nephrotoxicity and also provide high-throughput methods to screen multiple compounds for in vivo nephrotoxicity. In addition, the methods of the present invention may be adapted to screen for nephroprotectant compounds, including those that protect cells and animals from the nephrotoxic effects of aminoglycoside antibiotics. | 09-03-2009 |
| 20090220983 | CELL-BASED METHODS FOR DETECTING AND/OR MEASURING BMP-12-RELATED PROTEIN ACTIVITY - The invention provides cell-based methods to detect and/or measure the BMP-12-related protein activity of a sample containing a BMP-12-related protein. The methods involve contacting a suitable cell with the sample, and measuring the expression level of at least one BMP-12-related-activity-marker. A dose-dependent increase(s) in the level(s) of the BMP-12-related-activity-markers is indicative of the BMP-12-related protein activity in the sample. The levels of the BMP-12-related-activity-markers of the invention exhibit a dose-responsive increase in response to known BMP-12-related proteins BMP-12, BMP-13, and MP-52, but not to the osteogenic protein, BMP-2. | 09-03-2009 |
| 20090220984 | HEAT FLOW POLYMERASE CHAIN REACTION SYSTEMS AND METHODS - Methods and systems for polymerase chain reactions (PCR) that are capable of detecting amplified DNA during or after the PCR process. The methods and systems may utilize DSC or DTA analysis techniques. | 09-03-2009 |
| 20090220985 | RAPID EFFICACY ASSESSMENT METHOD FOR LUNG CANCER THERAPY - The present invention discloses a method for rapid assessment of lung cancer therapy efficacy in a few days instead of weeks by conventional imaging methods. This method can also be used to detect relapse of the cancer and to improve the current TNM cancer staging method for more accurate prognosis. The rapid assessment of therapy efficacy is based on detecting circulating cancer cells in body fluid with high positive detection rate. The high positive detection rate is achieved by using qPCR amplification of multiple marker genes identified by in silico search of DNA sequence database. This invention also discloses a scoring method to calculate the cancer cell load based on qPCR results to correlate the amount of circulating cancer cells in lung cancer patients and predict the treatment outcomes. | 09-03-2009 |
| 20090233270 | Secreted and cytoplasmic tumor endothelial markers - To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed many differentially expressed genes, including a large nujber of genes that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions fo the liver. Theses results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic. | 09-17-2009 |
| 20090233271 | Species-Specific And Quantitative Detection Of CNS Tissue In Meat And Meat Products - The present invention concerns a method for the species-specific and quantitative detection of CNS tissue in meat and meat products of the ruminant species bovine, ovine and caprine or porcine by a real-time PCR method, using glial fibrillary acidic protein (GFAP) messenger (m)-RNA. The method is very reliable and can be easily conducted even in heat-treated samples. | 09-17-2009 |
| 20090233272 | Multiplexed Nucleic Acid Analysis with High Specificity - A test kit and method includes amplification and extension primers that are selected to allow multiplex PCR and extension at increased specificity. Preferably, the extension primers include a tag that hybridizes with a capture probe on a biochip, wherein the tag is distinct from the target nucleic acid sequence to be analyzed. Further preferred kits include a biochip and various instructions. | 09-17-2009 |
| 20090233273 | Transgenic aloe plants for production of proteins and related methods - The present inventions provide transgenic aloe plants and recombinant constructs for transforming aloe plants, aspects of which, may be applied to other monocots. The recombinant constructs may include one or more DNA sequences encoding mammalian proteins and at least one promoter capable of directing the expression of recombinant proteins in an aloe plant. The present inventions also provide methods for constructing and reproducing a transgenic aloe plant. The present inventions include methods for transfection of an aloe plant with several genes of interest simultaneously. The aloe plant production methods of the inventions may provide the potential to inexpensively and more safely mass-produce some biologically active compounds including biopharmaceuticals for disease therapy, diagnosis and prevention, and is more accessible to the less affluent countries. The aloe plant production methods may also produce proteins for cosmetics. | 09-17-2009 |
| 20090233274 | DRUG DEVELOPMENT TARGET PROTEIN AND TARGET GENE, AND METHOD OF SCREENING - The present invention provides novel target proteins and target genes for drug discovery, and the means that enable the development of novel drugs using the same. More particularly, the present invention provides NCS proteins and genes thereof; screening methods for drug (for example, anti-central nervous disease drug); agents for regulating disease (for example, central nervous disease); production methods of a drug derivative; a complex comprising a drug and NCS protein, and a method of producing the complex; a kits comprising a drug or a salt thereof; determination methods for the onset or risk of onset of a specified disease, determination methods for susceptibility to a drug, and determination kits used for the determination methods; and the like. | 09-17-2009 |
| 20090233275 | EOTAXIN-3 IN EOSINOPHILIC ESOPHAGITIS - Eotaxin-3, as a marker for eosinophilic esophagitis and methods of assessing, mitigating, and monitoring eosinophilic esophagitis by altering eotaxin-3 and/or CCR3 function, are disclosed. | 09-17-2009 |
| 20090233276 | Method Enabling the Use of Extracellular Ribonucleic Acid (RNA) Extracted from Plasma or Serum to Detect, Monitor or Evaluate Cancer or Premalignant Conditions - This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue. | 09-17-2009 |
| 20090233277 | PRIMER GENERATION ROLLING CIRCLE AMPLIFICATION - A method of amplifying a nucleic acid is provided which comprises: generating a first nucleic acid primer from a first nucleic acid sequence; combining the first nucleic acid primer with a first polymerase and a first circular nucleic acid probe, wherein the first circular nucleic acid probe contains at least one antisense sequence to a second nucleic acid sequence and at least one antisense sequence to the first nucleic acid primer; producing at least one repeat of a sequence copy of the first circular nucleic acid probe by rolling circle amplification using the first polymerase, wherein the sequence copy contains at least the second nucleic acid sequence; generating a second nucleic acid primer from the second nucleic acid sequence; combining the second nucleic acid primer with a second polymerase and a second circular nucleic acid probe, where the second circular nucleic acid probe contains at least one antisense sequence to the second nucleic acid primer; and producing at least one repeat of a sequence copy of the second circular nucleic acid probe by rolling circle amplification using the second polymerase. The method may be employed to detect molecules of interest such as nucleic acid sequences, DNA methylation, single nucleotide polymorphisms (SNP), proteins and posttranslational modifications. Furthermore, a ribbon probe is provided that comprises a circular nucleic acid probe and a nucleic acid lock probe, wherein: the nucleic acid lock probe contains at least a cleavable linker, and the circular nucleic acid probe and the lock probe are unable to dissociate without cleaving the cleavable linker. | 09-17-2009 |
| 20090233278 | Branched-chain amino acid aminotransferase gene and use thereof - The present invention relates to a branched-chain amino acid aminotransferase gene and a use thereof, particularly, to a brewery yeast for producing alcoholic drinks with enhanced flavor, to alcoholic drinks produced with said yeast and to a method for producing said drinks. More particularly, the present invention relates to a yeast whose capacity of producing amyl alcohol and/or isobutanol and/or isoamyl acetate that contribute to the product flavor is controlled by controlling the expression levels of BAT1 and BAT2 genes coding for brewery yeast branched-chain amino acid aminotransferases Bat1p and Bat2p, respectively, particularly nonScBAT1 or nonScBAT2 gene specific to lager brewing yeast, and to a method for producing alcoholic drinks using said yeast. | 09-17-2009 |
| 20090233279 | Methods and Compositions for Predicting Death from Cancer and Prostate Cancer Survival Using Gene Expression Signatures - The emerging concept of cancer stem cells suggests that activation in transformed cells of “sternness” genetic pathways (e.g., normal stem cells' self-renewal pathways) may contribute to the survival life cycle of cancer stem cells, and to tumor progression and metastasis of the malignancy. Thus, activation of “sternness” genes in cancer cells may be associated with aggressive clinical behavior and increased likelihood of therapy failure. General methods and kits associated with prediction of clinical outcome for a disease state of a subject based on gene expression analysis are described. The invention includes determining expression of at least three genes selected from the group consisting of GBX2, MKI67, CCNB1, BUB1, KNTC2, USP22, HCFC1, RNF2, ANK3, FGFR2, and CES1, and mouse homologs thereof. | 09-17-2009 |
| 20090233280 | METHOD OF ACQUIRING INFORMATION REGARDING BASE SEQUENCE AND INFORMATION READING DEVICE FOR THE SAME - Information regarding a base sequence of a target nucleic acid is acquired by preparing a sample comprising the target nucleic acid hybridized with a primer or a sample comprising the target nucleic acid containing a promoter sequence, a polymerase, a nucleotide derivative having an electrochemically convertible moiety; allowing the three components to coexist in a solvent; and detecting whether the nucleotide derivative is introduced into the primer or a transcription product of the target nucleic acid or not using an electrochemical reaction. | 09-17-2009 |
| 20090233281 | DIAGNOSTIC MARKER FOR ALLERGY - The present invention provides a test system that specifically detects allergy, a test system that highly sensitively reflects aggravation of allergy and the like. | 09-17-2009 |
| 20090233282 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof. | 09-17-2009 |
| 20090233283 | STABLE COMPOSITIONS FOR NUCLEIC ACID AMPLIFICATION AND SEQUENCING - The present invention is directed to compositions comprising mixtures of reagents, including thermostable enzymes (e.g., thermostable DNA polymerases), buffers, cofactors and other components, suitable for immediate use in nucleic acid amplification or sequencing techniques without dilution or addition of further components. The compositions contain no stabilizing agents (e.g., glycerol or serum albumin) and unexpectedly maintain activity for extended periods of time upon storage at temperatures above freezing. These compositions are useful, alone or in the form of kits, for nucleic acid amplification (e.g., by the Polymerase Chain Reaction) and sequencing (e.g., by dideoxy or “Sanger” sequencing), or for any procedure utilizing thermostable DNA polymerases in a variety of medical, forensic and agricultural applications. In particular, the compositions and methods are useful for amplifying and sequencing nucleic acid molecules that are larger than about 7 kilobases in size. | 09-17-2009 |
| 20090233284 | METHOD FOR THE SIMULTANEOUS DETECTION OF MUTATIONS OCCURRING IN RELATED GENOMES, EXPLOITING MOBILITY VARIATIONS IN 2-D ELECTROPHORESIS OF DNA DUPLEXES UNDERGOING DIFFERENTIAL HELIX-COIL TRANSITION IN A DENATURING GRADIENT - A method for the simultaneous mutation detection exploiting the variable electrophoretic mobility of related DNA samples, caused by the differential onset of helix-coil transition in denaturing gradients, comprises the following subsequent steps: a) preparation of DNA samples; b) fragmentation of the samples through a first restriction; c) terminal labeling of the fragments of each genome with a different fluorochrome; d) mixing the samples; e) carrying out a simultaneous second restriction, converting each long duplex into a set of shorter fragments with two of them labeled at only one of their ends e) carrying out a 2D separation of the mixed digestion products in order to obtain: a first dimension consisting of a standard 20 polyacrylamide gel; and a second dimension against a denaturing gradient; f) spotting, picking of singly labeled spots and sequencing of their DNA. | 09-17-2009 |
| 20090233285 | SPECIFIC METHOD OF PROSTATE CANCER DETECTION BASED ON PCA3 GENE, AND KITS THEREFOR - The present invention relates, in general, to prostate cancer. More specifically, the present invention relates to a method to diagnose prostate cancer in a patient by detecting a PCA3 sequence, and more particularly a PCA3 RNA, the PCA3 sequence detected in a sample from the patient being specifically associated with prostate cancer. In a particular embodiment the method and kit enables an amplification of a PCA3 RNA through an exon-exon junction of a spliced PCA3 mRNA. The invention also relates to methods and kits to detect such an amplified PCA3 RNA, using a probe which spans the amplified exon-exon junction. In particular the methods and kits are designed to detect a PCA3 RNA which lacks one intron or more, and in particular case is intron-less. The invention further relates to a method of detecting PCA3 RNA expressed in non-prostate tissue or cells of the urinary tract, that comprises PCA3 intron 3. | 09-17-2009 |
| 20090233286 | Methods of diagnosis and prognosis of pancreatic cancer - Disclosed herein are methods of diagnosing pancreatic cancer in a subject. Also provided are methods of monitoring the efficacy of a therapeutic treatment of pancreatic cancer as well as methods of determining the likelihood that a subject having pancreatic cancer will survive, and methods of determining the suitability of a subject having pancreatic cancer for surgical resection therapy. | 09-17-2009 |
| 20090233287 | PRODUCTION OF COMPOUNDS IN A RECOMBINANT HOST - The present invention provides a recombinant | 09-17-2009 |
| 20090233288 | PRIMER SET FOR GENE AMPLIFICATION, REAGENT FOR GENE AMPLIFICATION INCLUDING THE SAME, AND USES THEREOF - Primer sets for amplifying two genes (the CYP2C9 gene and the VKORC1 gene) by a gene amplification method are provided, wherein the primer sets can amplify respective target regions of the two genes specifically and efficiently in the same reaction system simultaneously. Two pairs of primer sets are used including forward primers consisting of the base sequences of SEQ ID NOs: 5 and 29 as well as reverse primers consisting of the base sequences of SEQ ID NOs: 18 and 38, respectively. The use of these primer sets makes it possible to specifically amplify target regions including sites where polymorphisms to be detected are generated in the CYP2C9 gene and the VKORC1 gene, in the same reaction solution simultaneously. | 09-17-2009 |
| 20090233289 | Novel DNA threading intercalators - The invention is directed to a compound having the general formula (1): | 09-17-2009 |
| 20090233290 | Mutant SepRS, and method for site-specific introduction of phosphoserine into protein using the same - A mutant SepRS which is suitable for a site-specific introduction of phosphoserine into a protein is prepared by analyzing the structure and functions of a phosphoseryl-tRNA synthetase (SepRS) derived from an archaebacterium. A mutant SepRS composed of an amino acid sequence depicted in SEQ ID NO:2, in which any one or more of glutamic acids at position-418 and position-420 and threonine at position-423 are substituted with other amino acid, and having enhanced binding affinity with a suppressor tRNA as compared with a wild type phosphoseryl-tRNA synthetase (SepRS) composed of an amino acid sequence depicted in SEQ ID NO:2 is provided. | 09-17-2009 |
| 20090233291 | Paired end sequencing - An embodiment of a method for obtaining a DNA construct comprising two end regions of a target nucleic acid in an in vitro reaction is described that comprises the steps of: fragmenting a large nucleic acid molecule to produce a target nucleic acid molecule; ligating a recombination adaptor element to each end of the target nucleic acid molecule to produce an adapted target nucleic acid molecule; exposing the adapted target nucleic acid to a site specific recombinase to produce a circular nucleic acid product and a linear nucleic acid product from the adapted target nucleic acid, wherein the circular nucleic acid product comprises the target nucleic acid molecule; and fragmenting the circular nucleic acid product to produce a template nucleic acid molecule comprising a sequence region from each end of the target nucleic acid molecule. | 09-17-2009 |
| 20090233292 | Method and kit for identification of genetic polymorphisms - Provided herein are primer sets, kits, and methods for identifying mtDNA polymorphisms in a sample. In one embodiment, the primer sets, kits and methods are directed to identifying global haplogroups (“Global”). In another embodiment, the primer sets, kits, and methods are directed to identifying specific European haplogroups (“European”). | 09-17-2009 |
| 20090233293 | TTK DIRECTED DIAGNOSTICS FOR NEOPLASTIC DISEASE - Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of TTK in the test cell sample or fluid sample as compared to the level of expression of TTK in a control cell sample or fluid sample isolated from a normal subject. | 09-17-2009 |
| 20090233294 | UHRF1 DIRECTED DIAGNOSTICS FOR NEOPLASTIC DISEASE - Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of UHRF1 in the test cell sample or fluid sample as compared to the level of expression of UHRF1 in a control cell sample or fluid sample isolated from a normal subject. | 09-17-2009 |
| 20090233295 | TRIM59 DIRECTED DIAGNOSTICS FOR NEOPLASTIC DISEASE - Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of TRIM59 in the test cell sample or fluid sample as compared to the level of expression of TRIM59 in a control cell sample or fluid sample isolated from a normal subject. | 09-17-2009 |
| 20090233296 | Thiamin production by fermentation - The present invention provides a method for producing thiamin products using a microorganism containing a mutation that causes it to overproduce and release thiamin products into the medium. Biologically pure cultures of the microorganisms and isolated polynucleotides containing the mutations are also provided. In addition, methods for detecting a pathogenic microorganism in a clinical sample, assays for identifying an antibiotic, as well as, antibiotics identified by such assays are provided. | 09-17-2009 |
| 20090233297 | MICRORNA MARKERS FOR RECURRENCE OF COLORECTAL CANCER - The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as colorectal cancer, and using the profile in the diagnosis and/or prognosis of a patient for a condition, such as colorectal cancer and colorectal cancer recurrence or response to therapy. | 09-17-2009 |
| 20090233298 | FIG4 GENE MUTATIONS IN NEURODEGENERATION - The present invention relates to neurological disease, in particular to mutations in the FIG4 gene. The present invention also provides assays for the detection of variant FIG4 alleles, and assays for detecting FIG4 polymorphisms and mutations associated with disease states such as ALS. | 09-17-2009 |
| 20090233299 | Physiogenomic Method for Predicting Statin Injury to Muscle and Muscle Side Effects - The present invention relates to the use of genetic variants of associated marker genes to predict an individual's susceptibility to muscular injury and muscular side effects in response to statin therapy. The present invention further relates to analytical assays and computational methods using the novel marker gene set. The present invention has utility for personalized medical treatment, drug safety, statin compliance, and prophylaxis of muscle side effect. | 09-17-2009 |
| 20090233300 | Markers for Diagnosis of Pulmonary Inflammation and Methods Related Thereto - The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA112, CSPG2, TLR2, and CD163. | 09-17-2009 |
| 20090233301 | In Vitro System for Assessing Immune Activity Using Pig Immune Cells - An in vitro system in which immune cells of a non-immunized pig are used for assessing immunoactivity of a substance. | 09-17-2009 |
| 20090233302 | LABELED REACTANTS AND THEIR USES - Labeled reactant compositions, and particularly labeled nucleic acid reaction compositions, that include structural components that maintain potentially damaging labeling components sufficiently distal from the reactant portion of the molecule such that damaging effects of the label group on other reaction components, such as enzymes, are reduced, minimized and/or eliminated. | 09-17-2009 |
| 20090233303 | METHODS FOR ASSESSING BREAKDOWN PRODUCTS AND STABILITY OF SIRNA AND OTHER TARGET OLIGONUCLEOTIDES - The disclosure provides methods and compositions for assessing by sequencing the type and quantity of in vivo or in vitro breakdown products and stability of nucleic acids such as small interfering RNA (siRNA) and other target oligonucleotides. In general, the disclosed methods involve the use of tester oligonucleotides that comprise a double-stranded region, an optional loop (in the case of hairpin testers), and a single-stranded 3′ overhang that is complementary to the full-length and a shortened target oligonucleotide. A tester is designed so that the 3′ end of a respective target oligonucleotide anneals to the overhang immediately adjacent to the 5′ end of the tester. The juxtaposed ends of the tester and target at adjacent positions allow for a ligase to ligate the chain if there is a match between a tester and its respective target. By sequencing the ligated product in the region of the ligation site, one may determine the sequence of the 3′ end of the target oligonucleotide or of the entire target and its relative amount in the sample. | 09-17-2009 |
| 20090233304 | Biomarkers for Inflammatory Bowel Disease and Irritable Bowel Syndrome - The present invention provides compositions and their use in diagnosing and/or distinguishing inflammatory bowel disease and irritable bowel syndrome. | 09-17-2009 |
| 20090233305 | Biomarkers for Inflammatory Bowel Disease and Irritable Bowel Syndrome - The present invention provides compositions and their use in diagnosing and/or distinguishing inflammatory bowel disease and irritable bowel syndrome. | 09-17-2009 |
| 20090233306 | Biomarkers for Inflammatory Bowel Disease and Irritable Bowel Syndrome - The present invention provides compositions and their use in diagnosing and/or distinguishing inflammatory bowel disease and irritable bowel syndrome. | 09-17-2009 |
| 20090233307 | METHODS FOR DETECTION OF SINGLE STRAND BREAKS IN DNA - Methods are provided for detecting single strand breaks in DNA sample comprising: contacting the DNA with a neutral hydroxylamine, denaturing the DNA and detecting single strand breaks in the denatured DNA. Methods are also provided for the detecting single strand breaks in DNA from a cell, the methods comprising lysing the cell, denaturing the DNA from the lysed cell, wherein the DNA is contacted with a neutral hydroxylamine prior to and/or during the denaturing step and detecting single strand breaks in the DNA from the cell. In addition, methods are provided for distinguishing between true single strand breaks and artifactual single strand breaks resulting from cleaved alkaline labile sites. | 09-17-2009 |
| 20090233308 | NOVEL METHOD OF ASSAYING NUCLEIC ACID USING LABELED NUCLEOTIDE - A novel method is provided to assay at least one nucleic acid. According to this method, a nucleic acid polymerization reaction is conducted in a nucleic acid polymerization reaction system, which contains (A) the at least one nucleic acid as a template, (B) at least one nucleotide monomer labeled with at least one label selected from the group consisting of (a) fluorescent dyes, (b) quenchers and (c) immune related substances with a fluorescent dye or quencher contained therein, and (C) at least one nucleic acid-synthesizing enzyme. The template nucleic acid or a nucleic acid, which has been synthesized using the template nucleic acid as a template, is then assayed from a change or an amount of a change in an optical character of the nucleic acid polymerization system. This method makes it possible to specifically and accurately assay at least one nucleic acid, which is contained in a single system and can be an unknown nucleic acid and/or a known nucleic acid, with excellent sensitivity, in short time and with ease. | 09-17-2009 |
| 20090233309 | BIOLOGICAL SPECIMEN COLLECTION/TRANSPORT COMPOSITIONS AND METHODS - Disclosed are compositions for collecting, storing, and transporting populations of nucleic acids from biological specimens, and clinical, forensic, or environmental samples. Also disclosed are methods for using these compositions as one-step formulations for killing pathogens, inactivating nucleases, and releasing polynucleotides from other cellular components within the sample, and stabilizing the nucleic acids prior to further processing or assay. In particular embodiments, the invention provides a single, one-step, sample collection/transport/storage formulation containing a known quantity of a non-genomic, nucleic acid carrier molecule that serves as an internal reference control to monitor the fidelity of the collection/transportation medium, and measure the integrity of nucleic acids subsequently isolated and purified from the processed sample. | 09-17-2009 |
| 20090239211 | Method For Enrichment Involving Elimination By Mismatch Hybridisation - The present invention relates to a method for selecting a molecule from a library of such molecules associated with identifier oligonucleotides, said molecule having affinity towards a target. The method involves contacting library with a target to allow for an interaction between the molecules and the target and partitioning a fraction enriched in identifier oligonucleotides of molecules interacting with the target. After an optional nucleic acid amplification of the partitioned fraction, the fraction is subjected to conditions at which hetero-duplexes and homo-duplexes are formed. The homo-duplexes are subsequently recovered and decoded to identify the identity of the molecule interacting with the target. | 09-24-2009 |
| 20090239212 | Screening for the Genetic Defect Causing Tibial Hemimelia in Bovines - The invention provides methods, materials and kits for analyzing DNA samples from bovine to determine whether the animal is a recessive carrier of a genetic mutation that is associated with tibial hemimelia. DNA-containing samples are analyzed by genetic testing to determine whether or not a deletion mutation is present in one of the alleles that encodes Aristaless-like4 (ALX4) protein, wherein the deletion mutation is associated with tibial hemimelia. | 09-24-2009 |
| 20090239213 | Identifying a target polynucleotide - A method for identifying the presence of a single stranded target polynucleotide in a sample comprising the steps of (i) contacting the target polynucleotide, under hybridising conditions, with at least first and second polynucleotide probes, each of which comprise a first region complementary to adjacent non-overlappïng regions of the target polynucleotide; (ii) ligating together those first and second polynucleotides that hybridise to the target polynucleotide; (iii) optionally, amplifying any ligated polynucleotides; and (iv) determining whether the target polynucleotide is present in the original sample, by detecting any ligated polynucleotide, wherein at least one of the first and second polynucleotides comprise a second region having a defined polynucleotide sequence, with each individual nucleotide of the first region being represented by at least two nucleotides on the second region, and the ligated polynucleotide being identified by determining the second region of at least one of the first and second polynucleotide probes. | 09-24-2009 |
| 20090239214 | Prognosis of breast cancer patients - The present invention relates to sets of genetic markers whose expression is correlated with prognosis of breast cancer in individuals having breast cancer. Specifically, the invention provides sets of markers whose expression patterns can be used to differentiate individuals having a good prognosis, e.g., no reoccurrence or metastasis within five years of initial diagnosis, and individuals having a poor prognosis, e.g., reoccurrence or metastasis within five years of initial diagnosis. The invention relates to methods of prognosis using these markers. The invention also relates to microarrays containing probes to these markers, and to kits containing ready-to-use microarrays and computer software for data analysis using the prognostic and statistical methods disclosed herein. | 09-24-2009 |
| 20090239215 | Clonable Tag for Purification and Electron Microscopy Labeling - The disclosure provides compositions and methods for heavy atom labeling of a target protein using a clonable tag. The clonable tag comprises a metal binding protein, or fragment thereof, such as metallothionein, which may be fused to a target protein of interest. The tag permits the target protein to be labeled with a heavy atom, such as gold, silver, or mercury, and thus permits visualization of the target protein by electron microscopy. Also provided are methods for purification of a target protein using metallothionein, or a fragment thereof, as an affinity tag. The metallothionein fusion may be purified on immobilized metal affinity chromatography (IMAC) column charged with a metal such as cadmium. | 09-24-2009 |
| 20090239216 | Novel Tannase Gene And Protein Thereof - A polynucleotide encoding a protein as defined in the following (a), (b) or (c):
| 09-24-2009 |
| 20090239217 | STEM-LIKE CELLS IN BONE SARCOMAS - Isolation and purification of stem cells from within a bulk sarcoma tumor. These cells express the marker genes of pluripotent embryonic stem cells, Stat 3, Oct 3/4, and Nanog. A subset of these cells show the surface marker of mesenchymal stem cells Stro-1, as well as express attributes of mesodermal, ectodermal, and endodermal differentiation. The isolation, purification and characterization of these stem cells now provides the ideal target for the development of highly effective therapies against tumors. | 09-24-2009 |
| 20090239218 | METHOD FOR THE DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASES - The present invention refers to a method for the in vitro or in vivo diagnosis of cardiovascular diseases, in particular high blood pressure, stenosis, vessel occlusion and/or other thrombotic events, wherein the nucleotide at position 950 of a nucleic acid coding for the human ARK2 protein or the amino acid at position 298 of the human ARK2 protein of a sample of a person is determined as well as to the use of ARK2 for the development and/or production of a medicament for treating a cardiovascular disease. | 09-24-2009 |
| 20090239219 | TELOMERASE EXPRESSION REPRESSOR PROTEINS AND METHODS OF USING THE SAME - Telomerase repressor proteins and nucleic acid compositions encoding the same are provided. The subject repressor proteins bind to a repressor site in the TERT minimal promoter, e.g., a Site C site, and thereby inhibit TERT expression. Also provided are methods of modulating, e.g., inhibiting or enhancing, TERT expression. The subject invention finds use in a variety of different applications, including therapeutic and therapeutic agent screening applications. | 09-24-2009 |
| 20090239220 | DLC-1 GENE DELETED IN CANCERS - A cDNA molecule corresponding to a newly discovered human gene is disclosed. The new gene, which is frequently deleted in liver cancer cells and cell lines, is called the DLC-1 gene. Because the gene is frequently deleted in liver cancer cells, but present in normal cells, it is thought to act as a tumor suppressor. This gene is also frequently deleted in breast and colon cancers, and its expression is decreased or undetectable in many prostate and colon cancers. Also disclosed is the amino acid sequence of the protein encoded by the DLC-1 gene. Methods of using these biological materials in the diagnosis and treatment of hepatocellular cancer, breast cancer, colon cancer, prostate cancer, and adenocarcinomas are presented. | 09-24-2009 |
| 20090239221 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - Recurrent gene fusions in prostate cancer of androgen regulated genes or housekeeping genes and ETS family member genes are described. Compositions and methods having utility in prostate cancer diagnosis, research, and therapy are also provided. | 09-24-2009 |
| 20090239222 | COMPOSITION FOR NUCLEIC-ACID TRANSFECTION - To provide a nucleic-acid-transfecting composition which exhibits low cytotoxicity, which facilitates a nucleic acid transfection into cells, and which improves expression of the nucleic acid in the cells. | 09-24-2009 |
| 20090239223 | Prediction of Breast Cancer Response to Taxane-Based Chemotherapy - The invention relates to methods and kits for the prediction of a likely outcome of chemotherapy in a cancer patient. More specifically, the invention relates to the prediction of tumour response to chemotherapy based on measurements of expression levels of a small set of marker genes. The set of marker genes is useful for the identification of breast cancer subtypes responsive to taxane based chemotherapy, such as e.g. a taxane-anthracycline-cyclophosphamide-based (e.g. Taxotere (docetaxel)-Adriamycin (doxorubicin)-cyclophosphamide, i.e. (TAC)-based) chemotherapy. | 09-24-2009 |
| 20090239224 | Methods for identifying bioagents - The present invention provides methods for rapid forensic analysis of mitochondrial DNA and methods for characterizing heteroplasmy of mitochondrial DNA, which can be used to assess the progression of mitochondrial diseases. | 09-24-2009 |
| 20090239225 | PREDICTION AND DIAGNOSIS OF CANINE DEGENERATIVE MYELOPATHY - The present invention provides for methods of identifying a dog carrying a major genetic risk factor in the SOD1 gene for degenerative myelopathy, a potential model for human amyeotrophic lateral sclerosis. Also provided a methods of early diagnosis, treatment and breeding based on the presence or absence of the marker. | 09-24-2009 |
| 20090239226 | MARKERS FOR BREAST CANCER - Correlations between polymorphisms and breast cancer are provided. Methods of diagnosing, prognosing, and treating breast cancer are provided. Systems and kits for diagnosis, prognosis and treatment of breast cancer are provided. Methods of identifying breast cancer modulators are also described. | 09-24-2009 |
| 20090239227 | Method of diagnosing risk of myocardial infarction - It is intended to provide a means of diagnosing myocardial infarction which shows a high accuracy and a high predictability. The risk of myocardial infarction is diagnosed by a method comprising the following steps: (i) the step of analyzing 2 or more polymorphisms among 10 gene polymorphisms or 5 gene polymorphisms proved as relating to myocardial infarction; (ii) the step of determining the genotype of a nucleic acid sample based on the polymorphism data obtained in the above step; and (iii) the step of determining the genetic risk of myocardial infarction from the genotype thus obtained. | 09-24-2009 |
| 20090239228 | CHIMERIC PROMOTER MOLECULES FOR GENE EXPRESSION IN PROKARYOTES - The present invention provides regulatory polynucleotide molecules isolated from a 16S rDNA for enhanced expression of heterologous genes. The invention further discloses compositions, polynucleotide constructs, transformed host cells containing the regulatory polynucleotide sequences, and methods for preparing and using the same. | 09-24-2009 |
| 20090239229 | DNA Repair Proteins Associated With Triple Negative Breast Cancers and Methods of Use Thereof - The present invention provides methods of detecting triple negative breast cancer recurrence using biomarkers. | 09-24-2009 |
| 20090239230 | Lung Cancer Diagnosis Based on Expression Levels of GIMAP Genes - Diagnosis of lung cancer based on the expression level(s) of one or more GTPase of Immunity-Associated Proteins (GIMAP) and method for identifying anti-lung cancer drug candidates based on their up-regulation of GIMAP activity. | 09-24-2009 |
| 20090239231 | RNA From Cytology Samples To Diagnose Disease - The invention relates to methods and kits for detecting the likelihood that a subject has cancer, e.g., squamous cell carcinoma, by assaying the expression levels of tumor associated genes. More specifically, the expression levels of nucleic acids or proteins can be assayed in the tumor associated genes, e.g., beta-2 microgobulin (B2M) and cytochrome p450 1B1 (CYP1B1). The expression levels compared to standards can be indicative of the likelihood a subject has squamous cell carcinoma. For example, over-expression of B2M and under-expression of CYP1B1 can be indicative of the likelihood a subject has squamous cell carcinoma. Also, over-expression of B2M and over-expression of CYP1B1 can be indicative of the likelihood a subject has a precancerous squamous cell disorder. The expression levels of B2M and CYP1B1 can also be repeatedly assayed to monitor the progression of a squamous cell neoplasia. | 09-24-2009 |
| 20090239232 | METHODS OF RNA AMPLIFICATION IN THE PRESENCE OF DNA - The invention provides methods for amplification of RNA. The methods are particularly suitable for specifically amplifying RNA in the presence of DNA. The methods involve producing a marked first primer extension product from a target RNA in the presence of a DNA-dependent DNA polymerase inhibitor, which prevents replication of DNA by the reverse transcriptase enzyme. The marked nucleic acid products are subsequently selectively amplified in the presence on non-marked nucleic acids. The methods are useful for production and analysis of polynucleotide sequences complementary to an RNA sequence. The methods are useful for preparation of nucleic acid libraries and substrates for analysis of gene expression of cells in biological samples. The invention also provides compositions and kits for practicing the amplification methods, as well as methods which use the amplification products. | 09-24-2009 |
| 20090239233 | SINGLE-TUBE, READY-TO-USE ASSAY KITS, AND METHODS USING SAME - An assay kit is provided that includes assay reagents stored in a single-tube container, and a data storage medium containing information about the contents of the container. Methods are provided for using the data provided with the kit to direct instruments and/or processes, for example, to control an instrument to perform amplification and/or sequencing reactions. | 09-24-2009 |
| 20090239234 | IDENTIFICATION AND/OR QUANTIFICATION METHOD OF NUCLEOTIDE SEQUENCE(S) ELEMENTS SPECIFIC OF GENETICALLY MODIFIED PLANTS ON ARRAYS - A method for identifying a genetically modified plant by identification and/or quantification of different, multiple nucleotide sequence elements corresponding to at least a portion of an exogenous nucleotide sequence integrated into the genome of the genetically modified plant. The method involves amplifying a nucleic acid sequence element into target nucleic acid sequences, contacting the target nucleic acid sequences with single stranded capture nucleotide sequences, detecting binding of the target nucleotide sequences, constructing a genetic map, and identifying the genetically modified plant. | 09-24-2009 |
| 20090239235 | Facs- and Reporter Protein-Based System for High Throughput Development of Therapeutic Proteins - Methods are disclosed to identify, select and produce a clonal population of recombinant eukaryotic host cells that stably and highly express a polypeptide of interest. Also disclosed herein are products produced by the disclosed methods and assemblies of components useful to conduct the methods. | 09-24-2009 |
| 20090239236 | GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN EGFR ANTAGONIST CANCER THERAPY - The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject in whose tumor cells erbB1 gene has been found to be amplified e.g., by fluorescent in situ hybridization. EGFR antagonists described include an anti-EGFR antibody. | 09-24-2009 |
| 20090239237 | METHOD FOR THE IDENTIFICATION OF A RISK FOR A THROMBOGENIC DISORDER BY DETERMINING THE TAFl-lle347 POLYMORPHISM - The present invention is directed to a method identifying a risk for a thrombogenic disorder including, without limitation, atrial fibrillation, stroke, prolonged intermitted neurological deficit (PRIND), transitory ischemic attack (TIA), atherosclerotic cerebrovascular disease (CVD) and/or coronary heart disease, as well as to a method for selecting patients with a risk for a thrombogenic disorder, to a method for identifying a pharmaceutical for the therapy or prophylaxis of a thrombogenic disorder as well as to a method for producing a medicament and a diagnostic by employing the TAFI-Ile347 polymorphism. | 09-24-2009 |
| 20090246755 | Method of examining chemical using gene-disrupted strain - A method having higher sensitivity in a bioassay method utilizing cell response of a microorganism, for detecting the presence of a chemical in a test specimen is provided. The method of the present invention is characterized in that it uses specified gene-disrupted strains. | 10-01-2009 |
| 20090246756 | Thermostable polypeptide having polynucleotide kinase activity and/or phosphatase activity - Isolated polypeptides having 5′-kinase and/or 3′-phosphatase activity and temperature optimum of at least 60° C. are described. The invention also relates to isolated nucleic acids encoding the polypeptides, nucleic acid constructs and host cells comprising the nucleic acid sequences as well as methods using the polypeptides and kits for practicing the methods. | 10-01-2009 |
| 20090246757 | Method, Program, and System for Normalizing Gene Expression Amounts - The present invention aims at presenting novel means for analyzing and correcting gene expression amounts. There is provided a gene expression amount normalizing method in which the number of cells in a sample is obtained by measuring a repeated sequence present in a substantially fixed proportion in a genome contained in the sample, and the number of cells obtained is used as an index for normalizing gene expression amounts obtained from the same sample. For example, a DNA sample | 10-01-2009 |
| 20090246758 | Peptide nucleic acid probes for analysis of microorganisms - The instant invention provides PNA probes for detection, identification and/or quantitation of microorganisms, e.g., | 10-01-2009 |
| 20090246759 | TEST AND MODEL FOR INFLAMMATORY DISEASE - The present invention relates to a means and methods for determining susceptibility to SEEK1 mediated diseases, such as psoriasis. In addition, there is provided polynucleotides encoding the SEEK1 protein having one or more nucleotide insertions, deletions or substitutions at one or novel positions, and the SEEK1 protein having one or more amino acid insertions, deletions and substitutions. Host cells and transgenics non-human animals comprising polynucleotides or proteins of the invention are also provided. Methods of screening for agents for use in treating SEEK1 mediated disease are also provided. | 10-01-2009 |
| 20090246760 | METHODS OF EQUALIZING REPRESENTATION LEVELS OF NUCLEIC ACID TARGETS - The disclosure provides methods of reducing the range of representation levels of nucleic acid targets. The methods are particularly useful for multi-target analyses benefiting from a low variance of target representations, such as, e.g., single molecule sequencing and/or heterozygous genotyping, and pathogen diagnosis. Two general methods are provided. In Method 1, starting concentrations of probes are adjusted. In Method 2, target-specific probes are “binned,” i.e., several subsets of probes are selected based on similar representation levels. Thereafter, each subset of corresponding targets is extracted, with or without amplification, using a separate portion of the sample (i.e., separate vessels). | 10-01-2009 |
| 20090246761 | DEVELOPMENT OF PROGNOSTIC MARKERS FROM THE SALIVA OF HEAD AND NECK CANCER PATIENTS - The present invention relates to biomarkers that are useful for the detection of cancer. The invention further relates to biomarkers and methods of using biomarkers for the early detection of head and neck cancer. | 10-01-2009 |
| 20090246762 | NUCLEIC ACID TERMINATORS INCORPORATING A CATIONIC MOIETY AND METHODS FOR THEIR USE - Disclosed are methods and kits applicable to sequencing methods, such as Sanger dideoxy sequencing methods. The methods and kits disclosed utilize a cationically charged nucleic acid terminator in combination with a discriminatory polymerase. | 10-01-2009 |
| 20090246763 | ELECTROCHEMICAL LABELS DERIVED FROM SIDEROPHORES - Disclosed are tri-nuclear metal complexes and salts thereof, such as tri-nuclear osmium or ruthenium complexes or salts thereof, suitable for use as electrochemical labels. Also disclosed are oligonucleotide probes with an attached electrochemical label, methods of nucleic acid amplification, methods of sequencing, and kits for nucleic acid amplification and sequencing having oligonucleotide probes including an electrochemical label. The electrochemical labels are synthesized from siderophores. | 10-01-2009 |
| 20090246764 | Method for the detection of group B Streptococcus (GBS) (Streptococcus agalactiae) in mammals - A method for the detection of all strains of Group B Streptococcus (GBS) ( | 10-01-2009 |
| 20090246765 | METHOD AND DEVICE FOR DETECTING TARGET SUBSTANCE USING PROBE CARRIER - A detecting device for detecting an enzyme present on a predetermined location on a substrate using a luminescence reaction, includes a mounting stage for mounting the substrate, a spotting means for locally applying a micro-droplet substance which contributes to a luminescence reaction with the enzyme onto a predetermined location on the substrate, and a detecting means for detecting a luminescence signal generated by applying the substance based on the timing of discharging a liquid droplet. | 10-01-2009 |
| 20090246766 | High throughput screening of genetically modified photosynthetic organisms - The present invention provides a method and compositions for high throughput screening of genetically modified photosynthetic organisms for plasmic state. The present invention provides methods of producing one or more proteins, including biomass degrading enzymes in a plant. Also provided are the methods of producing biomass degradation pathways in alga cells, particularly in the chloroplast. Single enzymes or multiple enzymes may be produced by the methods disclosed. The methods disclosed herein allow for the production of biofuel, including ethanol. | 10-01-2009 |
| 20090246767 | Compositions and methods for detecting Cryptococcus neoformans - Disclosed are oligonucleotides useful in methods for determining whether a sample contains | 10-01-2009 |
| 20090246768 | Predicting and Diagnosing Patients With Autoimmune Disease - The present invention provides methods for the prediction and diagnosis of autoimmune diseases, including Systemic Lupus Erythematosus, by identifying polymorphisms in the gene for MECP2. | 10-01-2009 |
| 20090246769 | MOLECULAR DIAGNOSIS OF OVARIAN CANCERS - A molecular diagnosis system of ovarian cancers encompasses a detection device configured to obtain a detected value of an expression amount of an apolipoprotein A1 gene in ovarian tissue as a diagnosis subject, a storage device configured to store a normal value of the expression amount of the apolipoprotein A1 gene in normal ovarian tissue, and a determination mechanism configured to determine that the ovarian tissue as the diagnosis subject is clear cell adenocarcinoma when the detected value is lower than the normal value. | 10-01-2009 |
| 20090246770 | GLYCEMIC CONTROL FOR REDUCTION OF CARDIOVASCULAR DISEASE RISK IN DIABETIC PATIENTS EXPRESSING HAPTOGLOBIN 2-2 - This invention relates to methods of reducing risk of developing cardiovascular complications in diabetic patients. Specifically, the invention relates to the use of haptoglobin genotyping for determining the importance of maintaining tight glycemic control in diabetic subjects expressing Hp 2-2 allele. | 10-01-2009 |
| 20090246772 | NOVEL DIBENZO[c,h][1,5]NAPHTHYRIDINES AND THEIR USE AS DNA PROBES - The present invention concerns novel dibenzo[c,h][1,5]naphthyridine of formula (I) and their use as DNA probes, as well as the methods for marking DNA using the same. | 10-01-2009 |
| 20090246773 | DIAGNOSTIC COMPOSITIONS AND TREATMENT METHODS FOR CONDITIONS INVOLVING TROPHOBLAST CELL DEATH, DIFFERENTIATION, INVASION AND/OR CELL FUSION AND TURNOVER - The invention provides a method for diagnosing in a subject a condition requiring modulation of or involving trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover, comprising detecting HIF Iα and the factors which modulate or are modulated by this protein, specifically TGFβ3, sFLT, VEGF, SMAD2, 3 and 7, MtdP, MtdL, MclI 1, MclIc, VHL, SiahI, Siah2, ENG, and PHD. The invention also provides a method for diagnosing or distinguishing in a subject a specific condition requiring modulation of or involving trophoblast cell death, differentiation, invasion, and/or cell fusion and turnover, in particular early onset severe preeclampsia (EPE), late onset preeclampsia (LPE) and mtre-uterme growth restriction (IUGR) comprising detecting HLF Iα and the factors which modulate or are modulated by this protein as defined above. | 10-01-2009 |
| 20090246774 | Chromosomal Blocks as Markers for Traits - The present invention provided a method for predicting a phenotype in a bovine animal, the method comprising analysing a nucleic acid sample from said animal for the presence of at least one genetic marker known to reside in an Linkage Disequilibrium (LD) block in any one of bovine chromosomes BTA-I to BTA-29, wherein said LD block is associated with said phenotype. The phenotype can be Australia profit ranking (APR), Australian selection index (ASR), protein yield (PROT), protein percent (PROT %), milk volume (MILK), fat yield (FAT), fat percent (FAT %), breeding value overall type (Overall Type), somatic cell count (SCC), and/or breeding value cow fertility (Cow Fertility). Also provided is a linkage disequilibrium unit (LDU) map of any one or more of bovine chromosomes BTA-I to BTA-29, the map comprising a plurality of chromosomal regions, and the regions defined by their co-inheritance across generations substantially as entire linkage disequilibrium (LD) blocks. | 10-01-2009 |
| 20090246775 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 65 to 67 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 10-01-2009 |
| 20090246776 | Modulators of scarb-1 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of the SCARB-1 receptor, and the use of modulators of the expression or activity of this receptor for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 10-01-2009 |
| 20090246777 | ALLELIC DISCRIMINATION ANALYSIS USING AN EFFICIENCY RELATED VALUE (EFR) - In various embodiments this invention provides novel methods for discriminating two or more different target nucleic acids. In certain embodiments the methods comprise providing data amplification reactions comprising reagents to amplify two or more different target nucleic acids where the data comprise signals comprising an amplitude measurement representing the degree of amplification of each target nucleic acid in the amplification reaction and the time point in the amplification reaction at which the amplitude is measured; determining an efficiency related transform of the data, determining an efficiency related value for each target nucleic acid that is the maximum magnitude of the efficiency related transform; and outputting the efficiency related values in the amplification reaction for each target nucleic acid, where the relative amplitudes of the efficiency related values for each target nucleic acid is an indicator of the presence of each of said nucleic acids in said sample. | 10-01-2009 |
| 20090246778 | IDENTIFICATION OF FAT AND LEAN PHENOTYPES IN CHICKENS USING MOLECULAR MARKERS - The present invention identifies genetic markers for lean and fat phenotypes in chickens and provides methods of screening chickens to determine those more likely to have a lean or fat phenotype. The invention also provides methods of screening chickens to identify a polymorphism in THRSPα associated with a fat or lean phenotype. | 10-01-2009 |
| 20090246779 | INCREASING GENOMIC INSTABILITY DURING PREMALIGNANT NEOPLASTIC PROGRESSION REVEALED THROUGH HIGH RESOLUTION ARRAY-CGH - The present invention relates to a method of diagnosing a premalignant condition based on the presence of chromosomal alterations at one or more fragile chromosome sites. Methods of determining chromosomal alterations are disclosed. The present invention also relates to methods of establishing a prognosis and a therapeutic regimen for the subject having the premalignant condition are also disclosed. | 10-01-2009 |
| 20090246780 | HIGH THROUGHPUT PHYSICAL MAPPING USING AFLP - The present invention relates to a high throughput method for the identification and detection of molecular markers wherein restriction fragments are generated and suitable adaptors comprising (sample-specific) identifiers are ligated. The adapter-ligated restriction fragments may be selectively amplified with adaptor compatible primers carrying selective nucleotides at their 3′ end. The amplified adapter-ligated restriction fragments are, at least partly, sequenced using high throughput sequencing methods and the sequence parts of the restriction fragments together with the sample-specific identifiers serve as molecular markers. | 10-01-2009 |
| 20090246781 | Method for early determination of recurrence after therapy for prostate cancer - This invention describes compositions and methods for use in PSA assays having low functional sensitivity which are useful, for example, in the detection of early stage recurrence of prostate disease following treatment and in the determination of whether patients have early stage biochemical reoccurrence (ES-BCR) or stable disease. | 10-01-2009 |
| 20090246782 | BARRIERS FOR FACILITATING BIOLOGICAL REACTIONS - The present invention relates to systems, devices, and methods for performing biological reactions. In particular, the present invention relates to the use of lipophilic, water immiscible, or hydrophobic barriers in sample separation, purification, modification, and analysis processes. | 10-01-2009 |
| 20090246783 | METHOD OF MEASURING PYROPHOSPHATE - Provided is a novel and useful method of measuring pyrophosphate in a sample. There may be provided a novel and useful method of measuring pyrophosphate in a sample using pyruvate orthophosphate dikinase, nicotinamide-nucleotide adenylyltransferase, and dehydrogenase. | 10-01-2009 |
| 20090246784 | METHOD OF ANALYZING METHYLATED DNA - The present invention provides a method of analyzing methylated DNA, comprising steps of: (A) treating a DNA-containing sample with a restriction enzyme to obtain a sample containing a DNA fragment; (B) concentrating methylated DNA contained in the sample obtained in step (A) to obtain a methylated DNA concentrate; (C) subjecting the methylated DNA concentrate obtained in step (B) and a primer set to nucleic acid amplification reaction, wherein the primer set performs the nucleic acid amplification reaction in step (C) by using a template DNA which does not have a CpG site; (D) detecting an amplification product obtained in step (C); (E) judging whether the methylated DNA concentrate obtained in step (B) is appropriate as a sample for detection of methylated DNA, on the basis of the detection result of the amplification product in step (D); and(F) analyzing the methylated DNA contained in the methylated DNA concentrate. | 10-01-2009 |
| 20090246785 | NOVEL STEROID 5-ALPHA-REDUCTASE - The invention provides an isolated, novel steroid 5α-reductase enzyme termed SRD5AIII. The protein has an estimated molecular weight of 37 kDa and is capable of converting testosterone to dihydrotestosterone at a pH of about 7.0. Also provided is a method for identifying inhibitors of SRD5AIII by contacting SRD5AIII with a test compound and measuring the activity of the enzyme. A reduced activity relative to a control indicates that the test compound is an inhibitor of SRD5AIII. A method is also provided for detecting androgen stimulated prostate cancer or recurrent prostate cancer in an individual. The method comprises obtaining a prostate biopsy from an individual and determining the level of expression of SRD5AIII gene or protein relative to a normal control. An increased expression of SRD5AIII relative to the control is indicative of androgen stimulated prostate cancer or recurrent prostate cancer. | 10-01-2009 |
| 20090246786 | NOVEL RAT VOLTAGE-GATED POTASSIUM CHANNEL - Disclosed herein are nucleic acid and polypeptide sequences of a novel rat voltage-gated potassium channel, KCNQ5. Also disclosed herein are methods related to the use of the aforementioned potassium channel. | 10-01-2009 |
| 20090246787 | METHOD AND APPARATUS FOR DETERMINING CHEMOSENSITIVITY - A method for determining chemosensitivity of a malignant tumor cell to anthracycline is described herein. According to this method, first tumor cell and second tumor sell are first prepared. The first tumor cell is not treated with anthracycline, and on the other the second tumor cell is treated with anthracycline. Secondly, first and second activity levels of CDK1 are measured. The first activity level is activity of CDK1 in the first tumor cell and the second activity level is that of CDK1 in the second tumor cell. Finally, chemosensitivity of the malignant tumor cell is determined. The determination is based on the first and second activity levels. | 10-01-2009 |
| 20090246788 | Methods and Assays for Capture of Nucleic Acids - The present disclosure provides methods and systems for sequence specific nucleic acid target capture comprising enzymatic reactions. The present disclosure relates to a plurality of oligonucleotide probes for capture and subsequent detection of target nucleic acid sequences, using flap endonucleases, ligases, and/or additional enzymes, proteins or compounds, on substrates, for example microarray slides, and in solution formats. | 10-01-2009 |
| 20090246789 | Gene Mutation Profiling of CSMD1 - A method for assessing risk of node-positive colorectal cancer in an individual is described. The method includes detecting mutations in CSMD1 genes in a tumor sample from the individual, the mutations being associated with increased risk of node-positive colorectal cancer. | 10-01-2009 |
| 20090246791 | ENGINEERED FLUORESCENT DYE LABELED NUCLEOTIDE ANALOGS FOR DNA SEQUENCING - Engineered nucleotide compositions, having polymerase interacting components that improve the interactivity of the polymerase and the nucleotide, particularly for nucleic acid sequencing applications. Compositions include the interactive polymerases along with the nucleotide analogs. Kits, methods and systems are provided for analysis of nucleic acid synthesis reactions. | 10-01-2009 |
| 20090246792 | METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIATIONS - The invention employs an unlabeled signal primer comprising a 5′ adapter sequence for detection of variations in nucleic acid target sequences. The detection system further comprises a reporter probe, the 3′ end of which hybridizes to the complement of the 5′ adapter sequence of the signal primer to produce a 5′ overhang. Polymerase is used to fill in the overhang and synthesize the complement of the 5′ overhang of the reporter probe. Synthesis of the reporter probe complement is detected, either directly or indirectly, as an indication of the presence of the target. | 10-01-2009 |
| 20090246793 | CUDR AS BIOMARKER FOR CANCER PROGRESSION AND THERAPEUTIC RESPONSE - Disclosed is a novel human gene designated CUDR. Provides is also a CUDR gene as a biomarker in the diagnosis of human cancers and a cancer therapy. | 10-01-2009 |
| 20090253125 | Denaturat stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same, their uses and methods of increasing a specific activity thereof - Novel denaturant-stable, protease resistant, homo-oligomeric proteins, also referred to herein as stable proteins (SPs), having chaperone-like activity; methods of production and purification of SPs; nucleic acids encoding SPs; methods of isolating nucleic acids encoding SPs; antibodies recognizing SPs; the use of SPs for stabilizing, refolding, repairing, preventing aggregation and de-aggregating macromolecules such as proteins; fusion proteins including SPs; nucleic acid constructs encoding the fusion proteins; and their uses in a variety of methods and applications. | 10-08-2009 |
| 20090253126 | Biomarker Detection Assays - A method for identifying compounds capable of modulating the Notch pathway. The test compound is either administered to an animal or is brought into contact with a cell in culture, after which the expression of the basic helix-loop-helix transcription factor Math1 in a sample from said animal or cell is directed. A change in Math1 expression in the presence of said test compound as compared to in the absence of said compound indicates that said compound modulates the Notch pathway. | 10-08-2009 |
| 20090253127 | Compositions for Marking Objects with DNA and Methods for Marking and Linking an Object to its Owner - The invention can be summarized as follows. There is provided one or more DNA coating compositions that comprise one or more polymer compounds, water, and optionally one or more non-water polar solvents. The DNA coating composition may also comprise DNA. Also provided are methods and kits for marking objects with a DNA coating composition comprising DNA. | 10-08-2009 |
| 20090253128 | NUCLEOTIDE SEQUENCE FOR IDENTIFYING OF ACINETOBACTER BACTERIA, AND METHOD AND KIT OF IDENTIFICATION OF ACINETOBACTER BACTERIA - Nucleotide primers for identifying | 10-08-2009 |
| 20090253129 | IDENTIFICATION OF USA300 COMMUNITY-ASSOCIATED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS - The present invention provides methods for identifying the US A300 strain of methicillin-resistant | 10-08-2009 |
| 20090253130 | BIO MEMORY DISC AND BIO MEMORY DISC DRIVE APPARATUS, AND ASSAY METHOD USING THE SAME - The present invention provides a bio memory disc where a lab-on-a-chip process system including an assay-diagnosis unit, a nucleic acid hybridization assay unit, or an immuno-assay unit and a semiconductor memory is disposed, a bio memory disc drive apparatus including a controller for controlling and driving an optical disc including CD or DVD and the bio memory disc and an assay method using the same. | 10-08-2009 |
| 20090253131 | HYBRID FUSION REPORTER AND USES THEREOF - The invention provides vectors encoding hybrid fusion proteins and vector sets encoding different hybrid fusion proteins useful, for instance, in protein complementation assays. | 10-08-2009 |
| 20090253132 | MUTATED ACVR1 FOR DIAGNOSIS AND TREATMENT OF FIBRODYPLASIA OSSIFICANS PROGRESSIVA (FOP) - This invention is directed to mutated Activin A type I receptor proteins (ACVR1) and isolated nucleic acids encoding same. The invention also relates to the use of mutated ACVR1 in the diagnosis and treatment of Fibrodysplasia Ossificans Progressiva (FOP). | 10-08-2009 |
| 20090253133 | ENHANCED T CELL RECEPTOR-MEDIATED TUMOR NECROSIS FACTOR SUPERFAMILY AND CHEMOKINE MRNA EXPRESSION IN PERIPHERAL BLOOD LEUKOCYTES IN PATIENTS WITH CROHN'S DISEASE - A method is disclosed for determining whether a human having Crohn's disease is likely to respond to a therapy targeting a TNFSF member or a cytokine by measuring the level of certain mRNAs in response to a stimulus. A method of evaluating the effectiveness of a Crohn's disease therapy in a human is also disclosed. Furthermore, a method of screening compounds for use in the treatment of Crohn's disease is disclosed. A method of monitoring the disease state over time in Crohn's disease patients is also disclosed. | 10-08-2009 |
| 20090253134 | Cellular Pyrogen Test - The invention concerns methods, agents and kits for qualitative and quantitative detection and identification of pathogens and pathogen spectra based on endotoxins and other pyrogens. | 10-08-2009 |
| 20090253135 | POLYMORPHISMS OF THE BLyS GENE AND USE IN DIAGNOSTIC METHODS - The present invention provides an isolated polynucleotide comprising at least one polymorphic nucleotide sequence, for example, the major alleles of the SNPs described as rs12583006, rs1224141, and rs1248930 and diagnostic assays for detecting the presence of these polymorphism associated with a condition associated with BLyS activity, such as hematological malignancy including B cell malignancies. The diagnostic assays are useful in predicting an individual's likelihood of developing a condition associated with BLyS activity, such as hematological malignancies, and for methods for treating an individual clinically diagnosed with a condition associated with BLyS activity, such as prediction of a patient's likelihood to respond to a specific drug treatment. The invention also provides an array of nucleic acid molecules immobilized on a solid surface, where at least one of the nucleic acid molecules comprises a BLyS polymorphic nucleic acid molecule. The nucleic acid arrays of the invention allow rapid detection of hybridizing nucleic acid-molecules, in a nucleic acid sample from an individual, of a BLyS polymorphism associated with hematological malignancy. | 10-08-2009 |
| 20090253136 | GENETIC RISK ASSESSMENT TECHNOLOGY FOR EPITHELIAL CANCER INVOLVING GENE-ENVIRONMENT INTERACTION BETWEEN ERCC5 AND TOBACCO USE - Methods and compositions for assessing ERCC5 gene expression in view of certain environmental exposures and determining the risk of an individual for developing one or more epithelial cancers are provided. | 10-08-2009 |
| 20090253137 | METHODS OF SCREENING FOR RISK OF PROLIFERATIVE DISEASE AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASE - A method of screening a subject for a proliferative disease risk factor comprises detecting the presence or absence of upregulation of the CLN3 gene in the subject. The upregulation of the CLN3 gene in the subject indicates the subject is at increased risk of developing a proliferative disease. Methods of screening compounds for the treatment of proliferative diseases based on the CLN3 gene and its product are also disclosed, along with methods of treating such diseases and vectors useful therefore. | 10-08-2009 |
| 20090253138 | KIF20A DIRECTED DIAGNOSTICS FOR NEOPLASTIC DISEASE - Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of KIF20A in the test cell sample or fluid sample as compared to the level of expression of KIF20A in a control cell sample or fluid sample isolated from a normal subject. | 10-08-2009 |
| 20090253139 | Compositions and methods for glioma classification - The present invention provides novel compositions and their use in classifying gliomas. In a preferred embodiment, the methods are used to discriminate between oligodendroglioma and glioblastoma. | 10-08-2009 |
| 20090253140 | ASSAY FOR GENETIC POLYMORPHISMS USING SCATTERED LIGHT DETECTABLE LABELS - Described are methods for determining the presence or absence of particular polymorphisms in CYP2D6 and other genes using scattered light detectable particles as detectable labels, and compositions useful in such methods. | 10-08-2009 |
| 20090253141 | METHODS AND APPARATUSES FOR ANALYZING POLYNUCLEOTIDE SEQUENCES - Methods for high speed, high throughput analysis of polynucleotide sequences, and apparatuses with which to carry out the methods are provided in the invention. | 10-08-2009 |
| 20090253142 | COMPOSITIONS AND METHODS FOR ANALYSIS OF NUCLEIC ACID MOLECULES DURING AMPLIFICATION REACTIONS - The present invention provides systems, methods and kits for performing a detection assay (e.g., invasive cleavage assay) in combination with an amplification assay (e.g., PCR), where the detection assay employs enzyme footprint probes with relatively short (e.g., 6-12 bases) analyte-specific regions configured to provide a preferred footprint length of duplex for use with a particular nucleic acid modifying enzyme. In some embodiments, such assays are used for target quantification, and in other embodiments, such assays are used for genotyping. In certain embodiments, the use of such short probes allows for assays with increased dynamic range. | 10-08-2009 |
| 20090253143 | FLUOROPHORE COMPOUNDS - Provided herein are fluorophore compounds including rhodol and rhodamine compounds which can be used as fluorescent labels and/or fluorogenic probes and methods of making same. Provided also herein are methods that can be used to track, measure, detect, or screen biological species such as protein, DNA, enzyme, antibody, organelle, cell, tissue, drug, hormone, nucleotide, nucleic acid, polysaccharide or lipid in living organisms. Specifically, the methods include the steps of contacting any of the fluorophore compounds, rhodol compounds and rhodamine compounds disclosed herein with the biological species to form one or more fluorescent compounds, and measuring fluorescence properties of the fluorescent compounds. Provided also herein are high-throughput screening fluorescent methods for detecting or screening biological species. | 10-08-2009 |
| 20090253144 | METHODS OF ASSESSING DNA DAMAGE - This invention relates to the finding that HP1β is phosphorylated at Thr51 at an early stage in the DNA damage response in cells. Thr51P HP1β is therefore a biomarker for DNA damage which may be useful, for example, in assessing DNA damage, cancer susceptibility or the responsiveness of an individual to DNA damaging therapies. | 10-08-2009 |
| 20090253145 | METHOD FOR DETECTING AND QUANTITATING MULTIPLE SUBCELLULAR COMPONENTS - A method for detecting and quantitating multiple and unique fluorescent signals from a cell sample is provided. The method combines immunohistochemistry and a fluorescent-labeled in situ hybridization techniques. The method is useful for identifying specific subcellular components of cells such as chromosomes and proteins. | 10-08-2009 |
| 20090258344 | METHODS FOR IDENTIFYING RISK OF BREAST CANCER AND TREATMENTS THEREOF - Provided herein are methods for identifying risk of breast cancer in a subject and/or a subject at risk of breast cancer, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating breast cancer, and therapeutic methods for treating breast cancer in a subject. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome. | 10-15-2009 |
| 20090258345 | PROTEIN ASSOCIATED WITH COLORECTAL CANCER, POLYNUCLEOTIDE INCLUDING SINGLE-NUCLEOTIDE POLYMORPHISM ASSOCIATED WITH COLORECTAL CANCER, MICROARRAY AND DIAGNOSTIC KIT INCLUDING THE SAME, AND METHOD OF DIAGNOSING COLORECTAL CANCER USING THE SAME - Provided are an isolated nucleolar protein having an amino acid sequence of NCBI GenBank Accession No. XP_033371, a method of diagnosing colorectal cancer in an individual, including measuring an expression level of a protein having an amino acid sequence of NCBI GenBank Accession No. XP_033371 in the individual, and a polynucleotide for diagnosis or treatment of colorectal cancer including at least 10 contiguous nucleotides of a nucleotide sequence selected from the group consisting of nucleotide sequences of SEQ ID NOS: 1-5 and including a nucleotide at position 101 of the nucleotide sequence, or a complementary polynucleotide thereof. | 10-15-2009 |
| 20090258346 | Method of selecting sunflower genotypes with high oleic acid content in seed oil - The present invention relates to the selection of sunflower genotypes with high oleic acid content in seed oil. The invention concerns more particularly molecular markers useful for a rapid and easy selection of sunflower lines and then sunflower hybrids capable of producing seeds having high oleic acid content. | 10-15-2009 |
| 20090258347 | METHOD FOR DIAGNOSING AND MONITORING CELLULAR RESERVOIRS OF DISEASE - The invention provides an assay for diagnosing and/or monitoring a viral infection or disease in a patient, the assay including the steps of mixing a sample of leucocytes with a fluorescent cell membrane-permeable dye which stains RNA or both DNA and RNA within the leucocytes; identifying from all the leucocytes at least two of the three major sub-populations of leucoytes selected from the group consisting of monocytes, granulocytes and lymphocytes; determining the fluorescence intensity for each of the identified sub-populations; and comparing the fluorescence intensity of at least two cell sub-populations to each other to obtain at least one of the following ratios: monocytes:granulocytes, monocytes:lymphocytes, and granulocytes lymphocytes. The viral infection may be HIV and the disease may be AIDS. The invention also provides a method of monitoring the cellular viral, parasitic or bacterial reservoir of a patient with a viral or bacterial infection by the steps described above. A, kit for performing the assay or method is also provided. | 10-15-2009 |
| 20090258348 | ESTERASES FOR MONITORING PROTEIN BIOSYNTHESIS IN VITRO - The present invention relates to the use of an esterase for monitoring and/or tracking the synthesis of a protein, polypeptide or peptide in a cell-free translation system or in an in vivo expression system in which the synthesis of a protein, polypeptide or peptide can occur, wherein said monitoring and/or tracking comprises the detection of the function of said esterase. The present invention further relates to a vector comprising a nucleic acid molecule coding for an esterase and expressing an esterase fusionprotein. Moreover, the present invention relates to a vector comprising a nucleic acid molecule coding for an esterase and comprising in frame at least one multiple cloning site for a further protein/polypeptide/peptide, to be expressed in form of a fusion protein comprising said esterase (esterase activity) and said further proteinaceous peptide structure. The present invention also provides for a protein, polypeptide or peptide encoded by the vectors of the present invention. Additionally, the present invention relates to a kit comprising a vector of the present invention or a nucleic acid molecule as comprised by the vectors of the present invention. Also disclosed is a method for monitoring and/or tracking the synthesis of a protein, polypeptide or peptide in a cell-free translation system or in an in vivo expression system, comprising the step of detecting the function of an esterase. The present invention also teaches a method for immobilising a protein, polypeptide or peptide comprising the steps of (a) tagging said protein, polypeptide or peptide with an esterase and (b) binding said esterase to an esterase inhibitor, wherein said esterase inhibitor is immobilized on a solid substrate. Moreover, the present invention relates to uses of the vectors of the present invention or the nucleic acid molecules comprised therein for the preparation of a kit or for monitoring and/or tracking the synthesis of a protein, polypeptide or peptide in a cell-free translation system, whereby the monitoring and/or tracking comprises the detection of the function of said esterase. | 10-15-2009 |
| 20090258349 | METHOD FOR DETECTING AND QUANTIFYING PERCHLORATE-REDUCING BACTERIA - The present invention provides methods, compositions, and kits for detecting and quantitating perchlorate-reducing bacteria in samples using reagents that hybridize to and allow amplification of the pcrA gene. The invention includes a quantitative real-time PCR assay for amplification of the pcrA gene which may be used to detect and quantitate perchlorate-reducing bacteria in samples. | 10-15-2009 |
| 20090258350 | Diagnostic methods for determining prognosis of non-small cell lung cancer - The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at two or more of chromosome 5p15, 7p12, 8q24 and centromere 6 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. Assessment of the copy number abnormality patterns using four classifiers produced statistically significant prognostic classification for NSCLC: (i) the Range3 pattern of cells showing a difference on a cell by cell basis, of at least three FISH probe signals between the FISH signals at the chromosomal locus with the largest number of FISH signals minus the FISH signals at the chromosomal locus with the lowest number of FISH signals; (ii) the MYC/EGFR % loss pattern assessing the percentage of cells showing fewer MYC FISH probe signals than EGFR FISH probe signals; (iii) a combination of the Range3 pattern and the MYC/CEP6 ratio pattern of a percentage of cells showing a relative loss of MYC FISH probe signals to the FISH probe signal for CEP6; (iv) the combination of the MYC/5p15 ratio pattern showing the relative ratio of MYC and 5p15 locus signals of ≧0.80 and the 5p15/CEP6 ratio pattern assessing percentage of cells having a relative ratio of 5p15 FISH probe signals to CEP6 FISH probe signals ≧1.1 versus MYC/5p15 ratio of <0.80 or 5p15/CEP6<1.1; and (v) a combination of the average range of probe signal differences of equal to or greater than about 2.5 with the Range3 pattern in a percentage of the cells. The invention can be used to identify those early stage NSCLC patients at higher risk of recurrence who should be treated with neoadjuvant chemotherapy before surgery or with adjuvant chemotherapy after surgery. | 10-15-2009 |
| 20090258351 | Methods and Reagents for Combined PCR Amplification - An oligonucleotide probe is disclosed, the probe including an oligonucleotide, a fluorescer molecule attached to a first end of the oligonucleotide and a quencher molecule attached to the opposite end of the oligonucleotide. The probe is rendered impervious to digestion by the 5′→3′ exonuclease activity of a polymerase and the 5′→3′ extension of by a polymerase. The invention also includes methods for performing combined PCR amplification and hybridization probing, one such method including the steps of contacting a target nucleic acid sequence with PCR reagents and an oligonucleotide probe as described above, and subjecting these reagents to thermal cycling. One preferred refinement of the above method further includes the addition of a strand displacer to facilitate amplification. Additional similar combined PCR hybridization methods are disclosed, such methods not requiring probes having their 5′ ends protected, wherein (i) the polymerase lacks 5′→3′ exonuclease activity, (ii) a 5′→3′ exonuclease inhibitor is included, and (iii) an exonuclease deactivation step is performed. | 10-15-2009 |
| 20090258352 | Pin1 as a marker for abnormal cell growth - Methods for the use of Pin1 as a marker of abnormal cell growth are disclosed. In one embodiment, the method includes detecting a level of Pin1 to stage an abnormal cell growth, such as breast or prostate cancer. In another embodiment, the method includes evaluating the efficacy of a treatment of an abnormal cell growth, such as cancer, by monitoring the levels of Pin1. In another embodiment, the method includes evaluating the extent of metastasis of abnormal cell growth, such as cancer. The levels of Pin1 can be protein levels or nucleic acid levels. | 10-15-2009 |
| 20090258353 | PCR primer capable of reducing non-specific amplification and PCR method using the PCR primer - The present invention relates to a PCR primer facilitating hot-start PCR by suppressing non-specific amplification at room temperature and at the same time capable of reducing significantly non-specific amplification by dominating the amplification of the PCR product rather than the amplification of the original template from the third PCR cycle, more precisely a PCR primer prepared by additionally inserting the reverse-complementary sequence to a certain region starting from the 5′-start site of the 5′-terminus of the original primer which is composed of priming sequence to anneal to a PCR template into the 5′-terminus of the original primer and a PCR method using the same. The primer of the present invention has a original primer sequence composed of priming sequence to anneal to a PCR template and an additional reverse-complementary sequence, which inserted into the 5′-terminus of the original primer, to a certain region starting from the 5′-start site of the 5′-terminus of the original primer sequence, suggesting that a template-specific sequence and its reverse-complementary sequence are included in the same primer. The present invention can improve PCR specificity by reducing non-specific amplification. | 10-15-2009 |
| 20090258354 | Methods for DNA Length and Sequence Determination - Methods for determining nucleic acid length and sequence variation are provided, for example, between an unknown sample and a reference sample. In various embodiments, a method amplifies one or more specific regions of an oligonucleotide molecule in a sample comprising oligonucleotide molecules to produce a sample of amplicons, the sample of amplicons comprising two or more different amplicons. In various embodiments, two or more specific regions are amplified. In various embodiments, the methods (i) denature the amplicons in the sample of amplicons to produce a first set of single-stranded amplicons and a second set of single-stranded amplicons, single stranded amplicons of the second set being complementary to the corresponding single stranded amplicons of the first set and (ii) subject at least the first and second set of single stranded amplicons to mass spectrometric analysis to obtain the masses of the amplicons in the first and second set of single-stranded amplicons. The masses of the amplicons are then used, at least ultimately in part, to determine nucleic acid length and sequence variation. | 10-15-2009 |
| 20090258355 | Nanoscale Clusters and Methods of Making Same - The present invention is a method of making a nanocluster. The method comprises providing a surface comprising at least one anchoring biomolecule, wherein the surface is in a solution; adding an initial recognition-nano-component to the solution wherein the initial recognition-nano-component comprises i) a nanoparticle and one specifically-bindable-biomolecule, or ii) a nanoparticle and two different types of specifically-bindable-biomolecules, wherein a biomolecule of the initial recognition-nano-component specifically binds to the anchoring biomolecule; and adding a releasing biomolecule to the solution, wherein the releasing biomolecule binds to the anchoring biomolecule with a greater binding strength than the anchoring biomolecule binds to the initial recognition-nano-component, or wherein the releasing biomolecule binds to the initial recognition-nano-component with a greater binding strength than anchoring biomolecule binds to the initial recognition-nano-component, thereby making a nanocluster. | 10-15-2009 |
| 20090258356 | Modulators of the transporter ABCD3 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of the peroxisome membrane transporter 1 comprising a type 3 ATP-binding site of the sub-family D (ABCD3), and the use of modulators of the expression or activity of this transporter for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 10-15-2009 |
| 20090258357 | CYTOKINE RECEPTOR COMMON GAMMA CHAIN LIKE - The present invention relates to a novel human gene encoding a polypeptide which is a member of the Cytokine Receptor family. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named Cytokine Receptor Common Gamma Chain Like, or “CRCGCL.” This invention also relates to CRCGCL polypeptides, as well as vectors, host cells, antibodies directed to CRCGCL polypeptides, and the recombinant methods for producing the same. Also provided are diagnostic methods for detecting disorders related to the immune system, and therapeutic methods for treating diagnosing, detecting, and/or preventing such disorders. The invention further relates to screening methods for identifying agonists and antagonists of CRCGCL activity. | 10-15-2009 |
| 20090258358 | Methods for Diagnosing and Treating Kidney and Colorectal Cancer - Methods, reagents and kits for diagnosing and treating cancer such as kidney or colorectal cancer are disclosed. An immunoassay for detecting kidney or colorectal cancer is based on the relative change of the ADAMTSL4 protein in urine or blood compared with normal tissue. An immunohistochemical assay for detecting kidney or colorectal cancer is based on the relative absence of labeled antibody binding to cancerous tissue, compared with normal tissue. | 10-15-2009 |
| 20090258359 | MODULAR COMPOSITING-MULTIPLE LOT SCREENING PROTOCOLS FOR DETECTION OF PATHOGENS, MICROBIAL CONTAMINANTS AND/OR CONSTITUENTS - Provided are methods for sampling, testing and validating test lots, comprising: assembling a plurality of product portions from each of a plurality of test lots and combining the portions to provide a corresponding set of test lot samples; enriching the test lot samples; removing portions of each enriched sample, and combining the removed portions to provide a modular composite sample; and testing of the modular composite sample, and individual testing of the enriched test lot samples, using at least one suitable detection assay for a target microbe or organism, wherein when such testing is negative all test lots are validated, and wherein when such testing is positive with respect to the modular composite sample, or with respect to an individual enriched test lot sample, individual test lots may nonetheless yet be validated by further testing of a portion of respective initially-negative enriched test lot samples and obtaining negative results. | 10-15-2009 |
| 20090258360 | METHOD OF DETECTING EQUINE POLYSACCHARIDE STORAGE MYOPATHY - The present invention relates to diagnosing Polysaccharide Storage Myopathy (PSSM) disease in equines. | 10-15-2009 |
| 20090258361 | VARIANT TLR4 NUCLEIC ACID AND USES THEREOF - The invention provides methods to identify polymorphisms at the human TLR4 locus, as well as methods to identify individuals at risk of indications that increase their morbidity and mortality. | 10-15-2009 |
| 20090258362 | RNA Bioassay - The present invention relates to methods for characterizing the pathological state of the kidney, methods of characterizing an agent, methods of evaluating the kidney protective and therapeutic characteristics of an agent and methods of monitoring the effect of a pharmaceutical agent on the kidney of a subject, related to measuring a kidney RNA marker in the urine of a subject. | 10-15-2009 |
| 20090258363 | Targeted integration and expression of exogenous nucleic acid sequences - Disclosed herein are methods and compositions for targeted integration of a exogenous sequence into a predetermined target site in a genome for use, for example, in protein expression and gene inactivation. | 10-15-2009 |
| 20090258364 | Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib - A method of determining if a cancer patient is amenable to treatment with EGFR inhibitors including but not limited to cetuximab, panitumumab or erlotinib by the following steps:
| 10-15-2009 |
| 20090258365 | METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH - The present invention describes methods and probe composition for an automated FISH assay of a blood sample containing circulating tumor cells expressing the IGF-1R gene. The assay provides genetic analysis of suspect circulating tumor cells that have been identified after immunomagnetic selection and fluorescent labeling. Using unique, repeat-free probes to the IGF-1R locus and a chromosome 15 reference probe, cell lines expressing an aberrant number of IGF-1R and Chr 15 signals were detected, including one cell line with a low level of IGF-1R amplification. The ability to directly examine the genetic profile of IGF-1R on circulating tumor cells may provide an automated means for assessing disease and patient response to therapy. | 10-15-2009 |
| 20090258366 | pCryptoRNAi - A vector developed to transform fungi can be used to study the expression of a gene of interest. The vector can provide for the expression of signal proteins in fungi that can be observed and/or monitored. The vector can be used to investigate the effects of RNA interference on a gene of interest in pathogenic fungi. Systems and methods of using the vector are provided. | 10-15-2009 |
| 20090258367 | METHOD OF MAPPING OF mRNA DISTRIBUTION WITH ATOMIC FORCE MICROSCOPY - The present invention relates to a method of mapping of mRNA distribution, comprising the steps of a preparing a probe DNA attached to a apical liner region of the dendron on AFM cantilever where the probe DNA can specifically hybridize a target mRNA and measuring specific adhesive force between the probe DNA and the target mRNA on sectioned tissue at nanometer resolution. | 10-15-2009 |
| 20090258368 | PARAMAGNETIC NUCLEATION NANOPARTICLES - A nucleic acid binding substance which has affinity for nucleic acid polymers. The nucleic acid binding substance is comprised of a nucleic acid binding element capable of specific binding to nucleic acid molecules and connected to a nucleation nanoparticle having paramagnetic properties. | 10-15-2009 |
| 20090258369 | OVER-EXPRESSION AND MUTATION OF A TYROSINE KINASE RECEPTOR FGFR4 IN TUMORS - This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR4 variants, which are linked to increased risk of tumor metastasis. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions. | 10-15-2009 |
| 20090258370 | Acute Myelogenous Leukemia Biomarkers - The present invention provides novel compositions and their use in classifying acute myelogenous leukemia. | 10-15-2009 |
| 20090263789 | Method for Detecting Nucleic Acid Sequences - The invention is directed to a method for detecting a target nucleic acid sequence by non-linear amplification. | 10-22-2009 |
| 20090263790 | Methods for Identifying Functionally Related Genes and Drug Targets - The identification and evaluation of mRNA and protein targets associated with mRNP complexes and implicated in the expression of proteins involved in common physiological pathways is described. Effective targets are useful for treating a disease, condition or disorder associated with the physiological pathway. | 10-22-2009 |
| 20090263791 | Chemically Cleavable 3'-O-Allyl-DNTP-Allyl-Fluorophore Fluorescent Nucleotide Analogues and Related Methods - This invention provides a nucleotide analogue comprising (i) a base selected from the group consisting of adenine, guanine, cytosine, thymine and uracil, (ii) a deoxyribose, (iii) an allyl moiety bound to the 3′-oxygen of the deoxyribose and (iv) a fluorophore bound to the base via an allyl linker, and methods of nucleic acid sequencing employing the nucleotide analogue. | 10-22-2009 |
| 20090263792 | ATOPIC DERMATITIS MARKER AND TECHNIQUE OF USING THE SAME - It is an object of the present invention to find substances that can be used as disease markers for atopic dermatitis and the present invention provides a method for determining atopic dermatitis, including measurement of the expression of specific proteins and/or their genes in skin cells and/or skin tissues, wherein the specific proteins change their expression with inflammation caused by atopic dermatitis or change their expression according to the degree of predisposition to atopic dermatitis. The present invention also provides a kit for determining the degree of inflammation of atopic dermatitis or risk of developing atopic dermatitis, as well as a method for determining substances effective in the treatment and/or prevention of atopic dermatitis. | 10-22-2009 |
| 20090263793 | NOVEL METHOD FOR DIAGNOSING OF MYCOBACTERIUM Tuberculosis - The present invention relates to a method and a kit for detecting | 10-22-2009 |
| 20090263794 | High Throughput Flow Through Sample Preparation Using Magnetic Beads - A polymerase chain reaction system for analyzing a sample containing nucleic acid includes providing magnetic beads; providing a flow channel having a polymerase chain reaction chamber, a pre polymerase chain reaction magnet position adjacent the polymerase chain reaction chamber, and a post pre polymerase magnet position adjacent the polymerase chain reaction chamber. The nucleic acid is bound to the magnetic beads. The magnetic beads with the nucleic acid flow to the pre polymerase chain reaction magnet position in the flow channel. The magnetic beads and the nucleic acid are washed with ethanol. The nucleic acid in the polymerase chain reaction chamber is amplified. The magnetic beads and the nucleic acid are separated into a waste stream containing the magnetic beads and a post polymerase chain reaction mix containing the nucleic acid. The reaction mix containing the nucleic acid flows to an analysis unit in the channel for analysis. | 10-22-2009 |
| 20090263795 | DIAGNOSTIC METHODS INVOLVING DETERMINING GENE COPY NUMBERS AND SNPs IN THE FcyRII/FcyRIII GENE CLUSTER, AND PROBES FOR USE IN SUCH METHODS TO DETECT SUSCEPTIBILITY TO AND TREATMENT EFFICACY IN AUTOIMMUNE DISEASES - The invention relates to diagnostic methods to predict whether a subject is predisposed for acquiring a disease or to predict the therapy responsiveness of an individual patient. Provided is a method for determining whether a subject is predisposed for developing an autoimmune disease, comprising determining in a sample isolated from said subject the amount of intact genes, or gene products thereof, of the FcγRII/FcγRIII gene cluster, said gene cluster comprising the FCGR2C, FCGR3A, FCGR2A and FCGR3B genes encoding an activating FcγR, and FCGR2B encoding an inhibitory Fcγ R; and correlating said amount to the amount observed in a healthy population. Also provided is a method to predict the responsiveness of a subject to therapy with intravenous immunoglobulin (IVIg) therapy or a monospecific biological, such as a humanized or human monoclonal antibody or a chimeric molecule, comprising the C-terminal Fc-tail of IgG. | 10-22-2009 |
| 20090263796 | METHODS AND COMPOSITIONS FOR DIAGNOSING OR MONITORING AUTOIMMUNE AND CHRONIC INFLAMMATORY DISEASES - Methods of diagnosing or monitoring an autoimmune or chronic inflammatory disease, particularly SLE in a patient by detecting the expression level of one or more genes or surrogates derived therefrom in the patient are described. Diagnostic oligonucleotides for diagnosing or monitoring chronic inflammatory disease, particularly SLE infection and kits or systems containing the same are also described. | 10-22-2009 |
| 20090263797 | REVERSIBLE DI-NUCLEOTIDE TERMINATOR SEQUENCING - The present teachings provide methods, compositions, and kits for synthesizing and sequencing nucleic acids. In some embodiments, reversible di-nucleotide compounds are employed along with cleaving reactions that remove a label and a blocking moiety. Improved sequencing efficiency is achieved by the rapid polymerase-mediated incorporation of reversible di-nucleotide compounds. In some embodiments, the di-nucleotides do not contain conventional nucleotide triphosphates, but rather employ amino acid phosphoramidate nucleotides (AAPNs). | 10-22-2009 |
| 20090263798 | Method For Identification Of Novel Physical Linkage Of Genomic Sequences - The invention is directed to methods to identify the location in a genome of a nonfixed or multicopy genomic element using microarrays or sequencing. | 10-22-2009 |
| 20090263799 | ASSAY FOR PROSTATE CANCER - In certain embodiments, a method for detecting a prostate proliferative cell disorder, a prostate cancer or a prostate tumor and/or categorizing Gleason's Sum of the tumors includes performing a digital rectal examination on a subject; obtaining one or more expressed prostatic secretion (EPS) samples from the subject; measuring PSA levels in the EPS; and measuring a biomarker, wherein the biomarker is TMPRSS2:ERG fusion RNA. Optionally, the biomarker may be methylated copies of GSTPI, APC, RARB and/or RASSFI DNA or PCA3 RNA. A kit for performing any of the above embodiments is also contemplated. | 10-22-2009 |
| 20090263800 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION - Methods of diagnosing or monitoring transplant rejection or cytomegalovirus infection in a patient by detecting the expression level of one or more genes or surrogates derived therefrom in the patient are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant rejection or cytomegalovirus infection and kits or systems containing the same are also described. | 10-22-2009 |
| 20090263801 | Phenotype-Genotype Relationship in Age-Related Macular Degeneration - Age-Related Macular Degeneration (AMD) cases possessing the LOC387715 (rs10490924) variant have a higher risk of neovascular AMD. Individuals with AMD who are homozygous for both variants might be at greater risk for earlier onset of neovascular AMD. Determining the presence of this variant indicates which path the disease may take and which nutritional, supplement, or medicaments are appropriate. | 10-22-2009 |
| 20090263802 | Methods and compositions for efficient base calling in sequencing reactions - The present invention is directed to methods and compositions for acquiring nucleotide sequence information of target sequences. In particular, the present invention provides methods and compositions for improving the efficiency of sequencing reactions by using fewer labels to distinguish between nucleotides and by detecting nucleotides at multiple detection positions in a target sequence. | 10-22-2009 |
| 20090263803 | MIRNAS DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS - The present invention provides diagnostics and/or prognostic methods by identifying miRNAs that are differentially expressed or mis-regulated in various states of diseased, normal, cancerous, and/or abnormal tissues, including but not limited to cervix, skin, colon, breast, bladder, esophagus, liver, ovary, prostate, lung, pancreas, thyroid, kidney, stomach, testicle, uterus, spleen, tongue, brain, thymus, trachea and/or small intestine. In certain apsects, differential miRNA expression is initially determined by comparing miRNA expression between a normal tissue and cancer negative lymph node (LNneg), a normal tissue and a cancer positive lymph node (LNpos), a cancerous tissue and LNneg and/or LNpos, LNneg and LNpos. The methods of the invention are used to identify the presence or absence of non-lymphoid cells from other organs or tissues, and/or metastatic cancer cells present in lymph nodes. | 10-22-2009 |
| 20090263804 | Biomarkers for aging - A statistical and functional correlation strategy to identify changes in cellular pathways specifically linked to impaired cognitive function with aging. Analyses using the strategy identified multiple groups of genes expressed in the hippocampi of mammals, where the genes were expressed at different levels for several ages. The aging changes in expression began before mid-life. Many of the genes were involved in specific neuronal and glial pathways with previously unrecognized relationships to aging and/or cognitive decline. These identified genes and the proteins they encode can be used as novel biomarkers of brain aging and as targets for developing treatment methods against age-related cognitive decline, Alzheimer's Disease and Parkinson's Disease. | 10-22-2009 |
| 20090263805 | Methods of identifying point mutations in a genome that affect the risk for or the age of appearance of disease - The invention relates to a method for identifying inherited point mutations in a targeted region of the genome in a large population of individuals and determining which inherited point mutations are deleterious, harmful or beneficial. Deleterious mutations are identified directly by a method of recognition using the set of point mutations observed in a large population of juveniles. Harmful mutations are identified by comparison of the set of point mutation observed in a large set of juveniles and a large set of aged individuals of the same population. Beneficial mutations are similarly identified. | 10-22-2009 |
| 20090263806 | Method for detecting chikungunya virus - Compositions, methods and kits for detecting Chikungunya viral nucleic acids. Particularly described are methods for detecting very low levels of the viral nucleic acids using nucleic acid amplification. | 10-22-2009 |
| 20090263807 | OPTICAL DETECTION FIELD HAVING DIAMOND-LIKE CARBON THIN FILM FORMED THEREIN - An optical detection field, wherein a diamond-like carbon thin film containing therein fluorine is formed on a surface facing an existence region of a substance. | 10-22-2009 |
| 20090263808 | Genetic Analysis For Stratification of Cancer Risk - The present invention provides new methods for the assessment of cancer risk in the general population. These methods utilize particular alleles of two or more genes, in combination, to identify individuals with increased or decreased risk of cancer. Exemplified is risk assessment for breast cancer in women. In addition, personal history measures such as age and race are used to further refine the analysis. Using such methods, it is possible to reallocate healthcare costs in cancer screening to patient subpopulations at increased cancer risk. It also permits identification of candidates for cancer prophylactic treatment. | 10-22-2009 |
| 20090263809 | Methods for Identification of Bioagents - Methods for detecting and identifying known and unknown bioagents, particularly bacteria, by nucleic acid amplification and amplicon size determination are provided. Nucleic acid amplification utilises multiple primers which hybridize to conserved bioagent ribosomal sequence regions and which bracket variable bioagent ribosomal sequence regions to produce multiple amplicons that uniquely identify the bioagent. | 10-22-2009 |
| 20090263810 | BISULFITE CONVERSION OF DNA - The present invention provides an improved method for the bisulfite conversion of DNA, and facilitates the analysis of cytosine methylation of genomic DNA. Novel combinations of denaturing solvents, new reaction conditions and new purification methods provide surprisingly efficacious methods for bisulfite conversion of DNA relative to prior art methods. The converted DNA may subsequently be analyzed by many different methods. | 10-22-2009 |
| 20090263811 | TARGET BASE DISCRIMINATION METHOD - A target base-specific primer for use in discrimination of the base type of a target base in a nucleic acid in a nucleic acid sample, which is capable of discriminating the target base clearly with less possibility of false positive, and a target base discrimination method using the target base-specific primer, are provided. The target base discrimination method of the present invention uses a target base-specific primer for use in discrimination of the base type of a target base in a nucleic acid having a target nucleotide sequence including the target base in a nucleic acid sample, in the case where a plurality of base types can be enumerated for the target base, wherein the primer has a target base-corresponding base which is a base complementary to a base predicted as the target base, and the base type of a mismatch base is a specific base type when the mismatch base refers to a base adjacent to the 5′ side of the target base-corresponding base, and a mismatch-corresponding base refers to a base adjacent to the 3′ side of the target base in the target nucleotide sequence. | 10-22-2009 |
| 20090263812 | USE OF ID4 FOR DIAGNOSIS AND TREATMENT OF CANCER - The invention relates to a method of determining whether a human subject is suffering from or at risk for developing pancreatic cancer by determining the methylation level of an ID4 gene promoter or the expression level of an ID4 gene in a biological sample from a human subject. Also disclosed are a method of analyzing the methylation level of an ID4 gene promoter or the expression level of an ID4 gene in a pancreatic cancer cell, and a method of inhibiting the methylation of an ID4 gene promoter or enhancing the expression of an ID4 gene by contacting a pancreatic cancer cell with a compound that decreases the methylation level of an ID4 gene promoter or increases the expression level of an ID4 gene in the cell. | 10-22-2009 |
| 20090263813 | RIBONUCLEOTIDE TAG NUCLEIC ACID DETECTION - The present application provides polynucleotides comprising 5′-tails with sequence segments useful for the detection of target nucleic acid sequences, and methods for their use in detecting target nucleic acids. The polynucleotides are used to amplify a subsequence of a target nucleic acid in the presence of one or more ribonucleotides. The ribonucleotides are incorporated into amplification products at regular intervals complementary to the 5′-tail sequence segments. Cleavage of amplification products at the bond immediately 3′ to incorporated ribonucleotides produces detectably distinct fragments indicative of the presence or absence of a target nucleic acid. | 10-22-2009 |
| 20090263814 | Physiogenomic Method for Predicting Metabolic and Cardiovascular Side Effects of Thiazolidinediones - Disclosed herein are genetic markers related to the efficacy and/or safety of thiazolidinedione therapy identified by a physiogenomic methodology that correlates the genetic markers with a physiological response. The genetic markers described herein were not previously associated with the efficacy and/or safety of thiazolidinedione therapy. The markers related to safety are those associated with the important side effects of BMI increase and development of edema. In one embodiment, markers related to efficacy of thiazolidinedione therapy are associated with glycosylated hemoglobin. Method of assessing an individual for markers associated with the safety and/or efficacy of thiazolidinedione therapy are described. | 10-22-2009 |
| 20090263815 | CELL CULTURE SYSTEM, PROCESS FOR THE PRODUCTION THEREOF, AND THE USE THEREOF IN PRECLINICAL INVESTIGATION - The invention relates to a cell culture system, in particular for the preclinical testing of active substances, comprising a first and a second compartment which are in communication with one another via a separating layer between the first and the second compartment, the separation layer being permeable for cellularly secreted substances, wherein the first compartment includes a syntopic culture with tissue cells and immune cells and the second compartment includes a culture with blood cells. The invention further relates to a method in this regard and to a kit and uses for the preclinical testing of active substances. | 10-22-2009 |
| 20090263816 | LABELLED BEADS - A labelled polymeric bead wherein individual beads comprise a primary particle formed of a synthetic polymeric material, and at least one secondary particle entrapped within the primary particle of the bead and being comprised of a synthetic polymer material incorporating reporter moieties. | 10-22-2009 |
| 20090263817 | METHODS FOR DIAGNOSING AND TREATING SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE AND COMPOSITIONS THEREOF - The present invention is directed to novel methods for diagnosis and prognosis of Systemic lupus erythematosus by identifying differentially expressed genes. Moreover, the present invention is also directed to methods that can be used to screen test compounds and therapies for the ability to inhibit systemic lupus erythematosus. Additionally, methods and molecule targets (genes and their products) for therapeutic intervention in systemic lupus erythematosus are described. | 10-22-2009 |
| 20090263818 | Method of estimating the risk of expression of adverse drug reaction caused by the administration of a compound, which is either metabolized per se by UGT1A1 enzyme or whose metabolic intermediate is metabolized by the enzyme - A method of estimating a risk of the expression of an adverse drug reaction caused by the administration of irinotecan, and a method of reducing the adverse drug reaction caused by the administration of irinotecan. A polymorphism on the basis of a difference in the repeating numbers of TA repetitive sequences in the promoter region of UGT1 gene and two types of polymorphisms (bases at the 211- and 686-positions) on the basis of single nucleotide polymorphisms in the exon 1 are analyzed. Based on the analytical data, the risk of the expression of an adverse drug reaction caused by the administration of irinotecan is estimated. Further, the administration doses of irinotecan is designed for individual patients depending on the risk of the expression of the adverse drub reaction, thereby reducing the adverse drug reaction caused by the administration of irinotecan. | 10-22-2009 |
| 20090263819 | GENE AND PROTEIN EXPRESSION PROFILES ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF EGFR-TK INHIBITORS - The present invention provides protein and gene expression profiles indicative of whether a patient afflicted with non-small cell lung cancer is likely to be responsive to treatment with a therapeutic compound that is a EGFR-TK inhibitor. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and protein expression profiles, and assays for identifying the presence of a gene or protein expression profile in a patient sample. | 10-22-2009 |
| 20090263820 | Optimization of Gene Expression Analysis using Immobilized Capture Probes - Disclosed are methods of multiplexed analysis of oligonucleotides in a sample, including: methods of probe and target “engineering”, as well as methods of assay signal analysis relating to the modulation of the probe-target affinity constant, K by a variety of factors including the elastic properties of target strands and layers of immobilized (“grafted”) probes; and assay methodologies relating to: the tuning of assay signal intensities including dynamic range compression and on-chip signal amplification; the combination of hybridization-mediated and elongation-mediated detection for the quantitative determination of abundance of messages displaying a high degree of sequence similarity, including, for example, the simultaneous determination of the relative expression levels, and identification of the specific class of, untranslated AU-rich subsequences located near the 3′ terminus of mRNA; and a new method of subtractive differential gene expression analysis which requires only a single color label. | 10-22-2009 |
| 20090269736 | Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients - Aspects of the present invention provide compositions and methods for prognosis of, and/or predicting the estrogen treatment outcome of breast cell proliferative disorder patients, and in particular of patients with breast carcinoma. In preferred embodiments, this is achieved, at least in part, by determining the expression level of PITX2, and/or the genetic or the epigenetic modifications of the genomic DNA associated with the gene PITX2. Additional aspects of the invention provide novel sequences, oligomers (e.g., oligonucleotides or peptide nucleic acid (PNA)-oligomers), and antibodies, which have substantial utility in the described inventive methods and compositions. | 10-29-2009 |
| 20090269737 | Integrated non-homogeneous nucleic acid amplification and detection - The present invention relates to an integrated method of amplifying and analyzing target nucleic acids, in which immobilized or immobilizable oligonucleotide capture probes are provided and a nucleic acid containing sample to be analyzed is added together with a reagent mixture, which mixture contains all reagents needed for amplification and subsequent analysis of said target nucleic acids. In the method amplification of the target nucleic acids, hybridization of said amplified target nucleic acids to the capture probes and separating the hybrids formed from un-reacted components, as well as the detection and measuring of the amount of labeled, hybridized target nucleic acids by means of a detectable signal, is performed in one reaction chamber. Further provided are reagent mixtures and kits for use in such methods. | 10-29-2009 |
| 20090269738 | Method of Screening for the Presence of a Genetic Defect Associated With Deep Venous Thrombosis - The present invention relates to a method for screening an individual for the presence in his/her genome of a genetic marker that is indicative of an increased risk of deep venous thrombosis, wherein the genetic marker is haplotype 2 of the fibrinogen γ gene (FGG-H2) as given in FIG. | 10-29-2009 |
| 20090269739 | Kit for detection of telomerase reverse transcriptase nucleic acids - The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers. | 10-29-2009 |
| 20090269740 | Pancreatic Cancer Genes - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia. | 10-29-2009 |
| 20090269741 | Method for assessing traits selected from longissimus dorsi peak force, intramuscular fat, retail beef yield and net feed intake in bovine animals - A method for assessing a trait in a bovine animal selected from the group consisting of longissimus dorsi peak force, intramuscular fat, retail beef yield and net feed intake, comprising the steps of: (1) providing a nucleic acid from the bovine animal or carcass; (2) assaying for the occurrence of a single nucleotide polymorphism (SNP), wherein the identification of said nucleotide occurrence as set forth herein is associated with variation in longissimus dorsi peak force, intramuscular fat deposition, retail beef yield or net feed intake. | 10-29-2009 |
| 20090269742 | SUBSTRATE FOR IMMOBILIZING BIOPOLYMER AND METHOD OF IMMOBILIZING BIOPOLYMER BY USING THE SAME - [Problems] To immobilize a chain-type biopolymer in an elongated state at a predetermined position on a substrate. | 10-29-2009 |
| 20090269743 | DNA Collection Sticker and Method for Isolating DNA From the Sticker - The present invention relates a sticker for DNA collection and a method for isolating DNAs using the same. Particularly, the sticker for DNA collection is covered with a paint solution comprising EDTA, Tris, SDS and peyonine to isolate keratins exclusively when attached onto human skin and detached. Further, the specific sticker for DNA collection separates DNAs efficiently to amplify genes by using a PCR technique. Therefore, the present invention can be applied to identify a real child and investigate a crime with a fingerprint and to screen genetic diseases. | 10-29-2009 |
| 20090269744 | CANCER DETECTION METHOD - The present application concerns methods and compositions which can be used to detect cancer in mammals, in particular in humans. It notably describes serum markers of cancers and their uses in diagnosis methods. It also concerns tools and/or kits which can be used to implement these methods (reagents, probes, primers, antibodies, chips, cells, etc.), their preparation and their uses. The invention can be used to detect the presence or the progression of a cancer, particularly breast cancer, including at an early stage. | 10-29-2009 |
| 20090269745 | RNA EXTRACTION METHOD AND RNA DETECTION METHOD - The present invention provides a method for inactivating RNase which generally presents in a sample such as biological sample (especially an excrement sample), or in a sample such as a living body-derived sample (especially an excrement-derived sample) obtained by separation of an RNA-including body therefrom or the like; a method for extracting and detecting RNA from the sample. An RNA extraction method, comprising the steps of: obtaining a mixture under a heating condition, said mixture comprising: a sample comprising an RNA-including body and RNase, and an alkaline treating reagent comprising at least a reducing agent, and having pH of 8.1 or higher, and conducting inactivation of the RNase and extraction of RNA from the RNA-including body by keeping the mixture under the heating condition. An RNA detection method, comprising conducting RNA amplification reaction by mixing a treated sample liquid comprising RNA extracted by the extraction method and an amplification reaction solution. | 10-29-2009 |
| 20090269746 | MICROSEQUENCER-WHOLE GENOME SEQUENCER - The method and apparatus are disclosed to support speedy sequencing of genomes of individuals. The method comprises random digestion of a stretch of DNA; adaptor ligation of adaptor DNA fragments to DNA segments produced in random digestion, each said adaptor DNA fragment containing a sequence which is complementary to a single DNA primer; PCR amplification of the ligated segments produced in adaptor ligation, utilizing a single DNA primer; distributing the ligated segments into one or more pre-defined isolated locations of a sequencing apparatus, each said location containing DNA fragments placed there for capturing a unique kind of digested DNA segments; capturing at each location a unique kind of amplified DNA segments by hybridization with the DNA fragments, dislodging captured DNA segments from DNA fragments; adding DNA sequencing reaction components into the locations; performing sequencing reactions at each location; separating the products of the sequencing reactions in the sequencing apparatus; and determining the sequences of DNA segments captured at individual locations of the sequencing apparatus. The apparatus comprises one or more isolated locations, each location has a reservoir containing DNA fragments placed there for capturing a unique kind of DNA segments from a DNA solution after dispensing the DNA solution into the reservoir; one or more channels performing DNA separation according to size, said channels being associated with one or more reservoirs; one or more gates controlling the flow of substances in the reservoirs; an optical system which induces fluorescence excitation in, and detects fluorescence emission in the channels; and a computer to produce DNA sequence data. | 10-29-2009 |
| 20090269747 | Marker Genes Based on Amiodarone Treatment for Screening of Drug Inducing Toxicity and Screening Method Therefor - The present invention relates to a marker gene for screening of drug candidates inducing pulmonary toxicity and a screening method using the same, more precisely a marker gene up- or down regulated by amiodarone which is a drug inducing pulmonary toxicity and a method for screening drug candidates inducing pulmonary toxicity using the same. The marker gene of the present invention can be effectively used for monitoring and identifying drugs or chemical having high risk of inducing pulmonary toxicity and can be used as an effective tool for examining the mechanism of amiodarone which causes pulmonary toxicity and side effects. | 10-29-2009 |
| 20090269748 | IDENTIFICATION OF SUBSTANCES THAT INHIBIT NEMO OLIGOMERIZATION - The present invention provides methods for screening for substances which inhibit the oligomerization of NEMO and/or IKK-related complexes and/or signaling pathways based on the interference with NEMO oligomerization | 10-29-2009 |
| 20090269749 | METHOD FOR HIGH-THROUGHPUT AFLP-BASED POLYMORPHISM DETECTION - The invention relates to a method for the high throughput discovery, detection and genotyping of one or more genetic markers in one or more samples, comprising the steps of restriction endonuclease digest of DNA, adaptor-ligation, optional pre-amplification, selective amplification, pooling of the amplified products, sequencing the libraries with sufficient redundancy, clustering followed by identification of the genetic markers within the library and/or between libraries and determination of (co-) dominant genotypes of the genetic markers. | 10-29-2009 |
| 20090269750 | MARKER AND METHOD FOR CANCER DIAGNOSIS - The present invention relates to a diagnostic cancer marker using variation of a granulocyte colony stimulating factor (G-CSF) gene and a method for preparing the same, and more specifically, relates to a method for diagnosing cancer and/or assessing the state of cancer progression using an oligonucleotide having the 3′-terminal end of exon 2 region linked to the 5′-terminal end of exon 4 region of a G-CSF gene as a diagnostic cancer marker. According to the present invention, cancer can be quickly and exactly diagnosed using variation in a G-CSF gene expression. | 10-29-2009 |
| 20090269751 | DOT1 HISTONE METHYLTRANSFERASES AS A TARGET FOR IDENTIFYING THERAPEUTIC AGENTS FOR LEUKEMIA - The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject. | 10-29-2009 |
| 20090269752 | METHOD FOR SELECTING NUCLEIC ACIDS THAT BOND WITH HIGH-AFFINITY TO A TARGET - The invention relates to a method for selecting nucleic acids that bond with high affinity to a target molecule from a mixture of nucleic acids, comprising the following steps: a) loading a column with the target molecules whereby the target molecules are immobilized in said column, b) feeding the mixture of nucleic acids into a first end of the column, to create a defined volumetric flow of medium through the column, running from the first end to the second end of said column, c) immobilizing the nucleic acids to the target molecule wherein an affinity of the nucleic acids to the target molecule decreases as the distance from the first end of the column increases, d) stopping the volumetric flow of medium through the column after a defined period of time, e) cutting the column into column segments, and allocating a routing co-ordinate to each segment, and f) identifying and collecting nucleic acids that bond with a high affinity to the target molecule by desorbing the immobilized nucleic acids from at least one segment in a non-specific manner and extracting the nucleic acids, wherein the routing co-ordinate allocated a segment in step e) is allocated to the nucleic acids desorbed from that segment. | 10-29-2009 |
| 20090269753 | GENOTYPING FOR SRC-1 PREDICTS FOR BONE LOSS - Osteoporosis is a common skeletal disease characterized by loss of bone mineral density (BMD) and increased risk of fracture. Osteoporosis most commonly occurs in postmenopausal women due to estrogen deficiency. We identified 3 genetic variants in steroid receptor coactivator 1 (SRC-1) that are significantly associated with a decrease in BMD in women. We characterized a functional variant in exon 18 of SRC-1 that is associated with increased loss of bone mineral density in women who received tamoxifen for treatment or prevention of breast cancer. In vitro experiments show that this variant decreases estrogen receptor alpha response (ER-alpha) to hormone, suggesting an attenuated response to endogenous and exogenous hormones in the bone of these women, and therefore a need for additional bone protective measures. | 10-29-2009 |
| 20090269754 | METHOD OF PRODUCING AMPLIFICATION PRODUCT BY PCR AND USAGE THEREOF - A method of producing a PCR amplification product is provided that suppresses an effect of precipitate, turbidity, or the like derived from a whole blood sample on a detection in the detection of an amplified nucleic acid by an optical unit. The amplification product complementary to a target nucleic acid in the whole blood sample is produced by PCR in a condition where a ratio of the whole blood sample in a PCR reaction solution is in the range of 0.1 to 0.9% by volume or 0.01 to 1.8 g/L in term of hemoglobin content. When the PCR is carried out with such conditions, even with an untreated whole blood sample, a monitoring of the amplification product by the optical unit can be done while suppressing the effect of the precipitate or the turbidity. | 10-29-2009 |
| 20090269755 | MEANS AND METHOD FOR INDUCING EXON-SKIPPING - In the present invention means and method are provided for optimising exon-skipping using exon-internal AON. We show that skipping efficiencies are improved by targeting putative splicing regulatory sequences (ESEs) within an exon. Such double targeting may be particularly useful for exons with which efficient skipping was difficult to obtain prior to the invention. | 10-29-2009 |
| 20090269756 | PRIMER SET FOR AMPLIFYING CYP2C19 GENE, REAGENT FOR AMPLIFYING CYP2C19 GENE CONTAINING THE SAME, AND THE USES THEREOF - Primer sets for amplifying target regions containing sites to be detected in the CYP2C19 gene by a gene amplification method are provided, wherein the primer sets can amplify the regions specifically. Two pairs of primer sets are used including forward primers consisting of the base sequences of SEQ ID NOs: 12 and 32 as well as reverse primers consisting of the base sequences of SEQ ID NOs: 22 and 48, respectively. The use of these primer sets makes it possible to amplify two target regions including parts where two types of polymorphisms (CYP2C19*2 and CYP2C19*3) of the CYP2C19 gene are generated, respectively, in the same reaction solution at the same time. | 10-29-2009 |
| 20090269757 | DIAGNOSIS KITS AND METHOD FOR DETECTING CANCER USING POLYMORPHIC MINISATELLITE - The present invention relates to a kit and a method for diagnosing cancer using polymorphic minisatellites (MS), more specifically, relates to a primer set for detecting polymorphic minisatellites MUC2-MS6 or MUC2-MS7 in the MUC2 gene, a DNA typing kit comprising said primer set, and a kit and a method for diagnosing cancer using a primer set for detecting polymorphic minisatellites MUC2-MS6, MUC2-MS7 or hTERT-VNTR 2-2. According to the present invention, DNA typing of MUC2-MS6 and MUC2-MS7 can effectively achieve the parentage identification, kinship identification or medicolegal examination, because the polymorphic minisatellites MUC2-MS6 and MUC2-MS7 are inherited through meiosis according to Mendelian genetics. In addition, the polymorphic minisatellites MUC2-MS6, MUC2-MS7 and hTERT-VNTR 2-2 can be used to predict and diagnose various cancers; such as gastric cancer, colon cancer, rectal cancer and prostate cancer etc. | 10-29-2009 |
| 20090269758 | Diagnostic methods and kits for functional disorders - The present invention relates to methods for the diagnosis of functional disorders in humans. A method of the invention, in certain embodiments, comprises the detection of one or more polymorphisms in mitochondrial DNA of a human. The current invention further provides kits for use in a method of the invention. | 10-29-2009 |
| 20090269759 | UNNATURAL POLYMERASE SUBSTRATES THAT CAN SUSTAIN ENZYMATIC SYNTHESIS OF DOUBLE STRANDED NUCLEIC ACIDS FROM A NUCLEIC ACID TEMPLATE AND METHODS OF USE - Nucleotide analogs that can sustain the enzymatic synthesis of double-stranded nucleic acid from a nucleic template are described. The nucleotide analogs include: (i) a base selected from the group consisting of adenine, guanine, cytosine, thymine, uracil and their analogs; (ii) a label attached to the base or analog of the base via a cleavable linker; (iii) a deoxyribose; and (iv) one or more phosphate groups. The linker and/or the label inhibits template directed polymerase incorporation of a further nucleotide substrate onto an extended primer strand. In addition, cleavage of the linker leaves a residue attached to the base which is not present in the natural nucleotide and which does not inhibit extension of the primer strand. The nucleotide analogs can therefore be used as reversible terminators in sequencing by synthesis methods without blocking the 3′ hydroxyl group. Methods of sequencing DNA using the substrates are also described. | 10-29-2009 |
| 20090269760 | ENRICHMENT METHODS FOR THE DETECTION OF PATHOGENS AND OTHER MICROBES - The present invention provides novel enrichment, testing and detection methods for detection of pathogens or other microbes in a food, water, wastewater, industrial, pharmaceutical, botanical, environmental samples and other types of samples analyzed by enrichment-detection methods. In preferred aspects, a sample is obtained at a first location and is diluted (e.g., in the case of a solid or semi-solid sample or liquid) at the first location at a ratio of about 1:0 (wt./vol.) to 1:2 (wt./vol.), or greater, preferably at a ratio of about 1:0.1 (wt./vol.) or greater, or more preferably, at a ratio of about 1:2 (wt./vol.) or greater. The diluted sample is incubated at an optimal temperature in an incubator and either tested locally, or sent in a shipping incubator to a second location that is a remote test location. The incubated sample is received and tested at the second location by assaying the sample, or a portion thereof, with an assay suitable to detect the pathogen or other microbe. In alternate embodiments, no dilution at the first location is required, and optionally minimal additions to adjust intrinsic deficiencies may be made, but the sample is nonetheless incubated during transit to the test location. | 10-29-2009 |
| 20090269761 | Genetic markers associated with age-related macular degeneration, methods of detection and uses thereof - Disclosed is a method for identifying an individual who has an altered risk for developing age related macular degeneration comprising detecting a single nucleotide polymorphism (SNP) | 10-29-2009 |
| 20090269762 | Cotton event PV-GHGT07(1445) and compositions and methods for detection thereof - The present invention provides DNA compositions and assays for detecting the presence of the DNA compositions in PV-GHGT07(1445) cotton event based on the DNA sequence of the recombinant construct inserted into the cotton genome and of the genomic sequences flanking the insertion site. Kits and conditions useful in conducting the assays are provided. | 10-29-2009 |
| 20090269763 | Reprogramming a cell by inducing a pluripotent gene through RNA interference - The invention relate to methods, compositions, and kits for reprogramming a cell. In one embodiment, the invention relates to a method for inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In yet another embodiment, the method comprises inhibiting the expression of a gene that codes for a protein involved in transcriptional repression. In yet another embodiment, the invention relates to a reprogrammed cell or an enriched population of reprogrammed cells that can have characteristics of an ES-like cell, which can be re- or trans-differentiated into a differentiated cell type. | 10-29-2009 |
| 20090269764 | COMPOSITIONS AND METHODS FOR DETECTION OF PROPIONIBACTERIUM ACNES NUCLEIC ACID - Methods for amplifying and detecting | 10-29-2009 |
| 20090269765 | Compositions And Methods For Detection Of Small Molecules Using Dyes Derivatized with Analyte Responsive Receptors in a Chemiluminescent Assay - Compositions, methods, and systems for detecting small molecules using chemiluminescent signaling assay technology are provided. One system provided herein comprises a chromophore; an oxalate ester, a peroxide, and a modulating agent, wherein the modulating agent will perturb a chemiluminescent signal generated by an interaction among the chromophore, the oxalate ester, and a peroxide; and the perturbation will occur in response to an analyte. One method provided herein comprises combining a chromophore, an oxalate ester, a peroxide, and a modulating agent, wherein: the modulating agent will perturb a chemiluminescent signal generate by an interaction among the chromophore, the oxalate ester, and a peroxide; and the perturbation will occur in response to an analyte. Another method provides a calorimetric or fluorometric signal response in the presence of an analyte. | 10-29-2009 |
| 20090269766 | NUCLEIC ACID AMPLIFICATION IN THE PRESENCE OF MODIFIED RANDOMERS - The present invention is directed to a composition comprising a DNA Polymerase which is preferably thermostable, Deoxynucleotides, at least one primer oligonucleotide or a pair of amplification primers, and randomized 5-8 mer oligonucleotide, characterized in that said oligonucleotide comprises a modification with an organic hydrophobic moiety Such a composition is specifically useful for performing hot start PCR. | 10-29-2009 |
| 20090269767 | MICROFLUIDIC CHIP DEVICES AND THEIR USE - A microfluidic chip device (MCD) and its use for performing miniaturized assays on magnetic microbeads (MMs) are described. The MCD is particularly useful for carrying out miniaturized transcript analysis by aiding affinity capturing (TRAC) assays, including PCR. The MCD comprises at least one reaction chamber with sealable liquid connections and at least one fluidic pillar filter in each chamber. The fluidic pillar filter comprises rods with spacings allowing MMs to pass. The sealable liquid connections feed liquid to the reaction chamber, wherein air bubbles are removed. The liquid stream contacts the MMs, which are manipulated with a magnetic rod. The liquid connections enable trapping of the MMs behind the pillar filters or in the channel, while the liquid is changed. | 10-29-2009 |
| 20090269768 | DETECTION OF HIGH GRADE DYSPLASIA IN CERVICAL CELLS - Methods of using probes and probe sets for the detection of high grade dysplasia and carcinoma in cervical cells are described. Methods of the invention include hybridizing one or more chromosomal probes to a biological sample obtained from a subject and detecting the hybridization pattern of the chromosomal probes to the sample to determine whether the subject has high grade dysplasia or carcinoma. Methods of the invention also include preliminary screening the cells for a marker associated with a risk for cancer, and preferably involves screening for HPV infected cells by in situ hybridization using an HPV probe mixture. | 10-29-2009 |
| 20090269769 | Drug Discovery Methods Involving A Preclinical, In Vitro Isolated Gastrointestinal Epithelial Stem Cell-Like Progenitor Cell System - The described invention relate to systems comprising isolated human gastrointestinal segment-specific epithelial stem cell-like progenitor cells and uses thereof in drug discovery. | 10-29-2009 |
| 20090269770 | METHODS FOR EVALUATION PROGNOSIS AND FOLLOW-UP OF DRUG TREATMENT OF PSYCHIATRIC DISEASES OR DISORDERS - The present invention provides methods for evaluating the pharmacological efficacy of drugs or drug candidates in treatment of psychiatric diseases or disorders, particularly schizophrenia, and for predicting the efficacy of drugs or drug combinations indicated for treatment of both positive and negative symptoms of psychiatric diseases or disorders in an individual having such a disease or disorder. In both methods, the drugs or drug candidates evaluated are assessed for their ability to produce certain changes in the expression of specific genes in peripheral mononuclear cells in blood of psychiatric patients, which are similar to the changes obtained following treatments with reference drugs or drug combinations effective against both positive and negative symptoms of psychiatric diseases or disorders. | 10-29-2009 |
| 20090269771 | METHOD OF SEQUENCING AND MAPPING TARGET NUCLEIC ACIDS - The present teachings pertain to methods, compositions, reaction mixtures, and kits for mapping a low complexity sequence to a locus in a genome. In some embodiments, the low complexity sequence can be used to determine the methylation profile of a target nucleic acid. A strand-replacing reaction results in a product containing a first strand and a second strand, which can be connected together with a stem-loop adapter to form a single strand. A sequencing reaction can compare the two strands of the product, allowing the experimentalist to both map the sequence to a locus in a reference genome, as well as ascertain the methylation profile of the original target nucleic acid. | 10-29-2009 |
| 20090269772 | SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST - Systems, methods, and apparatus for searching for a combination of compounds of therapeutic interest are provided. Cell-based assays are performed, each cell-based assay exposing a different sample of cells to a different compound in a plurality of compounds. From the cell-based assays, a subset of the tested compounds is selected. For each respective compound in the subset, a molecular abundance profile from cells exposed to the respective compound is measured. Targets of transcription factors and post-translational modulators of transcription factor activity are inferred from the molecular abundance profile data using information theoretic measures. This data is used to construct an interaction network. Variances in edges in the interaction network are used to determine the drug activity profile of compounds in the subset of compounds. The drug activity profiles are used to form a filter set of compound combinations from the subset of compounds. | 10-29-2009 |
| 20090269773 | METHODS OF DETERMINING THE HEALTH STATUS OF AN INDIVIDUAL - Methods of determining health status based on analysis of single cells in a sample or set of samples from an individual are described. | 10-29-2009 |
| 20090269774 | EVALUATION OF EOSINOPHILIC ESOPHAGITIS - A method to evaluate eosinophilic esophagitis based on information in an eosinophilic esophagitis transcriptome. | 10-29-2009 |
| 20090269775 | PROGNOSTIC MARKERS FOR CLASSIFYING COLORECTAL CARCINOMA ON THE BASIS OF EXPRESSION PROFILES OF BIOLOGICAL SAMPLES - The invention relates to the use of gene expression profiles for predicting the probability of recurrence or metastases to develop in remote organs of patients from which a primary colon carcinoma has been removed. | 10-29-2009 |
| 20090275017 | Novel Nucleoside or Nucleotide Derivative and Use Thereof - The object of the present invention is to provide a nucleoside or nucleotide having a 5-substituted-2-oxo(1H)pyridin-3-yl group as a base, as well as a method using the same. | 11-05-2009 |
| 20090275018 | Detection of hepatotoxic cyanobacteria - The present invention relates to methods and kits for the detection of toxic cyanobacteria, in particular of hepatotoxin-producing cyanobacteria. | 11-05-2009 |
| 20090275019 | Pancreatic Cancer Genes - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia. | 11-05-2009 |
| 20090275020 | Traceability of Cellular Cycle Anomalies Targeting Oncology and Neurodegeneration - The present invention relates to the field of medicine and biology. It concerns a novel test for screening and for therapeutic follow-up in oncology. More particularly, it relates to diagnostic and/or therapeutic tests in oncology and on neurodegenerative diseases. It is a diagnostic test and a prognostic test for various cancers (breast cancer, bladder cancer, ovarian cancer, lung cancer, skin cancer, prostate cancer, colon cancer, liver cancer, gliboblastoma, sarcoma, leukemia, etc.) and therapeutics solutions for specific neurodegenerative diseases. More particularly, the invention concerns the use of the LIV21 protein, LIV21 gene and of derivatives thereof as diagnostic and prognostic markers for cancers. The invention therefore concerns the detection of the LIV21 protein with a kit comprising LIV21-specific antibodies. | 11-05-2009 |
| 20090275021 | NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS OF USE THEREOF FOR DIAGNOSIS - Novel splice variants, amino acid sequences and nucleotide sequences thereof, and methods of using same. | 11-05-2009 |
| 20090275022 | STAT6 EFFECTS ON LIVESTOCK ANIMAL GROWTH - The present invention provides for selection of livestock animals, including bovines, whose genotypes based in the STAT6 gene are correlated with phenotypes reflecting desirable carcass and feedlot traits. These phenotypes include back fat (BFAT), calculated yield grade (CALCYG), cutability (CUT), hot carcass weight (HCW), dry matter intake (DMI), days on feed (DOF), back fat rate (BFAT RATE) and average daily gain (ADG), based on the knowledge of the STAT6 genotypes. The predictive value is based in part on the discovery that certain single nucleotide polymorphisms (SNPs) within the STAT6 gene are linked to phenotypes of economically these important carcass and feedlot traits. Also provided are SNPs within the STAT6 gene useful in reliably distinguishing between a | 11-05-2009 |
| 20090275023 | Compositions and methods for detecting borrelia afzelii - Disclosed are oligonucleotides useful in methods for determining whether a sample contains | 11-05-2009 |
| 20090275024 | Novel centrerosome-associated protein and applications thereof - A method for diagnosing a genetic disease associated with disturbances in mitotic spindle organization or with cell division anomalies or both, which comprises demonstrating a functional alteration of the gene encoding an ASAP protein comprising at least the following steps of: obtaining DNA containing the gene encoding the ASAP protein from a biological sample; bringing said DNA into contact with a probe, and under conditions for hybridization between the DNA and the probe; and detecting the hybrid formed; and wherein the ASAP protein is selected from the group consisting of a human protein having sequence SEQ ID NO:1 and proteins having a sequence exhibiting at least 80% identity or at least 90% similarity with entire SEQ ID NO. 1. | 11-05-2009 |
| 20090275025 | HPV Detection and Quantification by Real-Time Multiplex Application - The present invention relates to amplification primers and detection probes, which are useful for the detection of human papillomaviruses (HPV), and more particularly of HPV, which can be oncogenic for the mucosal epithelia. The amplification and detection systems provided by the present invention are group-targeted systems, namely A5-, A6- A7-, and A9-targeted systems. The amplification and detection systems of the invention allow for an amplification of HPV in multiplex as well as for a real-time detection, whereby at least the thirteen HR HPV can be detected in a single-tube assay. The invention further allows for a reliable quantitation of HPV viral loads in real-time multiplex amplification. | 11-05-2009 |
| 20090275026 | Primer and Probe for Detection of Mycobacterium Intracellulare, and Method for Detection of Mycobacterium Intracellulare by Using the Primer and Probe - The present invention discloses an oligonucleotide which comprises a part or the entire sequence of the nucleotide sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8, or a part or the entire sequence of a sequence complementary to the nucleotide sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8, wherein the oligonucleotide is capable of hybridizing with a nucleotide sequence of | 11-05-2009 |
| 20090275027 | Medium scale intergration of molecular logic gates in an automaton - Compositions and methods for optically detecting the presence of a plurality of oligonucleotides in a sample, wherein each oligonucleotide to be detected comprises consecutive nucleotides having a sequence different than the remaining oligonucleotides of the plurality are provided. | 11-05-2009 |
| 20090275028 | METHOD OF DETECTING TARGET NUCLEIC ACID - The present invention provides a method of detecting a target nucleic acid which includes a step of examining whether a washing step has been normally conducted. In an aspect of the invention, a monitoring nucleic acid probe to monitor the washing level is used. The probe shows a change in signal intensity by washing at a washing temperature changed in the optimum temperature range for washing the target nucleic acid and in a temperature range in the vicinity of the optimum temperature range for washing. | 11-05-2009 |
| 20090275029 | Systems and Methods to Quantify and Amplify Both Signaling and Probes for CDNA Chips and Gene Expression Microarrays - The invention provides a series of reagent compositions and methods for making and amplifying novel cDNA based probe sets from RNA samples to improve analysis with gene expression arrays. The methods globally produce probe sets with common universal linkers at one or both ends, called WRAP-Probes, wherein the linkers do not bind to the target sequences and they can efficiently bind added reporters to the probes. The universal linkers are also designed as primer binding sites for copying and amplifying the probes, either linearly with one linker, or exponentially with double linkers. The capacity to globally and exponentially amplify the probe set by PCR is a primary advantage. Adding reporters by terminal linkers also improves quantification since each probe gets equivalent signaling. The invention allows expression analysis of small research, clinical and forensic samples to enable improved diagnostics, drug discovery, therapeutic monitoring, and medical, agricultural and general research. | 11-05-2009 |
| 20090275030 | CELL CALCIFICATION SUPPRESSING PROTEINS, AND GENES OF THE PROTEINS - This invention provides cell-calcification inhibitory proteins as well as genes encoding the proteins. Based on the discovery of a novel isoform gene of the c-erg gene (herein referred to as “C-11 gene”) which is an erg gene derived from chickens, the nucleotide sequence of the gene has been determined, and then the expression of a protein encoded by such gene (herein referred to as “C-11 protein”) has been confirmed. Further, it has been discovered that when the c-erg or C-11 gene is introduced into osteoblasts, the calcification of the cells is inhibited. | 11-05-2009 |
| 20090275031 | Biomolecular nano device - Methods for measuring environmental parameters using chemical recording are provided. In some embodiments, the methods include generating a polymer comprising an ordered series of chemical units, wherein the position and number of each chemical unit in the polymer is indicative of a reading of the environmental state variable at a given point in time. The presently disclosed subject matter also provides compositions that can be employed in and/or that employ the disclosed methods for recording environmental state variables. | 11-05-2009 |
| 20090275032 | Reprogramming a cell by inducing a pluripotent gene through use of an HDAC modulator - The invention relate to methods, compositions, and kits for reprogramming a cell. In one embodiment, the invention relates to a method comprising inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In yet another embodiment, the method comprises inhibiting the activity of an HDAC with an HDAC inhibitor and inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In still another embodiment, the invention relates to a method for reprogramming comprising exposing a cell to more than one agent to inhibit more than ore type of regulatory protein. In yet another embodiment, the invention relates to a reprogrammed cell or an enriched population of reprogrammed cells that can have characteristics of an ES-like cell, which can be re- or trans-differentiated into various differentiated cell types | 11-05-2009 |
| 20090275033 | Uses of BNIPXL-Beta in premature canities - The present invention concerns the use of a polypeptide comprising a sequence having at least 90% identity with all or part of BNIPXLβ, for cosmetic or therapeutic applications, in the treatment or prevention of premature canities in humans, said portion comprising at least 30 amino acids, as well as the use, for the same purpose, of a molecule comprising a RNAi sequence having at least 90% identity with all or part of the cDNA sequence of BNIPXLβ, said part comprising at least 18 nucleotides. | 11-05-2009 |
| 20090275034 | TEMPERATURE CONTROL SYSTEM - Single molecule technologies generally require sensitive optical detection and the ability to operate at multiple temperatures simultaneously in different parts of the instrument. The system for controlling the temperature of a microfluidic device and methods for controlling the temperature of sequencing reactions includes a chamber for receiving a microfluidic device, a heating control device in fluid communication with the chamber for delivering a heated fluid to the chamber to heat the microfluidic device, and a cooling control device in liquid communication with the chamber for delivering a cooled fluid to the chamber to cool the microfluidic device. A temperature control unit in liquid communication with a cooling element and/or a heating element are used to regulate temperature of sequencing substrates and objective lenses for optical detection of sequencing reactions. | 11-05-2009 |
| 20090275035 | PRIMERS FOR HUMAN MITOCHONDRIAL HYPERVARIABLE REGION AND METHOD FOR DETECTING HUMAN DNA BY USING THE PRIMERS - The present invention relates to primer pairs for human mitochondrial hypervariable region and a method for detecting human DNA by using the primer pairs. | 11-05-2009 |
| 20090275036 | SYSTEMS AND METHODS FOR REAL TIME SINGLE MOLECULE SEQUENCE DETERMINATION - A sequencing methodology is disclosed that allows a single DNA or RNA molecule or portion thereof to be sequenced directly and in substantially real time. The methodology involves engineering a polymerase and/or dNTPs with atomic and/or molecular tags that have a detectable property that is monitored by a detection system. | 11-05-2009 |
| 20090275037 | FLUORESCENT DOUBLE STRANDED DNA BINDING DYES - The present invention is directed to a fluorescent dye comprising a benzothiazolium moiety and a pyrimidinium moiety connected by a mono-methine bridge, characterized in that (i) the 2-position of the pyrimidine carries a substituent which starts with a C-atom and (ii) the 5- and 6-positions of the pyrimidine ring are an integral part of a further aromatic ring structure. | 11-05-2009 |
| 20090275038 | METHOD AND APPARATUS FOR FORENSIC SCREENING - This invention relates to methods and system for forensic screening. More specifically, this invention relates to various methods to detect or screen for at least one designated genetic sequences in a plurality of biological sample | 11-05-2009 |
| 20090275039 | METHODS FOR DETECTION AND QUANTIFICATION OF SMALL RNA - Disclosed are methods, kits, and components for detecting small RNA molecules, such as microRNA and siRNA, in a sample. The methods utilize primers and reporter molecules comprising non-natural bases. The disclosed kits may include one or more components for performing the disclosed methods. | 11-05-2009 |
| 20090275040 | DETECTING BCL-B EXPRESSION IN CANCER AND USES THEREOF - Provided herein are compositions and methods of detecting Bcl-B expression in cancer cells to prognose, monitor, or select therapies for cancers such as breast cancer, prostate cancer, lung cancer, or gastric cancer. | 11-05-2009 |
| 20090275041 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 193P1E1B USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 0193P1E1B (also designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 193P1E1B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 193P1E1B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 193P1E1B can be used in active or passive immunization. | 11-05-2009 |
| 20090275042 | Method of Detecting and/or Quantifying Expression of a Target Protein Candidate in a Cell, and a Method of Identifying a Target Protein of a Small Molecule Modulator - The present invention relates to a method of detecting and/or quantifying expression of a target protein candidate in a cell, and to a method of identifying a target protein of a small molecule modulator. | 11-05-2009 |
| 20090275043 | Genetic variants in the TCF7L2 gene as diagnostic markers for risk of type 2 diabetes mellitus - Polymorphisms in the gene TCF7L2 are shown by association analysis to be a susceptibility gene for type II diabetes. Methods of diagnosis of susceptibility to diabetes, of decreased susceptibility to diabetes and protection against diabetes, are described, as are methods of treatment for type II diabetes. | 11-05-2009 |
| 20090275044 | METHOD FOR DETECTING HUMAN PAPILLOMAVIRUS mRNA - An in vitro method is provided for screening human female subjects to assess their risk of developing cervical carcinoma which comprises screening the subject for expression of mRNA transcripts from the E6 and optionally the L1 gene of human papillomavirus, wherein subjects positive for expression of L1 and/or E6 mRNA are scored as being at risk of developing cervical carcinoma. Kits for carrying out such methods are also provided. | 11-05-2009 |
| 20090275045 | METHOD FOR DETECTING MAMMARY CANCER CELLS - The present invention provides a novel method for detecting mammary cancer cells which uses, as an index, an expression level of a specific gene in human mammary cancer tissue (or cells). The method is characterized by including (1) measuring an expression level of a gene having a specific nucleotide sequence in human mammary cancer tissue (or cells), (2) measuring an expression level of the gene in human normal mammary gland tissue (or cells), and (3) detecting mammary cancer cells on the basis of the difference between measurement values obtained in (1) and (2). | 11-05-2009 |
| 20090280475 | Droplet-based pyrosequencing - The present invention relates to a droplet microactuator and to systems, apparatuses and methods employing the droplet microactuator for executing various protocols using droplets. The invention includes a droplet microactuator or droplet microactuator system having one or more input reservoirs loaded with reagents for conducting sequencing protocols, such as the reagents for conducting a pyrosequencing protocol. The invention also includes a droplet microactuator or droplet microactuator system, having one or more input reservoirs loaded with a sample for conducting a pyrosequencing protocol. | 11-12-2009 |
| 20090280476 | Droplet-based affinity assay device and system - The present invention relates to a droplet-based affinity assay device and system. According to one embodiment, a droplet microactuator is provided and includes an antibody immobilized on a surface. According to another embodiment, a droplet microactuator is provided and includes a droplet on the droplet microactuator, the droplet comprising an antibody. | 11-12-2009 |
| 20090280477 | Turn Over Probes and Use Thereof for Nucleic Acid Detection - The invention provides turnover probes for use in a variety of detection assays, for example, nucleic acid detection assays. In addition, the invention provides assays, for example, nucleic acid detection assays, using such turnover probes. | 11-12-2009 |
| 20090280478 | GENE METHYLATION AND EXPRESSION - The invention provides a method of analyzing the methylation status of all or part of an entire genome. Moreover, the invention features methods of and reagents for characterizing biological cells containing DNA that is susceptible to methylation. Such methods include methods of diagnosing cancer, e.g., breast cancer. | 11-12-2009 |
| 20090280479 | USE OF FREE CIRCULATING DNA FOR DIAGNOSIS, PROGNOSIS, AND TREATMENT OF CANCER FUNDING - A method of detecting circulating DNA in a body fluid. The method comprises identifying a subject suffering from or at risk for developing cancer, obtaining a body fluid sample from the subject, and determining the sequence integrity of circulating DNA in the sample, wherein the circulating DNA is not purified from the sample. | 11-12-2009 |
| 20090280480 | Devices from Prion-Like Proteins - The present invention provides novel polypeptides comprising a prion-aggregation domain and a second domain; novel polynucleotides encoding such polypeptides; host cells transformed or transfected with such polynucleotides; novel fibrils with specific functionalities and unusually high chemical and thermal stability; and methods of making and using the foregoing in, for example, the production of nanoscale devices. | 11-12-2009 |
| 20090280481 | Enhanced Sequencing by Hybridization Using Pools of Probes - The invention provides methods for sequencing by hybridization (SBH) using pools of probes that allow greater efficiency in conducting SBH by reducing the number of separate measurements of hybridization signals required to identify each particular nucleotide in a target nucleic acid sequence. The invention also provides pools and sets of pools of probes, as well as methods of generating pools of probes. | 11-12-2009 |
| 20090280482 | Novel nucleic acid sequences encoding adenylate kinases, alcohol dehydrogenases, ubiquitin proteases, lipases, adenylate cyclases, and GTPase activators - The invention provides isolated nucleic acids molecules that encode novel polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a sequence of the invention has been introduced or disrupted. The invention still further provides isolated proteins, fusion proteins, antigenic peptides and antibodies. Diagnostic methods utilizing compositions of the invention are also provided. | 11-12-2009 |
| 20090280483 | Methods for Screening Interleukin-6 (IL-6) Signal Transduction Inhibitors - The present invention provides methods for screening compounds which inhibit activation of a member of the IL-6 signaling pathways, comprising: (a) a positive screening step using a cell capable of being killed by IL-6 stimulation to select compounds which inhibit death of the cell when it is stimulated by IL-6; and then (b) a biochemical screening step to further select compounds which inhibit activation of a member of the IL-6 signaling pathways by a biochemical means from the compounds selected in step (a). The present invention also provides compounds which inhibit activation of a member of the IL-6 signaling pathways identified using said methods. | 11-12-2009 |
| 20090280484 | METHODS FOR GENE MAPPING AND HAPLOTYPING - The present invention is directed to methods for providing a definitive haplotype of a subject. The haplotype information generated by the methods described herein is more accurate than that provided by prior art methods that only give an inferred haplotype. Accordingly, in one aspect the present invention provides a method for determining a definitive haplotype of a subject the method including the steps of providing a substantially isolated haploid element from the subject, and obtaining nucleotide sequence information from the haploid element. Applicants propose that the use of a substantially isolated haploid element eliminates the problem of incorrect or misleading inferences concerning the phase of two or more loci within a haplotype, and allows for revelation of two or more participatory genes within a haplotype, uncomplicated by differences in modes of inheritance. The guarantee of strictly cis-phase associations is provided in the present methods by the use of a substantially isolated haploid element as starting material for sequence analysis. | 11-12-2009 |
| 20090280485 | Methods and Reagents for the Determination of Telomere Length in a Semi-Automatic Manner of Every Single Cell in a Immobilized Cell Population - The invention relates to methods and reagents for the determination of telomere length in tissue sections by the single cell telomeric mapping technique based on a fluorescent in situ hybridization step using a telomere-specific probe and an interpolation step using a standard curve correlating fluorescent intensity and telomere length obtained from a collection of cell lines of known telomere length. The invention further relates to methods for the identification of stem cell niches within tissues and for the identification of compounds capable of triggering stem cell mobilization using the telomere length as criteria for the identification of stem cells and which rely on the single cell telomeric mapping technique of the invention. | 11-12-2009 |
| 20090280487 | METHODS FOR PRODUCING OLFACTORY GPCRS - The subject invention provides a method for producing an olfactory GPCR in a cell. In general, the methods involve introducing an expression cassette containing a promoter operably linked to a nucleic acid encoding an olfactory PCR into a macroglial cell, e.g., a Schwann or oligodendritic cell, and maintaining the cell under conditions suitable for production of the olfactory GPCR. Also provided is a macroglial cell containing a recombinant nucleic acid encoding an olfactory GPCR, methods of screening for modulators of olfactory GPCR activity, and a kit for producing an olfactory GPCR in a macroglial cell. The invention finds most use in research on flavors and fragrances, and, consequently, has a variety of research and industrial applications. | 11-12-2009 |
| 20090280488 | Prophylactic/therapeutic agent for neurodegenerative disease - To provide a prophylactic/therapeutic agent for neurodegenerative diseases (such as polyglutamine diseases), the agent containing an HMGB family protein or a derivative thereof, such as a protein according any one of (a) and (b) below:
| 11-12-2009 |
| 20090280489 | Ig genes specific oligonucleotides and uses thereof - The present invention provides oligonucleotides for detection of rearrangement of immunoglobulin genes for identifying clonality of cells, cancer cells, hypermutation in immunoglobulin gene, antibody isotype producing cell and/or assaying B cell repertoire in a sample. The oligonucleotides disclosed in the present invention are very specific to the immunoglobulin genes. | 11-12-2009 |
| 20090280490 | Expression Profile Algorithm and Test for Cancer Prognosis - The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk. | 11-12-2009 |
| 20090280491 | PREDICTING CANCER INVASIVENESS - Provided are methods of determining the likelihood of a human cancer being invasive. Also provided are methods of determining whether a lung adenocarcinoma is a bronchioloalveolar carcinoma (BAC). Additionally provided are methods of deciding a course of treatment for a patient with a cancer. | 11-12-2009 |
| 20090280492 | DIAGNOSIS OF FETAL ABNORMALITIES USING POLYMORPHISMS INCLUDING SHORT TANDEM REPEATS - The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, i.e. aneuploidy. In addition, the present invention provides methods to determine when there are insufficient fetal cells for a determination and report a non-informative case. The present invention involves quantifying regions of genomic DNA from a mixed sample. More particularly the invention involves quantifying DNA polymorphisms from the mixed sample. | 11-12-2009 |
| 20090280493 | Methods and Compositions for the Prediction of Response to Trastuzumab Containing Chemotherapy Regimen in Malignant Neoplasia - The invention relates to methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of neoplastic disease. Neoplastic disease is often caused by chromosomal rearrangements which lead to over- or underexpression of the rearranged genes. The invention discloses genes which are overexpressed in neoplastic tissue and are useful as diagnostic markers and targets for treatment. Methods are disclosed for predicting, diagnosing and prognosing as well as preventing and treating neoplastic disease. | 11-12-2009 |
| 20090280494 | Method for the detection of cytosine methylations in immobilized DNA samples - A method is described for the analysis of cytosine methylation patterns in genomic DNA samples. In the first method step, the genomic DNA is isolated from cells or other accompanying materials and bound essentially irreversibly to a surface. Then the DNA bound to the surface is treated, preferably with a bisulfite, in such a way that cytosine is converted into a base that is different in its base pairing behavior in the DNA duplex, while 5-methylcytosine remains unchanged. Then the reagents that were used are removed in a washing step. Finally, selected segments of the immobilized DNA are amplified in a polymerase reaction and the amplified products are investigated with respect to their sequence. | 11-12-2009 |
| 20090280495 | ACTIVATING MUTATIONS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS - This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions. | 11-12-2009 |
| 20090280496 | NON-INVASIVE METHOD FOR DIAGNOSING FETAL CELLS AND CANCER CELLS - A non-invasive method for determining the developmental age of a fetus or detecting cancer cells in a sample is provided. The method utilizes, for example, a sample of blood from a pregnant female and telomeric nucleic acid probes. | 11-12-2009 |
| 20090280497 | Multiplex Detection Compositions, Methods, and Kits - The present invention generally relates to the detection of analytes, particularly biomolecules in samples. The invention also relates to compositions, methods, and kits for detecting the presence of analytes, typically in multiplex detection formats. The invention also relates to methods for determining the presence of at least one analyte in a sample, the methods employing employ single molecule detection techniques to individually detect at least one molecular complex or at least part of a molecular complex. | 11-12-2009 |
| 20090280498 | RAPID AND EFFICIENT CAPTURE OF DNA FROM SAMPLE WITHOUT USING CELL LYSING REAGENT - Nucleic acids can be made available for amplification or other treatment after admixture of a sample with specific weakly basic polymers to form a precipitate with the nucleic acids at acidic pH. After removing non-precipitated materials, the pH is then made basic, thereby releasing the nucleic acids from the polymer. This method for preparing specimen samples is simple and quite rapid, and the released nucleic acids can be further treated in hybridization assays or amplification procedures. No surfactant or other cell lysing reagents are employed. The weakly basic polymers are water-soluble and cationic at acidic pH, but neutral in charge at basic pH. | 11-12-2009 |
| 20090286233 | Method for Diagnosing Diabetic Retinopathy by Single Nucleotide Polymorphism, DNA Fragment Thereof, and Primer Thereof - Disclosed is a method for diagnosing diabetic retinopathy by a single nucleotide polymorphism of VEGF and its receptor. | 11-19-2009 |
| 20090286234 | IL10 SNP ASSOCIATED WITH ACUTE REJECTION - The present invention concerns a method for the prediction of acute renal transplant rejection by detecting a poly-morphism in the promoter region of the IL 10 gene, optionally in combination with polymorphisms of the MDR1 and IMPDH2 genes which were found to be associated with this disease. | 11-19-2009 |
| 20090286235 | Mdr1 Snp in Acute Rejection - The present invention concerns a method for the prediction of acute renal transplant rejection by detecting a polymorphism in exon 26 of the MDR1 gene, optionally in combination with polymorphisms of the IMPDH2 and IL 10 genes which were found to be associated with this disease. | 11-19-2009 |
| 20090286236 | Method for detecting cell proliferative disorders - The present invention relates to the detection of a cell proliferative disorder associated with alterations of microsatellite DNA in a sample. The microsatellite DNA can be contained within any of a variety of samples, such as urine, sputum, bile, stool, cervical tissue, saliva, tears, or cerebral spinal fluid. The invention is a method to detect an allelic imbalance by assaying microsatellite DNA. Allelic imbalance is detected by observing an abnormality in an allele, such as an increase or decrease in microsatellite DNA which is at or corresponds to an allele. An increase can be detected as the appearance of a new allele. In practicing the invention, DNA amplification methods, particularly polymerase chain reactions, are useful for amplifying the DNA. DNA analysis methods can be used to detect such a decrease or increase. The invention is also a method to detect genetic instability of microsatellite DNA. Genetic instability is detected by observing an amplification or deletion of the small, tandem repeat DNA sequences in the microsatellite DNA which is at or corresponds to an allele. The invention is also a kit for practicing these methods. | 11-19-2009 |
| 20090286237 | Diagnostic Kits and Methods for Oesophageal Abnormalities - The invention relates to kits and methods for aiding the diagnosis of Barrett's oesophagus or Barrett's associated dysplasia. Preferred is a method comprising assaying cells from the surface of a subject's oesophagus for a non-squamous cellular marker, wherein detection of such a marker indicates increased likelihood of the presence of Barrett's or Barrett's associated dysplasia, preferably wherein said sample of cells is not directed to a particular site within the oesophagus. The invention also encompasses a method comprising sampling the cellular surface of the oesophagus of said subject. The invention also relates to a kit comprising a swallowable device comprising abrasive material capable of collecting cells from the surface of the oesophagus, together with printed instructions for its use in detection of Barrett's oesophagus or Barrett's associated dysplasia. Preferably said device comprises a capsule sponge. | 11-19-2009 |
| 20090286238 | Methods to Monitor, Diagnose and Identify Biomarkers for Psychotic Disorders - A stimulated or non-stimulated T-cell sample can be used to diagnose or monitor a psychotic disorder, to identify a biomarker, or as to test a considerate as a potential therapeutic agent. | 11-19-2009 |
| 20090286239 | Method of Detecting Individual Encapsulated Influenza Viruses, Primer Set for the Detection and Kit for the Detection - The present invention provides a method of rapidly, simply and accurately detecting capsular serotype | 11-19-2009 |
| 20090286240 | BIOMARKERS OVEREXPRESSED IN PROSTATE CANCER - Biomarkers are identified by analyzing gene expression data using support vector machines (SVM) to rank genes according to their ability to separate prostate cancer from normal tissue. Proteins expressed by identified genes are detected in patient samples to screen, predict and monitor prostate cancer. | 11-19-2009 |
| 20090286241 | SYSTEM AND METHOD FOR DETECTING A GENE MUTATION - A system for detecting a gene mutation encompasses a spectrum generation mechanism configured to acquire an amplified product containing the specific site sandwiched by recognition sites of a restriction enzyme by using a recognition site introduction-oriented primer, and to generate a mass spectrum of an oligonucleotide fragment, which is cut out from the amplified product by using the restriction enzyme; an area ratio calculation mechanism configured to calculate an area ratio of a peak of a wild-type sequence of the specific site and a peak of a mutation-type sequence of the specific site in the mass spectrum; and an abundance ratio calculation mechanism configured to obtain an abundance ratio of the wild-type sequence and the mutation-type sequence based on a relationship between a previously acquired area ratio and the abundance ratio of the wild-type sequence and the mutation-type sequence. | 11-19-2009 |
| 20090286242 | MicroRNA Expression Profiling and Uses Thereof - Provided are methods and reagents for obtaining microRNA expression profiles in selected cell populations or sub-populations, such as stem cell or progenitor cell populations, and using such microRNA expression profiles for cell characterization, isolation/purification, and/or reinforcement of cell fate specification, both in research & development, and in therapeutic applications. Also provided are methods of identifying and isolating mammary progenitor cells using miRNA sensor constructs. | 11-19-2009 |
| 20090286243 | Compositions and methods for spinocerebellar ataxia - Mutations in the KCNC3 (Kv3.3) voltage-gated potassium channel gene result in spinocerebellar ataxia. | 11-19-2009 |
| 20090286244 | Fluorescent Color Markers - The invention provides a yeast-enhanced red fluorescent protein. In an embodiment of the invention, the yeast-enhanced red fluorescent protein is monomeric and is expressible in | 11-19-2009 |
| 20090286245 | TWO SLOW-STEP POLYMERASE ENZYME SYSTEMS AND METHODS - Compositions, kits, methods and systems for nucleotide sequencing comprising producing polymerase reactions that exhibit two kinetically observable steps within an observable phase of the polymerase reaction. Two slow step systems can be produced, for example, by selecting the appropriate polymerase enzyme, polymerase reaction conditions including cofactors, and polymerase reaction substrates including the primed template and nucleotides. | 11-19-2009 |
| 20090286246 | Methods for Identifying Compounds that Affect Expression of Cancer-Related Protein Isoforms - Provided herein are methods for screening compounds for their ability to modulate the expression of certain isoforms of proteins that are associated with cancer, such as isoforms of proteins that participate in Wnt signaling in cancer cells. | 11-19-2009 |
| 20090286247 | Novel nucleic acid base pair - A novel artificial nucleic acid base pair which is obtained by forming a selective base pair by introducing a group having steric hindrance (preferably a group having steric hindrance and static repulsion and a stacking effect) and can be recognized by a polymerase such as DNA polymerase; a novel artificial gene; and a method of designing nucleic acid bases so as to form a selective base pair with the use of steric hindrance, static repulsion and stacking effect at the base moiety of the nucleic acid. An artificial nucleic acid comprising these bases; a process for producing the same; a codon containing the same; a nucleic acid molecule containing the same; a process for producing a non-natural gene by using the same; a process for producing a novel protein by using the above nucleic acid molecule or non-natural gene, and the like. | 11-19-2009 |
| 20090286248 | Methods for Determining Drug Responsiveness - The invention provides a diagnostics assay for measuring the responsiveness to a drug by comparing the mRNA levels of a gene that responds to the drug, such as a steroid, to the MRNA levels of a gene that does not respond to the drug. Methods according to the invention are useful for predicting the ability of a patient (or a tissue, body fluid or cell sample in vitro) to respond to a drug or steroid at any stage of their treatment (i.e., before, during or after), and to monitor the patient (or a tissue, body fluid or cell) over time to assess continued responsiveness to the drug or steroid. | 11-19-2009 |
| 20090286249 | INACTIVATABLE TARGET CAPTURE OLIGOMERS FOR USE IN THE SELECTIVE HYBRIDIZATION AND CAPTURE OF TARGET NUCLEIC ACID SEQUENCES - The present invention provides compositions, kits and methods for the selective hybridization and capture of a specific target nucleic acid. The specific target nucleic acid may be present in a heterogeneous mixture of nucleic acids. Selective hybridization and capture provides a target nucleic acid that is substantially free of non-target and/or contaminating nucleic acids. Target nucleic acids that have been selectively hybridized and captured using the current invention are then used in subsequent analysis, wherein the presence of non-target and/or contaminating nucleic acids that interfere with said subsequent analysis have been substantially reduced or eliminated, thereby providing improved analysis results. The invention offers the further advantage of requiring less stringent purification and/or sterility efforts than conventionally needed in order to ensure that enzymes and other reagents used in subsequent analysis, or present in the environment in which an assay is performed, are free of bacterial or other contaminating nucleic acids. | 11-19-2009 |
| 20090286250 | INCORPORATING SOLUBLE SECURITY MARKERS INTO CYANOACRYLATE SOLUTIONS - Methods for authenticating an article with a cyanoacrylate solution comprising a water soluble security marker compound are described. The methods for producing a nucleophilic security marker/cyanoacrylate solution as well as methods for labeling an item and detecting the nucleophilic security marker/cyanoacrylate from an item being authenticated are also described. A method for using a nucleophilic cyanoacrylate security marker for antitheft purposes is also described. | 11-19-2009 |
| 20090286251 | Enzyme Reagents for Amplification of Polynucleotides in the Presence of Inhibitors - Compositions and methods are provided for amplifying polynucletoides from samples containing inhibitors that normally inhibit amplification using an enzyme blend containing a plurality of polymerases. The ability to amplify polynucleotides efficiently in the presence of inhibitors allows the enzyme reagent to be used in both routine amplification and real-time amplification from inhibitor-containing samples. | 11-19-2009 |
| 20090286252 | NRIF3, NOVEL CO-ACTIVATOR FOR NUCLEAR HORMONE RECEPTORS - Nucleic acids encoding NRIF3 are described. Polypeptides having amino acid sequences of NRIF3 proteins are also provided. A method is also provided for isolating and cloning NRIF3 cDNA. NRIF3 is useful in development/implementation of high throughput screens to identify novel thyroid hormone receptor (TR) and retinoid X receptor (RXR) agonists and antagonists. Methods are also provided for identifying compounds that directly interfere with the interaction of NRIF3 and TR or RXR. Finally, therapies based on modulation of NRIF3 activity are disclosed. | 11-19-2009 |
| 20090286253 | GENETIC LOCI ASSOCIATED WITH SCLEROTINIA TOLERANCE IN SOYBEAN - The invention relates to methods and compositions for identifying soybean plants that are tolerant, have improved tolerance or are susceptible to | 11-19-2009 |
| 20090286254 | GENE SILENCING - Methods are disclosed for screening for the occurrence of gene silencing (e.g., post transcriptional gene silencing) in an organism. Also provided are methods for isolating silencing agents so identified. | 11-19-2009 |
| 20090286255 | METHODS FOR ASSESSING EFFICACY OF CHEMOTHERAPEUTIC AGENTS - Methods are provided for accurately predicting efficacy of chemotherapeutic agents. Methods of the invention increase the positive predictive value of chemosensitivity assays by assessing both the ability of a chemotherapeutic to destroy cells and the genetic propensity of those cells for resistance. Results obtained using methods of the invention provide insight into the in vivo effectiveness of a therapeutic, and lead to more effective chemotherapeutic treatment. | 11-19-2009 |
| 20090291431 | COMPOSITIONS AND METHODS TO DETECT LEGIONELLA PNEUMOPHILA NUCLEIC ACID - Compositions are disclosed as nucleic acid sequences that may be used as amplification oligomers, including primers, capture probes for sample preparation, and detection probes specific for | 11-26-2009 |
| 20090291432 | Genetic profiles associated with the 957C>T polymorphism in the DRD2 gene - The present invention relates to a method for profiling an individual or group of individuals with respect to a neurological, psychiatric or psychological condition, phenotype or state, including a sub-threshold neurological, psychiatric or psychological condition, phenotype or state. More particularly, the present invention identifies a genetic profile associated with the 957C>T polymorphysm within the dopamine receptor D2 (DRD2), indicating a predisposition to schizophrenia and other neurological diseases. | 11-26-2009 |
| 20090291433 | Droplet-based nucleic acid amplification method and apparatus - The present invention relates to a droplet-based nucleic acid amplification method and apparatus. According to one embodiment, a method of amplifying a nucleic acid in a biological sample is provided, wherein the method includes: (a) providing a system comprising a droplet microactuator electronically coupled to and controlled by a processor capable of executing instructions, the droplet microactuator comprising: (i) a sample potentially comprising a target nucleic acid; (ii) a substrate comprising electrodes for conducting droplet operations; and (iii) one or more temperature control means arranged in proximity with one or more of the electrodes for heating a region of the droplet microactuator such that a droplet can be transported into the region for heating; (b) using droplet operations to combine on the droplet microactuator one or more amplification reagent droplets and one or more sample droplets to yield an amplification-ready droplet; and (c) thermal cycling the amplification-ready droplet sufficient to result in amplification of a target nucleic acid when present in the amplification-ready droplet. | 11-26-2009 |
| 20090291434 | Gene expression markers for colorectal cancer prognosis - A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject. | 11-26-2009 |
| 20090291435 | THERMAL REACTION DEVICE AND METHOD FOR USING THE SAME - Devices and methods for performing the relative concentration of a target in a sample, the sample containing both target and non-target components, the method performed by partitioning the sample into a large number of reaction volumes such that the target is concentrated relative to the non-target, and performing a detection assay upon each reaction volume to detect the target. | 11-26-2009 |
| 20090291436 | METHODS FOR DETECTING NUCLEIC ACIDS INDICATIVE OF CANCER - The invention provides methods for screening tissue or body fluid samples for nucleic acid indicia of cancer or precancer. | 11-26-2009 |
| 20090291437 | METHODS FOR TARGETING QUADRUPLEX SEQUENCES - Provided are quadruplex nucleotide sequences and methods for identifying interacting molecules. | 11-26-2009 |
| 20090291438 | Methods for Analysis of Extracelluar RNA Species - The invention provides methods and kits for enabling quantitative or qualitative analysis of extracellular RNA species in non-cellular bodily fluids including plasma and serum to detect, infer, evaluate, or monitor cancer and other neoplasia or other diseases of interest. | 11-26-2009 |
| 20090291439 | PHOSPHATASES INVOLVED IN THE REGULATION OF CARDIOMYOCYTE DIFFERENTIATION - An object of the invention is to provide a dephosphorylation enzyme that regulates cardiomyocyte differentiation, dominant negative enzyme thereof, a gene encoding the enzyme protein and use thereof. A protein or the like consisting of any one of the following amino acid sequences (A) to (C) is used: | 11-26-2009 |
| 20090291440 | METHOD FOR SYNTHESIZING NUCLEIC ACID USING DNA POLYMERASE BETA AND SINGLE MOLECULE SEQUENCING METHOD - The present invention provides a nucleic acid synthesis method capable of continuously carrying out an extension reaction and a single molecule sequencing method capable of obtaining base information accurately at high speed. A method for synthesizing a nucleic acid, including the steps of: forming a complex of a target nucleic acid hybridized to a primer oligonucleotide and a DNA polymerase β; allowing the DNA polymerase β to incorporate a fluorescently-labeled dNTP so that the fluorescently-labeled dNTP is bound to the 3′ end of the primer oligonucleotide; and allowing the DNA polymerase β to continuously incorporate fluorescently-labeled dNTP to extend a nucleic acid complementary to the target nucleic acid from the 3′ end of the bound fluorescently-labeled dNTP. A method for sequencing a single nucleic acid molecule, including the steps of said method for synthesizing a nucleic acid, wherein fluorescence emitted from each of the fluorescently-labeled dNTP incorporated into the DNA polymerase β is sequentially detected to carry out the sequencing of the target nucleic acid. | 11-26-2009 |
| 20090291441 | POLYPEPTIDE, NUCLEIC ACID MOLECULE ENCODING IT AND THEIR USES - A polypeptide containing epitope of the amino acid sequence shown in SEQ ID NO:3 is provided, which is selected from the amino acid sequence of SEQ ID NO:3 and amino acids at 16-32 positions, amino acids at 1-30 positions, amino acids at 50-80 positions and amino acids at 17-200 positions of the amino acid sequence shown in SEQ ID NO:3. The nucleic acid molecule encoding the polypeptide, recombinant vectors and host cells comprising the nucleic acid molecule are also provided. The polypeptide and the nucleic acid molecule encoding it can be used for preparing reagents, kits or devices for diagnosing the diseases characterized by EECP expression and pharmaceutical compositions for preventing or treating the diseases characterized by EECP expression by increasing or inhibiting EECP expression and/or activity. | 11-26-2009 |
| 20090291442 | HSPA1A AS A MARKER FOR SENSITIVITY TO KSP INHIBITORS - The present invention relates to methods for predicting a response to treatment with a kinesin spindle protein inhibitor using heat shock protein 70, isoform A1a, also known as HSPA1a, as a marker for sensitivity to the kinesin spindle protein (KSP) inhibitors. Method are provided for predicting a response to treatment with a kinesin spindle protein inhibitor of a first mammal in need thereof comprising determining an amount of HSPA1a mRNA transcript produced by said first mammal, wherein the amount of said HSPA1a mRNA transcript produced by said first mammal is indicative of said mammal's sensitivity to said kinesin spindle protein inhibitor | 11-26-2009 |
| 20090291443 | USE OF HIGHLY PARALLEL SNP GENOTYPING FOR FETAL DIAGNOSIS - The present invention provides apparatus and methods for enriching components or cells from a sample and conducting genetic analysis, such as SNP genotyping to provide diagnostic results for fetal disorders or conditions. | 11-26-2009 |
| 20090291444 | METHODS AND MATERIALS FOR DETECTING AND TREATING DEMENTIA - This document relates to methods and materials involved in detecting mutations linked to dementia (e.g., frontotemporal lobar degeneration). For example, methods and materials for determining whether or not a mammal is homozygous for a mutant T allele of rs5848 are provided. This document also relates to methods and materials involved in treating mammals having or being susceptible to developing neurodegenerative disorders (e.g., frontotemporal lobar degeneration). For example, methods and materials for inhibiting the ability of miRNA to suppress GRN polypeptide expression in mammals are provided. | 11-26-2009 |
| 20090291445 | BIOMARKER OF LUNG INJURY AND REPAIR - The present invention resides in the discovery that circulating cytokaretin 5 (CK5) mRNA level correlates with the presence of a lung injury or disease as well as the severity or stage of the injury or disease. Diagnostic methods and kits are provided. | 11-26-2009 |
| 20090291446 | METHOD FOR CONFIRMING THE PRESENCE OF AN ANALYTE - The invention provides methods and kits for the rapid confirmation of an initial analyte test result. In a preferred embodiment, the process confirms the presence of a given microbial target in a mixed culture, or a mixed enrichment media, even when the competing organisms in the mix belong to related species, or are various biotypes of the same species. | 11-26-2009 |
| 20090291447 | Method of detecting colon cancer marker - It is intended to provide a non-invasive and convenient method of detecting a tumor marker for diagnosing colon cancer which is superior in sensitivity and specificity to the existing fecal occult blood test. More specifically speaking, a method of detecting a tumor marker for diagnosing colon cancer which comprises collecting biological sample which is immediately frozen using liquid nitrogen in some cases, homogenizing the sample in the presence of an inhibitor of an RNA digesting enzyme to give a suspension, extracting RNA from the obtained suspension, subjecting the extracted RNA to reverse transcription to give cDNA, amplifying the obtained cDNA and then detecting the thus amplified cDNA. This method is characterized by involving no procedure of separating cell components from the biological sample. | 11-26-2009 |
| 20090291448 | Prognostic and Predictive Gene Signature for Non-Small Cell Lung Cancer and Adjuvant Chemotherapy - The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application. | 11-26-2009 |
| 20090291449 | METHOD AND APPARATUS TO MINIMIZE DIAGNOSTIC AND OTHER ERRORS DUE TO TRANSPOSITION OF BIOLOGICAL SPECIMENS AMONG SUBJECTS - A method and apparatus for minimizing diagnostic errors due to transposition of biological specimens among subjects provides for independent biometric confirmation that a given specimen is from a given donor. In certain embodiments, a biological specimen confirmation kit comprises a portable and openable case housing components of the kit, at least one biological specimen container adapted to receive a biological testing specimen from a donor, and at least one reference sample device adapted to receive a biological reference specimen from the same donor, such that the testing and reference specimens can later be compared for donor match verification by a reference verification entity. | 11-26-2009 |
| 20090291450 | CATERPILLER GENE FAMILY - The present invention relates to a new family of structurally and functionally related nucleic acids and proteins, designed the CATERPILLER family, which is characterized by landmark structural motifs including a nucleotide binding domain and leucine-rich repeat domains. | 11-26-2009 |
| 20090291451 | METHODS AND PRIMERS FOR DIAGNOSING IDIOPATHIC CONGENITAL CENTRAL HYPOVENTILATION SYNDROME - The present invention provides assays and kits for diagnosing idiopathic congenital central hypoventilation syndrome. The present assays and kits focus on the second polyalanine repeat of the PHOX2b gene or gene product, which is normally 20 residues in length. A polyalanine repeat 25 to 33 residues in length is strongly correlated with idiopathic congenital central hypoventilation syndrome. | 11-26-2009 |
| 20090291452 | MICRO-RNA PROFILES ASSOCIATED WITH ENDOMETRIAL CANCER DEVELOPMENT AND RESPONSE TO CISPLATIN AND DOXORUBICIN CHEMOTHERAPY - A method predicting of cancer chemoresponse of the population of cancer cells to the one or more chemotherapeutic agents. Our ability to treat patients with advanced stage and recurrent endometrial cancer is hampered by an incomplete understanding of the molecular basis of disease development and response to therapy. A novel class of gene products called microRNA (miRNA) has recently been implicated in the etiology of several different human cancers. Altered levels of expression of specific miRNAs may contribute to cancer development in a variety of cancers such as endometrial cancer and may also influence response to cytotoxic chemotherapy or other cancer treatments. Evidence is provided that differential expression of miRNAs contributes to endometrial carcinogenesis and further associates with sensitivity of endometrial cancer cells to various chemotherapeutic agents including cisplatin and doxorubicin chemotherapy. MiRNA profiles and their gene targets show promise as biomarkers of endometrial cancer chemo-response, and as a novel class of therapeutic targets for patients with endometrial cancer. | 11-26-2009 |
| 20090298052 | Diagnosing or Predicting the Course of Breast Cancer - A method of diagnosing the presence or predicting the course of breast cancer by measuring the expression of a combination of Marker genes comprising a tissue-specific gene and a non-tissue specific gene in a cell or tissue sample derived from a patient. In one aspect of the invention, the genes are mammaglobin and CK19. Kits, nucleic acid primers and probes and controls are provided. | 12-03-2009 |
| 20090298053 | Use of novel biomarkers for detection of testicular carcinoma in situ and derived cancers in human samples - The present invention relates to methods and kits for identification of testicular carcinoma in situ (CIS), gonadoblastoma (a CIS-like pre-cancerous lesion found in dysgenetic gonads) and CIS-derived cancers based on at least one of the biomarkers included in the invention. It also relates to diagnosis of a subject's status of the testicular carcinoma in situ and the derived cancers based on the measurement of a relative abundance of one of the biomarkers. | 12-03-2009 |
| 20090298054 | Epigenetic methods and nucleic acids for the detection of breast cell proliferative disorders - The present application provides methods and nucleic acids for the detection and differentiation of breast cell proliferative disorders. This is achieved by the analysis of the methylation of a panel of genes, or subsets thereof. The invention may be used for the detection and/or differentiation of a variety of tissue types including breast cancer and benign breast disorders as well as other cancers and tissue types. | 12-03-2009 |
| 20090298055 | PRODUCTION OF PROTEINS - The present invention is of a method of producing proteins in mammalian cells using a permanent selection in the absence of cytotoxic drugs. Specifically, the present invention can be used to produce large quantities of highly pure human proteins which are suitable for pharmaceutical applications. | 12-03-2009 |
| 20090298056 | Method of identifying cd4+ t cell antigens - The present invention is directed to a method of identifying CD4+ T cell antigens as well as to antigens which were identified by such a method. The present invention further is directed to the application of those identified antigens in medicine. | 12-03-2009 |
| 20090298057 | Primer and Probe for Use in Detection of Mycobacterium Kansasii and Method for Detection of Mycobacterium Kansasii Using the Same - The present invention discloses an oligonucleotide which comprises a part or the entire sequence of the nucleotide sequence depicted in SEQ ID NO: 1, 2, 3 or 4, or a part or the entire sequence of a nucleotide sequence complementary to the nucleotide sequence, wherein the oligonucleotide is capable of hybridizing with the nucleotide sequence of | 12-03-2009 |
| 20090298058 | Inhibitors of PGHS-2Transactivator Activity - Prostaglandin-endoperoxide H synthase (PGHS-2) converts arachidonic acid to prostaglandin H | 12-03-2009 |
| 20090298059 | System for the Integrated and Automated Analysis of DNA or Protein and Method for Operating Said Type of System - An embodiment of the present invention relates to a system for the integrated and automated analysis of DNA or protein, including a single-use cartridge, an analysis device comprising a control device, and devices for capturing and processing signals. An embodiment of the present invention relates, in particular, to the control device for carrying out a completely automatic process and evaluation of molecular diagnostic analysis via single-use cartridges (Lab-on-a-Chip). The first devices are provided for controlling an analysis process which occurs in the cartridge, subsequently the displacement and the thermostatisation of liquids, and the second devices are provided for processing the signals which are obtained during the analysis. The first and the second devices are synchronised in such a manner that the analysis process of the sample can be carried out in a totally integrated manner thus producing an immediate result. | 12-03-2009 |
| 20090298060 | METHODS FOR DIAGNOSING AND MONITORING THE STATUS OF SYSTEMIC LUPUS ERYTHEMATOSUS - The invention presents a method of diagnosing or monitoring the status of systemic lupus erythematosus (SLE) in a subject or patient comprising detecting the expression of all genes of a diagnostic set in the subject or patient wherein the diagnostic set comprises two or more genes having expression correlated with the classification or status of SLE; and diagnosing or monitoring the status of SLE in the subject or patient by applying at least one statistical method to the expression of the genes of the diagnostic set. | 12-03-2009 |
| 20090298061 | Diagnostic Methods for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapy - Described are 12 human genes which are differentially expressed in neoplastic tissues of patients responding well to treatment as compared to patients not responding well as determined by overall survival time in the non responding cohort. Moreover, methods for prognosis of the therapeutic success in cancer therapy are described. These methods are based on determination of expression levels of particular genes which are differentially expressed in cancer patients, preferably the genes encoding VEGFC, ERBB3 and Her2/neu, prior to the onset of anti-cancer chemotherapy. These methods are particularly useful in the investigation of advanced head and neck cancer, but are useful in the investigation of other types of cancer and therapies as well. | 12-03-2009 |
| 20090298062 | METHOD FOR DETERMINATION OF THE LENGTH OF THE G-TAIL SEQUENCE AND KIT FOR THE METHOD - A method of measuring the length of a G tail sequence, characterized by hybridizing the G tail of an nondenatured chromosomal DNA in a sample with a labeled DNA probe having a sequence complementary to the telomere repeat sequence, measuring chemiluminescence from the hybridized DNA probe, and determining the length of the G tail sequence from the measured value, and a kit used for use in such a method. | 12-03-2009 |
| 20090298063 | IL-1 Gene Cluster and Associated Inflammatory Polymorphisms and Haplotypes - The invention provides methods and compositions relating to identification and use of genetic information from the IL-1 gene cluster—including the structure and organization of novel IL-1-like genes found within the IL-1 locus as well as polymorphisms and associated haplotypes within these genes. The invention thereby expands the repertoire of useful genetic information available from the IL-1 locus—which contains the previously-identified IL-1α, EL-1β and IL-1RN genes, for predicting IL-1 associated phenotypes (e.g. increased or decreased risks of inflammatory disease) and for treating IL-1 haplotype associated inflammatory phenotypes. | 12-03-2009 |
| 20090298064 | Genomic Sequencing - Genomic sequencing is implemented for high throughput applications that can include short reads. In one example, whole-genome sequencing involves a method in which a subset of fragments of a target genome are selected as a random function, and each fragment is replicated into clones. The clones are ordered into clone contigs based on sets of overlapping clones, and potential read overlaps are determined from clone read data. The method can also involve reading local assemblies of contigs from regions smaller than a clone length and assembling the local assemblies into read sets, combining the assembled read sets into clone-sized regions and assembling the clone-sized regions, and assembling the clone-sized regions into clone contigs. Overlapping sets of clones and their ordering can be determined computationally from read data, with a high depth of clone coverage to provide a large number of boundaries on which the assemblies can be segmented into overlapping regions of pooled reads. | 12-03-2009 |
| 20090298065 | Methods for Identifying Functional Noncoding Sequences - The present invention relates to methods for identifying functional noncoding human sequences. Methods may comprise one or more of the following: a comparative genomic sequence analysis step, a genetic analysis step, and a functional analysis step. The functional analysis step comprises transposon-based transgenesis in zebrafish. Also disclosed here in a transposon-based vector to facilitate efficient transgenesis in zebrafish. | 12-03-2009 |
| 20090298066 | Sex-Specific Marker for Shrimps and Prawns - The present invention relates to a sex-specific marker for shrimps and prawns. More specifically, it relates to a sex-specific PCR-based molecular marker, derived from | 12-03-2009 |
| 20090298067 | DEVICES AND METHODS FOR DETECTING CELLS AND OTHER ANALYTES - The invention features methods, devices, and kits for the isolation of analytes (e.g., a cell). A sample containing a desired analyte is introduced into a microfluidic device containing moieties that bind the desired analyte. A shear stress is applied that is great enough to prevent binding of undesired analytes and low enough to allow binding of the analyte of interest. Once bound, the desired analytes can be analyzed (e.g., counted). The invention also features methods for determining a shear stress for isolating a desired analyte. | 12-03-2009 |
| 20090298068 | METHOD AND TEST KIT FOR THE DIAGNOSIS AND/OR MAKING PREDICTIONS ABOUT AND/OR FOR THE ASSESSMENT OF THE EFFICACY OF THERAPEUTIC AGENTS FOR THE TREATMENT OF OVARIAN CANCER AND METHOD OF PLANNING A REGIMEN FOR THE TREATMENT OF OVARIAN CANCER - The invention relates to a method and a test kit for diagnosing ovarian cancer and/or making predictions in case of ovarian cancer as well as a method for estimating the effectiveness of therapeutic agents during the treatment of ovarian cancer, the promoter hypermethylation of the TUSC3 marker in a biological sample that is to be analyzed, preferably in a tissue sample or biological liquid that is to be analyzed, being measured. The result of said method can be used for planning an ovarian cancer treatment. | 12-03-2009 |
| 20090298069 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 38 and 39 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 12-03-2009 |
| 20090298070 | METHOD FOR ANALYZING METABOLITES FLUX USING CONVERGING RATIO DETERMINANT AND SPLIT RATIO DETERMINANT - The present invention relates to a method for analyzing metabolic flux using CRD and SRD. Specifically, the method comprising: selecting a specific target organism, constructing the metabolic network model of the selected organism, identifying the correlations between specific metabolic fluxes in the metabolic network model, defining the correlation ratios as CRD and SRD, determining the correlation ratios of the metabolic fluxes through the experiment for measuring metabolic flux ratios, modifying a stoichiometric matrix with the determined CRD, SRD and correlation ratios, and applying the modified stoichiometric matrix of the metabolic network model for linear programming. According to the inventice method, the correlation between influent/effluent metabolic fluxes with respect to specific metabolites in target organisms (including | 12-03-2009 |
| 20090298071 | METHOD FOR TESTING DRUG SENSITIVITY IN SOLID TUMORS BY QUANTIFYING MRNA EXPRESSION IN THINLY-SLICED TUMOR TISSUE - A method is disclosed for assaying the sensitivity of neoplastic tissue to therapeutic agents, and in particular, for the quantification of pro-apoptotic marker mRNA expression in cells obtained from thinly-sliced living tumor tissue in such methods. The method may comprise ascertaining a particular apoptosis marker mRNA for an individual tumor or tumor type as well as exposure of thin-sliced live cancer tissues from the individual tumor to candidate chemotherapeutic drug regimes in vitro, followed by an assessment of the level of the marker mRNA in the tissue. | 12-03-2009 |
| 20090298072 | DNA Sequencing by Nanopore Using Modified Nucleotides - This invention provides a process for sequencing single-stranded DNA by employing a nanopore and modified nucleotides. | 12-03-2009 |
| 20090298073 | Kidney Toxicity Biomarkers - Novel biomarkers for kidney toxicity. Said biomarkers may be useful for optimization of lead compounds, or in safety assessment. | 12-03-2009 |
| 20090298074 | Modulators of ELOVL5 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of ELOVL5 and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 12-03-2009 |
| 20090298075 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCING - Compositions and methods for nucleic acid sequencing include template constructs that comprise double stranded portions in a partially or completely contiguous constructs, to provide for redundant sequence determination through one or both of sequencing sense and antisense strands, and iteratively sequencing the entire construct multiple times. Additional sequence components are also optionally included within such template constructs. Methods are also provided for the use and preparation of these constructs as well as sequencing compositions for their application. | 12-03-2009 |
| 20090298076 | DETECTION OF SALMONELLA BY REAL-TIME MULTIPLEX PCR - The invention relates to the detection of | 12-03-2009 |
| 20090298077 | ASSAY FOR MEASUREMENT OF APURINIC/APYRIMIDINIC (AP) SITES AND FOR SCREENING AP-SITE REACTIVE COMPOUNDS - A method of detecting abasic (AP) sites in DNA from a subject includes isolating a sample of DNA from a subject under examination, contacting the DNA with a fluorescent aldehyde reactive probe (FARP), and detecting FARP labeled AP sites in the DNA sample. | 12-03-2009 |
| 20090298078 | METHOD FOR THE DETECTION OF AN ACTIVATION OF THE IMMUNE SYSTEM OR THE EXTENT OF CELL DEATH - The present invention relates to a method for the detection of an activation of the immune system, preferably in the sense of an NET formation, or the extent of cell death in a non-tumorous tissue or in a body fluid, wherein free DNA is measured in a sample from an individual. Furthermore, the invention relates to a method for the production of a kit for the detection of an activation of the immune system or the extent of cell death in an individual, comprising the packaging of a fluorescent dye and a DNA standard in at least one container. | 12-03-2009 |
| 20090298079 | HIGH AFFINITY BINDING SITE OF HGFR AND METHODS FOR IDENTIFICATION OF ANTAGONISTS THEREOF - Use of a polynucleotide encoding or a polypeptide comprising at least the extracellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor. | 12-03-2009 |
| 20090298080 | METHODS AND REAGENTS FOR DETECTING CpG METHYLATION WITH A METHYL CpG BINDING PROTEIN (MBP) - The present invention provides a simple and sensitive technology for the detection of CpG methylation in DNA without chemical modification of sample DNA by bisulfite treatment or PCR amplification. Signal generation is based on an Abscription (Abortive Transcription) technology in which DNA signal generators called Abortive Promoter Cassettes (APCs) are bound to target mCpG sites via mCpG target specific probes based on methyl binding polypeptides or methyl binding domains thereof. RNA polymerase produces uniform, short RNA molecules from synthetic promoters in APCs as signals of the presence of methylated CpGs. Detection of CpG methylation and hypermethylation of DNA targets such as CpG islands provides a convenient means for detecting and monitoring cancer in a subject. | 12-03-2009 |
| 20090298081 | METHODS OF TREATMENT UTILIZING BINDING PROTEINS OF THE INTERLEUKIN-21 RECEPTOR - The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders. | 12-03-2009 |
| 20090298082 | BIOMARKER PANELS FOR PREDICTING PROSTATE CANCER OUTCOMES - This document provides methods and materials related to assessing male mammals (e.g., humans) with prostate cancer. For example, methods and materials for predicting (1) which patients, at the time of PSA reoccurrence, will later develop systemic disease, (2) which patients, at the time of retropubic radial prostatectomy, will later develop systemic disease, and (3) which patients, at the time of systemic disease, will later die from prostate cancer are provided. | 12-03-2009 |
| 20090298083 | Phospho-Specific Anti-Pax3 Antibodies - Pax3, a member of the paired class homeodomain family of transcription factors and an essential protein for early skeletal muscle development, was shown to be phosphorylated in proliferating mouse primary myoblasts. Furthermore, Ser205, Ser201 and Ser209 were identified as the only sites of phosphorylation on Pax3 in proliferating mouse primary myoblasts. Phosphorylation of Ser205 was shown to be required for the efficient phosphorylation of Ser201 and/or Ser209. Site-specific antibodies were made to each of these three sites when phosphorylated. These three sites are also present and phosphorylated in the Pax3-FOXO1 fusion protein, and phosphorylation of these sites may play a role in ARMS. Thus, these new antibodies may be used in studying the regulation of nerve and muscle development and differentiation and in finding therapeutic solutions for certain disorders, including Waardenburg syndrome and childhood solid muscle tumor alveolar rhabdomyosarcoma (ARMS). | 12-03-2009 |
| 20090298084 | GENE AND PROTEIN EXPRESSION PROFILES ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF IRINOTECAN - The present invention includes gene and protein expression profiles indicative of whether a cancer patient is likely to respond to treatment with irinotecan. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and/or protein expression profiles and assays for identifying the presence of a gene and/or protein expression profile in a patient sample. | 12-03-2009 |
| 20090298085 | Detection of Extracellular Tumor-Associated Nucleic Acid in Blood Plasma or Serum Using Nucleic Acid Amplification Assays - This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such as oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease. The invention thereby provides methods for early identification of colorectal, pancreatic, lung, breast, bladder, ovarian, lymphoma and all other malignancies carrying tumor-related mutations of DNA and methods for monitoring cancer and other neoplastic disorders in humans and other animals. | 12-03-2009 |
| 20090298086 | PLANT FARNESYLTRANSFERASES - This invention relates to an isolated nucleic acid fragment encoding a farnesyltransferase subunit. The invention also relates to the construction of a chimeric gene encoding all or a portion of the farnesyltransferase subunit, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the farnesyltransferase subunit in a transformed host cell. | 12-03-2009 |
| 20090298087 | METHODS AND PROBES FOR THE DETECTION OF CANCER - Probe sets and methods of using probes and probe sets for the detection of cancer are described. Methods for detecting cancer that include hybridizing a set of chromosomal probes to a biological sample obtained from a patient, and identifying if cancer cells are present the sample. Also included are methods of selecting a combination of probes for the detection of cancer. | 12-03-2009 |
| 20090305233 | Methods and Reagents for Polynucleotide Assembly - The present invention provides methods, compositions, and kits for polynucleotide assembly. | 12-10-2009 |
| 20090305234 | Specific DNAS for Epigenetic Characterisation of Cells and Tissues - The present invention provides methods, nucleic acids and molecular markers for the characterization of cells, tissues and heterogeneous mixtures of cells. Specifically, it describes particular genes and genomic regions in which DNA methylation patterns are a consistent and characteristic property of different cell types, states and stages of differentiation. The invention is useful in determining the identity, composition, quality and potency of cells and cell populations. Furthermore, the invention will be useful in monitoring the differentiation of cells. | 12-10-2009 |
| 20090305235 | Novel Targets For The Identification Of Antibiotics That Are Not Susceptible To Antibiotic Resistance - To identify conserved and variable regions of the 16 S rRNA, an instant evolution experiment was performed on the entire 16 S rRNA. Analysis of these mutants identified regions that are required for function. These conserved sequences may be used as targets for pharmaceuticals that are taxonomically specific and which are refractory to the development of drug resistance. | 12-10-2009 |
| 20090305236 | METHODS OF ENRICHING FETAL CELLS - The present invention relates to methods of enriching fetal cells from a pregnant female. The present invention relates to removing, from a sample, cells that comprise at least one MHC molecule. The present invention also relates to methods that rely on using telomerase, mRNA encoding components thereof, as well as telomere length, as markers for fetal cells. Enriched fetal cells can be used in a variety of procedures including, detection of a trait of interest such as a disease trait, or a genetic predisposition thereto, gender typing and parentage testing. | 12-10-2009 |
| 20090305237 | QUANTIFICATION OF NUCLEIC ACIDS AND PROTEINS USING OLIGONUCLEOTIDE MASS TAGS - The invention provides a method for detecting and quantifying the amount of target molecules, such as nucleic acids or proteins in a sample. The target molecules are first recognized and bounded by target-specific probes, generally nucleic acids or proteins that bind specifically to the targets, each of which is labeled with a short single-stranded nucleic acid probe, either DNA or RNA, with distinct molecular weight. This label is called an oligonucleotide mass tag. One or several standard oligonucleotide sequences can be designed with similar sequence but distinct molecular weight to those oligonucleotide mass tags. Then the oligonucleotide mass tags associated with bounded probes and the standard sequences are co-amplified using a pair of common primers. The presence and/or amount of each oligonucleotide mass tag, which corresponds to the amount of corresponding target molecule, is determined by a primer extension reaction and quantification of the primer extension product. | 12-10-2009 |
| 20090305238 | Microarray Microcard - A fluid processing device is provided that comprises a substrate including a surface and a fluid processing pathway at least partially formed in or on the surface. The fluid processing pathway can comprise a channel, a reaction region in fluid communication with the channel, a microarray in fluid communication with the channel, and optionally a deformable valve. The microarray can comprise binding and/or detection sites, and each site can comprise a binding moiety. A method and a system using the fluid processing device, are also provided. | 12-10-2009 |
| 20090305239 | Methods and compositions for determing a level of biologically active serum paraoxonase - A method of determining a level of biologically active PON enzyme is provided. The method comprising determining lactonase activity of the PON enzyme, the lactonase activity being indicative of the level of biologically active PON enzyme. Also provided are novel compounds which may be used for measuring a lactonase activity of an enzyme. | 12-10-2009 |
| 20090305240 | METHOD FOR DETECTION OF MICROORGANISM AND KIT FOR DETECTION OF MICROORGANISM - Live cells of a microorganism in a test sample are detected by the following steps:
| 12-10-2009 |
| 20090305241 | DNA demethylases and uses thereof - Polypeptides with DNA demethylase activity as well as methods of their use are provided. | 12-10-2009 |
| 20090305242 | SKIN AGING MARKER AND TECHNIQUE FOR USE THEREOF - It is an object of the present invention to find substances that can be used as skin aging markers, and the present invention provides a method for determining the degree of skin aging, including measurement of expression of secretory proteins and/or intracellular proteins and/or their genes in skin cells and/or skin tissues, wherein the secretory proteins and/or intracellular proteins change their expression with aging of skin. The present invention also provides a kit for determining the degree of skin aging and a method for identifying substances effective in the prevention of skin aging. | 12-10-2009 |
| 20090305243 | Oligonucleotides, Use Thereof, Detecting Method and Kit for Diagnosing the Presence of H5 and N1 Genes of the Influenza a Virus - The present invention relates to a double pair of oligonucleotides for amplifying two target sequences located, respectively, in the H5 and N1 genes of the genome of the Influenza A virus, said oligonucleotides being of a length ranging between 10 and 50 nucleotides and comprising at least one fragment of 10 consecutive nucleotides derived from the following sequences: | 12-10-2009 |
| 20090305244 | Selection, Propagation and Use of Mosaic Aneuploid Stem Cells - The distribution of cell karyotypes within a population of cells can determine the phenotype and ability of stem cells to differentiate into desired cell types, to function normally, as well as represent risk for adverse events like cancer. Therefore, determination of the aneuploid mosaic status of a cell population is useful in identifying and/or maintaining desirable traits and eliminating undesirable traits in stem cells, and for defining them at the level of their chromosomal complement. | 12-10-2009 |
| 20090305245 | Method of Examining Zinc-Deficient Taste Disturbance - The present invention provides: a method for testing zinc deficiency dysgeusia, which is characterized in that it comprises correlating the expression levels of a gene encoding a gustatory receptor belonging to the THTR family and a gene encoding a gustatory receptor belonging to the T2R family obtained from a sample derived from the oral cavity of a subject, with a serum zinc level obtained from the sample of the subject; and a kit used for the aforementioned test. | 12-10-2009 |
| 20090305246 | SCHIZOPHRENIA ASSOCIATED GENES AND MARKERS - The invention discloses schizophrenia-associated polymorphism located on chromosome 6q23 within the human Abelson Helper Integration Site 1 gene (AHI1), or a genomic region linked to the AHI1 gene that includes the C6orf217 gene. The invention further discloses systems and methods for diagnosing schizophrenia or predisposition to schizophrenia. | 12-10-2009 |
| 20090305247 | NANOPARTICLE AND METHODS THEREFOR - There is provided an electroactive nanoparticle, which may be used as a label in electrochemical detection assays. The nanoparticle comprises a transition metal oxide and a capping agent, the capping agent comprising a ligand group and a functional group. The capping agent is coordinated to a transition metal centre in the transition metal oxide via the ligand group. Also provided are methods relating to preparation of the nanoparticle and detection of an analyte molecule in a sample using electrochemical methods. | 12-10-2009 |
| 20090305248 | METHODS FOR INCREASING ACCURACY OF NUCLEIC ACID SEQUENCING - The invention provides methods for improving the fidelity of a sequencing-by-synthesis reaction by resequencing at least a portion of a nucleic acid template. | 12-10-2009 |
| 20090305249 | METHOD OF DETECTING CYP2A6 GENE VARIANTS - The present invention relates to methods for amplifying various regions of the CYP2A6 gene. Methods are provided for amplifying one or more fragments of the CYP2A6 gene in a single tube. The methods can identify mutations, deletion, duplication, and/or rearrangement in a sample containing the CYP2A6 gene. | 12-10-2009 |
| 20090305250 | DETERMINATION OF THE BIOLOGICAL FUNCTION OF A TARGET GENE IN A CELL - Disclosed herein is a method to determine the biological function(s) of a target gene in a cell, the steps of which involve separately culturing a first population and a second population of the cell under same culturing conditions, the first population of the cell differing from the second population of the cell in that the first population of the cell has accepted the introduction of a methylated polynucleotide; comparing the first population and the second population of the cell to determine which biological difference(s) is/are present therebetween; and determining which biological function(s) the target gene is associated with based on the determined biological difference(s) between the first population and the second population of the cell. | 12-10-2009 |
| 20090305251 | BRCA1/BRCA2 SCREENING PANEL - A method for analyzing a biological sample is performed by analyzing a biological sample for the presence of one or more mutations or polymorphisms in the BCRA1 and/or BCRA2 genes. | 12-10-2009 |
| 20090305252 | Methods and species-specific primers for detection and quantification of Streptococcus mutans and Streptococcus sanguinis in mixed bacterial samples - Dental caries is a polymicrobial infectious disease. Of the hundreds of bacteria present in the biofilms coating teeth, the | 12-10-2009 |
| 20090305253 | Methods and Compositions Related to the Modulation of Riboswitches - Disclosed herein are methods and compositions related to the detection of conformational changes and interactions with trigger molecules in riboswitches. | 12-10-2009 |
| 20090305254 | Method and Apparatus for Assaying Test Substance in Sample - Disclosed are a method for assaying a target substance in a sample and an apparatus for the method. The method can specifically assay the target substance in the sample without using any antibody against the target substance. The assaying method includes simultaneously or successively bringing a labeled aptamer, the target substance in the sample and a solid phase into contact together, and then measuring the label of the aptamer which has not been bound on the solid phase. The labeled aptamer has a property of binding to the target substance. The solid phase carries an oligonucleotide immobilized on it in an excess amount relative to the target substance. The oligonucleotide is hybridizable with the labeled aptamer when the labeled aptamer is in a state that it is not bound to the target substance, but is not hybridizable with the labeled aptamer when the labeled aptamer is in a state that it is bound to the target substance. | 12-10-2009 |
| 20090305255 | Substrate Protein for M-Phase Kinase and use Thereof - An isolated protein of (a) a protein having an amino acid sequence of SEQ ID No. 2; (b) a protein having an amino acid sequence partially different from the amino acid sequence of SEQ ID No. 2 that is a substrate of M-period kinase and has nucleic acid-methylating activity suppressed by phosphorylation; (c) a protein having the amino acid sequence of SEQ ID No. 2 that is phosphorylated by M-period kinase; or (d) a protein having an amino acid sequence partially different from the amino acid sequence of SEQ ID No. 2 that is phosphorylated by M-period kinase. | 12-10-2009 |
| 20090305256 | DNA methylation biomarkers for lung cancer - The present invention relates to the identification of novel DNA biomarkers and the use of the aberrant methylation patterns of the biomarkers to diagnose a disease or a condition (e.g., a cancer) associated therewith. In particular, the present invention relates to the use of the novel DNA biomarkers to diagnose lung cancers, e.g., squamous cell carcinomas and adenocarcinomas. | 12-10-2009 |
| 20090305257 | BIOMARKERS DOWNREGULATED IN PROSTATE CANCER - Biomarkers are identified by analyzing gene expression data using support vector machines (SVM), recursive feature elimination (RFE) and/or linear ridge regression classifiers to rank genes according to their ability to separate prostate cancer from normal tissue. Proteins expressed by identified genes are detected in patient samples to screen, predict and monitor prostate cancer. | 12-10-2009 |
| 20090305258 | METHODS FOR THE DIAGNOSIS OF PROLIFERATIVE AND/OR CONFORMATIONAL DISEASES - The present invention discloses methods to diagnose and/or to make prognostic predictions and/or to monitor the efficacy of a therapy of a proliferative or conformational disease, or to establish the state of ageing in a subject. Kit for performing such methods are also disclosed. | 12-10-2009 |
| 20090305259 | Early Diagnosis of Congenital Abnormalities in the Offspring of Diabetic Mothers - The present invention relates to the identification of a series of biomarkers, the detection of which is prognostic for women at risk of becoming hyperglycemic during pregnancy and/or fetuses at risk of developing congenital anomalies as a result of maternal hyperglycemia. | 12-10-2009 |
| 20090305260 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 59 to 61 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 12-10-2009 |
| 20090305261 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 65 to 67 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 12-10-2009 |
| 20090305262 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 56 to 58 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 12-10-2009 |
| 20090305263 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 43 to 45 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 12-10-2009 |
| 20090305264 | COOPERATIVE PROBES AND METHODS OF USING THEM - The present invention provides inter alia, cooperative probe assays for analyzing and identifying biological substances. | 12-10-2009 |
| 20090305265 | INTERLEUKIN-33 (IL-33) FOR THE DIAGNOSIS AND PROGNOSIS OF CARDIOVASCULAR DISEASE - The present invention includes methods for the use of interleukin-33 (IL-33) in the diagnosis of cardiovascular conditions including acute coronary syndrome (ACS), myocardial infarction, and/or heart failure, angina, cardiac hypertrophy, arteriosclerosis, myocarditis, pancarditis, endocarditis, stroke and/or pulmonary embolism and the determination of the severity of such conditions (prognosis). | 12-10-2009 |
| 20090305266 | TEST FOR OVARIAN CANCER BY DETECTING ABNORMALITY IN FANCD2 PATHWAY - Methods are provided for determining diagnosing ovarian and breast cancer in a subject, including diagnosing the predisposition of a subject's risk of developing breast or ovarian cancer. The methods include selecting a subject, for example a subject with one or more risk factors for developing ovarian cancer or breast cancer, and detecting a decrease in the activity of the Fanconi anemia (FA) non-nuclear core (NNC) component in the subject. Such a decrease is indicative of a predisposition to ovarian cancer and/or breast cancer in the subject. These methods can be used to monitor the response of a subject to agents designed to prevent breast and ovarian cancer, for example an anti-neoplastic agent. Methods also are provided for identifying agents of use in preventing breast and ovarian cancer. | 12-10-2009 |
| 20090305267 | MICROBIAL MARKERS OF INFLAMMATORY BOWEL DISEASE - The present invention relates to bacterial serine protease autotransporter (SPATE) and Antigen 43 (Ag43) and their various uses relating to inflammatory bowel disease (IBD), specifically in the diagnosis of IBD and the screening of potential agent for treating IBD. The invention also relates to methods for cultivating and identifying enteric microbes. | 12-10-2009 |
| 20090305268 | METHOD OF DETERMINING AN AMOUNT OF FATTY ACID CONTENTS IN BOVINE INTRAMUSCULAR FAT ON THE BASIS OF GENOTYPE OF FATTY ACID SYNTHASE GENE AND METHOD OF DETERMINING GOODNESS OF EATING QUALITY OF BEEF ON THE BASIS OF THE RESULTS THEREOF - The present invention has an object to provide a method of determining fatty acid composition in intramuscular fat on the basis of bovine genotype, in particular a method of simply determining an amount of an oleic acid content with a high degree of accuracy, and a method of objectively determining the goodness of eating quality of beef on the basis of the results of the determination. The present invention provides a method of determining an amount of fatty acid content in bovine intramuscular fat on the basis of the genotype of fatty acid synthase determined by determining base <1> and/or base <2> described below, and a method of determining whether cattles are those from which beef with an excellent eating quality is obtained on the basis of the results thereof. | 12-10-2009 |
| 20090305269 | PCR SCREENING METHOD - A tooling system ( | 12-10-2009 |
| 20090305271 | In Vitro Assay Based on Camp Levels Modulated by Gi-Coupled Receptors - The present invention relates to a reliable and effective in vitro assay based on cAMP levels modulated by Gi-coupled receptors expressed in a selected cell for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular receptor. | 12-10-2009 |
| 20090305272 | METHOD OF CHARACTERIZING ENDOGENOUS POLYNUCLEOTIDE-POLYPEPTIDE INTERACTIONS - A method for characterizing an endogenous polypeptide includes introducing epitope tag-encoding polynucleotide into an endogenous locus of a somatic cell by homogenous recombination mediated knock-in so that an epitope tagged endogenous polypeptide is expressed by the cell, and characterizing the epitope tagged endogenous polypeptide using an immunoassay. | 12-10-2009 |
| 20090305273 | NANONOZZLE DEVICE ARRAYS: THEIR PREPARATION AND USE FOR MACROMOLECULAR ANALYSIS - Constricted nanochannel devices suitable for use in analysis of macromolecular structure, including DNA sequencing, are disclosed. Also disclosed are methods for fabricating such devices and for analyzing macro-molecules using such devices. | 12-10-2009 |
| 20090305274 | Method for determining azole resistance in candida glabrata - There is disclosed a method for determining azole resistance in | 12-10-2009 |
| 20090305275 | DNAs AND PROTEINS OR PEPTIDES SPECIFIC TO BACTERIA OF THE SPECIES NEISSERIA MENINGITIDIS, PROCESS FOR OBTAINING THEM AND THEIR BIOLOGICAL USES - The DNA of the invention are characterised in that they concern the whole or pan of genes, with their reading frame, to be found in | 12-10-2009 |
| 20090305276 | Method for Predicting Skin Sensitizing Activity of Compounds - The present invention provides methods for predicting the in vivo skin sensitizing activity of chemical compounds using a combination of mammalian cell models with multiple endpoint analysis, time and concentration response curves. The methods allow the determination of a predicted in vivo sensitization value of a compound—for example, a EC3 LLNA value, a GPMT value or a IVTI value—without the use of animals, with a high degree of accuracy. The methods involve detecting expression levels of genes implicated in skin sensitization, combining expression level data with concentration response data, conducting a computational analysis, and comparing test compound data to a database of known skin sensitizers. | 12-10-2009 |
| 20090305277 | GENE EXPRESSION MARKERS FOR PREDICTION OF PATIENT RESPONSE TO CHEMOTHERAPY - The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e.g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e.g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant gene sets and therefore is compatible with the most widely available type of biopsy material. | 12-10-2009 |
| 20090305278 | SEQUENCE DETERMINATION IN CONFINED REGIONS - A sequencing methodology is disclosed that allows a single DNA or RNA molecule or portion thereof to be sequenced directly and in substantially real time. The methodology involves engineering a polymerase and/or dNTPs with atomic and/or molecular tags that have a detectable property that is monitored by a detection system. | 12-10-2009 |
| 20090305279 | METHOD OF DIAGNOSIS - Provided are methods, kits and arrays for use in determining whether a scar of interest is keloid or non-keloid in nature. These determine keloid or non-keloid nature based on comparison of gene expression in the scar of interest with expression in a control sample. If expression of at least one gene, selected from the group of genes set out in Table 1, is decreased in a sample representative of gene expression in the scar of interest compared to expression of the same gene (or genes) in the control sample this indicates that the scar of interest comprises a keloid. | 12-10-2009 |
| 20090305280 | Luciferase biosensors for camp - A modified luciferase protein which is a sensor for molecules including cAMP is provided. The modified luciferase protein includes one or more heterologous amino acid sequences, at least one of which directly or indirectly interacts with cAMP. | 12-10-2009 |
| 20090305281 | NOVEL INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTACE - Disclosed are nucleic acid molecules, and methods of their use, which have a specific structure including a double helical domain and a G-quadruplex domain physically connected by a linker domain which may be nucleosidic or non-nucleosidic. These aptamers demonstrate potent inhibition of phylogenetically diverse primate lentiviral reverse transcriptases, which effect is largely independent of aptamer sequence provided that the aptamer has the specified structure. | 12-10-2009 |
| 20090305282 | NOVEL HUMAN VIRUS CAUSING RESPIRATORY TRACT INFECTION AND USES THEREOF - The present invention provides the complete genomic sequence of a novel human coronavirus, coined as coronavirus-HKU1 (“CoV-HKU1”), isolated in Hong Kong from a patient who had a recent history of visit to Schenzhen. China. The virus belongs to the order Nidovirales of the family Coronavirdae, being a single-stranded RNA virus of positive polarity. The invention also provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the CoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by CoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the CoV-HKU1 based on the nucleotide sequences and deduced amino acid sequences of the CoV-HKU1. | 12-10-2009 |
| 20090305283 | CLEAVAGE OF NUCLEIC ACIDS - The present invention relates to means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences. The present invention also relates to methods for forming a nucleic acid cleavage structure on a target sequence and cleaving the nucleic acid cleavage structure in a site-specific manner. The structure-specific nuclease activity of a variety of enzymes is used to cleave the target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof. | 12-10-2009 |
| 20090305284 | Methods for Identifying Risk of Breast Cancer and Treatments Thereof - Provided herein are methods for identifying risk of breast cancer in a subject and/or a subject at risk of breast cancer, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating breast cancer, and therapeutic methods for treating breast cancer in a subject. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome. | 12-10-2009 |
| 20090305285 | ASYMMETRIC CYANINE COMPOUNDS, THEIR PREPARATION METHODS AND THEIR USES - Asymmetric cyanine compounds represented by general formula I are provided, wherein X, n, R | 12-10-2009 |
| 20090305286 | Method for the Identification of Suitable Fragmentation Sites in a Reporter Protein - The invention concerns a combinatorial method for the generation of new split-protein sensors, and its application towards the (β/α) | 12-10-2009 |
| 20090305287 | Method and System for Multiplex Genetic Analysis - A method for identifying nucleotides in a nucleic acid sequence is disclosed. A plurality of polymerization complexes are provided within a plurality of confined reaction environments. Each complex comprises a polymerase enzyme and a template nucleic acid. The plurality of complexes are contacted with a plurality of types of nucleotide analogs labeled with distinguishable fluorescent labels under conditions suitable for polymerization. Fluorescent signals associated with incorporation of a nucleotide analog are transmitted to a detector, wherein the location of the fluorescent signal on the detector is indicative of the individual confined reaction environment and the type of nucleotide incorporated. The nucleotide in a nucleic acid sequence is identified based upon the type of nucleotide incorporated and the confined reaction environment. | 12-10-2009 |
| 20090305288 | METHODS FOR AMPLIFYING NUCLEIC ACIDS AND FOR ANALYZING NUCLEIC ACIDS THEREWITH - An object of the present invention is to control the increase in amplification errors generated during the nucleic acid amplification and thus to obtain an amplification product having a good reproducibility. The present invention is characterized in that a target nucleic acid to be amplified is amplified through a two-stage amplification process in which the amplification only of a single strand is first performed and a strand which is complementary to its amplified product is then amplified. The amplification uses a first primer which is employed for the first-stage amplification and a second primer which is employed for the second-stage amplification. These primers are each used separately, or alternatively designed to have a different stringency and used at the same time. | 12-10-2009 |
| 20090305289 | SCREENING METHOD TO IDENTIFY PROTECTIVE SUBSTANCES FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR ISCHAEMIC DISEASES - The present invention relates to a screening method for the identification of protective substances which influence haemoglobin formation in neuronal, myocardial and/or skeletomuscular cells, as well as to recombinant constructs, host cells and transgenic animals for the implementation of this method. In addition, the present invention relates to a diagnostic method for the differential diagnosis of neurodegenerative and/or ischaemic diseases in mammals and the use of haemoglobin, a globin or a mutein or fusion protein thereof or a corresponding nucleic acid for the treatment of neurodegenerative and/or ischaemic diseases in mammals. The invention furthermore relates to constructs for gene therapy of such diseases. | 12-10-2009 |
| 20090305290 | LATERAL FLOW NUCLEIC ACID DETECTOR - Point-of-care binding assays include at least one target nucleic acid binding in a multiplex structure with at least one sequence in a partner nucleic acid associated with a label, due to complementary base pairings between at least one sequence in the target nucleic acid and at least one sequence in the partner nucleic acid. The assays overcome the inherent deficiencies of antibody-protein antigen assays. In a preferred embodiment, color tagged nucleic acid sequences are used to bind a complementary target nucleic acid. The tagged nucleic acid sequences are preferably made from deoxyribonucleotides, ribonucleotides, or peptide nucleotides. | 12-10-2009 |
| 20090305291 | METHOD AND A MICRODEVICE FOR THE IDENTIFICATION AND/OR QUANTIFICATION OF AN ANALYTE IN A BIOLOGICAL SAMPLE - A method and device, based on a film of a luminescent substance, such as colloidal semiconductor nanocrystals dispersed in a polymer matrix, for conducting quantitative and real-time analyses of PCR processes or of biomolecular interactions in genomics and/or proteomics. The optical detection system is based on FRET processes between the luminescent substance (which acts as the donor in the FRET process) and a suitable fluorophore (which acts as the acceptor species) with which the DNA or other biomolecule is marked. The device is essentially composed of a reaction microchamber with a wall formed by a thin film made of polymer material, in which the nanocrystals are uniformly dispersed, or made of a photoluminescent or electroluminescent polymer. Molecular probes are chemically immobilized on the surface of the polymer film for the specific recognition of the analyte which is to be determined in real time. The film of nanocrystals is excited by radiation at low wavelength (for example, UV/blue), and the radiation in the spectral emission window characteristic of the fluorescent marker of the biomolecule is detected. The specific photophysical characteristics of FRET processes make it possible to monitor in a selective way, in real time and in quantitative mode, the biomolecular interactions, which take place in the close proximity of the surface of the film (typically at distances of <10 nanometres), thus almost completely reducing possible interference caused by background signals and by the free biomolecules in solution (which have not interacted with the corresponding recognition sites). The characteristics of the device also enable simultaneous analyses to be conducted in parallel on different biomolecules (multiplexing). | 12-10-2009 |
| 20090305292 | DNA POLYMERASE - The present invention relates to DNA polymerases. In particular the invention relates to a method for the generation of DNA polymerases exhibiting a relaxed substrate specificity. Uses of mutant polymerases produced using the methods of the invention are also described. | 12-10-2009 |
| 20090305293 | COMPOSITIONS AND METHODS TO DETECT CANDIDA ALBICANS NUCLEIC ACID - Compositions are disclosed as nucleic acid sequences that may be used as amplification oligomers, including primers, capture probes for sample preparation, and detection probes specific for | 12-10-2009 |
| 20090305294 | METHOD OF ISOLATING NUCLEIC ACIDS FROM STOOL SAMPLES - The present invention relates to a method of isolating a nucleic acid molecule form a biological sample. More particularly, the present invention relates to a method of isolating ribonucleic acid molecule from a biological sample. The method of the present invention is useful in a range of applications including, but not limited to, diagnostic applications and research and development applications, to the extent that the isolation of nucleic acid molecules, and in particular ribonucleic acid molecules, is required. Most particularly, the method of the present invention provides for the isolation of ribonucleic acid molecules which are suitable for analysis by reverse transcriptase-PCR. | 12-10-2009 |
| 20090305295 | IDENTIFICATION OF A GENE EXPRESSION PROFILE THAT DIFFERENTIATES ISCHEMIC AND NONISCHEMIC CARDIOMYOPATHY - A method of preparing a gene expression prediction profile for distinguishing ischemic and nonischemic cardiomyopathy comprises the steps of obtaining clinical specimens from patients suffering from ischemic or nonischemic cardiomyopathy, isolating nucleic acid sequences from at least a plurality of said specimens, obtaining a gene expression level corresponding to each individual of said nucleic acid sequence by a gene expression profiling method, identifying genes having differences in gene expression by comparing the gene expression level of an ischemic specimen with the gene expression level of a nonischemic specimen, and identifying a gene expression prediction profile comprises genes identified as having differences in gene expression so that said prediction profile distinguishes ischemic and nonischemic cardiomyopathy. | 12-10-2009 |
| 20090311671 | Diagnosis of risk of breast cancer - A diagnostic method is disclosed which can he used to predict the risk of cancer, in particular breast cancer. The method comprises: (i) isolating a sample of the patient's genome: and (ii) detecting the presence or expression of the gene comprised within the sequence identified herein as SEQ ID No. 1, wherein the presence or expression of the gene indicates the presence of or the risk of cancer. | 12-17-2009 |
| 20090311672 | Detection of amplicon contamination during pcr exhibiting two different annealing temperatures - A method to perform PCR reactions with one set of primers comprising sequence elements that are complementary to the target sequence and comprising sequence elements that server as tagging sequences. By conducting amplification reactions at different temperatures, the presence of contaminations arising from amplification products of previous reactions can be determined, improving reliability of the reaction and reducing the need for control reactions and reproduction of reactions. | 12-17-2009 |
| 20090311673 | NUCLEIC ACID AMPLIFICATION METHODS - The present invention is directed to devices for performing PCR and monitoring the reaction of a sample comprising a nucleic acid and a fluorescent dye. Illustrative devices comprise a heat exchange component for heating and cooling the sample, a control device for repeatedly operating the heat exchange component to subject the sample to thermal cycling, an excitation source for optically exciting the sample to cause the sample to fluoresce, a photodetector for detecting temperature-dependent fluorescence levels from the sample, and a processor configured to record and process emissions from the fluorescent dye. | 12-17-2009 |
| 20090311674 | Phosphate Biosensors and Methods of Using the Same - Phosphate biosensors are disclosed, which comprise a phosphate binding domain conjugated to donor and fluorescent moieties that permit detection and measurement of Fluorescence Resonance Energy Transfer upon phosphate binding. Such biosensors are useful for real time monitoring of phosphate metabolism in living cells. | 12-17-2009 |
| 20090311675 | Apparatus for Monitoring Thrombus Formation and Method of Mointoring Thrombus Formation - An apparatus for monitoring thrombus formation wherein anticoagulated blood is flown through a channel simulating a blood vessel while releasing the anticoagulant treatment or promoting blood coagulation to thereby monitor thrombus formation. This apparatus for monitoring thrombus formation comprises: a thrombus formation chamber in at least a part of which a thrombus formation inducer inducing thrombus formation is provided; an inlet tube which is connected to the thrombus formation chamber and through which blood is flown into the thrombus formation chamber; and a drug tube which is connected to the inlet tube and through which a drug releasing the anticoagulant treatment or a drug promoting blood coagulation is supplied. A method of monitoring thrombus formation which comprises flowing anticoagulated blood into a thrombus formation chamber, in at least a part of which a thrombus formation inducer inducing thrombus formation is provided, while releasing the anticoagulant treatment or promoting blood coagulation to thereby monitor thrombus formation. | 12-17-2009 |
| 20090311676 | Method for preparing primer used for determining the mutation in PDS gene related to large vestibular aqueduct syndrome in vitro and the use of the primer - The present invention relates to a method of preparing a primer used for determining the IVS7-2A→G site mutation involved in the large vestibular aqueduct syndrome. The method comprises the steps of: designing a primer pair which may introduce any base substitutive mutation in the region of 1-13 bases between upstream and downstream including the IVS7-2 mutation site (A→G) based upon the IVS7-2 A→G mutation site in the PDS gene, so as to obtain a new restriction site which may be used for distinguishing IVS7-2 wild type A site and mutant G site in the amplification products. The present invention further relates to the primers prepared according to this method, the kit or reagent or identical product comprising the primers, and a method for determining the IVS7-2A→G site mutation of large vestibular aqueduct syndrome with said primers in vitro. | 12-17-2009 |
| 20090311677 | Identification of contaminating bacteria in industrial ethanol fermentations - A method for determining the presence of a contaminating organism in a fermentation process includes initiating the fermentation process using a syngas and obtaining a first aliquot from the fermentation process. The method further includes subjecting said first aliquot to a polymerase chain reaction using at least one oligonucleotide primer capable of hybridizing to a target sequence of a genomic nucleic acid from a suspected contaminating organism, producing a first amplified product based on the polymerase chain reaction, separating the first amplified product based on size, and determining the presence of the suspected contaminating organism based on the first separated amplified product. | 12-17-2009 |
| 20090311678 | METHOD OF DISCRIMINATING AT LEAST TWO CELL POPULATIONS, AND APPLICATION - A subject of the invention is a method for discriminating between and counting at least two populations of biological elements carrying specific characteristics, optionally present in a sample. The invention allows the clear and unambiguous detection of at least three populations of biological elements by the use of only two detection means, which means that at least two populations of biological elements are detected by one and the same detection means. The invention can be carried out if three different probes are used, each recognizing and becoming fixed to one of the populations of biological elements to be detected, each of the probes being itself rendered detectable by a different marker, two of said markers having two emission spectra having at least one common part (overlapping emission spectra) and the third having an emission spectrum having essentially no part in common with the other two (non-overlapping spectrum). | 12-17-2009 |
| 20090311679 | TaqMan MGB probe useful for detecting the mitochondrial gene C1494T mutation associated with maternally inherited deafness and the use thereof - The present invention relates to a real time quantitative TaqMan MGB probe useful for detecting the mitochondrial gene C1494T mutation associated with maternally inherited deafness and the use thereof. The present invention design a Taqman mutant probe and a wild type MGB probe, and a pair of primers. A maternally inherited deafness associated with mitochondrial gene C1494T mutation can be diagnosed by the method of real time quantitative Taqman MGB probe. This method is characteristic of easily operating, fast, high specificity, high sensitivity, and the interpretation of the result is intuitionistic, accurate and reliable. It's suitable for large scale screen and preventive examination of mitochondrial gene C1494T mutation associated with maternally inherited deafness. | 12-17-2009 |
| 20090311680 | Method for Identifying Useful Proteins of Brewery Yeast - The invention relates to a method for identifying a useful protein of brewery yeast. More specifically, the invention relates to (a) cultivating yeast under a predetermined cultivation condition; (b) extracting a protein sample from the cultivation product of the yeast; (c) separating the protein sample by a protein separation means, selecting a target peak or spot, and recovering the target protein or a fragment thereof contained in the peak or spot; (d) determining the amino acid sequence of the target protein; (e) comparing the amino acid sequence determined in step (d) with the amino acid sequence determined in advance based on all or a part of genome sequence information of bottom fermenting yeast; (f) identifying the target protein and the gene encoding the target protein based on the results of comparison; and (g) analyzing functions of the identified gene to identify characters given to the yeast by the gene. | 12-17-2009 |
| 20090311681 | PHARMACODIAGNOSTIC TEST TARGETING ONCOLOGY AND NEURODEGENERATION - A first objective of the present invention is to demonstrate a method for the detection and prognosis of cancer and of its metastatic potential. Preferably, the cancer is selected from breast cancer, bladder cancer, ovarian cancer, lung cancer, skin cancer, prostate cancer, colon cancer, liver cancer, a sarcoma and a leukaemia, without being limited thereto. One aspect of the present invention consists of the use of the LIV21 complex as a prognostic indicator for cancer and in the therapeutic monitoring thereof. The LIV21 complex is defined in terms of the extract of proteins and peptides studied by Maldi and ESI MS/MS or Maldi Tof/Tof mass spectrometry. Said extract was obtained by attachment of the LIV21 complex to one of these LIV21 polyclonal antibodies. The LIV21 complex is also defined in terms of its overall mass spectrometry profile (FIG. | 12-17-2009 |
| 20090311682 | COMBINATION OF AVIAN CELL MARKERS - The present invention relates to a novel combination of avian cell markers which make it possible to characterize the said cells according to their phenotype, whether they are StX cells, stem cells or germ cells. The present invention also relates to a method for characterizing avian cells with the said markers, and to a method for culturing avian cells, in which the cells are characterized by the method according to the invention. | 12-17-2009 |
| 20090311683 | COMPOSITIONS FOR THE USE IN IDENTIFICATION OF FUNGI - The present invention provides compositions, kits and methods for rapid identification and quantification of fungi by molecular mass and base composition analysis. | 12-17-2009 |
| 20090311684 | ENHANCED FC RECEPTOR-MEDIATED TUMOR NECROSIS FACTOR SUPERFAMILY AND CHEMOKINE MRNA EXPRESSION IN PERIPHERAL BLOOD LEUKOCYTES IN PATIENTS WITH RHEUMATOID ARTHRITIS - A method for predicting patient responsiveness to rheumatoid arthritis treatments involving altering expression of TNFSF-3, TNFSF-4, TNFSF-7, TNFSF-11, or TNFSF-14 is disclosed. A method for monitoring the effectiveness of such therapy is also disclosed. Furthermore, a method of screening compounds for use in the treatment of rheumatoid arthritis is disclosed. A method of monitoring the disease state over time in rheumatoid arthritis patients is also disclosed. | 12-17-2009 |
| 20090311685 | NMU-GHSR1b/NTSR1 oncogenic signaling pathway as a therapeutic target for lung cancer - The present invention relates to a method of and a kit for assessing the prognosis of lung cancer by detecting the expression level of the neuromedin U (NMU) gene in a patient-derived biological sample. The method and kit are particularly preferred for assessing the prognosis of non-small cell lung cancer (NSCLC). Furthermore, the present invention relates to a method of screening for a therapeutic agent for cancer, in particular, lung cancer, by detecting compounds that inhibit the binding of the NMU protein with the heterodimer of growth hormone secretagogue receptor 1 | 12-17-2009 |
| 20090311686 | METHOD RELATING TO SWEETNESS ENHANCEMENT - We have discovered a method to enhance sweetness comprising the use of a sweetener at a sub- to near-threshold concentration which is used in combination with a suprathreshold concentration of another sweetener. The sweetener used at the near-threshold concentration is selected based on its likely binding site in the human sweet taste receptor. The invention relates to the identification of agents that can modulate the taste response in humans (such as sweet taste enhancers) through assays based on a novel sweet receptor protein, heterologous expression systems containing nucleic acid constructs forming said novel sweet receptor protein, and the use of the novel sweet receptor protein in screening. | 12-17-2009 |
| 20090311687 | MICROORGANISMS DETECTION AND ENUMERATION METHOD - A method for detecting and enumerating viable microorganisms, preferably selected from the group consisting of | 12-17-2009 |
| 20090311688 | Novel Labeled oligonucleotide - The present invention relates to a labeled oligonucleotide comprising a first nucleotide segment and a second nucleotide segment, complementary to a target sequence, characterized in that it comprises a fluorophore, a quencher and at least one alpha-anomeric nucleoside. The invention also relates to the use of such an oligonucleotide and also to a process using such an oligonucleotide. | 12-17-2009 |
| 20090311689 | Genomic marker for tenderness meat - The invention concerns the use of a genomic marker comprising a nucleotide sequence corresponding to all or part of the nucleotide sequence SEQ ID No. 1, or to all or a part of an allele of the nucleotide sequence SEQ ID No. 1 and associated with the phenotype relating to the tenderness of the meat from bovines, for the implementation of any identification method for the quantification of DNAJA1 expression level with the aim of selecting and/or sorting ruminant animals of the bovine type which produce tender meat and/or for the implementation of an identification method of tender meats at the moment of slaughter by direct sampling from the carcass. | 12-17-2009 |
| 20090311690 | VECTOR FOR SCREENING ANTIBODY - It is an object of the present invention to provide a simple and efficient means capable of evaluating the VH/VL interaction without expressing/purifying VH and VL. The present invention provides a recombinant vector comprising: (i) a nucleotide sequence which can express a hetero-assembly composed of two types of fusion proteins wherein heavy chain variable region (VH) and light chain variable region (VL) of antibody are respectively fused with mutually associable first polypeptide and second polypeptide, by means of secretion, or in a form of a fusion protein tethered to a phage coat protein; and (ii) a restriction enzyme recognition sequence at two sites within, or in a vicinity of, a nucleotide sequence encoding said first polypeptide or second polypeptide. | 12-17-2009 |
| 20090311691 | Nucleic acid analysis by random mixtures of non-overlapping fragments - The invention provides methods and kits for ordering sequence information derived from one or more target polynucleotides. In one aspect, one or more tiers or levels of fragmentation and aliquoting are generated, after which sequence information is obtained from fragments in a final level or tier. Each fragment in such final tier is from a particular aliquot, which, in turn, is from a particular aliquot of a prior tier, and so on. For every fragment of an aliquot in the final tier, the aliquots from which it was derived at every prior tier is known, or can be discerned. Thus, identical sequences from overlapping fragments from different aliquots can be distinguished and grouped as being derived from the same or different fragments from prior tiers. When the fragments in the final tier are sequenced, overlapping sequence regions of fragments in different aliquots are used to register the fragments so that non-overlapping regions are ordered. In one aspect, this process is carried out in a hierarchical fashion until the one or more target polynucleotides are characterized, e.g. by their nucleic acid sequences, or by an ordering of sequence segments, or by an ordering of single nucleotide polymorphisms (SNPs), or the like. | 12-17-2009 |
| 20090311692 | ISOLATION OF NUCLEIC ACID FROM MOUTH EPITHELIAL CELLS - The present invention is directed to a scraping instrument for collection of a biological sample, and a non-invasive method for obtaining nucleic acid from buccal mucosa epithelial cells using the scraping instrument. Such nucleic acid can be used for example for gene expression profiling, including to assess lung disease risk associated with airway pollutants. | 12-17-2009 |
| 20090311693 | METHOD FOR THE IN VITRO SCREENING OF ANTI-CANCER COMPOUNDS THAT INHIBITS SK3 ACTIVITY, AND SAID ANTI-CANCER COMPOUNDS - The present invention relates to methods for the in vitro screening of an anti-metastatic compound that inhibits activity, methods for determining in vitro the presence or absence of a metastatic cancer in a subject by quantifying SK3 activity, methods for the in vitro assessment of the progression of the metastatic property of a cancer by quantifying SK3. | 12-17-2009 |
| 20090311694 | Splice variants of human IL-23 receptor (IL-23R) mRNA and use of a delta 9 isoform in predicting inflammatory bowel diseases - There is disclosed the cloning and identification of human IL-23R splice variants caused by alternative splicing of the IL-23R mRNA in human. Alternative mRNA forms occur through skipping one, multiple full exons or partial exons, within the IL-23R gene. A total of twenty-five (25) different IL-23R transcripts were identified. A novel exon deletion (exon 9) isoform in the interleukin 23 receptor is disclosed, denoted as Δ9. The present application also describes a quantitative assay to measure different IL-23R isoform. Detection of Δ9 isoform of IL-23R is predominantly present in colon and cervical tissues. A decrease in Δ9 is observed in inflamed colon tissues in Crohn's patients. There is disclosed a method of predicting Crohn's disease by measuring Δ9 isoform of IL-23R. | 12-17-2009 |
| 20090311695 | Method - In one aspect, there is described a method for determining the effect of a genetic variation or mutation on the integrity of an RNA transcript comprising the steps of: (a) providing a nucleic acid construct comprising two different reporters separated by an in frame splicing unit, wherein said splicing unit comprises at least two exons separated by at least one intron and wherein at least one exon (eg. the exon downstream of said intron) comprises the genetic variation; (b) transfecting said construct into a cell and/or generating a stable cell line; (c) culturing said cell; and (d) determining the effect of said genetic variation on the integrity of the RNA transcript, wherein a difference in reporter activity in comparison to a cell comprising the nucleic acid construct without the genetic variation is indicative that said genetic variation affects the integrity of the RNA transcript. Assays—such as high throughput assays—are also described for identifying agents (nucleic acids, peptides and small molecules) that modulate the integrity of the RNA transcript and/or are involved in modulating RNA metabolism. | 12-17-2009 |
| 20090311696 | POLYMORPHISMS IN THE HUMAN CYP2B6 GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - Described are general means and methods of diagnosing and treating the phenotypic spectrum as well as the overlapping clinical characteristics with several forms of inherited abnormal expression and/or function of the CYP2B6 genes. In particular, polynucleotides of molecular variant CYP2B6 genes which, for example, are associated with insufficient metabolization and/or sensitively of drugs, and vectors comprising such polynucleotides are provided. Furthermore, host cells comprising such polynucleotides or vectors and their use for the production of variant CYP2B6 proteins are described. In addition, variant CYP2B6 proteins and antibodies specifically recognizing such proteins as well as transgenic non-human animals comprising the above-described polynucleotide or vectors are provided. Described are also methods for identifying and obtaining inhibitors for therapy of disorders related to the malfunction of the CYP2B6 gene as well as methods of diagnosing the status of such disorders. Pharmaceutical and diagnostic compositions useful for diagnosing and treating various diseases with drugs that are substrates, inhibitors or modulators of the CYP2B6 gene product are described as well. | 12-17-2009 |
| 20090311697 | METHODS FOR SCREENING FOR GENETIC PREDISPOSITION TO TYPE I DIABETES - A method of genetically screening large numbers of individuals to identify those individuals requiring follow-up testing for active Type I diabetes (T1D) is provided. The method includes obtaining a nucleic-acid containing biological sample from each individual and testing for the presence of specific combinations of HLA II alleles in the sample. | 12-17-2009 |
| 20090311698 | DIAGNOSTIC ASSAY - Certain embodiments of the present invention relate to methods for detecting DNA or RNA (including, but not limited to, mRNA). | 12-17-2009 |
| 20090311699 | METHOD OF SURFACE PLASMON RESONANCE (SPR) TO DETECT GENOMIC ABERRATIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA - This invention discloses using SPR technology to detect CLL related genomic aberrations in peripheral blood samples. An efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of CLL related DNA markers used for the detection of genomic aberrations for patients with chronic lymphocytic leukemia (CLL) is also disclosed. | 12-17-2009 |
| 20090311700 | Methods for Breast Cancer Prognosis - The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer in untreated breast cancer patients. More specific, the present invention relates to the prognosis of breast cancer based on measurements of the expression levels of marker genes in tumor samples of breast cancer patients. Marker genes are disclosed which allow for an accurate prognosis of breast cancer in patients having node negative, fast proliferating breast cancer. | 12-17-2009 |
| 20090311701 | Organ-specific gene, method for identifying the same and use thereof - The present invention provides a method of extracting an organ- or tissue-specific highly expressed gene, including: | 12-17-2009 |
| 20090311702 | TESTS TO PREDICT RESPONSIVENESS OF CANCER PATIENTS TO CHEMOTHERAPY TREATMENT OPTIONS - The present disclosure provides methods and compositions to facilitate prediction of the likelihood of responsiveness of cancer patients to treatment including a taxane and/or a cyclophosphamide. | 12-17-2009 |
| 20090311703 | METHODS FOR IDENTIFYING FACTORS FOR DIFFERENTIATING DEFINITIVE ENDODERM - Disclosed herein are methods of identifying one or more differentiation factors that are useful for differentiating cells in a cell population comprising definitive endoderm cells into cells which are capable of forming tissues and/or organs that are derived from the gut tube. | 12-17-2009 |
| 20090311704 | COMPOSITIONS AND METHODS FOR DIAGNOSIS OF AUTOPHAGIC VACUOLAR MYOPATHY - Transmembrane V-ATPase proton pump complexes regulate pH of extracellular space or intracellular compartments of cells. V-ATPase complexes are ubiquitous in cells across species. A human orthologue of yeast vma21, LOC203547 (VMA21), is likely involved in the assembly of the V-ATPase. Hypomorphic mutations of VMA21 are identified from XMEA patients. Methods to diagnose and/or distinguish between different forms of vacuolar or vacuolated myopathy in an individual or patient are provided based either on the sequence of the VMA21 gene and/or the level and/or activity of the V-ATPase complex. Compositions of the present invention may comprise DNA, RNA, or protein molecules corresponding to all or a portion of VMA21 and including one or more of the mutations in VMA21 identified. Cultured cells or cell lines having one or more mutations in the VMA21 gene derived from patients having a form of vacuolar or vacuolated myopathy are provided. | 12-17-2009 |
| 20090311705 | METHOD OF DETERMINING EFFICIENCY OF OVUM COLLECTION IN BOVINE - The novel means by which an efficiency of ovum collection can be easily determined in bovine at gene level is disclosed. The present inventors performed the genomic linkage analysis using bovine populations with high and low efficiency of ovum collection and to identify GRIA1 gene, which encodes an ion channel protein, as a factor deeply related to an efficiency of ovum collection. Bovines having a mutation (e.g. the amino acid substitution of aa306) in GRIA1 produce significantly fewer ova on superovulatory treatment than those not having the mutation. Therefore, the efficiency of ovum collection can be determined based on the existence of a mutation in GRIA1 gene. | 12-17-2009 |
| 20090311706 | QUANTITATIVE ANALYSIS OF IN VIVO MUTATION AT THE PIG-A LOCUS - The invention relates to methods and kits for the quantitative analysis of in vivo mutation frequencies of the Pig-A gene in individuals exposed to a genotoxicant, particularly using peripheral blood samples of vertebrates. | 12-17-2009 |
| 20090311707 | O-GLYCANS AS DIAGNOSTIC MARKERS FOR INFLAMMATORY BOWEL DISEASE - The present invention provides diagnostic methods for inflammatory bowel disorders (e.g., Crohn's disease or ulcerative colitis) comprising assessing expression, structure and/or function of O-glycans in a sample from a subject, as well as antibodies to such molecules. | 12-17-2009 |
| 20090311708 | METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON ERCC1 AND TS EXPRESSION - The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing TS and/or ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and prognosticate the probable resistance of a patient's tumor to treatment with 5-FU and oxaliplatin-based therapies by examination of the amount of TS and/or ERCC1 mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level for those genes. More specifically, the invention provides to oligonucleotide primer pairs ERCC1 and TS and methods comprising their use for detecting levels of ERCC1 and TS mRNA, respectively. | 12-17-2009 |
| 20090311709 | Compositions, Methods, and Kits for (MIS)Ligating Oligonucleotides - Methods, reagents, and kits for (mis)ligating oligonucleotide probes or for identifying at least one target nucleotide are disclosed. One can enhance the generation of misligation product using a ligase under reaction conditions and with reagents where that particular ligase is prone to misligation. Alternatively, one can decrease or avoid generating misligation products using a particular ligase under reaction conditions and using reagents where that ligase is at least less prone to misligation. In certain embodiments, the recombinant ligase from | 12-17-2009 |
| 20090311710 | MUTAGENESIS METHODS USING RIBAVIRIN AND/OR RNA REPLICASES - The use of RNA-replicases for introducing mutations into and selecting for improved RNA molecules is described. The use of ribavirin, or a derivative/analogue thereof, in methods for introducing one or more mutations during replication or transcription of a target nucleic acid molecule is also described. These methods can be used to screen for nucleic acids, or proteins encoded thereby, with altered or new activity. Also provided are kits comprising ribavirin, or a derivative/analogue thereof, for use in mutagenesis procedures. | 12-17-2009 |
| 20090311711 | CRH and POMC Effects on Animal Growth - The present invention provides for selection of bovine animals that will display phenotypes associated with increased rates of growth. These phenotypes include hot carcass weight, average daily gain, shipping weight, end of test rib eye area, and adjusted weaning weight which is a measure of post-natal growth, based on the knowledge of their CRH, POMC and MC4R genotypes. The predictive value comes from the discovery that certain single nucleotide polymorphisms (SNPs) in these genes are linked to higher growth rate phenotypes. Specifically, the phenotypes that correlated with specific SNP's are end-of-test rib-eye area, adjusted weaning weight, average daily gain, shipping weight and hot carcass weight. The invention also provides novel kits that can be used in making the determination of these genotypes. The invention further provides for methods of screening bovines to predict which animals will have higher growth rate, allowing producers to selectively breed and manage animus based on desired characteristics, thereby maximizing productivity and profitability in commercial meat production operations. | 12-17-2009 |
| 20090311712 | METHOD OF SCREENING MULTIPLE SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH SUSCEPTIBILITY TO SPECIFIC DISEASE OR DRUG RESPONSE - Provided is a method of screening multiple single nucleotide polymorphisms (SNPs) having significance with a case group, the method comprising: selecting one or more SNPs from nucleic acid sequences of the case group and a control group; generating all combinable genotype patterns of multiple SNPs comprised of two or more of the selected SNPs; determining frequencies of the genotype patterns from the case group and the control group; and determining and choosing genotype patterns having statistical significance with the case group using the frequencies. According to the method of screening multiple SNPs, multiple SNPs associated with a specific disease or drug can be effectively selected from the entire genome of an individual. Methods of identifying susceptibility of an individual to development of Type II diabetes are also disclosed. | 12-17-2009 |
| 20090311713 | Method of Detecting an Analyte - The invention relates to certain novel approaches to reducing or eliminating the movement of contaminants from one droplet to another on a droplet actuator via liquid filler fluid. In one application, a method of detecting an analyte is provided and includes providing in a detection window a droplet including a signal-producing substance indicative of the presence and/or quantity of an analyte and one or more magnetically responsive beads which may interfere with signal produced by the signal producing substance. The method further includes using a magnetic field for magnetically removing the magnetically responsive beads from the detection window and/or magnetically restricting the magnetically responsive beads from entering the detection window while transporting and/or retaining the droplet in the detection window. The method additionally includes detecting a signal produced by the signal-producing substance. | 12-17-2009 |
| 20090317797 | Non-Invasive, Prenatal, In-Vitro Method for Detecting the Normal Healthy Condition, the Condition of a Healthy Carrier or the Condition of a Carrier Inflicted with Cystic Fibrosis - The invention relates to a non-invasive, prenatal, in-vitro method for detecting the normal healthy condition, the condition of a healthy carrier or the condition of a carrier inflicted with cystic fibrosis, from the fetal cell(s) from a maternal sample, comprising the DNA of an individual to be tested. The invention also relates to oligonucleotide primers and to their use within the scope of a non-invasive, prenatal, in-vitro method for detecting the condition of a healthy carrier or of a carrier inflicted with cystic fibrosis. | 12-24-2009 |
| 20090317798 | ANALYSIS USING MICROFLUIDIC PARTITIONING DEVICES - The invention relates to methods, reagents and devices for detection and characterization of nucleic acids, cells, and other biological samples. Assay method are provided in which a sample is partitioned into sub-samples, and analysis of the contents of the sub-samples carried out. The invention also provides microfluidic devices for conducting the assay. The invention also provides an analysis method using a universal primers and probes for amplification and detection. | 12-24-2009 |
| 20090317799 | Variants at chr8q24.21 confer risk of cancer - A locus on chromosome 8q24.21 has been demonstrated to play a major role in particular forms of cancer. It has been discovered that certain markers and haplotypes are indicative of a susceptibility to particular cancers. Diagnostic applications for identifying susceptibilty to cancer are described. | 12-24-2009 |
| 20090317800 | REPORTER VECTOR FOR USE IN EVALUATION OF CYP1A2 INDUCTION - A reporter vector which can evaluate the ability of a drug to induce CYP1A2 or both of CYP1A1 and CYP1A2 and a method for evaluation of the ability of a drug to induce CYP1A2 or both of CYP1A1 and CYP1A2 by using the reporter vector. A reporter system which can evaluate the ability of a drug capable of inducing CYP1A2 or both of CYP1A1 and CYP1A2 is completed by constructing a reporter vector having a reporter gene linked to the 3′ end of a region between CYP1A1 and CYP1A2 or a reporter vector having different reporter genes linked to the both ends of the region, respectively, so as to sandwich the region, and a reporter vector having a deletion mutation in the region, and confirming that the expression of a reporter molecule is increased by the drug capable of inducing CYP1A2 or both of CYP1A1 and CYP1A2 in the reporter system using the reporter vector. | 12-24-2009 |
| 20090317801 | METHODS AND COMPOSITIONS FOR DISEASE PROGNOSIS BASED ON NUCLEIC ACID METHYLATION - A large scale DNA methylation study was performed in patients with acute myeloid leukemia (AML) that revealed quantitative methylation patterns correlated with patient survival. Based on these results, a prognostic model was built which categorizes a patient's risk—either in a good or poor prognosis group. The findings provided herein support the use of genomic methylation markers for improved molecular classification and disease management in adult AML. Also, the results provide insight into the pathophysiology of AML and offer novel AML gene targets. Thus provided are methods and compositions for the prognosis of a subject suffering from acute myeloid leukemia (AML) based on the methylation state of nucleic acids. The methods may used alone to determine a patient's prognosis or in combination with other prognostic factors or markers such as gene expression. | 12-24-2009 |
| 20090317802 | Compositions and Methods to Monitor RNA Delivery to Cells - Methods and compositions for tracking or monitoring uptake of siRNA by mammalian cells are provided. The methods and compositions may be used to monitoring the silencing activity of the internalized siRNA. The compositions contain an siRNA, an optically or magnetically detectable nanoparticle such as a quantum dot and, optionally, a transfection reagent. Cells are contacted with an siRNA and an optically or magnetically detectable nanoparticle, optionally in the presence of a transfection reagent. Detection of internalized nanoparticles is indicative of siRNA uptake. The invention allows analysis, identification, processing, etc., of cells that have efficiently taken up siRNA. In one embodiment, cells are sorted into at least two populations based on the amount of siRNA taken up. | 12-24-2009 |
| 20090317803 | ENZYMATIC TIME-RESOLVED LUMINESCENT ASSAY FOR NUCLEIC ACIDS QUANTITATION - The objects of the present invention are to provide a new technology platform for quantitation number of copies of nucleic acid molecules of interest by lumonogenic (i.e., enzymatic luminescence) detection. The detection approach of the method of present invention is essentially employing time-resolved approach, e.g., based on detection transient parameters of luminescent signal. The various disclosed embodiments allow DNA and RNA quantification in a broad dynamic range; can be used for detection of DNA, as well as long (mRNA) and short (microRNA) RNA targets. The present invention provides methods, instruments, and kits for fast and highly sensitive identification and measurements of nucleic acids in various life science and biomedical applications. | 12-24-2009 |
| 20090317804 | METHODS OF DETERMINING ANTIBIOTIC RESISTANCE - This disclosure relates to methods of determining an antibiotic resistance profile of a bacterium, and methods of treating a patient with a therapeutically effective antibiotic. The methods include comparing the restriction map of the nucleic acid with a restriction map database, and determining antibiotic resistance of the bacterium by matching regions of the nucleic acid to corresponding regions in the database. | 12-24-2009 |
| 20090317805 | Proteolytic Markers as Diagnostic Biomarkers for Cancer, Organ Injury and Muscle Rehabilitation/Exercise Overtraining - The present invention identifies biomarkers that are diagnostic of nerve cell injury, organ injury, and/or neuronal disorders. Detection of different biomarkers of the invention are also diagnostic of the degree of severity of nerve injury, the cell(s) involved in the injury, and the subcellular localization of the injury. | 12-24-2009 |
| 20090317806 | SYSTEMS AND METHODS FOR MONITORING THE AMPLIFICATION OF DNA - A system and method for amplifying and detecting nucleic acids are disclosed. In one embodiment, the system includes: a microfluidic device comprising a channel for receiving a sample of solution containing real-time PCR reagents; a temperature control system configured to cycle the temperature of the sample; an excitation source for illuminating the sample; a fiber optic probe comprising (i) an optical fiber having a distal end and a proximal end and (ii) a probe head connected to the distal end of the optical fiber and positioned between the distal end of the optical fiber and the channel; and a detector configured to detect emissions exiting the proximal end of the optical fiber. | 12-24-2009 |
| 20090317807 | Primers for Use in Detecting Metallo-Beta-Lactamases - Oliognucleotide primers are provided that are specific for nucleic acid characteristic of certain beta-lactamases. The primers can be employed in methods to identify nucleic acid characteristic of family-specific beta-lactamase enzymes in samples, and particularly, in clinical isolates of Gram-negative bacteria. | 12-24-2009 |
| 20090317808 | NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES AND METHODS OF USE THEREOF FOR DIAGNOSIS - Novel splice variants, amino acid sequences and nucleotide sequences thereof, and methods of using same. | 12-24-2009 |
| 20090317809 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 52 to 54 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 12-24-2009 |
| 20090317810 | METHODS AND NUCLEIC ACIDS FOR THE DETECTION OF COLORECTAL CELL PROLIFERATIVE DISORDERS - The invention provides methods, nucleic acids and kits for detecting, or for distinguishing between or among colorectal cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of and differentiation between said class of disorders, thereby enabling the improved diagnosis and treatment of patients. | 12-24-2009 |
| 20090317811 | TWO PORE CHANNELS AS REGULATORS OF PROLIFERATION IN CANCER - The present invention relates to the discovery that two pore K+ channel (2PK) gene expression is increased in tumors and tumor cell lines, especially prostate tumor cells. The present invention encompasses methods for disease diagnosis, drug screening and the treatment of cancer. | 12-24-2009 |
| 20090317812 | METHOD OF DETECTING PREECLAMPSIA - The invention provides a method for detecting a propensity toward or risk of developing preeclampsia, comprising detecting in a female subject the presence of a single base pair point mutation, ΔA at position +1754, in the HLA-G mRNA 3′UTR. The mutation is associated with preeclampsic subjects, and with decreased RNA stability in vitro. The presence of this ΔA mutation may provide an explanation for lower levels of HLA-G expression seen in association with preeclampsia. | 12-24-2009 |
| 20090317813 | METHOD OF PREDICTING METASTASIS OF ORAL CAVITY CANCER INTO CERVICAL LYMPH NODE AND DIAGNOSIS KIT TO BE USED IN THE PREDICTION - A method for objectively predicting possibility of metastasis to a cervical lymph node in an early stage for an individual case diagnosed as an oral cavity cancer, and a diagnosis kit to be used in the prediction are provided. The method includes a step of assaying expression amounts of metastasis prediction genes in which the expression amounts are changed between a metastasis group and a non-metastasis group, with respect to a sample collected from a primary legion of the oral cavity cancer. Further, the method includes a step of predicting the possibility of the metastasis by comparing the expression amounts of the metastasis gene group with the expression amounts of the metastasis prediction genes in a metastasis group and/or a non-metastasis group. Herein, the metastasis prediction gene group includes two genes MSR1 (NM_138716.1) and RET (M31213.1). | 12-24-2009 |
| 20090317814 | Mitochondrion-bound nucleic acid for determining a health status of an individual - The invention describes means and methods for determining mitochondrion-bound nucleic acid and describes the use thereof in diagnostics. Preferable cell-free mitochondrion-bound nucleic acid is determined. | 12-24-2009 |
| 20090317815 | Mononucleotide repeats microsatellite markers for detecting microsatellite instability - A method for evaluating microsatellite instability associated with a tumour, which entails the steps of amplifying microsatellite loci in a biological sample containing genomic DNA from the tumour and determining sizes of DNA amplification products, wherein at least one microsatellite locus selected from the group consisting of NR 21, NR 22, NR 24 and NR 27, is amplified. | 12-24-2009 |
| 20090317816 | METHODS FOR IDENTIFYING RISK OF BREAST CANCER AND TREATMENTS THEREOF - Provided herein are methods for identifying risk of breast cancer in a subject and/or a subject at risk of breast cancer, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating breast cancer, and therapeutic methods for treating breast cancer in a subject. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome. | 12-24-2009 |
| 20090317817 | NUCLEIC ACID-BASED TESTS FOR PRENATAL GENDER DETERMINATION - Provided herein are compositions, processes and kits for noninvasive, early determination of fetal sex from, and/or amount of fetal nucleic acid in, an extracellular nucleic acid sample from a pregnant female. Such compositions, processes and kits are useful for detection of low genomic copy numbers of male fetal nucleic acid in a high copy number background of female nucleic acid, thereby determining the sex of a fetus and/or amount of fetal nucleic acid in a sample. | 12-24-2009 |
| 20090317818 | RESTRICTION ENDONUCLEASE ENHANCED POLYMORPHIC SEQUENCE DETECTION - Provided in part herein is an improved method for the detection of specific polymorphic alleles in a mixed DNA population. The method comprises enriching the relative percentage of a given polymorphic allele that is exponentially amplifiable by PCR. Provided also are methods for selectively enriching target nucleic acid, for example, fetal nucleic acid in a maternal sample. In the case of detecting fetal nucleic acid in a maternal sample, a restriction enzyme is introduced that can discriminate between the alleles of a polymorphic site. In some embodiments, the maternal allele is digested and nucleic acid comprising the paternal allele is relatively enriched. | 12-24-2009 |
| 20090317819 | PHOSPHOLIPID OXIDATION AND Lp-PLA2 AS PREDICTORS OF CORONARY ARTERY DISEASE - Provided herein are compositions and methods for identifying individuals at risk for developing coronary artery disease (CAD). | 12-24-2009 |
| 20090317820 | MICRO-RNA PROFILE IN HUMAN SALIVA AND ITS USE FOR DETECTION OF ORAL CANCER - The present invention provides for the first time the detection of micro-RNA in human saliva and the correlation between such micro-RNA and oral cancers. The present invention therefore provides methods and kits for diagnosing oral cancers by examining pertinent micro-RNA in saliva. | 12-24-2009 |
| 20090317821 | METHODS AND COMPOSITIONS FOR IDENTIFYING INDIVIDUALS AT REDUCED RISK OF SEPSIS - The present invention provides a method of identifying a subject having a reduced risk of developing sepsis, comprising detecting at least one APOE3 allele in nucleic acid from the subject. | 12-24-2009 |
| 20090317822 | SELECTION OF INTRACELLULAR IMMUNOGLOBULINS - A general immunoglobulin-target assay system is provided, in which a positive outcome (the generation of a signal) depends only on the intracellular interaction of immunoglobulin with target. This can be accomplished for many immunoglobulins expressed in yeast and/or in mammalian cells and allows the selection of immunoglobulins which are capable of functioning in an intracellular environment. | 12-24-2009 |
| 20090317823 | MUTATIONS IN CAPILLARY MORPHOGENESIS GENE-2 (CMG-2) AND USE THEREOF - Mutations and polymorphisms in a particular gene, the capillary morphogenesis gene-2 (CMG-2) have been identified. The mutations have been associated with infantile systemic hyalinosis (ISH) and juvenile hyaline fibromatosis (JHF), as well as conditions associated with these disorders. Described herein are variant CMG-2 nucleic acids and variant CMG-2 polypeptides; cells comprising such variant CMG-2 nucleic acids and/or expressing variant CMG-2 polypeptides; and methods of diagnosing and treating such disorders and conditions. Variant CMG-2 proteins include those comprising one or more of E220X, G105D, L329, P257insC, I189T, A357P, and A322S. Variant CMG-2 nucleic acids include those encoding these mutant CMG-2 proteins, as well as silent mutations or polymorphisms. | 12-24-2009 |
| 20090317824 | Fluid Processing Device Comprising Radial Channels - The present invention provides, in one aspect, an apparatus that comprises a disc-shaped substrate defining (1) a central reservoir region, (2) a plurality of channels in fluid communication with, and emanating substantially radially from, the central reservoir region, the channels being coplanar with each other, and each channel having (i) a proximal end which is linked to the reservoir region, and (ii) a distal end, and preferably (3) for each channel, at least one chamber, and preferably three chambers, linked by a passageway in fluid communication with the distal end of that channel. Preferably, each passageway leads from each chamber in a direction that is initially away from the central reservoir region, whereby centrifugation of the substrate about a central axis that is perpendicular to the channels is effective to disperse liquid from the central reservoir region into the channels and chambers, such that any air bubbles in the chambers, channels, and passageways are forced towards the axis of rotation, when such liquid is present in the central reservoir region. | 12-24-2009 |
| 20090325150 | KLF6 ALTERNATIVE SPLICE FORMS AND A GERMLINE KLF6 DNA POLYMORPHISM ASSOCIATED WITH INCREASED CANCER RISK - Disclosed are methods of identifying and diagnosing certain types of cancers and pre-stages thereof in a patient by identifying alternatively spliced isoforms of wild type KLF6 (KLFwt), in particular anyone of the isoforms selected from the group consisting of: KLF6 splice variant-1 (KLF6SV1), KLF6 splice variant-2 (KLF6SV2), and KLF6 splice variant-3 (KLF6SV3). Also disclosed are methods diagnosing cancer using the polypeptides and polynucleotides identified herein, as well as methods of treating certain types of cancers by inhibiting polynucleotides and polypeptides identified herein. | 12-31-2009 |
| 20090325151 | Pharmacogenomics of Blood Pressure Lowering Agents - A method of determining a suitable blood pressure lowering treatment for an individual comprises a step of assaying a biological sample from the individual for the presence or absence of the C-5312T SNP in a distal enhancer region of the renin gene. The presence of at least one T allele is indicative of an increased response to a blood pressure lowering treatment selected from the group comprising: angiotensin-2-receptor blockers; ACE Inhibitors; aldosterone receptor blockers; and beta-receptor blockers. The absence of at least one T allele is indicative of an increased response to a blood pressure lowering treatment selected from the group comprising: renin inhibitors; calcium channel blockers; and diuretics. | 12-31-2009 |
| 20090325152 | USE OF GENE ACTIVITY CLASSIFIERS FOR THE IN VITRO CLASSIFICATION OF GENE EXPRESSION PROFILES OF PATIENTS WITH INFECTIOUS/NON-INFECTIOUS MULTIPLE ORGAN FAILURE - The present invention relates to the use of gene activity markers for classification of patients suffering from infectious and non-infectious multiple organ failure, respectively. | 12-31-2009 |
| 20090325153 | ANALYSIS OF HETEROGENEOUS NUCLEIC ACID SAMPLES - Methods for capturing and characterizing low frequency nucleic acid molecules indicative of diseases such as cancer (e.g. adenomas or early stage cancers) are provided. In some aspects, a low complexity capture technique is combined with a high complexity analytical technique. In some aspects, samples may be analyzed using a digital analysis and/or a single molecule sequencing technique. | 12-31-2009 |
| 20090325154 | Pyrosequencing Methods and Related Compositions - This invention provides methods for pyrosequencing and compositions comprising 3′-O— modified deoxynucleoside triphosphates. | 12-31-2009 |
| 20090325155 | Aureobasin a synthetase - Disclosed are polynucleotides encoding polypeptides having Aureobasidin A synthetase activity and Aureobasidin A synthetase-like activity. The invention also provides methods for detecting AbA synthetase proteins and nucleic acids and AbA synthetase-like proteins and nucleic acids in cells, and method for producing AbA synthetase polypeptides. | 12-31-2009 |
| 20090325156 | MATERIALS AND METHODS FOR ABCB1 POLYMORPHIC VARIANT SCREENING, DIAGNOSIS, AND TREATMENT - The invention provides methods and materials for screening for polymorphic variants in ABCB1 and diagnosing altered susceptibilities for drug-induced heart rhythm irregularities based on the same. These methods allow better treatment regimens for using drugs that bind a protein encoded by the ABCB1 and/or induce heart rhythm irregularities such as the anti-cancer drug FK228. | 12-31-2009 |
| 20090325157 | PATHOGEN DETECTION AND SCREENING - Disclosed is a rapid dual purpose PCR based method for identifying two or more pathogens in a sample, such as a stool or environmental (soil, water) sample, including | 12-31-2009 |
| 20090325158 | 5-Bromo-2'-Deoxy-Uridine Labeled Nucleotide Triphosphates and Nucleic Acid Probes and Methods of Making and Using the Same - 5-bromo-2′-deoxy-uridine (BrdU) labeled nucleotide triphosphates and nucleic acid probes are described herein. The BrdU labeled nucleotide triphosphates include a linker between the nucleotide triphosphate and the BrdU moiety. The linker can be cleavable or non-cleavable. The nucleotide triphosphates can be a ribonucleotide triphosphates, 2′-deoxyribonucleotide triphosphates or 2′,3′-dideoxyribonucleotide triphosphates. The nucleic acid probes can be used for in situ hybridization. | 12-31-2009 |
| 20090325159 | SYSTEM AND METHOD TO PREVENT CROSS-CONTAMINATION IN ASSAYS PERFORMED IN A MICROFLUIDIC CHANNEL - The present application discloses systems and methods for preventing contamination in assays performed in microfluidic channels. In one embodiment, a buffer of non-reactive fluid is provided between an input port and a microchannel in which assays are performed during such times that flow from the input port is stopped. In general, an amount of non-reactive fluid is drawn into a channel connecting the stopped input port to the microchannel. Thus, any seepage, or diffusion, from the channel connecting the stopped input port to the microchannel will be of the non-reactive fluid, not the reagent, or other potentially-contaminating fluid, introduced through the input port. In one embodiment, microvalves and a negative pressure differential source control flow of reagents into the microchannel and the flow of non-reactive fluid into the inlet conduits. | 12-31-2009 |
| 20090325160 | COMPOSITIONS AND METHODS FOR PROGNOSIS AND THERAPY OF LIVER CANCER - This invention provides a composition comprising the following polynucleotide probes: IL7R (AA485865) (SEQ ID NO:7), NDRGI (AA486403) (SEQ ID NO:8), EST1 (H50345) (SEQ ID NO:9), TRPC1 (AA017132) (SEQ ID NO:10), GFRA1 (AA512935) (SEQ ID NO:11), EST2 (AA454543) (SEQ ID NO:12), CLDN10 (R54559) (SEQ ID NO:13), DNALI1 (R93087) (SEQ ID NO:14), RBP5 (AA453198) (SEQ ID NO:15), EST3 (AA621761) (SEQ ID NO:16), EST4 (N63706) (SEQ ID NO:17), PCOLCE (AA670200) (SEQ ID NO:18), TDO2 (T72398) (SEQ ID NO:19), EST5 (T47454) (SEQ ID NO:20), HIST1H2BD (N33927) (SEQ ID NO:21), PXMP2 (N70714) (SEQ ID NO:22), ACAS2 (AA455146) (SEQ ID NO:23), ANAPC7 (T68445) (SEQ ID NO:24), EST6 (AA576580) (SEQ ID NO:25), RBP5 (N92148) (SEQ ID NO:26), ANXAI (H63077) (SEQ ID NO:27), CKB (AA894557) (SEQ ID NO:28), ITGBL1 (N52533) (SEQ ID NO:29), KPNA2 (AA676460) (SEQ ID NO:30), EST7 (W90740) (SEQ ID NO:31) and MEG3 (W85841) (SEQ ID NO:32). This invention further provides methods for determining the likelihood of recurrence of hepatocellular carcinoma (HCC) in a subject afflicted with HCC, for determining the likelihood of death of a subject afflicted with HCC or for determining whether to administer adjuvant therapy. | 12-31-2009 |
| 20090325161 | KIT AND METHOD FOR QUANTITATIVELY DETECTING MULTIPLEPATHOGENS WITHOUT GENE AMPLIFICATION - A non-amplification multiple quantitative detection kit is characterized in that there are provided a single strand poly nucleotide having a base sequence invented to recognize a specific gene portion of a multilepathogens microorganism to be detected by a fishing probe, and a double strand poly nucleotide indicated with a tag having a base sequence invented to recognize different gene portions which are not duplicated with the recognition portion of the fishing probe in the specific genes of the multilepathogens microorganism to be detected by a reporter probe. | 12-31-2009 |
| 20090325162 | FATTY ACID SYNTHETASE, POLYNUCLEOTIDE ENCODING THE SAME, AND USES THEREOF - The present invention provides fatty acid synthetases which are responsible for novel fatty acid synthesis, polynucleotides which encode such fatty acid synthetases (e.g., a polynucleotide comprising (a) a polynucleotide consisting of the nucleotide sequence of Positions 1 to 12486 of SEQ ID NO: 1, or (b) a polynucleotide which hybridizes under stringent conditions to a polynucleotide comprising a nucleotide sequence complementary to the nucleotide sequence of Positions 1 to 12486 of SEQ ID NO: 1, and which encodes a protein having a fatty acid synthetase activity), expression vectors and transformants comprising such polynucleotides, methods for producing food and other products using such transformants, food products produced by such methods, and methods for assessing and selecting lipid-producing test fungi. | 12-31-2009 |
| 20090325163 | GENETIC MARKERS FOR RISK MANAGEMENT OF CARDIAC ARRHYTHMIA - The invention relates to procedure and methods of determining a susceptibility to cardiac arrhythmia, including Atrial Fibrillation, Atrial Flutter and Stroke, by assessing the presence or absence of alleles at polymorphic markers found to be associated with Atrial Fibrillation, Atrial Flutter and Stroke. The invention further relates to kits encompassing reagents for assessing such markers, and diagnostic methods, uses and procedures for utilizing such susceptibility markers. | 12-31-2009 |
| 20090325164 | MICROELECTRONIC SENSOR DEVICE FOR DNA DETECTION - The invention relates to a microelectronic sensor device and a method for the investigation of biological target substances ( | 12-31-2009 |
| 20090325165 | Recombinase polymerase amplification - This disclosure describe three related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of the bacterial RecA and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods has the advantage of not requiring thermocycling or thermophilic enzymes. Further, the improved processivity of the disclosed methods allow amplification of DNA up to hundreds of megabases in length. | 12-31-2009 |
| 20090325166 | SUBSTRATES FOR PERFORMING ANALYTICAL REACTIONS - Substrates, including zero mode waveguide substrates that have been fabricated to provide additional functional elements and/or components including increased volumes for positioning of active surfaces and/or components for the mitigation of negative electrochemical properties of the underlying substrates. | 12-31-2009 |
| 20090325167 | METHOD OF USING CYTOKINE ASSAY TO DIAGNOSE, TREAT, AND EVALUATE INFLAMMATORY AND AUTOIMMUNE DISEASES - The invention provides methods for diagnosing, treating, or evaluating inflammatory and autoimmune diseases by sampling peripheral blood, serum, plasma, tissue, cerebrospinal fluit, or other bodily fluids from a human subject having a suspected diagnosis. The sample is analyzed for the presence and amount of certain cytokines, which provides the diagnosis, prognosis or evaluation of therapeutic response. | 12-31-2009 |
| 20090325168 | HOMO-DOUBLY LABELED COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES - The present invention provides for novel reagents whose fluorescence changes upon cleavage or a change in conformation of a backbone. The reagents comprise a backbone (e.g. nucleic acid, polypeptide, etc.) joining two fluorophores of the same species whereby the fluorophores form an H-dimer resulting in quenching of the fluorescence of the fluorophores. When the backbone is cleaved or changes conformation, the fluorophores are separated, no longer forming an H-type dimer, and are de-quenched thereby providing a detectable signal. The use of a single fluorophore rather than an “acceptor-donor” fluoresecence resonance energy transfer system offers synthesis and performance advantages. | 12-31-2009 |
| 20090325169 | RNASE H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS - The present invention pertains to novel oligonucleotide compounds for use in various biological assays, such as nucleic acid amplification, ligation and sequencing reactions. The novel oligonucleotides comprise a ribonucleic acid domain and a blocking group at or near the 3′ end of the oligonucleotide. These compounds offer an added level of specificity previously unseen. Methods for performing nucleic acid amplification, ligation and sequencing are also provided. Additionally, kits containing the oligonucleotides are also disclosed herein. | 12-31-2009 |
| 20090325170 | MEANS AND METHODS FOR DIAGNOSING AND/OR TREATING A SUBJECT AT RISK OF DEVELOPING HEART FAILURE - The present invention relates to a method for identifying a subject at risk of developing heart failure, comprising: (a) determining the level of one or more biological markers in a biological sample of said subject; (b) comparing the level of said biological marker to a standard level of the same biological marker; and (C) determining whether the level of the marker is indicative of a risk for developing heart failure, wherein the biological marker is Krüppel Like Factor 15 (KLF-15) and/or lysosomal integral membrane protein-2 (LIMP-2) and/or fragments and/or variants thereof, and/or wherein the biological marker is a gene coding for KLF15 and/or LIMP-2, and/or fragments and/or variants thereof. The invention further relates to use of the KLF15 and/or LIMP-2 protein, and/or the gene coding for KLF15 and/or LIMP2, and/or fragments, and/or variants of said genes and/or proteins, for the preparation of a medicament for a prophylactic and/or a therapeutic medicament for prevention and/or treatment of heart failure. | 12-31-2009 |
| 20090325171 | Vesicles for use in biosensors - Vesicles for use in biosensors that have both high specificity and high sensitivity, where the vesicles include a receptor specific for the intended analyte and a signal generating component. | 12-31-2009 |
| 20090325172 | Modified nucleotides - The invention provides modified nucleotide or nucleoside molecule comprising a purine or pyrimidine base and a ribose or deoxyribose sugar moiety having a removable 3′-OH blocking group covalently attached thereto, such that the 3′ carbon atom has attached a group of the structure —O-Z wherein Z is any of —C(R′)2-O—R″, —C(R′)2-N(R″)2, —C(R′)2-N(H)R″, —C(R′)2-S—R″ and —C(R′)2-F, wherein each R″ is or is part of a removable protecting group; each R′ is independently a hydrogen atom, an alkyl, substituted alkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic, acyl, cyano, alkoxy, aryloxy, heteroaryloxy or amido group, or a detectable label attached through a linking group; or (R′)2 represents an alkylidene group of formula ═C(R′″)2 wherein each R′″ may be the same or different and is selected from the group comprising hydrogen and halogen atoms and alkyl groups; and wherein said molecule may be reacted to yield an intermediate in which each R″ is exchanged for H or, where Z is —C(R′)2-F, the F is exchanged for OH, SH or NH2, preferably OH, which intermediate dissociates under aqueous conditions to afford a molecule with a free 3′OH; with the proviso that where Z is —C(R′)2-S—R″, both R′ groups are not H. | 12-31-2009 |
| 20090325173 | Methods and kits useful for detecting an alteration in a locus copy number - A method of identifying an alteration in a locus copy number is provided. The method is effected by determining a methylation state of at least one gene in the locus, wherein a methylation state differing from a predetermined methylation state of the at least one gene is indicative of an alteration in the locus copy number. | 12-31-2009 |
| 20090325174 | Rapid, Sensitive and Quantitative Methods for Tissue and Cell-Based Proteomics via Consecutive Addition of Quantifiable Extenders - Methods, systems and kits are provided for detecting and quantifying multiple immunogens in a sample via consecutive addition of quantifiable extenders to immunogen bound complexes of immunogen binding agent attached to a DNA containing an RNA polymerase promoter. | 12-31-2009 |
| 20090325175 | METHODs OF DETECTION AND QUANTIFICATION OF HOST CELL DNA CONTAMINATION OF PURIFIED PROTEINS - The present invention provides a novel robust, sensitive, reproducible, and accurate method of detecting and quantifying host cell genomic DNA contamination utilizing quantitative real time Polymerase Chain Reaction (qPCR), wherein the qPCR primers are complementary to the highly repetitive host cell genomic DNA sequences, e.g., Alu-equivalent sequences. The present invention is particularly useful for determining the levels of residual genomic DNA in biological products to be administered as therapeutics, e.g., therapeutic proteins. | 12-31-2009 |
| 20090325176 | Gene Expression Profiles Associated with Asthma Exacerbation Attacks - The present invention provides methods for the assessment, diagnosis, or prognosis of asthma exacerbation, by assessing the level of expression of asthma exacerbation gene products in a sample derived from a patient. The markers of the present invention can be used in methods to identify or evaluate agents capable of modulating marker expression levels in subjects with asthma. | 12-31-2009 |
| 20090325177 | Sensitive And Rapid Methods Of Using Chimeric Receptors To Identify Autoimmune Disease And Assess Disease Severity - The present invention provides methods and compositions useful in the diagnosis and management of autoimmune diseases. In particular, the present invention provides improved methods and compositions for the diagnosis and management of Graves' disease. The methods of the present invention not only avoids the need for radioactivity and are much simpler, economical, and rapid than methods traditionally used for the diagnosis of Graves' disease, but also improve upon the sensitivity and detection abilities of previous luciferase-based autoantibody detection assays. Such improvements are based upon the superior performance of assays comprising a chimeric TSH receptor in the presence of a glucocorticoid including, but not limited to, dexamethasone. | 12-31-2009 |
| 20090325178 | Method for Testing the Response of Cells to Exposure with Therapeutics - The invention relates to methods for testing the response of spheroids to exposure with therapeutics. Preferably the spheroids are derived from primary isolate biological tissue and/or cell-containing bodily fluid. Further embodiments relate to spheroid sections and arrays including kits suitable for carrying out the method according to the present invention. | 12-31-2009 |
| 20090325179 | Methods for Detecting Thiol-Containing Nucleotide Diphosphates with Thiol-Reactive Fluorescent Reagents - Disclosed are methods for detecting thiol-containing nucleotide diphosphates. The methods utilize thiol-reactive fluorescent reagents. | 12-31-2009 |
| 20090325180 | Drug Screening using Islet Cells and Islet Cell Progenitors from Human Embryonic Stem Cells - This disclosure provides a system for producing pancreatic islet cells from embryonic stem cells. Differentiation is initiated towards endoderm cells, and focused using reagents that promote emergence of islet precursors and mature insulin-secreting cells. High quality populations of islet cells can be produced in commercial quantities for use in research, drug screening, or regenerative medicine. | 12-31-2009 |
| 20090325181 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA - The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery. | 12-31-2009 |
| 20090325182 | METHODS FOR DETECTING A CYCLOPHILIN B SNP ASSOCIATED WITH HERDA - This invention provides compositions and methods for identification of carriers of Hereditary Equine Regional Dermal Asthenia (HERDA) in equine species. In particular, this invention identifies a single nucleotide polymorphorism (SNP) in cyclophlin B that can be used to identify carriers of HERDA and individuals affected by HERDA. | 12-31-2009 |
| 20090325183 | SEQUENCING METHODS - The present teachings provide methods and compositions for sequencing one or more target nucleic acids. High levels of multiplexing are provided by the use of an emulsion PCR comprising primer-immobilized beads. The resulting reaction products can be sequenced by any of a variety of mobility-dependent analytical techniques, such as mass spectrometry. In some embodiments, a first collection of amplification products on a first collection of beads are transferred to a second collection of beads. In some embodiments, a first collection of amplification products on a first collection of beads is amplified in a rolling circle amplification reaction. The present teachings also provide compositions, kits, and devices for performing and sequencing the products of the emulsion amplification reactions as described herein. | 12-31-2009 |
| 20090325184 | Compositions and Methods for Clonal Amplification and Analysis of Polynucleotides - Compositions and methods of use are disclosed for clonally amplifying and analyzing one or more polynucleotides. | 12-31-2009 |
| 20090325185 | Method of analyzing expression of gene - A cDNA is prepared from mRNA. The prepared cDNA is subjected to incision with two different types of restriction enzymes. The sequence of a portion of each of the fragments obtained as a result of treatment is determined, and the fragments are classified on the basis of the determined sequence by using a primer set. At the same time, the fragments are amplified in a manner that the relative expression magnitude thereof continues to be reflected therein. When the fragments have been classified into a predetermined number of fractions, the respective fractions are subjected to electrophoresis, and a gene expression profile is produced from the results. | 12-31-2009 |
| 20100003669 | Primer for Detection of Cytochrome P450 Hydroxylase Specific to Polyene - The present invention relates to a primer for detection of cytochrome P450 hydroxylase specific to polyene and a method for detecting a strain of bacteria which produces polyene, by using the primer. More particularly, the present invention is directed in a forward degenerate primer of following sequence (I) and a reverse degenerate primer of following sequence (II), which are complementary to conserved region which resides in the polyene-specific CYP (cytochrome P450 hydroxylose) encoding sequences: (I) 5′-TGGATCGGCGACGACCGSVYCGT-3′ and (II) 5′-CCGWASAGSAYSCCGTCOTACTT-3′, wherein S indicated Guanine or Cytosine, V indicates Adrenine, Guanine or Cytosine, Y indicates Thymine or Cytosine and W indicates Thymine or Adenine. | 01-07-2010 |
| 20100003670 | CHARACTERIZING PROSTATE CANCER - Methods and kits for predicting the course or aggressiveness of prostate cancer include detecting the methylation status of various genes. | 01-07-2010 |
| 20100003671 | NUCLEOTIDE PRIMER SET AND NUCLEOTIDE PROBE FOR DETECTING GENOTYPE OF N-ACETYLTRANSFERASE-2 (NAT2) - There is provided a nucleotide primer set for LAMP amplification, used for detecting genotypes of single-nucleotide polymorphisms G590A, G857A and T341C of a NAT2 gene. There is also provided a nucleotide probe for detection of an amplification product amplified with the primer set according to the present invention. There is also provided a method of detecting the genotypes of NAT2 gene single-nucleotide polymorphisms G590A, G857A and T341C by using the primer set according to the present invention. | 01-07-2010 |
| 20100003672 | CDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE AND USES THEREOF - The invention features methods for diagnosing subjects at risk for or suffering from a disease or disorder, such as a psychosis. Methods are also provided for selecting a preferred therapy for a particular subject or group of subjects. | 01-07-2010 |
| 20100003673 | Gene and methods for diagnosing neuropsychiatric disorders and treating such disorders - A mammalian 22444 gene and gene products which are predictive of a susceptibility or predisposition to various neuropsychiatric disorders are provided. Methods of predicting an individual's susceptibility to developing or having a neuropsychiatric disorder via detection of these diagnostic markers are also provided. In addition, compositions and methods for identifying compositions for use in the treatment of neuropsychiatric disorders via these genes and gene products are described. | 01-07-2010 |
| 20100003674 | Adult stem cells, molecular signatures, and applications in the evaluation, diagnosis, and therapy of mammalian conditions - MicroRNA genes are associated with regulatory elements of living cells of all species. The perturbations of the expression of these genes and their gene products in the cell or genomic structure or chromosomal architecture of a cell provide specific signatures on the condition of the cell and even the organism. Evaluation of miR gene expression can therefore be used to indicate the presence and state of specific cell types and/or their state of differentiation relative to their surrounding tissue. The present invention relates to the identification of a stem cell-specific signature or signatures composed of protein and/or nucleic acid markers expressed by virtue of the position of a cell or cells in the time line of its/their development and the impact of the cells' environment on this signature as it relates to the cells' stem cell potential. The composition and combination of these signatures provides a means of identifying, manipulating and differentiating said adult stem cells and thus, their acquisition and utilization in research, diagnosis, and therapy of normal and pathological conditions. | 01-07-2010 |
| 20100003675 | Qtls for Mastitis Resistance in Cattle - The invention relates to a method for determining mastitis resistance in bovine subjects, wherein mastitis resistance comprise resistance to both sub-clinical and clinical mastitis. In particular, the method of the invention involves identification of genetic markers and/or Quantitative Trait Locus (QTL) for the determination of mastitis resistance in a bovine subject. The determination of mastitis resistance involves resolution of the specific microsatellite status. Furthermore, the invention relates to a diagnostic kit for detection of genetic marker(s) associated with mastitis resistance. The method and kit of the present invention can be applied for selection of bovine subjects for breeding purposes. Thus, the invention provides a method of genetically selecting bovine subjects with mastitis resistance, thereby yielding cows less prone to mastitis. | 01-07-2010 |
| 20100003676 | THERMOSTABLE DNA POLYMERASE OF THE ARCHAEAL AMPULLAVIRUS ABV AND ITS APPLICATIONS - The present invention is directed to the thermostable DNA-polymerase protein of the archaeal ampullavirus ABV (Acidianus Bottle-shaped virus) and the nucleic acid encoding said DNA polymerase. The invention also relates to method of synthesizing, amplifying or sequencing nucleic acid implementing said DNA polymerase protein and kit or apparatus comprising said DNA polymerase protein. | 01-07-2010 |
| 20100003677 | IDENTIFICATION OF TUMOR SUPPRESSOR GENES IN AN ACUTE MYELOID LEUKAEMIA MODEL - The present invention comprises a method method to identify tumor suppressor genes by detecting genes in a mouse retroviral insertion mutagenesis model which expression is inhibited by methylation of the viral insertion or the VIS-flanking gene. This is preferably accomplished by first randomly cutting the mouse genomic DNA, immunoprecipitating the methylated DNA and amplifying the VIS-flanking DNA by inverse PCR, optionally followed by cloning and sequencing of the amplicons. | 01-07-2010 |
| 20100003678 | SENSITIVE MAGNETIC ASSAY THROUGH AMPLICATION OF A LABEL SIGNAL - This invention relates to a device and a method for amplifying a signal generated from primary nanoparticle labels in an assay by using secondary nanoparticle labels, typically magnetic labels, wherein by binding the secondary labels to the primary labels the results in that the signal produced from the labels will be amplified. | 01-07-2010 |
| 20100003679 | ASSESSMENT OF CELLULAR COMPOSITION AND FRACTIONAL VIABILITY AND USES THEREOF - A method of assessing cellular composition and fractional viability that can be predictive of post-transplant cell potency and transplantation outcome, comprises identifying cellular composition and assessing cellular viability. This has particular importance in the field of tissue and cell transplantation, cell therapy and regenerative medicine, providing a method for tissue and cell characterization, viability and potency testing, that could be useful for the definition of product release criteria for research and clinical applications. | 01-07-2010 |
| 20100003680 | Method For Determining The Methylation Rate of a Nucleic Acid - The invention relates to a method for quantitatively determining the methylation rate of a nucleic acid through sequencing. According to the invention, the method comprises at least the following steps: a) treating the nucleic acid with a chemical reagent or an enzyme containing solution, whereby the base pairing behavior of methylated cytosine bases and/or unmethylated cytosine bases of the nucleic acid are altered such that methylated cytosine bases become distinguishable from unmethylated cytosine bases, and b) introducing into the nucleic acid at least one base for generating a sequencing signal to be used as a reference signal for normalization, and c) sequencing the nucleic acid, whereby a signal from each cytosine base of the nucleic acid, or a signal from each guanine base of the nucleic acid and a reference signal from the at least on introduced base is obtained, and d) normalizing the signal obtained from each cytosine base of the nucleic acid, or the signal obtained from each guanine base of the nucleic acid to the reference signal from the at least one introduced base. | 01-07-2010 |
| 20100003681 | GENE POLYMORPHISM USEFUL FOR ASSISTANCE/THERAPY FOR SMOKING CESSATION - Disclosed is a method for determination of a smoking trend in a subject which is useful for the assistance or therapy for smoking cessation, which comprises the steps of detecting one or more polymorphisms occurring on one or more genes selected from the genes (1) to (3) or a genome or in the neighborhood of the genes or the genome and determining the smoking trend based on the results of the detection: (1) nicotinic acetylcholine receptor β2 subunit (CHRNB2) gene; (2) serotonin transporter (SLC6A4(5HTT)) gene; and (3) nicotinic acetylcholine receptor α4 subunit (CHRNA4) gene. | 01-07-2010 |
| 20100003682 | Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer - The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided. | 01-07-2010 |
| 20100003683 | Disposable Device for Analyzing a Liquid Sample Containing a Nucleic Acid With a Nucleic Acid Amplification Apparatus - The invention is directed to a disposable sample holding and processing device ( | 01-07-2010 |
| 20100003684 | SINGLE COPY GENOMIC HYBRIDIZATION PROBES AND METHODS OF GENERATING SAME - Nucleic acid (e.g., DNA) hybridization probes are described which comprise a labeled, single copy nucleic acid which hybridizes to a deduced single copy sequence interval in target nucleic acid of known sequence. The probes, which are essentially free of repetitive sequences, can be used in hybridization analyses without adding repetitive sequence-blocking nucleic acids. This allows rapid and accurate detection of chromosomal abnormalities. The probes are preferably designed by first determining the sequence of at least one single copy interval in a target nucleic acid sequence, and developing corresponding hybridization probes which hybridize to at least a part of the deduced single copy sequence. In practice, the sequences of the target and of known genomic repetitive sequence representatives are compared in order to deduce locations of the single copy sequence intervals. The single copy probes can be developed by any variety of methods, such as PCR amplification, restriction or exonuclease digestion of purified genomic fragments, or direct synthesis of DNA sequences. This is followed by labeling of the probes and hybridization to a target sequence. | 01-07-2010 |
| 20100003685 | POLYNUCLEOTIDE - A polynucleotide consisting of the base sequence of SEQ ID NO: 2, or a complementary strand thereto, wherein the X is one of the group being defined by the bases A, C or T. A primer and a probe specific for that polynucleotide, wherein the primer and/or probe contains at the least 10 consecutive nucleotides, and finally use of the probe for proving parkinsonism inheritance. | 01-07-2010 |
| 20100003686 | PROCESS FOR PRODUCING TETRACYCLINE INDUCIBLE GENE EXPRESSING CELL LINE AND CONDITIONAL GENE KNOCKOUT CELL LINE, AND USES THEREOF - It is intended to provide a method of screening a so-called Tc inducible gene expressing cell line, in which the expression of a gene of interest is regulated depending on the presence/absence of a Tc compound regardless of the type of cell, easily with high efficiency. A gene-of-interest expression vector for transfecting a gene of interest into the genome of a host cell and a TA expression vector that expresses a transactivator that is switched to be bound or not to be bound to a tet operator sequence depending on the presence or absence of tetracycline are prepared. The gene-of-interest expression vector is a vector with a bicistronic regulatory sequence arranged downstream of the tet operator sequence and promoter sequence and between a gene-of-interest coding sequence and a selection marker coding sequence. These vectors are transfected into a host cell, and cell lines in which the selection marker of the gene-of-interest expression vector is expressed are selected. Thus, inducible gene expressing cell lines can be obtained in which the expression of a gene of interest can be controlled with Tc. | 01-07-2010 |
| 20100003687 | System and method for detection of HIV tropism variants - An embodiment of a method for detecting low frequency occurrence of one or more HIV sequence variants associated with drug resistance is described that comprises the steps of: generating cDNA species from each RNA molecule in an HIV sample population; amplifying at least one first amplicon from the cDNA species, wherein each first amplicon comprises a plurality of amplified copies and is amplified with a pair of nucleic acid primers that define a locus of the first amplicon; clonally amplifying the amplified copies of the first amplicons to produce a plurality of second amplicons wherein a plurality of the second amplicons comprise an immobilized population of substantially identical copies from one of the amplified copies of first amplicons; determining a nucleic acid sequence composition of the substantially identical copies from at least 100 of the immobilized populations in parallel on a single substrate; and detecting one or more sequence variants that occur at a frequency of 5% or less in the nucleic acid sequence composition of the at least 100 immobilized populations; and correlating the detected sequence variants with variation associated with HIV tropism. | 01-07-2010 |
| 20100003688 | METHODS FOR MOLECULAR DETECTION - This invention relates to methods for molecular detection, particularly to methods utilizing target-specific molecular probes. In exemplary embodiments, target-specific molecular probes include single-stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) aptamers. In general, the molecular probe may bind with relatively high specificity to a given target. In one aspect, a method for molecular detection comprises a molecular probe paired to a reporter molecule wherein the molecular probe impairs the amplification of the reporter molecule in the absence of the target molecule. | 01-07-2010 |
| 20100003689 | Use of Methylation Status of MINT Loci as a Marker for Rectal Cancer - The invention relates to methods for predicting the outcome of rectal cancer and stratifying a rectal cancer treatment according to the level of DNA methylation at MINT 1, 3, 12, or 17. Also disclosed is a method of detecting rectal adenoma or malignancy based on the level of DNA methylation at MINT 2, 3, or 31. | 01-07-2010 |
| 20100003690 | COMPOSITIONS AND METHODS FOR DISCOVERING AGENTS FOR PHARMACOLOGICAL RESCUE OF HERG 1B SUBUNITS FOR THE TREATMENT OF LONG QT SYNDROME - Cells engineered to express a detectable hERG 1b polypeptide and methods for identifying agents that facilitate hERG 1b maturation using such cells are provided. A method for analyzing a biological sample for the presence of an amino acid substitution at position 8 of the hERG 1b N-terminus is further provided. | 01-07-2010 |
| 20100003691 | Genetic Markers Associated with Degenerative Disc Disease and Uses Thereof - The present invention relates to novel genetic markers associated with degenerative disc disease (DDD), risk of developing DDD and risk of DDD progression, and methods and materials for determining whether a human subject has DDD, is at risk of developing DDD or is at risk of DDD progression. | 01-07-2010 |
| 20100003692 | GAMMA SECRETASE NOTCH BIOMARKERS - The present invention relates to the biomarker TFF-3 that measures γ-secretase mediated Notch processing. TFF-3 has utility in predicting and/or determining in vivo Notch-related toxicity associated with inhibition of Notch processing mediated by γ-secretase. The reagents and methods of the invention can be utilized before, after, or concurrently with, pre-clinical, clinical, and/or post-clinical testing. The reagents and methods of the invention can be used to identify and maintain preferred doses of test compounds and thereby prevent medical complications, such as gastrointestinal cellular damage. | 01-07-2010 |
| 20100003693 | Compositions and Methods For Detecting The Presence Of Cryptosporidium Organisms In A Test Sample - The present invention describes novel oligonucleotides targeted to nucleic acid sequences derived from | 01-07-2010 |
| 20100009345 | Compositions and methods comprising a ligand of chemerin R - The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screeing assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of G-protein coupled receptor signaling. | 01-14-2010 |
| 20100009346 | Lafora's disease gene - A novel gene (EPMZA) that is deleted or mutated in people with Lafora's disease is described. The EPM2A gene encodes a protein having an active catalytic site of a protein tyrosine phosphatase. Many different sequence mutations as well as several microdeletions in EMP2A have been found that co-segregate with Lafora's disease. | 01-14-2010 |
| 20100009347 | Kit and method for detecting urothelial cancer - This invention relates to a method for detecting in vitro a urothelial cancer, comprising measuring CXCL1 protein, or expression of a gene encoding the protein, in a biological sample from a subject, and to a kit for diagnosing a urothelial cancer comprising an antibody or nucleic acid probe, which is capable of binding specifically to the CXCL1 protein or a gene encoding the protein, respectively. | 01-14-2010 |
| 20100009348 | Methods and Constructs for Analyzing Biological Activities of Biological Specimens and Determining States of Organism - This application provides methods of determining biological activities of a biological sample comprising, for example, comparing the profile of transcription factor activities in a cell contacted with the biological sample to a control profile, such as a profile of transcription factor activities in a cell not contacted with the biological sample. | 01-14-2010 |
| 20100009349 | Method for Treating a Biological Sample - The invention relates to a method for treating a biological sample, comprising the following method steps: i) preparation of a biological sample and ii) bringing the biological sample into contact with a composition, comprising: (1) 1 to 100 wt. % of at least one polyol and (2) 0 to 99 wt. % of at least one additive, wherein the total amount of components (1) and (2) is 100 wt. %. The invention further relates to biological samples obtained by said method, a method for analysis of a treated biological sample, devices for treating a biological sample, use of said devices, various kits and use of a composition. | 01-14-2010 |
| 20100009350 | METHOD FOR QUANTITATIVE ANALYSIS OF TRANSCRIPTS WITH NUCLEOTIDE POLYMORPHISM AT SPECIFIC SITE - The present invention provides a quantitative method for assaying the expression ratio between alleles differed by a single nucleotide polymorphism. | 01-14-2010 |
| 20100009351 | Polynucleotide Capture Materials, and Method of Using Same - Methods for processing polynucleotide-containing biological samples, and materials for capturing polynucleotide molecules such as DNA from such samples. The DNA is captured by polyethyeleneimine (PEI) bound to a surface, such as the surface of magnetic particles. The methods and materials have high efficiency of binding DNA and of release, and thereby permit quantitative determinations. | 01-14-2010 |
| 20100009352 | Method for Modeling a Disease - The invention described herein provides for methods of profiling cellular models of disease. Cellular systems biology is the investigation of the integrated and interacting networks of genes, proteins, and metabolites that are responsible for normal and abnormal cell functions. Methods and reagents for the profiling a disease state, the treatment of a disease state and assaying of treatments of a disease state are provided. | 01-14-2010 |
| 20100009353 | Dye Compounds and the Use of their Labelled Conjugates - Novel rhodamine dye compounds, labelled conjugates comprising the dyes are described, together with methods for their use. The dyes and labelled conjugates are useful as molecular probes in a variety of applications, such as in assays involving staining of cells, protein binding, and analysis of nucleic acids, such as hybridization assays and nucleic acid sequencing. | 01-14-2010 |
| 20100009354 | METHOD FOR DETERMINING BASE SEQUENCE OF DNA - The present invention provides a method for determining the base sequence of a DNA. According to the method for determining the base sequence of a DNA of the present invention, a probe is used, which is a probe having a protruding end and identification-labeled according to the species of the base at the protruding end, containing a recognition sequence of a class IIS restriction enzyme, to carry out simultaneously in a chain reaction, for a plurality of DNAs to be analyzed, ligation of the end base of a DNA to be analyzed and a probe and cleavage of the end base of the DNA to be analyzed, allowing the base sequence to be determined sequentially by a single molecule spectrofluorimetry method, such that an effective determination of the base sequence of a DNA becomes possible. | 01-14-2010 |
| 20100009355 | SELECTIVE AMPLIFICATION OF MINORITY MUTATIONS USING PRIMER BLOCKING HIGH-AFFINITY OLIGONUCLEOTIDES - In certain embodiments this invention pertains to methods of detecting and/or quantifying rare mutant nucleic acids in populations of nucleic acids in which the wild-type nucleic acids are in substantially greater abundance than the rare mutants. In various embodiments the methods utilize short high affinity oligonucleotides targeted to the wild type rather than the minority or mutant sequence. Rather than directly detecting mutant DNA, these probes block detection of wild type DNA. These “blocker” probes can be used in combination with longer “detection” probes or PCR primers to amplify and/or identify the minority mutation in, e.g., clinical specimens. The combination of short high affinity blocker probes and longer, lower affinity detection probes eliminates the single base specificity/complexity tradeoff in the design of nucleic acid probes. | 01-14-2010 |
| 20100009356 | DIAGNOSIS OF CARDIOVASCULAR DISEASE - This invention relates to methods for the detection of cardiovascular disease, e.g., acute coronary syndrome, heart failure and/or pulmonary embolism, in high body mass index (BMI) individuals, e.g., with a BMI of 25-29, or 30 or above, and those with impaired renal function. | 01-14-2010 |
| 20100009357 | PREDICTION OF LUNG CANCER TUMOR RECURRENCE - The invention provides methods of estimating the likelihood of lung cancer recurrence in a subject, including those afflicted with NSCLC. The methods of the invention are useful for developing a therapeutic treatment plan to prevent cancer recurrence for subjects deemed to be at high risk, and withholding treatments from those subjects deemed to be at low risk. The invention also provides methods of generating and using metagene-based prediction tree models for estimating the likelihood of lung cancer recurrence. The invention also provides reagents, such as DNA microarrays, software and computer systems useful for estimating cancer recurrence, and provides methods of conducting a diagnostic business for the prediction of cancer recurrence. | 01-14-2010 |
| 20100009358 | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer - The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of newly identified markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of breast cancer. | 01-14-2010 |
| 20100009359 | Methods and compositions for detecting colon cancers - This application describes methods and compositions for detecting and treating vimentin-associated neoplasia. Differential methylation of the vimentin nucleotide sequences has been observed in vimentin-associated neoplasia such as colon neoplasia. | 01-14-2010 |
| 20100009360 | METHOD FOR THE DETECTION OF EGFR MUTATIONS IN BLOOD SAMPLES - The present invention refers to the detection of EGFR mutations in a blood (serum/plasma) sample from a subject. The method comprises: (i) obtaining the DNA from said sample; (ii) amplifying the nucleic acid sequence corresponding to a specific region of the EGFR gene by means of PCR using a Protein-Nucleic Acid probe; 10 and (iii) detecting said mutation. | 01-14-2010 |
| 20100009361 | COMPOSITIONS AND METHODS FOR DETECTING NOONAN SYNDROME - Diagnostic and therapeutic applications for Noonan Syndrome are described. The diagnostic and therapeutic applications are based on certain mutations in a RAS-specific guanine nucleotide exchange factor gene SOS1 or its expression product. The diagnostic and therapeutic applications are also based on certain mutations in a serine/threonine protein kinase gene RAF1 or its expression product thereof. Also described are nucleotide sequences, amino acid sequences, probes, and primers related to RAF1 or SOS1, and variants thereof, as well as host cells expressing such variants. | 01-14-2010 |
| 20100009362 | Fluorescent water-soluable conjugated polyene compounds that exhibit aggregation induced emission and methods of making and using same - The presently described subject matter is directed to water-soluble conjugated polyene compounds that exhibit aggregation induced emission, as well as to water dispersible, fluorescent, polymeric microparticles and/or nanoparticles comprising the water-soluble conjugated polyene compounds. Also provided are methods of making and using the compounds and particles. The described conjugated polyene compounds are useful as bioprobes for the detection biomacromolecules, as well as in the manufacture of sensors. | 01-14-2010 |
| 20100009363 | RBP4 In Insulin sensitivity/resistance, diabetes, and obesity - Methods for screening molecules that modulate the activity of Retinol Binding Protein 4 (RBP4) and their use in treatment of insulin resistance are described. Also described are methods of diagnosing insulin resistance and related conditions by detecting modulation of RBP4 activity. | 01-14-2010 |
| 20100009364 | Methods for diagnosis, prognosis and methods of treatment - The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN. | 01-14-2010 |
| 20100009365 | PROCESS FOR HIGH-THROUGHPUT DNA METHYLATION ANALYSIS - There is disclosed an improved high-throughput and quantitative process for determining methylation patterns in genomic DNA samples based on amplifying modified nucleic acid, and detecting methylated nucleic acid based on amplification-dependent displacement of specifically annealed hybridization probes. Specifically, the inventive process provides for treating genomic DNA samples with sodium bisulfite to create methylation-dependent sequence differences, followed by detection with fluorescence-based quantitative PCR techniques. The process is particularly well suited for the rapid analysis of a large number of nucleic acid samples, such as those from collections of tumor tissues | 01-14-2010 |
| 20100009366 | POLYMORPHISMS IN THE HUMAN GENES FOR OCT1 AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - The present invention relates to a polymorphic OCT1 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit. | 01-14-2010 |
| 20100009367 | MICRO RNAS AND THEIR METHODS OF USE FOR THE TREATMENT AND DIAGNOSIS OF SCHIZOPHRENIA AND SCHIZOPHRENIA SPECTRUM DISORDERS - A method of diagnosing, assessing susceptibility, and/or treating schizophrenia involving the identification and/or observation of microRNAs (miRNA) and variant miRNA are provided. Micro RNAs alleles associated with schizophrenia and schizophrenia spectrum disorders were identified and ultra-rare variants in the precursor or mature miRNA were identified. Functional analyses of ectopically expressed copies of the variant miRNA precursors demonstrate loss of function, gain of function and altered expression levels. The present invention also provides methods for selecting a preferred therapy for a particular subject or group of subjects or individuals at risk for or suffering from schizophrenia or psychosis by use of miRNAs. | 01-14-2010 |
| 20100009368 | METHODS AND COMPOSITIONS FOR THE ASSESSMENT OF CARDIOVASCULAR FUNCTION AND DISORDERS - The present invention provides methods for the assessment of risk of developing acute coronary syndrome (ACS), arterial inflammation, or ACS-associated impaired vascular function, in smokers and non-smokers using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's risk of developing ACS, arterial inflammation, or ACS-associated impaired vascular function. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided. | 01-14-2010 |
| 20100009369 | GENE EXPRESSION LEVEL ANALYZING METHOD, GENE EXPRESSION LEVEL ANALYZING PROGRAM, AND GENE EXPRESSION LEVEL ANALYZING DEVICE - A gene expression level analyzing method includes the steps of: acquiring expression levels of a plurality of target genes in a target cell every measurement time; extracting a maximum expression level and a minimum expression level from the expression levels of the target genes every measurement time; calculating a correlation coefficient of a frequency distribution of the gene having the maximum expression level at each measurement time and a frequency distribution of the gene having the minimum expression level at each measurement time; and comparing the correlation coefficient with a threshold value of the correlation coefficient. | 01-14-2010 |
| 20100009370 | GENE ASSAYING METHOD, GENE ASSAYING PROGRAM, AND GENE ASSAYING DEVICE - A gene assaying method includes the steps of: acquiring two or more data which should be compared and represents expression levels of a plurality of target genes; converting the expression levels represented by the acquired two or more data into ratios based on the expression level of one of the two or more data; extracting a minimum ratio and a maximum ratio of each target gene; and classifying the plurality of target genes using as a classification border at least one of a first ratio with the peak in a frequency distribution of the minimum ratios and a second ratio with the peak in a frequency distribution of reciprocals of the maximum ratios. | 01-14-2010 |
| 20100009371 | SELECTION OF MARKERS - Methods of selecting a portfolio of markers for use in a diagnostic applications include defining diagnostic parameters, establishing a relationship among the parameters so that they are optimized, and selecting an optimal group of markers for the diagnostic application. The diagnostic parameters can include a measure of the relative degree of expression of a gene, a measure of the variation in the measurement of the degree of expression of the gene, and the relationship between the diagnostic and discriminating parameters can be a mean variance relationship. | 01-14-2010 |
| 20100009372 | METHOD FOR ESTIMATING TARGET NUCLEIC ACID RATIO - The present invention provides a method for estimating a ratio between the amount of target nucleic acid and the amount of reference nucleic acid in the examined nucleic acid samples from the PCR reaction solutions at the endpoint. | 01-14-2010 |
| 20100009373 | METHODS AND COMPOSITIONS RELATING TO MULTIPLEX GENOMIC GAIN AND LOSS ASSAYS - Compositions and methods are provided for detecting genomic DNA gain and loss. Embodiments of inventive compositions and methods include composite nucleic acid probes which specifically hybridize to two or more genomic loci in a genomic region of a reference genome for detection of genomic gain and/or loss in a subject genome. In some embodiments, a substrate-attached composite nucleic acid probe is provided which includes a mixture of separate populations of beads having attached DNA probes wherein all of the beads are identically encoded and wherein each individual bead has exclusively DNA derived from one source, such as a particular large insert vector containing chromosomal DNA, or amplicons generated by amplification of DNA derived from a large insert vector containing chromosomal DNA. | 01-14-2010 |
| 20100009374 | SIRE EARLY SELECTION FOR MALE FERTILITY USING SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) OF THE DAZL GENE - Methods and materials for identifying bovine males which will produce semen which will exhibit a higher rate of successfully impregnation by either artificial insemination or natural mating. The method employs SNPs that have been identified in the bDAZL gene which are associated with enhanced (or decreased) male fertility in bovine males and haplotypes formed from such SNPs. The method herein can be used to identify male dairy or beef cattle. The method herein can be applied to bovine animals at an appropriate time and particularly at birth or in utero. The invention further provides kits for conduction assays to assess bovine male fertility/infertility. The invention additionally provides a method of breeding cattle employing the methods and materials herein. | 01-14-2010 |
| 20100009375 | Silica Magnetic Particles with a High Nucleic Acid Binding Capacity - Magnetic particles for nucleic acid isolation are coated with silica and separated from impurities and nanoparticulates using a multi-step fractionation process. In each cycle of the fractionation process, the particles are stirred, sedimented, and resuspended, resulting in a decline in pH of the suspended particles. Repeating the fractionation process until the resuspended particles have dropped to a target pH in the range of about 9 to 10.5, and their zeta potential is more negative than about −40 mV, results in a purified population of particles with a high and reproducible binding capacity for nucleic acids. The silica-treated magnetic beads produced by the method offer improved sensitivity and consistency for recovery of nucleic acids in a sample. | 01-14-2010 |
| 20100009376 | METHOD FOR MEASURING DNA METHYLATION - The present invention relates to a method of measuring the content of methylated DNA in a DNA region of interest in a genomic DNA contained in a biological specimen, and so on. | 01-14-2010 |
| 20100009377 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTO IMMUNE AND CHRONIC INFLAMMATORY DISEASES - Methods of diagnosing or monitoring autoimmune and chronic inflammatory diseases, particularly systemic lupus erythematosis and rheumatoid arthritis, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring autoimmune and chronic inflammatory diseases, particularly systemic lupus erythematosis and rheumatoid arthritis and kits or systems containing the same are also described. | 01-14-2010 |
| 20100015599 | ISOLATED REDUCTIVE DEHALOGENASE GENES - The invention is directed to novel reductive dehalogenase genes encoding for reductive dehalogenases which are capable of dehalogenating halogenated organic compounds and may be useful in the bioremediation of pollutants. In particular, the invention provides an isolated polynucleotide of a novel vinyl chloride dehalogenase gene (bvcA). The novel vinyl chloride dehalogenase gene encodes a reductive dehalogenase that is capable of the complete reduction of vinyl chloride to ethene. | 01-21-2010 |
| 20100015600 | METHOD FOR DIAGNOSING AND TREATING CROHN'S DISEASE - The invention concerns an in vitro method for diagnosing Crohn's disease, or for determining predisposition in a person to develop Crohn's disease, by detecting an overexpression of the CD66c receptor in subjects suffering from said disease or at risk. The invention also concerns preventive or curative treatment of Crohn's disease. | 01-21-2010 |
| 20100015601 | BIOLOGICAL CONFIRMATION AND DETECTION SYSTEM - The present disclosure describes a method and apparatus for collecting samples of particles from air or other gases at one or more monitored locations, and identifying in real-time whether biological agents, such as bacterial or viral pathogens, are present in the samples. The apparatus preferably uses a liquid-assisted collector to collect the sample of particles, which are suspended in a liquid that contains dyes that detect the presence of nucleic acids. An integrated detector with a light source and a light detector detects whether there is a change in the fluorescence of the liquid, which indicates the presence of a biological agent in the sample. | 01-21-2010 |
| 20100015602 | REVERSE TRANSCRIPTION AND AMPLIFICATION OF RNA WITH SIMULTANEOUS DEGRADATION OF DNA - The invention relates to a method for processing RNA, in particular, a RNA reaction method and kits for carrying out said RNA reaction method. | 01-21-2010 |
| 20100015603 | Chimeric proteins for measuring atp concentrations in pericellular space and related screening method - The invention relates to luminescent chimeric proteins comprising a first N-terminal protein sequence, a second protein sequence and a third C-terminal protein sequence wherein:
| 01-21-2010 |
| 20100015604 | Composition and method for determination of ck19 expression - Disclosed is a method for quantitative determination of CK-19 mRNA positive cells in a biological sample. The method can be used, for instance, with peripheral blood to detect cancer in a patient. In one embodiment, the method can be used to detect the cancer before initiation of adjuvant treatment, thereby providing information about therapeutic efficacy. Practice of the invention method is sensitive, reliable, and easy to perform. | 01-21-2010 |
| 20100015605 | HEPATOCELLULAR CARCINOMA CLASSIFICATION AND PROGNOSIS - Methodology for the in vitro classification and/or prognosis of hepatocellular carcinoma (HCC) from a HCC sample is based on the determination of the expression profile of particular gene combinations. | 01-21-2010 |
| 20100015606 | MICROFLUIDIC DROPLET QUEUING NETWORK - A multi-port liquid bridge ( | 01-21-2010 |
| 20100015607 | NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF - The present invention relates to compositions and methods for detection and quantification of individual target molecules in biomolecular samples. In particular, the invention relates to coded, labeled probes that are capable of binding to and identifying target molecules based on the probes' label codes. Methods of making and using such probes are also provided. The probes can be used in diagnostic, prognostic, quality control and screening applications. | 01-21-2010 |
| 20100015608 | BINARY DEOXYRIBOZYME PROBES FOR NUCLEIC ACID ANALYSIS - New binary deoxyribozyme or ribozyme probes and methods are described for nucleic acid analysis, which allows the detection of nucleic acids under mild physiologic conditions with extraordinary specificity and high sensitivity to single nucleotide mismatches without PCR amplification. | 01-21-2010 |
| 20100015609 | Method for Determining the Ratio of Two Distinct Peptides or Polynucleic Acids - The invention relates to a method for determining the ratio of two distinct target-peptides or polynucleic acids comprising: a) obtaining a sample containing said two distinct target-peptides or polynucleic acids, b) providing a precursor-peptide or precursor-polynucleic acid, comprising the two distinct target-peptides or -polynucleic acids in a known ratio, wherein the two distinct target-peptides or -polynucleic acids are connected by a cleavage site, c) cleaving the precursor-peptide or precursor-polynucleic acid at the cleavage site to obtain a standard with the known ratio of the two distinct target-peptides or -polynucleic acids, d) detecting a signal of each distinct target-peptide or -polynucleic acid of the standard in an analyzer, comparing the signals with the known ratio and determining a correction factor, e) detecting the signal of each distinct target-peptide or -polynucleic acid of the sample in the analyzer and f) determining the ratio of the two distinct target-peptides or -polynucleic acids by means of the correction factor or by double ratio calculation (calculation of the ratio of two intensity ratios—namely of the peptide and isoform-peptide with their corresponding labelled standards) to eliminate the compound-specific correction factors. | 01-21-2010 |
| 20100015610 | DIAGNOSTIC SCREENING METHODS FOR DISORDERS OF THE ENDOPLASMIC RETICULUM-TO-GOLGI TRAFFICKING OF PROTEINS - The invention relates to methods of diagnosing Cranio-lenticulo-sutural dysplasia and other disorders that occur as a result of defective endoplasmic reticulum-to-Golgi trafficking using immunofluorescence based screening tests using antibodies against protein disulfide isomerase. | 01-21-2010 |
| 20100015611 | REACTION MONITORING - The invention provides a method and apparatus for detecting a signal of a specific spectrum emitted in the course of a chemical or biochemical reaction. The method comprises conducting the reaction in a reaction vessel, which is arranged so that light emanating from the reaction vessel is received by a detector comprising a plurality of photosensors in an array, wherein each photosensor is activated by light falling within a particular waveband range only, and where photosensors activated by light in different waveband ranges are distributed throughout the array. Output from one or more subsets of those photosensors which receive wavebands which contribute to the said specific spectrum is monitored and the output from a subset, or the relationship between the outputs of each subset are used to determine the signal in the specific spectrum. | 01-21-2010 |
| 20100015612 | METHODS AND SYSTEMS FOR EVALUATION OF HYDROCARBON RESERVOIRS AND ASSOCIATED FLUIDS USING BIOLOGICAL TAGS AND REAL-TIME PCR - This invention relates in general to characterizing hydrocarbon reservoirs and/or determining flow properties of fluids associated with the reservoir-including fluids introduced into the reservoir to provide for hydrocarbon extraction-using biological tags and real-time polymerase chain reactions for tag detection. In embodiments of the present invention, one or more biological tags may be added to one or more liquids associated with the hydrocarbon reservoir and subsequently one or more liquid samples may be taken from locations associated with the hydrocarbon and the presence of the one or more biological tag may be qualitatively and/or quantitatively tested for in the samples using real-time PCR. | 01-21-2010 |
| 20100015613 | Systems and Methods for Improving Protein and Milk Production of Dairy Herds - The present invention provides for a direct correlation between milk production in livestock animals and the presence of alleles of a gene encoding an adipocyte-specific polypeptide, termed leptin, which gene is hereinafter referred to as ob. The invention also provides novel compositions consisting essentially of specific oligonucleotides that are useful as primers to amplify particular regions of the genome during enzymatic nucleic acid amplification, thus providing a rapid, sensitive and specific method for the detection of the ob-gene polymorphism which may be present in a specimen. The invention further provides for methods of screening bovine to determine those having predictably more milk productivity and advantageously selecting those livestock for future breeding and management purposes based on the ob polymorphisms. | 01-21-2010 |
| 20100015614 | Chip-Based Device for Parallel Sorting, Amplification, Detection, and Identification of Nucleic Acid Subsequences - An apparatus for chip-based sorting, amplification, detection, and identification of a sample having a planar substrate. The planar substrate is divided into cells. The cells are arranged on the planar substrate in rows and columns. Electrodes are located in the cells. A micro-reactor maker produces micro-reactors containing the sample. The micro-reactor maker is positioned to deliver the micro-reactors to the planar substrate. A microprocessor is connected to the electrodes for manipulating the micro-reactors on the planar substrate. A detector is positioned to interrogate the sample contained in the micro-reactors. | 01-21-2010 |
| 20100015615 | Identification and Isolation of Adult Stem Cells and Related Methods of Use - Inhibitor of DNA Binding-1 (Id-1) is a marker protein found in stem cells, including adult stem cells, which can be used an indicator of the “stem-ness” of the cells. This allows Id1 expression to be used in a method for identifying cells as potential stem cells involving the step of screening the cells for expression of Id1; and a method for isolating cells as potential stem cells comprising the step of separating cells that express Id1 from cells that do not. Expression of GFAP can be used as a secondary screen to isolate rare B1 type adult neuronal stem cells. | 01-21-2010 |
| 20100015616 | High Speed, High Fidelity, High Sensitivity Nucleic Acid Detection - The present invention provides methods, compositions, and kits for nucleic acid detection. | 01-21-2010 |
| 20100015617 | Nucleic Acid Amplification Method - Disclosed is a nucleic acid amplification method which is based on a new principle and enables to amplify a nucleic acid having a specific nucleotide sequence in a simple manner, within a short time and with efficiency. The nucleic acid amplification method comprises the steps of: (a) conducting a DNA polymerase chain reaction by using, as a template, DNA comprising a nucleotide sequence to be amplified and using a primer pair having a nucleotide sequence complementary to the nucleotide sequence to be amplified, thereby producing a linear DNA fragment; and (b) conducting a chain-substituting DNA polymerase chain reaction in a chaining manner by using cyclic single-stranded DNA comprising the same nucleotide sequence as that of at least one of the primer pair as a template and employing the 3′-terminus of the linear DNA fragment produced in step (a) as the replication origin. | 01-21-2010 |
| 20100015618 | DNA FRAGMENT USED AS ATTACHED TO 5' END OF PRIMER USED IN NUCLEIC ACID AMPLIFICATION REACTION AND USE OF DNA FRAGMENT - A method is provided which enables quick, convenient, inexpensive, and high sensitivity confirmation of nucleic acid amplification after a nucleic acid amplification reaction. The DNA fragment in accordance with the present invention is a single-stranded DNA fragment containing a hairpin structure which in turn contains a bulge, wherein the DNA fragment is used as being attached to the 5′ end of a primer used in nucleic acid amplification. The nucleic acid amplification confirmation method in accordance with the present invention quantifies a hairpin primer containing the DNA fragment at its 5′ end by using bulge-binding fluorescent molecules after carrying out PCR or like nucleic acid amplification reaction using the hairpin primer. SNPs are detected quickly and conveniently at low cost and with high sensitivity by applying the nucleic acid amplification confirmation method, for example, to allele specific PCR. | 01-21-2010 |
| 20100015619 | METHOD OF DETECTING GENOMIC ABERRATIONS FOR PRENATAL DIAGNOSIS - This invention relates to assays used to detect and confirm genomic aberrations, such as chromosomes 13, 18, 21, X and Y aneuploidy as well as 22q11.2 deletions, for prenatal diagnosis. For the detection, combined STR markers (all tetra-nucleotide repeats) are employed to cover different chromosome regions. For the confirmation step, individual chromosome specific STR markers (tetra-nucleotide repeats) are utilized. This invention particularly relates to multiplex analysis for the presence or absence of STR markers in genomic DNA isolated from peripheral blood, amniotic fluid, cultured amniocytes, chorionic villi, or fetal cells existing in maternal blood. This invention offers an efficient approach to identify chromosomal abnormalities by using STR markers. | 01-21-2010 |
| 20100015620 | CANCER-LINKED GENES AS BIOMARKERS TO MONITOR RESPONSE TO IMPDH INHIBITORS - Sets of biomarker genes useful for monitoring exposure and response to anti-tumor agents that inhibit IMPDH and related biomolecules are disclosed along with methods for identifying such sets of genes, methods of using such sets to identify additional therapeutic agents as well as methods for stratifying patients into groups that are sensitive or resistant to such therapeutic agents. Methods of screening patients for recurrence of disease by monitoring changes in gene expression associated with malignancy are also described. The nucleotide sequence of such biomarkers are presented. | 01-21-2010 |
| 20100015621 | METHOD FOR DIRECT AMPLIFICATION FROM CRUDE NUCLEIC ACID SAMPLES - The present teachings relate to improved methods, kits, and reaction mixtures for amplifying nucleic acids. In some embodiments a novel direct buffer formulation is provided which allows for the direct amplification of the nucleic acids in a crude sample with minimal sample purification. | 01-21-2010 |
| 20100015622 | MOLECULAR BEACON-BASED METHODS FOR DETECTION OF TARGETS USING ABSCRIPTION - The present invention provides methods for detecting targets using an Abscription assay that exploits molecular beacon-based detection technology. The methods of the invention are highly sensitive and can be performed on a NanoDrop scale and can be multiplexed for simultaneous detection of multiple targets. | 01-21-2010 |
| 20100015623 | GENETIC LOCI ASSOCIATED WITH MECHANICAL STALK STRENGTH IN MAIZE - The invention relates to methods and compositions for identifying and for selecting maize plants with mechanical stalk strength characteristics. The methods use molecular markers to identify and select plants with increased mechanical stalk strength or to identify and counter-select plants with decreased mechanical stalk strength. Maize plants generated by the methods of the invention are also a feature of the invention. | 01-21-2010 |
| 20100015624 | PEPTIDE HAVING ABILITY TO ACTIVATE CANCER-RELATED GENE - To provide a cancer diagnostic reagent for determining malignancy of a cancer patient or a cancer cell and a tendency of canceration of a healthy subject, the reagent including a peptide having an ability to activate a cancer-related gene and extracted from cell membrane surfaces of human squamous-cell carcinoma cells or including a synthetic polynucleotide encoding the peptide or a partial amino acid sequence of the peptide. | 01-21-2010 |
| 20100015625 | CTIP2 EXPRESSION IN SQUAMOUS CELL CARCINOMA - The present disclosure provides methods of diagnosing and staging squamous cell carcinomas, for instance head and neck (HNSCC), by detecting chicken ovalbumin upstream promoter-transcription factor-interacting protein 2 (CTIP2) expression. For example, it is demonstrated herein that expression of CTIP2 is increased in SCC relative to a corresponding normal sample. Also included are kits for detecting SCC, as well as methods for identifying CTIP2 inhibitors. | 01-21-2010 |
| 20100015626 | MULTIPLEX NUCLEIC ACID REACTIONS - The invention is directed to a variety of multiplexing methods used to amplify and/or genotype a variety of samples simultaneously. | 01-21-2010 |
| 20100015627 | SELECTION METHOD - The current invention comprises a method for the selection of a mammalian cell by transfecting a mammalian cell with a nucleic acid comprising a part of a nucleic acid encoding a polypeptide that catalyzes an α1,6-glycosidic bond formation between fucose and an asparagine-linked N-acetylglucosamine and cultivating the transfected mammalian cell in the presence of Lens culinaris agglutinin (LCA) and selecting a mammalian cell viable under these conditions. | 01-21-2010 |
| 20100015628 | AMBIENT TEMPERATURE STABLE CHEMICAL/BIOLOGICAL REAGENTS ON MEMBRANES OR FILTERS - The present invention provides a biological sample preparation system including ambient temperature stable reagent mixture and a separation filter or membrane. In particular, the system includes a dried reagent in a glassy, porous state, on top of a separation column, whereby sample preparation is streamlined and simplified. Also provided are methods of making and using the system. A kit for preparing a biological sample is also provided. | 01-21-2010 |
| 20100015629 | Light Emission Modifiers and Their Uses in Nucleic Acid Detection, Amplification and Analysis - The present invention relates to methods and reagents for modifying the emission of light from labeled nucleic acids for the purpose of real time detection, analysis, and quantitation of nucleic acid sequences, e.g., using singly labeled probes. These methods and reagents exploit advantageous properties of thiazine dyes and diazine dyes. Furthermore, the use of these light emission modifiers in background reduction, nucleic acid duplex stabilization and other uses is also described. Related kits, reaction mixtures and integrated systems are described. | 01-21-2010 |
| 20100015630 | Light Emission Modifiers and Their Uses in Nucleic Acid Detection, Amplification and Analysis - The present invention relates to methods and reagents for modifying the emission of light from labeled nucleic acids for the purpose of real time detection, analysis, and quantitation of nucleic acid sequences, e.g., using singly labeled probes. These methods and reagents exploit advantageous properties of thiazine dyes and diazine dyes. Furthermore, the use of these light emission modifiers in background reduction, nucleic acid duplex stabilization and other uses is also described. Related kits, reaction mixtures and integrated systems are described. | 01-21-2010 |
| 20100015631 | CONCATAMERIC LIGATION PRODUCTS: COMPOSITIONS METHODS AND KITS FOR SAME - The present teachings relate to methods, compositions, and kits for detecting one or more target polynucleotide sequences in a sample, and methods compositions and kits for forming concatameric ligation products. In some embodiments of the present teachings, oligonucleotides are hybridized to complementary target polynucleotides and are ligated together to form a concatameric ligation product. In some embodiments of the present teachings, the concatameric ligation product can be amplified, and the identity and quantity of the target polynucleotides determined based on sequence introduced in the ligation reaction. Some embodiments of the present teachings provide methods for removing unligated probes from the reaction mixture. Some embodiments of the present teachings provide for highly multiplexed detection, identification, and quantification of a plurality of target polynucleotides using a variety of analytical procedures. | 01-21-2010 |
| 20100015632 | METHOD FOR EXAMINING COLORECTAL CANCER AND COLORECTAL ADENOMA - The present invention provides a method for examining colorectal cancer and colorectal adenoma, which enables to detect colorectal cancer patients and patients at high risk of colorectal cancer at a high probability and is useful for diagnosis of colorectal cancer and colorectal adenoma, and provides the examination reagents thereof. There are significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, among non-cancer colorectal tissues, colorectal cancer tissues and colorectal adenoma tissues. Furthermore, colorectal cancers and adenomas are detected specifically by assaying a definite range of GlcNAc-6-sulfated sugar residues in tissues from patients or feces samples. MECA-79 antibody (Pharmingen, catalog No. 09961D, Distributor: Becton Dickinson), reacting with GlcNAc-6-sulfated sugar residues, which are produced specifically by the enzyme present in colorectal cancer and colorectal adenoma tissues could be used for the examination of colorectal cancers and colorectal adenomas. | 01-21-2010 |
| 20100021883 | DETECTING, MEASURING AND CONTROLLING PARTICLES AND ELECTROMAGNETIC RADIATION - A method is provided for detecting, measuring or controlling particles and/or electromagnetic radiation, comprising providing a deformable material containing a deformable aperture defining a path for particles or radiation, adjusting the deformable aperture to a prescribed geometry and/or size by deforming the deformable material to change at least one of the parameters of the path defined by the deformable aperture, and causing the particle or radiation to be detected, measured or controlled to enter the deformable aperture. The method includes the step of monitoring the geometry and/or size of the deformable aperture and controlling the adjustment of the size of the deformable aperture in response to such monitoring. The required apparatus is easily fabricated from inexpensive materials. Furthermore the deformable aperture can be tuned to the appropriate geometry post fabrication, and the ability to adjust the aperture geometry renders it capable of discriminating a plurality of differently sized particles. | 01-28-2010 |
| 20100021885 | REAGENT SETS AND GENE SIGNATURES FOR NON-GENOTOXIC HEPATOCARCINOGENICITY - The invention discloses gene signatures for predicting onset of non-genotoxic hepatocarcinogenicity in a subject. The invention also provides methods, apparatuses and reagent sets useful for predicting non-genotoxic hepatocarcinogenicity based on expression levels of genes in specific gene signatures. | 01-28-2010 |
| 20100021886 | Methods and Materials for Identifying the Origin of a Carcinoma of Unknown Primary Origin - The present invention provides a method of identifying origin of a metastasis of unknown origin by obtaining a sample containing metastatic cells; measuring Biomarkers associated with at least two different carcinomas; combining the data from the Biomarkers into a linear discrimination analysis where the linear discrimination analysis normalizes the Biomarkers against a reference; and imposes a cut-off which optimizes sensitivity and specificity of each Biomarker, weights the prevalence of the carcinomas and selects a tissue of origin determining origin based on highest probability determined by the linear discrimination analysis or determining that the carcinoma is not derived from a particular set of carcinomas; and optionally measuring Biomarkers specific for one or more additional different carcinoma, and repeating the steps for additional Biomarkers. | 01-28-2010 |
| 20100021887 | PROBE FOR TAGGING VALUABLES BASED ON DNA-METAL COMPLEX - Methods are disclosed involving the formation of complex DNA-Metal and the detection of the complex, such as by employing several analytical methods, e.g., X-Ray Fluorescence, FT-IR and Raman spectroscopy. | 01-28-2010 |
| 20100021888 | Screening for disease susceptibility by genotyping the CCR5 and CCR2 genes - Provided are compositions, methods and uses for identifying persons at an increased risk of infection by, transmission of, or accelerated progression of a disease caused by an HIV-1 virus. Diagnostic, prognostic and combined therapeutic kits are also provided. | 01-28-2010 |
| 20100021889 | USING GENETIC POLYMORPHISMS OF THE BICD1 GENE AS A METHOD FOR DIAGNOSING AND TREATING MYOPIA - Using the BICD | 01-28-2010 |
| 20100021890 | METHOD FOR ANALYTE DETECTION USING PROXIMITY PROBES - The present invention relates to a method for detecting an analyte in a sample, comprising (a) contacting said sample with at least one set of at least first, second and third proximity probes, which probes each comprise an analyte-binding domain and a nucleic acid domain and can simultaneously bind to the analyte, the nucleic acid domain of said third proximity probe being a splint which is capable of hybridising at least to the nucleic acid domains of said first and second proximity probes, wherein when all of the at least three proximity probes bind to said analyte, the nucleic acid domains of said first and second proximity probes are conjugatable by means of an interaction mediated by said hybridised splint of said third proximity probe; (b) conjugating the nucleic acids, of said first and second proximity probes; and (c) detecting said conjugation. Also provided is a kit for use in such a method. | 01-28-2010 |
| 20100021891 | RGS2 GENOTYPES ASSOCIATED WITH EXTRAPYRAMIDAL SYMPTOMS INDUCED BY ANTIPSYCHOTIC MEDICATION - The present invention identifies genotypes associated with resistance to extrapyramidal symptoms induced by antipsychotic drugs. The present invention further identifies genotypes associated with predisposition to the onset or aggravation of extrapyramidal symptoms induced by antipsychotic drugs and use thereof for assessment of patient populations. Specifically, the present invention relates to particular polymorphisms in the RGS2 gene that are associated with resistance or susceptibility to drug-induced extrapyramidal symptoms. | 01-28-2010 |
| 20100021892 | Modulators of SC4MOL for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of sterol-C4-methyl oxidase (SC4MOL), and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 01-28-2010 |
| 20100021893 | Modulators of lanosterol synthetase for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of lanosterol synthetase (LSS), and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 01-28-2010 |
| 20100021894 | Nanoparticle-Based Colorimetric Detection Of Cysteine - The invention provides methods to detect cysteine which employ oligonucleotide functionalized nanoparticles. | 01-28-2010 |
| 20100021895 | Vectors for Inducing Homozygous Mutations and Methods of Using Same - The present invention provides vectors for inducing homozygous mutations in cells. Also provided are cells and populations of cells comprising a vector of the present invention. Further provided are methods of identifying cells with homozygous mutations. Also provided are methods of identifying agents that increase the frequency of homozygous mutations in cells. The present invention also provides methods of identifying a gene that is responsible for a recessive genetic trait. | 01-28-2010 |
| 20100021896 | Method for Evaluating and Comparing Immunorepertoires - Disclosed is a method for amplifying RNA and/or DNA from immune cell populations and using the amplified products to produce an immune response profile and evaluate the possible correlation between a normal or abnormal immune response and the development of a disease such as an autoimmune disease, cancer, diabetes, or heart disease. | 01-28-2010 |
| 20100021897 | Mycobacterium Avium Subspecies Paratuberculosis (Map) Diagnostic Test - The subject invention provides PCR primers and other nucleic acid sequences derived from | 01-28-2010 |
| 20100021898 | MAMMALIAN OOCYTE DEVELOPMENT COMPETENCY GRANULOSA MARKERS AND USES THEREOF - The present invention relates to the competence of oocytes for uterine implantation and development into living individuals. The invention more particularly relates to markers that are detected and measured in granulosa cells collected along with the oocytes during oocyte aspiration as it is done in assisted reproduction techniques. Markers include cytochrome P450 aromatase (CYP19A1), cell division cycle 42 (CDC42), 3-β-hydroxysteroid dehydrogenase 1 (3βHSD1), serpm peptidase inhibitor clade E member 2 (SERPINE 2), and adrenodoxm (ADX) that are detected and measured, using RT-PCR. | 01-28-2010 |
| 20100021899 | METHOD OF ASSAYING TARGET SUBSTANCE IN SAMPLE, APTAMER MOLECULE AND METHOD OF CONSTRUCTING THE SAME - A method for measuring a test substance whereby the test substance in a sample can be specifically measured without using an antibody against the test substance; an aptamer molecule used therefor; and a method for creating the aptamer are disclosed. An aptamer capable of hybridizing with an oligonucleotide when it is bound to a test substance, but is incapable of hybridizing with the oligonucleotide when it is not bound to the test substance, is utilized. The aptamer is brought into contact with a sample, and the aptamer bound to the test substance is brought into contact with an immobilized oligonucleotide which hybridizes with the aptamer, to bind the aptamer to a solid phase, followed by measurement of the aptamer immobilized on the solid phase. | 01-28-2010 |
| 20100021900 | USE OF OMENTIN 1 AND OMENTIN 2 IN THE DIAGNOSIS AND TREATMENT OF DISEASE - The present invention is directed to methods of diagnosing a disease or predicting an increased risk of a disease, such as obesity, obesity-dependent subacute inflammation, atherosclerosis, cardiovascular disease and a metabolic disease, by determining the levels of omentin 1 and 2 protein in a subject, or by determining the levels of omentin 1 and 2 gene expression in a subject. The present invention is also directed to methods of disease treatment using omentin 1 protein and omentin 2 protein. | 01-28-2010 |
| 20100021901 | Compositions and methods for detecting analytes - Embodiments disclosed herein relate generally to probes (e.g. self-quenching probes), methods, and kits for detecting the presence of a target analyte using probes. | 01-28-2010 |
| 20100021902 | Method for methylation-selective amplification - Aspects of the invention relate to a method for methylation selective amplification. The method comprising a DNA treatment, wherein cytosine is converted to uracil, uracil sulfonate or another base having a different binding behavior than cytosine, while methylated cytosine remains unchanged, and the amplification of treated DNA in the presence of at least one restriction enzyme, said enzyme digesting the amplification product derived either from converted methylated DNA or from converted unmethylated DNA during amplification. Aspects of the invention relate to a kit for performing the inventive method. Aspects of the invention relate also to the use of the inventive methods and kits. | 01-28-2010 |
| 20100021903 | Use of Genetic Determinants in Cardiovascular Risk Assessment - The invention generally provides compositions and methods of using a subject's genetic information for the selection of prophylactic or therapeutic agents and treatment regimens, and related methods for assaying the risk of an adverse cardiovascular event in the patient. | 01-28-2010 |
| 20100021904 | SHIELDED CROSS-LINKING PROBES - The present invention relates to the use of nucleic acid probes to bind to targets. In some embodiments, the probe comprises a shielded cross-linking probe. | 01-28-2010 |
| 20100021905 | COMPOSITIONS AND METHODS OF SELECTIVE NUCLEIC ACID ISOLATION - The invention relates to methods for isolating and/or identifying nucleic acids. The invention also provides kits for isolating and/or identifying nucleic acids. | 01-28-2010 |
| 20100021906 | SALIVARY BIOMARKERS FOR SJOGREN'S SYNDROME - The present invention provides for the first time the identification of salivary protein and RNA factors that can be used in the detection of primary Sjögren's Syndrome. The present invention therefore provides methods of diagnosing and providing a prognosis for Sjögren's Syndrome, by examining relevant proteins (including certain autoantigens and autoantibodies) and RNA in a patient's saliva. | 01-28-2010 |
| 20100021907 | METHOD OF DETECTING A PLURALITY OF NUCLEIC ACIDS - The present invention provides a method of detecting a plurality of nucleic acid samples, includes a first step of preparing a nucleic acid sample detection device, a second step of preparing 1 | 01-28-2010 |
| 20100021908 | NOVEL 2,5-DIKETO-L-GLUCONIC ACID REDUCTASES AND METHOD OF USE - Described herein are novel nucleic acids, proteins and methods that can be used to provide new catalysts with desirable traits for industrial processes. In particular, novel reductases isolated from the environment using PCR methods are described. | 01-28-2010 |
| 20100021909 | Concurrent Optimization In Selection of Primer and Capture Probe Sets for Nucleic Acid Analysis - Disclosed is a method of iteratively optimizing two (or more) interrelated sets of probes for the multi-step analysis of sets of designated sequences, each such sequence requiring, for conversion, at least one conversion probe (“primer”), and each converted sequence requiring, for detection, at least one capture probe. The iterative method disclosed herein for the concurrent optimization of primer and probe selection invokes fast logical string matching functions to perform a complete cross-correlation of probe sequences and target sequences. The score function assigns to each probe-target alignment a “degree of matching” score on the basis of position-weighted Hamming distance functions introduced herein. Pairs of probes in the final selection may differ in several positions, while other pairs of probes may differ in only a single position. Not all such positions are of equal importance, and a score function is introduced, reflecting the position of the mismatch within the probe sequence. | 01-28-2010 |
| 20100021910 | Methods and Systems for Microfluidic DNA Sample Preparation - The present invention relates to methods and systems for microfluidic DNA sample preparation. More specifically, embodiments of the present invention relate to methods and systems for the isolation of DNA from patient samples on a microfluidic device and use of the DNA for downstream processing, such as performing amplification reactions and thermal melt analysis on the microfluidic device. | 01-28-2010 |
| 20100021911 | PRODUCTION HOST CELL LINES - The invention concerns the field of cell culture technology. The invention describes production host cell lines comprising vector constructs comprising a DHFR expression cassette. Those cell lines have improved growth characteristics in comparison to DHFR-deficient or DHFR-reduced cell lines such as CHO DG44 and CHO DUKX-B11. The invention especially concerns two cell lines, a representative of each cell line is deposited with the DSMZ under the number DSM ACC2909 (CHOpper® Discovery) and DSM ACC2910 (CHOpper® Standard). The invention further concerns a method of producing proteins using the cells generated by the described method. | 01-28-2010 |
| 20100021912 | Methods of Modulating Lipid Concentrations in Eukaryotic Cells - The present invention is based on the discovery of a set of genes that are involved in lipid-droplet formation and regulation. Accordingly, the present invention provides methods of increasing or decreasing lipid concentrations in eukaryotic cells by decreasing or increasing expression of one of these genes. Increased lipid concentrations may be useful, for example, in the generation of biofuels. Decreased lipid concentration may be useful in the treatment of diseases characterized by excessive lipid storage. In addition, the invention provides methods of identifying markers of diseases characterized by excessive lipid storage. | 01-28-2010 |
| 20100021913 | Stimulus-Elicited Genomic Profile Markers of Alzheimer's Disease - The present invention relates to a method for diagnosing Alzheimer's Disease (AD) using PKC-elicited gene expression profiles PKC-activation elicits different genomic profiles in AD cells, as compared with control cells, which can he used to diagnose AD and individuals at risk for developing AD. | 01-28-2010 |
| 20100021914 | OLIGONUCLEOTIDES FOR MODULATING TARGET RNA ACTIVITY - The present invention describes oligonucleotides that bind to microRNA target sites in target RNAs, such as mRNAs. The oligonucleotides of the invention may mediate RNase H degradation of the target RNA, mediate RNAi of the target RNA or prevent microRNA regulation of the target RNA. The oligonucleotides of the invention are useful e.g. as research tools for studying microRNA:mRNA interactions and for therapeutic development. The present invention also describes methods of identifying microRNA target sites, methods of validating microRNA target sites, methods of identifying oligonucleotides of the invention and methods of modulating the activity of a target RNA using the oligonucleotides of the invention. | 01-28-2010 |
| 20100021915 | HIGH THROUGHPUT DNA SEQUENCING METHOD AND APPARATUS - The present invention relates to a method for high throughput nucleic acid sequencing using a multi-bead flow cell and pyrophosphate sequencing, a sequencer capable of performing this method, and a kit of the pyrophosphate sequencing reagents. | 01-28-2010 |
| 20100021916 | MICROSATELLITE-BASED FINGERPRINTING SYSTEM FOR SACCHARUM COMPLEX - This invention relates to | 01-28-2010 |
| 20100021917 | METHODS OF USING GENES AND GENETIC VARIANTS TO PREDICT OR DIAGNOSE INFLAMMATORY BOWEL DISEASE - This invention provides methods of diagnosing or predicting susceptibility to inflammatory bowel disease by determining the presence or absence of genetic variants. In one embodiment, a the invention is practiced by determining the presence or absence of NOD2 variants in an individual where the presence of NOD2 variants are indicative of susceptibility to Crohn's Disease in the individual. In another embodiment, the invention further determines the presence or absence of TLR8 variants where the presence of TLR8 variants are inflammatory bowel disease in female individuals. In another embodiment, the invention further determines the presence or absence of TR2 variant P631H where the presence of TLR2 variant P631H is indicative of susceptibility to Crohn's Disease. | 01-28-2010 |
| 20100021918 | METHOD FOR ASSAYING ACTION OF ANTITUMOR AGENT USING SPLICING DEFECTS AS INDEX - An object of the present invention is to provide a method, a probe, a primer, an antibody, a reagent, and a kit for assaying an action of a pladienolide derivative to a living subject. According to the present invention, there is provided a method for assaying an action of the pladienolide derivative using splicing defect as an index. | 01-28-2010 |
| 20100021919 | Production of Polyhydroxyalkanoates From Polyols - Recombinant processes are provided whereby additional genes are introduced into | 01-28-2010 |
| 20100021920 | MUTATED ABL KINASE DOMAINS - The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides. | 01-28-2010 |
| 20100021921 | MUTATED ABL KINASE DOMAINS - The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides. | 01-28-2010 |
| 20100021922 | DARK QUENCHERS FOR DONOR-ACCEPTOR ENERGY TRANSFER - The present invention provides a family of dark quenchers, termed Black Hole Quenchers (“BHQs”), that are efficient quenchers of excited state energy but which are themselves substantially non-fluorescent. Also provided are methods of using the BHQs, probes incorporating the BHQs and methods of using the probes. | 01-28-2010 |
| 20100021923 | METHOD FOR THE EFFICIENCY-CORRECTED REAL-TIME QUANTIFICATION OF NUCLEIC ACIDS - The present invention concerns a method for the quantification of a target nucleic acid in a sample comprising the following steps: (i) determination of the amplification efficiency of the target nucleic acid under defined amplification conditions, (ii) amplification of the target nucleic acid contained in the sample under the same defined reaction conditions, (iii) measuring the amplification in real-time, (iv) quantification of the original amount of target nucleic acid in the sample by correction of the original amount derived from step (iii) with the aid of the determined amplification efficiency. The efficiency correction of PCR reactions according to the invention for the quantification of nucleic acids can be used for absolute quantification with the aid of an external or internal standard as well as for relative quantification compared to the expression of housekeeping genes. | 01-28-2010 |
| 20100021924 | Transgenic animal and methods for decreasing cardiac cell death via cardiac-specific sir2alpha overexpression - The present invention relates to a transgenic animal and methods for increasing the expression or activity of Sir2α protein. An increase in the expression of Sir2α protein prevents stress- and age-related cardiac cell death thereby facilitating the treatment of cardiac diseases or conditions associated with aging. | 01-28-2010 |
| 20100021925 | Isolation of nucleic acids on surfaces - New processes and equipment to isolate and purify nucleic acids on surfaces are provided. The invention focuses on processes which use surfaces, for example, porous membranes, on which the nucleic acids are immobilized in a simple manner from the sample containing the nucleic acids and can be released again by way of simple procedural steps, whereby the simple performance of the process according to the invention makes it possible to perform the processes specifically in a fully automatic manner. An additional aspect of the present invention focuses on binding the nucleic acids to an immobile phase, especially to a membrane, in such a way and manner, that they can be released without difficulty during an additional reaction stage from this phase and, if desired, can be used in other applications, such as restriction digestion, RT, PCR or RT-PCR, or in any of the suitable analyses or enzyme reactions mentioned in the disclosure. Special isolation devices are provided that can be used to carry out the processes according to the invention. | 01-28-2010 |
| 20100028861 | Probe set and method for identifying hla allele - Provided is a probe set that is useful for identifying each allele of HLA individually, and a method of identification of an allele of HLA by the use thereof for each type. The probe set is composed of probes that cover all of the partial sequences that contain a unique base to each allele. Using this probe set HLA contained in a specimen is identified. | 02-04-2010 |
| 20100028862 | BACTERIAL REPLICATION SYSTEMS AND METHODS - Reconstituted bacterial replication assemblies and methods for their use are provided. | 02-04-2010 |
| 20100028863 | HIGH THROUGHPUT ASSAY FOR CANCER CELL GROWTH INHIBITION - A high-throughput, anchorage-independent assay is described, which screens compounds for inhibition of cancer cell growth. The assay utilizes a three-dimensional matrix or semi-solid media transfected with the subject compound, and enables live colony growth determination and imaging. | 02-04-2010 |
| 20100028864 | REAGENTS AND METHODS FOR DETECTING NEISSERIA GONORRHOEAE - This invention provides compositions and methods for detecting | 02-04-2010 |
| 20100028865 | Method for Identifying Regulatory T Cells - The present invention relates to methods and kits for identifying, quantifying and isolating regulatory T cells, to methods and kits for diagnosing or monitoring autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer, cancer treatment and/or organ transplantation based on regulatory T cell quantity, to methods and kits for predicting responses to therapy for autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer and/or organ transplantation based on regulatory T cell quantity, and to methods and kits for therapy using isolated regulatory T cells. | 02-04-2010 |
| 20100028866 | DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL MARKER Nato3 - The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of a Nato3 gene, or a complementary sequence thereto, and an antibody against a Nato3 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell. | 02-04-2010 |
| 20100028867 | LRRTM1 Compositions and Methods of Their Use for the Diagnosis and Treatment of Cancer - Microarray analysis, confirmed by RT-PCR, demonstrated that mRNA from certain cancer tissues, for example, ovarian cancer tissue, pancreatic cancer tissue, and colorectal cancer tissue, hybridizes specifically and preferentially to LRRTM1. LRRTM1 is a leucine-rich repeat transmembrane protein overexpressed on the surface of cancer cells compared to normal tissues and thus provides a therapeutic target for treating cancer. Modulators of LRRTM1, highly expressed in cancerous as compared to normal tissues, are provided for the diagnosis and treatment of proliferative disorders such as cancer. The invention further provides methods of treating cancer with therapeutic agents directed toward LRRTM1. | 02-04-2010 |
| 20100028868 | Responsiveness to Therapy for Liver Disorders - Sets of nucleic acids and methods for predicting a subject's responsiveness to therapy for liver disorders. | 02-04-2010 |
| 20100028869 | METHOD TO ASSESS SUSCEPTIBILITY TO ANDROGENIC ALOPECIA - The present invention relates to a method to assess the susceptibility to androgenetic alopecia comprising detecting the presence of polymorphisms in the EDA2R gene. | 02-04-2010 |
| 20100028870 | DESIGN OF SYNTHETIC NUCLEIC ACIDS FOR EXPRESSION OF ENCODED PROTEINS - Methods for determining a property that affects expression of polynucleotides are provided. A plurality of polynucleotides each encoding a polypeptide sequence is constructed. A frequency that a sequence element is used in a first polynucleotide is different than in a second polynucleotide. Each polynucleotide is expressed in an expression system to obtain an expression property value thereby constructing a dataset that contains, for each respective polynucleotide, sequence element occurrence in the respective polynucleotide and the measured expression property value of the respective polynucleotide. A model is computed that describes variation in the measured expression property values as a function of a plurality of variables and weights. From the model, a property that affects expression of polynucleotides in the expression system is determined, where the property is an effect that the frequency of occurrence of one or more sequence elements has on the expression property of polynucleotides in the expression system. | 02-04-2010 |
| 20100028871 | Light-inducible and rhythmically expressed genes and method for screening substances that affect an internal clock system - A method for screening a substance that affect an internal clock system in an organism, comprising the detection of the expression level of a gene exhibiting a light-inducible and rhythmic expression in a circadian manner, which is typically expressed in the suprachiasmatic nucleus of mammalian, such as for example, Dusp4, Snk, Slc39a6 or Nnat. | 02-04-2010 |
| 20100028872 | Methods for the Detection of Cancer - Methods, compositions, and kits for the detection of cancer, particularly renal cancer, are provided. | 02-04-2010 |
| 20100028873 | METHODS AND MEANS FOR NUCLEIC ACID SEQUENCING - The present invention provides a nucleic acid sequencing method. The method comprises enriching a nucleic acid sample for target nucleic acids, where the nucleic acid sample is enriched through at least a first round of hybridization selection and amplification, and a second round of hybridization selection and amplification. The enriched nucleic acids are in a form convenient for sequencing with the Cantaloupe sequencing technology, which employs shotgun sequencing by hybridization (SBH) of immobilized rolling circle amplicons. | 02-04-2010 |
| 20100028874 | HEPATITIS C VIRUS INFECTION BIOMARKERS - A signature set of genes associated with hepatitis C virus infection is described. | 02-04-2010 |
| 20100028875 | METHOD FOR DIAGNOSING CANCER BY DETECTING THE METHYLATION OF TRANSITIONAL ZONES - The present invention relates to a method for diagnosing cancer and predicting metastasis or prognosis by measuring the methylation of transitional zones and a primer for detecting the methylation. According to the present invention, a novel transitional zone is understood and a primer for detecting the methylation of the zone is provided, indicating that the present invention contributes to increase accuracy and liability of cancer prediction by measuring the methylation of transitional zones and chromosomal loss at the same time. | 02-04-2010 |
| 20100028876 | DIAGNOSTIC TESTS USING GENE EXPRESSION RATIOS - The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from cell or tissue samples, such as cancer cell or tissue samples. The invention also provides sets of genes that are expressed differentially in normal and cancer lung cells and tissues. These sets of genes can be used to discriminate between normal and malignant cells or tissues, and between classes of malignant cells or tissues. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumour progression/regression also are provided. | 02-04-2010 |
| 20100028877 | MOLECULE FOR PROVIDING A STANDARD FOR THE QUANTITATIVE ANALYSIS OF THE METHYLATIONS STATUS OF A NUCLEIC ACID - The invention refers to a nucleic acid for providing a standard in the quantitative bisulfite based analysis of the methylation status of a DNA molecule with a given sequence, wherein the given sequence comprises at least one CpG position that is to be analyzed for its methylation status. This nucleic acid comprises: a first and a second sequence portion, both of which comprise at least part of the given sequence with at least one CpG position, wherein in the first sequence portion, all of the CpG positions represent the methylated status, and in the second sequence portion, all of the CpG positions represent the unmethylated status. | 02-04-2010 |
| 20100028878 | Modulators of UDP-glucose ceramide glucosyltransferase for treating acne or hyperkeratinization - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of UDP-glucose ceramide glucosyltransferase (UGCG), and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperkeratinization; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 02-04-2010 |
| 20100028879 | Modulators of HSD17b7 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of hydroxysteroid (17-beta) dehydrogenase type 7, and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or in vitro prognosis of these pathologies are also described. | 02-04-2010 |
| 20100028880 | METHOD FOR SUSTAINED EXPRESSION OF AN EXOGENOUS GENE - A method for sustained expression of an exogenous gene forms a circular episomal plasmid to solve the problem of transient expression of baculovirus in the transduced mammalian cells caused by the dilution and degradation when mammalian cells replicate and also prevents dysfunctional cell metabolism. | 02-04-2010 |
| 20100028881 | EXTRACELLULAR AND MEMBRANE-ASSOCIATED PROSTATE CANCER MARKERS - This document relates to methods and materials involved in identifying, assessing, and monitoring prostate cancer in male mammals. For example, this document provides arrays for detecting polypeptides or nucleic acids that can be used to identify prostate cancer in male mammals. In addition, methods and materials for assessing and monitoring prostate cancer in mammals are provided herein. | 02-04-2010 |
| 20100028882 | METHODS FOR DIAGNOSING OSTEOARTHRITIS - Methods are disclosed for assessing risk of developing osteoarthritis. Said methods comprise determining the cellular localizations, blood or synovial fluid concentrations, sumoylation states and post-translational modifications of pituitary homeobox transcription factor 1 (pitx-1) repressor proteins, identifying mutations in genes which encode said proteins and identifying any mutations or post-translational modifications causing the nuclear accumulation or retention of said proteins. Said proteins include prohibitin (PHB-I), prohibitone (PHB-2) and B cell lymphoma-6 transcriptional repressor interacting co-repressor (BCoR). | 02-04-2010 |
| 20100028883 | METHOD FOR EVALUATION OF TISSUE PRESERVATION SOLUTION - The present invention provides a method for evaluating preservative effect of a tissue preservation solution, comprising immersing a mammalian tissue introduced with a luminescence or fluorescence labeling gene in the tissue preservation solution, measuring a luminescence or fluorescence level by the labeling gene in the tissue after immersion, and evaluating the preservative effect of the tissue preservation solution based on the luminescence or fluorescence level. | 02-04-2010 |
| 20100028884 | Detection of penicillin tolerance in group B streptococcus: single nucleotide polymorphisms in penicillin binding protein 4 - Disclosed are methods of detecting penicillin tolerance in Group B | 02-04-2010 |
| 20100028885 | Labelled nucleotides - Nucleosides and nucleotides are disclosed that are linked to detectable labels via a cleavable linker group. | 02-04-2010 |
| 20100028886 | METHODS OF DETERMINING PROPERTIES OF MOLECULES - This disclosure features, inter alia, methods for determining at least one property of a nucleic acid. The methods include: (a) fixing the nucleic acid on a planar surface; (b) digesting the nucleic acid into fragments with at least one enzyme; (c) imaging the nucleic acid; and (d) analyzing the imaged nucleic acid to determine the property of the nucleic acid, wherein no internal nucleic acid standard is added during the method. | 02-04-2010 |
| 20100028887 | METHOD, KIT AND SYSTEM FOR COLLECTING AND PROCESSING SAMPLES FOR DNA AND RNA DETECTION - This invention relates to a method, kit and system for collecting and processing of samples to release and treat DNA and RNA for gene sequence detection. The method described here in provides for rapid and convenient release, and recovery of DNA and RNA from tissues and cellular materials. | 02-04-2010 |
| 20100028888 | METHODS FOR PRODUCING A PAIRED TAG FROM A NUCLEIC ACID SEQUENCE AND METHODS OF USE THEREOF - Methods for producing a paired tag from a nucleic acid sequence are provided in which the paired tag comprises the 5′ end tag and 3′ end tag of the nucleic acid sequence. In one embodiment, the nucleic acid sequence comprises two restriction endonuclease recognition sites specific for a restriction endonuclease that cleaves the nucleic acid sequence distally to the restriction endonuclease recognition sites. In another embodiment, the nucleic acid sequence further comprises restriction endonuclease recognition sites specific for a rare cutting restriction endonuclease. Methods of using paired tags are also provided. In one embodiment, paired tags are used to characterize a nucleic acid sequence. In a particular embodiment, the nucleic acid sequence is a genome. In one embodiment, the characterization of a nucleic acid sequence is karyotyping. Alternatively, in another embodiment, the characterization of a nucleic acid sequence is mapping of the sequence. In a further embodiment, a method is provided for identifying nucleic acid sequences that encode at least two interacting proteins. | 02-04-2010 |
| 20100028889 | COMPANION DIAGNOSTIC ASSAYS FOR CANCER THERAPY - Methods for identifying cancer patients eligible to receive Bcl-2 family inhibitor therapy and for monitoring patient response to Bcl-2 family inhibitor therapy comprise assessment of the expression levels of the biomarker combinations set out in TABLES 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 in a patient tissue sample. The methods of the invention allow more effective identification of patients to receive Bcl-2 family inhibitor therapy and of determination of patient response to the therapy. | 02-04-2010 |
| 20100028890 | COMPOSITIONS, METHODS, AND KITS FOR ANALYZING DNA METHYLATION - Compositions, methods, and kits for reducing strand amplification bias using bisulfite treated gDNA are provided. Methods for detecting and for quantitating the amplified bisulfite treated gDNA and inferring the presence, absence, and/or degree of methylation of target cytosine(s) in the gDNA are also provided. Such methods typically employ tailed first primer pairs, which can, but need not comprise nucleotide analogs, and optionally second primer pairs. | 02-04-2010 |
| 20100028891 | METHOD FOR DETERMINING THE SENSITIVITY OR RESISTANCE OF RETROVIRUS ISOLATES TO MOLECULES, THERAPEUTIC RETROVIRAL TREATMENTS BASED ON VIRAL PROTEASE INHIBITORS AND DIAGNOSTIC KITS - A method of determining sensitivity or resistance of isolates of HIV retroviruses to a molecule includes a) amplifying sequences coding for a protease of a retrovirus to be studied, with or without the or some of amino acid sequences situated upstream and downstream of a cleavage site of a precursor in which the amino acid sequences are situated, b) recombining fragments of DNA, a final product of the amplification, and an expression vector allowing expression of sequence coding for the protease of the retrovirus to be studied under control of a known inducible promoter through co-transformation of the vector and the DNA fragments with at least one yeast cell, c) culturing co-transformed yeast cell or cells to obtain a sufficient number of transformants to perform a sensitivity or resistance test, and recovering transformants issuing from the co-transformed cell, on any suitable medium, d) incubating the transformants in the presence of a molecule to be tested, e) qualitatively or quantitatively analyzing the living cells, and f) deducing the sensitivity or resistance phenotype. | 02-04-2010 |
| 20100028892 | YEAST BASED EXPRESSION OF PROTEASES AND METHODS OF USE - This disclosure generally relates to components and methods of using a high throughput screening (HTS) systems for intracellular proteases, using Caspases as a prototype. Genetic systems are disclosed for monitoring exogenous caspase activation pathways in the yeast, | 02-04-2010 |
| 20100028893 | METHODS AND COMPOSITIONS FOR PHARMACOGENETIC ANALYSIS OF ANTI-INFLAMMATORY DRUGS IN THE TREATMENT OF RHEUMATOID ARTHRITIS AND OTHER INFLAMMATORY DISEASES - The invention provides methods and compositions for the pharmacogenetic analysis of anti-inflammatory compounds, especially for the pharmacogenetic association of responsiveness to rheumatoid arthritis medications that target TNFα. | 02-04-2010 |
| 20100028894 | Photographic Determination of Analytes - The present invention refers to a detection method for analytes using the principle of black-and-white photography and to reagent kits for performing the method, furthermore applied this new technology to detect a biologically relevant sequence in the nanomolar range (femtomoles) in an application circumventing the necessity of a PCR. There are still numerous ways to optimize this methodology that is suitable for a large variety of applications in the genomic diagnostics and proteomics areas. | 02-04-2010 |
| 20100028895 | METHOD FOR DETERMINING THE STABILITY OF ORGANIC METHYLENEAMINES IN THE PRESENCE OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE - The present invention provides methods for determining the stability of methyleneamine, methyleneamine-like compounds or compounds containing an methyleneamine moiety in the presence of semicarbazide-sensitive amine oxidase (SSAO) or a biological sample containing SSAO activity. The disclosed methods may be configured in an assay format for high throughput screening applications. | 02-04-2010 |
| 20100028896 | ROTARY EXTRACTION CONTAINER AND METHOD OF IDENTIFYING CELL SPECIES, METHOD OF DETECTING GENE, AND AUTOMATIC NUCLEIC ACID EXTRACTOR USING THE SAME - Disclosed is a rotary extraction container enabling to safely and simply perform extraction and separation of a target substance from a sample containing plural substances. Specifically, there is disclosed a rotary extraction container enabling to simply perform extraction and separation of a nucleic acid from a biological sample or from a bio-derived sample without any risk of infection, contamination or the like, which has conventionally required cumbersome operations and a large, expensive apparatus. Further, there is disclosed a method of identifying a cell species a method of detecting a gene and an automatic nucleic acid extractor using the same. The foregoing rotary extraction container, which is a rotary extraction container to extract a target substance from a sample comprises a cylindrical container section, a rotating section and a cover section, and a solution or solid contained in any one of the small chambers of the cylindrical container section is allowed to transfer to another of the small chambers by an operation including rotation of the rotating section and the target substance is extracted from the sample by such an operation including the transfer. | 02-04-2010 |
| 20100028897 | APPARATUS AND METHOD FOR EXAMINING BIOPOLYMER - A biopolymer examining apparatus includes a capsule-forming unit configured to form a capsule by sealing a target biopolymer and a reagent with a capsule film, a transferring unit configured to transfer the capsule, an amplification reaction unit configured to amplify the target biopolymer while having the target biopolymer enclosed in the capsule, and a detecting unit configured to detect the amplified target biopolymer while having the target biopolymer enclosed in the capsule. | 02-04-2010 |
| 20100028898 | METHOD OF IDENTIFYING A TARGET ANALYTE USING PHOTONIC CRYSTAL RESONATORS, AND RELATED DEVICE - A method of identifying target analytes in a sample, particularly a biological sample, comprising the steps of putting a plurality of target analytes, bound to a common luminescent marker, in contact with a plurality of molecular probes immobilized on a support, each of said molecular probes being capable of complementary binding to a respective target analyte, if said target analyte is present in the sample, providing to said support an excitation radiation and detecting an emission radiation coming from said support as a result of at least one complementary binding event, characterized by the fact that:
| 02-04-2010 |
| 20100028899 | CELL CYCLE PHASE MARKERS - The present invention relates to polypeptide and nucleic acids constructs which are useful for determining the cell cycle status of a mammalian cell. Host cells transfected with these nucleic acid constructs can be used to determine the effects that test agents have upon the mammalian cell cycle. | 02-04-2010 |
| 20100028900 | SCREENING METHODS AND SEQUENCES RELATING THERETO - Disclosed are screening methods and sequences related thereto. Disclosed are methods for detecting mutations in the MYH gene of an individual. Also disclosed are methods of genotyping and methods of predicting for an individual the likelihood of developing certain cancers, such as colorectal cancer. | 02-04-2010 |
| 20100035238 | Anti-freeze protein enhanced nucleic acid amplification - Methods and compositions are provided for enhanced signal intensity and storage stability of standard nucleic acid amplification buffers, real-time PCR buffers or both. Buffers in accordance with the present invention include anti-freeze protein(s) (AFPs), optionally with a carrier protein, such as BSA. | 02-11-2010 |
| 20100035239 | Compositions for use in identification of bacteria - The present invention provides oligonucleotide primers and compositions and kits containing the same for rapid identification of bacteria by amplification of a segment of bacterial nucleic acid followed by molecular mass analysis. | 02-11-2010 |
| 20100035240 | METHODS AND KIT FOR THE PROGNOSIS OF BREAST CANCER - The present invention relates to a method and kit, including parts thereof, for the prognosis of breast cancer. In particular, the method involves identifying a gene expression pattern, or molecular signature, that indicates the likelihood of survival of a patient with breast cancer, and/or likelihood of recurrence of the disease in a patient being treated, or having been treated, for breast cancer, and the likelihood of a patient having a metastatic form of cancer. Six molecular signatures, comprising twelve groups/sets of molecular markers have been identified, which have relevance in determining the prognosis of a given breast cancer. Each molecular signature comprises a plurality of genetic markers whose expression, either high or low in respect of normal tissue, is indicative of a given outcome, such as survival or recurrence. | 02-11-2010 |
| 20100035241 | Isolation Of Allergen-Specific Immunoglobulin Genes From Human B-Cells From Atopy Sufferers - A process is disclosed which enables the establishing of comprehensive immunoglobulin-specific reaction profiles of subjects with disorders of the immune function by the individual V gene repertoire of Ig-expressing B cells. The process comprises the isolation of B cells from body fluids, the isolation of individual B cells and their genetic material, the amplification of nucleic acids coding the variable regions of an antibody expressed by a B cell, the recombinant preparation of antibodies by expressing the amplificates, and the determination of the binding | 02-11-2010 |
| 20100035242 | Methods and nucleic acids for the detection of metastasis of colon cell proliferative disorders - The invention provides methods, nucleic acids and kits for detecting metastasis of colon cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of metastasis of colon cell proliferative disorders, thereby enabling the improved diagnosis and treatment of patients. | 02-11-2010 |
| 20100035243 | Ultra-sensitive detection of analytes - The present invention relates to screening methods, compositions, and kits for detecting for the presence or absence of one or more target analytes, e.g. biomolecules, in a sample. In particular, the present invention relates to methods that utilize nanoparticle probes in an in-solution homogeneous assay system for high-sensitivity detection of target proteins or nucleic acids based on flow analysis of single particles. | 02-11-2010 |
| 20100035244 | Diagnostic for lung disorders using class prediction - The present invention provides methods for diagnosis and prognosis of lung cancer using expression analysis of one or more groups of genes, and a combination of expression analysis with bronchoscopy. The methods of the invention provide far superior detection accuracy for lung cancer when compared to any other currently available method for lung cancer diagnostic or prognosis. The invention also provides methods of diagnosis and prognosis of other lung diseases, particularly in individuals who are exposed to air pollutants, such as cigarette or cigar smoke, smog, asbestos and the like air contaminants or pollutants. | 02-11-2010 |
| 20100035245 | Analyte test system using non-enzymatic analyte recognition elements - An analyte test element for the qualitative and/or quantitative determination of at least one analyte in a physiological or aqueous sample fluid having a first surface ( | 02-11-2010 |
| 20100035246 | Methods and Kits for Analyzing Genetic Material of a Fetus - A non-invasive method of analyzing a genetic material of a fetus is provided. The method is achieved by detecting a cell-free nucleus in a sample such as a transcervical specimen obtained from a pregnant woman and/or detecting in a cell-free nucleus at least one fetal-nucleus specific marker thereby identifying a fetal nucleus; and molecularly analyzing the genetic material in the fetal nucleus, thereby analyzing the genetic material of the fetus. | 02-11-2010 |
| 20100035247 | Heterogeneous Assay of Analytes in Solution Using Polymers - The invention relates to methods and systems for identifying, quantitating and/or analyzing analytes from samples. The analytes may be organic or inorganic in nature and include but are not limited to pathogens such as viruses. | 02-11-2010 |
| 20100035248 | SURFACE-BASED NUCLEIC ACID ASSAYS EMPLOYING MORPHOLINOS - The sequence determination, detection, and quantification of nucleic acid molecules through sequence-specific binding (hybridization) on a solid support, specifically when Morpholinos are used as the surface-immobilized probe species in surface-based nucleic acid assays, and the assays as disclosed herein. | 02-11-2010 |
| 20100035249 | RNA SEQUENCING AND ANALYSIS USING SOLID SUPPORT - The present invention provides methods for the sequencing of all RNA species within an RNA sample, such as the RNA content obtained from a cell, a tissue, a living organism, or from an artificial source. RNA molecules within the samples are labeled in a RNA-specific manner prior to immobilization on a solid support. One label is used to mark the location of the RNA molecule on the solid support, whereas the second label is used to mark selectively the S′ end of full-length mRNA molecules. RNA molecules are sequenced while being bound to the solid support in one or more sequencing reactions, and sequences of individual RNA molecules can be forwarded to computational analysis for assembling sequence information from individual sequencing reads obtained from the same location on the solid support. Not only unsupervised expression profiling on a genome-wide scale, but also the direct analysis of RNA-RNA interactions become possible as revealed by the analysis of the sequencing information obtained along with genomic information. | 02-11-2010 |
| 20100035250 | USE OF PHENANTHRIDIUM DERIVATIVES FOR DISTINGUISHING BETWEEN INTACT AND MEMBRANE COMPROMISED CELLS USING MOLECULAR NUCLEIC ACID-BASED TECHNIQUES - The present invention provides novel chemicals and methods for selectively excluding DNA of dead cells from a mixture containing live and dead cells from molecular detection. | 02-11-2010 |
| 20100035251 | BioMarkers for the Progression of Alzheimer's Disease - The genetic polymorphism LRRK2 (leucine-rich repeat kinase 2)-T1602S is significantly associated with conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD), with the patients with TT genotype being at greater risk to progress to Alzheimer's disease. The LRRK2-T2352 also showed a trend for conversion to Alzheimer's disease, with the patients with CC genotype tending to progress to Alzheimer's disease. Similar to the APOE-E4 allele, in the presence of a BuChE-K variant, LRRK2-T1602S and LRRK2-T2352 showed a greater association with the rate of conversion from mild cognitive impairment to Alzheimer's disease. In another study with placebo-treated Alzheimer's disease patients, LRRK2-T1602S and LRRK2-T2352 showed a same trend of association. The Alzheimer's disease patients with TT genotype of LRRK2-T1602S or CC genotype of LRRK2-T2352 tended to decline faster on cognitive performance over 6 months, especially in the presence of a BuChE-K variant. The association between the two common LRRK2 polymorphisms and Alzheimer's disease progression shows that LRRK2 may play a role in Alzheimer's disease pathogenesis, especially disease progression, and that polymorphisms of LRRK2 can be used as biomrkers of this progression. | 02-11-2010 |
| 20100035252 | Methods for sequencing individual nucleic acids under tension - The invention provides apparatuses and methods of use thereof for sequencing nucleic acids subjected to a force, and thus considered under tension. The methods may employ but are not dependent upon incorporation of extrinsically detectably labeled nucleotides. | 02-11-2010 |
| 20100035253 | Methods And Compositions For Incorporating Nucleotides - The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses. | 02-11-2010 |
| 20100035254 | COMPOSITION AND METHOD FOR NUCLEIC ACID SEQUENCING - The present invention provides compositions and methods for detecting incorporation of a labeled nucleotide triphosphate onto the growing end of a primer nucleic acid molecule. The method is used, for example, to genotype and sequence a nucleic acid. In a preferred embodiment, the method described herein detects individual NTP molecules. | 02-11-2010 |
| 20100035255 | METHOD AND KIT FOR ASSESSING RISK OF GOUT AND HYPERURICEMIA - A method for assessing a risk of suffering from a gout of a subject is provided. The method includes steps of obtaining a nucleotide sample from the subject; determining a genetic polymorphism of one of a Urate transporter 1 (URAT1) gene and an alpha-kinase 1 (ALPK1) gene in the nucleotide sample, wherein the genetic polymorphism is associated with an occurrence of the gout; and comparing the genetic polymorphism with a predetermined genetic polymorphism so as to assess the risk of suffering from the gout of the subject. | 02-11-2010 |
| 20100035256 | ENDURACIDIN BIOSYNTHETIC GENE CLUSTER FROM STREPTOMYCES FUNGICIDICUS - This disclosure describes the molecular cloning of an enduracidin biosynthetic gene cluster from | 02-11-2010 |
| 20100035257 | METHODS TO DETERMINE THE RESPONSIVENESS TO CISPLATIN TREATMENT - The present invention relates, generally, to methods to identity subjects responsive to p73/p63 targeting agents such as platinum-based chemotherapy agents such as, but not limited to, cisplatin and cisplatin derivatives and analogues thereof. More particularly, the present invention relates to methods to identify a cancer responsive to a p73/p63 targeting treatment, such as chemotherapeutic agents such as cisplatin, by determining if the cancer expresses and/or has the activity of p63 isoforms such as DNp63 isoforms, and expresses and/or has the activity of p73 isoforms such as TAp73 or DNp73 isoforms. The present invention also relates to methods to identify a cancer unresponsive to a p73/p63 targeting treatment, such as chemotherapeutic agents such as cisplatin by determining if the cancer lacks the expression and/or activity of p63 isoforms such as DNp63 isoforms. The invention further provides kits to determine the expression and/or activity of p63 isoforms such as DNp63 isoforms, and/or the expression and/or activity of p73 isoforms such as TAp73 and/or DNp73 isoforms in a biological sample. | 02-11-2010 |
| 20100035258 | ASSAY AND METHOD - The present invention relates to a method and assay useful for determining the sensitivity of the cells of a subject to genetic damage from electromagnetic radiation. The assay may comprise a substrate suitable for mounting a sample of lymphocytes from a subject and an electromagnetic radiation source. | 02-11-2010 |
| 20100035259 | BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 MODULATORS - VEGFR-2 biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an VEGFR-2 modulator, wherein the method comprises (a) exposing the mammal to the VEGFR-2 modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the VEGFR-2 modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a VEGFR-2 modulator indicates that the mammal has responded therapeutically to the method of treating cancer | 02-11-2010 |
| 20100035260 | Compositions, devices, systems, for using a Nanopore - The invention herein disclosed provides for devices and methods that can detect and control an individual polymer in a mixture is acted upon by another compound, for example, an enzyme, in a nanopore in the absence of requiring a terminating nucleotide. The devices and methods are also used to determine rapidly (˜>50 Hz) the nucleotide base sequence of a polynucleotide under feedback control or using signals generated by the interactions between the polynucleotide and the nanopore. The invention is of particular use in the fields of drug discovery, molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof. | 02-11-2010 |
| 20100035261 | METHOD OF DETECTING LARGE GENOMIC REARRANGEMENTS - A method for detecting large genomic rearrangements is disclosed, which is particularly useful in detecting deletions and duplications in the large genes such as BRCA1, BRCA2, MLH1 and MSH2. | 02-11-2010 |
| 20100035262 | METHOD FOR DETECTING THYROID CARCINOMA - It is an object of the present invention to identify a gene that exhibits behavior which is characteristic of carcinomas such as thyroid carcinoma, so as to provide a method for detecting carcinoma and a cell growth suppressing agent. The present invention provides a method for detecting carcinoma, which comprises detecting malignant transformation by detecting at least one alteration of gene existing in chromosomal regions 1q41, 3q28, 7q31.2, 8p12, 8q22.2, 8q24.21, 11q4.1, 17q12, 20q11, 9p21.3, 16q13.2, and 16q23.1 in a specimen. | 02-11-2010 |
| 20100035263 | BIOMARKERS FOR RENAL DISEASE - The invention provides methods and kits for diagnosing a renal disease in a patient or for predicting the risk of a patient for developing a renal disease. In one embodiment, the invention provides a method for diagnosing a renal disease in a patient, comprising determining the level of a ubiquitin fragment having a mass-to-charge ratio (m/z) of 6188 (ubiquitin m/z 6188), or the level of a nucleic acid encoding ubiquitin m/z 6188, in a sample derived from said patient, wherein the substantial absence or a reduced level of less than 25% of ubiquitin m/z 6188 or the nucleic acid encoding ubiquitin m/z 6188 compared to a control is indicative of the renal disease in said patient. | 02-11-2010 |
| 20100035264 | METHODS AND VECTORS FOR PRODUCING TRANSGENIC PLANTS - Methods of, and compositions for, assembling one or more transcription units in a genome without a linked selectable marker or other unwanted transcription unit are provided. Also provided methods of, and compositions for, assembling one or more transcription units in a genome with a reduced frequency of vector backbone. | 02-11-2010 |
| 20100035265 | Biomarkers for Drug-Induced Liver Injury - The present invention provides a method for predicting the risk of a patient for developing adverse drug reactions, particularly Drug-Induced Liver Injury (DILI) or hepatotoxicity. The invention also provides a method of identifying a subject afflicted with, or at risk of, developing DILI. In some aspects, the methods comprise analyzing at least one genetic marker, wherein the presence of the at least one genetic marker indicates that the subject is afflicted with, or at risk of, developing DILI. | 02-11-2010 |
| 20100035266 | Methods for Assessing Risk of Alzheimer's Disease in a Patient - Disclosed are methods for diagnosis or prognosis of Alzheimer's disease in a patient. The methods may include assessing whether a patient has Alzheimer's disease or assessing a patient's risk for developing Alzheimer's disease. The methods typically include determining, either directly or indirectly, whether the patient has mutations, such as single nucleotide polymorphisms, in a plurality of genes that encode gene products that function in steroid biosynthesis. | 02-11-2010 |
| 20100035267 | Detection of Individual T-Cell Reaction Patterns Against Tumor-Associated Antigens (TAA) in Tumor Patients as a Basis for the Individual Therapeutic Vaccination of Patients - The present invention relates to a method for identifying the preferential target antigens of antitumoural T-cells of a tumour patient, comprising: a) providing T-cells from the blood of at least one tumour patient, b) providing dendritic cell (DCs) and/or B-lymphocytes (BLCs) that are autologous for said tumour patient, wherein said DCs and BLCs were transfected beforehand with a selection of mRNAs encoding for T-cell-immunogenic tumour-associated antigens (TAA), and express these, c) contacting said T-cells with the DCs and/or BLCs, d) identifying of those T-cells that recognize antigens of the DCs and/or BLCs, and e) identifying of the preferential target antigens of antitumoural T-cells of the at least one tumour patient on the basis of the T-cells that recognize antigens of the DCs and/or BLCs. The method can furthermore comprise the expansion of the T-cells that recognize the antigens of the DCs and/or BLCs. The present invention furthermore relates to a method for producing an individualized tumour vaccine or individualized tumour therapeutic, as well as corresponding methods for treating a tumourous disease using the individualised tumour vaccine or individualised tumour therapeutic. | 02-11-2010 |
| 20100035268 | MATERIALS AND METHODS FOR SINGLE MOLECULE NUCLEIC ACID SEQUENCING - Provided herein are methods and compositions for real time single molecule sequencing of short nucleotide sequences using nucleotide fluorescent semiconductor nanocrystals-conjugated nucleotide primers. | 02-11-2010 |
| 20100035269 | PREVENTION AND ALLEVIATION OF STERIC HINDRANCE DURING SINGLE MOLECULE SYNTHESIS - The present invention provides compositions and methods for reducing steric hindrance in the product of nucleic acid polymerase reaction. Methods and compositions of the invention encompass application of exonucleases, endonucleases, and uracil-DNA glycosylases to a nucleic acid polymerase reaction such that newly formed nucleic acid strands are modified (e.g., cleaved) while the polymerase reaction continues to proceed. | 02-11-2010 |
| 20100035270 | Methods and Compositions for the Detection of Bovine Pregnancy - Provided herein are pregnancy specific marker genes, such as those shown in Tables I-III, and methods of detecting the same to determine bovine pregnancy. | 02-11-2010 |
| 20100035271 | Modification of Collagenous Materials and Medical Treatment, Diagnosis and Monitoring of Fibrotic Conditions - The present invention relates to the gene PLOD2 which codes for telopeptide lysyl hydroxylase (TLH). This enzyme converts telopeptidyl Lys into telopeptidyl Hyl, that can subsequently be converted into hydroxyallysine cross-links. Collagen with hydroxyallysine cross-links shows a higher resistance to degradation by proteinases than collagen with cross-links derived from allysine. | 02-11-2010 |
| 20100035272 | DETECTION OF NEGATIVELY CHARGED POLYMERS USING WATER-SOLUBLE, CATIONIC, POLYTHIOPHENE DERIVATIVES - Novel methods allowing for the simple optical and electrochemical detection of double-stranded oligonucleotides are disclosed. The methods are rapid, selective and versatile. Advantageously, they do not require any chemical reaction on the probes or on the analytes since they are based on different electrostatic interactions between cationic poly(3-alkoxy-4-methylthiophene) derivatives and single-stranded or double-stranded (hybridized) oligonucleotides. | 02-11-2010 |
| 20100041023 | Inactivated FCV vaccines - The present invention relates to improved inactivated feline calicivirus (FCV) vaccines. The invention also provides a process for producing stabilized inactivated FCV, and the use of such stabilized inactivated FCV, in the production of FCV immunogenic compositions. The invention further provides methods of inducing an immune response in an animal of the Felidae family, preferably a cat, using the immunogenic compositions according to the invention. | 02-18-2010 |
| 20100041024 | Bisulfite Conversion of DNA - The present invention relates to an improved method for the bisulfite conversion of DNA. In certain time-temperature ranges the efficacy of the bisulfite conversion is clearly improved. By combination with denaturating solvents, new reaction conditions and new purification methods the efficacy can be further increased The converted DNA can subsequently be analysed by different methods. The present invention facilitates the analysis of cytosine methylation. | 02-18-2010 |
| 20100041025 | Compositons, methods and kits for real-time nucleic acid analysis in live cells - The present invention includes compositions, methods and kits for the real-time detection of transcription and translation in live cells, tissues and organisms. The present invention further provides method for the rapid sequencing of nucleic acids without using conventional sequencing techniques or reactions. | 02-18-2010 |
| 20100041026 | Method for Identiflying Modulators of Rufy2 Useful for Treating Alzheimer's Disease - Compositions and methods for identifying modulators of RUFY2 are described. The methods are particularly useful for identifying analytes that antagonize RUFY2's effect on processing of amyloid precursor protein to Aβ peptide and thus useful for identifying analytes that can be used for treating Alzheimer disease. | 02-18-2010 |
| 20100041027 | METHODS OF ASSESSING CORONARY ARTERY DISEASE - An association between the Ala allele of the P12A variant of the human PPARγ gene and development of CAD, particularly premature CAD, in individuals, and specifically in women, particularly Caucasian women, is described, as are methods of assessing or predicting the likelihood or risk that an individual, such as a woman, will develop premature CAD. Single nucleotide polymorphisms in the human resistin gene, human resistin gene variants, gender-related increase in premature coronary artery disease, methods of assessing or aiding in assessing the risk that an individual will develop premature CAD, and methods of predicting the likelihood or aiding in predicting the likelihood that an individual will develop premature CAD are described. | 02-18-2010 |
| 20100041028 | Zinc finger binding domains for GNN - Zinc finger-nucleotide binding polypeptides having binding specificity for target nucleotides containing one or GNN triplets are provided. Compositions containing such polypeptides and the use of such polypeptides and compositions for regulating gene expression are also provided. | 02-18-2010 |
| 20100041029 | SYNTHESIS OF FOUR COLOR 3'O-ALLYL, MODIFIED PHOTOCLEAVABLE FLUORESCENT NUCLEOTIDES AND RELATED METHODS - This invention provides a process for making 3′-O-allyl-dGTP-PC-Biodopy-FL-510, 3′-O-allyl-dATP-PC-ROX, 3′-O-allyl-dCTP-PC- and 3′-O-allyl-dUTP-PC-R6G, and related methods. | 02-18-2010 |
| 20100041030 | DISPLACEMENT ASSAY FOR DETECTING NUCLEIC ACID OLIGOMER HYBRIDIZATION EVENTS - Described is a method for detecting nucleic acid oligomer hybridization events that comprises the steps providing a modified surface, the modification consisting in attaching at least one type of probe nucleic acid oligomer, providing at least one type of signal nucleic acid oligomer, the signal nucleic acid oligomers being modified with at least one detection label and the signal nucleic acid oligomers having a section that is complementary or largely complementary to the probe nucleic acid oligomers, providing a sample having target nucleic acid oligomers, bringing a defined quantity of the signal nucleic acid oligomers into contact with the modified surface, bringing the sample and the target nucleic acid oligomers contained therein into contact with the modified surface, detecting the signal nucleic acid oligomers and comparing the values obtained when detecting the signal nucleic acid oligomers with reference values. According to the present invention, the signal nucleic acid oligomers have a larger number of bases than the probe nucleic acid oligomers and exhibit at least one docking section, the docking section exhibiting no structure that is complementary or largely complementary to any section of the probe nucleic acid oligomers, and the target nucleic acid oligomers having a section that is complementary or largely complementary to the docking section. | 02-18-2010 |
| 20100041031 | Optoelectronic detection system - The invention described herein provides methods for the detection of soluble antigens. In particular, the methods provide for the detection of soluble proteins and chemicals. In addition, the invention provides methods of detecting a nucleic acid sequence in a sample. Also described is an emittor cell comprising an Fc receptor and an emittor molecule for the detection of a target particle in a sample wherein the target particle to be detected is bound by one or more antibodies. Also provided is an optoelectronic sensor device for detecting a target particle in a plurality of samples. | 02-18-2010 |
| 20100041032 | COMPOSITION AND METHODS FOR THE DETECTION OF CRIPTO-3 - The present invention is based, at least in part, on the discovery that the pseudogene TDGF3 (Cripto-3) is expressed in cells and, in particular, that TDGF3 overexpression is associated with transformation of a cell, e.g., TDGF3 is overexpressed in cancer cell lines and cells from tumor tissue. Accordingly, the invention provides compositions, kits, and methods for detecting the presence of a TDGF3 polynucleotide or polypeptide in a sample. The invention further provides compositions, kits and methods for assessing whether a cell is transformed as well as for assessing whether a patient is a suitable candidate for an anti-Cripto antibody therapy. | 02-18-2010 |
| 20100041033 | SITE SPECIFIC SYSTEM FOR GENERATING DIVERSITY PROTEIN SEQUENCES - This invention relates to the diversification of nucleic acid sequences by use of a nucleic acid molecule containing a region of sequence that acts as a template for diversification. The invention thus provides nucleic acid molecules to be diversified, as well as those which act as the template region (TR) and in concert with the TR for directional, site-specific diversification. Further provided are methods of preparing and using these nucleic acid sequences. | 02-18-2010 |
| 20100041034 | METHOD FOR MANIPULATING SAMPLES WITH MAGNETIC NUCLEATION NANOPARTICLES - A method for manipulating a sample by utilizing a nucleic acid binding substance which has affinity for nucleic acid polymers. The nucleic acid binding substance is comprised of a nucleic acid binding element capable of specific binding to nucleic acid molecules and connected to a nucleation nanoparticle having paramagnetic properties. | 02-18-2010 |
| 20100041035 | IDENTIFICATION OF CENTROMERE SEQUENCES AND USES THEREFOR - Provided herein are methods for identifying centromeres and centromeres identified by such methods. Centromeres of organisms such as algae, fungi, and protists can be used, for example, for constructing artificial chromosomes and cells containing such artificial chromosomes. | 02-18-2010 |
| 20100041036 | GENOMIC MORSE CODE - The present invention relates to a method of detection of the presence of at least one domain of interest on a macromolecule to test, wherein said method comprises the following steps: a) determining beforehand at least two target regions on the domain of interest, designing and obtaining corresponding labeled probes of each target region, named set of probe of the domain of interest, the position of these probes one compared to the others being chosen and forming the specific signature of said domain of interest on the macromolecule to test; b) after spreading of the macromolecule to test on which the probes obtained in step a) are bound, detection of the position one compared to the others of the probes bound on the linearized macromolecule, the detection of the signature of a domain of interest indicating the presence of said domain of interest on the macromolecule to test, and conversely the absence of detection of signature or part of signature of a domain of interest indicating the absence of said domain or part of said domain of interest on the macromolecule to test. | 02-18-2010 |
| 20100041037 | GENETIC VARIANTS CONTRIBUTING TO RISK OF PROSTATE CANCER - The present invention is characterised by certain genetic variants being susceptibility variants for prostate cancer. The invention relates to methods of determining increased susceptibility to prostate cancer, as well as methods of determining decreased susceptibility to prostate cancer, using such variants. The invention further relates to kits for determining a susceptibility to prostate cancer. | 02-18-2010 |
| 20100041038 | METHOD FOR DISCRIMINATING SINGLE NUCLEOTIDE POLYMORPHISMS - A method for discriminating single nucleotide polymorphisms (SNPs) offers improved sensitivity and specificity. A test kit is also provided. The method may be for genotyping in typing assays applied to a biological sample. The method may include steps of performing a real-time amplification of the target, generating multiple copies of amplicons, in presence of at least two different labeled probes, each probe allowing real-time detection at the SNP position of both the wildtype and at least one possible mutation, assessing the discriminatory variable value(s) based on the signals of each combination of two detection probes, and discriminating between the genotypes. The methods may be for diagnostic, preventive and therapeutic applications. | 02-18-2010 |
| 20100041039 | Analysis of nucleic acid obtained from nucleated red blood cells - The present invention is particularly useful for extracting DNA from nucleated RBCs. Therefore, the methods of the invention can be applied towards the genetic analysis of avians, fish, reptiles and amphibians. | 02-18-2010 |
| 20100041040 | Internally Controlled Multiplex Detection and Quantification of Microbial Nucleic Acids - The present invention relates to new methods and uses for the detection and quantification of microbial nucleic acids employing an internal quantitative reference. Preferred methods are based on the amplification of nucleic acids, preferably the polymerase chain reaction. Further provided are kits comprising components for performing said methods and uses. Moreover, an analytical system for advantageously performing the method according to the invention is disclosed. | 02-18-2010 |
| 20100041041 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING - The present invention relates generally to labeled and unlabled cleavable terminating groups and methods for DNA sequencing and other types of DNA analysis. More particularly, the invention relates in part to nucleotides and nucleosides with chemically cleavable, photocleavable, enzymatically cleavable, or non-photocleavable groups and methods for their use in DNA sequencing and its application in biomedical research. | 02-18-2010 |
| 20100041042 | BREEDING AND MILKING COWS FOR MILK FREE OF BETA-CASEIN A1 - A milk or other dairy product, capable of minimising the onset of disease such as coronary heart disease or enhancing the immune response is derived from animals which are substantially free of the β-casein A allele. Bulk milk can be produced by testing for and culling cows who test positive for the β-casein A allele, or by producing immunoglobulins and other immune response proteins, in cow's milk from animals not possessing the β-casein A | 02-18-2010 |
| 20100041043 | METHOD FOR THE DIAGNOSIS AND FOLLOW-UP OF SCHIZOPHRENIA AND OTHER MENTAL AND NEUROLOGICAL DISORDERS - A method for the diagnosis and follow up of a mental disorder or of a neurodegenerative disorder in an individual, comprises: (i) measuring mRNA of D | 02-18-2010 |
| 20100041044 | AMPLICON MELTING ANALYSIS WITH SATURATION DYES - Methods are provided for nucleic acid analysis wherein a target nucleic acid that is at least partially double stranded is mixed with a dsDNA binding dye having a percent saturation of at least 50% to form a mixture. In one embodiment, the nucleic acid is amplified in the presence of the dsDNA binding dye, and in another embodiment a melting curve is generated for the target nucleic acid by measuring fluorescence from the dsDNA binding dye as the mixture is heated. Dyes for use in nucleic acid analysis and methods for making dyes are also provided. | 02-18-2010 |
| 20100041045 | NUCLEIC ACID FLUORESCENT STAINS - The present invention provides fluorescent dye compounds and methods of using the compounds for the staining of nucleic acids including qPCR applications. In particular, the dye compounds comprise heterocyclic molecules with hydroxy alkyl and aromatic substituents, and the dye compounds form highly fluorescent complexes upon nucleic acid binding. | 02-18-2010 |
| 20100041046 | METHOD AND APPARATUS FOR THE DISCRETIZATION AND MANIPULATION OF SAMPLE VOLUMES - Embodiments of the present invention relate to methods and apparatuses for the discretization and manipulation of sample volumes that is simple, robust, and versatile. It is a fluidic device that partitions a sample by exploiting the interplay between fluidic forces, interfacial tension, channel geometry, and the final stability of the formed droplet and/or discretized volume. These compartmentalized volumes allow for isolation of samples and partitioning into a localized array that can subsequently be manipulated and analyzed. The isolation of the discretized volumes along with the device's inherent portability render our invention versatile for use in many areas, including but not limited to PCR, digital PCR, biological assays for diagnostics and prognostics, cancer diagnosis and prognosis, high throughput screening, single molecule and single cell reactions or assays, the study crystallization and other statistical processes, protein crystallization, drug screening, environmental testing, and the coupling to a wide range of analytical detection techniques for biomedical assays and measurements. The minimal fluid interconnects and simple flow geometry makes the device easy to use and implement, economical to fabricate and operate, and robust in its operations. | 02-18-2010 |
| 20100041047 | EFFICIENT REDUCTION OF TARGET RNA'S BY SINGLE- AND DOUBLE-STRANDED OLIGOMERIC COMPOUNDS - The present invention provides, inter alia, methods of selecting a single-stranded oligomeric compounds for inhibiting RNA expression, methods of generating double-stranded oligomeric compounds, methods of identifying optimized double-stranded oligomeric compounds, methods of selecting optimized single-stranded oligomeric compounds, methods of selecting optimized double-stranded oligomeric compounds, methods of identifying multifunctional oligomeric compounds, methods for optimizing target region selection for modulation of RNA expression, methods of optimizing expression modulation of RNA, and the like. The present invention further provides oligomeric compounds, 8-80 nucleobases in length targeted to a target RNA, wherein said oligomeric compound hybridizes to said target RNA and inhibits RNA levels by at least 50% in both single-stranded and double-stranded forms, and multifunctional oligomeric compounds. | 02-18-2010 |
| 20100041048 | Circulating Mutant DNA to Assess Tumor Dynamics - DNA containing somatic mutations is highly tumor specific and thus, in theory, can provide optimum markers. However, the number of circulating mutant gene fragments is small compared to the number of normal circulating DNA fragments, making it difficult to detect and quantify them with the sensitivity required for meaningful clinical use. We apply a highly sensitive approach to quantify circulating tumor DNA (ctDNA) in body samples of patients. Measurements of ctDNA can be used to reliably monitor tumor dynamics in subjects with cancer, especially those who are undergoing surgery or chemotherapy. This personalized genetic approach can be generally applied. | 02-18-2010 |
| 20100041049 | DETECTING NUCLEIC ACID - This document provides methods and materials for detecting target nucleic acid. For example, methods and materials for detecting the presence or absence of target nucleic acid, methods and materials for detecting the amount of target nucleic acid present within a sample, kits for detecting the presence or absence of target nucleic acid, kits for detecting the amount of target nucleic acid present within a sample, and methods for making such kits are provided. | 02-18-2010 |
| 20100041050 | Disposable Reactor Module and Detection System - A disposable reactor module, monitoring/optical detection system and related hardware for, inter alia, chemical reactions including Polymerase Chain Reactions. | 02-18-2010 |
| 20100041051 | Prostate Cancer Methylation Assay - An assay for diagnosing or prognosticating prostate cancer incorporates the detection of hypermethylation of SEQ ID NO 1, SEQ ID NO 3, and SEQ ID NO 2 genes and may be incorporated into a nomogram. | 02-18-2010 |
| 20100041052 | Receptor Tyrosine Kinase Assays - Methods for detecting phosphorylation of receptor tyrosine kinases (“RTKs”) upon activation are provided. The method employs cells comprising two fusion products: (1) an RTK fused to a small fragment of β-galactosidase and (2) a phosphotyrosine binding peptide fused to the large fragment of β-galactosidase, where the 2 fragments weakly complex to form an active enzyme, and optionally a construct for a cytosolic RTK phosphorylating kinase, when the RTK does not autophosphoryate. To detect phosphorylation a β-galactosidase substrate is added to the cells, whereby product formation indicates the occurrence of phosphorylation. | 02-18-2010 |
| 20100041053 | PROOFREADING PRIMER EXTENSION - The present invention provides for primer extension reactions, including polymerase chain reactions, in which a polymerase having 3′-5′ exonuclease activity edits a primer that is not fully complementary thereby allowing for amplification and detection of target nucleic acids that may have variability in their sequences. | 02-18-2010 |
| 20100041054 | METHODS FOR THE PRODUCTION OF IPS CELLS - Methods and composition of induction of pluripotent stem cells are disclosed. For example, in certain aspects methods for generating induced pluripotent stem cells using reporter genes are described. Furthermore, the invention provides novel reprogramming vectors employing reporter genes. | 02-18-2010 |
| 20100041055 | NOVEL GENE NORMALIZATION METHODS - Measurement of gene expression relative to an endogenous control gene is prone to excessive variability between samples and even replicates. The disclosure provides methods for normalizing expression levels of a gene by scaling gene expression levels to that of the most highly expressed gene in the set of genes whose expression levels are measured, rather than a house-keeping gene. | 02-18-2010 |
| 20100041056 | TEMPERATURE CONTROLLED NUCLEIC-ACID DETECTION METHOD SUITABLE FOR PRACTICE IN A CLOSED-SYSTEM - The invention relates to a method that utilizes thermophilic proteases for the treatment of nucleic acids in a closed-system to be used in tandem with methods for the rapid detection of target nucleic acids present in a sample. These combined methods enable simplified, temperature-controlled devices to be used for accurate, streamline testing at the point of care for a wide variety of applications in the medical, industrial, environmental, quality control, security and research fields. | 02-18-2010 |
| 20100041057 | DNA METHYLATION DETECTION METHODS - The present teachings provide DNA methylation quantification methods that avoid bisulfite treatment of DNA. Methylation-specific binding proteins (MeDNA binding proteins) and non-methylation specific binding proteins (non-MeDNA binding proteins) are employed in various embodiments to modulate the accessibility of nucleic acids to primer extension reactions. After selectively removing the target nucleic acids, the extension products can be analyzed and methylation quantitated. In some embodiments, the analysis comprises real-time PCR. | 02-18-2010 |
| 20100041058 | PIM-3 KINASE AS A TARGET FOR TYPE 2 DIABETES MELLITUS - The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus. | 02-18-2010 |
| 20100041059 | METHOD OF PREDICTING A BENEFIT OF ANTIOXIDANT THERAPY FOR PREVENTION OF CARDIOVASCULAR DISEASE IN HYPERGLYCEMIC PATIENTS - A method of determining a potential of a diabetic patient to benefit from anti oxidant therapy for treatment of a vascular complication, the method comprising determining a haptoglobin phenotype of the diabetic patient and thereby determining the potential of the diabetic patient to benefit from said anti oxidant therapy, whereby a patient having a haptoglobin 2-2 phenotype benefits from anti oxidant therapy more than a patient having a haptoglobin 1-2 phenotype or a patient having a haptoglobin 1-1 phenotype. | 02-18-2010 |
| 20100041060 | IRON-REGULATING PROTEIN-2(IRP-2) AS A DIAGNOSTIC FOR NEURODEGENERATIVE DISEASE - The present invention relates to the discovery of markers for neurodegenerative disease. More particularly, it was discovered that forms of IRP-2 protein that are unable to undergo oxidation at critical cysteine residues are diagnostic for neurodegenerative disease including, but not limited to Alzheimer's disease. Embodiments include nucleic acids that encode mutant IRP-2 proteins and fragments thereof, mutant IRP-2 proteins and fragments thereof, antibodies directed to epitopes present on mutant IRP-2 proteins and fragments thereof, methods of making these nucleic acids and polypeptides, as well as, approaches to diagnose neurodegenerative disease in animals, such as humans at risk of contracting Alzheimer's disease. | 02-18-2010 |
| 20100047769 | NOVEL PROTEIN HAVING AN EGF-LIKE REPEAT SEQUENCE - The present invention provides SELF protein having controlling effects on growth and differentiation of undifferentiated cells, wherein the protein contains a novel EGF-like repeat sequence, SELF gene encoding the same, a recombinant vector and a transformed cell containing the SELF gene, a method for treatment or prophylaxis with SELF protein or a recombinant expression vector containing SELF gene, SELF promoter, a recombinant vector and a transformed cell containing SELF promoter, and a screening method using the transformed cell containing SELF promoter. | 02-25-2010 |
| 20100047770 | Detection of Breast Cancer - A method for the detection of the presence or risk of cancer in a patient, comprises the steps of: (i) isolating a sample of the patient's genome; and (ii) detecting the presence or expression of the gene characterized by any of the nucleotide sequences identified as SEQ ID No 1, SEQ ID No. 10 and SEQ ID No. 13 wherein the presence or expression of the gene indicates the presence of or the risk of cancer. | 02-25-2010 |
| 20100047771 | MARKERS FOR THE DIAGNOSIS OF LUNG CANCER - Disclosed is a diagnostic marker specific for lung cancer. Also, the present invention relates to a composition and a kit, comprising an agent measuring the presence of the marker, and a method of diagnosing lung cancer using the composition or kit. | 02-25-2010 |
| 20100047772 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES CHARACTERIZED BY A-33 RELATED ANTIGENS - The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer, and nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing such antigens PRO301, PRO362 or PRO245. | 02-25-2010 |
| 20100047773 | Novel circle probes and their use in the identification of biomolecules - The present invention provides oligonucleotides and methods for efficient detection of target nucleic acids using rolling circle replication. In one aspect, the oligonucleotides of the invention are characteristic in that they can be circularised without an external ligation template. In another aspect, the oligonucleotides of the invention are characteristic in that they can generate a free 3′end of the target nucleic acid necessary for rolling circle replication. The oligonucleotides and detection methods of the invention are useful e.g. as research tool and for diagnosis. | 02-25-2010 |
| 20100047774 | CARTRIDGE, SYSTEM AND METHOD FOR AUTOMATED MEDICAL DIAGNOSTICS - Disclosed is a cartridge for the detection of the presence, absence and/or amount of a target nucleotide sequence in a sample comprising one or more nucleic acid sequences. The cartridge comprises a generic part and one or more separate application-specific parts, which are connectable to the generic part. Also disclosed is a system for the detection of the presence, absence and/or amount of a target nucleotide sequence in a sample comprising one or more nucleic acid sequences. This system comprising a reusable apparatus, wherein said apparatus is configured to receive a cartridge and to control a process for the detection of the presence, absence and/or amount of a target nucleotide sequence in the sample, being present in said cartridge. | 02-25-2010 |
| 20100047775 | Method of identifying individuals at risk of perioperative myocardial injury, major adverse cardiac events, cognitive decline, arrhythmias, depression or bleeding - The present invention relates to methods of identifying individuals at risk of perioperative myocardial injury, major adverse cardiac events, cognitive decline, arrhythmias, depression and bleeding. | 02-25-2010 |
| 20100047776 | Cell-based screening assays for compounds that regulate the expresion of a tumor marker dj-1 - The present invention generally provides compositions and methods that are useful for the treatment or prevention of a neoplasm, and screening methods that can be used to detect compounds that modulate the activity of a DJ-I gene. | 02-25-2010 |
| 20100047777 | METHODS FOR IDENTIFYING MUTATIONS IN CODING AND NON-CODING DNA - The present invention provides methods of identifying mutations in nucleic acid. Also provided herein are methods of identifying subjects having Hirschsprung disease risk and diagnostic markers for Hirschsprung disease. | 02-25-2010 |
| 20100047778 | Methylation Specific Primer Extension Assay for the Detection of Genomic Imprinting Disorders - Provided is a method for determining genomic imprinting disorders in a patient based upon methylation specific primer extension in a format amenable to high throughput and multiplex formats. After bisulfite modification of a genomic sample, DNA is amplified and hybridized to discrimination primers specific for a CpG dinucleotide site in the sample. Because no extension products from the discrimination primers are produced from DNA that has a deletion or functional inactivation at the CpG site, the sample may be diagnosed as having a genomic imprinting disorder by way of comparison with a normal sample. | 02-25-2010 |
| 20100047779 | BIOMARKERS - The present invention provides circulating biomarkers for conditions associated with metabolic syndrome, including diabetes mellitus, hypertension and congestive heart failure. The biomarkers include plasma DNA, neuron-specific enolase, 11β-hydroxysteroid dehydrogenase, rhodopsin, retinoschisin, RPE65 and cardiac troponin T. Methods and kits for detecting these biomarkers in the prediction, monitoring and diagnosing of disease are provided, particularly for determining mRNA levels thereof in a subject's blood. | 02-25-2010 |
| 20100047780 | TARGET AND METHOD FOR INHIBITION OF BACTERIAL RNA POLYMERASE - Target and method for inhibition of bacterial RNA polymerase disclosed are targets and methods for specific binding and inhibition of RNAP from bacterial species. | 02-25-2010 |
| 20100047781 | PRIMER SET FOR DETECTION OF DEKKERA YEAST OR BRETTANOMYCES YEAST - An object of the present invention is to provide a primer set for use in a LAMP method, which can accurately, rapidly and simply identify yeast species of genus | 02-25-2010 |
| 20100047782 | ASSESSMENT OF RISK FOR COLORECTAL CANCER - Disclosed is a method for identifying an individual who has an altered risk for developing colorectal cancer comprising detecting a single nucleotide polymorphism (SNP). | 02-25-2010 |
| 20100047783 | SMALL MOLECULE MODULATORS OF P53 FAMILY SIGNALING - This invention relates to methods for identifying compound capable of activating p53-responsive transcriptional activity in a p53-deficient tumor cell and the use of these compounds. | 02-25-2010 |
| 20100047784 | Method for detecting nucleic acids - Described herein are methods and compositions for detecting, amplifying and labeling targeted nucleic acids, including microRNAs. | 02-25-2010 |
| 20100047785 | Pkd mutations and evaluation of same - The present invention relates to methods of detecting novel mutations in a PKD1 and/or PKD2 gene that have been determined to be associated with autosomal dominant polycystic kidney disease (ADPKD) in order to detect or predict the occurrence of ADPKD in an individual. | 02-25-2010 |
| 20100047786 | DNA-based test for detection of annual and intermediate ryegrass - We have developed a novel TaqMan quantitative PCR (Q-PCR) based DNA test for detecting annual and/or intermediate ryegrass types in perennial ryegrass. This DNA test was designed using an insertion/deletion (InDel) site in the LpVRN2_2 gene. The new DNA test is more reliable, accurate, and cost effective in detecting annual and intermediate type contamination in perennial ryegrass, having a sensitivity of 0.04% in a sample size of 5000 seeds. Use of a higher sample size (12.5-fold higher compared to the SRF test) provides additional accuracy in detecting the level of contamination A forward and reverse set of primers also identified an approximately 450 bp fragment in or near the LpVRN1 promoter, the fragment being present for all perennial, but not annual, varieties tested. | 02-25-2010 |
| 20100047787 | PROSTATE CANCER SURVIVAL AND RECURRENCE - The disclosure includes the identification and use of gene expression profiles, or patterns, with clinical relevance to prostate cancer. In particular, the disclosure is based on the identities of genes that are correlated with patient survival and prostate cancer recurrence. The gene expression profiles may be embodied in nucleic acid expression, protein expression, or other expression formats and used to predict the survival of subjects afflicted with prostate cancer and to predict prostate cancer recurrence. The profiles may also be used in the study and/or diagnosis of prostate cancer cells and tissue as well as for the study and/or determination of prognosis of a patient. When used for diagnosis or prognosis, the profiles may be used to determine the treatment of prostate cancer based upon probable life expectancy and cancer recurrence and/or metastasis. | 02-25-2010 |
| 20100047788 | METHOD AND KIT FOR DIAGNOSIS AND MONITORING OF THE TREATMENT OF CHRONIC TRIPANOSSOMIASIS AND CHAGAS DISEASE - The present invention is related to the diagnosis and monitoring of the tripanossomiasis treatment aiming to identify the severity of the disease and to make possible the choice of a treatment with the purpose of curing of individuals, suffering from chronic disease, that were infected by the protozoa of the Trypanosomatidae family. | 02-25-2010 |
| 20100047789 | METHOD OF SURFACE PLASMON RESONANCE (SPR) TO DETECT GENOMIC DISORDERS FOR POSTNATAL DIAGNOSIS - The present invention discloses using SPR technology to postnatally detect specific DNA loss or gain related to some genomic disorders. An efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of DNA markers used for the identification of subtelomere imbalances and chromosome microdeletion syndromes is also disclosed. | 02-25-2010 |
| 20100047790 | Sample analyser - There are provided processes for analysing a plurality of different samples. The processes comprise the steps of: a) applying the samples to a support, to which an analytical component is immobilised; and b) allowing the samples to interact with the analytical component, thus permitting analysis of the samples. The samples are applied in step a) to different areas of the support to produce a spatial arrangement of samples on the support. The spatial arrangement of the samples is maintained in step b), thus permitting the results of the analysis to be matched to individual samples. | 02-25-2010 |
| 20100047791 | MOLECULAR ACCESSIBILITY ASSAY - Methods and compositions are provided for determining polypeptide-nucleic acid interactions. | 02-25-2010 |
| 20100047792 | LABEL-FREE OPTICAL DETECTION METHOD - The present provides optical sensor based sensitive, label-free binding assay methods and kits for isothermal real-time detection of the binding of specific analytes (such as nucleic acids, proteins and low molecular weight antigenic or receptor binding ligands) present in low amount in different biological samples. In the binding assays of the invention, the analyte is captured at the specifically pretreated solid surface of optical biosensors in specific recognition reactions (such as hybridization, specific protein-protein interactions and receptor-ligand interactions). The specificity of the methods of the invention is further enhanced by a second specific recognition step using a padlock probe comprising an indicator sequence designed to keep the products of a subsequently performed isothermal nucleic acid amplification method (e.g. rolling circle amplification: RCA) anchored on the sensor surface, enhancing thereby the sensitivity of the detection of the specific binding of the analyte occurred on the sensor surface. | 02-25-2010 |
| 20100047793 | METHODS TO STIMULATE BIOGENIC METHANE PRODUCTION FROM HYDROCARBON-BEARING FORMATIONS - The present invention describes methods of identifying stimulants for the biogenic production of methane in hydrocarbon-bearing formations. Methods involve the use of microbial nucleic acid sequence information for the determination of gene products that are enzymes in a variety of pathways involved in the conversion of hydrocarbons to methane. Enzymes and stimulants identified by invention methods can be used in processes for enhancing biogenic methane production, for example, by addition to coal seams and coalbed methane wells. | 02-25-2010 |
| 20100047794 | METHOD FOR DISCRIMINATING BETWEEN NUCLEOTIDE SEQUENCES OF NUCLEIC ACIDS - It is an object of the present invention to provide a method for discriminating between nucleic acid sequences with high accuracy by utilizing a method for specifically amplifying nucleic acid sequences under isothermal conditions. The present invention provides a method for discriminating between the nucleotide sequence of a first nucleic acid and the nucleotide sequence of a second nucleic acid by a nucleic acid amplification method that is performed under substantially isothermal conditions, wherein (1) at least one type of oligonucleotide (hereinafter “primer”) substantially complementary to the first nucleic acid, and (2) at least one type of oligonucleic acid (hereinafter “mask oligo”) that is designed such that it hybridizes to the nucleotide sequence portions of the first nucleic acid and the second nucleic acid to be discriminated, such that it is more complementary to the second nucleic acid than to the first nucleic acid, and such that it does not become an origin of an elongation reaction with polymerase, are used, the method being characterized in that a portion of the primer and a portion of the mask oligo hybridize to the same regions on the first nucleic acid and the second nucleic acid. | 02-25-2010 |
| 20100047795 | Promoter Variants Of The Alpha-7 Nicotinic Acetylcholine Receptor - The present invention is directed to methods and compositions related to α7 acetylcholine nicotinic receptor genes, in particular, the human α7 nicotinic acetylcholine receptor gene. The human α7 nicotinic acetylcholine receptor gene is associated with the pathophysiological aspects of the disease schizophrenia. The present invention further provides methods and compositions to screen populations for abnormal α7 alleles, as well as methods and compositions for development of therapeutics. | 02-25-2010 |
| 20100047796 | Reversible Terminator Nucleotides And Methods of Use - Disclosed herein a reversible terminator nucleotides and methods of use. | 02-25-2010 |
| 20100047797 | CYTOLETHAL DISTENDING TOXINS AND DETECTION OF CAMPYLOBACTER BACTERIA USING THE SAME AS A TARGET - The present inventors succeeded in cloning the CDT genes of | 02-25-2010 |
| 20100047798 | ADENOSINE A1 AND A3 RECEPTOR GENE SEQUENCE VARIATIONS FOR PREDICTING DISEASE OUTCOME AND TREATMENT OUTCOME - The present invention relates to methods for identify subjects for responsiveness to adenosine agonist treatment. Another aspect of the present invention relates to methods to predict a relative infarct size in response to ischemia reperfusion injury. In particular, the present invention relates to methods for to identify responsiveness to adenosine agonist treatment and/or relative infarct size by identifying a sequence differences such as mutations and/or polymorphisms in the human A1 adenosine receptor (A1-AR) gene that alters the stability of the A1-AR mRNA. Other aspect of the present invention relates to methods to identify responsiveness to adenosine agonist treatment and/or relative infarct size by identifying a sequence differences, such as mutations and/or polymorphisms in the human A3 adenosine receptor (A3-AR) gene that alters the A3-AR protein function. Other aspect of the present invention also relate to kits and assays to detect sequence differences in the human A1 adenosine receptor (A1-AR) gene and/or A3 adenosine receptor (A3-AR) gene. | 02-25-2010 |
| 20100047800 | Reagents and Methods for Detecting CYP2C9 Polymorphisms - The present invention relates to oligonucleotide sequences for amplification primers and detection probes and their use in nucleic acid amplification methods for the specific detection of clinically relevant CYP2C9 polymorphisms, in particular CYP2C9 polymorphisms associated with adverse drug response. The oligonucleotide sequences are also provided assembled as kits that can be used to predict how an individual will respond to drugs or other xenobiotic compounds that are metabolized, at least in part, by CYP2C9. | 02-25-2010 |
| 20100047801 | METHOD AND SYSTEM FOR DATA DRIVEN MANAGEMENT OF INDIVIDUAL SEEDS - A method for managing seed includes non-destructively sampling individual seeds to assist in providing evaluation data for each of the individual seeds, storing the evaluation data and seed identifiers associated with each of the individual seeds in a data store, selecting a subset of seed for planting at least partially based on the evaluation data, and planting the subset of seed. A system for management of seed on an individual seed basis includes an evaluation subsystem for evaluating individual non-destructively sampled seeds to provide evaluation data for the seeds, a selection subsystem for selecting a subset of the individual seeds at least partially based on the evaluation data, and a planting subsystem for planting the subset of individual seeds. | 02-25-2010 |
| 20100047802 | NUCLEIC ACID SYNTHESIS COMPOSITIONS AND METHODS AND SYSTEMS FOR USING SAME - The Application relates to compositions, kits, methods, and systems for nucleotide sequencing comprising producing polymerase reactions that comprise both catalytic and non-catalytic divalent metal ions. Effective ratios and amounts of catalytic and non-catalytic divalent metal ions are described. | 02-25-2010 |
| 20100047803 | BIOMARKERS FOR ACETAMINOPHEN TOXICITY - Materials and methods for evaluating cellular responses to acetaminophen and assessing susceptibility to liver damage. | 02-25-2010 |
| 20100047804 | METHODS FOR DISTINGUISHING BETWEEN LUNG SQUAMOUS CARCINOMA AND OTHER NON SMALL CELL LUNG CANCERS - The present invention provides nucleic acid sequences that are used for identification, classification and diagnosis of specific types of nonsmall-cell lung cancers (NSCLC). The nucleic acid sequences can also be used for prognosis evaluation of a subject based on the expression pattern of a biological sample. | 02-25-2010 |
| 20100047805 | Methods and compositions for targeted single-stranded cleavage and targeted integration - Disclosed herein are methods and compositions for generating a single-stranded break in a target sequence, which facilitates targeted integration of one or more exogenous sequences. | 02-25-2010 |
| 20100047806 | PROBES FOR DETECTING IMMUNE-RELATED GENE POLYMORPHISMS AND APPLICATIONS OF THE SAME - Polymorphism detection probes that can distinguish polymorphisms that have only one different base are provided. At least one oligonucleotide selected from the group consisting of the oligonucleotides of SEQ ID NOS. 4, 23, 30, 47, 57 and 64 is used as a probe in a Tm analysis. A Tm analysis using such probes allows easy detection of specific polymorphisms of the FCGR3A gene, the FCGR2A gene, the IL-10 gene, the TNF α gene and the TNF 8 gene that have an effect on the pharmaceutical effects of antibody drugs or the like. Moreover, such probes allow detection of two or more types of polymorphisms in a single reaction system by introducing two or more types of the probes concomitantly. | 02-25-2010 |
| 20100047807 | GENETIC VARIANTS ASSOCIATED WITH PERIODIC LIMB MOVEMENTS AND RESTLESS LEGS SYNDROME - The present inventions discloses genetic markers and haplotypes that have been found to be associated with risk of Restless Legs Syndrome (RLS), Periodic Limb Movement Disorder (PLMD), and Periodic Limb Movements of Sleep (PLMS). Methods for determination of susceptibility of these disorders are disclosed using such markers, as are kits useful in such determination. | 02-25-2010 |
| 20100047808 | DEVICE AND METHOD FOR EXTRACTION AND ANALYSIS OF NUCLEIC ACIDS FROM BIOLOGICAL SAMPLES - Device and methods for extracting and analyzing nucleic acids from biological samples. | 02-25-2010 |
| 20100047809 | PCA3, PCA3 GENES, AND METHODS OF USE - The present invention relates, in general, to a prostate-specific antigen, PCA3. In particular, the present invention relates to nucleic acid molecules coding for the PCA3 protein; purified PCA3 proteins and polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antibodies having binding affinity specifically to PCA3 proteins and polypeptides; hybridomas containing the antibodies; nucleic acid probes for the detection of nucleic acids encoding PCA3 proteins; a method of detecting nucleic acids encoding PCA3 proteins or polypeptides in a sample; kits containing nucleic acid probes or antibodies; bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with prostate cancer; therapeutic uses; and methods of preventing prostate cancer in an animal. | 02-25-2010 |
| 20100047810 | Compositions and Methods for Treating Diseases Associated with T-Box and N-Myc - The invention herein provides a mode of treating a disease associated with the regulation of T-Box and N-Myc gene, which includes cancers and heart disease in human and other subjects by identifying and administering a compound which modulates T-Box or N-Myc function. The invention also provides polynucleotides, polypeptides, vectors, cells, tissues and organisms useful in the identification and treatment of metabolic syndrome. A number of desirable cell proliferation and senescence regulating aspects are achieved by various embodiments of the present invention. | 02-25-2010 |
| 20100055676 | METHOD OF ASSAYING ALPHA 1, 4-N-ACETYLGLUCOSAMINE TRANSFERASE (ALPHA 4GNT) MRNA - A method for assaying α1,4-N-acetylgiucosamine transferase (α4GnT) mRNA present in a sample, the method comprising a step of using a first primer homologous to at least a portion downstream from the 5′-end of a specified nucleotide sequence of the RNA and a second primer complementary to at least a portion upstream from the 3′-end of the specified nucleotide sequence to produce double-stranded DNA containing the promoter sequence and the specified nucleotide sequence downstream from the promoter sequence, wherein at least one of the first and second primers has a promoter sequence at the 5′-end, a step of using the double-stranded DNA as template to produce an RNA transcript, a step of using the RNA transcript in turn as template for DNA synthesis to produce the double-stranded DNA, a step of nucleic acid amplification in which the aforementioned steps are repeated under conditions that simultaneously promote each of the steps, and a step of assaying the amount of the RNA transcript. | 03-04-2010 |
| 20100055677 | Method for genetic identification of unknown organisms - A method of rapid, genome and proteome based identification of unknown pathogenic or non-pathogenic organisms in a complex sample. The entire sample is analyzed by creating millions of emulsion encapsulated microdroplets, each containing a single pathogenic or non-pathogenic organism sized particle and appropriate reagents for amplification. Following amplification, the amplified product is analyzed. | 03-04-2010 |
| 20100055678 | Method of profiling a cell population - The present invention relates to a method of profiling a cell population comprising a step of detecting the presence or absence of at least two biological markers in said cell population, wherein at least one of said markers is a cell surface marker, which is a sialylated N-glycan marker with structure NeuNAcα3Gal, and at least one of said markers is a mRNA marker related to glycoproteins and/or glycosynthase proteins. The invention also relates to method for purification of cord blood cell population and to a complete cell population from cord blood purified by said method. | 03-04-2010 |
| 20100055679 | Method for the Quantitative Analysis of the Number of Copies of a Pre-Determined Sequence in a Cell - The invention relates to a method for the quantitative analysis of the number of a pre-determined sequence, and optionally of sequences homologous to the pre-determined sequence, in a biological sample, whereby a defined quantity of a biological sample is subjected to at least one amplification reaction which is adapted in such a way as to amplify at least two non-homologous sequences contained in the pre-determined sequence. The number of different amplification products obtained is then determined and compared with a frequency distribution. The invention further relates to a kit for the quantitative analysis of the number of a pre-determined sequence in a biological sample, and a device which is especially suitable for carrying out the inventive method. | 03-04-2010 |
| 20100055680 | GENOMIC DNA LABELING AND AMPLIFICATION - Methods of amplifying genomic DNA are provided which include contacting template genomic DNA, a plurality of random primers, and a DNA polymerase, wherein the ratio of template genomic DNA to random primers is in the range of about 1:10-1:35,000,000 (w/w), inclusive, to produce a reaction mixture; and incubating the reaction mixture under isothermal conditions suitable for DNA synthesis, thereby producing amplified genomic DNA characterized by less than 10 percent gene copy number error. The template genomic DNA used in described methods can be in denatured condition and/or in non-denatured condition to achieve production of amplified genomic DNA characterized by less than 10 percent gene copy number error. In a particular option, the reaction mixture includes detectably labeled nucleotides and detectably labeled amplified genomic DNA characterized by less than 10 percent gene copy number error is produced. | 03-04-2010 |
| 20100055681 | PRIMER-DIRECTED CHROMOSOME PAINTING - An oligonucleotide composition is provided. The subject composition comprises: a mixture of at least 10 of sets of oligonucleotides, wherein each of the sets of oligonucleotides comprises at least 100 different oligonucleotides of the following formula: X | 03-04-2010 |
| 20100055682 | Procedure and methods for detecting alzheimers's disease - This application concerns methods and compositions that can be used for detecting the Alzheimer disease in mammals, particularly in humans. It describes in particular serum markers for Alzheimer's disease and the way they are used for diagnostic procedures. It also concerns tools and/or kits that can be used for applying these procedures (reagents, probes, primers, antibodies, chips, cells, etc.) with the preparation thereof and the way to use them. The invention can be used to detect the presence or the progression of Alzheimer illness in mammals, including at early stages of the disease. | 03-04-2010 |
| 20100055683 | DIAGNOSIS OF PULMONARY AND/OR CARDIOVASCULAR DISEASE - Described are methods and kits for determining the likelihood of the presence of cardiovascular disease (CVD) or pulmonary disease (PD) in a subject using ST2/Interleukin 1 Receptor Like 1 (IL1RL1) and/or Interleukin 33 (IL-33), and a biomarker for CVD, e.g., a natriuretic peptide, e.g., brain natriuretic peptide (BNP), prohormone BNP (proBNP), N-Terminal proBNP (NT-proBNP), atrial natriuretic peptide (ANP), proANP, or NT-proANP. | 03-04-2010 |
| 20100055684 | COMPOSITION FOR NUCLEIC ACID TRANSFECTION - The invention provides a nucleic-acid-transfecting composition which exhibits low cytotoxicity, which facilitates an effective nucleic acid transfection into a cell, and which improves expression of the nucleic acid in the cell. | 03-04-2010 |
| 20100055685 | ISOTHERMAL DETECTION METHODS AND USES THEREOF - The present invention relates to methods and probes for rapid, single temperature (isothermal) detection of specific nucleic acid sequences. The methods and probes provide an easily automatable system for detecting bioagents including bacteria and viruses, and the detection of specific genetic markers on any nucleic sequence. | 03-04-2010 |
| 20100055686 | Methods for diagnosis of pediatric common acute lymphoblastic leukemia by determining the level of gene expression - The present invention refers to a method and a kit for diagnosing pediatric common acute leukemia by distinguishing between normal and common acute lymphoblastic leukemic (cALL) cells, wherein the method comprises the step of determining the gene expression of specific genes (markers) referring to this disease and the step of determining whether these genes are up-regulated or down-regulated. The method for determining the gene expression levels can apply hybridization techniques or PCR methods or combinations thereof. The present invention provides new gene markers, which have not been reported in context with cALL and are suitable for the diagnosis of this disease. In addition, the present invention refers to utilizing these targets for the development of targeted therapies employing RNA- and DNA-interference, antibodies, aptamers, anticalins and other small molecules. | 03-04-2010 |
| 20100055687 | Mutations in the BCR-ABL tyrosine kinase associated with resistance to ST1-571 - The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS. | 03-04-2010 |
| 20100055688 | SLIT2 CANCER MARKERS - This invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, this invention relates to SLIT2 cancer markers that are useful as diagnostic markers and clinical targets for prostate cancer. | 03-04-2010 |
| 20100055689 | MULTIFACTORIAL METHODS FOR DETECTING LUNG DISORDERS - Described herein are multifactorial methods for detecting, diagnosing or aiding in the diagnosis of lung disorders or disease, e.g., lung cancer. The methods disclosed utilize multiple diagnostic paradigms, for example, to improve diagnostic sensitivity, specificity, negative predictive value and/or positive predictive value over each of the paradigms alone. For example, a clinicogenomic model is disclosed for lung cancer diagnosis which combines clinical factors and gene expression, particularly a sensitive and specific gene expression biomarker. | 03-04-2010 |
| 20100055690 | PROGNOSTIC BIOMARKERS IN PATIENTS WITH OVARIAN CANCER - The present invention provides methods for assessing an ovarian cancer patient's survival status. Also, methods for evaluating the ovarian cancer state of a patient are described herein. These methods involve the detection, analysis, and classification of biological patterns in biological samples. The biological patterns are obtained using, for example, mass spectrometry systems and other techniques. | 03-04-2010 |
| 20100055691 | SCREENING METHOD FOR THERAPEUTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS - The objective of the present invention is to provide methods of screening therapeutic agents for juvenile familial amyotrophic lateral sclerosis (ALS2). The invention provides a method of screening therapeutic agents for juvenile familial amyotrophic lateral sclerosis, comprising a step of assessing a substance that suppresses the expression of Tollip in cells as a therapeutic agent for juvenile familial amyotrophic lateral sclerosis; a method of screening therapeutic agents for juvenile familial amyotrophic lateral sclerosis, comprising a step of assessing a substance that promotes migration of Tollip in cells from the cytoplasm to the cell nucleus as a therapeutic agent for juvenile familial amyotrophic lateral sclerosis; and a method of screening therapeutic agents for juvenile familial amyotrophic lateral sclerosis, comprising a step of assessing a substance that inhibits the interaction between Tollip and IRAK-1 in cells as a therapeutic agent for juvenile familial amyotrophic lateral sclerosis. | 03-04-2010 |
| 20100055692 | METHOD FOR SELECTION OF HOP STRAIN, BLEEDING MARKER FOR USE IN SELECTION OF HOP STRAIN, AND PRIMER SET - It is an object of the invention to screen for hop varieties with high α acid contents, as well as hop varieties with high contents of α acids, β acids, myrcene and/or xanthohumol in addition to α acids, within a short time period utilizing a molecular screening method that employs a breeding marker. The invention provides a breeding marker represented by the following (a) or (b), which is used for screening of hop varieties with high α acid contents. | 03-04-2010 |
| 20100055693 | LUCIFERASE SIGNAL ENHANCING COMPOSITIONS - Reagents and compositions for use in reactions catalysed by luciferase enzymes, and in particular for use in luciferase-based gene reporter assays are described. The invention also provides methods and compositions for, inter alia, increasing the sensitivity and/or improving the kinetics of luciferase-catalysed reactions. | 03-04-2010 |
| 20100055694 | Molecular signature representative of dysfunctions in epidermal homeostasis - The present invention concerns a method for evaluating the epidermal homeostasis of the skin of a subject, comprising differential analysis of the expression of a gene, preferably of two genes, selected from the group of genes consisting of KRT6B, KRT16, ESRRA, CBX3, MAP3K5, TRIO, PIK3CD, TCRB, PRRG2, ICP22BP, GPX3, GBA, BPGM, NID1, SMT3H2, LGALS2, DOC1, PRKCG, S100A8, S100A9, S100A2, S100A7, K15, SPRR1B and GSN in response to a physical or chemical challenge of the stratum corneum. It also concerns various methods for diagnosing the state of the epidermis of an individual and methods for detecting and screening products or procedures which can improve epidermal homeostasis. The invention also pertains to kits and arrays which can be used in these various methods and processes. | 03-04-2010 |
| 20100055695 | Method For Generating Aptamers with Improved Off-Rates - The present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. This invention relates to the field of diagnostic histology, cytology, histopathology, and cytopathology methods and reagents for the detection of various disease states. More specifically, the invention relates to the use of aptamers in histologic, cytologic, histopathic, and/or cytopathic diagnostic methods. Aptamers may be provided that react with specific target molecules contained within a histological or cytological sample. Aptamers may be used to assess localization, relative density, and presence or absence of one or more target. Targets may be selected that are specific and diagnostic of a given disease state for which the sample was collected. Aptamers may be used to introduce target specific signal moieties. Antigen retrieval methods may be applied to the sample prior to reaction with the specific aptamer/s to improve interaction of the aptamer and target within the sample. Or aptamers may be developed for the specific target that eliminates the need for the antigen retrieval process. In addition to target identification, aptamers may be used to amplify signal generation through a variety of methods. | 03-04-2010 |
| 20100055696 | DRG11-Responsive (DRAGON) Gene Family - This invention features methods and compositions useful for treating and diagnosing diseases of the nervous system, retina, skin, muscle, joint, and cartilage using a Dragon family protein. Protein and nucleic acid sequences of human, murine, zebrafish, and | 03-04-2010 |
| 20100055697 | POSITIVE SELECTION OF SERUM PROTEINS FOR PROTEOMIC ANALYSIS - This invention relates to methods and kits for positive selection of species of interest based on peptide/protein sequence from a biological sample. The species of interest may be proteins and/or peptides of interest which may be placed through a mass spectrometer to obtain a blood peptide/protein signature. The blood peptide/protein signature may be used in proteomic analysis. The techniques include but are not limited to the use of collectors comprising nucleic acid molecules to extract a composition that has a lower concentration of a high abundance species of interest from a sample. This limits the level of influence that any collectors species may have on the results of a mass spectra. | 03-04-2010 |
| 20100055698 | REACTOR FOR PERFORMING BIOCHEMICAL PROCESSES - A reactor ( | 03-04-2010 |
| 20100055699 | METHOD OF MANUFACTURING A SEMICONDUCTOR SENSOR DEVICE AND SEMICONDUCTOR SENSOR DEVICE OBTAINED WITH SUCH METHOD - The invention relates to a method of manufacturing a semiconductor sensor device ( | 03-04-2010 |
| 20100055700 | ROLE OF IL-12, IL-23 AND IL-17 RECEPTORS IN INFLAMMATORY BOWEL DISEASE - This invention provides methods of diagnosing or predicting susceptibility or protection against Inflammatory Bowel Disease in an individual by determining the presence or absence of genetic variants in the genes for IL-12, IL-23, and/or IL-17 receptors. In one embodiment, a method of the invention is practiced by determining the presence or absence of risk and/or protective haplotypes of IL-12, IL-23, and/or IL-17 receptors. | 03-04-2010 |
| 20100055701 | FUSION PROTEINS FOR IMAGING THE NUCLEUS AND CHROMOSOMES OF LIVE CELLS - Fusion proteins that fluoresce and bind DNA, as well as nucleic acid constructs encoding the same are described herein. These imaging agents function in live cells to bind DNA and are thus useful for visualizing nuclei and chromosomes to make observations of nuclear and chromosomal structure and dynamics. The imaging agents may be used in screening assays to test the activity of biological effector molecules. | 03-04-2010 |
| 20100055702 | Pathogenecity Islands of Pseudomonas Aeruginosa - Disclosed are | 03-04-2010 |
| 20100055703 | Organism-Specific Hybridizable Nucleic Acid Molecule - The present invention relates to a method for producing an organism-specific hybridizable nucleic acid molecule, a nucleic acid molecule produced by this method, a kit comprising at least any of the nucleic acid molecules, the use of a nucleotide sequence located between two elements on the genomic information of an organism for producing an organism-specific hybridizable nucleic acid molecule, and a method for detecting an organism in a biological sample. | 03-04-2010 |
| 20100055704 | EXPRESSION PROFILE OF THYROID CANCER - The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with thyroid cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of thyroid cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications. | 03-04-2010 |
| 20100055705 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER - The invention is drawn novel methods and compositions for the treatment of cancer, and for the diagnosis and prognosis of cancer in a subject. In particular aspects, the invention relates to the finding that the protein tristetraprolin (TTP) is decreased or repressed in a myriad and diversity of cancers. To this end, TTP represents a viable therapeutic option for the treatment of cancer. Additionally, TTP represents a clinically useful biomarker for the diagnosis and prognosis of cancer. | 03-04-2010 |
| 20100055706 | Screening Methods for Transfusion Related Acute Lung Injury (TRALI) - The invention relates to the discovery that HNA-3a and HNA-3b are antigens within a polypeptide sequence that is highly similar to the CTL2 amino acid sequence. This invention provides methods and kits for screening for HNA-3a and HNA-3b specific antibodies, HNA-3a and HNA-3b polypeptides and HNA-3a and HNA-3b nucleic acids in a sample of a biological tissue intended for transplantation | 03-04-2010 |
| 20100055707 | METHODS OF SCREENING FOR COMPOUNDS FOR USE AS MODULATORS OF LEFT-RIGHT ASYMMETRY IN SCOLIOTIC SUBJECTS AND FOR MONITORING EFFICACY OF AN ORTHOPAEDIC DEVICE - A method of screening for a compound for treating or preventing adolescent idiopathic scoliosis (AIS), said method comprising: (a) contacting a test compound with a paraspinal skin fibroblast or a paraspinal muscle cell sample from the right and/or left side of the spine of a subject; and (b) determining at least one of Nodal, Notch1, Pitx2, Lefty1 and Lefty2's expression and/or activity in the cell sample; wherein the test compound is selected as potentially useful in treating or preventing AIS if at least one of Nodal, Notch1, Pitx2, Lefty1 and Lefty2's expression and/or activity in the cell sample is different in the presence of the test compound as compared to in the absence thereof. | 03-04-2010 |
| 20100055708 | Assay for Chlamydia trachomatis by amplification and detection of Chlamydia trachomatis cytotoxin gene - A region of the | 03-04-2010 |
| 20100055709 | Tubulin Mutation Diagnostic - The present invention relates to methods for determining the potential of a subject to respond to a particular therapeutic agent, by determining the presence of one or more nucleotide or amino acid variants in the β-tubulin gene or protein. Also provided are methods for treating subjects whose potential to respond to a therapeutic agent has been evaluated. For use in the methods of the invention, there are provided variants of the β-tubulin gene. variants of the β-tubulin protein, nucleic acid molecules and agents which bind to the variant β-tubulin nucleic acid molecules and variant β-tubulin protein, respectively, and kits comprising the same. | 03-04-2010 |
| 20100062422 | Optical component for observing a nanometric sample, system comprising same, analysis method using same, and uses thereof - The invention concerns an optical component for observing a sample, which includes a substrate and at least one complex index layer of predetermined thickness, designed to show a high intensity or color contrast for optical path variations, reliefs, nanometric thicknesses and diameters when it is observed by incoherent light reflection convergent around the normal incidence under polarization extinction conditions. The upper index layer has specific surface properties providing it with selective affinity relative to at least one characteristic of the sample. An analysis system includes such a component, an analysis method using the component and uses of the method. | 03-11-2010 |
| 20100062423 | Fret Probes for Fluorescent Detection of the ESPS Gene - The present invention relates to a primer pair for the detection of a specific gene, and more particularly to a probe pair for the detection and analysis of an EPSPS (5-enolpyruvylshikimate-3-phosphate synthase) gene, in which primers complementary to the base sequences in the EPSPS gene are labeled with fluorophores acting as an energy donor and an energy acceptor, respectively. By introducing the inventive probe pair into cells, hybridizing the primers of the probe pair with the target gene and then analyzing the biological cells in a single cell unit using laser fluorescence measurement technique, cells containing the EPSPS gene of GMOs can be detected and the percentage of the GM cells in a cell mixture can also be quantified. | 03-11-2010 |
| 20100062424 | Assessment of Infectious Bacteria - Disclosed herein are methods for determining whether an opportunistic bacterium is infectious. | 03-11-2010 |
| 20100062425 | CAT ALLERGEN - The invention relates to a method for determining the level of Fel d1 expression in a cat, the method comprising: a) typing one or more polymorphic positions of the Fel d1 gene in a sample from the cat; and b) thereby determining the level of Fel d1 expression. | 03-11-2010 |
| 20100062426 | AGR2 and TFF3 Regulation in the Diagnosis and Treatment of Cancer - A method for assessing tumor progression is described by assessing AGR2 and/or TFF3 expression in a biological sample after induction of a physiological stress, such as hypoxia or serum deprivation in an enriched sample. Assessing the role of these indicators and their expression levels in an enriched CTC sample provides diagnostic and prognositic information on a patient. This method is also useful as a pharmatool in drug discovery. | 03-11-2010 |
| 20100062427 | METHOD FOR DETECTING DISEASE-ASSOCIATED MUTATIONS - A method is described for diagnosing individuals as having hypertrophic cardiomyopathy, e.g. familial or sporadic hypertrophic cardiomyopathy. The method provides a useful diagnostic tool which becomes particularly important when testing asymptomatic individuals suspected of having the disease. Symptomatic individuals have a much better chance of being diagnosed properly by a physician. Asymptomatic individuals from families having a history of familial hypertrophic cardiomyopathy may be selectively screened using the method of this invention allowing for a diagnosis prior to the appearance of any symptoms. Individuals having the mutation responsible for the disease may be counseled to take steps which hopefully would prolong their life, i.e. avoid rigorous exercise. The methodology used in the above method also has broad applicability and may be used to detect other disease-associated mutations in DNA obtained from subject being tested for other disease-associated mutations. | 03-11-2010 |
| 20100062428 | Methods for collecting and detecting oligonucleotides - Methods, pharmaceutical compositions, and kits are provided which includes accurately sampling a RNA from a tissue of an animal and analyzing RNA in the tissue of the animal as an indicator of physiological state, infectious disease, neoplastic disease, autoimmune disease, inflammatory disease, cardiovascular disease, atherosclerotic disease, or neurological disease in the animal. A method is provided which includes administering at least one compound to an animal wherein the at least one compound is configured to prevent the cleavage of at least one tissue RNA by a ribonuclease. The method further includes collecting a sample of at least a portion of tissue from the animal. | 03-11-2010 |
| 20100062429 | Fluorochromes for organelle tracing and multi-color imaging - Provided are compounds, methods and kits for identifying in cells of interest organelles including nuclei and a wide variety of organelles other than nuclei (non-nuclear organelles), as well as cell regions or cell domains. These compounds and methods can be used with other conventional detection reagents for identifying the location or position or quantity of organelles and even for distinguishing between organelles in cells of interest. | 03-11-2010 |
| 20100062430 | METHOD AND KIT FOR MOLECULAR CHROMOSOMAL QUANTIFICATION - Diagnosis of chromosomal abnormalities or genetic disorders is performed using at least two marker sequences, wherein one marker sequence is a sequence known to be present on the chromosome or in the gene of interest, another marker sequence is a sequence known to be present on an autosomal chromosome, and the marker sequences are partially homologous. A kit for performing this diagnosis is also claimed. | 03-11-2010 |
| 20100062431 | USE OF ADAMTS4 GENE AND PROTEIN POLYMORPHISMS - The use of the single nucleotide polymorphism (SNP) of the ADAMTS4 gene for the identification of cardiovascular and peripheral vascular disorders or of an increased risk for developing cardiovascular and peripheral vascular disorders in a biological sample taken from an individual to be examined; the use of ADAMTS4 for identifying substances active in preventing and/or treating cardiovascular and peripheral vascular disorders and methods for doing so. | 03-11-2010 |
| 20100062432 | METHOD OF DETECTING OR QUANTITATING ENDOGENOUS WHEAT DNA AND METHOD OF DETERMINING CONTAMINATION RATE OF GENETICALLY MODIFIED WHEAT IN TEST SAMPLE - An object of the present invention is to discover an endogenous wheat sequence satisfying the conditions of: a) it is universally present in varieties of wheat, b) the amount present (detected amount) is not affected depending on the wheat variety, c) even if other grains are present, only wheat can be detected without cross-reactivity, and d) it is amplified quantitatively by the PCR reaction. A further object of the present invention is to provide a method of accurately detecting and quantitating endogenous wheat DNA in a test sample by the polymerase chain reaction. The present invention provides a method of detecting or quantitating endogenous wheat DNA in a test sample by the polymerase chain reaction, the method comprising: a step of using a nucleic acid in the test sample or a nucleic acid extracted from the test sample as a template to amplify the nucleic acid of a region consisting of the base sequence identified as SEQ ID NO: 2 or a partial sequence thereof with a primer pair capable of amplifying that region; and a step of detecting or quantitating the amplified nucleic acid. | 03-11-2010 |
| 20100062433 | KIT FOR DETECTION/QUANTIFICATION OF ANALYTE, AND METHOD FOR DETECTION/QUANTIFICATION OF ANALYTE - Disclosed are a detection/quantification kit and a detection/quantification method for detecting/quantifying an analyte rapidly at a low cost and in a simple manner. Specifically, disclosed is a kit for detecting an analyte in a sample, comprising a first conjugate and a second conjugate, wherein the first conjugate comprises a first substance comprising a stimuli-responsive polymer and a first affinity substance having affinity for the analyte and bound to the first substance, and the second conjugate comprises a second substance carrying an electrical charge and a second affinity substance having affinity for the analyte and bound to the second substance. The first and second affinity substances can bind to different sites on the analyte simultaneously. | 03-11-2010 |
| 20100062434 | DETECTION OF CHROMOSOMAL INVERSIONS - A method and a kit for the identification of chromosomal inversions is described. Chromosomal inversions are difficult to detect unless they are quite large. The improved ability to detect chromosomal inversions is important to a number of medical applications, such as cancer and birth defects, as examples. Reporter species are attached to oligonucleotide strands designed such that they may hybridize to portions of only one of a pair of single-stranded sister chromatids prepared by the CO-FISH procedure, as an example. If an inversion has occurred, these marker probes will be detected on the sister chromatid at the same location as the inversion on the first chromatid. | 03-11-2010 |
| 20100062435 | Methods for Stem Cell Production and Therapy - The present invention relates to methods for rapidly expanding a stem cell population with or without culture supplements in simulated microgravity conditions. The present invention relates to methods for rapidly increasing the life span of stem cell populations without culture supplements in simulated microgravity conditions. The present invention also relates to methods for increasing the sensitivity of cancer stem cells to chemotherapeutic agents by culturing the cancer stem cells under microgravity conditions and in the presence of omega-3 fatty acids. The methods of the present invention can also be used to proliferate cancer cells by culturing them in the presence of omega-3 fatty acids. The present invention also relates to methods for testing the sensitivity of cancer cells and cancer stem cells to chemotherapeutic agents by culturing the cancer cells and cancer stem cells under microgravity conditions. The methods of the present invention can also be used to produce tissue for use in transplantation by culturing stem cells or cancer stem cells under microgravity conditions. The methods of the present invention can also be used to produce cellular factors and growth factors by culturing stem cells or cancer stem cells under microgravity conditions. The methods of the present invention can also be used to produce cellular factors and growth factors to promote differentiation of cancer stem cells under microgravity conditions. | 03-11-2010 |
| 20100062436 | Methods for Detection of a Single- or Double-Stranded Nucleic Acid Molecule - The present invention is related to a method for the detection of a nucleic acid molecule comprising at least a strand comprising a sequence of nucleotides in a sample, whereby the method comprises the following steps:
| 03-11-2010 |
| 20100062437 | PARALLEL PROFILLING OF SIGNALING PATHWAYS - Methods for identifying signaling pathways that regulate the expression of a test gene are provided. | 03-11-2010 |
| 20100062438 | NATURAL SELECTION AND CELLULAR IMMORTALITY - The invention provides new insights into the manner in which cells evolve and age thereby providing methods for assessing and studying those processes. | 03-11-2010 |
| 20100062439 | Method for Detecting Cyst Nematodes - The present invention relates to a method for determining the presence of a cyst nematode in a sample comprising the steps of : providing a pair of bidirectional oligonucleotide primers or an oligonucleotide probe that hybridizes specifically, under stringent hybridization conditions, to a nucleic acid sequence encoding the SSU rRNA or LSU rRNA, or the complement or transcript thereof, of a sub genus-cluster of nematodes, said subgenus-cluster comprising cyst nematodes belonging to at least one species of nematode, and wherein said primers or probe do not hybridize to a nucleic acid sequence encoding the LSU rRNA, or the complement or transcript thereof, of cyst nematodes not part of said subgenus-cluster of cyst nematodes; providing a sample in which the presence of the cyst nematode is to be detected, and performing a nucleic acid detection assay on said sample using said pair of bidirectional oligonucleotide primers or said oligonucleotide probe. | 03-11-2010 |
| 20100062440 | MARKERS FOR CANCER - The present invention relates to novel markers for hypermethylation of gene promoters in cancers. In particular the present invention relates to a method of determining whether a tumour is developing in the aero-digestive system, or whether a subject is relapsing after treatment of such a tumour. The method comprises determining the methylation level, the number of methylated CpG sites or the methylation state of CpG sites in a nucleic acid sequence in the promoter region, first exon or intron, of one or more genes selected from the group consisting of CNRIP1, MAL, FBN1, SPG20, SNCA, and INA. The method further relates to a diagnostic kit for detecting tumours in the aero-digestive tract. | 03-11-2010 |
| 20100062441 | C-MET MUTATIONS AND USES THEREOF - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns methods and compositions useful for diagnosing and treating human lung cancer associated with mutated c-Met. | 03-11-2010 |
| 20100062442 | CELL DETECTION - In one aspect the present invention provides a method of identifying a cell or cell colony which produces a polypeptide of interest, the method comprising exposing one or more cells to a marker compound which associates with a reference polypeptide, wherein production of the polypeptide of interest by the cells is linked to production of the reference polypeptide, and detecting association of the marker compound with the one or more cells, thereby identifying a cell or cell colony which produces the polypeptide of interest. | 03-11-2010 |
| 20100062443 | Methods for the Diagnosis and Treatment of Lung Cancer - The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition. | 03-11-2010 |
| 20100062444 | TLE3 AS A MARKER FOR CHEMOTHERAPY - Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer. | 03-11-2010 |
| 20100062445 | Chromosome 1p36 polymorphisms and low bone mineral density - The invention provides methods and compositions for diagnosing risk of low BMD and risk of osteoporosis based on the detection of SNP identity for human chromosome 1p36 polymorphisms designated in the NCBI SNP database (dbSNP) as rs2794328, rs446529, rs397559 and rs1802353. | 03-11-2010 |
| 20100062446 | REACTOR PLATE AND REACTION PROCESSING METHOD - Disclosed herein is a reactor plate which prevents the entry of foreign matter from the outside and the pollution of an outside environment. The reactor plate includes sealed reaction wells ( | 03-11-2010 |
| 20100062447 | Methods for Identifying Cancer Risk - The present invention provides methods and kits for identifying an increased risk of developing cancer in a subject. The methods include analyzing a first biological sample, such as a blood sample, from the subject for loss of imprinting of the IGF2 gene. According to the methods a loss of imprinting is indicative of an increased risk of developing cancer. The method can include analyzing genomic DNA from the sample for altered methylation of the IGF2 gene. The altered methylation for example includes hypomethylation of a differentially methylated region of IGF2, corresponding to SEQ ID NO:1 or a polymorphism thereof. The method can be performed on a subject having no apparent or suspected hyperproliferative disorder such as cancer. | 03-11-2010 |
| 20100062448 | PROTEIN KINASE C ZETA AS A DRUG TARGET FOR ARTHRITIS AND OTHER INFLAMMATORY DISEASES - The present invention is based on the discovery that ζPKC expression is increased in the tissues of arthritis patients as compared to normal individuals. Accordingly, the present invention provides methods of diagnosing, prognosing, and monitoring the course of arthritis in a patient based on increased ζPKC gene expression in arthritic tissue. The present invention further provides compounds that inhibit the expression of ζPKC for use as remedies in the treatment of arthritis, including, but not limited to, inhibitory polynucleotides and polypeptides, small molecules, and peptide inhibitors. In addition, the present invention provides pharmaceutical formulations and routes of administration for such remedies, as well as methods for assessing their efficacy. | 03-11-2010 |
| 20100068699 | Assay System For Monitoring The Effects Of Genetically Engineered Cells To Alter Function Of A Synctium - This invention provides methods for determining the ability of a gene construct to alter the rhythm and contractility of a syncytial cell. Furthermore, this invention provides methods for constructing a gene construct capable of altering the rhythm or contractility of a syncytial cell. Finally, this invention provides a method for constructing a gene construct capable of coupling to a syncytial cell. | 03-18-2010 |
| 20100068700 | Methods of using gpr 119 receptor to identify compounds useful for increasing bone mass in an individual - The present invention relates to methods of using GPR119 receptor to identify compounds useful for increasing bone mass in an individual. Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. Agonists of GPR119 receptor promote bone formation in an individual. | 03-18-2010 |
| 20100068701 | CHROMOSOME LABELING METHOD - A method of sample analysis is provided. In certain embodiments, the method may involve a) contacting a genomic sample comprising a test chromosome with a plurality of sets of labeled oligonucleotide probes under in situ hybridization conditions to produce a contacted sample having an oligonucleotide binding pattern; b) imaging the contacted sample to provide an image showing the oligonucleotide binding pattern; and c) analyzing the oligonucleotide binding pattern to identify a chromosomal rearrangement in the test chromosome relative to a reference chromosome. | 03-18-2010 |
| 20100068702 | Method for Detecting Disease-Related Marker Using Gastric Mucosal Lavage Fluid - The invention relates to a sample containing a gastric mucosa lavage fluid collected from a subject who has received a gastric mucus removal treatment and a method for detecting a disease-related marker using the same. By using the sample of the invention, the disease-related marker can be detected conveniently, less invasively, highly sensitively and highly accurately. | 03-18-2010 |
| 20100068703 | ENHANCED MEDICAL TREATMENTS RESULTING FROM CHEMICAL IDENTIFICATION OF CALCIUM INFLUX FACTOR, IDENTITY WITH THE FACTOR ACTIVATING PHOSPHOLIPOLYSIS AND PRECIPITATING SUDDEN DEATH DURING MYOCARDIAL INFARCTION, AND DETERMINATION OF SIMILAR ACTIVATING MECHANISMS IN MULTIPLE CELL TYPES THROUGH DISINHIBITION OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2BETA - A method for treating a mammal comprises administering at least one of a gene, enzyme and pharmaceutical which modulates the concentration of iPLA | 03-18-2010 |
| 20100068704 | OLIGONUCLEOTIDES COMPRISING SIGNALLING PAIRS AND HYDROPHOBIC NUCLEOTIDES, STEMLESS BEACONS, FOR DETECTION OF NUCLEIC ACIDS, METHYLATION STATUS AND MUTANTS OF NUCLEIC ACIDS - The invention relates to novel oligonucleotides comprising a signalling pair and at least hydrophobic nucleotide. The oligonucleotide analogues are useful for detecting the status of nucleic acid sequences, such as presence, expression, methylation and/or mutation, in particular single point mutations and other sequences where the variation between the correct target and other targets may vary in as little as one nucleotide. The invention also relates to new ways of detecting sequence differences and optimizing conditions by using oligonucleotide analogues and readily available instruments. In particular the invention relates to specifically detecting quantity of a target nucleic acids or detecting one sequence over others that may vary in as little as one nucleotide using oligonucleotides or oligonucleotide analogues comprising a signalling pair and at least one hydrophobic nucleotide, such as a nucleotide analogue comprising an intercalator. | 03-18-2010 |
| 20100068705 | GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE - The invention relates to methods of diagnosing susceptibility to cardiovascular disease, including coronary artery disease. MI, abdominal aorta aneurysm, intracranial aneurysm restenosis and peripheral arterial disease, by assessing the presence or absence of alleles of certain polymorphic markers found to be associates with cardiovascular disease. The invention further relates to kits encompassing reagents for assessing such markers, and methods for assessing the probability of response to therapeutic agents and methods using such markers. | 03-18-2010 |
| 20100068706 | METHOD FOR SEPARATING AN ANALYTE FROM A SAMPLE - An analyte is separated from a fluid sample by introducing the sample into a cartridge having a sample port and a first flow path extending from the sample port. The first flow path includes an extraction chamber containing a solid support for capturing the analyte from the sample. The cartridge has a second flow path for eluting the captured analyte from the extraction chamber, the second flow diverging from the first flow path after passing through the extraction chamber. The sample is forced to flow through the extraction chamber and into a waste chamber, thereby capturing the analyte with the solid support as the sample flows through the extraction chamber. The captured analyte is then eluted from the extraction chamber by forcing an elution fluid to flow through the extraction chamber and along the second flow path. | 03-18-2010 |
| 20100068707 | METHOD FOR SCREENING FOR VITAMIN D RECEPTOR LIGANDS - The present invention relates to a screening method for a compound and includes a step of detecting binding between a vitamin D receptor and CDP. A novel method enabling screening in vitro of a compound having strong bone forming action and low side effects, a compound participating in osteoblast differentiation and selected by the method of screening, a therapeutic agent containing the compound for diseases intervening in the increase in vitamin D-mediated transcriptional activity by a complex of a vitamin D receptor and CDP, and a kit for performing the screening method are provided. | 03-18-2010 |
| 20100068708 | Methods for Identifying Compounds that Modulate WNT Signaling in Cancer Cells - Provided herein are methods for screening compounds for their ability to modulate Wnt signaling in cancer cells. | 03-18-2010 |
| 20100068709 | METHOD FOR DETERMINING A TONGUE CANCER - An object is to provide: a method for determining a tongue cancer in which the malignancy of tongue cancer can be objectively and accurately determined; a method for analyzing a tongue cancer tissue specimen; and a kit for analyzing a tongue cancer tissue specimen. There is provided: a method for determining a tongue cancer, comprising measuring mRNA quantity of an integrin family gene and a reference gene in the tongue cancer tissue specimen, and determining the malignancy of the tongue cancer based on a ratio of the mRNA quantity of the integrin family gene/the mRNA quantity of the reference gene; a method for analyzing a tongue cancer tissue specimen, comprising the steps of measuring mRNA quantity of an integrin family gene and a reference gene in the tongue cancer tissue specimen, and correlating a ratio of the mRNA quantity of the integrin family gene/the mRNA quantity of the reference gene with clinical data; and a kit for analyzing a tongue cancer tissue specimen. | 03-18-2010 |
| 20100068710 | METHODS AND PRODUCTS FOR IN VITRO GENOTYPING - An in vitro method for genotyping genetic variations in an individual, and products for use in the method. | 03-18-2010 |
| 20100068711 | Methods of PCR-Based Detection of "Ultra Short" Nucleic Acid Sequences - The present invention provides highly sensitive methods used for diagnosing and monitoring various diseases and disorders by detecting and analyzing “ultra short” (20-50 base pair) nucleic acids obtained from bodily fluids. | 03-18-2010 |
| 20100068712 | OLIGONUCLEOTIDES FOR USE IN ALLELE-SPECIFIC PCR - The present invention relates to oligonucleotides complementary to a target polynucleotide, wherein the oligonucleotide comprises an LNA unit, a mismatch nucleobase, and an allele-specific nucleobase corresponding to an allele of the target polynucleotide. The invention further includes methods of using such oligonucleotides to detect and quantitate the frequency of particular alleles of a target polynucleotide. | 03-18-2010 |
| 20100068713 | PROBE FOR DETECTING MUTATION IN JAK2 GENE AND USE THEREOF - A probe for detecting a mutation in the JAK2 gene is provided that can detect a target sequence containing a mutation even when the target sequence containing the mutation and a non-target sequence containing no mutation coexist, which are different only in a single base from each other. The probe to be used is an oligonucleotide that is at least one oligonucleotide having a sequence identical to that of a region extending from a cytosine base (C) at position 84 to be considered as the first base to any one of the 17th to 22nd bases in the direction toward the 5′ end in exon 12 of the JAK2 gene consisting of the base sequence of SEQ ID NO: 1, with the cytosine base (C) being the 3′ end. Even in the case of a sample containing both the JAK2 genes with a mutation that has occurred and without a mutation that has occurred, the use of such a probe in, for example, Tm analysis allows the former mutation to be detected. Preferably, the probe is labeled with a fluorescent dye. | 03-18-2010 |
| 20100068714 | MULTIVARIATE DETECTION OF MOLECULES IN BIOSSAY - The invention relates to detection of target molecules in an assay, such as a bio-assay, and in particular to multi-variate detection of target molecules. A detector system is disclosed, the detection system comprising an optical guide element ( | 03-18-2010 |
| 20100068715 | MARKER GENES FOR USE IN THE IDENTIFICATION OF CHONDROCYTE PHENOTYPIC STABILITY AND IN THE SCREENING OF FACTORS INFLUENCING CARTILAGE PRODUCTION - The present invention relates to a set of genes which can be used to predict the potential of a cell population to form cartilage when implanted in vivo. The set of markers is used inter alia as a quality control of cells and in screening assays to evaluate the impact of compounds and conditions on the cartilage forming ability of cells. | 03-18-2010 |
| 20100068716 | DISPOSABLE ARTICLES FOR ANALYSIS AND DIAGNOSTICS FOR A LABORATORY - The invention relates to disposable articles for a laboratory and in particular to prepared reaction vessels for conducting the polymerase chain reaction for analytical and diagnostic purposes. The invention further relates to a method for the stable storage and drying of minute amounts of oligonucleotides and reference nucleic acids in reaction vessels. The oligonucleotides and the nucleic acids are dried on the wall of the reaction vessel in the presence of 1 to 5 mM trehalose, without any further components. | 03-18-2010 |
| 20100068717 | CANCER THERAPY PROGNOSIS - Methods and compositions based on FOXA1 expression to predict long-term disease-free survival in patients with breast cancer are disclosed. In ER+ positive patients, expression of FOXA1 is useful in identifying a subgroup of patients with a better prognosis. FOXA1 expression correlates with luminal subtype breast cancer, and serves as a clinical marker for luminal subtype breast cancer. Expression of FOXA1 is useful as a prognostic marker for an effective response tumors and as a predictive marker for a greater likelihood of response to an anti-hormonal therapy. Prognostic ability of FOXA1 in low-risk breast cancers is useful in treatment decision making. | 03-18-2010 |
| 20100068718 | Methods and Compositions for Identifying Yeast - The invention relates to a method of identifying a specific yeast species in patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the yeast species from the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the yeast species, and specifically identifying the yeast species. The invention also relates to a method of identifying a yeast mycotoxin in patient tissue or body fluid. The method comprises the steps of extracting and recovering the yeast mycotoxin from the patient tissue or body fluid, contacting the yeast mycotoxin with an antibody directed against the yeast mycotoxin, and identifying the yeast myocotoxin. Both of these methods can be used to determine if a patient is at risk for or has developed a disease state related to a yeast infection, and to develop an effective treatment regimen for the patient. | 03-18-2010 |
| 20100068719 | Cell culture system for determinging the sensitizing, allergenic and/or irritating effect of a substance - The present invention refers to a cell culture system especially for investigating the sensitizing, allergenic and/or irritating effect of substances, comprising a first and a second compartment that can communicate with each other via a permeable interlayer, whereby the first compartment has an epidermis model and the second a cell culture based on immune cells. | 03-18-2010 |
| 20100068720 | Method and kit for detection of early cancer or pre-cancer using blood and body fluids - This invention is related to a method for the detection of early or pre-cancer using DNA isolated from blood and body fluids. This invention provides an improved methylation-based PCR assay, a panel of methylated-based cancer-related gene markers for the detection of general cancer and a panel of unmethylation-based tissue- or cell-specific gene markers for discriminating different type of cancer detected from blood samples. This method couples a sequential cancer-related gene marker detection and tissue or cell-specific gene marker assay and is particularly useful as a simultaneous screening test for following type of cancer: lung, breast, ovarian, colon, stomach, prostatic, pancreatic and liver cancer. | 03-18-2010 |
| 20100068721 | Method and system for protection and cross protection of algae and cyanobacteria from virus an bacteriophage infections - Virus contaminations of bioreactors can cause considerable losses in the industry and prevention of such contaminations is usually a major concern, especially in continuous cultures and particularly in outdoor/uncovered operations such as ponds or “racing ponds”. Use of transgenic algae/cyanobacteria harboring introgressed virus/phage DNA fragments, cultured in these bioreactors/ponds will provide protection to a range of viruses/phages. Molecular mechanisms such as lysogeny and post transcriptional gene silencing (PTGS) are being exploited to produce protected algae/cyanobacteria with cross protective resistance against various viruses/phage, thus gaining bioreactor stability. | 03-18-2010 |
| 20100068722 | Modified nucleosides and nucleotides and uses thereof - The invention is directed to modified guanine-containing nucleosides and nucleotides and uses thereof. More specifically, the invention relates to modified fluorescently labelled guanine-containing nucleosides and nucleotides which exhibit enhanced fluorophore intensity by virtue of reduced quenching effects. | 03-18-2010 |
| 20100068723 | MICROFLUIDIC DEVICES - Methods and devices for the interfacing of microchips to various types of modules are disclosed. The technology disclosed can be used as sample preparation and analysis systems for various applications, such asDNA sequencing and genotyping, proteomics, pathogen detection, diagnostics and biodefense. | 03-18-2010 |
| 20100075302 | Assays for Resistance to Echinocandin-Class Drugs - Nucleic acid amplification assays for mutations to two short sections of the fungal gene FKS1. Mutations in these target sequences have been shown to correlate with resistance to echinocandin-class drugs. Assays may include detection by sequencing or by labeled hybridization probes. Also, primers, probes and reagent kits for performing such assays. | 03-25-2010 |
| 20100075303 | METHODS FOR TARGETTED MUTAGENESIS IN GRAM-POSITIVE BACTERIA - The present invention provides a method of targeted mutagenesis in Gram-positive bacteria. In particular, the present invention provides a method that effectively integrates a suicide integrative vector into a target gene in the chromosome of a Gram-positive bacterium, resulting in inactivation of the target gene. | 03-25-2010 |
| 20100075304 | PROCESS FOR MONITORING COLORECTAL CANCER - Disclosed in this specification is a method for determining the stage of colorectal cancer by observing regulatory changes in select miRNA sequences. These sequences may include hsa-miR-31, hsa-miR-7, hsa-miR-99b, hsa-miR-378*, hsa-miR-133a, hsa-miR-125a and combinations of these sequences. | 03-25-2010 |
| 20100075305 | Detection of bacterium by utilizing dnaj gene and use thereof - Disclosed is a method for detecting the species of a bacterium in a simple manner. Specifically disclosed is a method for detecting the species of a bacterium, which can detect at least one bacterial species selected from | 03-25-2010 |
| 20100075306 | METHOD FOR DIAGNOSIS OF AND FOLLOWING A BACTERIAL VAGINOSIS BY MOLECULAR QUANTIFICATION - The present invention relates to a method for in vitro diagnosis and follow-up of vaginal bacterial flora status in relation to the presence of bacterial vaginosis, and for monitoring its treatment where applicable, wherein the presence of bacterial vaginosis or failure of on-going treatment is determined if the concentrations of specific sequences present in a single copy in the DNA of the bacteria | 03-25-2010 |
| 20100075307 | ANALYTE DETECTION ASSAYS - The present invention provides methods, kits and compositions for the detection of an analyte. In the methods of the invention, a binding molecule coupled to a first polymerase is incubated with a modified polynucleotide template to form a copy of the modified polynucleotide template without any modified nucleotides. The unmodified copy is detected in a second amplification/primer extension reaction using a second polymerase that is unable to amplify the modified polynucleotide template. Detection of the unmodified copy is indicative of the presence and/or amount of the analyte in the sample. In place of the binding molecule coupled to a first polymerase, a pair of analyte-specific probes can also be used. The first analyte specific probe comprises a first binding moiety and a first portion of a first polymerase and the second analyte specific probe comprises a second binding moiety and a second portion of the first polymerase. When the binding moieties are bound to the analyte the first and second portions of the polymerase interact to form a functional polymerase complex that is used to form a copy of the modified polynucleotide template without any modified nucleotides. | 03-25-2010 |
| 20100075308 | POLYMORPHISMS IN GENES AFFECTING CNS DISORDERS AND USES THEREOF - Diagnostic and prognostic methods, compositions, assays, and kits useful for predicting the phenotype of subjects who have, or are at risk of developing, a mental disorder. The methods also include predicting the prognostic outcome of a subject's mental disorder as well as the subject's responsiveness to drug treatments for the mental disorder. The methods and kits include determining the allelic status of polymorphisms in the MAOA, TPH2 and DRD2 genes. | 03-25-2010 |
| 20100075309 | INTERMITTENT DETECTION DURING ANALYTICAL REACTIONS - Methods, devices, and systems for performing intermittent detection during analytical reactions are provided. Such methods facilitate collection of reaction data from disparate reaction times. Further, such methods are useful for reducing photo-induced damage of one or more reactants in an illuminated analytical reaction at a given reaction time. In preferred embodiments, the reaction mixture is subjected to at least one illuminated and non-illuminated period and allowed to proceed such that the time in which the reaction mixture is illuminated is less than a photo-induced damage threshold period. | 03-25-2010 |
| 20100075310 | Methods for Microorganism Detection and Identification - Methods for detecting and identifying microorganisms in a biologic sample are provided. The methods utilize identifying rRNA from microorganisms to both show the presence and identity for the majority of infectious agents present in clinical samples. The methods are preferably adapted for use in a clinical setting. | 03-25-2010 |
| 20100075311 | CARTRIDGE SYSTEM - A cartridge system includes a reagent component for storing one or more reagents and a processing component for processing the one or more reagents in an assay. The reagent component and the processing component are configured to be coupled together to form a cartridge. The reagent component and/or the processing component include at least one compartment configured to accept waste from the assay. The reagent component does not take part in processing the reagents in the assay, except to accept waste from the processing component. In one aspect, the cartridge system further includes a sensing component with at least one sensing element for detecting an analyte. In another aspect, the cartridge system further includes a sample preparation component for preparing a sample for the assay. | 03-25-2010 |
| 20100075312 | QPCR ANALYSIS APPARATUS - An apparatus ( | 03-25-2010 |
| 20100075313 | DEVICE FOR THE LYSIS OF MICROORGANISMS PRESENT IN AN ENVIRONMENTAL OR CLINICAL SAMPLE AND THE EXTRACTION OF NUCLEIC ACIDS FROM SAID MICROORGANISMS FOR ANALYSIS - The present invention relates to a cartridge which can be positioned inside an air collection means and receive a means for recovering nucleic acids, said cartridge being substantially cylindrical and comprising a microorganism retaining zone, said retaining zone comprising microorganism lysis means. The invention also relates to a device for collecting microorganisms contained in the air and a device for microorganism lysis. | 03-25-2010 |
| 20100075314 | CHEMICALLY-MODIFIED GOLD NANOPARTICLES AND METHODS FOR USE IN DETECTING TARGET MOLECULES - The invention provides stable bioconjugate-nanoparticle probes which are useful for detecting nucleic acids and other target analytes, e.g., proteins, and methods of preparing those probes. | 03-25-2010 |
| 20100075315 | Microvesicle-Based Compositions and Methods - Methods and compositions for diagnosis and/or analysis of a condition in a mammal are disclosed in which RNA from microvesicles is enriched and differentiated to so obtain a result that is indicative of the condition of tissue or organ from which the microvesicle originated. In especially preferred embodiments, the condition is a neoplastic disease of a human and can be identified and staged by differential analysis of one or more distinct RNAs, optionally together with identification and analysis of a non-RNA component of the microvesicle. | 03-25-2010 |
| 20100075316 | METHOD FOR IDENTIFYING ALTERED VITAMIN D METABOLISM - A method is provided for identifying an individual as having altered vitamin D metabolism comprising analyzing a biological sample from the individual for the presence of CYP24 SNPs and/or aberrantly spliced CYP24 mRNA. The presence of the SNPs and/or the aberrantly spliced CYP24 mRNA indicates that the individual has altered vitamin D metabolism. Also provided are methods for customizing dosages of biologically active vitamin D compounds for individuals who are determined to have altered vitamin D metabolism. | 03-25-2010 |
| 20100075317 | Airborne Particulate Sampler - An airborne particulate sampling device is disclosed. The device includes a conduit whose interior allows the flow of air through the device. The conduit, or at least its surface, is a conductor. The device also includes an electrode with a sharp tip or edge on or near the output side of the conduit. An electrically conducting particle collector outside the conduit is positioned so that a surface is perpendicular or approximately perpendicular to the axis of the funnel. A fan or other blower forces air through the funnel. A power supply imparts an electrostatic potential difference between the electrode, on the one hand, and the holder and particle collector, on the other hand. The electrostatic potential difference produces a corona field in the air in the vicinity of the electrode's sharp tip. The corona field imparts a charge to airborne particles. The combined effect of the air flow, electrostatic repulsion from the funnel and electrode, and electrostatic attraction toward the particle collector causes the airborne particles to move toward and then to adhere to the particle collector. | 03-25-2010 |
| 20100075318 | METHOD OF DETERMINING THE HAPLOTYPE OF MULTIPLE ALLELIC GENES - In amplifying a region containing two allelic genes, the polymorphism of one of the allelic genes is positioned at or near the 3′ end of an amplification primer, so that the chain would extend only from one of the two primers, one that matches the mutant type nucleotide(s) and one that matches the wild-type nucleotide(s). The other primer is unaffected by the allelic genes but is positioned to include the other allelic gene in the amplicon. The PCR amplifies only the target genomic DNA having one specific allele of the first allelic gene. The technique exploits the fact that the haplotype of the first and the second allelic genes can be determined if the allele of the second allelic gene in the amplicon can be identified. Designing probes with complementary sequences for identifying the two alleles (major and minor) of the second allelic gene, and fixing the probe set on a solid support and hybridizing them with the amplicon to identify the probe that forms a hybrid, are characteristic features of the present invention. | 03-25-2010 |
| 20100075319 | Blocking Agents Comprising Non-Natural Nucleic Acids and Detection Methods Using such Blocking Agents - This invention relates to nucleic acid analog blocking agents that may reduce nonspecific interactions between components of a biological or chemical detection assay. The blocking agents may help to reduce the background observed in biological or chemical detection assays, such as in situ assays and blots, and may thus enhance the signal to noise in the assays. The invention also encompasses sets of nucleic acid analog segments, for instance, made from PNA and/or non-natural bases, which may act as blocking agents and/or detection reagents, reagent kits containing those sets, and related methods of detection. In some embodiments, the blocking agents are designed such that they block one or more sets of complementary strands of nucleic acids on a detection reagent or in a sample, but do not hybridize to each other. In some embodiments, the blocking agents may block genomic repeat sequences such as one or more of Alu repeats, Kpn repeats, di-nucleotide repeats, tri-nucleotide repeats, penta-nucleotide repeats, and hexa-nucleotide repeats. | 03-25-2010 |
| 20100075320 | PAXILLIN MUTATIONS, METHODS OF ASSESSING RISK OF METASTASIS AND METHODS OF STAGING TUMORS - Disclosed herein are methods for assessing risk of metastasis of a tumor in a mammal by determining the paxillin gene copy number per cell in the tumor or by detecting the presence of a paxillin mutation in the tumor. The presence of an increased paxillin gene copy number or a paxillin mutation is indicative of an increased risk of metastasis. Methods of staging tumors and methods of reducing invasiveness or metastasis of a cancer cell are also provided. Oligonucleotides comprising a paxillin mutation and antibodies capable of recognizing a paxillin mutant are disclosed. | 03-25-2010 |
| 20100075321 | LABELED COMPOUND AND DETECTION METHOD USING THE SAME - A labeled compound is so designed that an aromatic tertiary amine compound is bondable with a biomolecule. One of S | 03-25-2010 |
| 20100075322 | Methods and Compositions for Identifying Mycotoxins and Fungal Species - The invention relates to a method of testing for a mycotoxin in patient tissue or body fluid and testing for a fungal species in the patient tissue or body fluid. The method can also be used to determine if a patient is at risk for or has developed a disease state related to a fungal infection, and to develop an effective treatment regimen for the patient. | 03-25-2010 |
| 20100075323 | MOLECULAR MARKERS FOR LUNG AND COLORECTAL CARCINOMAS - Molecular markers for lung and colorectal carcinomas and methods of using them in blood sample assays are disclosed. The method comprises measuring the expression of the markers in a blood sample from a subject for detecting the presence and/or severity of lung and/or colorectal cancer, and for monitoring and/or assessing the prognosis of the subject's response to a cancer therapy. Also disclosed are kits for detecting, diagnosing, and/or monitoring lung or colorectal carcinomas. | 03-25-2010 |
| 20100075324 | PROCESSES FOR DETECTING TOXIC SUBSTANCES - Biology-based processes for detecting toxic substances are provided. The processes comprise detecting mRNA that is expressed in the presence of toxic substances by a cell comprising a yeast gene as followed, or a gene that is homologous to the yeast genes and is derived from other species, wherein the mRNA corresponds to said yeast gene or said homologous gene thereof | 03-25-2010 |
| 20100075325 | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER - The invention relates to nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided. | 03-25-2010 |
| 20100075326 | YEAST SURFACE TWO-HYBRID SYSTEM FOR QUANTITATIVE DETECTION OF PROTEIN-PROTEIN INTERACTIONS - The present invention provides methods and related vectors and host cells for quantitative analysis of protein interactions in eukaryotic expression system. More specifically, the invention provides a yeast surface two-hybrid (YS2H) system that can express a pair of proteins, one protein (“bait”) as a fusion to a yeast cell wall protein, and the other (“prey”) in a secretory form. When two proteins interact in this system, they associate in the secretory pathway, and the prey that would otherwise be released into the media is captured on the cell surface by the bait. Expression of the bait and the prey proteins can be designed to promote a synchronized and comparable level of expression. The affinity of two interacting molecules can be quantitatively determined by two exemplary schemes: either flow cytometric detection of antibody binding to the epitope tags fused to the prey and the bait, or the readout from a protein-fragment complementation assay (“PCA”) such as complementation of split GFP fragments fused to the prey and the bait. | 03-25-2010 |
| 20100075327 | INTERMITTENT DETECTION DURING ANALYTICAL REACTIONS - Methods, devices, and systems for performing intermittent detection during analytical reactions are provided. Such methods facilitate collection of reaction data from disparate reaction times. Further, such methods are useful for reducing photo-induced damage of one or more reactants in an illuminated analytical reaction at a given reaction time. In preferred embodiments, the reaction mixture is subjected to at least one illuminated and non-illuminated period and allowed to proceed such that the time in which the reaction mixture is illuminated is less than a photo-induced damage threshold period. | 03-25-2010 |
| 20100075328 | IMMOBILIZED NUCLEIC ACID COMPLEXES FOR SEQUENCE ANALYSIS - Provided are methods for sequencing a nucleic acid that include fixing a template to a surface through a template localizing moiety and sequencing the nucleic acid with a sequencing enzyme, e.g. a polymerase or exonuclease. The sequencing enzyme can optionally be exchanged with a second sequencing enzyme, which continues the sequencing of the nucleic acid. The template localizing moiety can optionally anneal with the nucleic acid and/or associate with the sequencing enzyme. Also provided are compositions comprising a nucleic acid fixed to a surface via a template localizing moiety, and a first sequencing enzyme, which can sequence the nucleic acid and optionally exchange with a second sequencing enzyme present in the composition. Compositions in which a template localizing moiety is immobilized on a surface are provided. Compositions for sequencing reactions are provided. Also provided are sequencing systems comprising reaction regions in which or near which template localizing moieties are immobilized. | 03-25-2010 |
| 20100075329 | METHODS FOR PREDICTING PRODUCTION OF ACTIVATING SIGNALS BY CROSS-LINKED BINDING PROTEINS - The present invention provides human binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL21R), and uses therefore. The invention further provides methods to predict whether the binding proteins of the invention may take on agonistic activities in vivo and produce a cytokine storm. In addition, the invention provides methods for determining whether an anti-IL21R binding protein is a neutralizing anti-IL21R binding protein, based on the identification of several IL21-responsive genes. The binding proteins can act as, e.g., antagonists of IL21R activity, thereby modulating immune responses in general, and those mediated by IL21R in particular. | 03-25-2010 |
| 20100075330 | APPARATUS AND METHODS FOR PARALLEL PROCESSING OF MICRO-VOLUME LIQUID REACTIONS - Disclosed herein are apparatuses and methods for conducting multiple simultaneous micro-volume chemical and biochemical reactions in an array format. In one embodiment, the format comprises an array of microholes in a substrate. Besides serving as an ordered array of sample chambers allowing the performance of multiple parallel reactions, the arrays can be used for reagent storage and transfer, library display, reagent synthesis, assembly of multiple identical reactions, dilution and desalting. Use of the arrays facilitates optical analysis of reactions, and allows optical analysis to be conducted in real time. Included within the invention are kits comprising a microhole apparatus and a reaction component of the method(s) to be carried out in the apparatus. | 03-25-2010 |
| 20100075331 | CpG island sequencing - The present invention is directed to a method for analyzing the methylation status of a genomic DNA sample, comprising the steps of (i) fragmenting said sample and enriching said sample for sequences comprising CpG islands, (ii) generating a single stranded DNA library, (iii) subjecting said sample to Bisulfite treatment, (iv) clonally amplifying individual members of said single stranded DNA library by means of emulsion PCR, and (v) sequencing said amplified clonally amplified single stranded DNA library. | 03-25-2010 |
| 20100075332 | Engineering polymerases and reaction conditions for modified incorporation properties - Provided are methods for enhanced sequencing of nucleic acid templates. Also provided are reaction conditions that increase branching fractions during polymerization reactions. Also provided are compositions comprising modified recombinant polymerases that exhibit branching fractions that are higher than the branching fractions of the polymerases from which they were derived. Provided are compositions comprising modified recombinant polymerases that exhibit delayed translocation relative to the polymerases from which they were derived. Also provided are compositions comprising modified recombinant polymerases that exhibit increased nucleotide or nucleotide analog residence time at an active site of the polymerase. Provided are methods for generating polymerases with the aforementioned phenotypes and methods of using such polymerases to sequence a DNA template or make a DNA. Also provided are methods and nucleic acid sequencing systems for determining which labeled nucleotide is incorporated at a site during a template-dependent polymerization reaction. | 03-25-2010 |
| 20100075333 | METHOD OF DETERMINING THE RISK OF SCOLIOSIS - A method for determining the risk for developing a scoliosis comprising monitoring osteopontin (OPN) expression in a sample from a subject over time; wherein an OPN expression that increases in the subject sample over time is indicative that the subject is at risk for developing a scoliosis. | 03-25-2010 |
| 20100075334 | METHYLATION BIOMARKER FOR EARLY DETECTION OF GASTRIC CANCER - The present application describes a method of diagnosing gastric cancer or a stage in the progression of the cancer in a subject comprising assaying for loss of expression of a marker gene such as POPDC3, CCDC67, LRRC3B, PRKD1, CYP1B1, LIMS2, DCBLD2, LOC149351, ADCY8, BACH2, ALOX5, TCF4, CXXC4, CAMK2N2, EMX1, KCNK9, NCAM2, AMPD3, NOG, SP6, LOC100128675, or CHSY3, or a combination thereof. | 03-25-2010 |
| 20100075335 | COLORIMETRIC METHOD AND KIT FOR THE DETECTION OF SPECIFIC NUCLEIC ACID SEQUENCES USING METAL NANOPARTICLES FUNCTIONALIZED WITH MODIFIED OLIGONUCLEOTIDES - The present invention relates to a colorimetric method for the detection of specific nucleic acids sequences, including mutations or single nucleotide polymorphisms within nucleic acid sequences, through the aggregation of nanoparticles functionalized with modified oligonucleotides, induced by an increase of the medium's ionic strength. Another aspect of the present invention relates with the development of a kit based on the method of the present invention, allowing for a quick and easy detection of specific nucleic acids sequences, including mutations or single nucleotide polymorphisms within nucleic acid sequences. | 03-25-2010 |
| 20100075336 | SYSTEM FOR PERFORMING MULTI-FORMATTED ASSAYS - An automated analyzer for performing multiple diagnostic assays simultaneously includes multiple stations in which discrete aspects of the assay are performed on fluid samples contained in sample vessels. The analyzer includes stations for automatically preparing a sample, incubating the sample, preforming an analyte isolation procedure, ascertaining the presence of a target analyte, and analyzing the amount of a target analyte. An automated receptacle transporting system moves the sample vessels from one station to the next. A method for performing an automated diagnostic assay includes an automated process for isolating and amplifying a target analyte, and, in one embodiment, a method for real-time monitoring of the amplification process. | 03-25-2010 |
| 20100081128 | Self-assembled single molecule arrays and uses thereof - The present invention provides methods of making and using self-assembled arrays of single polynucleotide molecules for carrying out a variety of large-scale genetic measurements, such as gene expression analysis, gene copy number assessment, and the like. Random arrays used in the invention are “self-assembled” in the sense that they are formed by deposition of polynucleotide molecules onto a surface where they become fixed at random locations. The polynucleotide molecules fixed on the surface are then identified by direct sequence determination of component nucleic acids, such as incorporated probe sequences, or by other decoding schemes. Such identification converts a random array of determinable polynucleotides, and their respective probes into an addressable array of probe sequences. | 04-01-2010 |
| 20100081129 | Genemap of the human genes associated with crohn's disease - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs. | 04-01-2010 |
| 20100081130 | Multifunctional particles providing cellular uptake and magnetic motor effect - Preparation of novel multifunctional particles and nanomaterials having a useful combination of magnetic and optical properties and biocompatibility. The internalization efficiencies in various in vitro cell studies have been investigated, and the external magnetic motor effect on the floating cells internalized with magnetic nanoparticles were clearly observed, for the first time. The particle surfaces can be derivatized with, for example, DNA or antibodies. The system is stable, versatile, and well-controlled. Novel gene delivery can be achieved using nanoparticles as a carrier. | 04-01-2010 |
| 20100081131 | IDENTIFICATION OF MICROBES USING OLIGONUCLEOTIDE BASED IN SITU HYBRIDIZATION - A method of sample analysis is provided. In certain embodiments, the method may comprise: a) contacting a sample comprising a microbe with a set of at least two labeled oligonucleotides under in situ hybridization conditions to produce a contacted sample, where the labeled oligonucleotides i. hybridize to different RNA molecules of the microbe at sites that are unique to the microbe, ii. provide a predetermined optically detectable signature that identifies the microbe when the labeled oligonucleotides are hybridized to the different RNA molecules of the microbe, and iii. do not hybridize to ribosomal RNA of the microbe; b) reading the contacted sample to detect hybridization of the labeled oligonucleotides; and c) determining the identity of the microbe on the basis of the predetermined optically detectable signal, where the predetermined optically detectable signal indicates the identity of the microbe in the sample. | 04-01-2010 |
| 20100081132 | BIOSENSORS AND BIOSENSING INCORPORATING RF AND MICROWAVE REDIATION - Devices capable applying microwave and RF electromagnetic radiation to specific molecular interactions between a capture molecule and a target analyte and capable of sensing the specific molecular interaction are provided. Specific molecular interactions include, for example, specific recognition events such as, receptor-ligand, antigen-antibody, DNA-protein, sugar-lectin, RNA-ribosome, and enzyme substrate interactions and nucleic acid-nucleic acid hybridizations. Additionally, methods are provided for detecting the presence or absence of a target analyte in a sample. The presence or absence of the target analyte is detected, in part, through the detection of a binding complex between the target analyte and a capture molecule in the presence of microwave and or RF electromagnetic radiation. | 04-01-2010 |
| 20100081133 | Methods of Detecting Root Knot Nematodes - The present invention relates to a method of testing a sample for the presence of a | 04-01-2010 |
| 20100081134 | BIO-BARCODE BASED DETECTION OF TARGET ANALYTES - The present invention relates to screening methods, compositions, and kits for detecting for the presence or absence of one or more target analytes, e.g. biomolecules, in a sample. In particular, the present invention relates to a method that utilizes reporter oligonucleotides as biochemical barcodes for detecting multiple protein structures or other target analytes in a solution. | 04-01-2010 |
| 20100081135 | Single nucleotide polymorphisms and use of same predicting male- specific prenatal loss - The present invention is directed to a panel of single nucleotide polymorphisms (SNPs) in specific genes that serve as biomarkers for sex-specific prenatal loss of a conceptus or embryo. There is provided herein methods and reagents for assessing the specific SNPs in those genes. The method useful in applying these SNPs in predicting an increased risk of prenatal loss is also disclosed. | 04-01-2010 |
| 20100081136 | CRTAC AS A BIOMARKER, THERAPEUTIC AND DIAGNOSTIC TARGET - The invention provides CRTAC, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of CRTAC as well as pharmaceutical compositions comprising such compounds. The invention also provides CRTAC as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. | 04-01-2010 |
| 20100081137 | Click Chemistry for the Production of Reporter Molecules - The present invention relates to methods for producing reporter molecules suitable for the detection of analytes, e.g. nucleic acids. Further, the present invention relates to methods and regions for detecting analytes. | 04-01-2010 |
| 20100081138 | Nucleotide sequences for the detection of enterohaemorrhagic Escherichia coli (EHEC) - Nucleic sequences of plasmid origin are isolated from bacteria of the enterohaemorrhagic | 04-01-2010 |
| 20100081139 | METHOD FOR DETECTION OF PRESENCE OF TARGET POLYNUCLEOTIDE IN SAMPLES - A method for detecting the presence of a target polynucleotide in a sample, including providing a mixture of the sample and target binding agent and measuring a signal from the mixture, where the target binding agent is capable of assuming a first position where the target binding agent is not bound to the target polynucleotide and a second position where the target binding agent is bound to the target polynucleotide, and the intensity of the signal depends on the proportion of target binding agent in the first and second positions. The method is suitable for detecting a PCR product using a homogeneous detection method. | 04-01-2010 |
| 20100081140 | CHEMICALLY CLEAVABLE PHOSPHORAMIDITE LINKERS FOR SEQUENCING BY LIGATION - Linkers and methods for determining a nucleotide sequence of a reference oligonucleotide are provided. | 04-01-2010 |
| 20100081141 | Genome-Wide Chromosome Conformation Capture - The invention relates to the use of GCC (Genome Conformation Capture) technology in determining the three dimensional arrangement of an entire genome. | 04-01-2010 |
| 20100081142 | BIOMARKERS FOR KIDNEY DISEASES AND METHOD FOR USING SAME - The present invention provides biomarkers for detecting kidney disease, selected from the oligonucleotide sequence, complementary sequence or derivatives, amino acid sequence or derivatives, fragment, variants, antibody of annexin A2 or S100A6 or combinations thereof. Moreover, the present invention also provides an assay kit and a method for kidney disease detecting, practically for the kidney disease resulting from acute tubular necrosis. | 04-01-2010 |
| 20100081143 | Preparations, Compositions, and Methods for Nucleic Acid Sequencing - Preparations, compositions and methods of sequencing nucleic acids are provided. The preparations, methods and compositions employ multiple priming sites on a target nucleic acid and typically utilize single molecule sequencing processes to identify sequence portions of the target which are then assembled to obtain the sequence of the target. | 04-01-2010 |
| 20100081144 | POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF - This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications. | 04-01-2010 |
| 20100081145 | Detecting Prostate Cancer - Methods and kits for detecting prostate cancer in urine samples include detecting the methylation status of various genes. | 04-01-2010 |
| 20100086909 | Method for the prediction of individual disease course in sepsis - The invention relates to the use of gene expression profiles, obtained in vitro from a patient sample, for the generation of criteria for the prediction of an individual course of disease in sepsis. The invention is further of use for determining the probability of survival in sepsis, the assessment of the course of disease in sepsis during treatment and for the classification of sepsis patients. | 04-08-2010 |
| 20100086910 | Surface-modified single-walled carbon nanotubes and methods of detecting a chemical compound using same - A method for surface modification of single walled carbon nanotubes. In one embodiment, the method includes the steps of providing a detergent solution, adding a plurality of single walled carbon nanotubes into the detergent solution, performing a first sonication to disperse the single walled carbon nanotubes in the detergent solution, and performing a second sonication after the first sonication to make detergent encased single walled carbon nanotubes. At least one of the plurality of single walled carbon nanotubes is at least partially wrapped by one or more detergent molecules to make it a detergent encased single walled carbon nanotube. In one embodiment, the detergent comprises SDS, PSS or a combination of them. | 04-08-2010 |
| 20100086911 | PREVENTIVE/THERAPEUTIC AGENT FOR CANCER - Identification of a novel target molecule for preventing/treating cancer and a preventive/remedy agent for cancer which targets the molecule, specifically, an agent for promoting the apoptosis in cancer cells and/or inhibiting the growth of cancer cells and a preventive/remedy agent for cancer, which comprise an antibody against a protein including the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 10; an antisense polynucleotide of the protein (preferably, siRNA against mRNA of the protein); and a substance controlling the expression and/or activity of the protein, are provided by the present invention. A method of screening for a substance that promotes apoptosis in cancer cells and/or inhibits the growth of cancer cells and a preventive/remedy substance for cancer, in which the method comprises using a protein (preferably a cell producing the protein), an antibody against the protein, or a polynucleotide encoding the protein, is also provided by the present invention. | 04-08-2010 |
| 20100086912 | AZGP Gene Single Nucleotide Polymorphisms (SNPs) - The present invention provides single nucleotide polymorphisms and haplotypes in the AZGP1 gene that can be used for determining the predisposition of an individual to obesity. | 04-08-2010 |
| 20100086913 | Methods of Identification Using Methylation of CPG - The present invention relates to the materials and methods for the identification of methylated nucleotides in samples of genomic DNA. The present invention also relates to methods of diagnosis of specific conditions by identification of specific methylated nucleotides. | 04-08-2010 |
| 20100086914 | HIGH RESOLUTION, HIGH THROUGHPUT HLA GENOTYPING BY CLONAL SEQUENCING - The invention provides methods and reagent for performing full, multi-locus HLA genotyping for multiple individuals in a single sequencing run using clonal sequencing. | 04-08-2010 |
| 20100086915 | DETECTION OF ESR1 AMPLIFICATION IN BREAST CANCER - The present invention relates to an in-vitro method of identifying a tumor resulting from a proliferative breast disease as responsive to anti-estrogen treatment. Further, the invention relates to an in-vitro method of identifying a candidate patient with a proliferative breast disease as suitable for anti-estrogen treatment. In a further aspect, the invention provides an in-vitro method of identifying an individual with a non-cancerous proliferative breast disease who is at risk of developing breast cancer. The invention also provides kits for performing the above methods. | 04-08-2010 |
| 20100086916 | OLIGONUCLEOTIDE PROBES AND USES THEREOF - The present invention provides a dually labeled oligonucleotide probe, methods of preparing and using the same. The subject probes are particularly useful for high-sensitive nucleic acid detection via hybridization assays including but not limited to template-directed polymerization reactions. | 04-08-2010 |
| 20100086917 | Isolated polynucleotides, nucleic acid constructs, methods and kits for localization of rna and/or polypeptides within living cells - An isolated polynucleotide comprising a first nucleic acid sequence which comprises two functionally compatible recognition sites for a site-specific recombination enzyme and a second nucleic acid sequence encoding a protein binding-RNA sequence is provided. Also provided are nucleic acid constructs, methods and kits for localization of an mRNA and/or a polypeptide encoded by a given gene-of-interest within living cells. | 04-08-2010 |
| 20100086918 | Methods for High Sensitivity Detection of Genetic Polymorphisms - Multiplex PCR-based methods for detecting a variant polynucleotide having a nucleotide sequence differing from the wild-type nucleotide sequence of a nucleic acid molecule, wherein the variant polynucleotide is in a sample containing an excess of the wild-type nucleic acid molecule. The methods are particularly useful for detection of deletions from, or translocations and inversions in, genomic DNA. The susceptibility to, diagnosis of, and progression of a disease clinically related to the occurrence of such polymorphisms in an individual may also be confirmed and monitored using the multiplex PCR-based methods or by detecting RNA fusion transcripts in a sample that correspond to previously identified deletions, translocations or inversions in genomic DNA. | 04-08-2010 |
| 20100086919 | Devices and methods for immunoglobulin production - The present invention relates to devices and methods that are useful for screening and isolating cells that express a desired immunoglobulin. The present invention further relates to devices and methods that are useful in producing monoclonal antibodies from non-immortal cells (such as B cells) or immortalized cells (such as hybridoma cells). The devices and methods disclosed herein significantly improve the efficiency for monoclonal antibody production. | 04-08-2010 |
| 20100086920 | METHOD TO ASSESS CANCER SUSCEPTIBILITY AND DIFFERENTIAL DIAGNOSIS OF METASTASES OF UNKNOWN PRIMARY TUMORS - This invention discloses using SPR technology to simultaneously and quantitatively measure the concentrations of different tumor markers in a serum sample, which can be used to screen for and determine susceptibility to cancer as well as for the differential diagnosis of metastases from an unknown primary tumor. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of monoclonal antibodies used for cancer susceptibility assessment and for differential diagnosis of metastases from an unknown primary tumor. | 04-08-2010 |
| 20100086921 | GENETIC SUSCEPTIBILITY VARIANTS OF TYPE 2 DIABETES MELLITUS - Association analysis has shown that certain genetic variants are susceptibility variants for Type 2 diabetes. The invention relates to diagnostic applications of such susceptibility variants, including methods of determining increased susceptibility to Type 2 diabetes, as well as methods of determining decreased susceptibility to Type 2 diabetes in an individual. The invention further relates to kits for determining a susceptibility to Type 2 diabetes based on the variants described herein. | 04-08-2010 |
| 20100086922 | Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment - Disclosed herein are chromosomal loci associated with clinical outcome to treatment for multiple myeloma. Genome-wide changes observed in myeloma relate to prognosis and treatment response to a proteasome inhibitor. Compositions and methods are provided to assess DNA copy number at corresponding to markers of loci and genes found thereon which are amplified or deleted, overexpressed or underexpressed in myeloma tumors to predict response to treatment, time-to-progression and survival upon treatment. | 04-08-2010 |
| 20100086923 | USE OF ACETALS FOR ISOLATION OF NUCLEIC ACIDS - The invention provides the use of water-miscible liquid cyclic acetals for adsorbing a nucleic acid to a solid phase such as a substrate with a silica surface. To this end, the invention also provides compositions comprising said acetals. Methods are disclosed and claimed to purify nucleic acids from samples, as well as kits useful for performing these methods. The nucleic acids purified by a method of the invention are suited for assays aiming at the detection of a target nucleic acid. | 04-08-2010 |
| 20100086924 | USE OF TDE FOR ISOLATION OF NUCLEIC ACIDS - The invention provides the use of tetraethylene glycol dimethyl ether for adsorbing nucleic acids to solid phases such as those with silica surfaces. To this end, the invention also provides compositions comprising TDE. Methods are disclosed and claimed to purify nucleic acids from samples, as well as kits useful for performing these methods. Particularly, the invention encompasses methods for the purification of nucleic acids with low molecular weight. The nucleic acids purified by a method of the invention are suited for assays aiming at the detection of a target nucleic acid. | 04-08-2010 |
| 20100086925 | MICROFLUIDIC STRUCTURE FOR MULTI-ASSAY AND MICROFLUIDIC DEVICE COMPRISING THE SAME - Exemplary embodiments relate to a microfluidic structure including: a plurality of sample chambers; a reaction chamber in which at least two types of materials, which respectively specifically react with at least two types of target materials, are immobilized; a detection chamber connected to the reaction chamber; a path connecting the chambers; and a valve for opening and closing the path, and a microfluidic device including the microfluidic structure. Since at least two types of materials specifically binding to target materials are immobilized in a reaction chamber of the microfluidic structure, space may be efficiently used and the target materials may be assayed in a one-step test. An internal space of the microfluidic device using the microfluidic structure, the amount of samples, and costs for manufacturing the microfluidic device may be reduced, and internal quality control may be efficiently performed using the microfluidic structure as a control for the operations. | 04-08-2010 |
| 20100086926 | METHOD OF CHARACTERIZING SEQUENCES FROM GENETIC MATERIAL SAMPLES - Among other aspects provided herein is a method describing the use of Single Nucleotide Polymorphism (SNP) genotyping microarrays to resolve whether genetic material (such as genomic DNA) derived from a particular individual is present in a genetic material mixture (such as a complex genomic DNA mixture) is disclosed. Furthermore, it is demonstrated that the identification of the presence of genetic material (such as genomic DNA) of specific individuals within a series of complex genomic mixtures is possible. | 04-08-2010 |
| 20100086927 | DEPOSITION OF METAL OXIDES ONTO SURFACES AS AN IMMOBILIZATION VEHICLE FOR CARBOXYLATED OR PHOPHATED PARTICLES OR POLYMERS - Intermediates and methods for forming activated metal complexes bound to surfaces on oxide layers, immobilizing beads to the modified surface and articles produced thereby are described. Hydroxyl groups on the oxide surfaces are reacted with a metal reagent complex of the formula Y(L-Pol) | 04-08-2010 |
| 20100086928 | DETECTION OF ORGAN REJECTION - The present invention features methods and compositions for the non-invasive detection of organ rejection using a microRNA score. | 04-08-2010 |
| 20100086929 | DETECTION OF ANALYTES - A kit and article of manufacture for detecting an analyte is disclosed. The kit comprises:
| 04-08-2010 |
| 20100086930 | IMPROVED HOMOGENEOUS LUMINESCENCE BIOASSAY - A homogenous bioassay including i) a first group containing a short lifetime fluorescent acceptor capable of energy transfer, and ii) a second group containing a quencher capable of energy transfer from an acceptor, with the first and second groups linked by at least a first linkage. The bioassay measures the acceptor's fluorescence increase resulting from cleavage of the first linkage. The bioassay also includes iii) a third group containing a donor for energy transfer to the acceptor, where the donor is an up-conversion fluorescent compound, a long-lifetime fluorescent compound or an electrogenerated luminescent compound. A conformational or terminal epitope is created on the first group through cleavage of the linkage, and the third group includes a binder with affinity for this conformational or terminal epitope. The acceptor's fluorescence is brought about by exciting the donor. Also disclosed are kits for homogenous bioassays according to the method of the invention. | 04-08-2010 |
| 20100086931 | METHOD FOR ASSAYING ACTION OF ANTITUMOR AGENT USING DECREASE IN GENE EXPRESSION LEVEL AS INDEX - An object of the present invention is to provide a method, a probe, a primer, an antibody, a reagent, and a kit for assaying an action of a pladienolide derivative to a living subject. According to the present invention, there is provided a method for assaying an action of the pladienolide derivative using a decrease in gene expression level as an index. | 04-08-2010 |
| 20100086932 | BLADDER CANCER DIAGNOSIS AND/OR PROGNOSIS METHOD - The present invention relates to an in vitro non-invasive bladder cancer diagnosis and/or prognosis method based on the detection and quantification in bladder fluids of the gene expression of certain genes and/or combinations thereof acting as genetic markers of said disease. A bladder cancer diagnosis and/or prognosis kit based on the use of a set of probes suitable for the detection and quantification of the expression pattern of said genes is also contemplated. | 04-08-2010 |
| 20100086933 | SENSOR FOR DETECTING AN ANALYTE - The present invention relates to a sensor for detecting an analyte, to a sensor array, and to a method of detecting an analyte using the sensor of the invention. | 04-08-2010 |
| 20100086934 | Use of non-clonal chromosomal aberrations for cancer research and clinical diagnosis - A diagnostic method of determining tumorigenicity of a tissue specimen includes the steps of determining a magnitude of genome diversity in the tissue specimen, and diagnosing a likelihood of cancer in response to said step of determining the magnitude of genome diversity. The magnitude of genome diversity includes the determination of karyotypic heterogeneity in the tissue specimen, illustratively by detecting non-clonal chromosome aberrations (NCCAs). The detection of NCCAs includes the detection the frequency of NCCAs, and the diagnosis is responsive to the step of detecting the frequency of NCCAs. Detection of NCCAs advantageously includes the further step of screening lymphocytes. Also, the step of determining the presence of elevated genome diversity includes the step of applying Spectral Karyotyping to detect translocations throughout the genome. The diagnostic method is useful to determine drug resistance of a patient. | 04-08-2010 |
| 20100086935 | Identification, Monitoring and Treatment of Disease and Characterization of Biological Condition Using Gene Expression Profiles - A method provides an index that is indicative of the state of a subject, as to a biological condition, based on a sample from the subject. An embodiment of this method includes: deriving from the sample a profile data set, the profile data set including a plurality of members, each member being a quantitative measure of the amount of a distinct RNA or protein constituent in a panel of constituents selected so that measurement of the constituents enables evaluation of the biological condition; and in deriving the profile data set, achieving such measure for each constituent under measurement conditions that are substantially repeatable; and applying values from the profile data set to an index function that provides a mapping from an instance of a profile data set into a single-valued measure of biological condition, so as to produce an index pertinent to the biological condition of the subject | 04-08-2010 |
| 20100086936 | HEPATOCYTE PRECURSOR CELL LINES - The present invention is directed to methods for readily generating hepatocyte precursor cell lines that retain hepatocyte-specific functions after extensive in vitro culturing. The methods comprise isolating and culturing hepatocyte precursor cell lines under permissive culture conditions that suppress asymmetric cell kinetics and allow exponential growth of the precursor cells, followed by transferring the hepatocyte precursor cell lines to non-permissive culture conditions that allow expression of asymmetric cell kinetics and induce expression of hepatocyte-specific characteristics. | 04-08-2010 |
| 20100092946 | Genetic methods for speciating Campylobacter - The phylogeny of twelve | 04-15-2010 |
| 20100092947 | Impdh2 snp associated with acute rejection - The present invention concerns a method for the prediction of acute renal transplant rejection by detecting a polymorphism in intron 7 of the IMPDH2 gene, optionally in combination with polymorphisms of the MDR1 and IL 10 genes which were found to be associated with this disease. | 04-15-2010 |
| 20100092948 | BIOLOGICAL BAR CODE - The invention provides compositions and methods useful for identifying, verifying or authenticating any type of sample, whether the sample, is biological or non-biological. | 04-15-2010 |
| 20100092949 | METHODS FOR DETECTING STAPHYLOCOCCUS AUREUS - Methods and oligonucleotides for detecting staphylococci, such as | 04-15-2010 |
| 20100092950 | Fuidi herd management schema - The invention is a herd management schema based upon the inventor's analysis of the natural history of bovine infection due to | 04-15-2010 |
| 20100092951 | METHOD FOR METHYLATION ANALYSIS OF NUCLEIC ACID - The present invention relates to a method for methylation analysis. It comprises the providing of a double stranded nucleic acid; its conversion, whereby unmethylated bases become distinguishable in their base-pairing behavior from methylated bases, and the analysis of both of the converted nucleic acid strands. | 04-15-2010 |
| 20100092952 | FOUR-COLOR DNA SEQUENCING BY SYNTHESIS USING CLEAVABLE FLUORESCENT NUCLEOTIDE REVERSIBLE TERMINATORS - This invention provides a process for sequencing single-stranded DNA by employing a nanopore and modified nucleotides. | 04-15-2010 |
| 20100092953 | METHODS AND NUCLEIC ACIDS FOR ANALYSES FOR CELLULAR PROLIFERATIVE DISORDERS - The invention provides methods, nucleic acids and kits for detecting a cell proliferative disorder. The invention discloses genomic sequences of RASSF-2 the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients. | 04-15-2010 |
| 20100092954 | Method for Determining the Genetic Basis for Physiological Changes in Organisms - The present invention provides a method for discovering the basis of changes in the observable properties of organisms by subjecting an organism to selection. Individual organisms with observable differences will thus become more prevalent in a population during selection. The basis for the differences are then determined by identifying genetic differences among the individual organisms and the original organism, followed by evaluation of the effects of each genetic difference either alone or in combination by using site-directed mutagenesis followed by observation of the effects. | 04-15-2010 |
| 20100092955 | GEL MICRODROP COMPOSITION AND METHOD OF USING THE SAME - A gel microdrop composition is provided. In certain embodiments, the gel microdrop composition contains a polymer matrix, an effector particle that releases an effector molecule into the polymer matrix, a first reporter particle that emits a first optically detectable signal and a second reporter particle that emits a second optically detectable signal that is distinguishable from the first optically detectable signal, where the effector particle and said first and second reporter particles are encapsulated by the polymer matrix. Methods of screening that employ the gel microdrop composition and methods of making the gel microdrop composition are also disclosed. | 04-15-2010 |
| 20100092956 | Analytical Processing and Detection Device - An analytical processing and detection device is described which comprises a rack capable of holding at least one reaction receptacle, at least one magnetic unit for exerting a magnetic field on at least one reaction receptacle comprising magnetic particles in a fluid, wherein said at least one magnetic unit is reversibly or irreversibly connected to said rack, and wherein said magnetic field causes the magnetic particles to be sequestered to the side walls of said at least one reaction receptacle, and a detection unit for detecting a signal in the fluid in said reaction receptacle. | 04-15-2010 |
| 20100092957 | COMPOSITIONS AND METHODS FOR NUCLEOTIDE SEQUENCING - The invention provides nucleoside and nucleotide molecules containing cleavable linkers linking a label such as a dye. The invention also provides nucleosides and nucleotide molecules containing a blocking group, either removable or non-removable. The invention additionally provides methods of using the nucleoside and nucleotide molecules containing a cleavable linker and/or a blocking group. | 04-15-2010 |
| 20100092958 | Methods for Determining Collateral Artery Development in Coronary Artery Disease - The present invention relates to a method for determining collateral artery development in a human subject with coronary artery disease based upon the levels of expression of markers associated with collateral artery development in coronary artery disease. | 04-15-2010 |
| 20100092959 | Single nucleotide polymorphisms as genetic markers for childhood leukemia - The present invention is directed to a panel of single nucleotide polymorphisms (SNPs) in specific genes that serve as biomarkers for sex-specific childhood leukemia risk. There is provided herein methods and reagents for assessing the specific SNPs in those genes. The method useful in applying these SNPs in predicting an increased risk or a decreased risk for childhood leukemia for males and females is also disclosed. | 04-15-2010 |
| 20100092960 | Helicase-assisted sequencing with molecular beacons - Provided are compositions that include an at least partially single-stranded nucleic acid, at least one first molecular beacon, and an enzyme comprising a helicase activity, which enzyme is capable of removing the first molecular beacon from the single-stranded nucleic acid wherein the first molecular beacon is hybridized to a first complementary subsequence of the nucleic acid. Also provided are methods of determining the sequence of a template nucleic acid that include removing molecular beacons that are hybridized to the template from the template in a sequential manner using an enzyme that exhibits a helicase activity, detecting a sequence of fluorescent signals that is produced by the removal of a molecular beacons, and converting the sequence of fluorescent signals into nucleotide sequence information. Sequencing systems in which compositions and methods of the invention can be used are also provided. | 04-15-2010 |
| 20100092961 | Methods and compositions for detection of Cowden Syndrome (CS) and CS-like syndrome - In one aspect, the invention is directed to a method of detecting Cowden syndrome (CS) or CS-like syndrome in an individual comprising detecting the presence of a mutated succinate dehydrogenase B (SDHB), mutated succinate dehydrogenase D (SDHD) or combination thereof in the individual, wherein detection of a mutated SDHB, SDHD or a combination thereof indicates that the individual is positive for CS or CS-like syndrome. In another aspect, the invention is directed to a method of determining whether an individual is at risk for developing Cowden syndrome (CS) or CS-like syndrome comprising detecting the presence of a mutated succinate dehydrogenase B (SDHB), mutated succinate dehydrogenase D (SDHD) or combination thereof in the individual, wherein detection of a mutated SDHB, SDHD or a combination thereof indicates that the individual is at risk for developing for CS or CS-like syndrome. In yet another aspect, the invention is directed to an article of manufacture for detecting Cowden syndrome (CS) or Cowden-like syndrome in an individual, comprising one or more agents that detects mutated succinate dehydrogenase B (SDHB), mutated succinate dehydrogenase D (SDHD) or combination thereof in the individual, and instructions for use. | 04-15-2010 |
| 20100092962 | Method of Detecting Colorectal Cancer - A method for predicting the presence of colorectal cancer based on the concentration of DNA in a sample of exfoliated cells collected directly from the surface of the rectal mucosa of a subject. The method consists of quantifying the concentration of DNA in a lysate containing exfoliated cells and correlating the concentration with a range within a statistical model which indicated the likelihood of the presence of colorectal cancer as well as the likely location of the cancer. | 04-15-2010 |
| 20100092963 | KITS AND METHODS FOR SELECTIVE AMPLIFICATION AND DETECTION OF NUCLEIC ACID TARGET - The application relates generally to kits and methods useful for the selective capture, amplification and/or detection of one or more nucleic acid targets, as well as compositions comprising said amplification reaction mixtures. More specifically, the application relates to a signal primer that comprises (i) a target-specific sequence which hybridizes specifically to a nucleic acid target, and (ii) a signal sequence upstream of the target-specific sequence, wherein the signal sequence is preferably not found in the nucleic acid target or its complementary sequence; and a detection means for detecting the presence of the complementary sequence of the signal sequence in amplified nucleic acid target products. | 04-15-2010 |
| 20100092964 | Genetic Diagnosis Using Multiple Sequence Variant Analysis - The present invention is in the field of nucleic acid-based genetic analysis. More particularly, it discloses novel insights into the overall structure of genetic variation in all living species. The structure can be revealed with the use of any data set of genetic variants from a particular locus. The invention is useful to define the subset of variations that are most suited as genetic markers to search for correlations with certain phenotypic traits. Additionally, the insights are useful for the development of algorithms and computer programs that convert genotype data into the constituent haplotypes that are laborious and costly to derive in an experimental way. The invention is useful in areas such as (i) genome-wide association studies, (ii) clinical in vitro diagnosis, (iii) plant and animal breeding, (iv) the identification of micro-organisms. | 04-15-2010 |
| 20100092965 | GENETIC VARIATIONS ASSOCIATED WITH TUMORS - Nucleotide and amino acid variations associated with tumors are provided. Methods for detecting variations and for diagnosing and treating tumors are provided. | 04-15-2010 |
| 20100092966 | METHOD FOR DETECTING PYROPHOSPHATE BY MEANS OF BIOLUMINESCENCE DETECTION - The invention relates to methods for detecting pyrophosphate by means of bioluminescence detection. In addition, methods for measuring chemical, especially enzyme-catalyzed, reactions in which pyrophosphate is formed or consumed are described. Such reactions are catalyzed for example by guanylyl cyclases, adenylyl cyclases, DNA polymerases or RNA polymerases. | 04-15-2010 |
| 20100092967 | BIOLUMINESCENT ASSAYS UTILISING SECRETED LUCIFERASES - Disclosed herein are methods for determining the amount or activity of one or more luciferases and methods for measuring the luminescent signal generated by one or more luciferases in a sample, the methods comprising incubating the sample with a reactive substrate(s) of the luciferase(s) to be analysed and a reducing agent to inactivate a first luciferase, wherein the first luciferase, in its native form, is a secreted luciferase. | 04-15-2010 |
| 20100092968 | Method and Means for Enrichment, Removal and Detection of Gram-Positive Bacteria - The present invention relates to polypeptides comprising a enzymatically non-active cell wall binding domain of an endolysin or another cell wall lysing enzyme, and a sequence according to SEQ ID NO: 1 or derivatives thereof, wherein the polypeptide besides the cell wall binding domain comprises no further domains of an endolysin, as well as means for their preparation. The present invention further relates to methods for binding, enriching, removing from a sample, capturing and/or detecting bacteria, particularly gram positive bacteria. | 04-15-2010 |
| 20100092969 | CELL ISOLATION METHOD, CELL TESTING METHOD AND REAGENT KIT THEREFOR - The present invention provides a cell isolation method, a cell screening process, and a reagent kit therefor. In the present invention, the recognition substance is a polynucleotide specifically bound to a particular antigen that exists on the surface of a specific cell. This recognition substance is made to bind with a magnet of paramagnetic material. The specific cell is obtained by mixing a sample and the magnet, recovering the magnet through the use of magnetic force, applying nuclease, digesting the polynucleotide bound to the particular antigen of a specific cell, and using magnetic force to remove the magnet. According to the present invention, loss of cell functionality during the classification process can be avoided when cell identification or isolation is necessary. | 04-15-2010 |
| 20100092970 | DETERMINING THE PHASE OF DUPLICATED CYP2D6 ALLELES - This document relates to methods and materials involved in detecting duplicated CYP2D6 alleles (e.g., CYP2D6/CYP2D7−CYP2D6 arrangements) in mammals (e.g., humans). | 04-15-2010 |
| 20100092971 | COMPOUND HAVING STRUCTURE DERIVED FROM MONONUCLEOSIDE OR MONONUCLEOTIDE, NUCLEIC ACID, LABELING SUBSTANCE, AND METHOD AND KIT FOR DETECTION OF NUCLEIC ACID - The present invention provides, for example, a labeling substance that allows the double helix structure of a nucleic acid to be detected effectively. The present invention provides a compound having a structure derived from mononucleoside or mononucleotide, with the structure being represented by the following formula (1), (1b), or (1c), a tautomer or stereoisomer thereof, or a salt thereof. | 04-15-2010 |
| 20100092972 | ASSAY FOR GENE EXPRESSION - An assay for gene expression comprising treating RNA with an agent such as bisulphate that substantially removes secondary structure of the RNA; and measuring the presence or amount of treated RNA so as to obtain an indication of gene expression. The invention also includes use of oligonucleotide, PNA, LNA or INA probes in the assay. | 04-15-2010 |
| 20100092973 | METHODS AND DEVICES FOR DIGITAL PCR - The invention provides methods of conducting a nucleic acid reaction, including methods for performing digital PCR using a “droplet-in-oil” technology. In the methods, the starting sampled is segmented at least partially into a set of sample droplets each containing on average about one or fewer copies of a target nucleic acid. The droplets are passed in a continuous flow of immiscible carrier fluid through a channel that passes through a thermal cycler, whereby the target is amplified. In one implementation, the droplets are about 350 nl each and the number of positively amplified droplets is counted at the near-saturation point. | 04-15-2010 |
| 20100092974 | METHODS FOR SCREENING FOR MODULATORS OF CCRL2 - The invention provides methods and compositions for identifying a modulator of CCRL2 and chemerin. The present invention also provides methods and compositions for treating an inflammatory disease by administering a compound that modulates the interaction of CCRL2 with chemerin. | 04-15-2010 |
| 20100092975 | USE OF NOVEL CYTOKINE RECEPTORS AS BIOMARKERS AND THERAPEUTIC TARGETS IN HUMAN CANCER - Nucleic acids encoding erythropoietin isoforms are described herein, as well as the encoded isoforms, methods of detecting the same, and methods of screening for and treating cancer. | 04-15-2010 |
| 20100092976 | THERMOSTABLE DUPLEX-SPECIFIC NUCLEASE - The present invention provides a thermostable duplex-specific nuclease (DSN) and a method for digesting a nucleic acid using said DSN, namely, a protein having a Brachyura-derived duplex-specific nuclease activity, a gene encoding for said protein, a recombinant vector comprising said gene and a transformed cell or transduced cell comprising said vector and a method for producing a protein having a duplex-specific nuclease activity, which comprises culturing said transformed cell or transduced cell using a medium and collecting the protein having a duplex-specific nuclease activity from the cultured mixture, a method for digesting a nucleic acid using said protein having duplex-specific nuclease activity, a method for detecting RNA using said DSN and a reagent kit to be used in the aforementioned methods. | 04-15-2010 |
| 20100092977 | IRF-5 HAPLOTYPES IN SYSTEMIC LUPUS ERYTHEMATOSUS - Methods and materials involved in diagnosing SLE are provided herein. The methods and materials can be used to diagnose SLE and/or assess a mammal's susceptibility to develop SLE, based on the presence or absence of one or more IRF-5 variants. | 04-15-2010 |
| 20100092978 | CADHERIN-17 AS DIAGNOSTIC MARKER AND THERAPEUTIC TARGET FOR LIVER CANCER - Compositions and methods for diagnosing, treating and/or preventing cancers characterized by CDH17 overexpression based on the detection of CDH17 or the use of CDH17 as a target for therapeutic intervention or prophylactic intervention are provided. Methods for diagnosing and/or monitoring liver cancers using the expressing of CDH17 involve detecting and/or quantitating the CDH17 protein or encoding nucleic acids (DNA or RNA) in a biological sample such as urine from the subject. Methods for treating liver cancers using CDH17 as a target and of sensitizing cells with aberrant expression of CDH17 have also been developed. The methods include suppression or knockdown of the expression of CDH17 by administering an effective amount of a CDH17 inhibitor. | 04-15-2010 |
| 20100092979 | METHODS AND COMPOSITIONS FOR ISOLATING NUCLEIC ACID - The present invention relates to compositions and methods for isolating and purifying nucleic acid. In particular, the present invention relates to methods of isolating nucleic acid from cells for use in further analysis. | 04-15-2010 |
| 20100092980 | REAGENT FOR ELIMINATION OF RED BLOOD CELLS AND HEMOGLOBIN IN A SAMPLE - The invention relates to a method for isolating nucleic acid from a blood sample, including individual blood samples or pooled samples, such as in blood banks. Furthermore, this invention relates to a reagent kit suitable for carrying out the method of the invention. | 04-15-2010 |
| 20100092981 | METHODS OF DETECTING HYPERMETHYLATION - Aspects of the invention relate to methods of detecting cancer, such as colon cancer. In aspects of the invention, methods for detecting the presence of hypermethylated genomic DNA in a biological sample are disclosed. Methods of the invention relate to detecting small amounts of hypermethylated nucleic acids in a biological sample. | 04-15-2010 |
| 20100092982 | Regulation of Gene Expression by Protein Methylation - The invention relates to the cDNA and deduced amino acid sequence of the Coactivator Associated arginine (R) Methyltransferase protein, CARM1. A method is described for the use CARM1 to regulate gene expression in vivo. CARM1 has also been used to methylate arginine residues of histones, synthetic peptides, and other proteins. A method to use CARM1 to screen for drugs that inhibit its methyltransferase activity is also described, as is a method to screen for drugs that modulate CARM1's interactions with other proteins. | 04-15-2010 |
| 20100092983 | METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 04-15-2010 |
| 20100092984 | METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 04-15-2010 |
| 20100092985 | SOLID SUPPORT WITH ENHANCED DENSITY OF SIGNAL MATERIAL, KIT CONTAINING THE SAME AND METHOD OF DETECTING TARGET MATERIAL USING THE SAME - A solid support on which a labeled nucleic acid including a high density of signal materials, a kit containing the same, and a method of detecting a target material are provided. | 04-15-2010 |
| 20100092986 | METHODS AND TOOLS FOR DETECTING THE PRESENCE OF COLORECTAL ADENOCARCINOMA CELLS - The present invention discloses methods and tools for reliably detecting the presence of adenocarcinoma cells in a patient, at the genetic level. The present invention fine-maps the regions of chromosomal aberrations linked to progression of adenomas into adenocarcinoma cells and provides methods and tools for detection based thereon. | 04-15-2010 |
| 20100092987 | MICROFLUIDIC ANALYSIS SYSTEM - A microfluidic analysis system ( | 04-15-2010 |
| 20100092988 | Methods and Compounds For Chemical Ligation - Compositions and methods for chemical ligation are provided. Methods for nucleic acid sequencing, nucleic acid assembly and nucleic acid synthesis are also provided. | 04-15-2010 |
| 20100092989 | GENES USEFUL FOR DIAGNOSING AND MONITORING INFLAMMATION RELATED DISORDERS - Described herein is a system for monitoring gene expression for diagnosing and monitoring inflammation disorders, and for monitoring gene expression in inflammation disorders in response to a particular drug treatment regimen. This system for detecting nucleic acid expression in a body fluid uses an isolated polynucleotide to detect expression of a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 5; SEQ ID NO:11; SEQ ID NO:17; and SEQ ID NO: 23. These nucleic acids are differentially expressed in body fluid in an individual with a disease criterion for a disease as listed in Table 1 as compared to an individual without the disease criterion. | 04-15-2010 |
| 20100092990 | NUCLEIC ACIDS ENCODING SODIUM CHANNEL SCN1A ALPHA SUBUNIT PROTEINS AND MUTATIONS ASSOCIATED WITH EPILEPSY - The present invention relates to epilepsy. More particularly, the present invention relates to idiopathic generalized epilepsy (IGE) and to the identification of three genes mapping to chromosome 2, which show mutations in patients with epilepsy. The invention further relates to nucleic acid sequences, and protein sequences of these loci (SCNA) and to the use thereof to assess, diagnose, prognose or treat epilepsy, to predict an epileptic individual's response to medication and to identify agents which modulate the function of the SCNA. The invention also provides screening assays using SCN1A, SCN2A and/or SCN3A which can identify compounds which have therapeutic benefit for epilepsy and related neurological disorders. | 04-15-2010 |
| 20100092991 | RAPID DETECTION PROCESSES AND RELATED COMPOSITIONS - An improved detection method is described for an antigen such as a chemical compound, a peptide, or a nucleic acid. The detection time for an antigen can be dramatically reduced relative to conventional technologies. The technology can particularly be used, for example, to modify and reduce the detection time significantly in traditional Western blot, Dot blot, ELISA and Immunohistology methods. | 04-15-2010 |
| 20100099080 | NUCLEIC ACID MEMORY DEVICE - This invention pertains to methods of imparting information onto nucleic acid sequences. In specific embodiments, the present invention provides site-specific recombinase systems and error-prone polymerase systems to alter nucleotide sequences such as DNA and mini-genomes, as well as for the production of microarrays. The present invention also provides methods of analyzing the modified nucleotides sequences provided herein. Methods of engineering and screening for novel modified polymerases that incorporate chain terminating nucleotides and/or labeled nucleotides more efficiently than wild-type polymerases are also provided. | 04-22-2010 |
| 20100099081 | Method for Typing HLA Alleles - The present invention relates to the typing of HLA alleles. The sequence of exon 2 and exon 3 of the alleles HLA-B*3913, HLA-B*1406 and HLA-B*51 new and of exon 2 of the alleles HLA-DRB1*0820, HLA-DRB1*04 new and HLA-DRB4*01 new are disclosed. The present invention relates to methods for typing of said alleles. According to a preferred embodiment, said typing comprises the following steps: i) amplifying a relevant fragment of said alleles using at least one suitable pair of primers; ii) hybridizing the amplification product of step i) to at least one probe that specifically hybridizes to a target region comprising one or more polymorphic nucleotides in said relevant fragment; iii) determining from the result of step ii) the absence or presence of said alleles in the sample. The present invention further provides primers and probes to be used in said methods for typing. A diagnostic kit comprising said primers and probes is also part of the present invention. | 04-22-2010 |
| 20100099082 | Allele Detection - Method for simultaneously determining alleles present in a set of loci from at least one nucleic acid sample comprising the steps: a) providing said at least one sample, b) subjecting said sample to a nucleic acid amplification reaction using a primer pair simultaneously primer pairs specific and optimized for each of the loci of a set of at least three loci selected from the group consisting of D2S1360, D7S1517, D8S1132, D9S1118, D10S2325, D11S554, D12S1064, D12S391, D17S1290, D19S253, MYCLl, P450CYP19 and SE-33, and c) evaluating the length and optionally the relative quantity of amplification products obtained from step b) or from the analysis of one or two of the above loci to determine and/or optionally quantify the alleles present at each of the loci analyzed in the set within said sample. | 04-22-2010 |
| 20100099083 | CROHN DISEASE SUSCEPTIBILITY GENE - The present invention relates to the ATG16l1 gene and genetic variants associated with Crohn's disease. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs. | 04-22-2010 |
| 20100099084 | DETECTION OF NPM1 NUCLEIC ACID IN ACELLULAR BODY FLUIDS - The present inventions relates to methods for detecting NPM1 nucleic acid in acellular body fluid samples and determining whether the nucleic acid contains one or more mutations including insertions and deletions. The methods are useful for predicting prognosis of AML patients that have cells with mutations in the NPM1 gene. | 04-22-2010 |
| 20100099085 | Serum DNA Methylation Screening for Cancer - We disclose a method of screening a mammal for a cancer associated with methylation of promoters of tumor-suppressor genes by collecting a sample of a body fluid or tissue of the mammal containing free DNA; isolating the free DNA from the sample; amplifying at least a portion of the promoter of each of a plurality of turner-suppressor genes associated with the cancer from the free DNA, to yield a plurality of amplified promoters; and quantifying methylation of each of the plurality of amplified promoters, to yield a methylation quantity. The method can have a high sensitivity and high specificity and can thus reduce the proportion of unneeded biopsies. It can also be performed with minimal invasiveness and discomfort to a patient. | 04-22-2010 |
| 20100099086 | Method and apparatus for determining a probability of colorectal cancer in a subject - A method of determining a probability that a human test subject has colorectal cancer as opposed to not having colorectal cancer is disclosed. The method comprises, for each gene of a set of one or more genes selected from the group consisting of ANXA3, CLEC4D, IL2RB, LMNB1, PRRG4, TNFAIP6 and VNN1: determining a level of RNA encoded by the gene in blood of the test subject, thereby generating test data; providing positive control data representing levels of RNA encoded by the gene in blood of human control subjects having colorectal cancer, and providing negative control data representing levels of RNA encoded by the gene in blood of human control subjects not having colorectal cancer; and determining a probability that the test data corresponds to the positive control data and not to the negative control data, where the probability that the test data corresponds to the positive control data and not to the negative control data represents the probability that the test subject has colorectal cancer as opposed to not having colorectal cancer. | 04-22-2010 |
| 20100099087 | GENE SEQUENCE VARIANCES IN GENES RELATED TO FOLATE METABOLISM HAVING UTILITY IN DETERMINING THE TREATMENT OF DISEASE - The present disclosure describes the use of genetic variance information for folate transport or metabolism genes or pyrimidine transport or metabolism genes in the selection of effective methods of treatment of a disease or condition. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described. | 04-22-2010 |
| 20100099088 | RELIABLE DETECTION OF VANCOMYCIN-INTERMEDIATE STAPHYLOCOCCUS AUREUS - The present invention relates to a method for identifying a VISA strain in a sample comprising measuring SAV2095 expression levels, a kit and use of SAV2095 for same. The present invention also relates to a method for facilitating the development of an individualized treatment regimen comprising measuring the expression level of SAV2095. The present invention further relates to a method for monitoring the progression of a vancomycin treatment of an infection comprising measuring the expression level of SAV2095. The present invention also relates to the detection of | 04-22-2010 |
| 20100099089 | REPORTER UNIT FOR DETECTION OF TARGET MOLECULES USING POLYMERISABLE SUBSTRATE - The invention relates to a reporter unit for detecting a target molecule comprising at least one component attached to a target molecule specific probe, wherein said at least one component is liberated from said probe by the activity of a first enzyme thereby making the at least one component available as a substrate for a second enzyme which employs the substrate in a polymerization reaction to obtain a detectable structure. | 04-22-2010 |
| 20100099090 | BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO CTLA-4 ANTAGONISTS - CTLA-4 biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an CTLA-4 antagonist, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker s, (b) exposing a biological sample from the mammal to the CTLA-4 antagonist, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer. | 04-22-2010 |
| 20100099091 | GENETIC COMPONENT OF COMPLICATIONS IN TYPE 2 DIABETES - The invention provides with means to predict, in subjects affected by type 2 diabetes (T2D), the probability of developing complications related to the disease. The invention involves 1) use of genetic features (SNPs, STRs, or other genomic markers) together with other chromosomal features and phenotypic information to establish a patient profile specifically developed for prediction of complications of T2D 2) use of a set of SNPs allowing to discriminate between individuals according to their descent. A preferred set of genomic markers selected for their association with complications of T2D is provided that can be used with a set of complementary phenotypic markers to evaluate the risk for an individual affected by T2D to develop complications related to the disease and to evaluate the likelihood that an individual affected by T2D type will benefit from treatments reducing the risk of developing such complications. | 04-22-2010 |
| 20100099092 | Methods for determination of haplotype dissection - A method for molecular haplotyping of a subject is disclosed. The method comprises: randomly selecting a set of chromosomes in each of a plurality of lyzed diploid cells of the subject, collecting the selected chromosomes from said plurality of cells into a plurality of sample tubes, wherein each sample tube contains chromosomes selected from one or more cells, genotyping genomic DNA in each sample tube, and determining haplotype of the alleles based on allele nucleotide sequence information and corresponding nucleotide signal intensities from genotyping data. Other methods for molecular haplotyping using single cell lysate or single cell microdissection are also disclosed. | 04-22-2010 |
| 20100099093 | Biomarkers for the Identification Monitoring and Treatment of Head and Neck Cancer - This present invention compositions and methods of treating cancer and methods of accessing/monitoring the responsiveness of a cancer cell to a therapeutic compound. | 04-22-2010 |
| 20100099094 | METHOD OF DETECTING NUCLEIC ACID AMPLIFICATION REACTION - The present invention provides a method of detecting a nucleic acid amplification reaction, including the steps of adding a sample nucleic acid to a nucleic acid amplification buffer containing a reducing agent molecule, a redox molecule and a magnesium ion, to conduct an amplification reaction, measuring a reduction current produced by a reduction reaction of the reducing agent molecule with the redox molecule, under the conditions that when the amplification reaction of the sample nucleic acid has proceeded in the buffer, pyrophosphoric acid formed with the progress of amplification of the sample nucleic acid forms magnesium pyrophosphate with the magnesium ion, thereby decreasing a magnesium ion concentration of the buffer, and determining, from the magnitude of the reduction current measured above, whether the sample nucleic acid has been amplified or not. | 04-22-2010 |
| 20100099095 | METHODS FOR DETERMINING PROGNOSES AND THERAPEUTIC INTERVENTIONS FOR OVARIAN CARCINOMAS - Methods for determining the prognosis and therapeutic interventions for cancer and for utilizing the expression of the homeoprotein Six1 to determine the prognosis and therapeutic interventions for cancer, in particular for ovarian carcinomas. | 04-22-2010 |
| 20100099096 | Compositions and Methods for Identifying Factors Affecting Protein Stability - The present invention is directed to retroviral vectors, and libraries generated from the vectors that can be used in assessing the stability of proteins and in correlating degradation with a specific E3 ubiquitin ligase. The libraries can also be used to identify factors that alter the degradation of proteins of therapeutic value and which have potential use clinically. | 04-22-2010 |
| 20100099097 | A Flow Through System, Flow Through Device And A Method Of Performing A Test - The invention relates to a flow through system for quantifying a target component in a liquid. The flow through system comprises a flow-through device comprising a flow path comprising a marker section, a capture section downstream to said marker section, and at least two quantification sections. The marker section comprises a non-immobilized marker. The capture section comprises a capture zone with an immobilized capture agent, and the at least two quantification sections comprise a pre-capture quantification section placed downstream to the marker section and up stream to the capture section, and a post-capture quantification section placed downstream to the capture section. The system further comprises a quantification unit for each of said quantification sections. The quantification unit(s) being arranged to quantify marker containing components and/or particles passing through said respective quantification sections. The invention also relates to a flow through device for such flow through system and a method of determining the amount of target component in a liquid using a flow through system. | 04-22-2010 |
| 20100099098 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION - Methods of diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection and kits or systems containing the same are also described. | 04-22-2010 |
| 20100099099 | METHOD AND TEST KIT FOR THE RAPID DETECTION OF SPECIFIC NUCLEIC ACID SEQUENCES, ESPECIALLY FOR DETECTING OF MUTATIONS OR SNPs - A method and a test kit for rapid detection of specific nucleic acid sequences, especially for detection of mutations or single nucleotide polymorphisms (SNPs), in which the detection reaction takes place in two steps. The first step involves the target-specific amplification reaction, coupled with the probe-hybridization reaction using fluorescence-labeled allele-specific amplification primers. In the second step, the fluorescence is detected by means of commercial fluorescence readers. Genotyping is carried out from the ratio of the end-point fluorescence of the samples and negative controls. | 04-22-2010 |
| 20100099100 | 'ULTRA-HIGH MULTIPLEX ANALYTICAL SYSTEMS AND METHODS" - Apparatus, systems and methods for use in analyzing discrete reactions at ultra high multiplex with reduced optical noise, and increased system flexibility. Apparatus include substrates having integrated optical components that increase multiplex capability by one or more of increasing density of reaction regions, improving transmission of light to or collection of light from discrete reactions regions. Integrated optical components include reflective optical elements which re-direct illumination light and light emitted from the discrete regions to more efficiently collect emitted light. Particularly preferred applications include single molecule reaction analysis, such as polymerase mediated template dependent nucleic acid synthesis and sequence determination. | 04-22-2010 |
| 20100099101 | METHODS FOR TREATING, DIAGNOSING, AND MONITORING LUPUS - Methods of identifying, diagnosing, and prognosing lupus, including certain subphenotypes of lupus, are provided, as well as methods of treating lupus, including certain subpopulations of patients. Also provided are methods for identifying effective lupus therapeutic agents and predicting responsiveness to lupus therapeutic agents. | 04-22-2010 |
| 20100099102 | Development of Diagnostic Markers From the Saliva of Head and Neck Cancer Patients - The present invention relates to biomarkers that are useful for the detection of cancer. The invention further relates to biomarkers and methods of using biomarkers for the early detection of head and neck cancer. | 04-22-2010 |
| 20100099103 | Antibody Libraries - The present invention features improved in vitro RNA display libraries to allow reliable expression and selection of scFv antibody molecules from expression libraries. The scFv antibody libraries of the invention contain an optimized, shortened inter-domain linker that improves expression scFv antibody expression. The scFv antibody libraries also include short nucleic acid barcodes that allow for identification of individual library clones, libraries or subsets thereof. Primers for generating, amplifying and spectratyping the scFv antibody libraries of the invention are also provided. | 04-22-2010 |
| 20100099104 | GENETIC TEST FOR THE IDENTIFICATION OF CARRIERS OF COMPLEX VERTEBRAL MALFORMATIONS IN CATTLE - Genetic markets for identifying bovine carriers of complex vertebral malformation (CVM) disease gene are described. The genetic markers, including the microsatellite markers, BM4129, INRAA003, BMS2790, ILSTS029, INRA123, BM220, HUJ246, BMS862, BMS937, BL1048, BMS2095 and BMS1266 and the bovine SLC35A3 gene, are located on bovine chromosome BTA3. The G/T polymorphism at position 559 of the bovine SLC35A3 gene is identified as being causative and diagnostic for CVM in cattle. | 04-22-2010 |
| 20100099105 | ANTIBODIES HAVING BINDING SPECIFICITY FOR THE EXTRACELLULAR DOMAIN OF A BREAST CANCER RESISTANCE PROTEIN (BCRP) - The present invention includes methods of identifying and/or isolating stem cells based on expression of BCRP. The present invention also describes methods of obtaining and/or using cell populations enriched for stem cells. In addition, methods are provided for diagnosing and/or prognosing leukemia, particularly human acute myelogenous leukemia (AML), through assaying for BCRP expression in leukemic cells. | 04-22-2010 |
| 20100099106 | CELL DEATH INHIBITOR - The cell death inhibitor comprising a substance capable of binding to macrophage migration inhibitory factor is useful as a preventive/therapeutic agent for, e.g., heart diseases, neurodegenerative diseases, cerebrovascular diseases, central nervous infections, traumatic diseases, demyelinating diseases, bone/joint diseases, kidney diseases, liver diseases, myelodysplastic diseases, arteriosclerosis, diabetes, pulmonary hypertension, sepsis, inflammatory bowel diseases, autoimmune diseases, failure accompanying rejection in organ transplantation, AIDS, cancer, etc. | 04-22-2010 |
| 20100099107 | METHOD FOR IDENTIFYING AN INTESTINAL PHENOTYPE - The present invention relates to a method for identifying cells having a predisposition to develop an intestinal phenotype, wherein the cells are characterized by the loss of expression of the RUNX3 gene and the expression of one or more intestinal marker genes. In particular, the invention is directed to the identification of cells, which exhibit an intestinal phenotype representing a precursor of gastric cancer. Furthermore, the invention discloses a method for identifying a compound inhibiting the development of an intestinal phenotype in cells having a predisposition to develop an intestinal phenotype. Finally, the invention also relates to kits of parts for performing these methods. | 04-22-2010 |
| 20100099108 | Method for Detecting, Isolating, and Characterizing Cells from Body Samples by Transfection with Nucleic Acid Constructs - A method for detecting or isolating disease-associated cells or pluripotent stem cells from body samples is provided where cells of a body sample are transfected with nucleic acid constructs that include the following components: (a) a promoter element containing at least one DNA site for binding one or more transcription factors; and (b) a reporter gene that enables the diseased or stem cells to be detected. When the method is used for detecting disease-associated cells, the transcription factor initiates at least one signalling activity in the disease-associated cells that is not present in healthy cells. | 04-22-2010 |
| 20100099109 | Methods for Analyzing Drug Response - The present invention provides methods, instruments, reagents, kits and the biology involved in analyzing drug response. An embodiment of the present invention provides an approach for the characterization a plurality of pathways in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states of cellular molecules such as proteins, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Some of these categories include redox potential, ITIM phosphorylation, intracellular pH and other categories allows for characterization of such pathways and cell populations. Also, the present analysis is useful for the analysis of the effect of compounds on potential target cells. | 04-22-2010 |
| 20100099110 | Allele-Specific Amplification - The present invention includes a method of allele-specific amplification, utilizing an allele-specific oligonucleotide, at least partially complementary to more than one variant of the target sequence, but having a 3′-terminal nucleotide complementary to only one variant of the target sequence and having at least one nucleotide with a base covalently modified at the exocyclic amino group, wherein the allele-specific oligonucleotide is extended by a nucleotide-incorporating biocatalyst predominantly when hybridized to the variant of the target sequence for which it has said complementary 3′-terminal nucleotide. | 04-22-2010 |
| 20100099111 | ANTIBODIES AGAINST A PROTEIN ENTITLED 161P2F10B - Antibodies and methods of using same against products of the gene designated 161P2F10B and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit a humoral or cellular immune response. | 04-22-2010 |
| 20100105028 | PROBE FOR DETECTING NUCLEIC ACIDS - The invention relates to a probe for detecting nucleic acids, to a method for producing the probe, methods for carrying out analytical reactions and test kits containing the reagents that are required for carrying out the probe-based analytical reaction. | 04-29-2010 |
| 20100105029 | Self-contained biological analysis - Devices, containers, and methods are provided for performing biological analysis in a closed environment. Illustrative biological analyses include nucleic acid amplification and detection and immuno-PCR. | 04-29-2010 |
| 20100105030 | NUCLEIC ACID BASE PAIRS - The invention relates to non-natural bases and base pairs that expand the normal DNA-based encoding system. Compositions herein may comprise at least one non-natural base that may interact with another base via a Watson Crick-type hydrogen bonding geometry and/or a Hoogsteen-type hydrogen bonding geometry. The bases may be used in a molecular entity, such as an oligomer or any other entity wherein the bases are attached to a backbone. For example, they may be comprised in DNA, RNA, or PNA, or a variety of other nucleic acid-type systems. | 04-29-2010 |
| 20100105031 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR - Disclosed is a method for the prediction of the efficacy of a vascularization inhibitor. In the method, the anti-tumor effect of a vascularization inhibitor can be predicted by measuring the number of blood vessels surrounded by pericytes in a tumor and using the measurement value as a measure for the anti-tumor effect. | 04-29-2010 |
| 20100105032 | HIGHLY SENSITIVE MULTIPLEX SINGLE NUCLEOTIDE POLYMORPHISM AND MUTATION DETECTION USING REAL TIME LIGASE CHAIN REACTION MICROARRAY - A method and apparatus for real-time, simultaneous, quantitative measurement of one or more single nucleotide polymorphisms in one or more target nucleic acids is provided. This method involves combining a ligase chain reaction (LCR), a ligase detection reaction (LDR), and/or a polymerase chain reaction (PCR) technique with an evanescent wave technique. | 04-29-2010 |
| 20100105033 | METHOD FOR SINGLE NUCLEOTIDE POLYMORPHISM AND MUTATION DETECTION USING REAL TIME POLYMERASE CHAIN REACTION MICROARRAY - A method and apparatus for real-time, simultaneous, qualitative measurement of one or more single nucleotide polymorphisms in one or more target nucleic acids is provided. This method involves combining a polymerase chain reaction (PCR) technique with an evanescent wave technique. | 04-29-2010 |
| 20100105034 | DETECTING AND TREATING DEMENTIA - This document relates to methods and materials for detecting mutations that can be linked to dementia. For example, methods and materials for detecting one or more mutations within PGRN nucleic acid are provided. This document also provides methods and materials for detecting the level of progranulin expression. In addition, this document relates to methods and materials for treating mammals having a neurodegenerative disorder (e.g., dementia). For example, methods and materials for increasing PGRN polypeptide levels in mammals are provided, as are methods and materials for identifying agents that can be used to increase PGRN polypeptide levels in mammals. | 04-29-2010 |
| 20100105035 | ELECTROLUMINESCENT-BASED FLUORESCENCE DETECTION DEVICE - The present invention provides compositions providing and methods using fluorescence detection device, comprising an electroluminescent light (EL) source, for measuring fluorescence in biological samples. In particularly preferred embodiments, the present invention provides an economical, battery powered and Hand-held device for detecting fluorescent light emitted from reporter molecules incorporated into DNA, RNA, proteins or other biological samples, such as a fluorescence emitting biological sample on a microarray chip. Further, a real-time hand-held PCR Analyzer device comprising an EL light source for measuring fluorescence emissions from amplified DNA is provided. | 04-29-2010 |
| 20100105036 | SIR2 Activity - This invention relates to methods of screening compounds that modulate cellular and organismal processes by modification of the activity of SIR2 and/or transcription factors, e.g., p53, particularly methods of screening for compounds that modify lifespan and/or metabolism of a cell or an organism by modulation of the activity of SIR2 and/or transcription factors, e.g., p53, and more particularly to methods of screening for compounds that modulate the activity of Sir2 and/or transcription factors, e.g., p53. In particular, the present invention relates to a method for screening a compound, by providing a test mixture comprising a transcription factor, Sir2, and a Sir2 cofactor with the compound, and evaluating an activity of a component of the test mixture in the presence of the compound. The invention further relates to therapeutic uses of said compounds. The invention further relates to a method of modifying the acetylation status of a transcription factor binding site on histone or DNA by raising local concentrations of Sir2. | 04-29-2010 |
| 20100105037 | METHODS FOR AMPLIFYING AND DETECTING NUCLEIC ACID SEQUENCES - The present invention, in different aspects and embodiments, provides nucleic acid amplification and detection methods that are both sensitive and fast. In various aspects there are disclosed amplification methods employing different combinations of primers to which can achieve exponential amplification and strand displacement, such as to generate a more than two fold increase of the amount of a target nucleic acid sequence during repeated cycles, while additionally permitting the production of single stranded products. Also provided are detection systems and kits. | 04-29-2010 |
| 20100105038 | GENETIC MARKERS FOR WEIGHT MANAGEMENT AND METHODS OF USE THEREOF - This application relates to methods and tests that allow for the establishment of personalized weight-loss programs for a subject based upon the subject's metabolic genotype in key metabolic genes. Kits and methods are disclosed for determining a subject's metabolic genotype, which may be used to select an appropriate therapeutic/dietary regimen or lifestyle recommendation based upon the likelihood of a subject's responsiveness to certain diets and activity levels. Such a personalized weight-loss program will have obvious benefits (e.g., yield better results in terms of weight loss and weight maintenance) over traditional weight-loss programs that do not take into account genetic information. | 04-29-2010 |
| 20100105039 | LABEL-FREE COLORIMETRIC DETECTION - The present invention provides a sensor system kit for detecting an analyte, consisting essentially of: a nucleic acid enzyme, wherein the nucleic acid enzyme cleaves a substrate in the presence of the analyte; the substrate for the nucleic acid enzyme, comprising a polynucleotide; an aggregator; and particles. | 04-29-2010 |
| 20100105040 | MICROFLUIDIC SYSTEMS INCLUDING POROUS POLYMER ELECTRODES - Microfluidic devices that incorporate a porous polymer electrode assemblies, including microfluidic device useful for detection of nucleic acids, as well as methods of using the microfluidic devices. | 04-29-2010 |
| 20100105041 | REAGENTS AND METHODS FOR DETECTING CYP2D6 POLYMORPHISMS - The present invention relates to oligonucleotide sequences for amplification primers and detection probes and their use in nucleic acid amplification methods for the specific detection of clinically relevant CYP2D6 polymorphisms, in particular CYP2D6 polymorphisms associated with adverse drug response. The oligonucleotide sequences are also provided assembled as kits that can be used to predict how an individual will respond to drugs or other xenobiotic compounds that are metabolized, at least in part, by CYP2D6. | 04-29-2010 |
| 20100105042 | NOVEL METHODS - The present invention provides methods for site-specifically integrating at least one first nucleic acid into a genome of at least one cell, comprising:
| 04-29-2010 |
| 20100105043 | METHODS FOR MODULATING EMBRYONIC STEM CELL DIFFERENTIATION - Described herein is Zscan4, a gene exhibiting 2-cell embryonic stage and embryonic stem cell specific expression. Identification of nine Zscan4 co-expressed genes is also described Inhibition of Zscan4 expression inhibits the 2-cell to 4-cell embryonic transition and prevents blastocyst implantation, expansion and outgrowth. Provided herein are methods of inhibiting differentiation of a stem cell, promoting blastocyst outgrowth of embryonic stem cells and identifying a subpopulation of stem cells expressing Zscan4. Further described is the identification of Trim43 as a gene exhibiting morula-specific expression. Also provided are isolated expression vectors comprising a Zscan4 promoter, or a Trim43 promoter operably linked to a heterologous polypeptide and uses thereof. Further provided are transgenic animals comprising transgenes encoding marker proteins operably linked to Zscan4 and Trim43 promoters. | 04-29-2010 |
| 20100105044 | ILEAL POUCH-ANAL ANASTOMOSIS (IPAA) FACTORS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - A common long term problem after Ileal Pouch-Anal Anastomosis (IPAA) is the inflammation of the pouch, called pouchitis. Additionally, about 5-10% of patients undergoing IPAA with a diagnosis of ulcerative colitis at the time of surgery are subsequently diagnosed with Crohn's disease. In one embodiment, the present invention provides methods of diagnosing and predicting susceptibility to pouchitis after IPAA by detecting the presence or absence of pANCA and/or Cbir1 Flagellin expression. | 04-29-2010 |
| 20100105045 | DNP63A Gene and Screening Methods of Anticancer Agent by Using it - This invention relates to a gene encoding ΔNp63α and screening methods of anticancer-drugs thereof, more specifically a gene encoding ΔNp63α and a protein which is transported from nucleus to cytoplasm by contacting with potential anti-cancer-drugs in an epithelial cell carcinoma, a recombinant vector comprising said gene and reporter genes, and carcinoma cells comprising said vector. Also, This invention relates to high throughput screening methods of anticancer-drug comprising identifying the transportation of ΔNp63α protein from nucleus to cytoplasm by contacting with potential anticancer-drug in a carcinoma cell. | 04-29-2010 |
| 20100105046 | METHODS OF DIAGNOSING CARDIOVASCULAR DISEASE - The invention relates to predicting which individuals are at risk of developing atherosclerotic vascular disease, and once having disease, which individuals are at risk of experiencing plaque rupture which, depending on the site of the plaque, could produce myocardial infarction, stroke, critical limb ischemia, or other vascular event. The invention further relates to methods of diagnosing and aiding in the diagnosis of vascular conditions such as atherosclerosis, premature coronary artery disease and coronary artery disease, by detecting a resistin gene product in an individual. The invention further relates to methods of predicting, and aiding in predicting, the likelihood that an individual will experience a vascular event, such as but not limited to, a myocardial infarction, acute coronary syndrome, stroke, transient ischemic attack (TIA), or critical limb ischemia. | 04-29-2010 |
| 20100105047 | Method for the Simultaneous Determination of Blood Group and Platelet Antigen Genotypes - RBC and platelet (Plt) alloimmunization requires antigen-matched blood to avoid adverse transfusion reactions. Some blood collection facilities use unregulated Abs to reduce the cost of mass screening, and later confirm the phenotype with government approved reagents. Alternatively, RBC and Plt antigens can be screened by virtue of their associated single nucleotide polymorphisms (SNPs). We developed a multiplex PCR-oligonucleotide extension assay using the GenomeLab SNPStream platform to genotype blood for a plurality of blood group antigen-associated SNPs, including but not limited to: RhD (2), RhC/c, RhE/e, S/s, K/k, Kp | 04-29-2010 |
| 20100105048 | FUNCTIONALIZED FLUORESCENT NANOCRYSTAL DETECTION SYSTEM - The present invention include fluorescent nanocrystals which have high fluorescence intensity, are water soluble, exhibit physical and chemical stability, and whose spectral properties are detectably modified as the size of functional groups bonded to the nanocrystal surface change when contacted with target molecules in a sample. The molecules in the sample add to or reduce the size of functional groups on the fluorescent nanocrystal proportional to the activity and amount of the target molecules. The present invention may be used to detect telomerase in a sample. | 04-29-2010 |
| 20100105049 | PROCESSES AND COMPOSITIONS FOR METHYLATION-BASED ENRICHMENT OF FETAL NUCLEIC ACID FROM A MATERNAL SAMPLE USEFUL FOR NON INVASIVE PRENATAL DIAGNOSES - Provided are compositions and processes that utilize genomic regions differentially methylated between a mother and her fetus to separate, isolate or enrich fetal nucleic acid from a maternal sample. The compositions and processes described herein are useful for non-invasive prenatal diagnostics, including the detection of chromosomal aneuplodies. | 04-29-2010 |
| 20100105050 | REAL TIME DETECTION OF GENETIC SEQUENCES USING A BIPARTITE PROBE - The present invention concerns a method for detection or quantification of a Target Genetic Sequence in a Genetic Sample using a Bipartite Probe. A Bipartite Probe is made of a Target Binding Sequence capable of hybridizing a Target Genetic Sequence and a Nucleic Acid Binding Probe Sequence capable of being transcribed during PCR into the Capture Probe Sequence where it can hybridize with a Signal Generation Molecule. The Signal Generation Molecule participates in the PCR reaction and confers a fluorescent quality to the PCR amplified product. The reaction temperature of each PCR cycle is reduced below the Tm of the Quencher Oligonucleotide thereby allowing quenching of the fluorescence of the non-incorporated Signal Generation Molecule. Fluorescent detection of each PCR cycle establishes a quantitative PCR result. | 04-29-2010 |
| 20100105051 | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER - The invention relates to newly discovered nucleic acid molecules and proteins associated with breast cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers are provided. | 04-29-2010 |
| 20100105052 | Nucleic acid sequencing and process - The present invention is directed to compositions and methods for nucleic acid identification and detection. Compositions and methods of the present invention include extracting and fragmenting target nucleic acids from a sample, using the fragmented target nucleic acids to produce target nucleic acid templates and subjecting those target nucleic acid templates to amplification methods to form nucleic acid nanoballs. The invention also includes methods of detecting and identifying sequences using various sequencing applications, including sequencing by ligation methods. | 04-29-2010 |
| 20100105053 | APTAMER BASED SENSORS AND RELATED METHODS AND SYSTEMS - An aptamer based-sensor comprising: a target binding aptamer attaching a Raman probe and a metal coated surface; and related methods and systems | 04-29-2010 |
| 20100105054 | GENE EXPRESSION IN DUCHENNE MUSCULAR DYSTROPHY - Gene expression in peripheral blood from individuals with Duchenne muscular dystrophy (DMD), compared to control individuals, demonstrated differential gene sets that could be used in a method to diagnose DMD, to evaluate effect of DMD therapy, and/or to evaluate propensity to DMD. | 04-29-2010 |
| 20100105055 | SYSTEMS AND METHODS OF ANALYZING NUCLEIC ACID POLYMERS AND RELATED COMPONENTS - Systems and methods of identifying, sequencing and/or detecting nucleic acid polymers, as well as related components (e.g., substrates, software and the like) are disclosed. | 04-29-2010 |
| 20100105056 | Method and apparatus for performing multiple simultaneous manipulations of biomolecules in a two dimentional array - This invention relates to methods and apparati for performing multiple simultaneous manipulations of biomolecules in a two-dimensional array, such as a gel, membrane, tissue biopsy, etc. Such manipulations particularly include assays and nucleic acid amplification protocols. | 04-29-2010 |
| 20100105057 | HUMAN DIABETES SUSCEPTIBILITY TNFRSF10D GENE - The present invention relates to a diagnostic method of determining whether a subject is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the TNFRSF10D gene locus in a biological sample of said subject. | 04-29-2010 |
| 20100105058 | Method for Measuring DNA Methylation - The present invention relates to a method of measuring the content of methylated DNA in a DNA region of interest in a genomic DNA contained in a biological specimen, and so on. | 04-29-2010 |
| 20100105059 | ASSAY FOR CHLAMYDIA TRACHOMATIS BY AMPLIFICATION AND DETECTION OF CHLAMYDIA TRACHOMATIS PMPA GENE - A region of the | 04-29-2010 |
| 20100105060 | FAST RESULTS HYBRID CAPTURE ASSAY ON AN AUTOMATED PLATFORM - The present invention comprises a method that provides fast and reliable results for detecting the presence of a target nucleic acid molecule in a sample. | 04-29-2010 |
| 20100105061 | AUTOIMMUNE GENES IDENTIFIED IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) - The present invention relates to a genes and autoimmunity. More specifically, the invention relates to the identification of genes that are associated with Systemic Lupus Erythematosus (SLE) in children and/or adults. Also disclosed are methods for making and using the genetic selection tool used to identify SLE associated genes, and their uses in diagnosis and treatment of the disease. | 04-29-2010 |
| 20100105062 | Genetic Markers for Optimizing Treatment for Schizophrenia - This document provides methods and materials related to genetic markers for predicting response to a treatment for schizophrenia (SZ). For example, methods for using such genetic markers to select optimal treatments are provided. | 04-29-2010 |
| 20100105063 | Methods for evaluating the methylation status of a polynucleotide - The invention provides methods related to evaluating the methylation status of a polynucleotide that includes an internal control. | 04-29-2010 |
| 20100105064 | METHOD OF SCREENING TEST SUBSTANCES FOR TREATING OR PREVENTING A DISEASE MEDIATED BY PLASMA CELLS - The present invention relates to a method of screening a compound for potential effectiveness in treating or preventing a mammalian disease mediated by plasma cells or a mammalian disease caused by virus infection of mammalian cells. Compounds are tested for their ability to inhibit IRE1-mediated processing of untranslatable XBP-1 mRNA into translatable XBP-1 mRNA. Drugs that are useful in treating or preventing a mammalian disease mediated by plasma cells and a method for detecting XBP-1 activity in living cells are also described. | 04-29-2010 |
| 20100105065 | Miniaturized Fluid Delivery and Analysis System - The present invention provides a method for combining a fluid delivery system with an analysis system for performing immunological or other chemical of biological assays. The method comprises a miniature plastic fluidic cartridge containing a reaction chamber with a plurality of immobilized species, a capillary channel, and a pump structure along with an external linear actuator corresponding to the pump structure to provide force for the fluid delivery. The plastic fluidic cartridge can be configured in a variety of ways to affect the performance and complexity of the assay performed. | 04-29-2010 |
| 20100105066 | Tissue Rejection - This document relates to methods and materials involved in detecting tissue rejection (e.g., organ rejection). For example, this document relates to methods and materials involved in the early detection of kidney tissue rejection. | 04-29-2010 |
| 20100112551 | Approaches to identifying mutations associated with hereditary nonpolyposis colorectal cancer - The present invention relates to the field of genetic screening. More specifically, the described embodiments concern methods to screen multiple samples, in a single assay, for the presence or absence of mutations or polymorphisms in a plurality of genes. Approaches to screen for the presence or absence of mutations that are associated with Hereditary Nonpolyposis Colorectal Cancer (HNPCC) and approaches to design primers that generate extension products that facilitate the resolution of multiple extension products in a single lane of a gel or in a single run on a column are also provided. | 05-06-2010 |
| 20100112552 | NUCLEIC ACID-BINDING CHIPS FOR DETECTING NITROGEN DEFICIENCIES AS PART OF BIOPROCESS CONTROL - The invention relates to nucleic acid-binding chips for monitoring bioprocesses, specifically for detecting nitrogen deficiencies. Said chips carry probes that are sensitive to at least three of the following 50 genes: kdgR, citA, htrA, ycn1, yppF, trpB, ggt, alsR, glnA, nrgA, yciC, yvtA, nrgB, ycnJ, glnR, yvlA, yncE, yvlB, trpF, ydfS, trpD, ycnK, trpB, trpC, nasD, ycdH, nasC, nasB, trpE, pckA, nasF, yrkC, and tnrA or the homolgs to SEQ ID NO: 91, 41, 53, 19, 55, 47, 21, 17, 9, 85, 45, 49, 95, 63, 15, 93, or 81 at a maximum of 80 different probes that are specific of nitrogen metabolism. The invention also relates to the use of corresponding gene probes, especially on the aforementioned chips, to corresponding methods and possible uses. | 05-06-2010 |
| 20100112553 | LUCIFERASE GENE OPTIMIZED FOR USE IN IMAGING OF INTRACELLULAR LUMINESCENCE - The present invention provides a gene construct encoding pH insensitive luciferase for visualizing intracellular information, wherein an intracellular expression activity is higher compared with a gene construct of luciferase derived from a firefly. | 05-06-2010 |
| 20100112554 | NUCLEIC ACID LIGANDS TO COMPLEX TARGETS - The present invention relates to a nucleic acid ligands capable of binding to one or more target molecules in a complex mixture. | 05-06-2010 |
| 20100112555 | METHOD FOR THE DIAGNOSIS OF COLORECTAL CANCER - The object of the present invention refers to an in vitro method for diagnosing colorectal cancer based on the determination from a biological sample obtained from a subject, of promoter methylation status of at least one of the genes APC, RARB2 and p14 and, optionally, MGMT and p16. Likewise, object of the present invention is a kit for performing the method of the invention. | 05-06-2010 |
| 20100112556 | METHOD FOR SAMPLE ANALYSIS USING Q PROBES - A method of sample analysis is provided. In certain embodiments, the method may comprise: a) contacting a plurality of Q probes with a nucleic acid sample comprising a target polynucleotide under hybridization conditions to form a plurality of flap endonuclease substrates each comprising a Q probe and a site in the target polynucleotide; b) contacting the plurality of flap endonuclease substrates with a flap endonuclease under cleavage conditions to produce cleavage products, in which each of the Q probes of the flap endonuclease substrates is cleaved to produce cleavage products that include at least a first fragment that is hybridized with a site in the target polynucleotide and a second fragment that is linear and free in solution; and c) detecting at least one of the cleavage products. | 05-06-2010 |
| 20100112557 | METHOD FOR HIGH RESOLUTION MELT GENOTYPING - Various methods are described that provide for high resolution melt (HRM) genotyping. The embodiments include providing a locus specific primer and two allele specific primers each having a 5′ end with a short tail, providing a nucleic acid having a single nucleotide polymorphism (SNP) base located within 1-20 base pairs of the 3′ end of nucleic acid, hybridizing the locus specific primer and the allele specific primers to the nucleic acid, amplifying the sample using pyrophosphorolysis activated polymerization (PAP) PCR enzyme, and determining the Tm of the amplicons using HRM. In other embodiments, reactions mixtures and kits for HRM genotyping are provided and disclosed. These kits comprise a locus specific primer, one or more allele specific primers each having a 5′ end with a short tail, a nucleic acid, and a pyrophosphorolysis activate polymerization (PAP) PCR enzyme. | 05-06-2010 |
| 20100112558 | Probe Bead Synthesis and Use - The present invention relates to the field of methods and devices of miniaturized synthesis. More specifically, the present invention relates to the parallel synthesis of large number of different types of molecules and oligomers, such as oligonucleotides (oligos), peptides, lipids, carbohydrates, small ligand molecules, and other organic and inorganic molecules as probes for multiplexing assays. The probes may be synthesized from and/or attached to nanobeads to microbeads. The present invention provides for assays of multiplexing large scale biology, such as analysis of genomic DNAs and RNAs and proteomic proteins or peptides performed simultaneously on the synthetic beads. | 05-06-2010 |
| 20100112559 | PRIMER SET FOR AMPLIFYING OBESITY GENE, REAGENT FOR AMPLIFYING OBESITY GENE CONTAINING THE SAME, AND THE USES THEREOF - Primer sets for amplifying target regions containing sites to be detected in the obesity gene (the β2AR gene, the β3AR gene, and the UCP1 gene) by a gene amplification method are provided, wherein the primer sets can amplify the regions specifically. Three pairs of primer sets are used including forward primers composed of the base sequences of SEQ ID NO: 9 or SEQ ID NO: 109, SEQ ID NO: 25, and SEQ ID NO:43 as well as reverse primers composed of the base sequences of SEQ ID NO: 18, SEQ ID NO: 30, and SEQ ID NO: 63, respectively. The use of these primer sets makes it possible to specifically amplify a target region including a site where a polymorphism to be detected is generated in the β2AR gene, the β3AR gene, and the UCP1 gene, in the same reaction solution at the same time. | 05-06-2010 |
| 20100112560 | MECHANISM TO SIGNAL RECEPTOR-LIGAND INTERACTIONS WITH LUMINESCENT QUANTUM DOTS - Semiconductor quantum dots are becoming valuable analytical tools for use in biomedical applications. Indeed, their unique properties offer the opportunity to design luminescent probes for imaging and sensing with unprecedented performance. In this context, we have identified operating principles to transduce supramolecular association of complementary receptor-ligand binding pairs into enhancement or suppression in the luminescence of sensitive quantum dots. Thus, complementary receptor-ligand binding pairs can be identified with luminescence measurements relying on our design logic. In fact, we have demonstrated with a representative example that our protocol can be adapted to signal receptor-ligand binding. | 05-06-2010 |
| 20100112561 | FLUORESCENT NUCLEOSIDE ANALOGUES - Briefly described, embodiments of the present disclosure include novel fluorescent nucleoside analogs (fNAs) including a fluorescent nucleobase, selected from a purine and a pyrimidine base or analog thereof, and a modified sugar moiety that differs in structure from a sugar moiety of a naturally occurring nucleoside. In embodiments, the fNAs of the present disclosure are analogues of NA prodrugs used to treat viral disorders. Embodiments of the present disclosure also include methods of making the novel fNAs of the present disclosure. | 05-06-2010 |
| 20100112562 | Mutation Implicated in Abnormality of Cardiac Sodium Channel Function - A novel mutation in the SCN5A gene is associated with loss of cardiac sodium channel function. Analysis of the novel mutation provides an early diagnosis of subjects with cardiac diseases or disorders caused by loss of cardiac sodium channel function, particularly Brugada syndrome. Diagnostic methods include analyzing the sequences of the SCN5A gene or protein of an individual to be tested and comparing them with the sequences of the native, nonvariant SCN5A gene or protein. Pre-symptomatic diagnosis of these syndromes will enable practitioners to treat these disorders using existing medical therapy, e.g., using sodium channel blockers or through electrical stimulation. | 05-06-2010 |
| 20100112563 | MULTIPLEX ANALYSIS OF NUCLEIC ACIDS - A method for identifying target nucleic acids includes the steps of contacting a sample containing a plurality of target nucleic acids with at least one series of nucleotide primers under conditions that allow binding of said primers to at least one of said target nucleic acids and labeling of said bound primers with a detectable signal, wherein one member within each series has a lower level of specificity than other members of the series; and measuring said detectable signal of each labeled primer to determine the identity of said target nucleic acids. | 05-06-2010 |
| 20100112564 | Methods for detecting therapeutic effects of anti-cancer drugs - precancerous lesions, and subject having precancerous lesions and being treated with an anti-cancer agent; (2) isolating total microbial genomic DNA from the fecal samples to provide total microbial genomic DNA; (3) comparing the total microbial genomic DNA using fingerprint spectrum analysis; (4) identifying key fingerprint bands correlated with the effect of the anti-cancer agent; (5) identifying key microorganisms associated with the key fingerprint bands; (6) designing microbial sequence-specific primers and probes; and (7) determining the quantitative differences of the key microorganisms in fecal samples to identify an indicator microorganism for monitoring the effect of the anti-cancer agent. | 05-06-2010 |
| 20100112565 | Methods, kits, and reaction mixtures for high resolution melt genotyping - Various methods are described that provide for high resolution melt (HRM) genotyping. Some embodiments comprise providing a locus specific primer, and two allele specific primers each comprising at least one single nucleotide polymorphism (SNP) allele-hybridizable sequence, wherein at least one of the allele specific primers also comprises at least one nucleotide alteration. In some embodiments, a nucleic acid is provided comprising a SNP base located within 1-20 bases of its 3′ end. Some embodiments comprise hybridizing the locus specific primer and at least one of the allele specific primers to the nucleic acid, amplifying the hybridized nucleic acid using pyrophosphorolysis activated polymerization (PAP) PCR, and determining the melting temperature (Tm) of the resulting amplicons, for example, using HRM. In some embodiments, reaction mixtures and kits for HRM genotyping are provided. The reaction mixtures and kits can each comprise a locus specific primer, one or more allele specific primers each comprising at least one SNP allele-hybridizable sequence, and a PAP PCR enzyme, wherein at least one of the allele specific primers also comprises a nucleotide alteration, for example, a tail. | 05-06-2010 |
| 20100112566 | VIPR1S as Modifiers of the E2F/RB Pathway and Methods of Use - Human VIPR1 genes are identified as modulators of the E2F/RB pathway, and thus are therapeutic targets for disorders associated with defective E2F/RB function. Methods for identifying modulators of E2F/RB, comprising screening for agents that modulate the activity of VIPR1 are provided. | 05-06-2010 |
| 20100112567 | RANDOM ACCESS SYSTEM AND METHOD FOR POLYMERASE CHAIN REACTION TESTING - A random access, high-throughput system and method for preparing a biological sample for polymerase chain reaction (PCR) testing are disclosed. The system includes a nucleic acid isolation/purification apparatus and a PCR apparatus. The nucleic acid isolation/purification apparatus magnetically captures nucleic acid (NA) solids from the biological sample and then suspends the NA in elution buffer solution. The PCR testing apparatus provides multiple cycles of the denaturing, annealing, and elongating thermal cycles. More particularly, the PCR testing apparatus includes a multi-vessel thermal cycler array that has a plurality of single-vessel thermal cyclers that is each individually-thermally-controllable so that adjacent single-vessel thermal cyclers can be heated or cooled to different temperatures corresponding to the different thermal cycles of the respective PCR testing process. | 05-06-2010 |
| 20100112568 | METHODS AND KITS FOR DIAGNOSIS OF MULTIPLE SCLEROSIS IN PROBABLE MULTIPLE SCLEROSIS SUBJECTS - Provided are methods and kits for determining the probability of a subject diagnosed with probable multiple sclerosis to develop definite diagnosis of multiple sclerosis by determining the expression level of polynucleotides which are differentially expressed between subjects diagnosed with probable multiple sclerosis and which further develop definite multiple sclerosis and unaffected subjects. Also provided are methods and kits for selecting a treatment regimen of a subject diagnosed with probable multiple sclerosis. | 05-06-2010 |
| 20100112569 | MICROFLUIDIC DEVICES AND METHODS OF GENERATING AND USING SAME - A microfluidic device comprising a substrate having formed therein microfluidic paths, at least a portion of the microfluidic paths having attached thereto a plurality of monolayers, wherein at least a portion of the monolayers comprises a photoactivatable group capable of generating a reactive group upon exposure to a light source, the reactive group being for binding a screenable moiety. | 05-06-2010 |
| 20100112570 | Genetic Markers for Weight Management and Methods of Use Thereof - This application relates to methods and tests that allow for the establishment of personalized weight-loss programs for a subject based upon the subject's metabolic genotype in key metabolic genes. Kits and methods are disclosed for determining a subject's metabolic genotype, which may be used to select an appropriate therapeutic/dietary regimen or lifestyle recommendation based upon the likelihood of a subject's responsiveness to certain diets and activity levels. Such a personalized weight-loss program will have obvious benefits (e.g., yield better results in terms of weight loss and weight maintenance) over traditional weight-loss programs that do not take into account genetic information. | 05-06-2010 |
| 20100112571 | COMPOSITIONS AND METHODS FOR DETECTING MUTATIONS IN JAK2 NUCLEIC ACID - The invention disclosed herein is based on the identification of novel mutations in the JAK2 gene and JAK2 protein. The invention provides compositions and methods useful for diagnosing hematopoietic diseases including, for example, myeloproliferative diseases. The invention also provides compositions and methods useful for determining a prognosis of an individual diagnosed as having a hematopoietic disease. | 05-06-2010 |
| 20100112572 | COMPOSITIONS, METHODS, AND KITS FOR FABRICATING CODED MOLECULAR TAGS - The teachings herein generally relates to probes comprising fabricated coded molecular tags for detecting analytes. The teachings also relate to compositions, methods, and kits for fabricating coded molecular tags comprising a multiplicity or reporter groups in an ordered pattern. | 05-06-2010 |
| 20100112573 | Methods, Compositions, and Kits Comprising Linker Probes for Quantifying Polynucleotides - The present invention is directed to methods, reagents, kits, and compositions for identifying and quantifying target polynucleotide sequences. A linker probe comprising a 3′ target specific portion, a loop, and a stem is hybridized to a target polynucleotide and extended to form a reaction product that includes a reverse primer portion and the stem nucleotides. A detector probe, a specific forward primer, and a reverse primer can be employed in an amplification reaction wherein the detector probe can detect the amplified target polynucleotide based on the stem nucleotides introduced by the linker probe. In some embodiments a plurality of short miRNAs are queried with a plurality of linker probes, wherein the linker probes all comprise a universal reverse primer portion a different 3′ target specific portion and different stems. The plurality of queried miRNAs can then be decoded in a plurality of amplification reactions. | 05-06-2010 |
| 20100112574 | Method for the Simultaneous Determination of Blood Group and Platelet Antigen Genotypes - RBC and platelet (Plt) alloimmunization requires antigen-matched blood to avoid adverse transfusion reactions. Some blood collection facilities use unregulated Abs to reduce the cost of mass screening, and later confirm the phenotype with government approved reagents. Alternatively, RBC and Plt antigens can be screened by virtue of their associated single nucleotide polymorphisms (SNPs). We developed a multiplex PCR-oligonucleotide extension assay using the GenomeLab SNPStream platform to genotype blood for a plurality of blood group antigen-associated SNPs, including but not limited to: RhD (2), RhC/c, RhE/e, S/s, K/k, Kp | 05-06-2010 |
| 20100112575 | Noninvasive Diagnosis of Fetal Aneuploidy by Sequencing - Disclosed is a method to achieve digital quantification of DNA (i.e., counting differences between identical sequences) using direct shotgun sequencing followed by mapping to the chromosome of origin and enumeration of fragments per chromosome. The preferred method uses massively parallel sequencing, which can produce tens of millions of short sequence tags in a single run and enabling a sampling that can be statistically evaluated. By counting the number of sequence tags mapped to a predefined window in each chromosome, the over- or under-representation of any chromosome in maternal plasma DNA contributed by an aneuploid fetus can be detected. This method does not require the differentiation of fetal versus maternal DNA. The median count of autosomal values is used as a normalization constant to account for differences in total number of sequence tags is used for comparison between samples and between chromosomes. | 05-06-2010 |
| 20100112576 | FOCUSING CHAMBER - Aspects of the invention relate to devices and methods of use thereof for concentrating, positioning and/or manipulating agents within a fluid, including but not limited to genomic DNA. | 05-06-2010 |
| 20100112577 | APPARATUS AND METHODS FOR EFFICIENT PROCESSING OF BIOLOGICAL SAMPLES ON SLIDES - Methods for treating biological samples on microscope slides are set forth. One aspect of the invention is the use of predried reagents in wells on trays onto which the slides are placed, especially the use of predried reagents which dissolve sequentially. Yet another aspect of the invention is the use of external controls placed directly on a microscope slide in conjunction with a biological sample to be assayed. The external controls can be conveniently placed on a membrane which can be affixed to the slide. A further aspect of the invention is a specially designed tray to allow whole chromosome painting of all chromosomes of a cell sample on a single slide. The invention is also drawn to a coverslip with concave wells which act as reaction chambers when placed against a slide and filled with buffer. Preferably a reagent is predried in the well. A further aspect of the invention is a method of reacting samples on slides by placing them into a reaction chamber together with a coverslip which has a predried reagent on it. | 05-06-2010 |
| 20100112578 | Test chip, detection apparatus, and method for detecting analyte - A test chip for detecting an analyte modified with a modulator releasing electrons upon photoexcitation, comprising: semiconductor electrode part including a metal layer formed on a semiconductor layer; a probe immobilized on the metal layer, the probe trapping the analyte; and a counter electrode part including a conductive layer. A detection apparatus and a method for detecting an analyte are also disclosed. | 05-06-2010 |
| 20100112579 | METHOD AND DEVICE FOR THE DETECTION OF GENETIC MATERIAL BY POLYMERASE CHAIN REACTION - The present invention relates to a method and a portable device to detect a genetic material in a biological sample using the technique known as PCR (Polymerase Chain Reaction). The device comprises a reaction chamber which incorporates means of heating arranged to heat said chamber. The detection method is characterized in that the main phases are performed in the reaction chamber. The miniaturized system has the object of increasing efficiency, simplicity of use and the portability of the PCR in comparison with laboratory scale analysis. | 05-06-2010 |
| 20100112580 | MEANS AND METHODS FOR HAPLOTYPING MHC-DRB LOCI IN MAMMALS AND USES THEREOF - The invention relates to the typing of MHC-DRB loci in mammals. In particular, the invention provides a typing procedure for the mammalian DRB region that allows an easy, economical, high resolution, fast and accurate haplotyping protocol. The invention further provides the use of said typing procedure in genetic applications, and provides a kit for typing of MHC-DRB loci. | 05-06-2010 |
| 20100112581 | METHODS FOR NORMALIZING AND FOR IDENTIFYING SMALL NUCLEIC ACIDS - The present teachings are generally directed to methods for normalizing at least one species of small nucleic acid that is present in a population of small nucleic acid species, wherein the relative concentration of at least one small nucleic acid species is substantially greater than the relative concentration of at least one other small nucleic acid species in the population. At least one small nucleic acid species is normalized using a multiplicity of primers comprising degenerate sequences. In some embodiments, a small nucleic acid species is identified by inserting at least part of an extension product from a normalized population into a vector and subsequently sequencing the insert. In some embodiments, a small nucleic acid species is identified by determining the sequence of at least part of an extension product. | 05-06-2010 |
| 20100112582 | GENE ENCODING LABYRINTHIN, A MARKER FOR CANCER - A cDNA molecule that encodes a protein designated Labyrinthin (Lab) isolated and its nucleotide sequence is determined. The protein, or peptides derived from the protein, are markers useful to define novel classes of cancers. Diagnostic assays for these cancers use antibodies to Lab or nucleotide probes that hybridize with the lab gene or a fragment therefrom. Vaccines useful either to prevent recurrence of cancers in subjects who test positive for Lab (or lab), or to prevent initial occurrence of cancer, use proteins or peptides derived from Lab. Expression of Lab via immunogenic assays is used to monitor effects of cancer treatments. Antisense molecules against lab are used in treatments. Sense molecules of lab are used to restore lost lab function in diseased normal cells, for example, gland cells. | 05-06-2010 |
| 20100112583 | BLOOD DIAGNOSIS METHOD FOR DIALYSIS PATIENT AND DIALYSIS MACHINE - Provided is a blood diagnosis method and a dialysis machine, using a diagnostic marker which is versatile and which can contribute to the improvements in dialysis treatment and the evaluation of clinical effects,
| 05-06-2010 |
| 20100112584 | CYANINE COMPOUNDS AND THEIR USE IN STAINING BIOLOGICAL SAMPLES - Cyanine compounds having the general formula I for staining biological samples, wherein R | 05-06-2010 |
| 20100112585 | Method for Enriching Methylated CpG Sequences - Compositions and methods are provided for facilitating the enrichment of single-stranded DNA containing methylated CpG in a mixture containing methylated and unmethylated DNA. The compositions relate to methylation-binding protein domains that selectively bind to methylated single strand DNA. In embodiments of the invention, the methylated DNA is eluted in 0.4M-0.6M NaCl while the unmethylated single strand DNA is eluted in less than 0.4M salt. The ability to readily enrich for methylated DNA permits high throughput sequencing of the methylated DNA and identification of abnormal methylation patterns associated with disease. | 05-06-2010 |
| 20100112586 | DIAGNOSIS OF FETAL ABNORMALITIES BY COMPARATIVE GENOMIC HYBRIDIZATION ANALYSIS - The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, e.g. aneuploidy. The present invention involves performing comparative genomic hybridization (CGH) analysis when fetal cells are present in a mixed population of cells. The present invention involves detecting the presence of fetal cells in a mixed maternal sample by detecting the presence of non-maternal alleles in said sample. Furthermore, the present invention also involves correlating the presence of fetal cells in a mixed sample with CGH analysis results to detect a fetal abnormality or declare a test non-informative. | 05-06-2010 |
| 20100112587 | TRANSCRIPTOMIC BIOMARKERS FOR INDIVIDUAL RISK ASSESSMENT IN NEW ONSET HEART FAILURE - A novel transcriptomic biomarker for prognosis in heart failure has a direct clinical application in prediction of prognosis in new onset heart failure, heart disease, heart disorders and associated heart conditions. This approach should improve individualization of cardiac care and help identify patients at highest risk for circulatory collapse within the first years of presentation with heart failure. | 05-06-2010 |
| 20100112588 | METHODS FOR SANGER SEQUENCING USING PARTICLE ASSOCIATED CLONAL AMPLICONS AND HIGHLY PARALLEL ELECTROPHORETIC SIZE-BASED SEPARATION - Methods for highly parallel Sanger sequencing are discussed. In particular, provided herein are methods using particles to clonally amplify templates and to introduce the amplified nucleic acids into many parallel channels with a single template per channel. Once in the channels, the nucleic acids are separated by size using electrophoresis to produce long read length sequencing information. Methods involving optical detection of the size-separated nucleic acids and analysis of the resulting electropherograms to yield the sequences are disclosed. | 05-06-2010 |
| 20100112589 | ALLELE-ALLELE INTERACTIONS OF MTHFR GENE VARIANTS, AND USES THEREOF IN PREDICTING DISEASE RISK - The invention provides methods of predicting risk of developing a hyper-homocysteine-associated disease in a subject, based on genotyping of the methylenetetrahydrofolate reductase (MTHFR) gene, wherein the risk varies depending on whether the 677T polymorphism and the 1298C polymorphism are present in a cis configuration within a MTHFR gene or not. A preferred hyperhomocysteine-associated disease is myocardial infarction. Kits for predicting risk of developing a hyperhomocysteine-associated disease are also provided. | 05-06-2010 |
| 20100112590 | Diagnosing Fetal Chromosomal Aneuploidy Using Genomic Sequencing With Enrichment - Embodiments of this invention provide methods, systems, and apparatus for determining whether a fetal chromosomal aneuploidy exists from a biological sample obtained from a pregnant female. Nucleic acid molecules of the biological sample are sequenced, such that a fraction of the genome is sequenced. Respective amounts of a clinically-relevant chromosome and of background chromosomes are determined from results of the sequencing. The determination of the relative amounts may count sequences of only certain length. A parameter derived from these amounts (e.g. a ratio) is compared to one or more cutoff values, thereby determining a classification of whether a fetal chromosomal aneuploidy exists. Prior to sequencing, the biological sample may be enriched for DNA fragments of a particular sizes. | 05-06-2010 |
| 20100112591 | Tumor Suppressor Gene - A full-length cDNA encoding novel proteins involved in the control of cell proliferation (human Gros1-L and S) was successfully isolated from the human testis cDNA libraries. A full-length cDNA encoding the mouse homologues of the human Gros1 (mouse Gros1-L and S) was also isolated. The colony forming activity of cells exogenously expressing Gros1-L was significantly reduced, while that of cells expressing Gros1 antisense RNA was significantly increased. | 05-06-2010 |
| 20100112592 | METHODS FOR IDENTIFYING AN INCREASED LIKELIHOOD OF RECURRENCE OF BREAST CANCER - Methods of identifying a mammal having an increased likelihood of recurrence of breast cancer includes identifying in a breast tissue sample of the mammal expression of at least two genes selected from the group consisting of Hs.125867 (EVL), Hs.591847 (NAT1), Hs.208124 (ESR1), Hs.26225 (GABRP), Hs.408614 (ST8SIA1), Hs.480819 (TBC1D9), Hs.504115 (TRIM29), Hs.523468 (SCUBE2), Hs.532082 (IL6ST), Hs.592121 (RABEP1), Hs.79136 (SLC39A6), Hs.82128 (TPBG), Hs.95243 (TCEAL1), Hs.95612 (DSC2), Hs.654961 (FUT8), Hs.1594 (CENPA), Hs.184339 (MELK), Hs.26010 (PFKP), Hs.592049 (PLK1), Hs.370834 (ATAD2), Hs.437638 (XBP1), Hs.444118 (MCM6), Hs.469649 (BUB1), Hs.470477 (PTP4A2), Hs.473583 (YBX1), Hs.480938 (LRBA), Hs.524134 (GATA3), Hs.531668 (CX3CL1), Hs.532824 (MAPRE2), Hs.591314 (GMPS), Hs.83758 (CKS2) and Hs.99962 (SLC43A3) and subsets of the genes. | 05-06-2010 |
| 20100112593 | Method of Predicting the Clinical Response to Chemotherapeutic Treatment with Alkylating Agents - The present invention provides methods relating to chemotherapeutic treatment of a cell proliferative disorder. In particular, a method is provided for predicting the clinical response to certain types of chemotherapeutic agents. Alkylating agents, used for the treatment of certain types of tumors including tumors of the nervous system and lymph system, are efficacious agents when the damage they do to tumor cell DNA is not repaired by cellular DNA repair mechanisms. The present invention provides a method for determining the activity of a gene encoding a DNA repair enzyme, thus providing a prediction of the clinical response to alkylating agents. | 05-06-2010 |
| 20100112594 | METHOD FOR ENUMERATING MAMMALIAN CELL MICRONUCLEI WITH AN EMPHASIS ON DIFFERENTIALLY STAINING MICRONUCLEI AND THE CHROMATIN OF DEAD AND DYING CELLS - The present invention relates a method for the enumeration of mammalian cell micronuclei, while distinguishing micronuclei from the chromatin of dead and dying cells. The method utilizes differential staining of chromatin from dead and dying cells, to distinguish the chromatin from micronuclei and nuclei that can be detected based upon fluorescent emission and light scatter following exposure to an excitatory light source. Counting of micronuclei events relative to the number of nuclei can be used to assess the DNA-damaging potential of a chemical agent, the DNA-damaging potential of a physical agent, the effects of an agent which can modify endogenously-induced DNA damage, and the effects of an agent which can modify exogenously-induced DNA damage. Kits for practicing the invention are also disclosed. | 05-06-2010 |
| 20100112595 | Bisulfite Conversion Reagent - Disclosed, among other things, are packaged bisulfite solutions comprising bisulfite reagent in an oxygen-impermeable container and methods. | 05-06-2010 |
| 20100120022 | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis - Novel splice variant nucleic acid sequences. The novel splice variants and their nucleic acid sequences according to the present invention may optionally be used for diagnosis of a variant-detectable disease as described herein. | 05-13-2010 |
| 20100120023 | Detection of macromolecular complexes with harmonic cantilevers - Method and apparatus which uses harmonic cantilevers, such as used in atomic force microscopy, to detect variations in the attractive and repulsive forces on a solid surface as a result of macromolecular binding, for example, hybridization of a single stranded DNA molecule attached to the surface with another DNA molecule. The complexed macromolecule is less flexible than an uncomplexed molecule. It will typically have more negative charge due to amino acids or DNA monomers. Both stiffness of the surface and the attractive capillary forces will change after binding and may be detected. By scanning the harmonic cantilever across a surface with macromolecules attached in tapping-mode and by recording the signals at the high frequency vibrations provided by harmonic cantilever, complexed molecules on a surface may be identified and quantified. | 05-13-2010 |
| 20100120024 | Materials and methods for the generation of transcripts comprising modified nucleotides - Materials and Methods are provided for producing aptamer therapeutics having modified nucleotide triphosphates incorporated into their sequence. | 05-13-2010 |
| 20100120025 | Compositions and Methods for Prognosis, Diagnosis, Prevention and Treatment of Cancers - The present invention provides compositions and methods of using the EPHB2 gene or its related signaling pathways to detect, prognosticate, assess the risk of, prevent, or treat cancers. Cancers amenable to the present invention include, but are not limited to, prostate cancer, breast cancer, and neuroblastoma. In one aspect, the present invention provides compositions which comprise an agent capable of eradicating or alleviating an abnormality in the EPHB2 gene or its related signaling pathways. This abnormality may cause or contribute to the development or progression of cancers. In another aspect, the present invention provides methods comprising detecting an abnormality in the EPHB2 gene or its related signaling pathways. The presence or absence of such an abnormality is indicative of the risk or disease status of cancer in a person of interest. | 05-13-2010 |
| 20100120026 | Particulate Substrates for Improved Recovery of Microbes - Specially modified microbial growth surfaces improve bacterial recovery or counts when testing for the presence or absence of microbial cells or performing microbial enumerations. | 05-13-2010 |
| 20100120027 | PROGNOSTIC TEST FOR EARLY STAGE NON SMALL CELL LUNG CANCER (NSCLC) - The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at chromosome 10q23.3 and centromere 10 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. The chromosome copy number can also be determined using, for example, PCR or array CGH. Assessment of the copy number abnormality patterns with a classifier based on the relative loss of 10q23.3 signals compared to the centromere 10 signals produced statistically significant prognostic classification for NSCLC. The ratio of PTEN/CEP 10 signals, using a cutoff of 0.80, was capable of dividing patients into a group of 41 (≧0.80) in which 33 (80.5%) had the favorable prognosis, and a group of 18 (<0.80) in which 6 (33.3%) had the favorable prognosis (p=0.0008). Median times to recurrence in the former and latter groups were 83.0 and 13.0 months, respectively (p<0.0001). | 05-13-2010 |
| 20100120028 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 40 to 42 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 05-13-2010 |
| 20100120029 | Mutagenesis of aspergillus fungi and genes essential for growth - The present invention is directed to polynucleotides encoding proteins Essential For the Growth (EFG) of filamentous fungi. The invention also deals with namely polypeptides encoded by said polynucleotides, screening assays for identifying compounds capable of inhibiting said EFG proteins activities, pharmaceutical or phytosanitary compositions comprising such compounds. | 05-13-2010 |
| 20100120030 | Extracellular serine protease - The present invention provides a DNA encoding a TADG-14 protein selected from the group consisting of: (a) isolated DNA which encodes a TADG-14 protein; (b) isolated DNA which hybridizes to isolated DNA of (a) above and which encodes a TADG-14 protein; and (c) isolated DNA differing from the isolated DNAs of (a) and (b) above in codon sequence due to the degeneracy of the genetic code, and which encodes a TADG-14 protein. Also provided is a vector capable of expressing the DNA of the present invention adapted for expression in a recombinant cell and regulatory elements necessary for expression of the DNA in the cell. | 05-13-2010 |
| 20100120031 | SYNTHESIS OF TRANS-TERT-BUTYL-2-AMINOCYCLOPENTYLCARBAMATE - The present invention concerns methods of synthesis of trans-tert-butyl-2-aminocylcopentylcarbamate comprising contacting 6-tosyl-6-azabicyclo[3.1.0]hexane with TMSN | 05-13-2010 |
| 20100120032 | TRANSGENIC PLANT EVENT DETECTION - The present invention relates to detection of materials derived from transgenic plant events. In particular, the invention provides methods, reagents, kits and reference materials for detecting the presence or absence in a sample of genetic material derived from and attributable to select transgenic plant events. | 05-13-2010 |
| 20100120033 | METHOD FOR MEASURING DNA METHYLATION - The present invention relates to a method of measuring the content of methylated DNA in a DNA region of interest in a genomic DNA contained in a biological specimen, and so on. | 05-13-2010 |
| 20100120034 | METHYLATION ANALYSIS OF MATE PAIRS - Various embodiments of the present teachings relate to methods for the methylation analysis of nucleic acids. The subject methods include methods that result in the preparation of mate-pair libraries suitable for highly multiplexed DNA sequencing. Embodiments include methods of preparing mate-pair libraries comprising a first tag sequence and a second tag sequence, wherein one of the tag sequences has been converted by a methylation conversion agent and the other tag sequence has not been converted by the methylation conversion agent. Other embodiments provided include intermediates for making the mate-pair library and kits for making the mate-pair libraries. Also provided is software and computer systems for analyzing the methylation levels of genomic DNA from which the tag sequences were derived. | 05-13-2010 |
| 20100120035 | METHOD FOR ACCURATE ASSESSMENT OF DNA QUALITY AFTER BISULFITE TREATMENT - The present invention is directed to methods useful for determining DNA quality after bisulfite treatment. The methods include a PCR-based assay, which allows ab-initio assessment of the DNA quality after bisulfite treatment and can help to prevent inaccurate quantitative measurement resulting from poor bisulfite treatment. | 05-13-2010 |
| 20100120036 | METHOD FOR AMPLIFYING DNA FRAGMENT - To measure the methylation degree of a genomic DNA simply and correctly as well as exhaustively, there is provided a method for amplifying a DNA fragment, characterized by comprising the following steps (1) to (5):
| 05-13-2010 |
| 20100120037 | METHOD FOR ISOLATING AND CULTURING UNCULTURABLE MICROORGANISMS - The invention provides a method for isolating and culturing a previously unculturable microorganism, which comprises: (i) collecting a sample from an environmental source; (ii) counting/estimating the number of microorganisms in the sample; (iii) diluting the sample in an appropriate medium; (iv) adding a gelating agent such as to entrap one or more microorganisms within a sphere of the gelating agent; (v) coating the spheres containing the entrapped microorganism(s) with a natural or synthetic polymer to form a polymeric membrane; (vi) incubating the coated spheres in the original environment for an appropriate time; (vii) cutting the spheres and scanning for microorganisms colonies; and (viii) isolating the microorganisms, and repeating steps (iii) to (vii) until a pure clone of said previously unculturable microorganism is obtained. | 05-13-2010 |
| 20100120038 | ASSAY METHODS FOR INCREASED THROUGHPUT OF SAMPLES AND/OR TARGETS - The present invention provides assay methods that increase the number of samples and/or target nucleic acids that can be analyzed in a single assay. | 05-13-2010 |
| 20100120039 | METHODS AND COMPOSITIONS IN BREAST CANCER THERAPY RESISTANCE - The present invention is directed to methods and/or compositions regarding a specific mutation in estrogen receptor alpha and their use for identifying resistance to breast cancer therapy and/or treatment therefor. More specifically, the present invention concerns presence or absence of an A908G mutation in an estrogen receptor alpha nucleic acid sequence, and/or the corresponding K303R mutation in the estrogen receptor alpha polypeptide sequence, for example, as a predictive marker for resistance to breast cancer therapy. Therapeutic embodiments for overcoming the resistance are also provided. | 05-13-2010 |
| 20100120040 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY EVENTS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF - The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection. | 05-13-2010 |
| 20100120041 | METHODS FOR DETECTING AND TREATING KIDNEY DISEASE - A method is provided for diagnosing and monitoring kidney disease or a predisposition to kidney disease, in a subject comprising detecting pVHL, VEGF-A, CXCR4, integrin β-1, PDGF-A, HIF1α and/or TGFβ in a sample from the subject. Screening methods for test agents for inhibiting kidney disease, and therapeutic applications are also described. | 05-13-2010 |
| 20100120042 | METHOD OF SCREENING MATERIAL FOR IMPROVING SKIN FUNCTIONS - A method of screening a material for improving skin functions includes: (a) treating a skin cell with a candidate material; (b) detecting a change in a relative expression level of membrane-associated protein 17 (MAP17) gene; and (c) selecting a candidate material inducing the change in the expression level of the gene as a material for improving skin functions. That is to say, a material for improving skin functions is screened using MAP17 gene as a marker, on the basis of the change in the expression level of the MAP17 gene. A material for improving skin functions, which is useful in improving skin barrier function, promoting skin moisturization, preventing skin aging, or ameliorating skin troubles, may be effectively screened. | 05-13-2010 |
| 20100120043 | SEQUENTIAL ANALYSIS OF BIOLOGICAL SAMPLES - Methods for detecting a plurality of targets in a biological sample are provided. The method comprises contacting the biological sample with a plurality of target-binding probes simultaneously to form a plurality of target-bound probes and observing the signals from the target-bound probes sequentially. An associated kit and device for detection of the plurality of targets are also provided. | 05-13-2010 |
| 20100120044 | MODIFIED POLYNUCLEOTIDES COMPRISING RIBOSE RINGS - The invention pertains to different methods employing the use of a polynucleotide comprising ribose rings which carry a modification at the 2′-OH group. | 05-13-2010 |
| 20100120045 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENTS OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION - The invention relates to methods of risk assessment and diagnosis of susceptibility to coronary artery disease and myocardial infarction, by assessing the presence or absence of alleles of certain polymorphic markers found to be associated with coronary artery disease and myocardial infarction. The invention also relates to methods for use of such polymorphic markers for predicting drug response to drugs for treating cardiovascular disease, or for monitoring the effectiveness of such drugs. The invention further relates to kits encompassing reagents for use in these methods. | 05-13-2010 |
| 20100120046 | Genetic Markers for Assessing Risk of Developing Bipolar Disorder - This document provides methods and materials related to genetic markers of Bipolar Disorder (BD) and Schizophrenia (SZ). For example, methods for using such genetic markers to assess risk of developing BD and/or SZ are provided, as are methods for making a differential diagnosis between BD and SZ. | 05-13-2010 |
| 20100120047 | PURIFICATION OF TARGET CELLS FROM COMPLEX BIOLOGICAL FLUIDS - A method for conducting a molecular analysis on target cells of a complex biological fluid can include the steps of reducing the complexity by selectively depleting at least a portion of non-target cells from the biological fluid, labeling target cells or non-target cells for identification, isolating target cells from non-target cells based on (i) a size, or (ii) a label, of the target cells or the non-target cells using a microfluidic sorting apparatus, and molecularly analyzing the target cells. Reducing can include separating the non-target cells from the biological fluid using a Magnetic Activated Cell Sorting apparatus or using magnetic beads that include a plurality of different antibodies including one or more of CD45, CD16 and 235a. Labeling can include using a label selected from fluorescent, colorimetric, magnetic and biochemical labels. The biological fluid can be selected from blood sputum, peritoneal fluid, tissue cell suspension, fine needle aspirates, fecal matter and cerebral spinal fluid. The target cells can be selected from tumor cells, fetal cells, stem cells, endothelial cells, myocardial cells and lymphocytes. The step of molecularly analyzing the target cells can include one of RNA analysis, antigen expression and mutation profiling. | 05-13-2010 |
| 20100120048 | ASSAYS FOR SHORT SEQUENCE VARIANTS - The invention provides assays that can detect multiple genetic variants of a gene (e.g., a mycobacterium gene) in a sample using a pool (using 2, 3, 4, or more) of oligonucletide hybridization probes. | 05-13-2010 |
| 20100120049 | BIOMARKERS FOR SERIOUS SKIN RASH - The present invention provides a method for predicting the risk of a patient for developing adverse drug reactions, particularly Serious Skin Rash (SSR), including such severe adverse reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The invention also provides a method of identifying a subject afflicted with or at risk of developing SSR. In some aspects, the methods comprise analyzing at least one genetic marker, wherein the presence of the at least one genetic marker indicates that the subject is afflicted with or at risk of developing SSR. Genetic markers useful in accordance with the methods of the invention are disclosed. | 05-13-2010 |
| 20100120050 | Biomarkers For Assessing Altherosclerotic Potential - The invention also provides methods, apparatuses and reagents useful for predicting future atherosclerosis based on expression levels of genes selected from the set of 68 genes with differential expression in response to pioglitazone and rosiglitazone. The invention also discloses reagent sets and biomarkers for predicting progression of atherosclerosis induced by anti-diabetic therapy in a subject. In one particular embodiment the invention provides a method for predict whether a compound will induce atherosclerosis using gene expression data from sub-acute treatments. | 05-13-2010 |
| 20100120051 | CYANINE DYE COMPOUNDS - Cyanine dye compounds having a negatively charged substituent that are nucleic acid stains, particularly for fluorescent staining of DNA, including compounds having the formula | 05-13-2010 |
| 20100120052 | Orotate Transporter Encoding Marker Genes - A recombinant marker gene encoding an orotate transporter polypeptide comprising an amino acid sequence at least 60% identical to SEQ ID NO: 2, a polynucleotide construct comprising at least one copy of the recombinant marker gene, a cell comprising at least one exogenous copy of the marker gene, and a method of selecting or identifying a cell comprising at least one copy of the recombinant marker gene, and/or selecting or identifying a cell which has been cured of the recombinant marker gene. | 05-13-2010 |
| 20100120053 | TISSUE ANALYSIS AND KITS THEREFOR - This invention relates to methods of analyzing a tissue sample from a subject. In particular, the invention combines morphological staining and/or immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) within the same section of a tissue sample. The analysis can be automated or manual. The invention also relates to kits for use in the above methods. | 05-13-2010 |
| 20100124739 | Methods and Compositions for Diagnosing Pelvic Floor Dysfunction - The present invention relates to, among other things, methods and compositions for diagnosing and preventing pelvic floor dysfunction, genital prolapse, and similar medical conditions. For example, according to certain embodiments of the present invention, methods of diagnosing genital prolapse and/or pelvic floor dysfunction are provided. Such methods generally comprise (1) collecting a sample of a patient's uterosacral ligament tissue, (2) extracting total genomic DNA from the tissue, (3) amplifying a promoter region operably connected to a nucleic acid sequence encoding lysyl oxidase (LOX), lysyl oxidase like-1 (LOXL1), lysyl oxidase like-2 (LOXL2), lysyl oxidase like-3 (LOXL3), and/or lysyl oxidase like-4 (LOXL4), and (4) determining whether the promoter region comprises methylated CpG islands. | 05-20-2010 |
| 20100124740 | Somatic transfer of modified genes to predict drug effects - The present invention relates to somatic cell gene transfer methods for mimicking one or more effects of a drug candidate compound. In one aspect, the methods mimic the effect of a drug candidate compound with potential to potentiate or suppress activity of a selected target molecule. In another aspect, the methods provide means of identifying a molecular target for the drug candidate compound. The present methods have a variety of uses including providing identified molecular targets for use in drug screens. | 05-20-2010 |
| 20100124741 | METHODS FOR DETECTING IgH/BCL-1 CHROMOSOMAL TRANSLOCATION - The invention provides methods for detection of Bcl-1 nucleic acid in acellular body fluid. The methods can be used to detect the IgH/Bcl-1 translocations (11;14)(q13;q32) in acellular body fluid. The chromosomal translocation (11;14)(q13;q32) is often associated with mantle cell (centrocytic) lymphoma and occasionally in other B-cell neoplasms, notably myeloma. The invention is useful in the diagnosis of mantle cell lymphoma (MCL) and also for determining the prognosis of the disease. | 05-20-2010 |
| 20100124742 | Methods and Compositions to Identify Increased Risk of Breast Cancer by Detection of CPG Island Methylator Phenotype (CIMP) - The present invention is directed to kits and methods for identifying a female subject as having an increased risk of developing breast cancer, comprising detecting a CPG island methylator phenotype (CIMP) in nucleic acid of the subject. | 05-20-2010 |
| 20100124743 | METHOD FOR DIAGNOSIS OF CANCER - Disclosed is a method for diagnosing cancer with high accuracy through quantification of cancer cell-derived DNA, which comprises the steps of: (1) extracting free DNA from a plasma collected from a test subject; (2) quantifying the extracted free DNA and calculating the free DNA content per unit volume of the plasma to obtain a first calculation value; (3) comparing the first calculation value with a second threshold value which is equal to or higher than a first threshold value; and (4) determining that the test subject is highly unlikely affected by cancer if the first calculation value is lower than the first threshold value, determining that the test subject is likely affected by cancer if the first calculation value is equal to or higher than the first threshold value and lower than the second threshold value, or determining that the plasma used for the quantification is contaminated by normal cell-derived DNA if the first calculation value is equal to or higher than the second threshold value. | 05-20-2010 |
| 20100124744 | DETECTION OF TARGET VARIANTS USING A FLUORESCENT LABEL AND A SOLUBLE QUENCHER - Methods, reaction mixtures and systems for detecting the presence or absence of a target nucleic acid variant from a selection of possible variants is described. | 05-20-2010 |
| 20100124745 | Methods ofr the detection of gene trannscripts in blood and uses thereof - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 05-20-2010 |
| 20100124746 | Method for the detection of gene transcripts in blood and uses thereof - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 05-20-2010 |
| 20100124747 | COMPOSITIONS AND METHODS FOR DIAGNOSIS OR PROGNOSIS OF TESTICULAR CANCER - Provided are compositions and methods for diagnosis or prognosis of testicular or male germ-cell derived cancer, comprising: obtaining sperm DNA from a test subject; determining the methylation status of at least one CpG dinucleotide sequence of at least one gene sequence selected from HRAS, NTF3, MT1A, PAX8, DIRAS3, PLAGL1, SFN, SAT2CHRM1, MEST, RNR1, CYP27B1 and ICAM1; and thereby determining or diagnosing testicular or male germ-cell derived cancer. Provided are compositions and methods for identifying agents that cause testicular or male germ-cell derived cancer, comprising: obtaining human ES-cell derived primordial germ cells; contacting the germ cells or descendants thereof, with a test agent; culturing the contacted cells; determining, using a genomic DNA of the sample, the methylation status of at least one CpG dinucleotide sequence of at least one gene sequence selected from the above group; and identifying at least one test agent that causes testicular or male germ-cell derived cancer. | 05-20-2010 |
| 20100124748 | METHOD FOR THE SPECIFIC DETECTION OF LOW ABUNDANCE RNA SPECIES IN A BIOLOGICAL SAMPLE - The present invention relates to a method and a kit for the detection of low abundance RNA species in a biological sample and to a method and a kit for the detection of a | 05-20-2010 |
| 20100124749 | COMPOSITIONS, KITS AND METHODS FOR DETECTION OF CAMPYLOBACTER NUCLEIC ACID - The disclosed invention is related to compositions, kits and methods comprising one or more oligomers targeting 16S rRNA target nucleic acid from | 05-20-2010 |
| 20100124750 | ANALYZING METHODS AND DEVICES FOR BIOLOGICAL REACTIONS BETWEEN A LIQUID PHASE AND A SOLID PHASE - The invention relates to a device for performing immunological, histochemical and cytochemical, molecular biological, enzymological, clinical-chemical and other analyses, wherein the device comprises an object holder having one or more elongate adhesive surfaces and a reagent holder having one or several channels. The object holder is detachably connectable to the reagent holder in such a manner that the elongate adhesive surfaces each face one of the channels and, when reaction partners bound to a solid phase are disposed on the elongate adhesive surfaces and reactants dissolved in liquid are present in the channels, the reaction partners and the reactants are in contact. Means are provided for preventing the liquid from passing from one channel into an adjacent channel. A method for performing a corresponding analysis can be performed with this device, by connecting the object holder to the reagent holder in such a manner that the elongate adhesive surfaces each face a channel, liquid having reactants dissolved therein is introduced into the channels such that the solid phase substrates having reaction partners bound thereto and being disposed on the adhesive surfaces come into contact with the liquid, and the object holder and the reagent holder are moved together in such a manner that the liquid alternately moves into the two longitudinal directions of the channels. | 05-20-2010 |
| 20100124751 | Non-Invasive Fetal Genetic Screening by Digital Analysis - The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital PCR is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents. | 05-20-2010 |
| 20100124752 | Non-Invasive Fetal Genetic Screening by Digital Analysis - The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital PCR is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents. | 05-20-2010 |
| 20100124753 | SYSTEM AND METHOD FOR IDENTIFYING ERYTHROPOIETIN-RESPONSIVE GENES - The present invention relates to the generation of a population of Epo-responsive marrow derived cells that express Epo-responsive genes and gene products. The present invention also relates to the detection of Epo-responsive genes and gene products as well as to the detection of the administration of Epo, Epo-derivatives and Epo-mimetics in subjects. | 05-20-2010 |
| 20100129790 | Method for Determining Phospholipidosis - It is intended to provide a rapid, simple and noninvasive novel in vivo method for determining phospholipidosis (PLsis) by detecting a PLsis marker gene. More specifically, it is intended to provide a method for determining phospholipidosis in a mammal comprising the step of detecting change in expression of one or more genes whose expression changes correlated with the onset of phospholipidosis in a sample collected from the mammal, in which at least one of the genes comprises a base sequence identical or substantially identical to the base sequence represented by any of SEQ ID NO: n (wherein n is an odd number between 1 and 57, an integer number between 59 and 63, an even number between 64 and 98, 100 or 101.) | 05-27-2010 |
| 20100129791 | cDNA Encoding a Gene Bog (B5T Over-Expressed Gene) and its Protein Product - Nucleic acids that encode novel polypeptides, designated in the present application as “BOG” (B5T Over-expressed Gene) are provided. BOG binds to pRb and is over-expressed in a number transformed rat liver epithelial (RLE) cell lines resistant to the growth inhibitory effect of TGF-β1 as well as in primary liver tumors. Compositions including BOG chimeras, nucleic acids encoding BOG and antibodies to BOG are also provided. Methods of using BOG to modulate pRb-protein interactions and to alter cellular phenotype are further provided. | 05-27-2010 |
| 20100129792 | DIRECT MONITORING AND PCR AMPLIFICATION OF THE DOSAGE AND DOSAGE DIFFERENCE BETWEEN TARGET GENETIC REGIONS - Disclosed herein are methods of detecting target nucleic acids. In particular, methods for anti-primer quenching real-time PCR (aQRT-PCR) are described. The methods provide for detection of target nucleic acids in simplex or multiplex formats for gene copy number determination and SNP-genotyping. Also described are methods for determining the dosage difference between two target nucleic acids. | 05-27-2010 |
| 20100129793 | COMPOSITE PARTICLES - Composite particles and methods of synthesizing a composite particle are disclosed, in particular, methods of synthesizing a composite particle comprising a dielectric component, a magnetic component, and a gold shell are disclosed. Further disclosed herein are methods of detecting a target compound using the composite particles of the present invention. Also disclosed are photonic crystals that can be manipulated with an external magnetic field comprising the composite particles of the present invention. | 05-27-2010 |
| 20100129794 | Magnetic Polymer Particles - The present invention relates to magnetic polymer particles including magnetic particles selected from the group of ferromagnetic, ferrimagnetic and/or superparamagnetic particles, where the magnetic particles are embedded in a crosslinked polyacrylate or polyalkylacrylate matrix. | 05-27-2010 |
| 20100129795 | AGENTS AND METHODS FOR SPECTROMETRIC ANALYSIS - Disclosed herein are agents, methods, and kits for determining the presence or concentration of a target, or multiple targets, in a sample, in a uniplexed or multiplexed fashion. In general, the methods enable the analysis of small molecules produced or consumed in liquid-phase that may be analyzed using gas or vapor phase detection methods. | 05-27-2010 |
| 20100129796 | DYE PROBE FLUORESCENCE RESONANCE ENERGY TRANSFER GENOTYPING - An improved method for detecting, identifying and screening single polynucleotide polymorphisms, insertion/deletion loci, and microsatellites is provided. The method includes adding a donor intercalating dye to a sample containing an amplified target nucleic acid sequence, adding a probe containing an acceptor fluorophore to the sample, hybridizing the probe to the target sequence, exciting the donor dye with a specific wavelength of light, monitoring fluorescence from the sample due to FRET energy transfer from the dye to the probe fluorophore associated with one or both of the hybridization of the probe to the target sequence and the dissociation of the probe from the target sequence, and analyzing the sample using a melt-curve analysis to identify at least one single (or multiple) known or unknown nucleotide polymorphism, insertion/deletion loci, or microsatellite therein. | 05-27-2010 |
| 20100129797 | USE OF GENETIC MODIFICATIONS IN HUMAN GENE CHK1 WHICH CODES FOR CHECKPOINT KINASE 1 - The invention relates to an in vitro method for predicting disease risks, progression of diseases, drug risks, success of treatment and for finding drug targets by looking for one or more genetic modifications in the promoter region of the CHK1 (CHEK1) gene on human chromosome 11q23, the genetic modifications being a substitution thymine for guanine in position -1143 in the promoter of CHK1, of thymine for cytosine in position -1400, a substitution of cytosine for thymine in position -1453 or an insertion of one cytosine in position -1454 and the genetic modifications being detected individually or in any combinations by way of known methods. | 05-27-2010 |
| 20100129798 | DETECTING GENETIC PREDISPOSITION TO OSTEOARTHRITIS ASSOCIATED CONDITIONS - This application relates to methods and kits for detecting predisposition to increased risk for osteoarthritis associated conditions. | 05-27-2010 |
| 20100129799 | CANCER SUSCEPTIBILITY VARIANTS ON CHR8Q24.21 - A region on chromosome 8q24.21 has been demonstrated to play a major role in particular forms of cancer. It has been discovered that certain markers and haplotypes are indicative of a susceptibility to particular cancers, including prostate cancer. Diagnostic applications for identifying a susceptibility to cancer using these markers and haplotypes are described. | 05-27-2010 |
| 20100129800 | POLYMERS AND THEIR USE AS FLUORESCENT LABELS - The present invention relates to a polymer composed by two to ten monomers of formula (I) as well as to a process for its preparation and its use as fluorophore wherein: X is a radical of formula (II) wherein —R | 05-27-2010 |
| 20100129801 | NON-INVASIVE RECOVERY OF RNA AND ANALYSIS OF GENE EXPRESSION IN SKIN - A liquid is placed on an area of skin in which an RNA sample is to be extracted. The liquid is configured to harden which allows for the hardened material to be peeled off. In some implementations, a substrate is attached to the liquid before it hardens to facilitate removal of the skin sample. | 05-27-2010 |
| 20100129802 | Method of Sequencing a Genome - A method and computer-program product for sequencing nucleic acid sequences using restriction fragment maps derived from end-sequenced nucleotide fragments. The initial nucleotide sequence can be processed to form a shot-gun-data set. The present teachings employ a technique called Restriction Site Shotgun Sequencing (RSSS.) It can reduce the amount of overlap required between fragment ends while still producing a good assembly. A decrease in overlap can be achieved by using additional information in the fragments to assist in determining that two fragments overlap. | 05-27-2010 |
| 20100129803 | METHOD FOR DETERMINING DNA FRAGMENTATION IN MICROORGANISMS - The invention relates to a method for determining DNA integrity in microorganisms and to a kit for evaluating DNA integrity in same. Since cell death results in DNA fragmentation, the inventive method can be used to determine DNA fragmentation levels in microorganisms clearly, simply, quickly and precisely. | 05-27-2010 |
| 20100129804 | SPINK1 AS A PROSTATE CANCER MARKER AND USES THEREOF - Compositions and methods for cancer research, diagnosis, and treatment, including but not limited to, cancer markers are provided. In particular, SPINK1 and other markers for prostate cancer are provided. | 05-27-2010 |
| 20100129805 | SLC1A1 ANTIPSYCHOTIC DRUG RESPONSE MARKERS - The invention relates to methods for predicting a subject's response to antipsychotic drug treatment comprising the steps of obtaining a biological sample from the subject, and determining the presence or absence of one or more polymorphisms in the SLC1A1 gene of the subject, wherein the presence of the one or more polymorphisms indicates that the subject's response to antipsychotic drug treatment. The invention also provides for kits for performing these methods. | 05-27-2010 |
| 20100129806 | REGULATION OF CELL SURVIVAL BY HSP90 AND IP6K2 - Anti-cancer drugs are identified by screening for agents and compounds which inhibit the binding of HSP90 and IP6K2. In vitro and in vivo assays can be used. Any phenomenon associated with the binding or inhibition can be monitored, including cell death, subcellular localization, catalytic activity of IP6K2, and IP7 formation. | 05-27-2010 |
| 20100129807 | STABILIZATION OF CYCLIC PEPTIDE STRUCTURES - In various aspects, the invention provides methods for cyclizing proteins, including methods for enhancing the stability of cyclized proteins under cytosolic conditions. The invention also provides various methods for using the cyclized proteins. For example, cyclized proteins of the invention may be used in screening assays analogous to the yeast two hybrid assay. Selected embodiments of the invention provide cyclized single chain variable fragment (ScFv) molecules, including molecules in the form of an immunoglobulin fold. | 05-27-2010 |
| 20100129808 | PARTICLES FOR DETECTING INTRACELLULAR TARGETS - Methods describing the use of nanoparticles modified with binding moieties are provided. | 05-27-2010 |
| 20100129809 | INHIBITORS OF Rv0256c - Described herein are methods for identifying inhibitors of Rv0256c functions, e.g., inhibitors of Rv0256c expression, DNA binding, nuclear localization and iNOS inhibition. | 05-27-2010 |
| 20100129810 | METHODS AND SYSTEMS FOR NUCLEIC ACID SEQUENCING VALIDATION, CALIBRATION AND NORMALIZATION - A system for performing quality control for nucleic acid sample sequencing is disclosed. The system has a set of solid supports, each support having attached thereto a plurality of nucleic acid sequences. The set has plural groups of solid supports and each group contains solid supports having the same nucleic acid sequences attached thereto. The nucleic acid sequences of each group differ from each other. The nucleic acid sequences are synthetically derived. A method of preparing a quality control for performing nucleic acid sample sequencing and a method of validating a nucleic acid sequencing instrument are also disclosed. | 05-27-2010 |
| 20100129811 | COMPOSITIONS FOR USE IN IDENTIFICATION OF PSEUDOMONAS AERUGINOSA - The present invention relates generally to identification of | 05-27-2010 |
| 20100129812 | Nucleic acid hybridization essay method - A cleavable signal element applicable to quantitative and qualitative assay devices, using a cleavable technique specifically responsive to a complementary double strand or single strand of nucleic acids, and a nucleic acid hybridization assay method and device using the cleavable signal element are provided. Using the cleavable technique responsive to the complementary double strand or single strand of nucleic acids, detection sensitivity to a target nucleic acid can be increased, and diagnosis and detection reliability can be improved twice through in-situ determinations. Through simultaneous single nucleotide polymorphism (SNP) detection and expression profile determination, more accurate diagnosis for many diseases can be achieved. The assay device can be easily modified to be suitable for detection with general laser-based detection systems such as CD-ROM readers. Information read from the assay device is digitized as software and transmitted to and received by doctors and patients through a computer network or wirelessly, which enables construction of remote diagnosis systems. | 05-27-2010 |
| 20100129813 | Compositions and methods for detecting food-borne pathogens - The present invention provides formulations and methods for isolating food-borne pathogens from a great variety of food matrices. Methods for isolating microorganisms from clinical and environmental specimens are also disclosed. The invention also concerns methods for rapid and efficient isolation of sufficiently pure DNA from small amounts of various pathogenic microorganisms, which then can be used, according to the methods of the instant invention, for selective identification of a live pathogenic microorganism present in a sample from which the microorganism was isolated. The methods of the instant invention are also useful for identification of new pathogenic microorganisms, diagnostics of food-borne illnesses, treatment of food-borne diseases and quality control of food items offered for sale to consumers. | 05-27-2010 |
| 20100129814 | Method for separation and characterization of microorganisms using identifier agents - The present invention is directed to a method for separating, characterizing and/or identifying microorganisms in a test sample. The method of the invention comprises an optional lysis step for lysing non-microorganism cells that may be present in a test sample, followed by a subsequent separation step. The method may be useful for the separation, characterization and/or identification of microorganisms from complex samples such as blood-containing culture media. The invention further provides for the use of one or more identifier agents and interrogating the microorganism sample and/or said one or more identifier agents to produce measurements which characterizing and/or identifying the microorganism based on the produced measurements and/or the presence or absence of the identifier agent or a metabolized form of the identifier agent in the microorganism sample. | 05-27-2010 |
| 20100129815 | IDENTIFICATION OF CARDIAC SPECIFIC MYOSIN LIGHT CHAIN KINASE - The subject invention pertains to the association of a MLCK homologue with cardiac tissue and methods of identifying candidate compounds that can modulate the activity of this MLCK homologue and the expression of MLCK gene product. Additionally, methods of treating heart failure are also provided by the subject invention. | 05-27-2010 |
| 20100129816 | Microbial Population Analysis - The current invention relates to a method for analysis of a population of micro-organisms (e.g. bacterial population) of different taxonomic groups in an environment suspected to contain said bacteria, primers, primer sets and pair of primer sets suitable for use is such method, and use of such method in determining the effect of external factors like drugs, nutrients and pesticides on bacterial populations of different taxonomic groups. | 05-27-2010 |
| 20100129817 | IDENTIFYING GERMLINE COMPETENT EMBRYONIC STEM CELLS - Methods and compositions for selecting ES cells that are germline competent are provided, including gene expression arrays of from one to about 300 or more genes. Selecting ES cells that are competent for germline transmission by comparing the expression of one or more genes between an ES cell that is competent at germline transmission with an ES cell of interest is described. Selecting ES cells likely to be competent at germline transmission, based on their level of expression of gtl2, is also described. | 05-27-2010 |
| 20100129818 | Polymorphisms in Genes Affecting CYP2C9-Related Disorders and Uses Thereof - A method for predicting a subject's risk factors for CYP2C9-related disorders includes detecting the allelic status of one or more polymorphisms in a nucleic acid sample of the subject. | 05-27-2010 |
| 20100129819 | METHODS AND COMPOSITIONS IN PARTICLE-BASED DETECTION OF TARGET MOLECULES USING LINKING MOLECULES - Methods and compositions which can be used to increase the strength and/or probability of forming a binding complex comprising a target molecule and a substrate are disclosed. In one aspect, linking molecules are disclosed which can be used to increase the number of intra-complex binding interactions. Covalent bonds can be introduced to further increase the strength of these binding interactions. Inter-complex cross-linking can be utilized in connection with these methods to further strengthen and stabilize the disclosed binding complexes. | 05-27-2010 |
| 20100129820 | STRONGLY QUENCHING OLIGOMERIC EXCIMER/QUENCHER PAIRS FOR DETECTION SCHEMES - Compositions and systems are provided for the high efficiency quenching small water-soluble oligomers, or oligofluors, of from about 1-10 kd in size, where the oligofluors comprise multiple excimeric or exciplex forming fluorophores arranged on a scaffold, which are efficiently quenched by a quencher entity linked to the oligomer through a cleavable moiety. Fluorophores of interest include, without limitation, aromatic fluorophores such as pyrenes, e.g. benzopyrene, perylene, pyrene, etc. In some embodiments the oligofluor/quencher combination provides for a Stern-Vollmer constant (K | 05-27-2010 |
| 20100129821 | BROAD RANGE PCR-BASED COMPOSITIONS AND METHODS FOR THE DETECTION AND IDENTIFICATION OF FUNGAL PATHOGENS - Disclosed herein are methods for detecting a fungal pathogen in a patient sample, involving isolating the sample, carrying out a PCR reaction on the sample to generate an amplicon that includes a region of the fungal 28S ribosomal RNA gene, and detecting the PCR amplicon. Also disclosed are sequences of primers for specifically detecting a broad range of fungal pathogens in the presence of human ribosomal DNA. In certain embodiments, the amplicon is detected by sequencing or by two-dimensional melt-curve analysis. In yet other embodiments, more than one fungal pathogen is detected in a sample using the methods disclosed herein. | 05-27-2010 |
| 20100129822 | COMPOSITIONS AND METHODS FOR DETECTING SMALL RNAS, AND USES THEREOF - Compositions and methods are provided for the detection of small RNA target nucleic acids, preferably miRNA target nucleic acids, wherein the compositions and methods provide for sensitive and specific detection of the target nucleic acids. The compositions and methods include using one or more of a first amplification oligomer that is preferably an extender primer, a target capture oligomer that is preferably at least partially double stranded, a promoter primer/provider, a reverse primer that is preferably a universal primer and a detection probe. The compositions and methods are useful for diagnostics, prognostics, monitoring the effectiveness of treatment and/or determining a treatment. | 05-27-2010 |
| 20100129823 | METHODS FOR IDENTIFYING SUBJECTS SUSCEPTIBLE TO ATAXIC NEUROLOGICAL DISEASE - In one aspect, the invention provides methods of identifying genetic mutations that are associated with ataxic neurological disease. The methods comprise identifying a difference between a nucleic acid sequence of a protein kinase C gamma gene from a mammalian subject exhibiting ataxia and a nucleic acid sequence of a protein kinase C gamma gene from a subject which is not exhibiting ataxia, wherein the difference is a genetic mutation associated with ataxic neurological disease. In another aspect, isolated nucleic acid molecules encoding protein kinase C gamma missense mutations are provided. In another aspect, a method of screening a subject to determine if the subject has a genetic predisposition to develop an ataxic neurological disease is provided. In another aspect, the invention provides kits for determining susceptibility or presence of ataxic neurological disease in a mammalian subject. | 05-27-2010 |
| 20100129824 | DISTINGUISHING PCA3 MESSENGER RNA SPECIES IN BENIGN AND MALIGNANT PROSTATE TISSUES - This invention concerns the discovery of two distinct PCA3 mRNA sequences. One of these sequences corresponds to a short PCA3 mRNA molecule whereas the other PCA3 RNA molecule is longer as it comprises an additional sequence between exon 3 and exon 4a. The short RNA is associated with prostate cancer whereas the long RNA sequence is associated with a non-malignant state of the prostate. Based on the differential expression levels of these two PCA3 RNA sequences, protocols for the diagnosis of prostate disease are provided. The invention also relates to therapeutic approaches to prostate cancer. | 05-27-2010 |
| 20100129825 | METHOD FOR THE DETECTION OF BACTERIAL SPECIES OF THE GENERA ANAPLASMA/EHRLICHIA AND BARTONELLA - The present invention relates to a method for the detection and identification of bacterial species belonging to the genera | 05-27-2010 |
| 20100129826 | Double stranded RNA receptor (dsRNA-R) and methods relating thereto - The present invention is directed to nucleic acid molecules and polypeptides encoding a dsRNA receptor (dsRNA-R). The dsRNA-R contains a THD, interacts with the MyD88 adapter protein, and may bind to dsRNA. The present invention is also directed to antibodies against dsRNA-R and to methods of modulating an immune response and the methods of identifying compounds which bind to and/or modulate dsRNA-R. | 05-27-2010 |
| 20100129827 | METHOD AND DEVICE FOR SAMPLE PREPARATION CONTROL - A method for preparing a sample suspected to contain a target nucleic acid sequence for a nucleic acid amplification reaction and for verifying the effectiveness of the sample preparation comprises the step of mixing the sample with sample preparation controls. The sample preparation controls are cells, spores, microorganisms, or viruses that contain a marker nucleic acid sequence. The sample mixed with the sample preparation controls is subjected to a lysis treatment, and nucleic acid released by the lysis treatment is subjected to nucleic acid amplification conditions. The presence or absence of the target nucleic acid sequence and of the marker nucleic acid sequence is then determined. Positive detection of the marker nucleic acid sequence indicates that the sample preparation process was satisfactory, while the inability to detect the marker nucleic acid sequence indicates inadequate sample preparation. | 05-27-2010 |
| 20100136522 | ENDOGENOUS RETROVIRUSES UP-REGULATED IN PROSTATE CANCER - Human endogenous retroviruses of the HML-2 family show up-regulated expression in prostate tumors. This finding can be used in prostate cancer screening, diagnosis and therapy. | 06-03-2010 |
| 20100136523 | Molecular signature and assay for fluoroquinoline resistance in bacillus anthracis - The preferred therapeutic for human anthrax infections are therapeutics from the fluoroquinolone class, in particular, Ciprofloxacin (CIP). This invention discloses the molecular basis for fluoroquinolone (CEP in particular) action and provides the molecular signatures which form the basis of diagnostic assays. This invention further discloses nucleotide signatures associated with CIP-resistance are useful in diagnostic tests to rapidly identify CIP resistant | 06-03-2010 |
| 20100136524 | TARGET PROTEIN AND TARGET GENE IN DRUG DESIGNING AND SCREENING METHOD - The present invention provides a novel target protein and a gene for drug discovery, and a means that enables development of a novel pharmaceutical agent by using the same. More particularly, the present invention provides CARP and genes thereof; screening methods for drugs (e.g., antiallergic drugs); a regulator of diseases (e.g., allergic diseases); a drug derivative production method; a complex comprising a drug and CARP, and a production method thereof; kits comprising a drug or a salt thereof; determination methods for the onset or risk of onset of a specified disease, determination methods for susceptibility to a drug, and determination kits used for said methods, and the like. | 06-03-2010 |
| 20100136525 | FLUID ANALYSIS DEVICE AND METHOD - The invention provides an analysis device ( | 06-03-2010 |
| 20100136526 | Therapeutic Agent for Neuroblastoma Targeting ARID3b - It is intended to provide a therapeutic agent for neuroblastoma. More particularly, it is intended to provide the therapeutic agent for neuroblastoma containing an ARID3b inhibitor. | 06-03-2010 |
| 20100136527 | Dominant B Cell Epitopes and Methods of Making and Using Thereof - Disclosed are methods for obtaining at least one epitope suitable for detecting the presence of an antibody against a tumor associated antigen of a cancer in a sample. Kits, assays, and substrates employing the epitopes of the present invention are disclosed. Also disclosed are epitopes of NY-ESO-1 and XAGE-1b and methods of using thereof. | 06-03-2010 |
| 20100136528 | FIAT NUCLEIC ACIDS AND PROTEINS AND USES THEREOF - The invention provides FIAT nucleic acids and proteins, and methods of using such nucleic acids and proteins. | 06-03-2010 |
| 20100136529 | Rare cell analysis using sample splitting and DNA tags - The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, e.g. aneuploidy. The present invention involves labeling regions of genomic DNA in each cell in said mixed sample with different labels wherein each label is specific to each cell and quantifying the labeled regions of genomic DNA from each cell in the mixed sample. More particularly the invention involves quantifying labeled DNA polymorphisms from each cell in the mixed sample. | 06-03-2010 |
| 20100136530 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 62 to 64 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 06-03-2010 |
| 20100136531 | NUCLEIC ACID DETECTION USING LATERAL FLOW METHODS - Methods and kits for use in detecting a target nucleic acid in a sample are disclosed. In one particular application, the methods and kits allow for the detection of an undesirable micro-organism (e.g. | 06-03-2010 |
| 20100136532 | AQP5 Polymorphism - In order to predict disease risks, disease courses and the response of an individual patient to pharmacological and non-pharmacological therapies a polymorphism in the AQP5 gene has been investigated, in particular in the promoter region of said gene,on the human 12q13 chromosome, wherein the therapy can also be a cosmetic treatment. | 06-03-2010 |
| 20100136533 | COMPOUND CONTAINING FARNESYL DIPHOSPHATE FOR MODULATING TRPV3 FUNCTION AND USE THEREOF - The present invention relates to a method for activating TRPV3 (transient receptor potential vanilloid 3) using FPP (farnesyl diphosphate) and a method for screening a TRPV3 activity inhibitor. FPP of the present invention has TRPV3 specific activity and therefore it can be effectively used for the study on TRPV3 mechanism and functions and for the development of a TRPV3 based pain reliever. | 06-03-2010 |
| 20100136534 | METHOD OF IDENTIFIYING A SEROTYPE OF KLEBSIELLA PNEUMONIAE AND APPLICATION THEREOF - The present invention relates to a method of identifying a serotype of | 06-03-2010 |
| 20100136535 | MEANS AND METHODS FOR DETECTING PROTEIN-PEPTIDE INTERACTIONS - A novel method of detecting and characterizing protein-peptide interactions is provided, which can be used for isolating peptides and proteins, respectively, as well as in drug screening and development. | 06-03-2010 |
| 20100136536 | Molecular Switches And Methods For Their Use - The present invention relates to compositions and methods that allow the manipulation of the catalytic activity of multi-component nucleic acid complexes. Further, the invention provides methods which use these compositions and methods to create molecular sensors, molecular switches, and/or modulators or propagators of autocatalytic self-replicating cascades and other iterative processes. More particularly, the invention relates to compositions allowing self-assembly of active and inactive multicomponent nucleic acid complexes, methods of making such compositions, and methods for use. | 06-03-2010 |
| 20100136537 | PHOTORECEPTOR PRECURSOR CELLS - The present invention relates to photoreceptor cells. In particular, the present invention provides photoreceptor cells comprising heterologous nucleic acid sequences and transgenic animals comprising the same. The present invention also provides photoreceptor precursor cells (e.g., rod photoreceptor precursor cells), and methods of identifying, characterizing, isolating and utilizing the same. Compositions and methods of the present invention find use in, among other things, research, clinical, diagnostic, drug discovery, and therapeutic applications. | 06-03-2010 |
| 20100136538 | MARKING REAGENTS BEARING DIAZO AND NITRO FUNCTIONS, METHODS FOR THE SYNTHESIS OF SUCH REAGENTS AND METHODS FOR DETECTING BIOLOGICAL MOLECULES - The present invention relates to a labeling reagent of formula: | 06-03-2010 |
| 20100136539 | EZRIN ASSAY METHOD FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER - A method for the in vitro diagnosis of colorectal cancer by determining the presence of the Ezrin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-Ezrin monoclonal antibody directed against an Ezrin epitope chosen from the epitopes of sequence SEQ ID No.1, SEQ ID No.2, SEQ ID No.3, SEQ ID No.4+SEQ ID No.5, SEQ ID No.6+SEQ ID No.7 and SEQ ID No.8. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer. | 06-03-2010 |
| 20100136540 | Methods and compositions for characterizing patients for clinical outcome trials - The invention provides with methods for characterizing and selecting, within a population of subjects with type-2 diabetes, subjects that are suited for clinical trials based on the identification of one or more genetic features, which are single nucleotide polymorphisms (SNPs), short tandem repeats (STRs), and/or other genomic markers. The invention further involves characterizing these subjects based on the probability of developing complications related to type-2 diabetes, such as, myocardial infarction, stroke and albuminuria. Also described are combinations and kits for carrying out the above-described methods. | 06-03-2010 |
| 20100136541 | IDENTIFICATION AND VERIFICATION OF METHYLATION MARKER SEQUENCES - The present invention relates to methods for identifying among the genes that are down-regulated in cells or tissues having disease including cancer, the CpG sites within the CpG islands of said genes, wherein the identified CpG sites show great potential for diagnostic utility. In another aspect, the present invention also provides methods of using the selected CpG sites for purposes of diagnosis, prognosis, staging, assessing or monitoring the therapy of or recovery from a disease such as cancer. | 06-03-2010 |
| 20100136542 | NUCLEIC ACID AMPLIFICATION AND TESTING - Methods for amplifying a target nucleic acid by self-sustained amplification methods are described. The methods are designed, in particular, to be carried out without use of specialised lab facilities or instruments. Compositions, lyophilised formulations, and kits for carrying out the methods are also described. | 06-03-2010 |
| 20100136543 | METHOD FOR DETERMINING THE GENOTYPE AT THE CROHN'S DISEASE LOCUS - The present invention refers to a method for determining the genotype of an individual at the 5p13.1 Crohn's disease risk locus, the method comprising: providing a sample from the individual; determining whether a DNA sequence corresponding to a DNA sequence polymorphism located between coordinated 40,300,000 and 40,600,000 of human chromosome (coordinates corresponding to the march 2006 assembly of the human genome) is present in the sample; and determining the nature of the DNA sequence polymorphism genotype located between coordinated 40,300,000 and 40,600,000 of human chromosome as it relates to the genetic risk to develop Crohn's disease. | 06-03-2010 |
| 20100136544 | ASSAYS AND OTHER REACTIONS INVOLVING DROPLETS - The present invention generally relates to droplets and/or emulsions, such as multiple emulsions. In some cases, the droplets and/or emulsions may be used in assays, and in certain embodiments, the droplet or emulsion may be hardened to form a gel. In some aspects, a heterogeneous assay can be performed using a gel. For example, a droplet may be hardened to form a gel, where the droplet contains a cell, DNA, or other suitable species. The gel may be exposed to a reactant, and the reactant may interact with the gel and/or with the cell, DNA, etc., in some fashion. For example, the reactant may diffuse through the gel, or the hardened particle may liquefy to form a liquid state, allowing the reactant to interact with the cell. As a specific example, DNA contained within a gel particle may be subjected to PCR (polymerase chain reaction) amplification, e.g., by using PCR primers able to bind to the gel as it forms. As the DNA is amplified using PCR, some of the DNA will be bound to the gel via the PCR primer. After the PCR reaction, unbound DNA may be removed from the gel, e.g., via diffusion or washing. Thus, a gel particle having bound DNA may be formed in one embodiment of the invention. | 06-03-2010 |
| 20100136545 | Cytokines and Genes Differentially Affected by TNF Blockers - The present invention is directed to cytokines and genes that are differentially affected by TNF blockers and the use of these genes and cytokines to help asses the TB risks of new immunosuppressive therapies, to help evaluate the effects of new TB vaccines, and to help assess TB susceptibility in persons exposed to | 06-03-2010 |
| 20100136546 | GENETIC MARKER FOR ADVERSE BEHAVIORAL CONDITIONS - The present invention concerns genetic marker for adverse behavioral conditions. In particular aspects, the marker is present at chromosome 15q13 and comprises CHRNA7. In certain cases, the marker is a microdeletion or point mutation in CHRNA7. | 06-03-2010 |
| 20100136547 | Pure miRNA Sample Preparation Method - The present teachings provide novel methods, compositions, and kits for analyzing mature micro RNAs (miRNAs). By taking advantage of the observation that most mature miRNAs in cells are tightly associated with RISCs, the present teachings provide approaches for studying mature miRNAs without the complications of additional nucleic acids. For example, in some embodiments the present teachings provide a method of purifying mature miRNAs comprising heating a sample to form a lysate, and, degrading the additional nucleic acids. The resulting mixture lacks the additional nucleic acids, and contains mature miRNAs associated with RISCs. Liberating the mature miRNAs from RISCs, for example by a protease, a detergent, and/or heat, can result in a pure collection of mature miRNAs. | 06-03-2010 |
| 20100136548 | METHODS AND COMPOSITIONS FOR ORDERING RESTRICTION FRAGMENTS - The invention relates to methods and systems for sequencing and constructing a high resolution physical map of a polynucleotide. In accordance with the invention, nucleotide sequences are determined at the ends of restriction fragments produced by a plurality of digestions with a plurality of combinations of restriction endonucleases so that a pair of nucleotide sequences is obtained for each restriction fragment. A physical map of the polynucleotide is constructed by ordering the pairs of sequences by matching the identical sequences among the pairs. | 06-03-2010 |
| 20100136549 | REPRODUCIBLE QUANTIFICATION OF BIOMARKER EXPRESSION - A method is described for the reproducible quantification of biomarker expression, including biomarker expression in a tissue sample. Methods and systems are described whereby reproducible scores for biomarker expression are obtained independent of instrument, its location, or operator. | 06-03-2010 |
| 20100136550 | Methods and Compounds for the Diagnosis of Inflammatory Disease and Identification of Pharmacological Agents Useful in the Treatment of Inflammatory Disease - Methods for the diagnosis of inflammatory bowel diseases and the identification of agents useful in the treatment of such diseases based upon the agent's effect on reducing Pim-2 expression. | 06-03-2010 |
| 20100136551 | MICROFLUIDIC PLATFORM AND RELATED METHODS AND SYSTEMS - A microfluidic platform comprising one or more chambers connectable through microfluidic channels, and comprising a substrate presenting aptamer sensors detectable through Raman active molecules, and related methods and systems. | 06-03-2010 |
| 20100136552 | Methods and compositions for DMXL-associated mental retardation - The present invention provides a method of identifying a human subject as having an increased likelihood of having DMXL-associated mental retardation, comprising detecting, in a nucleic acid sample from the subject, a mutation in a nucleotide sequence encoding DMXL1 and/or a mutation in a nucleotide sequence encoding DMXL2. The present invention further provides a method of identifying a human subject as having an increased likelihood of having DMXL-associated mental retardation, comprising detecting, in a sample from the subject, a mutation in a DMXL1 protein and/or a mutation in a DMXL2 protein. | 06-03-2010 |
| 20100136553 | Prognosis prediction for melanoma cancer - The invention relates to prognostic markers and prognostic signatures, and compositions and methods for determining the prognosis of cancer in a patient, particularly for melanoma. Specifically, the invention relates to the use of genetic and protein markers for the prediction of the risk of progression of a cancer, such as melanoma, based on markers and signatures of markers. In various aspects, the invention provides methods, compositions, kits, and devices based on prognostic cancer markers, specifically melanoma prognostic markers, to aid in the prognosis and treatment of cancer. | 06-03-2010 |
| 20100136554 | SUPPORTED REAGENTS, METHODS, AND DEVICES - Methods of providing at least one reagent for use in a device for processing sample material, delivering at least one reagent to a device for processing sample material, and adding at least one reagent to at least one of the steps in a process for detecting or assaying a nucleic acid; a support film coated with a dry reagent layer; and a device for processing sample material having a support film coated with a dry reagent layer contained within at least one chamber of the device are disclosed. | 06-03-2010 |
| 20100136555 | Burkholderia Pseudomallei Diagnostic Genetic Elements that Predict Mortality in Melioidosis - The present invention provides methods for predicting the likelihood of mortality from melioidosis and detecting the presence of | 06-03-2010 |
| 20100136556 | DETECTION DEVICE FOR DETECTING BIOLOGICAL MICROPARTICLES SUCH AS BACTERIA, VIRUSES, SPORES, POLLEN OR BIOLOGICAL TOXINS, AND DETECTION METHOD - A device for the detection of micro particles that can be marked by probes or antibodies capable of being detected by radiation has a filter, a supply system, and a detection system. Fluid to be examined is passed over a filter to filter out the micro particles and to perform the marking steps by supplying corresponding marking substances to the filter. | 06-03-2010 |
| 20100136557 | Methods and Compositions for Isolating Nucleic Acid Sequence Variants - The invention is drawn to isolating sequence variants of a genetic locus of interest using a modified iterative primer extension method. The nucleic acids analyzed are generally single stranded and have a reference sequence which is used as a basis for performing iterative single nucleotide extension reactions from a hybridized polymerization primer. The iterative polymerization reactions are configured such that polymerization of the strand will continue if the sequence of the nucleic acid being analyzed matches the reference sequence, whereas polymerization will be terminated if the nucleic acid being analyzed does not match the reference sequence. Nucleic acid strands that have mutations can be isolated using a variety of methods and sequenced to determine the precise identity of the mutation/polymorphism. By performing the method on both strands of the nucleic acid being analyzed, virtually all possible mutations can be identified. | 06-03-2010 |
| 20100136558 | CANINE CD20 GENE - It is intended to clarify the CD20 amino acid sequence and its gene sequence which are essentially required in constructing an anti-CD20 antibody useful in treating animal malignant lymphoma. It is also intended to provide a method of diagnosing canine malignant lymphoma by using the CD20 gene sequence. Using monocytes in canine blood as a sample, mRNA is obtained and the full base sequence of canine CD20 gene (SEQ ID NO:2) is determined. Based on this sequence, its amino acid sequence (SEQ ID NO:1) is determined. Comparing the homologies with human and mouse CD20 genes and amino acid sequences, it is identified as canine CD20 gene. Moreover, a primer specific to the canine CD20 gene is constructed and the expression of the CD20 gene in a sample is examined, thereby giving a method of diagnosing canine B lymphocyte-origin malignant lymphoma. | 06-03-2010 |
| 20100136559 | CHROMATIN STRUCTURE DETECTION - The present application provides methods and compositions for determining accessibility of a DNA modifying agent in genomic DNA. | 06-03-2010 |
| 20100136560 | Integrated Analyses of Breast and Colorectal Cancers - Genome-wide analysis of copy number changes in breast and colorectal tumors used approaches that can reliably detect homozygous deletions and amplifications. The number of genes altered by major copy number changes—deletion of all copies or amplification of at least twelve copies per cell—averaged thirteen per tumor. These data were integrated with previous mutation analyses of the Reference Sequence genes in these same tumor types to identify genes and cellular pathways affected by both copy number changes and point alterations. Pathways enriched for genetic alterations include those controlling cell adhesion, intracellular signaling, DNA topological change, and cell cycle control. These analyses provide an integrated view of copy number and sequencing alterations on a genome-wide scale and identify genes and pathways that are useful for cancer diagnosis and therapy. | 06-03-2010 |
| 20100136561 | Genetic Markers for Weight Management and Methods of Use Thereof - This application relates to methods and tests that allow for the establishment of personalized weight-loss programs for a subject based upon the subject's metabolic genotype in key metabolic genes. Kits and methods are disclosed for determining a subject's metabolic genotype, which may be used to select an appropriate therapeutic/dietary regimen or lifestyle recommendation based upon the likelihood of a subject's responsiveness to certain diets and activity levels. Such a personalized weight-loss program will have obvious benefits (e.g., yield better results in terms of weight loss and weight maintenance) over traditional weight-loss programs that do not take into account genetic information. | 06-03-2010 |
| 20100136562 | Multivariate Analysis Involving Genetic Polymorphisms Related To Mediators Of Inflammatory Response For Prediction Of Outcome Of Critcally Ill Patients - A method of using genetic polymorphisms related to pro-inflammatory mediators to predict clinical outcome in critically ill patients admitted to an ICU is provided. | 06-03-2010 |
| 20100136563 | SYSTEM AND METHOD FOR NUCLEIC ACIDS CONTAINING FLUID PROCESSING - A system and method for the processing of nucleic acids containing fluids involving manipulation of magnetically responsive particles contained therein are disclosed. In the system, a holder holds a plurality of containers containing the fluids, a heating device applies thermal energy to the fluids for incubation, and a separating device magnetically separates the particles. The heating and separating devices move into at least one operative position for processing the fluids and at least one inoperative position with respect to the containers, in which the containers are kept stationary at least during and in-between incubating the fluids and manipulating the magnetically responsive particles. | 06-03-2010 |
| 20100136564 | STEROID RESPONSIVE NUCLEIC ACID EXPRESSION AND PREDICTION OF DISEASE ACTIVITY - The invention relates to methods useful for diagnosing and monitoring the steroid responsiveness of a subject by detecting expression of steroid modulated genes and for predicting transplant rejection and non-rejection. | 06-03-2010 |
| 20100136565 | Compositions and Methods for Diagnosing Autism - Mutations located within the gene encoding the homeobox transcription factor, ENGRAILED 2 (EN2), have now been identified as molecular markers associated with susceptibility for autism and related disorders. Thus, the present invention relates to compositions in the form of diagnostic kits, primers and target sequences, for use in methods for determining the predisposition, the onset or the presence of autism spectrum disorder in a mammal. Moreover, therapeutic methods for treating a person inflicted with, or predisposed to, an autism spectrum disorder based upon modulating the level or activity of EN2 are also provided. | 06-03-2010 |
| 20100136566 | LATERAL FLOW STRIP ASSAY WITH IMMOBILIZED CONJUGATE - The present invention discloses analyte detection devices for detecting one or more analytes present in test samples, especially biological samples. In particular, the devices of the invention are lateral flow assay devices comprising immobilized metal nanoparticle conjugates as the detection means. Methods of using the devices and kits comprising the devices are also described. | 06-03-2010 |
| 20100136567 | CYANINE DYES - The invention provides a novel class of cyanine dyes that are functionalized with a linker moiety that facilitates their conjugation to other species. Also provided are conjugates of the dyes, methods of using the dyes and their conjugates and kits including the dyes and their conjugates. | 06-03-2010 |
| 20100136568 | Compositions and Methods for Regulating RNA Translation via CD154 CA-Dinucleotide Repeat - Compositions and methods for regulating CD154 gene expression are provided that rely on the interaction of hnRNP L with the CA-dinucleotide rich sequence of the 3′-untranslated region of CD154. | 06-03-2010 |
| 20100136569 | COMPOSITIONS, METHODS AND KITS FOR POLYNUCLEOTIDE AMPLIFICATION REACTIONS AND MICROFLUIDIC DEVICES - Antifoam agents improve detection of polynucleotide amplification reactions and improve manipulation of fluids in microfluidic devices. | 06-03-2010 |
| 20100136570 | SENSITIVE AND RAPID DETERMINATION OF ANTIMICROBIAL SUSCEPTIBILITY - The present invention relates to moving microorganisms to a surface, where they are grown in the presence and absence of antimicrobials, and by monitoring the growth of the microorganisms over time in the two conditions, their susceptibility to the antimicrobials can be determined. The microorganisms can be moved to the surface through electrophoresis, centrifugation or filtration. When the movement involves electrophoresis, the presence of oxidizing and reducing reagents lowers the voltage at which electrophoretic force can be generated and allows a broader range of means by which the target can be detected. Monitoring can comprise optical detection, and most conveniently includes the detection of individual microorganisms. The microorganisms can be stained in order to give information about their response to antimicrobials. | 06-03-2010 |
| 20100143893 | Method for detection of cytosine methylation - Herein described is a method for the detection of cyto-sine methylation in a nucleic acid sample, comprising the steps of: a) treating a nucleic acid sample with an agent convert-ing unmethylated cytosine bases into uracil bases and not converting methylated cytosine bases within said nucleic acid sample, b) amplifying selected segments of the treated nucleic acid sample, by providing two first oligonucleotide primers (A and B) that are capable of producing an amplificate under certain chosen amplification conditions inde-pendently of the methylation status of the nucleic acid before treatment in step a), and further providing at least two additional second oligonucleotide primers (C and D) that can each produce a product with one of the first primers (A or B) under said same amplification conditions, wherein at least one of the second primers binds to the nucleic acid in a methylation specific manner, thereby distinguishing between unconverted initially methylated and converted unmethylated nucleic acids and/or blocking molecules are provided that hinder the binding of at least one of the second primers to the nucleic acid in a methylation specific manner, thereby distinguishing between unconverted initially methylated and converted unmethylated nucleic acids, c) detecting the amplificates of the treated nucleic acid. | 06-10-2010 |
| 20100143894 | Quantitative Detection of Hdv by Real-Time Rt-Pcr - Specific reagents for quantitative assay of HDV and more specifically to follow HDV viral load in chronically infected patients and such a quantitative assay. | 06-10-2010 |
| 20100143895 | METHODS AND SYSTEMS FOR ADDING A REAGENT TO AN ANALYTE IN A GEL - The present invention relates to methods and systems for adding a reagent to an analyte in a gel. The invention further provides methods and systems for transferring liquid analyte reagent mixtures from a gel to a second vessel, such as a microtitre plate. The invention is useful in the manipulation of biological molecules such as nucleic acids, carbohydrates, proteins and peptides. In particular, the invention has utility for manipulating proteins and peptides in isoelectric focusing gels. | 06-10-2010 |
| 20100143896 | Sequence capable of enhancing the expression of gene under moderately low temperature - The object is to increase the amount of a protein produced by recombinant DNA method using an eukaryotic cell, particularly a mammalian cell. The object is achieved by using a moderately low temperature transcription control element comprising the nucleotide sequence: X1cccX5X6x7 (wherein x1 represents c t or a; x5 represents g, c, a, or t; x6 represents c, t, a or g; and x7 represents, c, a, g, or t) or a nucleotide sequence complementary to the nucleotide sequence or moderately low temperature transcription enhancer having the moderately low temperature transcription control element linked thereto. | 06-10-2010 |
| 20100143897 | Materials and Methods for Assaying for Glyoxylate - The subject invention concerns enzyme-based methods for detecting and assaying for glyoxylate. In particular, the invention is directed to methods for assaying for glyoxylate produced by the reaction of peptidylglycine α-amidating monooxygenase (PAM). The subject invention also concerns methods for assaying for the enzyme peptidylglycine α-amidating monooxygenase. The detection of glyoxylate using the present invention is indicative of the presence of PAM. The subject invention also concerns methods for screening for peptide hormones and any N-acyl-glycine or N-aryl-glycine conjugated molecule. | 06-10-2010 |
| 20100143898 | USE OF PRODUCTS OF PCR AMPLIFICATION CARRYING ELEMENTS OF SECONDARY STRUCTURE TO IMPROVE PCR-BASED NUCLEIC ACID DETECTION - Particular aspects comprise amplifying target nucleic acid using PCR and an oligonucleotide primer pair wherein at least one of the primers is designed to incorporate a 5′-specialty sequence to provide for an amplification product that intramolecularly folds into a secondary structure; and detecting the amplification product by a method comprising: providing an oligonucleotide cleavage component, hybridizing said oligonucleotide cleavage component with the amplification product to form a three-strand cleavage structure wherein two strands of the three-strand cleavage structure are provided by the secondary structure of the amplification product, cleaving 3′- or 5′-strands of the three-strand cleavage structure using a duplex-specific nuclease activity resulting in a cleavage product, and detecting the cleavage product indicative of the presence of the target nucleic acid. In certain aspects both primers incorporate a 5′-specialty sequence and detecting comprises cleaving 3′- or 5′-strands of a three-strand cleavage structure using duplex-specific nuclease to provide a cleavage product. | 06-10-2010 |
| 20100143899 | METHODS AND PRODUCTS FOR DIAGNOSING CANCER - The present invention relates to methods and kits for the detection and diagnosis of cancer or precancerous conditions. Methylation of specific genes has been identified as indicative of cancer and methods of the invention, in part, relate to the detection of methylation levels in cells as a determination of cancer or a precancerous condition in the cell. | 06-10-2010 |
| 20100143900 | ASYNCHRONOUS SEQUENCING OF BIOLOGICAL POLYMERS - The present invention provides methods, reagents and apparatus for conducting single molecule sequencing in an asynchronous manner. The subject methods and compositions are particularly useful for high throughput and multiplexed sequencing. | 06-10-2010 |
| 20100143901 | Nuclease-Free Real-Time Detection of Nucleic Acids - The invention is a method for amplification and detection of nucleic acids using primers and at least one hybridization probe labeled with a first fluorescent moiety and a second moiety, capable of changing the fluorescence of said first fluorescent moiety. The method comprises the steps of effecting denaturation of said target, formation of hybrids between said primers and probe and said target and detecting the change in fluorescence of said first fluorescent moiety, upon formation of said hybrids. Reaction mixtures and kits for practicing the method of the present invention are also disclosed. | 06-10-2010 |
| 20100143902 | METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS - The invention provides methods, nucleic acids and kits for detecting colorectal cell proliferative disorders based on underexpression or methylation of a least one gene selected from RASSF2, TFAP2E, SND1, PCDHGC3, EDNRB, STOM, GLI3, RXFP3, LimK1, GPR73L1, PCDH1O, DOCKIO and MRPS21, and optionally Septin-9. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said class of disorders, thereby enabling the improved diagnosis and treatment of patients. | 06-10-2010 |
| 20100143903 | Methods of Detecting and Monitoring Cancer Using 3D Analysis of Centromeres - The present application relates to a method of detecting and monitoring cancer or precancer in a cell using three-dimensional analysis to assess centromere organization. In addition, the application relates to a method and system for characterizing the 3D organization of centromeres. | 06-10-2010 |
| 20100143904 | METHOD FOR THE GENOMIC TYPING OF ERYTHROCYTE SYSTEMS, OLIGONUCLEOTIDE PROBES AND RELATIVE DIAGNOSTIC KITS - The invention relates to a method for the genomic typing of erythrocyte systems, oligonucleotide probes and relative diagnostic kits. | 06-10-2010 |
| 20100143905 | METHODS AND COMPOSITIONS FOR MULTIVALENT BINDING AND METHODS FOR MANUFACTURE OF RAPID DIAGNOSTIC TESTS - The invention provides reagents and methods for multivalent binding and quantitative capture of components in a sample. In one aspect, reagents and methods for diagnostic assay for antigen, ligand, binding agent, or antibody are provided. Compositions of a non-natural or deliberately constructed nucleic acid-like polymeric scaffold are provided, to which multiple antibodies, peptides or other binding agents can be affixed by hybridization of a oligonucleotide: binding agent complex such that the nucleic acid: binding agent construction displays multivalent behavior when interacting with a multivalent analyte. Methods for constructing and using the scaffolds are described. Such compositions may include assembly of mixed specificity binding agents such that the composition displays multivalent binding behavior against a target containing mixed analytes which can be bound by the construct to effect a binding affinity increase such as is observed in avidity reagents against single analytes expressed multiply on the target analyte. A manufacturing method for producing rapid diagnostic assays in a decentralized manner is also described. The method generates net economic advantages over conventional diagnostic manufacturing practices. | 06-10-2010 |
| 20100143906 | METHOD AND COMPUTER PROGRAM PRODUCT FOR DISTINGUISHING AND SORTING SEEDS CONTAINING A GENETIC ELEMENT OF INTEREST - A method for distinguishing and sorting seeds containing a genetic element of interest from a bulk sample. In various embodiments, the present invention comprises associating a marker with at least some of the seeds containing a genetic element of interest of the bulk sample, exciting the seeds using an photonic emitting device, evaluating at least some of the seeds of the bulk sample for the presence or absence of the marker, and sorting the seeds containing a genetic element of interest based on the presence or absence of the marker. In various other embodiments, the method may comprise associating a red fluorescent protein marker with at least some of the seeds containing a genetic element of interest of the bulk sample, evaluating at least some of the seeds of the bulk sample for the presence of the red fluorescent protein marker using an evaluating device, and sorting the seeds containing a genetic element of interest based on the presence of the red fluorescent protein marker. In some embodiments, the red fluorescent protein marker is discernable when excited by a certain energy and the evaluating step comprises exciting the seeds containing a genetic element of interest with the certain energy and detecting an emission resulting at least in part from the exciting step. | 06-10-2010 |
| 20100143907 | METHODS AND USES INVOLVING GENETIC ABNORMALITIES AT CHROMOSOME 12 - The present invention relates to the fields of genetics and oncology and provides methods for predicting and identifying tumors of epithelial origin. Specifically, the present invention relates to a novel method of predicting tumor initiation, tumor progression and/or carcinomas, the method comprising detecting genetic abnormality associated with tumors of epithelial origin. The present invention further relates to a novel method of identifying an individual with potential for developing carcinoma, the method comprising detection of genetic abnormalities. The present invention also relates to a method of predicting the progression of carcinomas and the transformation thereof to an aggressive variant, the method comprising detection of genetic abnormalities, which indicate the probability to develop carcinoma. The present invention also relates to a use of specific chromosomal region, a gene or a fragment thereof, and/or genetic markers for predicting tumor initiation, tumor progression and/or carcinoma. The present invention also relates to a use of specific chromosomal region or a gene or a fragment thereof in therapy, for the development of therapy, and for the preparation of a medicament for treating tumors of epithelial origin. | 06-10-2010 |
| 20100143908 | MULTITAG SEQUENCING ECOGENOMICS ANALYSIS-US - Embodiments of the invention herein described relate to multiplex polynucleotide sequence analysis without the use of size separation methods or blotting. In certain particulars the invention relates to multiplex sequencing using massively parallel sequencing methods, such as pyrosequencing methods and sequencing by synthesis. The invention provides increased throughput, increased accuracy of enumerating sample components, and the ability to analyze greater numbers of samples simultaneously or serially on presently available systems, as well as others yet to be developed. In certain of its embodiments the invention relates to the analysis of complex microbial communities, particularly to in-depth analysis thereof in large numbers of samples. | 06-10-2010 |
| 20100143909 | METHOD FOR DETECTION OF APPLE MOSAIC VIRUS, PRIMER SET FOR THE DETECTION, AND KIT FOR THE DETECTION - The invention provides a detection method for apple mosaic virus that comprises an extraction step in which apple mosaic virus RNA is extracted from a specimen, an amplification step in which a primer set containing 4 different oligonucleotides consisting of the nucleotide sequences represented by SEQ ID NO: 1-4 of the Sequence Listing is used for amplification of cDNA by RT-LAMP using the RNA as template, and a judging step in which apple mosaic virus is judged to be present when amplification of cDNA containing the nucleotide sequence represented by SEQ ID NO: 8 of the Sequence Listing has occurred in the amplification step. | 06-10-2010 |
| 20100143910 | NUCLEIC ACIDS PROBES FOR DETECTION OF YEAST AND FUNGAL SPECIES - The present invention use of to a portion of the RPS7 gene or its corresponding mRNA in a diagnostic assay for fungal and yeast species and sequences for use in such assays and methods. | 06-10-2010 |
| 20100143911 | METHOD FOR SCREENING ESSENTIAL METABOLITES IN GROWTH OF MICROORGANISMS - The present invention disclosed is a method for screening metabolites essential for the growth of microorganism using metabolic flux analysis. More specifically, the present invention relates to the method for screening metabolites essential for the growth of microorganism, by selecting a target microorganism, constructing a metabolic network model of the selected microorganism, inactivating the consumption reaction of each of metabolites in the constructed metabolic network model, analyzing the metabolic flux of the metabolites to select metabolites essential for the growth of the microorganism, and confirming the selected metabolites using the utilization of each of the metabolites, defined as flux sum (Φ). According to the present invention, metabolites essential for the growth of microorganism, and genes involved in the essential metabolites, can be screened in a convenient manner, and drug-target genes against pathogenic microorganisms can be predicted by deleting genes associated with the metabolites screened according to the method. | 06-10-2010 |
| 20100143912 | SPECIFIC N-TERMINAL LABELING OF PEPTIDES AND PROTEINS IN COMPLEX MIXTURES - This invention provides general methods for selective labeling of proteins on their N-termini with synthetic peptides. The methods of this invention can be applied to the global proteomic profiling of complex mixtures of proteins and polypeptides. | 06-10-2010 |
| 20100143913 | COMBINED SCALABLE IN VITRO DIFFERENTIATION SYSTEM FOR HUMAN BLASTOCYST-DERIVED STEM (HBS) CELLS OR CELLS DERIVED FROM HBS CELLS FOR DIRECT ASSAY APPLICATION IN MULTIWELL PLATES - A combined scalable in vitro differentiation and assay system based on human blastocyst-derived stem (hBS) cells or cells derived from hBS cells is provided. This system makes it possible to merge both the differentiation and the assay parts of the system into one. The advantage of the combined assay system is that the hBS cells or the cells derived from hBS cells in the differentiation system are directly applicable for assays, in a large variety of assay units, such as different multiwell plates. The system offers a major improvement compared to the prior art, since the cells are differentiated in the same format as when further being subject to analysis. The starting cell material can be homogenously distributed across a variety of different plates, for use and can be cultured when attached, when semi-attached or when in suspension. | 06-10-2010 |
| 20100143914 | METHOD FOR DETERMINATION OF PRESENCE OF CROSSING WITH CULTIVATED ROSE IN WILD ROSE - Disclosed is a method for determining whether or not a wild rose of interest is crossed with a cultivated rose. The method comprises the steps of: examining whether or not a KSN gene containing a transposon (an indicator) is contained in the rose of interest; and determining that the rose of interest is crossed with a cultivated rose when the individual has the transposon-containing KSN gene. | 06-10-2010 |
| 20100143915 | Cells Modified or Altered for a Rice-diverged Glycosyltransferase - The present invention provides for a cell comprising a modified or altered enzymatic activity of a rice-diverged glycosyltransferase (GT). | 06-10-2010 |
| 20100143916 | OSTEOARTHRITIS BIOMARKERS AND USES THEREOF - The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in osteoarthritis and/or in a particular stage of osteoarthritis, as well as a means of selecting the novel biomarker combinations. The measurement of expression of the products of the biomarkers and combinations of biomarkers of the invention demonstrates particular advantage in one or more of the following: (a) diagnosing individuals as having arthritis, (b) differentiating between two stages of osteoarthritis (OA) and (c) diagnosing individuals as having a particular stage of osteoarthritis (OA). As would be understood, in order to measure the products of biomarkers of the invention, polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are kits containing said polynucleotides and proteins for use in (a) diagnosing individuals as having arthritis, (b) differentiating between two stages of osteoarthritis (OA) and (c) diagnosing individuals as having a particular stage of osteoarthritis (OA). Further encompassed by the invention is the use of the polynucleotides and proteins which specifically and/or selectively hybridize to the product of the biomarkers of the invention to monitor disease progression in an individual and to monitor the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for osteoarthritis. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of compounds that bind and/or modulate the activity of the genes of the invention. The compounds identified via such methods are useful for the development of assays to study osteoarthritis and osteoarthritis progression. Further, the compounds identified via such methods are useful as lead compounds in the development of prophylactic and therapeutic compositions for the prevention, treatment, management and/or amelioration of osteoarthritis or a symptom thereof. | 06-10-2010 |
| 20100143917 | FLUORESCENT CHEMICAL COMPOUNDS HAVING HIGH SELECTIVITY FOR DOUBLE STRANDED DNA, AND METHODS FOR THEIR USE - Chemical compounds having a high selectivity for double stranded DNA over RNA and single stranded DNA are disclosed. The chemical compounds are stains that become fluorescent upon illumination and interaction with double stranded DNA, but exhibit reduced or no fluorescence in the absence of double stranded DNA. The compounds can be used in a variety of biological applications to qualitatively or quantitatively assay DNA, even in the presence of RNA. | 06-10-2010 |
| 20100143918 | TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN NON-SMALL CELL LUNG CARCINOMA - In accordance with the invention, a novel gene translocation, (4p15, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in fusion proteins combining part of Sodium-dependent Phosphate Transporter Isoform NaPi-3b protein (SLC34A2) with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The SLC34A2-ROS fusion proteins are anticipated to drive the proliferation and survival of cancer cells, and particularly drive the proliferation and survival of a subgroup of NSCLC tumor cells. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of the new fusion protein enables new methods for determining the presence of these mutant ROS kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention. | 06-10-2010 |
| 20100143919 | In vitro assay for early diagnosis of diabetes mellitus type 1 - An in vitro assay is disclosed for early diagnosis of insulin-dependent diabetes mellitus type 1. In at least one embodiment, the assay includes i) determining susceptibility markers for diabetes mellitus type 1 in a biological sample from a symptom-free individual; ii) determining inflammatory markers in the same or in a further biological sample from the individual; iii) determining the presence or the risk of developing insulin-dependent diabetes mellitus type 1 on the basis of the values obtained in i) and ii); and, possibly, iv) performing step ii) after a defined time interval or v) performing an imaging method for the pancreas. At least one embodiment is further directed to the use of this assay for monitoring the progression of a diabetes mellitus type 1 disease. | 06-10-2010 |
| 20100143920 | Surfactant Protein D is a Biomarker for Steroid Responsiveness in Asthma and Chronic Obstructive Pulmonary Disease - The present invention relates to the identification of a biomarker, the detection of which is prognostic for individuals who are responsive to inhalation of corticosteroids as a therapy for asthma and COPD. | 06-10-2010 |
| 20100143921 | Polymorphisms in Genes Affecting Dopamine Transporter Disorders and Uses Thereof - A method for predicting a subject's risk factors for dopamine transporter or SLC6A3-related disorders. The method includes detecting the allelic status of one or more polymorphisms in a nucleic acid sample of the subject. The present invention also provides a related kit, comprising an assay for detecting the allelic status of one or more polymorphisms in a nucleic acid sample of a subject. | 06-10-2010 |
| 20100143922 | METHODS FOR REDUCING OVER-REPRESENTATION OF FRAGMENT ENDS - Methods for preparing fragments for nucleic acids sequence analysis that demonstrates uniform coverage across the full fragment length. The methods disclosed herein are useful for candidate gene re-sequencing wherein the detailed analysis is performed on selected, amplified regions of the genome. | 06-10-2010 |
| 20100143923 | DETECTION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS - This invention relates to the use of genetic probes for detection of the presence of the SCCmec cassette in | 06-10-2010 |
| 20100143924 | NEGATIVE CORRELATION BETWEEN IRP-2 AND TRANSFERRIN RECEPTOR EXPRESSION AS A DIAGNOSTIC OF ALZHEIMER'S DISEASE - A method of diagnosing Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) is disclosed which was identified by the fact that an increased level of iron regulating protein-2 (IRP-2) was identified in Alzheimer's patients. Further, diseases of increased cellular metabolism such as cancer showed high levels of both IRP-2 and transferrin receptor. This suggests that, in diseases of increased cellular metabolism, both aspects of iron accumulation are highly expressed, while in Alzheimer's disease only IRP-2 is highly expressed. From these results, a non-invasive test for Alzheimer's disease may be produced using patient samples containing peripheral blood cells and identifying the level of expression of IRP-2 and Transferrin receptor. Those patients which: 1. over-express IRP-2 as compared with normal controls, and 2. have comparable levels of Transferrin receptor expression to normal controls, can be identified as having or prone to AD and MCI. Further, it can be envisioned that this may be used for further diagnosis and staging of cancers of the blood. | 06-10-2010 |
| 20100143925 | CONJUGATE COMPLEXES FOR ANALYTE DETECTION - The present invention relates to novel conjugate complexes for immunoassays as well as kits comprising these conjugate complexes, methods of producing these complexes, and methods of detecting an analyte by use of these complexes. The conjugate complexes of the invention comprise one or more non-nucleic acid receptors capable of specifically binding an analyte, one or more nucleic acid markers comprising a predetermined nucleotide sequence, one or more first linker molecules capable of specifically binding the non-nucleic acid receptor and the nucleic acid marker, and one or more second linker molecules capable of specifically binding the first linker molecules. | 06-10-2010 |
| 20100143926 | Classification of Patients Having Diffuse Large B-cell Lymphoma Based upon Gene Expression - Methods and kits for classifying patients having diffuse large B-cell lymphoma (DLBCL) based upon expression of a plurality of genes are disclosed. Real-time quantitative RT-PCR can be used to measure expression values. Correlating expression values of the plurality of genes in a tumor sample from the patient to reference expression values obtained from DLBCL patients can stratify patients in the classification groups. The methods and kits can be used to predict overall patient survival. | 06-10-2010 |
| 20100143927 | Methods and Assays for Measuring p95 and/or p95 in a Sample and Antibodies Specific for p95 - The invention provides methods of measuring and/or quantifying the presence and/or amount of p95 and/or p95 complex in a sample. The invention also provides antibodies specific for p95. | 06-10-2010 |
| 20100143928 | CHD7 GENE POLYMORPHISMS ARE ASSOCIATED WITH SUSCEPTIBILITY TO IDIOPATHIC SCOLIOSIS - The present invention includes compositions and methods for diagnosis of polymorphisms associated with susceptibility to idiopathic scoliosis in a patient by determining the presence of a mutation in a nucleic acid sample provided from the patient for a mutation in a transcription factor binding site in one or more non-coding regions of the chromodomain helicase DNA binding protein 7 gene. | 06-10-2010 |
| 20100143929 | DNA METHYLATION BASED TEST FOR MONITORING EFFICACY OF TREATMENT - A DNA methylation-based test for efficiency of treatments is based on a plurality of genes. The test is suitable for monitoring treatment of subjects with neurological diseases, e.g., multiple sclerosis (MS); with cancer, e.g., breast and ovarian cancer, and with other diseases for which methylation of biomarkers differs in the diseased compared to the non-diseased state. | 06-10-2010 |
| 20100143930 | Biological indicator - A biological indicator for monitoring the effectiveness of a sterilizing or disinfecting treatment or process. A compound or condition is disclosed which comprises a substrate having a surface layer containing functional groups thereon desirably free of silicon linking groups. The functional groups are desirably in the form of a monolayer of a uniformed distribution and of a selected quantity. Various types of microorganism indicators, such as spores, and/or etiological agent indicators are covalently bonded to the surface layer functional groups through a crosslinking reagent and thus form a uniform number and distribution of the microorganism and/or etiological agent indicators. After being subjected to sterilization or other similar disinfecting treatments or processes, along with various articles such as instruments, the indicator can be cultivated to determine the effectiveness of the sterilization, disinfection, etc. treatment or process. | 06-10-2010 |
| 20100143931 | Stable Metal/Conductive Polymer Composite Colloids and Methods for Making and Using the Same - Stable metal/conductive polymer composite colloids and methods for making the same are provided. The subject colloids find use in a variety of different applications, including analyte detection applications. Also provided are kits that include the subject colloids. | 06-10-2010 |
| 20100143932 | SINGLE MOLECULE SEQUENCING OF CAPTURED NUCLEIC ACIDS - The invention provides methods and devices for detecting, enumerating or identifying target nucleic acid molecules using immobilized capture probes and single molecule sequencing techniques. | 06-10-2010 |
| 20100151448 | Asymmetric PCR Amplification, its Special Primer and Application - The present invention discloses an asymmetric PCR amplification method, its special primer and application, aims to provide a simple, effective PCR amplification for preparation of single-stranded product. The asymmetric PCR primer of the invention comprises some PCR primer pairs, in which an unrelated nucleic acids sequence to target sequence to be detected is added onto 5′-terminal of one primer. The asymmetric PCR amplification provided includes the steps: 1) preparative denaturing; 2) repetitiously denaturing, primers annealing, extending cycles as the first stage of PCR amplification; 3) repetitiously denaturing, primer extending cycles as the second stage of PCR amplification, wherein an unrelated nucleic acids sequence to target sequence to be detected is added onto 5′-terminal of one PCR primer of each pair in extension. With the asymmetric PCR amplification of the invention, high throughput of single-stranded products can be obtained, single PCR amplification or multiple PCR amplification can be carried out. And the method can be widely used in detection of nucleic acids. | 06-17-2010 |
| 20100151449 | Method for poduction of l-amino acids by fermentation - The invention relates to a method for production of L-amino acids by fermentation. According to the invention, the activity of the alanine transaminase is ether reduced or inhibited, whereby in particular the amino acids L-valine, L-lysine and L-isoleucine are produced with increased yield. Furthermore, the nucleic acids according to seq. No. 1 from position 101 to 1414 are identified as the sequence coding for the alanine transaminase gene. Use of the above permits the production of L-alanine. | 06-17-2010 |
| 20100151450 | Classification Method - The invention provides a method of classifying a microorganism present in a sample comprising the steps of (a) digesting nucleic acid derived from the microorganism with at least one restriction enzyme; and (b) determining the melting profile of the restriction fragments produced in step (a). The melting profiles may he subjected to further statistical analysis. Classification may be effected by reference to predetermined melting profiles or the results of previously analysed melting profiles. According to the invention, the melting profiles and statistical analyses obtained from the methods of the invention may be stored on digital media to produce a database. These databases and retrieval of data therefrom as part of the methods of the invention are encompassed by the present invention. Methods applicable to higher eukaryotes and kits for carrying out the methods of the invention are also provided. | 06-17-2010 |
| 20100151451 | Method for Identifying the Genotype in Position 171 of the Ovine Prion Protein as well as Kits for Implementing said Method - The invention relates a method to identify genotype at position 171 of the ovine PrP, and a method to select an ovine for reproduction. | 06-17-2010 |
| 20100151452 | Methods and Systems for Searching for Regulators of the Fer Protein and for Monitoring the Effects of the Fer Protein - A method for modulating a Fer mediated pathway in a cell, for monitoring the effect of a Fer protein in a cell, for altering and inhibiting one or more effects of a Fer protein in a cell is provided. The method includes modulating, monitoring, altering or inhibiting any one or more or of the association of the Fer protein to PP1; the phosphorylation of PP1, the phosphatase activity of PP1, and the tumor suppressive activity of the retinoblastoma protein (RB). In a preferred embodiment, modulating a Fer mediated pathway in a cell, monitoring the effect of a Fer protein in a cell, for altering and inhibiting one or more effects of a Fer protein in a cell involves administrating to a cell a compound having a molecular weight of up to 1000 Dalton capable of modulating, altering or inhibiting an effect of Fer. Further provided is a method for determining whether a substance is capable of altering or inhibiting an effect of a Fer protein in a cell. The method includes presenting the substance to a first cell expressing an exogenous Fer gene or Fer cDNA; and measuring a rate of proliferation of the cell. A significant difference between the growth rate of the first cell and the growth rate of a second cell not expressing an exogenous Fer gene or Fer cDNA indicates that the substance is capable of altering a fer mediated pathway. | 06-17-2010 |
| 20100151453 | DOT1 HISTONE METHYLTRANSFERASES AS A TARGET FOR IDENTIFYING THERAPEUTIC AGENTS FOR LEUKEMIA - The present invention provides polypeptides with histone H3 lysine 79 methyltransferase activity as well as nucleic acids encoding the same. Also provided are methods of using the polypeptides and nucleic acids of the invention in screening assays to identify compounds of interest. Further provided are diagnostic methods for leukemia and prognostic methods to predict the course of the disease in a subject. | 06-17-2010 |
| 20100151454 | MICROFLUIDIC APPARATUS, SYSTEMS, AND METHODS FOR PERFORMING MOLECULAR REACTIONS - Disclosed herein are methods, apparatuses, and systems for performing nucleic acid sequencing reactions and molecular binding reactions in a microfluidic channel. The methods, apparatuses, and systems can include a restriction barrier to restrict movement of a particle to which a nucleic acid is attached. Furthermore, the methods, apparatuses, and systems can include hydrodynamic focusing of a delivery flow. In addition, the methods, apparatuses, and systems can reduce non-specific interaction with a surface of the microfluidic channel by providing a protective flow between the surface and a delivery flow. | 06-17-2010 |
| 20100151455 | USE OF BASE-MODIFIED DEOXYNUCLEOSIDE TRIPHOSPHATES TO IMPROVE NUCLEIC ACID DETECTION - Aspects of the invention provide novel and surprisingly effective methods for the detection of nucleic acids, comprising nucleic acid amplification using base-modified deoxynucleoside 5′-triphosphates (dNTPs). Particular aspects relate to methods for enhancing hybridization properties of oligonucleotide primers and probes in assays detecting nucleic acids, comprise amplifying target DNAs in presence of base-modified duplex-stabilizing deoxyribonucleoside 5′-triphosphates to provide for modified target DNAs, and thereby considerably improving performance of the detection assays. The disclosed methods allow for increasing of the reaction temperature in PCR-based detection systems or, alternatively, reducing the length of the oligonucleotide primers and probes. Certain aspects relates to improvement of real time PCR assays, wherein nucleic acids of interest are detected as the reaction proceeds using fluorescent agents or oligonucleotide FRET probes. | 06-17-2010 |
| 20100151456 | METHOD FOR THE ASSAY OF LIVER FATTY ACID BINDING PROTEIN, ACE AND CA 19-9 FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER - A method for the in vitro diagnosis of colorectal cancer by determining the presence of Liver Fatty Acid-Binding Protein, ACE and CA19-9 tumor markers in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer. | 06-17-2010 |
| 20100151457 | Detection of Unhealthy Cell and Uses Thereof - Provided herein is a method for detecting the presence of unhealthy cell in a subject using the expression of PDPK F | 06-17-2010 |
| 20100151458 | OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA - Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2′-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein “ds” indicates the RNase's specificity for certain double-stranded RNA substrates. The artificial substrates for the dsRNases described herein are useful in preparing affinity matrices for purifying mammalian ribonuclease as well as non-degradative RNA-binding proteins. | 06-17-2010 |
| 20100151459 | MARKER FOR DETECTING THE PROPOSED EFFICACY OF TREATMENT - The invention relates to a method of identifying a marker responsive to aripiprazole treatment comprising the steps of:
| 06-17-2010 |
| 20100151460 | Systems and Methods for Biological and Chemical Detection, Comprising Automatic Selection of Reagent Sets - The instant invention relates to systems of reagents and methods for the detection of chemical and biological targets in a sample. Some embodiments comprise methods for automatically selecting a set of reagents to detect one or more targets in a sample, wherein the set of reagents comprises at least two layers for detection of a first target, and at least two layers for detection of a second target, wherein the set comprises reagents that are at least partially redundant. In some embodiments, the redundancy is created by at least one degenerate reagent such that the reagent may interact specifically with more than one other component of a detection system or sample. In some embodiments, the system or method also includes reagent containers with a computer-generated code which may further serve to match targets to appropriate reagents. | 06-17-2010 |
| 20100151461 | GENETIC MARKERS FOR SCHIZOPHRENIA AND BIPOLAR DISORDER - The invention provides haplotypes and SNPs of the HPCAL1 and SV2C genes which predict the risk for developing schizophrenia or bipolar disorder and predict which patients are likely to respond to a given treatment or are more likely to experience negative side effects. | 06-17-2010 |
| 20100151462 | HUMAN DIABETES SUSCEPTIBILITY SHANK2 GENE - The present invention relates to a diagnostic method of determining whether a subject is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the SHANK2 gene locus in a biological sample of said subject. | 06-17-2010 |
| 20100151463 | Method for Determining the Likelihood of Response to HER2 Inhibitors - The present disclosure provides methods for determining the HER2 Status of a cancer tumor sample. | 06-17-2010 |
| 20100151464 | COMPOSITIONS AND METHODS FOR PREPARING OLIGONUCLEOTIDE SOLUTIONS - The present invention is directed to methods and compositions for generating a pool of oligonucleotides. The invention finds use in preparing a population or subpopulations of oligonucleotides in solution. The pool of oligonucleotides finds use in a variety of nucleic acid detection and/or amplification assays. | 06-17-2010 |
| 20100151465 | Selective Capture and Release of Analytes - The described subject matter includes techniques and components for minimally invasive, selective capture and release of analytes. An aptamer is selected for its binding affinity with a particular analyte(s). The aptamer is functionalized on a solid phase, for example, microbeads, polymer monolith, microfabricated solid phase, etc. The analyte is allowed to bind to the aptamer, for example, in a microchamber. Once the analyte has been bound, a temperature control sets the temperature to an appropriate temperature at which the captured analyte is released. | 06-17-2010 |
| 20100151466 | DIAGNOSIS AND TREATMENT OF CERVICAL CANCER - In certain aspects, the invention relates to methods of diagnosing cervical cancer by using a combination of certain biomarkers such as hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length. In other aspects, the invention relates to methods of detecting immortalization of cervical cells by using a combination of certain biomarkers. In yet other aspects, the invention relates to methods of classifying the grade of a cervical lesion for diagnostic and prognostic purposes in a female. In further aspects, the invention relates to methods of treating cervical cancer by administering a therapeutic agent that targets one or more of these biomarkers. | 06-17-2010 |
| 20100151467 | Methods and compositions for diagnosing and monitoring transplant rejection - Methods of diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection and kits or systems containing the same are also described. | 06-17-2010 |
| 20100151468 | EPIGENETIC BIOMARKERS FOR EARLY DETECTION, THERAPEUTIC EFFECTIVENESS, AND RELAPSE MONITORING OF CANCER - The present invention provides methods of detection, including early detection, for cancer or other diseases and normal physiologic processes mediated by global epigenetic changes, by using one or more of the following biomarkers: a global DNA methylation index, a global histone H4 acetylation index, and a global histone H4 trimethylation index. These methods are useful for, among other things, assessing the effectiveness of treatment, monitoring relapse, and clinical staging of cancer and other chronic as well as acute diseases. These methods are also useful for among other things monitoring the effectiveness of strategies and therapies used to modify lifestyle and contextual effects to prevent disease, foster wellness and enable health promotion. | 06-17-2010 |
| 20100151469 | SAMPLE-PROCESSING REAGENT COMPOSITIONS, METHODS, AND DEVICES - Stable compositions comprising a nucleic acid binding support material comprising a substrate with functional groups attached to the substrate; a lysing enzyme; a water dispersible matrix material; and a saccharide, methods of using the compositions, and products and devices which include the compositions are disclosed. | 06-17-2010 |
| 20100151470 | METHODS AND COMPOSITIONS FOR LOCATING SNP HETEROZYGOSITY FOR ALLELE SPECIFIC DIAGNOSIS AND THERAPY - The present invention provides methods for the rapid and cost effective identification of the presence of a disease-associated mutation and a particular SNP in the same allele of a gene without the need to clone and sequence the entire gene. The compositions and methods of the invention are useful for identification of patient to subpopulations amenable to treatment as part of a therapeutic strategy for treating genetic disorders, for example, dominant, gain-of-function gene mutations, for example, Huntington's Disease (HD). | 06-17-2010 |
| 20100151471 | METHODS OF MONITORING CONDITIONS BY SEQUENCE ANALYSIS - There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer. Provided herein are methods for using DNA sequencing to identify personalized biomarkers in patients with autoimmune disease and other conditions. Identified biomarkers can be used to determine the disease state for a subject with an autoimmune disease or other condition. | 06-17-2010 |
| 20100151472 | Detection Composition - The invention provides methods, kits, devices and compositions for detecting one or more target analytes. In some embodiments, the invention provides binding elements and labeling elements capable of being joined through a plurality of joining elements. | 06-17-2010 |
| 20100151473 | METHODS AND COMPOSITIONS FOR HYBRIDIZING NUCLEIC ACIDS - Methods and compositions for hybridizing nucleic acids are disclosed herein. Also disclosed herein are methods and compositions to detect a nucleic acid provided to an array. | 06-17-2010 |
| 20100151474 | Multifunctional Device For Diagnostics and Method For Testing Biological Objects - A multifunctional device for measuring fluorescence, luminescence and light transmission for diagnostics. A sample carrier is designed in the form of a biochip, cell, pan or microplate. The device comprises a first and second group of screens mounted behind the rear surface of a sample solid carrier. Light sources of the sample are provided with light-absorbing elements for suppressing light reflected from the front surface of the sample carrier and from screen surfaces. Screen holders allow for alternatively mounting light reflective/retroreflective screens to maximize fluorescent or luminescent signal. A diffusing screen measures light transmission through the sample. Light-absorbing screens behind the rear surface of the sample and light-absorbing elements on light sources from the sample's top surface, increase signal-to-noise ratio. Said device permits measuring signals on biochip surfaces and in solutions during hybridization or amplification reactions. The device and diagnostic method are suitable for mass screening of biological material samples. | 06-17-2010 |
| 20100151475 | Chemical reaction cartridge, its fabrication method, and a chemical reaction cartridge drive system - The present invention makes it possible to realize a chemical reaction cartridge, which enables prescribed protocols to be achieved easily without differences among operators, which is sealed and disposable, and which has a safe structure against viruses or dangerous drugs. | 06-17-2010 |
| 20100151476 | PHENYLTHIOCARBAMIDE (PTC) TASTE RECEPTOR - The invention provides isolated nucleic and amino acid sequences of a taste cell receptor that serves as a sensor for the bitter taste of phenylthiocarbamide (PTC), antibodies to such PTC taste receptor, methods of detecting such nucleic and amino acid sequences, and methods of screening for modulators of such PTC taste receptor. | 06-17-2010 |
| 20100151477 | REDUCING NON-TARGET NUCLEIC ACID DEPENDENT AMPLIFICATIONS: AMPLIFYING REPETITIVE NUCLEIC ACID SEQUENCES - The present invention provides for compositions and methods for amplifying target nucleic acids using nucleic acid primers designed to limit non-target nucleic acid dependent priming events. The present invention permits amplifying and quantitating the number of repetitive units in a repetitive region, such as the number of telomere repetitive units. | 06-17-2010 |
| 20100151478 | METHODS FOR DISEASE DETECTION - The present invention provides methods for detecting disease by analysis of a patient sample to determine the integrity of nucleic acids in the sample. | 06-17-2010 |
| 20100151479 | SENSING APPARATUS AND METHOD - A sensing apparatus comprising an ion sensitive field effect transistor arranged to generate an electrical output signal in response to localised fluctuations of ionic charge at or adjacent the surface of the transistor, and means for detecting the electrical output signal from the ion sensitive field effect transistor, the localised fluctuations of ionic charge indicating events occurring during a chemical reaction. | 06-17-2010 |
| 20100151480 | EXOSOME-ASSOCIATED MICRORNA AS A DIAGNOSTIC MARKER - The presently disclosed subject matter provides methods of diagnosis of cancer or adverse pregnancy outcomes in a subject by measuring amounts of one or more RNAs present in cancer-derived exosomes isolated from a biological sample from the subject. | 06-17-2010 |
| 20100151481 | CELL-SIGNALING ASSAYS - Assays for detecting the presence and activity of cell-signaling components. These assays include luminescence polarization assays for detecting cell-signaling nucleotides and modulators of receptors and enzymes related to the generation and activity of such nucleotides. | 06-17-2010 |
| 20100159445 | METHOD FOR THE INDIVIDUAL STAGING OF TUMOR DISEASES - The present invention concerns a method for the individual staging of the tumor disease of an individual cancer patient, a method for the individual decision on the method of treatment as well as a method for treating a cancer patient as well as their use in the treatment of various cancer diseases like colorectal tumor, prostate tumor, breast tumor, lung tumor, as primary tumors, tumor relapse and/or metastases. The present invention further provides a new prognosis factor in cancer treatment. This inventive method includes the step of analyzing at least one disseminated tumor cell present in a sample taken from a patient for the expression of at least one mRNA of at least one of growth factors, growth factor receptors and tumor associated transcripts. | 06-24-2010 |
| 20100159446 | Detection Assays and Use Thereof - The invention provides compositions and methods for the detection and/or quantification of biological targets (e.g., nucleic acids and proteins) by the nucleic acid-templated creation of one or more reaction products, for example, epitopes, enzyme substrates, enzyme activators, and ligands. The reaction products can be detected and/or quantitated after signal amplification using an amplification system. | 06-24-2010 |
| 20100159447 | QUANTITATIVE AMPLIFICATION WITH A LABELED PROBE AND 3' TO 5' EXONUCLEASE ACTIVITY - This invention provides methods and kits for performing a quantitative amplification reaction. The method employs a polymerase enzyme and an enzyme having a 3′ to 5′ exonuclease activity that cleaves the 3′ oligonucleotide of the probe. | 06-24-2010 |
| 20100159448 | METHOD FOR DETECTION AND MULTIPLE, SIMULTANEOUS QUANTIFICATION OF PATHOGENS BY MEANS OF REAL-TIME POLYMERASE CHAIN REACTION - A method for the detection and multiple, simultaneous quantification of any combination of | 06-24-2010 |
| 20100159449 | Continuous Assay Method for Measuring Receptor- and Ion Channel-Mediated Calcium Response and Subsequent Gene Expression - To measure a receptor-mediated increase in intracellular calcium concentration, use is made of a calcium-responding luminescent protein localized in the cytoplasm or mitochondria and a reporter gene having a promoter responding to the second messenger in cells and | 06-24-2010 |
| 20100159450 | DPYD GENE VARIANTS AND USE THEREOF - Variants in DPYD gene are disclosed which can result in abnormal synthesis of DPD proteins and alteration of DPD activities. The invention provides methods for detecting the newly discovered genetic variants. The DPD genetic variants of the invention can be used as biomarkers in predicting toxicity to 5-FU and other drugs metabolized by the DPD enzyme. | 06-24-2010 |
| 20100159451 | Method of detecting interaction between nucleic acid and protein, and apparatus for the same - The invention is to easily detect an interaction between nucleic acid and protein with high sensitivity without the need of sample labeling with a fluorescent molecule or sample anchorage onto a metal thin-film. As means for it, the presence or absence of occurrence of the interaction between nucleic acid and protein in a sample (S) is detected in an optical manner. Specifically, the sample (S) is irradiated with excitation rays (Le) and with measuring rays (L | 06-24-2010 |
| 20100159452 | Method For Detecting a Target Nucleic Acid in a Sample - The invention relates to a method for detecting a target nucleic acid in a sample using fluorescent probe pairs which include fluorescent reporter and quencher molecules which may be used in hybridization assays and in nucleic acid amplification reactions, especially polymerase chain reactions (PCR). | 06-24-2010 |
| 20100159453 | GENES INVOLVED IN INTESTINAL INFLAMMATORY DISEASES AND USE THEREOF - The invention concerns genes involved in inflammatory and/or immune diseases and some cancers, in particular intestinal cryptogenic inflammatory diseases, and proteins coded by said genes. The invention also concerns methods for diagnosing inflammatory diseases. | 06-24-2010 |
| 20100159454 | HtSNPs FOR DETERMINING A GENOTYPE OF CYTOCHROME P450 1A2, 2A6 AND 2D6, PXR AND UDP-GLUCURONOSYLTRANSFERASE 1A GENE AND MULTIPLEX GENOTYPING METHODS USING THEREOF - The present invention relates to htSNPs for determining a genotype of cytochrome P450 1A2 (CYP1A2), 2A6 (CYP2A6) and 2D6 (CYP2D6), PXR and UDP-glucuronosyltransferase Ia (UGT1A) genes and a gene chip using the same, and more particularly, to a selection method of htSNPs for determining a haplotype of human CYP1A2, CYP2A6, CYP2D6, PXR and UGT1A genes, a method of determining a genotype of the genes by using the htSNPs and a gene chip therefor. | 06-24-2010 |
| 20100159455 | RECEPTOR FAMILY PROFILING - The invention provides compositions and methods, e.g., assay technologies and their use in biodetection and diagnostics. More particularly, the invention provides compositions and methods based on nucleic acid-templated chemistry in biodetection and profiling of receptors (and their families) and proteins (and their families), and the use of same in diagnostics. | 06-24-2010 |
| 20100159456 | METHODS FOR DETECTING TCR-GAMMA GENE REARRANGEMENT - The invention provides methods for detection of TCR-γ nucleic acid in acellular body fluid. The methods can be used to detect the TCR-γ gene rearrangement in acellular body fluid. The detection of TCR-γ gene rearrangement is useful in determination of clonality of T-cell population. The invention is useful in the diagnosis of lymphoproliferative disorder. | 06-24-2010 |
| 20100159457 | SYSTEM AND METHOD FOR PRESENTING DNA BINDING SPECIFICITIES USING SPECIFICITY LANDSCAPES - A system and method for analyzing DNA binding specificities is provided. The potential binding motifs are compared to a plurality of DNA sequences. The DNA sequences are plotted within a specificity landscape, which provides details otherwise unavailable, relating to binding affinities and binding specificities of the motif-sequence combination. | 06-24-2010 |
| 20100159458 | METHOD FOR PREDICTING THE RESPONSE TO A THERAPY - The present invention relates to cancer treatment and particularly to a method for predicting the response of a cancer subject to a given therapy. The invention provides a gene or gene product useful as a predictive marker for classifying the subjects. Also disclosed are diagnostic tools, test kits and compositions and their use in the method. The invention is based on the use of NAD(P)H:Quinone oxidoreductase 1, NQO1, which enables the identification and classification of subjects who would benefit from being excluded from a treatment, particularly from anthracycline-based adjuvant chemotherapy with epirubicin. | 06-24-2010 |
| 20100159459 | PRODUCTION OF REPROGRAMMED CELLS WITH RESTORED POTENTIAL - A method for treating cells and/or nuclear transfer units and/or stem cells in culture with such compounds, individually or in combinations, is described. The method results in a globally hypomethylated genome and a restoration of cell differentiation and/or developmental potential, or potentiality. In addition, a method for the in vitro production of reprogrammed cells which have had differentiation potential (totipotential, pluripotential, or multipotential) restored by demethylating the genome is described. | 06-24-2010 |
| 20100159460 | Isolation of nucleic acids on surfaces - New processes and equipment to isolate and purify nucleic acids on surfaces are provided. The invention focuses on processes which use surfaces, for example, porous membranes, on which the nucleic acids are immobilized in a simple manner from the sample containing the nucleic acids and can be released again by way of simple procedural steps, whereby the simple performance of the process according to the invention makes it possible to perform the processes specifically in a fully automatic manner. An additional aspect of the present invention focuses on binding the nucleic acids to an immobile phase, especially to a membrane, in such a way and manner, that they can be released without difficulty during an additional reaction stage from this phase and, if desired, can be used in other applications, such as restriction digestion, RT, PCR or RT-PCR, or in any of the suitable analyses or enzyme reactions mentioned in the disclosure. Special isolation devices are provided that can be used to carry out the processes according to the invention. | 06-24-2010 |
| 20100159461 | Ion sensitive field effect transistors - According to a first aspect of the present invention there is provided a digital signal processing circuit, one or more switches of the circuit being provided by an ion sensitive field effect transistor. | 06-24-2010 |
| 20100159462 | TUNABLE ELASTOMERIC NANOCHANNELS FOR NANOFLUIDIC MANIPULATION - The invention relates to tunable elastomeric nanochannels for nanofluidic manipulation. In particular, the present invention relates to nanochannels for performing biological assays. | 06-24-2010 |
| 20100159463 | FAST RESULTS HYBRID CAPTURE ASSAY AND SYSTEM - The present invention comprises a method that provides fast and reliable results for detecting the presence of a target nucleic acid molecule in a sample. | 06-24-2010 |
| 20100159464 | Method for Detection of DNA Methyltransferase RNA in Plasma and Serum - The methods of the invention detect in a qualitative or quantitative fashion DNA methyltransferase RNA in blood plasma, serum, and other bodily fluids. The inventive methods are useful for aiding detection, diagnosis, monitoring, treatment, or evaluation of neoplastic disease, and for identifying individuals who might benefit from therapeutic approaches that target DNA methyltransferase RNA or protein. | 06-24-2010 |
| 20100159465 | Screening of Abundantly Secreted Proteins and Their Use as Fusion Partners for the Production of Recombinant Proteins - The present invention relates techniques for identifying suitable secretion fusion partner (SFP) for hyper-secretory production of recombinant proteins. The SFPs can be obtained from secretome analyses. Recombinant proteins are produced in a fusion form with a secretion fusion partner (SFP) and can be separated from the SFP by in vitro protease treatment. SFPs of this invention greatly improve the secretion level of target proteins and peptides which are valuable for bio-pharmaceuticals and the bio-industry. | 06-24-2010 |
| 20100159466 | TARGETS FOR USE IN DIAGNOSIS, PROGNOSIS AND THERAPY OF BREAST CANCER - The invention is directed to methods of diagnosing breast cancer, susceptibility to breast cancer, nodal metastasis of a breast cancer and screening for breast cancer in an individual in need thereof comprising detecting the presence of a loss of heterozygosity/allelic imbalance (LOH/AI) at one or more specific loci (markers) in the genome of the individual, wherein the presence of the LOH/AI at the one or more specific loci in the genome of the individual is indicative of a diagnosis of breast cancer in the individual. | 06-24-2010 |
| 20100159467 | METHOD FOR REPLICATING THE HEPATITIS C VIRUS - A process for screening anti-HCV agents, including the steps of introducing a compound to be tested for its anti-HCV properties with transformed Vero/6418 cells, having a nucleic acid selected from the group consisting of a nucleic acid coding for the structural and non-structural proteins of the HCV, a nucleic acid coding for the non-structural proteins of the HCV, and a replicon containing a resistance gene to an antibiotic and a nucleotide sequence coding for the non-structural proteins of the HCV; extracting total RNA of the cells; and analyzing any reduction of the rate, of synthesis of the RNA of the HCV of the cells relative to a control value corresponding to the rates of synthesis of the RNAs of the HCV of the cells in the absence of the tested compound. | 06-24-2010 |
| 20100159468 | SMALL MOLECULE INHIBITION OF INTRACELLULAR TRANSPORT - The present disclosure characterizes the activity of Golgicide A (GCA), as a potent, specific and reversible small molecule inhibitor of Golgi BFA resistance factor 1 (GBF1) function. A mutant GBF1 gene that is resistant to GCA is also described. Methods of using GCA and the GCA-resistant GBF1 gene are described including methods for modulating GBF1 activity for research and therapeutic purposes. Also described are compositions incorporating a GCA-resistant GBF1. | 06-24-2010 |
| 20100159469 | Compositions and Methods for Breast Cancer Prognosis - The present invention provides novel compositions and their use in classifying breast tumors. | 06-24-2010 |
| 20100159470 | SCDs As Modifiers of the p53 Pathway and Methods of Use - Human SCD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SCD are provided. | 06-24-2010 |
| 20100167273 | Method for Selectively Quantifying Vegf Isoforms in a Biological Sample and Uses Thereof - The present invention pertains to a novel method for quantifying VEGF various isoforms in a biological sample, with a very high selectivity and sensitivity. It also concerns a method for establishing a diagnostic and/or a prognosis concerning a patient potentially suffering from cancer, diabetes, or cardiovascular disease, comprising a step of determining the level of at least one of the VEGF isoforms, in a biological sample from said patient. | 07-01-2010 |
| 20100167274 | Methods and kits for identifying nucleic acid sequences - Methods and kits for detecting a nucleic acid sequence-of-interest in a sample are provided. The methods and kits use RecA-mediated strand exchange which is sensitive to a single-mismatch and which can exchange strands of non-denatured polynucleotide sequences of a sample. Thus the methods and kits of the present invention can be used for the identification of single nucleotide polymorphisms (SNPs), length of telomeric ends, numeration of chromosomes and disease-associated genes in a sample. | 07-01-2010 |
| 20100167275 | Potassium channel mutants of the yeast Saccharomyces cerevisiae and their use for screening eukaryotic potassium channels - The invention relates to processes for identifying inhibitors and activators of eukaryotic potassium channels, in which a mutated | 07-01-2010 |
| 20100167276 | HIGH-THROUGHPUT METHODS FOR QUANTIFYING CELLS IN ENVIRONMENTAL AND LABORATORY SAMPLES - The invention provides compositions (e.g., kits) and methods for determine the number of bacteria and other microbes in samples having low concentrations of microbes, for use, e.g., in biological warfare defense, microbe detection and agricultural and environmental sciences. | 07-01-2010 |
| 20100167277 | Fret sequencing by DNA scanning proteins - This patent describes a novel method for DNA sequencing. A DNA hybrid is created such that one strand contains nucleotides (A, G, C, T/U) bound to different FRET acceptor fluorophores that emits a distinct, differentiable wavelength. A DNA scanning protein carrying a FRET donor fluorophore is also added. A laser with a wavelength that excites the donor molecule irradiates the reaction. As the protein complex passes over a nucleotide on the DNA strand, a FRET reaction occurs between the donor and acceptor fluorophores. The acceptor fluorophore will emit a distinct wavelength which is detected and correlated to a specific nucleotide. As the DNA scanning protein moves along the DNA molecule the entire sequence of nucleotides can be determined by correlating the wavelengths emitted with the specific nucleotide associated with it. | 07-01-2010 |
| 20100167278 | Novel Method of Diagnosing, Monitoring, and Staging Prostate Cancer - The present invention provides a new method for detecting, diagnosing, monitoring, staging and prognosticating prostate cancer. | 07-01-2010 |
| 20100167279 | UNSYMMETRICAL CYANINE DYES FOR HIGH RESOLUTION NUCLEIC ACID MELTING ANALYSIS - The present invention relates to novel unsymmetrical cyanine dyes and to methods of performing nucleic acid analysis in the presence of such dyes. More specifically, the present invention relates to novel unsymmetrical cyanine dyes that have high affinity to double-stranded nucleic acids and that do not inhibit amplification reactions, particularly the polymerase chain reaction (PCR). | 07-01-2010 |
| 20100167280 | OLIGONUCLEOTIDES FOR DISCRIMINATING RELATED NUCLEIC ACID SEQUENCES - An in vitro selection method is described which identifies oligonucleotide probes that discriminate amongst closely related nucleic acid sequences and which involves iterative hybridizations, including subtractive hybridization. Using the method, oligonucleotides are identified which can discriminate among human papilloma virus (HPV) subtypes. Corresponding methods and kits for the detection of nucleic acids are described, which methods and kits may be used in analytical, diagnostic, research and related applications. | 07-01-2010 |
| 20100167281 | SEQUENCE ANALYSIS METHOD - It is intended to provide an assay for the presence, absence or amount of a nucleic-acid fragment having a certain nucleotide sequence, for example, a polyA length, a difference in the number of repetition of a direct repeat sequence (e.g., microsatellite), single nucleotide substitution (or single nucleotide polymorphism), and nucleotide sequence insertion or deletion, and to provide a genetic testing using the same. The present invention relates to a nucleotide analysis method, comprising: hybridizing at least two probes to a nucleic-acid fragment; ligating the at least two probes using ligase; exchanging, to ATP, pyrophosphoric acid produced through the ligation reaction; and detecting chemiluminescence reaction dependent on the ATP. | 07-01-2010 |
| 20100167282 | LATERAL-FLOW DEVICE AND METHOD TO ENHANCE DETECTION SIGNAL FOR CHARGED MOLECULAR TARGETS - The present invention proposes a lateral-flow device and method to enhance the detection signal for charged molecular targets. The device includes a detection assembly and a direct current source. The direct current is applied on the device to reduce the amount of residual target on the membrane and the detection limit is thus improved. | 07-01-2010 |
| 20100167283 | Analyte Detection - A method of detecting an analyte in a sample, comprises the steps of: a) contacting the sample with a first ligand which binds specifically to the analyte and which is immobilised either on, or in the vicinity of, a sensor; b) prior to step (a) contacting the sample, or subsequent to step (a) contacting the immobilised analyte, with a material including a second ligand which binds specifically to the analyte, the material being activatable to form a polymerisation initiator; and c) activating the material; wherein the polymerisation initiator interacts with the sensor to change its physical properties, which causes a change in the optical or acoustic properties of the sensor. | 07-01-2010 |
| 20100167284 | NUCLEIC ACID SIZE DETECTION METHOD - The present invention provides methods of determining the size of a particular nucleic acid segment of interest in a sample of nucleic acids through fragmentation of DNA, size fractionation, an optional second fragmentation, and identification using a marker sequence. In particular aspects, an expansion or reduction of tandem repeat sequences can be detected. In further aspects, carriers and individuals afflicted with fragile X syndrome or other diseases associated with tandem repeats can be distinguished from normal individuals. | 07-01-2010 |
| 20100167285 | METHODS AND AGENTS FOR EVALUATING INFLAMMATORY BOWEL DISEASE, AND TARGETS FOR TREATMENT - The invention provides methods for evaluating irritable bowel disease (IBD), including Crohn Disease and Ulcerative Colitis, methods for determining a patient's susceptibility to developing an IBD, and methods for determining a patient's IBD genotype. The invention includes methods, polynucleotides, polypeptides, and antibodies relating to disclosed variants of, and polymorphisms in, the nel-like 1 precursor (NELL1), as well as the 5p13.1 locus, and other genes disclosed herein to be associated with IBD. Thus, the invention provides diagnostic and/or therapeutic targets for IBD, as well as diagnostic and therapeutic agents for IBD. | 07-01-2010 |
| 20100167286 | Pluripotent cell lines and methods of use thereof - Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided. | 07-01-2010 |
| 20100167287 | CRUDE BIOLOGICAL DERIVATIVES COMPETENT FOR NUCLEIC ACID DETECTION - The invention relates generally to the fields of making biological unit lysates or admixtures of body fluids and of RNA analysis. More specifically, it relates to direct methods for the detection of a specific sequence of RNA in a biological unit, for example a virus, cell or tissue sample, or a body fluid, for example saliva, sputum, blood plasma, etc. More generally, the invention may be used to enzymatically manipulate and protect the RNA in lysate or bodily fluids for a number of applications. | 07-01-2010 |
| 20100167288 | Methods and Compositions Related to Continuous Flow Thermal Gradient PCR - Disclosed are compositions and a method for amplification and detection of nucleic acid sequences based on continuous flow thermal gradient PCR. | 07-01-2010 |
| 20100167289 | MULTI-COLOR TIME RESOLVED FLUOROPHORES BASED ON MACROCYCLIC LANTHANIDE COMPLEXES - The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quantum yields of lanthanide ion luminescence in aqueous media without the need for secondary activating agents. Preferred compounds incorporate hydroxy-isophthalamide moieties within their macrocyclic structure and are characterized by surprisingly low, non-specific binding to a variety of polypeptides such as antibodies and proteins as well as high kinetic stability. These characteristics distinguish them from known, open-structured ligands. | 07-01-2010 |
| 20100167290 | MOLECULE ATTACHMENT TO NANOPARTICLES - Disclosed herein are molecule-modified nanoparticles and methods of making and using the same. More specifically, disclosed herein are molecule-modified nanoparticles wherein the molecule is attached to the surface of the nanoparticle via an oligonucleotide. Also disclosed are methods of preparing nanoparticles having oligonucleotides and molecules (e.g., biomolecules, such as proteins, peptides, antibodies, lipids, and/or carbohydrates) attached to the nanoparticle surface, wherein the oligonucleotide and molecule are covalently attached. Further disclosed are methods of detecting an analyte of interest using these disclosed molecule-modified nanoparticles. | 07-01-2010 |
| 20100167291 | ASSESSING EXPRESSION OF ENDOGENOUS AND EXOGENOUS GENES - The present invention relates to compositions and methods to assess gene expression in cells. In particular, the present invention provides compositions and methods to assess expression from an exogenous gene and an endogenous version of the same gene in induced pluripotent stem cells. | 07-01-2010 |
| 20100167292 | HIGH FIDELITY POLYMERASES AND USES THEREOF - The present invention relates to a DNA and RNA polymerases which have increased fidelity (or reduced misincorporation rate). In particular, the invention relates to a method of making such polymerases by modifying or mutating the nucleotide binding domain of the polymerase (e.g., the O-helix). The invention also relates to DNA molecules containing the genes encoding the polymerases of the invention, to host cells containing such DNA molecules and to methods to make the polymerases using the host cells. The polymerases are particularly suited for nucleic acid synthesis, sequencing, amplification and cDNA synthesis. | 07-01-2010 |
| 20100167293 | Digital Assay - The invention relates to methods and compositions for the detection of targets in a sample. | 07-01-2010 |
| 20100167294 | METHODS FOR DETECTING NUCLEIC ACIDS IN A SAMPLE - Systems and methods are provided for immobilizing nucleic acid amplicons and protein antigens on a test device. Amplicons comprising a synthetic binding unit and a detectable label are generated and immobilized at predetermined locations on a test device by specific binding interactions between the synthetic binding unit and a synthetic capture unit located at the predetermined locations. The synthetic binding unit may include a unique design such that during amplification, a region of the synthetic binding unit is not subject to the amplification reaction, and thus the amplicon remains single stranded and available for binding to the synthetic capture unit during the capture process. In certain embodiments, the synthetic binding unit and a synthetic capture unit include synthetic nucleic acid analogs that do not interact with native nucleic acids or enzymes that act thereon. In one embodiment the synthetic binding unit and synthetic capture unit comprises puranosyl RNA (pRNA). | 07-01-2010 |
| 20100167295 | METHODS FOR HAPLOTYPING GENOMIC DNA - The present invention provides a novel method for specifically isolating and separating large segments of genomic DNA that can subsequently be used to determine a genomic haplotype. The invention relies on using a solid phase having a flat surface arrayed with oligonucleotides designed to specifically hybridize to each particular haplotype of an individual sample, e.g., oligonucleotides designed to specifically hybridize with each of the two HLA-B haplotypes, HLA-A, HLA-C, HLA-DR, HLA-DQ, and the like. The genomic DNA is contacted and hybridized to the arrayed oligonucleotides to form a genomic DNA/oligonucleotide complex. The excess genomic DNA is washed away and the haplotype separated genomic DNA is denatured from the oligonucleotide probe and collected. The method of the present invention allows for the separation of genomic DNA fragments of between approximately 2 to about 4 megabases (Mb). Separation of the haplotypes of large genomic DNA fragments allows for linkage analysis of other HLA alleles and polymorphisms, microsatellite, SNPs, and the like across a large span of the HLA region, including HLA-A, -B, -C, and HLA-DRB1 regions. This linkage analysis is particularly useful when HLA typing for an individual with limited family HLA typing available. | 07-01-2010 |
| 20100167296 | METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIME AND SURVIVAL EXPECTANCY FOR NON SMALL CELL LUNG CANCER BASED ON EGFR/CSF-1/CA IX EXPRESSION - The present invention relates to a screening method for classifying and for deciding to apply chemotherapy to patients suffering from non-small-cell lung cancer (NSCLC), based on detecting the levels of EGFR, CSF-1 and CA IX. | 07-01-2010 |
| 20100167297 | METHOD OF DETERMINING THE TIME TO PROGRESSION OF NON SMALL CELL LUNG CANCER AFTER CHEMOTHERAPY BASED ON THIOREDOXIN EXPRESSION - The present invention relates to a method for predicting the Time to Progression (TTP) of non small cell lung carcinoma (NSCLC) patients treated with chemotherapy, based on the detecting the levels of expression of thioredoxin (TRX) in a biological sample of the patient, or based on simultaneously detecting the expression levels of thioredoxin and the methylation status of the 14-3-3σgene. | 07-01-2010 |
| 20100167298 | PURO-DHFR Quadrifunctional Marker and its use in Protein Production - This invention relates to industrial production of proteins. More specifically, the invention relates to the res-DHFR surrogate marker, which corresponds to a fusion between DHFR and a protein conferring resistance to a toxic compound or conferring a metabolic advantage. The invention further relates to the use of res-DHFR for screening cells for high expression of a protein of interest. The invention is illustrated by the Puro-DHFR surrogate marker, which corresponds to a fusion between the puromycin N-acetyltransferase and dihydrofolate reductase (DHFR). | 07-01-2010 |
| 20100167299 | PHOSPHOLINK NUCLEOTIDES FOR SEQUENCING APPLICATIONS - The present invention provides labeled phospholink nucleotides that can be used in place of naturally occurring nucleotide triphosphates or other analogs in template directed nucleic acid synthesis reactions and other nucleic acid reactions and various analyses based thereon, including DNA sequencing, single base identification, hybridization assays, and others. | 07-01-2010 |
| 20100167300 | MICROENVIRONMENT NICHE ASSAY FOR CiPS SCREENING - The present invention provides three-dimensional microenvironment niches prepared from biomaterial compositions that supports growth and self renewal of stem cells. The invention also provides methods for inducing pluripotency in a somatic cell using chemical compounds, as well as methods for screening for compounds that can induce pluripotency in a somatic cell. | 07-01-2010 |
| 20100167301 | METHOD AND DEVICE FOR IMMUNOASSAY USING NUCLEOTIDE CONJUGATES - A composition of matter for use in an immunoassay devices and method comprising a signal antibody, e.g., FAB fragment, covalently linked to a first nucleotide; and one or more signal elements, e.g., signal enzymes such as ALP or fluorescent dyes, each covalently linked to a second nucleotide, wherein the first nucleotide has one or more repeated sequences, and the second nucleotide is bound to one of the one or more repeated sequences on said first nucleotide, and wherein the ratio of the signal antibody to the signal element is controlled by the number of repeated sequences. | 07-01-2010 |
| 20100167302 | METHOD FOR PREDICTING THE RESPONSE OF A SUBJECT SUFFERING FROM A VIRAL INFECTION OF THE LIVER TO AN ANTIVIRAL THERAPY - The application relates to treatments for improving antiviral therapies and to method for determining whether or not antiviral therapies will be effective. In particular, the present application provides a method for determining the likelihood that a subject having a viral infection of the liver will be responsive to antiviral therapy that includes stimulation of Interferon (IFN) activity, and kits for the performance of said determination. | 07-01-2010 |
| 20100167303 | SEQUENCES DIAGNOSTIC FOR SHRIMP PATHOGENS - Primers have been isolated that are diagnostic for the detection of | 07-01-2010 |
| 20100167304 | VARIABLE VALVE APPARATUS AND METHODS - Sample processing devices with variable valve structures and methods of using the same are disclosed. The valve structures allow for removal of selected portions of the sample material located within the process chamber. Removal of the selected portions is achieved by forming an opening in a valve septum at a desired location. The valve septums may be large enough to allow for adjustment of the location of the opening based on the characteristics of the sample material in the process chamber. If the sample processing device is rotated after the opening is formed, the selected portion of the material located closer to the axis of rotation exits the process chamber through the opening. The remainder of the sample material cannot exit through the opening because it is located farther from the axis of rotation than the opening. | 07-01-2010 |
| 20100167305 | Methods of Detecting Mutations Associated With Ataxia-Ocular Apraxia 2 (AOA2) - Methods of identifying polymorphisms associated with ataxia-ocular apraxia 2 (AOA2), are described. The polymorphisms associated with AOA2 include specific mutations in the senataxin (SETX) gene. Also described are methods of diagnosis of | 07-01-2010 |
| 20100173285 | Methods and Compositions for Detecting a Drug Resistant Egfr Mutant - Polymerase chain reaction primers and methods directed to detecting the EGFR mutant C→T at the position corresponding to base 2369 of EGFR cDNA. The invention provides a PCR primer that hybridizes under suitable PCR conditions to a polynucleotide sequence 5′ in each respective strand to a mutation of an EGFR gene that encodes a substitution of threonine by methionine at position 790 of the EGFR polypeptide. The invention also provides a PCR primer hybridizes to a sequence that includes a mutant T at the position corresponding to base 2369 of EGFR cDNA but not to a second EGFR polynucleotide containing a wild type C. The invention provides several methods and kits for detecting a mutant epidermal growth factor receptor (EGFR) gene in a sample comprising probing the sample with a means for selectively detecting a nucleotide sequence comprising a mutant T at the position corresponding to base 2369 of EGFR cDNA, and identifying that the base at said position is T. These methods and kits are also useful to predict resistance to the therapeutic effects of gefitinib or erlotinib in a subject suffering from or suspected of having a cancer. | 07-08-2010 |
| 20100173286 | Mutant Cells Suitable for Recombinant Polypeptide Production - A mutated bacterial cell producing at least one heterologous polypeptide of interest, wherein said cell has a reduced expression-level of YugJ (SEQ ID NO: 2) or a homologue thereof when compared with an otherwise isogenic but non-mutated cell; methods for producing said cell, and methods for producing a polypeptide of interest using said cell. | 07-08-2010 |
| 20100173287 | METHOD OF ANALYZING NUCLEIC ACID - According to the present invention, stable amplification of a small amount of nucleic acid and analysis of the same with good sensitivity can be realized by improving efficiency of hybridization primers or probes with a probe. Specifically, the present invention relates to a method of analyzing nucleic acid comprising: a step of hybridizing at least one type of a first probe comprising a 1 | 07-08-2010 |
| 20100173288 | SERUM/PLASMA MICRONAS AND USES THEREOF - This invention provides a combination of microRNAs for evaluating the physiological and/or pathological condition of a subject, wherein the combination comprises all detectable microRNAs stably existing in the serum/plasma of a subject; and a method for evaluating the physiological and/or pathological condition of a subject, wherein the method includes determining all detectable microRNAs stably existing in the serum/plasma of a subject; and a kit for evaluating the physiological and/or pathological condition of a subject, wherein the kit contains the tools for determining all detectable microRNAs that stably existing in the serum/plasma of a subject; and a biochip for evaluating the physiological and/or pathological condition of a subject, wherein the biochip contains the components for determining all detectable microRNAs stably existing in the serum/plasma of a subject. The aforementioned combination, method, kit and biochip can be used for diagnosis as well as differentially diagnosis of diseases including various tumors; various acute/chronic infectious diseases, e.g. viral diseases such as viral influenza, viral hepatitis, AIDS, SARS, bacterial diseases such as tuberculosis, bacterial pneumonia, and other acute/chronic infectious diseases caused by various pathogenic microorganisms; other acute/chronic diseases such as diseases of respiratory system, diseases of immune system, diseases of blood and hematopoietic system, diseases of circulatory system such as cardio-cerebrovascular diseases, metabolic diseases of endocrine system, diseases of digestive system, diseases of nervous system, diseases of urinary system, diseases of reproductive system and diseases of locomotor system, prediction of complications occurrence and malignant diseases relapse, evaluation of therapeutic effects, screening of pharmaceutical active ingredients, assessment of drug efficacy as well as forensic authentication and prohibited drug inspection and the like, possessing a number of advantages such as extensive detection spectrum, high sensitivity, low cost, convenience for sampling, ease for sample preservation, etc. The said method can be widely used in work related to general survey of diseases and so on, improve the low-specificity and low-sensitivity caused by individual differences which single markers are difficult to overcome, significantly increasing the clinical detection rate of diseases, all of which make it become an effective means for diagnosing diseases in an early phase. | 07-08-2010 |
| 20100173289 | Methods for Assessing Cancer Susceptibility to Carcinogens in Tobacco Products - The present invention demonstrates the differential sensitivity of PBLs from lung cancer patients and healthy controls to NNK-induced genetic damage. The data provide convincing evidence that the preferred CBMN assay is a robust test for detection of this sensitivity and yields results that are a good predictor of, for example, lung cancer risk. The simplicity, rapidity, and sensitivity of the CBMN test make it a valuable tool for screening and, for example, prioritizing potential cases for early detection of the disease. | 07-08-2010 |
| 20100173290 | MONITORING OF ENZYMATIC PROCESSES BY USING MAGNETIZABLE OR MAGNETIC OBJECTS AS LABELS - The present invention provides a method and device for monitoring an enzymatic process of a biological molecule by, at least once, during the enzymatic process determining an amount of magnetic particles attached to a sensor surface. The method and device according to embodiments of the present invention may be used for monitoring an enzymatic process as a function of time. | 07-08-2010 |
| 20100173291 | METHODS AND KITS FOR DETECTING FETAL CELLS IN THE MATERNAL BLOOD - Provided is a method of identifying a trophoblast by detecting in cells of a biological sample, with the proviso that the biological sample does not comprise a placental tissue, expression of a trophoblast marker selected from the group consisting of an annexin IV, a cytokeratin-7, a cytokeratin-8 and a cytokeratin-19; and classifying cells exhibiting expression of the trophoblast marker as trophoblasts. Also provided are methods of detecting a pregnancy in a subject, isolating trophoblasts from biological samples and prenatally diagnosing a conceptus using the identified trophoblasts. | 07-08-2010 |
| 20100173292 | NOVEL GPIIIa GENE - An object of the present invention is to provide a probe, primer, primer set and antibody for determining neonatal alloimmune thrombocytopenic purpura or the risk of developing it. According to the present invention, there is provided a probe, primer, primer set and antibody for use in the detection of the thymine residue at position 1297 in the GPIIIa. | 07-08-2010 |
| 20100173293 | High Density Sequence Detection Methods - A method for performing PCR on a liquid sample comprising a plurality of polynucleotide targets, wherein each polynucleotide target is present at very low concentration within the sample. The method comprises applying PCR reactants to the surface of a substrate to produce a plurality of reaction spots on the surface of the substrate; loading the liquid sample and a PCR reagent mixture onto the reaction spots; forming a sealed reaction chamber, having a volume of less than about 20 nanoliters, over each of the reaction spots; and amplifying the sample. | 07-08-2010 |
| 20100173294 | DIAGNOSTIC TEST FOR SUSCEPTIBILITY TO B-RAF KINASE INHIBITORS - The present invention provides methods and reagents for the detection of a mutation in BRAF and methods of selecting patients for treatment if a B-Raf kinase inhibitor, such as a selective B-Raf kinase inhibitor | 07-08-2010 |
| 20100173295 | FIXATION OF A BIOLOGICAL MATERIAL - The present invention relates to a method for the treatment of a biological material, comprising the steps i) providing a biological material, and ii) contacting the biological material with a first non-aqueous composition comprising: (a1) 10 to 90 vol. % methanol, and (a2) at least one additional additive, and (a3) optionally an acid. iii) transferring the biological material into a second composition (B) comprising up to 99 vol. % ethanol as well as to a new composition for preservation of a biological material usable in said method and the biological material resulting from this method, a method for the analysis of a treated biological material, various kits as well as the use of the composition in such a method. | 07-08-2010 |
| 20100173296 | METHODS OF STRATIFYING ADOLESCENT IDIOPATHIC SCOLIOSIS, ISOLATED NUCLEIC ACID MOLECULES FOR USE IN SAME AND KITS USING SAME - A method of stratifying a subject having adolescent idiopathic scoliosis (AIS) comprising: providing a cell sample isolated from the subject; detecting Paired-like homeodomain transcription factor 1 (Pitxi) expression in the cell sample; whereby the results of the detecting step enables the stratification of the subject having AIS as belonging to an AIS subclass. | 07-08-2010 |
| 20100173297 | NOVEL SERPENTINE TRANSMEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCERS AND USES THEREOF - Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers. | 07-08-2010 |
| 20100173298 | HCV GENE - The present invention provides a hepatitis C virus gene, a replicon RNA derived from the gene, a replicon-replicating cell into which the replicon RNA is introduced, and a method for screening a drug using the replicon-replicating cell. By introducing a replicon RNA comprising (A) a polynucleotide having the nucleic acid sequence shown in SEQ ID NO: 5; (B) a polynucleotide having the nucleic acid sequence shown in SEQ ID NO: 7; (C) a polynucleotide coding for a polypeptide having the amino acid sequence shown in SEQ ID NO: 6; (D) a polynucleotide coding for a polypeptide having the amino acid sequence shown in SEQ ID NO: 8; or (E) a polynucleotide having a nucleic acid sequence having a homology of not less than 90% with the nucleic acid sequence shown in SEQ ID NO: 5 or SEQ ID NO: 7; or a replicon RNA of the genotype 1b comprising nucleotides coding for the 1804th amino acid leucine and the 1966th amino acid lysine in the amino acid sequence of a hepatitis C virus polyprotein and a polynucleotide coding for an NS4B protein, into a cell, the replicon-replicating cell can be prepared. By using the replicon-replicating cell, the screening for the drug can be carried out. | 07-08-2010 |
| 20100173299 | MUTANT NUCLEIC ACID RELATED TO CHRONIC MYELOPROLIFERATIVE DISORDER AND METHOD OF EVALUATING CHRONIC MYELOPROLIFERATIVE DISORDER - A new mutant gene related to the onset of CMPD, particularly, the new mutant gene related to the onset of CMPD in patients who develop CMPD despite of JAK2 | 07-08-2010 |
| 20100173300 | NONCONTACT STIRRING METHOD, NONCONTACT STIRRING APPARATUS, METHOD AND APPARATUS FOR REACTING NUCLEIC ACID HYBRIDIZATION USING THE APPARATUS, METHOD FOR DETECTING NUCLEIC ACID IN SAMPLE, APPARATUS FOR DETECTING NUCLEIC ACID, METHOD FOR DETECTING ANTIBODY IN SAMPLE, APPARATUS FOR DETECTING ANTIBODY - A noncontact stirring method, a noncontact stirring apparatus, a method and apparatus for reacting nucleic acid hybridization using the apparatus, a method for detecting nucleic acid in a sample, an apparatus for detecting nucleic acid, a method for detecting antibodies in a sample, and an apparatus for detecting antibodies in minute droplets 1 μmL or less in an electric field are proposed that can be utilized to speed up biodetection processes, hybridization processes in DNA analysis, ELISA antigen fixing processes, blocking processes, antibody-antigen reaction processes and color reaction processes; and pathogen identification, CRP tests, methods of propagating cells or bacilli such as colon bacilli in a liquid culture medium, and chemical analyses. | 07-08-2010 |
| 20100173301 | PROGNOSTIC TOOLS TO PREDICT THE EFFICACY OF DRUG TREATMENT TARGETING CHROMATIN DNA OR ENZYMES ACTING ON DNA - Disclosed are methods of predicting cell response to drug-based therapy using both PCR-Stop assays and real time PCR assays. Methods herein may be used for assessment of drug effect, evaluation of regimen suitability for a given patient, and/or for determination of an optimal drug dose. Also provided are isolated oligonucleotide primers such as primers capable of annealing under PCR conditions to a segment of a c-myc locus, where the primers may be used in the disclosed methods. Further disclosed are kits and systems that may be used for predicting a cell response to drug-based therapy. | 07-08-2010 |
| 20100173302 | POSITIVE CONTROL PROTEINS FOR GLUCOSE TRANSPORTER PROTEINS AND PROCESSES FOR THE GENERATION OF SUCH POSITIVE CONTROL PROTEINS - Positive controls for experimentation related to membrane-bound glucose transporter proteins and methods for preparing such positive controls, such proteins including GLUT1, GLUT4, GLUT5, and GLUT12. | 07-08-2010 |
| 20100173303 | MULTIBASE DELIVERY FOR LONG READS IN SEQUENCING BY SYNTHESIS PROTOCOLS - The present technology relates to molecular sciences, such as genomics. More particularly, the present technology relates to methods for obtaining long lengths of sequencing data. | 07-08-2010 |
| 20100173304 | METHOD OF DNA SEQUENCING - The invention includes a method for sequencing DNA by partially sequencing the bases of complementary strands of double-stranded DNA and combining the partial information from both strands of the double strand DNA to fully sequence the DNA. The invention also includes DNA sequences sequenced by the methods, computer readable mediums including program instructions for such methods, and kits adapted to perform such methods. | 07-08-2010 |
| 20100173305 | COMPOSITIONS, KITS AND RELATED METHODS FOR THE DETECTION AND/OR MONITORING OF LISTERIA - Provided are compositions, kits, and methods for the identification of | 07-08-2010 |
| 20100173306 | METHOD FOR DETECTING G-QUADRUPLEX, METHOD FOR DETECTING G-QUADRUPLEX-FORMING DNA AND METHOD FOR DETERMINING TELOMERASE ACTIVITY - The present invention provides a method for specifically detecting a G-quadruplex, and the like. | 07-08-2010 |
| 20100173307 | NUCLEIC ACID MODULES FOR EXPRESSION AND TAGGING OF MEMBRANE PROTEINS AND METHODS OF USE - Described herein are nucleic acid modules for cloning, expression and tagging of eukaryotic membrane proteins. The nucleic acid modules include a receptor for advanced glycation end products (RAGE) signal sequence, a nucleic acid sequence encoding a tag and a multiple cloning sequence (MCS). Any membrane protein of interest can be cloned into the MCS for expression in cells. The nucleic acid modules can encode any type of tag, such as an epitope tag or affinity tag. The nucleic acid modules disclosed herein can be used to express any type of membrane protein and are particularly suited to the expression and tagging of Type I and Type III membrane proteins. | 07-08-2010 |
| 20100173308 | Systems for genome selection - Systems, methods, compositions and apparatus relating to genome selection are disclosed. | 07-08-2010 |
| 20100173309 | SITU METHODS FOR GENE MAPPING AND HAPLOTYPING - The present invention is directed to in situ methods for providing a definitive haplotype of a subject. The haplotype information generated by the methods described herein is more accurate than that provided by prior art methods that only give an inferred haplotype. Accordingly, in one aspect the present invention provides an in situ method for obtaining genetic information for a polyploid subject, the method including the steps of obtaining a biological sample from the subject, the sample containing: (i) at least one paternally-derived DNA molecule, and/or (ii) at least one maternally-derived DNA molecule, analyzing any one or more of the paternally- or maternally-derived DNA molecules for nucleotide sequence information, wherein the step of analyzing determines whether any two DNA markers are present in cis on one chromosome, or in trans across two sister chromosomes. Use of in situ methods such as FISH allows for the provision of phase-specific information on DNA markers without recourse to methods for physically separating sister chromosomes. Applicants propose that method eliminates the problem of incorrect or misleading inferences concerning the phase of two or more loci within a haplotype, and allows for revelation of two or more participatory genes within a haplotype, uncomplicated by differences in modes of inheritance. | 07-08-2010 |
| 20100173310 | MICROCHIP LARGE-VOLUME PCR WITH INTEGRATED REAL-TIME CE DETECTION - A microfluidic device is provided with appropriate integrated structures to conduct large volume PCR and end-point or real-time capillary electrophoresis detection The microfluidic device includes a substrate having an amplification chamber of a volume of nucleic acid, wells disposed on the substrate, flow channels connecting the wells and the chamber in the substrate to allow for solution flow through the chamber, and one or more separation channels provided in the substrate and connected to the chamber for separating and detecting a fraction of the amplified nucleic acid The chamber, the flow channels, and the one or more separation channels are configured such that the hydrodynamic flow resistance of the chambers and the flow channels combined is at least 10Λ3 times smaller than the hydrodynamic flow resistance in the one or more separation channels The microfluidic device can achieve a very high sensitivity in detection while being highly cost effective | 07-08-2010 |
| 20100173311 | NUCLEIC ACID AMPLIFICATION WITH ALLELE-SPECIFIC SUPPRESSION OF SEQUENCE VARIANTS - The present invention is an improved method of selective amplification of certain variants of the target sequence, enhanced by allele-specific suppression of amplification of one or more of the other variants of the target sequence. The improvement is accomplished by providing an oligonucleotide, capable of hybridizing to the desired variant of the target sequence with the lesser affinity than to the undesired variants of the target sequence and optionally, by providing chemically modified primers and hot-start conditions. | 07-08-2010 |
| 20100173312 | GENETIC LESION ASSOCIATED WITH CANCER - The invention comprises methods for identifying mutations within the 3′ UTRs of genes that lead to increased risk or probability of developing cancer. | 07-08-2010 |
| 20100173313 | BIOMARKERS OF INFLAMMATION - Methods for the detection of DP | 07-08-2010 |
| 20100173314 | DIAGNOSTIC METHODS USING TENASCIN-W COMPOSITIONS - Tenascin-W. an extracellular matrix molecule that is specifically expressed in metastatic tumours is provided. A system comprising a sample expressing tenascin-W is used as an in vitro method for screening possible anti-tumour agents or for agents that promote osteogenesis. | 07-08-2010 |
| 20100173315 | Assay Particles and Methods of Use - The invention provides assay particles useful, for example, for detecting analytes and binding molecule interactions. One type of assay particle includes a core portion encased by a shell portion, wherein the shell portion comprises an inorganic phosphor that binds selectively to a target molecule. Another type of an assay particle includes a core portion encased by a shell portion, and a coat portion covering the shell portion, wherein the coat portion comprises an inorganic phosphor that binds selectively to a target molecule. A further type of assay particle includes a core portion encased by a shell portion, and a coat portion covering the shell portion, wherein the coat portion comprises an inorganic phosphor and a target selective binding moiety, and wherein the assay particle is buoyant in aqueous media. An additional type of assay particle includes a core portion encased by a shell portion, and a coat portion covering the shell portion, wherein the shell portion comprises an inorganic phosphor and the coat portion comprises a target selective binding moiety, and wherein the assay particle is buoyant in aqueous media. Also provided are kits and related methods. | 07-08-2010 |
| 20100173316 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 2 and mutated sequences thereof. | 07-08-2010 |
| 20100173317 | METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCER - Disclosed are methods for detecting non-small cell lung cancer (NSCLC) using differentially expressed genes KIF11, GHSR1b, NTSR1, and FOXM1. Also disclosed are methods of identifying compounds for treating and preventing NSCLC, based on the interaction between KOC1 and KIF11, or NMU and GHSR1b or NTSR1. | 07-08-2010 |
| 20100173318 | METHOD AND SYSTEM FOR MODELING CELLULAR METABOLISM - This invention relates to methods and systems for in silico or bioinformatic modeling of cellular metabolism. The invention includes methods and systems for modeling cellular metabolism of an organism, comprising constructing a flux balance analysis model, and applying constraints to the flux balance analysis model, the constraints selected from the set consisting of: qualitative kinetic information constraints, qualitative regulatory information constraints, and differential DNA microarray experimental data constraints. In addition, the present invention provides for computational procedures for solving metabolic problems. | 07-08-2010 |
| 20100173319 | COMPOSITIONS AND METHODS FOR CANCER DIAGNOSIS AND THERAPY - The miR15 and miR16 micro RNA genes are located at 13q14 within a 30 kb region of loss characteristic of cells from certain cancers, such as cells from chronic lymphocytic leukemia or prostate cancer. Chronic lymphocytic leukemia or prostate cancer can be diagnosed by detecting a reduction in miR15 or miR16 gene copy number, by determining miR15 or miR16 gene mutational status, or by detecting a reduction in the RNA transcribed from these genes. The miR15 or miR16 gene products can inhibit the neoplastic or tumorigenic growth of cancers such as chronic lymphocytic leukemia or prostate cancer cells when administered to subjects suffering from these diseases. | 07-08-2010 |
| 20100173320 | Methods for Detecting Nucleic Acids Indicative of Cancer - The invention provides methods for screening tissue or body fluid samples for nucleic acid indicia of cancer or precancer. | 07-08-2010 |
| 20100178649 | GENOMICS-BASED QUALITY DIAGNOSTICS FOR PREDICTION OF COLD-SWEETENNG DURING STORAGE IN PROCESSING POTATO - The invention relates to the field of quality testing of fresh potato products. Methods, carriers and kits for determining and/or predicting the quality stage of potato batches are provided. | 07-15-2010 |
| 20100178650 | CAPILLARY-BASED CELL AND TISSUE ACQUISITION SYSTEM (CTAS) - The present invention relates to a capillary-based cell and tissue acquisition system that integrates the capillary approach with a microscope manipulator to collect and sort cells of interest. Cells of interest are determined by using a laser beam focus to identify the initial contact between the capillary and the cells. | 07-15-2010 |
| 20100178651 | Bifunctional Predictors of Cancer Treatment Sensitivity and Resistance - The present invention provides the identification of genes that are expressed in tumors to indicate responsiveness or resistance to an agent or class of agents. More particularly, these genes show expression associated with responsiveness to one agent or class of agents is inversely related to expression in association with another class of agents. One or more of theses genes of the present invention can be used as markers (or surrogate markers) to identify tumors that are likely to be successfully treated by the responsive agent as well as to identify tumors that should avoid treatment by the resistant agent. | 07-15-2010 |
| 20100178652 | Materials and Methods for the Detection, Prevention and Treatment of Autoimmune Disease - The subject invention provides materials and methods for the detection, prevention, and treatment of diabetes and other autoimmune conditions. | 07-15-2010 |
| 20100178653 | GENE EXPRESSION SIGNATURE FOR CLASSIFICATION OF CANCERS - The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy. | 07-15-2010 |
| 20100178654 | REAGENT AND REAGENT KIT FOR ANALYSIS OF IMMATURE LEUKOCYTE - The present invention provides a reagent for analysis of immature leukocytes comprising:
| 07-15-2010 |
| 20100178655 | SINGLE-CELL NUCLEIC ACID ANALYSIS - The present invention provides methods for analysis of genomic DNA and/or RNA from small samples or even single cells. Methods for analyzing genomic DNA can entail whole genome amplification (WGA), followed by preamplification and amplification of selected target nucleic acids. Methods for analyzing RNA can entail reverse transcription of the desired RNA, followed by preamplification and amplification of selected target nucleic acids. | 07-15-2010 |
| 20100184020 | Chip-Based Sequencing Nucleic Acids - A system for fast DNA sequencing by amplification of genetic material within microreactors, denaturing, demulsifying, and then sequencing the material, while retaining it in a PCR/sequencing zone by a magnetic field. One embodiment includes sequencing nucleic acids on a microchip that includes a microchannel flow channel in the microchip. The nucleic acids are isolated and hybridized to magnetic nanoparticles or to magnetic polystyrene-coated beads. Microreactor droplets are formed in the microchannel flow channel. The microreactor droplets containing the nucleic acids and the magnetic nanoparticles are retained in a magnetic trap in the microchannel flow channel and sequenced. | 07-22-2010 |
| 20100184021 | NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND METHODS OF USE THEREOF FOR DIAGNOSIS - The present invention relates to diagnostic markers comprising novel splice variants of known proteins and polynucleotides encoding same, useful in the qualitative and/or quantitative detection of various diseases and/or pathological conditions in a subject, and to the use of known proteins and polynucleotides encoding same for diagnosis. Particularly, the invention relates to the diagnosis of a disease in a sample of body fluid or secretion obtained from the subject, and to the diagnosis of cancer. | 07-22-2010 |
| 20100184022 | Hybridization Probe Assay and Array - A probe suitable for coupling with a particulate support such as a microbead, the probe comprising:
| 07-22-2010 |
| 20100184023 | Prostate Specific Gene, PCGEM1, and Methods of Using PCGEM1 to Detect, Treat, and Prevent Prostate Cancer - A nucleic acid sequence that exhibits prostate-specific expression and over-expression in tumor cells is disclosed. The sequence and fragments thereof are useful for detecting, diagnosing, preventing, and treating prostate cancer and other prostate related diseases. The sequence is also useful for measuring hormone responsiveness of prostate cancer cells. | 07-22-2010 |
| 20100184024 | Method of Characterizing Nucleic Acids in a Mixed Sample - A method is provided for characterizing a mixed sample having at least two particles with nucleic acids from different individuals, where each particle has nucleic acid from one or more individuals, in particular for the quantitative determination of the absolute and/or relative copy number of a predetermined sequence of an individual, of which nucleic acid is present in the mixed sample, having the steps:
| 07-22-2010 |
| 20100184025 | METHOD FOR SCREENING FOR A TOBIANO COAT COLOR GENOTYPE - A method for screening for a Tobiano genotype includes obtaining a nucleic acid from an equine animal, and analyzing the nucleic acid for the presence of an inversion in a chromosome ECA3q which is indicative of the genotype for Tobiano. The method includes detecting at least one of a telomeric breakpoint of an inverted ECA3q chromosome and/or a centromeric breakpoint of an inverted ECA3q chromosome. In one embodiment, the nucleic acid may be analyzed by the steps of hybridizing the group of probes or primers having the sequences set forth herein in SEQ ID NO:8, SEQ ID NO: 9, and SEQ ID NO: 10, or sequences complementary thereto, and preparing an amplification product. A 209 bp nucleic acid amplification product (SEQ ID NO:11) indicates the presence of the inversion. | 07-22-2010 |
| 20100184026 | Companion Diagnostic Assays For Endothelin Receptor Antagonists - Methods for identifying cancer patients eligible to receive endothelin receptor antagonist therapy and for monitoring patient response to endothelin receptor antagonist therapy comprise assessment of the expression levels of at least one of PAI-1, uPA, TGFbeta2, IL-6, IL-8 and OPG in a patient tissue sample. The methods of the invention allow more effective identification of patients to receive endothelin receptor antagonist therapy and of determination of patient response to the therapy. | 07-22-2010 |
| 20100184027 | METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS - The invention provides methods, nucleic acids and kits for detecting, or for detecting and distinguishing between or among proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of and differentiation between said class of disorders, thereby enabling the improved diagnosis and treatment of patients. | 07-22-2010 |
| 20100184028 | METHOD AND SYSTEM FOR REAL TIME QUANTIFICATION AND MONITORING OF NUCLEIC ACID AMPLIFICATION USING ELECTROCONDUCTIVE OR ELECTROCHEMICALLY ACTIVE LABELS - A method and device for real time electrochemically or electrically monitoring and detecting nucleic acid amplification products, i.e. after each polymerase chain reaction cycle, utilizes electrochemically active or electrically conductive reporter materials. An electric voltage is applied and electric signals are measured during a PCR amplification process to the electrodes that is suitable for quantifying the amplified products of a sample's nucleic acid(s) produced. This technique is suitable for point-of-use applications, e.g. detecting bioanalytes in remote locations. | 07-22-2010 |
| 20100184029 | METHODS AND COMPOSITIONS FOR IDENTIFYING BIOMARKERS USEFUL IN CHARACTERIZING BIOLOGICAL STATES - The present invention relates to methods, compositions, and kits for identifying biomarkers useful in characterizing biological states. In particular, the invention relates to methods and compositions for molecular characterization of biological states by gene expression profiling. The invention also relates to assessing effects of DNA polymorphisms on regulation of transcription. The biomarkers and polymorphisms identified find use in diagnostic and treatment approaches, e.g., some embodiments of the invention provide methods and kits for detecting bronchogenic carcinoma and risks thereof. | 07-22-2010 |
| 20100184030 | METHOD, COMPOSITIONS AND KITS FOR INCREASING EFFICIENCY OR SPECIFICITY OF HYBRIDIZATION BETWEEN PNA PROBES IMMOBILIZED ON SUPPORT AND TARGET NUCLEIC ACIDS - Disclosed are a process for increasing efficiency or specificity of hybridization between peptide nucleic acid (PNA) probes immobilized on a support and target nucleic acids, which comprises the step of fragment the target nucleic acids to reduce the size of the target nucleic acids, or selectively degrading the target nucleic acids which mismatch with the PNA probes, in the hybridization reaction between the PNA probes supported on a support and the target nucleic acids; and a composition and a kit therefor. | 07-22-2010 |
| 20100184031 | NOVEL ADIPOCYTOKINE VISFATIN/PBEF1 IS AN APOPTOSIS ASSOCIATED FACTOR INDUCED IN MONOCYTES DURING IN VIVO HIV-1 INFECTION - The present invention relates to the use of monocyte markers for diagnostic, prognostic or theranostic applications during diseases and syndromes caused by HIV infection. More specifically, it relates to a method comprising isolation of monocytes and determining gene expression, preferably PBEF1 gene expression. The method is useful to determine the evolution of the disease or can be used to evaluate the efficacy of a treatment. | 07-22-2010 |
| 20100184032 | Stem-Progenitor Cell Specific Micro-Ribonucleic Acids and Uses Thereof - Provided herein are methods and compositions for modulating the differentiation of incompletely differentiated cells, such as stem-progenitor cells, e.g., hematopoietic stem-progenitor cells. A method may comprise contacting a cell with an agononist or an antagonist of a miRNA comprising a nucleotide sequence from SEQ ID NO: 1-34. | 07-22-2010 |
| 20100184033 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY - Aspects of the present invention relate to methods to differentiate pluripotent primordial stem cells, such as human embryonic stem (“hES”) cells, human embryonic germ (“hEG”) cells, human embryo-derived (“hED”) cells and human embryonal carcinoma (“hEC”) cells, to obtain subpopulations of cells from heterogeneous mixtures of cells, wherein the subpopulation of cells possess reduced differentiation potential compared to the original pluripotent stem cells and where the subpopulation is capable of being propagated 20 or more population doublings. This invention also provides novel compositions of such subpopulations of cells and methods to propagate and differentiate said cells. | 07-22-2010 |
| 20100184034 | Gene Expression Profiling for Identification, Monitoring and Treatment of Lung Cancer - A method is provided in various embodiments for determining a profile data set for a subject with lung cancer or conditions related to lung cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-5. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that arc substantially repeatable. | 07-22-2010 |
| 20100184035 | METHODS FOR RAPID FORENSIC DNA ANALYSIS - The present invention provides methods and primer pairs for rapid, high-resolution forensic analysis of DNA and STR-typing by using amplification and mass spectrometry, determining the molecular masses and calculating base compositions of amplification products and comparing the molecular masses with the molecular masses of theoretical amplicons indexed in a database. | 07-22-2010 |
| 20100184036 | METHODS FOR DETECTING NUCLEIC ACID SEQUENCES - The present invention provides methods and kits for detecting the presence or absence or amount of a target nucleic acid or at least one variant nucleotide in one or more target nucleic acids contained in a sample using appropriate primers. The invention is based on systems whereby there is extension-dependent degradation of the primers in the presence of the target, which degradation leads to a detectable signal. | 07-22-2010 |
| 20100184037 | DEATH ASSOCIATED PROTEIN KINASE 1 (DAPK1) AND USES THEREOF FOR THE TREATMENT OF CHRONIC LYMPOCYTIC LEUKEMIA - A method for determining susceptibility to chronic lymphocytic leukemia in a subject includes determining a loss or reduced expression of death associated protein kinase 1 (DAPK1) or fragments or functional equivalents thereof. | 07-22-2010 |
| 20100184038 | System and Method For the Heterologous Expression of Polyketide Synthase Gene Clusters - A system and method for heterologous expression of polyketide biosynthetic pathways from streptomycetes hosts in | 07-22-2010 |
| 20100184039 | METHODS AND COMPOSITIONS RELATING TO LABELED RNA MOLECULES THAT REDUCE GENE EXPRESSION - The present invention concerns methods and compositions involving labeled, double-stranded RNA (dsRNA), including siRNA, capable of triggering RNA-mediated interference (RNAi) in a cell. Compositions of the invention include labeled dsRNA for RNAi, which may be a single strand of RNA that basepairs with itself or two separate RNA strands. In some embodiments, the label is fluorescent. The present invention further concerns methods for preparing such composition and kits for implementing such methods. Other methods of the invention include ways of using labeled dsRNA for RNAi. | 07-22-2010 |
| 20100184040 | COMPOSITIONS AND METHODS FOR DETERMINING LIKELIHOOD OF TWINNING - Collections of polynucleotides useful for estimating breeding value or detecting likelihood of twinning are disclosed. The polynucleotides are used to detect genomic sequences quantitatively associated with the twinning trait. Also disclosed are methods and kits for using the collections to estimate breeding value or predict likelihood of twinning. | 07-22-2010 |
| 20100184041 | Molecular Indicators of Breast Cancer Prognosis and Prediction of Treatment Response - The present invention relates to quantitative molecular indicators that can guide clinical decisions in breast cancer, such as estrogen receptor (ESR1)-positive, lymph node-negative breast cancer. In particular, the invention concerns certain genes, the varied expression of which indicates the likelihood of recurrence of surgically resected breast cancer in patients who are not treated with a therapeutic agent in the adjuvant setting. In addition, the invention concerns the use of quantitative measurement of the expression of certain genes, including the ESR1 gene, that measure as a continuous variable, to determine (a) the likelihood of a beneficial response to the anti-estrogen therapeutic agent, such as tamoxifen; and (b) the potential magnitude of beneficial response to chemotherapy. | 07-22-2010 |
| 20100184042 | Processes for quantitative or qualitative detection of single-stranded nucleic acids - This invention provides for compositions for use in real time nucleic acid detection processes. Such real time nucleic acid detection processes are carried out with energy transfer elements attached to nucleic acid primers, nucleotides, nucleic acid probes or nucleic acid binding agents. Real time nucleic acid detection allows for the qualitative or quantitative detection or determination of single-stranded or double-stranded nucleic acids of interest in a sample. Other processes are provided by this invention including processes for removing a portion of a homopolymeric sequence, e.g., poly A sequence or tail, from an analyte or library of analytes. Compositions useful in carrying out such removal processes are also described and provided. | 07-22-2010 |
| 20100184043 | Detecting Genetic Abnormalities - The present invention is directed to compositions and methods for detecting genetic abnormalities. The present invention encompasses methods and compositions for comparing alleles in a sample containing both maternal and fetal nucleic acids in order to identify genetic abnormalities. | 07-22-2010 |
| 20100184044 | Detecting Genetic Abnormalities - The present invention is directed to compositions and methods for detecting genetic abnormalities. The present invention encompasses methods and compositions for comparing alleles in a sample containing both maternal and fetal nucleic acids in order to identify genetic abnormalities. | 07-22-2010 |
| 20100184045 | Methods for sequencing degraded or modified nucleic acids - The invention provides methods and compositions for sequencing DNA or RNA samples that would be impossible to do via standard means. Samples that are part of mixtures or are degraded or modified may be sequenced so that the individual from whom the sample originated can be determined or useful biological information can be associated with the sample. Methods are described that allow high efficiency sequencing of degraded nucleic acid samples such as are typically found with FFPE. Samples from severely degraded sources or that have been treated with preservatives such as formalin may be sequenced. In addition to permitting identification of samples, information about disease or treatment status may also be determined. | 07-22-2010 |
| 20100184046 | Methods and systems of using exosomes for determining phenotypes - Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin. | 07-22-2010 |
| 20100184047 | SCREENING AND THERAPEUTIC METHOD FOR NSCLC TARGETING THE CDCA8-AURKB COMPLEX - The present invention is based on the observation that the co-activation of CDCA8 and AURKB, and their cognate interactions, play a significant role in lung-cancer progression. Accordingly, inhibiting the formation of the CDCA8-AURKB complex finds utility in the treatment of non-small-cell lung cancer. The present invention also provides methods for identifying for compounds suitable for the treatment and/or prevention non-small-cell lung cancer, using, for example, the transcriptional regulatory region of the CDCA8 or AURKB gene, as well as diagnostic and prognostic methods that utilize the expression levels of CDCA8 and/or AURKB as a determining index. | 07-22-2010 |
| 20100184048 | EPIDERMAL GROWTH FACTOR (EGF) EXPRESSION AND/OR POLYMORPHISMS THEREOF FOR PREDICTING THE RISK OF DEVELOPING CANCER - The present invention relates to diagnostic and prognostic methods to determine the likelihood of a subject who has a inflammatory disease or liver disease of developing cancer. In particular, the present invention relates to methods for identifying subjects with increased susceptibility to developing cancer, such as hepatocellular carcinoma (HCC) where the subject has an inflammatory disease, such as, but not limited to cirrhosis, by identifying a variance or polymorphism in the human EGF gene. In particular, the methods of the present invention relate to identifying subjects with increased susceptibility to developing cancer such as HCC, where the subject has an inflammatory disease, such as but not limited to cirrhosis, and the subject is identified to have a single nucleotide polymorphism 61A>G in the 5′UTR of the EGF gene. Alternatively, the methods of the present invention relate to identifying subjects with increased susceptibility to developing cancer such as HCC, where the subject has an inflammatory disease, such as but not limited to cirrhosis, and the subject is identified to have increased expression of EGF as compared to a reference level of EGF expression. The present invention also relates to administering an effective amount of an anti-cancer therapy to subjects identified to have an increased susceptibility of developing cancer such as HCC by the methods as disclosed herein, and kits to identify a subject with a 61A>G polymorphism in the 5′UTR of the EGF gene or kits to determine increased EGF expression in subjects with chronic inflammatory disease. | 07-22-2010 |
| 20100184049 | Glycoprotein Profiling of Bladder Cancer - The present invention relates to a method for the diagnosis, prognosis, and monitoring of bladder cancer, such as early or late stage bladder cancer, by detecting in a urine sample from a subject at least one biomarker for bladder cancer identified herein, such as alpha-1B-glycoprotein, haptoglobin, serotransferrin, or alpha- | 07-22-2010 |
| 20100184050 | DIAGNOSIS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE IN THE PUERTO RICAN POPULATION - This invention provides methods of diagnosis and treatment of inflammatory bowel disease. In one embodiment, the invention provides methods of diagnosing and/or predicting susceptibility for inflammatory bowel disease in the Puerto Rican population by determining the presence or absence of a risk variant at the HPS1 locus. In another embodiment, the invention further provides methods of diagnosing and/or predicting protection against inflammatory bowel disease by determining the presence or absence of a protective variant at the IRF1 locus. In another embodiment, the presence in an individual of a risk variant at the CARD8 locus is diagnostic of susceptibility to Crohn's Disease in a Puerto Rican individual. In another embodiment, the presence of a risk variant at the TLR-9 locus in an individual is diagnostic of susceptibility to Crohn's Disease. | 07-22-2010 |
| 20100184051 | METHODS OF GENERATING PLURIPOTENT CELLS FROM SOMATIC CELLS - Disclosed herein are methods to select for the generation of mouse and human pluripotent stem cells during developmental reprogramming. The methods described herein relate to the selection of induced pluripotent stem cells, i.e., pluripotent stem cells generated or induced from differentiated cells without a requirement for genetic selection. Described herein are particular embodiments for selection of reprogrammed cells based on 1) colony morphology, or 2) X chromosome reactivation in female cells. | 07-22-2010 |
| 20100184052 | PROGNOSTIC GENE EXPRESSION SIGNATURE FOR NON SMALL CELL LUNG CANCER PATIENTS - The invention relates to a method of typing non-small cell lung cancer cells by determining RNA levels for a set of genes. Said typing can be used for determining a metastasizing potential of the cancer cells. The invention further relates to a set of probes and a set of primers that can be used for typing non-small cell lung cancer cells. | 07-22-2010 |
| 20100184053 | IDENTIFICATION AND QUANTIFICATION OF ONCOGENIC HPV NUCLEIC ACIDS BY MEANS OF REAL-TIME PCR ASSAYS - Method for the identification and quantification of oncogenic HPV nucleic acids comprising: a) first line screening by means of 5 independent SYBR Green I Real-time PCR assays to determine the total viral load and to identify the presence of one or more of 13 high risk HPV genotypes in the sample; b) second line assays to be applied to samples positives for: 5 independent TaqMan Real-time PCR assays to determine the presence and the viral load of the most common oncogenic HPV types: HPV types: 16, 18, 31, 45, 33 group (including 33, 52, 58, 67 genotypes).6 independent SYBR Green I RT Real-time PCR assays to determine the presence in the sample of the oncogenic transcripts E6/E7 of HPV types 16, 18, 31, 33, 45, 58. | 07-22-2010 |
| 20100184054 | BINDING OF PATHOLOGICAL FORMS OF PRION PROTEINS - A process for the selective binding of an aggregating abnormal form of a protein in the presence of the nonaggregating normal form of the protein, including contacting under selective binding conditions a material containing both the abnormal and normal forms with a binding agent which is a polyionic material having a binding avidity for the aggregating form of the protein as present in the sample. | 07-22-2010 |
| 20100184055 | Method for Distinguishing Follicular Thyroid Adenoma (FTA) From Follicular Thyroid Carcinoma (FTC) - Follicular thyroid adenoma (FTA) is distinguished from follicular thyroid carcinoma (FTC) by comparing amount of an expression product of at least one gene selected from the group consisting of DDIT3, ARG2, ITM1, C1orf24, TARSH, and ACO1 in a test follicular thyroid specimen to a normal control thyroid specimen. The test follicular thyroid specimen is identified as FTA if the amount of expression product of TARSH is equal to or greater in the test follicular thyroid specimen than in the normal control thyroid specimen. The test follicular thyroid specimen is identified as FTC if the amount of expression product of DDIT3, ARG2, ITM1, C1orf24, or ACO1 is greater in the test follicular thyroid specimen than in the normal control thyroid specimen. | 07-22-2010 |
| 20100184056 | Sample collection and measurement in a single container by back scattering interferometry - This invention provides a device and method for collection and analysis of heterogeneous samples in a single sample container by back scattering interferometry. The sample container is configured to allow collection of a heterogeneous sample, such as blood, from a subject, separation of insoluble materials, such as blood cells by, for example, centrifugation, and mounting on a back scattering interferometer for analysis. In certain embodiments the container is a capillary tube and the interferometer comprises a mounting to hold the capillary tube in position for analysis. The device and method allow point-of-care analysis of samples. | 07-22-2010 |
| 20100184057 | Methods and probes for identifying a nucleotide sequence - The present invention provides a method for identifying a set of target nucleotide sequences capable of identifying a member of a group of related nucleotide sequences, the method comprising the step of dividing the nucleotide sequence of each member of the group into a plurality of subsequences, wherein at least two of the subsequences overlap. The method is useful in generating probe sets capable of assigning alleles at HLA or KIR loci. | 07-22-2010 |
| 20100184058 | PERIPHERICAL TISSUE SAMPLE CONTAINING CELLS EXPRESSING THE 5HTR2C AND/OR ADARS AS MARKERS OF THE ALTERATION OF THE MECHANISM OF THE 5HTR2C MRNA EDITING AND ITS APPLICATIONS - The present invention relates to an in vitro method for predicting a pathology related to an alteration of the mechanism of the mRNA editing of ADAR dependent A to I mRNA editing, particularly the serotonin 2C receptor (5HTR2C), in a patient from a peripherical tissue sample containing cells expressing said mRNA, such as the 5HTR2C mRNA, and/or adenosine deaminases acting on RNA (ADARs), such as skin and/or blood tissue sample. The present invention further comprises a method for identifying if an agent is capable of in vivo modifying the editing of the 5HTR2C mRNA in brain tissue or to control the efficiency of a drug intended to prevent or to treat a pathology related to an alteration of the mechanism of the 5HTR2C mRNA editing brain tissue, these methods comprising the implementation of said peripherical tissue markers. In a particular aspect, the present invention relates to such methods wherein the 5HTR2C mRNA editing rate or profile, when it is necessary, is determined by a single strand conformation polymorphism (SSCP) method after amplification by a PCR, preferably by a nested PCR, of the specific mRNA fragment containing the edition sites, making it possible, under given analytical conditions, to obtain the editing rate and/or profile of this edited 5HTR2C mRNA from said peripherical tissue. Finally the invention relates to particular nucleic acid primers implemented in said nested PCR. | 07-22-2010 |
| 20100184059 | COMPOSITIONS - A composition for carrying out a chemical or biochemical reaction, said composition being in a freeze-dried form and comprising (i) a set of reagents comprising at least some of the chemical or biochemical reagents necessary for conducting said chemical or biochemical reaction, including at least one reagent which is fluorescent (ii) a glass forming agent, and (iii) threonine. Kits comprising these compositions and methods of using them form a further aspect of the invention. | 07-22-2010 |
| 20100184060 | METHOD FOR THE IDENTIFICATION OF PROPANE-OXIDIZING BACTERIA - The invention relates to a method for the identification of propane-oxidizing bacteria which is based on the identification of at least one fragment of the prmA gene encoding the alpha subunit of the propane monooxygenase enzyme and/or the prmD gene encoding an ancillary protein involved in the oxidation reaction of propane by gene amplification in the presence of pairs of primers selected in correspondence of homologous portions, deduced from the alignment of the prmA and prmD sequences. | 07-22-2010 |
| 20100184061 | REAGENT AND REAGENT KIT FOR ANALYSIS OF IMMATURE LEUKOCYTE - The present invention provides a reagent for analysis of immature leukocytes comprising:
| 07-22-2010 |
| 20100184062 | Method for Identifying and Quantifying Organic and Biochemical Substances - The invention relates to a method for identifying organic or biochemical substances and for determining their concentration in a fluid medium using a nanogap sensor that comprises at least two electrodes. The invention is characterized in that: a nanogap sensor) with electrodes of different materials is used, a respective probe molecule is bonded to each surface of the two electrodes of the sensor and the free remainder of the probe molecules have at least one bondable group with specificity for bonding to a sought substance or to an analyte molecule in the fluid medium. The analyte molecule has at least two binding sites and passes selectively out of the fluid medium in which it is contained, binds to the free ends of the probe molecules, forming a bridge with the probe molecule, and modifies the resulting impedance between the electrodes. The concentration of the substance in the fluid medium can be determined as a result of the modification. | 07-22-2010 |
| 20100184063 | PROGNOSTIC AND PREDICTIVE GENE SIGNATURE FOR NON-SMALL CELL LUNG CANCER AND ADJUVANT CHEMOTHERAPY - The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application. | 07-22-2010 |
| 20100184064 | DNA MOLECULES ENCODING LIGAND GATED ION CHANNELS FROM DERMACENTOR VARIABILIS - The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode | 07-22-2010 |
| 20100184065 | Method of Predicting Non-Response to First Line Chemotherapy - The invention provides a method for determining a prognosis of colorectal cancer in a colorectal cancer patient, comprising classifying said patient as having a good prognosis or a poor prognosis using measurements of a plurality of gene products in a cell sample taken from said patient, said gene products being respectively products of at least 1 of the genes listed in Table 1, or respective functional equivalents thereof, wherein said good prognosis predicts a positive response to standard chemotherapy regimens, and said poor prognosis predicts non-responsiveness. Provided herein, the invention includes a gene signature to predict which patients will to benefit from standard colon cancer therapy; alternatively, patients who are classified as non-responders may be more likely to benefit from a novel agent such as a Notch inhibitor. | 07-22-2010 |
| 20100184066 | ASSAY FOR TRICHOMONAS VAGINALIS BY AMPLIFICATION AND DETECTION OF TRICHOMONAS VAGINALIS AP65-1 GENE - A region of the | 07-22-2010 |
| 20100184067 | PRIMER EVALUATION METHOD, PRIMER EVALUATION PROGRAM, AND REAL-TIME POLYMERASE CHAIN REACTION APPARATUS - A primer evaluation method includes: acquiring a signal indicating time change in an amplification amount obtained when sample sets prepared for the number of temperature conditions that should be made different from each other at an annealing stage in units of target nucleic acids diluted in a stepwise manner are so amplified that a temperature condition at a stage other than the annealing stage is fixed; acquiring a signal indicating initial amounts of the target nucleic acids diluted in a stepwise manner; obtaining amplification efficiency for each of the temperature conditions based on the time change in the amplification amount and the initial amount, and calculating a variation degree of the amplification efficiency; and submitting the variation degree and a reference value for quality evaluation of a primer, set with respect to the variation degree. | 07-22-2010 |
| 20100184068 | METHOD OF MEASURING REVERSE-TRANSCRIBED SINGLE STRANDED DNA, METHOD OF MEASURING REVERSE TRANSCRIPTASE ACTIVITY AND KIT FOR THE SAME - Provided are a method of measuring a single stranded DNA reverse-transcribed from a RNA using RNaseH, RNaseT1, and RNase A, a method of measuring activity of a reverse transcriptase, and kits for the same. | 07-22-2010 |
| 20100184069 | PRESERVATION OF FETAL NUCLEIC ACIDS IN MATERNAL PLASMA - A method for preserving and processing fetal nucleic acids located within maternal plasma is disclosed, wherein a sample of maternal blood containing fetal nucleic acids is treated to reduce both cell lysis of the maternal blood cells and deoxyribonuclease (DNase) and ribonuclease (RNase) activity within the fetal nucleic acids. The treatment of the sample aids in increasing the amount of fetal nucleic acids that can be identified and tested while maintaining the structure and integrity of the fetal nucleic acids. | 07-22-2010 |
| 20100184070 | Methods and Devices for Diagnosis of Appendicitis - A method is provided for diagnosing appendicitis in a patient that includes identifying at least one symptom of appendicitis in the patient and identifying the presence of at least one molecule differentially associated with appendicitis in a fluid or tissue sample of said patient. MRP-8/14 and haptoglobin are examples of molecules differentially associated with appendicitis. Devices and kits for performing the appendicitis assays of this invention are also provided. In one embodiment, the device is in a flow-through immunoassay format for testing blood samples. Further, methods for screening for molecules differentially associated with appendicitis are provided that include the use of samples from patients being operated on for suspected appendicitis. | 07-22-2010 |
| 20100184071 | COMPARTMENTALIZED SELF TAGGING - The present invention relates to the development of a novel method for the selection of nucleic acid processing and other enzymes. In particular the invention relates to a method for the selection of nucleic acid polymerases and other enzymes with desired properties based on the method of compartmentalized self-tagging. | 07-22-2010 |
| 20100184072 | METHOD OF DETECTION OF PREDISPOSITION TO EMPHYSEMA IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE - The present invention relates to a method of detection of predisposition to emphysema in chronic obstructive pulmonary disease (COPD). It particularly relates with the regulation of the key molecular and biochemical components of the pathway leading to the manifestation of emphysema in COPD. | 07-22-2010 |
| 20100184073 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 3 and mutated sequences thereof. | 07-22-2010 |
| 20100184074 | UNIVERSAL NUCLEOTIDES FOR NUCLEIC ACID ANALYSIS - The invention includes methods and kits for making and analyzing primer extension products incorporating one or more universal bases, including methods and kits for nucleic acid sequencing and microsatellite analysis. | 07-22-2010 |
| 20100184075 | Haplotype Analysis - The present invention provides an efficient way for high throughput haplotype analysis. Several polymorphic nucleic acid markers, such as SNPs, can be simultaneously and reliably determined through multiplex PCR of single nucleic acid molecules in several parallel single molecule dilutions and the consequent statistical analysis of the results from these parallel single molecule multiplex PCR reactions results in reliable determination of haplotypes present in the subject. The nucleic acid markers can be of any distance to each other on the chromosome. In addition, an approach wherein overlapping DNA markers are analyzed can be used to link smaller haplotypes into larger haplotypes. Consequently, the invention provides a powerful new tool for diagnostic haplotyping and identifying novel haplotypes. | 07-22-2010 |
| 20100184076 | SOLUBLE ANALYTE DETECTION AND AMPLIFICATION - The present invention relates to a method of detection of a compound of interest that is present at low levels in a sample. In particular, the present invention relates to a method of detection of a compound of interest in solution by a nucleic acid-labelled binding construct, separation of the unbound nucleic acid-labelled binding construct, and the detection of the bound nucleic acid-labelled binding construct in the solution phase. The present invention is particularly adaptable to be used in conjunction with a nucleic acid amplification reaction for detecting the presence or absence of the nucleic acid portion of binding construct in a sample indicating the presence or absence of the compound of interest. | 07-22-2010 |
| 20100184077 | Allelic Form of the HMGA2 Gene Predisposing Women to the Formation of Leiomyomas - The present invention is directed to diagnostic assays that can be used to determine if a woman carries an allelic form of the HMGA2 gene that predisposes her to the formation of fibroid tumors. The invention also encompasses vectors containing this allele, cells transformed with these vectors and transgenic animals that carry at least one copy of the allele. | 07-22-2010 |
| 20100184078 | OLIGONUCLEOTIDE SEQUENCES THAT IDENTIFY SPECIES OF ANIMAL - The present invention provides a method for identifying animal species, said method comprises a step of amplifying a DNA fragment by PCR using a DNA in a sample as a template and animal-specific DNA sequences as a primer pair, wherein the animal-specific DNA sequences are derived from a ATP synthase subunit 8 gene or a region proximal thereto of a mitochondrial genome; and a step of detecting the amplified DNA fragment. | 07-22-2010 |
| 20100184079 | SOYBEAN EVENT 3560.4.3.5 AND COMPOSITIONS AND METHODS FOR THE IDENTIFICATION AND DETECTION THEREOF - Compositions and methods related to transgenic glyphosate/ALS inhibitor-tolerant soybean plants are provided. Specifically, soybean plants having a 3560.4.3.5 event which imparts tolerance to glyphosate and at least one ALS-inhibiting herbicide are provided. The soybean plant harboring the 3560.4.3.5 event at the recited chromosomal location comprises genomic/transgene junctions having at least the polynucleotide sequence of SEQ ID NO:10 and/or 11. The characterization of the genomic insertion site of the 3560.4.3.5 event provides for an enhanced breeding efficiency and enables the use of molecular markers to track the transgene insert in the breeding populations and progeny thereof. Various methods and compositions for the identification, detection, and use of the soybean 3560.4.3.5 events are provided. | 07-22-2010 |
| 20100184080 | Methods of Detecting Charcot-Marie Tooth Disease Type 2A - Methods are described for screening a subject for risk of Charcot-Marie-Tooth Disease Type 2A or for diagnosing Charcot-Marie-Tooth disease or a predisposition for developing Charcot-Marie-Tooth disease in a subject, by detecting the presence or absence of a mutation in the mitofusin gene in a biological sample collected from the subject. Methods are also described for detecting the presence of a genetic polymorphism associated with Charcot-Marie-Tooth Disease Type 2A in a sample of patient nucleic acid, by amplifying a mitofusin gene sequence in the patient nucleic acid to produce an amplification product; and identifying the presence of a Charcot-Marie-Tooth Disease Type 2A associated polymorphism in the amplification product. | 07-22-2010 |
| 20100184081 | GENETIC MARKERS FOR OBESITY - The present invention is directed to new genetic variants or polymorphisms at the perilipin locus (PLIN) including PLIN1: 6209T (allele 1)>C (allele 2); PLIN3 10171 (allele 1) A >T (allele 2); PLIN4: 11482G (allele 1)>A (allele 2); PLIN5: 13041A (allele 1)>G (allele 2) and PLIN6: 14995A (allele 1)>T (allele 2), and their use in diagnostic and prognostic applications for obesity and obesity-related diseases, such as metabolic syndrome and cardiovascular disease. | 07-22-2010 |
| 20100190150 | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators - EGFR biomarkers useful in a method for identifying a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) exposing the mammal to the EGFR modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the EGFR modulator indicates that the mammal will respond therapeutically to the method of treating cancer. | 07-29-2010 |
| 20100190151 | FLUORESCENTLY LABELED NUCLEOSIDE TRIPHOSPHATES AND ANALOGS THEREOF FOR SEQUENCING NUCLEIC ACIDS - The invention provides methods for sequencing a nucleic acid, and particularly methods for synthesizing fluorescently labeled nucleoside triphosphates and related analogs for sequencing nucleic acids. | 07-29-2010 |
| 20100190152 | Apparatus for Analysing A Sample and Assessing its Global Position - An apparatus for analysing a sample and assessing its global position, the apparatus comprising a portable sample analysing device and a global positioning device. | 07-29-2010 |
| 20100190153 | SINGLE-MOLECULE PCR ON MICROPARTICLES IN WATER-IN-OIL EMULSIONS - Modulation of the viscosity of the oil phase of a microemulsion used for amplification of DNA on a bead increases the homogeneity of product beads and the amount of amplified DNA per bead. Moreover the number of separate microemulsion populations that can be formed in parallel is increased using multi-well plates and mixer mill disruptor machines designed to lyse biological samples. | 07-29-2010 |
| 20100190154 | Development of low allergen soybean seeds using molecular markers for the P34 allele - A mutation in the gene encoding the P34 protein in soybean which affects allergenicity is characterized. Soybean homozygous for a mutant allele comprising a four base pair insertion at the start codon of the gene encoding the P34 protein, exhibit significantly reduced P34 protein accumulation. Nucleic acid samples of soybean may be assayed for the presence of this insertion to detect the mutant allele, and soybean containing the allele may be selected for breeding to generate reduced P34 soybean lines. Molecular markers have been developed for detecting the presence or absence of the four base pair insertion. | 07-29-2010 |
| 20100190155 | METHODS AND KITS FOR MEASUREMENT OF LYMPHOCYTE FUNCTION - The present invention provides simple and rapid methods for measuring the function of a desired subset of lymphocytes, for example, T cells, B cells or NK cells. In addition, the present invention provides an all-in-one kit that contains reagents which permit a rapid and reliable analysis of the functions of T cells, B cells and NK cells obtained directly from whole blood or cord blood. | 07-29-2010 |
| 20100190156 | Quality control of agricultural products based on gene expression - The invention relates to the field of quality testing of fresh plant-based and mushroom based products. Methods, carriers and kits for determining the quality stage are provided. | 07-29-2010 |
| 20100190157 | METHOD FOR DETECTION OF MUTANT ALLELES COMBINING REAL TIME PCR AND REMS-PCR - The instant invention refers to a method for simultaneous selective amplification and detection of mutant DNA sequences, to oligonucleotides to be used for said method and to kit for the same. The invention refers aldo to a method for identifying a specific mutated DNA sequence, to oligonucleotides to be used for said method and to kit for the same. | 07-29-2010 |
| 20100190158 | Rapid Test for Detecting DNA Sequences - The present invention relates to an in vitro method for detecting a target DNA sequence in cells using an oligonucleotide which is labelled with a beta-D-galactopyranoside which, on hydrolysis of the glycosidic linkage, forms a water-insoluble dye. The invention relates in particular to an in vitro method for detecting a target DNA sequence from a group of DNA sequences whose members differ from one another in exactly one predetermined nucleotide position, by using an oligonucleotide which is labelled with a beta-D-galactopyranoside which, on hydrolysis of the glycosidic linkage, forms a water-insoluble dye. The invention additionally relates to the use of such an oligonucleotide in DNA hybridization methods. The invention finally relates to kits for carrying out the above methods. | 07-29-2010 |
| 20100190159 | FLUORESCENCE-PRODUCING MOLECULE - It is an object of the present invention to provide an on-off type fluorescent compound used in gene analyses, which is highly stable and highly sensitive, and which enables amplification of a trace amount of gene signal and observation thereof. The present invention provides a compound represented by the following formula (1) or (2): | 07-29-2010 |
| 20100190160 | INDICATOR CELL LINES AND METHODS FOR MAKING SAME - Methods of making an indicator cell are described. The methods include, e.g., contacting a vertebrate cell comprising a functional endogenous target gene under control of an endogenous inducible promoter with a parvoviral vector comprising a construct comprising a targeting DNA sequence linked to a DNA encoding a reporter gene, wherein the construct enters the cell and undergoes homologous recombination with the target gene, thereby operably linking the reporter gene and the target gene; inducing expression of the target gene thereby causing expression of the reporter gene; and selecting the cell based on expression of the reporter gene. | 07-29-2010 |
| 20100190161 | MUTATIONS IN HUMAN UBIAD1 - The invention relates to polynucleotides and polypeptides which encode UBIAD1. | 07-29-2010 |
| 20100190162 | METHODS OF USING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE TL1A GENE TO PREDICT OR DIAGNOSE INFLAMMATORY BOWEL DISEASE - This invention provides methods of diagnosing or predicting susceptibility to Inflammatory Bowel Disease by determining the presence or absence of genetic variants in the TL1A gene. In one embodiment, a method of the invention is practiced by determining the presence or absence of TL1A production following Fc-gamma-R activation. In another embodiment, the invention provides methods of treatment of inflammatory bowel disease by inhibition of TL1A. | 07-29-2010 |
| 20100190163 | CANCER ANTIGEN-SPECIFIC T-CELL RECEPTOR GENE, PEPTIDE ENCODED BY THE GENE, AND USE OF THEM - Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence. | 07-29-2010 |
| 20100190164 | DIAGNOSIS AND MONITORING OF RENAL FAILURE USING PEPTIDE BIOMARKERS - Methods for the determination of renal failure, especially chronic renal failure and acute kidney injury, by measurement of peptide or protein biomarkers are described. The methods are useful to determine stages of renal failure, especially the early stages such as stage | 07-29-2010 |
| 20100190165 | Methods of screening compounds for bioactivity in organized tissue - The invention provides a method of screening a compound for bioactivity, comprising contacting a candidate bioactive compound with an organized tissue, and measuring in at least a cell of the organized tissue a biological parameter that is associated with bioactivity, wherein a change in the biological parameter that occurs as a result of the contacting step is indicative of bioactivity of the candidate compound. | 07-29-2010 |
| 20100190166 | TISSUE REJECTION BIOMARKERS - This document relates to methods and materials involved in assessing tissue rejection (e.g., organ rejection) in mammals. For example, methods and materials involved in detecting tissue rejection (e.g., kidney rejection) are provided, as are methods and materials for distinguishing types of tissue rejection (e.g., antibody-mediated rejection versus T cell-mediated rejection) in mammals (e.g., humans). | 07-29-2010 |
| 20100190167 | Methods, Reagents and Kits for Detection of Nucleic Acid Molecules - Methods, reagents and kits are provided for the production and use in detection assays of labeled nucleic acid molecules wherein a labeling molecule is attached directly to the 3′ end of the nucleic acid molecules. | 07-29-2010 |
| 20100190168 | COMPETITOR MOLECULES USEFUL FOR LOWERING NONSPECIFIC ADSORPTION OF DYE LABELED NUCLEOTIDES - Methods are described which enable higher signal/noise when performing surface measurements at the single molecule level. Methods are particularly useful in the field of molecular biology when performing single molecule nucleic acid sequencing by synthesis using dye labeled nucleotides. The method employs using a competitor molecule which blocks nonspecific binding of analog molecules to the surface. | 07-29-2010 |
| 20100190169 | SINGLE NUCLEOTIDE POLYMORPHISMS PREDICTING CARDIOVASCULAR DISEASE - The present invention relates to an isolated polynucleotide encoding a Na | 07-29-2010 |
| 20100190170 | MICROTITER PLATE MASK AND METHODS FOR ITS USE - Provided is a masking system of masks for use with multiwell plates such as microtiter plates to facilitate sample dispensing and assay accuracy, especially when dispensing more than one solution into the wells. One or more masks, adapted in size to fit snugly over a multiwell plate and the mask formed with openings each aligned with a subset of one or more wells of the plate beneath, aids the user in sample and/or reagent administration. Advantageously, the masks contain registration aids so that proper orientation with respect to the plate below is achieved; the registration aid may be a cut corner, registration peg or mark, or visual marking or stamping. | 07-29-2010 |
| 20100190171 | MICROORGANISM CONCENTRATION PROCESS - A process for capturing or concentrating microorganisms for detection or assay comprises (a) providing a concentration agent that comprises an amorphous metal silicate and that has a surface composition having a metal atom to silicon atom ratio of less than or equal to about 0.5, as determined by X-ray photoelectron spectroscopy (XPS); (b) providing a sample comprising at least one microorganism strain; and (c) contacting the concentration agent with the sample such that at least a portion of the at least one microorganism strain is bound to or captured by the concentration agent. | 07-29-2010 |
| 20100190172 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual to treatment of cardiovascular disorders with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 07-29-2010 |
| 20100190173 | Gene Expression Markers For Colorectal Cancer Prognosis - A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject. | 07-29-2010 |
| 20100190174 | ADAM12, A NOVEL MARKER FOR ABNORMAL CELL FUNCTION - The present invention provides a method, an assay and a kit for providing an indication of abnormal cell function. It was surprisingly found that the change in the serum ADAM12 concentration in individuals was useful as a prognostic tool to predict the clinical outcome, complications and mortality following an abnormal cell function. | 07-29-2010 |
| 20100190175 | METHODS OF RANDOM MUTAGENESIS AND METHODS OF MODIFYING NUCLEIC ACIDS USING TRANSLESION DNA POLYMERASES - The invention is related generally to methods of amplifying or synthesizing or producing nucleic acid molecules using Translesion DNA polymerases. In particular, the invention relates to methods of introducing a random mutation into a nucleic acid and encoded polypeptide using Translesion DNA polymerases. The invention also relates to methods of introducing a modified nucleotide into a nucleic acid using Translesion DNA polymerases. The invention also relates to mutagenized and modified nucleic acid molecules and proteins produced by these methods, and to fragments or derivatives thereof. The invention also relates to vectors and host cells comprising mutagenized nucleic acid molecules, fragments, or derivatives. The invention also relates to the use of mutagenized nucleic acid molecules to produce desired polypeptides and uses of modified nucleic acid molecules to analyze samples. The invention also relates to kits or compositions or compounds for use in the invention or for carrying out the invention. | 07-29-2010 |
| 20100190176 | TUMOR SUPPRESSOR DESIGNATED TS10Q23.3 - A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed. | 07-29-2010 |
| 20100190177 | TARGET ACTIVATED MICROTRANSFER - A method of removing a target from a biological sample which involves placing a transfer surface in contact with the biological sample, and then focally altering the transfer surface to allow selective separation of the target from the biological sample. In disclosed embodiments, the target is a cell or cellular component of a tissue section and the transfer surface is a film that can be focally altered to adhere the target to the transfer surface. Subsequent separation of the film from the tissue section selectively removes the adhered target from the tissue section. The transfer surface is activated from within the target to adhere the target to the transfer surface, for example by heating the target to adhere it to a thermoplastic transfer surface. Such in situ activation can be achieved by exposing the biological sample to an immunoreagent that specifically binds to the target (or a component of the target). The immunoreagent can alter the transfer surface directly (for example with a heat generating enzyme carried by the immunoreagent), or indirectly (for example by changing a characteristic of the target). In some embodiments, the immunoreagent deposits a precipitate in the target that increases its light absorption relative to surrounding tissue, such that the biological specimen can be exposed to light to selectively heat the target. Alternatively, the immunoreagent is an immunofluorescent agent that carries a fluorophore that absorbs light and emits heat. | 07-29-2010 |
| 20100190178 | Altered Recombinases for Genome Modification - The present invention describes methods of identifying altered recombinases and compositions thereof, wherein at least one amino acid is different from a parent, wild-type recombinase and the altered recombinase has improved recombination efficiency towards wild-type and/or pseudo att site sequences relative to the parent, wild-type recombinase. The present invention also includes methods of modifying the genomes of cells using the altered recombinases, including methods of site-specifically integrating a polynucleotide sequence of interest in a genome of a eucaryotic cell. | 07-29-2010 |
| 20100190179 | Lateral Flow Methods and Devices for Detection of Nucleic Acid Binding Proteins - Methods and devices are provided for detecting the presence or absence of nucleic acid binding proteins, such as NMP22, and other proteins, in bodily fluids. | 07-29-2010 |
| 20100196880 | COMPOSITIONS AND MULTIPLEX ASSAYS FOR MEASURING BIOLOGICAL MEDIATORS OF PHYSIOLOGICAL HEALTH - Multiplex assays are provided including panels of probes for development of multiplex assays capable of simultaneously measuring multiple biologically-relevant proteins using very small quantities of biological samples to rapidly assess the health status of animals, especially companion animals, as well as to formulate nutritional regimens for improving the health status of animals. The probes are provided as are methods for using them to assess the health status of animals, as well as their responses to therapeutic or nutritional interventions therein. | 08-05-2010 |
| 20100196881 | REVERSE RESTRICTION FRAGMENT LENGTH POLYMORPHISM ASSAY AND USES THEREOF - The present invention presents a Reverse Restriction Fragment Length Polymorphism (RRFLP) method for the detection of the presence of an informative restriction enzyme site in a nucleotide sequence. The method includes digesting a sample with the informative restriction enzyme; performing polymerase chain reaction (PCR) on the digested sample with an oligonucleotide primer pair that flanks the informative restriction enzyme site; determining the Ct value of the sample; comparing the Ct value of the sample to the Ct value from a control sample; and calculating a ΔCt value, wherein a ΔCt value is the Ct value of the sample minus the Ct value of a control; and wherein a ΔCt value ≧+1 indicates that the informative restriction enzyme sites is present in the nucleotide sequence. The present invention includes the application of the RRFLP method for detection of the infectious laryngotracheitis virus (ILTV). | 08-05-2010 |
| 20100196882 | GALECTIN-3 nsSNP MARKER FOR CANCER - A diagnostic biomarker including a mechanism for determining a patient's propensity to develop cancer. A diagnostic kit for determining a patient's propensity to develop cancer. A method of predicting both a patient's and a population's propensity to develop cancer, by detecting the presence of an H | 08-05-2010 |
| 20100196883 | ANDROGEN-REGULATED GENES AND USES FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF PROSTATE NEOPLASTIC CONDITIONS - The invention provides a method for diagnosing or predicting susceptibility to a prostate neoplastic condition in an individual. The method involves (a) determining a level of RDC1 in a sample from the individual, and (b) comparing the level of RDC1 in the sample to a reference level of RDC1, wherein a level of RDC1 in the sample 2-fold or more higher than the reference level indicates the presence of, or susceptibility to, a prostate neoplastic condition in the individual. | 08-05-2010 |
| 20100196884 | Nucleic Acid Preparation - The present invention is directed to methods, devices and computer programs for preparing nucleic acids from a template nucleic acid by subjecting a sample to thermocycles. After a first number of thermocycles, a partial amount of the reaction mixture is being subjected to a second number of thermocycles. This two step amplification method speeds up overall reaction time without affecting the limit of detection. | 08-05-2010 |
| 20100196885 | METHODS OF VALIDATING CANDIDATE COMPOUNDS FOR USE IN TREATING COPD AND OTHER DISEASES - The present invention relates to methods of diagnosing and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease. | 08-05-2010 |
| 20100196886 | SCREENING, DIAGNOSING, TREATING AND PROGNOSIS OF PATHOPHYSIOLOGIC STATUS BY RNA REGULATION - A relationship between cancer and ribonucleic acid (RNA) regulation is described by determining intracellular levels of niRN A regulators. Generally, mRNA levels are decreased in cancer cells that may be a reflection of either reduced mRNA expression and/or increased mRNA degradation. miRNAs are identified that hybridize to an mRNA that are suspected to mediate intracellular mRNA steady state levels. Alternatively, ribonucleic acid binding protein (RBP) levels may also mediate intracellular mRNA steady state levels. In particular, this invention demonstrates an effective clinical management strategy for uterine cell cancers may be implemented by taking advantage of an exemplary relationship between P2X | 08-05-2010 |
| 20100196887 | COMPOSITIONS AND METHODS FOR MULTIPLEX ANALYSIS OF POLYNUCLEOTIDES - Provided herein are compositions and methods for the multiplex analysis and/or detection of polynucleotides having one or more distinguishable target sequences. The methods employ signal-quencher probe pairs having specific relative differential thermal melting temperatures that permit the detection of one or more target sequences on one or more polynucleotides. | 08-05-2010 |
| 20100196888 | Genotyping Using Multiple Variant-Specific Primer Pools - This invention relates to the identification of variants of an organism using variant-specific oligonucleotide primer pools to specifically hybridize to those polynucleotides in an sample comprising a plurality of polynucleotides that contain a target sequence that is unambiguously identifiable with a particular variant of the organism. | 08-05-2010 |
| 20100196889 | Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer - A method is provided in various embodiments for determining a profile data set for a subject with colorectal cancer or conditions related to colorectal cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-5. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable. | 08-05-2010 |
| 20100196890 | PRIMERS FOR MELTING ANALYSIS - Methods and kits are provided for nucleic acid analysis. In an illustrative method a target nucleic acid is amplified using a first primer and a second primer, wherein the first primer comprises a probe element specific for a locus of the target nucleic acid and a template-specific primer region, and the probe element is 5′ of the template-specific primer region, subsequently allowing the probe element to hybridize to the locus to form a hairpin, generating a melting curve for the probe element by measuring fluorescence from a dsDNA binding dye as the mixture is heated, wherein the dye is not covalently bound to the first primer, and analyzing the shape of the melting curve. Kits may include one or more of the first and second primers, the dsDNA binding dye, a polymerase, and dNTPs. | 08-05-2010 |
| 20100196891 | IBC-1 (Invasive Breast Cancer-1), a Putative Oncogene Amplified in Breast Cancer - This invention encompasses antibodies specific for IBC-1 (Invasive Breast Cancer-1), methods for diagnosis and prognosis of metastatic breast cancer and degenerative neural conditions, methods of identifying and manufacturing therapeutic compounds, and methods of treating patients with invasive and metastatic breast cancer or degenerative neural conditions. | 08-05-2010 |
| 20100196892 | Methods and Systems for Molecular Fingerprinting - This invention relates in general to a method for molecular fingerprinting. The method can be used for forensic identification (e.g. DNA fingerprinting, especially by VNTR), bacterial typing, and human/animal pathogen diagnosis. More particularly, molecules such as polynucleotides (e.g. DNA) can be assessed or sorted by size in a microfabricated device that analyzes the polynucleotides according to restriction fragment length polymorphism. In a microfabricated device according to the invention, DNA fragments or other molecules can be rapidly and accurately typed using relatively small samples, by measuring for example the signal of an optically-detectable (e.g., fluorescent) reporter associated with the polynucleotide fragments. | 08-05-2010 |
| 20100196893 | Method for genotyping DNA tandem repeat sequences - The present invention provides methods for determining the number of tandem repeat units in a region of double stranded DNA based on the use of RecA-like recombinase protein and oligonucleotide ligation. The methods of the present invention provide RecA coated, specific DNA oligonucleotide probes (RecA filaments) for homology searching in duplex DNA where the location of homologous sequences results in the formation of D-loop structures containing a duplex region comprising the oligonucleotide probe and one strand of the target DNA. The present invention further provides sets of oligonucleotide probes (ligation partners) selected to have sequence complementary to non-repeat sequence flanking a region of tandem repeats and sequence complementary to varying numbers of repeat units such that only that pair of oligonucleotides that can be aligned, via RecA mediated homology searching, with the target sequence such that their terminal bases are paired with adjacent nucleotides in the target sequence will be substrates for ligation. Thus, the present invention provides methods whereby successful ligation is diagnostic of the number of repeat units in the target DNA sequence. Also disclosed are compositions and kits useful for practicing the foregoing methods. | 08-05-2010 |
| 20100196894 | PROCEDURE FOR THE DETECTION OF PARATUBERCULOSIS - The present invention relates to a procedure for the specific and sensitive detection of | 08-05-2010 |
| 20100196895 | METHOD FOR DETERMINATION OF ONSET RISK OF GLAUCOMA - A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 514 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 514 (step B). According to the method of the present invention, the level of an onset risk of glaucoma in a sample donor can be determined by analyzing an allele or a genotype of a single nucleotide polymorphism in the present invention on the sample, so that the sample donor can take a preventive measure of glaucoma, or can receive appropriate treatments, on the basis of this risk. | 08-05-2010 |
| 20100196896 | METHOD AND A KIT FOR IDENTIFYING A HUMAN WHO HAS THE PREDISPOSITION FOR INCREASED CONSUMPTION OF CARBOHYDRATES AND METHOD FOR MANAGING THE NAMED HUMAN'S DIETARY INTAKE OF NUTRITIONAL ENERGY - A method and a kit for determining the human with genetic predisposition to increased consumption of carbohydrates and to develop metabolic, psychiatric or neurological disease or disorder, or obesity. The invention pertains to the detection of a human's ADRA2A genotype, and if there is detected the homozygous nucleotide G at the position C-1291 of the ADRA2A gene, then the patient possesses a predisposition to increased consumption of carbohydrates and to develop metabolic, psychiatric or neurological diseases or disorders or obesity, and there is a need to decrease intake of carbohydrates. | 08-05-2010 |
| 20100196897 | Method and Device for Non-Invasive Prenatal Diagnosis - Method for non-invasive prenatal diagnosis comprising the following steps: a. obtain a sample of an organic fluid having a high probability of containing foetal cells from a pregnant woman; b. enrich said sample of organic fluid in at least one population of cells comprising at least one type of foetal nucleated cells; c. isolate at least one cell from among said at least one type of foetal nucleated cells; d. perform a genetic analysis on said at least one cell isolated from among said at least one type of foetal nucleated cells in order to highlight at least one genetic characteristic of said at least one foetal nucleated cell suitable for permitting said diagnosis; wherein the step of isolating at least one cell from among said at least one type of foetal nucleated cells is performed by individually selecting single cells in a microfluidic device designed for said purpose. | 08-05-2010 |
| 20100196898 | DISEASE-ASSOCIATED GENETIC VARIATIONS AND METHODS FOR OBTAINING AND USING SAME - The invention provides a comprehensive, rapid, unbiased, and accurate method for identifying and/or discovering disease-associated genetic variations, e.g., disease-associated variations. The present invention further provides novel disease-associated genetic variations for use as genetic markers of disease, e.g., cancer. The invention further provides methods for assessing an individual's risk for developing a disease, e.g., cancer, by detecting the presence the novel disease-associated genetic variations of the invention. | 08-05-2010 |
| 20100196899 | Systems for genome selection - Systems, methods, compositions and apparatus relating to genome selection are disclosed. | 08-05-2010 |
| 20100196900 | METHOD OF DETECTING CANINE EXERCISE-INDUCED COLLAPSE - The present invention relates to diagnosing Canine Exercise-Induced Collapse (EIC). | 08-05-2010 |
| 20100196901 | Method for Obtaining Information on Biological Rhythm by Using Hair - To provide a simple and low-invasive method for obtaining information on a biorhythm of an individual organism. Provided is a method for obtaining information on a biorhythm of an individual organism based on variations over time in an expression level of a clock gene in a hair follicle cell of the individual organism. According to this method, a phase shift of the biorhythm of the individual organism can be detected by preparing a plurality of times about the individual organism and conducting a collation. Further, a phase shift of the biorhythm of the individual organism can also be detected by collating an expression level of the clock gene at a predetermined time with the molecular clock table. | 08-05-2010 |
| 20100196902 | PROSTATE CANCER BIOMARKERS - Disclosed are biomarkers, at least, useful for the diagnosis and/or prognosis of cancer and for making treatment decisions in cancer, for example prostate cancer. | 08-05-2010 |
| 20100196903 | COMPOSITIONS AND METHODS TO DETECT TMPRSS2/ERG TRANSCRIPT VARIANTS IN PROSTATE CANCER - Compositions and methods for detecting TMPRSS2/ERG transcript variants in prostate cancer are provided. The compositions and methods have utility in prostate cancer diagnosis. | 08-05-2010 |
| 20100196904 | AMBIENT TEMPERATURE STABLE KITS FOR MOLECULAR DIAGNOSTICS - A method for processing DNA polymerase and/or dNTPs for use in an amplification procedure, includes providing a solution mixture, the solution mixture including a DNA polymerase and/or dNTPs, a buffer solution and at least one stabilizing agent and hydration reducing the solution mixture. The solution mixture is hydration reduced at a temperature between 0° C. and about 100° C. | 08-05-2010 |
| 20100196905 | Adult Stem Cell Assays - Provided are methods for quantifying adult stem cells in a test sample, methods of quantifying adult stem cells in a patient, and methods for quantifying differentiated cells in a test sample. Also provided are kits for quantifying adult stem cells or differentiated cells in a sample. | 08-05-2010 |
| 20100196906 | Accelerated Progression Relapse Test - Disclosed is an accelerated progression relapse test for use in the prognosis of disease states. According to the test disclosed herein, it can be determined whether a patient would benefit from treatment for a disease state or whether the patient's prognosis would not have a high probability of benefit with additional treatment. In particular, the test is useful in determining a patient's prognosis for cancer (breast, colon, lung, etc). For example, the test of the invention can be used to determine the prognosis for estrogen receptor positive (ER+) breast cancer patients. In the test for ER+ breast cancer patients, four genetic probes are employed that target MK167, CDC6, and SPAG5 gene products. The ER+ breast cancer test stratifies a patient population into two groups, with the low gene expression group identifying a group that is less likely to benefit from additional treatment measures, and a high gene expression group, identifying a group more likely to benefit from additional treatment measures. | 08-05-2010 |
| 20100196907 | MARKERS TO PREDICT AND MONITOR RESPONSE TO AURORA KINASE B INHIBITOR THERAPY - The present invention relates to identifying the presence or absence of one or more copy number gains in the ABCB1 gene, the ABCB4 gene or combinations thereof, identifying patients eligible to receive Aurora kinase inhibitor therapy, either as monotherapy or as part of combination therapy, and monitoring patients' response to such therapy. | 08-05-2010 |
| 20100196908 | SYSTEMS AND METHODS FOR DETECTING A SIGNAL AND APPLYING THERMAL ENERGY TO A SIGNAL TRANSMISSION ELEMENT - A signal detection system configured for detecting a signal emitted by the contents of a reaction receptacle is also configured to apply thermal energy to a portion of the reaction receptacle to affect a reaction occurring within the reaction receptacle. More particularly, a system for detecting electromagnetic radiation emitted by the contents of a reaction receptacle includes a transmission element configured for transmitting electromagnetic radiation from the contents of the receptacle, a thermal element associated with the transmission element and configured to apply thermal energy to at least a portion of the receptacle, and a detector configured to receive electromagnetic radiation from the transmission element and to generate a signal corresponding to a characteristic of the electromagnetic radiation received by the detector. | 08-05-2010 |
| 20100196909 | PARP-BASED CYTOCHEMICAL AND HISTOCHEMICAL DETECTION METHODS AND KITS THEREFORE - The present invention relates to new cytochemical and histochemical detection methods based on the enzymatic activity of poly-ADP-ribose-polymerases (PARP). In particular, the present invention provides methods and systems for cytochemical or histochemical detection of a molecule of interest based on detecting poly-ADP-ribose (PAR). Further, the present invention provides methods for screening for compounds altering the amount of NAD or analogs thereof in subcellular compartments based on detecting the amount of PAR formed in said subcellular compartment as well as methods for determining the spatial distribution of a molecule of interest. In a further aspect, the present invention provides systems and kits for conducting said methods as well as a new expression vectors suitable for said systems. | 08-05-2010 |
| 20100196910 | METHODS OF GENERATING HUMAN CARDIAC CELLS AND TISSUES AND USES THEREOF - A method of generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype is disclosed. The method comprises (a) partially dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates; (b) subjecting the cell aggregates to culturing conditions suitable for generating embryoid bodies; (c) subjecting the embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of the embryoid bodies, the culturing conditions suitable for inducing cardiac lineage differentiation including adherence of the embryoid bodies to a surface, and culture, medium supplemented with serum, thereby generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype. | 08-05-2010 |
| 20100196911 | AUTOMATED IDENTIFICATION OF GENETIC TEST RESULT DUPLICATION - The present invention relates to a method and system for determining whether an ordered genetic test will duplicate at least one existing genetic test result. The method includes receiving an ordered genetic test that is for a particular genetic sequence or variant thereof for an individual. The method further includes determining whether the individual has at least one existing genetic test result for the particular genetic sequence or variant thereof. Upon determining that the individual has at least one existing genetic test result for the particular genetic sequence or variant thereof, a notification of the existence of the at least one existing genetic test result is provided. | 08-05-2010 |
| 20100196912 | Polyelectrolyte-Coated Size-Exclusion Ion-Exchange Particles - A polyelectrolyte-coated particle, devices for using the particle, methods for using the particle for separating PCR reaction products and/or DNA sequencing reaction products, and compositions for coating the particle are provided. | 08-05-2010 |
| 20100196913 | Mutant AOX1 Promoters | 08-05-2010 |
| 20100196914 | RARE CELL DETECTION USING FLAT-PANEL IMAGER AND CHEMILUMINESCENT OR RADIOISOTOPIC TAGS - Disclosed is a method using a large area flat panel imager which is specifically adapted for rare cell detection methods. The method generally includes an imager having a sample receiving surface which can provide a digital or electronic image of a sample deposited on the surface. The method also includes a selectively positionable microscope and/or camera which are used to obtain high resolution images of the deposited samples. An electronic controller can also be used in conjunction with the imager, microscope, and/or camera to selectively position at least one of those components to focus on desired regions of the deposited sample. The noted method is particularly adapted for use with chemiluminescence or other tagging technologies. | 08-05-2010 |
| 20100196915 | Method of Detecting Oncogenesis of Hematopoietic Cells - Disclosed in a method of detecting cancer using IL-27 receptors. IL27R is a cytokine receptor identified as a novel oncogene from an acute myeloid leukemia patient. It induces cancer-like properties when expressed in cells and can activate a protein that causes various myeloid cell disorders. The data show cytokine receptors play unappreciated roles in mediating activation of signaling pathways in circulatory system cancers. Also method of screening for novel oncogenes using a functional, approach is disclosed using cytokine-dependent cells to screen for transforming events. | 08-05-2010 |
| 20100196916 | Drug Screening using Islet Cells and Islet Cell Progenitors from Human Embryonic Stem Cells - This disclosure provides a system for producing pancreatic islet cells from embryonic stem cells. Differentiation is initiated towards endoderm cells, and focused using reagents that promote emergence of islet precursors and mature insulin-secreting cells. High quality populations of islet cells can be produced in commercial quantities for use in research, drug screening, or regenerative medicine. | 08-05-2010 |
| 20100196917 | CELL ANALYSIS APPARATUS AND CELL ANALYSIS METHOD - A cell analysis apparatus that can accurately distinguish between an aggregating cell and a non-aggregating cell is provided. The cell analysis apparatus ( | 08-05-2010 |
| 20100203502 | Method for the in Vitro Detection of a Predisposition to the Development of Alterations in Ovarian Function - The invention relates to a method for the in vitro detection of a predisposition to the development of alterations in ovarian function. The inventive method is based on the detection of polymorphisms −673C>T, −9C>G, IVS1+905A>G and N103S of gene BMP15 and combinations of same. The invention can be used for the diagnosis or prognosis of a predisposition in women to alterations in ovarian function, such as the onset of menopause at an unusually young age, including both early menopause and premature ovarian failure, a reduction in the reproductive window or the development of ovarian hyperstimulation syndrome (OHS) following controlled ovarian stimulation (COS) with FSH in treatments to increase fertility. | 08-12-2010 |
| 20100203503 | GENETIC POLYMORPHISMS ASSOCIATED WITH MYOCARDIAL INFARCTION AND USES THEREOF - A genetic polymorphism associated with myocardial infarction is provided. More particularly, provided are a polynucleotide including a single nucleotide polymorphism (SNP) or a haplotype associated with myocardial infarction, a polynucleotide hybridized with the polynucleotide, a polypeptide encoded by one of the polynucleotides, an antibody bound to the polypeptide, a microarray and a kit including one of the polynucleotides, a myocardial infarction diagnosis method, a SNP detecting method and a method of screening pharmaceutical compositions for myocardial infarction. | 08-12-2010 |
| 20100203504 | Substance-Information Acquisition Method Using Evanescent Light Beam, Substance-Information Measurement Apparatus, Base-Sequence Determination Method and Base-Sequence Determination Apparatus - Information on the position and displacement of a detection-subject substance T can be presented by adoption an evanescent light illumination technology. An evanescent light beam PE has a property that the intensity thereof abruptly attenuates in accordance with an exponential function with increases in distance Z from a boundary surface S capable of generating the evanescent light beam PE. The detection-subject substance T fixed on the boundary surface S is excited by the evanescent light beam PE having the property described, generating the original fluorescent light beam f of the detection-subject substance T. On the basis of the intensity I of the fluorescent light beam f, information Z on the position of the detection-subject substance T and information Δz on the displacement of the detection-subject substance T can be acquired. In addition, by making use of the information Z and the information Δz, it is possible to obtain information on the structure of the detection-subject substance T, its structural change, a base sequence of a nucleic acid chain serving as the detection-subject substance T, the existence/non-existence of substance interactions and the state of progress of the interactions. | 08-12-2010 |
| 20100203505 | DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL MARKER Msx1/2 - The present invention is a probe, a primer, and an antibody, for detecting a dopaminergic neuron proliferative progenitor cell. According to the present invention, there is provided a polynucleotide probe and a polynucleotide primer for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell, which can hybridize with a polynucleotide consisting of a nucleotide sequence of an Msx1 gene or an Msx2 gene, or a complementary sequence thereto, and an antibody against an Msx1 protein or an Msx2 protein, or a part thereof for use in the detection or selection of a dopaminergic neuron proliferative progenitor cell. | 08-12-2010 |
| 20100203506 | VIRAL VARIANTS AND METHODS FOR DETECTING SAME - The present invention relates generally to viral variants exhibiting reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful in monitoring anti-viral therapeutic agents. | 08-12-2010 |
| 20100203507 | METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY - The present invention provides methods for analyzing genetic and/or metabolite biomarkers to individualize methotrexate (MTX) therapy. For example, the assay methods of the present invention are useful for predicting whether a patient will respond to MTX and/or has a risk of developing toxicity to MTX based upon the genotype of one or more folate pathway genes. The assay methods of the present invention are also useful for optimizing the dose of MTX in a patient already receiving the drug to achieve therapeutic efficacy and/or reduce toxic side-effects based upon the genotype of one or more folate pathway genes. In addition, the assay methods of the present invention are useful for predicting or optimizing the therapeutic response to MTX in a patient based upon the methotrexate polyglutamate and/or folate polyglutamate levels in a sample from the patient. | 08-12-2010 |
| 20100203508 | METHODS OF PREDICTING METHOTREXATE EFFICACY AND TOXICITY - The present invention provides methods for analyzing genetic and/or metabolite biomarkers to individualize methotrexate (MTX) therapy. For example, the assay methods of the present invention are useful for predicting whether a patient will respond to MTX and/or has a risk of developing toxicity to MTX based upon the genotype of one or more folate pathway genes. The assay methods of the present invention are also useful for optimizing the dose of MTX in a patient already receiving the drug to achieve therapeutic efficacy and/or reduce toxic side-effects based upon the genotype of one or more folate pathway genes. In addition, the assay methods of the present invention are useful for predicting or optimizing the therapeutic response to MTX in a patient based upon the methotrexate polyglutamate and/or folate polyglutamate levels in a sample from the patient. | 08-12-2010 |
| 20100203509 | Inducible fluorescently-tagged protein expression system - The present invention is related to an antibiotic inducible/repressible genetic construct for controlling transcription of a gene of interest in a cell, and methods for its use. The genetic construct provides a plasmid vector comprising a polynucleotide molecule, two tetO sequences, and a single CMV promoter, wherein the polynucleotide molecule further comprises a fluorescent protein gene and an MCS upstream of the fluorescent protein gene, wherein a gene of interest encoding a protein of interest is cloned into the MCS so that a fusion protein comprising the protein of interest and the fluorescent protein may be produced, the polynucleotide molecule being operably linked to two tetO sequences and the single CMV promoter, and wherein the two tetO sequences are incorporated into the single CMV promoter. | 08-12-2010 |
| 20100203510 | PPIA MARKER FOR DIAGNOSIS OF LIVER CANCER AND ANTIBODY, AND SCREENING METHOD OF COMPOUNDS USEFUL FOR INHIBITING LIVER CANCER - Disclosed is a marker for diagnosis of liver cancer comprising polynucleotide useful for diagnosis of liver cancer. The marker for liver cancer diagnosis comprises at least one polynucleotide selected from a group consisting of the following polynucleotides (a) to (d):(a) polynucleotide having a base sequence defined by Seq. No. 1 or substantially similar sequence to Seq. No. 1; (b) polynucleotide encoding specific protein composed of an amino acid sequence defined by Seq. No. 2; (c) polynucleotide that comprises Seq. No. 2, in which at least one amino acid is substituted, deleted, inserted and/or added, and that encodes protein functionally equivalent to specific protein composed of Seq. No. 2; and (d) polynucleotide that is encoded by another polynucleotide hybridized with polynucleotide having Seq. No. 1 under stringent conditions, and that encodes protein functionally equivalent to specific protein composed of Seq. No. 2. | 08-12-2010 |
| 20100203511 | Retinoid metabolizing protein - Amino acid sequences and corresponding nucleic acid sequence of retinoid metabolizing protein found in human, mouse and zebrafish are described, as well as methods of using same. | 08-12-2010 |
| 20100203512 | METHOD FOR RENAL DISEASE DIAGNOSIS AND PROGNOSIS USING ANNEXIN A1 AND RAB23 AS MARKERS - Use of Annexin A1 or Rab23 as a biomarker for diagnosing kidney disease or assessing efficacy of kidney disease treatment. | 08-12-2010 |
| 20100203513 | MICRORNA AS BIOMARKER IN CANCER - The present invention relates to the discovery of certain microRNAs that correlate with certain information regarding cancer. The microRNAs of the invention are selected from the group consisting of hsa-miR-15b, hsa-miR-181b, hsa-miR-191, hsa-miR-200c, and hsa-let-7g. If the expression of these microRNAs is increase, then the increased expression of these microRNAs is diagnostic for cancer, characterizes the cancer, prognosticates an expected response to cancer treatments, and/or prognosticates an expected survival of a patient. Embodiments of this discovery include a method, composition, kit and isolated nucleic acid. | 08-12-2010 |
| 20100203514 | METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE DEVELOPMENT OF PROSTATE CELL PROLIFERATIVE DISORDERS - The invention provides methods, nucleic acids and kits for detecting prostate cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients. | 08-12-2010 |
| 20100203515 | DETECTION OF GENE EXPRESSION IN CELLS BY SCANNING FCS - The present invention relates to a method for determination of an analyte in a cell by fluorescent correlation spectroscopy. | 08-12-2010 |
| 20100203516 | DETECTING ANALYTES USING BOTH AN OPTICAL AND AN ELECTRICAL MEASUREMENT METHOD - Provided is a method for detecting an analyte, wherein the analyte is labelled with one or more labels relatable to the analyte, which method comprises: a) performing an optical detection method on the labelled analyte to obtain optical data from the one or more labels; b) performing an electrical detection method on the labelled analyte to obtain electrical data from the one or more labels; and c) determining the identity and/or quantity of the analyte from both the optical and electrical data. Further provided is a method for detecting a plurality of analytes, wherein the each different analyte is labelled with one or more different labels relatable to the analyte, which method comprises: a) performing an optical detection method on a plurality of labelled analytes to obtain optical data from the labels; b) performing an electrochemical detection method on the plurality of labelled analytes to obtain electrical data from the labels; and c) determining the identity and/or quantity of the plurality of analytes from both the optical and electrical data. | 08-12-2010 |
| 20100203517 | HUMAN DIABETES SUSCEPTIBILITY PEBP4 GENE - The present invention relates to a diagnostic method of determining whether a subject, preferably an obese subject, is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the PEBP4 gene locus in a biological sample of said subject. | 08-12-2010 |
| 20100203518 | Quantitative Assay for the Simultaneous Detection and Speciation of Bacterial Infections - An adaptation of the real-time PCR assay allows for highly sensitive detection of any eubacterial species with simultaneous speciation. The assay relies on a ‘multiprobe’ design in which a single set of highly conserved sequences encoded by the 16S rRNA gene serves as the primer pair, and it is used in combination with both an internal highly conserved sequence, the universal probe, and an internal variable region, the species-specific probe. A pre-PCR ultrafiltration step can be used to effectively decontaminate or remove background DNA. The real-time system reliably identifies 14 common bacterial species with a detection limit of 50 fg. | 08-12-2010 |
| 20100203519 | Method for the detection of gene transcripts in blood and uses thereof - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 08-12-2010 |
| 20100203520 | Method for the detection of gene transcripts in blood and uses thereof - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 08-12-2010 |
| 20100203521 | METHOD FOR BACTERIAL LYSIS - The present invention is directed to a microfluidic device for lysis of cells, such as bacteria and microorganisms. In particular, the present invention relates to microfluidic devices and methods of manufacture of such microfluidic devices comprising a substrate with at least one channel packed with a polymer monolith embedded with carbon particles, for example carbon nanotubes. The microfluidic devices and methods of the present invention are useful for cell lysis of cells within a biological sample, such as a untreated biological sample comprising microorganisms, such as but not limited to gram positive and gram negative bacteria. In some embodiments, the microfluidic devices of the present invention can also optionally comprise other modules enabling further processing of the biological sample, for example isolation, purification and detection of biomolecules released from the lysed cells, such as but not limited to nucleic acids or proteins or peptides from the lysed cells, providing a complete Lab-on-a-Chip analysis system for biomolecules released from difficult to lyse microorganisms in a single step or process. The microfluidic devices of the present invention can also be adapted and are useful to methods to enrich for microorganisms in a biological sample, for example enrich for a desired type of bacteria within a biological sample. The microfluidic devices and methods of the present invention can be adapted to perform highly efficient lysis of microorganisms within a biological sample for diagnostic tests, for example for diagnosis of infectious agents and pathogens, such as bacteria, viruses or parasites. | 08-12-2010 |
| 20100203522 | METHOD TO PREDICT OR DIAGNOSE A GASTROINTESTINAL DISORDER OR DISEASE - The disclosure provides methods and compositions useful for identifying a subject's predisposition to a gastrointestinal disease or disorder. | 08-12-2010 |
| 20100203523 | MEANS AND METHODS FOR CLASSIFYING SAMPLES OF MULTIPLE SCLEROSIS PATIENTS - The invention in one aspect provides a method for classifying cells from a human individual said method comprising: providing a sample comprising cells from said individual that are typically responsive to exposure to a type I interferon; determining a level of activity of a pathway that is modulated by type 1 interferon; and classifying said cells on the basis of the determined level of activity. Cells present in said sample are preferably cultured said cells in the presence of a type I interferon prior to determining a level of activity of said pathway. This is activity is preferably compared to the activity of said pathway in cells in said sample prior to said culture. Preferably the sample is from an individual that is not treated with a type I interferon prior to collecting said sample. Preferably the method is used to determine, prior to initiating treatment with a type I interferon, whether said individual is likely to be a good, a normal or a poor responder to the contemplated treatment. | 08-12-2010 |
| 20100203524 | POLYMERASES AND METHODS OF USE THEREOF - The invention generally relates to polymerases for efficient and controlled sequencing-by-synthesis reactions. In certain embodiments, the invention provides a polymerase enzyme including at least one mutation that enhances ability of the polymerase as compared to a wild-type polymerase to incorporate a nucleotide into a nascent strand of DNA or cDNA including at least one modified nucleotide. | 08-12-2010 |
| 20100203525 | DETECTION OF GENE DUPLICATIONS - Methods of detecting a candidate genetic anomaly such as a candidate duplication in a genome are disclosed. The methods comprise quantifying fluorogenic assays for alleles of a genetic locus from a plurality of individual genomes, identifying ranges of fluorescent intensities indicative of individual genomes homozygous for a first allele, homozygous for a second allele, or heterozygous for both alleles, and identifying individual genomes in which the fluorescence intensities are outside the range of intensities indicative of homozygosity or heterozygosity for the genetic locus. | 08-12-2010 |
| 20100203526 | MECP2E1 gene - The invention is a novel MECP2E1 splice variant and its corresponding polypeptide. The invention also includes methods of using these nucleic acid sequences and proteins in medical diagnosis and treatment of neuropsychiatric disorders or development disorders. | 08-12-2010 |
| 20100203527 | Process for identifying fish signals - Among embodiments is disclosed a process for immunostaining a sample such that the stain is stable under FISH conditions. | 08-12-2010 |
| 20100203528 | System for obfuscating identity - Compositions, apparatus, systems, kits, and methods for obfuscating the nucleic acid and/or protein content of an environment. | 08-12-2010 |
| 20100203529 | Methods and systems of using exosomes for determining phenotypes - Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin. | 08-12-2010 |
| 20100203530 | Systems for genome selection - Systems, methods, compositions and apparatus relating to genome selection are disclosed. | 08-12-2010 |
| 20100203531 | PREDICTING RESPONSIVENESS TO TEMOZOLOMIDE - This document features methods and materials involved in predicting responsiveness of a mammal (e.g., human) having cancer (e.g., glioblastoma multiforme) to treatment with chemotherapy (e.g., temozolomide). For example, methods and materials for using the methylation status at one or more CpG methylation sites (e.g., CpG 89) in O6-methylguanine methyl-transferase nucleic acid to determine whether or not a mammal having cancer is responsive to treatment with chemotherapy (e.g., temozolomide) are provided. | 08-12-2010 |
| 20100203532 | Enrichment of a Target Sequence - The present invention is directed to methods, compositions, software and devices for enriching low abundance alleles from a sample. The method is based in part on a modified nucleic acid amplification protocol that includes incubating the reaction mixture at a critical denaturing temperature or “Tc”. By employing the present invention the current detection limits of all PCR-based technologies are greatly improved. | 08-12-2010 |
| 20100203533 | POLYMERIZED CONJUGATES FOR BIOLOGICAL APPLICATIONS - Polymerized conjugates of at least two proteins that have increased sensitivity for detecting proteins in biological assays such as gels and blots, and methods of preparing the conjugates, and a protein assay detection kit using the conjugates. In one embodiment, proteins are polymerized by reacting a carbohydrate group on the protein that has been oxidized with an amine group. | 08-12-2010 |
| 20100203534 | USE OF POLYNUCLEOTIDES FOR DETECTING GENE ACTIVITES FOR DISTINGUISHING BETWEEN LOCAL AND SYSTEMIC INFECTIONS - The present invention concerns the use of polynucleotides having a length of 2 to 100% of the number of nucleotides of the single sequences according to SEQ ID No. 1 to SEQ ID No. 69 and/or their gene loci and/or their transcripts for detecting gene activities for the differentiation of a condition accompanying a local infection from a condition accompanying a systemic infection of a patient, wherein all of the sequences according to SEQ ID No. 1 to SEQ ID No. 69 are used; as well as a method and a kit for performing the method. | 08-12-2010 |
| 20100203535 | GENETIC ANALYSIS - The present invention provides methods for excluding a gene as being involved in, associated with or causative of a genetic disorder in a family. | 08-12-2010 |
| 20100203536 | DIAGNOSTICS OF B-CELL LYMPHOMA - The present invention relates to the fields of genetics and oncology and provides methods and means for diagnosing and monitoring of patients having B-cell lymphomas, such methods and means allowing an early diagnosis of the B-cell lymphoma. Specifically, the present invention relates to a novel method and a biomarker for diagnosing B-cell lymphomas and for differentiating the B-cell lymphomas into prognostic groups of indolent and aggressive B-cell lymphomas. | 08-12-2010 |
| 20100203537 | DUAL OLIGONUCLEOTIDE METHOD OF NUCLEIC ACID DETECTION - Methods for amplifying and detecting nucleic acids are described, as well as sets of 5′ labeled oligonucleotides. | 08-12-2010 |
| 20100203538 | DETERMINATION OF COPY NUMBER DIFFERENCES BY AMPLIFICATION - The present invention provides for determining relative copy number difference for one or more target nucleic acid sequences between a test sample and a reference sample or reference value derived therefrom. The methods facilitate the detection of copy number differences less than 1.5-fold. | 08-12-2010 |
| 20100203539 | METHODS FOR PREDICTING METHOTREXATE POLYGLUTAMATE LEVELS USING PHARMACOGENETICS - The present invention provides methods for determining a level of methotrexate polyglutamates (MTXPGs) in an individual undergoing methotrexate (MTX) therapy and for optimizing dose efficacy of MTX therapy in an individual by genotyping the individual at a polymorphic site in at least one folate pathway gene (e.g., a reduced folate carrier (RFC-1) gene, a gamma glutamyl hydrolase (GGH) gene, etc.). Methods are also provided for determining a level of MTXPGs in an individual undergoing MTX therapy and for optimizing dose efficacy of MTX therapy in an individual by generating a pharmacogenetic index based upon the genotype of the individual at a polymorphic site in an RFC-1 gene and/or a GGH gene. | 08-12-2010 |
| 20100203540 | DEVICE FOR SEPARATING AND/OR ANALYZING SEVERAL MOLECULAR TARGETS DISSOLVED IN A COMPLEX MIXTURE - The invention relates to a device for separating and/analyzing several molecular targets dissolved in a complex mixture which is characterized in that it comprises
| 08-12-2010 |
| 20100203541 | NUCLEOTIDE ANALOGS - The disclosure provides nucleotide analogs and methods of their use. Analogs of the invention comprise a reporter molecule (label) attached via the N4, N6, O4, or O6 position of the nitrogenous base portion of the analog. In a preferred embodiment, nucleotide analogs of the invention comprise a label attached to the nitrogenous base portion of the analog via a cleavable linker at the N4, O4, N6 or O6 position. | 08-12-2010 |
| 20100203542 | METHOD FOR TREATING AUTOIMMUNE DISEASES AND SCREENING METHOD FOR PREVENTIVE OR THERAPEUTIC AGENT FOR THE SAME - A screening method for a preventive or therapeutic agent for an autoimmune disease and/or for an apoptosis inhibitor, comprising determining retinoblastoma associated protein (RBAp48) production suppressing effect or RBAp48 production inhibitory effect of a sample. | 08-12-2010 |
| 20100203543 | BIOLOGICAL ENCODING OF LARGE NUMBERS OF CELLS - Mixtures of cell types can be analyzed by having at least two signal markers, with at least one at three different levels to provide a barcode for each cell type. The mixture of cells may be subjected to a common candidate moiety and the effect of the moiety on the cells determined along with identification of the cell by the barcode. Conveniently, surface marker proteins and labeled antibodies can be used to create the barcode and the cells analyzed with flow cytometry. | 08-12-2010 |
| 20100203544 | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER ASSOCIATED CHROMOSOMAL FEATURES - MicroRNA genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the miR gene(s) located in close proximity to that chromosomal feature. Evaluation of miR gene expression can therefore be used to indicate the presence of a cancer-causing chromosomal lesion in a subject. As the change in miR gene expression level caused by a cancer-associated chromosomal feature may also contribute to cancerigenesis, a given cancer can be treated by restoring the level of miR gene expression to normal. microRNA expression profiling can be used to diagnose cancer and predict whether a particular cancer is associated with an adverse prognosis. The identification of specific mutations associated with genomic regions that harbor miR genes in CLL patients provides a means for diagnosing CLL and possibly other cancers. | 08-12-2010 |
| 20100203545 | Two-color Real-time/End-point Quantitation of MicroRNAs (miRNAs) - The present invention is directed to methods, reagents, kits, and compositions for detecting target polynucleotide sequences, especially small target polynucleotides such as miRNAs, between two samples. A pair of linker probes can be employed in two different reactions to query a particular species of target polynucleotide. A pair of detector probes, a single forward primer specific for the target polynucleotide, and a reverse primer can be employed in an amplification reaction to query the difference in expression level of the target polynucleotide between the two samples. In some embodiments a plurality of small miRNAs are queried with a plurality of linker probes. The plurality of queried miRNAs can then be decoded in a plurality of amplification reactions. | 08-12-2010 |
| 20100203546 | Allele Determining Device, Allele Determining Method And Computer Program - According to an allele determining device | 08-12-2010 |
| 20100203547 | METHOD FOR ACCESSING THE CONTENTS OF A CLOSED VESSEL CONTAINING A SPECIMEN RETRIEVAL DEVICE - Method for obtaining a fluid from a collection device assembled to isolate a specimen retrieval device from the pathway of a fluid transfer device used to penetrate a cap of the collection device and to draw and remove the fluid from the collection device for analysis. | 08-12-2010 |
| 20100203548 | DIAGNOSTIC METHOD FOR EPILEPSY - A method for the diagnosis of SMEI in a patient comprising:
| 08-12-2010 |
| 20100209906 | Methods and compositions for detecting colon cancers - This application describes methods and compositions for detecting and treating vimentin-associated neoplasia. Differential methylation of the vimentin nucleotide sequences has been observed in vimentin-associated neoplasia such as colon neoplasia. | 08-19-2010 |
| 20100209907 | ISOLATED MAMMALIAN MONOCYTE CELL GENES; RELATED REAGENTS - Nucleic acids encoding various monocyte cell proteins from a primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided. | 08-19-2010 |
| 20100209908 | SYSTEM AND METHOD FOR NUCLEOTIDE SEQUENCE PROFILING FOR SAMPLE IDENTIFICATION - The invention includes a method of sample profiling for identification. The method includes the steps of performing less than four nucleotide-specific chemical cleavage reactions to obtain nucleotide sequence fragments, performing size separation on the fragments, detecting the fragments' separation, generating a profile based on the detection, and comparing the profile to a data base to identify the sample. | 08-19-2010 |
| 20100209909 | ASSAYS BASED ON DETECTION OF PHOTOBLEACHING REACTION PRODUCTS FROM DYE CATALYTIC COMPLEX - The present invention relates to the methods for assaying an analyte comprising a nucleic acid analog binding substrate in a sample, comprising reacting a catalytic complex comprising a nucleic acid analog, a nucleic acid analog specific binding substrate and a light reactive dye with a light stimulus, and detecting the presence or absence or amount of a reaction product of the catalytic complex and light stimulus. The present invention also relates to a method of assaying a nucleic acid analyte in a sample using an analyte-specific reporter complex. The present invention also relates to a method of assaying an analyte in a sample using a reporter molecule. | 08-19-2010 |
| 20100209910 | Methods and systems for identifying polynucleotide sequences with translational self-cleavage activity - Provided herein are methods and systems for identifying 2A-like sequences with translational self-cleavage activity in an insect expression system. | 08-19-2010 |
| 20100209911 | Microsatellite maker combination and method for identifying Lanyu pig breed - The present invention provides a microsatellite marker combination for identifying Lanyu pig breed, and the identification method thereof. The identification method comprises the following steps: (a) providing a genomic DNA sample obtained from a pig; (b) identifying the polymorphism of microsatellite markers of said genomic DNA sample; and (c) analyzing the results obtained from step (b) to determine the phylogenetic relationship between said pig and Lanyu pig. | 08-19-2010 |
| 20100209912 | METHOD FOR THE TREATMENT OF A SAMPLE CONTAINING BIOMOLECULES - The invention generally provides a method for the sample preparation for a subsequent preparation, processing or analysis method of a sample containing an at least one species of nucleic acid and/or one species of protein, whereby the method comprises the following steps: A) providing a sample which contains at least one species of a nucleic acid and/or of a protein, B) contacting the sample with a fluid or solid composition to produce a fluid sample preparation, whereby the composition contains at least a nitrogenous compound, which is selected from the group consisting of a) polyamines, b) amino acids, and oligo- and polypeptides, c) nitrogenous heterocyclic compounds, including homo- oder heteropolymers, which comprise these nitrogenous compounds, d) amines of the type R | 08-19-2010 |
| 20100209914 | METHODS, SYSTEMS, AND KITS FOR EVALUATING MULTIPLE SCLEROSIS - The present invention provides a method for evaluating multiple sclerosis (MS), or excluding MS as a diagnosis for a patient The method comprises determining a gene expression profile for a sample from such a patient. The gene expression profile, which contains gene expression values for a plurality of genes that are differentially expressed in white blood cells of MS patients, is compared to an MS-profile and/or a non-MS profile, and classified. The invention also provides a method for monitoring treatment of an MS patient Pre-treatment and post-treatment gene expression profiles contain gene expression values for a plurality of genes that are differentially expressed upon treatment of MS patients. The expression profiles may then be compared, to identify differences between pre-treatment and post-treatment gene expression. These differences are indicative of the patient's response to treatment The invention further provides kits and systems for performing the methods of the invention. | 08-19-2010 |
| 20100209915 | Gene Expression Profiling for Identification, Monitoring, and Treatment of Ocular Disease - A method is provided in various embodiments for determining a profile data set for a subject with ocular disease or conditions related to ocular disease based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least one constituent from Tables 1-5, 7-9, and 11-13. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable. | 08-19-2010 |
| 20100209916 | Apparatus, System, And Method Using Immiscible-Fluid-Discrete-Volumes - Various embodiments of the teachings relate to a system or method for sample preparation or analysis in biochemical or molecular biology procedures. The sample preparation can involve small volume processed in discrete portions or segments or slugs, herein referred to as discrete volumes. A molecular biology procedure can be nucleic acid analysis. Nucleic acid analysis can be an integrated DNA amplification/DNA sequencing procedure. | 08-19-2010 |
| 20100209917 | POLYMORPHIC LENGTH OF FOXE1 ALANINE STRETCH AND GENETIC SUSCEPTIBILITY TO THYROID DYSGENESIS - The present invention concerns a method for diagnosis an increased likelihood of developing a thyroid dysgenesis (TD) for an individual, wherein said method comprises determining the length of the polyalanine repeat of the protein encoded by at least one allele of the FOXE1 (Forkhead box E1) gene in a tissue sample obtained from said individual; and a kit for diagnosis an increased likelihood of developing a thyroid dysgenesis (TD) in an individual comprising at least one nucleic acid probe or oligonucleotide which can be used in such a method. | 08-19-2010 |
| 20100209919 | POLYNUCLEOTIDE MARKERS - The invention relates to polynucleotides that are closely linked to the bolting gene or B gene within the sugar beet genome and can be used for the development of molecular markers. The invention further relates to molecular markers and kits comprising said markers that can be used for mapping, identification and isolation of the bolting gene or S gene in the sugar beet genome and to discriminate between the annual and bienniai genotype or between different haplotypes within plant groupings of sugar beet plants exhibiting a biennial genotype. The invention also relates to assays and methods of breeding sugar beet plants involving said markers. | 08-19-2010 |
| 20100209920 | Gene Expression Profiling in Biopsied Tumor Tissues - The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. The invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies. | 08-19-2010 |
| 20100209921 | Digital Amplification - The identification of pre-defined mutations expected to be present in a minor fraction of a cell population is important for a variety of basic research and clinical applications. The exponential, analog nature of the polymerase chain reaction is transformed into a linear, digital signal suitable for this purpose. Single molecules can be isolated by dilution and individually amplified; each product is then separately analyzed for the presence of pre-defined mutations. The process provides a reliable and quantitative measure of the proportion of variant sequences within a DNA sample. | 08-19-2010 |
| 20100209922 | METHOD OF DETERMINING THE NUCLEOTIDE SEQUENCE OF OLIGONUCLEOTIDES AND DNA MOLECULES - The present invention relates to a novel method for analyzing nucleic acid sequences based on real-time detection of DNA polymerase-catalyzed incorporation of each of the four nucleotide bases, supplied individually and serially in a microfluidic system, to a reaction cell containing a template system comprising a DNA fragment of unknown sequence and an oligonucleotide primer. Incorporation of a nucleotide base into the template system can be detected by any of a variety of methods including but not limited to fluorescence and chemiluminescence detection. Alternatively, microcalorimetic detection of the heat generated by the incorporation of a nucleotide into the extending template system using thermopile, thermistor and refractive index measurements can be used to detect extension reactions. | 08-19-2010 |
| 20100209923 | Probe for diagnosis of marfan syndrome and a method for screening using the probe - The purpose of this invention is to provide a probe for diagnosis of Marfan syndrome, which enables early diagnosis of Marfan syndrome, and to provide a method for screening using said probe. The invention is a probe for a Marfan Syndrome characterized by using a nucleic acid comprising following (a) or (b);
| 08-19-2010 |
| 20100209924 | Nuclear localization of Src-family tyrosine kinases is required for growth factor-induced euchromatinization - A method for quantitatively evaluating chromatin structural changes using pixel imaging of the nucleus is provided. Pixel imaging of the nucleus can include capturing one or more images of a nucleus of one or more nucleic acid stain treated cells. The stain intensity can be measured by quantitating the intensity. The mean and/or standard deviation of stain intensity per pixel can be used to determine chromatin condensation levels or chromatin structural change. | 08-19-2010 |
| 20100209925 | HYBRIDIZATION METHOD AND APPARATUS - A target nucleic acid contained in a sample solution is hybridized with a probe nucleic acid capable of binding specifically to the target nucleic acid and immobilized on a substrate. The process includes hybridizing the target nucleic acid with the probe nucleic acid, collecting the sample solution that has undergone the hybridization, amplifying the target nucleic acid contained in the collected sample solution, and hybridizing the amplified nucleic acid with the probe nucleic acid. | 08-19-2010 |
| 20100209926 | METHODS FOR DETECTING NEUTRALIZING ANTIBODIES FOR BONE MORPHOGENETIC PROTEINS - The present invention relates to methods of detecting neutralizing antibodies for bone morphogenetic proteins (BMP). More particularly, it relates to a highly specific, robust, rapid and accurate cell-based assay for detecting the presence of anti-BMP neutralizing antibodies. | 08-19-2010 |
| 20100209927 | PROCESSING DEVICE TABLET - A microfluidic processing device includes a tablet comprising a reagent, where the tablet is configured to fit within at least one chamber of the processing device. In addition, in some embodiments, at least two tablets are disposed within a single process chamber of the processing device. Further, in some embodiments, each tablet may comprise one or more different types of reagents. In some embodiments, the tablet is a microtablet including a greatest dimension of less than about five millimeters. | 08-19-2010 |
| 20100209928 | Grading, Staging and prognosing Cancer using Osteopontin-C - The present disclosure provides methods and kits that can be used to determine the grade or stage of a breast or other cancer, such as a ductal carcinoma in situ (DCIS). By determining the grade, stage, or aggressiveness of a cancer, appropriate therapeutic regiments can be selected and administered to the patient with the cancer. The method includes detecting osteopontin-c (OPN-c), wherein the presence of high amounts of OPN-c in the cancer sample indicates that the subject has a more aggressive form of cancer (e.g., grade 3). | 08-19-2010 |
| 20100209929 | MULTIPLE MECHANISMS FOR MODULATION OF JAK/STAT ACTIVITY - An embodiment of the present invention is a method for subjecting a hematopoetic cell to a JAK/STAT inhibitor, determining the activity of gain-of-function mutations of a Jak family kinase, determining the expression levels and activity of JAK/STAT regulatory proteins, correlating the expression levels and the activity of JAK/STAT regulatory proteins with the activity of gain-of-function mutations of a Jak family kinase and with a response to the JAK/STAT inhibitor, and then classifying the cells. A further embodiment of the invention includes determining the clinical outcome based on the cell classification, determining a method of treatment, determining dosing and scheduling of at least one of the JAK/STAT inhibitors or other compounds. | 08-19-2010 |
| 20100209930 | PRESERVATION OF CELL-FREE NUCLEIC ACIDS - A method for preserving and processing cell-free nucleic acids located within a blood sample is disclosed, wherein a blood sample containing cell-free nucleic acids is treated to reduce both blood cell lysis and nuclease activity within the blood sample. The treatment of the sample aids in increasing the amount of cell-free nucleic acids that can be identified and tested while maintaining the structure and integrity of the nucleic acids. | 08-19-2010 |
| 20100209931 | Compositions for Identifying Novel Compositions for the Treatment of Disease and Methods of Using Same - Disclosed herein are compositions useful for identification of potential therapeutic agents for the treatment of a disorder associated with RAS deregulation or dysregulation. The compositions may be a yeast cell having one or more mutations in an IRA gene or an ERG gene. Also disclosed are methods of using these compositions. | 08-19-2010 |
| 20100209932 | MicroRNA and Messenger RNA Detection On Arrays - The present teachings provide methods for reverse transcribing, and detecting, a plurality of small nucleic acids such as micro RNAs, from the same reaction mixture as a plurality of messenger RNAs. High levels of multiplexing are provided by the use of a plurality of zip-coded stem-loop reverse transcription primers, along with an oligo-dT-promoter-containing reverse transcription primer, in the same reverse transcription reaction mixture. The resulting products can be amplified in an in vitro transcription reaction, and detected on a solid support such as an array. The present teachings also provide compositions, kits, and devices for performing and detecting the reverse transcription reactions described herein. | 08-19-2010 |
| 20100209934 | METHOD OF IDENTIFYING AGENTS WHICH MODULATE THE ACTIVITY OF CALCIUM-ACTIVATED CHLORIDE CHANNEL - The present invention provides a method of identifying an agent which modulates an activity of a protein, wherein the protein is represented by the amino acid sequence of SEQ ID NO: 1 or has at least 90% amino acid sequence identity to SEQ ID NO: 1 and transports chloride ions across a cell membrane, comprising: (a) exposing cells which express the protein to the agent; and (b) measuring degree of chloride ion transport in the exposed cells, wherein a change in the degree of chloride ion transport compared to control cells, which express the protein but not exposed to the agent, is indicative of an agent capable of modulating an activity of the protein. The agents identified by this method can be used for the prevention or treatment of various diseases caused by the dysfunction of calcium activated chloride channel. | 08-19-2010 |
| 20100209935 | Nucleic Acid Ligand Diagnostic Biochip - A nucleic acid ligand “biochip” is disclosed, consisting of a solid support to which one or more specific nucleic acid ligands is attached in a spatially defined manner. Each nucleic acid ligand binds specifically and avidly to a particular target molecule contained within a test mixture, such as a bodily fluid. The target molecules include, but are not limited to, proteins (cellular, viral, bacterial, etc.) hormones, sugars, metabolic byproducts, cofactor, and intermediates, drugs, and toxins. Contacting the test mixture with the biochip leads to the binding of a target molecule to its cognate nucleic acid ligand. The biochip may then be contacted with a reagent(s) that reacts covalently with proteins and not with nucleic acids. Each protein target in the test mixture may then detected by detecting the presence of the reagent at the appropriate address on the biochip. | 08-19-2010 |
| 20100216121 | Method for the detection of predisposition to high altitude pulmonary edema - The present invention encompasses methods, compositions and kits for the detection of susceptibility to high altitude pulmonary edema in a human subject. The present invention further encompasses isolated polynucleotides for the detection of susceptibility to high altitude pulmonary edema in a human subject. | 08-26-2010 |
| 20100216122 | ENZYMATIC NUCLEIC ACID SYNTHESIS: METHODS FOR DIRECT DETECTION OF TAGGED MONOMERS - Nucleotide triphosphate probes containing a molecular and/or atomic tag on a γ and/or β phosphate group and/or a base moiety having a detectable property are disclosed, and kits and method for using the tagged nucleotides in sequencing reactions and various assay. Also, phosphate and polyphosphate molecular fidelity altering agents are disclosed. | 08-26-2010 |
| 20100216123 | METHOD OF DETECTING MUTATION AND KIT USED IN THE SAME - A method of detecting a mutation is provided that uses Tm analysis and is excellent in detection sensitivity. A detection probe consisting of a polynucleotide complementary to a sequence to be detected containing a detection site that has been mutated and an inhibitory polynucleotide complementary to a sequence not to be detected containing the detection site that is unmutated are added to a sample containing a DNA to be detected in which the detection site has been mutated and a DNA not to be detected in which the detection site is unmutated, so that the detection probe is hybridized with the DNA. Then while the hybridization product between the DNA and the detection probe is heated, a signal variation associated with an increase in temperature is measured, then the signal variation is analyzed, and thereby a Tm value is determined, based on which the presence of the mutation is determined. | 08-26-2010 |
| 20100216124 | GENETIC MARKERS OF THE RISK OF DEVELOPING RESTENOSIS - Methods and kits for diagnosing the risk of developing restenosis after revascularization by implantation of stents based on the detection of single-nucleotide polymorphisms (SNPs). | 08-26-2010 |
| 20100216125 | NUCLEIC ACID ANALYSIS USING SEQUENCE TOKENS - The present invention provides methods and compositions for tagging nucleic acid sequence fragments, e.g., a set of nucleic acid sequence fragments from a single genome, with one or more unique members of a collection of oligonucleotide tags, or sequence tokens, which, in turn, can be identified using a variety of readout platforms. As a general rule, a given sequence token is used once and only once in any tag sequence. In addition, the present invention also provides methods for using the sequence tokens to efficiently determine variations in nucleotide sequences in the associated nucleic acid sequence fragments. | 08-26-2010 |
| 20100216126 | MICROFLUIDIC DEVICE - A microfluidic device comprising; i) an inlet; ii) a first layer comprising at least first and second current carrying structures, wherein the at least first and second current carrying structures each comprise a plurality of teeth, and wherein the teeth of the first and second current carrying structures are optionally offset such that the teeth of the first current carrying structure are positioned between the teeth of the second current carrying structure; iii) a second layer comprising a first microfluidic chamber in fluid communication with the inlet positioned above the at least first and second current carrying structures of the first layer; and iv) a third layer comprising at least third and fourth current carrying structures wherein the at least third and fourth current carrying structures each comprise a plurality of teeth, and wherein the teeth of the third and fourth current carrying structures are optionally offset such that the teeth of the third current carrying structure are positioned between the teeth of the fourth current carrying structure; and wherein the at least third and fourth current carrying structures are positioned in the third layer so as to be above the first microfluidic chamber and such that the teeth of the third current carrying structure are positioned substantially vertically above or offset from the teeth of the first current carrying structure and the teeth of the fourth current carrying structure are positioned substantially vertically above or offset from the teeth of the second current carrying structure; wherein the teeth have a stem having substantially elliptical tip. | 08-26-2010 |
| 20100216127 | PRIMER SET FOR USE IN DETECTION OF YEAST OF GENUS SACCHAROMYCES - An object of the present invention is to provide a primer set, which can accurately, rapidly and simply identify yeast species of genus | 08-26-2010 |
| 20100216128 | METHODS FOR ANALYZING AGRICULTURAL AND ENVIRONMENTAL SAMPLES - The present invention generally relates methods for analyzing agricultural and/or environmental samples using liquid bridges. In certain embodiments, the invention provides a method for analyzing an agricultural sample for a desired trait including obtaining a gene or gene product from an agricultural sample, in which the gene or gene product is in a first fluid; providing a liquid bridge for mixing the gene or gene product with at least one reagent to form a mixed droplet that is wrapped in an immiscible second fluid; and analyzing the mixed droplet to detect a desired trait of the agricultural sample. | 08-26-2010 |
| 20100216129 | GENETIC LOCI ASSOCIATED WITH FUSARIUM SOLANI TOLERANCE IN SOYBEAN - The invention relates to methods and compositions for identifying soybean plants that are tolerant, have improved tolerance or are susceptible to | 08-26-2010 |
| 20100216130 | SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH AMYOTROPHIC LATERAL SCLEROSIS - Methods for determining the genetic predisposition of a human subject to developing ALS are provided herein. These methods include methods for determining the genetic predisposition to any form of ALS, as well as specific methods for determining the genetic predisposition to early onset, late onset, bulbar onset and limb onset ALS. The method can detect amyotrophic lateral sclerosis in a human subject or a specific form of ALS in the subject (early onset, late onset, bulbar onset or limb onset). The method can also detect the risk of developing amyotrophic lateral sclerosis (ALS) in a human subject. The methods utilize the detection of one or more haplotype bocks comprising tag single nucleotide polymorphisms (SNPs). In several embodiments, the methods including detecting the presence of one or more tag SNPs. | 08-26-2010 |
| 20100216131 | GENE EXPRESSION PROFILING OF ESOPHAGEAL CARCINOMAS - The present invention generally regards gene expression profiling of esophageal cancers, including localized esophageal cancers. In particular, gene expression for a particular group of genes identifies individuals that are either going to be responsive to cancer therapy, for example chemotherapy and/or radiation, or that are not going to be responsive to cancer therapy. Exemplary genes having such expression profiles include, for example, PERP, S100A2, and SPRR3. | 08-26-2010 |
| 20100216132 | METHODS AND COMPOSITIONS FOR DIRECT DETECTION OF DNA DAMAGE - The present invention is a method for detecting the extent of DNA damage in a subject suspected of having DNA damage wherein the damage results in the formation of aldehyde moieties in DNA comprising, obtaining a DNA sample from the subject, combining the DNA sample with a fluorescent, chromogenic, pro-fluorescent or pro-chromogenic hydrazine compound to from a fluorescent DNA, detecting the presence of the fluorescent DNA by monitoring the fluorescent emission and quantitating the fluorescent emission thereby determining the extent of DNA damage in the subject. | 08-26-2010 |
| 20100216133 | POLYNUCLEOTIDES FOR USE AS TAGS AND TAG COMPLEMENTS, MANUFACTURE AND USE THEREOF - A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 210 24 mers is described. | 08-26-2010 |
| 20100216134 | POLYNUCLEOTIDES FOR USE AS TAGS AND TAG COMPLEMENTS, MANUFACTURE AND USE THEREOF - A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 210 24mers is described. | 08-26-2010 |
| 20100216135 | POLYNUCLEOTIDES FOR USE AS TAGS AND TAG COMPLEMENTS, MANUFACTURE AND USE THEREOF - A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 210 24mers is described. | 08-26-2010 |
| 20100216136 | METHOD FOR IDENTIFYING A PORK CONTENT IN A FOOD - Pork-specific PCR assay is performed for Halal authentication, by detecting porcine DNA in food products. DNA from raw meat samples is extracted. The extracted DNA is tested using primers that react by amplifying pork DNA but not beef and chicken DNA. The real-time PCR assay is sensitive with a low detection limit when using samples that can be obtained from food products. The methods described herein can have a sensitivity threshold as low as 0.001 ng pork DNA or lower, whereas convention techniques typically do not have a detection limit lower than 0.1 ng pork DNA. | 08-26-2010 |
| 20100216137 | Gene Expression Profiling for Identification, Monitoring and Treatment of Ovarian Cancer - A method is provided in various embodiments for determining a profile data set for a subject with ovarian cancer or conditions related to ovarian cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-5. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable. | 08-26-2010 |
| 20100216138 | METHOD FOR DNA BREAKPOINT ANALYSIS - The present invention relates to a method for identifying a DNA breakpoint and agents for use therein. More particularly, the present invention provides a method for identifying a gene translocation breakpoint based on the application of a novel multiplex DNA amplification technique. The method of the present invention facilitates not only the identification of the break-point position but, further, enables the isolation of the DNA segment across which the breakpoint occurs. This provides a valuable opportunity to conduct further analysis of the breakpoint region, such as to sequence across this region. The method of the present invention is useful in a range of applications including, but not limited to, providing a routine means to characterise the gene break-point associated with disease onset in a patient and thereby enable the design of patient specific probes and primers for ongoing monitoring of the subject disease condition. In addition to monitoring the progression of a condition characterised by the existence of the breakpoint, there is also enabled assessment of the effectiveness of existing therapeutic drugs and/or new therapeutic drugs and, to the extent that the condition is a neoplasm, prediction of the likelihood of a subject's relapse from a remissive state. | 08-26-2010 |
| 20100216139 | METHODS, COMPOSITIONS, AND DEVICES UTILIZING MicroRNA TO DETERMINE PHYSIOLOGICAL CONDITIONS - Methods, compositions, and devices are disclosed which use microRNA to detect, predict, treat, and monitor physiological conditions such as disease or injury. microRNA are isolated and their differential expression is measured to provide diagnostic information. This information may then be utilized for evaluation and/or treatment purposes. | 08-26-2010 |
| 20100216140 | Novel Human Dickkopf-Related Protein and Nucleic Acid Molecules and uses Therefor - Novel Dkk and Dkk-related polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length Dkk and Dkk-related proteins, the invention further provides isolated fusion proteins, antigenic peptides and antibodies. The invention also provides Dkk and Dkk-related nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Dkk and Dkk-related gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 08-26-2010 |
| 20100216141 | COMPOSITIONS AND METHODS TO DETECT LEGIONELLA PNEUMOPHILA NUCLEIC ACID - Compositions are disclosed as nucleic acid sequences that may be used as amplification oligomers, including primers, capture probes for sample preparation, and detection probes specific for | 08-26-2010 |
| 20100216142 | MICRORNA BIOMARKERS IN LUPUS - The present invention provides methods of screening a subject for systemic lupus erythematosus (SLE), comprising detecting an increase in an amount of one or more markers associated with SLE in a biological sample from the subject, wherein the one or more markers is selected from the group consisting of miR-16-1, miR-16-2, miR-223, let7a-1, let7a-2, let7a-3, let 7c, let7g, and any combination thereof, whereby detection of the increase in the amount of the one or more markers identifies the subject as having SLE. The invention further provides methods of screening a subject for SLE comprising detecting a decrease in miR-95 in a biological sample from the subject, whereby detection of the decrease in the amount of miR-95 identifies the subject as having SLE. | 08-26-2010 |
| 20100216143 | Apparatus and Method for Differentiating Multiple Fluorescence Signals by Excitation Wavelength - An apparatus and method are provided for differentiating multiple detectable signals by excitation wavelength. The apparatus can include a light source that can emit respective excitation light wavelengths or wavelength ranges towards a sample in a sample retaining region, for example, in a well. The sample can contain two or more detectable markers, for example, fluorescent dyes, each of which can be capable of generating increased detectable emissions when excited in the presence of a target component. The detectable markers can have excitation wavelength ranges and/or emission wavelength ranges that overlap with the ranges of the other detectable markers. A detector can be arranged for detecting an emission wavelength or wavelength range emitted from a first marker within the overlapping wavelength range of at least one of the other markers. | 08-26-2010 |
| 20100216144 | ANALYSIS OF DNA SAMPLES - The invention provides an improved method for obtaining information about DNA analysis of samples of uncertain origin by establishing the likelihood that they arose in certain manners compared with other possible manners. In this way all of the analysis information is taken into account and likelihood ratios are provided to express the results. The invention is particularly useful in analysing small DNA samples or DNA samples where the contribution from one or more sources is small. | 08-26-2010 |
| 20100216145 | Assay for Detecting Circulating Free Nucleic Acids - This invention is directed, inter alia, to methods and kits for rapid, easy and cost-effective methods of all free nucleic acid quantification in inter alia, biological fluid samples. | 08-26-2010 |
| 20100216146 | Methods and Kits for Hybridizing Multiple PNA Probe Panels to Nucleic Acid Samples - Described herein are methods and kits that employ multiple probe sets in combination with sequential steps of hybridization analysis for multiplex analysis and/or detection of nucleic acids having one or more distinguishable target sequences. | 08-26-2010 |
| 20100216147 | SEQUENCE-SPECIFIC LARGE VOLUME SAMPLE PREPARATION METHOD AND ASSAY - Methods of selectively and rapidly identifying target nucleic acid molecules in large volumes of collection media where the target is present in a low concentration are disclosed. The methods can be used to identify, isolate, purify, or enrich a nucleic acid molecule containing a specific target sequence from a sample of nucleic acid molecules that do not contain the specific target sequence. Once isolated, the nucleic acid molecule containing a specific target sequence may be amplified or used in a variety of detection assays. | 08-26-2010 |
| 20100216148 | NOVEL TUMOR MARKER - The present invention concerns a gene product largely homologous to the epithelial growth factor receptor (EGFR). It further refers to mRNA coding for such epithelial growth factor receptor. The present invention provides such an epithelial growth factor receptor which is characterized in that either exons 12 to 14 or exons 12 to 15 are deleted. These novel variants of the epithelial growth factor receptor can be used for a diagnosis, stratification, therapy guidance of a tumor or therapy guidance of tumor surgery. | 08-26-2010 |
| 20100216149 | SUSCEPTIBILITY GENES FOR AGE-RELATED MACULOPATHY (ARM) ON CHROMOSOME 10q26 - Allelic variations in the genes PLEKHA1 and LOC387715 are identified herein as risk factor for Age Related Maculopathy (ARM). A method is therefore provided for identifying a risk of development of ARM in an individual that comprises identification of allelic variations in PLEKHA1 and/or LOC387715. Related apparatus, such as an array, are identified as being useful in implementing those methods. | 08-26-2010 |
| 20100216150 | Method for Identifying a Compound That Modulates Telomerase Activity - The present invention embraces methods for identifying compounds that modulate the activity of telomerase. Compounds of the invention are identified by designing or screening for a compound which binds to at least one amino acid residue of the TRBD, “thumb,” “finger,” and/or “palm” domain; or FP-pocket, PT-pocket or Th-pocket of telomerase and testing the compound for its ability to modulate the activity of telomerase. | 08-26-2010 |
| 20100216151 | METHODS FOR DETECTING FETAL NUCLEIC ACIDS AND DIAGNOSING FETAL ABNORMALITIES - The invention generally relates to methods for detecting fetal nucleic acids and methods for diagnosing fetal abnormalities. In certain embodiments, the invention provides methods for determining whether fetal nucleic acid is present in a maternal sample including obtaining a maternal sample suspected to include fetal nucleic acids, and performing a sequencing reaction on the sample to determine presence of at least a portion of a Y chromosome in the sample, thereby determining that fetal nucleic acid is present in the sample. In other embodiments, the invention provides methods for quantitative or qualitative analysis to detect fetal nucleic acid in a maternal sample, regardless of the ability to detect the Y chromosome, particularly for samples including normal nucleic acids from a female fetus. | 08-26-2010 |
| 20100216152 | Method for the Carry-Over Protection in DNA Amplification Systems Targeting Methylation Analysis Achieved by a Modified Pre-Treatment of Nucleic Acids - Particular aspects provide methods for specific amplification of template DNA in the presence of potentially contaminating PCR products from previous amplification experiments. Particular embodiments comprise, in a first step, contacting DNA with a bisulfite solution, which sulfonates unmethylated (but not methylated) cytosines, resulting in cytosine deamination and generation of sulfonated uracil. Such sulfonation protects the template nucleic acid from being a target for the enzyme uracil-DNA-glycosylase (UNG), whereas any contaminating DNA, which contains unprotected unsulfonated or desulfonated uracils, is degraded enzymatically while the UNG is active. After UNG treatment and inactivation thereof, the sulfonated uracil bases are converted into uracil by desulfonation. Such aspects have substantial utility for decontamination of nucleic acid samples; e.g., for avoiding amplification of ‘carry over products’ in the context of DNA methylation analysis. In further aspects, the inventive methods can be generally used as simplified methods of bisulfite treatment. | 08-26-2010 |
| 20100216153 | METHODS FOR DETECTING FETAL NUCLEIC ACIDS AND DIAGNOSING FETAL ABNORMALITIES - The invention generally relates to methods for detecting fetal nucleic acids and methods for diagnosing fetal abnormalities. In certain embodiments, the invention provides methods for determining whether fetal nucleic acid is present in a maternal sample including obtaining a maternal sample suspected to include fetal nucleic acids, and performing a sequencing reaction on the sample to determine presence of at least a portion of a Y chromosome in the sample, thereby determining that fetal nucleic acid is present in the sample. In other embodiments, the invention provides methods for quantitative or qualitative analysis to detect fetal nucleic acid in a maternal sample, regardless of the ability to detect the Y chromosome, particularly for samples including normal nucleic acids from a female fetus. | 08-26-2010 |
| 20100216154 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 08-26-2010 |
| 20100216155 | Method and Kit for Identifying Antibiotic-Resistant Microorganisms - The invention provides a rapid sample-processing method for preparing hybridization reaction mixtures substantially depleted of RNA, and a method of identifying the methicillin-resistance status and vancomycin-resistance status of an organism. | 08-26-2010 |
| 20100221702 | Methods for detection and typing of nucleic acids - Disclosed are methods and kits for identifying and characterizing polynucleotide sequences in a sample which may include a heterogeneous sample. Some of the methods and kits are directed to the identification and characterization of a virus in a sample, which may include HIV capable of cause AIDS or AIDS-like symptoms. The virus may be HIV-1, and may also include drug resistant mutations. The methods may include reacting a mixture that includes, in addition to nucleic acid isolated from the sample, at least one oligonucleotide capable of specifically hybridizing to HIV nucleic acid where the oligonucleotide includes at least one non-natural base. In addition, the methods may include detection of one or more mutations in HIV nucleic acid that are associated with drug resistance. | 09-02-2010 |
| 20100221703 | Chemiluminescence proximity nucleic acid assay - This invention relates to the detection and quantitation of target nucleic acids in a heterogeneous mixture in a Sample and the methods of use thereof. The detection system includes a chemiluminescent molecule, a chemiluminescent substrate, a dye that is light responsive when intercalated into nucleic acids and nucleic acids. This invention is useful in any application where detection of a specific nucleic acid sequence is desirable, or where the detection of enzymes that modify nucleic acids is desirable such as diagnostics, research uses and industrial applications. | 09-02-2010 |
| 20100221704 | Method of Dispensing Nonvolatile Liquid in Reaction Vessel and Reaction Vessel Processing Apparatus - It is intended to easily dispense a minute amount of nonvolatile liquid. In a preferred embodiment, in dispensing of mineral oil (nonvolatile liquid), dispensing is conducted in the condition that the amount of air contained in a tip ( | 09-02-2010 |
| 20100221705 | IN SITU HYBRIDIZATION DETECTION METHOD - The invention provides compositions and methods for the detection of targets in a sample; in particular, an in situ hybridization (ISH) sample. Probes and detectable labels may be provided in multiple layers in order to increase the flexibility of a detection system, and to allow for amplification to enhance the signal from a target. The layers may be created by incorporating probes and detectable labels into larger molecular units that interact through nucleic acids base-pairing, including peptide-nucleic acid (PNA) base-pairing. Optional non-natural bases allow for degenerate base pairing schemes. The compositions and methods are also compatible with immunohistochemistry (IHC), immunocytochemistry (ICC), flow cytometry, enzyme immuno-assays (EIA), enzyme linked immuno-assays (ELISA), blotting methods (e.g. Western, Southern, and Northern), labeling inside electrophoresis systems or on surfaces or arrays, and precipitation, among other general detection assay formats. The invention is also compatible with many different types of targets, probes, and detectable labels. | 09-02-2010 |
| 20100221706 | KIT FOR THE AMPLIFICATION OF NUCLEIC ACIDS - A ready-to-use kit for the PCR amplification of nucleic acids is described, comprising at least one vessel into which a master mix comprising the salts, the buffer and the deoxynucleotide triphosphates required for the PCR amplification is prealiquotted, the said master mix being mixed with an effective amount of an inert temperature controllable polymer such that the final mixture thus formed is in the liquid phase at a predetermined temperature and in the gel phase at a temperature lower than a second predetermined temperature. | 09-02-2010 |
| 20100221707 | DIAGNOSTIC METHODS FOR DETECTING CONGENITAL BONE DEFECTS - The present disclosure is directed to compositions and methods for screening for patients at risk for autosomal recessive hypophosphatemic rickets. More particularly, diagnostic reagents and procedures are provided for analyzing samples to detect defective DMP1 expression. | 09-02-2010 |
| 20100221708 | METHOD FOR CHROMOSOME ENUMERATION - A method of sample analysis is provided. The method comprises: a) contacting a genomic sample comprising a plurality of intact chromosomes, i.e., metaphase or interphase chromosomes, with a first set of labeled oligonucleotide probes under in situ hybridization conditions to produce a contacted sample comprising labeled chromosomes, where i. each of the labeled oligonucleotide probes is complementary to a non-repetitive, unique sequence in a region that flanks the centromere of a single chromosome of the plurality of chromosomes; and ii. hybridization of the labeled oligonucleotide probes to the chromosomes produces a distinct labeling pattern for each hybridized chromosome, thereby allowing each of the labeled chromosomes to be distinguished from one another; b) imaging the hybridized chromosomes to provide an image showing the labeling pattern for each labeled chromosome; and c) enumerating a labeled chromosome based on the labeling pattern of said labeled chromosome. A composition and kits for performing the method are also provided. | 09-02-2010 |
| 20100221709 | METHODS FOR IDENTIFYING AGENTS THAT MODULATE APOPTOSIS IN CELLS THAT OVER-EXPRESS A BCL-2 FAMILY MEMBER PROTEIN - The present invention provides methods and combinations of methods for identifying agents that modulate the apoptotic state of a cell by binding to the hydrophobic groove of a Bcl-2 family member anti-apoptotic protein. In certain embodiments, the methods generally comprise the use of Bcl-2 family member proteins having one or more mutations in the hydrophobic groove that, relative to a corresponding protein lacking the mutation, affect, e.g., binding of desired agents or in vitro antimycin sensitivity without substantially altering tertiary protein structure. In these embodiments, the methods comprise the identification of agents that exhibit reduced binding affinities and/or other biological activities for the mutant proteins relative to the corresponding Bcl-2 family member lacking the mutation. In other embodiments, the methods generally comprise the detection of the ability of an agent to induce increased glucose uptake or lactate production in proportion to the level of expression of an anti-apoptotic Bcl-2 family member protein. | 09-02-2010 |
| 20100221710 | ASSAYS FOR FUNGAL INFECTION - Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera | 09-02-2010 |
| 20100221711 | Respiratory Syncytial Virus (RSV) Viral Load Detection Assay - The invention concerns a method for the extraction of nucleic acids from biological samples e.g. tissue material or sputum derived from human or animal species and the quantitative detection thereafter of said nucleic acids e.g. in terms of viral load, more specifically RSV viral load detection. | 09-02-2010 |
| 20100221712 | CELL-MEDIATED IMMUNE RESPONSE ASSAY AND KITS THEREFOR - The present invention provides methods and kits for measuring a cell-mediated immune (CMI) in a small volume of whole undiluted blood collected from a subject. In particular, the methods are for measuring responses in undiluted whole blood samples having a volume of, for example, 50 μl to 500 μl. Thus, capillary sampling and rapid testing of subjects including pediatric, adult or geriatric human subjects are facilitated. | 09-02-2010 |
| 20100221713 | Droplet Actuator Devices, Systems, and Methods - The invention relates to certain novel approaches to reducing or eliminating the movement of contaminants from one droplet to another on a droplet actuator via liquid filler fluid. In one application, droplet actuators are used to conduct genetic analysis using polymerase chain reaction (PCR) techniques. The invention addresses the need for improved methods of performing PCR on a droplet actuator that provide for optimum amplification and detection of a sample target. | 09-02-2010 |
| 20100221714 | ANALYSIS AND USE OF PAR1 POLYMORPHISMS FOR EVALUATING THE RISK OF CARDIOVASCULAR DISEASE - The invention relates to polynucleotide sequences comprising genetic variations of the PAR1 gene at positions 3090 and/or 3329. The occurrence of these variants in humans correlates with increased occurrence of particular cardiovascular disorders. The invention furthermore relates to methods for detecting said genetic variations for the purpose of patient diagnosis. | 09-02-2010 |
| 20100221715 | DETECTION OF BORDETELLA - The invention provides methods to detect | 09-02-2010 |
| 20100221716 | Classification of Nucleic Acid Templates - Methods, compositions, and systems are provided for characterization of modified nucleic acids. In certain preferred embodiments, single molecule sequencing methods are provided for identification of modified nucleotides within nucleic acid sequences. Modifications detectable by the methods provided herein include chemically modified bases, enzymatically modified bases, abasic sites, non-natural bases, secondary structures, and agents bound to a template nucleic acid. | 09-02-2010 |
| 20100221717 | Methods, Compositions, and Kits for Detecting Allelic Variants - In some embodiments, the present inventions relates generally to compositions, methods and kits for use in discriminating sequence variation between different alleles. More specifically, in some embodiments, the present invention provides for compositions, methods and kits for quantitating rare (e.g., mutant) allelic variants, such as SNPs, or nucleotide (NT) insertions or deletions, in samples comprising abundant (e.g., wild type) allelic variants with high specificity and selectivity. In particular, in some embodiments, the invention relates to a highly selective method for mutation detection referred to as competitive allele-specific TaqMan PCR (“cast-PCR”). | 09-02-2010 |
| 20100221718 | METHOD AND RAPID TEST FOR DETECTION OF SPECIFIC NUCLEIC ACID SEQUENCES - A universally usable method for specific detection of target nucleic acid sequences, which method can be performed very rapidly and also simply and furthermore which does not need any expensive instrumental systems. The method is intended to be suitable as a molecular genetic rapid test and to respect the requirements of diagnostic specificity assurance. In this regard it is important that only one specific amplification product be detected and that amplification artifacts can be unambiguously discriminated. A nucleic acid amplification kit suitable for performing this method. | 09-02-2010 |
| 20100221719 | Probes for detecting protein nuclear transport and method for detecting and quantifying protein nuclear transport using the same - A convenient and highly accurate method for detecting protein nuclear transport induced by an endogenous or exogenous substance in local areas of living cells or animals is provided. The method uses a pair of probes for detecting protein nuclear transport, comprising Probe I and Probe II. In Probe I, a protein whose nuclear transport is to be detected or quantified is connected to an N-terminal end or a C-terminal end of a fusion protein [intein-C/reporter protein-C] wherein at least a C-terminal side polypeptide of an intein and a C-terminal side polypeptide of a reporter protein are connected in this order, and in Probe II, a nuclear localization signal is connected to an N-terminal end or a C-terminal end of a fusion protein [reporter protein-N/intein-N] wherein at least the remaining N-terminal side polypeptide of the reporter protein and the remaining N-terminal side polypeptide of the intein are connected in this order. | 09-02-2010 |
| 20100221720 | Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes - Methods for preparing cell lines that contain plant artificial chromosomes, methods for preparation of plant artificial chromosomes, methods for targeted insertion of heterologous DNA into plant artificial chromosomes, and methods for delivery of plant chromosomes to selected cells and tissues are provided. In particular, plant artificial chromosomes that are substantially composed of repeated nucleic acid units of varying amounts of heterochromatin and euchromatin are provided. Also provided are methods of using plant and animal artificial chromosomes in the production of valuable transgenic plants. Methods for identifying plant genes encoding particular traits using artificial chromosomes and for producing an acrocentric plant chromosome also are provided. | 09-02-2010 |
| 20100221721 | System for genome selection - Systems, methods, compositions and apparatus relating to genome selection are disclosed. | 09-02-2010 |
| 20100221722 | METHODS FOR EVALUATING BREAST CANCER PROGNOSIS - Methods for diagnosing and for evaluating the prognosis of a cancer patient, particularly a breast cancer patient, are provided. The methods include determining expression levels of at least five biomarkers in a body sample including a cancer cell from the patient, where expression levels of the biomarkers are indicative of cancer prognosis. Overexpression of the biomarkers of the invention is indicative of a poor prognosis. In some embodiments, the body sample is a breast tissue sample, particularly a primary breast tumor sample. The methods of the invention can be used in combination with assessment of conventional clinical factors and permit a more accurate evaluation of breast cancer prognosis. | 09-02-2010 |
| 20100221723 | EARLY DETECTION OF CANCER BY METHYLATED DNA IN BLOOD - This invention relates to early detection of cancer by detecting methylated DNA in blood. In one embodiment, there is provided a method of predicting the occurrence of hepatocellular carcinoma in a subject, comprising the steps of preparing DNA samples from blood samples of the subject; and determining methylation status of a group of genes comprising RASSF1A, p16 and p15, wherein hypermethylation of these genes as compared to normal control samples indicates the subject is likely to develop hepatocellular carcinoma in the future. | 09-02-2010 |
| 20100221724 | PATCHED POLYPEPTIDES AND USES RELATED THERETO - Methods for isolating patched genes, including the mouse and human patched genes, as well as invertebrate patched genes and sequences, are provided. Decreased expression of patched is associated with the occurrence of human cancers, particularly basal cell carcinomas of the skin. The patched and hedgehog genes are useful in creating transgenic animal models for these human cancers. The patched nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as treatment of cancer, identification of cell type based on expression, and the like. The DNA is further used as a diagnostic for a genetic predisposition to cancer, and to identify specific cancers having mutations in this gene. | 09-02-2010 |
| 20100221725 | REAL TIME GENE EXPRESSION PROFILING - The invention relates to methods of monitoring the amplification of one or more nucleic acid sequences of interest. More particularly, the invention relates to methods of monitoring the amplification of sequences of interest in real time. The methods disclosed herein provide methods for monitoring the amplification of one sequence or two or more sequences from a single sample, as well as methods for monitoring the amplification of one or more than one sequence from two or more samples. The monitoring methods of the invention permit improved determination of the abundance of one or more target nucleic acids, especially target RNA species, in one or more original samples. | 09-02-2010 |
| 20100221726 | RELATING TO DEVICES - A method of analysis, instrument for analysis and device for use in such an instrument are provided, which perform a number of processes need to reach a useful result in the context of a wide variety of samples. The sequence of those processes being optimised. A device, instrument using the device and method of use are also provided which offer reliable performance of a heating based process, with minimal condensation and/or sample loss issues. | 09-02-2010 |
| 20100221727 | SITE-SPECIFIC ENZYMATIC DEPOSITION OF METAL IN SITU - The present invention provides compositions, kits, assembles of articles and methodology for carrying out processes that permit biological enzymes to act directly on metals and metal particles. In particular, the invention relates to use of enzymes to selectively deposit metal to the vicinity of a target molecule. The invention also relates to linking of metals to enzyme substrates, control of enzymatic metal deposition and applications of enzymatic metal deposition to sensitively and selectively detect target molecules such as biomarkers in various biological samples, such as chromogenic immunohistochemical (IHC) detection in situ by using bright field light microscope. | 09-02-2010 |
| 20100221728 | METHOD FOR QUANTIFYING INITIAL CONCENTRATION OF NUCLEIC ACID FROM REAL-TIME NUCLEIC ACID AMPLIFICATION DATA - Provided is a method for quantifying an initial concentration of a nucleic acid from a real-time nucleic acid amplification data. Nucleic acid (DNA or RNA) extracted from organism or virus is amplified using an enzyme. Then, the initial concentration of the nucleic acid is found by calculating the characteristic amplification cycle number or the characteristic amplification time at which the fluorescence intensity of the nucleic acid subtracted by the background fluorescence intensity of the nucleic acid has half of its maximum value, or the characteristic amplification cycle number or the characteristic amplification time at which the amplification efficiency has the maximum or the minimum value, or the prior-to-amplification fluorescence intensity of the nucleic acid subtracted by the background fluorescence intensity of the nucleic acid. Accordingly, the initial concentration of the nucleic acid can be calculated without differentiation or integration. | 09-02-2010 |
| 20100221729 | Methods for assessing Calpain 2 Resistance, Disease Progression, and Treatment Efficacy in Ovarian Cancer - The invention provides methods for predicting whether an ovarian cancer patient's tumor will be resistant to chemotherapy. The invention also provides methods for monitoring the effectiveness of treatment, particularly a chemotherapeutic treatment, in a patient treated for ovarian cancer. The invention further provides methods for treating ovarian cancer, by reducing chemotherapeutic drug resistance in said cells. In addition, the invention provides methods of screening compounds to identify tumor cell growth inhibitors in tumor cells resistant to conventional chemotherapeutic treatment regimes. | 09-02-2010 |
| 20100221730 | Methods for assessing SPARC Resistance, Disease Progression, and Treatment Efficacy in Ovarian Cancer - The invention provides methods for predicting whether an ovarian cancer patient's tumor will be resistant to chemotherapy. The invention also provides methods for monitoring the effectiveness of treatment, particularly a chemotherapeutic treatment, in a patient treated for ovarian cancer. The invention further provides methods for treating ovarian cancer, by reducing chemotherapeutic drug resistance in said cells. In addition, the invention provides methods of screening compounds to identify tumor cell growth inhibitors in tumor cells resistant to conventional chemotherapeutic treatment regimes. | 09-02-2010 |
| 20100221731 | Methods for assessing MetAP2 Resistance, Disease Progression, and Treatment Efficacy in Ovarian Cancer - The invention provides methods for predicting whether an ovarian cancer patient's tumor will be resistant to chemotherapy. The invention also provides methods for monitoring the effectiveness of treatment, particularly a chemotherapeutic treatment, in a patient treated for ovarian cancer. The invention further provides methods for treating ovarian cancer, by reducing chemotherapeutic drug resistance in said cells. In addition, the invention provides methods of screening compounds to identify tumor cell growth inhibitors in tumor cells resistant to conventional chemotherapeutic treatment regimes. | 09-02-2010 |
| 20100221732 | METHODS AND COMPOSITIONS FOR EVALUATING CHRONIC IMMUNE DISEASES - Methods and compositions are provided for evaluating a subject for chronic immune disease, including predicting whether a subject is susceptible to a chronic immune disease, diagnosing whether a subject has a chronic immune disease and/or determining a treatment for a subject suffering from a chronic immune disease. Aspects of the methods include genotyping a subject to determine whether the subject has a least one polymorphism in at least one gene chosen from TLR4, Hsp60, IL-23R, IL-6 and IL-17F. In addition, reagents, devices and kits thereof that find use in practicing the subject methods are provided. | 09-02-2010 |
| 20100221733 | BIOMARKER OF ALLERGIC DISEASE AND USE OF THE SAME - A biomarker is provided for an allergic disease caused by an allergic reaction that is caused not exclusively by histamine release, such as pruritus, and use of the same. Use of Granzyme A as a biomarker makes it possible to provide an indication for chronic itching skin disease, for which existing antiallergic drugs have little effect, and easily and adequately allow diagnosis of the disease. It is possible to, for example, make a diagnosis of an allergic disease with an IV type allergy-like reaction not depending on the antigen-antibody reaction system. Screening with the use of Granzyme A enables the development of novel remedies for allergic diseases. Moreover, a drug capable of specifically controlling the action of a granzyme enables treatment of allergic disease with little side effect. | 09-02-2010 |
| 20100221734 | SHOTGUN DNA MAPPING BY UNZIPPING - The present invention provides a method of mapping a nucleic acid molecule such as, for example, DNA. Generally, the method includes providing a nucleic acid molecule comprising an unzipping force; comparing the unzipping force of the nucleic acid molecule to unzipping forces of a plurality of reference nucleic acid molecules, thereby generating a match score for each comparison; and identifying the reference nucleic acid that produces the best match score when compared to the nucleic acid molecule. | 09-02-2010 |
| 20100221735 | DIAGNOSTIC TEST FOR PARKINSON'S DISEASE - The present invention relates to molecular markers for detection, prognosis and follow up of Parkinson's disease (PD), wherein said molecular markers are one or more genes with altered expression pattern, or gene products thereof (RNA or protein). Genes which expression is upregulated or downregulated in PD patients are tools for early diagnosis od PD, for monitoring the progress of the disease and can serve as targets for screening new agents for treatment of PD. | 09-02-2010 |
| 20100221736 | METHOD FOR PREDICTING SUSCEPTIBILITY TO A MENTAL DISORDER - This invention relates generally to the field of mental disorders and, in particular, to a method for predicting susceptibility to a mental disorder, or a mental associated disorder. | 09-02-2010 |
| 20100221737 | Translocation and Mutant ROS Kinase in Human Non-Small Cell Lung Carcinoma - In accordance with the invention, a novel gene translocation, (5q32, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of CD74 with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The CD74-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of the new fusion protein enables new methods for determining the presence of these mutant ROS kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention. | 09-02-2010 |
| 20100221738 | METHOD OF DIAGNOSIS OF A PREDISPOSITION TO DEVELOP THROMBOTIC DISEASE AND ITS USES - The present invention refers to a method of diagnosis of a predisposition to develop thrombotic disease, to test systems and their use for the diagnosis of a predisposition to develop thrombotic disease, to a P | 09-02-2010 |
| 20100221739 | SUPPRESSION OF TLA1 GENE EXPRESSION FOR IMPROVED PHOTOSYNTHETIC PRODUCTIVITY - The invention provides method and compositions to minimize the chlorophyll antenna size of photosynthesis by decreasing TLA1 gene expression, thereby improving solar conversion efficiencies and photosynthetic productivity in plants, e.g., green microalgae, under bright sunlight conditions. | 09-02-2010 |
| 20100227315 | Biosensor Using Whispering Gallery Modes in Microspheres - A biosensor for detecting the presence of a target analyte is disclosed. The biosensor is formed from microspheroidal particles which have had a binding partner for the target analyte immobilized on their surfaces. The binding partners may be nucleotides; peptides, proteins, enzymes, antibodies and so on. When the analyte binds to its partner, the whispering gallery mode (WGM) profiles of the microspheroidal particles change such that the profile peaks undergo a red-or blue-shift. The immobilised binding partners may include fluorophores and the like so that they emit fluorescence, phosphorescence, incandescence and the like. These fluorophores may take the form of a nanocrystal or quantum dot. | 09-09-2010 |
| 20100227316 | LUMINESCENSE MEASURING APPARATUS AND LUMINESCENSE MEASURING METHOD - There is provided a novel luminescence measuring apparatus that enables measuring a luminescence amount or a luminescence intensity from plural living biological samples, such as tissues, cells, and biological individuals, into which a gene expressing a luminescent protein has been introduced, individually for the respective biological samples. The inventive luminescence measuring apparatus comprises an image acquisition portion that acquires a luminescence image of biological samples; a measurement region determination portion that determines at least one measurement region in the luminescence image; and a luminescence measurement portion that measures the luminescence amount or luminescence intensity in the determined measurement region; thereby measuring the luminescence amount or luminescence intensity individually by the biological sample(s) included in the measurement region. Irrespective of an efficiency of transfer of a luminescent protein gene into a cell, etc., it becomes possible to execute a luminescence measurement successfully while observing only biological samples having a gene expression. | 09-09-2010 |
| 20100227317 | Method for the Molecular Diagnosis of Prostate Cancer and Kit for Implementing Same - The invention relates to a method for the molecular diagnosis of prostate cancer, comprising the in vitro analysis of the overexpression or underexpression of combinations of genes that can distinguish, with high statistical significance, tumorous prostate samples from non-tumorous prostate samples. The invention also relates to a kit for the molecular diagnosis of prostate cancer, which can perform the above-mentioned detection. | 09-09-2010 |
| 20100227318 | METHOD FOR CONTROLLING THE AMOUNT OF GENE PRODUCT, AND AGENT FOR CONTROLLING THE AMOUNT OF GENE PRODUCT - The invention relates to a method of intracellularly controlling amounts of gene products, which can increase an amount of gene product intracellularly, comprising a step of introducing into the cell a substance having a sequence complementary to the base sequence of mRNA corresponding to the gene product, its precursor or another substance which can have equivalent action in the cell. | 09-09-2010 |
| 20100227319 | USE OF RUNX3 AND MIR-532-5P AS CANCER MARKERS AND THERAPEUTIC TARGETS - The invention relates to methods for cancer diagnosis, prognosis, and treatment based on the expression or activity levels of RUNX3 and miR-532-5p. Also disclosed is a method of reducing the inhibition of RUNX3 by miR-532-5p with an agent that interferes with the interaction between RUNX3 and miR-532-5p transcripts. | 09-09-2010 |
| 20100227320 | NUCLEIC ACID DETECTION - This invention provides methods and kits for enriching and/or detecting a nucleic acid with at least one variant nucleotide from a nucleic acid population in a sample. Methods employ the use of enriching primers and bridge-probes for enriching and detecting target nucleic acids. Extension of the enriching primer permits amplification of the target nucleic acid having the variant nucleotide. | 09-09-2010 |
| 20100227321 | METHODS AND DEVICES FOR NUCLEIC ACID SEQUENCE DETERMINATION - Methods of the invention comprise methods and devices for nucleic acid sequence determination. Generally, the invention relates to preparing a substrate for sequencing a target nucleic acid | 09-09-2010 |
| 20100227322 | Detection of Bordetella - The invention provides methods to detect | 09-09-2010 |
| 20100227323 | MICROCHANNEL DETECTION DEVICE AND USE THEREOF - The present invention relates to a device and methods for detecting or quantifying an analyte in a test sample. The device includes a substrate defining one or more microchannels and having a reaction region in a first portion of the one or more microchannels, wherein the reaction region contains a first binding element selected to bind with a first portion of the analyte. The device also includes a detection region in fluid communication with the reaction region. The detection region includes a second binding element selected to immobilize the analyte within the detection region. Methods of detecting or quantifying an analyte in a test sample using the device of the present invention are also disclosed. A method for coating a polymer with a gold layer is also disclosed. | 09-09-2010 |
| 20100227324 | MEASUREMENT OF ARYLESTERASE ENZYMATIC ACTIVITY AND ASSESSMENT OF GENETIC POLYMORPHISMS LOCATED IN THE PON1 GENE AS A DIAGNOSTIC TOOL IN AUTISM-SPECTRUM DISORDERS - The present invention concerns a method for detecting the presence of or predisposition to autism, an autism spectrum disorder, or an autism-associated disorder in a subject, the method comprising measuring an arylesterase enzymatic activity in a sample from the subject, optionally combined with the determination of alleles of PON1 polymorphisms. | 09-09-2010 |
| 20100227325 | METHODS OF DETECTING SEPSIS - Methods of sepsis in a sample from a patient are provided. Methods of detecting changes in expression of one or more microRNAs associated with sepsis are also provided. Compositions and kits are also provided. | 09-09-2010 |
| 20100227326 | Detection System - A method for detecting the presence of a target nucleic acid sequence in a sample, said method comprising: performing nucleic acid amplification on the sample in the presence of (a) a DNA duplex binding agent, (b) a nucleic acid polymerase and (c) a reagent comprising an amplification primer which can hybridise to said target sequence when in single stranded form and which is connected at its 5′ end to a probe which carries a label by way of a chemical linking group, said labelled probe being of a sequence which is similar to that of the said target nucleic acid sequence, such that it can hybridise to a complementary region in an amplification product, and wherein the label is able to absorb fluorescence from or donate fluorescent energy to the DNA duplex binding agent; and monitoring fluorescence of said sample. | 09-09-2010 |
| 20100227327 | METHODS AND COMPOSITIONS FOR CONTINUOUS SINGLE-MOLECULE NUCLEIC ACID SEQUENCING BY SYNTHESIS WITH FLUOROGENIC NUCLEOTIDES - Disclosed herein are methods and compositions for continuous single-molecule nucleic acid sequencing by synthesis with fluorogenic nucleotides. | 09-09-2010 |
| 20100227328 | DNAZYMES AND SENSORS INCORPORATING THE SAME - An arsenic ion active DNAzyme includes a nucleotide sequence, which has a base sequence selected from ATCTCCTCCTGTTC (SEQ ID NO: 62), ATCTGCTCCTGTTC (SEQ ID NO: 63), ATCTCCTCATGTTC (SEQ ID NO: 64), ATCTCCTCTTGTTC (SEQ ID NO: 65), ATCTCCAACCTGTTC (SEQ ID NO: 66), and CCGTAGCGCAAAT (SEQ ID NO: 67). A mercury ion active DNAzyme includes a nucleotide sequence, which has a base sequence selected from AATTCCGTAGGTCCAGTG (SEQ ID NO: 68), AATTCCGTCGGTCCAGTG (SEQ ID NO: 69), AATTCCGCCGGTCCAGTG (SEQ ID NO: 70), GGTTCCGAGTCTCGCGTG (SEQ ID NO: 71), and CGTTCAAAAGGGGCACTG (SEQ ID NO: 72). Sensors incorporating the respective DNAzymes are also disclosed. | 09-09-2010 |
| 20100227329 | TOOLS AND METHODS FOR GENETIC TESTS USING NEXT GENERATION SEQUENCING - The present invention provides tools and methods for use in genetic tests involving high performant sequencing techniques. More particularly, the invention provides a robust multiplex PCR method wherein the respective primers for amplifying the different amplicons are physically isolated from one another. The invention further provides quality control methods allowing a stringent monitoring of genetic tests carried out according to the present invention. | 09-09-2010 |
| 20100227330 | METHODS FOR DIAGNOSING EPISODIC MOVEMENT DISORDERS AND RELATED CONDITIONS - The present invention provides compositions and methods for research, diagnostic, drug screening, and therapeutic applications related to paroxysmal dystonic choreoathetosis and related conditions. In particular, the present invention provides mutations in the myofibrillogenesis regulator 1 (MR-1) gene associated with such conditions. | 09-09-2010 |
| 20100227331 | DETECTION OF IMMOBILIZED NUCLEIC ACID - The present invention provides methods for determining the presence of immobilized nucleic acid employing unsymmetrical cyanine dyes that are derivatives of thiazole orange, a staining solution and select fluorogenic compounds that are characterized as being essentially non-genotoxic. The methods comprise immobilizing nucleic acid, single or double stranded DNA, RNA or a combination thereof, on a solid or semi solid support, contacting the immobilized nucleic acid with an unsymmetrical cyanine dye compound and then illuminating the immobilized nucleic acid with an appropriate wavelength whereby the presence of the nucleic acid is determined. The cyanine dye compounds are typically present in an aqueous staining solution comprising the dye compound and a tris acetate or tris borate buffer wherein the solution facilitates the contact of the dye compound and the immobilized nucleic acid. Typically the solid or semi-solid support is selected from the group consisting of a polymeric gel, a membrane, an array, a glass bead, a glass slide, and a polymeric microparticle. Preferably, the polymeric gel is agarose or polyacrylamide. The methods employing the non-genotoxic compounds represent an improvement over commonly used methods employing ethidium bromide wherein the present methods retain the advantages of ethidium bromide, ease of use and low cost, but without the disadvantageous, known mutagen requiring special handling and waste procedures. | 09-09-2010 |
| 20100227332 | Method for selecting antimicrobial agent and utilization thereof - The present invention provides for a method for selecting an antimicrobial agent, which comprises a microbe analyzing step in which microbes in the microbial biota of a sample are analyzed based on base sequence of DNA and an antimicrobial agent selecting step comprising performing search in a data base storing data for industrial antimicrobial agents applicable to the analyzed microbes recited at effective concentrations, picking up industrial antimicrobial agents effective for the microbial biota, dominant microbe or specific microbe(s) in the sample analyzed in the above microbe analyzing step and selecting among the picked up ones an industrial antimicrobial agent, which method permits to select an antimicrobial agent that is optimum for the treatment in a simple and assured manner within a brief time and to grasp whether the effect of the antimicrobial agent is revealed or not in a simple and assured manner within a brief time, by utilizing this selecting method for the selection of antimicrobial agent, for example, in an antimicrobial treating, in monitoring of the antimicrobial effect, in slime control in paper manufacturing process courses and in microbe inhibition in paper manufacturing process courses, whereby troubles caused by growth of microbes can be prevented beforehand. | 09-09-2010 |
| 20100233679 | DETECTION OF TRUNCATION MUTATIONS IN A LARGE BACKGROUND OF NORMAL DNA - Various methods and strategies are disclosed for detecting human tumors, and specifically colorectal tumors. Methods are also disclosed for detecting truncation mutations in a large background of wild-type DNA. And, methods for detecting AP mutations in a large background of wild-type DNA are also disclosed. | 09-16-2010 |
| 20100233680 | Gene Expression Profiles and Methods of Use - The present invention relates to gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, and methods of using expression profiles and microarrays. The invention also provides methods and compositions for diagnostic assays for detecting cancer and therapeutic methods and compositions for treating cancer. The invention also provides methods for designing, identifying, and optimizing therapeutics for cancer. | 09-16-2010 |
| 20100233681 | METHOD FOR CELL BASED ASSAYS - Disclosed is a method for cell storage on beads and subsequent utilisation of cryogenically stored cells in cellular assays. | 09-16-2010 |
| 20100233682 | FLUID PROCESSING AND VOLUME DETERMINATION SYSTEM - A fluid processing system is described having at least two chambers. Each of said chambers is separated in a first and a second part by a flexible membrane, the first part, in use, comprising essentially a gas and the second part, in use comprising essentially a non-gaseous fluid, an inlet and/or an outlet means. One or more channels are provided connecting said second parts of said at least two chambers, wherein at least one of said one or more channels includes a pressure sensitive one-way valve. Further, means for exerting pressure on said first part of at least one of said at least two chambers is provided to allow transfer of a sample liquid. | 09-16-2010 |
| 20100233683 | AMPLIFICATION OF DNA FRAGMENTS - A method for detecting a nucleic acid molecule having a target sequence adjacent a 3′ terminus is provided. Also provided is a method for differentiating nucleic acid molecules having a target sequence adjacent a 3′ terminus from nucleic acid molecules in which the same sequence is embedded within the molecule. | 09-16-2010 |
| 20100233684 | METHOD FOR DETERMINING INFLAMMATORY DISEASE - It is an object of the present invention to provide a method for determining inflammatory diseases including myocardial infarction as a typical example, which involves identifying polymorphisms associated with myocardial infarction and using the gene polymorphisms, an oligonucleotide that can be used for the method, a kit for diagnosing inflammatory diseases, a therapeutic agent for inflammatory diseases, and the like. The present invention provides a method for determining an inflammatory disease, which comprises detecting at least one type of gene polymorphism existing in a proteasome subunit α type 6 gene. | 09-16-2010 |
| 20100233685 | Two-Color Fluorescent Reporter for Alternative Pre-MRNA Splicing - The present invention provides reporter constructs for in vivo or in vitro monitoring of alternative pre-mRNA splicing events. The reporter constructs described herein are also particularly useful for high-throughput screening of compounds that affect alternative pre-mRNA splicing. Kits comprising the reporter constructs of the present invention find utility in a wide range of applications including, for example, basic research, drug screening, and drug design. | 09-16-2010 |
| 20100233686 | Multiplex Quantitative Nucleic Acid Amplification and Melting Assay - The invention is a single-tube multiplex assay, capable of simultaneously amplifying, detecting and quantifying multiple nucleic acid targets, using multiple hybridization probes, labeled with the same fluorescent reporter label, but each having a distinct melting temperature. The assay can be further multiplexed with the use of multiple sets of hybridization probes, each set labeled with a separate fluorescent reporter label. | 09-16-2010 |
| 20100233687 | METHOD AND SYSTEM FOR TEMPERATURE CORRECTION IN THERMAL MELT ANALYSIS - The present invention relates to methods and systems for temperature correction in thermal melt analysis. More specifically, embodiments of the invention relate to the correction of the melting temperature (T | 09-16-2010 |
| 20100233688 | METHOD FOR DIAGNOSING SPINAL MUSCULAR ATROPHY - A method for diagnosing spinal muscular atrophy is provided. The method includes providing a biological sample of a subject containing a nucleotide of SMN gene, amplifying SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8 by a universal multiplex PCR using the nucleotide as a template and the primers to obtain fragments of the SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8, labeling the fragments of the SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8 by a fluorescent primer to obtain fluorescence-labeled exon fragments, and analyzing the fluorescence-labeled exon fragments by a capillary electrophoresis. If the SMN1/SMN2 ratios in exon 7 and 8 are different, it indicates that the subject is susceptible to spinal muscular atrophy. Additionally, if the peak of certain exon fragment appears crossed, it indicates an intragenic mutation in the exon. | 09-16-2010 |
| 20100233689 | PYRAZOLOANTHRONE AND DERIVATIVES THEREOF FOR THE TREATMENT OF CANCER EXPRESSING 'MULLERIAN INHIBITING SUBSTANCE' TYPE II RECEPTOR (MISRII) AND OF EXCESS ANDROGEN STATES - The present invention relates to pyrazoloanthrones or functional derivatives or functional analogues thereof to activate MIS receptor-mediated downstream effects in a cell. In particular, the present invention relates to method to prevent and treat cancer that expresses MIS receptor type II (MISRII) by administering to a subject at least one pyrazoloanthrone or a functional derivative or a functional analogue thereof. Another aspect of the present invention relates to methods to lower plasma androgen levels in a subject, and/or for the treatment of a subject with a disease characterized by excess androgen, whereby the subject is administered at least one pyrazoloanthrone or a functional derivative or a functional analogue thereof. Another aspect provides pharmaceutical compositions comprising at least one pyrazoloanthrone or functional a derivative or a functional analogue thereof, and optionally with one or more additional agents such as chemotherapeutic agents. Another aspect of the present invention relates to methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with a pyrazoloanthrone or a functional derivative or a functional analogue thereof that lowers the effective dose of the chemotherapeutic agent, such as for example, paclitaxel. | 09-16-2010 |
| 20100233690 | Use of genes identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer - The invention relates to the use of inhibitors of the expressed proteins of the murine genes and/or their human homologues listed in Table 1 for the preparation of a therapeutical composition for the treatment of cancer, in particular for the treatment of solid tumors of lung, colon, breast, prostate, ovarian, pancreas and leukemia and the use of the genes listed in Table 1 for the diagnosis of cancer. The invention also relates to the therapeutical compositions comprising the inhibitors and to methods for development of the inhibitor compounds. | 09-16-2010 |
| 20100233691 | Gene Expression Profiling for Identification, Monitoring and Treatment of Prostate Cancer - A method is provided in various embodiments for determining a profile data set for a subject with prostate cancer or conditions related to prostate cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-4. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable. | 09-16-2010 |
| 20100233692 | FLUORESCENTLY LABELED FUSION PROTEIN FOR ASSAYING ADENOSINE TRIPHOSPHATE - The object of the present invention is to provide a substance, which is easy to handle and enables the measurement of ATP with a high sensitivity regardless of the concentration of protein, and further a measuring method of ATP using the substance. Such object is solved with a fluorescence labelled fusion protein obtained by attaching two types of fluorescent substances of potential donor and acceptor for fluorescence resonance energy transfer (FRET) respectively to a protein which can cause structural changes depending on ATP binding, namely ε protein, which is the subunit of ATP synthetase, and further solved by contacting the fluorescence labelled fusion protein with a subject substance and then measuring the fluorescence spectra. | 09-16-2010 |
| 20100233693 | METHODS FOR DIAGNOSING, PROGNOSING, OR THERANOSING A CONDITION USING RARE CELLS - The invention encompasses methods for diagnosing, theranosing, or prognosing a condition in a patient based on the results of one or more analysis methods. The methods can comprise enriching a sample obtained from the patient for one or more rare cells. The analysis methods can include performing enumeration of the one or more rare cells or cell subtypes, performing nucleic acid analysis, or detecting a serum marker. | 09-16-2010 |
| 20100233694 | DEVICES AND METHODS FOR DIAGNOSING, PROGNOSING, OR THERANOSING A CONDITION BY ENRICHING RARE CELLS - The invention encompasses methods and devices for diagnosing, theranosing, or prognosing a condition in a patient by enriching a sample in rare cells. The devices can be a microfluidic device comprising an array of obstacles and one or more binding moieties. The devices and methods can allow for enrichment of cells based on size and affinity, recovery of cells in locations on the microfluidic device, release of cells from the microfluidic device, flow of sample through the microfluidic device, and retention of rare cells from a sample obtained from a patient having a condition. | 09-16-2010 |
| 20100233695 | MOLECULAR DIAGNOSIS AND TYPING OF LUNG CANCER VARIANTS - Compositions and methods useful in determining the major morphological types of lung cancer are provided. The methods include detecting expression of at least one gene or biomarker in a sample. The expression of the gene or biomarker is indicative of the lung tumor subtype. The compositions include subsets of genes that are monitored for gene expression. The gene expression is capable of distinguishing between normal lung parenchyma and the major morphological types of lung cancer. The gene expression and somatic mutation data are useful in developing a complete classification of lung cancer that is prognostic and predictive for therapeutic response. The methods are suited for analysis of paraffin-embedded tissues. Methods of the invention include means for monitoring gene or biomarker expression including PCR and antibody-based detection. The biomarkers of the invention are genes and/or proteins that are selectively expressed at a high or low level in certain tumor subtypes. Biomarker expression can be assessed at the protein or nucleic acid level. | 09-16-2010 |
| 20100233696 | METHODS, FLOW CELLS AND SYSTEMS FOR SINGLE CELL ANALYSIS - A method, flow cell and/or device for increasing the recovery of a limiting analyte in a sample, e.g., for single molecule analysis is disclosed. Methods for preparing a nucleic acid sample from a single cell and capturing nucleic acids on a surface configured for use in or with single molecule analysis are also provided. | 09-16-2010 |
| 20100233697 | METHOD FOR STANDARIZING SURFACE BINDING OF A NUCLEIC ACID SAMPLE FOR SEQUENCING ANALYSIS - Methods are described which enable nucleic acid sample standardization prior to anchoring to a surface, especially useful in single molecule nucleic acid sequencing applications when sample is limiting or unamplified. | 09-16-2010 |
| 20100233698 | APPARATUS AND METHOD FOR MULTIPLEX ANALYSIS - The present invention provides miniaturized instruments for conducting chemical reactions where control of the reaction temperature is desired or required. Specifically, this invention provides chips and optical systems for performing and monitoring temperature-dependent chemical reactions. The apparatus and methods embodied in the present invention are particularly useful for high-throughput and low-cost amplification of nucleic acids. | 09-16-2010 |
| 20100233699 | PRIMERS AND METHODS FOR THE DETECTION AND DISCRIMINATION OF NUCLEIC ACIDS - The present invention provides novel primers and methods for the detection of specific nucleic acid sequences. The primers and methods of the invention are useful in a wide variety of molecular biology applications and are particularly useful in allele specific PCR. | 09-16-2010 |
| 20100233700 | UBIAD1 GENE AND HYPERLIPIDEMIA - The disclosure relates to genetic mutations in UBIAD1 gene that segregate with Schnyder's crystalline corneal dystrophy. The disclosure provides methods for detecting such mutations as a diagnostic for Schnyder's crystalline corneal dystrophy either before or after the onset of clinical symptoms. Also provided are screening methods for identifying medical conditions related to cholesterol metabolism, including atherosclerosis, risk of future loss of vision, and future need for corneal transplantation. | 09-16-2010 |
| 20100233701 | Use of non-clonal chromosomal aberrations for cancer research and clinical diagnosis - A diagnostic method of determining tumorigenicity of a tissue specimen includes the steps of determining the magnitude of genome diversity in the tissue specimen, and diagnosing a likelihood of cancer in response thereto. The magnitude of genome diversity includes the determination of karyotypic heterogeneity in tissue specimen, illustratively by detecting non-clonal chromosome aberrations (NCCAs). The detection of NCCAs includes the identification of various types and frequency of NCCAs, and diagnosis is responsive to the step of detecting the frequency of NCCAs. Detection of NCCAs includes the further step of screening lymphocytes. Also, the step of determining the presence of elevated genome diversity includes the step of applying Spectral Karyotyping to detect structural and numerical aberrations throughout the genome. The diagnostic method is useful to determine drug resistance in a patient and potential harmfulness, to evaluate the side effects of drugs, and to measure genome system stress. | 09-16-2010 |
| 20100233702 | METHOD TO PREDICT RESPONSE TO TREATMENT FOR PSYCHIATRIC ILLNESSES - The disclosure provides methods and compositions useful for identifying a subject's predisposition to lithium treatment. | 09-16-2010 |
| 20100233703 | EMX2 IN CANCER DIAGNOSIS AND PROGNOSIS - The present invention provides methods for determining a prognosis of disease free or overall survival in a patient suffering from cancer. The methods generally involve determining a normalized expression level of an EMX2 gene product, which correlates with prognosis and likelihood of survival. | 09-16-2010 |
| 20100233704 | METHODS OF DETECTING LUNG CANCER - Methods of lung cancer in a sample from a patient are provided. Methods of detecting changes in expression of one or more target RNAs associated with lung cancer are also provided. Compositions and kits are also provided. | 09-16-2010 |
| 20100233705 | METHOD OR SYSTEM USING BIOMARKERS FOR THE MONITORING OF A TREATMENT - The present invention relates to biomarkers to monitor the activity of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and especially its monoethanesulphonate salt form, when used alone or optionally in combination with further pharmaceutically active ingredients and/or further treatments, such as for example radiotherapy. | 09-16-2010 |
| 20100233706 | METHODS TO FIX AND DETECT NUCLEIC ACIDS - In one aspect, the invention relates to a method for fixing a short nucleic acid in a biological sample. In another aspect, the invention relates to a method for detecting a target short nucleic acid in a biological sample. The method includes contacting the biological sample with an aldehyde-containing fixative, and subsequently contacting the sample with a water-soluble carbodiimide. In a further aspect, the invention relates to a kit for fixing a short nucleic acid in a biological sample. The kit includes a support substrate for holding the sample; an aldehyde-containing fixative; and a water-soluble carbodiimide. | 09-16-2010 |
| 20100233707 | MATERIALS AND METHODS FOR PREDICTING RECURRENCE OF NON-SMALL CELL LUNG CANCER - Disclosed herein is a DNA methylation-based test for determining the recurrence or non-recurrence of a lung cancer such as NSCLC after treatment. The assays involve the detection of methylation of the BAX gene promoter alone or in combination with other genes. The test is suitable for monitoring treatment of subjects with lung cancer for which methylation differs by stage of the disease and by treatment regimen. | 09-16-2010 |
| 20100233708 | SPLIT FLOW DEVICE FOR ANALYSES OF SPECIFIC-BINDING PARTNERS - The present invention provides an analyte detection system for detecting a target analyte in a sample. In particular, the invention provides a detection system capable of one-step amplification of the detection signal by incorporating a secondary flow path that can deliver reagents to a reaction zone. Methods of using the detection system to detect analytes in samples, particularly biological samples, and kits comprising the detection system are also disclosed. | 09-16-2010 |
| 20100233709 | ABSCRIPTION BASED MOLECULAR DETECTION - The present invention provides methods for detecting biomarkers based on Abscription®, abortive transcription technology. Particularly, the present invention provides bisulfate free methods for detecting methylation of CpG islands from small samples of DNA. The methods are suitable for multiplexing and can be used to analyze multiple CpG islands from a single sample in a short time. | 09-16-2010 |
| 20100233710 | NUCLEIC ACID BINDING DYES AND USES THEREFOR - The invention provides novel compounds and compositions of Formulas I and II, as well as methods of using them. The compounds can be used, for example, to quantify an amount of double stranded DNA in a sample subjected to nucleic acid amplification, or for real time monitoring of a nucleic acid amplification reaction. The compounds can be provided in a kit, for example, with other reagents and instructions for using the compounds and reagents. | 09-16-2010 |
| 20100233711 | GENE ENCODING LABYRINTHIN, A MARKER FOR CANCER - A cDNA molecule that encodes a protein designated Labyrinthin (Lab) isolated and its nucleotide sequence is determined. The protein, or peptides derived from the protein, are markers useful to define novel classes of cancers. Diagnostic assays for these cancers use antibodies to Lab or nucleotide probes that hybridize with the lab gene or a fragment therefrom. Vaccines useful either to prevent recurrence of cancers in subjects who test positive for Lab (or lab), or to prevent initial occurrence of cancer, use proteins or peptides derived from Lab. Expression of Lab via immunogenic assays is used to monitor effects of cancer treatments. Antisense molecules against lab are used in treatments. Sense molecules of lab are used to restore lost lab function in diseased normal cells, for example, gland cells. | 09-16-2010 |
| 20100233712 | Method for Early Detection of Cancers - The invention includes methods for detecting the presence of a neoplastic condition by comparing a sample level of a BIF-1 to a reference, wherein a low level of BIF-1 in the sample correlates with the presence of a neoplastic condition. Another method involves determining the risk of relapse, tumor recurrence and/or metastasis by determining a sample level of a Bif-1 to a reference level of Bif-1, wherein low sample levels correlate with a likelihood of relapse, recurrence and/or metastasis. Yet another method includes detecting the presence of a pre-neoplastic condition, such as prostatic intraepithelial neoplasia. The method involves measuring a level of a Bif-1 in a sample and comparing the level of Bif-1 in the sample to a reference level of Bif-1. High levels of Bif-1 in the sample correlate with the presence of the pre-neoplastic condition. | 09-16-2010 |
| 20100233713 | METHOD FOR TREATING A SOLUTION IN ORDER TO DESTROY ANY RIBONUCLEIC ACID AFTER AMPLIFICATION - The present invention provides a method for treating a solution containing among others, target nucleic acid to be amplified in order to destroy any ribonucleic acid that is present in the solution and that could possibly be amplified in another assay. The method is useful to avoid carry-over contamination between experiments. | 09-16-2010 |
| 20100233714 | MULTISTATE AFFINITY LIGANDS FOR THE SEPARATION AND PURIFICATION OF ANTIBODIES, ANTIBODY FRAGMENTS AND CONJUGATES OF - Separation of antibodies, antibody fragments, and conjugates thereof using multistate affinity ligands rationally designed and selected to undergo analytically and functionally definable conformational transitions from a first affinity state under a first operator-defined environmental condition to a second affinity state under a second operator-defined environmental condition. | 09-16-2010 |
| 20100233715 | METHOD OF NUCLEIC ACID AMPLIFICATION AND MEASURING REAGENT AND REAGENT KIT THEREFOR - The object of the present invention is to provide a method that allows stable amplification of an internal standard material while maintaining an accurate assay value for a target nucleic acid in a nucleic acid detection system involving the use of an internal standard material and a reagent kit used therefor. The present invention relates to a method for nucleic acid amplification comprising preventing an internal standard amplification product from affecting amplification reaction of a target nucleic acid by performing amplification of an internal standard material prior to amplification of the target nucleic acid in the method for amplifying a target nucleic acid in a sample using an internal standard material and a reagent and reagent kit used therefor. | 09-16-2010 |
| 20100233716 | TRANSPLANT REJECTION MARKERS - The invention relates to the analysis and identification of genes that are regulated simultaneously in chronic kidney transplant rejection. This simultaneous regulation of genes provides a molecular signature to accurately detect, and optionally classify, chronic kidney transplant rejection. | 09-16-2010 |
| 20100233717 | METHODS FOR DETECTING TOXIGENIC MICROBES - The present invention provides methods and oligonucleotides for detecting toxigenic microbes, such as toxigenic | 09-16-2010 |
| 20100233718 | NON-INVASIVE TECHNIQUE FOR CONDUCTING SKIN INFLAMMATORY DISEASE PHARMACO-GENOMIC STUDIES AND DIAGNOSES THEREOF - Non-invasive techniques to conduct skin inflammatory disease pharmaco-genomic studies and diagnoses thereof feature discriminating biomarkers and genes and in vitro diagnostic methods employing such biomarkers. | 09-16-2010 |
| 20100233719 | Genetic Markers for Predicting Disease and Treatment Outcome - The present invention provides for a method for identifying patients that are suitably treated by a therapy, such as a therapy involving administration of a fluoropyrimidine drug and/or a platinum drug. The method includes determining the expression level of at least one gene selected from a phospholipase 2 (PLA2) gene, a thymidine phosphorylase (TP) gene, and a glutathione S-transferase P1 (GSTP-1) gene in suitable sample isolated from the patient. Overexpression of the gene or genes identifies the patient as not being suitable for the therapy. | 09-16-2010 |
| 20100233720 | BIOLOGICAL REAGENTS AND METHODS TO VERIFY THE EFFICIENCY OF SAMPLE PREPARATION AND NUCLEIC ACID AMPLIFICATION AND/OR DETECTION - This invention relates to reagent comprising: any one of cells, viral particles, organelles, parasites, cells comprising organelles, cells comprising viral particles, cells comprising parasites, cells comprising bacterial cells and any combination thereof, the cells, viral particles, organelles or parasites comprising at least one nucleic acid sequence serving as an internal control (IC) target for nucleic acid testing (NAT) assay; wherein the reagent is suitable to be added to a test sample undergoing sample preparation to release, concentrate and/or purify nucleic acids and amplification and/or detection of nucleic acids so as to be used to verify: (i) the efficiency of sample preparation; and (ii) the efficiency of nucleic acid amplification and/or detection. The present invention also relates to a method to verify or validate the preparation and amplification and/or detection of a nucleic acid target sequence in a sample spiked with a reagent of the present invention. | 09-16-2010 |
| 20100233721 | APPARATUS AND METHODS FOR DETECTING DNA IN BIOLOGICAL SAMPLES - Apparatus and methods are described for detecting target DNA in a biological sample using capture probes and electrically-assisted hybridization. The reaction cell is formed with an attachment surface of aluminum oxide for better thermal and physical properties, and the aluminum oxide surface is coated with anti-DIG antibody to provide a convenient attachment layer for the capture probes allowing their correct orientation, while the capture probes are formed with a DIG-label so that they attach to the surface of the cell through an anti-DIG/DIG linkage. | 09-16-2010 |
| 20100233722 | Methods for determining the biological effect and/or activity of r pharmaceutical compositions based on their effect on the methylation status of the DNA - This invention is related to methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions using their effect on DNA methylation as a marker for their biological effect(s). The invention is further related to the use of the inventive methods, systems and computer program products in obtaining new biologically active compounds for new and effective medicaments and treatment strategies of, in particular, human diseases. | 09-16-2010 |
| 20100240028 | METHOD TO IMPROVE QUALITY OF MICROARRAYS BY CONTROLLING EVAPORATION - Methods and compositions described here minimize loss due to evaporation during the process of preparing gel-element microarrays; maintain uniform gel density; minimize irregular spontaneous polymerization; and provide conditions to obtain reproducible and consistent gel-array elements. The materials and methods described herein present techniques for restoring the original composition of the droplets dispensed on the microarray substrates prior to and during the step of ultraviolet light polymerization. | 09-23-2010 |
| 20100240029 | Cholesterol-Regulating Complex of SIRT1 and LXR and Methods of Use - A cholesterol-regulating complex of SIRT1 and LXR and methods of use are disclosed. SIRT1 forms a complex with LXR bound to an LXR element. Methods of forming the complex, identifying an agent that modulates formation of the complex, increasing the ratio of cholesterol bound to high density lipoprotein (HDL) to total cholesterol in the plasma of a mammal, promoting ABCA1-mediated cholesterol efflux from a mammalian cell, treating a subject deemed to have a level of SIRT1 activity that is below normal, assessing whether a candidate substance modulates an LXR-dependent process, and assessing whether a candidate substance modulates an SIRT1-dependent effect of an LXR are disclosed. | 09-23-2010 |
| 20100240030 | NEW METHOD FOR QUALITATIVE AND QUANTITATIVE DETECTION OF SHORT NUCLEIC ACID SEQUENCES OF ABOUT 8-50 NUCLEOTIDES IN LENGTH - The present invention concerns a new analytical method for qualitative and quantitative detection of short nucleic acid sequences, preferably a DNA oligonucleotide or a modified DNA oligonucleotide such as antisense oligonucleotides or fragmented nucleic acid sequences of about 8-50 nucleotides in length. The invention relates to the introduction of modified nucleic acids into an oligonucleotide probe that hybridizes to the target sequence such that amplification and quantitation of the short nucleic acid sequence is enabled and sensitivity and specificity of the reaction is increased. The invention also embraces test kits for performing nucleic acid amplification to detect and quantitate short nucleic acid sequences and processes for preparing such and the use of new analytical methods. | 09-23-2010 |
| 20100240031 | Method of Predicting Metastatic Potential Prognosis or Overall Survival of Cancer Patients - A method of predicting metastatic potential, prognosis or overall survival of cancer patients is provided. The method utilizes reliable markers, HIF-1α, TWIST or Snail, to predict the probability of the metastatic potential, prognosis situation or overall survival of cancer patients. Moreover, the method provided by the present invention can reach relatively higher predictability of metastatic potential, prognosis situation or overall survival as compared with the current markers. | 09-23-2010 |
| 20100240032 | METHOD FOR DETERMINING THE ALLERGIC POTENTIAL OF A COMPOUND - The present invention is related to a method for determining the sensitizing potential of a chemical (test) compound, comprising the steps of:
| 09-23-2010 |
| 20100240033 | CONSTITUTIVELY ACTIVE MUTANTS OF THE PROLACTIN RECEPTOR - The invention relates to constitutively active mutants of the prolactin receptor (PRLR), wherein an Ile residue at position 76 or at position 146 of the mature form of said receptor has been substituted by another amino acid residue. The invention also provides methods useful for the diagnosis, prognosis, or treatment of diseases involving the PRLR. | 09-23-2010 |
| 20100240034 | Gene defects and mutant ALK kinase in human solid tumors - In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention. | 09-23-2010 |
| 20100240035 | MULTIGENE PROGNOSTIC ASSAY FOR LUNG CANCER - The present invention provides methods for providing a prognosis for lung adenocarcinoma, using a panel of eight molecular markers that are differentially expressed in lung adenocarcinoma. | 09-23-2010 |
| 20100240036 | NUCLEIC ACID PROBES AND METHODS FOR DETECTING PLASMODIUM PARASITES - This invention relates to novel nucleic acid-based probes and methods for detecting | 09-23-2010 |
| 20100240037 | IDENTIFICATION OF MARKERS IN ESOPHAGEAL CANCER, COLON CANCER, HEAD AND NECK CANCER, AND MELANOMA - Methods for identifying expression of markers indicative of the presence of esophageal, a squamous cell cancer, a squamous cell cancer of the head and neck, colon cancer and melanoma are provided. Also provided are articles of manufacture useful in such methods and compositions containing primers and probes useful in such methods. | 09-23-2010 |
| 20100240038 | Method of screening a drug such as insulin secretagogue - The screening method of the present invention is useful for screening drugs such as insulin secretagogues having an insulin secretagogue activity with minimized side effects (hypoglycemia induction, etc.). The transformant in which a polynucleotide encoding the fusion protein used for the screening method is introduced, the screening kit comprising the transformant, etc. are also useful for screening excellent drugs. | 09-23-2010 |
| 20100240039 | FHL1 MUTATIONS ASSOCIATED WITH NOVEL X-LINKED MUSCULAR MYOPATHIES - Four and a Half LIM domains protein 1 (FHL-1) mutations at positions 128 or 224 that are associated with X-linked muscular myopathy, methods of screening subjects to identify those susceptible to muscular myopathy including muscular dystrophy and cardiomyopathy and kits. | 09-23-2010 |
| 20100240040 | METHOD FOR SCREENING FOR SELECTIVE MODULATOR OF THE NF-KB PATHWAY ACTIVATION - The invention relates to methods for screening for selective modulator of NF-κB pathway activation. The invention concerns methods for primary screening molecules that potentially modulate (activate or inhibit) the NF-κB pathway activation by identifying and selecting molecules modulate the interaction of NEMO with other proteins. The invention also concerns methods for secondary screening for modulator (activator or inhibitor) of the NF-κB pathway activation. | 09-23-2010 |
| 20100240041 | MICROFLUIDIC DEVICE FOR TRAPPING SINGLE CELL - It is to provide a microfluidic device which separates and captures with high efficiency a large amount of cells in a sample at one-cell level without damaging the cells by utilizing a microfabrication technology. The device sequentially comprises: an upper substrate consisting of a plastic plate provided with a groove for forming a microchannel communicating a sample-supply opening and a sample-discharge opening; a plastic upper flat plate forming the microchannel by cooperating with the upper substrate, the plate being provided with an aperture for a micromesh; a holding plate holding a plastic micromesh having a plurality of micro through-pores for capturing cells; a plastic lower flat plate provided with an aperture for suctioning; and a lower substrate consisting of a plastic flat plate provided with a groove for forming a suction channel, wherein the micro through-pores for capturing cells of the micromesh have an inverted mortar-like shape or a cylindrical shape, and wherein the upper flat plate is constituted by a softer plastic as compared to the upper substrate. | 09-23-2010 |
| 20100240042 | METHOD OF DETECTING METHYLATED CYTOSINE - The method for detecting a methylated cytosine of the present invention comprises the steps of: | 09-23-2010 |
| 20100240043 | METHODS OF USING GENETIC VARIANTS TO DIAGNOSE AND PREDICT INFLAMMATORY BOWEL DISEASE - The present invention relates to methods of diagnosing susceptibility to Inflammatory Bowel Disease and subtypes of Inflammatory Bowel Disease. In one embodiment, the present invention provides a method of diagnosing susceptibility to Inflammatory Bowel Disease by determining the presence of one or more risk variants at the DR3 locus, GATA3 locus, SIN(EFS) locus, BTLA locus, LIGHT locus and MAGE locus. | 09-23-2010 |
| 20100240044 | Micro Chip - Instant invention is about a micro chip comprising plurality of layers of LTCC wherein a reaction chamber is formed in plurality of top layers to load samples. A heater embedded in at least one of the layers below the reaction chamber and a temperature sensor is embedded in at least one of the layers between the heater and the reaction chamber for analyzing the sample. The temperature sensor can be placed outside the chip to measure the chip temperature. | 09-23-2010 |
| 20100240045 | NUCLEOTIDE COMPOSITIONS AND USES THEREOF - The present invention relates to preparation of nucleotide compositions and uses thereof for conducting nucleic acid analyses. The compositions and methods embodied in the present invention are particularly useful for nucleic acid analyses that require high-resolution detection of labeled nucleotides or labeled nucleic acid targets. | 09-23-2010 |
| 20100240046 | Methods and Systems for Identifying PCR Primers Specific to One or More Target Genomes - Methods and systems for identifying a primer pair for polymerase chain reaction specific to one or more target genomes. Methods and systems of the present disclosure can be used to identify primers that can distinguish between target genomes and closely related non-target genomes. | 09-23-2010 |
| 20100240047 | METHODS AND COMPOUNDS FOR DETECTION OF MOLECULAR TARGETS - The present invention relates to methods and compounds for detection of molecular targets, such as biological or chemical molecules, or molecular structures, in samples using a host of experimental schemes for detecting and visualizing such targets, e.g. immunohistochemistry (IHC), in situ hybridization (ISH), ELISA, Southern, Northern, and Western blotting, etc. | 09-23-2010 |
| 20100240048 | BIOLOGICAL SAMPLE REACTION CHIP, BIOLOGICAL SAMPLE CHARGING DEVICE, BIOLOGICAL SAMPLE QUANTIFYING DEVICE, AND BIOLOGICAL SAMPLE REACTION METHOD - A biological sample reaction chip includes, a first path having a first width, a second path having a second width wider than the first width wherein the first path and the second path being connected, a first opening through which a first liquid is introduced into the first path, and a second opening through which a second liquid unmixable with the first liquid is introduced into the first path. | 09-23-2010 |
| 20100240049 | Methods of Detecting Cervical Cancer - Methods of detecting cervical dysplasia, such as cervical dysplasia likely to progress to carcinoma in a sample of human cervical cells, are provided. Methods of detecting changes in expression of one or more microRNAs or mRNAs associated with cervical dysplasia or cervical cancer are also provided. Compositions and kits are also provided. | 09-23-2010 |
| 20100240050 | Methods and Products For In Vivo Enzyme Profiling - The present invention relates to methods and products associated with in vivo enzyme profiling. In particular, the invention relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. The invention also relates to products, kits, and databases for use in the methods of the invention. | 09-23-2010 |
| 20100240051 | Device and Method for Preparing and Performing Multiple Polymerase Chain Reactions - The present invention relates to methods, kits and devices with multiple open reaction chambers having multiple pre-deposited primer compositions, and a basic sample loading mechanism that utilizes an immiscible companion fluid for preparing and performing multiple Polymerase Chain Reactions | 09-23-2010 |
| 20100240052 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof. | 09-23-2010 |
| 20100240053 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof. | 09-23-2010 |
| 20100240054 | IDENTIFICATION AND ISOLATION OF FETAL CELLS AND NUCLEIC ACID - The present invention provides methods, antibodies and kits useful for detecting the presence of a fetal cell and/or fetal nucleic acids in a biological sample obtained from a maternal host. It also provides methods and kits for isolating fetal nucleic acid from maternal cervical mucus samples, and for testing or screening the isolated fetal nucleic acid for genetic abnormalities in fetuses. | 09-23-2010 |
| 20100240055 | Method and System for Analyzing a Blood Sample - Methods, systems, and computer program products for the analysis of a blood sample are disclosed. One embodiment is a method of detecting and enumerating hard-to-ghost cells in a blood sample. Another embodiments is a method of analyzing reticulocytes in a blood sample. Methods of using blood count parameters are also provided. | 09-23-2010 |
| 20100240056 | Methods And Systems For Screening Species-Specific Insecticidal Candidates - Disclosed are methods and systems for identifying compounds that act to modulate insect growth and/or development in a species-specific manner. Such systems and methods may provide for the identification of species-specific insecticides. The methods and systems of the invention may include at least one an isolated nucleic acid molecule that encodes a polypeptide comprising an ecdysone receptor (EcR) isoform from a first distinct species and a second isolated nucleic acid molecule comprising a DNA sequence that encodes a polypeptide comprising at least a portion of an Ultraspiracle (USP) protein from a second distinct species. | 09-23-2010 |
| 20100240057 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC MYELOID LEUKEMIA AND ACUTE LYMPHOBLASTIC LEUKEMIA - Compositions and methods for the identification, prognosis, classification, treatment, and diagnosis of leukemia or a genetic predisposition to leukemia are provided. The present invention is based on the discovery of various genomic abnormalities of the IKZFl gene which are shown herein to be associated with acute lymphoblastic leukemia (ALL), more particularly, associated with BCR-ABL1 positive ALL and/or shown to be associated with chronic myeloid leukemia (CML), more particularly, associated with blast crisis chronic myeloid leukemia (BC-CML) and/or the likelihood of progression into blastic transformation of CML. These various genomic abnormalities of the IKZFl gene can further be used as prognostic markers to identify a subgroup of ALL having very poor outcomes. Such genomic abnormalities of IKZFl find use in methods and compositions useful in the identification and/or prognosis and/or predisposition and/or treatment of ALL, more particularly, BCR-ABL1 positive ALL and/or in the identification and/or prognosis and/or predisposition and/or treatment of CML, more particularly, of BC-CML and/or the likelihood of progression into blastic transformation of CML and/or as prognostic markers to identify a subgroup of ALL having very poor outcomes. | 09-23-2010 |
| 20100240058 | MicroRNA Antisense PNAs, Compositions Comprising the Same, and Methods for Using and Evaluating the Same - Disclosed are a microRNA antisense PNA capable of inhibiting the activity or function of microRNA, a composition for inhibiting the activity or function of microRNA containing the same, a method for inhibiting the activity or function of microRNA using the same, and a method for evaluating the effectiveness thereof. | 09-23-2010 |
| 20100240059 | MAIZE EVENT DP-098140-6 AND COMPOSITIONS AND MEHTODS FOR THE IDENTIFICATION AND/OR DETECTION THEREOF - Compositions and methods related to transgenic glyphosate/ALS inhibitor-tolerant maize plants are provided. Specifically, the present invention provides maize plants having a DP-098140-6 event which imparts tolerance to glyphosate and at least one ALS-inhibiting herbicide. The maize plant harboring the DP-098140-6 event at the recited chromosomal location comprises genomic/transgene junctions having at least the polynucleotide sequence of SEQ ID NO:5 and/or 6. The characterization of the genomic insertion site of the DP-098140-6 event provides for an enhanced breeding efficiency and enables the use of molecular markers to track the transgene insert in the breeding populations and progeny thereof. Various methods and compositions for the identification, detection, and use of the maize DP-098140-6 events are provided. | 09-23-2010 |
| 20100240060 | Detection and Diagnosis of Smoking Related Cancers - Gene probes for specific regions of chromosome 3 (3p21.3) and chromosome 10 (10q22) have been found to be tools for the diagnosis and prognosis of smoking related cancers such as non-small cell lung cancer (NSCLC). For example, these probes can be used with fluorescence in situ hybridization (FISH), and used to stratify smokers into high and low risk groups, as well as determine a patients susceptibility to the development of smoking related cancers. | 09-23-2010 |
| 20100240061 | Soybean Polymorphisms and Methods of Genotyping - Polymorphic soybean DNA loci useful for genotyping between at least two varieties of soybean. Sequences of the loci are useful for designing primers and probe oligonucleotides for detecting polymorphisms in soybean DNA. Polymorphisms are useful for genotyping applications in soybean. The polymorphic markers are useful to establish marker/trait associations, e.g. in linkage disequilibrium mapping and association studies, positional cloning and transgenic applications, marker-aided breeding and marker-assisted selection, and identity by descent studies. The polymorphic markers are also useful in mapping libraries of DNA clones, e.g. for soybean QTLs and genes linked to polymorphisms. | 09-23-2010 |
| 20100240062 | METHOD FOR PREPARING AND ANALYZING CELLS HAVING CHROMOSOMAL ABNORMALITIES - The present invention provides methods for preparing cells with highly condensed chromosomes, such as sperm, and methods for detecting and quantifying specific cellular target molecules in intact cells. Specifically, methods are provided for detecting chromosomes and chromosomal abnormalities, including aneuploidy, in intact cells using fluorescence in situ hybridization of cells in suspension, such as sperm cells. | 09-23-2010 |
| 20100240063 | SYSTEMS AND METHODS FOR DETECTING MULTIPLE OPTICAL SIGNALS - To minimize cross talk in systems and methods for detecting two or more different optical signals emitted from each of a plurality of reaction receptacles, an excitation signal associated with each of the optical signals has a known excitation frequency, and any detected signal having a frequency that is inconsistent with the excitation frequency is discarded. The receptacles are moved relative to optical sensors configured to detect each unique optical signal from an associated receptacle, and to further minimize cross talk, the optical sensors are arranged so that only one reaction receptacle at a time is in a signal detecting position with respect to one of its associated optical sensors, and the optical sensors are grouped by the optical signal they are configured to detect so that a first optical signal is detected from each of the reaction receptacles before a second optical signal is detected from the reaction receptacles. | 09-23-2010 |
| 20100240064 | DIFFERENTIAL ENZYMATIC FRAGMENTATION - The present invention provides methods for detecting the presence of methylation at a locus within a population of nucleic acids. | 09-23-2010 |
| 20100248218 | Conjugates, and use thereof in detection methods - The invention relates to methods for the quantitative and qualitative detection of an analyte in an assay as well as appropriate reagents therefor, especially a carrier molecule to which one or several analyte-specific binding partners are bound and which is provided with additional binding points for a specific binding partner X or Y that is associated with a component of a signal-forming system. Also disclosed is the use of such a conjugate particularly in homogeneous binding tests. | 09-30-2010 |
| 20100248219 | Compositions for use in identification of influenza viruses - The present invention provides oligonucleotide primers, compositions, and kits containing the same for rapid identification of viruses which are members of the influenza virus family by amplification of a segment of viral nucleic acid followed by molecular mass analysis. | 09-30-2010 |
| 20100248220 | Chlamydia Trachomatis Specific Oligonucleotide Sequences - The present invention relates to oligonucleotide sequences for amplification primers and detection probes and to their use in nucleic acid amplification methods for the selective and specific detection of | 09-30-2010 |
| 20100248221 | METHOD FOR IDENTIFICATION OF ORGANISM BY DNA TAG - The object is to provide a novel organism identification method which can be used as an alternative method to a conventional organism identification method which utilizes DNA and requires enormous labor. Developed is an organism identification method for determining whether or not an organism of interest is identical to a specific organism or a progeny thereof, which is characterized by introducing a DNA tag(s) in advance into a cell(s) of the specific organism, or a parasite or a symbiont with the specific organism, and determining whether or not the organism of interest is identical to the specific organism or a progenitor thereof based on the detection or non-detection of the DNA tag in DNA extracted from the organism of interest, or the parasite or the symbiont with the organism of interest. | 09-30-2010 |
| 20100248222 | METHOD OF FORMING SIGNAL PROBE-POLYMER - Provided are a method of forming a signal probe-polymer which makes it possible to form a polymer efficiently and quantitatively, a signal probe-polymer formed by the method, oligonucleotide probes for use in the method, and a method of detecting target analyte having high sensitivity and excellent quantitative capability. The method of forming a signal probe-polymer comprises reacting a plurality of pairs of oligonucleotide probes with each other to form a polymer, a first probe of the pair of oligonucleotide probes comprising three nucleic acid regions of X, Y, and Z regions, located in the stated order from the 5′-terminal and a second probe comprising three nucleic acid regions of X′, Y′, and Z′ regions, located in the stated order from the 5′-terminal, wherein each region of the oligonucleotide probes has a length of from 13 to 15 bases. | 09-30-2010 |
| 20100248223 | ASSESSING OUTCOMES FOR BREAST CANCER PATIENTS - This document provides methods and materials related to assessing the likely outcome for mammals (e.g., humans) with cancer (e.g., breast cancer). For example, methods and materials for using the ratio of HOXB13 polypeptide expression to IL-17BR polypeptide expression, CYP2D6 genotype, medication history, or combinations thereof to determine the likelihood of a breast cancer patient to experience breast cancer relapse or death are provided. | 09-30-2010 |
| 20100248224 | DNA FRAGMENTATION ASSAY - The present invention provides methods for the detection of agents that modify the formation of DNA fragmentation in cells. The disclosed methods are configured in an assay format amendable to high throughput screening applications. | 09-30-2010 |
| 20100248225 | GENE EXPRESSION PROFILING FOR IDENTIFICATION, MONITORING AND TREATMENT OF MELANOMA - A method is provided in various embodiments for determining a profile data set for a subject with skin cancer or a condition related to skin cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-6. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable. | 09-30-2010 |
| 20100248226 | METHODS FOR MEASURING CELL RESPONSE TO DNA DAMAGING AGENTS USING PROMYELOCYTIC LEUKEMIA PROTEIN NUCLEAR BODIES - Methods for assessing the potential efficacy of a DNA-damaging agent as a tumour treatment or for monitoring the efficacy of such treatment by determining promyelocytic leukemia protein nuclear body (PML NB) properties of the tumour are disclosed. PML NB properties, including morphology, number and biochemical composition, of cells or tissue are assessed following exposure to a DNA-damaging agent and compared to corresponding PML NB properties of cells or tissue not exposed to the DNA-damaging agent. The difference, or lack thereof, determines the efficacy of the DNA-damaging agent as a treatment for tumours or monitoring the efficacy of such treatment. | 09-30-2010 |
| 20100248227 | DRUG-PHOSPHORYLATING ENZYME - The objects of the present invention are: elucidation of an enzyme that phosphorylates in vivo a compound such as (2R)-2-amino-2-methyl-4-[5-(5-phenylpentanoyl)thiophen-2-yl]butan-1-ol and provision of a method of phosphorylating the aforementioned compound; provision of a method of screening for a substance phosphorylated by the aforementioned enzyme; provision of a method of determining the ability of a subject to phosphorylate a test compound. | 09-30-2010 |
| 20100248228 | Method for detecting DNA methylation in cancer cells - The present invention provides a detecting method of detecting malignant cells in a patient's specimen or a biological sample. Specifically, the inventive method includes the steps of extracting a genomic DNA, digesting said genomic DNA with one or multiple methylation sensitive restriction enzymes, and amplifying by PCR with one or multiple selected primers. The PCR can be performed in a conventional or a real-time platform. The inventive method can detect leukemia cells in 90% ALL patients at a sensitivity of up to 10 | 09-30-2010 |
| 20100248229 | INVITRO HUMAN EMBRYONIC MODEL AND A METHOD THEREOF - The present invention relates to the field of stem cells particularly development of a novel human embryonic model using human embryoid bodies obtained from the human embryonic stem cell. The novel human embryonic model disclosed thus can provide a screening assay for determining the toxic activity of the compound and/or drug. | 09-30-2010 |
| 20100248230 | NOVEL MEDICAL DIAGNOSTIC METHOD AND THERAPY IN THE CONTEXT OF INTERFREON-STIMULATED GENES THAT INDUCE DEPRESSION - The invention relates to a novel medical diagnostic method and treatment in conjunction with depression-inducing genes which are stimulated in particular by interferon. The invention relates in particular to the use of at least one nucleic acid molecule which induces depression and/or is associated with depression, in particular a gene and/or the DNA sequence thereof and/or the RNA sequence associated therewith, and/or a (poly)peptide encoded by the nucleic acid, for finding and/or providing a diagnostic method for detecting depression, or a medicament for the preventive and/or curative treatment of depression, and/or for determining the risk of developing depression, and/or for predicting the individual effects and/or side-effects of medicaments, in particular for treatment with interferon (for example, for the treatment of hepatitis). | 09-30-2010 |
| 20100248231 | HIGH SPECIFICITY AND HIGH SENSITIVITY DETECTION BASED ON STERIC HINDRANCE & ENZYME-RELATED SIGNAL AMPLIFICATION - The present invention relates to a molecular probe capable of high sensitivity and high specificity detection of target nucleic acid in a sample. Also disclosed is a detection method using this probe. | 09-30-2010 |
| 20100248232 | METHODS FOR DETERMINING THE PRESENCE OR ABSENCE OF ELITE EVENT MS-BN1 IN BRASSICA PLANT MATERIAL - This invention relates to transgenic winter oilseed rape (WOSR) plants, plant material and seeds, harboring a specific transformation event. It pertains to winter oilseed rape plants, more particularly to a pair of winter oilseed rape plants, which is particularly suited for the production of hybrid seed. More specifically, one plant is characterized by being male-sterile, due to the presence in its genome of a male sterility gene, while the other is characterized by carrying a fertility-restorer gene, capable of preventing the activity of the male-sterility gene. The invention further provides a method for producing hybrid seed, a process for producing a transgenic WOSR plant oil or plant, and a method to identify a transgenic plant, cell or tissue. A kit for identifying the transgenic plants comparing the elite event of the present invention is also described. The WOSR plants of the invention combine the ability to form hybrid seeds with optimal overall agronomic performance, genetic stability and adaptability to different generic backgrounds. | 09-30-2010 |
| 20100248233 | ACETYL-COA PRODUCING ENZYMES IN YEAST - The present invention relates to a method of identifying a heterologous polypeptide having enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA in (the cytosol of) a yeast cell comprising: a) providing a mutated yeast cell comprising a deletion of at least one gene of the (PDH) by-pass, selected from the genes encoding the enzymes pyruvate decarboxylase (PDC), acetaldehyde dehydrogenase (ALD), and acetyl-CoA synthetase (ACS); b) transforming said mutated yeast cell with an expression vector comprising a heterologous nucleotide sequence encoding a candidate polypeptide having potential enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA; c) testing said recombinant mutated yeast cell for its ability to grow on minimal medium containing glucose as sole carbon source, and d) identifying said candidate polypeptide as a heterologous polypeptide having enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA in (the cytosol of) said yeast cell when growth of said cell is observed. The invention further relates to a method of producing a fermentation production such as butanol. | 09-30-2010 |
| 20100248234 | CANCER DIAGNOSTIC KIT AND CANCER DIAGNOSTIC METHOD - The present invention provides a kit and method for diagnosing a cancer using a polynucleotide including a nucleotide sequence of SEQ ID No: 1 or 3 or a partial sequence thereof, a polypeptide consisting of an amino acid sequence of SEQ ID No: 2 or 4 or a partial sequence thereof, or an antibody binding specifically to a polypeptide consisting of an amino acid sequence of SEQ ID No: 2 or 4 or a partial sequence thereof. This makes it possible to find a CT antigen useful for testing, diagnosis, or treatment of a digestive system cancer and to develop a novel cancer diagnostic technique using the CT antigen. | 09-30-2010 |
| 20100248235 | BIOMARKERS FOR AUTISM SPECTRUM DISORDERS - Methods of determining the risk of ASD in an individual are provided which comprise identifying the presence of one or more genomic mutations in one or more of the genes, PTCHD1, SHANK3, NFIA, DPP6, DPP10, DYPD, GPR98, PQBP1, ZNF41 and FTSJ1. | 09-30-2010 |
| 20100248236 | Evaluating Genetic Disorders - The present invention relates to genetic analysis and evaluation utilizing copy-number variants or polymorphisms. The methods utilize array comparative genomic hybridization and PCR assays to identify the significance of copy number variations in a subject or subject group. | 09-30-2010 |
| 20100248237 | MINIATURIZED, HIGH-THROUGHPUT NUCLEIC ACID ANALYSIS - The present invention is directed to method for analyzing multiple nucleic acid molecules of interest comprising in the steps of (i) providing a plurality of beads, characterized in that each bead comprises at least two sequence specific amplification primers, further characterized in that at least one of the primers is bound to the bead via a cleavable linker, (ii) capturing the nucleic acid molecules of interest from a sample, (iii) clonally isolating the plurality of beads, (iv) cleaving the at least one primer, (v) clonally amplifying the nucleic acid thereby creating multiple amplification products, and (vi) analyzing the amplification products. | 09-30-2010 |
| 20100248238 | Detection Of Bacteria Belonging to the Genus Campylobacter By Targeting Cytolethal Distending Toxin - Multiplex PCR primers that can amplify the cdt genes of | 09-30-2010 |
| 20100248239 | METHODS AND MATERIALS FOR DETECTING FRAGILE X MUTATIONS - This document relates to methods and materials involved in detecting Fragile X mutations and assessing the methylation state of Fragile X alleles. For example, methods and materials for detecting Fragile X alleles using polymerase chain reaction and a hybridization probe (e.g., a non-radioactively labeled hybridization probe) are provided. | 09-30-2010 |
| 20100248240 | GENE AND PROTEIN RELATING TO HEPATOCELLULAR CARCINOMA AND METHODS OF USE THEREOF - The present invention provides a novel human gene ZNFN3A1 whose expression is markedly elevated in a great majority of HCCs compared to corresponding non-cancerous liver tissues. The gene encodes a protein having a zinc finger domain as well as a SET domain and has been found to form a regulatory complex with RNA helicase and RNA polymerase. | 09-30-2010 |
| 20100248241 | MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571 - The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS. | 09-30-2010 |
| 20100248242 | PROCESS FOR CONCENTRATING NUCLEIC ACID MOLECULES - A process concentrates nucleic acid molecules to be detected of a sample on a surface, with capture molecules that specifically bind the nucleic acid molecules. A support material has a capture probe that can specifically be linked to the nucleic acid molecules to be detected to give complexes. The support material and the nucleic acid molecules of the sample are incubated to form the complexes. The complexes are moved to the surface. At least one portion of the complexes becomes bound to the capture molecules via the capture probe. | 09-30-2010 |
| 20100248243 | METHOD AND ARRANGEMENT FOR CALIBRATING A SENSOR ELEMENT - A method is disclosed for calibrating a sensor element, which has an immobilized probe oligonucleotide, via which the bonding of a target nucleic acid (Z) can be detected by the sensor. In at least one embodiment, the method includes: a) bringing the sensor element into contact with a control nucleic acid (K), the melting temperature Tm(K) of which is less than the melting temperature Tm(Z) of the target nucleic acid (Z); b) hybridizing the control nucleic acid (K) to the probe oligonucleotide at a temperature T[p]Tm(K) and detecting a negative control signal at a temperature T[n]. According to a refinement of at least one embodiment of the invention, a measuring signal of the target nucleic acid (Z) is measured at a measuring temperature T [mess], where Tm(K)| 09-30-2010 | |
| 20100248244 | Characterization of ESM-1 as a Tumor Associated Marker of Colorectal Cancer - Disclosed herein is a colorectal cancer marker for diagnosing colorectal cancer based on ESM-I overexpression in tissues, cells or body fluids of colorectal cancer patients. Disclosed also is the use of the colorectal cancer marker in the development of therapeutic agents for cancer and in the diagnosis and treatment of colorectal cancer. | 09-30-2010 |
| 20100248245 | INTEGRATED APPARATUS FOR CONDUCTING AND MONITORING CHEMICAL REACTIONS - Apparatus for conducting and monitoring chemical reactions comprises a base and a thermal cycler mounted on the base. A plurality of heat-conducting receptacles are mounted on the thermal cycler and in heat-communication therewith. Each receptacle comprises an opaque body defining a bore having an open end, a first window, and a second window. A cartridge is removably mounted on the receptacles. The cartridge comprises a plurality of light-transmitting reaction vessels, and conduits connected to the reaction vessels for processing and transferring fluid. The reaction vessels are received in the bores of the receptacles through the open ends of the bores. A light emitter is mounted on the base for illuminating the reaction vessels through the first windows of the reaction vessels. A light detector is mounted on the base for selectively receiving and detecting light emitted from the reaction vessels through the second windows of the receptacles. | 09-30-2010 |
| 20100248246 | METHODS OF ENRICHING FOR AND IDENTIFYING POLYMORPHISMS - The invention encompasses methods for enriching for and identifying a polymorphism within a nucleic acid sample either by separating a subset of a nucleic acid sample or by selectively replicating a subset of a nucleic acid sample such that the polymorphism is contained within a nucleic acid population with reduced complexity, and then identifying the polymorphism within the enriched nucleic acid sample. Methods also are disclosed for enriching for and identifying a polymorphism by contacting a nucleic acid sample that includes a subset of nucleic acid molecules having a sequence that binds to a sequence-specific binding activity with a molecule having a sequence-specific binding activity under conditions which permit specific binding, such that the subset of nucleic acid molecules bound to the activity is enriched for nucleic acid molecules having the sequence recognized by the sequence-specific binding activity, and detecting a polymorphism with respect to a reference sequence in the subset of nucleic acid molecules. | 09-30-2010 |
| 20100248247 | BLOOD ANALYZER AND METHOD FOR DETERMINING EXISTENCE AND NONEXISTENCE OF LYMPHOBLASTS IN BLOOD SAMPLE - The invention provides a blood analyzer comprising a blood sample supply section, a sample preparation section for preparing an assay sample by mixing the blood sample with a nucleic acid-staining fluorescent dye, a light source for irradiating the assay sample, an optical detecting section for receiving fluorescence emitted from the irradiated assay sample and a controller for performing operations comprising detecting a cell group comprising lymphoblasts on the basis of the fluorescence received by the optical detecting section, and outputting an information on an appearance of the lymphoblasts in the blood sample, as well as a method for determining the existence and nonexistence of lymphoblasts in a blood sample. | 09-30-2010 |
| 20100248248 | Use of the Serological Assay of the Cytokine B-Lymphocyte Stimulator (Blys) as a Prognostic and Monitoring Test for Immune-Related Transfusion Reactions - The use for the serum quantification of the cytokine B-Lymphocyte Stimulator (BLyS) for the evaluation of the risk of immunization and transfusion reactions after blood transfusion, and for the monitoring of patients undergoing blood transfusion or re-transfusion in a patient that includes an initial step of taking a sample of blood from the patient, a step of analyzing the blood sample to determine the concentration of cytokine BLyS, a step of comparing the BLyS levels determined in the previous step and one or more reference values of concentration of cytokine BLyS, a step of identifying a significant deviation between the determined concentration of cytokine BLyS and the reference values of concentration of cytokine BLyS indicated in the previous step and a step of assigning a risk and/or therapeutic effectiveness with respect to the immune-mediated transfusion reactions mentioned above, based on the previous steps. | 09-30-2010 |
| 20100248249 | Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels - The present invention relates to a method for assessing the sensitivity of a patient's cancer to treatment with 10-propargyl-10-deazaminopterin and a method for selecting a patient for treatment of cancer with 10-propargyl-10-deazaminopterin, by determining the amount of a EGFR or other growth factor expressed by the cancer and comparing the amount with the amount of EGFR or other growth factor expressed by a reference cancer. | 09-30-2010 |
| 20100248250 | METHOD FOR PREPARING STOOL SAMPLE, SOLUTION FOR PREPARING STOOL SAMPLE, AND KIT FOR COLLECTING STOOL - Provided in the present invention are a method for preparing a stool sample without any need for complicated operations which is capable of efficiently recovering a nucleic acid or the like originating from mammalian cells, such as the cells exfoliated from the large intestine, in the stool; a solution for preparing a stool sample and a kit for stool collection which are used in the above method; and a method for recovering and analyzing the nucleic acid in stool using the stool sample prepared by the above method. More specifically, provided are a method for preparing a stool sample which is a method for preparing a stool sample in order to efficiently recover a nucleic acid from the stool sample, the method characterized in that the collected stool is mixed with a solution for preparing a stool sample which has a water-soluble organic solvent as an active ingredient; a solution for preparing a stool sample which is used in the method; a kit for collecting stool; a method for recovering a nucleic acid characterized by recovering a nucleic acid originating from indigenous enteric bacterium and a nucleic acid originating from an organism other than indigenous enteric bacterium at the same time from the stool sample prepared by the preparation method; and a method for analyzing a nucleic acid that analyzes the nucleic acid recovered by the method for recovering a nucleic acid. | 09-30-2010 |
| 20100248251 | Tissue Rejection - This document relates to methods and materials involved in detecting tissue rejection (e.g., organ rejection). For example, this document relates to methods and materials involved in the early detection of kidney tissue rejection. | 09-30-2010 |
| 20100248252 | METHODS FOR ANALYSIS OF MOLECULAR EVENTS - Methods and compositions are provided for detecting the presence of nucleic acid sequence variants in a subpopulation of nucleic acid molecules in a biological sample. These methods are particularly useful for identifying individuals with mutations indicative of cancer. | 09-30-2010 |
| 20100248253 | METHOD AND KIT FOR ASSESSING RISK OF GOUT AND HYPERURICEMIA - A method for assessing a risk of suffering from a gout of a subject is provided. The method includes steps of obtaining a nucleotide sample from the subject; determining a genetic polymorphism of one of a Urate transporter 1 (URAT1) gene and an alpha-kinase 1 (ALPK1) gene in the nucleotide sample, wherein the genetic polymorphism is associated with an occurrence of the gout; and comparing the genetic polymorphism with a predetermined genetic polymorphism so as to assess the risk of suffering from the gout of the subject. | 09-30-2010 |
| 20100248254 | ASSESSMENT AND REDUCTION OF RISK OF GRAFT-VERSUS-HOST DISEASE - Methods of assessing and reducing risk of graft versus host disease (GVHD) based on gene expression profiling are described, as well as methods of selecting a suitable transplant donor. Corresponding reagents and kits are also described. | 09-30-2010 |
| 20100255462 | FLUORESCENT MARKER FOR LIVING ORGANISM AND FLUORESCENT MARKING METHOD FOR THE SAME - A fluorescent marker comprising inorganic fluorescent nanoparticles having on a surface of the nanoparticles a modifying group containing a reactive portion, wherein the reactive portion is located at a most remote site of the modifying group from the surface of the nanoparticles; the reactive portion comprises at least one selected from the group consisting of bases consisting of DNA or RNA, nucleotides, polynucleotides and intercalators; and the reactive portion is capable of specifically binding to a living organism. | 10-07-2010 |
| 20100255463 | Compositions and methods for sequence determination - A sequencing methodology is disclosed that allows a single DNA or RNA molecule or portion thereof to be sequenced directly and in substantially real time. The methodology involves engineering a polymerase and/or dNTPs with atomic and/or molecular tags that have a detectable property that is monitored by a detection system. | 10-07-2010 |
| 20100255464 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis - Nucleotide triphosphate probes containing a molecular and/or atomic tag on a γ and/or β phosphate group and/or a base moiety having a detectable property are disclosed, and kits and method for using the tagged nucleotides in sequencing reactions and various assay. Also, phosphate and polyphosphate molecular fidelity altering agents are disclosed. | 10-07-2010 |
| 20100255465 | Nucleic Acid-Polymer Particle for and Method of Tracing Movement of a Liquid - A particle ( | 10-07-2010 |
| 20100255466 | Method for the in vitro diagnosis of bronchopulmonary carcinoma by detection of major alternative transcripts of the klk8 gene encoding kallicrein 8 and use thereof for prognosticating survival - The present invention relates to a method for the in vitro diagnosis of bronchopulmonary carcinoma, in particular of non-small cell bronchial carcinoma, characterized in that it comprises the stage of detecting, in a biological sample derived from a patient suspected to be suffering from said bronchopulmonary carcinoma, at least one of the major alternative transcripts of the KLK8 gene encoding kallikrein 8. This method is particularly useful for the survival prognostication of patients suffering from bronchopulmonary carcinoma. | 10-07-2010 |
| 20100255467 | ASSAYS FOR DETERMINING EXPOSURE TO MULTIWALLED CARBON NANOTUBES - Assays useful in determining exposure to multi-walled carbon nanotubes (MWCNTs) are provided. In one aspect, the MWCNT exposure assays operate by detecting a significant increase in the expression levels and/or status of certain cytokines shown to be responsive to MWCNT exposure. | 10-07-2010 |
| 20100255468 | METHOD OF ASSESSING GENE EXAMINATION DATA, PROGRAM THEREFOR AND APPARATUS OF THE SAME - The present invention provides a means of determining the presence or absence of chromosomal abnormalities with high reliability and high specificity in a gene examination in which a test sample is compared with a standard sample in terms of changes in quantitative ratios of alleles (particularly when test results are close to the threshold). | 10-07-2010 |
| 20100255469 | Cell monitoring and molecular analysis - The present invention provides a method for the real time analysis of cell cultures and their molecular content. More precisely, the present invention provides a method to monitor the cellular reaction of cells to certain stimuli in real time in order to figure out a reasonable point of time to perform an analysis of the molecular content of the cells. | 10-07-2010 |
| 20100255470 | Gene Expression Profiling for Identification, Monitoring and Treatment of Breast Cancer - A method is provided in various embodiments for determining a profile data set for a subject with breast cancer or conditions related to breast cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-5. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable. | 10-07-2010 |
| 20100255471 | Single cell gene expression for diagnosis, prognosis and identification of drug targets - Methods are provided for diagnosis and prognosis of disease by analyzing expression of a set of genes obtained from single cell analysis. Classification allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like. Single cell analysis also provides for the identification and development of therapies which target mutations and/or pathways in disease-state cells. | 10-07-2010 |
| 20100255472 | BIOMARKERS FOR PROSTATE CANCER - The instant invention provides methods and compositions for the detection of prostate cancer in a subject. | 10-07-2010 |
| 20100255473 | Assays - A device comprising a rigid substrate, a flexible cover element at least partially covering the substrate, a first structure formed in the substrate, adapted for accommodating liquids and adapted for releasing contents of one or more cells, spores, or viruses, the contents including the target molecules, a second structure formed in the substrate, adapted for accommodating liquids and comprising at least one binding member adapted for capturing the target molecules and for determining a value indicative for the presence and/or amount of the target molecules, a microfluidic network interconnecting at least the first structure and the second structure, and an actuator member adapted for effecting a fluid flow between the first structure and the second structure by pressing the flexible cover element against the substrate to selectively close a portion of the microfluidic network. | 10-07-2010 |
| 20100255474 | Method for Detecting Bacteria and Fungi - The present invention relates to methods and means for determining pathogenic fungi in a sample material, e.g. blood. In the method, the bacterial DNA is initially enriched from the total DNA of the sample material, and then the enriched DNA is amplified with specific primer pairs. Detection of the obtained amplicons allows the accurate identification of bacteria and fungi contained in the sample material and of their resistances. The methods and means of the invention allow an early diagnosis of inflammatory diseases, in particular involving non-detected infection (SIRS), and of infectious diseases such as sepsis, spontaneous bacterial peritonitis and endocarditis. | 10-07-2010 |
| 20100255475 | DIAGNOSTICS AND THERAPEUTICS FOR OSTEOPOROSIS - Diagnostics and therapeutics for osteoporosis, which are bases upon the identification of a subjects IL-1 haplotype and genotype pattern are described. | 10-07-2010 |
| 20100255476 | Composition For Increasing Microorganism Wall Permeability And Method For Detecting Said Microorganisms On A Membrane - The present invention relates to a composition for permeabilizing microorganism walls, comprising the combination of polyethyleneimine (PEI) with at least one alcohol, and also to a method using said composition for counting and detecting in a targeted manner the microorganisms on a membrane. The invention also relates to a kit and to probes that are suitable for carrying out said method. | 10-07-2010 |
| 20100255477 | METHODS AND COMPOSITIONS FOR ASSAYING A SAMPLE FOR AN AGGREGANT - This invention relates to an aggregation sensor useful for the detection and analysis of aggregants in a sample, and methods, articles and compositions relating to such a sensor. The sensor comprises first and second optically active units, where energy may be transferred from an excited state of the first optically active unit to the second optically active unit. The second optically active unit is present in a lesser amount, but its relative concentration is increased upon aggregation, increasing its absorption of energy from the first optically active units. This increase in energy transfer can be detected in variety of formats to produce an aggregation sensing system for various aggregants, including for quantitation. Other variations of the inventions are described further herein. | 10-07-2010 |
| 20100255478 | TARGETS FOR USE IN DIAGNOSIS, PROGNOSIS AND THERAPY OF CANCER - The invention is directed to a method of diagnosing cancer, or susceptibility to cancer, in an individual in need thereof comprising detecting homozygosity at one or more loci of the individual's nucleic acid, wherein the one or more loci is selected from the group consisting of: D2S1790, D3S2427, D4S2394, D5S2505, D6S1959, D7S3046, D9S1871, D10S1222, D11S1993, D11S1986, D11S4463, D13S793, D15S822, GATA178F11, D18S1376, and D20S477, and homozygosity at the one or more loci is indicative of a diagnosis of cancer, or susceptibility to cancer, in the individual. Also provided herein are kits for use in diagnosing cancer or susceptibility to cancer in an individual comprising one or more regents for detecting the presence of a homozygosity at one or more loci selected from the group consisting of: D2S1790, D3S2427, D4S2394, D5S2505, D6S1959, D7S3046, D9S1871, D10S1222, D11S1993, D11S1986, D11S4463, D13S793, D15S822, GATA178F11, D18S1376, and D20S477 and instructions for use. | 10-07-2010 |
| 20100255479 | DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS - The present invention provides a device for isolating target biomolecules or cells from samples, particularly biological samples. In particular, the device comprises a loading mixture, which contains the biological sample and a first binding entity that specifically binds to the target biomolecule or target cell; and a micro-channel coated with a second binding entity that binds directly or indirectly to the first binding entity. Methods of capturing, detecting, and/or evaluating target biomolecules or target cells (e.g. cancer cells) in biological samples are also disclosed. | 10-07-2010 |
| 20100255480 | COMPOSITION FOR ANALYZING NUCLEIC ACID - The present invention provides a firefly luciferase for inexpensive, highly accurate and highly sensitive nucleic acid analysis that uses dATP instead of an expensive reagent having low reactivity to DNA polymerase in the manner of dATPαS, a method of analyzing nucleic acid that uses that luciferase, and a kit for analyzing nucleic acid thereof. | 10-07-2010 |
| 20100255481 | METHOD FOR DETECTION OF ADENOMA OR CANCER BY GENETIC ANALYSIS - Disclosed is a method which enables an early stage detection of an adenoma or cancer by gene expression analysis of a biomarker in a readily collectable sample. Specifically disclosed is a method for detecting an adenoma or cancer, which comprises the steps of: measuring the quantity of a sequence constituting at least one housekeeping gene or an expression product thereof contained in a body fluid sample or an excrement sample collected from an examinee; and calculating the concentration of the sequence in the sample. | 10-07-2010 |
| 20100255482 | Hepatitis B Virus (HBV) Specific Oligonucleotide Sequences - The present invention relates to oligonucleotide sequences for amplification primers and detection probes and to their use in nucleic acid amplification methods for the detection of HBV in biological samples. In particular, oligonucleotide sequences are provided for the sensitive qualitative or quantitative detection of all eight HBV genotypes. The invention also provides oligonucleotide primer sets and primer/probe sets in the form of kits for the diagnosis of HBV infection. | 10-07-2010 |
| 20100255483 | LIQUID-FEEDING CHIP AND ANALYSIS METHOD - A liquid-feeding chip for feeding a liquid utilizing the action of centrifugal force and gravity by rotating the chip around an axis of rotation, includes a first storage tank ( | 10-07-2010 |
| 20100255484 | SAMPLE PREPARATION CONTAINER AND METHOD - A system and method for preparing and collecting samples for analyte testing. The system can include a sample preparation system and a sample collection system coupled to the sample preparation system. The sample preparation system can include at least one of a deformable self-supporting receptacle comprising a reservoir and a freestanding receptacle comprising a reservoir. The reservoir can be adapted to contain a liquid composition. The sample collection system can be positioned in fluid communication with a reservoir of the sample preparation system, and can be adapted to capture an analyte of interest. The method can include providing a fluid path defined at least partially by the sample preparation system and the sample collection system, positioning the liquid composition in a reservoir of the sample preparation system, and moving at least a portion of the liquid composition in the fluid path to the sample collection system. | 10-07-2010 |
| 20100255485 | BIOMARKERS FOR THE ONSET OF NEURODEGENERATIVE DISEASES - The present invention provides a method of predicting the imminent degeneration of motoneurons in a subject, said method comprising assessing in at least one motoneuron of said subject the expression of at least one particular gene, wherein an at least two-fold upregulation of the expression of the assessed genes is indicative of the imminent degeneration of motoneurons and/or of the imminent onset of a neurodegenerative disease. Kits therefor are also provided. | 10-07-2010 |
| 20100255486 | METHOD FOR DIAGNOSING LUNG CANCERS USING GENE EXPRESSION PROFILES IN PERIPHERAL BLOOD MONONUCLEAR CELLS - Methods and compositions are provided for diagnosing lung cancer in a mammalian subject by use of three or more selected genes, e.g., a gene expression profile, from the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of disease, a stage of the disease, or enables prognosis of recurrence of disease. The gene expression profile includes three or more genes of Table I, Table II, Table III, Table IV, Table V, Table VI or Table VII herein. Detection of changes in expression in the selected genes forming the gene expression profile from that of a reference gene expression profile are correlated with non-small cell lung cancer (NSCLC). One composition for use in such diagnosis includes three or more PCR primer-probe sets, wherein each primer-probe set amplifies a different polynucleotide sequence from the gene expression profile. Another composition for similar use contains a plurality of polynucleotides immobilized on a substrate, which probes hybridize to three or more gene expression products from genes in the gene expression profile. Still another composition involves detection of the protein expression products of genes from the gene expression profile. | 10-07-2010 |
| 20100255487 | METHODS AND APPARATUS FOR SINGLE MOLECULE SEQUENCING USING ENERGY TRANSFER DETECTION - Provided herein are systems and methods for nucleotide incorporation reactions. The systems comprise polymerases having altered nucleotide incorporation kinetics and are linked to an energy transfer donor moiety, and nucleotide molecules linked with at least one energy transfer acceptor moiety. The donor and acceptor moieties undergo energy transfer when the polymerase and nucleotide are proximal to each other during nucleotide binding and/or nucleotide incorporation. As the donor and acceptor moieties undergo energy transfer, they generate an energy transfer signal which can be associated with nucleotide binding or incorporation. Detecting a time sequence of the generated signals, or the change in the signals, can be used to determine the order of the incorporated nucleotides, and can therefore be used to deduce the sequence of the target molecule. | 10-07-2010 |
| 20100255488 | FRET-LABELED COMPOUNDS AND USES THEREFOR - FRET-labeled compounds are provided for use in analytical reactions. In certain embodiments, FRET-labeled nucleotide analogs are used in place of naturally occurring nucleoside triphosphates or other analogs in analytical reactions comprising nucleic acids, for example, template-directed nucleic acid synthesis, DNA sequencing, RNA sequencing, single-base identification, hybridization, binding assays, and other analytical reactions. | 10-07-2010 |
| 20100255489 | Systems for genome selection - Systems, methods, compositions and apparatus relating to genome selection are disclosed. | 10-07-2010 |
| 20100255490 | METHODS, COMPOSITIONS AND KITS FOR DETECTION AND ANALYSIS OF ANTIBIOTIC-RESISTANT BACTERIA - The present invention relates generally to detection of antibiotic-resistant bacteria in a sample. In particular, the invention provides methods, compositions and kits for detecting and analyzing methicillin-resistant | 10-07-2010 |
| 20100255491 | MAMMALIAN SELENOPROTEIN DIFFERENTIALLY EXPRESSED IN TUMOR CELLS - A 15 kDa selenium-containing protein (“selenoprotein”) is disclosed. The protein is shown to be differentially expressed in cancer cells, such as prostate cancer cells. There is a correlation between the presence of a polymorphism at nucleotide positions 811 and 1125 of the 15 kDa selenoprotein gene, and the presence of cancer. This polymorphism is more prevalent in the African American population. The determination of an individual's genotype may be used as an indicator of the need for dietary selenium supplementation to inhibit tumor development. Compositions including the isolated protein, specific binding agents that recognize the protein, as well as underlying nucleic acid sequences are presented, as are methods of using such compositions. | 10-07-2010 |
| 20100255492 | Non-Invasive Fetal Genetic Screening by Digital Analysis - The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital PCR is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents. | 10-07-2010 |
| 20100255493 | Non-Invasive Fetal Genetic Screening by Digital Analysis - The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital PCR is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents. | 10-07-2010 |
| 20100255494 | METHODS FOR PREDICTING THE RISK OF DIABETIC NEPHROPATHY USING GENETIC MARKERS AND ARRAYS CONTAINING THE SAME - A method for detecting a Chinese diabetic subject suffering from, at risk for developing, or suspected of suffering from a nephropathy. The method includes determining whether a sample from the subject has at least one of the following polymorphic sequences: an I/D genotype of an ACE gene, an M235T genotype of an AGT gene, a (CA)n-5′(z−2) genotype of an ALR2 gene, an C106T genotype of an ALR2 gene in the promoter region, a G-308A genotype of a TNF-α gene, or a complement thereof, provided that the ALR2 gene cannot be used alone, in which the presence of the polymorphic sequence indicates the subject suffering from, at risk for suffering from a nephropathy. An array for detecting a Chinese diabetic subject suffering from, or at risk for suffering from, a nephropathy. | 10-07-2010 |
| 20100255495 | METHODS FOR PREDICTING THE RISK OF DIABETIC NEPHROPATHY USING GENETIC MARKERS AND ARRAYS CONTAINING THE SAME - A method for detecting a Chinese diabetic subject suffering from, at risk for developing, or suspected of suffering from a nephropathy. The method includes determining whether a sample from the subject has at least one of the following polymorphic sequences: an I/D genotype of an ACE gene, an M235T genotype of an AGT gene, a (CA)n-5′(z−2) genotype of an ALR2 gene, an C106T genotype of an ALR2 gene in the promoter region, a G-308A genotype of a TNF-α gene, or a complement thereof, provided that the ALR2 gene cannot be used alone, in which the presence of the polymorphic sequence indicates the subject suffering from, at risk for suffering from a nephropathy. An array for detecting a Chinese diabetic subject suffering from, or at risk for suffering from, a nephropathy. | 10-07-2010 |
| 20100261158 | Method and System for Multiplex Genetic Analysis - The present disclosure provides apparatus, systems and method for detecting separately and substantially simultaneously light emissions from a plurality of localized light-emitting analytes. A system according to exemplary embodiments of the present disclosure comprises a sample holder having structures formed thereon for spatially separating and constraining a plurality of light-emitting analytes each having a single nucleic acid molecule or a single nucleic acid polymerizing enzyme, a light source configured to illuminate the sample holder, an optical assembly configured to collect and detect separately and substantially simultaneously light emissions associated with the plurality of light emitting analytes. The system may further include a computer system configured to analyze the light emissions to determine the structures or properties of a target nucleic acid molecule associated with each analyte. | 10-14-2010 |
| 20100261159 | Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof - The invention features methods of making devices, or “platens”, having a high-density array of through-holes, as well as methods of cleaning and refurbishing the surfaces of the platens. The invention further features methods of making high-density arrays of chemical, biochemical, and biological compounds, having many advantages over conventional, lower-density arrays. The invention includes methods by which many physical, chemical or biological transformations can be implemented in serial or in parallel within each addressable through-hole of the devices. Additionally, the invention includes methods of analyzing the contents of the array, including assaying of physical properties of the samples. | 10-14-2010 |
| 20100261160 | Methods of screening for modulators of cell proliferation and methods of diagnosing cell proliferation states - Described herein are methods that can be used for diagnosis and prognosis of cellular proliferation. Also described herein are methods that can be used to screen candidate bioactive agents for the ability to modulate cellular proliferation. Additionally, methods and molecular targets (genes and their products) for therapeutic intervention in cancers are described. | 10-14-2010 |
| 20100261161 | Method for determining the specific growth rate of a distinct cell population within a non-homogeneous system - The present invention provides a method for measuring the specific rate of ribosome synthesis for a distinct cell population, such as a distinct microbial population. For an actively growing (or non-growing) culture, the specific rate of ribosome synthesis is identical to the specific growth rate of the culture. With the method of the invention, researchers will be able to measure the specific growth rate of distinct cell populations in mixed cultures, such as biological reactor systems or environmental samples. In addition, the method of the invention provides the ability to identify members of a distinct cell population that are rapidly growing. | 10-14-2010 |
| 20100261162 | Methods of assaying for telomerase activity and compositions related to same - The present invention relates generally to the field of diagnostic and prognostic assays such as diagnostic assays for conditions associated with telomerase activity. More particularly, the present invention provides an assay for measuring telomerase activity as an indicator of cancer, an inflammatory disorder and/or a condition involving embryogenesis and/or requiring stem cell proliferation and agents and kits useful for same. Automated and partially automated assays permitting high throughput screening also form part of the present invention. The subject invention further contemplates methods of treatment using agents identified by the subject assay or where treatment protocols are monitored by the assay. | 10-14-2010 |
| 20100261163 | Method for simultaneous detection of Mycobacterium tuberculosis complex and identification of mutations in mycobacterial DNA resulting in the resistance of microorganisms to rifampicin and isoniazid on biological microarrays, set of primers, biochip, and set of oligonucleotide probes used in the method - The present invention relates to molecular biology, microbiology, and medicine and provides the method for detection of | 10-14-2010 |
| 20100261164 | Diagnostic detection of nucleic acids - This invention provides sensitive nucleic acid hybridization assay methods for the detection of target animal nucleic acids in a biological sample, such as acellular fluids. The methods are particularly useful in early diagnosis of animal diseases, particularly chronic illnesses. | 10-14-2010 |
| 20100261165 | Methods, Compositions and Kits for Use in Prognosis, Characterization and Treatment of Cancer - The present invention provides methods, compositions and kits for the prognosis, characterization and treatment of cancers. The methods, compositions and kits of the invention comprise a set of markers whose expression is correlated with estrogen receptor beta function. Therefore, the methods, compositions and kits of the invention find particular use in endocrine-related cancers such as breast cancers. | 10-14-2010 |
| 20100261166 | METHOD FOR SPECIFICALLY AND SENSITIVELY AMPLIFYING A TARGET SEQUENCE - The present invention aims to develop a method for amplifying only a target gene while reducing the noise from a non-target gene having a similar sequence, as well as to develop a new method of quantitation based on acquisition of the signal from the amplified sequence with high precision (in high sensitivity and specificity). | 10-14-2010 |
| 20100261167 | In vivo screen using chemical inducers of dimerization - A method for identifying a molecule that binds a known target in a cell from a pool of candidate molecules, comprising: (a) covalently bonding each molecule in the pool of candidate molecules to a methotrexate moiety to form a screening molecule; (b) introducing the screening molecule into a cell which expresses a first fusion-protein comprising a binding domain capable of binding methotrexate, a second fusion protein comprising the known target, and a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein; (c) permitting the screening molecule to bind to the first fusion protein and to the second fusion protein so as to activate the expression of the reporter gene; (d) selecting which cell expresses the reporter gene; and (e) identifying the small molecule that binds the known target. | 10-14-2010 |
| 20100261168 | Screening for Environmental DNAs Encoding Enzymes for Synthesizing Terpenoid-Based Therapeutic Compounds Using Genetically Modified E. Coli Strains - A screening method for identifying microbial genes involved in biosynthesis of therapeutic terpenoid-based compounds using genetically modified | 10-14-2010 |
| 20100261169 | NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND METHODS OF USE THEREOF FOR DIAGNOSIS - The present invention relates to diagnostic markers comprising novel splice variants of known proteins and polynucleotides encoding same, useful in the qualitative and/or quantitative detection of various diseases and/or pathological conditions in a subject, and to the use of known proteins and polynucleotides encoding same for diagnosis. Particularly, the invention relates to the diagnosis of a disease in a sample of body fluid or secretion obtained from the subject, and to the diagnosis of cancer. | 10-14-2010 |
| 20100261170 | SCREENING METHODS AND SEQUENCES RELATING THERETO - Disclosed are screening methods and sequences related thereto. Disclosed are methods for detecting mutations in the MYH gene of an individual. Also disclosed are methods of genotyping and methods of predicting for an individual the likelihood of developing certain cancers, such as colorectal cancer. | 10-14-2010 |
| 20100261171 | NUCLEIC ACID SEQUENCES FOR BIOSYNTHESIS OF NON-MCCJ25-RELATED LARIAT PEPTIDES - A nucleic acid sequence is provided, encoding at least one of a precursor of a lariat peptide, a processing factor of a lariat peptide, and an export factor of a lariat peptide, wherein the lariat peptide is a non-MccJ25 lariat peptide according to general structural formula (I) Also provided are biosynthesis systems useful for the synthesis of peptides according to formula (I), and methods of detecting and identifying nucleic acid sequences encoding the disclosed proteins. | 10-14-2010 |
| 20100261172 | INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS - The present invention encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders. | 10-14-2010 |
| 20100261173 | Identification Of Fat And Lean Phenotypes In Chickens Using Molecular Markers - The present invention provides methods of screening chickens to determine those more likely to have a lean or fat phenotype. The invention also provides methods of screening chickens to identify a polymorphism associated with a fat or lean phenotype. | 10-14-2010 |
| 20100261174 | Determination of 5-ASA efficacy in CRC prevention and/or treatment by gene expression analysis - A method is disclosed for the determination of 5-ASA efficacy in preventing and/or treating CRC in a mammalian, which comprises the analysis of the inhibition of the β-catenin pathway in presence of 5-ASA. More in details, the method comprises measuring the expression of at least one gene involved in the regulation of the β-catenin signalling pathway, such as μ-protocadherin, E-cadherin, β-catenin, Axin1, ICAT, p21 | 10-14-2010 |
| 20100261175 | USE OF SHORT OLIGONUCLEOTIDES FOR REAGENT REDUNDANCY EXPERIMENTS IN RNA FUNCTIONAL ANALYSIS - The present invention relates to functional analysis of miRNAs or other short non-coding RNAs involving the use of two or more sequence distinct miRNAs antagonising oligomeric compounds, which enables the reagent redundancy experiments to reduce the risk of reporting false positive effects of miRNA/ncRNA antagonists. | 10-14-2010 |
| 20100261176 | Methods of Tissue-Based Diagnosis - The current invention provides methods, as well as compositions useful in such methods, involving application of energy to a tissue of interest to generate a liquefied sample comprising tissue constituents so as to provide for rapid tissue sampling, as well as qualitative and/or quantitative detection of analytes that may be part of tissue constituents (e.g., several types of biomolecules, drugs, and microbes). Determination of tissue composition can be used in a variety of applications, including diagnosis or prognosis of local as well as systemic diseases, evaluating bioavailability of therapeutics in different tissues following drug administration, forensic detection of drugs-of-abuse, evaluating changes in the tissue microenvironment following exposure to a harmful agent, and various other applications. | 10-14-2010 |
| 20100261177 | INCREASING SPECIFICITY IN A scFV SCREEN USING DUAL BAIT REPORTERS - To increase the efficiency of the selection of antibodies of desired specificity, we create multi-bait strain(s) in which one bait is the target and one or more bait(s) are non-target. The non-target bait(s) may use one or more DNA-binding domain(s) that differ(s) from that of the target bait and thereby activate one or more different reporters from that activated by the target bait. Library hits that activate both sets of reporters are presumed to be inadequately specific and can be eliminated from further consideration. Alternatively, a non-target bait may be replaced with a second target bait, and hits selected that activate both sets of reporters. Other combinations of elements can be used. | 10-14-2010 |
| 20100261178 | High Throughput Assays for Inhibitors and Activators of PAQR Receptors - The subject invention provides methods of screening compounds or ligands that interact with human and/or non-human PAQR receptors or fungal osmotin receptors. These methods utilize a colorimetric assay to ascertain whether a compound binds to and activates a PAQR receptor or the osmotin receptor. | 10-14-2010 |
| 20100261179 | SAMPLE PREPARATION DEVICES AND ANALYZERS - The application provides sample preparation devices and analyses. The devices and analyzes allow for the rapid preparation and analysis of samples using a variety of techniques, including PCR, by even unskilled users. | 10-14-2010 |
| 20100261180 | RECOMBINANT PERFORIN, EXPRESSION AND USES THEREOF - The present invention relates to retroviral vectors capable of driving the expression of perforin in a cell and a method of expressing recombinant perforin in a cell. The present invention also relates to recombinant perforin polypeptides and nucleic acid molecules derived therefrom and uses thereof. Also encompassed are screening assays employing such recombinant perforin molecules, compounds identified by the screening assays and uses thereof. | 10-14-2010 |
| 20100261181 | LABELING AND DETECTION OF NUCLEIC ACIDS - Provided in certain embodiments are new methods for forming azido modified nucleic acid conjugates of reporter molecules, carrier molecules or solid support. In other embodiments are provided methods for enzymatically labeling nucleic acids with an azide group. | 10-14-2010 |
| 20100261182 | PPM1E PROTEINS AND NUCLEIC ACIDS AS TARGETS FOR NEURODEGENERATIVE DISEASES | 10-14-2010 |
| 20100261183 | METHOD OF DETERMINING RISK FOR CANCER - A method of determining risk of cancer in a mammal is provided. The method includes analyzing the genomic DNA of the mammal and determining genomic CNV frequency or genomic structural variation. An increase in either CNV frequency or genomic structural variation in comparison to a baseline mean value is indicative of cancer. | 10-14-2010 |
| 20100261184 | Micro-Chamber Plate, Manufacturing Method Thereof - The present invention relates to a micro-chamber plate and a manufacturing method of the same, more precisely a micro-chamber plate facilitating real-time measurement and analysis of fluorescence obtained from the reaction of multiple reaction solutions containing primers or probes selectively binding to each corresponding gene without cross-contamination in order to analyze biological samples containing numbers of genes and a manufacturing method of the same. | 10-14-2010 |
| 20100261185 | LABELED ENZYME COMPOSITIONS, METHODS AND SYSTEMS - Disclosed herein are conjugates comprising a biomolecule linked to a label that have biological activity and are useful in a wide variety of biological applications. For example, provided herein are labeled polymerase conjugates including a polymerase linked to one or more labels, wherein the conjugate has polymerase activity. Such conjugates can exhibit enhanced biological activity and/or superior detectability as compared to conventional labeled polymerases. Also disclosed herein are improved methods for preparing such conjugates, and methods and systems for using such conjugates in biological applications such as nucleotide incorporation, primer extension and single molecule sequencing. | 10-14-2010 |
| 20100261186 | POLYMORPHISM IDENTIFICATION METHOD - The present invention is to provide a method for identifying a polymorphism with high sensitivity and high accuracy. The method of the present invention includes: performing a nucleic acid chain extension reaction and identifying the polymorphism of the nucleic acid contained in a test nucleic acid sample. The extension reaction is conducted with use of: a nucleic acid in a test nucleic acid sample as a template, a type I detection primer which hybridizes with a region including the polymorphic site of a nucleic acid whose polymorphic site nucleotide sequence consists of a first nucleotide sequence, and a polymerase having no strand displacement activity. The reaction is conducted with the presence of an inhibitory oligonucleotide which contains a nucleotide sequence complementary to the sequence of a region including the polymorphic site of a nucleic acid whose polymorphic site nucleotide sequence consisting of a second nucleotide sequence. | 10-14-2010 |
| 20100261187 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual having a cardiovascular disorder to treatment of the disorder with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 10-14-2010 |
| 20100261188 | NON-INVASIVE PRENATAL GENETIC SCREEN - The present invention provides methods and kits useful for genetic testing or screening of fetuses using nucleic acid samples isolated from cervical mucus samples of fetus hosts. | 10-14-2010 |
| 20100261189 | System and method for detection of HLA Variants - A method for detecting one or more HLA sequence types is described that comprises the steps of: amplifying a plurality of first amplicons from a double stranded nucleic acid sample, wherein the first amplicons are amplified with a plurality of pairs of nucleic acid primers that define exons 2 and 3 of both strands of HLA loci from the group consisting of HLA-A, HLA-B, and HLA-C; amplifying the first amplicons to produce a plurality of populations of second amplicons, wherein each population of second amplicons is clonally amplified from one of the first amplicons; sequencing the plurality of populations of second amplicons to generate a nucleic acid sequence composition for each of the plurality of second amplicons; and detecting variation in the sequence composition from one or more of the second amplicons for one or more of the HLA loci. | 10-14-2010 |
| 20100261190 | Mammalian Genes; Related Reagents and Methods - Purified genes encoding proteins from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided. | 10-14-2010 |
| 20100261191 | STABLE CELL LINES EXPRESSING HERG - A stable eukaryotic cell line that expresses hERG and exhibits a stable current under electrophysiological test conditions is provided. | 10-14-2010 |
| 20100261192 | CLONING OF CYTOCHROME P450 GENES FROM NICOTIANA - The present invention relates to p450 enzymes and nucleic acid sequences encoding p450 enzymes in | 10-14-2010 |
| 20100261193 | Valve Structure for Consistent Valve Operation of a Miniaturized Fluid Delivery and Analysis System - A valve structure of a fluid delivery and analysis system having an upper substrate, a lower substrate and an intermediate layer with at least one opening and at least one open cavity having a first touch point between the upper substrate and the intermediate layer and a second touch point between the lower substrate and the intermediate layer where the first touch point and the second touch point are offset to create a torque so that when intermediate layer is compressed between the upper substrate and the lower substrate that the torque deforms the intermediate rubber layer in the direction of the opening for better sealing. | 10-14-2010 |
| 20100267011 | Method and apparatus for detecting nucleic acids using bead and nanopore - There are provided a method and apparatus for detecting nucleic acid using bead and nanopore, and more specifically, a method and apparatus capable of detecting nucleic acid fragments of 70 bps to 300 bps in length by a nanopore detection unit with nanopores of 20 to 120 nm in diameter by attaching a bead to a nucleic acid probe and then detecting the bead attached to nucleic acid not nucleic acid itself. Accordingly, the present invention can detect the nucleic acid fragments using the nanopore detection unit with nanopores of 20 to 120 nm in diameter, even in case where Polymerase Chain Reaction (PCR) products are given as the sample, particularly the PCR products are the nucleic acid fragments of 70 to 300 bps in length. | 10-21-2010 |
| 20100267012 | Highly conserved genes and their use to generate probes and primers for detection of microorganisms - Compositions and methods for the detection of vancomycin-resistant pathogens using primers and/or probes to the vanA and vanB genes. | 10-21-2010 |
| 20100267013 | METHODS TO INCREASE NUCLEOTIDE SIGNALS BY RAMAN SCATTERING - The methods and apparatus disclosed herein concern nucleic acid sequencing by enhanced Raman spectroscopy. In certain embodiments of the invention, nucleotides are covalently attached to Raman labels before incorporation into a nucleic acid. In other embodiments, unlabeled nucleic acids are used. Exonuclease treatment of the nucleic acid results in the release of labeled or unlabeled nucleotides that are detected by Raman spectroscopy. In alternative embodiments of the invention, nucleotides released from a nucleic acid by exonuclease treatment are covalently cross-linked to nanoparticles and detected by surface enhanced Raman spectroscopy (SERS), surface enhanced resonance Raman spectroscopy (SERRS) and/or coherent anti-Stokes Raman spectroscopy (CARS). Other embodiments of the invention concern apparatus for nucleic acid sequencing. | 10-21-2010 |
| 20100267014 | Method for Prognosis of a Response to a Treatment - The present invention concerns an in vitro method for determining, from a biological sample, the response to a patient suffering from rheumatoid arthritis to a treatment directed against a cytokine involved in the inflammatory process of the disease, characterized in that it consists in measuring the expression of the gene encoding synoviolin. | 10-21-2010 |
| 20100267015 | NUCLEIC ACID DETECTION - The invention provides methods for the detection of the amount of a nucleic acid in a sample. The described methods exploit the ability to disrupt and redirect a PCR direction, and the ability to physically pair nucleic acid molecules in a sample that have a reference sequence with nucleic acid molecules in the sample that have a target sequence. The redirection of the PCR reaction enables partial amplification as a preparatory step to other techniques within the same tube. The pairing can result in the presence of unpaired target or reference sequence indicating a difference in the amount of the target sequence versus the reference sequence. The methods are broadly applicable for the determination of differences in the amount of nucleic acids in diagnostic and research applications. | 10-21-2010 |
| 20100267016 | TRANSGENIC MICROBIAL POLYHYDROXYALKANOATE PRODUCERS - Transgenic microbial strains are provided which contain the genes required for PHA formation integrated on the chromosome. The strains are advantageous in PHA production processes, because (1) no plasmids need to be maintained, generally obviating the required use of antibiotics or other stabilizing pressures, and (2) no plasmid loss occurs, thereby stabilizing the number of gene copies per cell throughout the fermentation process, resulting in homogeneous PHA product formation throughout the production process. Genes are integrated using standard techniques, preferably transposon mutagenesis. In a preferred embodiment wherein multiple genes are incorporated, these are incorporated as an operon. Sequences are used to stabilize mRNA, to induce expression as a function of culture conditions (such as phosphate concentration), temperature, and stress, and to aid in selection, through the incorporation of selection markers such as markers conferring antibiotic resistance. | 10-21-2010 |
| 20100267017 | MONITORING REAL-TIME PCR WITH LABEL FREE INTRINSIC IMAGING - The invention provides a method for the detection of nucleic acid the method comprising carrying out a PCR reaction in a microfluidic device wherein the sample shuttles within the microfluidic channel and the amount of nucleic acid is determined based on the UV absorption of the nucleic acid. | 10-21-2010 |
| 20100267018 | OLIGONUCLEOTIDE ANALOGUES - The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications. | 10-21-2010 |
| 20100267019 | Identification And Use Of Genes Encoding Amatoxin And Phallotoxin - The present invention relates to compositions and methods comprising genes and peptides associated with cyclic peptide toxins and toxin production in mushrooms. In particular, the present invention relates to using genes and proteins from | 10-21-2010 |
| 20100267020 | GENETIC RISK FACTOR FOR NEURODEGENERATIVE DISEASE - The present invention relates to single base polymorphisms in the glycogen synthase kinase 3 beta and risk for developing neurodegenerative disease. | 10-21-2010 |
| 20100267021 | METHODS FOR DETERMINING CYTOSINE METHYLATION IN DNA AND USES THEREOF - Methods are described for determining the pattern of cytosine methylation in a DNA specimen, where the methods involve comparing the amount of DNA fragments generated by a methylation-sensitive restriction enzyme with the amount of DNA fragments generated by a methylation-insensitive isoschizomer of the methylation-sensitive restriction enzyme. | 10-21-2010 |
| 20100267022 | MONOCYTE-DERIVED NUCLEIC ACIDS AND RELATED COMPOSITIONS AND METHODS - Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also provided. | 10-21-2010 |
| 20100267023 | SELECTIVE RESTRICTION FRAGMENT AMPLIFICATION: FINGERPRINTING - The invention relates to a process for the controlled amplification of at least one part of a starting DNA containing a plurality of restriction sites for a determined specific restriction endonuclease, and of which at least part of its nucleic acid is unknown. Application of this process to human, animal or plant DNA fingerprinting, to identification of restriction fragment length polymorphisms. Kit for the application of the process. | 10-21-2010 |
| 20100267024 | MUTATIONS IN THE MACROPHAGE SCAVENGER RECEPTOR 1 GENE ALTER RISK OF PROSTATE CANCER, ASTHMA, AND CARDIOVASCULAR DISEASE - The present invention discloses methods of screening a subject for increased likelihood or risk of certain diseases or disorders. This method comprises detecting the presence or absence of at least one mutation in the MSR1 gene wherein the presence or absence of such mutation indicates an increased risk for certain diseases, such as cancer asthma and/or cardiovascular diseases. | 10-21-2010 |
| 20100267025 | METHODS AND COMPOSITIONS FOR THE ASSESSMENT OF CARDIOVASCULAR FUNCTION AND DISORDERS - The present invention provides methods for the assessment of risk of developing acute coronary syndrome (ACS) in smokers and non-smokers using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's risk of developing ACS. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided. | 10-21-2010 |
| 20100267026 | METHODS AND APPARATUS FOR CHARACTERIZING POLYNUCLEOTIDES - Systems and methods for analysis of polymers, e.g., polynucleotides, are provided. The systems are capable of analyzing a polymer at a specified rate. One such analysis system includes a structure having a nanopore aperture and a molecular motor, e.g., a polymerase, adjacent the nanopore aperture. | 10-21-2010 |
| 20100267027 | HER-2 BINDING ANTAGONISTS - There is disclosed a a pharmaceutical composition for treating solid tumors that overexpress HER-2, comprising an agent selected from the group consisting of (a) an isolated polypeptide having from about 50 to 79 amino acids taken from the sequence of SEQ ID NO:1, wherein the polypeptide binds to the extracellular domain ECD of HER-2 with an affinity binding constant of at least 10 | 10-21-2010 |
| 20100267028 | Tgfbr1 HAPLOINSUFFICIENCY MODIFIES RISK FOR CANCER - The present invention provides methods for assessing a genetic susceptibility to cancer in a subject which includes measuring allele specific expression or presence of at-risk haplotypes of TGFBR1, where a difference in expression or the presence of at-risk haplotypes is indicative of a cancer or susceptibility to a cancer. Methods to screen for agents that modify expression of TGRBR1 are also provided. | 10-21-2010 |
| 20100267029 | METHOD OF IDENTIFYING THE PLANT SPECIES OF THE GENUS UNCARIA - The present invention provides a method of identifying the plant species of the genus | 10-21-2010 |
| 20100267030 | SYSTEMS AND METHODS FOR MEASURING TRANSLATION ACTIVITY IN VIABLE CELLS - Systems for measuring protein translation and methods for measuring overall translation activity in viable cells or subcellular compartments is disclosed. The methods identify general ribosomal activity, if desired at sub-cellular resolution, thereby providing a signal indicating the rate of any of the steps of protein synthesis selected from initiation, elongation, termination or recycling. The translation system can be used to identify translation modulators in high-throughput-screening (HTS). | 10-21-2010 |
| 20100267031 | Method of Screening for RAGE-Amyloid-Beta Peptide Interaction Inhibiting Materials - Provided are a system and a method of screening for RAGE-amyloid beta peptide interaction inhibiting materials using a Transwell plate and a RAGE-expressing cell line. | 10-21-2010 |
| 20100267032 | Prediction of Likelihood of Cancer Recurrence - The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer. | 10-21-2010 |
| 20100267033 | Methods and Compositions For Detecting Autoimmune Disorders - The invention provides methods and compositions useful for detecting autoimmune disorders. | 10-21-2010 |
| 20100267034 | MARKERS FOR PRENATAL DIAGNOSIS AND MONITORING - Methods and kits are provided for diagnosing, monitoring, or predicting preeclaimpsia in a pregnant woman, trisomy 18 and trisomy 21 in a fetus, as well as for detecting pregnancy in a woman, by quantitatively measuring in the maternal blood the amount of one or more RNA species derived from a set of genetic loci and comparing the amount of the RNA species with a standard control. | 10-21-2010 |
| 20100267035 | METHODS OF IDENTIFYING COMPOUNDS THAT TARGET tRNA SPLICING ENDONUCLEASE AND USES OF SAID COMPOUNDS AS ANTI-PROLIFERATIVE AGENTS - The present invention relates to a method for screening and identifying compounds that modulate the activity tRNA splicing endonuclease. In particular, the invention provides assays for the identification of compounds that inhibit animalia tRNA splicing endonuclease. The methods of the present invention provide a simple, sensitive assay for high-throughput screening of libraries of compounds to identify pharmaceutical leads useful for treating and/or preventing cancer. | 10-21-2010 |
| 20100267036 | POLYMORPHISM IDENTIFICATION METHOD - The present invention is to provide a method for identifying a polymorphism. The method includes performing a nucleic acid chain extension reaction and identifying the polymorphism of the nucleic acid contained in the test nucleic acid sample. The extension reaction is conducted with use of a nucleic acid in a test nucleic acid sample as a template, a type I detection primer which hybridizes with a region including the polymorphic site of a nucleic acid whose polymorphic site nucleotide sequence consisting of a first nucleotide sequence, and a polymerase. The reaction is conducted with the presence of an inhibitory oligonucleotide, which hybridizes with the type I detection primer. The region of the type I detection primer to hybridize with the inhibitory oligonucleotide is located on the 5′ side of the polymorphism detection site of the type I detection primer to hybridize with the polymorphic site. | 10-21-2010 |
| 20100267037 | GENOTOXICITY AS A BIOMARKER FOR INFLAMMATION - The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of DNA damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation. The method can be adapted for quantitatively monitoring the efficacy of treatment of inflammatory disease in a subject. Markers of DNA damage include single- and/or double-stranded breaks in leukocytes, oxidative DNA damage in leukocytes, or a marker of nitric oxide oxidative activity (protein nitrosylation in leukocytes). The inflammatory disease can be inflammatory bowel disease (ulcerative colitis or Crohn's disease). The invention may also be used for detection of other types of inflammatory disease, such as non-immune intestinal inflammatory disease (diverticulitis, pseudomembranous colitis), autoimmune diseases (rheumatoid arthritis, lupus, multiple sclerosis, psoriasis, uveitis, vasculitis), or non-immune lung diseases (asthma, chronic obstructive lung disease, and interstitial pneumonitis). This unexpected discovery of markers of genotoxicity present in circulating leukocytes enables detection of inflammation occurring at a localized site with a relatively simple and minimally invasive assay using peripheral blood. | 10-21-2010 |
| 20100267038 | POLYNUCLEOTIDES FOR THE AMPLIFICATION AND DETECTION OF CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE - Polynucleotides useful for detecting | 10-21-2010 |
| 20100267039 | METHOD OF DIFFERENTIATING COCCIDIOIDES SPECIES - The invention pertains to methods and kits useful in the identification of and differentiation between | 10-21-2010 |
| 20100267040 | MN/CA IX and Cancer Prognosis - Herein disclosed are methods that are prognostic for neoplastic/preneoplastic disease in a subject vertebrate, wherein said disease is associated with a tissue that normally expresses MN, but which MN expression is lost or diminished upon carcinogenesis. Exemplary of the types of preneoplastic/neoplastic diseases subject to the prognostic methods of this invention are those of gastric mucosa, gallbladder, biliary ducts, and ductal cells of duodenal glands. An exemplary prognostic method comprises comparing the level of MN gene expression product in a tissue sample from the affected subject, with the average MN gene expression product level found in analogous preneoplastic/neoplastic tissue samples; an above average MN gene expression product level indicates poorer prognosis for the subject. MN gene expression products useful in the prognostic methods include MN protein, MN polypeptide, and/or MN nucleic acids. | 10-21-2010 |
| 20100267041 | SERIAL ANALYSIS OF BIOMARKERS FOR DISEASE DIAGNOSIS - The present invention generally relates to serial analysis of biomarkers for disease diagnosis. In certain embodiments, the invention provides methods for diagnosing a disease including obtaining a sample from a subject, conducting a first assay to determine whether a first biomarker in the sample is positive or negative for a disease, and conducting a second assay to determine whether a second biomarker in the sample is positive or negative for the disease if the first assay produced a negative result. | 10-21-2010 |
| 20100267042 | Antigen-Presenting Cell Populations And Their Use As Reagents For Enhancing Or Reducing Immune Tolerance - The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity. | 10-21-2010 |
| 20100267043 | System and method for identification of individual samples from a multiplex mixture - An embodiment of an identifier element for identifying an origin of a template nucleic acid molecule is described that comprises a nucleic acid element comprising a sequence composition that enables detection of an introduced error in sequence data generated from the nucleic acid element and correction of the introduced error, where the nucleic acid element is constructed to couple with the end of a template nucleic acid molecule and identifies an origin of the template nucleic acid molecule. | 10-21-2010 |
| 20100267044 | GENETICALLY ENGINEERED BIOLOGICAL INDICATOR - The disclosed technology relates to a genetically engineered biological indicator, comprising: at least one test organism and at least one reporter gene suitable for producing an indicator enzyme, the reporter gene being taken up by the test organism; and at least one repressor gene that inhibits expression of the reporter gene until the reporter gene is exposed to at least one inducer. A process and an apparatus for using the biological indicator are disclosed. | 10-21-2010 |
| 20100267045 | CUDR AS BIOMARKER FOR CANCER PROGRESSION AND THERAPEUTIC RESPONSE - Disclosed is a novel human gene designated CUDR. Provides is also a CUDR gene as a biomarker in the diagnosis of human cancers and a cancer therapy. | 10-21-2010 |
| 20100273146 | TB resistance assay - A diagnostic test for detecting multi-drug resistant | 10-28-2010 |
| 20100273147 | Medical diagnostic system and methods - A system and methods are provided for a medical diagnostic system that incorporates a genetically encoded digital signature to authenticate a patient. In an illustrative implementation, a platform is provided performing one or more functions including but not limited to patient authentication, diagnostics, transmission, and storage of data in a centralized secure database capable of being accessed by healthcare professionals. In the illustrative implementation, the exemplary medical diagnostic system can comprise a genetic material collector/analyzer. Responsive to inputting genetic material in the collector/analyzer, the collector/analyzer generates a unique genetic-based electronic signature representative of the genetic material. The unique genetic-base electronic signature can then be processed by cooperating parties to authenticate the person providing the genetic sample. In the illustrative operation, such comparison can be accomplished by comparing the generated unique genetic-based electronic signature with a stored genetic-based electronic signature as part of a patient authentication process. | 10-28-2010 |
| 20100273148 | Urine markers for detection of bladder cancer - Early detection of tumors is a major determinant of survival of patients suffering from tumors, including bladder tumors. Members of the BTM or UBTM family can be highly and consistently accumulated in bladder tumor tissue and other tumor tissue, and/or can be accumulated in urine of patients, and thus are markers for bladder and other types of cancer. In certain embodiments, BTMs or UBTMs can accumulate in the urine, and detection of UBTM family members can be an effective diagnostic approach. In some embodiments, quantitative PCR methods have advantages over microarray methods. In other embodiments, detection and quantification of a plurality of BTMs or UBTMs can increase the sensitivity and specificity of detection of bladder cancer, and therefore provides methods for determining the stage and type of bladder cancer. Kits provide easy, convenient ways for carrying out the methods of this invention. | 10-28-2010 |
| 20100273149 | PHOTOSYNTHETIC HYDROGEN PRODUCTION FROM THE GREEN ALGA CHLAMYDOMONAS REINHARDTII - The present invention relates generally to hydrogen production for use in fuel cells, foodstuffs and chemical production, and more particularly, to biologically and photosynthetically produced hydrogen. Specifically, disclosed is a method for producing bacteria and green alga that can produce hydrogen in quantities that exceed four hundred percent of the hydrogen produced by green alga in nature; thus, producing organisms which can serve as hydrogen generators for fuel cells, chemical production and numerous other applications. | 10-28-2010 |
| 20100273150 | SINGLE MOLECULE-FORMAT BIOLUMINESCENT PROBE - This application aims to provide a single molecule-format probe for detecting a target-specific ligand easily and accurately as an index of the presence or absence of a signal. | 10-28-2010 |
| 20100273151 | GENOME-WIDE ANALYSIS OF PALINDROME FORMATION AND DNA METHYLATION - The present disclosure provides methods for detecting the genome-wide presence of methylated DNA and palindrome formation. The present disclosure also provides methods for specific enrichment of methylated DNA or DNA having a DNA palindrome. These methods have demonstrated that somatic palindromes and methylated DNA occur frequently and are widespread in human cancers. Individual tumor types have a characteristic non-random distribution of palindromes in their genome and a small subset of the palindromic loci are associate with gene amplification. The disclosed method can be used to define the plurality of genomic DNA palindromes and regions having methylated DNA associated with various tumor types and can provide methods for the classification of tumors, and the diagnosis, early detection of cancer as well as the monitoring of disease recurrence and assessment of residual disease. | 10-28-2010 |
| 20100273152 | METHOD OF IDENTIFYING INDIVIDUALS AT RISK OF THIOPURINE DRUG RESISTANCE AND INTOLERANCE - The present invention is directed to a method of screening individuals for the presence or absence of one or more polymorphisms associated with the risk of thiopurine resistance or intolerance. | 10-28-2010 |
| 20100273153 | GENETIC DIAGNOSIS OF DEPRESSION - The present invention relates to compositions and methods for determining whether an individual is predisposed to major depressive disorder and/or to bipolar disorder. In particular, the present invention provides genetic markers useful alone or in combination with other genetic markers for the diagnosis, characterization and treatment of major (unipolar) depression and/or bipolar disorder. | 10-28-2010 |
| 20100273154 | NOVEL GLYCOSYLTRANSFERASES AND POLYNUCLEOTIDES ENCODING THE SAME - The present invention provides novel glycosyltransferase proteins produced by ascomycetous filamentous fungi (preferably species belonging to the genus | 10-28-2010 |
| 20100273155 | DETERMINATION OF QUALITY FEATURES IN AGRICULTURAL AND HORTICULTURAL CROPS - The present invention relates to a method for predicting the expected value of the quality features in agricultural and horticultural product and a method for predicting the expected optimal time of harvest by comparing expression parameters at the moment prior to harvest or during the postharvest path of genes and/or proteins related to such quality features for that agricultural and horticultural product, with (a) predetermined calibration line(s). The invention also comprises the markers M8, GAST and GDSL motif lipase and the uses thereof, as well as antibodies against them. | 10-28-2010 |
| 20100273156 | SEQUENCES AND METHODS FOR DETECTING INFLUENZA A AND INFLUENZA B VIRUS - Nucleic acid amplification primers and methods for specific detection of influenza A and influenza B nucleic acid targets are disclosed. The primer-target binding sequences are useful for detection of influenza A and influenza B targets in a variety of amplification and hybridization reactions. The oligonucleotide sequences are able to differentiate between influenza A and influenza B strains through specific hybridization to one or the other virus strain, enabling specific detection of the presence of influenza A and/or influenza B in a specimen. | 10-28-2010 |
| 20100273157 | System and Method for Authentication or Identification of Bio-Artifacts Related to President Abraham Lincoln - An invention for authenticating artifacts related to President Abraham Lincoln is presented. In an embodiment of the invention, an artifact is identified. The artifact has a biologically-derived component (“bio-component”). At least a portion of the bio-component is processed to yield matter that may be analyzed. This matter is analyzed and the analysis results interpreted. The interpretation is based on information related to a syndrome of marfanoid habitus and stable multiple lip dysmorphisms (an “MH/LD syndrome”). Two such syndromes are multiple endocrine neoplasia type 2B and pure mucosal neuroma syndrome. Other such syndromes may exist. Evidence of an MH/LD syndrome in the analysis results is evidence that the artifact is authentically associated with President Lincoln. A report is optionally produced. | 10-28-2010 |
| 20100273158 | HIN-1, A Tumor Suppressor Gene - The invention encompasses isolated DNAs encoding HIN-1 polypeptides, vectors containing such DNAs, cells containing the vectors, and isolated HIN-1 polypeptides. The invention also features methods of making and using HIN-1 polypeptides. | 10-28-2010 |
| 20100273159 | Nested Multiplex Amplification Method for Identification of Multiple Biological Entities - The present invention provides a novel molecular method for the simultaneous identification and semi-quantification of multiple targeted biological entities from amongst a plurality. This invention discloses a method based on a multiplex nested amplification reaction in a single closed tube. The first amplification reaction relies on a set of large oligonucleotides for the amplification of common loci in all the targeted biological entities. The second nested amplification reaction relies on a set of short oligonucleotide primers that amplifies specific nucleotide sequences from all the amplicons previously produced in the first amplification reaction and generates an amplified product pattern capable of identifying each targeted biological entity. This method offers fast and accurate simultaneous identification of many targeted biological entities in any sample. | 10-28-2010 |
| 20100273160 | METHODS TO IDENTIFY AND ENRICH FOR POPULATIONS OF OVARIAN CANCER STEM CELLS AND SOMATIC OVARIAN STEM CELLS AND USES THEREOF - The present invention relates to compositions and methods for treating, characterizing and diagnosing ovarian cancer. In particular, the present invention provides methods for treating and/or preventing ovarian cancer in a subject by administering to the subject an effective amount of Mullerian Inhibiting substance and/or an effective amount of an agent that inhibits BCRP1. The present invention further provides methods to identify and/or enrich for populations of ovarian cancer stem cells and populations of somatic ovarian stem cells, in particular, enrichment for populations of coelomic somatic ovarian stem cells, subcoelomic/stromal somatic ovarian stem cells and periphilar medullary somatic ovarian stem cells. The present invention also provides somatic ovarian stem cell markers and ovarian cancer stem cell markers, as well as methods to identify agents which selectively inhibit the proliferation of ovarian cancer stem cells as compared to somatic ovarian stem cells. | 10-28-2010 |
| 20100273161 | DETECTION OF BACTERIA BELONGING TO THE GENUS CAMPYLOBACTER BY TARGETING CYTOLETHAL DISTENDING TOXIN - An objective of the present invention is to provide the cytolethal distending toxin (CDT) of | 10-28-2010 |
| 20100273162 | RAPID DETECTION OF MICROORGANISMS - Methods for rapidly detecting Enterobacteriaceae and Micrococcaceae microorganisms utilizing non-amplified nucleic acids, acridiniu labeled ONA probes, and selective growth media are described, particularly for specific microbial species related to the food science industry and public health. Articles of manufacture that include reagents for detecting multiple microorganisms simultaneously are also described. | 10-28-2010 |
| 20100273163 | Methods for Identifying Agents that Inhibit Cell Migration, Promote Cell Adhesion and Prevent Metastasis - Disclosed are methods for identification of agents that modulate cell attachment, cell migration and cell viability. Cancer and primary cells adhered to a matrix are treated with agent(s) that modulate ActRII signaling and cell adhesion. Agents are tested that modulate cell adhesion, detachment, invasion and viability. Agents that modulate the expression, phosphorylation, function and translocation of ActRII signaling pathway members also can predict agents that modulate cell adhesion, detachment, invasion and viability. The methods have utility in identifying agents that prevent cancer cell metastasis, wound dehiscence, aortic dissection and aid retina attachment and skin replacement and fertility. | 10-28-2010 |
| 20100273164 | Targeted and Whole-Genome Technologies to Profile DNA Cytosine Methylation - Methods and compositions for determining a methylated cytosine profile of a target nucleic acid sequence are provided. | 10-28-2010 |
| 20100273165 | PROCESSES AND COMPOSITIONS FOR METHYLATION-BASED ENRICHMENT OF FETAL NUCLEIC ACID FROM A MATERNAL SAMPLE USEFUL FOR NON INVASIVE PRENATAL DIAGNOSES - Provided are compositions and processes that utilize genomic regions that are differentially methylated between a mother and her fetus to separate, isolate or enrich fetal nucleic acid from a maternal sample. The compositions and processes described herein are particularly useful for non-invasive prenatal diagnostics, including the detection of chromosomal aneuplodies. | 10-28-2010 |
| 20100273166 | BIOSENSOR DEVICE AND METHOD OF SEQUENCING BIOLOGICAL PARTICLES - A biosensor device ( | 10-28-2010 |
| 20100273167 | METHODS FOR DETERMINING PRENATAL ALCOHOL EXPOSURE - Provided herein are methods for determining ethanol exposure of a prenatal subject, including measuring whether or not amniotic fluid stem cells collected from amniotic fluid surrounding the prenatal subject have a upregulation or expression of one or more genes of a first predetermined combination and/or a downregulation of expression of one or more genes of a second predetermined combination. Also provided are methods for determining ethanol exposure of a prenatal subject which methods include measuring alkaline phosphatase activity and/or calcium deposition of amniotic fluid stem cells collected from amniotic fluid surrounding the prenatal subject. | 10-28-2010 |
| 20100273168 | METHOD FOR DISCRIMINATING RED BLOOD CELLS FROM WHITE BLOOD CELLS BY USING FORWARD SCATTERING FROM A LASER IN AN AUTOMATED HEMATOLOGY ANALYZER - A method for identifying, analyzing, and quantifying the cellular components of whole blood by means of an automated hematology analyzer and the detection of the light scattered, absorbed, and fluorescently emitted by each cell. More particularly, the aforementioned method involves identifying, analyzing, and quantifying the cellular components of whole blood by means of a light source having a wavelength ranging from about 400 nm to about 450 nm and multiple in-flow optical measurements and staining without the need for lysing red blood cells. | 10-28-2010 |
| 20100273169 | QUANTITATIVE PCR-BASED COMPOSITIONS AND METHODS FOR THE DIAGNOSIS OF INVASIVE PULMONARY ASPERGILLOSIS - Provided are quantitative PCR-based compositions and methods for the diagnosis of invasive pulmonary aspergillosis (IPA) in a patient sample, such as bronchoalveolar lavage (BAL) fluid. The methods presented herein involve isolating a patient sample, optionally extracting DNA from the sample, carrying out a quantitative PCR (qPCR) reaction on the sample to generate an amplicon that includes a region of an | 10-28-2010 |
| 20100273170 | METHOD AND DEVICE FOR PREPARING BIOLOGICAL SAMPLES FOR ANALYSIS - The invention relates to a method for preparing biological samples for analysis, comprising the following steps: (a) the biological sample is placed on a two-dimensional support; (b) application of a protein-precipitating or denaturing first solution L | 10-28-2010 |
| 20100273171 | GLOBAL GENE EXPRESSION ANALYSIS OF HUMAN BRONCHIAL EPITHELIAL CELLS EXPOSED TO CIGARETTE SMOKE, SMOKE CONDENSATES, OR COMPONENTS THEREOF - Aspects of the present invention concern the identification of several methods to analyze the genes that are modulated in normal human bronchial epithelial (NHBE) cells after exposure to cigarette smoke condensates (CSC) or cigarette smoke (CS). Embodiments described herein include methods to identify a gene that is modulated in response to exposure to CSC or CS, methods to identify tobacco products that have a reduced potential to contribute to tobacco-related disease, methods to make tobacco products that have a reduced potential to contribute to a tobacco-related disease, methods to identify a subject's predilection to acquire a tobacco related disease, the use of particular genes as biomarkers for tobacco-related disease, and patterns of gene expression or genetic signatures that are unique to each particular tobacco product. | 10-28-2010 |
| 20100273172 | MICRORNAS EXPRESSION SIGNATURE FOR DETERMINATION OF TUMORS ORIGIN - The present invention provides a process for classification of specific cancers and tumors origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA expression framework allows optimization of treatment, and determination of specific therapy. | 10-28-2010 |
| 20100273173 | METHOD FOR AMPLIFYING TARGET NUCLEIC ACID SEQUENCE AND PROBE USED FOR THE SAME - The present invention provides a method for amplifying a target sequence while suppressing inhibition of an amplification reaction in nucleic acid amplification in the presence of the probe. At the time of amplifying the target sequence, as the probe caused to coexist in amplification of the target sequence, a probe having a base sequence in which a melting temperature of the double-stranded nucleic acid is equal to or lower than a reaction temperature of the elongation reaction is used. In the presence of such a probe, for example, annealing of a primer and an elongation reaction from the primer are hardly inhibited by the presence of the probe so that amplification of the target sequence can be conducted sufficiently. Therefore, when a polymorphism of a target site in the target sequence is analyzed by a Tm analysis or the like, high reliability can be achieved. | 10-28-2010 |
| 20100273174 | ANTIBODIES TO TUMOR ASSOCIATED PROTEINS - A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization. | 10-28-2010 |
| 20100273175 | METHOD OF JUDGING RISK FOR ONSET OF DRUG-INDUCED GRANULOCYTOPENIA - Means for determining the presence of the risk of drug-induced granulocytopenia in a human is provided. | 10-28-2010 |
| 20100273176 | METHOD OF JUDGING RISK FOR ONSET OF DRUG-INDUCED GRANULOCYTOPENIA - Means for determining the presence of the risk of drug-induced granulocytopenia in a human is provided. | 10-28-2010 |
| 20100279278 | Methods of detecting one or more bioterrorism target agents - The present invention provides a methods and compositions for early diagnosis of exposure to or infection by a chemical or biological weapon by rapid and specific detection of one or more bioterrorism target agents in a sample. | 11-04-2010 |
| 20100279279 | Compositions and methods for analysis of target analytes - Compositions and methods are provided for analyzing a sample for the presence or absence of one or more target analytes. Microparticles bound to an analyte of interest are incubated in a solution containing a primary antibody directed towards the analyte. In direct assays of this invention, the microparticle-bound analyte competes with a labeled primary antibody do displace analyte from the primary antibody. Primary antibodies can be labeled with florescence or other labels detectable using a flow cytometer. The microparticle-bound analyte-primary antibody complex can be detected and quantified using a flow cytometer. In other, indirect assays, an unlabeled primary antibody can be used, and a labeled secondary antibody can react with a microparticle-bound analyte-primary antibody complex to form a labeled microparticle-bound analyte-primary antibody complex. The labeled microparticle-boudn alalyte-primary antibody complex can be detected using a flow cytometer. Using direct or indirect assays of this invention, peptides, proteins, nucleic acids or other analytes of interest can be detected and quantified. | 11-04-2010 |
| 20100279280 | FUNCTIONAL POLYMORPHISMS OF THE INTERLEUKIN-1 LOCUS AFFECTING TRANSCRIPTION AND SUSCEPTIBILITY TO INFLAMMATORY AND INFECTIOUS DISEASES - The invention provides methods and reagents for detecting a polymorphism associated with in an upstream region of the interleukin-1 beta (IL-B) gene (IL-1B (−3737)) that affects transcription of the gene and susceptibility to inflammatory and infectious diseases such as periodontal disease and Alzheimer's disease. | 11-04-2010 |
| 20100279281 | METHOD OF IDENTIFYING LUNG CANCERS ASSOCIATED WITH ASBESTOS-EXPOSURE - The present invention is related to a method for assessing the presence of, or disposition to, an asbestos-related disorder in a subject. Particularly, the invention provides a method of identifying lung cancers associated with asbestos-exposure. The association is confirmed by the detection of allelic imbalance (AI) in at least one of the following chromosomal regions of lung cancer cells: 19p13.3-p13.1; 9q32-34.3; 2p21-p16.3; 16p13.3; 22q12.3-q13.1; and 5q35.3. | 11-04-2010 |
| 20100279282 | METHODS FOR GENOTYPING MATURE COTTON FIBERS AND TEXTILES - Methods for distinguishing between cotton cultivars of a specific species by analyzing a sample of mature cotton fibers from raw cotton materials or from textile goods are disclosed. DNA is extracted from the mature cotton fiber sample and subjected to PCR techniques which enable the identification of the cultivar of a particular cotton species utilized in the textile or cotton material of interest. | 11-04-2010 |
| 20100279283 | METHOD FOR MOLECULAR BIOLOGY APPLICATIONS - The invention provides a method of nucleic acid synthesis and/or amplification, and/or of improving the efficiency, activity and/or stability of at least one nucleic acid-modifying enzyme, comprising carrying out the method in the presence of (a) at least one organic-based macromolecule having a molecular weight of 50 kDa to 500 kDa and neutral surface charge; or (b) at least one organic-based macromolecule of radius 2 to 50 nm and neutral surface charge. There is also provided a method of determining the optimum crowding conditions of macromolecule(s) in solution. | 11-04-2010 |
| 20100279284 | METHOD FOR SELECTING HOP LINE AND BREEDING MARKER AND PRIMER SET USED FOR SELECTING HOP LINE - It is an object of the invention to screen for hop varieties with low cohumulone ratio and low colupulone ratio, as well as hop varieties with high contents of farnesene and/or linalool within a short time period utilizing a molecular screening method that employs a breeding marker. The invention provides a breeding marker using a polymorphism at the position of the 623rd nucleotide or a polymorphism at the position of the 1820th nucleotide of a polynucleotide consisting of the nucleotide sequence as set forth in SEQ ID NO: 5. | 11-04-2010 |
| 20100279285 | GENETIC MARKERS OF MENTAL ILLNESS - This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ), and methods of use thereof. | 11-04-2010 |
| 20100279286 | METHOD OF DETECTING EQUINE POLYSACCHARIDE STORAGE MYOPATHY - The present invention relates to diagnosing Polysaccharide Storage Myopathy (PSSM) disease in equines. | 11-04-2010 |
| 20100279287 | COMPOSITIONS AND METHODS USEFUL FOR SITE-DIRECTED RECOMBINATION IN PLANTS - This invention relates generally to useful compositions and methods related to plant site-directed recombination. In particular, the invention relates to novel nucleic acid sequences unique to a portion of the sorghum NBS-LRR region, as well as vectors, seeds, plant parts and plants comprising these sequences. Methods to investigate recombination co-factors, and methods to investigate potential herbicides are within the scope. This invention also relates to fungal pathogens of sorghum, particularly | 11-04-2010 |
| 20100279288 | Method for Sequencing Nucleic Acid Molecules - The sequence of a target polynucleotide can be determined by: (i) contacting the target polynucleotide with a polymerase enzyme and one of the nucleotides A, T(U), G and C under conditions suitable for the polymerase reaction to proceed; (ii) measuring the time taken for the polymerase to bind to and subsequently dissociate from the target polynucleotide, to thereby determine whether the polymerase has incorporated the nucleotide onto the target polynucleotide; (iii) optionally repeating steps (i) and (ii) with additional nucleotides, to thereby identify the sequence of the target polynucleotide. | 11-04-2010 |
| 20100279289 | SIZE-DEPENDENT BIOLOGICAL EFFECT OF NANOPARTICLES - Nanoparticles are used increasingly in consumer products and biomedical applications. Yet the cellular interaction mechanism at the molecular level is not well understood for nanomaterials of different size, shape and surface chemistry. Gold nanoparticles (Au-NPs), which have been explored extensively for various applications in recent years, are used as the model system to help understand the size-dependent biological effects of nanoparticles. Jurkat cells treated with Au-NPs ranging from 2 nm to 200 nm were studied. Whole genome expression measurements indicate size-dependent effects, including linear scaling and threshold effects. In addition, a non-linear pattern of gene responses that persisted over time were observed in 20-40 nm Au-NP treated cells. Gene function, promoter, and pathway analyses reveal differential signaling processes that are correlated with nanoparticle sizes. The size may play a role in cellular sorting of naturally occurring particulates, particle interaction with the receptors, intracellular transportation, signaling and stress responses. | 11-04-2010 |
| 20100279290 | MICROBIOLOGICAL DETECTION METHOD - A method for detecting the presence of a hydrocarbon deposit ( | 11-04-2010 |
| 20100279291 | GENE SILENCING OF THE BROTHER OF THE REGULATOR OF IMPRINTED SITES (BORIS) - The present invention provides methods and compositions useful for inhibiting expression of the gene encoding the transcription factor, Brother of the Regulatory of Imprinted Sites (BORIS) by RNA interference. Methods of the present invention can be used to silence BORIS in cancer cells, which results in apoptosis and may be useful as for treating cancer in mammals. The methods of the invention directed to cancer therapy can be used alone or in combination with standard cancer treatments such as surgery, radiation, chemotherapy, and immunotherapy. | 11-04-2010 |
| 20100279292 | MicroRNA Expression in Human Peripheral Blood Microvesicles and Uses Thereof - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of disorders by examining samples containing microvesicles and miRs therein. | 11-04-2010 |
| 20100279293 | METHODS AND COMPOSITIONS FOR IDENTIFYING INCREASED RISK OF DEVELOPING FRAGILE X-ASSOCIATED DISORDERS - The present invention provides compositions and methods of identifying a subject as having an increased risk of developing fragile X-associated tremor and ataxia syndrome (FXTAS) or identifying a subject having an increased risk of developing fragile X syndrome (FXS), comprising analyzing messenger RNA (mRNA) transcripts and/or translation products of the antisense gene ASFMR1. | 11-04-2010 |
| 20100279294 | METHODS OF DETECTING AND GENOTYPING ESCHERICHIA COLI O157:H7 - A method for detecting and genotyping | 11-04-2010 |
| 20100279295 | USE OF THERMOSTABLE ENDONUCLEASES FOR GENERATING REPORTER MOLECULES - Provided are compositions and methods for amplifying, capturing and/or detecting target nucleic acids using cleavable oligonucleotides. | 11-04-2010 |
| 20100279296 | ENHANCED FC RECEPTOR-MEDIATED TUMOR NECROSIS FACTOR SUPERFAMILY MRNA EXPRESSION IN PERIPHERAL BLOOD LEUKOCYTES IN PATIENTS WITH RHEUMATOID ARTHRITIS - A method for predicting patient responsiveness to rheumatoid arthritis treatments involving altering expression of tumor necrosis factor superfamily (“TNFSF”)-2, TNFSF-8, or TNFSF-15 is disclosed. A method for monitoring the effectiveness of such therapy is also disclosed. Furthermore, a method of screening compounds for use in the treatment of rheumatoid arthritis is disclosed. A method of monitoring the disease state over time in rheumatoid arthritis patients is also disclosed. | 11-04-2010 |
| 20100279297 | Method for Identifying an Increased Susceptibility to Ulcerative Colitis - A method is provided for detecting an increased susceptibility to ulcerative colitis by determining the presence of a polymorphism at position 256 of the nucleotide sequence of rs3024505 in which C is substituted by T or the presence of a polymorphism at position 501 of the nucleotide sequence of rs12612347 in which G is substituted by A. | 11-04-2010 |
| 20100279298 | Methods and Compositions For Detecting Autoimmune Disorders - The invention provides methods and compositions useful for detecting autoimmune disorders. | 11-04-2010 |
| 20100279299 | Devices and Methods for Heating Biological Samples - This invention provides a systems and methods for regulating temperature and heat transfer in applications in which it is desirable to maintain temperature uniformity such as thermal cycling applications. A heat block is used to rapidly transfer heat to or from a set of one or more reaction vessels. | 11-04-2010 |
| 20100279300 | METHODS FOR DETERMINING THE PROGNOSIS FOR PATIENTS WITH A PROSTATE NEOPLASTIC CONDITION - The invention provide a method of identifying a biomarker that is diagnostic for survival of a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of IAPs in a neoplastic prostate cell-containing sample from patients with a prostate neoplastic condition, and (b) identifying a correlation between the level of IAPs in a sample from a patient with the survival of that patient, where the correlation of an IAP with survival in patients indicates the IAP is a biomarker diagnostic of survival of a patient with a prostate neoplastic condition. Also provided is a method of determining a prognosis for survival for a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of XIAP in a neoplastic prostate cell-containing sample from the patient, and (b) comparing the level of XIAP in the sample to a reference level of XIAP, where an increased level of XIAP in the sample correlates with increased survival of the patient. The invention further provides a method of determining a prognosis for survival for a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of two or more IAPs selected from the group consisting of XIAP, cIAP1, and cIAP2 in a neoplastic prostate cell-containing sample from a patient, and (b)comparing the level of the two or more IAPs in the sample to a reference level of the IAPs, where an increased level of XIAP and decreased level of cIAP1 or cIAP2 in the sample correlates with increased survival of the patient. | 11-04-2010 |
| 20100279301 | METHODS AND COMPOSITIONS FOR DIAGNOSING BLADDER CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to genes and gene panels as diagnostic markers and clinical targets for bladder cancer. Methods, compositions, and kits for diagnosing, determining, and determining risk of tumor aggressiveness are disclosed. | 11-04-2010 |
| 20100279302 | METHODS OF PREDICTING PAIRABILITY AND SECONDARY STRUCTURES OF RNA MOLECULES - Provided are methods of predicting a pairability of nucleotides of a plurality of RNA polynucleotides by (a) simultaneously determining a paired state or an unpaired state of nucleotides of the plurality of RNA polynucleotides; and (b) corresponding the paired state or the unpaired state of the nucleotides to a database of nucleic acid sequences, the database comprises nucleic acid sequences representing the plurality of RNA polynucleotides, thereby determining the pairability of nucleotides of the plurality of RNA polynucleotides. Also provided are methods of determining a secondary structure of a plurality of RNA molecules; methods of determining if a molecule is capable of modulating a secondary structure of at least one RNA polynucleotide of a plurality of RNA polynucleotides; and methods of screening for a marker associated with a pathology. | 11-04-2010 |
| 20100279303 | REACTION VESSEL, REACTION VESSEL LIQUID INTRODUCING DEVICE, LIQUID INTRODUCING AND REACTION MEASURING DEVICE, AND LIQUID INTRODUCING DEVICE - The invention relates to a reaction vessel, a reaction vessel liquid introducing device, a liquid introducing and reaction measuring device, and a liquid introducing device, and is directed to being able to perform temperature control of a liquid stored within the reaction vessel with a high accuracy and faithful responsiveness. The reaction vessel comprises: a storage chamber in which a liquid is storable, that has an opening part; a reaction chamber that is formed thinner or narrower than the storage chamber; and at least one flow passage that communicates between the storage chamber or the exterior and the reaction chamber. The reaction vessel is formed such that it is connectable to a liquid introducing section provided externally, and the liquid can be introduced into the reaction chamber by connecting to the liquid introducing section. | 11-04-2010 |
| 20100279304 | METHODS FOR PRODUCING NUCLEIC ACID HYBRIDIZATION PROBES THAT AMPLIFY HYBRIDIZATION SIGNAL BY PROMOTING NETWORK FORMATION - This invention describes methods for the generation of nucleic acid probes that improve the sensitivity of hybridization assays. The sensitivity increase results from structural modifications of nucleic acids that promote network formation during hybridization with the result that a single target molecule becomes attached to a complex of many probe molecules. The structural modification involves fragmentation of the probe nucleic acid followed by joining the fragments together such that their order and orientation and number is altered from the original probe molecule. The result is the generation of permuted probe libraries. Various fragmentation and joining methods are described. Labeling can be done by standard methods before during or after formation of permuted probe libraries. Individual members of permuted probe libraries can be isolated and amplified and perpetuated. Fixed mixtures of such isolated library members can be used as permuted probe libraries of limited variability to control network complexity. Libraries can be prepared with additional sequences not present in the target and the fraction of the library made up by such sequences can be controlled. Such extra-target additions can be used as targets for detection by secondary probes. Since their number can be far greater than equimolar with the probe sequences represented in the target they can be detected with higher sensitivity in the networks. Probes for different targets can incorporate different non-target sequences in hyper-molar quantities permitting sensitive detection of multiple hybridization targets in the same sample. Probes made according to this invention can be used in many kinds of hybridization assay including Southern. blots, Northern blots, Dot blots, Nucleic acid Array hybridization, ‘in situ’ hybridization with fluorescent or other labels (FISH) and various kinds of sandwich hybridization assays. | 11-04-2010 |
| 20100279305 | COMPOSITIONS, METHODS, AND KITS FOR DETECTING RIBONUCLEIC ACID - Compositions, methods, and kits for detecting one or more species of RNA molecules are disclosed. In one embodiment, a first adaptor and a second adaptor are ligated to the RNA molecule using a polypeptide comprising double-strand specific RNA ligase activity, without an intervening purification step. The ligated product is reverse transcribed, then at least some of the ribonucleosides in the reverse transcription product are removed. Primers are added and amplified products are generated. In certain embodiments, the sequence of at least part of at least one species of amplified product is determined and at least part of the corresponding RNA molecule is determined. In some embodiments, at least some of the amplified product species are detected, directly or indirectly, allowing the presence and/or quantity of the RNA molecule of interest to be determined. | 11-04-2010 |
| 20100285451 | DETECTION OF SUB-CELLULAR COMPARTMENT LOCALIZATION OF A MOLECULE USING A REDUCED AFFINITY ENZYME COMPLEMENTATION REPORTER SYSTEM - Methods and compositions for detecting the sub-cellular localization of a molecule are provided. Aspects of the invention include detecting translocation of a cell-surface receptor to a sub-cellular compartment, e.g., the endosome, using a reduced affinity enzyme complementation reporter system. Also provided are systems and kits for use in practicing embodiments of the methods. | 11-11-2010 |
| 20100285452 | Molecular Markers for the Diagnosis and Treatment of Tumors - The invention relates to the diagnosis, prognosis, monitoring, and treatment of neoplastic diseases such as tumor diseases, especially tumor diseases of the endometrium and the metastases thereof. | 11-11-2010 |
| 20100285453 | CELL CULTURE ARTICLE AND METHODS THEREOF - A biosensor or cell culture article including: a substrate having a bio-compatible layer. The bio-compatible layer can be obtained from surface oxidation of a substrate coating comprising the reaction product of a suitable oxidizable polymer and modifier compound, such as a triamine, attached to the oxidizable polymer. Methods for making the biosensor or cell culture article and methods for performing an assay of a ligand with the biosensor article are also disclosed. | 11-11-2010 |
| 20100285454 | ENCLOSED UNIT FOR RAPID DETECTION OF A TARGET NUCLEIC ACID AMPLIFICATION PRODUCT - The invention relates to a method for rapid detection of a target nucleic acid amplification product while preventing cross-contamination between target nucleic acid amplification products and avoiding false positives, comprising the steps of: a) leaving the reaction tube unopened after the amplification reaction is finished, so as to prevent the target nucleic acid amplification product from leaking out and resulting in contamination; b) placing the unopened reaction tube inside an enclosed unit, making the target nucleic acid amplification product be transferred to a test strip from the reaction tube in a physically enclosed environment; c) performing detection in a visual read-out manner, and determining the result; d) discarding the enclosed unit in a safety place as a whole without opening it after the detection. The invention also relates to a totally enclosed unit for detecting a target nucleic acid amplification product, and still relates to applications of the totally enclosed rapid detection unit in detection of infectious pathogens, food industry, agriculture, livestock husbandry, customs quarantine control, and determination of DNA. | 11-11-2010 |
| 20100285455 | PREDICTION OF SCHIZOPHRENIA RISK USING HOMOZYGOUS GENETIC MARKERS - Provided are methods of identifying a genetic profile influencing the relative probability of a subject manifesting a phenotype that is at least partially heritable. Also provided are methods of determining the relative likelihood that a subject will manifest a phenotype that is at least partially heritable. Additionally, methods of determining the relative risk of a human subject for manifesting schizophrenia are provided. Further provided are methods of screening a human embryo in vitro for the risk of becoming a human manifesting schizophrenia. Also, methods of identifying a single nucleotide polymorphism (SNP) variant affecting the risk of a human subject for manifesting schizophrenia are provided. Methods of screening for a compound that may affect schizophrenia are additionally provided. | 11-11-2010 |
| 20100285456 | Method for using DNA repair capacity as a biomarker of breast cancer risk in women - Methods for the development of a breast cancer biomarker aimed at determining the risk of a woman to 1) develop breast cancer, 2) be free of breast cancer based on levels of overall DNA repair capacity as determined in blood lymphocytes. Examples on applicability of the methods to a human population are presented in terms of its potential for differential diagnosis, risk assessment and screening of breast cancer. | 11-11-2010 |
| 20100285457 | High-Throughput Diagnostic Assay For the Human Virus Causing Severe Acute Respiratory Syndrome (SARS) - The present invention relates to a high-throughput diagnostic assay for the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). In particular, the invention relates to a high-throughput reverse transcription-PCR diagnostic test for SARS associated coronavirus (SARS-CoV). The present assay is a rapid, reliable assay which can be used for diagnosis and monitoring the spread of SARS and is based on the nucleotide sequences of the N (nucleocapsid)-gene of the hSARS virus. The present method eliminates false negative results and provides increased sensitivity for the assay. The invention also discloses the S (spike)-gene of the hSARS virus. The invention further relates to the deduced amino acid sequences of the N-gene and S-gene products of the hSARS virus and to the use of the N-gene and S-gene products in diagnostic methods. The invention further encompasses diagnostic assays and kits comprising antibodies generated against the N-gene or S-gene product. | 11-11-2010 |
| 20100285458 | Gene Expression Profiling for Identification, Monitoring, and Treatment of Lupus Erythematosus - A method is provided in various embodiments for determining a profile data set for a subject with lupus or conditions related to lupus based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RWA corresponding to at least one constituent from Tables 1-7, 9-13, and 15-20. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable. | 11-11-2010 |
| 20100285459 | Human Diabetes Susceptibility TNFRSF10A gene - The present invention relates to a diagnostic method of determining whether a subject is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the TNFRSF10A gene locus in a biological sample of said subject. | 11-11-2010 |
| 20100285460 | Biological Detection System and Method - The present disclosure, according to some embodiments, relates to phage-based biological detection systems, compositions, and methods. In some embodiments, it relates to a detection system and method using phage binding and bacterial infection to detect the presence of a target molecule (e.g., a toxin). One detection system may include a genetically engineered phage that expresses a surface molecule able to bind a target molecule and/or target microorganism; a bacterium susceptible to infection by the phage; and a detection component able to determine whether the bacterium has been infected by the phage. Infection of a bacterium by a phage may be indicative of phage binding to the target molecule and/or target microorganism. One method may include placing a sample suspected of containing the target molecule and/or target microorganism with a binder; adding a genetically engineered phage having reporter genetic material and able to bind the target molecule and/or target microorganism; washing away unbound phage; releasing phage bound to the target molecule and/or target microorganism; infecting a bacterium with the released phage; and detecting the presence of any reporter genetic material in the bacterium. Reporter material in the bacterium may correlate with target molecule and/or target microorganism in the sample. In some embodiments, the disclosure relates to a detection system and method using phage comprising a reporter to infect a microorganism (e.g., | 11-11-2010 |
| 20100285461 | Methods Of Producing And Sequencing Modified Polynucleotides - The present invention encompasses methods for producing a modified polynucleotide sequence that comprises a (e.g., one or more) phosphorothiolate linkage, methods for determining a polynucleotide sequence comprising a (e.g., one or more) phosphorothiolate linkage, and methods for separating forward and reverse extension products that comprise a (e.g., one or more) phosphorothiolate linkage. The invention also encompasses kits for producing and/or determining the sequence of a modified polynucleotide that comprises a (e.g., one or more) phosphorothiolate linkage. | 11-11-2010 |
| 20100285462 | METHODS AND MATERIALS RELATED TO HAIR PIGMENTATION AND CANCER - This document relates to methods and materials for determining whether or not a horse contains a Grey allele. For example, diagnostic methods such as nucleic acid-based detection methods and materials such as nucleic acid probes and primer pairs that can be used to determine whether or not a horse contains a duplication in intron 6 of STX17 nucleic acid are provided. This document also relates to methods and materials for treating a mammal having or being likely to develop cancer (e.g., benign, malignant, or metastatic cancer). For example, methods and materials for treating cancer in a mammal by administering an agent having the ability to reduce expression of an STX17 polypeptide and/or an NR4A polypeptide (e.g., an NR4A1, NR4A2, or NR4A3 polypeptide) in the mammal are provided. | 11-11-2010 |
| 20100285463 | SELECTING NUCLEIC ACID SAMPLES SUITABLE FOR GENOTYPING - The present invention relates to a method for selecting a DNA sample comprising genomic DNA suitable for genotyping, comprising the steps of: i) pre-genotyping said genomic DNA using a set of polymorphic markers; ii) determining out of said set of polymorphic markers the percentage of polymorphic markers for which said genomic DNA is homozygous; and iii) selecting said DNA sample when said genomic DNA is homozygous for less than 70% of said set of polymorphic markers. Furthermore, a method of genotyping comprising a step of using a DNA sample selected by the method in accordance with the present invention and/or a step of applying the method provided herein is disclosed. The present invention also relates to a method for identifying a gene or a locus on a genome, said method comprising a step of using a DNA sample selected by the method provided herein and a step of applying the method described herein. Further, the present invention relates to a kit for carrying out the method in accordance with the present invention comprising primers for the amplification of the set of polymorphic markers employed herein. | 11-11-2010 |
| 20100285464 | A CONSERVED REGION OF THE HIV-1 GENOME AND USES THEREOF - The present invention discloses sequences having a structure and sequence homology to lox-P recombinase target site corresponding to a highly conserved region within the Long Terminal Repeats (LTR) of HIV and to the use thereof for the identification of recombinase enzymes useful in treating HIV-1. | 11-11-2010 |
| 20100285465 | Molecular Typing of Neisseria Strains by Determining the Presence of Genes Involved in Lipooligosaccharide (LOS) Biosynthesis - The present invention relates to a method of LOS molecular typing of a | 11-11-2010 |
| 20100285466 | ESOPHAGEAL CANCER MARKERS - The present invention is directed to methods for diagnosing cancer in a subject. Morphologically normal epithelial cells of the esophagus are assayed for marker expression. Characteristic expression of the markers indicates the presence of cancer or the predisposition to cancer. A panel of eleven markers are particularly good at identifying cancer and the predisposition to cancer. | 11-11-2010 |
| 20100285467 | RAPID AND SENSITIVE METHOD FOR DETECTION OF BIOLOGICAL TARGETS - The present invention relates to a method of biological labeling that occurs via a free radical chain reaction. The labeling occurs due to deposition of a detectable reporter molecule from a media comprising a substance comprising at least two moieties of a peroxidase enzyme substrate (termed herein ‘cross-linker’) in a target site comprising peroxidase activity and a biological marker. The labeling reaction described herein may generally be used to detect targets in a host of experimental schemes for detecting and visualizing a biological or chemical target, including immunohistochemistry (IHC), in situ hybridization (ISH), antibody-based staining methods such as ELISA, Southern, Northern, and Western blotting, and others. | 11-11-2010 |
| 20100285468 | DETECTION AND/OR QUANTIFICATION OF NUCLEIC ACIDS - The present invention provides compositions, methods, and kits for nucleic acids analyses. In particular, melting analyses are used to detect the presence or absence and to quantify nucleic acids. | 11-11-2010 |
| 20100285469 | METHOD OF TUMOR SCREENING - A method for tumor screening using urine of a mammal, the method includes obtaining a total urine nucleic acid (e.g., DNA) from a urine sample of a mammal, extracting a high molecular weight urine nucleic acid (above 1000 bp) by contacting the total urine nucleic acid with an adsorbent in the presence of a buffer which promotes binding of the high molecular weight urine nucleic acid to the adsorbent, replacing the buffer which promotes binding of the high molecular weight urine nucleic acid with a buffer which promotes binding of the low molecular weight urine nucleic acid to the adsorbent, extracting the low molecular weight urine nucleic acid by contacting with the adsorbent, eluting the low molecular weight urine nucleic acid, and assaying the low molecular weight urine nucleic acid for a presence or absence of a gene sequence specific to a certain type of tumor. | 11-11-2010 |
| 20100285470 | MONOMETHINE DYES - Monomethine dyes that have no or minimal fluorescence in buffer or in the presence of single stranded DNA or RNA, but strongly fluoresce in the presence of double-stranded DNA. In one embodiment, the dye is useful in quantitative RT-PCR. | 11-11-2010 |
| 20100285471 | Methods and Compositions for the Diagnosis and Treatment of Esphageal Adenocarcinomas - Methods and compositions for the diagnosis, prognosis and/or treatment of esophageal adenocarcinoma and Barrett's esophagus associated adenocarcinoma are disclosed, along with more markers where a difference is indicative of esophageal adenocarcinoma and squamous cell carcinoma, and/or Barrett's esophagus associated adenocarcinomas or a predisposition thereto. The invention also provides methods and compositions of identifying anti-cancer agents therefor. | 11-11-2010 |
| 20100285472 | PRIMERS AND PROBES FOR DETECTION OF HIGH RISK GROUP GENO-TYPE HUMAN PAPILLOMAVIRUS DNA, A QUALITATIVE ASSAY METHOD OF THE SAME DNA USING THEM AND A QUALITATIVE ASSAY KIT OF THE SAME DNA - The present invention relates to a method for qualitative assay of high risk group Human Papillomavirus (HPV) DNA by PCR method using primers designed to detect the infection of 13 high risk group HPV which are closely associated with cervical cancer in a simple and precise way, and a kit for qualitative assay of high risk group HPV DNA. | 11-11-2010 |
| 20100285473 | THERMOPHILIC HELICASE DEPENDENT AMPLIFICATION TECHNOLOGY WITH ENDPOINT HOMOGENOUS FLUORESCENT DETECTION - Disclosed herein are methods of amplifying a target nucleic acid in a helicase-dependent reaction. Also disclosed are methods of amplifying and detecting a target nucleic acid in a helicase-dependent reaction as well as modified detection labels to assist in the detection. | 11-11-2010 |
| 20100285474 | DIAGNOSTIC, PREDICTIVE AND PROGNOSTIC TESTING FOR CANCER - The present invention relates to a method for determining a prognosis of progression of a cancer in a subject, a method for determining a treatment protocol for a subject having cancer or a method for determining efficacy of a therapeutic treatment of a subject, the method comprising the steps of:
| 11-11-2010 |
| 20100285475 | FUSED GENES - There is provided at least one isolated fused gene comprising at least one first gene and/or fragment thereof fused to at least one second gene and/or fragment thereof, wherein at least the first and/or the second gene, independently, is selected from the group consisting of: RCC2, CENPF, ARFGEF2, SULF2, MTAP, ATXN7, BCAS3, RPS6KB1, TMEM49, EAP30, a gene having the nucleotide sequence SEQ ID NO:1, and a gene having the nucleic acid SEQ ID NO:2, or a fragment thereof. There is also provided a diagnostic method and/or a kit for detecting the susceptibility, prognosis, and/or to tumour in a subject. | 11-11-2010 |
| 20100285476 | METHODS OF IDENTIFYING HISTONE DEACETYLASE INHIBITORS USEFUL FOR NEUROLOGICAL DISORDERS - A method of identifying a candidate compound for treatment of a neurological condition includes obtaining a test compound; assaying a first activity of the test compound to inhibit histone deacetylase activity of a histone deacetylase 3 (HDAC3); assaying a second activity of the test compound to inhibit histone deacetylase activity of a histone deacetylase other than a HDAC3; and identifying the test compound as a candidate compound for treatment of a neurological condition if the first activity of the test compound is greater than the second activity of the test compound. | 11-11-2010 |
| 20100285477 | Method for Predicting the Response to a Therapy - The invention concerns an in vitro method for selecting the therapy for a steroid resistant patient, wherein the method comprises isolating cells from a sample taken from said patient; cultivating said isolated cells in the presence of a steroid, an immunomodulatory oligonucleotide or a mixture thereof; determining an expression level of at least one marker gene in said isolated cells; and comparing said expression level of said at least one marker gene to a value obtained from the cultivation of cells from a healthy person in the presence of a steroid, an immunomodulatory oligonucleotide or a mixture thereof, or to a normalized value obtained from a healthy population. Examples of marker genes are CD163, Tsp1, IL1-R2, TLR2, TLR4, MKP-1 and TXK. | 11-11-2010 |
| 20100285478 | Methods, Compositions, and Kits for Detecting Allelic Variants - In some embodiments, the present inventions relates generally to compositions, methods and kits for use in discriminating sequence variation between different alleles. More specifically, in some embodiments, the present invention provides for compositions, methods and kits for quantitating rare (e.g., mutant) allelic variants, such as SNPs, or nucleotide (NT) insertions or deletions, in samples comprising abundant (e.g., wild type) allelic variants with high specificity and selectivity. In particular, in some embodiments, the invention relates to a highly selective method for mutation detection referred to as competitive allele-specific TaqMan PCR (“cast-PCR”). | 11-11-2010 |
| 20100285479 | SYSTEMS AND METHODS FOR POINT-OF-CARE AMPLIFICATION AND DETECTION OF POLYNUCLEOTIDES - Composition and methods for amplifying and detecting solution-state polynucleotide targets in a single device are described. In one aspect, a method for a coupled isothermal amplification and detection process utilizes a coated solid support, including a solid substrate, a cationic layer, and a plurality of target-specific probes attached to the coated solid support. Polynucleotide targets in the sample are amplified by an isothermal amplification process involving in situ hybridization onto the coated solid support. The entire process can be carried out with a high degree of specificity under low salt conditions in less than one hour. Further aspects of the present invention include methods for coupled hybridization/detection of polynucleotide targets, coated silicon biosensors optimized for use with the coupled detection systems to provide visual detection of polynucleotide targets under visible light conditions, and kits for practicing in the above described methods. | 11-11-2010 |
| 20100285480 | TCL-1 GENE AND PROTEIN AND RELATED METHODS AND COMPOSITIONS - The present invention relates to nucleotide sequences of TCL-1 genes and amino acid sequences of their encoded proteins, as well as derivatives and analogs thereof, and antibodies thereto. The TCL-1 gene sequence is preferentially expressed early in T and B lymphocyte differentiation. The present invention further relates to the use of TCL-1 genes and their encoded proteins as diagnostic and therapeutic reagents for the detection and treatment of disease states associated with chromosomal abnormalities. | 11-11-2010 |
| 20100285481 | METHODS FOR NUCLEIC ACID MANIPULATION - A method for replicating and amplifying a target nucleic acid sequence is described. A method of the invention involves the formation of a recombination intermediate without the prior denaturing of a nucleic acid duplex through the use of a recombination factor. The recombination intermediate is treated with a high fidelity polymerase to permit the replication and amplification of the target nucleic acid sequence. In preferred embodiments, the polymerase comprises a polymerase holoenzyme. In further preferred embodiments, the recombination factor is bacteriophage T4 UvsX protein or homologs from other species, and the polymerase holoenzyme comprises a polymerase enzyme, a clamp protein and a clamp loader protein, derived from viral, bacteriophage, prokaryotic, archaebacterial, or eukaryotic systems. | 11-11-2010 |
| 20100285482 | METHODS FOR NUCLEIC ACID MANIPULATION - A method for replicating and amplifying a target nucleic acid sequence is described. A method of the invention involves the formation of a recombination intermediate without the prior denaturing of a nucleic acid duplex through the use of a recombination factor. The recombination intermediate is treated with a high fidelity polymerase to permit the replication and amplification of the target nucleic acid sequence. In preferred embodiments, the polymerase comprises a polymerase holoenzyme. In further preferred embodiments, the recombination factor is bacteriophage T4 UvsX protein or homologs from other species, and the polymerase holoenzyme comprises a polymerase enzyme, a clamp protein and a clamp loader protein, derived from viral, bacteriophage, prokaryotic, archaebacterial, or eukaryotic systems. | 11-11-2010 |
| 20100285483 | Molecular diagnostic method and treatment in dementia with Lewy bodies - The invention describes methods of molecular diagnosis of a concrete form of α-synucleinopathy, the dementia with Lewy bodies (DLB), associated to the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) or the alteration of its ubiquityl-ligase activity. It also refers to the use of compounds that permit the modification of the UCH-L1 levels or of the enzymatic activity of UCH-L1. This invention has application in the diagnosis and treatment of patients suffering from DLB. | 11-11-2010 |
| 20100285484 | APOPTOSIS INDUCING POSITIVE CONTROL FOR EXPRESSION MODULATION EXPERIMENTS - The invention pertains to a method for performing an expression modulating analysis or assay, wherein an apoptosis inducing expression modulating compound targeting a repetitive element present in the untranslated region, in particular the 3′ UTRs of protein coding gene transcripts is introduced into cells to induce apoptosis in the cells as a positive control. Also provided are suitable kits and compositions. | 11-11-2010 |
| 20100285485 | PRIMER, PROBE, DNA CHIP CONTAINING THE SAME AND METHOD FOR DETECTING HUMAN PAPILLOMAVIRUS AND DETECTION KIT THEREOF - The present invention discloses a primer, a probe, a DNA chip, and a test kit for diagnosis and genotyping of Human Papilloma Virus (HPV) as well as a method for testing HPV genotype. According to the present invention, it is possible to screen HPV genotypes with high sensitivity and specificity, and to diagnose infection by multiple HPV types which was not possible in other conventional HPV testing methods | 11-11-2010 |
| 20100285486 | Non-Invasive Detection of Bladder Cancer by Fluorescence in Situ Hybridization of Aurora A - We disclose a method of detecting bladder cancer in a patient, comprising isolating bladder cells from the patient's urine; hybridizing the bladder cells with a labelled DNA probe, wherein the probe recognizes at least a portion of the aurora kinase A gene, to yield a sample of bladder cells hybridized with the labeled DNA probe; and counting the number of bladder cells in the sample, the number of copies of the aurora kinase A gene in each bladder cell in the sample, and the number of bladder cells in the sample having at least a first threshold number of copies of the aurora kinase A gene. | 11-11-2010 |
| 20100285487 | FLUORESCENT TWO-HYBRID (F2H) ASSAY FOR DIRECT VISUALIZATION OF PROTEIN INTERACTIONS IN LIVING CELLS - The present invention relates to an in vitro method for detecting protein-protein interactions comprising: (a) expressing in a eukaryotic cell a first fusion protein comprising (i) a (poly)peptide that, when expressed in a cell, accumulates at distinct sites in the nucleus of the cell or interacts with proteinaceous or non-proteinaceous structures accumulated at distinct sites in the nucleus of the cell; and (ii) a (poly)peptide specifically binding to GFP; (b) expressing in the same cell a second fusion protein comprising (i) GFP; and (ii) a bait (poly)peptide; (c) expressing in the same cell a third fusion protein comprising (i) a fluorescent (poly)peptide, the excitation and/or emission wavelength of which differs from that of GFP; and (ii) a prey (poly)peptide; and (d) detecting the fluorescence emission of the fluorescent parts of the second and the third fusion protein in the cell upon excitation, wherein a co-localization of the fluorescence emission of both fusion proteins in the cell nucleus is indicative of an interaction of the bait and the prey (poly)peptide. The invention also relates to an in vitro method for detecting protein-protein interactions comprising: (a) expressing in a eukaryotic cell a first fusion protein comprising (i) a fluorescent (poly)peptide; (ii) a (poly)peptide that, when expressed in a cell, accumulates at distinct sites in the nucleus of the cell; and (iii) a bait (poly)peptide (b) expressing in the same cell a second fusion protein comprising (i) a fluorescent (poly)peptide, the excitation and/or emission wavelength of which differs from that of the fluorescent (poly)peptide comprised in said first fusion protein; and (ii) a prey (poly)peptide and (c) detecting the fluorescence emission of the fluorescent parts of the first and the second fusion protein in the cell upon excitation, wherein a co-localization of the fluorescence emission of both fusion proteins in the cell nucleus is indicative of an interaction of the bait and the prey (poly)peptide. Furthermore, the present invention relates to methods for identifying a compound modulating the interaction of two (poly)peptides and methods of determining the relative strength of the interaction of two proteins with a third protein. | 11-11-2010 |
| 20100285488 | T-STRUCTURE INVASIVE CLEAVAGE ASSAYS, CONSISTENT NUCLEIC ACID DISPENSING, AND LOW LEVEL TARGET NUCLEIC ACID DETECTION - The present invention relates to systems, methods and kits for low-level detection of nucleic acids, detecting at least two different viral sequences in a single reaction vessel, and increasing the dynamic range of detection of a viral target nucleic acid in a sample. The present invention also relates to T-structure invasive cleavage assays, as well as T-structure related target dependent non-target amplification methods and compositions. The present invention further relates to methods, compositions, devices and systems for consistent nucleic acid dispensing onto surfaces. | 11-11-2010 |
| 20100285489 | METHOD FOR DIAGNOSING RENAL DISEASES OR PREDISPOSITIONS - The invention provides a method of diagnosing a disease or a predisposition to contract a disease by assaying for mutations of uromodulin (UMOD) within a test subject or patient. The presence of a mutation in the UMOD supports a diagnosis of a disease or a predisposition to contract a disease within the patient. | 11-11-2010 |
| 20100291548 | Methods of Detecting Target Nucleic Acids - The present disclosure relates to methods of identifying target nucleic acids by using coded molecules and its analysis by translocation through a nanopore. Generally, coded molecules are subject to a target polynucleotide dependent modification. The modified coded molecule is detected by isolating the modified coded molecules from the unmodified coded molecules prior to analysis through the nanopore or by detecting a change in the signal pattern of the coded molecule when analyzed through the nanopore. | 11-18-2010 |
| 20100291549 | METHODS AND COMPOSITIONS FOR ANTIBODY THERAPY - Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on a FcγRIIA polymorphism, or a FcγRIIIA polymorphism, or both an FcγRIIA polymorphism and a FcγRIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's FcγRIIA polymorphism, or FcγRIIIA polymorphism, or both the FcγRIIA polymorphism and the FcγRIIIA polymorphism. | 11-18-2010 |
| 20100291550 | Methods and compositions for modulating hair growth - The invention relates, in part, to methods and compounds that are useful to modulate hair growth in mammals. The invention, in part, also includes nucleic acids, polypeptides, and genetic constructs that may be used to diagnose and treat hair growth disorders, for screening for compounds that modulate hair growth, and for selecting treatment regimens for subjects with hair loss disorders or hair growth conditions. The invention in some aspects also includes kits that may include polypeptides and/or nucleic acids for diagnosis of hair growth disorders and/or for the modulation of hair growth in subjects. | 11-18-2010 |
| 20100291551 | GENEMAP OF THE HUMAN ASSOCIATED WITH CROHN'S DISEASE - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to IBD (e.g. Crohn's Disease) and/or their response to a particular drug or drugs. | 11-18-2010 |
| 20100291552 | DETECTION OF MUTATIONS IN A GENE ENCODING IkB KINASE-COMPLEX-ASSOCIATED PROTEIN TO DIAGNOSE FAMILIAL DYSAUTONOMIA - A method for detecting the presence in a subject of a polymorphism linked to a gene associated with familial dysautonomia, said method comprising detecting a disruptive mutation in a gene of said subject encoding the IκB kinase-complex-associated protein, and, preferably, detecting a T→C change in position 6 of the donor splice site of intron 20 and/or a G→C transversion of nucleotide 2390 in exon 19 of the gene encoding the IκB kinase-complex-associated protein which is present on chromosome 9q31. Also disclosed are oligonucleotide primers useful in the detection method. This abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to ascertain quickly the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. | 11-18-2010 |
| 20100291553 | NUCLEIC ACID STRAND USEFUL IN DETECTING SUBSTANCE AND METHOD THEREOF - To detect an infinitesimal substance with a high sensitivity without amplifying the infinitesimal substance. A nucleic acid strand for detection P having at least a fluorescent substance F which can serve as a donor of resonance excitation energy (fluorescence resonance energy), a quencher substance Q which is located at a position enabling it to receive the resonance excitation energy, and a nucleic acid strand region N which is located between the quencher substance Q and the fluorescent substance F and has an enzyme cleavage site X to be cleaved by an endonuclease; and a detection technique using the nucleic acid strand for detection P. | 11-18-2010 |
| 20100291554 | COMPOSITIONS AND METHODS FOR DETERMINING GENOTYPES - The present invention provides methods for determining the genotype of a selected gene present in at least two alleles in a sample. The methods involve amplifying DNA from the sample with a first pair of flanking primers that hybridize to nucleic acid sequences flanking a variant-specific gene sequence, the presence of which indicates the presence of a first gene variant, and the absence of which indicates the presence of a second gene variant. The DNA is also amplified with a third primer that specifically binds to the variant-specific sequence and together with one of the flanking primers forms a second pair of primers. Detection of one or more nucleic acid products of the amplification reaction is indicative of the genotype present in the sample. | 11-18-2010 |
| 20100291555 | PRIMER AND PROBE FOR DETECTION OF MYCOBACTERIUM AVIUM AND METHOD FOR DETECTION OF MYCOBACTERIUM AVIUM BY USING THE PRIMER OR PROBE - The object of the present invention is to provide a novel primer for use in the detection of | 11-18-2010 |
| 20100291556 | ISOLATED AEBP1 GENOMIC POLYNUCLEOTIDE FRAGMENTS FROM CHOMOSOME 7 AND THEIR USES - The invention is directed to isolated genomic polynucleotide fragments that encode human SNARE YKT6, human glucokinase, human adipocyte enhancer binding protein (AEBP1) and DNA directed 50 kD regulatory subunit (POLD2), vectors and hosts containing these fragments and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain SNARE YKT6, human glucokinase, AEBP1 protein and POLD2 and to diagnose, treat, prevent and/or ameliorate a pathological disorder. | 11-18-2010 |
| 20100291557 | BINARY PROBE AND CLAMP COMPOSITION AND METHODS FOR TARGET HYBRIDIZATION DETECTION - Binary probe and clamp compositions conduct methods for target hybridization detection. Where the probe is a substrate for exonuclease cleavage, the composition provides quantitation and detection of PCR products, by real-time and end-point measurements. Where the probe is an amplification primer, the composition provides an improved method for labelling and detection of PCR products. Probes and clamps may be labelled with fluorescent dyes, quenchers, hybridization-stabilizing moieties, chemiluminescent dyes, and affinity ligands. Clamps may be nucleic acid analogs, such as 2-aminoethylglycine PNA. | 11-18-2010 |
| 20100291558 | Magnetic particles for nucleic acid sequencing and method of sequencing nucleic acid using the same - Provided are magnetic particles for nucleic acid sequencing and a method of sequencing nucleic acid using the same. The nucleotide sequence of a target nucleic acid may be efficiently determined using the magnetic particles and the method of sequencing nucleic acid using the same. | 11-18-2010 |
| 20100291559 | Compositions of orthogonal lysyl-tRNA and aminoacyl-tRNA synthetase pairs and uses thereof - Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal lysyl-tRNAs, orthogonal lysyl-aminoacyl-tRNA synthetases, and orthogonal pairs of lysyl-tRNAs/synthetases, which incorporate homoglutamines into proteins are provided in response to a four base codon. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with homoglutamines using these orthogonal pairs. | 11-18-2010 |
| 20100291560 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DYSKERATOSIS CONGENITA AND RELATED DISORDERS - The present invention features methods of detection, diagnosing a presence or a predisposition to, or determining the risk for a subject to develop telomere-associated diseases or disorders. The methods include detecting the presence or absence of an alteration in a nucleic acid in a sample. The methods also include determining telomere length. In certain cases, average telomere length is a surrogate marker for a telomere-associated disease or disorder. | 11-18-2010 |
| 20100291561 | METHODS FOR DETECTING A TARGET NUCLEOTIDE SEQUENCE IN A SAMPLE UTILISING A NUCLEASE-APTAMER COMPLEX - The present invention relates to methods for detecting a target nucleotide sequence in a sample. More particularly, the present invention relates to methods for detecting a target nucleotide sequence in a sample which utilise a nuclease-aptamer complex. The present invention also provides nuclease-binding aptamers, nuclease-aptamer complexes and linker molecules that may be used in accordance with the methods of the present invention. | 11-18-2010 |
| 20100291562 | METHOD FOR THE DETECTION OF AN ANALYTE IN BIOLOGICAL MATRIX - The present invention relates to a method for the highly sensitive Immuno-PCR detection of an analyte in a sample comprising the use of a nucleic acids containing sample dilution buffer for diluting the sample as well as methods for the preparation of the sample dilution buffer and the use thereof. | 11-18-2010 |
| 20100291563 | ASSESSING TISSUE REJECTION - This document relates to methods and materials involved in assessing tissue rejection (e.g., organ rejection) in mammals. For example, methods and materials involved in detecting tissue rejection (e.g., kidney rejection) are provided, as are methods and materials for determining the extent of rejection in mammals (e.g., humans). | 11-18-2010 |
| 20100291564 | Methods for Detection of Micro-Organisms - NAD-dependent ligase is identified as an indicator of micro-organisms in a sample. A method of detecting the presence of an NAD-dependent ligase expressing micro-organism in a sample comprises the steps of: (a) contacting the sample with a nucleic acid molecule which acts as a substrate for NAD-dependent ligase activity in the sample, (b) incubating the thus contacted sample under conditions suitable for NAD-dependent ligase activity; and (c) specifically determining the presence of a ligated nucleic acid molecule resulting from the action of the NAD-dependent ligase on the substrate nucleic acid molecule to indicate the presence of the NAD-dependent ligase expressing micro-organism. The method has a number of applications and kits for carrying out the methods are also provided. Lysostaphin preparations substantially free from nuclease and/or ligase contaminants are produced by heating a lysostaphin preparation which contains nuclease and/or ligase contaminants under conditions whereby nuclease and/or ligase activity is reduced whereas endopeptidase activity of the lysostaphin is substantially unaffected. | 11-18-2010 |
| 20100291565 | Detection of Methylation in Nucleic Acid Sequences - The present invention provides a method for detecting and/or quantifying the presence of, and relative abundance of, methylated nucleic acid bases within double-stranded nucleic acid by i) contacting a double-stranded nucleic acid sample with an intercalating fluorescent dye when bound to the nucleic acid sample fluoresces when exposed to light of a wavelength capable of causing the dye to fluoresce; 2) altering the hybridisation conditions of the solution containing the double-stranded nucleic acid-dye complex such that dissociation of the two strands of the said nucleic acid-dye complex occurs at a rate that permits progressive release of the dye 3) and monitoring the difference in fluorescence, and uses thereof. | 11-18-2010 |
| 20100291566 | SYSTEMS AND METHODS FOR DIAGNOSIS AND MONITORING OF BACTERIA-RELATED CONDITIONS - The presently-disclosed subject matter provides systems, methods, and kits for diagnosing and/or monitoring a bacteria-related condition of interest in a subject by providing a cell sensing system, each system containing a reporter molecule capable of detecting binding of a quorum sensing molecule and capable of generating a detectable signal. | 11-18-2010 |
| 20100291567 | GENES AND POLYPEPTIDES RELATING TO HEPATOCELLULAR OR COLORECTAL CARCINOMA - The present application provides novel human genes WDRPUH and KRZFPUH, and PPIL1 whose expression is markedly elevated in a great majority of HCCs and colorectal cancers, respectively, compared to corresponding non-cancerous tissues, as well as novel human gene APCDD1 whose expression is elevated in primary colon cancers and down-regulated in response to the transduction of wild-type APC1 into colon-cancer cells. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of a cell proliferative disease, and as target molecules for developing drugs against the disease. | 11-18-2010 |
| 20100291568 | METHODS FOR GENETIC ANALYSIS OF DNA TO DETECT SEQUENCE VARIANCES - Methods for determining genotypes and haplotypes of genes are described. Also described are single nucleotide polymorphisms and haplotypes in the ApoE gene and methods of using that information. | 11-18-2010 |
| 20100291569 | ASSAY FOR PREDICTION OF RESPONSE TO MET ANTAGONISTS - A method for classifying cancer patients as likely to have lower response to MET receptor antagonist therapy comprises assessment of the presence or absence of a single nucleotide polymorphism in the MET promoter in a patient tissue sample. The invention provides more effective identification of patients to receive MET receptor antagonist therapy. | 11-18-2010 |
| 20100291570 | MATERIALS AND METHODS FOR DETECTION OF NUCLEIC ACIDS - Assays using non-natural bases are described. In one embodiment, the method involves contacting a sample suspected of containing the target nucleic acid with a polymerase and first and second primers; amplifying the target nucleic acid by PCR using the first and second primers to generate an amplification product having a double-stranded region and a single-stranded region that comprises the non-natural base; contacting the sample with a reporter comprising a label and a non-natural base that is complementary to the non-natural base of the single-stranded region; annealing at least a portion of the reporter to the single-stranded region of the amplification product; and correlating a signal of the label with the presence of the target nucleic acid in the sample. The invention also provides corresponding kits for use in detecting target nucleic acids in a sample. | 11-18-2010 |
| 20100291571 | DIAGNOSIS OF FETAL ANEUPLOIDY BY QUANTIFICATION OF GENOMIC DNA FROM MIXED SAMPLES - The present invention provides systems, apparatuses, and methods to detect the presence of fetal cells when mixed with a population of maternal cells in a sample and to test fetal abnormalities, i.e. aneuploidy. In addition, the present invention provides methods to determine when there are insufficient fetal cells for a determination and report a non-informative case. The present invention involves quantifying regions of genomic DNA from a mixed sample. More particularly the invention involves quantifying DNA polymorphisms from the mixed sample. | 11-18-2010 |
| 20100291572 | FETAL ANEUPLOIDY DETECTION BY SEQUENCING - The present invention provides apparatus and methods for enriching components or cells from a sample and conducting genetic analysis, such as SNP genotyping to provide diagnostic results for fetal disorders or conditions. | 11-18-2010 |
| 20100291573 | Methods of Predicting Cancer Risk Using Gene Expression in Premalignant Tissue - The present disclosure provides methods for assessing a patient's cancer risk and/or recurrence risk, which methods comprise assaying, in a biological sample obtained from the gastrointestinal (GI) tract of the patient, an expression level of a risk gene. The present disclosure also provides methods involving a cancer risk/recurrence risk sequence, i.e. the V600E mutation of the BRAF gene, which is useful for assessing cancer risk and/or recurrence risk in a patient. | 11-18-2010 |
| 20100291574 | Genotyping Assay to Predict Gamma Glutamyl Hydrolase (GGH) Activity - Single nucleotide polymorphisms (SNPs) in the gene encoding gamma glutamyl hydrolase (GGH) associated with reduced GGH activity are disclosed. The primary SNP is a change from a cytosine to a thymine at a position corresponding to nucleotide 511 of Genbank sequence accession no. NM 003878. Methods and kits for detecting these SNPs are provided, along with primers useful in detecting these SNP and for amplifying portions of the GGH gene containing these SNPs. | 11-18-2010 |
| 20100291575 | Detection of Changes in Cell Populations and Mixed Cell Populations - The invention provides methods of label-free detection of changes in cell populations and mixed cell populations. | 11-18-2010 |
| 20100291576 | IMPRINTED GENES AS EPIGENETIC MARKERS FOR USE IN CLONING AND REGENERATIVE CELL PROCEDURES - In general, the invention features methods of identifying and/or preparing a mammalian cell or a cell population (e.g., bovine or porcine cells) for use in cloning procedures or regenerative cell procedures using expression of one or more of the epigenetic markers, IGF2, p57, and NNAT. | 11-18-2010 |
| 20100291577 | Toll-Like Receptor 9 Modulators - TLR9 is localized to endoplasmic reticulum and upon stimulation with a TLR9 ligand, is transported to a tubular lysosomal compartment as is CpG-DNA. Furthermore, it is shown that TLR9 and CpG-DNA directly bind. It was also found that the MyD88 translocates in response to activation of TLR9-mediated signaling. Methods of identifying compounds that affect translocation and activity of TLR9 and MyD88 are described. | 11-18-2010 |
| 20100291578 | Droplet-Based Pyrosequencing - The present invention relates to droplet-based pyrosequencing including a method of identifying a base at a target position in a sample nucleic acid. The method includes: (a) providing a droplet microactuator including a first droplet including a sample nucleic acid immobilized on a bead; and (b) on the droplet microactuator: (i) contacting the first droplet with one or more reagent droplets to yield a second droplet, wherein the one or more reagent droplets include reagents for extending a double stranded portion of the sample nucleic acid by incorporating a nucleotide at the target position; (ii) splitting the second droplet to yield a third droplet including the bead and a fourth droplet lacking the bead; and (iii) assaying the third droplet to determine whether the nucleotide was incorporated at the target position. | 11-18-2010 |
| 20100291579 | Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses - The invention provides isolated nucleic acid molecules and polypeptide molecules. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 11-18-2010 |
| 20100291580 | BIOMARKERS FOR TRICHOGENICITY - Biomarkers for identifying trichogenic cells have been identified. The biomarkers include microRNA as wells as mRNA and proteins. Certain biomarkers are upregulated in trichogenic cells compared to non-trichogenic cells; whereas, other biomarkers are down-regulated in trichogenic cells compared to non-trichogenic cells. The cells can be dermal cells, epidermal cells, or a combination thereof. Preferably the cells are mammalian, more preferably the cells are human. One embodiment provides a method for selecting trichogenic cells by assaying the cells for expression of one or more biomarkers for trichogenicity, and selecting the cells having increased expression of the one or more biomarkers relative to a control, wherein increased expression of the a biomarker in the cells is indicative of trichogenicity. Preferably, the one or more biomarkers are selected from the group consisting of hsa-miR-200c, hsa-miR-205, hsa-miR-200a*, hsa-miR-200a, hsa-miR-141, hsa-miR-182, DEPDC1, hFLEG1, ESM1, TOME-1, THBD and combinations thereof. | 11-18-2010 |
| 20100291581 | Aldehyde Dehydrogenase 1 (ALDH1) as a Cancer Stem Cell Marker - The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides a novel stem cell cancer marker, ALDH | 11-18-2010 |
| 20100291582 | Detection of Group B Streptococcus - The invention provides methods to detect group B | 11-18-2010 |
| 20100291583 | METHODS FOR DETECTING NUCLEIC ACIDS USING MULTIPLE SIGNALS - Disclosed is are methods for identifying a nucleic acid in a sample. In one example, the method includes: (a) contacting the nucleic acid in the sample with an oligonucleotide that is specific for the nucleic acid in the sample and that is labeled with at least a first fluorescent dye; (b) contacting the nucleic acid in the sample with a second fluorescent dye that is different from the first fluorescent dye, such that the second fluorescent dye interacts with the nucleic acid; (c) amplifying the nucleic acid if present in the sample; and (d) detecting the nucleic acid if present in the sample by observing fluorescence from the first fluorescent dye after the oligonucleotide hybridizes to the amplified nucleic acid and determining the melting temperature of the amplified nucleic acid by measuring the fluorescence of the second fluorescent dye. The second fluorescent dye may include a fluorescent intercalating agent. | 11-18-2010 |
| 20100291584 | MICROFLUIDIC IMAGING CYTOMETRY - A microfluidic system has a pipette system comprising a plurality of pipettes, a microfluidic chip arranged proximate the pipette system, an imaging optical detection system arranged proximate the microfluidic chip, and an image processing system in communication with the imaging optical detection system. The microfluidic chip has a plurality of cell culture chambers defined by a body of the microfluidic chip, each cell culture chamber being in fluid connection with an input channel and an output channel defined by the microfluidic chip. The pipette system is constructed and arranged to at least one of inject fluid through the plurality of pipettes into the plurality of input channels or extract fluid through the plurality of pipettes from the plurality of output channels while the microfluidic system is in operation. | 11-18-2010 |
| 20100291585 | METHODS AND COMPOSITIONS FOR DIAGNOSING COMPLICATIONS OF PREGNANCY - The present invention provides methods and compositions for identifying subjects at risk of developing a complication of pregnancy, such as preeclampsia or preterm labor. The compositions are microRNAs and associated nucleic acids. | 11-18-2010 |
| 20100297613 | Nucleic acid, amino acid encoded by said nucleic acid, probe comprising said nucleic acid or said amino acid, and screening method using said probe - A nucleic acid involved in the control of the biological clock comprising following (a) or (b):
| 11-25-2010 |
| 20100297614 | PROCESS FOR THE DETECTION OF CYTOSINE METHYLATIONS - The invention concerns a method for the detection of cytosine methylations in DNA and a kit for undertaking an assay according to the method of the invention. | 11-25-2010 |
| 20100297615 | EGFR MUTATIONS - The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment. | 11-25-2010 |
| 20100297616 | SITU HYBRIDISATION METHOD - There is provided an improved method of in situ hybridisation. In particular, a method of in situ hybridisation of biopolymer(s) in a sample of cells, with the proviso that the digestion of polypeptides is not performed. The method may be applicable to detection of different types of biopolymers, including detection of nucleic acids and polypeptides in the same sample. In particular, the method is for the detection of chromosomal abnormalities in uncultured amniotic cells. | 11-25-2010 |
| 20100297617 | PRIMER SET FOR AMPLIFYING NAT2 GENE, REAGENT FOR AMPLIFYING NAT2 GENE CONTAINING THE SAME, AND THE USES THEREOF - Primer sets for amplifying target regions containing sites to be detected in the NAT2 gene by a gene amplification method are provided, wherein the primer sets can amplify the regions specifically. Three pairs of primer sets are used including forward primers consisting of the base sequences of SEQ ID NOs: 7, 33, and 60 as well as reverse primers consisting of the base sequences of SEQ ID NOs: 18, 48 and 81, respectively. The use of these primer sets makes it possible to amplify three target regions including parts where three types of polymorphisms (NAT2*5, NAT2*6, and NAT2*7) of the NAT2 gene are generated, respectively, in the same reaction solution at the same time. | 11-25-2010 |
| 20100297618 | METHODS FOR DETERMINING A PROGNOSIS OF COLORECTAL CANCER - The invention provides methods for determining a prognosis of colorectal cancer in an individual comprising determining an A-type lamin status of an individual and using the A-type lamin status to determine the prognosis of the colorectal cancer, and more particularly for predicting outcomes of colorectal cancer in the individual such as the survival or mortality of the individual or the likelihood of recurrence of the colorectal cancer. Kits for use in carrying out these methods are also provided. | 11-25-2010 |
| 20100297619 | GENETIC PREDICTION OF SCHIZOPHRENIA SUSCEPTIBILITY - Provided are methods of determining the likelihood that a patient will be diagnosed with schizophrenia. | 11-25-2010 |
| 20100297620 | ACTIVATED PROTEASE INDICATOR - It is an object of the invention to provide novel approaches capable of detecting activated protease and also detecting protease activation on real time at a high sensitivity in a noninvasive manner. By the method for detecting activated protease of the invention, an indicator in a circular form comprising the C-half fragment of luciferase (Luc-C) and the N-half fragment of luciferase (Luc-N) linked together through a substrate peptide for a protease is introduced in an in vitro assay system or in cells. Upon digestion of the substrate peptide by the protease, Luc-N and Luc-C together reconstructs active luciferase, so that the activated protease can be detected by assaying the luminescence signal from the luciferase. | 11-25-2010 |
| 20100297621 | USE OF PRE-MRNA SPLICING IN PLATELET CELLS FOR THE DIAGNOSIS OF DISEASE - The invention relates to materials and procedures for identifying or using tissue factor (TF) pre-mRNA splicing, CIk 1 activity or TF-dependent coagulation in platelet cells for the diagnosis, prognosis, or prediction of a disease or disorder associated with disordered coagulation. Since activated platelets splice pre-mRNAs to generate inflammatory and thrombotic mediators that contribute to diseases such as sepsis and septic shock, (TF) pre-mRNA splicing in platelets is an indicator of inflammatory and thrombotic disease states. TF pre-mRNA splicing in platelets is correlated with sepsis, increased age (≧65), APACHE II score, and bacteremia. Thus, TF mRNA expression patterns in platelets may be used for the diagnosis, prognosis, or prediction of a disease or disorder associated with disordered coagulation, for example, patients that are at a higher risk for severe sepsis, organ failure, and death. | 11-25-2010 |
| 20100297622 | Method for high-throughput gene expression profile analysis - The present invention embraces a method for high-throughput gene profiling with high specificity and sensitivity. With this system, >1000 mRNA species can be co-amplified using gene-specific primers from a single cell. The primers are designed to amplify sequences of desirable length, which are in different exons. The exons can be either adjacent and separated by a large intron or include more than two exons. The amplified sequences are then analyzed by microarray with probes hybridizing to neighboring exons. | 11-25-2010 |
| 20100297623 | NOVEL HUMAN ssDNA BINDING PROTEINS AND METHODS OF CANCER DIAGNOSIS - A method for detecting transformed cells or tumour cells, a method for diagnosing or prognosing cancer or for assessing a predisposition to cancer, and kits for use in the methods are disclosed. The methods particularly involve the detection of overexpression of an ssDNA binding protein (SSB) or polypeptide comprising the following amino acid sequence: FX | 11-25-2010 |
| 20100297624 | Involvement of Lipid Kinase, and Signal Transduction Pathway Comprising Said Lipid Kinase, in Resistance to HER2-Targeting Therapy - The invention is related to a method for determining whether an individual suffering from cancer is at risk of exhibiting or acquiring a reduced response towards HER2-targeting therapy. In one aspect, the invention utilizes the activity of a signal transduction pathway modulated by a lipid kinase for determining said risk. | 11-25-2010 |
| 20100297625 | BIOMARKERS FOR PSYCHOSIS - The present invention relates generally to the diagnosis of psychosis, schizophrenia and bipolar disorder, including psychotic bipolar disorder. | 11-25-2010 |
| 20100297626 | Reagents, Methods, and Libraries for Bead-Based Sequencing - The present invention provides methods for determining a nucleic acid sequence by performing successive cycles of duplex extension along a single stranded template. The cycles comprise steps of extension, ligation, and, preferably, cleavage. In certain embodiments the methods make use of extension probes containing phosphorothiolate linkages and employ agents appropriate to cleave such linkages. In certain embodiments the methods make use of extension probes containing an abasic residue or a damaged base and employ agents appropriate to cleave linkages between a nucleoside and an abasic residue and/or agents appropriate to remove a damaged base from a nucleic acid. The invention provides methods of determining information about a sequence using at least two distinguishably labeled probe families. In certain embodiments the methods acquire less than 2 bits of information from each of a plurality of nucleotides in the template in each cycle. In certain embodiments the sequencing reactions are performed on templates attached to beads, which are immobilized in or on a semi-solid support. The invention further provides sets of labeled extension probes containing phosphorothiolate linkages or trigger residues that are suitable for use in the method. In addition, the invention includes performing multiple sequencing reactions on a single template by removing initializing oligonucleotides and extended strands and performing subsequent reactions using different initializing oligonucleotides. The invention further provides efficient methods for preparing templates, particularly for performing sequencing multiple different templates in parallel. The invention also provides methods for performing ligation and cleavage. The invention also provides new libraries of nucleic acid fragments containing paired tags, and methods of preparing microparticles having multiple different templates (e.g., containing paired tags) attached thereto and of sequencing the templates individually. The invention also provides automated sequencing systems, flow cells, image processing methods, and computer-readable media that store computer-executable instructions (e.g., to perform the image-processing methods) and/or sequence information. In certain embodiments the sequence information is stored in a database. | 11-25-2010 |
| 20100297627 | MicroRNA Diagnostics for Cancer - Disclosed are methods for detecting breast cancer or prostate cancer by measuring levels of miR-204 and miR-510 in samples. | 11-25-2010 |
| 20100297628 | Methods Of Producing And Sequencing Modified Polynucleotides - The present invention encompasses methods for producing a modified polynucleotide sequence that comprises a (e.g., one or more) phosphorothiolate linkage, methods for determining a polynucleotide sequence comprising a (e.g., one or more) phosphorothiolate linkage, and methods for separating forward and reverse extension products that comprise a (e.g., one or more) phosphorothiolate linkage. The invention also encompasses kits for producing and/or determining the sequence of a modified polynucleotide that comprises a (e.g., one or more) phosphorothiolate linkage. | 11-25-2010 |
| 20100297629 | NUCLEIC ACID SUPPORTED PROTEIN COMPLEMENTATION - The present invention is directed to novel methods for in vitro and in vivo detection of target nucleic acid molecules, including DNA and RNA targets, as well as nucleic acid analogues. The present invention is based on protein complementation, in which two individual polypeptides are inactive. When the two inactive polypeptide fragment are brought in close proximity during hybridization to a target nucleic acid, they re-associate into an active, detectable protein. | 11-25-2010 |
| 20100297630 | METHOD FOR THE SIMULTANEOUS DETECTION OF MULTIPLE NUCLEIC ACID SEQUENCES IN A SAMPLE - The invention is in the technical field of detecting nucleic acid sequences in a sample, such as the detection of pathogenic organisms in clinical samples. More specifically, the invention relates to the field of detecting an infection caused by a pathogenic organism such as a virus or a bacterium in a clinical specimen by means of amplifying and detecting specific nucleic acid sequences from said pathogenic organism. It provides a multiplex assay with the possibility to determine about 30 different target nucleic acid sequences in a single one-tube assay combined with real-time probe detection. The method employs multiplex ligation dependent Probe Amplification (MLPA) employing labelled primers in combination with labelled, probes and detection of the fluorescence. | 11-25-2010 |
| 20100297631 | Compositions and Methods For Detecting Histamine Related Disorders - The present invention generally relates to methods and compositions (e.g., assay kit) for the diagnosis of histamine related disorders. The invention also relates to a novel molecular target of histamine related disorders and the uses thereof for detecting or diagnosing such diseases, as well as to develop adapted and efficient therapeutic treatment thereof. The invention may be used in any mammalian subject, particularly human subjects. | 11-25-2010 |
| 20100297632 | UPREGULATION OF RACK-1 IN MELANOMA AND ITS USE AS A MARKER - The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocyte cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocyte cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocyte cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein. | 11-25-2010 |
| 20100297633 | METHOD OF AMPLIFYING NUCLEIC ACID - The present invention provides a method for detecting a polymorphism or mutation in nucleic acid comprising a first phase to amplify or enrich for a sequence comprising a polymorphism or mutation and a second phase for detecting the polymorphism or mutation, wherein both phases are performed in the same reaction vessel. | 11-25-2010 |
| 20100297634 | GENE EXPRESSION SIGNATURES IN ENRICHED TUMOR CELL SAMPLES - The invention is embodied in methods for finding gene expression signatures of circulating melanoma cells, ovarian, breast, colorectal cancer cells, and circulating endothelial progenitor cells, which signatures are effective in distinguishing the circulating cancer cell from normal circulating cells and can also distinguish between different types of circulating cancer cells. | 11-25-2010 |
| 20100297635 | COLLECTION AND MEASUREMENT OF EXHALED PARTICLES - Particles are exhaled in the breath of animals. The nature and amounts of the particles can be indicative of certain medical conditions. They can therefore be collected, sorted according to size or mass and used in the diagnosis of one or more medical conditions. The invention provides a method and system for collecting and sorting exhaled particles and a method for diagnosis using said exhaled particles. | 11-25-2010 |
| 20100297636 | CC2D2A GENE MUTATIONS ASSOCIATED WITH JOUBERT SYNDROME AND DIAGNOSTIC METHODS FOR IDENTIFYING THE SAME - The present invention provides a method of screening a subject for mutations in the CC2D2A gene that are associated with Joubert syndrome, an autosomal recessive form of mental retardation. The present invention also provides proteins that are associated with Joubert syndrome including proteins comprising an amino acid sequence that terminates in DHEGGSGMES (SEQ ID NO: 1). Also provided are nucleotide sequences encoding such proteins and methods of screening subjects to identify nucleotide sequences or proteins associated with Joubert syndrome. | 11-25-2010 |
| 20100297637 | PRIMER FOR AMPLIFICATION OF RRNA OR BACTERIUM BELONGING TO THE GENUS LEGIONELLA, DETECTION METHOD, AND DETECTION KIT - To detect a bacterium belonging to the genus | 11-25-2010 |
| 20100297638 | MOLECULAR ADAPTORS - The invention relates to transmembrane protein pore for use in detecting a analyte in a sample. The pore comprises a molecular adaptor that facilitates an interaction between the pore and the analyte. The adaptor is covalently attached to the pore in an orientation that allows the analyte to be detected using the pore. | 11-25-2010 |
| 20100297639 | QUANTITATIVE/SEMI-QUANTITATIVE MEASUREMENT OF EPOR ON CANCER CELLS - The present invention provides for assays useful in predicting whether a cancer patient risks suffering erythropoietin-induced tumor progression if treated with erythropoietin. More specifically, one embodiment provides for a validated quantitative reverse transcriptase polymerase chain reaction assay that detects erythropoietin receptor expression, thus indicating whether a cancer patient risks suffering erythropoietin-induced tumor progression if treated with erythropoietin. | 11-25-2010 |
| 20100297640 | HAND HELD MICRO PCR DEVICE - Instant invention is about a hand held micro PCR device comprising a LTCC micro PCR chip comprising a heater, a reaction chamber to load a sample. It also comprises a heater control to regulate the heater on basis of input received from a temperature sensor. It further has an optical system having an optical fiber to detect a fluorescence signal from the sample, and at least one communication interface to interact with other device(s). | 11-25-2010 |
| 20100297641 | METHYLATION ALTERED DNA SEQUENCES AS MARKERS ASSOCIATED WITH HUMAN CANCER - There is disclosed 103 novel methylation-altered DNA sequences (“marker sequences”) that have distinct methylation patterns in cancer, compared to normal tissue. In many instances, these marker sequences represent novel sequences not found in the GenBank data base, and none of these marker sequences have previously been characterized with respect to their methylation pattern in human cancers including, but not limited to those of bladder and prostate. These 103 sequences have utility as diagnostic, prognostic and therapeutic markers in the treatment of human cancer, and as reagents in kits for detecting methylated CpG-containing nucleic acids. | 11-25-2010 |
| 20100297642 | METHOD FOR DETERMINING FRAMESHIFT MUTATIONS IN CODING NUCLEIC ACIDS - The present invention relates to a method for identifying frameshift mutations in coding nucleic acid sequences. | 11-25-2010 |
| 20100297643 | Terminus-Specific DNA Modification Using Random-Sequence Template Oligonucleotides - A method is provided for analyzing DNA molecules having unknown 3′ terminal sequences. The method involves contacting a DNA molecule with a plurality of template oligonucleotides blocked at their 3′ termini such that the template oligonucleotides are not extendable by DNA polymerase. The 3′ proximal portions of each of the template oligonucleotides comprise a region of random sequence and the 5′ proximal portions of each of the template oligonucleotides comprise the complement of a tag sequence. The DNA molecule and the template oligonucleotides are combined under conditions wherein the 3′ terminus of the DNA molecule hybridizes to the 3′ proximal portion of a template oligonucleotide and is extended by a DNA polymerase to produce a DNA molecule comprising a 3′ terminal tag sequence, and wherein the template oligonucleotide is not extended. | 11-25-2010 |
| 20100297644 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY SPACING - Nucleic acid sequencing methods and related devices, products and kits are disclosed. Methods for sequencing a target nucleic acid comprise providing a daughter strand produced by a template-directed synthesis, the daughter strand comprising a plurality of subunits coupled in a sequence corresponding to a contiguous nucleotide sequence of all or a portion of the target nucleic acid, wherein the individual subunits comprise a probe and a reporter construct. The subunit encodes sequence information in its reporter construct that is less than sequence information in the corresponding portion of the target nucleic acid. The reduced information allows for reduced resolution requirements on the detection system and for increased size of resolvable reporter groups. | 11-25-2010 |
| 20100297645 | AUTOMATIC DETECTION OF INFECTIOUS DISEASES - The invention relates to the detection of infectious diseases. A system for automatic detection of infectious diseases is disclosed. The system comprises an input unit for receiving a blood sample, a lysis unit, a PCR unit, a sample unit and a detection unit. The systemmay based on an inputted blood sample generate an output signal that isindicative of the presence of pathogen DNA in the blood sample. | 11-25-2010 |
| 20100297646 | METHOD FOR DETECTION OF CANCER - A method for detecting a cancer(s) based on an expression of prescribed polypeptides is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing in serum derived from cancer-bearing living body. Because these polypeptides react with antibodies specifically existing in serum of a cancer patient, cancers in a living body can be detected by measuring the antibody in a sample. Cancers in a living body can also be detected by measuring the antigen protein of the antibody per se or mRNA encoding it. | 11-25-2010 |
| 20100297647 | POLYMERASE-BASED SINGLE-MOLECULE SEQUENCING - The invention relates to an assay method for determining the base sequence in a nucleic acid sample which comprises detection of a single base in said sequence using a polymerase modified to include at least one fluorophore and a dark quencher group; detecting and deducing the amount of energy transfer. | 11-25-2010 |
| 20100297648 | METHOD FOR DIAGNOSING SUSCEPTIBILITY TO POST-TRAUMATIC SCAR-TISSUE FORMATION - Disclosed is an in vitro method for diagnosing susceptibility to post-traumatic scar tissue formation, wherein from a biological sample of a patient the nucleotide of the -509 position of the TGF-β1 gene is determined and if said -509 position contains exclusively C, thus it is the homozygotic wild type allele, then said patient is considered to be susceptible to post-traumatic scar tissue formation. The invention relates furthermore to diagnostic kits for the detection of susceptibility to post-traumatic scar tissue formation, preferably for the detection of susceptibility to tracheal stenosis from a biological sample. | 11-25-2010 |
| 20100297649 | METHODS AND MATERIALS FOR DETECTING GENE AMPLIFICATION - This document relates to methods and materials involved in detecting gene amplification in a mammal. For example, methods and materials for detecting amplification at CPM and MDM2 loci to determine the presence or absence of a malignant lipomatous neoplasm in a mammal are provided. | 11-25-2010 |
| 20100297650 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 193P1E1B USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 0193P1E1B (also designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 193P1E1B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 193P1E1B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 193P1E1B can be used in active or passive immunization. | 11-25-2010 |
| 20100297651 | Methods of Modulating Vesicular Trafficking - Described are methods of identifying compounds useful for modulating vesicular trafficking, particularly those that disrupt the interactions between ARNO and the V-ATPase a2-subunit. Also described are peptides that modulate vesicular trafficking. | 11-25-2010 |
| 20100297652 | MIRNA BIOMARKERS OF PROSTATE DISEASE - This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing prostate disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as prostate cancer. | 11-25-2010 |
| 20100297653 | METHODS OF DIAGNOSING AND TREATING CANCER - The invention features methods of evaluating the risk of cancer recurrence in a subject diagnosed with cancer. | 11-25-2010 |
| 20100297654 | THREE-COMPONENT BIOSENSORS FOR DETECTING MACROMOLECULES AND OTHER ANALYTES - The invention generally provides three-component molecular biosensors. The molecular biosensors are useful in several methods including in the identification and quantification of target molecules. | 11-25-2010 |
| 20100297655 | SOCS-1 GENE METHYLATION IN CANCER - Methods are provided for identifying a cell exhibiting unregulated growth associated with methylation-silenced transcription of a suppressor of cytokine signaling (SOCS)/cytokine-inducible SH2 protein (CIS) family member (SOCS/CIS) gene such as the SOCS-1 gene. In addition, methods of treating a cancer patient, wherein cancer cells in the patient exhibit methylation-silenced transcription of SOCS/CIS gene such as a SOCS-1 gene, are provided, as are reagents for practicing such methods. | 11-25-2010 |
| 20100297656 | AMPLICON MELTING ANALYSIS WITH SATURATION DYES - Methods are provided for nucleic acid analysis wherein a target nucleic acid that is at least partially double stranded is mixed with a dsDNA binding dye having a percent saturation of at least 50% to form a mixture. In one embodiment, the nucleic acid is amplified in the presence of the dsDNA binding dye, and in another embodiment a melting curve is generated for the target nucleic acid by measuring fluorescence from the dsDNA binding dye as the mixture is heated. Dyes for use in nucleic acid analysis and methods for making dyes are also provided. | 11-25-2010 |
| 20100297657 | EXPRESSION PROFILE OF PROSTATE CANCER - The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications. | 11-25-2010 |
| 20100297658 | DETECTING METHYLATED MAMMALIAN NUCLEIC ACID IN STOOL - This document includes methods and materials for enriching and detecting cancer markers. For example, this document includes methods and materials for enriching methylated mammalian nucleic acid from stool samples. | 11-25-2010 |
| 20100297659 | THIN-FILM LAYERED CENTRIFUGE DEVICE AND ANALYSIS METHOD USING THE SAME - Disclosed herein is a thin-film layered centrifuge device and an analysis method using the same. One example of an embodiment of the present invention is a thin film layered centrifuge device where a device, such as a lab on a chip, a protein chip and a DNA chip, for diagnosing and detecting a small amount of material in a fluid is integrated into a rotatable thin-film layered body, and to an analysis method using the thin-film layered centrifuge device. | 11-25-2010 |
| 20100297660 | SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH RENAL DISEASE - Methods for determining the genetic predisposition of a human subject to developing renal disease, such as focal segmental glomerulosclerosis (FSGS) or end-stage kidney disease are provided herein. These methods include methods for detecting renal disease, or determining the risk of developing renal disease in a human subject, such as a subject of African ancestry. The methods utilize the detection of one or more haplotype blocks comprising at least two tag single nucleotide polymorphisms (SNPs) in a non-coding region of a MYH9 gene or detecting the presence of at least one tag SNP in a non-coding region of a MYH9 gene. An array for detecting a genetic predisposition to renal disease using probes complementary to the tag SNPs in the non-coding region of the MYH9 gene are also disclosed. | 11-25-2010 |
| 20100304365 | MUTATION OF PRPS1 GENE CAUSING CMTX5 DISEASE AND THE USE THEREOF - Disclosed is a gene mutation associated with peripheral neuropathy associated with sensorineural hearing loss and optic neuropathy. More specifically, disclosed are: a polynucleotide comprising a mutation associated with peripheral neuropathy associated with sensorineural hearing loss and optic neuropathy, or a complementary polynucleotide thereof; a polynucleotide which hybridizes with said polynucleotide; a polypeptide which is encoded by said polynucleotide; an antibody which binds to said polypeptide; and a microarray chip and a kit, which comprise said polynucleotide. Also disclosed are a method for diagnosing a syndrome of peripheral neuropathy associated with sensorineural hearing loss and optic neuropathy, a method for detecting the mutation, and a method for screening drugs for treating these diseases. | 12-02-2010 |
| 20100304366 | Methods for Determining Virulence and Invasiveness Among Various Staphylococcus Aureus Strains - This invention describes quick diagnostic methods to distinguish CA-MRSA MW2 or CA-MRSA USA300 strains in clinical samples from various sources. Fluorescent labeled primers which amplify 1) two unique agr sequences from each strain, 2) a partial spa gene and 3) a partial pvl gene are packaged into a multiplex PCR kit. A real-time instrumentation to amplify and quantify the PCR amplification products, measured by the change of each of the labeled fluorescent reporter and their thermal melting curve, provides a simple and rapid identification of the most virulent and invasive MRSA strains in the United States. | 12-02-2010 |
| 20100304367 | COMPOSITIONS FOR REAL-TIME, SINGLE MOLECULE SEQUENCE DETERMINATION - A sequencing methodology is disclosed that allows a single DNA or RNA molecule or portion thereof to be sequenced directly and in substantially real time. The methodology involves engineering a polymerase and/or dNTPs with atomic and/or molecular tags that have a detectable property that is monitored by a detection system. | 12-02-2010 |
| 20100304368 | COMPONENTS AND METHOD FOR ENZYMATIC SYNTHESIS OF NUCLEIC ACIDS - Novel methods for enzymatic synthesis of nucleic acid chains and the substrates for the same are disclosed. The methods are based on a step-wise enzymatic reaction. The sequencing of nucleic acids is an example of the use of the claimed methods. | 12-02-2010 |
| 20100304369 | METHOD AND APPARATUS FOR DIAGNOSING AGE-RELATED MACULAR DEGENERATION - Disclosed is a method for identifying an individual who has an altered risk for developing age-related macular degeneration comprising detecting an insertion/deletion polymorphism in the ARMS2 gene | 12-02-2010 |
| 20100304370 | INTRACELLULAR PH SENSOR USING NUCLEIC ACID ASSEMBLIES - Disclosed are nucleic acid-based sensors for measuring the pH of a sample, including cells, regions thereof, and whole organisms. The sensor includes an I-switch that is triggered by protons, and which functions as a FRET-based pH sensor inside living cells and organisms. Also disclosed are compositions and methods for measuring the pH of a specific region of a cell, such as vesicles, the nucleus, mitochondrial matrix, or the Golgi lumen. | 12-02-2010 |
| 20100304371 | COMPOSITIONS AND METHODS FOR DETECTING MYCOBACTERIA - The present invention features compositions and methods that can be used to analyze samples for the presence of | 12-02-2010 |
| 20100304372 | Liver Cancer Methods and Compositions - The present invention provides a novel method for detection of liver cancer. This method detects high-sensitively, high-specifically, simply and accurately liver cancer, especially that in early stage by identifying and/or quantifying methylation on particular genes and/or their DNA fragments in clinical specimens, and by combining said methylated DNA values with existing tumor marker values and/or DNA amounts in blood. This invention also detects a precancerous lesion, detects a risk of recurrence after treatment of liver cancer, detects malignancy of liver cancer and monitors progression of liver cancer with time by the same method. As for particular genes, BASP1 gene, SPINT2 gene, APC gene, CCND2 gene, CFTR gene, RASSF1 gene and SRD5A2 gene are mentioned. | 12-02-2010 |
| 20100304373 | Methods for Assessing the Susceptibility of a Human to Diminished Health and Wellness - The present invention relates to methods for assessing the advisability that a human should employ a compensatory composition comprised of one or more antioxidant ingredients. The methods involve assessing occurrence in the human's genome of a plurality of certain polymorphisms. Methods for determining the composition of preferred compensatory compositions are also disclosed. | 12-02-2010 |
| 20100304374 | METHODS AND TOOLS FOR DISCRIMINATING COLORECTAL ADENOMAS AND ADENOCARCINOMAS - The present invention relates to the differential expression of genes in colorectal adenoma and adenocarcinoma cells and their correlation with chromosomal aberrations. The present invention provides tools for detecting chromosomal aberrations linked to progression of adenomas into adenocarcinoma cells. The present invention discloses methods and tools for in vivo and in vitro diagnosis of colorectal tumours. | 12-02-2010 |
| 20100304375 | Influenza Virus Genome Replication and Transcription System in Yeast Cells - A system in which vRNP purified from influenza virus particles is introduced into yeast ( | 12-02-2010 |
| 20100304376 | Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer - The present invention discloses methods of using the methylation status of the COX-2 gene promoter region as a biomarker for a gastric cancer patient to determine a prognosis and a treatment regimen, and to monitor the progress of a treatment regimen. | 12-02-2010 |
| 20100304377 | METHOD OF DETECTING NOROVIRUS RNA - The amount of an RNA transcription product amplified in an RNA amplification process is measured using a nucleic acid probe labeled with an intercalating fluorescent dye. The RNA amplification process comprises the steps of using at least two sets of primer pairs comprising a first primer and a second primer (in which one of these primers carries a promoter sequence added to the 5′ end thereof), both of which have high hybridization efficiency to a nucleic acid sequence that is homologous to or complementary to each norovirus genotype RNA; forming a double-stranded DNA containing the promoter sequence with a reverse transcriptase; forming an RNA transcription product with an RNA polymerase by using the double-stranded DNA as a template; and forming the double-stranded DNA by successively using the RNA transcription product as a template in the DNA synthesis with the reverse transcriptase. | 12-02-2010 |
| 20100304378 | Method for Detecting or Quantifying a Truncating Mutation - The present invention discloses a new method for detecting or quantifying a truncating mutation of a target gene in a subject, said method relying on the in vitro compartmentalization of single genetic constructs in aqueous droplets of a water-in-oil emulsion. | 12-02-2010 |
| 20100304379 | SPORES FOR THE STABILIZATION AND ON-SITE APPLICATION OF BACTERIAL WHOLE-CELL BIOSENSING SYSTEMS - The presently-disclosed subject matter is directed to biosensors comprising spore-forming bacterial cells and/or spores generated therefrom, a recognition unit within each spore-forming cell for binding an analyte of interest, and a reporter molecule within each spore-forming cell for detecting binding of the analyte of interest, wherein the reporter molecule generates a detectable signal upon binding of the analyte by the recognition element. The presently-disclosed subject matter further provides methods of using the biosensors and systems and kits including the biosensors. | 12-02-2010 |
| 20100304380 | Quantitative DNA Methylation Imaging of Cells and Tissues - The invention is a method using immunofluorescence, high-resolution imaging, and 3D image analysis to quantify spatial distribution of methylcytosine (MeC) in global DNA in individual cell nuclei, for the characterization of cells and tissues based on their nuclear MeC distribution patterns. The invented method is intended for basic research, clinical diagnostics and prognostics, pharmacology and toxicology, and molecular and cell-based therapy. | 12-02-2010 |
| 20100304381 | FLUORESCENT NUCLEOBASE CONJUGATES HAVING ANIONIC LINKERS - Provided are nucleotide-dye conjugates and related compounds in which a dye is linked to a nucleobase directly or indirectly by an anionic linker. The anionic character of the linker is provided by one or more anionic moieties which are present in the linker, such as phosphate, phosphonate, sulfonate, and carboxylate groups. When the dye is a provided as a donor/acceptor dye pair, the anionic linker can be located between the donor and the acceptor, or between the nucleobase and either the donor or acceptor, or both. In one embodiment, conjugates of the invention provide enhanced electrophoretic mobility characteristics to sequencing fragments, e.g., for dideoxy sequencing using labeled terminators. | 12-02-2010 |
| 20100304382 | Gene Defects and Mutant ALK Kinase in Human Solid Tumors - In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention. | 12-02-2010 |
| 20100304383 | BIOMARKERS FOR PRENATAL DIAGNOSIS OF CONGENITAL CYTOMEGALOVIRUS - The invention provides compositions and methods useful for early detection of congenital CMV infection, predicting the likelihood and severity of congenital CMV disease, and monitoring the efficacy of therapeutic approaches. Compositions of the present invention include biomarkers that are differentially expressed in CMV-infected mothers and fetuses compared to uninfected individuals. | 12-02-2010 |
| 20100304384 | METHOD OF IDENTIFYING COMPOUNDS THAT INDUCE OR INHIBIT ENDOPLASMIC RETICULUM STRESS OR OXIDATIVE STRESS - The present invention generally relates to a method for the identification of compounds for the treatment of neurodegenerative diseases. Said method is based on a cell model for neurodegeneration useful for the identification of potentially useful compounds for the treatment or the prevention of a neurodegenerative disease associated with deficient expression of the DDIT3 gene, also known as CHOP. | 12-02-2010 |
| 20100304385 | ASSAY - The invention provides a LAMP assay for detection of meningococcal disease, the test comprising at least one nucleic acid primer set capable of detecting | 12-02-2010 |
| 20100304386 | ENZYMES FOR AMPLIFICATION AND COPYING BISULPHITE MODIFIED NUCLEIC ACIDS - The invention relates to the use of enzymes for copying or amplifying bisulphite modified or treated nucleic acids, wherein the enzymes are more effective in copying or amplifying the nucleic acid compared with native Taq polymerase under substantially the same conditions. | 12-02-2010 |
| 20100304387 | METHODS AND COMPOSITIONS FOR SIGNAL ENHANCEMENT USING MULTIVALENT INTERACTIONS - Methods and materials are disclosed relating to an improved method for amplifying a signal in a diagnostic assay for an analyte, using an amplification polymer that multivalently binds to one or more non-analyte-specific binding site of the multivalent bridge conjugate, if present on the solid support. | 12-02-2010 |
| 20100304388 | Biomarker For Successful Aging Without Cognitive Decline - Methods and compositions for determining whether a subject will age without developing cognitive decline are provided. An exemplary method includes detecting one or more allelic variants in a gene encoding low density lipoprotein-related protein 1B. In a preferred embodiment, the detecting step is accomplished by contacting a sample obtained from the subject with a probe that forms a detectable complex with a nucleic acid in the sample containing an allelic variant indicative of aging without developing cognitive decline, wherein detection of the allelic variant in the sample indicates that the subject will age without developing cognitive decline. | 12-02-2010 |
| 20100304389 | Preparation And Isolation of 5' Capped mRNA - The synthesis of capped/tagged RNA, methods of use and kits providing same are contemplated. Tagged RNA permits isolation of RNA transcripts in vitro. The ability to isolate and purify capped RNA results in improved transcription and translation and provides a tool for identifying RNA-protein interactions. Such capped RNA finds use in therapeutic applications, diagnosis and prognosis and in the treatment of cancers and HIV. | 12-02-2010 |
| 20100304390 | METHODS FOR DETECTING GENE DYSREGULATIONS - Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g. translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5′ and 3′ regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5′ portion of a target gene relative to the 3′ region of the target gene. | 12-02-2010 |
| 20100304391 | METHODS FOR ASSESSMENT AND TREATMENT OF DEPRESSION VIA UTILIZATION OF SINGLE NUCLEOTIDE POLYMORPHISMS ANALYSIS - Described herein are assays, kits and methods for treating depression, including the diagnosis and treatment of depression based on the determination of genetic predispositions towards inhibition or enhancement of Ca2+/calmodulin-dependent protein kinase II (CaMKII). For example, described herein are methods and kits (including assays) for determining if one or more gene in an excitatory or inhibitory pathway for modulating CaMKII activity or expression is likely to be inhibited or enhanced by an SNP. Also described are methods and kits (including assays) for prescribing treatment based on the identification of SNPs that may modulate CaMKII. | 12-02-2010 |
| 20100304392 | HEPATITIS B VIRAL VARIANTS WITH REDUCED SUSCEPTIBILITY TO NUCLEOSIDE ANALOGS AND USES THEREOF - The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus. | 12-02-2010 |
| 20100304393 | Genetic predictors of international normalized ratio (INR) fluctuation with warfarin therapy - There are disclosed methods and kits for identifying a subject having genetic predictors of predisposition to abnormal international normalized ratio (INR) fluctuation during warfarin therapy. In an embodiment, a method includes testing the subject to check for a presence of a predetermined genetic variation. The predetermined genetic variation is correlated with abnormal INR fluctuation during warfarin therapy. The subject is identified as having a predisposition to abnormal INR fluctuation during warfarin therapy when the testing indicates the presence of the predetermined genetic variation. In one embodiment, a kit includes a test to check the subject for a presence of a predetermined genetic variation. The predetermined genetic variation is correlated with abnormal INR fluctuation during warfarin therapy. The kit includes an indicator to identify the presence of the predetermined genetic variation so as to identify the subject as having a predisposition to abnormal INR fluctuation during warfarin therapy. | 12-02-2010 |
| 20100304394 | Screening methods involving the detection of short-lived proteins - A method is provided for screening for agents that affect protein degradation rates, the method comprising: taking a library of cells, the cells expressing a fusion protein comprising a reporter protein and a protein encoded by a sequence from a cDNA library derived from a sample of cells, the sequence from the cDNA library varying within the cell library; contacting the library of cells with a plurality of agents which may affect protein degradation rates; for each agent, selecting cells in the library which express short-lived proteins based on whether the cells have different reporter signal intensities than other cells in the library, the difference being indicative of the selected cells expressing shorter lived fusion proteins than the fusion proteins expressed by the other cells in the library; and characterizing the fusion proteins expressed by the selected cells for each agent. | 12-02-2010 |
| 20100304395 | Method, Program, and System for Normalizing Gene Expression Amounts - The present invention aims at presenting novel means for analyzing and correcting gene expression amounts. There is provided a gene expression amount normalizing method in which the number of cells in a sample is obtained by measuring a repeated sequence present in a substantially fixed proportion in a genome contained in the sample, and the number of cells obtained is used as an index for normalizing gene expression amounts obtained from the same sample. For example, a DNA sample | 12-02-2010 |
| 20100304396 | ANIMAL HEALTH DIAGNOSTICS - A physical blood sample of animal is sent to a satellite laboratory facility. The blood sample is pre-processed into sub-samples of the sample and the sub-samples are coded. The coded blood sub-samples are physically carried to the main laboratory for analysis. The satellite facility electronically inputs a request for a laboratory analysis by a main laboratory. The request is electronically transmitted to the main laboratory, and the main laboratory coordinates the electronically received input from the satellite facility with the physical blood sub-samples. A computer report of the analysis from the laboratory is obtained for the satellite facility. A clinical pathologist with data of physical characteristics of the animal makes a diagnosis. A menu on a computer permits the generation of a supplemental report to support the diagnosis. An integrated computer report having the laboratory analysis, supplemental report, and a pathologist-enhanced report is electronically communicated to the client. | 12-02-2010 |
| 20100311040 | Dna Fragments, Primers, Kits, and Methods for Amplification the Detection and Identification of Clinically Relevant Candida Species - The present invention describes a novel molecular method based on the polymerase chain reaction (PCR) in a multiplex variant in order to detect and identify | 12-09-2010 |
| 20100311041 | PCR DIAGNOSTICS OF DERMATOPHYTES AND OTHER PATHOGENIC FUNGI - Dermatophytes which belong to one of the three genera | 12-09-2010 |
| 20100311042 | Amplifying bisulfite-treated template - Methods of amplifying nucleic acid are described. Primers on a solid support, e.g. a population of beads, are employed. A population of nucleic acid template molecules, wherein said nucleic acid template molecules have been treated with bisulfite, is amplified so as to create loaded beads comprising immobilized amplified nucleic acid. | 12-09-2010 |
| 20100311043 | RNA complexes, method of their production and sensors and analytical methods involving same - The invention includes RNA complexes comprising at least three monomeric units of an RNA molecule, each monomeric unit comprising an RNA polymer having first and second helical domains that have respective first and second binding sites, wherein the first binding sites are adapted to binding to one another and are not adapted to bind to the second binding sites, and the second binding sites are adapted to binding to one another and are not adapted to bind to the first binding sites; such that the at least three monomeric units are adapted to self-assemble by forming pairs of cognate interactions and so as to form the RNA complex in a circular closed complex. The invention also includes derivatives of these complexes including aptamers, and analytical methods and devices using same. | 12-09-2010 |
| 20100311044 | ASSAY KIT FOR IN-SITU HYBRIDIZATION OF RHOGDI2 GENE, METHOD THEREFOR AND USE THEREOF THE ASSAY KIT - An assay kit for in-situ hybridization (Rho GDP dissociation inhibitor beta, ISH) of RhoGDI2 gene, an assay method therefor and a use of the assay kit are provided. The assay kit includes: a hybridization probe, a marker, a hybridization solution, and an enhancement reagent. The hybridization probe has a sequence of SEQ ID NO. 1. The assay method includes steps of: (a) mixing the hybridization probe of the assay kit with a to-be-tested RNA on a substrate to form a hybridization complex; and (b) assaying the hybridization complex formed in the step (a). The use of the assay kit is applied the assay kit to prepare a therapeutic medicines for early metastasis of a carcinoma or a relapse disease. The assay kit of the present invention can enhance sensitivity and strengthen specificity. Meanwhile, the assay method of the present invention can increase operational convenience and simplify procedures, so that the assay method can be popularized in the medical institutions including local hospitals. | 12-09-2010 |
| 20100311045 | CANCER - The invention provides methods of diagnosis, prognosis and treatment of cancer related to the OBCAM and NTM genes. The methods are particularly suited to ovarian and colorectal cancers. | 12-09-2010 |
| 20100311046 | METHOD FOR THE DETECTION OF CHROMOSOMAL ANEUPLOIDIES - The non-invasive detection of fetal chromosomal aneuploidies is demonstrated. Alleles of fetal RNA-SNPs present in a biological sample (e.g. maternal blood) containing fetal RNA are detected and quantified in order to determine the ratio of the alleles. This ratio is compared to a standard control consisting of euploid fetuses. Deviation of allele ratio indicates the presence of chromosomal aneuploidy. | 12-09-2010 |
| 20100311047 | Identification Of Cancer Protein Biomarkers Using Proteomic Techniques - The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer. | 12-09-2010 |
| 20100311048 | Neural Crest Enhancers and Methods for Use - DNA enhancer sequences are provided for use in constructs to identify early stage embryonic cells. The enhancer sequences can be used in parallel with short-hairpin RNA in a vector construct for endogenously regulated gene knockdowns. The disclosed enhancer sequences can be used to isolate a selected population of early stage embryonic cells. | 12-09-2010 |
| 20100311049 | PCR-Based Kit For Detecting Chlamydia Trachomatis and Nelsseria Gonorrhoeae - The invention relates to a PCR based prototype kit for detecting | 12-09-2010 |
| 20100311050 | Compositions and methods for the diagnosis and treatment of tumor - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 12-09-2010 |
| 20100311051 | Calcium-binding photoprotein, gene encoding the same and use thereof - The invention provides calcium-binding photoproteins which can detect light emission with a higher sensitivity. The proteins of the invention comprising the amino acid sequence of SEQ ID NO: 2 can be used for the detection and measurement of calcium ions. The proteins of the invention are useful as reporter proteins, luminescent markers, etc. The polynucleotides of the invention are useful as reporter genes, etc. | 12-09-2010 |
| 20100311052 | PROGNOSTIC METHOD FOR THE DETERMINATION OF THE SUITABILITY OF BIOPHARMACEUTICAL TREATMENT - The invention refers to a method for the prognosis of a disease in a subject by the administration of a biopharmaceutical treatment in a subject suffering from, or likely to suffer from the disease, the method involving the analysis of SNP polymorphisms in the subjects pattern recognition receptor genes (PRRs), eg the analysis of polymorphisms' with the purpose of predicting the response of anti-TNFx antibody therapy in rheumatoid arthritis patients. Also the response to Beta-interferon in multiple sclerosis patients may be predicted. The genes whose polymorphisms are analysed may be TLRs, NOD-like receptors or retinoic acid-inducible gene I-like receptors (RLR). | 12-09-2010 |
| 20100311053 | USE OF CLEC1B FOR THE DETERMINATION OF CARDIOVASCULAR AND THROMBOTIC RISK - The use of the single nucleotide polymorphism (SNP) of the CLEC1B gene for the identification of cardiovascular and/or thrombotic disorders or of an increased risk for developing cardiovascular and/or thrombotic disorders in a biological sample taken from an individual to be examined; the use of CLEC1B for identifying substances active in preventing and/or treating cardiovascular and/or thrombotic disorders and methods for doing so. | 12-09-2010 |
| 20100311054 | Compositions and Methods for the Detection of Human T Cell Receptor Variable Family Gene Expression - Compositions and methods for the assessment of T cell receptor variable subunits. The present invention provides nucleotide sequences for the evaluation of the expression of TCRV families. These nucleotides sequences were obtained through a bioinformatic investigation of the nucleotide sequences for TCRVaα and TCRVβ families. The nucleotide sequences of the present invention uniquely recognize each and every subfamily and allelic member of a particular TCRV family, while at the same time not recognizing the members of any other TCRV family. This unique expression recognition profile of the nucleotide sequences of the present invention provides great utility for the assessment of TCR families in a clinical setting, such as through polymerase chain reactions, gene chip technology, and direct electrophoretic measurement of DNA or RNA. | 12-09-2010 |
| 20100311055 | COMPOSITIONS AND METHODS FOR TERMINATING A SEQUENCING REACTION AT A SPECIFIC LOCATION IN A TARGET DNA TEMPLATE - Compositions and methods for sequencing a template polynucleotide comprising a sequence of interest are provided herein. The compositions and methods employ at least one blocking probe that is designed to bind in a sequence-specific manner to a blocking sequence such that primer extension beyond the site where the blocking probe binds is reduced or prevented. | 12-09-2010 |
| 20100311056 | METHOD FOR HYBRIDIZING NUCLEIC ACIDS - The invention relates to a method for manipulating, isolating, detecting or amplifying a target nucleic acid in a sample by hybridization with an oligonucleotide-oligocation conjugate, comprising allowing said nucleic acid to react with an oligonucleotide-oligocation conjugate comprising at least A1 and Bj linked together directly or via a linker, wherein. A, is an i-mer oligonucleotides, with i=3 to 50, where Ai is an oligomer with naturally or non naturally occurring nucleobases and/or pentafuranosyl groups and/or native phosphodiester bonds, optionally comprising a marker group. Bj is a j-mer organic oligocation moiety, with j=1 to 50, where B is —HPO | 12-09-2010 |
| 20100311057 | Mitochondrial DNA Deletion Between About Residues 12317-16254 for Use in the Detection of Cancer - The present invention relates to methods for predicting, diagnosing and monitoring cancer. The methods comprise obtaining biological samples, extracting mitochondrial DNA (mtDNA) from the samples, quantifying mitochondrial DNA mutation in the sample and comparing the level of mtDNA mutation with a reference value. The methods of the invention may also be effective in screening for new therapeutic agents and treatment regimes, and may also be useful for monitoring the response of a subject to a preventative or therapeutic treatment. | 12-09-2010 |
| 20100311058 | METHOD FOR DETECTING NUCLEIC ACIDS BY SIMULTANEOUS ISOTHERMAL AMPLIFICATION OF NUCLEIC ACIDS AND SIGNAL PROBE - The present invention relates to a method for detecting target nucleic acids by simultaneous isothermal amplification of the target nucleic acids and a signal probe 5 using an external primer set, a DNA-RNA-DNA hybrid primer set and a DNA-RNA-DNA hybrid signal probe. The method according to the present invention can be used to amplify target nucleic acids in a sample, rapid and exact manner without the risk of contamination compared to the conventional methods such as PCR, and it can simultaneously amplify target nucleic acid and a signal probe, so that it can 0 be applied to various genome projects, detection and identification of a pathogen, detection of gene modification producing a predetermined phenotype, detection of hereditary diseases or determination of sensibility to diseases, and estimation of gene expression. Thus, it is useful for molecular biological studies and disease diagnosis. | 12-09-2010 |
| 20100311060 | Integrated Chip Carriers With Thermocycler Interfaces And Methods Of Using The Same - Methods and systems are provided for conducting a reaction at a selected temperature or range of temperatures over time. An array device is provided. The array device contains separate reaction chambers and is formed as an elastomeric block from multiple layers. At least one layer has at least one recess that recess has at least one deflectable membrane integral to the layer with the recess. The array device has a thermal transfer device proximal to at least one of the reaction chambers. The thermal transfer device is formed to contact a thermal control source. Reagents for carrying out a desired reaction are introduced into the array device. The array device is contacted with a thermal control device such that the thermal control device is in thermal communication with the thermal control source so that a temperature of the reaction in at least one of the reaction chamber is changed as a result of a change in temperature of the thermal control source. | 12-09-2010 |
| 20100311061 | REAL-TIME SEQUENCING METHODS AND SYSTEMS - The present invention is generally directed to compositions, methods, and systems for performing single-molecule, real-time analysis of a variety of different biological reactions. The ability to analyze such reactions provides an opportunity to study those reactions as well as to potentially identify factors and/or approaches for impacting such reactions, e.g., to either enhance or inhibit such reactions. In certain preferred embodiments, RNA templates are used in single-molecule real-time sequencing reactions. | 12-09-2010 |
| 20100311062 | E. COLI O157:H7 SPECIFIC ASSAY - Disclosed are assays, methods and kits for the specific detection of | 12-09-2010 |
| 20100311063 | METHODS AND COMPOSITIONS FOR LABELING NUCLEIC ACIDS - The present invention relates to methods for the labeling of nucleic acid polymers in vitro and in vivo. Certain methods are provided that include a [3+2] cycloaddition between a nucleotide analogue incorporated into a nucleic acid polymer and a reagent attached to a label. Other methods are provided that include a Staudinger ligation between a nucleotide analogue incorporated into a nucleic acid polymer and a reagent comprising a substituted triarylphosphine attached to a label. Such methods do not require fixation and denaturation and therefore can be applied to the labeling of nucleic acid polymers in living cells and in organisms. Also provided are methods for measuring cellular proliferation. In these methods, the amount of label incorporated into the DNA is measured as an indication of cellular proliferation. The methods of the invention can be used in a wide variety of applications including clinical diagnosis of diseases and disorders in which cellular proliferation is involved, toxicity assays, and as a tool for the study of chromosomes' ultrastructures. | 12-09-2010 |
| 20100311064 | MULTIPLEX NUCLEIC ACID REACTIONS - The invention is directed to a variety of multiplexing methods used to amplify and/or genotype a variety of samples simultaneously. | 12-09-2010 |
| 20100311065 | GENETICALLY MODIFIED MICROBES PRODUCING ISOPRENOIDS - Provided herein are methods of generating genetically modified yeast cells, e.g., genetically modified diploid and haploid yeast cells, that comprise novel polypeptides, and genetically modified yeast cells that persistently produce isoprenoid compounds in industrial fermentation processes, produced thereby. | 12-09-2010 |
| 20100311066 | METHODS AND COMPOSITIONS FOR GENERATION OF MULTIPLE COPIES OF NUCLEIC ACID SEQUENCES AND METHODS OF DETECTION THEREOF - The present invention provides novel isothermal methods of generating multiple copies of, detecting and/or quantifying nucleic acid sequences of interest based on limited primer extension or attachment of oligonucleotide pairs using composite RNA/DNA primers. Methods for generating multiple copies of and/or detecting and/or quantifying nucleic acid sequences, wherein products of primer extension or attachment of oligonucleotide pairs comprising a cleavable portion are generated, and wherein cleavage of the products results in dissociation of cleaved products from target polynucleotides, are provided. The invention further provides compositions, kits and systems for practicing these methods. | 12-09-2010 |
| 20100311067 | DETECTION OF MATERNAL ALCOHOL EXPOSURE - The present invention provides methods, compositions, and systems for detecting in utero alcohol exposure by detecting expression level changes in certain biomarkers (e.g., in placental tissue). In certain embodiments, the biomarkers are selected from glucocorticoid receptor (GR), thyroid hormone receptor alpha (TRα), iodothyronine deiodinase III (Dio3) and G-protein α-subunit (Gsα). | 12-09-2010 |
| 20100311068 | ASSAY - The invention relates to process for in vitro prediction of a potentially allergenic substance wherein monocytes and/or macrophages and/or myelomonocytic cell lines are cultivated in the presence of the substance and interferon-γ, whereby productions of cytokines and/or neopterin are increased and measured. The allergic reaction may be estimated by measuring up regulated or down-regulated genes chosen from G1P2, OASL, IFIT1, TRIM22, IFI44L, MXI, RSAD2, IFIT3, IFITM1, IFIT2, C 33.28 HERV-H protein mRNA, IFITM3, XK, GPR15, MT1G, MT1B; MT1A, ADFP, IL8, MT1E, MT1F, MT1H, SLC30A1, SERPINB2, CD83, TncRNA or expression products from them are measured. The invention also relates to a reagent kit for use in the process comprising interferon-γ and reagents which recognise cytokines preferably each of IL-8 and neopterin and/or reagents such as probes recognising up-regulated or down-regulated genes. | 12-09-2010 |
| 20100311069 | MULTIPLEX CELL SIGNALLING ASSAYS - Disclosed are methods useful in multiplex cell-based assays for compound screening employing imaging instrumentation. The methods described herein offer high content information relating to the biological potency of test agents, off-target effects and cellular toxicity of potential drug candidates. | 12-09-2010 |
| 20100311070 | POLYMERASE CHAIN REACTION (PCR) MODULE AND MULTIPLE PCR SYSTEM USING THE SAME - Provided are a PCR module and a multiple PCR system using the same. More particularly, provided are a PCR module with a combined PCR thermal cycler and PCR product detector, and a multiple PCR system using the same. | 12-09-2010 |
| 20100311071 | Compositions and Methods for Detecting Juvenile Renal Dysplasia or Calcium Oxalate Stones in Dogs - The application relates to Canine Cox2 allelic variants associated with Juvenile Renal Dysplasia, primer and probe compositions and methods and kits useful in detecting, monitoring and diagnosing Juvenile Renal Dysplasia or calcium oxalate stones. | 12-09-2010 |
| 20100311072 | FLUORESCENCE POLARIZATION BINDING ASSAY FOR CHARACTERIZING GLUCOKINASE LIGANDS - The subject matter disclosed and claimed herein concerns measuring the binding affinity of glucokinase (“GK”) using a fluorescence polarization (“FP”) assay. The FP method includes use of modified GK ligands bound to a fluorescent label. Binding affinity is determined by measuring displacement of fluorescent ligand by the known or suspected GK ligands. The subject matter disclosed and claimed herein provides a robust high-throughput FP assay for the determination of binding affinity of ligands to glucokinase. The FP binding assay displayed both glucose and nucleotide dependence, and a useful dynamic range. The binding IC | 12-09-2010 |
| 20100311073 | SR-BI AS A PREDICTOR OF ELEVATED HIGH DENSITY LIPOPROTEIN AND CARDIOVASCULAR DISEASE - The present invention relates to the field of single nucleotide polymorphisms (SNPs) and uses therefore as a predictor of diseases and conditions. Specifically, the present invention provides methods and kits useful in determining whether a subject is at increased risk for developing a cardiovascular disease by screening for the presence of a SNP in the scavenger receptor class B type I (SR-BI) gene of a subject. | 12-09-2010 |
| 20100316993 | METHOD FOR ENRICHING A PROKARYOTIC DNA - A method is described for enriching procaryotic DNA, said method including the steps of contacting at least one procaryotic DNA with at least one protein or polypeptide which is capable of specifically binding to non-methylated CpG motifs, and separating the protein/polypeptide-DNA complex. Moreover, the application relates to a kit for carrying out said method. | 12-16-2010 |
| 20100316994 | DIAGNOSIS AND THERAPY OF CANCER USING SGP28-RELATED MOLECULES - The present invention relates to methods and compositions for the diagnosis and therapy of prostate cancer which utilize isolated polynucleotides corresponding to the human SGP28 gene, proteins encoded by the SGP28 gene and fragments thereof, and antibodies capable of specifically recognizing and binding to SGP28 proteins. | 12-16-2010 |
| 20100316995 | CONSENSUS CODING SEQUENCES OF HUMAN BREAST AND COLORECTAL CANCERS - Analysis of 13,023 genes in 11 breast and 11 colorectal cancers revealed that individual tumors accumulate an average of ˜90 mutant genes but that only a subset of these contribute to the neoplastic process. Using stringent criteria to delineate this subset, we identified 189 genes (average of 11 per tumor) that were mutated at significant frequency. The vast majority of these genes were not known to be genetically altered in tumors and are predicted to affect a wide range of cellular functions, including transcription, adhesion, and invasion. These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention and monitoring. | 12-16-2010 |
| 20100316996 | Nasopharyngeal cancer malignancy biomarker and method thereof - The present invention discloses a nasopharyngeal cancer malignancy biomarker and a method thereof, wherein relative hnRNP K expression is used to evaluate the malignancy of nasopharyngeal cancer. The biomarker of the present invention assists the currently-existing inspections to find out cancer in the early stage and realize early diagnosis and early therapy. The present invention also functions as an effective indicator to monitor the metastasis and relapse of nasopharyngeal cancer. | 12-16-2010 |
| 20100316997 | Cell Markers for Human Embryonic Stem Cells - Polynucleotides associated with differentiation states of stem cells are provided. Also provided are methods and kits for detecting, identifying and/or discriminating differentiated stem cells from undifferentiated ones by measuring an expression level of one or more genes, such as CBARA1 and LHX 6, in the stem cells. | 12-16-2010 |
| 20100316998 | METHODS AND COMPOSITIONS FOR EMPIRICAL SELECTION OF DRUGS OR OTHER MOLECULES - Methods for identification and/or selection of species having activity for a target molecule are described, as well as related compounds. In some cases, the compounds and methods may be useful in a screening process, where species that exhibit a desired property or combination of properties are identified and isolated from a large library of species (e.g., 10 | 12-16-2010 |
| 20100316999 | Nucleic Acid Sequence Analysis - The present invention relates to a method for determining the sequence of a polynucleotide, the method comprising the steps of: (i) reacting a target polynucleotide with a polymerase enzyme immobilised on a solid support, and the different nucleotides, under conditions sufficient for the polymerase reaction; and (ii) detecting the incorporation of a specific nucleotide complementary to the target polynucleotide, by measuring radiation. | 12-16-2010 |
| 20100317000 | METHOD FOR DIAGNOSING BLADDER CANCER BY ANALYZING DNA METHYLATION PROFILES IN URINE SEDIMENTS AND ITS KIT - The present invention provides a method for detecting bladder cancer in a subject, comprising the following steps: (a) providing urine sediment sample from said subject; (b) determining methylation pattern of a given sequence within the promoter CpG islands of one or more genes (known as “gene” infra) in the samples; (c) comparing the methylation pattern from said subject with that from normal subject, wherein the hypermethylation of one or more of genes indicates that said subject is suffering from bladder cancer. The present invention also provides a kit for diagnosing bladder cancer. | 12-16-2010 |
| 20100317001 | METHOD OF USING TUMOUR RNA INTEGRITY TO MEASURE RESPONSE TO CHEMOTHERAPY IN CANCER PATIENTS - Cancerous tumours vary significantly in their response to chemotherapy agents. Currently, it is difficult to reliably assess the level of tumour responsiveness to a chemotherapy regimen during or post-administration. Biomarkers of tumour sensitivity to chemotherapy agents have hitherto been unknown. Such a biomarker would expedite identification of nonresponsive patients, who may then switch to other, possibly more effective regimens. The present invention provides a method for determining tumour responsiveness to a chemotherapy agent, wherein RNA is isolated from tumour cells of a patient before, during, and after chemotherapy. The quality of the RNA can be determined by capillary electrophoresis and assignment of an RNA integrity number (RIN). RIN values during and/or after chemotherapy are inversely proportionate to the level of tumour responsiveness. The tumour RIN is an easily accessed biomarker of tumour responsiveness to chemotherapy. The tumour RIN may also be used to assess the efficacy of a chemotherapy regimen. | 12-16-2010 |
| 20100317002 | METHODS AND KITS FOR DIAGNOSING LUNG CANCER - Provided is a method of identifying a genetically abnormal cell in a sputum sample, the method comprising: (a) staining a sputum sample using a morphological stain so as to identify a lower airway tract cell or lung cell in the sputum sample; and (b) staining the sputum sample using fluorescent in situ hybridization (FISH) so as to identify in the lower airway tract cell or lung cell a genetic abnormality in at least one of human chromosome 3p22.1 and 10q22-23, thereby identifying the genetically abnormal cell in the sputum sample. Also provided are methods and kits of diagnosing lung cancer by detecting a presence of genetically abnormal cells above a predetermined threshold in a sputum sample. | 12-16-2010 |
| 20100317003 | NOVEL COMPOSITIONS AND METHODS IN CANCER WITH ALTERED EXPRESSION OF KCNJ9 - The present invention relates to novel sequences for use in diagnosis and treatment of carcinomas, especially breast cancers. In addition, the present invention describes the use of novel compositions for use in screening methods. | 12-16-2010 |
| 20100317004 | PROBES - The present invention relates to probes, methods and apparatus for the detection of the presence or absence of non-contiguous cis-located nucleic acid sequences which are characteristic of alleles including those relating to the human leukocyte antigen (HLA) which is of interest in the field of human transplantation and disease. | 12-16-2010 |
| 20100317005 | Modified Nucleotides and Methods for Making and Use Same - Labeled nucleotide triphosphates are disclosed having a label bonded to the gamma phosphate of the nucleotide triphosphate. Methods for using the gamma phosphate labeled nucleotide are also disclosed where the gamma phosphate labeled nucleotide are used to attach the labeled gamma phosphate in a catalyzed (enzyme or man-made catalyst) reaction to a target biomolecule or to exchange a phosphate on a target biomolecule with a labeled gamme phosphate. Preferred target biomolecules are DNAs, RNAs, DNA/RNAs, PNA, polypeptide (e.g., proteins enzymes, protein, assemblages, etc.), sugars and polysaccharides or mixed biomolecules having two or more of DNAs, RNAs, DNA/RNAs, polypeptide, sugars and polysaccharides moieties. | 12-16-2010 |
| 20100317006 | SCA RISK STRATIFICATION BY PREDICTING PATIENT RESPONSE TO ANTI-ARRHYTHMICS - Genetic tests and methods for treatment based on markers to identify patients suffering from life-threatening ventricular tachy-arrhythmias, such as Ventricular Tachycardias (“VT”) and Ventricular Fibrillation (“VF”) that might lead to Sudden Cardiac Arrest (“SCA”) or Sudden Cardiac Death (“SCD”) are provided. Patients who cannot be sufficiently protected by medication alone, such as those refractory to anti-arrhythmic medication, are identified based on their genotype. The resulting information is used in a diagnostic test to identify and treat those patients who would benefit from the implantation of an Implantable Cardio Defibrillator (“ICD”). | 12-16-2010 |
| 20100317007 | Methods and Systems to Identify Operational Reaction Pathways - The present invention provides a method for identifying an operational reaction pathway of a biosystem. The method includes (a) providing a set of systemic reaction pathways through a reaction network representing said biosystem; (b) providing a set of phenomenological reaction pathways of said biosystem, and (c) comparing said set of systemic reaction pathways with said set of phenomenological reaction pathways, wherein a pathway common to said sets is an operational reaction pathway of said biosystem. Also described is a method of refining a biosystem reaction network; a method of reconciling biosystem data sets; a method of determining the effect of a genetic polymorphism on whole cell function; and a method of diagnosing a genetic polymorphism-mediated pathology. | 12-16-2010 |
| 20100317008 | Nonseparation Assay Methods - Assay methods are disclosed involving specific binding reactions which are simplified compared to known methods. A compound capable of producing chemiluminescence is immobilized on a solid support as is a member of a specific binding pair for capturing an analyte from a sample. An activator compound that activates the chemiluminescent compound and is conjugated to a specific binding pair member is added in excess along with the sample to the solid support. Addition of a trigger solution causes a chemiluminescent reaction at the sites where the activator conjugate has been specifically bound. The assay methods are termed non-separation assays because they do not require removal or separation of excess detection label (activator conjugate) prior to the detection step. The methods are applicable to various types of assays including immunoassays, receptor-ligand assays and nucleic acid hybridization assays. | 12-16-2010 |
| 20100317009 | Method for DNA Double-Strand Break Repair in Vitro and Applications Thereof - A system and a method for DNA double-strand break repair in vitro are disclosed. Applications of the disclosed method in multiple areas are also disclosed. | 12-16-2010 |
| 20100317010 | ELF3 gene compositions and methods - ELF3 gene compositions associated with cancer are provided, including ELF3 mRNA intron retention, a novel ELF3 5′ untranslated region, and a novel Alu, Alu | 12-16-2010 |
| 20100317011 | Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use - The invention relates to the molecule referred to as ALK-1, and its role as a type I receptor for members of the TGF-β family. The molecule has a role in the phosphorylation of Smad-5 and Smad1, which also act as activators of certain genes. Aspects of the invention relate to this interaction. | 12-16-2010 |
| 20100317012 | Massive parallel method for decoding DNA and RNA - This invention provides methods for attaching a nucleic acid to a solid surface and for sequencing nucleic acid by detecting the identity of each nucleotide analogue after the nucleotide analogue is incorporated into a growing strand of DNA in a polymerase reaction. The invention also provides nucleotide analogues which comprise unique labels attached to the nucleotide analogue through a cleavable linker, and a cleavable chemical group to cap the —OH group at the 3′-position of the deoxyribose. | 12-16-2010 |
| 20100317014 | COMPOSITIONS AND METHODS FOR THE ISOLATION OF NUCLEIC ACID - The present invention provides compositions and methods for the isolation of nucleic acids from a sample or subject. In particular, the present invention provides isolation, purification, and analysis of total DNA and RNA from a subject or sample. The compositions and methods find particular use in the isolation of nucleic acids associated with arthropods (e.g., ticks), including nucleic acid from pathogens carried by arthropods. | 12-16-2010 |
| 20100317015 | SPINOCEREBELLAR ATAXIA TYPE 8 AND METHODS OF DETECTION - The present invention provides an isolated nucleic acid molecule containing a repeat region of an isolated spinocerebellar ataxia type 8 (SCA8) coding sequence, the coding sequence located within the long arm of chromosome 13, and the complement of the nucleic acid molecule. Diagnostic methods based on identification of this repeat region are also provided. | 12-16-2010 |
| 20100317016 | DYES AND LABELED MOLECULES - Dimeric and trimeric nucleic acid dyes, and associated systems and methods are provided. Such a dye may form a hairpin-like structure that enables it to stain nucleic acids via a release-on-demand mechanism, for example. Such a dye may have low background fluorescence in the absence of nucleic acids and high fluorescence in the presence of nucleic acids, upon binding therewith, for example. A dye provided herein may be useful in a variety of applications, such as in DNA quantitation in real-time PCR, for example. | 12-16-2010 |
| 20100317017 | CYSTIC FIBROSIS GENE MUTATIONS - The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided. | 12-16-2010 |
| 20100317018 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION - Methods of diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection and kits or systems containing the same are also described. | 12-16-2010 |
| 20100317019 | NUCLEIC ACID DETECTION METHOD AND NUCLEIC ACID DETECTION KIT - The present invention is directed to a method with which one can detect a nucleic acid with sufficient accuracy, no matter the nucleotide length of a primer, and no matter if the analyte nucleotide consists of only a single nucleotide. Specifically disclosed is a method for detecting whether or not a nucleic acid sample contains a nucleic acid which has a target nucleotide sequence comprising one or more analyte nucleotide(s) in a nucleic acid sample. Firstly, in a step (a), a nucleic acid extension reaction is performed with use of a nucleic acid contained in the nucleic acid sample, an analyte nucleotide-identification primer, and a polymerase. Next, in a step (b), an extension product yielded from the step (a) is detected. The step (a) uses, as the primer, a polynucleotide which comprises a nucleotide sequence having an insertion site or a deletion site of one or more nucleotide(s), on the 5′ side of nucleotide(s) corresponding to the analyte nucleotide(s), in a nucleotide sequence homologous or complementary to an analyte nucleotide-containing partial region of the target nucleotide sequence. | 12-16-2010 |
| 20100317020 | METHODS AND COMPOSITIONS FOR DETECTING MICROORGANISMS - Methods of analyzing a sample for target microorganisms of interest are described. In particular, the methods are useful for detecting a variety of yeast and mold microorganisms based on the presence of a ubiquitous cell wall component, such as zymosan. Methods of analyzing a sample for fungal microorganisms using liposomes and/or culture media are also described. | 12-16-2010 |
| 20100323346 | Method of Examining Inflammatory Disease and Method of Screening Remedy for Inflammatory Disease - A single nucleotide polymorphism occurring on a leptin receptor gene is analyzed and an inflammatory disease is examined on the basis of the analytical data. Further, a substance capable of changing the interaction between the leptin receptor and galectin-2 is selected to thereby screen a remedy for an inflammatory disease. | 12-23-2010 |
| 20100323347 | Method for Evaluating or Selecting Agent for Preventing or Curing Photodamage of Skin - A method for evaluating or selecting a substance capable of preventing or curing photodamage of skin is provided. Provided is a method for evaluating or selecting an agent for preventing or curing photodamage of skin, the method including: (A) contacting cells that are capable of expressing TIMP-1 gene or TIMP-1 protein, with a test substance; (B) measuring the expression level of the TIMP-1 gene or the TIMP-1 protein in the cells; (C) comparing the expression level obtained in (B), with the expression level of TIMP-1 gene or TIMP-1 protein in a control group in which the cells capable of expressing TIMP-1 gene or TIMP-1 protein have not been contacted with the test substance; and (D) evaluating or selecting the test substance which increases the expression level of TIMP-1 gene or TIMP-1 protein, as an agent for preventing or curing photodamage of skin, based on the results of (C). | 12-23-2010 |
| 20100323348 | Methods and Compositions for Using Error-Detecting and/or Error-Correcting Barcodes in Nucleic Acid Amplification Process - The present invention provides methods and compositions for detecting and correcting errors in nucleic acid amplification processes, and methods for using the same. In particular, barcode amplification errors are detected and corrected such that integrity in sample assignment is maintained. The methods are compatible with high throughput sequencing techniques as some of the barcodes are based upon Hamming codes, thereby allowing self-correction for single bit errors. Some methods and compositions of the invention allow characterization (e.g., sequencing) of a plurality of nucleic acid samples simultaneously within a single sequencing reaction. | 12-23-2010 |
| 20100323349 | Identification of the Gene and Mutation Responsible for Progressive Rod-Cone Degeneration in Dog and a Method for Testing Same - Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1. | 12-23-2010 |
| 20100323350 | Methods And Devices For Sequencing Nucleic Acids In Smaller Batches - The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. A plurality of smaller flow cells is employed, each with a relatively small area to be imaged, in order to provide greater flexibility and efficiency. | 12-23-2010 |
| 20100323351 | TUMOR SUPPRESSOR GENE, P47ING3 - The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins. | 12-23-2010 |
| 20100323352 | Marker for Prenatal Diagnosis and Monitoring - The present invention relates to new methods for diagnosing a pregnancy-associated disorder by analyzing fetal DNA present in the mother's blood. More specifically, this invention relies on the discovery that the maspin gene is differentially methylated in fetal DNA and in maternal DNA and provides these new diagnostic methods, which distinguish fetal DNA from maternal DNA and detect prenatal disorders based on abnormalities in fetal DNA level and methylation status. | 12-23-2010 |
| 20100323353 | MARKER ASSISTED DIRECTED EVOLUTION - The present invention is directed at a novel method to enhance the genetic improvement of industrial microorganisms. More specifically, the present invention is directed at molecular methods for the identification of genetic variants that contribute to the genetic improvement of the microorganisms. The methods of the present invention comprise novel approaches for identifying genetic markers that linked to said genetic variants, and for using said genetic markers to select improved industrial microorganisms. In one of the embodiments, the genetic markers linked to said genetic variants are identified in microbial populations that are subjected to directed evolution. In another embodiment the genetic markers linked to said genetic variants are identified in microbial sub populations that have been prescreened for improved characteristics. The primary benefits of the use of the methods of the present invention include the speeding up of the directed evolution process for the genetic improvement of industrial microorganisms and the enhancement of the improvement itself. Indeed the improved industrial microorganisms obtained with the methods of the present invention are superior over those obtained by conventional methods because the methods allow more beneficial genetic variants to be combined together in a single genetic improvement step. Finally, it is anticipated that the methods of the present invention can be utilized on any industrial microorganism for which natural genetic diversity is available, including bacteria, yeasts, fungi and algae. | 12-23-2010 |
| 20100323354 | MEANS AND METHODS FOR THE DETECTION AND ISOLATION OF FETAL AND EMBRYONIC CELLS AND NUCLEIC ACID FROM MATERNAL BODY FLUID - The present invention is related to the use of an interaction partner of a high mobility group protein of the HMGA family for the detection of fetal and embryonic cells in a maternal body fluid. | 12-23-2010 |
| 20100323355 | MEANS AND METHODS FOR DETECTION OF NUCLEIC ACIDS - The present invention related to methods and tools for nuclease-dependent detection of nucleic acid hybridization. In these methods magnetic or magnetizable particles are used to discriminate between hybridized and non-hybridized DNA. | 12-23-2010 |
| 20100323356 | SMALL RNA-DEPENDENT TRANSLATIONAL REGULATORY SYSTEM IN CELL OR ARTIFICIAL CELL MODEL - An object of the present invention is to construct an mRNA which specifically responds to a short RNA sequence and can activate, repress, and regulate the translation of the desired gene, and to construct an artificial cell model system using a liposome comprising the mRNA and a cell-free translational system encapsulated therein. The present invention provides: an mRNA comprising a target RNA-binding site located immediately 5′ to the ribosome-binding site, and a nucleotide sequence located 5′ to the target RNA-binding site, the nucleotide sequence being complementary to the ribosome-binding site; an mRNA comprising a small RNA-binding site located 3′ to the start codon, and a nucleotide sequence located 3′ to the small RNA-binding site, the nucleotide sequence encoding a protein; and a liposome comprising any of these mRNAs encapsulated therein. | 12-23-2010 |
| 20100323357 | MicroRNA Expression Profiling and Targeting in Peripheral Blood in Lung Cancer - A method for the diagnosis, prognosis and treatment of lung cancer by detecting at least one microRNA in peripheral blood is disclosed. | 12-23-2010 |
| 20100323358 | Use of KIR genes for predicting response to therapy - The present invention relates to the use of at least one Killer cell immunoglobulin-like receptor gene for the identification of subjects likely to respond to tumour necrosis factor-based therapy. The invention also provides methods of identifying subjects likely to respond to tumour necrosis factor-based therapy, and finds utility in assisting with prospectively predicting the likely clinical response of patients to therapeutic agents used in TNF therapy, based on the genotype of the patient, in particular, by evaluating the status of at least one KIR gene. This predictive tool finds wide clinical utility in the management of autoimmune diseases, such as rheumatoid arthritis, and greatly assists clinicians in the prioritisation of patients for tumour necrosis factor-based therapy, possibly reducing the cost of treatment in terms of adverse side effects and health budgets. | 12-23-2010 |
| 20100323359 | Methods for identifying analgesic agents - The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders. | 12-23-2010 |
| 20100323360 | Oligonucleotide arrangements, processes for their employment and their use - Oligonucleotide arrangements are disclosed which, in each case, have at least two oligonucleotide sequences linked via at least one spacer. A process is disclosed using the oligonucleotide arrangements for the amplification and/or detection of nucleic acid sequences with formation of crosslinked conglomerates. The process can be used, for example, for the sensitive, simple and inexpensive detection of nucleic acid sequences. | 12-23-2010 |
| 20100323361 | METHODS, SYSTEMS AND KITS FOR DETECTING PROTEIN-NUCLEIC ACID INTERACTIONS - Methods, systems and kits for detecting protein-nucleic acid interactions, in particular, detecting the genomic location to near-base pair resolution at which a particular protein (e.g., transcription factor) binds includes combining steps of a convention chromatin immunoprecipitation (ChIP) assay with use of an exonuclease that digests DNA strands in the 5′-3′ or 3′-5′ direction until it reaches a bound protein including a protein crosslinked to DNA. A significant improvement of the resolution and dynamic range of the ChIP assay will increase one's ability to determine with confidence where a particular protein is binding in the genome. Importantly, proteins that inefficiently crosslink to DNA (either intrinsically or due to indirect crosslinking via another protein) and thus are very difficult to detect, are expected to be significantly detected by the kits and methods described herein. Inasmuch as most aspects of infectious diseases, inborn diseases, and cancers are rooted in the mis-expression of genes, having a better measure of the binding of proteins to genes or promoter regions will greatly enhance the ability of investigators to understand the driving molecular mechanisms behind these human maladies. | 12-23-2010 |
| 20100323362 | COMPOSITIONS AND METHODS FOR DETECTING NUCLEIC ACID FROM MOLLICUTES - Compositions, reaction mixtures, kits and methods used in amplifying and detecting nucleic acids from various species of the class Mollicutes. Particular regions of the 23S rRNA or its gene have been identified as preferred targets for nucleic acid amplification reactions of a sample suspected containing at least one species of Mollicutes. Some oligomers comprise tag regions, target closing regions, promoter sequences, and/or binding moieties. Samples can be from any source suspected of containing a species of the class Mollicutes. Preferred sample sources include bioreactors, cell lines, cell culture wares and pharmaceutical manufacturing wares. | 12-23-2010 |
| 20100323363 | METHOD FOR THE TREATMENT OF A SAMPLE CONTAINING BIOMOLECULES - The invention generally provides a method for the sample preparation for a subsequent preparation, processing or analysis method of a sample containing an at least one species of nucleic acid and/or one species of protein, whereby the method comprises the following steps: A) providing a sample which contains at least one species of a nucleic acid and/or of a protein, B) contacting the sample with a fluid or solid composition to produce a fluid sample preparation, whereby the composition contains at least a nitrogenous compound, which is selected from the group consisting of a) polyamines, b) amino acids, and oligo- and polypeptides, c) nitrogenous heterocyclic compounds, including homo- oder heteropolymeres, which comprise these nitrogenous compounds, d) amines of the type R | 12-23-2010 |
| 20100323364 | MODIFIED tRNA CONTAINING UNNATURAL BASE AND USE THEREOF - In the method for introducing a noncanonical amino acid residue into a desired position in a protein, the structure of tRNA is so modified as to have improved affinity for aminoacyl-tRNA synthetase or improved specificity to aminoacyl-tRNA synthetase. An unnatural base is contained at any position in tRNA, whereby the efficiency of aminoacylation of the tRNA with a noncanonical amino acid can be improved. | 12-23-2010 |
| 20100323365 | PRIMER AND PROBE FOR DETECTING CHLAMYDOPHILA CAVIAE, AS WELL AS A CHLAMYDOPHILA CAVIAE DETECTION METHOD USING THE SAME - Provided are a novel primer and a probe for the detection of | 12-23-2010 |
| 20100323366 | Methods of Selecting a Dopaminergic Neuron Proliferative Progenitor Cells Using LRP4/CORIN Markers - In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such. | 12-23-2010 |
| 20100323367 | METHOD OF DETECTING COLON CANCER MARKER - It is intended to provide a non-invasive and convenient method of detecting a tumor marker for diagnosing colon cancer which is superior in sensitivity and specificity to the existing fecal occult blood test. More specifically speaking, a method of detecting a tumor marker for diagnosing colon cancer which comprises collecting biological sample which is immediately frozen using liquid nitrogen in some cases, homogenizing the sample in the presence of an inhibitor of an RNA digesting enzyme to give a suspension, extracting RNA from the obtained suspension, subjecting the extracted RNA to reverse transcription to give cDNA. amplifying the obtained cDNA and then detecting the thus amplified cDNA. This method is characterized by involving no procedure of separating cell components from the biological sample. | 12-23-2010 |
| 20100330551 | Novel Restriction Endonucleases, DNA Encoding These Endonucleases and Methods for Identifying New Endonucleases with the Same or Varied Specificity - Specified restriction endonucleases have been characterized for the first time by their amino acid and DNA sequences. These sequences and those with at least 90% identity thereto have been used as probes in sequence similarity analyses to identify sequence matches in a sequence database that corresponds to novel restriction endonucleases or isoschizomers. The sequence similarity analyses includes selecting a positive sequence match from any sequence producing an expectation value of less than or equal to e-02. | 12-30-2010 |
| 20100330552 | Comparative cellular deficiency diagnosis genetic deviation diagnosis procedurecellular protein output deficiency - This procedure is intended to demonstrate the genetic foundation of infirmities caused by abnormal base pair sequences and protein deficiencies (which are an expression of genetic aberrations). | 12-30-2010 |
| 20100330553 | Chemically induced optical signals and DNA sequencing - Methods for sequencing nucleic acids are presented. Sequencing is accomplished through the chemical amplification of the products of DNA synthesis and the detection of the chemically amplified products. In embodiments of the invention, a substrate is provided having a plurality of molecules of DNA to be sequenced attached and a plurality of molecules capable of chelating pyrophosphate ions attached, the DNA molecules to be sequenced are primed, and a next complementary nucleotide is incorporated and excised a plurality of times leading to the buildup of pyrophosphate ions locally around the DNA molecule to be sequenced. Pyrophosphate ions are captured by the substrate-attached chelators and optically detected to determine the identity of the next complementary nucleic acid in the DNA molecule to be sequenced. | 12-30-2010 |
| 20100330554 | DIAGNOSTIC KIT FOR SOLID CANCER AND MEDICAMENT FOR SOLID CANCER THERAPY - The present invention provides novel solid cancer antigenic proteins, and diagnostic kits for solid cancer and therapeutic agents for solid cancer based on the antigenic proteins. Specifically, the present invention provides a human solid cancer antigenic polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 48, 50, 52, 54, 56, 59, 61, 63, 65, 67, 69, 71, 73, and 75. | 12-30-2010 |
| 20100330555 | ACCURACY FLUORESCENCE IN-SITU HYBRIDIZATION ASSAY OF SAMPLES WITH APOPTOTIC CELLS - The present application discloses a process for improving the accuracy of fluorescence in-situ hybridization (FISH) assays in which the sample being assayed is likely to contain cells in apoptosis by excluding these cells from the evaluation of the FISH assay. This is conveniently done by labeling the cells in apoptosis by incorporating labeled nucleotides into the apoptosis typical breaks in their nuclear DNA. The present application also discloses a kit and system adapted for carrying out this process for improving the accuracy of FISH assays. | 12-30-2010 |
| 20100330556 | GENOME ANALYSIS USING A NICKING ENDONUCLEASE - A method of genome analysis is provided. In certain embodiments, the method of comprises: a) contacting a genomic sample comprising a double-stranded DNA with a site-specific nicking endonuclease to provide a nicked double-stranded DNA comprising a plurality of nick sites, in which the nicking endonuclease nicks a site adjacent to a variable nucleotide; b) contacting the nicked double-stranded DNA with a polymerase in the presence of a nucleotide composition comprising a first labeled nucleotide comprising a first label, thereby producing a labeled double-stranded DNA that is not labeled at every nick site; c) stretching out the labeled double-stranded DNA to provide a stretched, labeled double-stranded DNA; and d) imaging the stretched, labeled double-stranded DNA to identify a labeling pattern on the stretched labeled double-stranded DNA. | 12-30-2010 |
| 20100330557 | GENOMIC COORDINATE SYSTEM - A method of sample analysis is provided. In certain embodiments, the method comprises: a) site-specifically labeling a test genome with at least two different labels to produce a labeled genome labeled at a plurality of discrete sites across the genome; b) stretching a nucleic acid of the labeled genome to produce a linear pattern of the different labels along a region of a stretched nucleic acid; c) reading the labels along the region to provide a test pattern comprising a sequence of colors emitted by the labels; d) comparing the test pattern to a plurality of reference patterns obtained from a reference genome, in which the reference patterns are mapped to corresponding genomic locations in the reference genome; and e) identifying one or more reference patterns that match the test pattern, thereby mapping a location for the region in the test genome. | 12-30-2010 |
| 20100330558 | Gene Expression Profiling for Identification, Monitoring and Treatment of Cervical Cancer - A method is provided in various embodiments for determining a profile data set for a subject with cervical cancer or conditions related to cervical cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-5. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable. | 12-30-2010 |
| 20100330559 | FORENSIC IDENTIFICATION - The invention provides allelic ladder mixtures and individual alleles suitable for use in such mixtures. The allelic ladder mixtures give improved identification and distinguishing capabilities, particularly suitable in forensic investigations. | 12-30-2010 |
| 20100330560 | Immunogenic polypeptide isolated from mycobacterium avium subspecies paratuberculosis and uses thereof - The present invention relates to an immunogenic polypeptide isolated from | 12-30-2010 |
| 20100330561 | Marker Gene For Detection of Tumor Promoter, and Method For Detection of Tumor Promoter - The present invention provides 27 marker genes comprising Orm1, Scarb1, Stmn1, Rad21, Nup54, Jun, Dmp1, Abi1, 6530403A03Rik, Slc2a1, Plf (Plf2, Mrpplf3), Fosl1, Chek1, Pik3r5, JunB, Vegfa, Rif1 (LOC671598), Il1rl1, Phex, Tfrc, Zfhx1b, Rad51ap1, Hells, Mcm3, Orm2, Car13 and Ccnb1, which enables the detection of a tumor promoter in a simple manner and within a short period of time in a test for predicting carcinogenicity as a tumor promoter using a cultured cell. The present invention further provide a tumor promoter detection method using at least one of the marker genes. | 12-30-2010 |
| 20100330562 | Unique Calibrator Polynucleotides and Methods of Using in Quantitative Nucleic Acid Assays - Disclosed herein are are polynucleotides which may be used to calibrate or standardize quantitative nucleic acid assays. As disclosed, the polynucleotides comprise a sequence derived from a plant viroid polynucleotide or a bacterial or chloroplast Type II intron polynucleotide. Also disclosed are methods of making and using the polynucleotides. | 12-30-2010 |
| 20100330563 | MEDICINAL AGENT FOR DISEASE ASSOCIATED WITH EPSTEIN-BARR VIRUS, AND METHOD FOR SCREENING OF THE MEDICINAL AGENT - 1-(2-Fluoro-4-thio-β-D-arabinofuranosyl)-5-methyluracil exhibits an anti-EB virus activity, and is therefore effective as a prophylactic or therapeutic agent for a disease associated with an EB virus. Each of a plasmid capable of expressing EB virus-TK and a plasmid capable of expressing human-TK is introduced into a TK-defect cell, thereby producing two types of cells respectively having the plasmids introduced therein. By using the two types of cells, it is possible to screen a medicinal agent which has cytotoxicity against the cell having the plasmid capable of expressing EB virus-TK introduced therein but has no toxicity against the cell having the plasmid capable of expressing human-TK introduced therein. In this manner, it becomes possible to screen a medicinal agent which specifically exhibits an anti-EB virus activity. | 12-30-2010 |
| 20100330564 | NUCLEIC ACID DETECTION METHOD AND NUCLEIC ACID DETECTION KIT - In the present invention, an amplified DNA fragment having a first substance binding site to which a first substance is specifically bindable is prepared, which amplified DNA fragment amplified by a nucleic acid amplification method. The amplified DNA fragment is concentrated by binding the amplified DNA fragment to the first substance. The concentration makes it possible to detect the DNA highly sensitively. Therefore, with the arrangement, it is possible to detect the amplified DNA fragment amplified by the nucleic acid amplification method, easily and highly accurately without requiring any special device. | 12-30-2010 |
| 20100330565 | REAGENT KIT FOR SAMPLE ANALYSIS AND SAMPLE ANALYSIS METHOD - The present invention provides a reagent kit for analyzing a sample comprising a first reagent containing a cationic surfactant, a nonionic surfactant and an aromatic carboxylic acid and a second reagent containing a fluorescent dye capable of staining nucleic acid, and a method for analyzing a sample using the kit. | 12-30-2010 |
| 20100330566 | GENETIC POLYMORPHISMS IN THE PROSTATE-SPECIFIC ANTIGEN GENE PROMOTER - The present invention includes methods of identifying a subject at risk for increased cellular PSA production and/or prostate cancer by detecting the presence or absence of a genetic polymorphism in the prostate specific antigen gene. | 12-30-2010 |
| 20100330567 | DNA MARKERS FOR MANAGEMENT OF CANCER - A method is provided for assessing allelic losses and hypermethylation of genes in CpG tumor promotor region on specific chromosomal regions in cancer patients, including melanoma, neuroblastoma breast, colorectal, and prostate cancer patients. The method relies on the evidence that free DNA and hypermethylation of genes in CpG tumor promotor region may be identified in the bone marrow, serum, plasma, and tumor tissue samples of cancer patients. Methods of melanoma, neuroblastoma, colorectal cancer, breast cancer and prostate cancer detection, staging, and prognosis are also provided. | 12-30-2010 |
| 20100330568 | ASSAY AND METHOD FOR THE ASSESSMENT OF RESPONDERS AND NON-RESPONDERS TO NK CELL MODULATION BY IMMUNOGLOBULIN THERAPY - A method of determining a patient's susceptibility for NK cell modulation by immunoglobulins in response to a treatment of a disease or prophylaxis of a disease with immunoglobulins wherein a modulation of natural killer cells caused by said immunoglobulins is determined. | 12-30-2010 |
| 20100330569 | Hydroxymethyl Linkers For Labeling Nucleotides - The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses. | 12-30-2010 |
| 20100330570 | NUCLEOTIDE TRANSIENT BINDING FOR SEQUENCING METHODS - Provided herein are compositions and systems for use in polymerase-dependent, nucleotide transient-binding methods. The methods are useful for deducing the sequence of a template nucleic acid molecule and single nucleotide polymorphism (SNP) analyses. The methods rely on the fact that the polymerase transient-binding time for a complementary nucleotide is longer compared to that of a non-complementary nucleotide. The labeled nucleotides transiently-binds the polymerase in a template-dependent manner, but does not incorporate. The methods are conducted under any reaction condition that permits transient binding of a complementary or non-complementary nucleotide to a polymerase, and inhibits nucleotide incorporation. | 12-30-2010 |
| 20100330571 | METHOD OF MEASURING ADAPTIVE IMMUNITY - A method of measuring immunocompetence is described. This method provides a means for assessing the effects of diseases or conditions that compromise the immune system and of therapies aimed to reconstitute it. This method is based on quantifying T-cell diversity by calculating the number of diverse T-cell receptor (TCR) beta chain variable regions from blood cells. | 12-30-2010 |
| 20100330572 | ORGANIC COMPOUNDS - The present invention relates to a novel selection system for use in a eukaryotic cell culture process and for expression of a recombinant product of interest. The selection system is based on the introduction of an exogenous functional membrane-bound folate receptor gene together with the polynucleotide or gene encoding the product of interest into a eukaryotic cell and can be widely utilized with eukaryotic cells for which cellular viability is dependent upon folic acid uptake. | 12-30-2010 |
| 20100330573 | OPTIMIZED OLIGONUCLEOTIDES AND METHODS OF USING SAME FOR THE DETECTION, ISOLATION, QUANTIFICATION, MONITORING AND SEQUENCING OF BORDETELLA - Described herein are oligonucleotides useful for detecting, isolating, quantitating, monitoring and sequencing | 12-30-2010 |
| 20100330574 | CHIMERIC PRIMERS WITH HAIRPIN CONFORMATIONS AND METHODS OF USING SAME - Methods and compositions for nucleic acid amplification, detection, and genotyping techniques are disclosed. In one embodiment, a nucleic acid molecule having a target-specific primer sequence; an anti-tag sequence 5′ of the target-specific primer sequence; a tag sequence 5′ of the anti-tag sequence; and a blocker between the anti-tag sequence and the tag sequence is disclosed. Compositions containing such a nucleic acid molecule and methods of using such a nucleic acid molecule are also disclosed. | 12-30-2010 |
| 20100330575 | MOLECULAR DIAGNOSTICS REAGENTS AND METHODS - The present invention relates to automated devices and methods for the extraction of nucleic acids from cells, the amplification of segments of nucleic acid and the detection of nucleic acids, all in a convenient and portable manner. The invention is particularly suited for use in point-of-care medical diagnostics testing. | 12-30-2010 |
| 20100330576 | Method, Kits, and Reaction Mixtures For High Resolution Melt Genotyping - Various methods are described that provide for high resolution melt (HRM) genotyping. Some embodiments comprise providing a locus specific primer, and two allele specific primers each comprising at least one single nucleotide polymorphism (SNP) allele-hybridizable sequence, wherein at least one of the allele specific primers also comprises at least one nucleotide alteration. In some embodiments, a nucleic acid is provided comprising a SNP base located within 1-20 bases of its 3′ end. Some embodiments comprise hybridizing the locus specific primer and at least one of the allele specific primers to the nucleic acid, amplifying the hybridized nucleic acid using pyrophosphorolysis activated polymerization (PAP) PCR, and determining the melting temperature (Tm) of the resulting amplicons, for example, using HRM. In some embodiments, reaction mixtures and kits for HRM genotyping are provided. The reaction mixtures and kits can each comprise a locus specific primer, one or more allele specific primers each comprising at least one SNP allele-hybridizable sequence, and a PAP PCR enzyme, wherein at least one of the allele specific primers also comprises a nucleotide alteration, for example, a tail. | 12-30-2010 |
| 20100330577 | METHODS FOR IDENTIFICATION OF AN ANTIBODY OR A TARGET - This disclosure relates to methods for identifying an antibody, a target molecule, or an agent by analyzing the immunoglobulin repertoire sequence data in a sample and by determining the most dominant VH and VL chains present in said sample, as well as materials used therewith. | 12-30-2010 |
| 20100330578 | THERMO-OPTICAL CHARACTERISATION OF NUCLEIC ACID MOLECULES - The present invention pertains to a method and a device for the determination of thermo-optical properties, particularly the size or size distribution, of fluorescently labeled biomolecules or biomolecule complexes, particularly nucleic acids, in a reaction solution. The method comprises the steps of: (i) providing a reaction solution with fluorescently labeled biomolecules or biomolecule complexes; (ii) irradiating a laser light beam into the solution to obtain a spatial temperature distribution in the solution around the irradiated laser light beam; (iii) exciting fluorescently said fluorescently labeled biomolecules and detecting the fluorescence at two or more defined regions representing different mean temperatures in said spatial temperature distribution, wherein said detection of fluorescence is performed at least once at a predetermined time after the start of the laser irradiation; and (iv) determining the thermo-optical properties, particularly the size or size distribution, of the fluorescently labeled biomolecules or biomolecule complexes from the detected fluorescence intensity or fluorescence intensity distribution. | 12-30-2010 |
| 20100330579 | DETECTION OF PCR PRODUCTS IN GEL ELECTROPHORESIS - Disclosed is a method for analyzing nucleic acids in a sample comprising the following steps: (i) adding a DNA binding dye containing a benzothiazolium or benzoxazolium group to the sample to be analyzed, (ii) carrying out a polymerase chain reaction, (iii) applying the sample to a gel matrix, (iv) separating the nucleic acid molecules according to their size by applying a voltage and (v) excitation with light of a suitable wavelength for the optical visualization of the nucleic acid/DNA binding dye complexes. | 12-30-2010 |
| 20100330580 | METHOD FOR THE IN VITRO DIAGNOSIS OR PROGNOSIS OF TESTICULAR CANCER - A method for in vitro diagnosis or prognosis of testicular cancer in a biological sample from a patient suspected of suffering from testicular cancer, having a step of detecting the presence or absence of methylation of CpG dinucleotides in at least one genomic DNA target sequence of the sample, the target sequence being selected from at least one of the sequences identified in SEQ ID NOS: 1 to 7 or from at least one sequence which exhibits at least 99% identity with one of the sequences identified in SEQ ID NOS: 1 to 7 and the sequences complementary thereto; to the DNA sequences and to the use thereof as a testicular cancer marker. | 12-30-2010 |
| 20100330581 | METHOD FOR IN VITRO DIAGNOSIS OR PROGNOSIS OF TESTICULAR CANCER - The invention relates to a method for in vitro diagnosis or prognosis of testicular cancer which comprises a step of detecting the presence or absence of at least one expression product from at least one nucleic acid sequence selected from the sequences identified in SEQ ID NOS: 1 to 6 or from the sequences which exhibit at least 99% identity with one of the sequences identified in SEQ ID NOS: 1 to 6, to isolated nucleic acid sequences and to the use thereof as a testicular cancer marker. | 12-30-2010 |
| 20110003281 | Device and method for multiple analyte detection - The invention is directed to a method and device for simultaneously testing a sample for the presence, absence, and/or amounts of one or more of a plurality of selected analytes. The invention includes, in one aspect, a device for detecting or quantitating a plurality of different analytes in a liquid sample. Each chamber may include an analyte-specific reagent effective to react with a selected analyte that may be present in the sample, and detection means for detecting the signal. Also disclosed are methods utilizing the device. | 01-06-2011 |
| 20110003282 | DIFFERENTIAL AMPLIFICATION OF MUTANT NUCLEIC ACIDS BY PCR IN A MIXTURE OF NUCLEIC ACIDS - A method for enriching a mutant nucleic acid in a mixture of nucleic acids, wherein the method comprises: (a) providing a nucleic acid mixture comprising a parental nucleic acid and a mutant nucleic acid of the parental nucleic acid; and (b) amplifying the nucleic acids in the nucleic acid mixture by polymerase chain reaction (PCR); wherein the mutant nucleic acid is a G→A mutant of the parental nucleic acid, which pairs with a fully complementary nucleic acid sequence to form an AT-rich nucleic acid variant of the parental nucleic acid; and wherein the AT-rich nucleic acid variant is denatured and selectively amplified by carrying out PCR using a denaturation temperature 1-3° C. lower than the lowest denaturation temperature (T | 01-06-2011 |
| 20110003283 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NO. 55 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 01-06-2011 |
| 20110003284 | Aberrantly Methylated Genes in Pancreatic Cancer - The present invention provides a method for detecting pancreatic carcinoma in a subject. The method includes contacting a nucleic acid-containing specimen from the subject with an agent that provides a determination of the methylation state of at least one gene or associated regulatory region of the gene and identifying aberrant methylation of regions of the gene or regulatory region, wherein aberrant methylation is identified as being different when compared to the same regions of the gene or associated regulatory region in a subject not having the pancreatic carcinoma, thereby detecting pancreatic carcinoma in the subject. | 01-06-2011 |
| 20110003285 | SEPARATION PURIFICATION METHOD AND MICROFLUIDIC CIRCUIT - A simple and accurate separation purification method for object biomolecules or bio-associated substance through a particulate aggregative reaction is provided. A microfluidic circuit utilizing a particulate aggregate as a detection marker in a nonfluorescence method such as an electrochemical method or surface plasmon resonance is provided. The separation purification method comprises the steps of forming a particulate aggregate by a reaction between particulates modified with a labeling substance specifically reacting with a label object substance and biomolecules or a bio-associated substance containing the label object substance and separation-purifying the particulate aggregate. The microfluidic circuit utilizes this separation purification method. | 01-06-2011 |
| 20110003286 | REACTOR PLATE AND REACTION PROCESSING METHOD - Disclosed herein is a reactor plate which prevents the entry of foreign matter from the outside and the pollution of a surrounding environment. A reactor plate ( | 01-06-2011 |
| 20110003287 | HUMAN DIABETES SUSCEPTIBILITY TNFRSF10C GENE - The present invention relates to a diagnostic method of determining whether a subject is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the TNFRSF10C gene locus in a biological sample of said subject. | 01-06-2011 |
| 20110003288 | DETECTION OF NUCLEIC ACIDS BY TYPE-SPECIFIC HYBRID CAPTURE METHOD - Target-specific hybrid capture (TSHC) provides a nucleic acid detection method that is not only rapid and sensitive, but also highly specific and capable of discriminating highly homologous nucleic acid sequences. The method produces DNA/RNA hybrids which can be detected by a variety of methods. | 01-06-2011 |
| 20110003289 | METHOD FOR DETECTION OF PRE-NEOPLASTIC FIELDS AS A CANCER BIOMARKER IN ULCERATIVE COLITIS - Among other aspects, the present invention provides biomarkers and methods of identifying precancerous fields in a subject in need thereof. Methods of diagnosing and for providing a prognosis for a subject with an increased risk of developing cancer are also provided, along with methods of determining surgical margins for a tumor or tissue resection procedure. Additionally, reagents and kits are provided for the practice of the methods disclosed herein. | 01-06-2011 |
| 20110003290 | Oligonucleotides and Uses Thereof - A method for determining the number of tandem repeats in a target polynucleotide, the method comprising (a) providing a sample containing the target polynucleotide, wherein one or more of the tandem repeats in the target polynucleotide is in single stranded form, (b) hybridising a labelled probe oligonucleotide to the single stranded portion of the target polynucleotide, wherein the probe oligonucleotide is complementary to at least one of the tandem repeats, and at least 5 nucleotides of the probe oligonucleotide are complementary to the tandem repeats, in the single stranded portion of the target polynucleotide, and (c) determining the number of tandem repeats in the target polynucleotide based on the hybridisation of the probe oligonucleotide to the single stranded portion of the target polynucleotide. | 01-06-2011 |
| 20110003291 | METHOD FOR STUDYING V(D)J COMBINATORY DIVERSITY - The invention relates to a method for analysing the diversity of the catalogue of T and/or B lymphocytes in an individual, based on the amplification, from a sample, of genomic DNA fragments by PCR multi-n-plexes, with n≧2, carried out with a combination of at least 3 primers defining at least 2 primer couples, each of which includes a primer specifically hybridising upstream and/or in a given V or D gene and a primer specifically hybridising downstream and/or in a given J gene, in order to obtain the amplification of at least two fragments characteristic of two distinct V-J or D-J rearrangements from each primer couple. The invention also relates to the applications of this method, in particular in the treatment follow-up or in the diagnosis and/or prognosis of certain diseases. | 01-06-2011 |
| 20110003292 | METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS - The invention provides methods, nucleic acids and kits for detecting lung carcinoma. The invention discloses genomic (FOXL2, ONECUT1, TFAP2E, EN2-2, EN2-3, SHOX2-2 and BARHL2) sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients. | 01-06-2011 |
| 20110003293 | FETAL ANEUPLOIDY DETECTION BY SEQUENCING - The present invention provides apparatus and methods for enriching components or cells from a sample and conducting genetic analysis, such as SNP genotyping to provide diagnostic results for fetal disorders or conditions. | 01-06-2011 |
| 20110003294 | Method of profiling gene expression in a healthy subject - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 01-06-2011 |
| 20110003295 | Method of profiling gene expression in a subject undergoing a treatment - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 01-06-2011 |
| 20110003296 | Method for the detection of gene transcripts in blood and uses thereof - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 01-06-2011 |
| 20110003297 | METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 01-06-2011 |
| 20110003298 | METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 01-06-2011 |
| 20110003299 | Canola Event PV-BNGT04(RT73) and Compositions and Methods for Detection Thereof - The present invention provides assays for detecting the presence of the PV-BNGT04(RT73) canola event based on the DNA sequence of the recombinant construct inserted into the canola genome and of genomic sequences flanking the insertion site. | 01-06-2011 |
| 20110003300 | RAPID STERILITY MICROASSAY - The present invention relates to a method for detecting a viable microorganism in a pharmaceutical composition comprising the steps of providing a filterable pharmaceutical composition; filtering the pharmaceutical composition to provide at least three membranes upon which the pharmaceutical composition is deposited, placing the three membranes onto solid culture media to produce at least three filtrand cultures, culturing under aerobic and anaerobic conditions and detecting a viable microorganism cell, micro-colony or colony, wherein the presence of a viable cell, micro-colony or colony on the membrane indicates the presence of a viable microorganism in the pharmaceutical composition. | 01-06-2011 |
| 20110003301 | METHODS FOR DETECTING GENETIC VARIATIONS IN DNA SAMPLES - The invention provides methods, compositions and kits for detecting genetic variation in a DNA sample at one or more polymorphic loci of interest. In some embodiments, the invention provides methods, compositions, and kits for determining the nucleotide present at a single nucleotide variant position of interest in a test sample. | 01-06-2011 |
| 20110003302 | Fibroblast Growth Factor-Like Polypeptides - The present invention provides novel Fibroblast Growth Factor-like (FGF-like) polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, antibodies and methods for producing FGF-like polypeptides. Also provided for are methods for the diagnosis and treatment of diseases associated with FGF-like polypeptides. | 01-06-2011 |
| 20110003303 | SHEATH FLOW DEVICES AND METHODS - The invention relates generally to fluid processing and, in particular aspects, processing fluids for detection, selection, trapping and/or sorting of particulate moieties. Sheath flow devices described allow isolation of target species from fluid samples while avoiding non-specific binding of unwanted species to the surfaces of the separation device. Biological fluid processing, detection, sorting or selection of cells, proteins, and nucleic acids is described. The invention finds particular use in diagnostic settings, analyzing a patient's medical condition, monitoring and/or adjusting a therapeutic regimen and producing cell based products. | 01-06-2011 |
| 20110003304 | METHOD AND KIT FOR DETECTION OF AUTOIMMUNE CHRONIC URTICARIA - Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with autoimmune chronic urticaria, which makes use of CD203c, and in some embodiments, additional proteins, as a marker for the disease. Test kits for diagnosis of an individual suspected of having autoimmune chronic urticaria are also disclosed. Also disclosed are a method of identifying compounds useful for treating autoimmune chronic urticaria and a method of treating autoimmune chronic urticaria. | 01-06-2011 |
| 20110003305 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID AMPLIFICATION - Compositions, reaction mixtures, and methods for performing an amplification reaction, including multiplex amplification reaction, wherein the method comprises using one or more amplification oligomer complexes comprising linked first and second amplification oligomer members. In one aspect, the amplification oligomer complex is hybridized to a target nucleic acid, the target nucleic acid with hybridized amplification oligomer complex is then captured, and other components are washed away. Target sequences of the target nucleic acids are pre-amplified to generate a first amplification product. The first amplification product is amplified in one or more secondary amplification reactions to generate second amplification products. | 01-06-2011 |
| 20110003306 | IDENTIFICATION OF ANTIBIOTIC RESISTANCE USING LABELLED ANTIBIOTICS - Subject of the present invention is a method for detection of an antibiotic resistance in a micro-organism comprising the steps of exposing suspected micro-organism to a labelled (fluorescent) antibiotic and observing the differences between it and a non-resistant micro-organism of the same type. | 01-06-2011 |
| 20110003307 | METHODS FOR PRODUCING INTERFERING RNA MOLECULES IN MAMMALIAN CELLS AND THERAPEUTIC USES FOR SUCH MOLECULES - Methods for producing interfering RNA molecules in mammalian cells are provided. Therapeutic uses for the expressed molecules, including inhibiting expression of HIV, are also provided. | 01-06-2011 |
| 20110003308 | NANOPARTICLE-MEDIATED SIGNAL AMPLIFICATION - There is described a new class or type of initiators for polymerization as a means of signal enhancement, nanoparticle initiators, and methods for amplifying signal resulting from recognition events, thereby enhancing the detection of those recognition events. Methods include amplification achieved through polymerization using a nanoparticle initiator conjugated recognition element that is not consumed during the reaction. The polymer formed as a result of the absorption of light by the nanoparticle initiator and introduction of reactive species into a surrounding polymerizable monomer solution occurs in a spatially-limited region directly surrounding the nanoparticle initiator and is indicative of the recognition event(s). In one embodiment, a semiconductor quantum dot nanoparticle initiator is utilized. In another embodiment, a metal nanoparticle is utilized. In another embodiment, the signal is detected without instrumentation. In yet another embodiment, the signal is detected via a transmission-based instrument which captures an image of the formed polymer. | 01-06-2011 |
| 20110003309 | Non-Competitive Internal Controls for Use in Nucleic Acid Tests - Provided are non-competitive internal controls for use in nucleic acid tests (NATs), which are obtained from the organisms | 01-06-2011 |
| 20110008769 | DOPAMINERGIC NEURON PROGENITOR CELL MARKER 187A5 - An object of the present invention is to provide a probe, a primer, a primer set and an antibody for use in the detection or selection of a dopaminergic neuron progenitor cell. The present invention provides a probe, a primer and a primer set for use in the detection or selection of a mesencephalon dopaminergic neuron progenitor cell, and preferably a dopaminergic neuron proliferative progenitor cell, which can hybridize with a nucleotide sequence of a 187A5 gene, or a complementary sequence thereto, and an antibody for use in the detection or selection of a mesencephalon dopaminergic neuron progenitor cell, and preferably a dopaminergic neuron progenitor cell, which is capable of binding to a 187A5 protein. | 01-13-2011 |
| 20110008770 | COMPOSITIONS AND METHODS FOR REVERSE TRANSCRIPTION OF NUCLEIC ACID MOLECULES - The present invention is generally related to compositions and methods for the reverse transcription of nucleic acid molecules, especially messenger RNA molecules. Specifically, the invention relates to compositions comprising mixtures of polypeptides having reverse transcriptase (RT) activity, and to methods of producing, amplifying or sequencing nucleic acid molecules (particularly cDNA molecules) using these compositions or polypeptides, particularly at temperatures above about 55° C. The invention also relates to nucleic acid molecules produced by these methods, to vectors and host cells comprising these nucleic acid molecules, and to the use of such nucleic acid molecules to produce desired polypeptides. The invention also relates to methods for producing Rous Sarcoma Virus (RSV) and Avian Myeloblastosis Virus (AMV) RTs or other Avian Sarcoma-Leukosis Virus (ASLV) RTs (α and/or β subunits thereof), to isolated nucleic acid molecules encoding such RSV RT, AMV RT or other ASLV RT subunits, to vectors and host cells comprising these isolated nucleic acid molecules and to RSV RT, AMV RT and other ASLV RT subunits produced by these methods. The invention further relates to nucleic acid molecules encoding recombinant heterodimeric RT holoenzymes, particularly heterodimeric RSV RTs, AMV RTs or other ASLV RTs (which may be αβ RTs, ββ RTs, or α RTs), vectors (particularly baculovirus vectors) and host cells (particularly insect and yeast cells) comprising these nucleic acid molecules, methods for producing these heterodimeric RTs and heterodimeric RTs produced by these methods. The invention also relates to kits comprising the compositions, polypeptides, or RSV RTs, AMV RTs or other ASLV RTs of the invention. | 01-13-2011 |
| 20110008771 | METHOD AND MATERIALS FOR TRIGGERED RELEASE OF A BIOLOGICAL SAMPLE - The invention relates to a method for releasing a biological sample from a solid matrix substantially without disintegration of biomolecules comtained in said biological sample by at least partially transferring the solid state of said matrix into a dissolved or liquid state by changing at least one physico-chemical property of the environment of said matrix. | 01-13-2011 |
| 20110008772 | PROBES FOR DETECTING MYCOBACTERIUM TUBERCULOSIS AND MYCOBACTERIUM TUBERCULOSIS COMPLEX AND METHOD USING THE SAME - The present invention relates to a probe for detecting | 01-13-2011 |
| 20110008773 | METHOD FOR THE DETERMINATION OF DATA FOR THE PREPARATION OF THE DIAGNOSIS OF PHAKOMATOSIS - The invention concerns a method for the determination of data for the preparation of presymptomatic or prenatal diagnosis of phakomatosis, in particular, a tumor suppressor gene disease, in a high-risk patient, in particular of neurofibromatosis, comprising the steps of: making available the tumor material from a person afflicted with the tumor suppressor gene disease, who is a relative of the high-risk patient; isolating tumor DNA from the tumor in the relative; isolating blood DNA from the blood of the relative; amplifying polymorphous DNA microsatellite markers from the tumor and the blood; separating the markers by length; observing the lengths of the markers; comparing the markers from the blood and the tumor; examining for a loss of alleles; optionally, comparing amplified markers from a second tumor of the relative; and amplifying polymorphous DNA microsatellite markers from the blood of an offspring and separating and observing the markers. | 01-13-2011 |
| 20110008774 | PROTEIN DISCOVERY USING INTRACELLULAR RIBOSOME DISPLAY - The present invention relates to a method of identifying a protein that binds to a target molecule and has intracellular functionality. This method includes providing a construct comprising a deoxyribonucleic acid molecule encoding the protein which binds to the target molecule, with the deoxyribonucleic acid molecule being coupled to a stall sequence. A host cell is transformed with the construct and then cultured under conditions effective to form, within the host cell, a complex of the protein whose translation has been stalled, the mRNA encoding the protein, and ribosomes. The protein in the complex is in a properly folded, active form and the complex is recovered from the cell. This method can be carried out with a cell-free extract preparation containing ribosomes instead of a host cell. The present invention also relates to a construct which includes a deoxyribonucleic acid molecule encoding a protein that binds to a target molecule and an SecM stalling sequence coupled to the deoxyribonucleic acid molecule. The deoxyribonucleic acid molecule and the SecM stalling sequence are coupled with sufficient distance between them to permit expression of their encoded protein, within the cell, in a properly folded, active form. | 01-13-2011 |
| 20110008775 | SEQUENCING OF NUCLEIC ACIDS - The present invention relates to the field of analysis of nucleic acid sequences. More specifically, the present invention relates to the method and instrument for high throughput parallel DNA sequencing. The present invention also provides method for selection of sequences from analyte samples for enrichment of the target sequences or depletion of the selected molecules and in particular undesirable sequence templates from sequencing samples. | 01-13-2011 |
| 20110008776 | INTEGRATED SEPARATION AND DETECTION CARTRIDGE USING MAGNETIC PARTICLES WITH BIMODAL SIZE DISTRIBUTION - The present invention relates to a device and a method for quantitative detecting of the presence or absence of a target analyte in a liquid sample, the device comprising a reaction chamber having a volume of less than 200 μl comprising an immobilization matrix capable of capturing the analyte, said immobilization matrix, preferably comprising a particulate magnetic material, having a size distribution that is at least bimodal. | 01-13-2011 |
| 20110008777 | PD-1 MODULATION AND USES THEREOF - Reagents, kits, methods and uses thereof useful for the modulation of immune function, such as the identification of modulators of PD-1 activity, are described. Such reagents, kits, methods and uses thereof may be useful, for example, in the diagnosis, prognostication, prevention and/or treatment of immune-related diseases and/or conditions. | 01-13-2011 |
| 20110008778 | Method of Generating p.degree. Cells - Described is a method of the generation of ρ° cells using a mitochondrial targeted restriction endonuclease. This method comprises (a) tranfecting cells with an expression vector containing a gene encoding a fusion protein comprising a mitochondrial targeting sequence (MTS) and a restriction endonuclease operatively linked to a suitable promoter, (b) culturing the transfected cells over a sufficient period of time; and (c) selected ρ° cells, e.g., via FACS analysis. | 01-13-2011 |
| 20110008779 | Method of profiling gene expression in a subject having disease - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 01-13-2011 |
| 20110008780 | METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 01-13-2011 |
| 20110008781 | ISOTHERMAL AMPLIFICATION OF NUCLEIC ACIDS ON A SOLID SUPPORT - Methods for isothermal amplification of nucleic acid by means of a solid support are disclosed. These methods are useful for applications needing high throughput, in particular nucleic acid sequencing. | 01-13-2011 |
| 20110008782 | Site-specific incorporation of redox active amino acids into proteins - Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases, which incorporate redox active amino acids into proteins are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with redox active amino acids using these orthogonal pairs. | 01-13-2011 |
| 20110008783 | FLUORIMETRIC PROCESS FOR EVALUATING THE INFLUENCE OF A CONDITION ON A BIOLOGICAL SAMPLE, AND APPLICATIONS THEREOF - The present invention relates to a process for determining the influence of a condition on a biological sample comprising a step consisting in establishing the kinetic profile of the fluorescence emitted, during the excitation at a suitable excitation wavelength, of a fluorescent compound bound to said biological sample, said sample having been, prior to said excitation, subjected to said condition and said process not necessitating the utilization of a fluorescence donor component and of a different fluorescence acceptor component. The present invention also relates to the various applications of such a process. | 01-13-2011 |
| 20110008784 | METHODS AND COMPOSITIONS FOR IDENTIFYING UNDIFFERENTIATED STEM CELLS AND ASSESSING CELL HEALTH - Disclosed herein are methods and compositions for the identification of teloRNA marks to assess the differentiation status of an individual stem cell or a population of stem cells, to diagnose whether and to what extent a stem cell or stem cell culture has already initiated cell differentiation, and to monitor the differentiation status of an individual stem cell or a stem cell culture during passage. The use of these methods and compositions to monitor the pluripotency and differentiation status of a stem cell or stem cell culture during differentiation enables the identification of undifferentiated and pluripotent stem cells prior to the initiation of differentiation. The methods and compositions can also be used to assess and maintain cell viability; to identify cells or a population of cells that are in a state of poor cell health; and to reduce cell growth or treat a diseased cell including, for example, pre-cancerous cells, cancerous cells, apoptotic cells, aging cells, cells undergoing stress, and otherwise diseased or dysfunctional cells. | 01-13-2011 |
| 20110008785 | METHODS FOR FORENSIC DNA QUANTITATION - Described herein are methods and devices for nucleic acid quantification and, in particular, to microfluidic methods and devices for nucleic acid quantification. In certain embodiments methods of quantifying a target nucleic acid without the need for amplification are provided. The methods involve, in some embodiments, allowing a binding agent to become immobilized with respect to the target nucleic acid. In some cases, the binding agent comprises a signaling moiety that can be used to quantify the amount of target nucleic acid. In another aspect, the quantification can be carried out rapidly. For example, in certain embodiments, the quantification can be completed within 5 minutes. In yet another aspect, samples containing a low amount of target nucleic acid can be quantified. For instance, in some cases, samples containing less than 100 nanograms per microliter may be quantified. Also described are devices and kits for performing such methods, or the like. | 01-13-2011 |
| 20110008786 | METHODS OF DETECTING AND CONTROLLING MUCOID PSEUDOMONAS BIOFILM PRODUCTION - Compositions and methods for detecting and controlling the conversion to mucoidy in | 01-13-2011 |
| 20110008787 | DETECTION PRIMERS FOR NUCLEIC ACID EXTENSION OR AMPLIFICATION REACTIONS - Disclosed are methods and compositions related to real-time PCR and other nucleic acid extension or amplification reactions. | 01-13-2011 |
| 20110008788 | CHEMICALLY MODIFIED LIGASE COFACTORS, DONORS AND ACCEPTORS - Provided herein are methods for ligation of polynucleotides containing modified ligation components, particularly modified ligase cofactors, modified acceptors and modified donors. The methods readily applied to ligation-based assays for detection of a nucleic acid sequence where the use of the modified cofactor improves discrimination between matched and mismatched templates. Furthermore, the use of the modified ligation components reduces or eliminates the ligation in the absence of nucleic acid template. | 01-13-2011 |
| 20110008789 | METHODS AND MATERIALS FOR TREATING INFLAMMATORY CONDITIONS - Methods and kits for treating inflammatory conditions are described that include modulating kallikrein 6 protease activity. | 01-13-2011 |
| 20110008790 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE MUTATIONS - The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided. | 01-13-2011 |
| 20110008791 | Molecular Diagnosis of Bacteremia - A highly specific assay can be used for the detection of bacteremia in the clinical setting. The ubiquitous background endogenous DNA present in all PCR reagents is eliminated using a restriction endonuclease digestion. Universal primers for eubacteria are used for detection, and specific primers or probes for bacterial species can be used for identification of species. | 01-13-2011 |
| 20110008792 | PROMOTERS FOR EXPRESSION IN MODIFIED VACCINIA VIRUS ANKARA - The invention concerns promoters, in particular for the expression of genes and/or coding sequences in vaccinia viruses such as Modified vaccinia virus Ankara (MVA). The invention further concerns expression cassettes comprising said promoter, vectors comprising said expression cassettes as well as pharmaceutical compositions and vaccines. | 01-13-2011 |
| 20110008793 | Maize Polymorphisms and Methods of Genotyping - Polymorphic maize DNA loci useful for genotyping between at least two varieties of maize. Sequences of the loci are useful for designing primers and probe oligonucleotides for detecting polymorphisms in maize DNA. Polymorphisms are useful for genotyping applications in maize. The polymorphic markers are useful to establish marker/trait associations, e.g. in linkage disequilibrium mapping and association studies, positional cloning and transgenic applications, marker-aided breeding and marker-assisted selection, hybrid prediction and identity by descent studies. The polymorphic markers are also useful in mapping libraries of DNA clones, e.g. for maize QTLs and genes linked to polymorphisms. | 01-13-2011 |
| 20110008794 | HIGH SPEED PARALLEL MOLECULAR NUCLEIC ACID SEQUENCING - A method and device is disclosed for high speed, automated sequencing of nucleic acid molecules. A nucleic acid molecule to be sequenced is exposed to a polymerase in the presence of nucleotides which are to be incorporated into a complementary nucleic acid strand. The polymerase carries a donor fluorophore, and each type of nucleotide (e.g. A, T/U, C and G) carries a distinguishable acceptor fluorophore characteristic of the particular type of nucleotide. As the polymerase incorporates individual nucleic acid molecules into a complementary strand, a laser continuously irradiates the donor fluorophore, at a wavelength that causes it to emit an emission signal (but the laser wavelength does not stimulate the acceptor fluorophore). In particular embodiments, no laser is needed if the donor fluorophore is a luminescent molecule or is stimulated by one. The emission signal from the polymerase is capable of stimulating any of the donor fluorophores (but not acceptor fluorophores), so that as a nucleotide is added by the polymerase, the acceptor fluorophore emits a signal associated with the type of nucleotide added to the complementary strand. The series of emission signals from the acceptor fluorophores is detected, and correlated with a sequence of nucleotides that correspond to the sequence of emission signals. | 01-13-2011 |
| 20110008795 | MARKER FOR DETECTION OF IL-17-PRODUCING HELPER T-CELL, AND METHOD FOR DETECTION OF IL-17-PRODUCING HELPER T-CELL - Disclosed is a polynucleotide marker or a protein marker for use in the specific detection of an IL-17-producing helper T-cell (a Th17 cell). Also disclosed is a method for detecting a Th17 cell, which is characterized by detecting the occurrence of the polynucleotide marker or the protein marker. | 01-13-2011 |
| 20110008796 | INDUSTRIAL METHOD FOR THE ENCAPSULATION OF BIOLOGICAL MATERIAL FOR THE PURPOSE OF STORAGE AT AMBIENT TEMPERATURE WITH A VACUUM SEAL TEST OF THE ENCAPSULATION - A method for the preparation of a sample of biological material in a container for the purpose of its storage, its recovery, and its subsequent use, includes the succession of the following stages:
| 01-13-2011 |
| 20110008797 | METHOD AND DEVICE FOR THE THERMAL CONTROL OF TEMPERATURE-DEPENDENT ENZYMATIC REACTIONS USING MAGNETIC PARTICLES OR MAGNETIC BEADS AND ALTERNATING MAGNETIC FIELDS - The invention relates to a method for the thermal control of at least one temperature-dependent enzymatic reaction in the presence of magnetic particles, particularly nanoparticles, or magnetic beads in vitro by means of the heating of the magnetic beads or magnetic particles to at least one certain target temperature by means of alternating magnetic fields. The enzymatic reaction which can be controlled with the method according to the invention is preferably a PCR reaction or another reaction for the elongation or amplification of nucleic acids, including DNA, RNA or hybrids or derivatives thereof, which takes place directly on the functionalized magnetic beads. Further aspects of the invention relate to a reactor for carrying out the method and the use of the method or the reactor in analytics and diagnostics. | 01-13-2011 |
| 20110014602 | Diagnostic composition for hepatocellular carcinoma, a diagnostic kit comprising it and diagnostic methods of hepatocellular carcinoma - In the present invention, it is confirmed that cystatin B (cystatin B, CSTB) can be used as a diagnostic marker for hepatocellular carcinoma. Accordingly, the invention relates to a method for early diagnosing hepatocellular carcinoma using the cystatin B as a diagnostic marker for hepatocellular carcinoma, a method for determining the progression or prognosis of hepatocellular carcinoma according to the CSTB expression level, and a method for applying to the prevention or treatment of hepatocellular carcinoma by adjusting the cystatin B expression. | 01-20-2011 |
| 20110014603 | TARGETS FOR USE IN DIAGNOSIS, PROGNOSIS AND THERAPY OF CANCER - Provided herein are targets that can be used for the diagnosis, prognosis and therapy of a variety of cancers. | 01-20-2011 |
| 20110014604 | METHODS FOR SEQUENCE DETERMINATION - A sequencing methodology is disclosed that allows a single DNA or RNA molecule or portion thereof to be sequenced directly and in substantially real time. The methodology involves engineering a polymerase and/or dNTPs with atomic and/or molecular tags that have a detectable property that is monitored by a detection system. | 01-20-2011 |
| 20110014605 | METHODS AND SYSTEMS FOR DNA ISOLATION ON A MICROFLUIDIC DEVICE - The present invention relates to methods and systems for the isolation of DNA on a microfluidic device and the subsequent analysis of the DNA on the microfluidic device. More specifically, embodiments of the present invention relate to methods and systems for the isolation of DNA from patient samples on a microfluidic device and use of the DNA for performing amplification reactions, such as PCR, and detection, such as thermal melt analysis, on the microfluidic | 01-20-2011 |
| 20110014606 | Assays - A device comprising a rigid substrate, a flexible cover element at least partially covering the substrate, a first structure formed in the substrate, adapted for accommodating liquids and adapted for releasing contents of one or more cells, spores, or viruses, the contents including the target molecules, a second structure formed in the substrate, adapted for accommodating liquids and comprising at least one binding member adapted for capturing the target molecules and for determining a value indicative of the presence and/or amount of the target molecules, a micro fluidic network interconnecting at least the first structure and the second structure, and an actuator member adapted for effecting a fluid flow between the first structure and the second structure by pressing the flexible cover element against the substrate to selectively close a portion of the micro fluidic network. | 01-20-2011 |
| 20110014607 | IMPRINTED GENES AND DISEASE - Methods for identifying imprinted genes. In some embodiments, the methods comprise (a) providing a first data set comprising a plurality of nucleic acid sequences, wherein the nucleic acid sequences comprise genomic DNA sequences corresponding to a plurality of genes known to be imprinted in the subject; (b) providing a second data set comprising a plurality of nucleic acid sequences, wherein the nucleic acid sequences comprise genomic DNA sequences corresponding to a plurality of genes known not to be imprinted in the subject; (c) identifying one or more features that by themselves or in combination are differentially present or absent from the first data set as compared to the second data set; and (d) applying the one or more features to a test data set comprising a plurality of genomic DNA sequences which correspond to one or more genes for which the imprinting status is unknown to thereby identify an imprinted gene in a subject. The presently disclosed subject matter also provides methods for identifying a feature in a subject with respect to an imprinted gene and methods for detecting a presence of or a susceptibility to a medical condition associated with parent-of-origin dependent monoallelic expression in a subject. | 01-20-2011 |
| 20110014608 | SCREENING FOR CD93 (C1qRp)-ASSOCIATED POLYMORPHISM(S) IN THE DIAGNOSIS, PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES - This invention is directed to a marker gene for autoimmune disease. Specifically, the invention is directed to the use of a polymorph of CD93 in methods and compositions for the detection, prognosis and therapy of Type I Diabetes and systemic lupus erythematosus (SLE). | 01-20-2011 |
| 20110014609 | NUCLEIC ACID SIGNAL ENHANCEMENT USING NANOPARTICLE-BASED HYBRIDIZATION - A method of enhancing signal detection through use of nanoparticle-conjugated nucleic acid probes is provided. Following chromosomal FISH hybridization of a target sequence with a genomic probe linked to a flag sequence, the flag sequence is hybridized to an anti-flag sequence conjugated to a nanoparticle. The enhanced fluorescent probe is then visualized using microscopy. | 01-20-2011 |
| 20110014610 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING NEUROPSYCHIATRIC DISORDERS - The present invention provides methods for diagnosing mental disorders (e.g., psychotic disorders such as schizophrenia and mood disorders such as major depression disorder and bipolar disorder). The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders. | 01-20-2011 |
| 20110014611 | DESIGN AND SYNTHESIS OF CLEAVABLE FLUORESCENT NUCLEOTIDES AS REVERSIBLE TERMINATORS FOR DNA SEQUENCES BY SYNTHESIS - This invention provides novel azido linkers for deoxynucleotide analogues having a detectable marker attached thereto. | 01-20-2011 |
| 20110014612 | POLYMERASE COMPOSITIONS & METHODS - Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein. | 01-20-2011 |
| 20110014613 | Genotyping for Risk of Atherosclerosis - The invention provides a kits, compositions and methods useful for determining atherosclerotic risk in a subject. In one aspect, the invention provides kit comprising a solid support comprising a capture probe set comprising a plurality of probes selected from (a) a probe selective for PTGS1, (b) a probe selective for PTGS2, (c) a probe selective for NOS3, (d) a probe selective for SERPINE1, (e) a probe selective for F5, (f) a probe selective for MTHFR, (g) a probe selective for ALOX5AP, (h) a probe selective for CETP, (i) a probe selective for APOE, (j) a probe selective for F2, (k) a probe selective for ACE, (l) a probe selective for LTA and (m) a probe selective for LPL. | 01-20-2011 |
| 20110014614 | Method of profiling gene expression in a subject having an infectious disease - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 01-20-2011 |
| 20110014615 | METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCERS BY tRNA-DIHYDROURIDINE SYNTHASE ACTIVITY OF URLC8 - The present invention features a method for determining t-RNA dihydrouridine-synthase activity of a polypeptide and screening for modulators of t-RNA dihydrouridine-synthase activity. The present invention further provides methods or pharmaceutical compositions for preventing and/or treating non-small cell lung cancer (NSCLC) using such modulators. Furthermore, the present invention provides methods for diagnosing non-small cell lung cancer (NSCLC) using the t-RNA dihydrouridine-synthase activity of IMS-E21 (URLC8) protein as an index. The present invention further provides methods for predicting and prognosing lung squamous-cell carcinoma (SCC). | 01-20-2011 |
| 20110014616 | Rapid screening of biologically active nucleases and isolation of nuclease-modified cells - Disclosed herein are methods and compositions for rapidly identifying active nucleases and cells having nuclease-mediated genomic modifications. | 01-20-2011 |
| 20110014617 | Methods and Systems for Detecting Nucleic Acids - Methods and kits for detecting a target nucleic acid in a sample are described. In some embodiments, the sample to be analyzed includes a primer which hybridizes to at least a portion of the target nucleic acid, a probe having a first region which hybridizes to at least a portion of the target nucleic acid and a second region having a detectable label, a polymerase which extends the hybridized primer and an enzyme comprising nuclease activity that can cleave the hybridized hybridization probe to thereby release a labeled probe fragment. In some embodiments, the sample can then be contacted with a solid support comprising surface bound capture probes which can hybridize to the labeled probe fragment(s). These capture probes more readily bind to the probe fragment(s) than to the intact hybridization probe. The label can then be detected on the support surface. In this manner, improved discrimination between the probe fragments and the intact hybridization probes can be achieved. | 01-20-2011 |
| 20110014618 | DETECTION OF NUCLEIC ACIDS AND PROTEINS - The invention generally relates to methods for detecting a target nucleic acid and a target protein in a single assay. | 01-20-2011 |
| 20110014619 | REACTION TREATMENT APPARATUS AND REACTION TREATMENT METHOD - Provided is a reaction treatment apparatus in which, in a case of mixing a plurality of solutions in a microchip used in a biochemical reaction system, an electric field generation area for changing solute concentration distribution in the solutions is provided in a solution upstream fluid path. Diffusion between the solutions is accelerated by bringing an area with a high solute concentration into contact with another solution. This may shorten a time required for mixing the solutions. | 01-20-2011 |
| 20110014620 | METHODS FOR IDENTIFICATION OF BONE ANABOLIC AGENTS - The present invention is related to methods for identifying bone anabolic agents and factors, identifying pathways that promote proliferation of osteoblasts for bone growth and/or repair, and for identifying new therapeutic targets for treatments for osteoporosis and other bone degenerative disorders characterized by osteopenia. | 01-20-2011 |
| 20110014621 | DETECTING MULTINUCLEOTIDE REPEATS - Methods of determining the length of a multinucleotide repeat region in a target nucleic acid are provided herein which include labeling amplified target nucleic acids with a target detection label independent of the number of multinucleotide repeats and a repeat-detection label proportional to the number of multinucleotide repeats, wherein the two types of labels are each independently incorporated in the amplified target nucleic acids during the amplifying or after the amplifying; binding the amplified target nucleic acids to a capture probe specific for the amplified target nucleic acids; detecting the target detection label associated with the capture probe to produce a first signal; detecting the repeat-detection label associated with the capture probe to produce a second signal; and determining a ratio of the first signal and the second signal, wherein the ratio is indicative of the length of the multinucleotide repeat region in the target nucleic acid. | 01-20-2011 |
| 20110014622 | GENETIC REFERENCE MATERIALS - The invention provides a genetic reference standard with at least one human genetic reference sequence (having a human DNA sequence containing at least one genetic variant whose presence in the DNA of a human subject is indicative of a pathological condition, a predisposition to a pathological condition, or a predisposition to an adverse reaction to external stimuli, or is indicative of a patient's likely response to a therapeutic intervention, i.e. a variant used in pharmacogenomic analysis) cloned into a non-mammalian animal cell line. There are also provided such reference standards where the human DNA is targeted to specific location in the host genome, using homologous recombination. The invention further provides a method of detecting a genetic variant using such reference standards. | 01-20-2011 |
| 20110014623 | TAGGED OLIGONUCLEOTIDES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION METHODS - The present invention provides nucleic acid amplification methods that desirably reduce or eliminate false positive amplification signals resulting from contaminating biological material, e.g., nucleic acid, that may be present in one or more reagents used in an amplification reaction and/or that may be present in the environment in which an amplification reaction is performed. The invention offers the further advantage of requiring less stringent purification and/or sterility efforts than conventionally needed in order to ensure that enzymes and other reagents used in amplification reactions, and the environment in which an amplification reaction is performed, are free of bacterial or other nucleic acid contamination that may yield false positive results. | 01-20-2011 |
| 20110014624 | Methods For Identifying Cells Suitable For Large-Scale Production of Recombinant Proteins - The present invention provides methods of identifying a clonal population of cells suitable for large-scale production of a protein of interest. The invention further provides methods for high-throughput screening for genetic rearrangements in the gene encoding the protein of interest, whereby the absence of a deletion in the gene encoding the protein of interest indicates that the cell is suitable for large-scale production of the protein of interest. | 01-20-2011 |
| 20110014625 | System and Method for Determining the Health of a Subject Using Polymorphic Risk Markers - A system and method for predicting the health of a subject comprising obtaining nucleic acid sequence data about the subject. Identifying at least one polymorphic risk marker associated with a change in promoter methylation of a gene associated with lung cancer; and predicting the health of the subject from a presence of at least one polymorphic risk marker identified and kits associated therewith. | 01-20-2011 |
| 20110020792 | DETECTION OF UTERINE LEIOMYOSARCOMA USING LMP2 - This invention provides a method for detecting the presence of uterine leiomyosarcoma using the transcription or expression level of LMP2 and/or cyclin E in uterine smooth muscle tissue as an indicator and a method for detecting uterine leiomyosarcoma using LMP2 and/or cyclin E as a marker. | 01-27-2011 |
| 20110020793 | Molecular counting by color-coded micelles - The invention provides a method of determining ratios of target DNA molecules in a sample. A digital readout of the target DNA molecules is provided by converting ratios of target DNA molecules into equivalent ratios of amplifiable tags, which are, in turn, converted into ratios of color-coded micelles in an emulsion reaction. The micelles may be detected and counted by various methods, including by flow cytometers or slide-based imaging devices. The invention is useful for detection of relative expression levels of selected genes, gene copy number polymorphisms, allelic imbalance, relative levels of iRNAs, and related phenomena of scientific and medical interest. | 01-27-2011 |
| 20110020794 | METHOD FOR THE DETECTION OF DIAGNOSTIC RNA - Methods for the direct detection of diagnostic target RNA have been developed, which obviate the need for time consuming RNA purification and isolation procedures. | 01-27-2011 |
| 20110020795 | ANALYZING THE FMR1 GENE - A method of predicting a degree of risk of early ovarian aging of a young female. The method includes analyzing the female's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele; determining the number of triple CGG repeats on each of the first and second alleles; defining a normal range of triple CGG repeats; comparing the number of triple CGG repeats on each of the first and second alleles to the normal range. If the triple CGG repeat numbers for both of the first and second alleles are within the normal range, then the female is at minimal risk for early ovarian aging. If the triple CGG repeat number for one of the first and second alleles is outside of the normal range and the other one of the first and second alleles is within the normal range, then the first and second alleles are heterozygous and the female is at increased risk for early ovarian aging. If the triple CGG repeat numbers for both of the first and second alleles are outside of the normal range, then the first and second alleles are homozygous and the female is also at an increased risk for early ovarian aging. | 01-27-2011 |
| 20110020796 | Compositions, Methods, and Kits for the Detection of Chlamydia Trachomatis - Method for the detection of | 01-27-2011 |
| 20110020797 | Methods For Identifying Patients With An Increased Likelihood Of Responding To DPP-IV Inhibitors - The invention provides novel in vitro diagnostic methods for identifying patients who may have an increased likelihood of responding to DPP-IV inhibitor therapy. The invention also provides novel polynucleotides associated with increased responsiveness of a patient to DPP-IV inhibition. Polynucleotide fragments corresponding to the genomic and/or coding regions of these polynucleotides, which comprise at least one polymorphic locus per fragment, are also provided. Allele-specific primers and probes which hybridize to these polymorphic regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, medicine, and genetic analysis. | 01-27-2011 |
| 20110020798 | Novel italy, LOR-2, strife, trash, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor - Novel ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST proteins, the invention further provides isolated ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST fusion proteins, antigenic peptides and anti-ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST antibodies. The invention also provides ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 01-27-2011 |
| 20110020799 | Screening method for damaged DNA repairing substance - Provided are a novel screening method for a substance that potentiates damaged DNA repair capability, based on a test with DNA repair as an index with improved sensitivity as a simplified version of the currently available unscheduled DNA synthesis (UDS) assay based on | 01-27-2011 |
| 20110020800 | Characterization of BBK07 antigen of Borrelia burgdorferi and methods of use - In this application is described the characterization | 01-27-2011 |
| 20110020801 | Carboxylesterase-1 Polymorphisms and Methods of Use Therefor - Methods and kits are provided for detecting polymorphisms in carboxylesterase-1 (CES1). Several single nucleotide polymorphisms (SNPs) in CES1 in humans, and methods for detecting the same, are provided (e.g., Gly143Glu, 12754T>del). Results indicate that the Gly143Glu (9486G>A) polymorphism has an allelic frequency of 1.5% in the Caucasian population. Polymorphisms of the present invention may alter the function of the carboxylesterase-1 enzyme (hCES1). Thus, the methods and kits of the present invention may be used to personalize a therapy and/or avoid adverse consequences of altered metabolism of a therapeutic or compound (e.g., enalapril, methylphenidate, etc.) which may result due to a CES1 polymorphism. In addition, recombinant cells lines overexpressing wild-type CES1 or expressing CES1 mutants are provided. Such cell lines may be used to assess the effects of candidate compounds on CES1, and the action of CES1 on these candidate compounds. | 01-27-2011 |
| 20110020802 | NUCLEIC ACIDS, METHODS AND KITS FOR THE DIAGNOSIS OF DYT6 PRIMARY TORSION DYSTONIA - The invention relates generally to the THAP1 gene and mutations in this gene, as well as the THAP1 protein and mutations in this protein, that are associated with dystonia. The invention relates to the identification, isolation, cloning and characterization of the DNA sequence corresponding to the wild type and mutant THAP1 genes, as well as isolation and characterization of their transcripts and gene products. The invention further relates to methods and kits useful for detecting mutations in THAP1 that are associated with dystonia, as well as to methods and kits useful for diagnosing dystonia. The present invention also relates to therapies for treating dystonia, including gene therapeutics and protein/antibody based therapeutics. | 01-27-2011 |
| 20110020803 | MARKERS FOR THE PROGNOSIS OF LUNG FUNCTION AND COLONIZATION WITH AN INFECTIOUS AGENT - The present invention provides a method and kit for determining the risk for impaired lung function and/or the susceptibility for colonization with an infectious agent. The method and kit comprise determining the presence or absence of one or more nucleic acid variants in a gene or a combination of genes. | 01-27-2011 |
| 20110020804 | PHOTOINDUCED ELECTRON TRANSFER (PET) PRIMER FOR NUCLEIC ACID AMPLIFICATION - This application provides photoinduced electron transfer (PET) nucleic acid molecules that can be used detect and amplify nucleic acid molecules, such as target nucleic acid molecules. These PET tags can be attached to the 5′-end of a target sequence-specific primer, thereby generating a PET primer. In particular examples, a PET tag includes a 5′-labeled nucleotide that can be quenched by at least two consecutive Gs within the tag sequence, and is unquenched when the PET tag hybridizes with its complementary nucleic acid molecule. Also disclosed are methods of using PET primers in nucleic acid amplification, such as real-time PCR. | 01-27-2011 |
| 20110020805 | MUTATIONAL ANALYSIS OF CHRONIC MYELOPROLIFERATIVE DISORDERS - The invention relates to molecular assays, reagents and kit for the mutational analysis, for diagnostic and prognostic purposes, of chronic myeloproliferative disorders, a group of neoplastic pathologies of the haemopoietic system. The invention relates to the identification of nucleic acid probes labelled with fluorochrome, allowing a quantitative assessment, in a specific and sensitive way, of mutation of MPL gene sequence and quantification of the mutated alleles of the MPL gene in Genomic DNA samples from patients with chronic myeloproliferative syndrome. | 01-27-2011 |
| 20110020806 | Rapid DNA Sequencing by Peroxidative Reaction - Disclosed is a method of polynucleic acid (e.g., DNA) sequencing which is based on the generation of pyrophosphate (PPi) that occurs when a complementary base is incorporated into a growing DNA strand being synthesized on a template. The method utilizes a cascade of enzymatic reactions catalyzed by hypoxanthine-phosphoribosyl transferase, xanthine oxidase, and peroxidase in addition to DNA polymerase and apyrase. The last chemical step in the cascade of reactions is the oxidation of a material such as an electrode or luminol by hydrogen peroxide. This generates a detectable electrical or optical signal. This method is independent of luciferase, does not require dATP analogue, and is intended to improve precision and sensitivity of DNA sequencing, and to lessen the unsynchronized polymerization. | 01-27-2011 |
| 20110020807 | Methylated CpG Island Amplification (MCA) - The present invention provides a method for identifying a methylated CpG containing nucleic acid by contacting a nucleic acid with a methylation sensitive restriction endonuclease that cleaves unmethylated PcG sites and contacting the sample with an isoschizomer of the methylation sensitive restriction endonuclease, which cleaves both methylated and unmethylated CpG sites. The method also includes amplification of the CpG-containing nucleic acid using CpG-specific oligonucleotide primers. A method is also provided for detecting an age associated disorder by identification of a methylated CpG containing nucleic acid. A method is further provided for evaluating the responses of a cell to an agent. A kit is useful for detection of a CpG containing nucleic acid is also provided. Nucleic acid sequences encoding novel methylated clones. | 01-27-2011 |
| 20110020808 | BIOMARKERS FOR DIAGNOSING SCHIZOPHRENIA AND BIPOLAR DISORDER - The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in blood and useful in diagnosing schizophrenia and/or bipolar disorder as well as monitoring therapeutic efficacy of treatment for schizophrenia or bipolar disorder. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention can be used to diagnose schizophrenia and/or bipolar disorder. Measurement of the expression level of products of biomarkers of the invention using polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are compositions and kits containing said polynucleotides and proteins. Further encompassed by the invention is the use of the polynucleotides and proteins to monitor the efficacy of therapeutic regimens. The invention also provides for the identification of methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets of schizophrenia and/or bipolar disorder and a method of screening the genes of said biomarkers for additional markers of disease. | 01-27-2011 |
| 20110020809 | MILD OSTEOARTHRITIS BIOMARKERS AND USES THEREOF - The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in individuals with mild osteoarthritis as compared with individuals without osteoarthritis. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are kits containing said polynucleotides and proteins for use in diagnosing mild osteoarthritis. Further encompassed by the invention is the use of the polynucleotides and proteins which specifically and/or selectively hybridize to the product of the biomarkers of the invention to monitor disease regression in an individual and to monitor the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for osteoarthritis. | 01-27-2011 |
| 20110020810 | TRPC6 INVOLVED IN GLOMERULONEPHRITIS - Focal and segmental glomerulosclerosis (FSGS) is a kidney disorder of unknown etiology and up to 20% of patients on dialysis have this diagnosis. A large family with hereditary FSGS carries a missense mutation in the TRPC6 gene on chromosome 11q, encoding the ion channel protein Transient Receptor Potential Cation Channel 6. The missense mutation is a P112Q substitution, which occurs in a highly conserved region of the protein, enhances TRPC6-mediated calcium signals in response to agonists such as angiotensin II, and alters the intracellular distribution of TRPC6 protein. Previous work has emphasized the importance of cytoskeletal and structural proteins in proteinuric kidney diseases. Our findings suggest a novel mechanism for glomerular disease pathogenesis. | 01-27-2011 |
| 20110020811 | HOST CELLS COMPRISING ALPHA 1,2 MANNOSIDASE AND CULTURE METHODS THEREOF - Improved host cells and culture methods involving overexpression of MAN1C1 activity to improve protein production are provided. | 01-27-2011 |
| 20110020812 | METHODS OF USING FET LABELED OLIGONUCLEOTIDES THAT INCLUDE A 3'-5' EXONUCLEASE RESISTANT QUENCHER DOMAIN AND COMPOSITIONS FOR PRACTICING THE SAME - Methods and compositions are provided for detecting a primer extension product in a reaction mixture. In the subject methods, a primer extension reaction is conducted in the presence of a polymerase having 3′→5′ exonuclease activity and at least one FET labeled oligonucleotide probe that includes a 3′→5′ exonuclease resistant quencher domain. Also provided are systems and kits for practicing the subject methods. The subject invention finds use in a variety of different applications, and are particularly suited for use in high fidelity PCR based reactions, including SNP detection applications, allelic variation detection applications, and the like. | 01-27-2011 |
| 20110020813 | ADVANCED PATHOGEN DETECTION AND SCREENING - Disclosed is a rapid, dual purpose, PCR-based method for identifying two or more pathogens, including | 01-27-2011 |
| 20110020814 | METHODS AND COMPOSITIONS FOR SELECTION OF STEM CELLS - Described herein are methods and compositions for selection of pluripotent stem cells from a population of mammalian cells (e.g., human) undergoing a process that induces some cells within the population to become pluripotent. | 01-27-2011 |
| 20110020815 | METHODS FOR GENOMIC ANALYSIS - The present invention relates to methods for identifying variations that occur in the human genome and relating these variations to the genetic basis of disease and drug response. In particular, the present invention relates to identifying individual SNPs, determining SNP haplotype blocks and patterns, and, further, using the SNP haplotype blocks and patterns to dissect the genetic bases of disease and drug response. The methods of the present invention are useful in whole genome analysis. | 01-27-2011 |
| 20110020816 | Precursor miRNA loop-modulated target regulation - By modifying nucleotides from either or both the stem and loop of precursor-miRNA, greater specificity is achieved as to the mRNAs targeted. The improved efficiency in target regulation can be either mediated by direct base-pairings between targets and precursor miRNAs or indirectly by energy constraints on the availability of such base-pairings. It is found that pri- and pre-miRNA are active in the absence of functional mature miRNA, so pri- or pre-miRNA or truncated portion thereof, but not as mature miRNA, can be used as RNAi agents by themselves. Furthermore, besides the seed sequence of the stem of the pre-miRNA and 3′-extensions thereof to provide greater complementarity to the target mRNA, nucleotides in the loop can affect the activity and specificity of the precursor-miRNA and the processing and binding to target mRNA. By using mutated sequences in the natural pri- or pre-miRNA or modified mimetics, one can screen for target mRNA, target a unique mRNA or a group of mRNAs for regulation, and modulate cell properties with greater specificity and investigate cellular activity as to phenotype and response to external stimuli in the presence or absence of at least partial target protein expression. | 01-27-2011 |
| 20110020817 | De novo synthesized plasmid, methods of making and use thereof - The invention relates to a de novo synthesized plasmid. The plasmid comprises relevant sequences for plasmid replication and plasmid selection. The methods of making and use of the plasmid are disclosed. The plasmid can be used to make other plasmids. These plasmids and their host cells can be used for biomedical applications. | 01-27-2011 |
| 20110020818 | REACTOR FOR THE QUANTITATIVE ANALYSIS OF NECLEIC ACIDS - A reactor for the quantitative analysis of target nucleic acids using an evanescent wave detection technique and a method of use thereof is provided. The reactor includes a substrate with a cavity, a buffer layer arranged over the substrate; a cover plate arranged over the buffer layer, and inlet and outlet ports. The reactor is thermally and chemically stable for PCR processing and suitable for an evanescent wave detection technique. | 01-27-2011 |
| 20110020819 | ISOTHERMAL DETECTION METHODS AND USES THEREOF - The present disclosure relates to methods and probes for rapid, single temperature (isothermal) detection of specific nucleic acid sequences. The methods and probes provide a simple method for detecting bioagents including bacteria and viruses, and the detection of specific genetic markers on any nucleic sequence. | 01-27-2011 |
| 20110020820 | METHOD FOR DETECTION OF MICROORGANISM AND KIT FOR DETECTION OF MICROORGANISM - A kit is disclosed for preparing a measurement sample for detecting live cells, injured cells, VNC cells and dead microorganism cells in a test sample by the following steps:
| 01-27-2011 |
| 20110020821 | METHOD FOR DETECTION OF MICROORGANISM AND KIT FOR DETECTION OF MICROORGANISM - According to the following steps, live cells, injured cells, VNC cells and dead cells of a microorganism in a test sample are detected by flow cytometry:
| 01-27-2011 |
| 20110020822 | MOLECULAR DETECTION OF CHROMOSOME ABERRATIONS - The invention relates to the field of cytogenetics and the application of genetic diagnostic techniques in pathology and hematology. Specifically, the invention relates to nucleic acid probes that can be used in hybridization techniques for the detection of chromosomal aberrations and other gene rearrangements such as immunoglobulin and T-cell receptor gene rearrangements. The probes provided by the invention are a distinct and balanced set of probes of comparable size, each preferably being from 1 to 100 kb, or smaller, and flanking a potential breakpoint in a chromosome. | 01-27-2011 |
| 20110020823 | SEQUENCES AND THEIR USE FOR DETECTION AND CHARACTERIZATION OF E. COLI O157:H7 - This invention relates to a rapid method for detection and characterization of | 01-27-2011 |
| 20110020824 | METHODS AND COMPOSITIONS FOR QUANTITATIVE AMPLIFICATION AND DETECTION OVER A WIDE DYNAMIC RANGE - Disclosed are compositions and methods for making differentiable amplicon species at unequal ratios using a single amplification system in a single vessel. The number of differentiable amplicons and their ratios to one another are chosen to span the required linear dynamic range for the amplification reaction and to accommodate limitations of the measuring system used to determine the amount of amplicon generated. Unequal amounts of distinguishable amplicon species are generated by providing unequal amounts of one or more amplification reaction components (e.g., distinguishable amplification oligomers, natural and unnatural NTP in an NTP mix, or the like). The amount of target nucleic acid present in a test sample is determined using the linear detection range generated from detection of one or more amplicon species having an amount within the dynamic range of detection. | 01-27-2011 |
| 20110020825 | PROTEIN C POLYMORPHISMS USEFUL AS AN INDICATOR OF PATIENT OUTCOME - The invention provides methods and kits for obtaining a prognosis for a patient having or at risk of developing an inflammatory condition. The method generally comprises determining a protein C promoter genotype of a patient for a polymorphism in the protein C promoter region of the patient, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the patient to recover from the inflammatory condition and identifying patients based on their prognosis. The invention also provides for methods of identifying other polymorphisms that correspond with the ability of the patient to recover from the inflammatory condition. | 01-27-2011 |
| 20110020826 | METHODS FOR ASSESSING EFFICACY OF CHEMOTHERAPEUTIC AGENTS - Methods are provided for accurately predicting efficacy of chemotherapeutic agents. Methods of the invention increase the positive predictive value of chemosensitivity assays by assessing both the ability of a chemotherapeutic to destroy cells and the genetic propensity of those cells for resistance. Results obtained using methods of the invention provide insight into the in vivo effectiveness of a therapeutic, and lead to more effective chemotherapeutic treatment. | 01-27-2011 |
| 20110020827 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USES THEREOF - The invention is directed to modified guanine-containing nucleosides and nucleotides and uses thereof. More specifically, the invention relates to modified fluorescently labelled guanine-containing nucleosides and nucleotides which exhibit enhanced fluorophore intensity by virtue of reduced quenching effects. | 01-27-2011 |
| 20110020828 | CE43-67B INSECTICIDAL COTTON - The present application relates an insect resistant transgenic cotton plant. In particular, it relates to a specific event, designated CE43-67B. The application also relates to polynucleotides which are characteristic of the CE43-67B event, plants comprising said polynucleotides, and methods of detecting the CE43-67B event. | 01-27-2011 |
| 20110020829 | RAPID ASSAY FOR DETECTING ATAXIA-TELANGIECTASIA HOMOZYGOTES AND HETEROZYGOTES - The present disclosure relates to methods for performing an assay to identify ataxia-telangiectasia homozygotes or heterozygotes. Some embodiments include the use of a rapid flow cytometry-based ataxiatelangiectasia (ATM) kinase assay that measures ATM-dependent phosphorylation of SMC1 following DNA damage. | 01-27-2011 |
| 20110020830 | DESIGN FOR RAPIDLY CLONING ONE OR MORE POLYPEPTIDE CHAINS INTO AN EXPRESSION SYSTEM - The present invention provides methods and compositions for the generation and identification of expression constructs that can be used to express sufficient levels of a polypeptide of interest. The compositions include a population of expression vectors, wherein members of the population have a type IIS restriction enzyme recognition site adjacent to a regulatory sequence, and wherein the regulatory element is distinct in at least two members of the population of expression vectors. In various embodiments, the expression vectors further comprise a polynucleotide sequence encoding a polypeptide of interest, wherein the polynucleotide encoding the polypeptide, the polynucleotide of the regulatory sequence, or both, are distinct in at least two members of the population. The compositions are useful for identifying a combination of coding sequences and/or regulatory elements useful for the heterologous expression of the polypeptide of interest. | 01-27-2011 |
| 20110020831 | GENETIC DETECTION OF HIV-1 STRAINS THAT USE THE CXCR4 CO-RECEPTOR - The invention relates to a method for obtaining clonal HIV-1 sequence information from a clinical isolate derived from an HIV-1 infected individual to guide highly active anti-retroviral therapy (HAART) comprising the following steps;
| 01-27-2011 |
| 20110020832 | METHOD FOR DETECTING CANCER CELL CAUSED BY HPV, METHOD FOR DETERMINING WHETHER OR NOT TISSUE IS AT STAGE OF HIGH-GRADE DYSPLASIA OR MORE SEVERE STAGE, AND PRIMER SET AND KIT USED THEREFOR - Provided are a primer set, a method and a kit therefor, which can easily perform with high accuracy the detection of a cancer cell caused by HPV and the determination of whether or not a tissue is a tissue with high-grade dysplasia or in a more severe phase. As a primer set, used is a primer set consisting of a first primer which hybridizes with a nucleic acid consisting of a nucleotide sequence in which cytosine present in a site other than a CpG site is converted into another base in a nucleotide sequence having a CpG site in L1 region or L2 region of HPV and a second primer which hybridizes with a nucleic acid consisting of a nucleotide sequence in which cytosine is converted into another base in a nucleotide sequence having a CpG site in LCR or E6 region of HPV. | 01-27-2011 |
| 20110027776 | KITS AND METHODS FOR ASSESSING ANTIOXIDANT REQUIREMENT OF A HUMAN - The invention relates to kits and methods for assessing the desirability of supplementing the diet of a human with reduced coenzyme Q (CoQH | 02-03-2011 |
| 20110027777 | METHOD FOR PERFORMING PROGNOSIS FOR HIGH-RISK BREAST CANCER PATIENTS USING TOP2A GENE ABERRATIONS - A first exemplary method for performing a prognosis for a breast cancer patient, comprises the steps of determining the status of an aberration of the TOP2A gene in a tissue sample taken from the patient; and estimating the probability of either recurrence-free survival or of overall survival of the patient at a later time based upon a pre determined Hazard Ratio corresponding to the determined status. A second such exemplary method comprises the steps of determining the status of an aberration of the TOP2A gene in a tissue sample taken from the patient; and estimating the probability of either recurrence-free survival or of overall survival of the patient at a later time based upon a pre-determined Kaplan-Meier plot corresponding to the determined status. | 02-03-2011 |
| 20110027778 | COMPOSITION COMPRISING AN OLIGONUCLEOTIDE MIXTURE FOR IMPROVED DETECTION OF HUMAN PAPILLOMAVIRUS GENOTYPES - The present invention relates to a composition comprising an oligonucleotide mixture. Moreover, the present invention relates to the use of said oligonucleotide mixture for diagnosing different HPV genotypes in a sample of a subject. Further encompassed is a method for diagnosing different HPV genotypes in a sample of a subject and a kit carrying out said method. | 02-03-2011 |
| 20110027779 | POLYNUCLEOTIDE PRIMERS - A polynucleotide comprising at least the final six nucleotides of one of the following primer sequences, or a sequence complementary thereto: SEQ. ID NOS. 3 to 16, 18, 20 to 33, 35 or 37 to 39. A method of detecting the presence or absence of a mutation in the PIK3CA gene, wherein the mutation is one of H1047R, H1047L, E542K and E545K, and preferably ARMS primers are combined with Scorpion primers. | 02-03-2011 |
| 20110027780 | AMPLIFICATION METHODS - Methods are provided for amplification and monitoring of oligonucleotide amplification in which a primer has an overlap with one or more bases of a detection probe. | 02-03-2011 |
| 20110027781 | System for Autonomous Monitoring of Bioagents - An autonomous monitoring system for monitoring for bioagents. A collector gathers the air, water, soil, or substance being monitored. A sample preparation means for preparing a sample is operatively connected to the collector. A detector for detecting the bioagents in the sample is operatively connected to the sample preparation means. One embodiment of the present invention includes confirmation means for confirming the bioagents in the sample. | 02-03-2011 |
| 20110027782 | PROBES AND METHODS FOR DETECTION OF PATHOGENS AND ANTIBIOTIC RESISTANCE - Described are probes and methods for detecting pathogens and antibiotic resistance of a specimen. The method comprises contacting the specimen with a growth medium; and lysing the specimen to release nucleic acid molecules from the specimen. The lysate of the specimen is contacted with a capture probe immobilized on a substrate, wherein the capture probe comprises an oligonucleotide that specifically hybridizes with a first target nucleic acid sequence region of ribosomal RNA. The lysate is in contact with a detector probe that comprises a detectably labeled oligonucleotide that specifically hybridizes with a second target nucleic acid sequence region of ribosomal RNA. The presence or absence of labeled oligonucleotide complexed with the substrate is determined. Detection of labeled oligonucleotide complexed with the substrate is indicative of the presence of pathogen. Performing the method in the presence and absence of an antibiotic permits detection of antibiotic resistance. | 02-03-2011 |
| 20110027783 | EXO1 Promotor Polymorphism Associated with Exceptional Life Expectancy in Humans - The invention relates to an exonuclease 1 (EXO1) promoter polymorphism associated with exceptional life expectancy in humans. More specifically, the invention relates to the promoter region of EXO1 where the gene has been found to be mutated. Moreover, the invention relates to a gene regulation mechanism involving transcription factor E47 as a transcriptional repressor of EXO1. | 02-03-2011 |
| 20110027784 | Novel Primers for Identification of Astrocytoma, Its Grades and Glioblastoma Prognosis - The present invention relates to novel primers for identification of astrocytoma, it's grades and glioblastoma prognosis. Further, disclosed is a method of diagnosing the presence of different grades of diffuse astrocytoma and glioblastoma, in a human subject, which involves detection of the expression levels of said genes in tumor tissue samples in comparison to normal brain. Also disclosed is a method of distinguishing between the two types of Glioblastoma—the progressive and de novo types. Also disclosed is a method of prognosis of glioblastoma based on the expression of the gene PBEF1, wherein the higher level of expression of the gene in the tumor sample, indicates poorer survival of the human subject. The disclosed compositions are useful, for example, in the diagnosis, prevention, treatment and/or prognosis of astrocytoma. The invention further provides kits for the detection and prognosis of the said diseases. | 02-03-2011 |
| 20110027785 | METHOD FOR DETERMINING SUSCEPTIBILITY OF INDIVIDUALS TO POLYPHENOLS - Consumption of high energy diets, lack of physical activity and sleep curtailment have all been linked to the development of type II diabetes and cardiovascular disease. Studies have also shown how powerful diet and lifestyle modification can be for preventing disease. However not everyone responds to lifestyle change in the same way. This is because genetic factors can modify biological response to environmental challenge. | 02-03-2011 |
| 20110027786 | PRIMERS FOR NUCLEIC ACID EXTENSION OR AMPLIFICATION REACTIONS - Disclosed are methods and compositions for use in nucleic acid amplification or extension reactions. | 02-03-2011 |
| 20110027787 | METHODS AND SYSTEMS FOR IDENTIFYING AND ISOLATING STEM CELLS AND FOR OBSERVING MITOCHONDRIAL STRUCTURE AND DISTRIBUTION IN LIVING CELLS - Methods and systems for a) identifying and isolating stem cells, b) assessing mitochondrial distribution and structure in living cells and c) performing fluorescence microscopy on living cells while the cells remain within a condition-controlled cell culture chamber. | 02-03-2011 |
| 20110027788 | REAGENT AND KIT FOR CLASSIFYING AND COUNTING LEUKOCYTES, THE PREPARATION THEREOF, AND PROCESS FOR CLASSIFYING AND COUNTING LEUKOCYTES - A reagent for classifying and counting leukocytes containing (1) a cyanine fluorescent dye; and (2) a glycoside compound; a reagent kit containing the reagent for classifying and counting leukocytes as well as its preparation process; and a process for classifying and counting blood cells using the reagent or kit are provided. Using the reagent, kit and/or process provided, leukocytes can be classified and counted in four groups with a high degree of differentiation and a better classification among each subpopulation of leukocytes, especially in that it successfully addresses the indistinct classification between lymphocytes and monocytes and between the eosinophils and neutrophils in a scattergram. | 02-03-2011 |
| 20110027789 | METHODS FOR PRESERVATION OF GENOMIC DNA SEQUENCE COMPLEXITY - The present invention relates to methods and kits for preserving genomic DNA sequence complexity within chemically and/or enzymatically converted DNA by an enzyme or series of enzymes that adds a methyl group to a cytosine outside of CpG dinucleotide sequences of genomic DNA. Further, the present invention relates to methylation analysis of the genomic DNA. | 02-03-2011 |
| 20110027790 | METHODS OF EQUALIZING REPRESENTATION LEVELS OF NUCLEIC ACID TARGETS - The disclosure provides methods of reducing the range of representation levels of nucleic acid targets. The methods are particularly useful for multi-target analyses benefiting from a low variance of target representations, such as, e.g., single molecule sequencing and/or heterozygous genotyping, and pathogen diagnosis. Two general methods are provided. In Method 1, starting concentrations of probes are adjusted. In Method 2, target-specific probes are “binned,” i.e., several subsets of probes are selected based on similar representation levels. Thereafter, each subset of corresponding targets is extracted, with or without amplification, using a separate portion of the sample (i.e., separate vessels). | 02-03-2011 |
| 20110027791 | METHOD FOR GENERATING SINGLE-STRANDED DNA MOLECULES REPRESENTATIVE OF A DNA SAMPLE - A method for generating a population of single stranded DNA molecules representative of a DNA sample, including digesting the DNA sample with a Type I restriction endonuclease; subjecting the DNA fragments to melt conditions to produce a melt-generated mixture of forward and reverse single stranded DNA fragments; contacting the mixture of forward and reverse single strand DNA fragments with a solid support having immobilized thereon the complement of either the forward or reverse strand, wherein the solid phase hybridizations are favored over self-annealing of the melt-generated single stranded DNA molecules; and releasing the captured forward or reverse single strand DNA fragments from the complement immobilized to the solid support to generate a population of single stranded DNA molecules representative of the DNA sample. | 02-03-2011 |
| 20110027792 | ASSAY FOR MYCOBACTERIUM AVIUM/INTRACELLULARE NUCLEIC ACID - Disclosed is a method for determining the presence of | 02-03-2011 |
| 20110027793 | KIT FOR MEASURING IN VIVO MUTATION FREQUENCY AT AN ENDOGENOUS GENE LOCUS - The present invention relates a method for the enumeration of in vivo gene mutation. The method utilizes differential staining of GPI-anchor deficient erythrocyte populations to distinguish between wild-type and pig-a gene mutants. Quantitative analyses can be conducted on erythrocytes and/or reticulocytes, and is based upon fluorescent emission and light scatter following exposure to an excitatory light source. Counting of mutant erythrocytes or reticulocytes relative to the number of total erythrocytes or reticulocytes can be used to assess the DNA-damaging potential of an exogenous chemical agent, the DNA-damaging potential of an exogenous physical agent, the effects of an exogenous agent which can modify endogenously-induced DNA damage, and the effects of an exogenous agent which can modify exogenously-induced DNA damage. Kits for practicing the invention are also disclosed. | 02-03-2011 |
| 20110027794 | Method for Synthesizing Nucleic Acids, and Application Thereof - The invention relates to a method for synthesizing a nucleic acid containing modified nucleotides. The method encompasses the following steps: a matrix strand is provided; —a primer which at least partially hybridizes on the matrix strand is provided; —nucleoside triphosphates, at least some of which are modified nucleoside triphosphates, are provided; —a polymerase activity is supplied; and—the matrix strand, the primer, and the nucleoside triphosphates are incubated so as to synthesize a nucleic acid that is substantially complementary to the matrix strand. The polymerase activity can be a reverse transcriptase activity. | 02-03-2011 |
| 20110027795 | CELL PROCESSING AND/OR ENRICHMENT METHODS - The present invention relates to methods of processing and/or enriching cells from a pregnant female. More particularly the invention provides methods for processing and/or enriching fetal cells from a pregnant female. The enriched fetal cells can be used in a variety of procedures including, detection of a trait of interest such as a disease trait, or a genetic predisposition thereto, gender typing and parentage testing. | 02-03-2011 |
| 20110027796 | METHOD FOR DETECTING LUNG CANCER USING LUNG CANCER-SPECIFIC METHYLATION MARKER GENE - The present invention relates to a method for detecting lung cancer using a lung cancer-specific biomarker, and more particularly to a biomarker for lung cancer diagnosis, which can detect methylation of PCDHGA12 gene whose 5′UTR or exon 1 region is specifically methylated in lung cancer cells, and to a method of detecting lung cancer and the stage of its progression using the biomarker. The diagnostic kit according to the present invention makes it possible to diagnose lung cancer at an early stage in an accurate and rapid manner compared to conventional methods and can be used for prognosis and monitoring of lung cancer and the stage of its progression. | 02-03-2011 |
| 20110027797 | Method for the Diagnosis of Higher- and Lower-Grade Astrocytoma Using Biomarkers and Diagnostic Kit Thereof - Disclosed is a method of diagnosing the presence of higher grade astrocytoma/glioblastoma (GBM) or lower-grade grade astrocytoma (DA or AA) in a human subject using secreted or plasma membrane associated biomarkers, which involves the detection of the expression levels of said genes, alone or in combination, in either tumor tissue samples or body fluids and a diagnostic kit thereof. | 02-03-2011 |
| 20110027798 | Hybridization Quantitation Method for Modified Micro-RNA and -DNA Based Oligonucleotides - Described herein is a method for the qualitative and/or quantitative determination of an analyte in a test sample which includes base pairing at least one oligonucleotide to a capture template having an overhang; and, hybridizing with a detection probe. | 02-03-2011 |
| 20110027799 | KIT AND METHOD FOR DETERMINING WHETHER OR NOT UNMETHYLATED CYTOSINE CONVERSION TREATMENT IS PROPERLY CARRIED OUT AND METHOD FOR ANALYZING METHYLATED DNA USING THE SAME - Success or failure of unmethylated cytosine conversion treatment is determined by using a first primer set comprising plural primers that hybridize with a nucleic acid comprising a nucleotide sequence not containing cytosine in the nucleotide sequence of biological DNA that is subject to an unmethylated cytosine conversion treatment and a second primer set comprising plural primers that hybridize with a nucleic acid comprising a nucleotide sequence in which cytosine in a nucleotide sequence containing cytosine and not containing a CpG site is converted into a base other than cytosine, in the nucleotide sequence of biological DNA. | 02-03-2011 |
| 20110033843 | METHOD FOR IN VITRO TESTING OF COMPOUNDS FOR ASSESSING THERAPEUTIC VALUE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND OTHER DISEASES WHEREIN FOAMY CELLS ARE INVOLVED IN THE DISEASE ETIOLOGY - The invention provides a method for assessing or determining activity of a test Compound on modulation of gene product levels comprising culturing cells, contacting at least one of the cultured cells with a lipid-rich fraction, contacting at least one of the cultured cells with the test Compound, determining the presence of a gene product of at least one cell of the cultured cells and, optionally, determining the presence of the gene product of at least one cultured cell not contacted with the test Compound. To assess human conditions most fully, it is preferred that the cell is of human origin, for example, a peripheral blood monocyte taken from a healthy donor. | 02-10-2011 |
| 20110033844 | USE OF LYSOSOMAL CARBOXYPEPTIDASE C (PRCP) AS A THERAPEUTIC OR DIAGNOSTIC TARGET - The invention provides a human PRCP which is associated with the cardiovascular diseases, hematological diseases, neurological diseases and cancer. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases and cancer. The invention also features compounds which bind to and/or activate or inhibit the activity of PRCP as well as pharmaceutical compositions comprising such compounds. | 02-10-2011 |
| 20110033845 | Methods For Amplification of Nucleic Acids Using Spanning Primers - The teachings relate to methods and kits for detecting whether target nucleic acid sequences are present and/or quantitating target nucleic acid sequences. | 02-10-2011 |
| 20110033846 | Concurrent Analysis of Multiple Patient Samples Using Solid Phase Addressable Multiplex Test with High Signal-to-Noise Ratio - Contemplated systems and methods allow analysis of multiple and distinct patient samples using a labeling scheme that entirely avoids carry-over of a label or reagent to the analytic platform, typically an addressable solid phase. In preferred aspects, a hybridization portion, a fluorophore, and/or a quencher are removed by a 5′-3′-exonuclease activity of a polymerase from a reporter oligonucleotide to so remove the oligonucleotide from the pool of molecules that bind to the solid phase and/or or to provide signal differentiation by removal of a fluorophore or quencher. | 02-10-2011 |
| 20110033847 | Methods for the characterization of microorganisms on solid or semi-solid media - The present invention relates to methods and systems for scanning, detecting, and monitoring microorganisms on solid or semi-solid media using intrinsic fluorescence (IF) measurements. The methods are further directed to detection, characterization and/or identification of microorganisms on a solid or semi-solid media using intrinsic fluorescence (IF) measurements that are characteristic of said microorganisms. | 02-10-2011 |
| 20110033848 | EPIGENETIC METHODS - The present invention provides methods for obtaining epigenetic information for a polyploid subject, the method including the steps of obtaining a biological sample from the subject, the sample containing: (i) at least one paternally-derived DNA molecule and/or associated protein and/or, (ii) at least one maternally-derived DNA molecule and/or associated protein, analyzing any one or more of the paternally- or maternally-derived DNA molecules or associated proteins for the presence or absence of modifications, wherein the step of analyzing determines whether any two modifications are present in cis on one chromosome, or in trans across two sister chromosomes. | 02-10-2011 |
| 20110033849 | OVINE IDENTIFICATION METHOD - The invention relates to method for identifying an ovine with a genotype indicative of one or more altered performance traits, the method including the step of detecting, in a sample derived from the ovine, the presence of at least one allele of the CP34 simple sequence repeat (SSR) marker, or at least one allele of a marker in linkage disequilibrium (LD) with CP34, wherein the presence of the allele is indicative of the altered performance traits in the ovine. | 02-10-2011 |
| 20110033850 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION - Methods of identifying inhibitors of retroviral propagation, tRNA used in the methods, and kits, including the tRNA, which can be used in the methods, are disclosed. Methods of treating or preventing retroviral infections by administering an effective amount of the inhibitors, and pharmaceutical compositions including the inhibitors, are also disclosed. The methods involve forming a mixture comprising a linear sequence of a tRNA anticodon stem loop fragment that is not capable of forming a stem-loop, a target nucleic acid molecule capable of binding to the tRNA anticodon stem loop fragment, and a test compound. The mixture is incubated under conditions that allow binding of the tRNA anticodon stem loop fragment and the target nucleic acid molecule in the absence of the test compound. Assays can then be performed that detect whether or not the test compound inhibits the binding of the tRNA anticodon stem loop fragment and the target nucleic acid molecule. | 02-10-2011 |
| 20110033851 | NUCLEIC ACID AMPLIFICATION - Provided herein is a method for the selective amplification of a target nucleotide sequence located within a nucleic acid molecule, the method comprising contacting the nucleic acid molecule (“template” molecule) with (i) at least one facilitator oligonucleotide, wherein the facilitator oligonucleotide includes at least one modification at or near its 3′ terminus such that 3′ extension from the facilitator oligonucleotide is blocked, and (ii) two or more oligonucleotide primers, at least one of which is an initiator primer modified such that the presence of the modification prematurely terminates complementary strand synthesis, wherein the facilitator oligonucleotide and the initiator primer bind to substantially the same or adjacent regions of the template nucleic acid molecule and the facilitator oligonucleotide further comprises sequences complementary to the target sequence 3′ to the binding location of the initiator primer; and carrying out thermocyclic, enzymatic amplification such that the specific target sequence is selectively amplified. | 02-10-2011 |
| 20110033852 | PRESENT INVENTION RELATES TO METHODS FOR PREDICTION OF THE THERAPEUTIC SUCCESS OF BREAST CANCER THERAPY - The present invention relates to a method for predicting a clinical response of a patient suffering from or at risk of developing gynecologic cancer towards a given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining the expression level of at least one gene selected from the group comprising ALCAM, Osteopontin, Her-2/neu, EGFR, uPA/PAI-1 and/or ESR1, in particular of ALCAM and/or Osteopontin, in said sample; c) comparing the pattern of expression level (s) determined in (b) with one or several reference pattern (s) of expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient or implementing therapeutic regimen in said patient from the outcome of the comparison in step (c). | 02-10-2011 |
| 20110033853 | CSNKS As Modifiers of the RAC Pathway and Methods of Use - Human CSNK genes are identified as modulators of the RAC pathway, and thus are therapeutic targets for disorders associated with defective RAC function. Methods for identifying modulators of RAC, comprising screening for agents that modulate the activity of CSNK are provided. | 02-10-2011 |
| 20110033854 | METHODS AND COMPOSITIONS FOR LONG FRAGMENT READ SEQUENCING - The present invention is directed to methods and compositions for long fragment read sequencing. The present invention encompasses methods and compositions for preparing long fragments of genomic DNA, for processing genomic DNA for long fragment read sequencing methods, as well as software and algorithms for processing and analyzing sequence data. | 02-10-2011 |
| 20110033855 | METHOD FOR QUANTIFYING TARGET NUCLEIC ACID MOLECULES AND KIT FOR QUANTIFYING TARGET NUCLEIC ACID MOLECULES - The present invention is to provide a method for highly sensitively and precisely quantifying nucleic acid molecules in a sample. The method for quantifying target nucleic acid molecules in a nucleic acid-containing sample comprises: (a) preparing a sample solution comprising a nucleic acid-containing sample, a first nucleic acid molecule probe comprising a sequence complementary to the target nucleic acid molecule and conjugated with a first marker, and a second nucleic acid molecule probe comprising a sequence complementary to the first nucleic acid molecule probe and conjugated with a second marker; (b) denaturing nucleic acid molecules in this sample solution; (c) hybridizing them; (d) forming a covalent bond between two nucleic acid strands in the hybrid under a same condition, regarding the temperature and the salt concentration, as that of the hybrid formation; and (e) quantifying the target nucleic acid molecules by detecting a time course change in an optical characteristic of the first marker or the second marker in the sample solution, wherein an optical characteristic of at least either one of the first marker and the second marker is changed depending on whether or not the first nucleic acid molecule probe and the second nucleic acid molecule probe are hybridized. | 02-10-2011 |
| 20110033856 | METHODS RELATING TO AROMATASE INHIBITOR PHARMACOGENETICS - Methods for aiding in determining therapeutic efficacy of an aromatase inhibitor in a subject are provided according to embodiments of the present invention which include detecting expression and/or function of at least one UDP-glucuronosyltransferase having activity to modify at least one aromatase inhibitor and/or metabolite of the aromatase inhibitor by glucuronidation, wherein detection of expression and/or function of the UDP-glucuronosyltransferase is correlated with therapeutic efficacy of the aromatase inhibitor in the subject. Detection of UDP-glucuronosyltransferase expression and/or function includes detection of a UDP-glucuronosyltransferase gene deletion polymorphism in the subject | 02-10-2011 |
| 20110033857 | PEPTIDE SEQUENCE THAT PROMOTES TUMER INVASION - An isolated sequence SGSSEEKQNAVSSEET (OPNcPEP) SEQ ID NO: | 02-10-2011 |
| 20110033858 | siRNA DETECTION METHOD - PolydG is added to the terminal overhangs of an siRNA. Next, a primer containing a polydC sequence added with a tag sequence is annealed and cDNA is synthesized by a reverse transcription reaction. Quantitative PCR is performed between a primer carrying the same sequence as the tag sequence, and a primer containing the same sequence as the siRNA sequence to be detected. The amount of siRNA of interest can be determined from a calibration curve produced using known amounts of short-chain dsDNA. | 02-10-2011 |
| 20110033859 | RNAi INHIBITION OF INFLUENZA VIRUS REPLICATION - The invention relates to compositions and methods for modulating the expression of influenza viral genes, and more particularly to the downregulation of influenza viral genes by chemically modified oligonucleotides. | 02-10-2011 |
| 20110033860 | Method For Searching Target Base Sequence Of Rna Interference, Method For Designing Base Sequence Of Polynucleotide For Causing Rna Interference, Method For Producing Double-Stranded Polynucleotide, Method For Inhibiting Gene Expression, Base Sequence Processing Apparatus, Program For Running Base Sequence Processing Method On Computer, Recording Medium, And Base Sequence Processing System - In the present invention, a sequence segment conforming to the following rules (a) to (d) is searched from the base sequences of a target gene of RNA interference and, based on the search results, siRNA capable of causing RNAi is designed, synthesized:
| 02-10-2011 |
| 20110033861 | METHOD FOR DIAGNOSING SPINAL MUSCULAR ATROPHY - A method for diagnosing spinal muscular atrophy is provided. The method includes providing a biological sample of a subject containing a nucleotide of SMN gene, amplifying SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8 by a universal multiplex PCR using the nucleotide as a template and the primers to obtain fragments of the SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8, labeling the fragments of the SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8 by a fluorescent primer to obtain fluorescence-labeled exon fragments, and analyzing the fluorescence-labeled exon fragments by a capillary electrophoresis. If the SMN1/SMN2 ratios in exon 7 and 8 are different, it indicates that the subject is susceptible to spinal muscular atrophy. Additionally, if the peak of certain exon fragment appears crossed, it indicates an intragenic mutation in the exon. | 02-10-2011 |
| 20110033862 | METHODS FOR CELL GENOTYPING - Methods for cell genotyping are disclosed herein. A method for determining the genomic data of one or a small number of cells, or from fragmentary DNA, where a limited quantity of genetic data is available may include adding one or more targeted primers to a whole genome amplification of a cell, increasing the accuracy with which key alleles are measured in the context of a whole genome amplification. The genetic material from a single cell may be divided into fractions, each of which may be separately genotyped, allowing the reconstruction of the cells haplotype. The genetic material from a single cell may be divided into fractions, each of which may be separately genotyped, and the distribution of the various alleles in the different fractions may be used to determine the ploidy state of one or a plurality of chromosomes in the cell. | 02-10-2011 |
| 20110033863 | RNA-SELECTIVE HYBRIDIZATION REAGENT AND USE OF THE SAME - Provided is a nucleoside derivative which has a high affinity for RNA. Use is made of a nucleoside derivative represented by either formula (1) or formula (2). (In formulae (1) and (2), Z represents a carbon atom or a nitrogen atom; R | 02-10-2011 |
| 20110033864 | PROLIFERATIVE DISEASE DETECTION METHOD - In the present invention, the methylation of the genomic DNA a Zar1 gene specifically found in proliferative disease is used as a marker. Specifically, the present invention provides a method for detecting proliferative disease, which comprises detecting the methylation of the genomic DNA of a Zar1 gene in a biological sample. There is thereby provided a method for detecting proliferative disease, using a marker having a high detection rate and a low false positive rate. | 02-10-2011 |
| 20110033865 | NOVEL METHOD FOR DIAGNOSING PREGNANCY-RELATED COMPLICATIONS - A method for diagnosing pregnancy-related complications in a pregnant woman is provided. The method includes the following steps: (a) determining the level of Placental Protein 17 (PP17) in a bodily substance obtained from the pregnant woman; and (b) comparing the determined level of PP17 to a standard level of PP17, a significant modification in the level of PP17 indicating the existence of a pregnancy-related complication in the pregnant woman. A diagnostic kit is also described. | 02-10-2011 |
| 20110039257 | Permuted and nonpermuted luciferase biosensors - A modified luciferase protein which is a sensor for molecules including cAMP, cGMP, calcium, chelators thereof, kinases, or phosphatases is provided. Also provided is a circularly permuted anthozoan luciferase protein and a decapod crustacean luciferase protein, optionally containing one or more heterologous amino acid sequences, at least one of which directly or indirectly interacts with a molecule of interest. Further provided is a modified anthozoan luciferase protein and a decapod crustacean luciferase protein containing an insertion of one or more heterologous amino acid sequences, at least one of which directly or indirectly interacts with a molecule of interest. | 02-17-2011 |
| 20110039258 | METHODS AND COMPOSITIONS FOR DIFFERENTIAL EXPANSION OF FETAL CELLS IN MATERNAL BLOOD AND THEIR USE - Disclosed is a method and compositions for the differential expansion of fetal cells over maternal cells. In the method, cells from a sample of maternal blood containing CD34+ cells of both maternal and fetal origin are incubated in the presence of Stem Cell Factor in serum free media. It has been discovered that incubation of fetal cells in the presence of SCF will preferentially expand the fetal cells relative to adult cells. Fetal cells can also be identified, enriched or obtained by differential expansion of the fetal cells during colony formation. It has been discovered that differential expansion of fetal cells can result in colonies of fetal cells that are larger than colonies of adult cells. The fetal CD34+ cells can be expanded without generation of significant clonal genetic artifacts during expansion. Also disclosed is a method and compositions for producing differentiated fetal cells. It has been discovered that differentiated fetal cells have markers that distinguish the fetal cells from adult cells. Also disclosed are fetal cells made or obtained using the disclosed methods. For example, disclosed are expanded and/or differentiated fetal cells. The disclosed fetal cells can be used for any purpose and in any way that fetal cells can be used. The disclosed fetal cells are particularly useful for prenatal analysis of a gestating fetus. | 02-17-2011 |
| 20110039259 | DNA SEQUENCE WITH NON-FLUORESCENT NUCLEOTIDE REVERSIBLE TERMINATORS AND CLEAVABLE LABEL MODIFIED NUCLEOTIDE TERMINATORS - This invention provides a process for sequencing nucleic acids using 3′ modified deoxynucleotide analogues or 3′ modified deoxyinosine triphosphate analogues, and 3′ modified dideoxynucleotide analogues having a detectable marker attached to a base thereof. | 02-17-2011 |
| 20110039260 | METHODS AND COMPOSITIONS FOR AMPLIFYING A DETECTABLE SIGNAL - Methods and materials are disclosed relating to an improved method for amplifying a signal in a diagnostic assay for a nucleic acid, comprising the steps of providing an amplification polymer bound to a nucleic acid analyte, wherein the amplification polymer comprises a plurality of amine groups; binding amine groups on the amplification polymer with a detectable label complex; and reacting under high salt conditions an acetylating compound with amine groups not bound with a detectable label complex. | 02-17-2011 |
| 20110039261 | MOBILE RAPID TEST SYSTEM FOR NUCLEIC ACID ANALYSIS - A mobile rapid test system for nucleic acid analysis. A method comprising the steps of amplification of the nucleic acids by means of rapid-PCR technology, conversion of a double-stranded amplification product into a single-stranded DNA fragment, hybridization with a labeled probe and detection of the nucleic acids on a lateral-flow test strip. A device comprising a reaction cavity which preferably consists of a thin film, inlet and outlet openings for the reaction cavity, one or more heatable sample blocks which are connected to miniaturized cooling bodies and a window for reading off the result. The lateral-flow test strip is a component of the mobile rapid test system. Operation of the instrument system requires no external power source, but only batteries or a rechargeable battery. | 02-17-2011 |
| 20110039262 | METHODS FOR DETECTING VIRULENT PLASMODIUM, FOR EVALUATING PLASMODIUM VIRULENCE, AND FOR SCREENING NEW DRUGS EMPLOYING THE 3'UTR OF PLASMODIUM SUB2 AND THE PLASMODIUM SUB2 SERINE PROTEASE - Methods for regulating the serine protease of | 02-17-2011 |
| 20110039263 | PLANTS HAVING ALTERED AGRONOMIC CHARACTERISTICS UNDER NITROGEN LIMITING CONDITIONS AND RELATED CONSTRUCTS AND METHODS INVOLVING GENES ENCODING LNT2 POLYPEPTIDES AND HOMOLOGS THEREOF - Isolated polynucleotides and polypeptides and recombinant DNA constructs particularly useful for altering agronomic characteristics of plants under nitrogen limiting conditions, compositions (such as plants or seeds) comprising these recombinant DNA constructs, and methods utilizing these recombinant DNA constructs. The recombinant DNA construct comprises a polynucleotide operably linked to a promoter functional in a plant, wherein said polynucleotide encodes an LNT2 polypeptide. | 02-17-2011 |
| 20110039264 | Format of Probes to Detect Nucleic Acid Differences - The invention provides, inter alia, novel probes, methods, reaction mixtures, and kits for detecting the presence or absence of a target nucleic acid sequence. | 02-17-2011 |
| 20110039265 | Method of detecting tumor-associated DNA in plasma or serum - This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in human or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such a oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease. The invention thereby provides methods for early identification of colorectal, pancreatic, lung, breast, bladder, ovarian, lymphoma and all other malignancies carrying tumor-related mutations of DNA and methods for monitoring cancer and other neoplastic disorders in humane and other animals. | 02-17-2011 |
| 20110039266 | FLOWCELL SYSTEMS FOR SINGLE MOLECULE DETECTION - The present invention provides compounds, methods and systems for sequencing nucleic acid using single molecule detection. Using labeled NPs that exhibit charge-switching behavior, single-molecule DNA sequencing in a microchannel sorting system is realized. In operation, sequencing products are detected enabling real-time sequencing as successive detectable moieties flow through a detection channel. By electrically sorting charged molecules, the cleaved product molecules are detected in isolation without interference from unincorporated NPs and without illuminating the polymerase-DNA complex. | 02-17-2011 |
| 20110039267 | Sample Preparation And Detection Of Analytes Using Silica Beads - This invention provides methods for concentration of analyte from biological sample, or various liquid samples and methods for identification of the analyte. The method includes providing silica beads conjugated with analyte recognition element for concentration of analyte from sample, packaging the beads into a cartridge, and attaching the cartridge to a sample holder. After the analyte concentration, additional steps can be implemented to identify the analyte to provide visual positive/negative, qualitative or quantitative results. Another exemplary embodiment of the present invention provides a system for concentration of analyte from biological sample or other various liquid samples using silica beads. According to an exemplary implementation, the system includes a cartridge comprising silica beads conjugated with analyte recognition element to concentrate at least one analyte from the sample, and a sample holder having the cartridge attached thereto. A sample is passed through the cartridge. | 02-17-2011 |
| 20110039268 | CYTOKINE PROTEIN FAMILY - The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides. | 02-17-2011 |
| 20110039269 | Gene Expression Markers for Colorectal Cancer Prognosis - A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject. | 02-17-2011 |
| 20110039270 | Gene Expression Markers for Colorectal Cancer Prognosis - A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject. | 02-17-2011 |
| 20110039271 | Gene Expression Markers for Colorectal Cancer Prognosis - A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject. | 02-17-2011 |
| 20110039272 | Gene Expression Markers for Colorectal Cancer Prognosis - A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject. | 02-17-2011 |
| 20110039273 | METHOD FOR MEASURING DNA METHYLATION - The present invention relates to a method of measuring the content of methylated DNA in a DNA region of interest in a genomic DNA contained in a biological specimen, and so on. | 02-17-2011 |
| 20110039274 | ANALYSIS OF NUCLEIC ACID AMPLIFICATION CURVES USING WAVELET TRANSFORMATION - A method comprising acquiring amplification data proportional to an amount of nucleic acid present for each of a plurality of PCR cycles includes applying wavelet transformation to the amplification data to determine a PCR cycle corresponding to a point within a growth period of the amplification data, and updating a display A device including a control module, an analysis module and an interface module for initialization of PCR analysis of a nucleic acid sample, receiving amplification data proportional to an amount of nucleic acid present applying wavelet transformation to the amplification data to determine a PCR cycle corresponding to a point within a growth period of the amplification data, and updating a display based on the amplification data is also provided. | 02-17-2011 |
| 20110039275 | Method for Predicting a Clinical Response of a Patient Suffering from or at Risk of Developing Cancer Towards a Given Mode of Treatment - The present invention relates to a method for predicting a clinical response of a patient suffering from or at risk of developing cancer, preferably colorectal cancer, towards a given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining the expression level of at least SPON-2, and optionally determining the expression level of SPON-1, in said sample; c) comparing the expression level or expression levels determined in (b) with one or several reference expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient or implementing therapeutic regimen in said subject from the outcome of the comparison in step (C). | 02-17-2011 |
| 20110045459 | Molecular determinants of EGFR kinase inhibitor response in glioblastoma - The invention disclosed herein provides methods for the examination and/or quantification of biochemical pathways that are disregulated in pathologies such as cancer and to reagents and kits adapted for performing such methods. | 02-24-2011 |
| 20110045460 | Mitochondrial complex I mutations in Parkinson's disease & aging - The present invention provides methods for diagnosing and treating Parkinson's disease based on mitochondrial mutations. The present invention also provides methods for diagnosing and treating other diseases and disorders based on mitochondrial mutations. | 02-24-2011 |
| 20110045461 | USE OF ANTI-MICROBIAL PEPTIDES AS BACTERIAL INFECTION RESISTANCE MARKERS IN PENAEOID SHRIMP - The present invention relates to the use of transcripts of genes encoding antimicrobial peptides, for evaluating the resistance of penaeid shrimp, in particular of the species | 02-24-2011 |
| 20110045462 | DIGITAL ANALYSIS OF GENE EXPRESSION - The disclosure provides methods and compositions useful for high throughput sequencing of nucleic acid sequences associated with gene expression, nucleic acid-polypeptide interactions, and/or chromosomal interactions. | 02-24-2011 |
| 20110045463 | METHOD FOR MEASURING DNA METHYLATION - The present invention relates to a method of measuring the content of methylated DNA in a DNA region of interest in a genomic DNA contained in a biological specimen, and so on. | 02-24-2011 |
| 20110045464 | METHODS AND COMPOSITIONS FOR IDENTIFICATION OF PROSTATE CANCER MARKERS - In some embodiments, the invention comprises methods and compositions for the assessment of prostate cancer in humans by determining the level of certain markers indicative of prostate cancer in vivo, including but not limited to SEQ ID NO:1 and SEQ ID NO:5, in tissue, blood, urine, or other biological samples. | 02-24-2011 |
| 20110045465 | Cancer Screening Method - A method for screening cancer comprises the following steps: (1) providing a test specimen; (2) detecting the methylation rate of the CpG sequence in at least one target gene of the test specimen, wherein the target genes is consisted of PTPRR, ZNF582, PDE8B and DBC1; and (3) determining whether there is cancer or cancerous pathological change in the specimen based on the methylation rate in the target gene. | 02-24-2011 |
| 20110045466 | Field-effect transistor type biosensor and bio-signal amplification method thereof - The present invention discloses a field-effect transistor (FET) type biosensor and a bio-signal amplification method. The biosensor comprises a field-effect transistor chip, a biomolecular immobilization layer and at least one primer. The biomolecular immobilization layer is formed on a gate surface of the FET chip or a surface of an external device connected to a gate. The primer used for performing a nucleic acid amplification is immobilized onto the gate surface or the external device surface by binding with the biomolecular immobilization layer, such that an analyte can have a nucleic acid amplification reaction with the primer at room temperature or a constant temperature environment. With an extension of a nucleic acid sequence, the inducing electricity of the FET gate surface can be increased so as to amplify an inspection signal, thereby enhancing the sensitivity of the FET type biosensor effectively. | 02-24-2011 |
| 20110045467 | PERIPHERAL NEUROPATHY DIAGNOSIS - Genes whose expression is correlated with the presence of CIDP or vasculitic neuropathy are disclosed. Probes and sets of nucleic acid and proteins specific for these genes are described, as are molecular and immunological methods for aiding in the diagnosis of these disease conditions in a subject. | 02-24-2011 |
| 20110045468 | Polynucleotides for the identification and quantification of group a streptococcus nucleic acids - The present invention provides polynucleotides that can specifically hybridize to Group A | 02-24-2011 |
| 20110045469 | SNPs ASSOCIATED WITH FATTY ACID COMPOSITION OF BOVINE MEAT AND MILK - The present invention provides compositions and methods for genotyping bovines including dairy cows and beef cattle More particularly, the invention is directed to single nucleotide polymorphisms in Stearoyl-CoA-Desaturase 5 (SCD5) Sterol regulatory element-binding protein-1 (SREBP1). SREBP cleavage-activating protein (SCAP), Insulin induced protein 1 (INS1G1). Insulin induced protein 2 (INS1G2) and Signal recognition particle receptor (SRPR) associated with fatty acid composition of bovine meat and milk. | 02-24-2011 |
| 20110045470 | PATHOGEN DETECTION IN LARGE-VOLUME PARTICULATE SAMPLES - Methods and filter systems for detecting microorganisms in a sample, such as a food sample, are disclosed. The filter is configured to attract the microorganism, for example by electrostatic charge. The filter containing the microorganism is incubated to grow the microorganism so that it may be detected. The filter may be degradable and the detection may involve extracting the microorganism or the molecular marker of the microorganism from the filter for detection. The filter system may also include a porous microbead component selected to trap dirt and other contaminants from the sample while allowing the microorganisms to pass among the microbeads. Methods are disclosed for detecting microorganisms in samples using the filter systems described. The methods may also include adding a polymer and/or a microorganism detection reagent to the filter to localize microorganism growth and prevent evaporation of reagents. | 02-24-2011 |
| 20110045471 | Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples - The present invention relates to methods for predicting, diagnosing and monitoring skin states and skin diseases. The methods combine the use of non-invasive skin collecting techniques with one or more assays for determining mitochondrial DNA (mtDNA) aberrations and Melanocortin 1 Receptor (MC1R) variants, thereby providing a comprehensive tool for identifying, predicting and/or monitoring photoageing, ultraviolet radiation (UVR) damage or skin disease. The methods of the invention may also be effective in screening for new therapeutic agents, skin care products and treatment regimes, and may also be useful for monitoring the response of a subject to a preventative or therapeutic treatment. | 02-24-2011 |
| 20110045472 | MONITORING ENZYMATIC PROCESS - Techniques, apparatus and systems are described for performing label-free monitoring of processes. In one aspect, a label-free monitoring system includes an array of label-free optical sensors to detect an optical signal in response to synthesis of one or more target genetic structures. Each label-free optical sensor is functionalized with a respective target genetic structure. The system also includes a fluid flow control module that includes fluid receiving units to provide paths for different fluids to flow into the fluid flow control module and at least one switch connected to the fluid receiving units to selectively switch among the fluid receiving units to receive a select sequence of the fluids through the fluid receiving units. The select sequence of the fluids includes at least a dNTP or base. A fluid channel is connected between the fluid flow control module and the array of sensors to allow the select sequence of the fluids to flow from the fluid flow control module to the array of label-free optical sensors. | 02-24-2011 |
| 20110045473 | LIVER SCREENING METHOD - The invention features a method of identifying therapeutically relevant compositions that include a therapeutic agent and a delivery component by screening for an effect of the agent on the liver of a model subject. | 02-24-2011 |
| 20110045474 | COPI MOLECULES AND USES THEREOF - The invention provides diagnostic, prognostic, and therapeutic uses for detecting COP1 overexpression in a variety of cancers. The methods and uses can further include detecting p53 expression. The invention also provides reagents and kits for use in screening for test compounds that interfere with COP1 and p53 binding. | 02-24-2011 |
| 20110045475 | UPREGULATION OF RACK-1 IN MELANOMA AND ITS USE AS A MARKER - The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocytic cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocytic cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocytic cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein. | 02-24-2011 |
| 20110045476 | INFLAMMATORY BOWEL DISEASE PROGNOSTICS - The methods and systems of the present invention are useful in the diagnosis of inflammatory bowel disease (IBD) and in the prognosis of IBD progression and disease complications. With the present invention, it is possible to predict outcome of disease and patients who will have a particular risk of disease complications and/or progression to surgery. | 02-24-2011 |
| 20110045477 | HUMAN SKIN EXPLANT CULTURE SYSTEM AND USE THEREFOR - The present invention features a human skin explant culture system and uses thereof. | 02-24-2011 |
| 20110045478 | Genetic Fingerprinting And Identification Method - The present disclosure provides methods for molecular fingerprinting for the characterization and identification of organisms. More specifically, in one aspect the present invention provides a method of identifying an organism in a sample comprising: (a) providing a sample comprising said organism, said organism comprising at least one nucleic acid; (b) combining said sample or the at least one nucleic acid therefrom with an amplification mix comprising at least one labeled oligonucleotide primer; (c) generating at least one labeled amplification product from the at least one nucleic acid of said organism using a nucleotide amplification technique employing said at least one labeled oligonucleotide primer; (d) combining said at least one labeled amplification product with products of a DNA sequencing reaction to create a separation mix; and (e) separating said separation mix on the basis of oligonucleotide length in a fluorescent DNA sequencing instrument to generate a sequence embedded fingerprint pattern for said organism. | 02-24-2011 |
| 20110045479 | Method For High Resolution Melt Genotyping - Various methods are described that provide for high resolution melt (HRM) genotyping. The embodiments include providing a locus specific primer and two allele specific primers each having a 5′ end with a short tail, providing a nucleic acid having a single nucleotide polymorphism (SNP) base located within 1-20 base pairs of the 3′ end of nucleic acid, hybridizing the locus specific primer and the allele specific primers to the nucleic acid, amplifying the sample using pyrophosphorolysis activated polymerization (PAP) PCR enzyme, and determining the Tm of the amplicons using HRM. In other embodiments, reactions mixtures and kits for HRM genotyping are provided and disclosed. These kits comprise a locus specific primer, one or more allele specific primers each having a 5′ end with a short tail, a nucleic acid, and a pyrophosphorolysis activate polymerization (PAP) PCR enzyme. | 02-24-2011 |
| 20110045480 | METHODS FOR PREDICTING THE EFFICACY OF TREATMENT - Clinical tests for testing therapeutic sensitivity of cancerous breast tissue and methods and kits for performing the same are described herein. Embodiments of the present invention are directed to methods for predicting the efficacy of treatment of breast cancer. In addition, certain embodiments are directed to a kit for testing therapeutic sensitivity of breast cancer tissue. | 02-24-2011 |
| 20110045481 | METHODS AND COMPOSITIONS FOR THE ASSESSMENT OF DRUG RESPONSE - The present invention provides methods for predicting or determining a subject's response to an antiplatelet agent, and methods for determining a subject's suitability to a treatment regime or intervention for a disease associated with platelet aggregation, using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's response to an antiplatelet agent. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided. | 02-24-2011 |
| 20110045482 | SCREENING METHODS FOR IDENTIFYING TARGET ANTIFUNGAL GENES AND COMPOUNDS BY DETECTING CELL SURFACE GLYCOPROTEINS - The present invention relates to an assay method that can be used for high-throughput detection of cell surface glycoproteins. Specifically, the secretion of a chimeric glycoprotein reporter signals disruption of GPI anchor-mediated attachment of the glycoprotein to the cell surface. This method provides a high signal-to-noise ratio and is particularly useful for screening compounds that affect GP1 anchor biosynthesis. The method of the present invention thus permits genome-wide screens for genes that are needed for GPI anchor-mediated attachment of a glycoprotein to the surface of a cell as well as chemical inhibitors of proteins that promote GP1 anchor-mediated attachment of a glycoprotein to the surface of a cell. Protein inhibitors identified by the present method could be useful in antifungal drug treatments as well. | 02-24-2011 |
| 20110045483 | Diagnostic Screens for Alzheimer's Disease - The present invention relates diagnostic screens for Alzheimer's disease, and in particular to diagnostic tests based on screening for the presence of cellular changes that occur early in the pathology of Alzheimer's disease. | 02-24-2011 |
| 20110045484 | METHOD OF DETECTING TARGET MOLECULE BY USING APTAMER - An aptamer-probe complex for detecting the presence of a target molecule is disclosed. The complex of the present invention contains an aptamer moiety which is able to bind to an indicator protein and change the properties of the indicator protein, and a probe moiety which is able to bind to a target molecule, wherein the aptamer moiety and the probe moiety are combined in such a manner that the binding mode between the aptamer moiety and the indicator protein changes when the probe moiety binds to the target molecule. A target molecule can be detected with combination of an aptamer which binds to a certain protein, and a probe which binds to the target molecule, utilizing the properties of that protein as an indicator. | 02-24-2011 |
| 20110045485 | ANALYTICAL METHOD AND KIT - RNA-containing probes and kits comprising RNA-containing probes for the detection and analysis of nucleic acid sequences are described. These probes are contacted with a sample suspected of containing the nucleic acid sequence and if they form duplexes, they are hydrolysed. This may be done, for example during an amplification reaction. AMP generated as a result of the hydrolysis is converted to ATP. The ATP may then be detected using bioluminescent reagents. Inclusion of modified adenosine in at least one probe means that the signal arising from one probe will give rise to a different and distinguishable bioluminescent signal thus enabling the use of for example an internal control in bioluminescently-reported nucleic acid tests. | 02-24-2011 |
| 20110045486 | Susceptibility Gene For Alzheimer's Disease - The invention relates to genetic screens for susceptibility to Alzheimer's disease. In particular, the invention provides genetic screens based on genotyping of the p21E2c31 A/T polymorphism and/or the p21E3+20 C/T polymorphism in the p21cip 1 gene. | 02-24-2011 |
| 20110045487 | METHODS OF DIAGNOSING MYELODYSPLASTIC SYNDROME (MDS) OR LEUKEMIA USING NUCLEIC ACIDS OR FRAGMENTS ENCODING FLT3 KINASE - To provide a nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane and is useful for diagnosis of leukemia; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to a region encoded by the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a nucleic acid capable of specifically binding to the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a method for detection of the nucleic acid encoding a receptor protein kinase; and a kit therefor. A nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to the portion of the polypeptide; a nucleic acid capable of specifically binding to the nucleic acid; a method for detection of the nucleic acid; and a kit for detection, | 02-24-2011 |
| 20110045488 | METHODS OF DIAGNOSING MYELODYSPLASTIC SYNDROME (MDS) OR LEUKEMIA USING NUCLEIC ACIDS OR FRAGMENTS ENCODING FLT3 KINASE - To provide a nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane and is useful for diagnosis of leukemia; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to a region encoded by the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a nucleic acid capable of specifically binding to the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a method for detection of the nucleic acid encoding a receptor protein kinase; and a kit therefor. A nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to the portion of the polypeptide; a nucleic acid capable of specifically binding to the nucleic acid; a method for detection of the nucleic acid; and a kit for detection. | 02-24-2011 |
| 20110045489 | Polymerases for Incorporating Modified Nucleotides - Compositions and methods are provided that relate to a recombinant protein with DNA polymerase activity in which one or more amino acids are mutated compared with the corresponding wild type protein. The recombinant protein is capable of incorporating one or more modified nucleotides into a nucleic acid substrate with a specific activity greater than 200. | 02-24-2011 |
| 20110053146 | COMPOUNDS AND METHODS FOR DETECTING RICIN AND USES THEREOF - This application provides fluorescent probes, substrates, kits and methods for detecting the presence or absence of an enzyme, such as ricin, that catalyzes the release of adenine from a GAGA RNA tetraloop. | 03-03-2011 |
| 20110053147 | HEAT-RESISTANT DNA LIGASE WITH HIGH REACTIVITY - Thermostable DNA ligases with enhanced DNA binding activity and reaction activity are obtained. These modified thermostable DNA ligases having enhanced DNA binding activity compared to the wild type can be obtained by substituting a negatively charged amino acid (for example, the amino acid corresponding to the aspartic acid at position 540 of SEQ ID NO: 1) present at the N-terminal side of the C-terminal helix moiety of thermostable DNA ligases from thermophilic bacteria, hyperthermophilic bacteria, thermophilic archaea, or hyperthermophilic archaea, with a non-negatively charged amino acid (for example, alanine, serine, arginine, or lysine). | 03-03-2011 |
| 20110053148 | COCCIDIOSIS VACCINES - The present invention relates to hydrophilic | 03-03-2011 |
| 20110053149 | METHYLATION DETECTION IN THE GENOMIC REGION OF A RECEPTOR PROTEINTYROSINE PHOSPHATASE GAMMA GENE FOR DETECTION AND/OR DIAGNOSIS OF A TUMOUR - The invention discloses means and methods for detecting methylation of a CpG in a region of a receptor protein tyrosine phosphatase gamma gene in samples obtained from a relevant site of an individual. The means and methods can be used to determine whether the individual is suffering from a tumor. | 03-03-2011 |
| 20110053150 | Method and Kit for Detection/Quantification of Target RNA - [Object] It is to provide a method and a kit capable of detecting or quantifying a target RNA simply and rapidly from trace amounts of RNA in a sample, in a case such as when one or more kinds of pathogenic microorganisms are to be detected or quantified. | 03-03-2011 |
| 20110053151 | MICROFLUIDIC DEVICE AND METHOD OF USING SAME - A microfluidic device comprising a plurality of reaction chambers in fluid communication with a flow channel formed in an elastomeric substrate, a vapor barrier for preventing evaporation from the plurality of reaction chambers, and a continuous phase fluid for isolation of each of the plurality of reaction chambers. | 03-03-2011 |
| 20110053152 | METHOD FOR CANCER DETECTION, DIAGNOSIS AND PROGNOSIS - The present invention provides a method for diagnosing cancer, predicting a disease outcome or response to therapy in a patient sample. The method involves isolating a circulating tumor cell (CTC), for example, a viable CTC, from a sample using a parylene microfilter device comprising a membrane filter having or consisting of a parylene substrate, which has an array of holes with a predetermined shape and size; and detecting and quantifying telomerase activity in blood circulating tumor cells. The invention further provides methods of using cells live-captured in various applications. | 03-03-2011 |
| 20110053153 | DNA Glycosylase/Lyase and AP Endonuclease substrates - A new class of nucleic acid substrates for AP endonucleases and members of the glycosylase/lyase family of enzymes is described. Representatives of each family, the enzymes Nfo and fpg, respectively, cleave nucleic acid backbones at positions in which a base has been replaced by a linker to which a variety of label moieties may be attached. The use of these synthetic substrates embedded within oligonucleotides is of utility in a number of applications. | 03-03-2011 |
| 20110053154 | 2'-nitrobenzyl-modified ribonucleotides - This disclosure provides novel reversibly terminated ribonucleotides which can be used as a reagent for DNA sequencing reactions. Methods of sequencing nucleic acids using the disclosed nucleotides are also provided. | 03-03-2011 |
| 20110053155 | POLAR DYES - The present invention relates to novel polar fluorescent and quenchers dyes, and minor groove binder with enhanced polarity. The present invention further relates to methods of preparing oligonucleotide probes labeled with polar arsonate dyes under the condition of automated synthesis and method of using such probes. | 03-03-2011 |
| 20110053156 | SMALL CELL LUNG CARCINOMA BIOMARKER PANEL - The invention relates generally to the field of cancer detection, diagnosis, subtyping, staging, prognosis, treatment and prevention. More particularly, the present invention relates to methods for the detection, and/or diagnosing and/or subtyping and/or staging of lung cancer in a patient. Based on a particular panel of biomarkers, the present invention provides methods to detect, diagnose at an early stage and/or differentiate small cell lung cancer (SCLC) from non-small cell lung cancer (NSCLC) and within NSCLC to differentiate between squamous cell carcinomas (SCC), adenocarcinomas (AC), within SCC to discriminate G2 and G3 stage and within lung cancer to differentiate for lung cancers with or without neuroendocrine origin. It further provides the use of said panel of biomarkers in monitoring disease progression in a patient, including both in vitro and in vivo imaging techniques. The in vitro imaging techniques typically include an immunoassay detecting protein or antibody of the biomarkers on a sample taken from said patient, e.g. serum or tissue sample. The in vivo imaging techniques typically include chest radiographs (X-rays), Computed Tomography (CT) imaging, spiral CT, Positron Emission Tomography (PET), PET-CT and scintigraphy for molecular imaging and diagnosis and to monitor disease progression and treatment response in patients. It is accordingly a further aspect to provide a kit to perform the aforementioned diagnosing and/or subtyping and/or staging assay and the imaging techniques, comprising reagents to determine the gene expression or protein level of the aforementioned panel of biomarkers for in vitro and in vivo applications. | 03-03-2011 |
| 20110053157 | USE OF MICROVESICLES IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF MEDICAL DISEASES AND CONDITIONS - The presently disclosed subject matter is directed to methods of aiding diagnosis, prognosis, monitoring and evaluation of a disease or other medical condition in a′ subject by detecting a biomarker in microvesicles isolated from a biological, sample from the subject. Moreover, disclosed subject matter is directed to methods of diagnosis, monitoring a disease by determining the concentration of microvesicles within a biological sample; methods of delivering a nucleic acid or protein to a target all by administering microvesicles that contain said nucleic acid or protein; methods for performing a body fluid transfusion by introducing a microvesicle-free or microvesicle enriched fluid fraction into a patient. | 03-03-2011 |
| 20110053158 | MIRNA BIOMARKERS OF LUNG DISEASE - This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing lung disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as lung cancer. | 03-03-2011 |
| 20110053159 | GENETIC MARKERS FOR ASSESSING RISK OF PREMATURE BIRTH RESULTING FROM PRETERM PREMATURE RUPTURE MEMBRANES - A method to identify women who are at risk for preterm delivery due to premature rupture of membranes (PPROM) is provided. The method entails detecting the presence of SERPINH1 gene variants that express low levels of the gene product, heat shock protein Hsp47. The occurrence of a T (rather than C) at a single nucleotide polymorphism (SNP) site at position −656 of the SERPINH1 gene promoter, together with the absence of a 12 base pair deletion at positions −694 to −683 of the promoter, result in an increased risk of PPROM. The method enables medical professionals to identify those at risk, and to provide suitable therapeutic intervention. | 03-03-2011 |
| 20110053160 | HCV NS3/4A REPLICON SHUTTLE VECTORS - The present invention provides for novel HCV NS3/4A replicon shuttle vectors useful for cloning in HCV polynucleotide sequences from samples of HCV-infected patients and testing the resulting replicons for drug susceptibility. | 03-03-2011 |
| 20110053161 | SEQUENTIAL SAMPLING FOR UNEXPECTED DAMAGE TO BT CORN FOR CORN ROOTWORM CONTROL - Methods are provided for the sequential sampling of pest resistant crop plants for determining resistance of a pest to a pesticidal activity of a pest resistant crop plant. The methods involve choosing a plant in a plot in an unbiased sampling manner. Trait expression is determined for each of the transgenic pest resistant plants to identify plants having pesticidal activity, and plants determined to have the pesticidal activity are a batch. Then the pest damage to the roots of the batch is rated with each batch having at least about five plants to determine the resistance of pests in the plot. | 03-03-2011 |
| 20110053162 | REACTIVE CYANINE COMPOUNDS - The invention provides compounds and compositions of Formulas I-VII, and methods of using the compounds. The compounds can be used to prepare dye conjugates that are uniformly and substantially more fluorescent on proteins, nucleic acids or other biopolymers, than conjugates labeled with structurally similar known carbocyanine dyes. In addition to having more intense fluorescence emission than structurally similar dyes at virtually identical wavelengths, and decreased artifacts in their absorption spectra upon conjugation to biopolymers, the compounds can have greater photostability and/or higher absorbance (extinction coefficients) at the wavelength(s) of peak absorbance than such structurally similar dyes. | 03-03-2011 |
| 20110053163 | Biomarker - The invention relates to a process for in vitro prediction of a potentially allergenic substance wherein monocytes and/or macrophages and/or myelomonocytic cell lines are cultivated in the presence of the substance and interferon-γ, whereby productions of cytokines and/or neopterin are increased and measured. | 03-03-2011 |
| 20110053164 | METHODS FOR DETERMINING CANCER RESISTANCE TO HISTONE DEACETYLASE INHIBITORS - Described herein are methods and compositions for determining whether a particular cancer is resistant to or susceptible to a histone deacetylase inhibitor or to histone deacetylase inhibitors. The methods include analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are methods and compositions for increasing the likelihood of a therapeutically effective treatment in a patient, comprising an analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are isolated populations of nucleic acids derived from a cancer sensitive to or resistant to a histone deacetylase inhibitor. Further described are kits and indications that are optionally used in conjunction with the aforementioned methods and compositions. | 03-03-2011 |
| 20110053165 | CACNB2 NUCLEIC ACID MUTATIONS AS INDICATORS OF SHORTER THAN NORMAL QT INTERVAL AND ST SEGMENT ELEVATION ASSOCIATED WITH SUDDEN CARDIAC DEATH - Previously unknown mutations of the CACNA1C and CACNB2b genes are disclosed which are involved in ion channel disruptions associated with shorter than normal QT interval and ST segment elevation syndrome. These mutations are utilized to diagnose and screen for shorter than normal QT interval and ST segment elevation syndrome, thus providing modalities for diagnosing syncope and/or sudden cardiac death and/or predicting susceptibility to syncope and/or sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant polypeptides described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations. | 03-03-2011 |
| 20110053166 | STEM CELL EXPRESSION CASSETTES - A stem cell expression cassette, comprising a nucleic acid comprising a pluripotent stem cell specific promoter, and a tag sequence, wherein the pluripotent stem cell specific promoter and tag sequences are operatively linked, is provided. Also provided are methods of identifying and methods of selecting a pluripotent cell, using the stem cell expression cassette. | 03-03-2011 |
| 20110053167 | GENE SIGNATURES - The present invention relates generally to a new cluster of correlating molecules in a tissue or at least one cell of a tissue for instance a cell of a blood tissue, preferably such myeloid cells and of identifying the condition of the genes expression said correlating molecules or of the expression levels of said molecules in a method or system for identifying obesity and the risk at obesity-related metabolic diseases such as the obesity associated cardiovascular risk or obesity-related insulin resistance. This system of method provides information on how to modulate the correlating molecules to treat or prevent obesity and to prevent the obesity-related metabolic diseases. | 03-03-2011 |
| 20110053168 | REAGENT COMPRISING PRIMER FOR DETECTION OF mRNA FOR CYTOKERATIN-7 - Disclosed is a primer for detecting mRNA for CK7. The primer comprises a first sequence on its 5′-terminal side and a second sequence on its 3′-terminal side. The first sequence has a length of 10 to 30 nucleotides, and can hybridize with a strand complementary to a first region which is a region contained in the sequence depicted in SEQ ID NO:1. The second sequence has a length of 10 to 30 nucleotides, and can hybridize with a second region which is located on the 3′-terminal side from the first region in the sequence depicted in SEQ ID NO:1. | 03-03-2011 |
| 20110053169 | METHOD FOR CONTINUOUS MODE PROCESSING OF THE CONTENTS OF MULTIPLE REACTION RECEPTACLES IN A REAL-TIME AMPLIFICATION ASSAY - An automated analyzer for performing multiple diagnostic assays simultaneously includes multiple stations in which discrete aspects of the assay are performed on fluid samples contained in sample vessels. The analyzer includes stations for automatically preparing a sample, incubating the sample, preforming an analyte isolation procedure, ascertaining the presence of a target analyte, and analyzing the amount of a target analyte. An automated receptacle transporting system moves the sample vessels from one station to the next. A method for performing an automated diagnostic assay includes an automated process for isolating and amplifying a target analyte, and, in one embodiment, a method for real-time monitoring of the amplification process. | 03-03-2011 |
| 20110053170 | Interleukin-33 (IL-33) for the Diagnosis and Prognosis of Cardiovascular Disease - The present invention includes methods for the use of interleukin-33 (IL-33) in the diagnosis of cardiovascular conditions including acute coronary syndrome (ACS), myocardial infarction, and/or heart failure, angina, cardiac hypertrophy, arteriosclerosis, myocarditis, pericarditis, endocarditis, stroke and/or pulmonary embolism and the determination of the severity of such conditions (prognosis). | 03-03-2011 |
| 20110059432 | METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM A REMOTE SAMPLE - Aspects of the present invention relate to compositions and methods for providing DNA fragments from a remote sample. In particular aspects a remote sample comprising DNA is provided, DNA is isolated from the remote sample, and the isolated DNA is treated in a way which allows differentiation of methylated and unmethylated cytosine. Additional, particular embodiments provide compositions and methods for methylation analysis of DNA derived from a remote sample. Other aspects provide for compositions and methods of whole genome amplification of bisulfite treated DNA. | 03-10-2011 |
| 20110059433 | Method for the detection and characterization of microorganisms on a filter - The present invention relates to a method for the specific detection on a filter of one or more microorganisms present in a fluid, characterized in that it comprises the following steps: a) contacting the microorganisms present in the fluid or on the surface with the filter; b) amplifying specifically the nucleic acids from the microorganism or microorganisms present on the filter, in an isothermal manner, in order to obtain amplification products, c) detecting the amplification products. The invention also relates to a device, a kit and oligonucleotides suitable for the implementation of this method. | 03-10-2011 |
| 20110059434 | P13k pathway mutations in cancer - Given the important role of protein kinases in pathways affecting cellular growth and invasion, we have analyzed 340 serine/threonine kinases for genetic mutations in colorectal cancers. Mutations in eight genes were identified, including three members of the phosphatidylinositol-3-kinase (PI3K) pathway; the alterations in the latter genes each occurred in different tumors and did not overlap with mutations in PIK3CA or other non-serine-threonine kinase (STK) members of the PI3K pathway, suggesting that mutations in any of these genes had equivalent tumorigenic effects. These data demonstrate that the PI3K pathway is a major target for mutational activation in colorectal cancers and provide new opportunities for therapeutic intervention. | 03-10-2011 |
| 20110059435 | Methods for Beaming - Improvements on the basic method used for BEAMing increase sensitivity and increase the signal-to-noise ratio. The improvements have permitted the determination of intrinsic error rates of various DNA polymerases and have permitted the detection of rare and subtle mutations in DNA isolated from plasma of cancer patients. | 03-10-2011 |
| 20110059436 | METHODS FOR SEQUENCE DETERMINATION - A sequencing methodology is disclosed that allows a single DNA or RNA molecule or portion thereof to be sequenced directly and in substantially real time. The methodology involves engineering a polymerase and/or dNTPs with atomic and/or molecular tags that have a detectable property that is monitored by a detection system. | 03-10-2011 |
| 20110059437 | PCR-BASED GENOTYPING | 03-10-2011 |
| 20110059438 | Method of Preparing DNA Fragments and Applications Thereof - A method of preparing DNA fragments, which entails at least the following steps of:
| 03-10-2011 |
| 20110059439 | COMPOSITION AND METHOD FOR IMAGING STEM CELLS - An expression vector, comprising a first reporter nucleic acid sequence operably linked to a first expression control sequence comprising a promoter; and a second reporter nucleic acid sequence operably linked to a second expression control sequence that comprises a response element that is activated or inactivated as one or more of the cells differentiate or dedifferentiate. Methods and kits for imaging and monitoring stem cells comprising the expression vector are also provided. | 03-10-2011 |
| 20110059440 | RAPID ANALYSIS OF VARIATIONS IN A GENOME - The invention provides a method useful for determining the sequence of large numbers of loci of interest on a single or multiple chromosomes. The method utilizes an oligonucleotide primer that contains a recognition site for a restriction enzyme such that digestion with the restriction enzyme generates a 5′ overhang containing the locus of interest. The 5′ overhang is used as a template to incorporate nucleotides, which can be detected. The method is especially amenable to the analysis of large numbers of sequences, such as single nucleotide polymorphisms, from one sample of nucleic acid. | 03-10-2011 |
| 20110059441 | METHOF OF PRODUCING BIOACTIVE PAPER - The present disclosure relates to methods for attaching bioactive agents to paper products by contacting the paper with a solution comprising colloidal support particles where said colloidal support particles are associated with bioactive agents. In specific embodiment of the disclosure, the colloidal support particles are functionalized poly(N-isopropylacrylamide) microgels. The disclosure further covers the bioactive paper produced by this method as well as uses thereof, in particular for pathogen detection. | 03-10-2011 |
| 20110059442 | Multiplex detection of nucleic acids - Methods of detecting nucleic acids, including methods of detecting two or more nucleic acids in multiplex branched-chain DNA assays, are provided. Nucleic acids captured on a solid support are detected, for example, through cooperative hybridization events that result in specific association of a label with the nucleic acids. Compositions, kits, and systems related to the methods are also described. | 03-10-2011 |
| 20110059443 | FLUORESCENT GFP VARIANT DISPLAYING HIGHLY INCREASED FLUORESCENCE INTENSITY WITHOUT A SPECTRAL SHIFT - The present invention relates to a nucleic acid molecule encoding a polypeptide having a fluorescence emission activity with a maximum emission at 505 to 515 nm, wherein said nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2; (b) a nucleic acid molecule having the DNA sequence of SEQ ID NO: 1; (c) a nucleic acid molecule hybridizing under stringent conditions to the complementary strand of (i.) a nucleic acid molecule of (a), wherein said nucleic acid molecule of (c) encodes a polypeptide having at the position corresponding to position 146 of SEQ NO:2 a phenylalanine and at the position corresponding to position 203 of SEQ NO:2 a threonine; or (ii) a nucleic acid molecule of (b), wherein said nucleic acid molecule of (c) has at the positions corresponding to positions 438 to 440 of SEQ ID NO: 1 a nucleotide triplet selected from the group consisting of TTT and TTC; and at the positions corresponding to positions 609 to 611 of SEQ ID NO: 1 a nucleotide triplet selected from the group consisting of ACT, ACC, ACA, ACG; wherein the polypeptide encoded by the nucleic acid molecule of (c) has a fluorescence enhanced by at least the factor of 2.5 as compared to the polypeptide having the amino acid sequence of SEQ ID NO: 10; or (d) a nucleic acid molecule degenerate with respect to the nucleic acid molecule of (b). The present invention furthermore relates to a polypeptide encoded by the nucleic acid molecule of the invention, a vector and a host cell comprising the nucleic acid molecule of the invention, a method of producing said polypeptide, a fusion protein comprising the polypeptide of the invention and methods of detecting the presence and/or localization of a protein of interest and methods of detecting the activity of a promoter. | 03-10-2011 |
| 20110059444 | Magnetic Detection of Small Entities - A novel detection or quantifying method for biological entities or molecules such as, but not limited to, DNA, microorganisms and pathogens, proteins and antibodies, that by themselves are target molecules or from which target molecules are extracted, comprises the steps of i) forming target molecule-dependent volume-amplified entities, ii) allowing magnetic nanoparticles to bind to said volume-amplified entities, and iii) measuring changes in dynamic magnetic response of the magnetic nanoparticles caused by the increase in hydrodynamic volume of said magnetic nanoparticles or measuring the magnetic field due to the magnetic nanoparticles as they bind to a sensor surface functionalized with a secondary capturing probe. Biosensors and kits are adapted to be used in such a method. | 03-10-2011 |
| 20110059445 | MUCOSAL GENE SIGNATURES - Infliximab (IFX) is an effective treatment for Crohn's disease (CD) and ulcerative colitis (UC) not responding to standard therapy. Thirty percent to forty percent of patients however do not improve and the response is often incomplete. We identified mucosal gene signatures predictive of response to EFX using high-density oligonucleotide arrays. Eight UC patients and twelve CD patients showed healing. In UC, only one probe set was differentially expressed in responders compared with non-responders, i.e., IL-13R(alpha)2. At PAM analysis, two probe sets, representing IL-13Ralpha2 and IL-I 1, separated IBD responders from non-responders with an overall misclassification error rate of 0.046 (2/43), with 100% sensitivity and 91.3% specificity. The IL-13R(alpha)2 probe set was a top-ranked probe set in all our analyses using both LIMMA and PAM strategies. Our gene array studies of mucosal biopsies identified IL-13R(alpha)2 in IBD as a predictor of response or non-response to IFX. | 03-10-2011 |
| 20110059446 | METHOD FOR DETERMINING METHYLATION AT CYTOSINE RESIDUES - The present invention refers to a method and reagent kits for determining methylation at cytosine (dC) residues in nucleic acids, such as DNA. | 03-10-2011 |
| 20110059447 | METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 03-10-2011 |
| 20110059448 | COMPOSITIONS AND METHODS FOR DETERMINING CANCER STEM CELL SELF-RENEWAL POTENTIAL - In alternative embodiments, the invention provides compositions and methods for determining the self-renewal potential of a cancer stem cell (CSC) through analysis of the cross-talk between cell self-renewal pathways leading to deregulation and enhanced self-renewal of the CSC, or for predicting the drugability (susceptibility to a drug) of a CSC, and/or for predicting the progression of a cancer that corresponds to the CSC, the method comprising detecting and quantifying in CSCs one or more B-cell lymphoma-2 (Bcl-2) family protein isoform(s) or transcripts (mRNAs, messages) encoding one or more Bcl-2 family protein(s) or protein isoform(s) thereof. In alternative embodiments, the invention provides compositions and methods to determine and measure the levels of Wnt, glycogen synthase kinase-3 beta (GSK-3 beta), glycogen synthase kinase-3 alpha (GSK-3 alpha), and/or Sonic Hedgehog Homolog (SHH or Shh) family proteins and alternatively spliced transcripts (mRNAs), and Wnt, GSK3beta, GSK3alpha and/or Shh family protein and alternatively spliced transcript ratios in cancer cells, e.g., stem cells, e.g., CSCs, for diagnostic, drug discovery and prognostic purposes. | 03-10-2011 |
| 20110059449 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION - Methods of diagnosing or monitoring transplant rejection or cytomegalovirus infection in a patient by detecting the expression level of one or more genes or surrogates derived therefrom in the patient are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant rejection or cytomegalovirus infection and kits or systems containing the same are also described. | 03-10-2011 |
| 20110059450 | LABELED NUCLEOTIDE ANALOGS AND USES THEREFOR - Labeled nucleotide analogs used in place of naturally occurring nucleoside triphosphates or other analogs in template directed nucleic acid synthesis reactions and other nucleic acid reactions, and various analyses based thereon, including DNA sequencing, single base identification, hybridization assays and others. | 03-10-2011 |
| 20110059451 | DETECTING FETAL CHROMOSOMAL ABNORMALITIES USING TANDEM SINGLE NUCLEOTIDE POLYMORPHISMS - The invention provides tandem single nucleotide polymorphisms and methods for their use, for example, in diagnosing Down Syndrome. | 03-10-2011 |
| 20110059452 | METHODS OF SCREENING FOR GASTRIC CANCER - Method and systems are provided for diagnosing or monitoring a gastric cancer in a subject. Such methods include providing a biological sample from the subject; determining an amount in the sample of at least one biomarker, selected from the group consisting of: CDH17 and OLFM4; and comparing the amount of the at least one biomarker in the sample, if present, to a control level of the at least one biomarker. Such systems include a probe for selectively binding each of at least one biomarker. | 03-10-2011 |
| 20110059453 | Poly(A) Tail Length Measurement by PCR - Methods and kits for measuring the length of the poly(A) tail of selected target mRNA are disclosed herein. In preferred aspects the mRNA population is modified by addition of a tail comprising guanosine and inosine (G/I tailing). The added tail is used as a priming site for reverse transcription. The resulting cDNA is then amplified using one or more target specific primers and a universal primer that recognizes the tailed region. The products are separated according to size and the size is used to estimate the polyA tail length. | 03-10-2011 |
| 20110059454 | FLUORESCENCE ENERGY TRANSFER BY COMPETITIVE HYBRIDIZATION - A method is provided for detecting the presence of nucleotides or monitoring nucleotide amplification. It utilizes fluorescence energy transfer by competitive hybridization. Competitive hybridization is achieved by using unequal length complementary probes which have a fluorophore on one probe and a quencher on the other. The fluorophore and quencher are juxtaposed in a manner wherein the proximity of the quencher to the fluorophore produces quenching of the fluorescence of the fluorophore. | 03-10-2011 |
| 20110059455 | METHODS AND COMPOSITIONS FOR DIRECT CHEMICAL LYSIS - A direct chemical lysis composition includes an assay compatible buffer composition and an assay compatible surfactant. When combined with a specimen storage composition, such compositions prevent undesired modifications to nucleic acid and proteins lysed from cells in the biological sample. Assays of samples from such compositions do not require expensive and time-consuming steps such as centrifugation and prolonged high temperature processing. The direct chemical lysis composition of the present invention permits direct nucleic acid extraction from the cells in the biological sample without the need to decant off the transport media or otherwise exchange the transport media with assay compatible buffers. There is no need to combine the sample with proteinase K or another enzyme to extract nucleic acids from the cells. A method for lysing cells to obtain target nucleic acid for assay and a kit for combining the direct chemical lysis composition with a sample are also contemplated. | 03-10-2011 |
| 20110059456 | System for the Cell-Specific and Development-Specific Selection of Differentiating Embryonic Stem Cells, Adult Stem Cells and Embryonic Germline Cells - The invention relates to a system for selecting differentiating embryonic or adult stem cells or embryonic germline cells in a cell-specific and development-specific manner, using a combination of resistance genes and detectable reporter genes under the common control of a cell-specific and/or development-specific promoter. | 03-10-2011 |
| 20110059457 | SELECTIVE RESTRICTION FRAGMENT AMPLIFICATION: FINGERPRINTING - The invention relates to a process for the controlled amplification of at least one part of a starting DNA containing a plurality of restriction sites for a determined specific restriction endonuclease, and of which at least part of its nucleic acid is unknown. This technology can be applied to human, animal or plant DNA fingerprinting, to identify restriction fragment length polymorphisms. Also encompassed by the inventive technology are kits for the application of the process. | 03-10-2011 |
| 20110059458 | COMPOSITIONS AND METHODS FOR CATALYZING DNA-PROGRAMMED CHEMISTRY - The present invention relates compositions and methods that are useful in catalyzing DNA-Programmed Chemistry (or Nucleic Acid-templated chemistry) for use in therapeutic and diagnostic applications. | 03-10-2011 |
| 20110059459 | BRCA1 mRNA EXPRESSION PREDICTS SURVIVAL IN PATIENTS WITH BLADDER CANCER TREATED WITH NEOADJUVANT CISPLATIN-BASED CHEMOTHERAPY - The invention relates to methods for predicting the clinical outcome of a patient which suffers from bladder cancer based on the expression levels of BRCA1 wherein high BRCA1 expression levels are indicative of a poor prognosis. Moreover, the invention relates to methods for predicting the response to chemotherapy of a patient which suffers from bladder cancer based on the expression levels of BRCA1, in particular, in patients which have been treated with chemotherapy prior to surgical removal of the tumor. | 03-10-2011 |
| 20110059460 | Infection Mediated Foam Dissolution Rate Measurement - The subject invention concerns methods and materials for determining the presence or absence of bacterial or fungal infection in a blood sample. In one embodiment, a method of the invention comprises exposing an anticoagulant treated blood sample to freezing the sample to a solid, followed by thawing of the sample and then agitation of the sample to develop foam and then observing the rate that foam dissolves. | 03-10-2011 |
| 20110059461 | METHODS OF DIAGNOSING MYELODYSPLASTIC SYNDROME (MDS) OR LEUKEMIA USING NUCLEIC ACIDS OR FRAGMENTS ENCODING FLT3 KINASE - To provide a nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane and is useful for diagnosis of leukemia; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to a region encoded by the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a nucleic acid capable of specifically binding to the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a method for detection of the nucleic acid encoding a receptor protein kinase; and a kit therefor. A nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to the portion of the polypeptide; a nucleic acid capable of specifically binding to the nucleic acid; a method for detection of the nucleic acid; and a kit for detection. | 03-10-2011 |
| 20110059462 | AUTOMATED PARTICULATE CONCENTRATION SYSTEM - An automated system for concentrating potentially harmful substances from various water types or other non-viscous liquids to facilitate detection of those substances is disclosed herein. The automated system comprises a water pressure driven or pump driven concentration unit that filters the test fluid through a hollow-fiber filter. Material collected on the filter is backflushed into a collection vessel by passing a small volume of sterile solution through the filter in the reverse direction. The automated system can be configured to be portable or to be integrated into a continuous liquid stream for online monitoring of test fluids. Optionally, an electronic signal at the end of the backflush sequence triggers a detector, such as an automated array biosensor, to begin processing and analyzing the sample. | 03-10-2011 |
| 20110065100 | Transcription biomarkers of biological responses and methods - This invention provides transcription regulatory control sequences, the activity of which function as biomarkers for a variety of biological responses. This invention also provides expression constructs in which a biomarker transcription regulatory sequence is operably linked with a sequence for a reporter. Cells that comprise these expression constructs can be used in assays to identify conditions that modulate activity of the biological response. | 03-17-2011 |
| 20110065101 | Multiple-sample microfluidic chip for DNA analysis - Aspects of the disclosure provide a microfluidic chip. The microfluidic chip includes a first domain configured for polymerase chain reaction (PCR) amplification of DNA fragments, and a second domain for electrophoretic separation. The first domain includes at least a first reaction reservoir designated for PCR amplification based on a first sample, and a second reaction reservoir designated for PCR amplification based on a second sample. The second domain includes at least a first separation unit coupled to the first reaction reservoir to received first amplified DNA fragments based on the first sample, and a second separation unit coupled to the second reaction reservoir to received second amplified DNA fragments based on the second sample. The first separation unit is configured to perform electrophoretic separation for the first amplified DNA fragments, and the second separation unit is configured to perform electrophoretic separation for the second amplified DNA fragments. | 03-17-2011 |
| 20110065102 | OSTEOARTHRITIS-SENSITIVE GENE - It is an object of the present invention to provide a method and kit for diagnosing osteoarthritis which involves genetic diagnosis or hemodiagnosis. The present invention provides a method for diagnosing a genetic susceptibility of a subject to osteoarthritis, which comprises detecting at least one polymorphism selected from polymorphisms existing in a gene (Dual Intracellular on Willebrand factor A gene; DIVA gene), encoding the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence substantially homologous thereto, in a DNA-containing sample collected from the subject, wherein an allele frequency of one of alleles is higher in arbitrary osteoarthritis group than in arbitrary non-osteoarthritis group. | 03-17-2011 |
| 20110065103 | USE OF RNA FOR REPROGRAMMING SOMATIC CELLS - The present invention provides methods for de-differentiating somatic cells into stem-like cells without generating embryos or fetuses. More specifically, the present invention provides methods for effecting the de-differentiation of somatic cells to cells having stem cell characteristics, in particular pluripotency, by introducing RNA encoding factors inducing the de-differentiation of somatic cells into the somatic cells and culturing the somatic cells allowing the cells to de-differentiate. | 03-17-2011 |
| 20110065104 | REAL-TIME ASSAYS OF NEURO-HUMORAL FACTORS TO ASSESS CARDIOVASCULAR STRESS - The present invention relates to rapid assays for neuro-humoral factors modulated in response to cardiovascular stress and integration of data obtained from such assays to provide profiles of response to cardiovascular stress that can guide therapy. | 03-17-2011 |
| 20110065105 | Novel transcription factor-based biosensor - The present invention provides for a system comprising a BmoR transcription factor, a σ | 03-17-2011 |
| 20110065106 | Recombinase polymerase amplification - This disclosure describe three related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of the bacterial RecA and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods has the advantage of not requiring thermocycling or thermophilic enzymes. Further, the improved processivity of the disclosed methods allow amplification of DNA up to hundreds of megabases in length. | 03-17-2011 |
| 20110065107 | Detection of gleevec resistance - The present invention relates to isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin- | 03-17-2011 |
| 20110065108 | Urine Transport Medium - A method of stabilizing a patient sample such as a urine sample to prevent degradation of nucleic acids for subsequent analysis for pathogen detection involves adding a stabilizing solution to an aliquot of the sample. A stabilizing solution comprising a chaotrope, a non-ionic detergent, and a buffer preserves urine samples for at least 28 days at room temperature for storage and transportation to an analytical facility for screening for pathogen nucleic acids. | 03-17-2011 |
| 20110065109 | RNA INTERFERENCE MEDIATING SMALL RNA MOLECULES - Double-stranded RNA (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). Using a | 03-17-2011 |
| 20110065110 | Method For The Extraction And Purification Of Nucleic Acids On A Membrane - The invention relates to a method for the extraction and detection of nucleic acids on a membrane, making it possible to identify the microorganisms present in low concentration in a liquid or gaseous medium, as well as a novel lysis composition comprising guanidium chloride and between 0.1 and 1% N-Lauroyl-Sarcosine (NLS) making it possible to implement this method. | 03-17-2011 |
| 20110065111 | Compositions For Use In Genotyping Of Klebsiella Pneumoniae - The present invention relates generally to identification and characterization of genotypes of | 03-17-2011 |
| 20110065112 | METHOD FOR IDENTIFYING LINEAGE-RELATED ANTIBODIES - In certain embodiments, the method may comprise: a) obtaining the antibody sequences from a population of B cells; b) grouping the antibody sequences to provide a plurality of groups of lineage-related antibodies; c) testing a single antibody from each of the groups in a bioassay and, after the first antibody has been identified, d) testing further antibodies that are in the same group as the first antibody in a second bioassay. In another embodiment, the method may comprise: a) testing a plurality of antibodies obtained from a first portion of an antibody producing organ of an animal; b) obtaining the sequence of a first identified antibody; c) obtaining from a second portion of said antibody producing organ the sequences of further antibodies that are related by lineage to said first antibody; and, c) testing the further antibodies in a second bioassay. | 03-17-2011 |
| 20110065113 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions as diagnostic markers and clinical targets for prostate cancer. | 03-17-2011 |
| 20110065114 | STEROIDOGENESIS MODIFIED CELLS AND METHODS FOR SCREENING FOR ENDOCRINE DISRUPTING CHEMICALS - An isolated steroidogenesis modified cell comprising one or more steroid biosynthesis knock down nucleic acid operatively linked to a promoter, wherein the steroid biosynthesis knock down nucleic acid reduces the expression of a gene selected from the group CYP21A2, CYP11A1, CYP17A1, CYP19A1, 3-βHSD1, 3-βHSD2, 17-βHSD1, StAR, HMGR, CYP11B2, CYP11B1, 5α-Reductase 2, SULT1E1, CYP3A4 and UTG1A1, wherein the cell comprises reduced expression of one or more of said genes. The cells are useful for identifying endocrine disruptors. Accordingly, the disclosure includes in a further aspect a screening assay for identifying an endocrine disruptor comprising:
| 03-17-2011 |
| 20110065115 | METHODS FOR IDENTIFYING AN INCREASED LIKELIHOOD OF RECURRENCE OF BREAST CANCER - Methods of identifying a mammal having an increased likelihood of recurrence of breast cancer includes identifying in a breast tissue sample of the mammal expression of at least two genes selected from the group consisting of Hs.125867 (EVL), Hs.591847 (NAT1), Hs.208124 (ESR1), Hs.26225 (GABRP), Hs.408614 (ST8SIA1), Hs.480819 (TBC1D9), Hs.504115 (TRIM29), Hs.523468 (SCUBE2), Hs.532082 (IL6ST), Hs.592121 (RABEP1), Hs.79136 (SLC39A6), Hs.82128 (TPBG), Hs.95243 (TCEAL1), Hs.95612 (DSC2), Hs.654961 (FUT8), Hs.1594 (CENPA), Hs.184339 (MELK), Hs.26010 (PFKP), Hs.592049 (PLK1), Hs.370834 (ATAD2), Hs.437638 (XBP1), Hs.444118 (MCM6), Hs.469649 (BUB1), Hs.470477 (PTP4A2), Hs.473583 (YBX1), Hs.480938 (LRBA), Hs.524134 (GATA3), Hs.531668 (CX3CL1), Hs.532824 (MAPRE2), Hs.591314 (GMPS), Hs.83758 (CKS2) and Hs.99962 (SLC43A3) and subsets of the genes. | 03-17-2011 |
| 20110065116 | Method for Detecting ATP - Methods are provided for detection of concentrations of less than 3.4 picomolar of adenosine triphosphate (ATP) using recombinant luciferase in the luciferin-luciferase reaction. Aspects include a low pH composition for use in detecting the presence of ATP. The low pH composition can include low concentrations of detergents and can be used in combination with methods for reading, calculating and interpreting luminescence generated by the ATP-luciferin-luciferase reaction. | 03-17-2011 |
| 20110065117 | Mesothelioma Specific Transferred Promoter And Use Thereof - Provided is a promoter showing transcriptional activity in a mesothelioma-specific manner and showing low transcriptional activity in other kinds of cancer cells and normal cells including mesothelium. Also provided are applications of the promoter, and more specifically, a gene therapy vector and a therapeutic agent for mesothelioma each including the promoter. The promoter includes a CRI1 gene-derived promoter, which is one kind of mesothelioma markers. The use of a vector including a cell death-inducing gene or a cell lysis-inducing gene as a transgene and carrying the CRI1 gene-derived promoter upstream of the transgene can induce a cell death or cell lysis action in a mesothelioma-specific manner. That is, the gene therapy vector and the therapeutic agent for mesothelioma each include a virus vector carrying the CRI1 gene-derived promoter. | 03-17-2011 |
| 20110065118 | Drug Screening Using Islet Cells and Islet Cell Progenitors from Human Embryonic Stem Cells - This disclosure provides a system for producing pancreatic islet cells from embryonic stem cells. Differentiation is initiated towards endoderm cells, and focused using reagents that promote emergence of islet precursors and mature insulin-secreting cells. High quality populations of islet cells can be produced in commercial quantities for use in research, drug screening, or regenerative medicine. | 03-17-2011 |
| 20110065119 | REVERSE PROGENY MAPPING - Provided is a method for mapping traits in organisms, in particular in plants. The method comprises a) providing a population of SDR-0 organisms, in particular plants, that each arise from one member of a population of unreduced cells resulting from second division restitution, in particular a population of unreduced spores; b) producing SDR-1 progeny populations of each of these SDR-0 organisms; c) phenotyping the SDR-1 progeny populations to identify segregating traits within each SDR-1 progeny population; d) if segregating progeny are present in a SDR-1 progeny population, genotyping the corresponding SDR-0 organism and comparing the genotype thereof with the genotype of the other SDR-0 organisms to identify heterozygous chromosomal regions associated with the occurrence of the segregating trait identified in the SDR-1 progeny population. | 03-17-2011 |
| 20110065120 | Method and a Reagent kit to Improve the Accuracy of Sample Classification - A method for increasing the veracity of classification by detecting protein YKL-40 and MASP2 levels in the samples, comprises detecting the content of the YKL-40 and MASP2 in the samples; the ratio of the content of YKL-40 to the that of MASP2 acted as variable, receiving the ROC curve according to the sensitivity and specialty of the difference threshold value to the diagnosis for the cancer, calculating an area under the curve AUC; classifying the samples according to the value of the AUC, sensitivity and specialty. And a kit for detecting the protein YKL-40 and MASP2 levels in the samples. | 03-17-2011 |
| 20110070575 | Immunomodulatory Compositions, Combinations and Methods - The invention provides immunomodulatory compositions, immunomodulatory combinations, and methods of modulating TLR7-mediated biological activity. Generally, the immunomodulatory compositions include an immunomodulatory oligonucleotide in an amount effective to reduce TLR7-mediated biological activity. In some cases, an immunomodulatory combination can further include an IRM compound. In some of these embodiments, the IRM compound can be a TLR7/8 agonist. Generally, the Imethods include contacting immune cells with an immunomodulatory composition in an amount effective to reduce TLR7-mediated biological activity. | 03-24-2011 |
| 20110070576 | VITRO DIAGNOSTIC KIT FOR IDENTIFICATION OF HUMAN PAPILLOMAVIRUS IN CLINICAL SAMPLES - A method and kit for detection and typing of HPV in a sample are described, as is a reaction vessel for use in the method. Universal HPV primers are used to amplify a sample by PCR; the amplified sample is then hybridised to an array of HPV type-specific probes to determine the HPV type. | 03-24-2011 |
| 20110070577 | Method for Detecting Target Nucleic Acids Using Template Catalyzed Transfer Reactions - The present invention relates to the detection and quantification of nucleic acid sequences and to the sequence determination of nucleic acids using template catalyzed transfer reactions. The invention also relates to methods, reagents, and kits for detecting and quantifying nucleic acid sequences and for determining the sequence of nucleic acids. | 03-24-2011 |
| 20110070578 | DNA analyzer - Aspects of the disclosure provide a microfluidic chip to facilitate DNA analysis. The microfluidic chip includes a first domain configured for polymerase chain reaction (PCR) amplification of DNA fragments, a dilution domain coupled to the first domain to dilute a PCR mixture received from the first domain, and a second domain that is coupled to the dilution domain so as to receive the amplified DNA fragments. The second domain includes a separation channel that is configured to perform electrophoretic separation of the amplified DNA fragments. In addition, the disclosure provides a DNA analyzer to act on the microfluidic chip to perform an integrated single chip DNA analysis. | 03-24-2011 |
| 20110070579 | POLYKETIDE SYNTHASE-NONRIBOSOMAL PEPTIDE SYNTHETASE GENE - The objective is to provide a method for rapidly, and highly accurately performing genetic detection of the cyclopiazonic acid-producing ability in a strain belonging to genus | 03-24-2011 |
| 20110070580 | Methods, Compositions, and Kits for Amplifying and Sequencing Polynucleotides - In one aspect, there are provided methods of amplifying and sequencing a polynucleotide. In some embodiments, the method includes (a) amplifying the polynucleotide with at least one amplification primer, a processive amplification polymerase, a sequencing primer, a sequencing polymerase, deoxynucleoside triphosphates suitable for template-dependent primer extension, and one or more terminating nucleotides, the incubation being carried out at a first temperature suitable for amplifying the polynucleotide with the processive amplification polymerase; (b) incubating the product of step (a) at a second temperature suitable for forming a plurality of differently-sized extended sequencing primers with the sequencing polymerase; (c) evaluating the extended sequencing primers in order to determine the sequence of the polynucleotide. The reactions at the first and second temperatures can be carried out in a single reaction vessel. In other aspects, compositions and kits for carrying out the methods are also provided. | 03-24-2011 |
| 20110070581 | Separation of Leukocytes - Leukocytes (e.g., neutrophils, monocytes and/or lymphocytes) can be captured and separated from blood by removing platelets using a spiral channel, followed by capturing individual leukocyte types in a series of cell capture channels having leukocyte binding moieties. Accordingly, various microfluidic-based cell affinity chromatography methods can be used to separate leukocytes from whole blood. | 03-24-2011 |
| 20110070582 | Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects - A method is provided in various embodiments for determining a profile data set for predicting the response top immunotherapy and or survivability of a subject with melanoma based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification under measurement conditions that are substantially repeatable for measuring the amount of RNA corresponding to at least 2, 3 or 4 constituents according to the gene models shown in Tables 2-3, 4-6 and 9. | 03-24-2011 |
| 20110070583 | Lsamp gene associated with cardiovascular disease - The LSAMP gene can be used for cardiovascular disease risk assessment, in particular Left Main Disease. The genetic risk attributable to LSAMP adds to known cardiovascular disease risk factors. Assessment of risk attributable to LSAMP permits early initiation of preventive and therapeutic strategies. Given the pronounced clinical risk associated with Left Main Disease, such risk assessment should significantly reduce morbidity and mortality. | 03-24-2011 |
| 20110070584 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE AND CHRONIC INFLAMMATORY DISEASES - Methods of diagnosing or monitoring autoimmune and chronic inflammatory diseases, particularly systemic lupus erythematosis and rheumatoid arthritis, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring autoimmune and chronic inflammatory diseases, particularly systemic lupus erythematosis and rheumatoid arthritis and kits or systems containing the same are also described. | 03-24-2011 |
| 20110070585 | INTEGRATED NUCLEIC ACID ANALYSIS - The present invention relates to an integrated method of nucleic acid analysis, and more particularly to a simplified sample pre-treatment, which renders the method more easily automated, where the sample is provided on or applied onto a solid matrix and the subsequent amplification and detection steps are performed in one single, sealed reaction vial without removing the matrix. | 03-24-2011 |
| 20110070586 | Multiplex Detection Of Agricultural Pathogens - Described are kits and methods useful for detection of agricultural pathogens in a sample. Genomic sequence information from agricultural pathogens was analyzed to identify signature sequences, e.g., polynucleotide sequences useful for confirming the presence or absence of a pathogen in a sample. Primer and probe sets were designed and optimized for use in a PCR based, multiplexed Luminex assay and/or an array assay to successfully identify the presence or absence of pathogens in a sample. | 03-24-2011 |
| 20110070587 | System For Genetic Surveillance and Analysis - A genetic surveillance system comprises a communications network and at least one reader-analyzer instrument. The reader-analyzer instrument has a communication interface to communicate over the network. The reader-analyzer instrument is adapted to perform genetic assay analysis of a sample obtained from a member of a population and to generate detection-related data based upon the analysis. The reader-analyzer instrument is adapted to associate qualifying information with the detection-related data and to communicate the associated qualifying information and detection-related data over the network. | 03-24-2011 |
| 20110070588 | Methods for Identifying Genomic Deletions - The genomic locus responsible for Van Buchem's disease is narrowed to an approximately 92 kb region of human chromosome 17 at 17q21. Individuals afflicted with or carriers of Van Buchem's disease exhibit a 52 kb deletion within this 92 kb region. Methods are provided that permit the differentiation between individuals homozygous for and therefore afflicted with Van Buchem's disease, individuals heterozygous for and therefore carriers of Van Buchem's disease, and individuals who are normal with respect to Van Buchem's disease. Also provided are general methodologies for the detection of a wide variety of large genomic deletions. | 03-24-2011 |
| 20110070589 | MAGNETIC LYSIS METHOD AND DEVICE - A method for lysing cells is disclosed. The method includes stirring cells with a magnetic stir element in the presence of a plurality of cell lysis beads at a speed sufficient to lyse the cells. Also disclosed is a device for lysing cells. The device includes a container having a magnetic stir element and a plurality of cell lysis beads disposed therein. The container is dimensioned to allow rotation of the magnetic stir element inside the container. | 03-24-2011 |
| 20110070590 | Primers and Methods for Determining RhD Zygosity - Provided herein are primers comprising a nucleotide sequence complementary to a portion of a RhD gene. Also provided herein are methods of determining a RhD zygosity in a subject. Also provided are methods of detecting a weak D allele in a subject. Further provided are kits for determining an RhD zygosity. | 03-24-2011 |
| 20110070591 | REPLICATION PROTEIN - This invention relates to a screening method for the identification of agents which modulate the activity of a DNA replication protein as a target for intervention in cancer therapy and includes agents which modulate said activity. The invention also relates to the use of the DNA replication protein, and its RNA transcripts in the prognosis and diagnosis of proliferative disease e.g., cancer. | 03-24-2011 |
| 20110076673 | Detection of bacteria - The invention relates to a method for detecting bacterial contaminations preferably in physiological samples as well as sequences of synthetic oligonucleotides used therefor. The method comprises the steps of i) extracting the nucleic acid, particularly bacterial DNA, ii) amplification by means of primers and detection by means of oligonucleotides, particularly fluorescence-marked oligonucleotides as hybridization probes, containing a sequence that is selected from among a group encompassing SEQ ID NO:5 to SEQ ID NO:35, preferably in real-time PCR, and iii) evaluation by means of fusion curve analysis. | 03-31-2011 |
| 20110076674 | RAPID EPIDEMIOLOGIC TYPING OF BACTERIA - Methods for typing a strain of an organism are provided, the methods comprising the steps of amplifying, in a single reaction mixture containing nucleic acid from the organism, dividing the reaction mixture into a plurality of sets of second-stage reaction wells, each set of second-stage reaction wells containing a different pair of second-stage primers, subjecting each of the second-stage reaction wells to amplification conditions to generate a plurality of second-stage amplicons, melting the second-stage amplicons to generate a melting curve for each second-stage amplicon, and identifying the strain of the organism from the melting curves. | 03-31-2011 |
| 20110076675 | NOVEL METHODS FOR QUANTIFICATION OF MICRORNAS AND SMALL INTERFERING RNAS - The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids. | 03-31-2011 |
| 20110076676 | Method of Purifying RNA Binding Protein-RNA Complexes - The present invention provides methods for purifying RNA molecules interacting with an RNA binding protein (RBP), and the use of such methods to analyze a gene expression profile of a cell. The invention also provides sequences of RNA molecules that mediate binding to an RBP, proteins encoded by the sequences, a method of identifying the sequences, and the use of the sequences in a screen to identify bioactive molecules. The invention also provides RNA motifs found among the sequences and compounds that bind the RNA motifs. In addition, the invention provides methods of treating diseases associated with a function of an RNA binding protein. | 03-31-2011 |
| 20110076677 | METHOD FOR DETECTING SINGLE NUCLEOTIDE POLYMORPHISMS - A method of detecting a single nucleotide polymorphism includes providing a first template polynucleotide, a second polynucleotide comprising a first and second sequence (complementary to a first portion of the first polynucleotide), and a third polynucleotide (complementary to a second portion of the first polynucleotide). The first, second and third polynucleotides are annealed, ligated and optionally, these steps are repeated. A fourth polynucleotide, which is essentially complementary to at least a portion of the first sequence, coupled to a first indicator is then provided. A fifth and/or sixth polynucleotide is provided. The fifth polynucleotide is essentially identical to at least a portion of the second sequence of the second polynucleotide and/or to at least a portion of the third polynucleotide. The sixth polynucleotide is essentially complementary to a portion of the second sequence of the second polynucleotide. The third or fifth polynucleotides may be coupled to a second indicator. | 03-31-2011 |
| 20110076678 | REPROGRAMMING OF SOMATIC CELLS - The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells. | 03-31-2011 |
| 20110076679 | 3'-O-FLUORESCENTLY MODIFIED NUCLEOTIDES AND USES THEREOF - The present invention relates to a DNA sequencing method using a nucleoside triphosphate with a fluorescent blocking group on its 3′-OH end as a reversible terminator. Further, the present invention relates to sequencing-by-synthesis method using the mono-modified reversible terminator (MRT), the novel nucleotide monomer having a reversible fluorescent blocking group removable chemically or enzymatically at its 3′-OH end. The sequencing method of the present invention facilitates sequencing of bases inserted by terminating extension of a nucleotide chain by the nucleotide monomer and then detecting fluorescence signal from 3′-OH end. At this time, after analyzing the fluorescence signal, the blocking group conjugated to the 3′-OH end can be effectively removed, indicating that a free 3′-OH functional group can be successfully restored, so that the next monomer insertion is possible, making continuous sequencing possible. | 03-31-2011 |
| 20110076680 | FLUORESCENT MOLECULE - It is an object of the present invention to provide an on-off type fluorescent compound (a fluorescence-producing molecule system) used in gene analyses, which is highly stable (namely, being active for a long period of time) and highly sensitive, and which enables amplification of a trace amount of gene signal and observation thereof. The present invention provides a nonfluorescent molecule having a fluorescent substance skeleton such as fluorescein skeleton and having a group represented by —O—C(Y1)(Y2)-N | 03-31-2011 |
| 20110076681 | Modified gene-silencing nucleic acid molecules and uses thereof - Methods and means for efficiently downregulating the expression of a target gene of interest in cell from an organism that is an animal, fungus, and protest. The invention provides chimeric nucleic acid molecules for downregulating target genes. The invention also provides modified cells and organisms comprising the chimeric nucleic acid molecules and compositions comprising the chimeric molecules. | 03-31-2011 |
| 20110076682 | Over-production of secondary metabolites by over-expression of the VEA gene - The invention provides a general and facile method to obtain secondary metabolites from fungal sources. The invention is based on the discovery that the fungal gene veA and protein encoded thereby regulates the activity of multiple secondary metabolite gene clusters in fungi. Over expression of the gene veA provides increased production of secondary metabolites in engineered cells. In particular, such a method of increasing secondary metabolite production allows the production of improved yields of valuable secondary metabolite products. | 03-31-2011 |
| 20110076683 | Identification, Isolation and Elimination of Cancer Stem Cells - Isolated populations of leukemic stem cells are provided. The cells are useful for experimental evaluation, and as a source of lineage and cell specific products, and as targets for the discovery of factors or molecules that can affect them. Detection of leukemic stem cells is useful in predicting disease progression, relapse, and development of drug resistance. Proliferation of LSC may be inhibited through interfering with activation of the β-catenin pathway. Methods are provided for the clinical staging of pre-leukemia and leukemias by differential analysis of hematologic samples for the distribution of one or more hematopoietic stem or progenitor cell subsets. | 03-31-2011 |
| 20110076684 | APPARATUS AND METHOD FOR ACQUIRING, DETECTING, AND ANALYZING CELLS IN A MICROFLUIDIC SYSTEM - An apparatus is disclosed for acquiring, detecting, and, optionally, analyzing cells in a biological liquid, which apparatus has a microfluidic system. In at least one embodiment, the apparatus includes at least one microfluidic channel having a small cross-section which is completely or partially coated with cell-specific binding molecules and which has no flow obstacles dividing the fluid flow; at least one apparatus for generating a steady and alterable liquid flow through the microfluidic channel, and optionally at least one apparatus for analyzing the genetic information of the cell. In at least one embodiment, the method includes a sample of a biological liquid being conducted through an apparatus defined above at a defined velocity V | 03-31-2011 |
| 20110076685 | METHOD FOR IN VITRO DETECTION AND DIFFERENTIATION OF PATHOPHYSIOLOGICAL CONDITIONS - The present invention relates to the use of defined polynucleotides to form at least one multi-gene biomarker for producing a multiplex assay as a tool for in vitro detection and/or early detection and/or differentiation and/or progress monitoring and/or evaluation of pathophysiological conditions of a patient, the pathophysiological condition selected from the group consisting of: SIRS, sepsis and its degrees of severity; sepsis-like conditions, septic shock, bacteremia, infective/non-infectious multiorgan failure, early detection of these conditions; focus control, control of surgical rehabilitation of the infection focus; responders/non-responders for a specific therapy, treatment monitoring; distinction between infectious and non-infectious etiology of systemic reactions of the organism, such as SIRS, sepsis, postoperative complications, chronic and/or acute organ dysfunction, shock response, inflammatory response and/or trauma. | 03-31-2011 |
| 20110076686 | WATER MANAGEMENT - A method for detecting and enumerating viable microorganisms in a sample suspected of containing said microorganisms comprising: (1) contacting said sample with a cell nutritive resource and a cellular proliferation inhibitor, (2) contacting said sample with at least one fluorescence labelled oligonucleotidic probe able to specifically hybridise at least one portion of ribosomal nucleic acids of said microorganisms, (3) detecting and quantifying the fluorescent signal, in which the microorganisms are of the species | 03-31-2011 |
| 20110076687 | FLUORESCENCE STANDARD, AND THE USE THEREOF - The invention concerns fluorescence standards, and in particular fluorescence standards for calibrating optical detectors. According to the invention, a fluorescent mineral or mixtures of minerals are employed for use as a fluorescence standard. The fluorescent mineral can be a naturally occurring mineral or a synthetically produced mineral. Preferred fluorescent minerals for use as fluorescence standards are corundum, fluorite, turquoise, amber, zircon, zoisite, iolite or cordierite, spinel, topaz, calcium fluorite, sphalerite or zincblende, calcite or calcspar, apatite, scheelite or calcium tungstate, willemite, feldspars, sodalite, a uranium mineral, a mineral containing Al | 03-31-2011 |
| 20110076688 | METHOD FOR ENUMERATION OF MAMMALIAN MICRONUCLEATED ERYTHROCYTE POPULATIONS, WHILE DISTINGUISHING PLATELETS AND/OR PLATELET-ASSOCIATED AGGREGATES - A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains DNA (micronuclei) in erythrocyte populations. Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample. In particular, the use of the second antibody prevents interference by platelet-associated aggregates in the scoring procedures. | 03-31-2011 |
| 20110076689 | PRIMER FOR DETECTING TYROSINASE mRNA - The present invention provides a means and method for detecting TYR mRNA. As a primer for detecting TYP mRNA, a primer comprising a first sequence at the 5′ end side and a second sequence at the 3′ end side, wherein the first sequence has 10 to 30 nucleotides in length, and the first sequence is a sequence of a polynucleotide capable of hybridizing with a strand complementary to a first region which is a partial region of SEQ ID NO: 1; and wherein the second sequence has 10 to 30 nucleotides in length, and the second sequence is a sequence of a polynucleotide capable of hybridizing with a second region located in the 3′ end side from the first region in SEQ ID NO: 1 is used. | 03-31-2011 |
| 20110076690 | TITER PLATE, READING DEVICE THEREFOR AND METHOD FOR DETECTING AN ANALYTE, AND USE THEREOF - A titer plate and a method for detecting an analyte, and the use thereof are disclosed. According to at least one embodiment of the invention, it is proposed that a plurality of depressions and a biochip of the titer plate sposed adjacent thereto be surrounded by a wall in order to effectively prevent sample contamination when there is a high degree of spatial integration. | 03-31-2011 |
| 20110081647 | NUCLEOTIDE ANALOGS - The invention generally relates to nucleotide analogs and methods of their use in sequencing-by-synthesis reactions. In certain embodiments, the invention provides a nucleotide analog including a detectable label attached to a nitrogenous base portion of a nucleotide analog by a cleavable linker, in which contact of the analog with at least one activating agent results in cleavage of the label and elimination of the linker, thereby producing a natural nucleotide, a 9-deaza-G, 9-deaza-A, or ψ-uridine. | 04-07-2011 |
| 20110081648 | Methods for diagnosing peripheral neuropathy - Genes whose expression is correlated with the presence of CIDP or vasculitic neuropathy are disclosed. Probes and sets of nucleic acids and proteins specific for these genes are described, as are molecular and immunological methods for aiding in the diagnosis of these disease conditions in a subject. | 04-07-2011 |
| 20110081649 | DIAGNOSIS, STAGING AND MONITORING OF INFLAMMATORY BOWEL DISEASE - A method of differentiating between active and inactive IBD in a gastrointestinal mucosa sample or a sample from a sentinel lymph node draining gastrointestinal mucosa comprises preparing a suspension of single cells from the sample, analyzing the suspension for expression of the inflammation activation marker CD69 on CD4+ T helper cells using directly labelled fluorescent DC69 antibody; comparing the number of T helper cells expressing DC69 in the sample with that obtained from a corresponding sample of a healthy person, a significantly increased level of T helper cells expressing CDD69 signifying the presence of active IBD and a less than significantly increased level of T helper cells signifying the presence of inactive IBD. Also disclosed are methods of differentiating between ulcerative colitis (UC) and Crohn's disease (CD), of detecting UC and CD, and of determining the susceptibility of an IBD patient to steroid treatment. | 04-07-2011 |
| 20110081650 | FREE NGAL AS A BIOMARKER FOR CANCER - Uncomplexed neutrophil gelatinase associated lipocalin (NGAL) is present at increased levels in individuals with atypical ductal hyperplasia (ADH), a major risk factor for future breast cancer development; in individuals that have ovarian cancer; and in individuals that have breast cancer, both invasive and noninvasive. Accordingly, the present invention is directed to measuring uncomplexed NGAL levels in urine as a primary screen to determine if an individual is either at risk of developing, or has developed cancer, e.g., cancer of epithelial origin including breast and ovarian cancer. | 04-07-2011 |
| 20110081651 | EGFR AND KRAS MUTATIONS - The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and KRAS and methods of detecting such mutations as well as prognostic methods for identifying tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein and/or a mutated KRAS gene or mutated KRAS protein in a tumor sample. | 04-07-2011 |
| 20110081652 | METHOD OF CLASSIFYING GENE EXPRESSION STRENGTH IN LUNG CANCER TISSUES - The present invention provides a method of confirming the gene expression, useful in the decision of a five year survival rate of a patient with lung cancer and the use of a DNA probe kit in the method. A method useful in the decision of a survival rate of a patient with non-small cell lung cancer comprising confirming the expression strength of at least one gene in lung cancer tissues isolated from the patient. | 04-07-2011 |
| 20110081653 | High Spatial Resolution Imaging of a Structure of Interest in a Specimen - In high spatial resolution imaging, a structure in a specimen is marked with a substance which, in a first electronic state, is excited by light of one wavelength to emit fluorescent light, which is also converted from its first into a second electronic state by that light, and which returns from its second into its first electronic state. The specimen is imaged onto a sensor at a spatial resolution not resolving an average spacing between neighboring molecules of the substance, and exposed to the light at such an intensity that the molecules in the first state are alternately excited to emit fluorescent light and converted into their second state, and that at least 10% of the molecules presently in their first state lie at a distance from their closest neighboring molecules in their first state which is greater than the spatial resolution of the imaging onto the sensor. | 04-07-2011 |
| 20110081654 | TRANSCRIPTIONAL PROFILING OF STEM CELLS AND THEIR MULTILINEAGE DIFFERENTIATION - The present invention concerns methods of screening cells for differentiation or de-differentiation, and/or for status as a pluripotent or multipotent (e.g., “stem”) cell, by detecting the differential expression (e.g., upregulation, downregulation) of genes. | 04-07-2011 |
| 20110081655 | NUCLEIC ACID ANALYZING DEVICE AND NUCLEIC ACID ANALYZER - An object of the present invention relates to distinguishing, from a fluorophore of an unreacted substrate, a single fluorophore attached to a nucleotide that is incorporated into a probe by a nucleic acid synthesis. The present invention relates to a nucleic acid analyzing device that analyzes a nucleic acid in sample by fluorescence, wherein a localized surface plasmon is generated by illumination, and a probe for analyzing the nucleic acid in the sample is on the site where the surface plasmon is generated. According to the present invention, since it is possible to efficiently produce fluorescence intensifying effects due to the surface plasmon and to immobilize the probe to a region within the reach of the fluorescence intensifying effects, it becomes possible to measure a nucleic acid synthesis without removing unreacted nucleotide to which fluorophores are attached. | 04-07-2011 |
| 20110086342 | Hepatocellular Carcinoma-Associated Gene - The present invention provides a method for evaluating cancer, which comprises the following steps of:
| 04-14-2011 |
| 20110086343 | METHOD FOR THE SCREENING OF BACTERIAL ISOLATES - Present invention relates to a method to determine the genotype of organisms by RAPD analysis and more specifically, to establish the relatedness of individual organisms across and within species. RAPD uses genotypic information of an organism to give an organism specific DNA fragment of different sizes. The present invention provide methods and a set of oligonucleotide primers for performing amplification and other enzymatic reactions on nucleic acid molecules that have been collected directly as environmental DNA or DNA derived form pure isolates. More specifically, the present invention relates to a novel method of genetic analysis using a set of sub-sequence, which occurs as inverted repeats in different genome with different frequencies. All bacterial cultures used in this study have been isolated from activated biomass collected from effluent treatment plants. The bacteria have been sub-cultured repeatedly to obtain pure cultures. All plating has been carried out on Luria Broth plates with 2% agar. The 16S rRNA gene has been amplified using universal primers to confirm the eubacterial nature of the isolates. The primers used to amplify a 1466-bp product were 27F forward primer 5′-AGAGTTTGATCMTGGCTCAG-3′ and 1492 reverse primer 5′-TACGGYTAC-CTTGTTACGACTT-Hence, in defined conditions two genome samples could be differentiated from each other. These features are applicable to DNA fingerprinting, marker assisted selection, genotyping, and high throughput laboratory screening methods for culturable microbes from any environmental niche. | 04-14-2011 |
| 20110086344 | METHODS OF CHARACTERIZING SMALL NUCLEIC ACID MOLECULES - The invention generally relates to methods of characterizing small nucleic acid molecules, such as plasmids or nucleic acid molecules obtained from a virus. In certain embodiments, the invention provides a method of characterizing a small circular nucleic acid molecule, the method including performing rolling circle amplification on a small circular nucleic acid molecule, thereby producing a concatamer, and generating an optical map of the concatamer, thereby characterizing the small circular nucleic acid molecule. | 04-14-2011 |
| 20110086345 | ISOLATION AND USE OF RYANODINE RECEPTORS - The genes encoding ryanodine receptor homologs have been characterized from multiple insect families including lepidopteran tobacco budworm ( | 04-14-2011 |
| 20110086346 | Novel haplotype tagging single nucleotide polymorphisms and use of same to predict childhood lymphoblastic leukemia - The present invention is directed to novel haplotype tagging single nucleotide polymorphisms (SNPs) in specific regions outside the HFE gene that serve as a reliable biomarker for a decreased risk for childhood lymphoblastic leukemia (ALL) in a child. There is provided herein methods and reagents for assessing the haplotype tagging SNPs selected from the group consisting of rs807212, rs198853, rs9467664, rs2213284, rs2230655 and rs12346. The method useful in applying these SNPs in predicting a decreased risk of childhood lymphoblastic leukemia (ALL) is also disclosed. | 04-14-2011 |
| 20110086347 | CELL DETECTION, MONITORING AND ISOLATION METHOD - The present invention relates generally to a method for identifying or distinguishing one type of cell from other cells within a population of cells. The present invention further provides the detection, monitoring and isolation of sub-populations cell types within a population of cells including a biological entity comprising such cell types. Kits, diagnostic agents and panels of nucleic acid probes for identifying and distinguishing cell types also form part of the present invention. The detection of particular cell types is based upon the use of a labelled probe that hybridizes to chromosomal DNA at the flanking sequences of a deletion. Alternatively two probes with distinguishable reporter molecules are used wherein only one probe is capable of hybridizing to chromosomal DNA in one cell type whereas both are capable of hybridizing to chromosomal DNA in another cell type. The methods are useful in the identification of cells with copy number variations, chromosomal deletions, additions or aberrations. | 04-14-2011 |
| 20110086348 | METHOD FOR ASSESSING HEART DISEASE - A method for assessing heart disease in a subject includes generating an expression profile of at least two or more miRNAs in a sample from the subject. The miRNAs can be selected from the group consisting of hsa-miRNA-1, hsa-miRNA-7, hsa-miRNA-29b, has-miRNA-125b, hsa-miRNA145, hsa-miRNA-181b, hsa-miRNA-214, hsa-miRNA-342, hsa-miRNA-378 and combinations thereof. | 04-14-2011 |
| 20110086349 | Proliferation Signatures and Prognosis for Gastrointestinal Cancer - This invention relates to methods and compositions for determining the prognosis of cancer in a patient, particularly for gastrointestinal cancer, such as gastric or colorectal cancer. Specifically, this invention relates to the use of genetic markers for the prediction of the prognosis of cancer, such as gastric or colorectal cancer, based on cell proliferation signatures. In various aspects, the invention relates to a method of predicting the likelihood of long-term survival of a cancer patient, a method of determining a treatment regime for a cancer patient, a method of preparing a personalized genomics profile for a cancer patient, among other methods as well as kits and devices for carrying out these methods. | 04-14-2011 |
| 20110086350 | ELIMINATION OF PATHOGENIC INFECTION IN FARMED ANIMAL POPULATIONS - Animal husbandry has always been susceptible to the ravages of pathogenic infections. Poultry flus and cattle diseases are but two examples that have dire consequences for animals and adversely affect the economic fortunes of farmers. A testing and culling methodology is presented that can eliminate pathogens from an infected herd. The sensitivity of PCR to detect very low levels of nucleic acid of an infecting pathogen is utilized to identify infected animals. In addition, it has been discovered that PCR analysis of manure samples can accurately identify infected animals and offspring for those species that consume placental remains after birth. Mink Aleutian Disease Virus (mADV) is one of several deadly DNA parvoviruses that can quickly reach epidemic proportions in a mink herd. PCR primers have been developed that generate amplicons to detect and identify the mADV. In addition, a previously unidentified strain of mADV has been discovered, genomically sequenced, and substantially detailed. | 04-14-2011 |
| 20110086351 | ELIMINATION OF PATHOGENIC INFECTION IN FARMED ANIMAL POPULATIONS - Animal husbandry has always been susceptible to the ravages of pathogenic infections. Poultry flus and cattle diseases are but two examples that have dire consequences for animals and adversely affect the economic fortunes of farmers. A testing and culling methodology is presented that can eliminate pathogens from an infected herd. The sensitivity of PCR to detect very low levels of nucleic acid of an infecting pathogen is utilized to identify infected animals. In addition, it has been discovered that PCR analysis of manure samples can accurately identify infected animals and offspring for those species that consume placental remains after birth. Mink Aleutian Disease Virus (mADV) is one of several deadly DNA parvoviruses that can quickly reach epidemic proportions in a mink herd. PCR primers have been developed that generate amplicons to detect and identify the mADV. In addition, a previously unidentified strain of mADV has been discovered, genomically sequenced, and substantially detailed. | 04-14-2011 |
| 20110086352 | Label Free Detection of Nucleic Acid Amplification - Provided are methods and devices for label-free detection of nucleic acids that are amplified by polymerase chain reaction. A solution containing the components necessary for a PCR is introduced to a microfluidic amplification chamber and an electric field applied to a confined region in which PCR occurs. PCR product generated in the confined region is detected by measuring an electrical parameter that is, for example, solution impedance. The devices and methods provided herein are used, for example, in assays to detect one or more pathogens or for point-of-care tests. In an aspect, the PCR product is confined to droplets and the assay relates to detecting an electrical parameter of a flowing droplet, thereby detecting PCR product without a label. In an aspect, the PCR occurs in the droplet. | 04-14-2011 |
| 20110086353 | Identification of MicroRNAs (miRNAs) in Fecal Samples as Biomarkers for Gastroenterological Cancers - A simple, rapid, inexpensive, and promising commercial biomarker assay method for multiple diseases is described herein. The present invention detects miRNA-based biomarkers in human stool specimens. The method of the present invention amplifies miRNA directly from stool specimens without any prior miRNA extraction. Differential expression of specific microRNAs in stool of colorectal cancer CRC and adenoma patients suggest fecal microRNAs as a novel potential biomarker for colorectal neoplasia detection. The method of the present invention has diagnostic, prognostic, and therapeutic relevance for gastroenterological cancers/colorectal cancer and as well as further acquired or hereditary GI diseases. | 04-14-2011 |
| 20110086354 | METHODS AND COMPOSITIONS FOR MULTIPLEX PCR AMPLIFICATIONS - The present invention concerns in general PCR reaction mixtures comprising a mixture of hot-start primers and non-hot-start primers for a given target sequence, including multiplex PCR reaction mixtures; methods utilizing same for detection of one or more target polynucleotide sequences; and kits comprising same. | 04-14-2011 |
| 20110086355 | BRCA1 mRNA EXPRESSION LEVELS PREDICT SURVIVAL IN BREAST CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY - The invention relates to methods for predicting the clinical outcome of a patient which suffers from breast cancer based on the expression levels of BRCA1, wherein low BRCA1 expression levels are indicative of a good prognosis. Moreover, the invention relates to methods for predicting the response to a neoadjuvant therapy based on a combination of an anti-metabolite, an intercalating agent and an alkylating agent of a patient which suffers from breast cancer based on the expression levels of BRCA1. | 04-14-2011 |
| 20110086356 | METHOD FOR MEASURING DNA METHYLATION - The present invention relates to a method of measuring the content of methylated DNA in a DNA region of interest in a genomic DNA contained in a biological specimen, and so on. | 04-14-2011 |
| 20110086357 | Methods for Evaluating a Disease Condition by Nucleic Acid Detection and Fractionation - This invention relates to the discovery that both non-particle and particle associated nucleic acids are present in blood plasma and serum and can be used to evaluate disease conditions. | 04-14-2011 |
| 20110086358 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof. | 04-14-2011 |
| 20110086359 | LATERAL FLOW ASSAYS - Assays and methods including mobile tagged single stranded nucleic acid reagents pre-loaded on an analysis device, which are preferably tagged, but not labeled and are complementary to a strand (preferably the anti-sense strand in double stranded DNA targets) of the target nucleic acid. The assay also includes a running buffer that includes a dye or other detectable label that nonspecifically binds only to double stranded nucleic acids. In addition, the analysis device includes a detection zone including one or more test zones that have an immobilized tag that binds to the tag on the mobile nucleic acid reagent. | 04-14-2011 |
| 20110086360 | METHOD FOR DETECTION OF IDIOPATHIC INTERSTITIAL PNEUMONIA - The present invention provides a method for detecting idiopathic interstitial pneumonia, which comprises measuring the expression level of a periostin gene or the amount of a periostin protein in a biological sample. Thereby, a method for detecting idiopathic interstitial pneumonia using a marker is provided. | 04-14-2011 |
| 20110086361 | AMPLIFICATION OF NUCEIC ACIDS USING TEMPERATURE ZONES - The present invention relates to the amplification and detection of amplified nucleic acid sequences employing methods and devices with distinct temperature zones. The methods and devices of the present invention may be used for quantitative analysis of target nucleic acid sequences, for simultaneous quantitative analysis of multiple target nucleic acid sequences or for analyzing a sample for the presence of a target nucleic acid. | 04-14-2011 |
| 20110091870 | MULTISITE BIOSENSOR AND ASSOCIATED METHOD - A method of detecting a biomarker in one embodiment includes identifying a quantity of biomolecule types in a sample, exposing the sample to a plurality of test sites, wherein the number of test sites in the plurality of test sites is equal to or greater than the identified quantity of biomolecule types, establishing, for each of the plurality of test sites, a respective test environment, wherein the test environment for each of the plurality of test sites is different from the test environment for each of the other of the plurality of test sites, obtaining a detection signal associated with each of the plurality of test sites, and determining the concentration of one of the biomolecule types based upon the obtained detection signals. | 04-21-2011 |
| 20110091871 | BIOMARKERS FOR PREDICTING RESPONSE OF ESOPHAGEAL CANCER PATIENT TO CHEMORADIOTHERAPY - The present invention relates to novel genetic markers associated with response of a patient with esophageal cancer (ECa) to chemoradiation therapy, and particularly to methods and kits for predicting an ECa patient's response to chemoradiation therapy by genotyping of the markers. | 04-21-2011 |
| 20110091872 | DETECTING TRIAZOLE RESISTANCE IN ASPERGILLUS - Methods are provided for detecting triazole -resistant fungi in a sample. The methods comprise evaluating the sample for the presence of a gene encoding a mutant AzRF1 transcription factor, or the level of the transcription factor, to determine whether a fungus is triazole-resistant. Primers, probes and kits also are provided. | 04-21-2011 |
| 20110091873 | INTEGRATED SAMPLE PREPARATION AND AMPLIFICATION FOR NUCLEIC ACID DETECTION FROM BIOLOGICAL SAMPLES - Beads are used to perform both a sample preparation and amplification process within a single processing chamber. A fluid sample including a plurality of cells is introduced into a processing chamber already including a plurality of beads. The plurality of cells are lysed within the processing chamber, and nucleic acid released from the lysed cells binds to the beads. The beads are retained in the processing chamber while the lysing reagents are removed. Amplification reagents, such as PCR reagents are added to the processing chamber and an amplification process is performed on the contents of the processing chamber. Nucleic acid captured on the beads is not eluted for amplification, instead amplification of the captured nucleic acid is performed while the nucleic acid is still bound to the beads. During the amplification process, the nucleic acid bound to the beads is amplified. Real-time or end-point detection can be performed on the content of the processing chamber to detect the presence of amplified product. | 04-21-2011 |
| 20110091874 | ULTRASENSITIVE DETECTION OF TARGET USING TARGET-READY PARTICLES - The invention relates to methods and reagents for detecting minute amounts of targets having affinity for nucleic acid. The present invention more particularly relates to target detection using aggregates of cationic polymer chains and nucleic acid capture probes linked to particles, such as controllable mobility particles. | 04-21-2011 |
| 20110091875 | THREE-COMPONENT GENE EXPRESSION REPORTING SYSTEM FOR MAMMALIAN CELLS AND APPLICATIONS OF THE SAME - Disclosed herein is a three-component gene expression reporting system for mammalian cells, the system including a first expression cassette, a second expression cassette, and a methylated polynucleotide. The three-component gene expression reporting system can be used to establish recombinant mammalian cells for use in the screening of a demethylating agent. | 04-21-2011 |
| 20110091876 | ZCYTOR19 POLYNUCLEOTIDES, POLYPEPTIDES, ANTIBODIES AND METHODS OF USE - Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class II cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor19, are located on chromosome 1p36.11, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 04-21-2011 |
| 20110091877 | SYSTEMS AND METHODS FOR MINIMIZATION OR ELIMINATION OF DIFFUSION EFFECTS IN A MICROFLUIDIC SYSTEM - The present invention relates to systems and methods for minimizing or eliminating diffusion effects. Diffused regions of a segmented flow of multiple, miscible fluid species may be vented off to a waste channel, and non-diffused regions of fluid may be preferentially pulled off the channel that contains the segmented flow. Multiple fluid samples that are not contaminated via diffusion may be collected for analysis and measurement in a single channel. The systems and methods for minimizing or eliminating diffusion effects may be used to minimize or eliminate diffusion effects in a microfluidic system for monitoring the amplification of DNA molecules and the dissociation behavior of the DNA molecules. | 04-21-2011 |
| 20110091878 | DAIRY CATTLE BREEDING FOR IMPROVED MILK PRODUCTION TRAITS IN CATTLE - Nucleic acid molecules comprising a SNP site at position 1296 of bovine uterine milk protein (UTMP) coding sequence (SEQ ID NO: 1), which SNP indicates a desirable productive life in a dairy cattle. Also disclosed are an array or a kit comprising the same, a method for detecting the SNPs, a method for progeny testing of cattle, and a method for selectively breeding of cattle. | 04-21-2011 |
| 20110091879 | MOBILE DEVICE FOR ISOLATION OF NUCLEIC ACIDS - The invention relates to a mobile device system, comprising a hand-held device and a test kit for the mobile isolation of nucleic acids. The hand-held device comprises at least one sample block for inserting sample containers, a sample block holder with boreholes or recesses for accommodating the sample blocks, a device base with electronic control units for the sample blocks, a voltage source and a connection to the sample block holder, as well as a test kit for the isolation of nucleic acids. The hand-held device is characterized in that the sample blocks can be removed from the sample block holder and the sample block holder can be removed from the device base. | 04-21-2011 |
| 20110091880 | SUSCEPTIBILITY VARIANTS FOR LUNG CANCER - The present invention discloses certain genetic variants as susceptibility variants for lung cancer. The invention relates to methods of risk assessment using such variants. The invention further relates to kits for use in risk assessment of lung cancer. | 04-21-2011 |
| 20110091881 | MYCOBACTERIAL GENES DOWN-REGULATED DURING LATENCY - A method is provided for identifying mycobacterial genes the expression of which is down-regulated during a stationary phase culture of mycobacteria under nutrient-starving conditions when compared with an exponential phase culture of mycobacteria under culture conditions that are not nutrient-starving and that support exponential growth of said mycobacteria. The described method optionally provides for identifying mycobacterial genes that are simultaneously down-regulated under low DOT conditions. The down-regulated genes of the present invention form the basis of nucleic acid vaccines, or provide targets to allow preparation of attenuated mycobacteria for vaccines against mycobacterial infections. Similarly, peptides encoded by said down-regulated genes are employed in vaccines. In a further embodiment, the identified genes/peptides provide the means for identifying the presence of a mycobacterial infection in a clinical sample by nucleic acid probe or antibody detection. | 04-21-2011 |
| 20110091882 | DETERMINATION OF METHYLATION STATUS OF POLYNUCLEOTIDES - The present invention provides compositions and methods for detecting the methylation status of a nucleic acid. In particular, the present invention provides a mass spectrometry-based method of determining DNA methylation status without sequencing. | 04-21-2011 |
| 20110091883 | METHODS FOR ANALYZING MINUTE CELLULAR NUCLEIC ACIDS - The invention generally relates to methods for analyzing cellular nucleic acid. Methods of the invention involve capturing RNA from a lysed cell onto a substrate, producing a cDNA/RNA duplex, removing the RNA from the cDNA/RNA duplex, priming the cDNA to produce a primer/cDNA duplex, exposing the primer/cDNA duplex to at least one detectably labeled nucleotide in the presence of a polymerase capable of catalyzing addition of the nucleotide to the primer/cDNA duplex, detecting incorporation of the nucleotide into the primer portion, and repeating the exposing and detecting steps at least once. | 04-21-2011 |
| 20110091884 | Method for Analysis of DNA Methylation - Provided is a method for analysis of DNA methylation. A first method comprises: (1) a step in which analyte DNA is digested with methylation-insensitive restriction enzyme(s) that produce overhanging end(s) and that contain methylated cytosine or methylatable cytosine in recognition sequence(s) thereof; (2) a step in which adaptor(s) capable of regenerating recognition sequence(s) of the aforesaid methylation-insensitive restriction enzyme(s) is/are ligated to both ends of DNA fragment(s) obtained at the aforesaid step (1); and (3) a step in which DNA construct(s) obtained at the aforesaid step (2) is/are digested with methylation-sensitive restriction enzyme(s) that recognize the same recognition sequence(s) as the aforesaid methylation-insensitive restriction enzyme(s). A second method comprises: (1) a step in which analyte DNA is digested with restriction enzyme(s); (2) a step in which adaptor(s) is/are ligated to both ends of DNA fragment(s) obtained at the aforesaid step (1); and (3) a step in which DNA construct(s) obtained at the aforesaid step (2) is/are digested with methylation-dependent restriction enzyme(s). | 04-21-2011 |
| 20110091885 | COMPOSITION COMPRISING AN OLIGONUCLEOTIDE MIXTURE FOR THE DETECTION OF CONTAMINATIONS IN CELL CULTURES - The present invention relates to a method for determining contaminations in a cell culture sample comprising the steps of: a) contacting a sample of a cell culture suspected to comprise contaminations with a composition comprising oligonucleotides under conditions which allow for amplification of polynucleotides, wherein said oligonucleotides comprise oligonucleotides of at least three different groups of oligonucleotides, and b) determining the contaminations based on the amplified polynucleotides obtained by using the oligonucleotide groups of step (a). Moreover, the invention relates to a composition comprising an oligonucleotide mixture. Further encompassed by the present invention is a composition comprising a probe oligonucleotide mixture. Finally, the present invention also relates to kits comprising said oligonucleotide mixtures. | 04-21-2011 |
| 20110091886 | METHOD OF DISTINGUISHING INFLAMMATORY PATHOGEN CAUSING ACUTE RESPIRATORY INFECTION - Disclosed is a method of distinguishing an inflammatory pathogen causing acute respiratory infection wherein the pathogen to be distinguished is a pathogen residing in the respiratory tract, which comprises: (a) a step for counting gene copies originating in subject cells in DNA prepared from a specimen containing secretion from the respiratory tract of the subject; (b) a step for counting the gene copies originating in the pathogen in the DNA; (c) a step for calculating the relative value of count of the gene copies originating in the pathogen to the count of the gene copies originating in the subject cells; and (d) a step for distinguishing whether the pathogen is an inflammatory pathogen causing the disease or not based on the distinguishing standard and the relative value. | 04-21-2011 |
| 20110091887 | METHOD FOR DETECTION OF METHYLCYTOSINE USING PHOTORESPONSIVE PROBE - The present invention provides a method for detecting methylcytosine in DNA rapidly, conveniently, and with high sensitivity. The present invention relates to a method for detecting methylcytosine by using a methylcytosine photocoupling agent (a photoresponsive probe) consisting of nucleic acids having a group represented by the Formula (I), (II), (III) or (IV) as a base moiety. | 04-21-2011 |
| 20110091888 | USE OF CATHEPSIN C - Present invention concerns the use of Cathepsin C. Other aspects of the invention concern methods for screening pharmaceuticals, for diagnosing pain susceptibility and for the treatment of pain. | 04-21-2011 |
| 20110091889 | CENTROSOME-ASSAY - The present invention provides a centrosome assay for the identification of preferably, Eg | 04-21-2011 |
| 20110091890 | TRICHOPLUSIA NI CELL LINE AND METHODS OF USE - An isolated cell from the cell line identified as TnT4. This cell may be infected with a baculovirus expression vector which may carry a heterologous nucleotide that encodes a polypeptide, such as a membrane protein, e.g., human neurotensin receptor 1. Also included is a method for using this cell line to produce a polypeptide, such as a membrane protein; and a method for identifying a cell-of-interest which expresses a protein-of-interest. | 04-21-2011 |
| 20110091891 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 3 and mutated sequences thereof. | 04-21-2011 |
| 20110091892 | Methods for the Diagnosis and Treatment of Lung Cancer - The present invention provides methods for aiding in the diagnoses of the neoplastic condition of a lung cell and methods of screening for a potential therapeutic agent for the reversal of the neoplastic condition. | 04-21-2011 |
| 20110091893 | BIOSENSORS FOR DETECTING MACROMOLECULES AND OTHER ANALYTES - The invention generally provides molecular biosensors. In particular, the invention provides molecular biosensors having one or more aptamers. The molecular biosensors are useful in several methods including in the identification and quantification of target molecules. | 04-21-2011 |
| 20110091894 | OLIGONUCLEOTIDES FOR AMPLIFYING CHLAMYDOPHILA PNEUMONIAE NUCLEIC ACID - Oligonucleotides for use in determining the presence of | 04-21-2011 |
| 20110091895 | Immunoassays to Detect Diseases or Disease Susceptibility Traits - Disclosed are immunoassay methods for the diagnosis/prognosis of diseases and disease susceptibility traits associated with gene mutations that cause protein truncation or allelic loss. The levels of one or more targeted wild-type proteins expressed by a subject gene or genes are immunologically quantitated in biological samples. Results indicating that a targeted wild-type protein is not present in an assayed sample, or that approximately 50% of the normal amount of such a wild-type protein is present in an assayed sample are considered to be positive for a mutation in one or both alleles of a subject gene, and correlated with the disease or the disease susceptibility trait associated with that mutation or mutations. Normal cells, particularly normal peripheral blood lymphocytes, are preferred biological samples. | 04-21-2011 |
| 20110091896 | METHOD FOR ANALYSIS/IDENTIFICATION OF ANTIBODY GENE AT ONE-CELL LEVEL - Disclosed are: a method for identifying/analyzing a gene for an antibody in one cell derived from a human; a technique for producing an antibody derived from an identified one B cell; and others. A gene for an antibody specific to a melanoma antigen is analyzed/identified at a one-cell level by using an immortalized B cell produced from peripheral blood monocytes from a melanoma patient or a primary B cell included in the peripheral blood monocytes. It is found that B cells capable of producing a specific antibody can be separated on one cell by one cell basis by staining the B cells with a GST-labeled melanoma-specific cancer antigen MAGE1, an Alexa-labeled anti-GST antibody and a PE-labeled anti-human IgG antibody and carrying out the single cell sorting of the stained B cells. Further, a practical technique for extracting total RNA from the separated one B cell and cloning a gene for a specific antibody into the total RNA efficiently can be established. | 04-21-2011 |
| 20110091897 | COMPOSITIONS COMPRISING NANOMATERIALS AND METHOD FOR USING SUCH COMPOSITIONS FOR HISTOCHEMICAL PROCESSES - Histochemical process compositions comprising at least one nanoparticle in an amount effective to reduce or substantially eliminate the average number of spots per slide that result from a sample staining protocol are disclosed. Various nanoparticles, or combinations thereof, including metals, metal alloys, metal oxides, ceramics, functionalized metals or metalloids, and other miscellaneous nanoparticles, such as carbon nanoparticles and diamond nanoparticles, can be used. The nanoparticle concentration typically is from about 2 parts per million to about 20 parts per million. One embodiment of a disclosed method concerns applying a histochemical process composition to a sample, followed by performing a staining protocol on the sample. Particular embodiments concern dispensing a nanosolution onto a sample using an automated system, heating the sample, and performing a sample staining process. | 04-21-2011 |
| 20110091898 | DETECTION PROBE - A nucleotide probe permitting the detection of nucleic acids and constituted of a labeled nucleotide strand having three fragments: a first fragment having a first closing sequence, a second fragment, all or part of which has a recognition sequence for the molecular recognition of the target nucleic acid and a third fragment having a second closing sequence, and at least two markers, one of the ends of the strand of the detection probe being free of any marker, in which, when the two closing sequences are hybridized together, the detection probe has a completely circular shape, the closing sequences thus maintaining the probe in a conformation that cannot be detected in the absence of the target nucleic acid. | 04-21-2011 |
| 20110091899 | COMBINATION OF RISK ALLELES ASSOCIATED WITH AUTISM - The present invention relates to a method of detecting the presence of or predisposition to autism, or to an autism spectrum disorder, the method comprising detecting the presence of an alteration in the gene loci PITX1, ATP2B2, SLC25A12 and EN2 in a sample from said subject. More particularly, the presence of specific single nucleotide polymorphisms (SNPs) within these genes correlates to a substantially increased risk to develop autism. | 04-21-2011 |
| 20110091900 | METHOD FOR DETERMINING DNA COPY NUMBER BY COMPETITIVE PCR - The present invention relates to a method for determining the number of copies of DNA at a specific locus. The method comprises the step of co-amplifying a DNA sample of an exploratory species comprising the test locus with a competitor sample comprising an orthologous DNA sequence derived from a closely related species. | 04-21-2011 |
| 20110097709 | Method for modifying a nucleic acid - Disclosed are methods for increasing the rate at which a nucleic acid can be translated by modifying the polynucleotide such that the rate at which the polynucleotide is translated is altered. Also disclosed are methods for modulating the translation of an mRNA by adding a nucleic acid that increases translation of the mRNA | 04-28-2011 |
| 20110097710 | Methods for detecting atrial fibrillation and related conditions - Methods for detecting disorders associated with atrial fibrillation, and, thus, at risk for stroke and/or heart failure) in a subject based on a monitoring plasma levels of apelin are provided. Diagnostic compositions for the detection of such disorders are additionally provided. | 04-28-2011 |
| 20110097711 | METHOD OF JUDGING INFLAMMATORY DISEASE BY USING SINGLE NUCLEOTDIE POLYMORPHISM - An object of the present invention is to identify a novel single nucleotide polymorphism (SNP) associated with the onset and the advancement of inflammatory diseases such as myocardial infarction. The present invention provides a method for judging an inflammatory disease which comprises detecting at least 1 type of genetic polymorphism existing in at least one gene selected from the group consisting of the LBP-32 gene, the TSBP gene, and the WAP gene. | 04-28-2011 |
| 20110097712 | METHOD FOR DETECTING AND QUANTIFYING RARE MUTATIONS/POLYMORPHISMS - The present invention is directed to a method for detecting and quantifying rare mutations in a nucleic acid sample. The nucleic acid molecules under investigation can be either DNA or RNA. The rare mutation can be any type of functional or non-functional nucleic acid change or mutation, such as deletion, insertion, translocation, inversion, one or more base substitution or polymorphism. Therefore, the methods of the present invention are useful in detection of rare mutations in, for example, diagnostic, prognostic and follow-up applications, when the targets are rare known nucleic acid variants mixed in with the wildtype or the more common nucleic acid variant(s). | 04-28-2011 |
| 20110097713 | Compositions and methods for pharmacogenomic screening of CYP2C9 and VKORC1 - Compositions and methods for determining an optimal dose of a medication for a subject are described that include determining the subject's genotype for the CYP2C9 and VKORC1 genes and determining the dose of the medication based on the genotype. Articles of manufacture also are provided that include polynucleotides for genotyping. | 04-28-2011 |
| 20110097714 | AMPLIFICATION METHOD OF METHYLATED OR UNMETHYLATED NUCLEIC ACID - The object of the present invention is to provide a gene amplification method, wherein the method can amplify both methylated and unmethylated nucleic acids present in a biological sample, and further regulate the amplification ratio of the methylated and/or unmethylated nucleic acid as needed. Such objects can be solved by an amplification method using a nonspecific primer which can hybridize both with methylated and unmethylated nucleic acids and a specific primer which specifically hybridizes with either methylated or unmethylated nucleic acid, and further by an amplification method which can change the amplification ratio of methylated or unmethylated nucleic acid by changing the mixing rate of these primers. | 04-28-2011 |
| 20110097715 | METHOD FOR PURIFYING OR DETECTING A TARGET PROTEIN - A method for purifying or detecting a target protein present in a solution, includes, before carrying out the actual detection or purification step, a step of contacting the solution with an aptamer binding specifically to the target protein, where the aptamer does not bind to a protein homologous to the target protein that could also be present in the solution. | 04-28-2011 |
| 20110097716 | Methods for Detecting Oligonucleotides - The invention provides methods and compositions for detecting and/or quantifying nucleic acid oligonucleotides. These methods and compositions are useful for detecting and quantifying diagnostic and/or therapeutic synthetic target oligonucleotides, such as aptamers, RNAi, siRNA, antisense oligonucleotides or ribozymes in a biological sample. | 04-28-2011 |
| 20110097717 | Gene Expression Profiling For Identification of Cancer - A method is provided for determining whether an individual has a particular cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables A-C. | 04-28-2011 |
| 20110097718 | MS-COMPATIBLE NONIONIC OR ZWITTERIONIC SURFACTANTS IN FREE-FLOW ELECTROPHORESIS - The invention relates to the use of MS compatible surfactants in free-flow electrophoretic methods, which allow the separation of analytes with differentiated electrophoretic mobility. The surfactant is preferably a cleavable surfactant, such as PPS. | 04-28-2011 |
| 20110097719 | Neprilysin Gene Polymorphism and Amyloid Beta Plaques in Traumatic Brain Injury - The invention relates to methods of diagnosing risk of amyloid β deposition following traumatic brain injury. More particularly, the invention relates to the discovery of a specific single nucleotide polymorphism in the neprilysin gene that is linked to an increased risk of amyloid β deposition after traumatic brain injury | 04-28-2011 |
| 20110097720 | SCREENING METHOD FOR SELECTED AMINO LIPID-CONTAINING COMPOSITIONS - The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-Dilinoley 1-4-dimethylaminomethyl-[1,3]-dioxolane by screening for an effect of the agent on the liver of a model subject. | 04-28-2011 |
| 20110097721 | IN VIVO GENE SENSORS - Described are methods and compositions for the detection of target genes. The inventors have developed a synthetic nucleic acid sensor-effector gene circuit. In cells without a target gene, the circuit suppresses e.g., effector production, but in the presence of the target gene the suppression is subject to competition, such that the synthetic sensor is de-repressed and permits expression of the effector gene. The methods and compositions described further permit the selective expression of an effector gene in those cells expressing the target gene. In this manner, cells expressing a target gene can be selectively targeted for treatment or elimination. In certain aspects, the methods and compositions described permit the selective expression of an agent such as a therapeutic gene product, in a specifically targeted population of cells in an organism. | 04-28-2011 |
| 20110097722 | Cold Shock Protein Compositions and Methods and Kits for the Use Thereof - The present invention provides cold shock protein-containing compositions for improved DNA synthesis reactions with improved reactivity, methods for synthesizing DNA using such compositions, kits for use in such methods, and DNA compositions yielded by such methods. The present invention further provides cold shock protein-containing compositions for the identification of endoribonuclease cleavage sites, methods for identifying endoribonuclease cleavage sites using such compositions, and kits for use in such methods. | 04-28-2011 |
| 20110097723 | Methods and reagents for analyte detection - The present invention relates to chemiluminescent method and regent to detect analyte. One aspect of the current invention relates to using chemiluminescent and fluorescent molecule/enzyme coupled with analyte binding molecules to detect specific analyte molecules. Another aspect of the current invention is to use gold nanoparticle triggered chemiluminescent reaction to detect analyte. | 04-28-2011 |
| 20110097724 | Detection of Head and Neck Cancer Using Hypermethylated Gene Detection - Methods and kits for detection of a cell proliferative disorder, such as head and neck cancer are provided utilizing analysis of the methylation state of targeted genes or regulatory regions of genes in a saliva or serum sample are described. The presence of hypermethylation of the genes or their regulatory regions is indicative of the presence, or a stronger possibility of recurrence and or a poorer prognosis in subjects with cancer. | 04-28-2011 |
| 20110097725 | RAPID DETECTION OF MYCOBACTERIA - The invention provides a method for detecting a | 04-28-2011 |
| 20110097726 | REGENERATION AND NEOGENESIS OF RETINAL PHOTORECEPTOR CELL USING OTX2 GENE - The present invention provides a medicine, comprising (a) an Otx2 protein or its partial peptide, or a salt thereof, or (b) a DNA or an RNA encoding an Otx2 protein or its partial peptide. The present medicine is useful as an agent for preventing, treating or suppressing progression of a retinal disease including retinal degeneration. In addition, the present medicine is useful, for example, as an agent for inducing differentiation from a retinal stem cell into a retinal photoreceptor cell, in the transplantation of a cell into the retina of patients suffering from retinal diseases. | 04-28-2011 |
| 20110097727 | DNA MARKERS FOR MANAGEMENT OF CANCER - A method is provided for assessing allelic losses and hypermethylation of genes in CpG tumor promotor region on specific chromosomal regions in cancer patients, including melanoma, neuroblastoma breast, colorectal, and prostate cancer patients. The method relies on the evidence that free DNA and hypermethylation of genes in CpG tumor promotor region may be identified in the bone marrow, serum, plasma, and tumor tissue samples of cancer patients. Methods of melanoma, neuroblastoma, colorectal cancer, breast cancer and prostate cancer detection, staging, and prognosis are also provided. | 04-28-2011 |
| 20110097728 | MATERIALS AND METHOD FOR ASSAYING FOR METHYLATION OF CpG ISLANDS ASSOCIATED WITH GENES IN THE EVALUATION OF CANCER - Provided are methods, reagents, and kits for evaluating cancer, such as prostate cancer, in a subject. Disclosed methods of evaluating cancer include methods of diagnosing cancer, methods of prognosticating cancer and methods of assessing the efficacy of cancer treatment. The methods include assaying a biological sample for methylation of a CpG island associated with specified genes. Provided reagents and kits include primers suitable for amplifying at least a portion of a target CpG islands associated with specified genes. | 04-28-2011 |
| 20110097729 | APPARATUS AND METHOD FOR SEQUENCING NUCLEIC ACID MOLECULES - The sequence of a target polynucleotide can be determined by:
| 04-28-2011 |
| 20110097730 | Recombinant Sars-Cov nsp12 and the Use of Thereof and the Method for Producing it - The present invention relates to a recombinant severe acute respiratory syndrome coronavirus (SARS-CoV) non-structural protein (nsp) 12 with an RNA polymerase activity, its expression vector, its preparation method, and its use. According to the present invention, a soluble recombinant SARS-CoV nsp12 with an RdRp activity of initiating SARS-CoV genome synthesis can be over-expressed in the transformed host cells, and conveniently purified with high purity. An in vitro replication system important for studying SARS-CoV replication can be established with the purified recombinant SARS-CoV nsp12. SARS-CoV nsp12 produced by the present invention can also be used as a target for the development of anti-viral agents against SARS-CoV. In addition, materials inhibiting RNA-dependent RNA polymerase (RdRp) activity of nsp12 can be screened efficiently according to the present invention as the optimal conditions for the RdRp assay with SARS-CoV nsp12 were found. | 04-28-2011 |
| 20110097731 | NOVEL MITOCHONDRIAL DYE - The present invention relates to the use of single-barrel genetically encoded GFP-based calcium indicator as an intramitochondrial dye and to nucleic acid molecules coding for said indicators, as well as to methods using said indicators. Examples of single-barrel genetically encoded GFP-based calcium indicator is a GCaMP, Case16 and/or Case12. In a particular embodiment, the single-barrel genetically encoded GFP-based calcium indicator is GCaMP2 or Case16. | 04-28-2011 |
| 20110104663 | Method for the Quantification of Methylated DNA - The method according to the invention concerns in particular a method for the quantification of methylated DNA. For this purpose, the DNA to be examined is first transformed such that unmethylated cytosine is converted to uracil while 5-methylcytosine remains unchanged. Subsequently, the transformed DNA is amplified in the presence of a pair of real-time probes. For this, a probe is constructed, which is specific for the methylated or for the unmethylated state of the DNA, and a probe, which binds methylation-unspecifically to the amplificate. The ratio of the signal intensities of the probes or the CT values allows for the calculation of the degree of methylation of the examined DNA. The method according to the invention is suited particularly for the diagnosis and prognosis of cancer and other diseases associated with a change in the methylation status, as well as, prediction of adverse for side-effects of pharmaceuticals. | 05-05-2011 |
| 20110104664 | BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO MICORTUBULE-STABILIZING AGENTS - Biomarkers that are useful for identifying a mammal that will respond therapeutically or is responding therapeutically to a method of treating cancer that comprises administering a microtubule-stabilizing agent. In one aspect, the cancer is breast cancer, and the microtubule-stabilizing agent is an epothilone or analog or derivative thereof, or ixabepilone. | 05-05-2011 |
| 20110104665 | MUTANT SODIUM CHANNEL NAV 1.7 AND METHODS RELATED THERETO - Described are mutant Na | 05-05-2011 |
| 20110104666 | INSULIN RESISTANCE MARKER - It is provided an insulin resistance marker, a method of evaluating insulin resistance, a method of screening a substance that improves insulin resistance, and a pharmaceutical composition for improving insulin resistance. An insulin resistance marker including a polypeptide comprising at least any 15 continuous amino acids in the specific amino acid sequence (sequence of a proepithelin protein). An insulin resistance marker including a polynucleotide selected from the group consisting of a polynucleotide comprising at least any 45 continuous bases in the base sequence encoding the above specific amino acid sequence, and a polynucleotide that is complementary to the polynucleotide. | 05-05-2011 |
| 20110104667 | METHODS FOR IDENTIFYING NUCLEIC ACID LIGANDS - The present invention generally relates to methods for identifying nucleic acid ligands of a target molecule. In certain embodiments, the invention provides methods for identifying a nucleic acid ligand of a target molecule from a candidate mixture of nucleic acids, including contacting at least one target molecule with a candidate mixture of nucleic acids, in which the nucleic acids have different affinities for the target molecule, and separating in a single step nucleic acids that bind the target molecule with greatest affinity from nucleic acids that bind the target molecule with a lesser affinity and nucleic acids that do not bind the target molecule, thereby identifying the nucleic acid ligand of the target molecule. | 05-05-2011 |
| 20110104668 | NUCLEIC ACID LIGANDS AGAINST INFECTIOUS PRIONS - The invention generally relates to nucleic acid ligands that specifically bind to infectious prions, and methods of diagnosing a transmissible spongiform encephalopathy disease in a subject. In certain embodiments, the invention provides an isolated nucleic acid ligand that binds to an infectious prion. In other embodiments, the invention provides a method for diagnosing a transmissible spongiform encephalopathy disease in a subject including obtaining a tissue or body fluid sample from a subject, contacting the tissue or body fluid with a nucleic acid ligand that binds to an infectious prion, thereby detecting the infectious prion in the sample, and diagnosing the transmissible spongiform encephalopathy disease based on results of the contacting step. | 05-05-2011 |
| 20110104669 | METHOD TO PREDICT IRIS COLOR - The invention comprises a method to predict iris color of a human from a nucleic acid/protein sample comprising assaying for one or more polymorphisms in the region 5′ proximal of the OCA2 gene up to and including the HERC2 gene on chromosome 15 between basepairs 26018062 and 26240890 according to NCBI build 36 or Ensemble | 05-05-2011 |
| 20110104670 | METHOD, DEVICE AND MOLECULAR BIOLOGY KIT FOR EXTRACTING AMPLIFIED GENETIC MATERIAL - A method for collecting cellular material from particular cells present in a liquid, that includes: a step ( | 05-05-2011 |
| 20110104671 | METHODS AND COMPOSITIONS FOR ASSESSING RESPONSIVENESS OF B-CELL LYMPHOMA TO TREATMENT WITH ANTI-CD40 ANTIBODIES - The invention provides methods and kits useful for predicting or assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies. | 05-05-2011 |
| 20110104672 | Method For Detection And/Or Analysis Of Yeast And Mold In Filterable Liquids - This invention is an improved process for preparing a food or beverage sample containing yeast or mold cells for analytical testing. The food sample is prepared into the form of a filterable liquid, and then filtered using a glass microfiber filter. The filter containing the fungal cell retentate is then placed into a disruption vessel and bead beaten until the glass microfiber filter is completely disrupted into glass fibers in suspension. An aliquot can then be tested directly using melting curve analysis of PCR amplification product derived from the nucleic acids of the sample to detect the presence of the fungal cells from the sample. | 05-05-2011 |
| 20110104673 | NUCLEIC ACID SEQUENCES AND METHODS FOR IDENTIFYING COMPOUNDS THAT AFFECT RNA/RNA BINDING PROTEIN INTERACTIONS AND mRNA FUNCTIONALITY - Disclosed herein are nucleic acid sequences and their optimized subfragments which are located in the mRNA untranslated regions of therapeutically-relevant genes. These sequences specifically bind RNA binding proteins (RBPs) and/or regulate the mRNA functionality. Also disclosed are methods of optimizing a subfragment of a parent nucleic acid sequence such that the RBP binding activity or mRNA functionality of the parent nucleic acid sequence is preserved in the optimized subfragment. | 05-05-2011 |
| 20110104674 | SNP DETECTION AND OTHER METHODS FOR CHARACTERIZING AND TREATING BIPOLAR DISORDER AND OTHER AILMENTS - The present application relates to the use of SNPs and differential exon expression to characterize, diagnose or treat bipolar disorder and other mental illnesses, such as major depressive disorder and schizophrenia. | 05-05-2011 |
| 20110104675 | Methods and Compositions for Diagnosing Carcinomas - The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble forms of mesothelin polypeptides, including mesothelin related antigen (MRA). In particular the invention provides a nucleic acid sequence encoding MRA and an MRA variant. The invention also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a mesothelin polypeptide with a molecule naturally occurring in soluble form in a sample from such a subject, and by hybridization screening using an MRA nucleotide sequence, as well as other related advantages. | 05-05-2011 |
| 20110104676 | HYBRIDIZATION CHAIN REACTION AMPLIFICATION FOR IN SITU IMAGING - The present invention relates to the use of fluorescently labeled nucleic acid probes to identify and image analytes in a biological sample. In the preferred embodiments, a probe is provided that comprises a target region able to specifically bind an analyte of interest and an initiator region that is able to initiate polymerization of nucleic acid monomers. After contacting a sample with the probe, labeled monomers are provided that form a tethered polymer. Triggered probes and self-quenching monomers can be used to provide active background suppression. | 05-05-2011 |
| 20110104677 | SELECTIVE RESTRICTION FRAGMENT AMPLIFICATION: FINGERPRINTING - The invention relates to a process for the controlled amplification of at least one part of a starting DNA containing a plurality of restriction sites for a determined specific restriction endonuclease, and of which at least part of its nucleic acid is unknown. This technology can be applied to human, animal or plant DNA fingerprinting, to identify restriction fragment length polymorphisms. Also encompassed by the inventive technology are kits for the application of the process. | 05-05-2011 |
| 20110104678 | POLYMERASE INHIBITOR AND METHOD OF USING SAME - The present invention provides nucleic acid based polymerase inhibitors and methods for reducing non-specific polymerase extension and amplification in nucleic acid amplification reactions. The polymerase inhibitors provide a double stranded nucleic acid portion that is recognized by a polymerase enzyme as a template for extension but is incapable of being extended by the polymerase enzyme. The polymerase binds to the polymerase inhibitor which sequesters the enzyme until the temperature achieves a level that denatures the double stranded portion of the inhibitor after which the polymerase is released and can then catalyze nucleic acid extension. | 05-05-2011 |
| 20110104679 | Methods and Compositions for the Diagnosis and Treatment of Angiogenic Disorders - The invention provides methods and compositions for determining whether an individual is at risk of developing, or has, one or more angiogenic disorders. The methods detect the presence and/or amount of one or more genes or gene products in a sample, including a RORA, CRIM1, CXCR4, C5orf26, IGHG3, NALP2, PLA2G4A, IGLJ3, SHQ1, UCHL1, TANC1, PKP2, DNAJC6, C6orf105, NALP1, RGS13, CXCL13, RPS6KA2, MMP7, IL1A, ABCA1, VCAN, KIAA0888, ENPP2, and FAM38B gene or gene product. In addition, the invention provides methods for using one or more of these genes or gene products as a target for preventing or delaying the onset of one or more angiogenic disorders or treating a patient with one or more such disorders. The angiogenic disorder can be, for example, an ocular angiogenic disorder, for example, a disorder associated with choroidal neovascularization, for example, age-related macular degeneration. | 05-05-2011 |
| 20110104680 | RECURRENT GENE FUSIONS IN LUNG CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions as diagnostic markers and clinical targets for lung cancer. | 05-05-2011 |
| 20110104681 | NOVEL TRANSGENE ASSAY USING STABLE AGROBACTERIUM RHIZOGENES TRANSFORMATION - A novel method is described for the screening of gene elements of interest using hairy roots of chimeric plants transformed with | 05-05-2011 |
| 20110104682 | RNA DETECTION ASSAYS - The present invention provides novel cleavage agents and polymerases for the cleavage and modification of nucleic acid. The cleavage agents and polymerases find use, for example, for the detection and characterization of nucleic acid sequences and variations in nucleic acid sequences. In some embodiments, the 5′ nuclease activity of a variety of enzymes is used to cleave a target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof. | 05-05-2011 |
| 20110104683 | PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) HAPLOTYPES USEFUL AS INDICATORS OF PATIENT OUTCOME - The invention provides methods and kits for obtaining a prognosis for a patient having or at risk of developing an inflammatory condition. The method generally comprises determining a Plasminogen Activator Inhibitor-1 (PAI-1) genotype of a patient for one or more polymorphisms in the PAI-1 gene of the patient, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the patient to recover from the inflammatory condition and identifying patients based on their prognosis. PAI-1 genotype screening may be useful in identifying patients who would benefit from increased monitoring by healthcare professionals, and/or possible therapeutic intervention, if the patient were to develop inflammation due to systemic inflammation response syndrome (SIRS), bacterial infection, bacteraemia, sepsis, septic shock, organ dysfunction, and trauma. The invention also provides for methods of identifying other polymorphisms that correspond with the ability of the patient to recover from the inflammatory condition. | 05-05-2011 |
| 20110104684 | Methods and Compositions for Identifying Sulfur and Iron Modifying Bacteria - The invention relates to methods and compositions for identifying specific bacterial species, which are sulfur and iron oxidizers and/or reducers, from wall board (e.g., dry wall) and/or a patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the bacterial species from the wall board and/or the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the bacterial species, and specifically identifying the bacterial species. Kits and nucleic acids for use in the methods are also provided. Methods for eliminating the sulfur and iron oxidizing and/or reducing bacteria from wall board using a zeolite are also provided. | 05-05-2011 |
| 20110104685 | METHOD FOR TESTING MICROORGANISM OR THE LIKE AND TESTING APPARATUS THEREFOR - A means for accurately counting desired cells or microorganisms (viable bacteria) in a sample fluid in which contaminants are included is provided. One or plural types of membrane-permeable fluorochromes whose fluorescence amount is amplified by binding to a nucleic acid and glycerin are added to a sample fluid containing cells or microorganisms to be counted and allowed to stand for a certain time. Glycerin is added before or after or simultaneously with the mixing of the sample fluid and the fluorochrome(s). The cells or microorganisms to be counted are counted by staining the cells or microorganisms to be counted, followed by irradiating with light having a specific wavelength to detect the fluorescence emitted from the cells or microorganisms. | 05-05-2011 |
| 20110104686 | RAPID DETECTION OF MYCOPLASMA CONTAMINATION IN CELL CULTURE SAMPLES - The present invention provides for methods of detecting | 05-05-2011 |
| 20110104687 | Methods and Kits for Detecting Congenital Stationary Night Blindness and Selecting Different Coat Patterns - The present application describes biomarkers and methods useful for screening for, diagnosing or detecting congenital stationary night blindness in a subject. The present application also provides methods for selecting or detecting horse coat patterns. | 05-05-2011 |
| 20110104688 | MICROFLUIDIC FLOW CELL - A microfluidic flow cell having a body with a fluid transport channel disposed therein, the fluid transport channel having a proximal end and a distal end defining a fluid flow path, a fluid inlet port disposed at the proximal end of the fluid transport channel at a central portion of the body and an outlet port disposed at the distal end of the fluid transport channel at an outer portion of the body, and a plurality sample wells disposed in the fluid transport channel substantially perpendicular to the fluid flow path in the fluid transport channel. The microfluidic flow cell may have hundreds or thousands of individual, sub-microliter sample wells. The microfluidic flow cell can be filled by applying a flowable liquid to the inlet port and spinning the flow cell to cause fluid to flow into fluid transport channel. The microfluidic flow cells described herein can be used in a variety of applications where small sample size and/or a large number of replicates are desirable. | 05-05-2011 |
| 20110104689 | Single nucleotide polymorphisms and the identification of lactose intolerance - The present invention relates generally to methods, kits, genotyping and/or nucleic acid molecules associated with the identification of a predisposition for lactase persistence, lactase non-persistence, lactose tolerance and/or lactose intolerance. The methods of the present invention comprise in general determining the presence or absence of at least one variant allele having one or more single nucleotide polymorphisms within a gene associated with the expression of lactase-phlorizin hydrolase. The single nucleotide polymorphism is selected from the group consisting essentially of C-14010, G-13915 and G-13907, as measured from the start of the LCT gene. | 05-05-2011 |
| 20110104690 | ENGINEERED NITRILE HYDRATASE-PRODUCING BACTERIUM WITH AMIDASE GENE KOUCKED-OUT, THE CONSTRUCTION AND THE USE THEREOF - An engineered nitrile hydratase-producing bacterium and its construction method as well as its applications, wherein the engineered nitrile hydratase-producing bacterium is a mutant strain of an original nitrile hydratase-producing bacterium strain obtained by knocking-out or inhibiting the amidase gene in the original strain. The construction method of the engineered bacterium is to block the expression of the amidase gene by inserting the large fragment of a recombinant suicide plasmid carrying an amidase gene fragment into a wild-type strain through the homologous recombination between the recombinant suicide plasmid and the amidase gene of the wild-type strain. Compared to the corresponding wild-type bacterium strain, both the cell growth and the nitrile hydratase expression of the engineered nitrile hydratase-producing bacterium according to the invention are increased. In the process of catalyzing the hydration of acrylonitrile to produce acrylamide, the yield of the product, acrylamide, is significantly increased, while the yield of the by-product acrylic acid is significantly decreased. The engineered nitrile hydratase-producing bacterium of the present invention has wide application prospect in the production of acrylamide by microbiological process. | 05-05-2011 |
| 20110104691 | ANDROGENETIC ALOPECIA - The present invention relates to methods for testing for a predisposition or presence of androgenetic alopecia comprising testing a sample obtained from a prospective patient or from a person suspected of carrying a predisposition for androgenetic alopecia. The invention also relates to a genetic marker for androgenetic alopecia characterised in that the genetic marker is located in a chromosomal region of human chromosome 20p11 and wherein the genetic marker is selected from the group consisting of a single nucleotide polymorphism (SNP), variable number of tandem repeat (VNTR), microsatellites or short tandem repeats (STR). Further, the invention relates to a diagnostic composition for the detection of androgenetic alopecia or a predisposition therefore as well as to a kit. | 05-05-2011 |
| 20110104692 | Oligonucleotide Primers - Disclosed herein is a method of amplifying a target nucleotide sequence in 16S rRNA or in 16S rDNA that includes (a) contacting a sample comprising a 16S rDNA and/or the reverse transcription product of a 16S rRNA with an oligonucleotide primer comprising the nucleotide sequence of TCC TAC GGG AGG CAG CAG (SEQ ID NO 1) or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO 1 and an oligonucleotide primer comprising the nucleotide sequence of CGG TTA CCT TGT TAC GAC TT (SEQ ID NO 2) or a nucleotide sequence capable of hybridising under high stringency conditions to the nucleotide sequence complementary to SEQ ID NO 2; and (b) performing a primer-dependent nucleic acid amplification reaction to amplify the target nucleotide sequence in the 16S rRNA or the 16S rDNA. | 05-05-2011 |
| 20110104693 | QUANTITATIVE NUCLEASE PROTECTION SEQUENCING (qNPS) - The present invention provides a new approach, quantitative Nuclease Protection Sequencing (qNPS™), for addressing several challenges that face sequencing and which provides improvements for research and diagnostic applications. The method uses a lysis-only nuclease protection assay to generate nucleic acid, e.g., DNA probes for sequencing, which can be coupled to gene-specific tags to permit the identification of the gene without necessitating the sequencing of the nuclease protection probe itself and/or can be coupled to experiment-specific tags whereby samples from different patients can be combined into a single run. The disclosed qNPS makes sequencing fixed or insoluble samples possible and affordable as a research and discovery tool and as a diagnostic test. | 05-05-2011 |
| 20110104694 | COMPOSITIONS AND METHODS FOR DETECTING CANCER - The present invention provides methods and compositions involving detecting the presence of and/or assessing the risk of cancer in a subject. These methods include methods of detecting and diagnosing cancer in an individual; methods of identifying individuals at risk of developing a cancer; and methods of staging a cancer. The methods generally involve detecting a palladin gene nucleotide sequence alteration that has been found to be associated with cancer and/or detecting a level of a palladin mRNA and/or protein in a biological sample. The present invention further provides nucleic acid probes, nucleic acid primers, and antibodies, as well as kits comprising one or more of the same, for use in a subject method. | 05-05-2011 |
| 20110104695 | METHODS OF PREDICTING THERAPEUTIC EFFICACY OF CANCER THERAPY - The present invention relates to novel methods and kits for predicting, prognosing, and/or monitoring therapeutic efficacy of cancer therapy on a subject having malignant tumor or cell proliferative disorder. | 05-05-2011 |
| 20110104696 | KIT FOR DETECTION OF BACTERIAL SPECIES BY MEANS OF DNA ANALYSIS - The present invention relates to the detection and identification of different bacterial species, all of which cause zoonosis, based on DNA analysis. More specifically, the invention provides the primers, probes, genes and genic regions required to apply a method for the simultaneous detection of bacteria and bacterial groups belonging to the genera | 05-05-2011 |
| 20110104697 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION - Methods of diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection and kits or systems containing the same are also described. | 05-05-2011 |
| 20110104698 | MARKERS FOR DETERMINING DNA DAMAGE AND TELOMERE DYSFUNCTION FOR THE DETERMINATION OF THE BIOLOGICAL AGE, REGENERATIVE CAPACITY, CANCER RISK, THE RISK OF DEVELOPING AGE-RELATED DISEASES AND THE PROGNOSIS OF CHRONIC DISEASES IN HUMANS AND ANIMALS - Process for determining the presence and extent of DNA damage and telomere dysfunction in humans or animals, comprising the following steps: | 05-05-2011 |
| 20110104699 | Method for Detection of Paecilomyces Variotii - A method of detecting | 05-05-2011 |
| 20110104700 | MOLECULAR SIGNATURE FOR FIBROSIS AND ATROPHY - Materials and Methods involved in assessing tissue fibrosis and atrophy in mammals. For example, materials and methods involved in detecting organ (e.g., kidney) fibrosis/atrophy due to organ rejection are provided, as are materials and methods for determining the extent of fibrosis/atrophy in mammals such as humans, for example. | 05-05-2011 |
| 20110104701 | PROTEIN DISULFIDE ISOMERASE ASSAY METHOD FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER - A method for the in vitro diagnosis of colorectal cancer by determining the presence of the protein disulfide isomerase tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-PDI monoclonal antibody directed against a PDI epitope chosen from the epitopes of sequence SEQ ID NO: 1, SEQ ID NO: 2 with an aromatic amino acid having a three-dimensional structure similar to that of PDI, and SEQ ID NO: 3. | 05-05-2011 |
| 20110104702 | Methods for Predicting Tumor Response to Chemotherapy and Selection of Tumor Treatment - Methods of selecting a treatment for further treatment of a tumor that has been exposed to chemotherapy and methods of predicting response of a tumor to chemotherapy are disclosed. Some of the methods involve performing gene expression analysis on a sample obtained from a patient having a tumor that has been exposed to chemotherapy so as to obtain a chemotherapy gene expression data set and analysing the chemotherapy gene expression data set to predict response of the tumor to the chemotherapy to which the tumor has been exposed. | 05-05-2011 |
| 20110104703 | NUCLEIC ACID ANALYZER, AUTOMATIC ANALYZER, AND ANALYSIS METHOD - This invention relates to a nucleic acid analyzer comprising: reaction containers capable of containing nucleic-acid-containing samples and reagents; an incubation mechanism capable of controlling temperatures of reaction containers set at different levels; an analysis mechanism for analyzing the samples contained in the reaction containers; and a transport mechanism for transporting a reaction container. In accordance with the assay technique to be performed on a nucleic-acid-containing sample, the transport mechanism transports a reaction container to a given incubation mechanism in a given order. The reaction container subjected to the process of sample preparation is transported to the analysis mechanism at a given time and the sample is analyzed. | 05-05-2011 |
| 20110104704 | ASSOCIATION OF EDG5 POLYMORPHISM V286A WITH TYPE II DIABETES MELLITUS AND VENOUS THROMBOSIS/PULMONARY EMBOLISM AND THE USE THEREOF - The present invention relates to a method of identifying an increase in risk for type II Diabetes mellitus, venous thrombosis, or pulmonary embolism in a subject, wherein the presence of an amino acid exchange at position 286 from valine (Val) to alanine (Ala) in the EDG5 protein in a biological sample taken from the subject. | 05-05-2011 |
| 20110111393 | PNA Probes, Mixtures, Methods And Kits Pertaining To The Determination Of Mycoplasma and related Mollicutes - This invention is related to PNA probes, probe sets, mixtures, methods and kits pertaining to the determination of | 05-12-2011 |
| 20110111394 | CTGF AS A BIOMARKER, THERAPEUTIC AND DIAGNOSTIC TARGET - The invention provides CTGF which is associated with the cardiovascular diseases and hematological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases and hematological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of CTGF as well as pharmaceutical compositions comprising such compounds. The invention also provides CTGF as a biomarker for diseases as cardiovascular diseases and hematological diseases | 05-12-2011 |
| 20110111395 | CD4+CELLS WITH CYTOLYTIC PROPERTIES - The present invention relates to CD4+ T cells, more specifically cytolytic or cytotoxic CD4+ T-cells and methods of obtaining and identifying them. | 05-12-2011 |
| 20110111396 | BIOMARKERS FOR MONITORING THE TREATMENT BY QUINAZOLINONE COMPOUNDS - Provided herein are the biomarkers for monitoring the treatment by quinazolinone compounds. For example, the use of SPARC, p21, and cyclin D1 mRNA levels as biomarkers to predict whether a quinazolinone compound is likely to be successful in treating certain types of cancer, such as NHL is provided. Further, the expression of these genes can be used to monitor progress of treatment effectiveness and patient compliance in cancer patients that are receiving treatment with quinazolinone compounds. | 05-12-2011 |
| 20110111397 | CONNEXIN ALLELE DETECTION ASSAYS - The present invention provides compositions and methods for the detection and characterization of mutations associated with non-syndromic hearing impairment. More particularly, the present invention provides compositions, methods and kits for using invasive cleavage structure assays (e.g. the INVADER assay) to screen nucleic acid samples, e.g., from patients, for the presence of any one of a collection of mutations in the Connexin 26, or gap junction beta 2, gene associated with non-syndromic hearing loss. | 05-12-2011 |
| 20110111398 | NUCLEIC ACID PROBE-BASED DIAGNOSTIC ASSAYS TARGETING SSRA GENES OF PROKARYOTIC AND EUKARYOTIC ORGANISMS - Use of the ssrA gene or tmRNA, an RNA transcript of the ssrA gene, or fragments thereof as target regions in a nucleic acid probe assay for the detection and identification of prokaryotic and/or eukaryotic organisms is described. Nucleotide sequence alignment of tmRNA sequences from various organisms can be used to identify regions of homology and non-homology within the sequences which in turn can be used to design both genus specific and species specific oligonucleotide probes. These newly identified regions of homology and non-homology provide the basis of identifying and detecting organisms at the molecular level. Oligonucleotide probes identified in this way can be used to detect tmRNA in samples thereby giving an indication of the viability of non-viral organisms present in various sample types. | 05-12-2011 |
| 20110111399 | Methods And Compositions Including Diagnostic Kits For The Detection of Staphylococcus Aureus - Methods and compositions, including diagnostic kits, for the detection of | 05-12-2011 |
| 20110111400 | METHOD FOR ENHANCING CHEMICAL SENSITIVITY OR RADIOSENSITIVITY OF CANCER CELLS BY INHIBITING EXPRESSION OF TSPYL5 - Disclosed herein is a method for enhancing sensitivity of cancer cells to compounds or radiation by inhibiting the expression of testis-specific protein, Y-encoded like 5 (TSPYL5). More specifically, because methylation of TSPYL5 protein expressed in lung cancer cell line was inhibited to increase the expression level of the gene, resistance to stress such as radiation or anticancer agents was increased. Because the sensitivity of cancer cells to stress such as radiation or anticancer agents was increased by inhibiting the expression of the TSPYL5 gene to promote the apoptosis of the cells, an anticancer supplement agent containing an inhibitor of the expression or activity of the TSPYL5 gene of the present invention inhibits the growth of cancer cells and enhances the sensitivity to various stresses to maximize the apoptosis. Thus, when used in combination with radiotherapy or chemotherapy, the anticancer supplement agent may be used very usefully for anticancer treatment. | 05-12-2011 |
| 20110111401 | METHOD FOR SEQUENCING NUCLEIC ACID MOLECULES - The present invention is directed to a method of sequencing a target nucleic acid molecule having a plurality of bases. In its principle, the temporal order of base additions during the polymerization reaction is measured on a molecule of nucleic acid, i.e. the activity of a nucleic acid polymerizing enzyme on the template nucleic acid molecule to be sequenced is followed in real time. The sequence is deduced by identifying which base is being incorporated into the growing complementary strand of the target nucleic acid by the catalytic activity of the nucleic acid polymerizing enzyme at each step in the sequence of base additions. A polymerase on the target nucleic acid molecule complex is provided in a position suitable to move along the target nucleic acid molecule and extend the oligonucleotide primer at an active site. A plurality of labelled types of nucleotide analogs are provided proximate to the active site, with each distinguishable type of nucleotide analog being complementary to a different nucleotide in the target nucleic acid sequence. The growing nucleic acid strand is extended by using the polymerase to add a nucleotide analog to the nucleic acid strand at the active site, where the nucleotide analog being added is complementary to the nucleotide of the target nucleic acid at the active site. The nucleotide analog added to the oligonucleotide primer as a result of the polymerizing step is identified. The steps of providing labelled nucleotide analogs, polymerizing the growing nucleic acid strand, and identifying the added nucleotide analog are repeated so that the nucleic acid strand is further extended and the sequence of the target nucleic acid is determined. | 05-12-2011 |
| 20110111402 | KIFS as Modifiers of the RHO Pathway and Methods of Use - Human KIF23 genes are identified as modulators of the RHO pathway, and thus are therapeutic targets for disorders associated with defective RHO function. Methods for identifying modulators of RHO, comprising screening for agents that modulate the activity of KIF23 are provided. | 05-12-2011 |
| 20110111403 | MULTI-PRIMER ASSAY FOR MYCOPLASMA DETECTION - Disclosed is a multi-primer amplification assay, method and kits for detecting | 05-12-2011 |
| 20110111404 | Novel genes and markers in type 2 diabetes and obesity - Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed. | 05-12-2011 |
| 20110111405 | Novel genes and markers in type 2 diabetes and obesity - Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed. | 05-12-2011 |
| 20110111406 | ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY - The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen. | 05-12-2011 |
| 20110111407 | METHOD FOR ANALYSING THE EPIGENETIC STATUS OF THE HTRA 1 GENE IN A BIOLOGICAL SAMPLE - The invention relates to a method for analysing a biological sample, wherein the epigenetic status of at least one section of the HtrA 1 gene is analysed. Furthermore, diagnostic kits as well as a screening method for identifying a molecule which inhibits the binding of an epigenetic factor to at least one section of the HtrA1 gene are provided. | 05-12-2011 |
| 20110111408 | METHODS AND COMPOSITION FOR SECRETION OF HETEROLOGOUS POLYPEPTIDES - The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria. The invention also concerns recombinant polypeptides and uses thereof. | 05-12-2011 |
| 20110111409 | METHODS FOR DEPLETING RNA FROM NUCLEIC ACID SAMPLES - The invention relates to methods of depleting RNA from a nucleic acid sample. The RNA may be any RNA, including, but not limited to, rRNA, tRNA, and mRNA. The method is useful for depleting RNA from a nucleic acid sample obtained from a fixed paraffin-embedded tissue (FPET) sample. The method may also be used to prepare cDNA, in particular, a cDNA library for further analysis or manipulation. | 05-12-2011 |
| 20110111410 | STABILIZATION OF RNA IN INTACT CELLS WITHIN A BLOOD SAMPLE - A method for preserving and processing nucleic acids located within a blood sample is disclosed, wherein a blood sample containing nucleic acids is treated to reduce both blood cell lysis and nuclease activity within the blood sample. The treatment of the sample aids in increasing the integrity and amount of cellular nucleic acids that can be identified and tested while avoiding contamination of the isolated nucleic acids with cell-free nucleic acids. | 05-12-2011 |
| 20110111411 | Protein-Responsive RNA Control Devices and Uses Thereof - The invention described herein relates to an RNA-based control device that senses the presence and/or concentration of at least one protein ligand, preferably through its protein-binding aptamer domain, and regulates a target gene expression through alternative splicing of the target gene in which the RNA-based control device is integrated. The device has uses in therapeutic as well as diagnostic applications. | 05-12-2011 |
| 20110111412 | Uses of Parylene Membrane Filters - The invention provides parylene membrane filters, filter devices and methods of making them and using them in the mechanical separation of cells and particles by size. The provision of parylene membrane filters with high figures of merit and finely controlled hole sizes allows the separation of cells and particles in a variety of biological and other fluids according to sizes. | 05-12-2011 |
| 20110111413 | METHOD OF OPTIMIZING CODON USAGE THROUGH DNA SHUFFLING - The present invention relates to codon optimization utilizing DNA shuffling. A method of producing gene sequences optimized for a desired functional property is described involving synthesizing a library of parental codon variant genes encoding some or all codon choices at some or all amino acid positions of a gene, reassorting the variant codons among the parental codon variant genes using DNA shuffling thereby forming progeny codon variant genes, expressing the progeny codon variant genes in a host; and screening or selecting for progeny codon variant genes encoding a desired functional property. | 05-12-2011 |
| 20110111414 | Detecting Agent and Therapeutic Agent for Highly Malignant Breast Cancer - A detection agent for high malignancy breast cancer includes an antibody against collagen XIV, or a variant or derivative or fragment of the antibody. A therapeutic agent for high malignancy breast cancer includes a conjugate of an anticancer drug and an antibody against that protein, or a variant or derivative or fragment thereof. Accordingly, it is possible to easily and accurately detect and diagnose high malignancy breast cancer. | 05-12-2011 |
| 20110111415 | MULTI-STAGE NUTRIGENOMIC DIAGNOSTIC FOOD SENSITIVITY TESTING IN ANIMALS - A multi-stage method for diagnosing an immunologic food sensitivity or intolerance in a companion animal. Firstly a saliva or blood spot or other non-serum bodily fluid sample is collected. The screening the saliva or blood spot or other non-serum bodily fluid sample detects the presence of at least one of IgA or IgM antibody to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody is diagnosed. Secondly a blood sample is collected and serum from the sample is screened to detect the semi-quantitative or quantitative presence of at least one of an IgA, IgM or IgG antibody or immune complex to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody or immune complex is diagnosed. Thirdly, a biologically active nutrient in relation to the animal from a molecular dietary signature is determined. The molecular dietary signature for the animal is a variation of expression of a set of genes, proteins or metabolites which may differ for the genotype of each animal. | 05-12-2011 |
| 20110111416 | Peptide Nucleic Acid Probes, Kits and Methods for Expression Profiling of Micrornas - Disclosed are peptide nucleic acid (PNA) probes, a kit and a method for expression profiling of microRNAs (miRNAs), which play an important role in regulation of expression of genes encoding proteins. | 05-12-2011 |
| 20110111417 | METHODS AND KITS FOR MONITORING THE EFFECTS OF IMMUNOMODULATORS ON ADAPTIVE IMMUNITY - The invention provides for noninvasive assessment of immunocompetence in various situations, for example, when modified by disease or by immunomodulators. The assessment determines the functional activity of germinal centers via measuring levels of immunogolublin isotype class switching. The invention provides for assessment of therapeutic efficacy of immunomodulators and for selection of treatment regimens. The invention also provides for determining the risk or susceptibility to adverse events upon receipt of therapy. Compositions, kits and methods are described herein. | 05-12-2011 |
| 20110111418 | USE OF IRON-RELATED PATHWAYS AND GENES FOR TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE - A collection of genetic variants having susceptability to, or protection from, Parkinson's Disease is provided. The variants are useful in method of diagnosing, prognosing, and treating Parkinson's Disease and related conditions | 05-12-2011 |
| 20110111419 | Copy Number Variations Predictive of Risk of Schizophrenia - The present invention relates to genomic copy number variations as risk factors for schizophrenia. The invention provides methods and kits for risk management of schizophrenia, by assessing such copy number variations in the genome of individuals. | 05-12-2011 |
| 20110111420 | Corn Event MIR604 - A novel transgenic corn event designated MIR604, is disclosed. The invention relates to DNA sequences of the recombinant constructs inserted into the corn genome and of genomic sequences flanking the insertion site that resulted in the MIR604 event. The invention further relates to assays for detecting the presence of the DNA sequences of MIR604, to corn plants and corn seeds comprising the genotype of MIR604 and to methods for producing a corn plant by crossing a corn plant comprising the MIR604 genotype with itself or another corn variety | 05-12-2011 |
| 20110111421 | Gene Expression Markers for Colorectal Cancer Prognosis - A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject. | 05-12-2011 |
| 20110117543 | DIAGNOSTIC METHOD AND PRODUCTS USEFUL THEREIN - A method for simultaneous detection and identification of | 05-19-2011 |
| 20110117544 | METHOD FOR PRODUCING AN AMPLIFIED POLYNUCLEOTIDE SEQUENCE - There is a method for converting at least a part of a target polynucleotide sequence into a different sequence, comprising the steps of: (i) hybridising two or more first polynucleotides to adjacent positions on the target and linking first polynucleotides together, wherein at least one of the first polynucleotides comprises at least one nucleotide that is not complementary to the target; and (ii) dissociating the hybrid of step (i) and forming a second polynucleotide hybridised to the first polynucleotide, the second polynucleotide comprising at least one portion complementary to a portion on the first polynucleotide and comprising the complement to the at least one nucleotide of step (i). | 05-19-2011 |
| 20110117545 | GENETIC VARIANTS ON CHR2 AND CHR16 AS MARKERS FOR USE IN BREAST CANCER RISK ASSESSMENT, DIAGNOSIS, PROGNOSIS AND TREATMENT - The invention pertains to certain genetic variants on Chr2q14, Chr2q35 and Chr16q12 as susceptibility variants of breast cancer. Methods of risk assessment and diagnosis of increased and/or decreased susceptibility to breast cancer, using such variants are described. The invention further relates to kits for diagnosing a susceptibility to breast cancer. | 05-19-2011 |
| 20110117546 | INCREASE OF SIGNAL SENSITIVITY USING DUAL PROBES IN PCR REACTIONS - A method increases the signal strength generated when performing real-time PCR on a target nucleic acid sequence. The method performs real-time PCR using forward primers, forward probes, reverse primers, reverse probes, nucleotides for strand/antistrand extension, and nucleic acid polymerase. Two different types of probes are used, a forward probe configured to anneal to a sense strand of a target nucleic acid sequence and a reverse probe configured to anneal to an antisense strand of the target nucleic acid sequence. The forward probe is complementary to an inner sequence of the target sense strand, and the reverse probe is complementary to an inner sequence of the target antisense strand. The forward probe and the reverse probe each include the same detectable element, that when released from the probe during strand extension results in an additive detectable signal. | 05-19-2011 |
| 20110117547 | TARGET DNA DETECTION METHOD AND TARGET DNA DETECTION KIT - The present invention provides a method for detecting a target DNA easily and highly accurately through simultaneous analysis of a sense strand and an antisense strand of the target DNA, and a kit therefor. The target DNA detection method of the present invention is a method for detecting a target DNA composed of a sense strand having a target nucleotide sequence and an antisense strand complementary to the sense strand, wherein: a first oligonucleotide which hybridizes with the sense strand, and a second oligonucleotide which hybridizes with the antisense strand are used; at least a part of a region, of the antisense strand, which hybridizes with the second oligonucleotide is complementary to at least a part of a region, of the sense strand, which hybridizes with the first oligonucleotide; and the first oligonucleotide and the second oligonucleotide are simultaneously added into one reaction solution to effect respective hybridizations with the target DNA, followed by ligation reactions and/or PCR, thereby detecting resultant products. | 05-19-2011 |
| 20110117548 | Detecting Fetal Chromosomal Abnormalities Using Tandem Single Nucleotide Polymorphisms - The invention provides tandem single nucleotide polymorphisms and methods for their use, for example, in diagnosing Down Syndrome. | 05-19-2011 |
| 20110117549 | METHOD FOR DETECTING NUCLEIC ACID, AND DEVICE OR KIT - The present invention has its object to provide a method and a device or kit for detecting a nucleic acid, which enable simple and precise visual detection of a nucleic acid amplified by a nucleic acid amplification method, without necessity of a special device. | 05-19-2011 |
| 20110117550 | METHOD OF DETERMINING ANTI-HYPERTENSIVE DRUG THERAPY BY GENETIC PROFILING - The present invention comprises a method for determining an anti-hypertension therapy for an individual based upon the presence or absence of specific alleles affecting baseline blood pressure and sensititivity to different therapeutic formulations. | 05-19-2011 |
| 20110117551 | DETECTION AND PROGNOSIS OF LUNG CANCER - Methods and tools are provided for detecting and predicting lung cancer. The methods and tools are based on epigenetic modification due to methylation of genes in lung cancer or pre-lung cancer. The tools can be assembled into kits or can be used seperately. Genes found to be epigentically silenced in association with lung cancer include ACSL6, ALS2CL, APC2, ART-S1, BEX1, BMP7, BNIP3, CBR3, CD248, CD44, CHD5, DLK1, DPYSL4, DSC2, EDNRB, EPB41L3, EPHB6, ERBB3, FBLN2, FBN2, FOXL2, GNAS, GSTP1, HS3ST2, HPN, IGFBP7, IRF7, JAM3, LOX, LY6D, LY6K, MACF1, MCAM, NCBP1, NEFH, NID2, PCDHB15, PCDHGA12, PFKP, PGRMC1, PHACTR3, PHKA2, POMC, PRKCA, PSEN1, RASSF1A, RASSF2, RBP1, RRAD, SFRP1, SGK, SOD3, SOX17, SULF2, TIMP3, TJP2, TRPV2, UCHL1, WDR69, ZFP42, ZNF442, and ZNF655. | 05-19-2011 |
| 20110117552 | METHODS OF USING A NOD2/CARD15 HAPLOTYPE TO DIAGNOSE CROHN'S DISEASE - The present invention provides a method of diagnosing or predicting susceptibility to Crohn's disease in an individual by determining the presence or absence in the individual of a disease-predisposing haplotype containing a JW1 variant allele at the NOD2/CARD15 locus, where the presence of the disease-predisposing haplotype is diagnostic of or predictive of susceptibility to Crohn's disease. | 05-19-2011 |
| 20110117553 | Methods for PCR and HLA typing using raw blood - Provided are methods for amplifying a gene or RNA or sets thereof of interest using a tandem PCR process. The primers in the first PCR or set of PCR reactions are locus-specific. The primers in the second PCR or set of PCR reactions are specific for a sub-sequence of the locus-specific primers and completely consumed during the secondary PCR amplification. For RNA amplification, the first PCR is reverse transcription and the resulting cDNA(s) provide a template for cRNA synthesis, endpoint PCR or real time PCR. Also provided is a method of allelotyping a gene or set thereof by amplifying the gene(s) using tandem PCR on DNA or RNA comprising the sample, hybridizing the resulting amplicon or sets thereof to probes with sequences of gene-associated allele variations. A detectable signal indicating hybridization corresponds to an allelotype of the gene or a set of allelotypes for the set of genes. | 05-19-2011 |
| 20110117554 | Formamide-containing mixtures for detecting nucleic acids - Specific sequences of DNA are often detected by a process that comprises a step where the sequence to be detected (the “analyte”) binds to give a duplex with a DNA molecule or analog that is complementary in the Watson-Crick sense to some portion of the analyte in an aqueous “assay environment” that may contain buffer, salt, and/or detergent. Such purely aqueous systems cannot be exposed indefinitely to the environment, however, as the water in the system will evaporate. Further, such systems often support the growth of bacteria and other organisms, destroying their effectiveness. This invention provides for compositions of matter and processes that use them that comprise assay mixtures containing more than 40% formamide. This mixture remains a liquid at equilibrium with water in environments normally inhabited by humans. This invention also provides for mixtures containing formamides that include detergents. Formamide is usually regarded as a denaturant for duplex formation, destabilizing the binding that is key to detection. This invention therefore also provides for materials that form duplexes in formamide-water mixtures. | 05-19-2011 |
| 20110117555 | CD38 as a prognostic indicator in chronic lymphocytic leukemia - The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation. | 05-19-2011 |
| 20110117556 | HIGH-SENSITIVE FLUORESCENT ENERGY TRANSFER ASSAY USING FLUORESCENT AMINO ACIDS AND FLUORESENT PROTEINS - The disclosure provides method and composition utilizing fluorescent amino acids and endogenous fluorescent proteins comprising a moiety capable of undergoing FRET. The methods and compositions of the disclosure are useful in analyzing protein structure and function, and screening molecular inhibitors. | 05-19-2011 |
| 20110117557 | Methods and Compositions For Diagnosis of Age-Related Macular Degeneration - The invention generally concerns methods and compositions for screening individuals for susceptibility to age-related macular degeneration (AMD). In particular, association with the various markers including complement factor H, LOC387717/ARMS2, C2/CFB, C3 and VEGF, indicates that a subject is at risk of AMD. | 05-19-2011 |
| 20110117558 | DIAGNOSIS OF HEREDITARY SPASTIC PARAPLEGIAS (HSP) BY IDENTIFICATION OF A MUTATION IN THE ZFYVE26 GENE OR PROTEIN - The Invention relates to an ex vivo method of diagnosing or predicting a hereditary spastic paraplegias (HSP), in a subject, which method comprises detecting a mutation in the ZFYVE26 gene or protein (spastizin), wherein said mutation is indicative of a hereditary spastic paraplegias (HSP). | 05-19-2011 |
| 20110117559 | SMALL RNA DETECTION ASSAYS - The present invention comprises use of cleavable primers to perform qPCR detection of cDNA made from small RNA species. The cleavable primers offer improved specificity over standard PCR primers and are the method is compatible with a variety of methods to introduce priming sites at the 5′-end and 3′-end of the small RNA species. | 05-19-2011 |
| 20110117560 | ASSESSING LEFT VENTRICULAR REMODELING VIA TEMPORAL DETECTION AND MEASUREMENT OF microRNA IN BODY FLUIDS - Disclosed are methods and materials for assessing cardiac failure, cardiac hypertrophy, and left ventricular remodeling using microRNA levels. The level of microRNAs can be measured in a body fluid, such as plasma and serum. | 05-19-2011 |
| 20110117561 | Magnetic Pigment - Magnetic particles with an outer glass surface being essentially poreless or having pores of a diameter of less then 10 nm as well as ferromagnetic particles with a glass surface are preferentially useful for the isolation of biological material from samples. They provide a quick and reliable purification. | 05-19-2011 |
| 20110117562 | Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) - The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL, particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided. | 05-19-2011 |
| 20110117563 | ANTIVIRAL THERAPY - The application relates to treatments for improving antiviral therapies and to method for determining whether or not antiviral therapies will be effective. In particular, the present application provides a method for determining the likelihood that a subject having a viral infection of the liver will be responsive to antiviral therapy that includes stimulation of Interferon (IFN) activity, and kits for the performance of said determination. | 05-19-2011 |
| 20110117564 | COMPOSITIONS, KITS AND RELATED METHODS FOR THE DETECTION AND/OR MONITORING OF SALMONELLA - Provided are compositions, kits, and methods for the identification of | 05-19-2011 |
| 20110117565 | SERUM OR PLASMA MICRORNA AS BIOMARKERS FOR NON-SMALL CELL LUNG CANCER - The present invention provides non-small cell lung cancer markers and the use thereof. The non-small cell lung cancer markers in the present invention include at least one of the 26 selected detectable mature microRNAs existing stably in human serum or plasma. The invention also provides a probe combination, kit and biochip for detecting the non-small cell lung cancer markers. The invention further provides a method for detecting microRNAs in the serum of lung cancer patients. By detecting the variations of microRNAs in the serum of lung cancer patients, the disease can be diagnosed in vitro; the progression course of the disease can be predicted; the occurrence of complications, the rate of relapse and the prognosis of the disease can be monitored; the drug efficacy and therapeutic effects can be analyzed. The method in the present invention enables extensive detection spectrum, high sensitivity, low cost, convenient sample taking and preservation. The method can be applied in the general survey of disease, solves problems of the low specificity and sensitivity encountered with previous single markers, and increases significantly the clinical detection rate of diseases, all of which make it an effective means for diagnosing diseases at an early stage. | 05-19-2011 |
| 20110117566 | Model System for Diagnosing Lipid Metabolism - The invention relates to a population model for the analysis of blood lipoprotein physiology in a test subject comprising: a. a submodel for the production of blood lipoproteins; b. a submodel for the lipolysis of blood lipoproteins; c. a submodel for the reabsorption of blood lipoproteins; and d. a submodel relating blood lipoprotein particle size to biochemical composition, more specifically triglyceride content, there-by providing an analysis of the physiological processes underlying a steady state particle population distribution. Each submodel is given as function, using the size of the lipoprotein particle as the independent variable. | 05-19-2011 |
| 20110117567 | Micro-RNA Associated With Rheumatoid Arthritis - An object of the present invention is to provide a novel marker for rheumatoid arthritis (RA), and more specifically, to provide a marker whose expression may be specifically increased or decreased in RA. Another object of the present invention is to confirm whether or not miRNA serving as the marker is involved as the etiology of RA, and to provide an inspection method for RA and a therapeutic agent for RA each using the miRNA involved. The marker includes miRNA (for example, miR124a) whose expression is specifically increased or decreased in RA synovial cells based on a small RNA expression profile in the RA synovial cells. In addition, the therapeutic agent for RA includes miRNA (for example, miR124a) as an active ingredient. | 05-19-2011 |
| 20110117568 | Method for Amplifying Target Nucleic Acid Sequence, Method for Detecting Mutation Using the Same, and Reagent Used for the Same - The present invention provides a method for detecting a mutation capable of detecting a mutation with high sensitivity and high reliability in one reaction system. Using primers (Xmt) and (Xwt), a target nucleic acid sequence whose objective base to be detected is a mutant-type is amplified with amplification efficiency higher than a target nucleic acid sequence whose objective base to be detected is a normal-type. The (Xmt) is a primer that is complementary to a region including a mutant-type base in the template nucleic acid and has a base complementary to a mutant-type base at a 3′ region, and the (Xwt) is a primer that is complementary to a region including a normal-type base in the template nucleic acid and has a base complementary to a normal-type base at a 3′ region. It is preferable that amplification efficiency by the (Xmt) with reference to a mutant-type template nucleic acid is higher than that by the (Xwt) with reference to a normal-type template nucleic acid. Then, a signal value that shows a molten state of a hybridization product between the thus obtained amplification product and the probe is measured, and the presence or absence of the mutation of the objective base site is determined from a change in the signal value accompanying a change in the temperature. | 05-19-2011 |
| 20110117569 | POLYMIDE NUCLEIC ACID DERIVATIVES, AND AGENTS AND PROCESSES FOR PREPARING THEM - The present invention relates to PNA derivatives which carry, at the C terminus, or at both the C and N termini of the PNA backbone, one or more phosphoryl radicals. The phosphoryl radicals carry, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the above-mentioned PNA derivatives and to their use as pharmaceuticals or diagnostic agents. | 05-19-2011 |
| 20110117570 | METHODOLOGIES, PROCESSES AND AUTOMATED DEVICES FOR THE ORIENTATION, SAMPLING AND COLLECTION OF SEED TISSUES FROM INDIVIDUAL SEED - Apparatus, methods, and systems for high throughput, useful sampling of seed, wherein viability is optionally maintained, are disclosed. Seed from one generation in a plant advancement experiment is individually sampled by removal and collection of tissue from the seed. The tissue is then processed to derive one or more biochemical, genetic, or phenotypic characteristic of the seed before a decision is made whether to utilize that seed further in a plant advancement experiment or other plant research and development. In some embodiments of the method, the sampling is controlled to remove a useful amount of tissue for analytical purposes without significant effect on viability potential of the sampled seed. In some embodiments, the sampling is controlled to deter contamination of the sample. In some embodiments, the seed is automatically positioned and oriented to facilitate efficient and accurate sampling. | 05-19-2011 |
| 20110123980 | SEQUENCE-SPECIFIC DETECTION OF NUCLEOTIDE SEQUENCES - A method for detecting the presence of a target nucleotide sequence in a sample of DNA is described herein in which a test sample comprising single stranded DNA is exposed to a DNA probe and a nicking endonuclease under conditions that would permit sequence-specific hybridization of the probe to a complementary target sequence. The probe comprises a sequence complementary to the target sequence to be detected and this sequence also includes a recognition sequence for the nicking endonuclease. If the sample contains the target sequence, the probe hybridizes to the target and is cleaved by the nicking endonuclease, which leaves the target intact. Observing the presence of probe cleaved by the nicking endonuclease indicates the presence of the target nucleotide sequence in the sample of DNA. | 05-26-2011 |
| 20110123981 | FTO GENE POLYMORPHISMS ASSOCIATED TO OBESITY AND/OR TYPE II DIABETES - The present invention provides means and methods for risk assessment and/or diagnosis and/or prognosis of obesity and/or type II diabetes in humans, based on the detection of nucleic acid biomarkers belonging to, or associated with, a set of SNPs in the fatso (FTO) gene. The present invention also provides means and methods for identifying a SNP haplotype associated with obesity and/or type II diabetes susceptibility in humans, for selecting pharmaceutical agents useful in prevention and/or treatment of obesity and/or type II diabetes in humans, for haplotyping the fatso (FTO) gene in humans. | 05-26-2011 |
| 20110123982 | NUCLEIC ACID BASED FLUORESCENT SENSOR FOR COPPER DETECTION - A nucleic acid enzyme responsive to copper, comprising an oligonucleotide comprising a nucleotide sequence of SEQ ID NO:1, wherein the nucleic acid enzyme is not self-cleaving. | 05-26-2011 |
| 20110123983 | Methods of Using Genetic Markers and Related Epistatic Interactions - The present invention provides methods for improving desirable animal traits including improved fitness and productivity in dairy animals. Also provided are methods for determining a dairy animal's genotype with respect to multiple markers associated with fitness and/or productivity. The invention also provides methods for selecting or allocating animals for predetermined uses such as progeny testing or nucleus herd breeding, for picking potential parent animals for breeding, and for producing improved progeny animals. Each of the above methods may be further improved through the incorporation of interaction effects between multiple SNPs. | 05-26-2011 |
| 20110123984 | FAM26C POLYMORPHISMS AND USE THEREOF FOR THE DIAGNOSTIC AND TREATMENT OF LATE ONSET ALZHEIMER'S DISEASE - Provided are methods of determining the likelihood that a subject will be diagnosed with Alzheimer's disease. Also provided are isolated and purified mammalian CALHM I, CALHM2, and CALHM3 proteins, vectors comprising a nucleic acid sequence encoding the CALHM 1, CALHM2, and CALHM3 proteins, and mammalian cells transfected with the vectors. Additionally, methods of affecting Ca2+ levels in a mammalian cell are provided. Further provided are methods of screening a test compound for the ability to alter calcium homeostasis in mammalian cells. Also, methods of affecting Ca2+levels in mammalian cells are provided. Additionally provided are methods of screening a test compound for the ability to inhibit ERK I/2 phosphorylation in a mammalian cell. Further provided are methods of screening a test compound for the ability to inhibit amyloid-beta peptide accumulation in a mammalian cell or biological fluid. Also provided are methods of screening for a test compound that may affect Alzheimer's disease. | 05-26-2011 |
| 20110123985 | COLUMN ENRICHMENT OF PCR BEADS COMPRISING TETHERED AMPLICONS - An enrichment module and method are provided for enriching a population of templated beads and separating them from non-templated beads. The method can include hybridizing a templated bead with an enrichment bead to form a complex, trapping the complex in a filtration medium, washing non-templated beads through the filtration medium while retaining the complex, and then eluting the templated bead from the complex. The module can include a column for enrichment and filtration material exhibiting desired size-exclusion properties. | 05-26-2011 |
| 20110123986 | METHODS FOR THE DIAGNOSIS OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS - Methods and formulations for diagnosing metabolic disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described. | 05-26-2011 |
| 20110123987 | METHODS FOR THE DIAGNOSIS OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS - Methods and formulations for diagnosing onocological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described. | 05-26-2011 |
| 20110123988 | ANTISENSE COMPOUNDS AND METHODS FOR DIAGNOSTIC IMAGING - Compounds comprising a diagnostic or therapeutic moiety can be retained inside a cell by conjugating the moiety to at least one PNA that is targeted to the transcripts from a gene of interest. The diagnostic or therapeutic moiety is also conjugated to at least one targeting moiety specific for an extracellular receptor or other cell surface molecule. The targeting moiety binds to the surface of a cell, and the entire compound is then internalized. Once inside the cell, the PNA portion of the diagnostic or therapeutic compound binds to RNA transcripts in a sequence specific manner. Binding of the PNA to its target RNA transcript retains the compound within the cell. The PNA can be designed to bind to a predetermined nucleic acid sequence from an RNA transcript, for example a mutated or overexpressed sequence that is characteristic of a pathological state. | 05-26-2011 |
| 20110123989 | METHOD FOR THE DETECTION OF SCHIZOPHRENIA RELATED GENE TRANSCRIPTS IN BLOOD - The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 05-26-2011 |
| 20110123990 | Methods To Predict Clinical Outcome Of Cancer - The present invention provides methods to determine the prognosis and appropriate treatment for patients diagnosed with cancer, based on the expression levels of one or more biomarkers. More particularly, the invention relates to the identification of genes, or sets of genes, able to distinguish breast cancer patients with a good clinical prognosis from those with a bad clinical prognosis. The invention further provides methods for providing a personalized genomics report for a cancer patient. The inventions also relates to computer systems and software for data analysis using the prognostic and statistical methods disclosed herein. | 05-26-2011 |
| 20110123991 | ISOTHERMAL NUCLEIC ACID AMPLIFICATION - An isothermal process for amplifying a nucleic acid target molecule that relies on an upstream primer, a downstream primer, a strand invasion system and an oligonucleotide, wherein the upstream and downstream primers are not substrates for the strand invasion system during the amplification process and do not amplify the target molecule independently of the strand invasion system, wherein the oligonucleotide is a substrate for the strand invasion system. | 05-26-2011 |
| 20110123992 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 3 and mutated sequences thereof. | 05-26-2011 |
| 20110129817 | BLOOD TRANSCRIPTIONAL SIGNATURE OF ACTIVE VERSUS LATENT MYCOBACTERIUM TUBERCULOSIS INFECTION - The present invention includes methods, systems and kits for distinguishing between active and latent | 06-02-2011 |
| 20110129818 | ASSAY FOR CARDIAC TROPONIN-T (cTnT) - The present disclosure describes immunoassays for detecting cardiac troponin-T (cTnT) in a test sample, and in particular immunoassays and kits for detecting cTnT in a test sample suspected of containing substances that may interfere with the determination of cTnT, such as heterophilic endogenous antibodies and autoantibodies to cTnT. The methods use more than one capture phase antibody and more than one detection antibody to improve specificity, and provide for the use of humanized immunoreagents to overcome heterophilic antibody interferences. | 06-02-2011 |
| 20110136103 | AUTOANTIBODY ENHANCED IMMUNOASSAYS AND KITS - The present disclosure provides immunoassays and kits for detection or quantification of an analyte of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyte. | 06-09-2011 |
| 20110136104 | MULTIPLEXED QUANTITATIVE PCR END POINT ANALYSIS OF NUCLEIC ACID TARGETS - Certain embodiments of the present invention are directed to one pot multiplexed quantitative PCR methods for end point analysis of a plurality of nucleic acid targets in a complex sample without user intervention, and to various encoded particles on which are immobilized one or more probes that hybridize with the plurality of targets. Certain other embodiments are directed to a new “multiple-color genetic variation detection method” that can detect SNPs and kit using one chamber multiplexed endpoint PCR and differentially labeled allele-specific primers (one recognizing only the wild type allele and one only the mutant allele). | 06-09-2011 |
| 20110136105 | METHODS OF QUANTIFYING NUCLEIC ACIDS - The present invention provides a method of detecting or quantifying a target nucleic acid by using fluorescently labeled oligonucleotide probes that do not rely on secondary structure or enzymatic action. The present invention provides improved methods of detecting or quantifying target nucleic acid by detecting or quantitating data during the annealing phase of PCR amplification. | 06-09-2011 |
| 20110151439 | SYSTEM AND METHOD FOR THE RAPID IDENTIFICATION OF BIOLOGICAL AND CHEMICAL ANALYTES - A system and method for the rapid identification of biological and chemical analytes that includes an enzyme substrate compound; an aptamer recognizing an analyte; and a recognition probe that comprises a first terminus operatively coupled to an enzyme catalyzing the enzyme substrate compound; a second terminus operatively coupled to an enzyme inhibitor corresponding to the enzyme, wherein the aptamer is positioned between the first terminus and the second terminus; and a stem loop structure positioned between the first terminus and second terminus is provided. | 06-23-2011 |
| 20110151440 | Screening for Arthrogryposis Multiplex in Bovines - Provided are methods, materials and kits for analyzing DNA samples from bovine to determine whether the animal is a recessive carrier of a genetic mutation that is associated with arthrogryposis multiplex (AM). DNA-containing samples are analyzed by genetic testing to determine whether or not a deletion mutation is present in one of the alleles that are responsible for the AM genetic mutation. In an aspect the deletion encompasses the entirety of the ISG15 ubiquitin-like modifier (ISG15) gene. In an aspect the deletion further encompasses one or both of the 5′ regulatory region of the hairy and enhancer split 4 (HES4) and of the agrin (AGRN) gene and of the first two exons of the AGRN gene. | 06-23-2011 |
| 20110151441 | ENDPOINT TAQMAN METHODS FOR DETERMINING ZYGOSITY OF CORN COMPRISING TC1507 EVENTS - A method for zygosity analysis of the maize Cry1F event TC1507 is provided. The method provides TC1507 event-specific and maize endogenous reference gene-specific primers and TaqMan probe combinations for use in an endpoint biplex TaqMan PCR assay capable of producing robust genotype calls for assisting in molecular breeding of TC1507. | 06-23-2011 |
| 20110151442 | Direct Molecular Diagnosis of Fetal Aneuploidy - Methods and materials for detection of aneuploidy and other chromosomal abnormalities using fetal tissue are disclosed. Results can be obtained rapidly, without cell culture. The method uses digital PCR for amplification and detection of single target sequences, allowing an accurate count of a specific chromosome or chromosomal region. Specific polynucleic acid primers and probes are disclosed for chromosomes 1, 13, 18, 21, X and Y. These polynucleic acid sequences are chosen to be essentially invariant between individuals, so the test is not dependent on sequence differences between fetus and mother. | 06-23-2011 |
| 20110151443 | MARKER FOR GASTRIC CANCER - Methods for detecting and assessing the progress and prognosis of gastric cancer are presented. Primers and probes for use in the methods are also disclosed as are methods for suppressing gastric cancer and kits for implementing the methods. | 06-23-2011 |
| 20110151444 | METHOD FOR DETECTION OF AN RNA MOLECULE, A KIT AND USE RELATED THEREFOR - Described is a method for the detection of a RNA molecule, the method involving the steps of providing a sample containing the RNA molecule; hybridizing to the RNA molecule a first polynucleotide; extending the first polynucleotide to generate a first strand cDNA; hybridizing a second polynucleotide to the first strand cDNA; extending the first strand cDNA to generate an extension reaction product; amplifying the extension reaction product by means of polymerase chain reaction; and detecting the amplification product by means of real-time fluorescence readout. Also described is a kit containing a first and a second polynucleotide as defined in the present invention, a set of dNTPs, a reverse transcriptase enzyme, and a detection moiety. | 06-23-2011 |
| 20110151445 | ALLELIC DISORDERS CAUSED BY MUTATIONS IN TRPV4 - The present invention provides methods, kits, and compositions for detecting mutations in transient receptor potential cation channel, subfamily V, member 4 (TRPV4). In particular, mutations are detected in TRPV4 to detect diseases such as scapuloperoneal spinal muscular atrophy (SPSMA) and hereditary motor and sensory neuropathy type IIC (HMSN IIC) or Charcot-Marie-Tooth disease type 2C (CMT2C). | 06-23-2011 |
| 20110159478 | METHOD FOR SCREENING DRUG CANDIDATES BY USING DOMAIN PROTEIN - The present invention relates to a method for screening and discovering bioactive materials using specifically selected protein domains interacting with specific intracellular proteins, and more particularly, to (1) a screening method including confirmation of changes in biological activities by introducing a specific protein domain into microorganisms or animal and plant cells and (2) a screening method including confirmation of changes in biological activities after introducing the specific protein domains into a number of microorganisms or animal and plant cells. Via this method, according to the present invention, it is possible that the selected protein domains can be used to develop novel antibiotic agents with antimicrobial activity effective on bacteria resistant to conventional antibiotics while requiring less genetic information compared with a conventional drug which targets specific genes. | 06-30-2011 |
| 20110159479 | GENETIC POLYMORPHISMS IN THE CYTOCHROME P450 GENE WITH CLOPIDOGREL RESISTANCE - The present invention relates to a method for predicting the resistance of a human subject to clopidogrel, which comprises detecting the presence or absence of a A allele at position 636 of exon 4 in the CYP2C19 gene, wherein the presence of the A allele is indicative of a clopidogrel resistance. The present method may be very useful in predicting the resistance of a human subject to clopidogrel and contribute to more effective chemotherapy for patients having coronary artery disease and drug-eluting stent. | 06-30-2011 |
| 20110159480 | CELL-BASED SCREENING ASSAY TO IDENTIFY MOLECULES THAT STIMULATE IFN-ALPHA/BETA TARGET GENES - A method using cells transformed with a construct containing a reporter gene operatively-linked to an interferon stimulated response element for identifying an agent, such as a chemical compound, peptide or polypeptide, which exhibits an interferon-like activity on the interferon stimulated response element (ISRE) and modulates genes activated by activation of the ISRE. | 06-30-2011 |
| 20110159481 | Solid-phase chelators and electronic biosensors - Methods for sequencing nucleic acids are presented. Sequencing is accomplished through the chemical amplification of the products of DNA synthesis and the detection of the chemically amplified products. In embodiments of the invention, a substrate is provided having a plurality of molecules of DNA to be sequenced attached and a plurality of molecules capable of chelating pyrophosphate ions attached, the DNA molecules to be sequenced are primed, and a next complementary nucleotide is incorporated and excised a plurality of times leading to the buildup of pyrophosphate ions locally around the DNA molecule to be sequenced. Pyrophosphate ions are captured by the substrate-attached chelators and electronically detected to determine the identity of the next complementary nucleic acid in the DNA molecule to be sequenced. Additionally, devices and methods are provided for detecting biomolecules through the detection of pyrophosphate ions. | 06-30-2011 |
| 20110159482 | METHOD FOR DETECTING MULTIPLE SMALL NUCLEIC ACIDS - The present invention discloses a method for simultaneously detecting multiple small nucleic acids, which comprises steps: mixing a specimen, fluorescent probes, and bridge nucleic acids having different lengths to form a tested liquid; hybridizing the mixed short nucleic acid molecules, probes and bridge nucleic acids; adding ligases to enable the ligations of the short nucleic acid molecules and the fluorescent probes with the bridge nucleic acids being the templates; injecting the tested liquid into a capillary, and applying a voltage to the capillary to generate an electrophoresis effect and separate the hybridization products; and using laser to induce different fluorescent rays from different reaction products, and measuring the fluorescent rays, whereby the present invention can simultaneously detect multiple types of short nucleic acid molecules in a single capillary. | 06-30-2011 |
| 20110159483 | CYANINE COMPOUNDS, COMPOSITIONS INCLUDING THESE COMPOUNDS AND THEIR USE IN CELL ANALYSIS - A compound having the general formula I or a conjugate thereof, wherein various groups are as defined in the specification. A composition includes: (i) a compound having the general formula I or a conjugate thereof; and (ii) at least one surfactant selected from cationic surfactants and nonionic surfactants. Also disclosed is a preparation method for the composition and a kit comprising the composition. Further disclosed is a method for identifying and differentiating erythroblasts, basophils and lymphocytes simultaneously using the composition according to the present disclosure. | 06-30-2011 |
| 20110159484 | APPARATUS AND METHOD OF AUTHENTICATING PRODUCT USING POLYNUCLEOTIDES - A method of authenticating a product includes; hybridizing a target polynucleotide which is associated with the product and which includes a first target region and a second target region adjacent to the first target region with a probe polynucleotide that comprises a first segment having a nucleotide sequence completely complementary to the first target region and a second segment having a nucleotide sequence completely complementary to the second target region, ligating one end of the first segment of the probe polynucleotide to one end of the second segment of the probe polynucleotide, amplifying the probe polynucleotide and detecting the amplified polynucleotide. | 06-30-2011 |
